<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<html>
 <body>
  <pmc-articleset>
   <article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <?properties open_access?>
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       J Antimicrob Chemother
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       J. Antimicrob. Chemother
      </journal-id>
      <journal-id journal-id-type="publisher-id">
       jac
      </journal-id>
      <journal-id journal-id-type="hwp">
       jac
      </journal-id>
      <journal-title-group>
       <journal-title>
        Journal of Antimicrobial Chemotherapy
       </journal-title>
      </journal-title-group>
      <issn pub-type="ppub">
       0305-7453
      </issn>
      <issn pub-type="epub">
       1460-2091
      </issn>
      <publisher>
       <publisher-name>
        Oxford University Press
       </publisher-name>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       23869049
      </article-id>
      <article-id pub-id-type="pmc">
       7109789
      </article-id>
      <article-id pub-id-type="doi">
       10.1093/jac/dkt281
      </article-id>
      <article-id pub-id-type="publisher-id">
       dkt281
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Reviews
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        Current and emergent strategies for disinfection of hospital environments
       </article-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author">
        <name>
         <surname>
          Abreu
         </surname>
         <given-names>
          Ana C.
         </given-names>
        </name>
        <xref ref-type="aff" rid="af1">
         1
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Tavares
         </surname>
         <given-names>
          Rafaela R.
         </given-names>
        </name>
        <xref ref-type="aff" rid="af2">
         2
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Borges
         </surname>
         <given-names>
          Anabela
         </given-names>
        </name>
        <xref ref-type="aff" rid="af1">
         1
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Mergulhão
         </surname>
         <given-names>
          Filipe
         </given-names>
        </name>
        <xref ref-type="aff" rid="af1">
         1
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Simões
         </surname>
         <given-names>
          Manuel
         </given-names>
        </name>
        <xref ref-type="aff" rid="af1">
         1
        </xref>
        <xref ref-type="corresp" rid="cor1">
         *
        </xref>
        <!--<email>mvs@fe.up.pt</email>-->
       </contrib>
      </contrib-group>
      <aff id="af1">
       <label>
        1
       </label>
       <addr-line>
        LEPAE, Department of Chemical Engineering, Faculty of Engineering
       </addr-line>
       ,
       <institution>
        University of Porto
       </institution>
       ,
       <addr-line>
        Rua Dr. Roberto Frias, s/n, 4200-465 Porto
       </addr-line>
       ,
       <country>
        Portugal
       </country>
      </aff>
      <aff id="af2">
       <label>
        2
       </label>
       <addr-line>
        Faculty of Engineering
       </addr-line>
       ,
       <institution>
        University of Porto
       </institution>
       ,
       <addr-line>
        Rua Dr. Roberto Frias, s/n, 4200-465 Porto
       </addr-line>
       ,
       <country>
        Portugal
       </country>
      </aff>
      <author-notes>
       <corresp id="cor1">
        <label>
         *
        </label>
        Corresponding author. Tel: +
        <phone>
         351225081654
        </phone>
        ; Fax: +
        <fax>
         351225081449
        </fax>
        ; E-mail:
        <email>
         mvs@fe.up.pt
        </email>
       </corresp>
      </author-notes>
      <pub-date pub-type="ppub">
       <month>
        12
       </month>
       <year>
        2013
       </year>
      </pub-date>
      <pub-date iso-8601-date="2013-07-18" pub-type="epub">
       <day>
        18
       </day>
       <month>
        7
       </month>
       <year>
        2013
       </year>
      </pub-date>
      <volume>
       68
      </volume>
      <issue>
       12
      </issue>
      <fpage>
       2718
      </fpage>
      <lpage>
       2732
      </lpage>
      <permissions>
       <copyright-statement>
        © The Author 2013. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com
       </copyright-statement>
       <copyright-year>
        2013
       </copyright-year>
       <license>
        <license-p>
         This article is made available via the PMC Open Access Subset for unrestricted re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the COVID-19 pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections.
        </license-p>
       </license>
      </permissions>
      <self-uri xlink:href="dkt281.pdf">
      </self-uri>
      <abstract>
       <title>
        Abstract
       </title>
       <p>
        A significant number of hospital-acquired infections occur due to inefficient disinfection of hospital surfaces, instruments and rooms. The emergence and wide spread of multiresistant forms of several microorganisms has led to a situation where few compounds are able to inhibit or kill the infectious agents. Several strategies to disinfect both clinical equipment and the environment are available, often involving the use of antimicrobial chemicals. More recently, investigations into gas plasma, antimicrobial surfaces and vapour systems have gained interest as promising alternatives to conventional disinfectants. This review provides updated information on the current and emergent disinfection strategies for clinical environments.
       </p>
      </abstract>
      <kwd-group>
       <kwd>
        antimicrobial resistance
       </kwd>
       <kwd>
        cross-contamination
       </kwd>
       <kwd>
        disinfection
       </kwd>
       <kwd>
        hospital-acquired infections
       </kwd>
      </kwd-group>
     </article-meta>
    </front>
    <sec id="s1" sec-type="intro">
     <title>
      Introduction
     </title>
     <p>
      The number of hospital-acquired infections (HAIs) has been growing exponentially worldwide since 1980, especially due to the emergence and wide spread of multidrug-resistant (MDR) bacteria. Multidrug resistance is an intrinsic and inevitable aspect of microbial survival and has been a major problem in the treatment of bacterial infections.
      <sup>
       <xref ref-type="bibr" rid="DKT281C1">
        1–4
       </xref>
      </sup>
      The evolution of bacterial resistance is a consequence of the indiscriminate use of antibiotics and of the transmission of resistance within and between individuals.
      <sup>
       <xref ref-type="bibr" rid="DKT281C5">
        5–8
       </xref>
      </sup>
      Also, the lack of new clinically relevant classes of antibiotics constitutes a major threat to public health.
     </p>
     <p>
      HAIs are among the major causes of death and increased morbidity among hospitalized patients, with a minimum of 175 000 deaths every year in industrialized countries.
      <sup>
       <xref ref-type="bibr" rid="DKT281C9">
        9–12
       </xref>
      </sup>
      Several investigations showed that &gt;60% of worldwide HAIs have been linked to the attachment of different pathogens to medical implants and devices, such as venous and urinary catheters, arthroprostheses, fracture-fixation devices and heart valves.
      <sup>
       <xref ref-type="bibr" rid="DKT281C13">
        13–18
       </xref>
      </sup>
      As a direct consequence, the replacement of implants, which entails significant costs and suffering for patients, often remains the only efficient therapy.
      <sup>
       <xref ref-type="bibr" rid="DKT281C19">
        19
       </xref>
      </sup>
      Additionally, it has been demonstrated that the increased incidence of HAIs is related to cross-infections from patient to patient or hospital staff to patient and to the presence of pathogenic microorganisms that are selected and maintained within the hospital environment (including equipment).
      <sup>
       <xref ref-type="bibr" rid="DKT281C1">
        1
       </xref>
       ,
       <xref ref-type="bibr" rid="DKT281C11">
        11
       </xref>
       ,
       <xref ref-type="bibr" rid="DKT281C20">
        20–23
       </xref>
      </sup>
      Poor infection control practices may facilitate patient-to-patient transmission of pathogens; for instance, in the accommodation of multiple patients in the same room. However, failure of the immune system due to illness and/or the use of immunosupressors and other therapeutic drugs can increase the patient's susceptibility to infections. Moreover, the use of antibiotics can inadvertently select antibiotic-resistant microorganisms.
      <sup>
       <xref ref-type="bibr" rid="DKT281C21">
        21
       </xref>
      </sup>
     </p>
     <p>
      Since the environment serves as an important reservoir for infectious organisms, the control of hospital infections is a matter of great concern and a major challenge. The introduction of optimized disinfection products and processes is critical to control and prevent the spread of nosocomial infections, cross-resistance and persister cells.
      <sup>
       <xref ref-type="bibr" rid="DKT281C24">
        24
       </xref>
      </sup>
      Within recent decades, requirements regarding the antimicrobial activity of disinfectants in the medical field have been defined in various European standards.
      <sup>
       <xref ref-type="bibr" rid="DKT281C25">
        25
       </xref>
      </sup>
      Also, guidelines have been developed by the CDC, which recommend hospitals to thoroughly clean and disinfect environmental and medical equipment surfaces on a regular basis.
      <sup>
       <xref ref-type="bibr" rid="DKT281C26">
        26
       </xref>
      </sup>
      However, there is a variety of products available on the market with moderate or even insufficient antimicrobial action.
      <sup>
       <xref ref-type="bibr" rid="DKT281C25">
        25
       </xref>
      </sup>
      New products and technologies with ‘permanent’ antimicrobial activity without the risk of generating resistant microorganisms are needed.
      <sup>
       <xref ref-type="bibr" rid="DKT281C12">
        12
       </xref>
      </sup>
      Hence, this manuscript provides information on the main pathogens causing HAI and the relevant in-use and emergent strategies for their control.
     </p>
    </sec>
    <sec id="s2">
     <title>
      Main hospital pathogens
     </title>
     <p>
      The increase in HAI is associated with the higher capacity of bacteria to resist and adapt to harsh environmental conditions, including the presence of antimicrobial agents. Deadly pathogens can survive for long periods of time on hospital surfaces, making the environment a continuous reservoir of infectious agents. The adhesion of pathogens to a surface followed by biofilm formation in &lt;24 h is a critical microbiological problem for healthcare services.
      <sup>
       <xref ref-type="bibr" rid="DKT281C10">
        10
       </xref>
      </sup>
      In fact, the concentration of disinfectants required to kill sessile bacteria may be 1000-fold higher than that required to kill planktonic bacteria of the same strain. Thus, antimicrobial therapies fail to kill biofilms most of the time.
      <sup>
       <xref ref-type="bibr" rid="DKT281C27">
        27–30
       </xref>
      </sup>
      Furthermore, there are few prevention techniques to control biofilm formation without causing side effects.
      <sup>
       <xref ref-type="bibr" rid="DKT281C31">
        31
       </xref>
      </sup>
     </p>
     <p>
      Some of the most important pathogens involved in HAIs include methicillin-resistant
      <italic>
       Staphylococcus aureus
      </italic>
      (MRSA),
      <italic>
       Clostridium difficile
      </italic>
      ,
      <italic>
       Pseudomonas aeruginosa
      </italic>
      , vancomycin-resistant
      <italic>
       Enterococcus
      </italic>
      spp. (VRE),
      <italic>
       Acinetobacter baumannii
      </italic>
      and some Enterobacteriaceae strains
      <italic>
       .
      </italic>
      <sup>
       <xref ref-type="bibr" rid="DKT281C1">
        1
       </xref>
       ,
       <xref ref-type="bibr" rid="DKT281C21">
        21
       </xref>
       ,
       <xref ref-type="bibr" rid="DKT281C32">
        32
       </xref>
       ,
       <xref ref-type="bibr" rid="DKT281C33">
        33
       </xref>
      </sup>
      To a lesser extent, pathogens such as
      <italic>
       Candida
      </italic>
      species, viruses [adenoviruses, noroviruses, rotaviruses, influenza, parainfluenza, hepatitis B viruses and severe acute respiratory syndrome (SARS)-associated coronaviruses] can also survive on surfaces and medical equipment, although there is little evidence of possible survival.
      <sup>
       <xref ref-type="bibr" rid="DKT281C2">
        2
       </xref>
       ,
       <xref ref-type="bibr" rid="DKT281C32">
        32–34
       </xref>
      </sup>
      Most of these pathogens can survive for months on surfaces.
      <sup>
       <xref ref-type="bibr" rid="DKT281C32">
        32
       </xref>
       ,
       <xref ref-type="bibr" rid="DKT281C35">
        35
       </xref>
      </sup>
      Some examples of the most persistent hospital pathogens are summarized in Table
      <xref ref-type="table" rid="DKT281TB1">
       1
      </xref>
      along with some of their characteristics. Some investigations have proposed that Gram-negative bacteria persist longer than Gram-positive bacteria and, although it has been suggested that the type of surface does not influence the period of persistence, it has also been shown that longer persistence may occur on plastic or even on steel.
      <sup>
       <xref ref-type="bibr" rid="DKT281C32">
        32
       </xref>
       ,
       <xref ref-type="bibr" rid="DKT281C36">
        36
       </xref>
      </sup>
      In terms of environmental conditions, lower temperatures (4–6°C) and high humidity (&gt;70%) improved the persistence of several bacteria, fungi and viruses.
      <sup>
       <xref ref-type="bibr" rid="DKT281C32">
        32
       </xref>
      </sup>
      Moreover, the frequency of contamination has been shown to vary depending on the body sites at which patients are colonized or infected. It was demonstrated that 36% of surfaces sampled in the rooms of patients with MRSA in a wound or urine were contaminated, compared with 6% of surfaces in the rooms of patients infected with MRSA at other body sites.
      <sup>
       <xref ref-type="bibr" rid="DKT281C37">
        37
       </xref>
      </sup>
     </p>
     <table-wrap id="DKT281TB1" orientation="portrait" position="float">
      <label>
       Table 1.
      </label>
      <caption>
       <p>
        Examples of clinically relevant nosocomial pathogens
       </p>
      </caption>
      <table frame="hsides" rules="groups">
       <colgroup span="1">
        <col align="left" span="1"/>
        <col align="left" span="1"/>
        <col align="left" span="1"/>
        <col align="left" span="1"/>
       </colgroup>
       <thead>
        <tr>
         <th align="left" colspan="1" rowspan="1">
          Microorganisms
         </th>
         <th align="center" colspan="1" rowspan="1">
          Mode of transmission
         </th>
         <th align="center" colspan="1" rowspan="1">
          Length of survival
         </th>
         <th align="center" colspan="1" rowspan="1">
          Disease/symptoms
         </th>
        </tr>
       </thead>
       <tbody>
        <tr>
         <td colspan="4" rowspan="1">
          Bacteria
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          <italic>
           Acinetobacter baumannii
          </italic>
         </td>
         <td colspan="1" rowspan="1">
          extensive environmental contamination
          <sup>
           <xref ref-type="bibr" rid="DKT281C33">
            33
           </xref>
          </sup>
         </td>
         <td colspan="1" rowspan="1">
          33 days on plastic laminate surface;
          <sup>
           <xref ref-type="bibr" rid="DKT281C33">
            33
           </xref>
          </sup>
          3 days to 5 months on dry inanimate surfaces
          <sup>
           <xref ref-type="bibr" rid="DKT281C32">
            32
           </xref>
          </sup>
         </td>
         <td colspan="1" rowspan="1">
          pneumonia and bloodstream infection
          <sup>
           <xref ref-type="bibr" rid="DKT281C33">
            33
           </xref>
          </sup>
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          <italic>
           Bordetella pertussis
          </italic>
         </td>
         <td colspan="1" rowspan="1">
          airborne droplet infection (person-to-person transmission)
          <sup>
           <xref ref-type="bibr" rid="DKT281C109">
            109
           </xref>
          </sup>
         </td>
         <td colspan="1" rowspan="1">
          3–5 days on dry inanimate surfaces
          <sup>
           <xref ref-type="bibr" rid="DKT281C32">
            32
           </xref>
          </sup>
         </td>
         <td colspan="1" rowspan="1">
          mild whooping cough syndrome
          <sup>
           <xref ref-type="bibr" rid="DKT281C110">
            110
           </xref>
          </sup>
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          <italic>
           Clostridium difficile
          </italic>
         </td>
         <td colspan="1" rowspan="1">
          extensive environmental contamination
          <sup>
           <xref ref-type="bibr" rid="DKT281C33">
            33
           </xref>
          </sup>
         </td>
         <td colspan="1" rowspan="1">
          5 months on dry inanimate surfaces and hospital floors
          <sup>
           <xref ref-type="bibr" rid="DKT281C32">
            32
           </xref>
           ,
           <xref ref-type="bibr" rid="DKT281C33">
            33
           </xref>
          </sup>
         </td>
         <td colspan="1" rowspan="1">
          diarrhoea and colitis
          <sup>
           <xref ref-type="bibr" rid="DKT281C111">
            111
           </xref>
          </sup>
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          <italic>
           Chlamydia pneumoniae
          </italic>
         </td>
         <td colspan="1" rowspan="1">
          transmission from asymptomatic carriers
          <sup>
           <xref ref-type="bibr" rid="DKT281C112">
            112
           </xref>
          </sup>
         </td>
         <td colspan="1" rowspan="1">
          ≤30 h on dry inanimate surfaces
          <sup>
           <xref ref-type="bibr" rid="DKT281C32">
            32
           </xref>
          </sup>
         </td>
         <td colspan="1" rowspan="1">
          acute respiratory disease, bronchitis, sinusitis, pneumonia, otitis media and chronic obstructive pulmonary disease, asthma, reactive airway disease, Reiter's syndrome and sarcoidosis
          <sup>
           <xref ref-type="bibr" rid="DKT281C113">
            113
           </xref>
          </sup>
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          <italic>
           Corynebacterium diphtheriae
          </italic>
         </td>
         <td colspan="1" rowspan="1">
          mainly by infected droplet spread through contact with an infected person
          <sup>
           <xref ref-type="bibr" rid="DKT281C114">
            114
           </xref>
          </sup>
         </td>
         <td colspan="1" rowspan="1">
          7 days to 6 months on dry inanimate surfaces
          <sup>
           <xref ref-type="bibr" rid="DKT281C32">
            32
           </xref>
          </sup>
         </td>
         <td colspan="1" rowspan="1">
          diphtheria
          <sup>
           <xref ref-type="bibr" rid="DKT281C115">
            115
           </xref>
          </sup>
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          <italic>
           Escherichia coli
          </italic>
         </td>
         <td colspan="1" rowspan="1">
          ingestion of contaminated food, water or milk; person-to-person transmission
          <sup>
           <xref ref-type="bibr" rid="DKT281C21">
            21
           </xref>
          </sup>
         </td>
         <td colspan="1" rowspan="1">
          1.5 h to 16 months on dry inanimate surfaces
          <sup>
           <xref ref-type="bibr" rid="DKT281C32">
            32
           </xref>
          </sup>
         </td>
         <td colspan="1" rowspan="1">
          blood and urinary tract infection
          <sup>
           <xref ref-type="bibr" rid="DKT281C30">
            30
           </xref>
          </sup>
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          <italic>
           Enterococcus
          </italic>
          spp., including VRE
         </td>
         <td colspan="1" rowspan="1">
          nosocomial and person-to-person transmission; also by transmission on food products
          <sup>
           <xref ref-type="bibr" rid="DKT281C116">
            116
           </xref>
          </sup>
         </td>
         <td colspan="1" rowspan="1">
          5 days to 4 months on dry inanimate surfaces;
          <sup>
           <xref ref-type="bibr" rid="DKT281C32">
            32
           </xref>
          </sup>
          ≤58 days on counter tops
          <sup>
           <xref ref-type="bibr" rid="DKT281C33">
            33
           </xref>
          </sup>
         </td>
         <td colspan="1" rowspan="1">
          blood, skin and respiratory tract infection
          <sup>
           <xref ref-type="bibr" rid="DKT281C30">
            30
           </xref>
          </sup>
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          <italic>
           Haemophilus influenzae
          </italic>
         </td>
         <td colspan="1" rowspan="1">
          person-to-person transmission through contact with discharges or droplets from the nose or throat of an infected person
          <sup>
           <xref ref-type="bibr" rid="DKT281C21">
            21
           </xref>
          </sup>
         </td>
         <td colspan="1" rowspan="1">
          12 days on dry inanimate surfaces
          <sup>
           <xref ref-type="bibr" rid="DKT281C32">
            32
           </xref>
          </sup>
         </td>
         <td colspan="1" rowspan="1">
          acute and chronic respiratory tract infections, meningitis
          <sup>
           <xref ref-type="bibr" rid="DKT281C117">
            117
           </xref>
          </sup>
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          <italic>
           Klebsiella pneumoniae
          </italic>
         </td>
         <td colspan="1" rowspan="1">
          contact with contaminated surfaces and objects, medical equipment and blood products
          <sup>
           <xref ref-type="bibr" rid="DKT281C118">
            118
           </xref>
          </sup>
         </td>
         <td colspan="1" rowspan="1">
          2 h to &gt;30 months on dry inanimate surfaces
          <sup>
           <xref ref-type="bibr" rid="DKT281C32">
            32
           </xref>
          </sup>
         </td>
         <td colspan="1" rowspan="1">
          urinary tract infections, pneumonia, septicaemias and soft tissue infections
          <sup>
           <xref ref-type="bibr" rid="DKT281C118">
            118
           </xref>
          </sup>
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          <italic>
           Mycobacterium tuberculosis
          </italic>
         </td>
         <td colspan="1" rowspan="1">
          sputum droplets (exhaled through a cough or sneeze) of a person with active disease
          <sup>
           <xref ref-type="bibr" rid="DKT281C21">
            21
           </xref>
          </sup>
         </td>
         <td colspan="1" rowspan="1">
          1 day to 4 months on dry inanimate surfaces
          <sup>
           <xref ref-type="bibr" rid="DKT281C32">
            32
           </xref>
          </sup>
         </td>
         <td colspan="1" rowspan="1">
          lung infection
          <sup>
           <xref ref-type="bibr" rid="DKT281C30">
            30
           </xref>
          </sup>
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          <italic>
           Pseudomonas aeruginosa
          </italic>
         </td>
         <td colspan="1" rowspan="1">
          contamination from tap water and different medical devices
          <sup>
           <xref ref-type="bibr" rid="DKT281C119">
            119
           </xref>
          </sup>
         </td>
         <td colspan="1" rowspan="1">
          6 h to 16 months on dry inanimate surface; 5 weeks on dry floor;
          <sup>
           <xref ref-type="bibr" rid="DKT281C32">
            32
           </xref>
          </sup>
          7 h on glass slides
          <sup>
           <xref ref-type="bibr" rid="DKT281C33">
            33
           </xref>
          </sup>
         </td>
         <td colspan="1" rowspan="1">
          lung and urinary tract infection
          <sup>
           <xref ref-type="bibr" rid="DKT281C30">
            30
           </xref>
          </sup>
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          <italic>
           Serratia marcescens
          </italic>
         </td>
         <td colspan="1" rowspan="1">
          direct hand-to-hand transmission; with contaminated invasive medical devices, work surfaces, intravenous and topical solutions
          <sup>
           <xref ref-type="bibr" rid="DKT281C120">
            120
           </xref>
          </sup>
         </td>
         <td colspan="1" rowspan="1">
          3 days—2 months on dry inanimate surfaces; 5 weeks on dry floor
          <sup>
           <xref ref-type="bibr" rid="DKT281C32">
            32
           </xref>
          </sup>
         </td>
         <td colspan="1" rowspan="1">
          urinary tract infections and pneumonia
          <sup>
           <xref ref-type="bibr" rid="DKT281C121">
            121
           </xref>
          </sup>
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          <italic>
           Staphylococcus aureus
          </italic>
          , including MRSA
         </td>
         <td colspan="1" rowspan="1">
          contact with the organism in a purulent lesion or on the hands; burn units extensively contaminated
          <sup>
           <xref ref-type="bibr" rid="DKT281C21">
            21
           </xref>
           ,
           <xref ref-type="bibr" rid="DKT281C33">
            33
           </xref>
          </sup>
         </td>
         <td colspan="1" rowspan="1">
          <italic>
           S. aureus
          </italic>
          can remain virulent for 10 days on dry surfaces;
          <sup>
           <xref ref-type="bibr" rid="DKT281C122">
            122
           </xref>
          </sup>
          MRSA can survive for 7 days to 9 weeks on dry inanimate surfaces and 2 days on plastic laminate surfaces
          <sup>
           <xref ref-type="bibr" rid="DKT281C32">
            32
           </xref>
           ,
           <xref ref-type="bibr" rid="DKT281C33">
            33
           </xref>
          </sup>
         </td>
         <td colspan="1" rowspan="1">
          blood, skin and respiratory tract infection, septicaemia and death
          <sup>
           <xref ref-type="bibr" rid="DKT281C23">
            23
           </xref>
          </sup>
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          <italic>
           Streptococcus pneumoniae
          </italic>
         </td>
         <td colspan="1" rowspan="1">
          person to person through close contact via respiratory droplets; illness among casual contacts and attendants is infrequent
          <sup>
           <xref ref-type="bibr" rid="DKT281C123">
            123
           </xref>
          </sup>
         </td>
         <td colspan="1" rowspan="1">
          1–20 days on dry inanimate surfaces
          <sup>
           <xref ref-type="bibr" rid="DKT281C32">
            32
           </xref>
          </sup>
         </td>
         <td colspan="1" rowspan="1">
          blood, lung and ear infections
          <sup>
           <xref ref-type="bibr" rid="DKT281C30">
            30
           </xref>
          </sup>
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          <italic>
           Streptococcus pyogenes
          </italic>
         </td>
         <td colspan="1" rowspan="1">
          respiratory droplets and skin contact with impetigo lesions
          <sup>
           <xref ref-type="bibr" rid="DKT281C124">
            124
           </xref>
          </sup>
         </td>
         <td colspan="1" rowspan="1">
          3 days to 6.5 months on dry inanimate surfaces
          <sup>
           <xref ref-type="bibr" rid="DKT281C32">
            32
           </xref>
          </sup>
         </td>
         <td colspan="1" rowspan="1">
          rheumatic fever, sepsis, severe soft-tissue invasion and toxic-shock-like syndrome (TSLS)
          <sup>
           <xref ref-type="bibr" rid="DKT281C125">
            125
           </xref>
          </sup>
         </td>
        </tr>
        <tr>
         <td colspan="4" rowspan="1">
          Fungi
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          <italic>
           Candida
          </italic>
          spp.
         </td>
         <td colspan="1" rowspan="1">
          via contaminated medical devices;
          <sup>
           <xref ref-type="bibr" rid="DKT281C126">
            126
           </xref>
          </sup>
          contact with secretions or excretions from infected persons
          <sup>
           <xref ref-type="bibr" rid="DKT281C21">
            21
           </xref>
          </sup>
         </td>
         <td colspan="1" rowspan="1">
          1–120 days on dry inanimate surfaces
          <sup>
           <xref ref-type="bibr" rid="DKT281C32">
            32
           </xref>
          </sup>
         </td>
         <td colspan="1" rowspan="1">
          infections of the gastrointestinal tract, vagina and oral cavity
          <sup>
           <xref ref-type="bibr" rid="DKT281C21">
            21
           </xref>
          </sup>
         </td>
        </tr>
        <tr>
         <td colspan="4" rowspan="1">
          Viruses
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          <italic>
          </italic>
          HBV
         </td>
         <td colspan="1" rowspan="1">
          percutaneous or permucosal exposure to blood or secretions via abrasions, sharing needles/syringes, sexual contact
          <sup>
           <xref ref-type="bibr" rid="DKT281C127">
            127
           </xref>
          </sup>
         </td>
         <td colspan="1" rowspan="1">
          &gt; 1 week on dry inanimate surfaces
          <sup>
           <xref ref-type="bibr" rid="DKT281C32">
            32
           </xref>
          </sup>
         </td>
         <td colspan="1" rowspan="1">
          nausea, vomiting, jaundice; chronic infection leads to hepatocellular carcinoma and cirrhosis
          <sup>
           <xref ref-type="bibr" rid="DKT281C21">
            21
           </xref>
          </sup>
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          <italic>
          </italic>
          influenza virus
         </td>
         <td colspan="1" rowspan="1">
          respiratory droplet or direct contact;
          <sup>
           <xref ref-type="bibr" rid="DKT281C127">
            127
           </xref>
          </sup>
          aerosolization after sweeping; survival on fomites
          <sup>
           <xref ref-type="bibr" rid="DKT281C33">
            33
           </xref>
          </sup>
         </td>
         <td colspan="1" rowspan="1">
          24–48 h on non-porous surfaces
          <sup>
           <xref ref-type="bibr" rid="DKT281C33">
            33
           </xref>
          </sup>
         </td>
         <td colspan="1" rowspan="1">
          influenza
          <sup>
           <xref ref-type="bibr" rid="DKT281C21">
            21
           </xref>
          </sup>
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          <italic>
          </italic>
          SARS-associated coronavirus
         </td>
         <td colspan="1" rowspan="1">
          spread person to person via infected droplets
          <sup>
           <xref ref-type="bibr" rid="DKT281C21">
            21
           </xref>
          </sup>
         </td>
         <td colspan="1" rowspan="1">
          24–72 h on fomites and in stool samples;
          <sup>
           <xref ref-type="bibr" rid="DKT281C33">
            33
           </xref>
          </sup>
          72–96 h on dry inanimate surfaces
          <sup>
           <xref ref-type="bibr" rid="DKT281C32">
            32
           </xref>
          </sup>
         </td>
         <td colspan="1" rowspan="1">
          respiratory infection and pneumonia
          <sup>
           <xref ref-type="bibr" rid="DKT281C21">
            21
           </xref>
          </sup>
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          <italic>
          </italic>
          norovirus
         </td>
         <td colspan="1" rowspan="1">
          faecal contaminated vehicle (food or water); person-to-person transmission
          <sup>
           <xref ref-type="bibr" rid="DKT281C128">
            128
           </xref>
          </sup>
         </td>
         <td colspan="1" rowspan="1">
          8 h to 7 days on dry inanimate surfaces
          <sup>
           <xref ref-type="bibr" rid="DKT281C32">
            32
           </xref>
          </sup>
         </td>
         <td colspan="1" rowspan="1">
          abdominal pain, nausea, vomiting, headache and chills
          <sup>
           <xref ref-type="bibr" rid="DKT281C128">
            128
           </xref>
          </sup>
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          <italic>
          </italic>
          rotavirus
         </td>
         <td colspan="1" rowspan="1">
          primarily faecal–oral transmission; faecal–respiratory transmission can also occur
          <sup>
           <xref ref-type="bibr" rid="DKT281C21">
            21
           </xref>
          </sup>
         </td>
         <td colspan="1" rowspan="1">
          6–60 weeks on dry inanimate surfaces
          <sup>
           <xref ref-type="bibr" rid="DKT281C32">
            32
           </xref>
          </sup>
         </td>
         <td colspan="1" rowspan="1">
          enteritis: diarrhoea, vomiting, dehydration and low-grade fever
          <sup>
           <xref ref-type="bibr" rid="DKT281C21">
            21
           </xref>
          </sup>
         </td>
        </tr>
       </tbody>
      </table>
     </table-wrap>
    </sec>
    <sec id="s3">
     <title>
      Influence of clinical environment on HAI propagation
     </title>
     <p>
      Pathogens can spread from patient to patient through contact with inanimate surfaces, including medical equipment and the immediate patient environment.
      <sup>
       <xref ref-type="bibr" rid="DKT281C38">
        38
       </xref>
      </sup>
      There is clinical evidence suggesting an association between poor environmental hygiene and the transmission of microorganisms causing HAIs.
      <sup>
       <xref ref-type="bibr" rid="DKT281C39">
        39
       </xref>
      </sup>
      Cheng
      <italic>
       et al
      </italic>
      .
      <sup>
       <xref ref-type="bibr" rid="DKT281C40">
        40
       </xref>
      </sup>
      found a strong correlation between environmental contamination by MRSA and hospital infection rates. Drees
      <italic>
       et al
      </italic>
      .
      <sup>
       <xref ref-type="bibr" rid="DKT281C41">
        41
       </xref>
      </sup>
      demonstrated an increase in VRE infection risk for an occupant of a room where a patient with this infection was previously treated. It was also demonstrated that nosocomial transmission of norovirus,
      <italic>
       C. difficile
      </italic>
      and
      <italic>
       Acinetobacter
      </italic>
      spp. was correlated with contaminated environmental surfaces.
      <sup>
       <xref ref-type="bibr" rid="DKT281C15">
        15
       </xref>
      </sup>
      In another study, a positive and measurable effect on the clinical environment was demonstrated with the introduction of one extra cleaner, which apparently protected the patients against MRSA infection.
      <sup>
       <xref ref-type="bibr" rid="DKT281C42">
        42
       </xref>
      </sup>
      The potential for contaminated environmental surfaces to contribute to pathogen transmission depends on two important factors: the pathogens must survive on dry surfaces and the contamination has to occur on surfaces commonly touched by patients and healthcare staff at a sufficiently high level to enable transmission to patients.
      <sup>
       <xref ref-type="bibr" rid="DKT281C35">
        35
       </xref>
      </sup>
      Moreover, pathogen transmission will also depend on the infectious dose and route of transmission, along with host susceptibility.
     </p>
     <p>
      Shared clinical equipment that comes into contact with intact skin, despite being unlikely to introduce infection, can also promote the transfer of microorganisms between patients.
      <sup>
       <xref ref-type="bibr" rid="DKT281C43">
        43
       </xref>
      </sup>
      The most frequently contaminated surfaces are floors, doorknobs, television remote control devices, bed-frame lockers, mattresses, bedside tables and toilet seats in rooms previously occupied by an infected patient.
      <sup>
       <xref ref-type="bibr" rid="DKT281C1">
        1
       </xref>
       ,
       <xref ref-type="bibr" rid="DKT281C12">
        12
       </xref>
       ,
       <xref ref-type="bibr" rid="DKT281C35">
        35
       </xref>
       ,
       <xref ref-type="bibr" rid="DKT281C44">
        44
       </xref>
      </sup>
      Wilcox
      <italic>
       et al
      </italic>
      .
      <sup>
       <xref ref-type="bibr" rid="DKT281C45">
        45
       </xref>
      </sup>
      found that ∼50% of commodes, toilet floors and bed frames sampled at a hospital were contaminated with
      <italic>
       C. difficile.
      </italic>
      Medical devices, including stethoscopes and otoscopes, are highly prone to be contaminated with bacteria and have been implicated as potential vectors of cross-transmission.
      <sup>
       <xref ref-type="bibr" rid="DKT281C46">
        46
       </xref>
      </sup>
      Moreover, bacteria were found on various plastic items in the hospital, including pagers and cell phones.
      <sup>
       <xref ref-type="bibr" rid="DKT281C47">
        47
       </xref>
      </sup>
      Cotterill
      <italic>
       et al
      </italic>
      .
      <sup>
       <xref ref-type="bibr" rid="DKT281C48">
        48
       </xref>
      </sup>
      provided suggestive evidence that contaminated ventilation grills were sources of MRSA outbreaks in hospitals. Additionally, an estimated 20%–40% of HAIs have been attributed to cross-infection via the hands of healthcare personnel, who have become contaminated from direct contact with the patient or indirectly by touching contaminated environmental surfaces.
      <sup>
       <xref ref-type="bibr" rid="DKT281C15">
        15
       </xref>
       ,
       <xref ref-type="bibr" rid="DKT281C38">
        38
       </xref>
      </sup>
      In fact, hand hygiene is a major contributing factor to the current infection threats to hospital inpatients.
      <sup>
       <xref ref-type="bibr" rid="DKT281C49">
        49
       </xref>
      </sup>
      Barker
      <italic>
       et al.
      </italic>
      <sup>
       <xref ref-type="bibr" rid="DKT281C50">
        50
       </xref>
      </sup>
      showed that norovirus is consistently transferred via the fingers to melamine surfaces and from there to other typical hand-contact surfaces, such as taps, door handles and telephone receivers. Pessoa-Silva
      <italic>
       et al
      </italic>
      .
      <sup>
       <xref ref-type="bibr" rid="DKT281C51">
        51
       </xref>
      </sup>
      demonstrated that hands become increasingly contaminated with commensal flora and potential pathogens during neonatal care and that gloves do not fully protect the workers' hands from contamination. Pittet
      <italic>
       et al.
      </italic>
      <sup>
       <xref ref-type="bibr" rid="DKT281C52">
        52
       </xref>
      </sup>
      concluded that bacterial contamination increased linearly with time on ungloved hands during patient care. This demonstrates the importance of decontaminating hands before every patient contact. Fendler
      <italic>
       et al.
      </italic>
      <sup>
       <xref ref-type="bibr" rid="DKT281C53">
        53
       </xref>
      </sup>
      concluded that the use of an alcohol gel hand sanitizer decreased infection rates during a 34 month period and can provide an additional tool for an effective infection control programme. The same conclusion was reached by Hilburn
      <italic>
       et al
      </italic>
      .
      <sup>
       <xref ref-type="bibr" rid="DKT281C54">
        54
       </xref>
      </sup>
      The gloves of medical staff are also easily infected from direct contact with an infected patient or, indirectly, by touching contaminated surfaces, which serve as a carrier for pathogenic microorganisms.
      <sup>
       <xref ref-type="bibr" rid="DKT281C11">
        11
       </xref>
      </sup>
      In a study focused on MRSA infection, 42% of personnel gloves that contacted the furniture/surfaces of a patient room but had no direct contact with infected patients were contaminated.
      <sup>
       <xref ref-type="bibr" rid="DKT281C37">
        37
       </xref>
       ,
       <xref ref-type="bibr" rid="DKT281C44">
        44
       </xref>
      </sup>
      More significantly, it was found that 65% of the nursing staff that had directly treated an infected individual contaminated their gowns/uniforms with the organism.
      <sup>
       <xref ref-type="bibr" rid="DKT281C55">
        55
       </xref>
      </sup>
      The white coats, shirts and ties of doctors have also been found to contain potentially pathogenic flora.
      <sup>
       <xref ref-type="bibr" rid="DKT281C56">
        56
       </xref>
      </sup>
     </p>
    </sec>
    <sec id="s4">
     <title>
      Disinfectant selection
     </title>
     <p>
      Maintenance of a good hospital environment requires the implementation of adequate strategies. Such strategies are described in guidelines proposed by several committees, particularly the Healthcare Infection Control Practice Advisory Committee.
      <sup>
       <xref ref-type="bibr" rid="DKT281C57">
        57
       </xref>
      </sup>
      For instance, in the case of surfaces with blood contamination, a disinfectant with activity against tuberculosis and hepatitis B virus (HBV)/HIV or a 5.25% bleach solution, at a final dilution of 1 : 10, can be used.
      <sup>
       <xref ref-type="bibr" rid="DKT281C11">
        11
       </xref>
      </sup>
      These documents describe procedures to be implemented in healthcare facilities in order to achieve efficient cleaning and disinfection and also review the main uses of disinfectants as well as their mechanism of action and activity. Rutala and Weber
      <sup>
       <xref ref-type="bibr" rid="DKT281C58">
        58
       </xref>
      </sup>
      developed a set of guidelines for hospital environment cleaning.
     </p>
     <p>
      Cleaning is related to the clearance of foreign material from a surface or equipment, allowing the removal of some organic material and microorganisms by detergents.
      <sup>
       <xref ref-type="bibr" rid="DKT281C11">
        11
       </xref>
       ,
       <xref ref-type="bibr" rid="DKT281C33">
        33
       </xref>
      </sup>
      However, this process does not kill bacteria, which, under favourable conditions, can redeposit elsewhere and form biofilms.
      <sup>
       <xref ref-type="bibr" rid="DKT281C31">
        31
       </xref>
      </sup>
      Consequently, cleaning must always precede disinfection and sterilization in order to eliminate infectious microorganisms.
      <sup>
       <xref ref-type="bibr" rid="DKT281C59">
        59
       </xref>
      </sup>
      A significant amount of microorganisms is destroyed by the disinfection process, which involves the use of chemical agents such as quaternary ammonium compounds, aldehydes, alcohols and halogens, or radiation and heat.
      <sup>
       <xref ref-type="bibr" rid="DKT281C11">
        11
       </xref>
       ,
       <xref ref-type="bibr" rid="DKT281C31">
        31
       </xref>
       ,
       <xref ref-type="bibr" rid="DKT281C33">
        33
       </xref>
       ,
       <xref ref-type="bibr" rid="DKT281C60">
        60
       </xref>
      </sup>
      The control of hospital infection must involve both disinfection and sterilization processes and sometimes the use of aerosols to clean the air.
      <sup>
       <xref ref-type="bibr" rid="DKT281C11">
        11
       </xref>
       ,
       <xref ref-type="bibr" rid="DKT281C33">
        33
       </xref>
      </sup>
     </p>
     <p>
      A biocide can target different locations on a cell as it may interact with the surface, the bacterial cell wall and the outer membrane, or it may penetrate the cell, where it can cause reversible or irreversible changes by interacting with nucleic acids, inhibiting enzymes and cell growth.
      <sup>
       <xref ref-type="bibr" rid="DKT281C24">
        24
       </xref>
       ,
       <xref ref-type="bibr" rid="DKT281C60">
        60
       </xref>
      </sup>
      When choosing a disinfectant, several factors must be taken into account, such as its efficiency, compliance with regulations, user acceptability, instrument compatibility, the types of surfaces and medical equipment, and the pathogenicity, infection rates and persistence of the microorganisms.
      <sup>
       <xref ref-type="bibr" rid="DKT281C61">
        61
       </xref>
      </sup>
      A disinfectant must be safe, easy to use and effective against a wide range of pathogenic microorganisms and should not leave toxic residues.
      <sup>
       <xref ref-type="bibr" rid="DKT281C31">
        31
       </xref>
       ,
       <xref ref-type="bibr" rid="DKT281C61">
        61
       </xref>
      </sup>
      The efficiency of the disinfectant depends on several factors, mainly surface characteristics (hydrophobicity, charge and roughness), the amount of organic and inorganic matter, temperature, pH, the chemical structure of the biocidal agent and the type of infection and pathogen.
      <sup>
       <xref ref-type="bibr" rid="DKT281C11">
        11
       </xref>
       ,
       <xref ref-type="bibr" rid="DKT281C24">
        24
       </xref>
       ,
       <xref ref-type="bibr" rid="DKT281C31">
        31
       </xref>
      </sup>
      The mode of action of the disinfectant and the route of entry into the cell (porin channels in the case of hydrophilic disinfectants and the hydrophobic path for hydrophobic disinfectants) also play significant roles.
      <sup>
       <xref ref-type="bibr" rid="DKT281C24">
        24
       </xref>
      </sup>
      The risk of infection of the room/surface/equipment must also be considered in the choice of the disinfectant, as well as its concentration and exposure time.
      <sup>
       <xref ref-type="bibr" rid="DKT281C24">
        24
       </xref>
       ,
       <xref ref-type="bibr" rid="DKT281C62">
        62
       </xref>
      </sup>
      Hospital areas should be defined according to the risk of infection in order to establish and promote proper cleaning/disinfection. Areas where contamination is expected, e.g. laboratories, operating theatres, ambulatory surgical units, labour and delivery rooms, areas with blood or body fluid spills, and neonatal and burn units, must be cleaned and disinfected frequently (often several times per day).
      <sup>
       <xref ref-type="bibr" rid="DKT281C1">
        1
       </xref>
      </sup>
      Areas of low risk, such as administration and waiting rooms, only require a daily cleaning.
     </p>
     <p>
      According to its efficiency and ability to kill bacterial spores, an antimicrobial product can belong to one of four distinct groups: sterilants or high-, intermediate- and low-level disinfectants (Table
      <xref ref-type="table" rid="DKT281TB2">
       2
      </xref>
      ). Given the increased resistance to antimicrobial agents displayed by bacteria upon biofilm formation, this hierarchy is only a rough guide.
      <sup>
       <xref ref-type="bibr" rid="DKT281C60">
        60
       </xref>
       ,
       <xref ref-type="bibr" rid="DKT281C63">
        63
       </xref>
       ,
       <xref ref-type="bibr" rid="DKT281C64">
        64
       </xref>
      </sup>
      A disinfectant is almost never 100% effective due to the resistance of some bacteria to specific compounds and due to inefficient cleaning protocols.
      <sup>
       <xref ref-type="bibr" rid="DKT281C1">
        1
       </xref>
      </sup>
      Once a disinfectant is removed, the surviving bacterial population can potentially regrow. Moreover, viable spores still attached to various materials can remain undetected by current sporicidal tests, resulting in overestimation of the sporicidal activity of sterilizing agents.
      <sup>
       <xref ref-type="bibr" rid="DKT281C65">
        65
       </xref>
      </sup>
     </p>
     <table-wrap id="DKT281TB2" orientation="portrait" position="float">
      <label>
       Table 2.
      </label>
      <caption>
       <p>
        Characterization of disinfectants according to their class
        <sup>
         <xref ref-type="bibr" rid="DKT281C11">
          11
         </xref>
         ,
         <xref ref-type="bibr" rid="DKT281C59">
          59
         </xref>
         ,
         <xref ref-type="bibr" rid="DKT281C65">
          65
         </xref>
         ,
         <xref ref-type="bibr" rid="DKT281C68">
          68
         </xref>
         ,
         <xref ref-type="bibr" rid="DKT281C83">
          83
         </xref>
        </sup>
       </p>
      </caption>
      <table frame="hsides" rules="groups">
       <colgroup span="1">
        <col align="left" span="1"/>
        <col align="left" span="1"/>
        <col align="left" span="1"/>
        <col align="left" span="1"/>
       </colgroup>
       <thead>
        <tr>
         <th align="left" colspan="1" rowspan="1">
          Disinfectant
         </th>
         <th align="center" colspan="1" rowspan="1">
          Spectrum of action
         </th>
         <th align="center" colspan="1" rowspan="1">
          Required for
         </th>
         <th align="center" colspan="1" rowspan="1">
          Examples
         </th>
        </tr>
       </thead>
       <tbody>
        <tr>
         <td colspan="1" rowspan="1">
          Sterilants
         </td>
         <td colspan="1" rowspan="1">
          all microorganisms, including bacterial spores
          <sup>
           <xref ref-type="bibr" rid="DKT281C65">
            65
           </xref>
          </sup>
         </td>
         <td colspan="1" rowspan="1">
          critical instruments that penetrate tissue or present a high risk if non-sterile (e.g. implants, needles and other surgical instruments)
         </td>
         <td colspan="1" rowspan="1">
          heat, steam, higher concentrations of hydrogen peroxide and peracetic acid, glutaraldehyde (in 6–10 h)
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          High-level disinfectants
         </td>
         <td colspan="1" rowspan="1">
          almost all microorganisms, but not spores
         </td>
         <td colspan="1" rowspan="1">
          semi-critical items that do not penetrate tissues or contact mucous membranes (except dental) (such as endoscopes, respiratory therapy equipment and diaphragms)
         </td>
         <td colspan="1" rowspan="1">
          hydrogen peroxide, glutaraldehyde, formaldehyde,
          <italic>
           ortho
          </italic>
          -phthalaldehyde, peracetic acid
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          Intermediate-level disinfectants
         </td>
         <td colspan="1" rowspan="1">
          almost all vegetative bacteria, fungi, tubercle bacilli and enveloped and lipid viruses
         </td>
         <td colspan="1" rowspan="1">
          non-critical items that touch intact skin (e.g. thermometers and hydrotherapy tanks)
         </td>
         <td colspan="1" rowspan="1">
          alcohols, hypochlorites, iodine and iodophor disinfectants
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          Low-level disinfectants
         </td>
         <td colspan="1" rowspan="1">
          not efficient for most bacteria, tubercle bacilli, spores, fungi and viruses
         </td>
         <td colspan="1" rowspan="1">
          non-critical items: items such as stethoscopes bedpans, blood pressure cuffs and bedside tables
         </td>
         <td colspan="1" rowspan="1">
          phenolics, quaternary ammonium compounds
         </td>
        </tr>
       </tbody>
      </table>
     </table-wrap>
     <p>
      The efficacy of diverse chemical disinfectants in inhibiting and killing some of the most clinically relevant bacteria, pathogenic fungi and yeasts has been evaluated by several authors. The activity of a disinfectant is generally analysed in terms of its MIC and MBC. However, the most suitable measure is the log
      <sub>
       10
      </sub>
      reduction of the number of cfu. The time taken to obtain a 5 log
      <sub>
       10
      </sub>
      reduction is also a reference to assess disinfection efficacy.
      <sup>
       <xref ref-type="bibr" rid="DKT281C61">
        61
       </xref>
      </sup>
     </p>
    </sec>
    <sec id="s5">
     <title>
      Traditional disinfection strategies
     </title>
     <p>
      The use of biocides has evolved over time. Alcohols such as ethanol have a long history of antiseptic use; around the 19th and 20th centuries phenolics and hypochlorites started to be employed and, later, quaternary ammonium compounds.
      <sup>
       <xref ref-type="bibr" rid="DKT281C66">
        66
       </xref>
      </sup>
      More recently, the most common products have been chlorhexidine and silver salts, peroxygens, glutaraldehyde and
      <italic>
       ortho
      </italic>
      -phthalaldehyde.
      <sup>
       <xref ref-type="bibr" rid="DKT281C66">
        66
       </xref>
       ,
       <xref ref-type="bibr" rid="DKT281C67">
        67
       </xref>
      </sup>
     </p>
     <p>
      Alcohol disinfectants cause protein denaturation and are effective against vegetative bacteria, fungi and viruses, but have no effect on spores.
      <sup>
       <xref ref-type="bibr" rid="DKT281C61">
        61
       </xref>
       ,
       <xref ref-type="bibr" rid="DKT281C68">
        68
       </xref>
      </sup>
      Chlorine-releasing agents can oxidize membrane proteins and are very effective in removing biofilms from surfaces, requiring short exposure times for growth inhibition.
      <sup>
       <xref ref-type="bibr" rid="DKT281C57">
        57
       </xref>
       ,
       <xref ref-type="bibr" rid="DKT281C61">
        61
       </xref>
       ,
       <xref ref-type="bibr" rid="DKT281C68">
        68
       </xref>
      </sup>
      However, these chemical agents are corrosive to metals and can be inactivated by the presence of organic matter.
      <sup>
       <xref ref-type="bibr" rid="DKT281C57">
        57
       </xref>
       ,
       <xref ref-type="bibr" rid="DKT281C61">
        61
       </xref>
       ,
       <xref ref-type="bibr" rid="DKT281C69">
        69
       </xref>
      </sup>
      Moreover, in the last few years the use of chlorine has been associated with the formation of carcinogenic compounds and some pathogens have been shown to be resistant to chlorine.
      <sup>
       <xref ref-type="bibr" rid="DKT281C70">
        70
       </xref>
      </sup>
      The aldehyde-based disinfectants disrupt proteins and nucleic acids by alkylation and have antimicrobial activity against spores, bacteria, viruses and fungi.
      <sup>
       <xref ref-type="bibr" rid="DKT281C61">
        61
       </xref>
       ,
       <xref ref-type="bibr" rid="DKT281C64">
        64
       </xref>
      </sup>
      Quaternary ammonium compounds and phenols solubilize the membrane and the cell wall.
      <sup>
       <xref ref-type="bibr" rid="DKT281C68">
        68
       </xref>
      </sup>
      Hydrogen peroxide and peracetic acid promote protein denaturation, and are active against several groups of microorganisms and pathogens implicated in nosocomial infections.
      <sup>
       <xref ref-type="bibr" rid="DKT281C38">
        38
       </xref>
       ,
       <xref ref-type="bibr" rid="DKT281C57">
        57
       </xref>
       ,
       <xref ref-type="bibr" rid="DKT281C61">
        61
       </xref>
       ,
       <xref ref-type="bibr" rid="DKT281C64">
        64
       </xref>
      </sup>
      The mechanism of action of different disinfectant categories has been presented elsewhere in greater detail.
      <sup>
       <xref ref-type="bibr" rid="DKT281C64">
        64
       </xref>
       ,
       <xref ref-type="bibr" rid="DKT281C71">
        71
       </xref>
       ,
       <xref ref-type="bibr" rid="DKT281C72">
        72
       </xref>
      </sup>
     </p>
     <p>
      Countless studies have been performed regarding the antimicrobial action and efficacy of different disinfectants. Rutala and Weber
      <sup>
       <xref ref-type="bibr" rid="DKT281C69">
        69
       </xref>
      </sup>
      reviewed the use of inorganic hypochlorite (bleach) in healthcare facilities for disinfection of medical devices and environmental surfaces, and concluded that the many advantages of chlorine (e.g. fast microbiocidal activity, cost-effectiveness and good track record) are likely to support its continued use in healthcare settings. Griffiths
      <italic>
       et al.
      </italic>
      <sup>
       <xref ref-type="bibr" rid="DKT281C73">
        73
       </xref>
      </sup>
      evaluated the efficacy of several disinfectants (sodium dichloroisocyanurate, chlorine dioxide, 70% industrial methylated spirits, 2% alkaline glutaraldehyde, 10% succinedialdehyde and formaldehyde mixture, 0.35% peracetic acid and a peroxygen compound at 1% and 3%) against different strains of mycobacteria and showed that disinfectants based on sodium dichloroisocyanurate were more effective. Moreover, they concluded that clinical strains were more resistant to biocides than laboratory type strains.
      <sup>
       <xref ref-type="bibr" rid="DKT281C73">
        73
       </xref>
      </sup>
      Other studies have shown that chlorhexidine at 0.5% concentration is the best choice, among several antiseptics and surface disinfectants (including betadine, hydrogen peroxide, sodium hypochlorite, alcohol and ultraviolet radiation), to kill clinical yeast isolates, either in planktonic cultures or in biofilm.
      <sup>
       <xref ref-type="bibr" rid="DKT281C74">
        74
       </xref>
      </sup>
      Oie
      <italic>
       et al
      </italic>
      .
      <sup>
       <xref ref-type="bibr" rid="DKT281C75">
        75
       </xref>
      </sup>
      analysed the effects of four different chemical treatments (0.2% alkyldiaminoethyl glycine, 0.01% or 0.1% sodium hypochlorite and 80% ethyl alcohol) on the disinfection of porous and smooth surfaces contaminated by
      <italic>
       S. aureus
      </italic>
      in a university hospital. The results demonstrated that the disinfection of porous surfaces was more difficult and none of the disinfectants was effective, highlighting the need for more frequent disinfection and the use of high-level disinfectants on these surfaces.
      <sup>
       <xref ref-type="bibr" rid="DKT281C75">
        75
       </xref>
      </sup>
      More recently, Speight
      <italic>
       et al.
      </italic>
      <sup>
       <xref ref-type="bibr" rid="DKT281C76">
        76
       </xref>
      </sup>
      evaluated the effect of 32 disinfectants on spores of
      <italic>
       C. difﬁcile
      </italic>
      by a suspension test and only eight products gave &gt;3 log
      <sub>
       10
      </sub>
      reduction in viability within 1 min (to have a more realistic simulation of probable real-life exposures) under dirty conditions (3% BSA). These results underscore the importance of carefully selecting the disinfectant to eliminate spores of this particular microorganism.
      <sup>
       <xref ref-type="bibr" rid="DKT281C76">
        76
       </xref>
      </sup>
      Kim
      <italic>
       et al
      </italic>
      .
      <sup>
       <xref ref-type="bibr" rid="DKT281C77">
        77
       </xref>
      </sup>
      analysed the effectiveness of 13 disinfectants used in hospitals, day-care centres and food service kitchens (ZEP FS Amine Z, ZEP DZ-7, Lemonex, ZEP Micronex, T.B.Q., ZEP FS Formula 386 L, Perosan Liquid Sanitizer, LpH se, Vesphene IIse, Coverage Spray HB Plus, Coverage Spray TB, ZEP Kitchen Surface Sanitizer and ZEP FS RTU-D2) against
      <italic>
       Enterobacter sakazakii
      </italic>
      in suspension, dried on stainless steel and in biofilm, and concluded that not all biocides used in hospitals can kill this microorganism. Also, the efficacy of disinfectants was higher for planktonic cells (reduction to undetectable levels).
      <sup>
       <xref ref-type="bibr" rid="DKT281C77">
        77
       </xref>
      </sup>
      Bridier
      <italic>
       et al
      </italic>
      .
      <sup>
       <xref ref-type="bibr" rid="DKT281C78">
        78
       </xref>
      </sup>
      studied the effects of three common disinfectants (peracetic acid, benzalkonium chloride and
      <italic>
       ortho
      </italic>
      -phthalaldehyde) on 77 bacterial strains and found that mycobacteria demonstrated a marked resistance to all the biocides. Benzalkonium chloride was inefficient even at very high concentrations. Also, resistance was dependent on the strain within the same species.
      <sup>
       <xref ref-type="bibr" rid="DKT281C78">
        78
       </xref>
      </sup>
      Gutiérrez-Martín
      <italic>
       et al
      </italic>
      .
      <sup>
       <xref ref-type="bibr" rid="DKT281C79">
        79
       </xref>
      </sup>
      analysed the activity of 16 active compounds and 11 commercial disinfectants against
      <italic>
       Campylobacter jejuni
      </italic>
      by performing a suspension test in the presence and absence of serum. High levels of reduction (&gt;6 log
      <sub>
       10
      </sub>
      ) for some disinfectants [chloramine-T, povidone iodine (1% available iodine), cetylpiridinium chloride, ethanol, isopropanol, chlorhexidine digluconate, formaldehyde, phenol and 10 of the 11 commercial formulations, especially those based on quaternary ammonium compounds] were obtained, regardless of the presence or absence of organic material.
      <sup>
       <xref ref-type="bibr" rid="DKT281C79">
        79
       </xref>
      </sup>
      Table
      <xref ref-type="table" rid="DKT281TB3">
       3
      </xref>
      compiles some of the available information regarding hospital disinfectants.
     </p>
     <table-wrap id="DKT281TB3" orientation="portrait" position="float">
      <label>
       Table 3.
      </label>
      <caption>
       <p>
        Efficacy of several chemical agents in hospital disinfection
       </p>
      </caption>
      <table frame="hsides" rules="groups">
       <colgroup span="1">
        <col align="left" span="1"/>
        <col align="left" span="1"/>
        <col align="left" span="1"/>
        <col align="left" span="1"/>
       </colgroup>
       <thead>
        <tr>
         <th align="left" colspan="1" rowspan="1">
          Disinfectant
         </th>
         <th align="center" colspan="1" rowspan="1">
          Microorganism
         </th>
         <th align="center" colspan="1" rowspan="1">
          Method/test
         </th>
         <th align="center" colspan="1" rowspan="1">
          Efficiency
         </th>
        </tr>
       </thead>
       <tbody>
        <tr>
         <td colspan="1" rowspan="1">
          Nu-Cidex
          <sup>
           ®
          </sup>
          (0.35% peracetic acid)
         </td>
         <td colspan="1" rowspan="1">
          <italic>
           Mycobacterium
          </italic>
          (5 strains)
         </td>
         <td colspan="1" rowspan="1">
          suspension and surface test
         </td>
         <td colspan="1" rowspan="1">
          complete inactivation after 5 min of exposure
          <sup>
           <xref ref-type="bibr" rid="DKT281C129">
            129
           </xref>
          </sup>
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          Nu-Cidex
          <sup>
           ®
          </sup>
          (0.35% peracetic acid)
         </td>
         <td colspan="1" rowspan="1">
          <italic>
           Bacillus subtilis
          </italic>
          spores
         </td>
         <td colspan="1" rowspan="1">
          suspension test
         </td>
         <td colspan="1" rowspan="1">
          &gt;5 log
          <sub>
           10
          </sub>
          reduction in 5 min with 10% serum
          <sup>
           <xref ref-type="bibr" rid="DKT281C130">
            130
           </xref>
          </sup>
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          Cidex Long-Life
          <sup>
           ®
          </sup>
          (2% glutaraldehyde)
         </td>
         <td colspan="1" rowspan="1">
          <italic>
           B. subtilis
          </italic>
          spores
         </td>
         <td colspan="1" rowspan="1">
          suspension test
         </td>
         <td colspan="1" rowspan="1">
          &gt;5 log
          <sub>
           10
          </sub>
          reduction in 2 h with 4% blood
          <sup>
           <xref ref-type="bibr" rid="DKT281C130">
            130
           </xref>
          </sup>
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          Titan Sanitizer
          <sup>
           ®
          </sup>
          (sodium dichloroisocyanurate with Cl content of 2.2%)
         </td>
         <td colspan="1" rowspan="1">
          <italic>
           B. subtilis
          </italic>
          spores
         </td>
         <td colspan="1" rowspan="1">
          suspension test
         </td>
         <td colspan="1" rowspan="1">
          &gt;5 log
          <sub>
           10
          </sub>
          reduction (disinfectant at 5% in 3 h); no reduction in the presence of 2% blood
          <sup>
           <xref ref-type="bibr" rid="DKT281C130">
            130
           </xref>
          </sup>
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          Presept
          <sup>
           ®
          </sup>
          disinfectant granules (sodium dichloroisocyanurate with Cl content of around 30%)
         </td>
         <td colspan="1" rowspan="1">
          <italic>
           B. subtilis
          </italic>
          spores
         </td>
         <td colspan="1" rowspan="1">
          suspension test
         </td>
         <td colspan="1" rowspan="1">
          &gt;5 log
          <sub>
           10
          </sub>
          reduction (disinfectant at 1% in 1 h in the absence of blood and in 2 h in the presence of 2% blood)
          <sup>
           <xref ref-type="bibr" rid="DKT281C130">
            130
           </xref>
          </sup>
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          Haz-Tab
          <sup>
           ®
          </sup>
          disinfectant granules (sodium dichloroisocyanurate with Cl content of around 60%)
         </td>
         <td colspan="1" rowspan="1">
          <italic>
           B. subtilis
          </italic>
          spores
         </td>
         <td colspan="1" rowspan="1">
          suspension test
         </td>
         <td colspan="1" rowspan="1">
          &gt;5 log
          <sub>
           10
          </sub>
          reduction (disinfectant at 1% in 5 and 30 min in the presence of 2% blood)
          <sup>
           <xref ref-type="bibr" rid="DKT281C130">
            130
           </xref>
          </sup>
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          Virkon
          <sup>
           ®
          </sup>
          (peroxygen)
         </td>
         <td colspan="1" rowspan="1">
          <italic>
           B. subtilis
          </italic>
          spores
         </td>
         <td colspan="1" rowspan="1">
          suspension test
         </td>
         <td colspan="1" rowspan="1">
          5 log
          <sub>
           10
          </sub>
          reduction (disinfectant at 1% in 2–3 h in the absence of blood, but little kill in 3 h in the presence of 2% blood)
          <sup>
           <xref ref-type="bibr" rid="DKT281C130">
            130
           </xref>
          </sup>
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          Sporicidin
          <sup>
           ®
          </sup>
          (2% glutaraldehyde, 7.05% phenol, 1.2% sodium phenate)
         </td>
         <td colspan="1" rowspan="1">
          <italic>
           B. subtilis
          </italic>
          spores
         </td>
         <td colspan="1" rowspan="1">
          suspension test
         </td>
         <td colspan="1" rowspan="1">
          4 log
          <sub>
           10
          </sub>
          reduction in 10 h and 2 log
          <sub>
           10
          </sub>
          reduction in 10 h in the presence of 2% blood
          <sup>
           <xref ref-type="bibr" rid="DKT281C130">
            130
           </xref>
          </sup>
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          Sterilox
          <sup>
           ®
          </sup>
          (9 : 1 v/v) (hypochlorous acid at a concentration of 144 mg/L and free chlorine radicals)
         </td>
         <td colspan="1" rowspan="1">
          <italic>
           C. difficile
          </italic>
          spores,
          <italic>
           Helicobacter pylori
          </italic>
          , VRE,
          <italic>
           C. albicans
          </italic>
          and 4
          <italic>
           Mycobacterium
          </italic>
          species
         </td>
         <td colspan="1" rowspan="1">
          suspension test
         </td>
         <td colspan="1" rowspan="1">
          &gt;5 log
          <sub>
           10
          </sub>
          reduction in 2 min with 5% horse serum (except for
          <italic>
           C. difficile
          </italic>
          spores since the disinfectant activity diminished in the presence of organic load)
          <sup>
           <xref ref-type="bibr" rid="DKT281C131">
            131
           </xref>
          </sup>
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          10% Povidone iodine
         </td>
         <td colspan="1" rowspan="1">
          10 MRSA, 10 methicillin-susceptible
          <italic>
           S. aureus
          </italic>
          (MSSA), 9 VRE and 10 vancomycin-susceptible
          <italic>
           Enterococcus faecalis
          </italic>
         </td>
         <td colspan="1" rowspan="1">
          European surface test method
          <sup>
           <xref ref-type="bibr" rid="DKT281C132">
            132
           </xref>
          </sup>
         </td>
         <td colspan="1" rowspan="1">
          3.14, 3.49, 3.47 and 3.78 log
          <sub>
           10
          </sub>
          reduction, after 1.5 min for VRE, VSE, MRSA and MSSA, respectively
          <sup>
           <xref ref-type="bibr" rid="DKT281C133">
            133
           </xref>
          </sup>
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          Perasafe
          <sup>
           ®
          </sup>
          (peroxygen system equivalent to peracetic acid at 0.26%)
         </td>
         <td colspan="1" rowspan="1">
          <italic>
           C. difficile
          </italic>
          and
          <italic>
           Bacillus atrophaeus
          </italic>
          spores
         </td>
         <td colspan="1" rowspan="1">
          surface test on stainless steel and polyvinyl chloride floor covering
         </td>
         <td colspan="1" rowspan="1">
          5.5–6 log
          <sub>
           10
          </sub>
          reduction in 10 min
          <sup>
           <xref ref-type="bibr" rid="DKT281C134">
            134
           </xref>
          </sup>
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          Perasafe
          <sup>
           ®
          </sup>
         </td>
         <td colspan="1" rowspan="1">
          <italic>
           S. aureus
          </italic>
          ATCC 25923, MRSA, MSSA,
          <italic>
           E. faecalis
          </italic>
          ,
          <italic>
           Enterobacter cloacae
          </italic>
          ,
          <italic>
           K. pneumoniae
          </italic>
          ,
          <italic>
           P. aeruginosa
          </italic>
          ,
          <italic>
           Acinetobacter anitratus
          </italic>
          ,
          <italic>
           C. albicans
          </italic>
          ,
          <italic>
           Mycobacterium fortuitum
          </italic>
          ATCC 609 and
          <italic>
           B. subtilis
          </italic>
          (spore strips).
         </td>
         <td colspan="1" rowspan="1">
          suspension, surface, sporicidal, endoscope model test, capacity and corrosion tests
         </td>
         <td colspan="1" rowspan="1">
          complete inactivation except for
          <italic>
           Mycobacterium
          </italic>
          and spores; resistance to inactivation after repeated inoculation; did not corrode clean instruments; when organic matter was added, it cleaned without corrosion
          <sup>
           <xref ref-type="bibr" rid="DKT281C135">
            135
           </xref>
          </sup>
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          2% Glutaraldehyde
         </td>
         <td colspan="1" rowspan="1">
          <italic>
           S. aureus
          </italic>
          ATCC 25923, MRSA, MSSA,
          <italic>
           E. faecalis
          </italic>
          ,
          <italic>
           E. cloacae
          </italic>
          ,
          <italic>
           K. pneumoniae
          </italic>
          ,
          <italic>
           P. aeruginosa
          </italic>
          ,
          <italic>
           A. anitratus
          </italic>
          ,
          <italic>
           C. albicans
          </italic>
          ,
          <italic>
           M. fortuitum
          </italic>
          ATCC 609 and
          <italic>
           B. subtilis
          </italic>
          (spore strips)
         </td>
         <td colspan="1" rowspan="1">
          suspension, surface, sporicidal, endoscope model test, capacity and corrosion tests
         </td>
         <td colspan="1" rowspan="1">
          complete inactivation except for
          <italic>
           Mycobacterium
          </italic>
          and spores; resistance to inactivation after repeated inoculation; did not corrode clean instruments; when organic matter was added it fixed the matter to the scalpel, causing corrosion within 2 h
          <sup>
           <xref ref-type="bibr" rid="DKT281C135">
            135
           </xref>
          </sup>
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          Sodium dichloroisocyanurate
         </td>
         <td colspan="1" rowspan="1">
          <italic>
           C. difficile
          </italic>
          and
          <italic>
           B. atrophaeus
          </italic>
          spores
         </td>
         <td colspan="1" rowspan="1">
          surface test on stainless steel and polyvinyl chloride floor covering
         </td>
         <td colspan="1" rowspan="1">
          0.7–1.5 log
          <sub>
           10
          </sub>
          reduction in 10 min
          <sup>
           <xref ref-type="bibr" rid="DKT281C134">
            134
           </xref>
          </sup>
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          Monopercitric acid (peroxy-acid-based disinfectant)
         </td>
         <td colspan="1" rowspan="1">
          <italic>
           Clostridium
          </italic>
          spores
         </td>
         <td colspan="1" rowspan="1">
          suspension test
         </td>
         <td colspan="1" rowspan="1">
          0.5% disinfectant is sporicidal within 5 min
          <sup>
           <xref ref-type="bibr" rid="DKT281C136">
            136
           </xref>
          </sup>
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          0.2% Alkyl-diaminoethylglycine and 80% (v/v) ethyl alcohol
         </td>
         <td colspan="1" rowspan="1">
          <italic>
           S. aureus
          </italic>
          , MRSA and MSSA
         </td>
         <td colspan="1" rowspan="1">
          wiping and membrane filtration technique
         </td>
         <td colspan="1" rowspan="1">
          reduction of bacteria to an undetectable level
          <sup>
           <xref ref-type="bibr" rid="DKT281C75">
            75
           </xref>
          </sup>
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          0.01% Sodium hypochlorite and 0.1% sodium hypochlorite
         </td>
         <td colspan="1" rowspan="1">
          <italic>
           S. aureus
          </italic>
          , MRSA and MSSA
         </td>
         <td colspan="1" rowspan="1">
          wiping and membrane filtration technique
         </td>
         <td colspan="1" rowspan="1">
          reduction of bacteria to a minimal detectable level
          <sup>
           <xref ref-type="bibr" rid="DKT281C75">
            75
           </xref>
          </sup>
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          <italic>
           Ortho
          </italic>
          -phthalaldehyde
         </td>
         <td colspan="1" rowspan="1">
          <italic>
           Pseudomonas fluorescens
          </italic>
          (planktonic)
         </td>
         <td colspan="1" rowspan="1">
          respirometry; adenosine triphosphate release; outer membrane protein expression and bacterial colour changes
         </td>
         <td colspan="1" rowspan="1">
          complete inactivation (MBC 0.5 mM)
          <sup>
           <xref ref-type="bibr" rid="DKT281C137">
            137
           </xref>
          </sup>
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          <italic>
           Ortho
          </italic>
          -phthalaldehyde
         </td>
         <td colspan="1" rowspan="1">
          <italic>
           P. fluorescens
          </italic>
          (planktonic)
         </td>
         <td colspan="1" rowspan="1">
          respiratory activity, membrane permeabilization and integrity, and physico-chemical characterization
         </td>
         <td colspan="1" rowspan="1">
          MIC 1500 mg/L
          <sup>
           24
          </sup>
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          <italic>
           Ortho
          </italic>
          -phthalaldehyde
         </td>
         <td colspan="1" rowspan="1">
          <italic>
           S. aureus
          </italic>
          ,
          <italic>
           E. coli
          </italic>
          ,
          <italic>
           P. aeruginosa
          </italic>
         </td>
         <td colspan="1" rowspan="1">
          suspension and carrier tests
         </td>
         <td colspan="1" rowspan="1">
          ≥5 log reduction in viability within 1 min of exposure
          <sup>
           <xref ref-type="bibr" rid="DKT281C138">
            138
           </xref>
          </sup>
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          <italic>
           Ortho
          </italic>
          -phthalaldehyde
         </td>
         <td colspan="1" rowspan="1">
          bacteria found in 100 endoscopes
         </td>
         <td colspan="1" rowspan="1">
          surface test
         </td>
         <td colspan="1" rowspan="1">
          5 log
          <sub>
           10
          </sub>
          reduction of bacteria with an exposure time of 5 min
          <sup>
           <xref ref-type="bibr" rid="DKT281C139">
            139
           </xref>
          </sup>
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          Glutaraldehyde
         </td>
         <td colspan="1" rowspan="1">
          <italic>
           P. fluorescens
          </italic>
          (planktonic)
         </td>
         <td colspan="1" rowspan="1">
          respirometry; adenosine triphosphate release; outer membrane protein expression and bacterial colour changes
         </td>
         <td colspan="1" rowspan="1">
          no bacterial inactivation was detected
          <sup>
           <xref ref-type="bibr" rid="DKT281C137">
            137
           </xref>
          </sup>
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          Cetyltrimethyl ammonium bromide
         </td>
         <td colspan="1" rowspan="1">
          <italic>
           P. fluorescens
          </italic>
          (planktonic)
         </td>
         <td colspan="1" rowspan="1">
          respirometry; adenosine triphosphate release; outer membrane protein expression and colony colour changes
         </td>
         <td colspan="1" rowspan="1">
          complete inactivation (MBC 5 mM)
          <sup>
           <xref ref-type="bibr" rid="DKT281C137">
            137
           </xref>
          </sup>
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          Polyhexamethylene guanidine hydrochloride
         </td>
         <td colspan="1" rowspan="1">
          <italic>
           S. aureus
          </italic>
          ,
          <italic>
           P. aeruginosa
          </italic>
          ,
          <italic>
           Salmonella choleraesuis
          </italic>
          , MRSA and
          <italic>
           E. coli
          </italic>
         </td>
         <td colspan="1" rowspan="1">
          phenol coefficient (PC)
          <sup>
           a
          </sup>
          value (for
          <italic>
           S. aureus
          </italic>
          ,
          <italic>
           P. aeruginosa
          </italic>
          and
          <italic>
           S. choleraesuis
          </italic>
          ); MIC and MBC (for MRSA and
          <italic>
           E. coli
          </italic>
          )
         </td>
         <td colspan="1" rowspan="1">
          PC values for
          <italic>
           S. aureus
          </italic>
          ,
          <italic>
           S. choleraesuis
          </italic>
          and
          <italic>
           P. aeruginosa
          </italic>
          were 7.5, 6.1 and 5, respectively; the MIC value for MRSA and
          <italic>
           E. coli
          </italic>
          was 0.04% and 0.005% (w/v), respectively, in 1.5 min
          <sup>
           <xref ref-type="bibr" rid="DKT281C140">
            140
           </xref>
          </sup>
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          Allrent
          <sup>
           ®
          </sup>
          (2-propanol: 1%–5% weight; tensides 1%–5% weight; 60%–100% weight water)
         </td>
         <td colspan="1" rowspan="1">
          <italic>
           B. subtilis
          </italic>
          ,
          <italic>
           S. aureus
          </italic>
          ,
          <italic>
           C. albicans
          </italic>
         </td>
         <td colspan="1" rowspan="1">
          colony counting in agar plates and bioluminescence detection of adenosine triphosphate
         </td>
         <td colspan="1" rowspan="1">
          final residual cfu percentage of 35.7%
          <sup>
           <xref ref-type="bibr" rid="DKT281C141">
            141
           </xref>
          </sup>
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          Appeartex
          <sup>
           ®
          </sup>
          (active polymer A-200, polyhexamethylene biguanide and a surfactant solution)
         </td>
         <td colspan="1" rowspan="1">
          <italic>
           S. aureus
          </italic>
          ,
          <italic>
           Enterococcus hirae
          </italic>
         </td>
         <td colspan="1" rowspan="1">
          contact agar plates; direct agar inoculation using swabs; swab rinse technique (on a laboratory scale and in a hospital ward)
         </td>
         <td colspan="1" rowspan="1">
          reduction in magnitude of 10–10
          <sup>
           3
          </sup>
          ,
          <sup>
           <xref ref-type="bibr" rid="DKT281C142">
            142
           </xref>
          </sup>
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          Aqueous chlorine dioxide solution
         </td>
         <td colspan="1" rowspan="1">
          <italic>
           B. anthracis
          </italic>
          spores
         </td>
         <td colspan="1" rowspan="1">
          quantitative bacteriological culture methods
         </td>
         <td colspan="1" rowspan="1">
          8 log
          <sub>
           10
          </sub>
          reduction in 3 min in sealed microfuge tubes and 1 log
          <sub>
           10
          </sub>
          reduction for spraying or spreading the disinfectant onto surfaces (when using the solution in 5% bleach—0.3% sodium hypochlorite—its full activity is restored)
          <sup>
           <xref ref-type="bibr" rid="DKT281C143">
            143
           </xref>
          </sup>
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          Dismozon
          <sup>
           ®
          </sup>
          pur; Kohrsolin
          <sup>
           ®
          </sup>
          extra; Kohrsolin
          <sup>
           ®
          </sup>
          FF
         </td>
         <td colspan="1" rowspan="1">
          <italic>
           C. difficile
          </italic>
          ribotype 027
         </td>
         <td colspan="1" rowspan="1">
          suspension test in different concentrations at various exposure times
         </td>
         <td colspan="1" rowspan="1">
          ≥4 log
          <sub>
           10
          </sub>
          (Dismozon pur at 1.5% and 2 h exposure time; Kohrsolin extra at 2% and 4 h exposure time; and Kohrsolin FF at 2% and 6 h exposure time)
          <sup>
           <xref ref-type="bibr" rid="DKT281C144">
            144
           </xref>
          </sup>
         </td>
        </tr>
       </tbody>
      </table>
      <table-wrap-foot>
       <fn>
        <p>
         <sup>
          a
         </sup>
         A measure of the bactericidal activity of a chemical compound in relation to phenol.
        </p>
       </fn>
      </table-wrap-foot>
     </table-wrap>
     <p>
      Disinfection methods employed in many intensive therapy units and other healthcare facilities include the use of antimicrobial wipes. Such products might be efficient in removing a microbial bioburden from a surface.
      <sup>
       <xref ref-type="bibr" rid="DKT281C80">
        80
       </xref>
      </sup>
      The use of alcohol wipes was also demonstrated to generally decrease the mean daily bacterial load on toilets where wipes were made available.
      <sup>
       <xref ref-type="bibr" rid="DKT281C81">
        81
       </xref>
      </sup>
      However, in most cases, antibacterial wipes used in hospitals were found to spread germs rather than eradicate them. Wipes can act as sources of cross-contamination when they are used on surfaces next to patients or on those commonly touched by staff and patients (e.g. tables, keypads).
      <sup>
       <xref ref-type="bibr" rid="DKT281C82">
        82
       </xref>
      </sup>
      Moreover, many hospital personnel use a single wipe several times to clean and disinfect multiple surfaces before discarding it. Instead, they should use a wipe on a single discrete surface that requires only low-level disinfection.
     </p>
     <p>
      A description of methods for hospital equipment disinfection with an analysis of the exposure time and the type of disinfectant and a summary of advantages and disadvantages of some chemical sterilants can be found elsewhere.
      <sup>
       <xref ref-type="bibr" rid="DKT281C11">
        11
       </xref>
       ,
       <xref ref-type="bibr" rid="DKT281C57">
        57
       </xref>
      </sup>
      Nevertheless, it has to be taken into account that some of these studies were performed with culture collection strains, whose responses to the presence of these disinfectants may differ from those of clinical isolates.
      <sup>
       <xref ref-type="bibr" rid="DKT281C60">
        60
       </xref>
      </sup>
      Furthermore, some studies evaluated only a single strain of the species. Therefore, the results obtained may not always be representative of what occurs in clinical practice. Most of the presented investigations were performed on a laboratory scale, which may not truly reflect the complexity of a hospital scenario.
     </p>
    </sec>
    <sec id="s6">
     <title>
      Alternatives to traditional disinfection
     </title>
     <p>
      The need for appropriate disinfection procedures is enhanced by the multitude of outbreaks that have resulted from improperly decontaminated patient-care items.
      <sup>
       <xref ref-type="bibr" rid="DKT281C83">
        83
       </xref>
      </sup>
      The disinfection processes previously described are executed by the application of chemical agents in solution. However, this kind of disinfection has some disadvantages: the application of disinfectants requires an exposure time of at least 5–10 min; the chemicals might react with acids; they might lose their activity in contact with organic substances; and some of them can cause skin, eye and respiratory tract irritation.
      <sup>
       <xref ref-type="bibr" rid="DKT281C23">
        23
       </xref>
      </sup>
     </p>
     <p>
      In this context, new disinfection strategies must be developed and their efficiencies must be evaluated in terms of their potential applications in hospital settings. This need for novel control methods has been emphasized by the increased resistance of bacterial species to some disinfectants, mainly as a consequence of biofilm formation.
      <sup>
       <xref ref-type="bibr" rid="DKT281C31">
        31
       </xref>
      </sup>
     </p>
     <p>
      One of these alternative strategies is steam vapour disinfection, which has been evaluated by different groups. Tanner
      <sup>
       <xref ref-type="bibr" rid="DKT281C84">
        84
       </xref>
      </sup>
      demonstrated a reduction of 7 log
      <sub>
       10
      </sub>
      in MRSA, VRE and
      <italic>
       P. aeruginosa
      </italic>
      (to undetectable values) within 5 s of application of a steam vapour system. Sexton
      <italic>
       et al.
      </italic>
      <sup>
       <xref ref-type="bibr" rid="DKT281C23">
        23
       </xref>
      </sup>
      applied a steam vapour system to combat MRSA, total coliform bacteria and
      <italic>
       C. difficile
      </italic>
      cells, attaining a 90% reduction in bacterial levels. Hydrogen peroxide vapour (HPV) is also used for decontamination of clinical surfaces and equipment. Otter and French
      <sup>
       <xref ref-type="bibr" rid="DKT281C85">
        85
       </xref>
      </sup>
      found that vegetative bacteria and spores (6–7 log
      <sub>
       10
      </sub>
      cfu) survived on surfaces for &gt;5 weeks, but were inactivated within 90 min of exposure to HPV in a 100 m
      <sup>
       3
      </sup>
      test room. Initial inocula of
      <italic>
       M. tuberculosis
      </italic>
      (∼3 log
      <sub>
       10
      </sub>
      ) and
      <italic>
       Geobacillus stearothermophilus
      </italic>
      (6 log
      <sub>
       10
      </sub>
      ) were exposed to HPV at 10 locations during room experiments and both microorganisms were inactivated in all locations within 90 min of HPV exposure.
      <sup>
       <xref ref-type="bibr" rid="DKT281C86">
        86
       </xref>
      </sup>
      Falagas
      <italic>
       et al
      </italic>
      .
      <sup>
       <xref ref-type="bibr" rid="DKT281C38">
        38
       </xref>
      </sup>
      reviewed other studies of disinfection with HPV against MRSA,
      <italic>
       C. difficile
      </italic>
      and other pathogens in several sampled hospital locations (including surgical wards, ward side rooms, single isolation rooms, multiple-bed ward bays and bathrooms); complete or almost complete disinfection of the sampled hospital sites was achieved with airborne hydrogen peroxide. HPV appears to have low toxicity and has good compatibility with most inanimate materials.
      <sup>
       <xref ref-type="bibr" rid="DKT281C87">
        87
       </xref>
      </sup>
     </p>
     <p>
      UV light exposure has also been applied for room decontamination. It has been used in air-handling systems and upper-room air-purifying systems to destroy microorganisms and can also inactivate microorganisms on surfaces.
      <sup>
       <xref ref-type="bibr" rid="DKT281C88">
        88
       </xref>
      </sup>
      UV-C was demonstrated to be effective in eliminating vegetative bacteria on contaminated surfaces (both in the line of sight and behind objects) within 15 min and in eliminating
      <italic>
       C. difficile
      </italic>
      spores within 50 min.
      <sup>
       <xref ref-type="bibr" rid="DKT281C89">
        89
       </xref>
      </sup>
      In other study, a mobile UV-C light unit significantly reduced aerobic colony counts and spores of
      <italic>
       C. difficile
      </italic>
      on contaminated surfaces in patient rooms.
      <sup>
       <xref ref-type="bibr" rid="DKT281C88">
        88
       </xref>
      </sup>
      It was also demonstrated that ceiling-mounted UV germicidal irradiation lamps were effective in reducing the viability of both
      <italic>
       Bacillus cereus
      </italic>
      and
      <italic>
       Bacillus anthracis
      </italic>
      vegetative cells and spores after a minimum exposure time of 1 h at an intensity as low as 8 μW/cm
      <sup>
       2
      </sup>
      .
      <sup>
       <xref ref-type="bibr" rid="DKT281C90">
        90
       </xref>
      </sup>
     </p>
     <p>
      Both the HPV and UV light methods have demonstrated good results. However, they require the removal of patients and healthcare personnel from the room, have a high acquisition cost and increase room turnover time.
      <sup>
       <xref ref-type="bibr" rid="DKT281C91">
        91
       </xref>
      </sup>
      Moreover, they do not replace standard cleaning and disinfection.
      <sup>
       <xref ref-type="bibr" rid="DKT281C92">
        92
       </xref>
      </sup>
     </p>
     <p>
      Bacterial adhesion to stainless steel surfaces (the most commonly used material in industry and hospitals) is one of the major reasons for cross-contamination in many scenarios.
      <sup>
       <xref ref-type="bibr" rid="DKT281C93">
        93
       </xref>
      </sup>
      Thus, more recently, different strategies for the production of antimicrobial surfaces with the purpose of reducing HAI have been extensively investigated and developed. Researchers have focused on the development of surfaces with antimicrobial coatings in order to inhibit biofilm formation by either killing the bacteria or preventing their adhesion. Bacterial growth control can then occur by three different modes of action: biocide leaching, which involves the release of a cytotoxic compound to kill attached microorganisms; adhesion prevention, which uses a super-hydrophobic covering in order to prevent microbial adhesion; and contact killing, which consists of disruption of cell membranes in contact with the surface.
      <sup>
       <xref ref-type="bibr" rid="DKT281C13">
        13
       </xref>
      </sup>
      Many of these techniques consist of surface modification by introduction of antimicrobial substances such as antibiotics, metals (such as copper and silver) and antiseptics.
      <sup>
       <xref ref-type="bibr" rid="DKT281C93">
        93–98
       </xref>
      </sup>
      These surfaces can be obtained by different methods, including adsorption, ligand–receptor pairing and covalent binding.
      <sup>
       <xref ref-type="bibr" rid="DKT281C94">
        94
       </xref>
      </sup>
      Surfaces that release antimicrobial products can work quite efficiently, although they eventually become exhausted and the diffusible antimicrobials pose the potential problem of inducing microbial resistance, since the surfaces are continually releasing active compounds to the environment for a long period of time.
      <sup>
       <xref ref-type="bibr" rid="DKT281C55">
        55
       </xref>
       ,
       <xref ref-type="bibr" rid="DKT281C99">
        99
       </xref>
      </sup>
      Alternatively, the design of surfaces that kill microbes on contact and do not release biocides may solve this problem. The covering of surfaces with transient metals, such as copper and silver as mentioned above, is a well-established strategy. Moreover, surfaces that catalytically produce biocides using externally applied chemical, electrical or optical energy are an interesting alternative.
      <sup>
       <xref ref-type="bibr" rid="DKT281C99">
        99
       </xref>
      </sup>
     </p>
     <p>
      An example of biocide leaching is the use of Surfacine, which incorporates an antimicrobial compound (silver iodide) in a surface-immobilized coating (a modified polyhexamethylenebiguanide).
      <sup>
       <xref ref-type="bibr" rid="DKT281C83">
        83
       </xref>
      </sup>
      This compound interacts with the microorganism by electrostatic attraction, penetrates the cell and finally kills it.
      <sup>
       <xref ref-type="bibr" rid="DKT281C83">
        83
       </xref>
      </sup>
      Surfaces treated with silver iodide resulted in excellent elimination of VRE at challenge levels of 100 cfu/in
      <sup>
       2
      </sup>
      for at least 13 days.
      <sup>
       <xref ref-type="bibr" rid="DKT281C11">
        11
       </xref>
      </sup>
      Furthermore, these surfaces retained the antimicrobial effect even after cleaning.
      <sup>
       <xref ref-type="bibr" rid="DKT281C11">
        11
       </xref>
      </sup>
      Photocatalytic oxidation on surfaces coated with titanium dioxide (TiO
      <sub>
       2
      </sub>
      ) is also a possible alternative. In the presence of water and oxygen, highly reactive OH
      <sup>
       −
      </sup>
      radicals generated by TiO
      <sub>
       2
      </sub>
      and mild UV-A are able to destroy bacteria, thus reducing bacterial contamination.
      <sup>
       <xref ref-type="bibr" rid="DKT281C100">
        100
       </xref>
      </sup>
      Another example of a product that releases an organic antimicrobial is Microban
      <sup>
       ®
      </sup>
      , which contains triclosan [5-chloro-2-(2,4-dichlorophenoxy)-phenol] as the antimicrobial agent, making the surface resistant to the growth of microorganisms.
      <sup>
       <xref ref-type="bibr" rid="DKT281C55">
        55
       </xref>
      </sup>
      This antimicrobial technology can be found in hundreds of consumer, industrial and medical products around the world.
     </p>
     <p>
      Covalent immobilization of bioactive compounds onto functionalized polymer surfaces has also seen rapid growth in the past decade in such industries as biomedical, textiles, microelectronics, bioprocessing and food packaging.
      <sup>
       <xref ref-type="bibr" rid="DKT281C101">
        101
       </xref>
      </sup>
      Table
      <xref ref-type="table" rid="DKT281TB4">
       4
      </xref>
      presents some examples of the application of these surfaces.
     </p>
     <table-wrap id="DKT281TB4" orientation="portrait" position="float">
      <label>
       Table 4.
      </label>
      <caption>
       <p>
        Examples of several coatings for the development of antimicrobial surfaces
       </p>
      </caption>
      <table frame="hsides" rules="groups">
       <colgroup span="1">
        <col align="left" span="1"/>
        <col align="left" span="1"/>
        <col align="left" span="1"/>
        <col align="left" span="1"/>
       </colgroup>
       <thead>
        <tr>
         <th align="left" colspan="1" rowspan="1">
          Surface coating
         </th>
         <th align="center" colspan="1" rowspan="1">
          Method
         </th>
         <th align="center" colspan="1" rowspan="1">
          Bacteria tested
         </th>
         <th align="center" colspan="1" rowspan="1">
          Results
         </th>
        </tr>
       </thead>
       <tbody>
        <tr>
         <td colspan="1" rowspan="1">
          Nanoparticulate silver-coated titania thin films
         </td>
         <td colspan="1" rowspan="1">
          sol-gel preparation
         </td>
         <td colspan="1" rowspan="1">
          MRSA and
          <italic>
           E. coli
          </italic>
         </td>
         <td colspan="1" rowspan="1">
          99.9% reduction due to the presence of the silver ion for
          <italic>
           E. coli
          </italic>
          and due to enhanced photocatalysis for MRSA
          <sup>
           <xref ref-type="bibr" rid="DKT281C97">
            97
           </xref>
          </sup>
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          Copolymer poly(butylmethacrylate)-co-poly(Boc-aminoethyl methacrylate) on silicon wafers and glass surfaces
         </td>
         <td colspan="1" rowspan="1">
          atom transfer radical polymerization
         </td>
         <td colspan="1" rowspan="1">
          <italic>
           E. coli
          </italic>
          and
          <italic>
           S. aureus
          </italic>
         </td>
         <td colspan="1" rowspan="1">
          100% reduction in &lt;5 min
          <sup>
           <xref ref-type="bibr" rid="DKT281C22">
            22
           </xref>
          </sup>
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          TiO
          <sub>
           2
          </sub>
          film on medical grade AISI 304 stainless steel
         </td>
         <td colspan="1" rowspan="1">
          arc ion plating
         </td>
         <td colspan="1" rowspan="1">
          <italic>
           E. coli
          </italic>
          and
          <italic>
           S. aureus
          </italic>
         </td>
         <td colspan="1" rowspan="1">
          log
          <sub>
           10
          </sub>
          reductions of 3.0 and 2.5 for
          <italic>
           S. aureus
          </italic>
          and
          <italic>
           E. coli
          </italic>
          , respectively, due to photocatalysis action
          <sup>
           <xref ref-type="bibr" rid="DKT281C145">
            145
           </xref>
          </sup>
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          Perfluorooctylated quaternary ammonium silane coupling agent in cotton fabrics
         </td>
         <td colspan="1" rowspan="1">
          pad-dry-cure
         </td>
         <td colspan="1" rowspan="1">
          <italic>
           S. aureus
          </italic>
         </td>
         <td colspan="1" rowspan="1">
          97.3% reduction and 95.6% reduction after 10 laundering cycles
          <sup>
           <xref ref-type="bibr" rid="DKT281C146">
            146
           </xref>
          </sup>
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          Ag and CuO layers on glass
         </td>
         <td colspan="1" rowspan="1">
          flame-assisted chemical vapour deposition (FACVD) and overlaid with TiO
          <sub>
           2
          </sub>
          using thermal CVD
         </td>
         <td colspan="1" rowspan="1">
          <italic>
           E. coli
          </italic>
          ,
          <italic>
           S. aureus
          </italic>
          and
          <italic>
           P. aeruginosa
          </italic>
         </td>
         <td colspan="1" rowspan="1">
          95%–99.9% reduction for hospital-related pathogens
          <sup>
           <xref ref-type="bibr" rid="DKT281C147">
            147
           </xref>
          </sup>
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          Magainin I and nisin peptides on stainless steel
         </td>
         <td colspan="1" rowspan="1">
          covalent binding via an intermediate chitosan layer
         </td>
         <td colspan="1" rowspan="1">
          <italic>
           Listeria ivanovii
          </italic>
         </td>
         <td colspan="1" rowspan="1">
          reduction of bacteria adhesion by a factor of 2–3
          <sup>
           <xref ref-type="bibr" rid="DKT281C94">
            94
           </xref>
          </sup>
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          Pseudo-polyelectrolytes (pPE) and poly(4-vinylphenol) (PVPh) into multilayer systems with poly(allylamine hydrochloride) (PAH) and poly(diallyldimethylammonium chloride) (PDADMAC)
         </td>
         <td colspan="1" rowspan="1">
          layer by layer
         </td>
         <td colspan="1" rowspan="1">
          <italic>
           S. epidermidis
          </italic>
         </td>
         <td colspan="1" rowspan="1">
          60% and 70% growth inhibition for PAH/PVPh and PDADMAC/PVPh, respectively
          <sup>
           <xref ref-type="bibr" rid="DKT281C13">
            13
           </xref>
          </sup>
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          Molybdic acid (H
          <sub>
           2
          </sub>
          MoO
          <sub>
           4
          </sub>
          ) and molybdenum trioxide (MoO
          <sub>
           3
          </sub>
          )
         </td>
         <td colspan="1" rowspan="1">
          sol-gel
         </td>
         <td colspan="1" rowspan="1">
          <italic>
           S. aureus
          </italic>
          and
          <italic>
           P. aeruginosa
          </italic>
         </td>
         <td colspan="1" rowspan="1">
          surfaces almost without microorganisms after 6 h
          <sup>
           <xref ref-type="bibr" rid="DKT281C12">
            12
           </xref>
          </sup>
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          Stainless steel surfaces with different copper content (with a maximum of 7.1 wt % for a gas pressure of 60 Pa)
         </td>
         <td colspan="1" rowspan="1">
          plasma surface alloying technique at various gas pressures
         </td>
         <td colspan="1" rowspan="1">
          <italic>
           E. coli
          </italic>
         </td>
         <td colspan="1" rowspan="1">
          reduction of 98% of cells within 1 h
          <sup>
           <xref ref-type="bibr" rid="DKT281C93">
            93
           </xref>
          </sup>
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          Copper-containing titanium nitride films on commercial stainless steel
         </td>
         <td colspan="1" rowspan="1">
          hybrid processes combining dual magnetron sputtering
         </td>
         <td colspan="1" rowspan="1">
          <italic>
           E. coli
          </italic>
         </td>
         <td colspan="1" rowspan="1">
          very effective in killing the bacteria; longer TiN deposition time may lead to superior antibacterial capability, corrosion and wear resistance
          <sup>
           <xref ref-type="bibr" rid="DKT281C96">
            96
           </xref>
          </sup>
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          Duplex-treated plasma alloyed AISI 304 stainless steel with Ni with plasma alloying with Cu
         </td>
         <td colspan="1" rowspan="1">
          double-glow plasma surface alloying technique
         </td>
         <td colspan="1" rowspan="1">
          <italic>
           E. coli
          </italic>
          and
          <italic>
           S. aureus
          </italic>
         </td>
         <td colspan="1" rowspan="1">
          reduction of 99.9% and 100% for
          <italic>
           E. coli
          </italic>
          and
          <italic>
           S. aureus
          </italic>
          , respectively
          <sup>
           <xref ref-type="bibr" rid="DKT281C148">
            148
           </xref>
          </sup>
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          Surfaces of titanium, Ti6Al4 V alloy or TiN, modified with SiO
          <sub>
           2
          </sub>
          –TiO
          <sub>
           2
          </sub>
          layer
         </td>
         <td colspan="1" rowspan="1">
          glow-discharge nitriding, sol-gel and electrophoresis
         </td>
         <td colspan="1" rowspan="1">
          <italic>
           S. epidermidis
          </italic>
         </td>
         <td colspan="1" rowspan="1">
          formation of biofilms on polished and ground titanium and titanium alloy surfaces covered with TiN, but not on those modified with SiO
          <sub>
           2
          </sub>
          –TiO
          <sub>
           2
          </sub>
          nanofilm
          <sup>
           <xref ref-type="bibr" rid="DKT281C149">
            149
           </xref>
          </sup>
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          Medical grade poly(vinyl chloride) (PVC) chemically modified with the incorporation of monovalent silver
         </td>
         <td colspan="1" rowspan="1">
          radio frequency oxygen (RF-O
          <sub>
           2
          </sub>
          ) glow discharge pre-functionalization and two-step wet treatment in sodium hydroxide and silver nitrate solutions
         </td>
         <td colspan="1" rowspan="1">
          <italic>
           P. aeruginosa
          </italic>
         </td>
         <td colspan="1" rowspan="1">
          100% reduction in initial bacterial adhesion
          <sup>
           <xref ref-type="bibr" rid="DKT281C98">
            98
           </xref>
          </sup>
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          Copolymer soft block containing trifluorethoxy (89 mol %) and C-12 alkylammonium (11 mol %) side chains
         </td>
         <td colspan="1" rowspan="1">
          cationic ring opening polymerization; nucleophilic substitution
         </td>
         <td colspan="1" rowspan="1">
          <italic>
           P. aeruginosa
          </italic>
          ,
          <italic>
           E. coli
          </italic>
          and
          <italic>
           S. aureus
          </italic>
         </td>
         <td colspan="1" rowspan="1">
          100% kill and 3.6–4.4 log reduction in 30 min
          <sup>
           <xref ref-type="bibr" rid="DKT281C150">
            150
           </xref>
          </sup>
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          Silicon wafers and glass surfaces functionalized with poly(butylmethacrylate)-
          <italic>
           co
          </italic>
          -poly(Boc-aminoethyl methacrylate)
         </td>
         <td colspan="1" rowspan="1">
          surface-initiated atom transfer radical polymerization
         </td>
         <td colspan="1" rowspan="1">
          <italic>
           S. aureus
          </italic>
          and
          <italic>
           E. coli
          </italic>
         </td>
         <td colspan="1" rowspan="1">
          100% kill in &lt;5 min
          <sup>
           <xref ref-type="bibr" rid="DKT281C22">
            22
           </xref>
          </sup>
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          Polyelectrolyte multilayers of poly(allylamine hydrochloride) (PAH) and poly(sodium 4-styrene sulfonate) (SPS)
         </td>
         <td colspan="1" rowspan="1">
          SPS/PAH PEMs assembled on plain glass slides with poly(sodium 4-styrene sulfonate)
         </td>
         <td colspan="1" rowspan="1">
          <italic>
           S. epidermidis
          </italic>
          ,
          <italic>
           E. coli
          </italic>
         </td>
         <td colspan="1" rowspan="1">
          viability of bacteria was effectively reduced on SPS/PAH multilayers displaying accessible cationic charge
          <sup>
           <xref ref-type="bibr" rid="DKT281C104">
            104
           </xref>
          </sup>
         </td>
        </tr>
       </tbody>
      </table>
     </table-wrap>
     <p>
      Furthermore, other kinds of surface are stimulating intensive research and some of them are already used, while others are promising candidates for practical application.
      <sup>
       <xref ref-type="bibr" rid="DKT281C102">
        102–104
       </xref>
      </sup>
      Examples include materials for medical implants (such as catheters), devices and instruments that are in contact with patients, surgical gowns and other protective clothing (such as surgical masks, caps) and polymeric coatings on surfaces such as shower walls.
      <sup>
       <xref ref-type="bibr" rid="DKT281C102">
        102
       </xref>
       ,
       <xref ref-type="bibr" rid="DKT281C103">
        103
       </xref>
      </sup>
      Antimicrobial polymers provide a very suitable strategy for achieving this objective since they can be applied to diverse objects. Polyelectrolyte multilayers (PEMs) have also been investigated extensively as biomaterials and biomaterial interfaces and also for bacterial contamination prevention.
      <sup>
       <xref ref-type="bibr" rid="DKT281C104">
        104
       </xref>
      </sup>
     </p>
     <p>
      Gas plasma is another promising alternative to sterilization that can be applied in healthcare services, although it is mainly targeted to equipment rather than to surfaces. Plasma consists of a mixture of photons, electrons, ions, atoms and radicals (such as atomic oxygen, ozone, nitrogen oxides, hydroxyl and superoxide). As a result of air plasma discharges, the gas enters an ionized state (by energetic transfer) and exhibits antimicrobial properties.
      <sup>
       <xref ref-type="bibr" rid="DKT281C9">
        9
       </xref>
       ,
       <xref ref-type="bibr" rid="DKT281C20">
        20
       </xref>
       ,
       <xref ref-type="bibr" rid="DKT281C105">
        105
       </xref>
       ,
       <xref ref-type="bibr" rid="DKT281C106">
        106
       </xref>
      </sup>
      Two types of plasma can be defined according to the conditions under which the plasma is formed: thermal and non-thermal plasmas. Compared with non-thermal plasmas, thermal plasmas require higher pressure and are characterized by higher temperatures and a local thermodynamic equilibrium.
      <sup>
       <xref ref-type="bibr" rid="DKT281C105">
        105
       </xref>
       ,
       <xref ref-type="bibr" rid="DKT281C106">
        106
       </xref>
      </sup>
      These systems have many advantages over more conventional disinfection techniques as they enable the disinfection of the interior of some types of equipment and materials, such as needles, at low cost and with easy handling.
      <sup>
       <xref ref-type="bibr" rid="DKT281C107">
        107
       </xref>
       ,
       <xref ref-type="bibr" rid="DKT281C108">
        108
       </xref>
      </sup>
      Furthermore, gas plasma does not require chemical products and it is not toxic to the skin.
      <sup>
       <xref ref-type="bibr" rid="DKT281C20">
        20
       </xref>
      </sup>
      Shimizu
      <italic>
       et al.
      </italic>
      <sup>
       <xref ref-type="bibr" rid="DKT281C108">
        108
       </xref>
      </sup>
      performed treatments with plasma using a surface micro-discharge device, under different temperature and humidity conditions. The antimicrobial effect was tested on
      <italic>
       Escherichia coli
      </italic>
      and
      <italic>
       Enterococcus mundtii
      </italic>
      with a reduction of 5 log
      <sub>
       10
      </sub>
      after 15 and 30 s of plasma treatment for
      <italic>
       E. mundtii
      </italic>
      and
      <italic>
       E. coli
      </italic>
      , respectively.
      <sup>
       <xref ref-type="bibr" rid="DKT281C108">
        108
       </xref>
      </sup>
      Other researchers have developed a large-scale plasma dispenser and evaluated its effect on
      <italic>
       E. coli
      </italic>
      and
      <italic>
       Candida albicans
      </italic>
      in agar plates in the presence and absence of textiles.
      <sup>
       <xref ref-type="bibr" rid="DKT281C107">
        107
       </xref>
      </sup>
      Their results demonstrated that the system was not affected by the presence of the textile, and in both cases a 15 s treatment caused a 5 log
      <sub>
       10
      </sub>
      reduction and, after treatment for 5 s, the fungi were reduced by 4 log
      <sub>
       10
      </sub>
      . Joshi
      <italic>
       et al.
      </italic>
      <sup>
       <xref ref-type="bibr" rid="DKT281C10">
        10
       </xref>
      </sup>
      studied the biocidal efficacy of non-thermal dielectric-barrier discharge plasma against
      <italic>
       E. coli
      </italic>
      ,
      <italic>
       S. aureus
      </italic>
      and MRSA in biofilms and planktonic cells. The planktonic cells were completely eliminated after 120 s of treatment, whereas the MRSA growing in biofilms were killed by &gt;60% within 15 s, suggesting that the effectiveness of a plasma system is highly dependent on exposure time and cell density.
      <sup>
       <xref ref-type="bibr" rid="DKT281C10">
        10
       </xref>
      </sup>
      Recent investigations evaluated the effect of non-thermal gas plasma on biofilms of
      <italic>
       Staphylococcus epidermidis
      </italic>
      and MRSA on glass surfaces; a log
      <sub>
       10
      </sub>
      reduction of 4 and 4.5 was observed after 1 h of exposure, respectively, and greater reductions could be attained with more prolonged exposure times.
      <sup>
       <xref ref-type="bibr" rid="DKT281C9">
        9
       </xref>
      </sup>
      Burts
      <italic>
       et al
      </italic>
      .
      <sup>
       <xref ref-type="bibr" rid="DKT281C20">
        20
       </xref>
      </sup>
      tested an atmospheric non-thermal plasma as a disinfectant for hospital pagers by analysis of MRSA reduction, and found complete disinfection within 30 s. Different cell densities and exposure times were also evaluated and a 4–5 log
      <sub>
       10
      </sub>
      reduction was obtained within 10 min. More information regarding this disinfection strategy has been reviewed by Moisan
      <italic>
       et al
      </italic>
      .
      <sup>
       <xref ref-type="bibr" rid="DKT281C105">
        105
       </xref>
       ,
       <xref ref-type="bibr" rid="DKT281C106">
        106
       </xref>
      </sup>
      These novel disinfection techniques are important means of reducing the high numbers of nosocomial infections and are more efficient than conventional disinfection methods.
     </p>
    </sec>
    <sec id="s7" sec-type="conclusions">
     <title>
      Conclusions
     </title>
     <p>
      There is great concern about the growth and prevalence of HAI due to the increased incidence of resistant bacteria. Furthermore, the development of new antibiotics is a difficult task because of high research costs and regulatory issues. Conventional cleaning methods for the eradication of hospital environmental contamination seem to be inefficient. This manuscript reviews several new disinfection alternatives as attempts to overcome these problems. Most of the data currently available have been generated by the manufacturers and need to be validated by independent investigations. Moreover, studies concerning bacterial biology and physiology allied to genomics and computer analysis should be applied to identify and understand the pathogenesis associated with resistant bacteria and crucial targets for novel biocides. Thus, further evaluation and implementation of new measures and new disinfection methods are necessary, not forgetting their validation in terms of effectiveness, safety and disposal. Additionally, it is important always to evaluate the risk of emerging phenotypic resistance when developing new disinfection strategies.
     </p>
    </sec>
    <sec id="s8">
     <title>
      Funding
     </title>
     <p>
      This work was supported by Operational Programme for Competitiveness Factors—COMPETE, FCT/MEC (PIDDAC) and FEDER through Projects Bioresist—PTDC/EBB-EBI/105085/2008 and Phytodisinfectants—PTDC/DTP-SAP/1078/2012 (COMPETE: FCOMP-01–0124-FEDER-028765) and the PhD grants awarded to A. C. A. (SFRH/BD/84393/2012) and A. B. (SFRH/BD/63398/2009).
     </p>
    </sec>
    <sec id="s9">
     <title>
      Transparency declarations
     </title>
     <p>
      None to declare.
     </p>
    </sec>
    <back>
     <ref-list>
      <title>
       References
      </title>
      <ref id="DKT281C1">
       <label>
        1
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Talon
          </surname>
          <given-names>
           D
          </given-names>
         </name>
        </person-group>
        <article-title>
         The role of the hospital environment in the epidemiology of multi-resistant bacteria
        </article-title>
        <source>
         J Hosp Infect
        </source>
        <year>
         1999
        </year>
        <volume>
         43
        </volume>
        <fpage>
         13
        </fpage>
        <lpage>
         7
        </lpage>
        <pub-id pub-id-type="pmid">
         10462634
        </pub-id>
       </element-citation>
      </ref>
      <ref id="DKT281C2">
       <label>
        2
       </label>
       <element-citation publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Schelz
          </surname>
          <given-names>
           Z
          </given-names>
         </name>
         <name>
          <surname>
           Hohmann
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Molnar
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        <person-group person-group-type="editor">
         <name>
          <surname>
           Chattopadhyay
          </surname>
          <given-names>
           D
          </given-names>
         </name>
        </person-group>
        <article-title>
         Recent advances in research of antimicrobial effects of essential oils and plant derived compounds on bacteria
        </article-title>
        <source>
         Ethnomedicine: A Source of Complementary Therapeutics
        </source>
        <year>
         2010
        </year>
        <publisher-loc>
         Kerala
        </publisher-loc>
        <publisher-name>
         Research Signpost
        </publisher-name>
        <fpage>
         179
        </fpage>
        <lpage>
         201
        </lpage>
       </element-citation>
      </ref>
      <ref id="DKT281C3">
       <label>
        3
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Dötsch
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Becker
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Pommerenke
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Genomewide identification of genetic determinants of antimicrobial drug resistance in
         <italic>
          Pseudomonas aeruginosa
         </italic>
        </article-title>
        <source>
         Antimicrob Agents Chemother
        </source>
        <year>
         2009
        </year>
        <volume>
         56
        </volume>
        <fpage>
         2522
        </fpage>
        <lpage>
         31
        </lpage>
       </element-citation>
      </ref>
      <ref id="DKT281C4">
       <label>
        4
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Guz
          </surname>
          <given-names>
           NR
          </given-names>
         </name>
         <name>
          <surname>
           Stermitz
          </surname>
          <given-names>
           FR
          </given-names>
         </name>
         <name>
          <surname>
           Johnson
          </surname>
          <given-names>
           JB
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Flavonolignan and flavone inhibitors of a
         <italic>
          Staphylococcus aureus
         </italic>
         multidrug resistance pump: structure-activity relationships
        </article-title>
        <source>
         J Med Chem
        </source>
        <year>
         2000
        </year>
        <volume>
         44
        </volume>
        <fpage>
         261
        </fpage>
        <lpage>
         8
        </lpage>
       </element-citation>
      </ref>
      <ref id="DKT281C5">
       <label>
        5
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Andersson
          </surname>
          <given-names>
           DI
          </given-names>
         </name>
         <name>
          <surname>
           Levin
          </surname>
          <given-names>
           BR
          </given-names>
         </name>
        </person-group>
        <article-title>
         The biological cost of antibiotic resistance
        </article-title>
        <source>
         Curr Opin Microbiol
        </source>
        <year>
         1999
        </year>
        <volume>
         2
        </volume>
        <fpage>
         489
        </fpage>
        <lpage>
         93
        </lpage>
        <pub-id pub-id-type="pmid">
         10508723
        </pub-id>
       </element-citation>
      </ref>
      <ref id="DKT281C6">
       <label>
        6
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Andersson
          </surname>
          <given-names>
           DI
          </given-names>
         </name>
        </person-group>
        <article-title>
         Persistence of antibiotic resistant bacteria
        </article-title>
        <source>
         Curr Opin Microbiol
        </source>
        <year>
         2003
        </year>
        <volume>
         6
        </volume>
        <fpage>
         452
        </fpage>
        <lpage>
         6
        </lpage>
        <pub-id pub-id-type="pmid">
         14572536
        </pub-id>
       </element-citation>
      </ref>
      <ref id="DKT281C7">
       <label>
        7
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Guillemot
          </surname>
          <given-names>
           D
          </given-names>
         </name>
        </person-group>
        <article-title>
         Antibiotic use in humans and bacterial resistance
        </article-title>
        <source>
         Curr Opin Microbiol
        </source>
        <year>
         1999
        </year>
        <volume>
         2
        </volume>
        <fpage>
         494
        </fpage>
        <lpage>
         8
        </lpage>
        <pub-id pub-id-type="pmid">
         10508727
        </pub-id>
       </element-citation>
      </ref>
      <ref id="DKT281C8">
       <label>
        8
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Monroe
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Polk
          </surname>
          <given-names>
           R
          </given-names>
         </name>
        </person-group>
        <article-title>
         Antimicrobial use and bacterial resistance
        </article-title>
        <source>
         Curr Opin Microbiol
        </source>
        <year>
         2000
        </year>
        <volume>
         3
        </volume>
        <fpage>
         496
        </fpage>
        <lpage>
         501
        </lpage>
        <pub-id pub-id-type="pmid">
         11050449
        </pub-id>
       </element-citation>
      </ref>
      <ref id="DKT281C9">
       <label>
        9
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cotter
          </surname>
          <given-names>
           JJ
          </given-names>
         </name>
         <name>
          <surname>
           Maguire
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Soberon
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Disinfection of meticillin-resistant
         <italic>
          Staphylococcus aureus
         </italic>
         and
         <italic>
          Staphylococcus epidermidis
         </italic>
         biofilms using a remote non-thermal gas plasma
        </article-title>
        <source>
         J Hosp Infect
        </source>
        <year>
         2011
        </year>
        <volume>
         78
        </volume>
        <fpage>
         204
        </fpage>
        <lpage>
         7
        </lpage>
        <pub-id pub-id-type="pmid">
         21601949
        </pub-id>
       </element-citation>
      </ref>
      <ref id="DKT281C10">
       <label>
        10
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Joshi
          </surname>
          <given-names>
           SG
          </given-names>
         </name>
         <name>
          <surname>
           Paff
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Friedman
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Control of methicillin-resistant
         <italic>
          Staphylococcus aureus
         </italic>
         in planktonic form and biofilms: a biocidal efficacy study of nonthermal dielectric-barrier discharge plasma
        </article-title>
        <source>
         Am J Infect Control
        </source>
        <year>
         2010
        </year>
        <volume>
         38
        </volume>
        <fpage>
         293
        </fpage>
        <lpage>
         301
        </lpage>
        <pub-id pub-id-type="pmid">
         20085853
        </pub-id>
       </element-citation>
      </ref>
      <ref id="DKT281C11">
       <label>
        11
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rutala
          </surname>
          <given-names>
           WA
          </given-names>
         </name>
         <name>
          <surname>
           Weber
          </surname>
          <given-names>
           DJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         Surface disinfection: should we do it?
        </article-title>
        <source>
         J Hosp Infect
        </source>
        <year>
         2001
        </year>
        <volume>
         48
        </volume>
        <fpage>
         S64
        </fpage>
        <lpage>
         8
        </lpage>
        <pub-id pub-id-type="pmid">
         11759030
        </pub-id>
       </element-citation>
      </ref>
      <ref id="DKT281C12">
       <label>
        12
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zollfrank
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Gutbrod
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Wechsler
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Antimicrobial activity of transition metal acid MoO
         <sub>
          3
         </sub>
         prevents microbial growth on material surfaces
        </article-title>
        <source>
         Mater Sci Eng C Mater Biol Appl
        </source>
        <year>
         2012
        </year>
        <volume>
         32
        </volume>
        <fpage>
         47
        </fpage>
        <lpage>
         54
        </lpage>
        <pub-id pub-id-type="pmid">
         23177771
        </pub-id>
       </element-citation>
      </ref>
      <ref id="DKT281C13">
       <label>
        13
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Pinto
          </surname>
          <given-names>
           MS
          </given-names>
         </name>
         <name>
          <surname>
           McGahan
          </surname>
          <given-names>
           ME
          </given-names>
         </name>
         <name>
          <surname>
           Steiner
          </surname>
          <given-names>
           WW
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         The use of the pseudo-polyelectrolyte, poly(4-vinylphenol), in multilayered films as an antimicrobial surface coating
        </article-title>
        <source>
         Colloids Surf A Physicochem Eng Asp
        </source>
        <year>
         2011
        </year>
        <volume>
         377
        </volume>
        <fpage>
         182
        </fpage>
        <lpage>
         6
        </lpage>
       </element-citation>
      </ref>
      <ref id="DKT281C14">
       <label>
        14
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Griffith
          </surname>
          <given-names>
           CJ
          </given-names>
         </name>
         <name>
          <surname>
           Cooper
          </surname>
          <given-names>
           RA
          </given-names>
         </name>
         <name>
          <surname>
           Gilmore
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         An evaluation of hospital cleaning regimes and standards
        </article-title>
        <source>
         J Hosp Infect
        </source>
        <year>
         2000
        </year>
        <volume>
         45
        </volume>
        <fpage>
         19
        </fpage>
        <lpage>
         28
        </lpage>
        <pub-id pub-id-type="pmid">
         10833340
        </pub-id>
       </element-citation>
      </ref>
      <ref id="DKT281C15">
       <label>
        15
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Weber
          </surname>
          <given-names>
           DJ
          </given-names>
         </name>
         <name>
          <surname>
           Rutala
          </surname>
          <given-names>
           WA
          </given-names>
         </name>
         <name>
          <surname>
           Miller
          </surname>
          <given-names>
           MB
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Role of hospital surfaces in the transmission of emerging health care-associated pathogens: norovirus,
         <italic>
          Clostridium difficile
         </italic>
         , and
         <italic>
          Acinetobacter
         </italic>
         species
        </article-title>
        <source>
         Am J Infect Control
        </source>
        <year>
         2010
        </year>
        <volume>
         38
        </volume>
        <issue>
         Suppl 1
        </issue>
        <fpage>
         S25
        </fpage>
        <lpage>
         33
        </lpage>
        <pub-id pub-id-type="pmid">
         20569853
        </pub-id>
       </element-citation>
      </ref>
      <ref id="DKT281C16">
       <label>
        16
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cozad
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Jones
          </surname>
          <given-names>
           RD
          </given-names>
         </name>
        </person-group>
        <article-title>
         Disinfection and the prevention of infectious disease
        </article-title>
        <source>
         Am J Infect Control
        </source>
        <year>
         2003
        </year>
        <volume>
         31
        </volume>
        <fpage>
         243
        </fpage>
        <lpage>
         54
        </lpage>
        <pub-id pub-id-type="pmid">
         12806363
        </pub-id>
       </element-citation>
      </ref>
      <ref id="DKT281C17">
       <label>
        17
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Otter
          </surname>
          <given-names>
           JA
          </given-names>
         </name>
         <name>
          <surname>
           Yezli
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           French
          </surname>
          <given-names>
           GL
          </given-names>
         </name>
        </person-group>
        <article-title>
         The role played by contaminated surfaces in the transmission of nosocomial pathogens
        </article-title>
        <source>
         Infect Control Hosp Epidemiol
        </source>
        <year>
         2011
        </year>
        <volume>
         32
        </volume>
        <fpage>
         687
        </fpage>
        <lpage>
         99
        </lpage>
        <pub-id pub-id-type="pmid">
         21666400
        </pub-id>
       </element-citation>
      </ref>
      <ref id="DKT281C18">
       <label>
        18
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Costerton
          </surname>
          <given-names>
           JW
          </given-names>
         </name>
         <name>
          <surname>
           Montanaro
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Arciola
          </surname>
          <given-names>
           CR
          </given-names>
         </name>
        </person-group>
        <article-title>
         Biofilm in implant infections: its production and regulation
        </article-title>
        <source>
         Int J Artif Organs
        </source>
        <year>
         2005
        </year>
        <volume>
         28
        </volume>
        <fpage>
         1062
        </fpage>
        <lpage>
         8
        </lpage>
        <pub-id pub-id-type="pmid">
         16353112
        </pub-id>
       </element-citation>
      </ref>
      <ref id="DKT281C19">
       <label>
        19
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wach
          </surname>
          <given-names>
           J-Y
          </given-names>
         </name>
         <name>
          <surname>
           Bonazzi
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Gademann
          </surname>
          <given-names>
           K
          </given-names>
         </name>
        </person-group>
        <article-title>
         Antimicrobial surfaces through natural product hybrids
        </article-title>
        <source>
         Angew Chem Int Ed
        </source>
        <year>
         2008
        </year>
        <volume>
         47
        </volume>
        <fpage>
         7123
        </fpage>
        <lpage>
         6
        </lpage>
       </element-citation>
      </ref>
      <ref id="DKT281C20">
       <label>
        20
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Burts
          </surname>
          <given-names>
           ML
          </given-names>
         </name>
         <name>
          <surname>
           Alexeff
          </surname>
          <given-names>
           I
          </given-names>
         </name>
         <name>
          <surname>
           Meek
          </surname>
          <given-names>
           ET
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Use of atmospheric non-thermal plasma as a disinfectant for objects contaminated with methicillin-resistant
         <italic>
          Staphylococcus aureus
         </italic>
        </article-title>
        <source>
         Am J Infect Control
        </source>
        <year>
         2009
        </year>
        <volume>
         37
        </volume>
        <fpage>
         729
        </fpage>
        <lpage>
         33
        </lpage>
        <pub-id pub-id-type="pmid">
         19559504
        </pub-id>
       </element-citation>
      </ref>
      <ref id="DKT281C21">
       <label>
        21
       </label>
       <element-citation publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Madigan
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Martinko
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Parker
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        <source>
         Brock Biology of Microorganisms
        </source>
        <year>
         2004
        </year>
        <publisher-loc>
         São Paulo
        </publisher-loc>
        <publisher-name>
         Prentice Hall
        </publisher-name>
       </element-citation>
      </ref>
      <ref id="DKT281C22">
       <label>
        22
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Madkour
          </surname>
          <given-names>
           AE
          </given-names>
         </name>
         <name>
          <surname>
           Dabkowski
          </surname>
          <given-names>
           JM
          </given-names>
         </name>
         <name>
          <surname>
           Nüsslein
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Fast disinfecting antimicrobial surfaces.
        </article-title>
        <source>
         Langmuir
        </source>
        <year>
         2009
        </year>
        <volume>
         25
        </volume>
        <fpage>
         1060
        </fpage>
        <lpage>
         7
        </lpage>
        <pub-id pub-id-type="pmid">
         19177651
        </pub-id>
       </element-citation>
      </ref>
      <ref id="DKT281C23">
       <label>
        23
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sexton
          </surname>
          <given-names>
           JD
          </given-names>
         </name>
         <name>
          <surname>
           Tanner
          </surname>
          <given-names>
           BD
          </given-names>
         </name>
         <name>
          <surname>
           Maxwell
          </surname>
          <given-names>
           SL
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Reduction in the microbial load on high-touch surfaces in hospital rooms by treatment with a portable saturated steam vapor disinfection system
        </article-title>
        <source>
         Am J Infect Control
        </source>
        <year>
         2011
        </year>
        <volume>
         39
        </volume>
        <fpage>
         655
        </fpage>
        <lpage>
         62
        </lpage>
        <pub-id pub-id-type="pmid">
         21641089
        </pub-id>
       </element-citation>
      </ref>
      <ref id="DKT281C24">
       <label>
        24
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Simões
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Simões
          </surname>
          <given-names>
           LC
          </given-names>
         </name>
         <name>
          <surname>
           Cleto
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Antimicrobial mechanisms of
         <italic>
          ortho
         </italic>
         -phthalaldehyde action
        </article-title>
        <source>
         J Basic Microbiol
        </source>
        <year>
         2007
        </year>
        <volume>
         47
        </volume>
        <fpage>
         230
        </fpage>
        <lpage>
         42
        </lpage>
        <pub-id pub-id-type="pmid">
         17518416
        </pub-id>
       </element-citation>
      </ref>
      <ref id="DKT281C25">
       <label>
        25
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Pitten
          </surname>
          <given-names>
           FA
          </given-names>
         </name>
         <name>
          <surname>
           Werner
          </surname>
          <given-names>
           HP
          </given-names>
         </name>
         <name>
          <surname>
           Kramer
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        <article-title>
         A standardized test to assess the impact of different organic challenges on the antimicrobial activity of antiseptics
        </article-title>
        <source>
         J Hosp Infect
        </source>
        <year>
         2003
        </year>
        <volume>
         55
        </volume>
        <fpage>
         108
        </fpage>
        <lpage>
         15
        </lpage>
        <pub-id pub-id-type="pmid">
         14529634
        </pub-id>
       </element-citation>
      </ref>
      <ref id="DKT281C26">
       <label>
        26
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Carling
          </surname>
          <given-names>
           PC
          </given-names>
         </name>
         <name>
          <surname>
           Von Beheren
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Kim
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Intensive care unit environmental cleaning: an evaluation in sixteen hospitals using a novel assessment tool
        </article-title>
        <source>
         J Hosp Infect
        </source>
        <year>
         2008
        </year>
        <volume>
         68
        </volume>
        <fpage>
         39
        </fpage>
        <lpage>
         44
        </lpage>
        <pub-id pub-id-type="pmid">
         18069083
        </pub-id>
       </element-citation>
      </ref>
      <ref id="DKT281C27">
       <label>
        27
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Costerton
          </surname>
          <given-names>
           JW
          </given-names>
         </name>
         <name>
          <surname>
           Stewart
          </surname>
          <given-names>
           PS
          </given-names>
         </name>
         <name>
          <surname>
           Greenberg
          </surname>
          <given-names>
           EP
          </given-names>
         </name>
        </person-group>
        <article-title>
         Bacterial biofilms: a common cause of persistent infections
        </article-title>
        <source>
         Science
        </source>
        <year>
         1999
        </year>
        <volume>
         284
        </volume>
        <fpage>
         1318
        </fpage>
        <lpage>
         22
        </lpage>
        <pub-id pub-id-type="pmid">
         10334980
        </pub-id>
       </element-citation>
      </ref>
      <ref id="DKT281C28">
       <label>
        28
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Olson
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Ceri
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Morck
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Biofilm bacteria: formation and comparative susceptibility to antibiotics
        </article-title>
        <source>
         Can J Vet Res
        </source>
        <year>
         2002
        </year>
        <volume>
         66
        </volume>
        <fpage>
         86
        </fpage>
        <lpage>
         92
        </lpage>
        <pub-id pub-id-type="pmid">
         11989739
        </pub-id>
       </element-citation>
      </ref>
      <ref id="DKT281C29">
       <label>
        29
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Toté
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Berghe
          </surname>
          <given-names>
           DV
          </given-names>
         </name>
         <name>
          <surname>
           Deschacht
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Inhibitory efficacy of various antibiotics on matrix and viable mass of
         <italic>
          Staphylococcus aureus
         </italic>
         and
         <italic>
          Pseudomonas aeruginosa
         </italic>
         biofilms
        </article-title>
        <source>
         Int J Antimicrob Agents
        </source>
        <year>
         2009
        </year>
        <volume>
         33
        </volume>
        <fpage>
         525
        </fpage>
        <lpage>
         31
        </lpage>
        <pub-id pub-id-type="pmid">
         19179053
        </pub-id>
       </element-citation>
      </ref>
      <ref id="DKT281C30">
       <label>
        30
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Simões
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <article-title>
         Antimicrobial strategies effective against infectious bacterial biofilms
        </article-title>
        <source>
         Curr Med Chem
        </source>
        <year>
         2011
        </year>
        <volume>
         18
        </volume>
        <fpage>
         2129
        </fpage>
        <lpage>
         45
        </lpage>
        <pub-id pub-id-type="pmid">
         21517762
        </pub-id>
       </element-citation>
      </ref>
      <ref id="DKT281C31">
       <label>
        31
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Simões
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Simões
          </surname>
          <given-names>
           LC
          </given-names>
         </name>
         <name>
          <surname>
           Vieira
          </surname>
          <given-names>
           MJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         A review of current and emergent biofilm control strategies
        </article-title>
        <source>
         Food Sci Technol
        </source>
        <year>
         2010
        </year>
        <volume>
         43
        </volume>
        <fpage>
         573
        </fpage>
        <lpage>
         83
        </lpage>
       </element-citation>
      </ref>
      <ref id="DKT281C32">
       <label>
        32
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kramer
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Schwebke
          </surname>
          <given-names>
           I
          </given-names>
         </name>
         <name>
          <surname>
           Kampf
          </surname>
          <given-names>
           G
          </given-names>
         </name>
        </person-group>
        <article-title>
         How long do nosocomial pathogens persist on inanimate surfaces? A systematic review
        </article-title>
        <source>
         BMC Infect Dis
        </source>
        <year>
         2006
        </year>
        <volume>
         6
        </volume>
        <fpage>
         130
        </fpage>
        <pub-id pub-id-type="pmid">
         16914034
        </pub-id>
       </element-citation>
      </ref>
      <ref id="DKT281C33">
       <label>
        33
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hota
          </surname>
          <given-names>
           B
          </given-names>
         </name>
        </person-group>
        <article-title>
         Contamination, disinfection, and cross-colonization: are hospital surfaces reservoirs for nosocomial infection
        </article-title>
        <source>
         Clin Infect Dis
        </source>
        <year>
         2004
        </year>
        <volume>
         39
        </volume>
        <fpage>
         1182
        </fpage>
        <lpage>
         9
        </lpage>
        <pub-id pub-id-type="pmid">
         15486843
        </pub-id>
       </element-citation>
      </ref>
      <ref id="DKT281C34">
       <label>
        34
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Dancer
          </surname>
          <given-names>
           SJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         How do we assess hospital cleaning? A proposal for microbiological standards for surface hygiene in hospitals
        </article-title>
        <source>
         J Hosp Infect
        </source>
        <year>
         2004
        </year>
        <volume>
         56
        </volume>
        <fpage>
         10
        </fpage>
        <lpage>
         5
        </lpage>
        <pub-id pub-id-type="pmid">
         14706265
        </pub-id>
       </element-citation>
      </ref>
      <ref id="DKT281C35">
       <label>
        35
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Boyce
          </surname>
          <given-names>
           JM
          </given-names>
         </name>
        </person-group>
        <article-title>
         Environmental contamination makes an important contribution to hospital infection
        </article-title>
        <source>
         J Hosp Infect
        </source>
        <year>
         2007
        </year>
        <volume>
         65
        </volume>
        <fpage>
         50
        </fpage>
        <lpage>
         4
        </lpage>
        <pub-id pub-id-type="pmid">
         17540242
        </pub-id>
       </element-citation>
      </ref>
      <ref id="DKT281C36">
       <label>
        36
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hirai
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
        </person-group>
        <article-title>
         Survival of bacteria under dry conditions; from a viewpoint of nosocomial infection
        </article-title>
        <source>
         J Hosp Infect
        </source>
        <year>
         1991
        </year>
        <volume>
         19
        </volume>
        <fpage>
         191
        </fpage>
        <lpage>
         200
        </lpage>
        <pub-id pub-id-type="pmid">
         1685507
        </pub-id>
       </element-citation>
      </ref>
      <ref id="DKT281C37">
       <label>
        37
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Boyce
          </surname>
          <given-names>
           JM
          </given-names>
         </name>
         <name>
          <surname>
           Potter-Bynoe
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Chenevert
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Environmental contamination due to methicillin-resistant
         <italic>
          Staphylococcus aureus
         </italic>
         : possible infection control implications
        </article-title>
        <source>
         Infect Control Hosp Epidemiol
        </source>
        <year>
         1997
        </year>
        <volume>
         18
        </volume>
        <fpage>
         622
        </fpage>
        <lpage>
         7
        </lpage>
        <pub-id pub-id-type="pmid">
         9309433
        </pub-id>
       </element-citation>
      </ref>
      <ref id="DKT281C38">
       <label>
        38
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Falagas
          </surname>
          <given-names>
           ME
          </given-names>
         </name>
         <name>
          <surname>
           Thomaidis
          </surname>
          <given-names>
           PC
          </given-names>
         </name>
         <name>
          <surname>
           Kotsantis
          </surname>
          <given-names>
           IK
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Airborne hydrogen peroxide for disinfection of the hospital environment and infection control: a systematic review
        </article-title>
        <source>
         J Hosp Infect
        </source>
        <year>
         2011
        </year>
        <volume>
         78
        </volume>
        <fpage>
         171
        </fpage>
        <lpage>
         7
        </lpage>
        <pub-id pub-id-type="pmid">
         21392848
        </pub-id>
       </element-citation>
      </ref>
      <ref id="DKT281C39">
       <label>
        39
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Dancer
          </surname>
          <given-names>
           SJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         Mopping up hospital infection
        </article-title>
        <source>
         J Hosp Infect
        </source>
        <year>
         1999
        </year>
        <volume>
         43
        </volume>
        <fpage>
         85
        </fpage>
        <lpage>
         100
        </lpage>
        <pub-id pub-id-type="pmid">
         10549308
        </pub-id>
       </element-citation>
      </ref>
      <ref id="DKT281C40">
       <label>
        40
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cheng
          </surname>
          <given-names>
           KL
          </given-names>
         </name>
         <name>
          <surname>
           Boost
          </surname>
          <given-names>
           MV
          </given-names>
         </name>
         <name>
          <surname>
           Chung
          </surname>
          <given-names>
           JWY
          </given-names>
         </name>
        </person-group>
        <article-title>
         Study on the effectiveness of disinfection with wipes against methicillin-resistant
         <italic>
          Staphylococcus aureus
         </italic>
         and implications for hospital hygiene
        </article-title>
        <source>
         Am J Infect Control
        </source>
        <year>
         2011
        </year>
        <volume>
         39
        </volume>
        <fpage>
         577
        </fpage>
        <lpage>
         80
        </lpage>
        <pub-id pub-id-type="pmid">
         21641084
        </pub-id>
       </element-citation>
      </ref>
      <ref id="DKT281C41">
       <label>
        41
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Drees
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Snydman
          </surname>
          <given-names>
           DR
          </given-names>
         </name>
         <name>
          <surname>
           Schmid
          </surname>
          <given-names>
           CH
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Prior environmental contamination increases the risk of acquisition of vancomycin-resistant enterococci
        </article-title>
        <source>
         Clin Infect Dis
        </source>
        <year>
         2008
        </year>
        <volume>
         46
        </volume>
        <fpage>
         678
        </fpage>
        <lpage>
         85
        </lpage>
        <pub-id pub-id-type="pmid">
         18230044
        </pub-id>
       </element-citation>
      </ref>
      <ref id="DKT281C42">
       <label>
        42
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Dancer
          </surname>
          <given-names>
           SJ
          </given-names>
         </name>
         <name>
          <surname>
           White
          </surname>
          <given-names>
           LF
          </given-names>
         </name>
         <name>
          <surname>
           Lamb
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Measuring the effect of enhanced cleaning in a UK hospital: a prospective cross-over study
        </article-title>
        <source>
         BMC Med
        </source>
        <year>
         2009
        </year>
        <volume>
         7
        </volume>
        <fpage>
         28
        </fpage>
        <pub-id pub-id-type="pmid">
         19505316
        </pub-id>
       </element-citation>
      </ref>
      <ref id="DKT281C43">
       <label>
        43
       </label>
       <element-citation publication-type="book">
        <collab>
         Microbiology Advisory Committee
        </collab>
        <source>
         Decontamination of Equipment, Linen or Other Surfaces Contaminated with Hepatitis B and/or Human Immunodeficiency Viruses
        </source>
        <year>
         1991
        </year>
        <publisher-loc>
         Department of Health, London
        </publisher-loc>
       </element-citation>
      </ref>
      <ref id="DKT281C44">
       <label>
        44
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Dancer
          </surname>
          <given-names>
           SJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         The role of environmental cleaning in the control of hospital-acquired infection
        </article-title>
        <source>
         J Hosp Infect
        </source>
        <year>
         2009
        </year>
        <volume>
         73
        </volume>
        <fpage>
         378
        </fpage>
        <lpage>
         85
        </lpage>
        <pub-id pub-id-type="pmid">
         19726106
        </pub-id>
       </element-citation>
      </ref>
      <ref id="DKT281C45">
       <label>
        45
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wilcox
          </surname>
          <given-names>
           MH
          </given-names>
         </name>
         <name>
          <surname>
           Fawley
          </surname>
          <given-names>
           WN
          </given-names>
         </name>
         <name>
          <surname>
           Wigglesworth
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Comparison of the effect of detergent versus hypochlorite cleaning on environmental contamination and incidence of
         <italic>
          Clostridium difficile
         </italic>
         infection
        </article-title>
        <source>
         J Hosp Infect
        </source>
        <year>
         2003
        </year>
        <volume>
         54
        </volume>
        <fpage>
         109
        </fpage>
        <lpage>
         14
        </lpage>
        <pub-id pub-id-type="pmid">
         12818583
        </pub-id>
       </element-citation>
      </ref>
      <ref id="DKT281C46">
       <label>
        46
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wood
          </surname>
          <given-names>
           MW
          </given-names>
         </name>
         <name>
          <surname>
           Lund
          </surname>
          <given-names>
           RC
          </given-names>
         </name>
         <name>
          <surname>
           Stevenson
          </surname>
          <given-names>
           KB
          </given-names>
         </name>
        </person-group>
        <article-title>
         Bacterial contamination of stethoscopes with antimicrobial diaphragm covers
        </article-title>
        <source>
         Am J Infect Control
        </source>
        <year>
         2007
        </year>
        <volume>
         35
        </volume>
        <fpage>
         263
        </fpage>
        <lpage>
         6
        </lpage>
        <pub-id pub-id-type="pmid">
         17482998
        </pub-id>
       </element-citation>
      </ref>
      <ref id="DKT281C47">
       <label>
        47
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Berendt
          </surname>
          <given-names>
           AE
          </given-names>
         </name>
         <name>
          <surname>
           Turnbull
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Spady
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Three swipes and you're out: how many swipes are needed to decontaminate plastic with disposable wipes?
        </article-title>
        <source>
         Am J Infect Control
        </source>
        <year>
         2011
        </year>
        <volume>
         39
        </volume>
        <fpage>
         442
        </fpage>
        <lpage>
         3
        </lpage>
        <pub-id pub-id-type="pmid">
         21306797
        </pub-id>
       </element-citation>
      </ref>
      <ref id="DKT281C48">
       <label>
        48
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cotterill
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Evans
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Fraise
          </surname>
          <given-names>
           AP
          </given-names>
         </name>
        </person-group>
        <article-title>
         An unusual source for an outbreak of methicillin-resistant
         <italic>
          Staphylococcus aureus
         </italic>
         on an intensive therapy unit
        </article-title>
        <source>
         J Hosp Infect
        </source>
        <year>
         1996
        </year>
        <volume>
         32
        </volume>
        <fpage>
         207
        </fpage>
        <lpage>
         16
        </lpage>
        <pub-id pub-id-type="pmid">
         8690884
        </pub-id>
       </element-citation>
      </ref>
      <ref id="DKT281C49">
       <label>
        49
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kampf
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Rudolf
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Labadie
          </surname>
          <given-names>
           JC
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Spectrum of antimicrobial activity and user acceptability of the hand disinfectant agent Sterillium
         <sup>
          ®
         </sup>
         Gel
        </article-title>
        <source>
         J Hosp Infect
        </source>
        <year>
         2002
        </year>
        <volume>
         52
        </volume>
        <fpage>
         141
        </fpage>
        <lpage>
         7
        </lpage>
        <pub-id pub-id-type="pmid">
         12392906
        </pub-id>
       </element-citation>
      </ref>
      <ref id="DKT281C50">
       <label>
        50
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Barker
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Vipond
          </surname>
          <given-names>
           IB
          </given-names>
         </name>
         <name>
          <surname>
           Bloomfield
          </surname>
          <given-names>
           SF
          </given-names>
         </name>
        </person-group>
        <article-title>
         Effects of cleaning and disinfection in reducing the spread of Norovirus contamination via environmental surfaces
        </article-title>
        <source>
         J Hosp Infect
        </source>
        <year>
         2004
        </year>
        <volume>
         58
        </volume>
        <fpage>
         42
        </fpage>
        <lpage>
         9
        </lpage>
        <pub-id pub-id-type="pmid">
         15350713
        </pub-id>
       </element-citation>
      </ref>
      <ref id="DKT281C51">
       <label>
        51
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Pessoa-Silva
          </surname>
          <given-names>
           CLMD
          </given-names>
         </name>
         <name>
          <surname>
           Dharan
          </surname>
          <given-names>
           SMT
          </given-names>
         </name>
         <name>
          <surname>
           Hugonnet
          </surname>
          <given-names>
           SMDM
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Dynamics of bacterial hand contamination during routine neonatal care
        </article-title>
        <source>
         Infect Control Hosp Epidemiol
        </source>
        <year>
         2004
        </year>
        <volume>
         25
        </volume>
        <fpage>
         192
        </fpage>
        <lpage>
         7
        </lpage>
        <pub-id pub-id-type="pmid">
         15061408
        </pub-id>
       </element-citation>
      </ref>
      <ref id="DKT281C52">
       <label>
        52
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Pittet
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Dharan
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Touveneau
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Bacterial contamination of the hands of hospital staff during routine patient care
        </article-title>
        <source>
         Arch Intern Med
        </source>
        <year>
         1999
        </year>
        <volume>
         159
        </volume>
        <fpage>
         821
        </fpage>
        <lpage>
         6
        </lpage>
        <pub-id pub-id-type="pmid">
         10219927
        </pub-id>
       </element-citation>
      </ref>
      <ref id="DKT281C53">
       <label>
        53
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Fendler
          </surname>
          <given-names>
           EJ
          </given-names>
         </name>
         <name>
          <surname>
           Ali
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Hammond
          </surname>
          <given-names>
           BS
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         The impact of alcohol hand sanitizer use on infection rates in an extended care facility
        </article-title>
        <source>
         Am J Infect Control
        </source>
        <year>
         2002
        </year>
        <volume>
         30
        </volume>
        <fpage>
         226
        </fpage>
        <lpage>
         33
        </lpage>
        <pub-id pub-id-type="pmid">
         12032498
        </pub-id>
       </element-citation>
      </ref>
      <ref id="DKT281C54">
       <label>
        54
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hilburn
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Hammond
          </surname>
          <given-names>
           BS
          </given-names>
         </name>
         <name>
          <surname>
           Fendler
          </surname>
          <given-names>
           EJ
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Use of alcohol hand sanitizer as an infection control strategy in an acute care facility
        </article-title>
        <source>
         Am J Infect Control
        </source>
        <year>
         2003
        </year>
        <volume>
         31
        </volume>
        <fpage>
         109
        </fpage>
        <lpage>
         16
        </lpage>
        <pub-id pub-id-type="pmid">
         12665745
        </pub-id>
       </element-citation>
      </ref>
      <ref id="DKT281C55">
       <label>
        55
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Page
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Wilson
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Parkin
          </surname>
          <given-names>
           IP
          </given-names>
         </name>
        </person-group>
        <article-title>
         Antimicrobial surfaces and their potential in reducing the role of the inanimate environment in the incidence of hospital-acquired infections
        </article-title>
        <source>
         J Mater Chem
        </source>
        <year>
         2009
        </year>
        <volume>
         19
        </volume>
        <fpage>
         3819
        </fpage>
        <lpage>
         31
        </lpage>
       </element-citation>
      </ref>
      <ref id="DKT281C56">
       <label>
        56
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lopez
          </surname>
          <given-names>
           P-J
          </given-names>
         </name>
         <name>
          <surname>
           Ron
          </surname>
          <given-names>
           O
          </given-names>
         </name>
         <name>
          <surname>
           Parthasarathy
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Bacterial counts from hospital doctors' ties are higher than those from shirts
        </article-title>
        <source>
         Am J Infect Control
        </source>
        <year>
         2009
        </year>
        <volume>
         37
        </volume>
        <fpage>
         79
        </fpage>
        <lpage>
         80
        </lpage>
        <pub-id pub-id-type="pmid">
         19171249
        </pub-id>
       </element-citation>
      </ref>
      <ref id="DKT281C57">
       <label>
        57
       </label>
       <element-citation publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rutala
          </surname>
          <given-names>
           WA
          </given-names>
         </name>
         <name>
          <surname>
           Weber
          </surname>
          <given-names>
           DJ
          </given-names>
         </name>
        </person-group>
        <source>
         Guideline for Disinfection and Sterilization in Healthcare Facilities, 2008
        </source>
        <publisher-name>
         Healthcare Infection Control Practices Advisory Committee (HICPAC)
        </publisher-name>
        <comment>
         Atlanta, GA, USA: CDC.
        </comment>
       </element-citation>
      </ref>
      <ref id="DKT281C58">
       <label>
        58
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rutala
          </surname>
          <given-names>
           WA
          </given-names>
         </name>
         <name>
          <surname>
           Weber
          </surname>
          <given-names>
           DJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         Sterilization, high-level disinfection, and environmental cleaning
        </article-title>
        <source>
         Infect Dis Clin North Am
        </source>
        <year>
         2011
        </year>
        <volume>
         25
        </volume>
        <fpage>
         45
        </fpage>
        <lpage>
         76
        </lpage>
        <pub-id pub-id-type="pmid">
         21315994
        </pub-id>
       </element-citation>
      </ref>
      <ref id="DKT281C59">
       <label>
        59
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rutala
          </surname>
          <given-names>
           WA
          </given-names>
         </name>
         <name>
          <surname>
           Weber
          </surname>
          <given-names>
           DJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         Disinfection and sterilization in health care facilities: what clinicians need to know
        </article-title>
        <source>
         Clin Infect Dis
        </source>
        <year>
         2004
        </year>
        <volume>
         39
        </volume>
        <fpage>
         702
        </fpage>
        <lpage>
         9
        </lpage>
        <pub-id pub-id-type="pmid">
         15356786
        </pub-id>
       </element-citation>
      </ref>
      <ref id="DKT281C60">
       <label>
        60
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Russell
          </surname>
          <given-names>
           AD
          </given-names>
         </name>
        </person-group>
        <article-title>
         Bacterial resistance to disinfectants: present knowledge and future problems
        </article-title>
        <source>
         J Hosp Infect
        </source>
        <year>
         1999
        </year>
        <volume>
         43
        </volume>
        <fpage>
         S57
        </fpage>
        <lpage>
         68
        </lpage>
        <pub-id pub-id-type="pmid">
         10658759
        </pub-id>
       </element-citation>
      </ref>
      <ref id="DKT281C61">
       <label>
        61
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Fraise
          </surname>
          <given-names>
           AP
          </given-names>
         </name>
        </person-group>
        <article-title>
         Choosing disinfectants
        </article-title>
        <source>
         J Hosp Infect
        </source>
        <year>
         1999
        </year>
        <volume>
         43
        </volume>
        <fpage>
         255
        </fpage>
        <lpage>
         64
        </lpage>
        <pub-id pub-id-type="pmid">
         10658801
        </pub-id>
       </element-citation>
      </ref>
      <ref id="DKT281C62">
       <label>
        62
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rutala
          </surname>
          <given-names>
           WA
          </given-names>
         </name>
         <name>
          <surname>
           Weber
          </surname>
          <given-names>
           DJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         Infection control: the role of disinfection and sterilization
        </article-title>
        <source>
         J Hosp Infect
        </source>
        <year>
         1999
        </year>
        <volume>
         43
        </volume>
        <fpage>
         S43
        </fpage>
        <lpage>
         55
        </lpage>
        <pub-id pub-id-type="pmid">
         10658758
        </pub-id>
       </element-citation>
      </ref>
      <ref id="DKT281C63">
       <label>
        63
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           McDonnell
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Burke
          </surname>
          <given-names>
           P
          </given-names>
         </name>
        </person-group>
        <article-title>
         Disinfection: is it time to reconsider Spaulding
        </article-title>
        <source>
         J Hosp Infect
        </source>
        <year>
         2011
        </year>
        <volume>
         78
        </volume>
        <fpage>
         163
        </fpage>
        <lpage>
         70
        </lpage>
        <pub-id pub-id-type="pmid">
         21664533
        </pub-id>
       </element-citation>
      </ref>
      <ref id="DKT281C64">
       <label>
        64
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           McDonnell
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Russell
          </surname>
          <given-names>
           AD
          </given-names>
         </name>
        </person-group>
        <article-title>
         Antiseptics and disinfectants: activity, action, and resistance
        </article-title>
        <source>
         Clin Microbiol Rev
        </source>
        <year>
         1999
        </year>
        <volume>
         12
        </volume>
        <fpage>
         147
        </fpage>
        <lpage>
         79
        </lpage>
        <pub-id pub-id-type="pmid">
         9880479
        </pub-id>
       </element-citation>
      </ref>
      <ref id="DKT281C65">
       <label>
        65
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sagripanti
          </surname>
          <given-names>
           J-L
          </given-names>
         </name>
         <name>
          <surname>
           Bonifacino
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        <article-title>
         Bacterial spores survive treatment with commercial sterilants and disinfectants
        </article-title>
        <source>
         Appl Environ Microbiol
        </source>
        <year>
         1999
        </year>
        <volume>
         65
        </volume>
        <fpage>
         4255
        </fpage>
        <lpage>
         60
        </lpage>
        <pub-id pub-id-type="pmid">
         10473448
        </pub-id>
       </element-citation>
      </ref>
      <ref id="DKT281C66">
       <label>
        66
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Russell
          </surname>
          <given-names>
           AD
          </given-names>
         </name>
        </person-group>
        <article-title>
         Bacterial adaptation and resistance to antiseptics, disinfectants and preservatives is not a new phenomenon
        </article-title>
        <source>
         J Hosp Infect
        </source>
        <year>
         2004
        </year>
        <volume>
         57
        </volume>
        <fpage>
         97
        </fpage>
        <lpage>
         104
        </lpage>
        <pub-id pub-id-type="pmid">
         15183238
        </pub-id>
       </element-citation>
      </ref>
      <ref id="DKT281C67">
       <label>
        67
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Russell
          </surname>
          <given-names>
           AD
          </given-names>
         </name>
        </person-group>
        <article-title>
         Introduction of biocides into clinical practice and the impact on antibiotic-resistant bacteria
        </article-title>
        <source>
         J Appl Microbiol
        </source>
        <year>
         2002
        </year>
        <volume>
         92
        </volume>
        <issue>
         Suppl
        </issue>
        <fpage>
         121S
        </fpage>
        <lpage>
         35S
        </lpage>
        <pub-id pub-id-type="pmid">
         12000621
        </pub-id>
       </element-citation>
      </ref>
      <ref id="DKT281C68">
       <label>
        68
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gilbert
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           McBain
          </surname>
          <given-names>
           AJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         Potential impact of increased use of biocides in consumer products on prevalence of antibiotic resistance
        </article-title>
        <source>
         Clin Microbiol Rev
        </source>
        <year>
         2003
        </year>
        <volume>
         16
        </volume>
        <fpage>
         189
        </fpage>
        <lpage>
         208
        </lpage>
        <pub-id pub-id-type="pmid">
         12692093
        </pub-id>
       </element-citation>
      </ref>
      <ref id="DKT281C69">
       <label>
        69
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rutala
          </surname>
          <given-names>
           WA
          </given-names>
         </name>
         <name>
          <surname>
           Weber
          </surname>
          <given-names>
           DJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         Uses of inorganic hypochlorite (bleach) in health-care facilities
        </article-title>
        <source>
         Clin Microbiol Rev
        </source>
        <year>
         1997
        </year>
        <volume>
         10
        </volume>
        <fpage>
         597
        </fpage>
        <lpage>
         610
        </lpage>
        <pub-id pub-id-type="pmid">
         9336664
        </pub-id>
       </element-citation>
      </ref>
      <ref id="DKT281C70">
       <label>
        70
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bermúdez-Aguirre
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Barbosa-Cánovas
          </surname>
          <given-names>
           GV
          </given-names>
         </name>
        </person-group>
        <article-title>
         Disinfection of selected vegetables under nonthermal treatments: chlorine, acid citric, ultraviolet light and ozone
        </article-title>
        <source>
         Food Control
        </source>
        <year>
         2013
        </year>
        <volume>
         29
        </volume>
        <fpage>
         82
        </fpage>
        <lpage>
         90
        </lpage>
       </element-citation>
      </ref>
      <ref id="DKT281C71">
       <label>
        71
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Denyer
          </surname>
          <given-names>
           SP
          </given-names>
         </name>
         <name>
          <surname>
           Stewart
          </surname>
          <given-names>
           GSAB
          </given-names>
         </name>
        </person-group>
        <article-title>
         Mechanisms of action of disinfectants
        </article-title>
        <source>
         Int Biodeter Biodegr
        </source>
        <year>
         1998
        </year>
        <volume>
         41
        </volume>
        <fpage>
         261
        </fpage>
        <lpage>
         8
        </lpage>
       </element-citation>
      </ref>
      <ref id="DKT281C72">
       <label>
        72
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Russell
          </surname>
          <given-names>
           AD
          </given-names>
         </name>
        </person-group>
        <article-title>
         Similarities and differences in the responses of microorganisms to biocides
        </article-title>
        <source>
         J Antimicrob Chemother
        </source>
        <year>
         2003
        </year>
        <volume>
         52
        </volume>
        <fpage>
         750
        </fpage>
        <lpage>
         63
        </lpage>
        <pub-id pub-id-type="pmid">
         14519671
        </pub-id>
       </element-citation>
      </ref>
      <ref id="DKT281C73">
       <label>
        73
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Griffiths
          </surname>
          <given-names>
           PA
          </given-names>
         </name>
         <name>
          <surname>
           Babb
          </surname>
          <given-names>
           JR
          </given-names>
         </name>
         <name>
          <surname>
           Fraise
          </surname>
          <given-names>
           AP
          </given-names>
         </name>
        </person-group>
        <article-title>
         Mycobactericidal activity of selected disinfectants using a quantitative suspension test
        </article-title>
        <source>
         J Hosp Infect
        </source>
        <year>
         1999
        </year>
        <volume>
         41
        </volume>
        <fpage>
         111
        </fpage>
        <lpage>
         21
        </lpage>
        <pub-id pub-id-type="pmid">
         10063473
        </pub-id>
       </element-citation>
      </ref>
      <ref id="DKT281C74">
       <label>
        74
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Théraud
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Bédouin
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Guiguen
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Efficacy of antiseptics and disinfectants on clinical and environmental yeast isolates in planktonic and biofilm conditions
        </article-title>
        <source>
         J Med Microbiol
        </source>
        <year>
         2004
        </year>
        <volume>
         53
        </volume>
        <fpage>
         1013
        </fpage>
        <lpage>
         8
        </lpage>
        <pub-id pub-id-type="pmid">
         15358824
        </pub-id>
       </element-citation>
      </ref>
      <ref id="DKT281C75">
       <label>
        75
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Oie
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Yanagi
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Matsui
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Contamination of environmental surfaces by
         <italic>
          Staphylococcus aureus
         </italic>
         in a dermatological ward and its preventive measures
        </article-title>
        <source>
         Biol Pharm Bull
        </source>
        <year>
         2005
        </year>
        <volume>
         28
        </volume>
        <fpage>
         120
        </fpage>
        <lpage>
         3
        </lpage>
        <pub-id pub-id-type="pmid">
         15635175
        </pub-id>
       </element-citation>
      </ref>
      <ref id="DKT281C76">
       <label>
        76
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Speight
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Moy
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Macken
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Evaluation of the sporicidal activity of different chemical disinfectants used in hospitals against
         <italic>
          Clostridium difficile
         </italic>
        </article-title>
        <source>
         J Hosp Infect
        </source>
        <year>
         2011
        </year>
        <volume>
         79
        </volume>
        <fpage>
         18
        </fpage>
        <lpage>
         22
        </lpage>
        <pub-id pub-id-type="pmid">
         21802172
        </pub-id>
       </element-citation>
      </ref>
      <ref id="DKT281C77">
       <label>
        77
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kim
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Ryu
          </surname>
          <given-names>
           J-H
          </given-names>
         </name>
         <name>
          <surname>
           Beuchat
          </surname>
          <given-names>
           LR
          </given-names>
         </name>
        </person-group>
        <article-title>
         Effectiveness of disinfectants in killing
         <italic>
          Enterobacter sakazakii
         </italic>
         in suspension, dried on the surface of stainless steel, and in a biofilm
        </article-title>
        <source>
         Appl Environ Microbiol
        </source>
        <year>
         2007
        </year>
        <volume>
         73
        </volume>
        <fpage>
         1256
        </fpage>
        <lpage>
         65
        </lpage>
        <pub-id pub-id-type="pmid">
         17172461
        </pub-id>
       </element-citation>
      </ref>
      <ref id="DKT281C78">
       <label>
        78
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bridier
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Briandet
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Thomas
          </surname>
          <given-names>
           V
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Comparative biocidal activity of peracetic acid, benzalkonium chloride and
         <italic>
          ortho
         </italic>
         -phthalaldehyde on 77 bacterial strains
        </article-title>
        <source>
         J Hosp Infect
        </source>
        <year>
         2011
        </year>
        <volume>
         78
        </volume>
        <fpage>
         208
        </fpage>
        <lpage>
         13
        </lpage>
        <pub-id pub-id-type="pmid">
         21664534
        </pub-id>
       </element-citation>
      </ref>
      <ref id="DKT281C79">
       <label>
        79
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gutiérrez-Martín
          </surname>
          <given-names>
           CB
          </given-names>
         </name>
         <name>
          <surname>
           Yubero
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Martínez
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Evaluation of efficacy of several disinfectants against
         <italic>
          Campylobacter jejuni
         </italic>
         strains by a suspension test
        </article-title>
        <source>
         Res Vet Sci
        </source>
        <year>
         2011
        </year>
        <volume>
         91
        </volume>
        <fpage>
         e44
        </fpage>
        <lpage>
         7
        </lpage>
        <pub-id pub-id-type="pmid">
         21338999
        </pub-id>
       </element-citation>
      </ref>
      <ref id="DKT281C80">
       <label>
        80
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Siani
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Cooper
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Maillard
          </surname>
          <given-names>
           J-Y
          </given-names>
         </name>
        </person-group>
        <article-title>
         Efficacy of ‘sporicidal’ wipes against
         <italic>
          Clostridium difficile
         </italic>
        </article-title>
        <source>
         Am J Infect Control
        </source>
        <year>
         2011
        </year>
        <volume>
         39
        </volume>
        <fpage>
         212
        </fpage>
        <lpage>
         8
        </lpage>
        <pub-id pub-id-type="pmid">
         21458683
        </pub-id>
       </element-citation>
      </ref>
      <ref id="DKT281C81">
       <label>
        81
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Giannini
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
         <name>
          <surname>
           Nance
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           McCullers
          </surname>
          <given-names>
           JA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Are toilet seats a vector for transmission of methicillin-resistant
         <italic>
          Staphylococcus aureus
         </italic>
        </article-title>
        <source>
         Am J Infect Control
        </source>
        <year>
         2009
        </year>
        <volume>
         37
        </volume>
        <fpage>
         505
        </fpage>
        <lpage>
         6
        </lpage>
        <pub-id pub-id-type="pmid">
         19243856
        </pub-id>
       </element-citation>
      </ref>
      <ref id="DKT281C82">
       <label>
        82
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Williams
          </surname>
          <given-names>
           GJ
          </given-names>
         </name>
         <name>
          <surname>
           Denyer
          </surname>
          <given-names>
           SP
          </given-names>
         </name>
         <name>
          <surname>
           Hosein
          </surname>
          <given-names>
           IK
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         The development of a new three-step protocol to determine the efficacy of disinfectant wipes on surfaces contaminated with
         <italic>
          Staphylococcus aureus
         </italic>
        </article-title>
        <source>
         J Hosp Infect
        </source>
        <year>
         2007
        </year>
        <volume>
         67
        </volume>
        <fpage>
         329
        </fpage>
        <lpage>
         35
        </lpage>
        <pub-id pub-id-type="pmid">
         17945392
        </pub-id>
       </element-citation>
      </ref>
      <ref id="DKT281C83">
       <label>
        83
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rutala
          </surname>
          <given-names>
           WA
          </given-names>
         </name>
         <name>
          <surname>
           Weber
          </surname>
          <given-names>
           DJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         New disinfection and sterilization methods
        </article-title>
        <source>
         Emerging Infect Dis
        </source>
        <year>
         2001
        </year>
        <volume>
         7
        </volume>
        <fpage>
         348
        </fpage>
        <lpage>
         53
        </lpage>
        <pub-id pub-id-type="pmid">
         11294738
        </pub-id>
       </element-citation>
      </ref>
      <ref id="DKT281C84">
       <label>
        84
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tanner
          </surname>
          <given-names>
           BD
          </given-names>
         </name>
        </person-group>
        <article-title>
         Reduction in infection risk through treatment of microbially contaminated surfaces with a novel, portable, saturated steam vapor disinfection system
        </article-title>
        <source>
         Am J Infect Control
        </source>
        <year>
         2009
        </year>
        <volume>
         37
        </volume>
        <fpage>
         20
        </fpage>
        <lpage>
         7
        </lpage>
        <pub-id pub-id-type="pmid">
         18834748
        </pub-id>
       </element-citation>
      </ref>
      <ref id="DKT281C85">
       <label>
        85
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Otter
          </surname>
          <given-names>
           JA
          </given-names>
         </name>
         <name>
          <surname>
           French
          </surname>
          <given-names>
           GL
          </given-names>
         </name>
        </person-group>
        <article-title>
         Survival of nosocomial bacteria and spores on surfaces and inactivation by hydrogen peroxide vapor
        </article-title>
        <source>
         J Clin Microbiol
        </source>
        <year>
         2009
        </year>
        <volume>
         47
        </volume>
        <fpage>
         205
        </fpage>
        <lpage>
         7
        </lpage>
        <pub-id pub-id-type="pmid">
         18971364
        </pub-id>
       </element-citation>
      </ref>
      <ref id="DKT281C86">
       <label>
        86
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hall
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Otter
          </surname>
          <given-names>
           JA
          </given-names>
         </name>
         <name>
          <surname>
           Chewins
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Use of hydrogen peroxide vapor for deactivation of
         <italic>
          Mycobacterium tuberculosis
         </italic>
         in a biological safety cabinet and a room
        </article-title>
        <source>
         J Clin Microbiol
        </source>
        <year>
         2007
        </year>
        <volume>
         45
        </volume>
        <fpage>
         810
        </fpage>
        <lpage>
         5
        </lpage>
        <pub-id pub-id-type="pmid">
         17166957
        </pub-id>
       </element-citation>
      </ref>
      <ref id="DKT281C87">
       <label>
        87
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           McDonnell
          </surname>
          <given-names>
           G
          </given-names>
         </name>
        </person-group>
        <article-title>
         Hydrogen peroxide fogging/fumigation
        </article-title>
        <source>
         J Hosp Infect
        </source>
        <year>
         2006
        </year>
        <volume>
         62
        </volume>
        <fpage>
         385
        </fpage>
        <lpage>
         6
        </lpage>
        <pub-id pub-id-type="pmid">
         16337711
        </pub-id>
       </element-citation>
      </ref>
      <ref id="DKT281C88">
       <label>
        88
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Boyce
          </surname>
          <given-names>
           JM
          </given-names>
         </name>
         <name>
          <surname>
           Havill
          </surname>
          <given-names>
           NL
          </given-names>
         </name>
         <name>
          <surname>
           Moore
          </surname>
          <given-names>
           BA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Terminal decontamination of patient rooms using an automated mobile UV light unit
        </article-title>
        <source>
         Infect Control Hosp Epidemiol
        </source>
        <year>
         2011
        </year>
        <volume>
         32
        </volume>
        <fpage>
         737
        </fpage>
        <lpage>
         42
        </lpage>
        <pub-id pub-id-type="pmid">
         21768755
        </pub-id>
       </element-citation>
      </ref>
      <ref id="DKT281C89">
       <label>
        89
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rutala
          </surname>
          <given-names>
           WA
          </given-names>
         </name>
         <name>
          <surname>
           Gergen
          </surname>
          <given-names>
           MF
          </given-names>
         </name>
         <name>
          <surname>
           Weber
          </surname>
          <given-names>
           DJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         Room decontamination with UV radiation
        </article-title>
        <source>
         Infect Control Hosp Epidemiol
        </source>
        <year>
         2010
        </year>
        <volume>
         31
        </volume>
        <fpage>
         1025
        </fpage>
        <lpage>
         9
        </lpage>
        <pub-id pub-id-type="pmid">
         20804377
        </pub-id>
       </element-citation>
      </ref>
      <ref id="DKT281C90">
       <label>
        90
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sambol
          </surname>
          <given-names>
           AR
          </given-names>
         </name>
         <name>
          <surname>
           Iwen
          </surname>
          <given-names>
           PC
          </given-names>
         </name>
        </person-group>
        <article-title>
         Biological monitoring of ultraviolet germicidal irradiation in a biosafety level 3 laboratory
        </article-title>
        <source>
         Appl Biosaf
        </source>
        <year>
         2006
        </year>
        <volume>
         11
        </volume>
        <fpage>
         81
        </fpage>
        <lpage>
         7
        </lpage>
       </element-citation>
      </ref>
      <ref id="DKT281C91">
       <label>
        91
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Weber
          </surname>
          <given-names>
           DJ
          </given-names>
         </name>
         <name>
          <surname>
           Rutala
          </surname>
          <given-names>
           WA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Self-disinfecting surfaces
        </article-title>
        <source>
         Infect Control Hosp Epidemiol
        </source>
        <year>
         2012
        </year>
        <volume>
         33
        </volume>
        <fpage>
         10
        </fpage>
        <lpage>
         3
        </lpage>
        <pub-id pub-id-type="pmid">
         22173516
        </pub-id>
       </element-citation>
      </ref>
      <ref id="DKT281C92">
       <label>
        92
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rutala
          </surname>
          <given-names>
           WA
          </given-names>
         </name>
         <name>
          <surname>
           Weber
          </surname>
          <given-names>
           DJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         Are room decontamination units needed to prevent transmission of environmental pathogens
        </article-title>
        <source>
         Infect Control Hosp Epidemiol
        </source>
        <year>
         2011
        </year>
        <volume>
         32
        </volume>
        <fpage>
         743
        </fpage>
        <lpage>
         7
        </lpage>
        <pub-id pub-id-type="pmid">
         21768756
        </pub-id>
       </element-citation>
      </ref>
      <ref id="DKT281C93">
       <label>
        93
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <name>
          <surname>
           Jiang
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Surface microstructures and antimicrobial properties of copper plasma alloyed stainless steel
        </article-title>
        <source>
         Appl Surf Sci
        </source>
        <year>
         2011
        </year>
        <volume>
         258
        </volume>
        <fpage>
         1399
        </fpage>
        <lpage>
         404
        </lpage>
       </element-citation>
      </ref>
      <ref id="DKT281C94">
       <label>
        94
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Héquet
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Humblot
          </surname>
          <given-names>
           V
          </given-names>
         </name>
         <name>
          <surname>
           Berjeaud
          </surname>
          <given-names>
           J-M
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Optimized grafting of antimicrobial peptides on stainless steel surface and biofilm resistance tests
        </article-title>
        <source>
         Colloid Surface B
        </source>
        <year>
         2011
        </year>
        <volume>
         84
        </volume>
        <fpage>
         301
        </fpage>
        <lpage>
         9
        </lpage>
       </element-citation>
      </ref>
      <ref id="DKT281C95">
       <label>
        95
       </label>
       <element-citation publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tiller
          </surname>
          <given-names>
           JC
          </given-names>
         </name>
        </person-group>
        <person-group person-group-type="editor">
         <name>
          <surname>
           Kohli
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Mittal
          </surname>
          <given-names>
           KL
          </given-names>
         </name>
        </person-group>
        <article-title>
         Coatings for prevention or deactivation of biological contamination
        </article-title>
        <source>
         Developments in Surface Contamination and Cleaning
        </source>
        <year>
         2008
        </year>
        <publisher-loc>
         Norwich, NY, USA
        </publisher-loc>
        <publisher-name>
         William Andrew
        </publisher-name>
        <fpage>
         1013
        </fpage>
        <lpage>
         65
        </lpage>
       </element-citation>
      </ref>
      <ref id="DKT281C96">
       <label>
        96
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tian
          </surname>
          <given-names>
           XB
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           ZM
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           SQ
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Antibacterial copper-containing titanium nitride films produced by dual magnetron sputtering
        </article-title>
        <source>
         Surf Coat Technol
        </source>
        <year>
         2007
        </year>
        <volume>
         201
        </volume>
        <fpage>
         8606
        </fpage>
        <lpage>
         9
        </lpage>
       </element-citation>
      </ref>
      <ref id="DKT281C97">
       <label>
        97
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Dunnill
          </surname>
          <given-names>
           CW
          </given-names>
         </name>
         <name>
          <surname>
           Page
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Aiken
          </surname>
          <given-names>
           ZA
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Nanoparticulate silver coated-titania thin films - photo-oxidative destruction of stearic acid under different light sources and antimicrobial effects under hospital lighting conditions
        </article-title>
        <source>
         J Photochem Photobiol A
        </source>
        <year>
         2011
        </year>
        <volume>
         220
        </volume>
        <fpage>
         113
        </fpage>
        <lpage>
         23
        </lpage>
       </element-citation>
      </ref>
      <ref id="DKT281C98">
       <label>
        98
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Balazs
          </surname>
          <given-names>
           DJ
          </given-names>
         </name>
         <name>
          <surname>
           Triandafillu
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Wood
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Inhibition of bacterial adhesion on PVC endotracheal tubes by RF-oxygen glow discharge, sodium hydroxide and silver nitrate treatments
        </article-title>
        <source>
         Biomaterials
        </source>
        <year>
         2004
        </year>
        <volume>
         25
        </volume>
        <fpage>
         2139
        </fpage>
        <lpage>
         51
        </lpage>
        <pub-id pub-id-type="pmid">
         14741629
        </pub-id>
       </element-citation>
      </ref>
      <ref id="DKT281C99">
       <label>
        99
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Siedenbiedel
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Tiller
          </surname>
          <given-names>
           JC
          </given-names>
         </name>
        </person-group>
        <article-title>
         Antimicrobial polymers in solution and on surfaces: overview and functional principles
        </article-title>
        <source>
         Polymers
        </source>
        <year>
         2012
        </year>
        <volume>
         4
        </volume>
        <fpage>
         46
        </fpage>
        <lpage>
         71
        </lpage>
       </element-citation>
      </ref>
      <ref id="DKT281C100">
       <label>
        100
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kühn
          </surname>
          <given-names>
           KP
          </given-names>
         </name>
         <name>
          <surname>
           Chaberny
          </surname>
          <given-names>
           IF
          </given-names>
         </name>
         <name>
          <surname>
           Massholder
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Disinfection of surfaces by photocatalytic oxidation with titanium dioxide and UVA light
        </article-title>
        <source>
         Chemosphere
        </source>
        <year>
         2003
        </year>
        <volume>
         53
        </volume>
        <fpage>
         71
        </fpage>
        <lpage>
         7
        </lpage>
        <pub-id pub-id-type="pmid">
         12892668
        </pub-id>
       </element-citation>
      </ref>
      <ref id="DKT281C101">
       <label>
        101
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Goddard
          </surname>
          <given-names>
           JM
          </given-names>
         </name>
         <name>
          <surname>
           Hotchkiss
          </surname>
          <given-names>
           JH
          </given-names>
         </name>
        </person-group>
        <article-title>
         Polymer surface modification for the attachment of bioactive compounds
        </article-title>
        <source>
         Prog Polym Sci
        </source>
        <year>
         2007
        </year>
        <volume>
         32
        </volume>
        <fpage>
         698
        </fpage>
        <lpage>
         725
        </lpage>
       </element-citation>
      </ref>
      <ref id="DKT281C102">
       <label>
        102
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kenawy
          </surname>
          <given-names>
           E-R
          </given-names>
         </name>
         <name>
          <surname>
           Worley
          </surname>
          <given-names>
           SD
          </given-names>
         </name>
         <name>
          <surname>
           Broughton
          </surname>
          <given-names>
           R
          </given-names>
         </name>
        </person-group>
        <article-title>
         The chemistry and applications of antimicrobial polymers: a state-of-the-art review
        </article-title>
        <source>
         Biomacromolecules
        </source>
        <year>
         2007
        </year>
        <volume>
         8
        </volume>
        <fpage>
         1359
        </fpage>
        <lpage>
         84
        </lpage>
        <pub-id pub-id-type="pmid">
         17425365
        </pub-id>
       </element-citation>
      </ref>
      <ref id="DKT281C103">
       <label>
        103
       </label>
       <element-citation publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ristić
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Zemljič
          </surname>
          <given-names>
           LF
          </given-names>
         </name>
         <name>
          <surname>
           Novak
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <person-group person-group-type="editor">
         <name>
          <surname>
           Méndez-Vilas
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        <article-title>
         Antimicrobial efficiency of functionalized cellulose fibres as potential medical textiles
        </article-title>
        <source>
         Science Against Microbial Pathogens: Communicating Current Research and Technological Advances
        </source>
        <year>
         2011
        </year>
        <publisher-loc>
         Badajoz, Spain
        </publisher-loc>
        <publisher-name>
         Formatex
        </publisher-name>
        <fpage>
         36
        </fpage>
        <lpage>
         51
        </lpage>
       </element-citation>
      </ref>
      <ref id="DKT281C104">
       <label>
        104
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lichter
          </surname>
          <given-names>
           JA
          </given-names>
         </name>
         <name>
          <surname>
           Rubner
          </surname>
          <given-names>
           MF
          </given-names>
         </name>
        </person-group>
        <article-title>
         Polyelectrolyte multilayers with intrinsic antimicrobial functionality: the importance of mobile polycations
        </article-title>
        <source>
         Langmuir
        </source>
        <year>
         2009
        </year>
        <volume>
         25
        </volume>
        <fpage>
         7686
        </fpage>
        <lpage>
         94
        </lpage>
        <pub-id pub-id-type="pmid">
         19317389
        </pub-id>
       </element-citation>
      </ref>
      <ref id="DKT281C105">
       <label>
        105
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Moisan
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Barbeau
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Moreau
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Low-temperature sterilization using gas plasmas: a review of the experiments and an analysis of the inactivation mechanisms
        </article-title>
        <source>
         Int J Pharm
        </source>
        <year>
         2001
        </year>
        <volume>
         226
        </volume>
        <fpage>
         1
        </fpage>
        <lpage>
         21
        </lpage>
        <pub-id pub-id-type="pmid">
         11532565
        </pub-id>
       </element-citation>
      </ref>
      <ref id="DKT281C106">
       <label>
        106
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Moreau
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Orange
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Feuilloley
          </surname>
          <given-names>
           MGJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         Non-thermal plasma technologies: new tools for bio-decontamination
        </article-title>
        <source>
         Biotechnol Adv
        </source>
        <year>
         2008
        </year>
        <volume>
         26
        </volume>
        <fpage>
         610
        </fpage>
        <lpage>
         7
        </lpage>
        <pub-id pub-id-type="pmid">
         18775485
        </pub-id>
       </element-citation>
      </ref>
      <ref id="DKT281C107">
       <label>
        107
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Morfill
          </surname>
          <given-names>
           GE
          </given-names>
         </name>
         <name>
          <surname>
           Shimizu
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Steffes
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Nosocomial infections - a new approach towards preventive medicine using plasmas
        </article-title>
        <source>
         New J Phys
        </source>
        <year>
         2009
        </year>
        <volume>
         11
        </volume>
        <fpage>
         1
        </fpage>
        <lpage>
         10
        </lpage>
       </element-citation>
      </ref>
      <ref id="DKT281C108">
       <label>
        108
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Shimizu
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Zimmermann
          </surname>
          <given-names>
           JL
          </given-names>
         </name>
         <name>
          <surname>
           Morfill
          </surname>
          <given-names>
           GE
          </given-names>
         </name>
        </person-group>
        <article-title>
         The bactericidal effect of surface micro-discharge plasma under different ambient conditions
        </article-title>
        <source>
         New J Phys
        </source>
        <year>
         2011
        </year>
        <volume>
         13
        </volume>
        <fpage>
         1
        </fpage>
        <lpage>
         7
        </lpage>
       </element-citation>
      </ref>
      <ref id="DKT281C109">
       <label>
        109
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gregory
          </surname>
          <given-names>
           DS
          </given-names>
         </name>
        </person-group>
        <article-title>
         Pertussis: a disease affecting all ages
        </article-title>
        <source>
         Am Fam Physician
        </source>
        <year>
         2006
        </year>
        <volume>
         74
        </volume>
        <fpage>
         420
        </fpage>
        <lpage>
         6
        </lpage>
        <pub-id pub-id-type="pmid">
         16913160
        </pub-id>
       </element-citation>
      </ref>
      <ref id="DKT281C110">
       <label>
        110
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hanna
          </surname>
          <given-names>
           HMD
          </given-names>
         </name>
         <name>
          <surname>
           Raad
          </surname>
          <given-names>
           IMD
          </given-names>
         </name>
         <name>
          <surname>
           Gonzalez
          </surname>
          <given-names>
           VBS
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Control of nosocomial
         <italic>
          Clostridium difficile
         </italic>
         transmission in bone marrow transplant patients
        </article-title>
        <source>
         Infect Control Hosp Epidemiol
        </source>
        <year>
         2000
        </year>
        <volume>
         21
        </volume>
        <fpage>
         226
        </fpage>
        <lpage>
         8
        </lpage>
        <pub-id pub-id-type="pmid">
         10738997
        </pub-id>
       </element-citation>
      </ref>
      <ref id="DKT281C111">
       <label>
        111
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sinh
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Barrett
          </surname>
          <given-names>
           TA
          </given-names>
         </name>
         <name>
          <surname>
           Yun
          </surname>
          <given-names>
           L
          </given-names>
         </name>
        </person-group>
        <article-title>
         <italic>
          Clostridium difficile
         </italic>
         infection and inflammatory bowel disease: a review
        </article-title>
        <source>
         Gastroenterol Res Pract
        </source>
        <year>
         2011
        </year>
        <volume>
         2011
        </volume>
        <fpage>
         136064
        </fpage>
        <comment>
         :
        </comment>
        <pub-id pub-id-type="pmid">
         21915178
        </pub-id>
       </element-citation>
      </ref>
      <ref id="DKT281C112">
       <label>
        112
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kuo
          </surname>
          <given-names>
           CC
          </given-names>
         </name>
         <name>
          <surname>
           Jackson
          </surname>
          <given-names>
           LA
          </given-names>
         </name>
         <name>
          <surname>
           Campbell
          </surname>
          <given-names>
           LA
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         <italic>
          Chlamydia pneumoniae
         </italic>
         (TWAR)
        </article-title>
        <source>
         Clin Microbiol Rev
        </source>
        <year>
         1995
        </year>
        <volume>
         8
        </volume>
        <fpage>
         451
        </fpage>
        <lpage>
         61
        </lpage>
        <pub-id pub-id-type="pmid">
         8665464
        </pub-id>
       </element-citation>
      </ref>
      <ref id="DKT281C113">
       <label>
        113
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Campbell
          </surname>
          <given-names>
           LA
          </given-names>
         </name>
         <name>
          <surname>
           Kuo
          </surname>
          <given-names>
           CC
          </given-names>
         </name>
        </person-group>
        <article-title>
         <italic>
          Chlamydia pneumoniae
         </italic>
         pathogenesis
        </article-title>
        <source>
         J Med Microbiol
        </source>
        <year>
         2002
        </year>
        <volume>
         51
        </volume>
        <fpage>
         623
        </fpage>
        <lpage>
         5
        </lpage>
        <pub-id pub-id-type="pmid">
         12171291
        </pub-id>
       </element-citation>
      </ref>
      <ref id="DKT281C114">
       <label>
        114
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bonnet
          </surname>
          <given-names>
           JM
          </given-names>
         </name>
         <name>
          <surname>
           Begg
          </surname>
          <given-names>
           NT
          </given-names>
         </name>
        </person-group>
        <article-title>
         Control of diphtheria: guidance for consultants in communicable disease control
        </article-title>
        <source>
         Commun Dis Public Health
        </source>
        <year>
         1999
        </year>
        <volume>
         2
        </volume>
        <fpage>
         242
        </fpage>
        <lpage>
         9
        </lpage>
        <pub-id pub-id-type="pmid">
         10598380
        </pub-id>
       </element-citation>
      </ref>
      <ref id="DKT281C115">
       <label>
        115
       </label>
       <element-citation publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Murphy
          </surname>
          <given-names>
           JR
          </given-names>
         </name>
        </person-group>
        <person-group person-group-type="editor">
         <name>
          <surname>
           Baron
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        <source>
         Medical Microbiology
        </source>
        <year>
         1996
        </year>
        <publisher-loc>
         Galveston, TX
        </publisher-loc>
        <publisher-name>
         University of Texas Medical Branch at Galveston
        </publisher-name>
        <comment>
         <italic>
          Corynebacterium diphtheriae
         </italic>
         Chapter 32
        </comment>
       </element-citation>
      </ref>
      <ref id="DKT281C116">
       <label>
        116
       </label>
       <element-citation publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Oprea
          </surname>
          <given-names>
           SF
          </given-names>
         </name>
         <name>
          <surname>
           Zervos
          </surname>
          <given-names>
           MJ
          </given-names>
         </name>
        </person-group>
        <person-group person-group-type="editor">
         <name>
          <surname>
           Simjee
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        <article-title>
         <italic>
          Enterococcus
         </italic>
         and its association with foodborne illness
        </article-title>
        <source>
         Foodborne Disease
        </source>
        <year>
         2007
        </year>
        <publisher-loc>
         Totowa, NJ
        </publisher-loc>
        <publisher-name>
         Humana Press
        </publisher-name>
        <fpage>
         157
        </fpage>
        <lpage>
         74
        </lpage>
       </element-citation>
      </ref>
      <ref id="DKT281C117">
       <label>
        117
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Foxwell
          </surname>
          <given-names>
           AR
          </given-names>
         </name>
         <name>
          <surname>
           Kyd
          </surname>
          <given-names>
           JM
          </given-names>
         </name>
         <name>
          <surname>
           Cripps
          </surname>
          <given-names>
           AW
          </given-names>
         </name>
        </person-group>
        <article-title>
         Nontypeable
         <italic>
          Haemophilus influenzae
         </italic>
         : pathogenesis and prevention
        </article-title>
        <source>
         Microbiol Mol Biol Rev
        </source>
        <year>
         1998
        </year>
        <volume>
         62
        </volume>
        <fpage>
         294
        </fpage>
        <lpage>
         308
        </lpage>
        <pub-id pub-id-type="pmid">
         9618443
        </pub-id>
       </element-citation>
      </ref>
      <ref id="DKT281C118">
       <label>
        118
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Podschun
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Ullmann
          </surname>
          <given-names>
           U
          </given-names>
         </name>
        </person-group>
        <article-title>
         <italic>
          Klebsiella
         </italic>
         spp. as nosocomial pathogens: epidemiology, taxonomy, typing methods, and pathogenicity factors
        </article-title>
        <source>
         Clin Microbiol Rev
        </source>
        <year>
         1998
        </year>
        <volume>
         11
        </volume>
        <fpage>
         589
        </fpage>
        <lpage>
         603
        </lpage>
        <pub-id pub-id-type="pmid">
         9767057
        </pub-id>
       </element-citation>
      </ref>
      <ref id="DKT281C119">
       <label>
        119
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Engelhart
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Krizek
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Glasmacher
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         <italic>
          Pseudomonas aeruginosa
         </italic>
         outbreak in a haematology–oncology unit associated with contaminated surface cleaning equipment
        </article-title>
        <source>
         J Hosp Infect
        </source>
        <year>
         2002
        </year>
        <volume>
         52
        </volume>
        <fpage>
         93
        </fpage>
        <lpage>
         8
        </lpage>
        <pub-id pub-id-type="pmid">
         12392900
        </pub-id>
       </element-citation>
      </ref>
      <ref id="DKT281C120">
       <label>
        120
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Manning
          </surname>
          <given-names>
           ML
          </given-names>
         </name>
         <name>
          <surname>
           Archibald
          </surname>
          <given-names>
           LK
          </given-names>
         </name>
         <name>
          <surname>
           Bell
          </surname>
          <given-names>
           LM
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         <italic>
          Serratia marcescens
         </italic>
         transmission in a pediatric intensive care unit: a multifactorial occurrence
        </article-title>
        <source>
         Am J Infect Control
        </source>
        <year>
         2001
        </year>
        <volume>
         29
        </volume>
        <fpage>
         115
        </fpage>
        <lpage>
         9
        </lpage>
        <pub-id pub-id-type="pmid">
         11287880
        </pub-id>
       </element-citation>
      </ref>
      <ref id="DKT281C121">
       <label>
        121
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Passaro
          </surname>
          <given-names>
           DJ
          </given-names>
         </name>
         <name>
          <surname>
           Waring
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Armstrong
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Postoperative
         <italic>
          Serratia marcescens
         </italic>
         wound infections traced to an out-of-hospital source
        </article-title>
        <source>
         J Infect Dis
        </source>
        <year>
         1997
        </year>
        <volume>
         175
        </volume>
        <fpage>
         992
        </fpage>
        <lpage>
         5
        </lpage>
        <pub-id pub-id-type="pmid">
         9086167
        </pub-id>
       </element-citation>
      </ref>
      <ref id="DKT281C122">
       <label>
        122
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Colbeck
          </surname>
          <given-names>
           JC
          </given-names>
         </name>
        </person-group>
        <article-title>
         Environmental aspects of staphylococcal infections acquired in hospitals
        </article-title>
        <source>
         Am J Public Health
        </source>
        <year>
         1960
        </year>
        <volume>
         50
        </volume>
        <fpage>
         468
        </fpage>
        <lpage>
         73
        </lpage>
       </element-citation>
      </ref>
      <ref id="DKT281C123">
       <label>
        123
       </label>
       <element-citation publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Nuorti
          </surname>
          <given-names>
           JP
          </given-names>
         </name>
        </person-group>
        <person-group person-group-type="editor">
         <name>
          <surname>
           Brunette
          </surname>
          <given-names>
           GW
          </given-names>
         </name>
         <name>
          <surname>
           Kozarsky
          </surname>
          <given-names>
           PE
          </given-names>
         </name>
         <name>
          <surname>
           Magill
          </surname>
          <given-names>
           AJ
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Pneumococcal disease (
         <italic>
          Streptococcus pneumoniae
         </italic>
         )
        </article-title>
        <source>
         CDC Health Information for International Travel
        </source>
        <year>
         2012
        </year>
        <publisher-loc>
         New York
        </publisher-loc>
        <publisher-name>
         Oxford University Press
        </publisher-name>
        <comment>
         Chapter 3
        </comment>
       </element-citation>
      </ref>
      <ref id="DKT281C124">
       <label>
        124
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bessen
          </surname>
          <given-names>
           DE
          </given-names>
         </name>
        </person-group>
        <article-title>
         Population biology of the human restricted pathogen,
         <italic>
          Streptococcus pyogenes
         </italic>
        </article-title>
        <source>
         Infect Genet Evol
        </source>
        <year>
         2009
        </year>
        <volume>
         9
        </volume>
        <fpage>
         581
        </fpage>
        <lpage>
         93
        </lpage>
        <pub-id pub-id-type="pmid">
         19460325
        </pub-id>
       </element-citation>
      </ref>
      <ref id="DKT281C125">
       <label>
        125
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cleary
          </surname>
          <given-names>
           PP
          </given-names>
         </name>
         <name>
          <surname>
           Schlievert
          </surname>
          <given-names>
           PM
          </given-names>
         </name>
         <name>
          <surname>
           Handley
          </surname>
          <given-names>
           JP
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Clonal basis for resurgence of serious
         <italic>
          Streptococcus pyogenes
         </italic>
         disease in the 1980s
        </article-title>
        <source>
         Lancet
        </source>
        <year>
         1992
        </year>
        <volume>
         339
        </volume>
        <fpage>
         518
        </fpage>
        <lpage>
         21
        </lpage>
        <pub-id pub-id-type="pmid">
         1346879
        </pub-id>
       </element-citation>
      </ref>
      <ref id="DKT281C126">
       <label>
        126
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Pfaller
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Nosocomial candidiasis: emerging species, reservoirs, and modes of transmission
        </article-title>
        <source>
         Clin Infect Dis
        </source>
        <year>
         1996
        </year>
        <volume>
         22
        </volume>
        <issue>
         Suppl 2
        </issue>
        <fpage>
         S89
        </fpage>
        <lpage>
         94
        </lpage>
        <pub-id pub-id-type="pmid">
         8722834
        </pub-id>
       </element-citation>
      </ref>
      <ref id="DKT281C127">
       <label>
        127
       </label>
       <element-citation publication-type="book">
        <collab>
         Queensland Health
        </collab>
        <source>
         Communicable Diseases Control Manual
        </source>
        <year>
         2011
        </year>
        <edition>
         5th edn.
        </edition>
        <comment>
         Brisbane, Queensland, Australia
        </comment>
       </element-citation>
      </ref>
      <ref id="DKT281C128">
       <label>
        128
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Mattner
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Sohr
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Heim
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Risk groups for clinical complications of norovirus infections: an outbreak investigation
        </article-title>
        <source>
         Clin Microbiol Infect
        </source>
        <year>
         2006
        </year>
        <volume>
         12
        </volume>
        <fpage>
         69
        </fpage>
        <lpage>
         74
        </lpage>
        <pub-id pub-id-type="pmid">
         16460549
        </pub-id>
       </element-citation>
      </ref>
      <ref id="DKT281C129">
       <label>
        129
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Holton
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Shetty
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           McDonald
          </surname>
          <given-names>
           V
          </given-names>
         </name>
        </person-group>
        <article-title>
         Efficacy of ‘Nu-Cidex’ (0.35% peracetic acid) against mycobacteria and cryptosporidia
        </article-title>
        <source>
         J Hosp Infect
        </source>
        <year>
         1995
        </year>
        <volume>
         31
        </volume>
        <fpage>
         235
        </fpage>
        <lpage>
         7
        </lpage>
        <pub-id pub-id-type="pmid">
         8586794
        </pub-id>
       </element-citation>
      </ref>
      <ref id="DKT281C130">
       <label>
        130
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Coates
          </surname>
          <given-names>
           D
          </given-names>
         </name>
        </person-group>
        <article-title>
         Sporicidal activity of sodium dichloroisocyanurate, peroxygen and glutaraldehyde disinfectants against
         <italic>
          Bacillus subtilis
         </italic>
        </article-title>
        <source>
         J Hosp Infect
        </source>
        <year>
         1996
        </year>
        <volume>
         32
        </volume>
        <fpage>
         283
        </fpage>
        <lpage>
         94
        </lpage>
        <pub-id pub-id-type="pmid">
         8744513
        </pub-id>
       </element-citation>
      </ref>
      <ref id="DKT281C131">
       <label>
        131
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Shetty
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Srinivasan
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Holton
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Evaluation of microbicidal activity of a new disinfectant: Sterilox 2500 against
         <italic>
          Clostridium difficile
         </italic>
         spores,
         <italic>
          Helicobacter pylori
         </italic>
         , vancomycin resistant
         <italic>
          Enterococcus
         </italic>
         species,
         <italic>
          Candida albicans
         </italic>
         and several
         <italic>
          Mycobacterium
         </italic>
         species
        </article-title>
        <source>
         J Hosp Infect
        </source>
        <year>
         1999
        </year>
        <volume>
         41
        </volume>
        <fpage>
         101
        </fpage>
        <lpage>
         5
        </lpage>
        <pub-id pub-id-type="pmid">
         10063471
        </pub-id>
       </element-citation>
      </ref>
      <ref id="DKT281C132">
       <label>
        132
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Vintov
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Aarestrup
          </surname>
          <given-names>
           FM
          </given-names>
         </name>
         <name>
          <surname>
           Zinn
          </surname>
          <given-names>
           CE
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Association between phage types and antimicrobial resistance among bovine
         <italic>
          Staphylococcus aureus
         </italic>
         from 10 countries
        </article-title>
        <source>
         Vet Microbiol
        </source>
        <year>
         2003
        </year>
        <volume>
         95
        </volume>
        <fpage>
         133
        </fpage>
        <lpage>
         47
        </lpage>
        <pub-id pub-id-type="pmid">
         12860083
        </pub-id>
       </element-citation>
      </ref>
      <ref id="DKT281C133">
       <label>
        133
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Block
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Robenshtok
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Simhon
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Evaluation of chlorhexidine and povidone iodine activity against methicillin-resistant
         <italic>
          Staphylococcus aureus
         </italic>
         and vancomycin-resistant
         <italic>
          Enterococcus faecalis
         </italic>
         using a surface test
        </article-title>
        <source>
         J Hosp Infect
        </source>
        <year>
         2000
        </year>
        <volume>
         46
        </volume>
        <fpage>
         147
        </fpage>
        <lpage>
         52
        </lpage>
        <pub-id pub-id-type="pmid">
         11049709
        </pub-id>
       </element-citation>
      </ref>
      <ref id="DKT281C134">
       <label>
        134
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Block
          </surname>
          <given-names>
           C
          </given-names>
         </name>
        </person-group>
        <article-title>
         The effect of Perasafe
         <sup>
          ®
         </sup>
         and sodium dichloroisocyanurate (NaDCC) against spores of
         <italic>
          Clostridium difficile
         </italic>
         and
         <italic>
          Bacillus atrophaeus
         </italic>
         on stainless steel and polyvinyl chloride surfaces
        </article-title>
        <source>
         J Hosp Infect
        </source>
        <year>
         2004
        </year>
        <volume>
         57
        </volume>
        <fpage>
         144
        </fpage>
        <lpage>
         8
        </lpage>
        <pub-id pub-id-type="pmid">
         15183245
        </pub-id>
       </element-citation>
      </ref>
      <ref id="DKT281C135">
       <label>
        135
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Vizcaino-Alcaide
          </surname>
          <given-names>
           MJ
          </given-names>
         </name>
         <name>
          <surname>
           Herruzo-Cabrera
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Fernandez-Aceñero
          </surname>
          <given-names>
           MJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         Comparison of the disinfectant efficacy of Perasafe
         <sup>
          ®
         </sup>
         and 2% glutaraldehyde in
         <italic>
          in vitro
         </italic>
         tests
        </article-title>
        <source>
         J Hosp Infect
        </source>
        <year>
         2003
        </year>
        <volume>
         53
        </volume>
        <fpage>
         124
        </fpage>
        <lpage>
         8
        </lpage>
        <pub-id pub-id-type="pmid">
         12586572
        </pub-id>
       </element-citation>
      </ref>
      <ref id="DKT281C136">
       <label>
        136
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wutzler
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Sauerbrei
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Schau
          </surname>
          <given-names>
           HP
          </given-names>
         </name>
        </person-group>
        <article-title>
         Monopercitric acid - a new disinfectant with excellent activity towards clostridial spores
        </article-title>
        <source>
         J Hosp Infect
        </source>
        <year>
         2005
        </year>
        <volume>
         59
        </volume>
        <fpage>
         75
        </fpage>
        <lpage>
         6
        </lpage>
        <pub-id pub-id-type="pmid">
         15571861
        </pub-id>
       </element-citation>
      </ref>
      <ref id="DKT281C137">
       <label>
        137
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Simões
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Pereira
          </surname>
          <given-names>
           MO
          </given-names>
         </name>
         <name>
          <surname>
           Machado
          </surname>
          <given-names>
           I
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Comparative antibacterial potential of selected aldehyde-based biocides and surfactants against planktonic
         <italic>
          Pseudomonas fluorescens
         </italic>
        </article-title>
        <source>
         J Ind Microbiol Biotechnol
        </source>
        <year>
         2006
        </year>
        <volume>
         33
        </volume>
        <fpage>
         741
        </fpage>
        <lpage>
         9
        </lpage>
        <pub-id pub-id-type="pmid">
         16609854
        </pub-id>
       </element-citation>
      </ref>
      <ref id="DKT281C138">
       <label>
        138
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Walsh
          </surname>
          <given-names>
           SE
          </given-names>
         </name>
         <name>
          <surname>
           Maillard
          </surname>
          <given-names>
           JY
          </given-names>
         </name>
         <name>
          <surname>
           Russell
          </surname>
          <given-names>
           AD
          </given-names>
         </name>
        </person-group>
        <article-title>
         <italic>
          Ortho
         </italic>
         -phthalaldehyde: a possible alternative to glutaraldehyde for high level disinfection
        </article-title>
        <source>
         J Appl Microbiol
        </source>
        <year>
         1999
        </year>
        <volume>
         86
        </volume>
        <fpage>
         1039
        </fpage>
        <lpage>
         46
        </lpage>
        <pub-id pub-id-type="pmid">
         10389251
        </pub-id>
       </element-citation>
      </ref>
      <ref id="DKT281C139">
       <label>
        139
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Alfa
          </surname>
          <given-names>
           MJ
          </given-names>
         </name>
         <name>
          <surname>
           Sitter
          </surname>
          <given-names>
           DL
          </given-names>
         </name>
        </person-group>
        <article-title>
         In-hospital evaluation of orthophthalaldehyde as a high level disinfectant for flexible endoscopes
        </article-title>
        <source>
         J Hosp Infect
        </source>
        <year>
         1994
        </year>
        <volume>
         26
        </volume>
        <fpage>
         15
        </fpage>
        <lpage>
         26
        </lpage>
        <pub-id pub-id-type="pmid">
         7910179
        </pub-id>
       </element-citation>
      </ref>
      <ref id="DKT281C140">
       <label>
        140
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Oulé
          </surname>
          <given-names>
           MK
          </given-names>
         </name>
         <name>
          <surname>
           Azinwi
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Bernier
          </surname>
          <given-names>
           A-M
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Polyhexamethylene guanidine hydrochloride-based disinfectant: a novel tool to fight meticillin-resistant
         <italic>
          Staphylococcus aureus
         </italic>
         and nosocomial infections
        </article-title>
        <source>
         J Med Microbiol
        </source>
        <year>
         2008
        </year>
        <volume>
         57
        </volume>
        <fpage>
         1523
        </fpage>
        <lpage>
         8
        </lpage>
        <pub-id pub-id-type="pmid">
         19018024
        </pub-id>
       </element-citation>
      </ref>
      <ref id="DKT281C141">
       <label>
        141
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Andersen
          </surname>
          <given-names>
           BM
          </given-names>
         </name>
         <name>
          <surname>
           Rasch
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Kvist
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Floor cleaning: effect on bacteria and organic materials in hospital rooms
        </article-title>
        <source>
         J Hosp Infect
        </source>
        <year>
         2009
        </year>
        <volume>
         71
        </volume>
        <fpage>
         57
        </fpage>
        <lpage>
         65
        </lpage>
        <pub-id pub-id-type="pmid">
         19013671
        </pub-id>
       </element-citation>
      </ref>
      <ref id="DKT281C142">
       <label>
        142
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hedin
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Rynbäck
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Loré
          </surname>
          <given-names>
           B
          </given-names>
         </name>
        </person-group>
        <article-title>
         Reduction of bacterial surface contamination in the hospital environment by application of a new product with persistent effect
        </article-title>
        <source>
         J Hosp Infect
        </source>
        <year>
         2010
        </year>
        <volume>
         75
        </volume>
        <fpage>
         112
        </fpage>
        <lpage>
         5
        </lpage>
        <pub-id pub-id-type="pmid">
         20381907
        </pub-id>
       </element-citation>
      </ref>
      <ref id="DKT281C143">
       <label>
        143
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chatuev
          </surname>
          <given-names>
           BM
          </given-names>
         </name>
         <name>
          <surname>
           Peterson
          </surname>
          <given-names>
           JW
          </given-names>
         </name>
        </person-group>
        <article-title>
         Analysis of the sporicidal activity of chlorine dioxide disinfectant against
         <italic>
          Bacillus anthracis
         </italic>
         (Sterne strain)
        </article-title>
        <source>
         J Hosp Infect
        </source>
        <year>
         2010
        </year>
        <volume>
         74
        </volume>
        <fpage>
         178
        </fpage>
        <lpage>
         83
        </lpage>
        <pub-id pub-id-type="pmid">
         20061062
        </pub-id>
       </element-citation>
      </ref>
      <ref id="DKT281C144">
       <label>
        144
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Horejsh
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Kampf
          </surname>
          <given-names>
           G
          </given-names>
         </name>
        </person-group>
        <article-title>
         Efficacy of three surface disinfectants against spores of
         <italic>
          Clostridium difficile
         </italic>
         ribotype 027
        </article-title>
        <source>
         Int J Hyg Environ Health
        </source>
        <year>
         2011
        </year>
        <volume>
         214
        </volume>
        <fpage>
         172
        </fpage>
        <lpage>
         4
        </lpage>
        <pub-id pub-id-type="pmid">
         21134785
        </pub-id>
       </element-citation>
      </ref>
      <ref id="DKT281C145">
       <label>
        145
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chung
          </surname>
          <given-names>
           C-J
          </given-names>
         </name>
         <name>
          <surname>
           Lin
          </surname>
          <given-names>
           H-I
          </given-names>
         </name>
         <name>
          <surname>
           Tsou
          </surname>
          <given-names>
           H-K
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         An antimicrobial TiO
         <sub>
          2
         </sub>
         coating for reducing hospital-acquired infection
        </article-title>
        <source>
         J Biomed Mater Res
        </source>
        <year>
         2008
        </year>
        <volume>
         85B
        </volume>
        <fpage>
         220
        </fpage>
        <lpage>
         4
        </lpage>
       </element-citation>
      </ref>
      <ref id="DKT281C146">
       <label>
        146
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Shao
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Meng
          </surname>
          <given-names>
           W-D
          </given-names>
         </name>
         <name>
          <surname>
           Qing
          </surname>
          <given-names>
           F-L
          </given-names>
         </name>
        </person-group>
        <article-title>
         Synthesis and surface antimicrobial activity of a novel perfluorooctylated quaternary ammonium silane coupling agent
        </article-title>
        <source>
         J Fluorine Chem
        </source>
        <year>
         2004
        </year>
        <volume>
         125
        </volume>
        <fpage>
         721
        </fpage>
        <lpage>
         4
        </lpage>
       </element-citation>
      </ref>
      <ref id="DKT281C147">
       <label>
        147
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Foster
          </surname>
          <given-names>
           HA
          </given-names>
         </name>
         <name>
          <surname>
           Sheel
          </surname>
          <given-names>
           DW
          </given-names>
         </name>
         <name>
          <surname>
           Sheel
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Antimicrobial activity of titania/silver and titania/copper films prepared by CVD
        </article-title>
        <source>
         J Photochem Photobiol A
        </source>
        <year>
         2010
        </year>
        <volume>
         216
        </volume>
        <fpage>
         283
        </fpage>
        <lpage>
         9
        </lpage>
       </element-citation>
      </ref>
      <ref id="DKT281C148">
       <label>
        148
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Xiangyu
          </surname>
          <given-names>
           Z
          </given-names>
         </name>
         <name>
          <surname>
           Ailan
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Ruihua
          </surname>
          <given-names>
           Z
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Antibacterial property and tribological behavior of duplex-surface-treated AISI 304 stainless steel
        </article-title>
        <source>
         IEEE Trans Plasma Sci
        </source>
        <year>
         2011
        </year>
        <volume>
         39
        </volume>
        <fpage>
         1598
        </fpage>
        <lpage>
         605
        </lpage>
       </element-citation>
      </ref>
      <ref id="DKT281C149">
       <label>
        149
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Belcarz
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Bieniaś
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Surowska
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Studies of bacterial adhesion on TiN, SiO2–TiO2 and hydroxyapatite thin layers deposited on titanium and Ti6Al4 V alloy for medical applications
        </article-title>
        <source>
         Thin Solid Films
        </source>
        <year>
         2010
        </year>
        <volume>
         519
        </volume>
        <fpage>
         797
        </fpage>
        <lpage>
         803
        </lpage>
       </element-citation>
      </ref>
      <ref id="DKT281C150">
       <label>
        150
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kurt
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Wood
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Ohman
          </surname>
          <given-names>
           DE
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Highly effective contact antimicrobial surfaces via polymer surface modifiers
        </article-title>
        <source>
         Langmuir
        </source>
        <year>
         2007
        </year>
        <volume>
         23
        </volume>
        <fpage>
         4719
        </fpage>
        <lpage>
         23
        </lpage>
        <pub-id pub-id-type="pmid">
         17388618
        </pub-id>
       </element-citation>
      </ref>
     </ref-list>
    </back>
   </article>
   <article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <?properties open_access?>
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       Cont Lens Anterior Eye
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       Cont Lens Anterior Eye
      </journal-id>
      <journal-title-group>
       <journal-title>
        Contact Lens &amp; Anterior Eye
       </journal-title>
      </journal-title-group>
      <issn pub-type="ppub">
       1367-0484
      </issn>
      <issn pub-type="epub">
       1476-5411
      </issn>
      <publisher>
       <publisher-name>
        British Contact Lens Association. Published by Elsevier Ltd.
       </publisher-name>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       32273245
      </article-id>
      <article-id pub-id-type="pmc">
       7129028
      </article-id>
      <article-id pub-id-type="publisher-id">
       S1367-0484(20)30055-2
      </article-id>
      <article-id pub-id-type="doi">
       10.1016/j.clae.2020.03.012
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Article
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        The COVID-19 pandemic: Important considerations for contact lens practitioners
       </article-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author" id="aut0005">
        <name>
         <surname>
          Jones
         </surname>
         <given-names>
          Lyndon
         </given-names>
        </name>
        <email>
         lwjones@uwaterloo.ca
        </email>
        <xref ref-type="aff" rid="aff0005">
         a
        </xref>
        <xref ref-type="corresp" rid="cor0005">
         ⁎
        </xref>
       </contrib>
       <contrib contrib-type="author" id="aut0010">
        <name>
         <surname>
          Walsh
         </surname>
         <given-names>
          Karen
         </given-names>
        </name>
        <email>
         karen.walsh@uwaterloo.ca
        </email>
        <xref ref-type="aff" rid="aff0010">
         b
        </xref>
       </contrib>
       <contrib contrib-type="author" id="aut0015">
        <name>
         <surname>
          Willcox
         </surname>
         <given-names>
          Mark
         </given-names>
        </name>
        <email>
         m.willcox@unsw.edu.au
        </email>
        <xref ref-type="aff" rid="aff0015">
         c
        </xref>
       </contrib>
       <contrib contrib-type="author" id="aut0020">
        <name>
         <surname>
          Morgan
         </surname>
         <given-names>
          Philip
         </given-names>
        </name>
        <email>
         philip.morgan@manchester.ac.uk
        </email>
        <xref ref-type="aff" rid="aff0020">
         d
        </xref>
       </contrib>
       <contrib contrib-type="author" id="aut0025">
        <name>
         <surname>
          Nichols
         </surname>
         <given-names>
          Jason
         </given-names>
        </name>
        <email>
         jjn@uab.edu
        </email>
        <xref ref-type="aff" rid="aff0025">
         e
        </xref>
       </contrib>
      </contrib-group>
      <aff id="aff0005">
       <label>
        a
       </label>
       School of Optometry &amp; Vision Science, Centre for Ocular Research &amp; Education (CORE), University of Waterloo, Waterloo, Ontario, Canada
      </aff>
      <aff id="aff0010">
       <label>
        b
       </label>
       Centre for Ocular Research &amp; Education (CORE), University of Waterloo, Waterloo, Ontario, Canada
      </aff>
      <aff id="aff0015">
       <label>
        c
       </label>
       School of Optometry and Vision Science, UNSW, Sydney, Australia
      </aff>
      <aff id="aff0020">
       <label>
        d
       </label>
       The University of Manchester, Manchester, UK
      </aff>
      <aff id="aff0025">
       <label>
        e
       </label>
       University of Alabama at Birmingham, Birmingham, AL, USA
      </aff>
      <author-notes>
       <corresp id="cor0005">
        <label>
         ⁎
        </label>
        Corresponding author.
        <email>
         lwjones@uwaterloo.ca
        </email>
       </corresp>
      </author-notes>
      <pub-date pub-type="pmc-release">
       <day>
        3
       </day>
       <month>
        4
       </month>
       <year>
        2020
       </year>
      </pub-date>
      <!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.-->
      <pub-date pub-type="epub">
       <day>
        3
       </day>
       <month>
        4
       </month>
       <year>
        2020
       </year>
      </pub-date>
      <elocation-id>
      </elocation-id>
      <history>
       <date date-type="received">
        <day>
         26
        </day>
        <month>
         3
        </month>
        <year>
         2020
        </year>
       </date>
       <date date-type="rev-recd">
        <day>
         29
        </day>
        <month>
         3
        </month>
        <year>
         2020
        </year>
       </date>
       <date date-type="accepted">
        <day>
         29
        </day>
        <month>
         3
        </month>
        <year>
         2020
        </year>
       </date>
      </history>
      <permissions>
       <copyright-statement>
        © 2020 British Contact Lens Association. Published by Elsevier Ltd. All rights reserved.
       </copyright-statement>
       <copyright-year>
        2020
       </copyright-year>
       <copyright-holder>
       </copyright-holder>
       <license>
        <license-p>
         Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
        </license-p>
       </license>
      </permissions>
      <abstract id="abs0005">
       <p>
        A novel coronavirus (CoV), the Severe Acute Respiratory Syndrome Coronavirus - 2 (SARS-CoV-2), results in the coronavirus disease 2019 (COVID-19). As information concerning the COVID-19 disease continues to evolve, patients look to their eye care practitioners for accurate eye health guidance. There is currently no evidence to suggest an increased risk of contracting COVID-19 through contact lens (CL) wear compared to spectacle lens wear and no scientific evidence that wearing standard prescription spectacles provides protection against COVID-19 or other viral transmissions.
       </p>
       <p>
        During the pandemic there will potentially be significant changes in access to local eyecare. Thus, it is imperative CL wearers are reminded of the steps they should follow to minimise their risk of complications, to reduce their need to leave isolation and seek care. Management of adverse events should be retained within optometric systems if possible, to minimise the impact on the wider healthcare service, which will be stretched. Optimal CL care behaviours should be the same as those under normal circumstances, which include appropriate hand washing (thoroughly with soap and water) and drying (with paper towels) before both CL application and removal. Daily CL cleaning and correct case care for reusable CL should be followed according to appropriate guidelines, and CL exposure to water must be avoided. Where the availability of local clinical care is restricted, practitioners should consider advising patients to reduce or eliminate sleeping in their CL (where patients have the appropriate knowledge about correct daily care and access to suitable lens-care products) or consider the option of moving patients to daily disposable lenses (where patients have appropriate lens supplies available). Patients should also avoid touching their face, including their eyes, nose and mouth, with unwashed hands and avoid CL wear altogether if unwell (particularly with any cold or flu-like symptoms).
       </p>
      </abstract>
      <kwd-group id="kwd0005">
       <title>
        Keywords
       </title>
       <kwd>
        COVID-19
       </kwd>
       <kwd>
        Contact lens
       </kwd>
       <kwd>
        lens care
       </kwd>
       <kwd>
        lens wear
       </kwd>
      </kwd-group>
     </article-meta>
    </front>
    <sec id="sec0005">
     <label>
      1
     </label>
     <title>
      Introduction
     </title>
     <p id="par0005">
      A novel coronavirus (CoV), the Severe Acute Respiratory Syndrome Coronavirus - 2 (SARS-CoV-2), results in the coronavirus disease 2019 (COVID-19). The World Health Organisation (WHO) declared the rapid spread of cases of COVID-19 a pandemic on 11
      <sup>
       th
      </sup>
      March, 2020. The global response to COVID-19 has resulted in substantial changes to business and social practices around the world. With concerns existing around the pandemic, many reports relating to how best to limit the chance of infection have been shared via various news outlets and on social media, with significant amounts of misinformation and speculation being reported [
      <xref ref-type="bibr" rid="bib0005">
       1
      </xref>
      ]. Among these, recent rumours have circulated stating that contact lens wear is unsafe, that wearers of contact lenses are more at risk of developing COVID-19, that certain contact lens materials are more “risky” than others and that contact lens wearers should immediately revert to spectacle wear to protect themselves. How true are these statements, and are they supported by evidence? Importantly, are contact lens wearers increasing their risk of contracting COVID-19 by wearing contact lenses? Furthermore, what are the ramifications of a potential reduction in the availability of local ophthalmic care for contact lens wearers during this pandemic?
     </p>
     <p id="par0010">
      Before answering these questions, it first is important to review the known structural biology and pathophysiological mechanism of an infection caused by SARS-CoV-2. All CoVs contain ribonucleic acid (RNA) as their genetic material, which is surrounded by a protein shell called a nucleocapsid. Like other CoVs, SARs-CoV-2 is an enveloped virus, meaning its nucleocapsid is surrounded by a lipid bilayer. SARs-CoV-2 has three proteins which are anchored into and protrude from the envelope, including an envelope, membrane and spike proteins [
      <xref ref-type="bibr" rid="bib0010">
       2
      </xref>
      ]. These proteins form the corona that can be seen by electron microscopy and gives the name to the CoVs. The spike proteins are glycoproteins that have high affinities for angiotensin converting enzyme 2 (ACE2), a component of the renin-angiotensin system (RAS) found in many human tissues [
      <xref ref-type="bibr" rid="bib0015">
       3
      </xref>
      ]. This affinity is believed to allow entry of the virus into host cells, where the virus releases its RNA into the host cell, leading to viral replication and further infection. Patients taking ACE inhibitors for hypertension may be at increased risk for adverse outcomes as taking this medication may increase ACE2 in cardiac tissues [
      <xref ref-type="bibr" rid="bib0020">
       4
      </xref>
      ]; there may also be concerns about patients with chronic renal disease [
      <xref ref-type="bibr" rid="bib0025">
       5
      </xref>
      ]. While many components of the RAS are found in the eye and many of its tissues, there appears to be inconsistency in the literature regarding ACE2, and more specifically, if it is present in the cornea, conjunctiva, or tears [
      <xref ref-type="bibr" rid="bib0030">
       [6]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0035">
       [7]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0040">
       [8]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0045">
       [9]
      </xref>
      ]. This may relate to the infrequent findings to date of SARS-CoV-2 presence in COVID-19 disease on the cornea, conjunctiva, or tear film of humans that is discussed later in this review. It is acknowledged that CoVs can cause a variety of infections in animals, including conjunctivitis, anterior uveitis, retinitis, and optic neuritis, many of which are severe [
      <xref ref-type="bibr" rid="bib0050">
       10
      </xref>
      ].
     </p>
     <sec id="sec0010">
      <label>
       1.1
      </label>
      <title>
       Coronavirus and contact lens wear
      </title>
      <p id="par0015">
       Contact lenses represent a highly effective form of vision correction for an estimated 140 million people worldwide, with a very low incidence of either microbial keratitis or symptomatic inflammatory keratitis in strict daily wear of contact lenses [
       <xref ref-type="bibr" rid="bib0055">
        11
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0060">
        12
       </xref>
       ]. It is well established that contact lens wear, and particularly overnight contact lens wear, increases the risk of bacterial keratitis [
       <xref ref-type="bibr" rid="bib0060">
        [12]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0065">
        [13]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0070">
        [14]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0075">
        [15]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0080">
        [16]
       </xref>
       ]. It is also well established that viral conjunctivitis is the overall most common type of conjunctivitis [
       <xref ref-type="bibr" rid="bib0085">
        17
       </xref>
       ]. Yet, the eye, ocular surface and tear film employ a variety of host-defense mechanisms such as physical barriers and immunological strategies that help reduce the chance of infection in the cornea and conjunctiva.
      </p>
      <p id="par0020">
       A PubMed search on 24
       <sup>
        th
       </sup>
       March 2020 found no evidence that contact lens wearers are more likely to contract COVID-19 than spectacle wearers. The likely belief for this being a concern relates to the fact that SARS-CoV-2 has been isolated in tears, albeit to date, infrequently [
       <xref ref-type="bibr" rid="bib0090">
        18
       </xref>
       ] and also that the virus is known to be transferred by hand contact, and thus could be transferred to contact lenses during their application and removal. In one report, positive tear and conjunctival secretions occurred in a single patient who developed conjunctivitis from a cohort of thirty patients with novel coronavirus pneumonia [
       <xref ref-type="bibr" rid="bib0090">
        18
       </xref>
       ]. In another report, [
       <xref ref-type="bibr" rid="bib0095">
        19
       </xref>
       ] 64 samples of the tear film from 17 patients with COVID-19 showed no evidence of SARS-CoV-2 by viral culture or reverse transcriptase polymerase chain reaction (RT-PCR). Further, the frequency of conjunctivitis in patients with COVID-19 reported to date is low, at &lt;3% [
       <xref ref-type="bibr" rid="bib0090">
        18
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0100">
        20
       </xref>
       ], although it has been suggested that CoVs could possibly be transmitted by aerosol contact with the conjunctiva in patients with active disease [
       <xref ref-type="bibr" rid="bib0090">
        18
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0100">
        [20]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0105">
        [21]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0110">
        [22]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0115">
        [23]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0120">
        [24]
       </xref>
       ]. However, the question of whether COVID-19 can occur through conjunctival exposure remains unknown [
       <xref ref-type="bibr" rid="bib0035">
        7
       </xref>
       ]. Recent papers concluded that
       <italic>
        “The eye is rarely involved by human CoV infection, nor is it a preferred gateway of entry for human CoVs to infect the respiratory tract
       </italic>
       [
       <xref ref-type="bibr" rid="bib0125">
        25
       </xref>
       ].” and that
       <italic>
        “The results from this study suggests that the risk of SARS-CoV-2 transmission through tears is low
       </italic>
       [
       <xref ref-type="bibr" rid="bib0095">
        19
       </xref>
       ].
       <italic>
        ”
       </italic>
       Thus, to date, there are no findings that support concerns that healthy patients are more at risk of contracting COVID-19 if they are contact lens wearers.
      </p>
      <p id="par0025">
       It could be argued that COVID-19 is so new that such data would not yet exist. However, the lack of evidence from previous outbreaks of coronavirus disease, including SARS, suggests that the risk of developing COVID-19 from contact lens wear is low. It is informative to consider viral diseases that are transmitted by direct contact and which could be used as a surrogate for evaluating the risks of COVID-19 in contact lens wearers. Viruses that are associated with human infections have been found on ocular surface tissues or in the tear film. These include, but are not limited to, both DNA and RNA viruses such as adenovirus, other coronaviruses, herpes virus, human immunodeficiency virus, influenza virus, and Zika virus [
       <xref ref-type="bibr" rid="bib0090">
        18
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0110">
        22
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0130">
        [26]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0135">
        [27]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0140">
        [28]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0145">
        [29]
       </xref>
       ]. That said, these viruses are typically found at low levels and it is generally believed that they are not transmitted from the ocular surface (with the exception of adenoviral infections).
      </p>
      <p id="par0030">
       One ocular viral infection to consider is epidemic keratoconjunctivitis (EKC), caused by the non-enveloped DNA virus adenovirus. This disease is highly contagious, spreads rapidly through direct contact, accounts for 65-90% of viral conjunctivitis cases [
       <xref ref-type="bibr" rid="bib0150">
        30
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0155">
        31
       </xref>
       ] and has been implicated in actively transmitted disease in eyecare clinics and other common healthcare settings where there is close contact between healthcare providers and patients [
       <xref ref-type="bibr" rid="bib0160">
        [32]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0165">
        [33]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0170">
        [34]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0175">
        [35]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0180">
        [36]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0185">
        [37]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0190">
        [38]
       </xref>
       ]. A review of the literature appears to show no increased risk for EKC in those wearing contact lenses versus non-lens wearers, with a reported frequency of 3-15% in contact lens wearers [
       <xref ref-type="bibr" rid="bib0160">
        32
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0180">
        36
       </xref>
       ]. Indeed, it has been proposed that bandage silicone hydrogel contact lenses can be used to help treat adenoviral infection in patients [
       <xref ref-type="bibr" rid="bib0195">
        39
       </xref>
       ]. There are conflicting data on herpes simplex keratitis (HSK, another DNA virus, but one that is enveloped) and contact lens wear. One prospective cohort study and one retrospective case control study showed no association between contact lens wear and HSK occurrence or reoccurrence, whereas one retrospective study and a case report did suggest an association [
       <xref ref-type="bibr" rid="bib0200">
        [40]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0205">
        [41]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0210">
        [42]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0215">
        [43]
       </xref>
       ].
      </p>
      <p id="par0035">
       Another virus for which there has been concern as it relates to the ocular surface is the human immunodeficiency virus (HIV), which causes acquired immunodeficiency syndrome (AIDS), with an estimated prevalence of 1.1 million in the US [
       <xref ref-type="bibr" rid="bib0220">
        44
       </xref>
       ]. HIV is an RNA virus, but a different form of RNA virus called a retrovirus, and has an envelope. HIV has been detected in most ocular tissues, including the cornea, conjunctiva and tear film of patients with AIDS [
       <xref ref-type="bibr" rid="bib0225">
        45
       </xref>
       ]. It has also been recovered from the surface of a contact lens [
       <xref ref-type="bibr" rid="bib0230">
        46
       </xref>
       ]. It is presently believed, however, that HIV has not been transmitted via ocular surface tissues or the tear film. The CDC specifically states,
       <italic>
        “HIV is not spread by saliva, tears, or sweat that is not mixed with the blood of an HIV-positive person.”
       </italic>
       [
       <xref ref-type="bibr" rid="bib0235">
        47
       </xref>
       ] Research has also indicated that with appropriate rubbing of contact lenses, most contact lens care systems would likely prevent the chance of the lens transferring the virus to the eye and resulting in HIV [
       <xref ref-type="bibr" rid="bib0240">
        48
       </xref>
       ]. However, because of the immunodeficiency and compromise, it is recognized that AIDS is associated with opportunistic infections that can put an individual at risk for ocular infection [
       <xref ref-type="bibr" rid="bib0245">
        49
       </xref>
       ]. HIV has been identified as a risk factor for hospitalization for corneal ulceration. While daily contact lens wear (not overnight wear) can be safe in a patient with AIDS, it is important that the eyecare practitioner play an active role in managing the patient and their ocular health as it relates to safe contact lens wear. A CD4+ count indicating immunocompetence may be key in guiding these decisions. On March 20, 2020, the CDC released information related to patients with AIDS and precautions as it relates to COVID-19 [
       <xref ref-type="bibr" rid="bib0250">
        50
       </xref>
       ]. Of course, there are many differences in these viruses in terms of their structural biology, vectors and other factors. However, with limited current data comparing contact lens wearers versus non-lens wearers in patients with COVID-19, this remains the best evidence available of disease spread via viral contaminants that are highly infectious and potentially spread by direct contact, and an exhaustive literature search would not support the apprehension that contact lens wear is a concern.
      </p>
      <p id="par0040">
       Coronaviruses are capable of producing a wide spectrum of ocular disease, including anterior segment diseases such as conjunctivitis and anterior uveitis, and posterior segment conditions like retinitis and optic neuritis [
       <xref ref-type="bibr" rid="bib0255">
        51
       </xref>
       ]. Current understanding about how SARS-CoV-2 spreads is based largely on what is known about other similar coronaviruses. Currently, two types of SARS-CoV-2 have been detected (L and S) [
       <xref ref-type="bibr" rid="bib0260">
        52
       </xref>
       ]. The L form is suspected to be the derived variant of the ancestral S type, which is suggested to be more aggressive and is significantly more prevalent in Wuhan, China (where COVID-19 was first reported) than other places, although its frequency of isolation has decreased since January 2020 [
       <xref ref-type="bibr" rid="bib0260">
        52
       </xref>
       ]. The virus spreads primarily via person-to-person contact through respiratory droplets produced when an infected person coughs or sneezes [
       <xref ref-type="bibr" rid="bib0265">
        53
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0270">
        54
       </xref>
       ]. However, it also could be spread if people touch an object or surface with virus present from an infected person, and then touch mucosal surfaces such as their mouth, nose or eyes [
       <xref ref-type="bibr" rid="bib0270">
        [54]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0275">
        [55]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0280">
        [56]
       </xref>
       ]. Given that contact lens wearers must touch their eyes when applying and removing their contact lenses, it is understandable this has been raised as a potential concern for increasing their risk of exposure to the virus. The consistent, unambiguous advice to protect individuals from the virus is to employ frequent handwashing with soap and water. The lipid envelope of the virus can be emulsified by surfactants such as those found in simple soap, which kills the virus [
       <xref ref-type="bibr" rid="bib0270">
        54
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0285">
        57
       </xref>
       ]. Best practice advice for contact lens wearers includes the same instructions that should be imparted under all situations, regardless of the COVID-19 pandemic. When using contact lenses, careful and thorough hand washing with soap and water followed by hand drying with unused paper towels (generally known as ‘kitchen roll’ in the United Kingdom) is paramount. For contact lens wearers, this should occur before every contact lens application and removal, and such practice reduces the risks of infection and inflammatory responses and is highly effective [
       <xref ref-type="bibr" rid="bib0290">
        58
       </xref>
       ]. It follows that as long as contact lens wearers are using correct hand hygiene techniques, they should be limiting any virus transmission to their ocular surface, and indeed, as already stated, there is currently no evidence that they are at any higher risk of developing COVID-19 infection than non-wearers.
      </p>
     </sec>
     <sec id="sec0015">
      <label>
       1.2
      </label>
      <title>
       Coronavirus and spectacle lens wear
      </title>
      <p id="par0045">
       A systematic review of the literature shows that there is no scientific evidence that wearing spectacles provides protection against SARS-CoV-2 or other viral transmissions, although this concept has been recently proposed in the media [
       <xref ref-type="bibr" rid="bib0295">
        [59]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0300">
        [60]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0305">
        [61]
       </xref>
       ]. This belief around the safety of spectacles likely exists because of the guidance to use approved personal protective eyewear (medical masks, goggles or face shields) in certain settings involved in the care of infected patients [
       <xref ref-type="bibr" rid="bib0310">
        62
       </xref>
       ]. However, these goggles and shields provide very different protection to that afforded by standard spectacles, a difference recognised by the U.S. Centers for Disease Control and Prevention (CDC), who state that
       <italic>
        “personal eyeglasses are NOT considered adequate eye protection
       </italic>
       [
       <xref ref-type="bibr" rid="bib0315">
        63
       </xref>
       ]
       <italic>
        .”
       </italic>
      </p>
      <p id="par0050">
       Despite the CDC’s clear delineation between standard spectacles and approved personal protective eyewear, it is understandable that a misplaced belief still exists for spectacles being preferable to contact lenses. There are a number of confounding factors, however, which do not support this theory. Consider firstly, part-time wearers of spectacles who only use their spectacles for occasional distance use or for reading. Their assumed ‘protection’ is intermittent, and additionally their increased frequency of putting on and removing their spectacles adds to the potential of touching their face each time, possibly in the absence of hand washing. Another point to consider is that some viruses such as SARS-CoV-2 can remain on hard plastic surfaces (similar to those found in spectacle frames and lenses) for hours to days [
       <xref ref-type="bibr" rid="bib0320">
        [64]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0325">
        [65]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0330">
        [66]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0335">
        [67]
       </xref>
       ]. Upon touching their spectacles, any virus particles could potentially be transferred to the wearers’ fingers and face and thus adequate hand hygiene practices should also extend to the regular handling of spectacle and sunglass frames to prevent transmission of viral particles to the fingers and subsequently to the face. Spectacles should be regularly cleaned with soap and water and dried with paper towel to remove any adhered viral particles.
      </p>
     </sec>
     <sec id="sec0020">
      <label>
       1.3
      </label>
      <title>
       The importance of hand hygiene
      </title>
      <p id="par0055">
       Hands are a common vector for the transmission of respiratory infection [
       <xref ref-type="bibr" rid="bib0340">
        68
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0345">
        69
       </xref>
       ]. An observational study of medical students examined the frequency with which they touched their face [
       <xref ref-type="bibr" rid="bib0350">
        70
       </xref>
       ]. On average, each of the students touched their face 23 times per hour. Of all face touches, 44% involved contact with a mucous membrane (eyes, nose or mouth) versus 56% that involved contact with non-mucosal areas (ears, cheeks, chin, forehead or ear). Of the mucous membrane touches, 36% involved the mouth, 31% the nose, 27% the eyes, and 6% were a combination of these regions. Given this very high number of face touches, hand washing becomes extremely important as a method to prevent transmission of any pathogenic organism from the fingers to the mucous membranes of the face. It is also important to remember that the generally younger demographic of contact lens wearers are often seen to practice more “risky” behaviors (such as the non-observance of social distancing seen recently during Spring break in the US) [
       <xref ref-type="bibr" rid="bib0355">
        71
       </xref>
       ], which poses an inherent increased risk for SARS-CoV-2 infection. Hence, it remains important to remind this age group of the role of hand hygiene in preventing both ocular and systemic infection, regardless of their mode of vision correction.
      </p>
      <p id="par0060">
       In addition to commons soaps used in hand washing, the SARS-CoV-2 virus is very likely susceptible to the same alcohol- and bleach-based disinfectants that eye-care practitioners commonly use to disinfect ophthalmic instruments and office furniture [
       <xref ref-type="bibr" rid="bib0330">
        66
       </xref>
       ]. To prevent SARS-CoV-2 transmission, the same disinfection practices already used to prevent office-based spread of other viral pathogens are recommended before and after every patient encounter. Many of these steps have been summarised in a recent editorial [
       <xref ref-type="bibr" rid="bib0360">
        72
       </xref>
       ], which covers a number of important considerations for conducting safe clinical practice during the pandemic.
      </p>
      <p id="par0065">
       The CDC and WHO recommend that people clean their hands often to reduce their risk of contracting the virus. Specifically, they advise all people to:
       <list id="lis0005" list-type="simple">
        <list-item id="lsti0005">
         <label>
          •
         </label>
         <p id="par0070">
          Wash their hands often with soap and water for at least 20 seconds especially after they have been in a public place, or after blowing their nose, coughing, or sneezing.
         </p>
        </list-item>
        <list-item id="lsti0010">
         <label>
          •
         </label>
         <p id="par0075">
          If soap and water are not readily available, they should use a hand sanitizer that contains at least 60% alcohol. They should cover all surfaces of their hands and rub them together until they feel dry.
         </p>
        </list-item>
        <list-item id="lsti0015">
         <label>
          •
         </label>
         <p id="par0080">
          They should avoid touching their eyes, nose, and mouth with unwashed hands.
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <sec id="sec0025">
      <label>
       1.4
      </label>
      <title>
       Contact lens material considerations
      </title>
      <p id="par0085">
       The use of daily disposable contact lenses substantially reduces the risks of many inflammatory complications [
       <xref ref-type="bibr" rid="bib0365">
        73
       </xref>
       ]. Contact lens wearers should always either dispose of their daily disposable lenses each evening, or regularly disinfect their monthly or two-week lenses according to manufacturer and eye care professional instructions.
      </p>
      <p id="par0090">
       A point to consider is whether there are differences in the risk of SARS-CoV-2 infection between the various contact lens materials available. Suggestions have been made that siloxane-based materials (silicone hydrogels) are more likely to bind SARS-CoV-2 than hydrogels, [
       <xref ref-type="bibr" rid="bib0305">
        61
       </xref>
       ] and that these contact lens materials are particularly “risky” to wear. A recent study showed that the aerosol and surface stability of both SARS-Cov-2 and its predecessor, SARS-CoV-1 (the viral strain associated with the prior SARS epidemic of 2002 and 2003) was similar [
       <xref ref-type="bibr" rid="bib0370">
        74
       </xref>
       ]. Specifically, both viruses could be detected in aerosols for up to three hours, on cardboard for 24 hours, and on plastic and stainless steel for 2-3 days. To date, there have been no laboratory studies reported on the ability of coronaviruses to adhere to contact lenses, and none on the ability of disinfectants to kill coronaviruses adhered to contact lenses.
      </p>
      <p id="par0095">
       There is no evidence of the presence of SARS-CoV-2 in the tears or conjunctival tissue of asymptomatic patients and even in those with confirmed disease, the presence of SARS-CoV-2 on the ocular surface is low [
       <xref ref-type="bibr" rid="bib0090">
        [18]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0095">
        [19]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0100">
        [20]
       </xref>
       ]. Thus, binding of SARS-CoV-2 to contact lenses from the ocular surface in asymptomatic wearers would be unlikely. It is advisable that patients with COVID-19 should not wear contact lenses and if a patient were to develop COVID-19 any contact lenses that were being worn at that time should be immediately disposed of as should any remaining disinfecting solutions and contact lens cases that the patient possess, the patient must revert to spectacle lens wear and when fully recovered should recommence wear with a new pair of lenses.
      </p>
      <p id="par0100">
       The issues that influence bacterial, viral, fungal and amoebic binding to contact lens materials are highly complex and variable, with confounding data on the factors that impact microbial binding [
       <xref ref-type="bibr" rid="bib0375">
        [75]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0380">
        [76]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0385">
        [77]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0390">
        [78]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0395">
        [79]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0400">
        [80]
       </xref>
       ]. To date, no studies have addressed this issue specifically for the virus that causes COVID-19. A recent paper [
       <xref ref-type="bibr" rid="bib0330">
        66
       </xref>
       ] has been cited as suggesting that silicone hydrogels are more likely to bind SARS-CoV-2 than hydrogels [
       <xref ref-type="bibr" rid="bib0305">
        61
       </xref>
       ]. However, this paper did not examine contact lens materials. The inanimate surfaces described in the paper [
       <xref ref-type="bibr" rid="bib0330">
        66
       </xref>
       ] which most closely resemble contact lens materials were “plastic” and silicon rubber [
       <xref ref-type="bibr" rid="bib0320">
        64
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0405">
        81
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0410">
        82
       </xref>
       ]. Neither of these materials appropriately represents the complex bulk and surface chemistry of contemporary contact lens materials [
       <xref ref-type="bibr" rid="bib0415">
        [83]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0420">
        [84]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0425">
        [85]
       </xref>
       ] and cannot be used to reflect the likely binding of any pathogenic organism to modern day contact lenses. Soft lens material surfaces are far more hydrophilic than the plastic and silicon rubber surfaces examined in this manuscript and the binding of virus particles to substrates is complex, depending upon the charges and topographic characteristics of the virus and the characteristics of the surface in question [
       <xref ref-type="bibr" rid="bib0430">
        86
       </xref>
       ]. The factors governing the binding of SARS-CoV-2 to inanimate surfaces are so far unknown, but for a variety of waterborne viruses the major driving factors were electrostatic interactions (charge driven), followed by hydrophobic interactions, with only minor impact from van der Waals interactions [
       <xref ref-type="bibr" rid="bib0430">
        86
       </xref>
       ].
      </p>
      <p id="par0105">
       Other factors of note in the paper by Kampf et al. are that the high concentration of inoculum used to examine the potential viral binding rates (10
       <sup>
        3
       </sup>
       – 10
       <sup>
        5
       </sup>
       ) are likely very much higher than those encountered on the ocular surface in asymptomatic wearers, and potentially much higher than that encountered following contamination transferred via fingertip application or removal of contact lenses. The viability time quoted is that found at room temperature, but the time for which viruses remain viable at ocular surface temperatures is significantly lower [
       <xref ref-type="bibr" rid="bib0405">
        81
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0410">
        82
       </xref>
       ] and to date the time for which SARS-CoV-2 remains viable on hydrophilic substrates such as contact lens materials remains unknown. Finally, these studies took place in a dry, static environment, which in no way reflect the moist condition of the ocular surface and did not take into consideration the impact of blinking on removal of potential viral contaminants from a lens surface. Furthermore, no evidence exists that would support the contention that silicone hydrogel lenses are more likely to be contaminated with SARS-CoV-2 (or indeed any virus) than hydrogel lenses.
      </p>
      <p id="par0110">
       To date, no evidence exists of the ability of currently marketed contact lens solutions to disinfect SARS-CoV-2, and evidence concerning the ability of contemporary care solutions to disinfect viruses remains equivocal [
       <xref ref-type="bibr" rid="bib0435">
        87
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0440">
        88
       </xref>
       ] and future work in this area is required. Over 30 years ago it was recognized that contact lens care systems of that time, based on chemical and thermal disinfection approaches, were effective at inactivating both herpes simplex and human immunodeficiency virus (HIV) [
       <xref ref-type="bibr" rid="bib0445">
        89
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0450">
        90
       </xref>
       ]. Another study showed that common commercial contact lens care systems were capable of “safely decontaminating” HIV-1 from contact lenses, particularly when a rub step was included [
       <xref ref-type="bibr" rid="bib0240">
        48
       </xref>
       ]. A recent paper showed that benzalkonium chloride, a common ophthalmic preservative, could slow or halt adenovirus [
       <xref ref-type="bibr" rid="bib0455">
        91
       </xref>
       ]. Another paper reported that a rub-and-rinse technique was more effective at removing viruses from contact lenses than one in which no rubbing occurred [
       <xref ref-type="bibr" rid="bib0440">
        88
       </xref>
       ]. Most modern lens care systems include a surfactant [
       <xref ref-type="bibr" rid="bib0460">
        92
       </xref>
       ], and given that SARS-CoV-2 has a lipid envelope, it is plausible that a rub-and-rinse of the lens with such a care system may well be effective at killing the virus, but further work in this area is required to confirm this. Finally, one study demonstrated that thorough cleansing of virus-infected contact imaging lenses (such as retinal and fundus lenses) with both bleach and water/detergent was possible [
       <xref ref-type="bibr" rid="bib0465">
        93
       </xref>
       ], although this is not suggested as a suitable option for contact lens disinfection.
      </p>
      <p id="par0115">
       A potentially important finding from the review paper by Kampf et al. [
       <xref ref-type="bibr" rid="bib0330">
        66
       </xref>
       ] was their investigation of the inactivation of coronaviruses by various biocidal agents. These studies included examining the effect of disinfectants such as benzalkonium chloride, chlorhexidine digluconate, hydrogen peroxide and povidone iodine, which are (or have been) used in contact lens solutions. Chlorhexidine digluconate was a relatively weak biocide when tested against mouse hepatitis virus or canine coronavirus, benzalkonium chloride had improved activity, 0.5% hydrogen peroxide (a concentration substantially less than that used in contact lens solutions) caused a &gt;4 log
       <sub>
        10
       </sub>
       reduction in human coronavirus within 1 minute, and povidone iodine at concentrations as low as 0.23% (much less than found in contact lens disinfection systems) caused &gt;4log
       <sub>
        10
       </sub>
       reduction in the coronaviruses that cause SARS or MERS (middle east respiratory syndrome) within 15 seconds.
      </p>
     </sec>
     <sec id="sec0030">
      <label>
       1.5
      </label>
      <title>
       Areas for further study
      </title>
      <p id="par0120">
       Clearly, this is a fast moving situation, with information and advice being produced based on the best available evidence at the time each manuscript, news report and social media post is written. There are many areas where further study could extend current knowledge of the interaction of SARS-CoV-2 with both the ocular surface and contact lenses. Already mentioned above, further study is required to investigate the interaction of SARS-CoV-2 with contact lens materials, and the ability of contact lens disinfecting systems to kill the virus. The tear film is another area of interest. The tear film has antiviral properties [
       <xref ref-type="bibr" rid="bib0470">
        94
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0475">
        95
       </xref>
       ] and it is plausible that the tear film could inactivate viruses that were to come in contact with the tears. For instance, the tear film contains the protein lactoferrin, which is thought to prohibit adenoviral entry into corneal epithelial cells [
       <xref ref-type="bibr" rid="bib0480">
        96
       </xref>
       ]. However, this is unknown for SARS-CoV-2, but given the low frequency thus far of patients infected with COVID-19 that demonstrate the virus in the tears [
       <xref ref-type="bibr" rid="bib0095">
        19
       </xref>
       ] this is an area also worthy of study. What is missing at this time is the minimum infectious dose of SARS-CoV-2 that can cause COVID-19 and such information would be valuable. This dose would likely differ depending upon where that viral dose was delivered (for example, on the conjunctiva versus into the respiratory tract), or indeed whether there is true evidence to date that COVID-19 could indeed occur through conjunctival transmission [
       <xref ref-type="bibr" rid="bib0035">
        7
       </xref>
       ].
      </p>
     </sec>
     <sec id="sec0035">
      <label>
       1.6
      </label>
      <title>
       Access to clinical care and considerations for contact lens wear during the pandemic
      </title>
      <p id="par0125">
       The evidence presented in this paper suggests the safety of contact lens wear has not altered due to the pandemic and that appropriate hygiene considerations for contact lens wear and care should be the same as that always recommended. However, with local access to eyecare being different at this time of social distancing, and potentially severely compromised during the height of the pandemic, what should eye care professionals bear in mind when discussing contact lens wear with their patients?
      </p>
      <p id="par0130">
       A key consideration is for practitioners to be cognizant of local clinical care facilities during the course of the pandemic and to act to minimise the impact of contact lens-related adverse events on the wider healthcare system, which may be very stretched as staff are moved from providing ophthalmic care to other areas more directly related to COVID-19 patients. The implications here will necessarily vary according to local and regional considerations. For example, as of March 24, 2020, routine eyecare has been suspended in many countries, with optometric practices moving to provide scaled-back provision, telephone-only consultations and/or emergency services. For example, in the United Kingdom, practitioners should work to manage cases within an optometric framework rather than refer into the National Health Service where possible. This could include telephone contact with patients reporting contact lens problems and/or a video consultation using a suitable mobile phone app to enable rapid triage and management, reducing the need for burdening other clinical colleagues. Some cases may be best managed by referral to optometric colleagues licensed to practice as Independent Prescribers (therapeutically qualified optometrists) and who can treat more significant contact lens adverse events. In other cases, local Minor Eye Conditions Services (MECS) may be an alterative care pathway. Under this service patients are sent to local optometrists who have undergone accredited training in advanced optometric care that can triage whether referral to ophthalmology is required and, where possible and within their scope of practice, treat minor eye conditions. It is imperative that eyecare professionals avail themselves of the relevant options as early as possible in order to act quickly in the interests of both their patients and the wider healthcare system, and not begin to investigate the possibilities only after a contact lens wearer reports having some form of adverse event.
      </p>
      <p id="par0135">
       In North America, Australia and other regions/countries, therapeutically-endorsed optometrists are more likely to be the first port of call for contact lens patients with clinical adverse events, although again, most health authorities have required deferral of non-emergent, routine care. Here also, appropriate pathways need to be considered and enacted where a reduced level of routine eyecare is available. In countries where contact lens fitters and practitioners are less likely to offer clinical care to patients with clinically significant adverse events, management pathways and advice should again be considered to minimise the impact on the wider healthcare system.
      </p>
      <p id="par0140">
       It is particularly imperative during the ongoing pandemic that practitioners redouble their efforts to provide clinical advice to their patients to minimise contact lens complications, not least because many parts of the world are in forms of ‘lockdown’ and even leaving home to seek attention may not be straightforward. The simplest approach, as recommended by the American Academy of Ophthalmology, would be to cease contact lens wear and return to spectacles during this time [
       <xref ref-type="bibr" rid="bib0485">
        97
       </xref>
       ]. However, given the personal motivation individuals may have for wearing contact lenses, or indeed those wearing lenses for a clinical reason (keratoconus for example), this suggestion is likely not practical for many contact lens wearers. In the UK, the General Optical Council have taken a pragmatic approach to contact lens wear and supply during the pandemic. Releasing a joint statement with a number of other health care regulators, they recognise the highly challenging circumstances and the need to depart from established procedures [
       <xref ref-type="bibr" rid="bib0490">
        98
       </xref>
       ]. They have offered guidance which enables practitioners to exercise their professional judgement on whether patients need to be seen, or whether, following remote consultation, that the best course of action is to continue to supply lenses, even in the case of an expired specification [
       <xref ref-type="bibr" rid="bib0490">
        98
       </xref>
       ]. This action will act to ensure a continual supply of new lenses to wearers and significantly reduce any temptation from patients to use lenses beyond the recommended replacement interval. Practitioners should also act to ensure patients receive a supply of their prescribed lens type and communicate this appropriately, to dissuade patients from sourcing alternative (non-prescribed) lens brands via online lens retailers.
      </p>
      <p id="par0145">
       It is important to remember that by any absolute measure, contact lens wear is a safe form of vision correction for millions of people around the world. A review of 1,276 soft contact lens wearers records, across 4,120 visits, found eighty-two percent did not present with any complications during the observation period of more than two years [
       <xref ref-type="bibr" rid="bib0495">
        99
       </xref>
       ]. The frequency of more significant complications such as corneal infiltrative events (CIEs) and microbial keratitis are well understood. The annual incidence of symptomatic CIEs in daily reusable soft lens wear is around 3%, and nearly zero in daily disposable wear [
       <xref ref-type="bibr" rid="bib0500">
        100
       </xref>
       ]. The incidence of symptomatic CIEs in extended wear is higher, with a 2-7x increased risk compared to daily wear [
       <xref ref-type="bibr" rid="bib0505">
        [101]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0510">
        [102]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0515">
        [103]
       </xref>
       ]. Annual incidence of microbial keratitis (MK) varies by modality, and is around 2 per 10,000 wearers with daily wear of soft lenses, [
       <xref ref-type="bibr" rid="bib0065">
        13
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0075">
        15
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0520">
        104
       </xref>
       ] increasing to around 20 per 10,000 wearers in extended soft lens wear, irrespective of material type [
       <xref ref-type="bibr" rid="bib0065">
        13
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0070">
        14
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0525">
        105
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0530">
        106
       </xref>
       ].
      </p>
      <p id="par0150">
       However, a valid concern arises that any contact lens complication that warrants a visit to a healthcare facility at this time of limited resources is potentially an issue. To put these risks into context it is helpful to consider the incidence of contact lens issues in relation to accidental home-based injuries that also require medical care. In the U.S in 2012, a total of 19.4 million home injuries occurred that required medical attention, representing a rate of 24.17 per 100,000 of population [
       <xref ref-type="bibr" rid="bib0535">
        107
       </xref>
       ]. A study across two years in Belgium estimated the annual incidence of home incidents requiring management by general practitioners to be 2,194 per 100,000 people [
       <xref ref-type="bibr" rid="bib0540">
        108
       </xref>
       ]. Within the context of these figures, contact lens wear, with a rate for microbial keratitis of 0.2-2 per 100,000 (i.e. 2-20 per 10,000) wearers does not represent a significant additional burden on the healthcare system compared to the inherent dangers of living within the home, which based on their incidence as quoted above, would result in a far greater number of injuries that may require medical attention during the pandemic.
      </p>
      <p id="par0155">
       How could the risks of contact lens wear be further minimised to reduce any potential burden on hospital visits at this time? The risk factors that result in CIEs and infectious keratitis are well understood. The relative risks of developing CIEs are summarised in the comprehensive review by Steele and Szczotka-Flynn, [
       <xref ref-type="bibr" rid="bib0055">
        11
       </xref>
       ] and include non-modifiable factors such as younger age (1.75-2.61x), higher prescription (≥5D) (1.21-1.6x) and history of a previous event (2.5-6.1x), along with modifiable risks such as overnight wear (2.5-7x), bacterial bioburden on the lens and lid margins (5-8x), and lens replacement schedule - reusable compared to daily disposable (12.5x). MK is associated with many similar factors, including overnight wear [
       <xref ref-type="bibr" rid="bib0065">
        13
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0525">
        105
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0530">
        106
       </xref>
       ], and for daily wear, poor lens and storage case hygiene, infrequent lens case replacement, exposure to water and smoking [
       <xref ref-type="bibr" rid="bib0545">
        109
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0550">
        110
       </xref>
       ]. Risk factors for MK in daily disposable wearers are more frequent use, any overnight wear, less frequent handwashing, and smoking [
       <xref ref-type="bibr" rid="bib0555">
        111
       </xref>
       ]. While it is not possible to change a non-modifiable risk factor such as the age of a patient, there are significant opportunities to address modifiable behaviours. Given the reduced incidence of CIEs in wearers of daily disposable lenses [
       <xref ref-type="bibr" rid="bib0495">
        99
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0500">
        100
       </xref>
       ], this form of lens wear seems ideal in a time of reduced clinical provision. Some patients hold supplies of both reusable and daily disposable contact lenses, with the latter normally used for sports or holidays. With appropriate practitioner discussion, a move to using daily disposable lenses could be recommended at the current time.
      </p>
      <p id="par0160">
       Ceasing planned or accidental overnight wear significantly lowers the risk of contact lens complications. Some patients may principally use their lenses on an extended wear basis for occupational reasons and the same benefits may no longer be present if they are currently working from home. In such situations, reverting to a daily wear schedule could be merited – although only if the patient has an appropriate care regimen and is suitably compliant in its correct use. In the same way, patients who habitually alter from daily wear to extended wear over time (for work or other reasons) may be best advised to adopt a routine daily wear modality until normal clinical provision is available. Such changes to contact lens wearing schedules should be undertaken only after consultation between the patient and their contact lens practitioner.
      </p>
      <p id="par0165">
       Scrupulous hand hygiene along with correct use of multipurpose solutions with rub and rinse cleaning of reusable lenses, daily case cleaning and regular replacement of the lens case are all positive changes about which eye care professionals should remind their patients at the current time. Likewise, an important point is to counsel on the avoidance of contact with water to reduce the risk of microbial keratitis, especially
       <italic>
        Acanthamoeba
       </italic>
       keratitis which has been increasing in recent years [
       <xref ref-type="bibr" rid="bib0560">
        112
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0565">
        113
       </xref>
       ]. Finally, a patient who has access to both reusable and daily disposable contact lenses at home could be advised to switch to daily disposables, the modality with the lowest risk of complications in soft lens wear [
       <xref ref-type="bibr" rid="bib0365">
        73
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0500">
        100
       </xref>
       ].
      </p>
      <p id="par0170">
       Adherence to compliant lens wear and care practices is an important aim for the profession all of the time, however, it can be argued during the current outbreak of SARS-CoV-2 this should be an area of heightened focus. The attention on thorough hand washing is welcome and an important start, but for eye care practitioners it is reasonable to use this time to go much further, revisiting patient education on safe wear and care practices with the aim of reducing the chance of developing contact lens-related complications requiring clinical care.
      </p>
     </sec>
    </sec>
    <sec id="sec0040">
     <label>
      2
     </label>
     <title>
      Conclusions
     </title>
     <p id="par0175">
      In conclusion, to date no evidence suggests that contact lens wearers who are asymptomatic should cease contact lens wear due to an increased risk of developing COVID-19, that wearing prescription spectacles provides protection against SARS-CoV-2 or that any one form of contact lens material is more likely to enhance or reduce the risk of future COVID-19 infection. However, information concerning this novel coronavirus is evolving at a rapid rate and eye care practitioners must remain attentive to new findings as they emerge.
     </p>
     <p id="par0180">
      Practitioners must remain vigilant about reminding contact lens wearers of the need to maintain good hand hygiene practices when handling lenses. A focus on fully compliant contact lens wear and especially on the modifiable risk factors associated with contact lens complications are especially important during the height of the pandemic, where access to primary and secondary optometric care may be substantially different to normal, and practitioners should act to minimise the burden on the wider healthcare system by considering their local clinical pathway options. Patients must be reminded of the need to dispose of daily disposable lenses upon removal, the need for appropriate disinfection with reusable lenses, including the use of a rub-and-rinse step where indicated, and appropriate case cleaning and replacement. Finally, consistent with guidance for other types of illness, particularly those of the respiratory tract [
      <xref ref-type="bibr" rid="bib0570">
       [114]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0575">
       [115]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0580">
       [116]
      </xref>
      ], no contact lens wearer with active COVID-19 should remain wearing their contact lenses. This is the time to cease contact lens wear and revert to spectacles.
     </p>
    </sec>
    <sec id="sec0045">
     <title>
      Declaration of Competing Interest
     </title>
     <p id="par0185">
      Lyndon Jones and Karen Walsh are employees of the Centre for Ocular Research &amp; Education (CORE) at the University of Waterloo. Over the past 3 years CORE has received research support or lectureship honoraria from the following companies: Alcon, Allergan, CooperVision, GL Chemtec, iMed Pharma, Johnson &amp; Johnson Vision Care, Lubris, Menicon, Nature’s Way, Novartis, Ote, PS Therapy, Safilens, Santen, Shire, SightGlass and Visioneering.
     </p>
     <p id="par0190">
      Lyndon Jones is a consultant and/or serves on an advisory board for Alcon, CooperVision, Johnson &amp; Johnson Vision Care, Novartis and Ophtecs.
     </p>
     <p id="par0195">
      Karen Walsh has received honoraria from Alcon, CooperVision and Johnson &amp; Johnson.
     </p>
     <p id="par0200">
      Mark Willcox is a consultant for Johnson &amp; Johnson Vision Care, CooperVision and Ophtecs. In the past three years he has received research funding or honoraria from Alcon, Allergan, CooperVision, Ophtecs, Australian Biotechnologies, Lumicare, Botanix and EcoAid.
     </p>
     <p id="par0205">
      Philip Morgan is Director of Eurolens Research at the University of Manchester. In the past three years, Eurolens Research has received research funding and/or honoraria from: Alcon, AMCo, CooperVision, Essilor, Johnson &amp; Johnson Vision, Menicon, RB, Shire and Ultravision.
     </p>
     <p id="par0210">
      Jason Nichols declares Alcon (research, consultant), Bruder Healthcare (research; spouse-consultant), Allergan (spouse-consultant, spouse-research), Kala pharmaceuticals (spouse-research, spouse-consultant), Olympic Ophthalmics (consultant), Shire (consultant), Johnson and Johnson Vision Care (research), Sun Pharmaceuticals (spouse-consultant), ScienceBased Health (spouse-consultant), Oyster Point (spouse-consultant), Sight Sciences (spouse-consultant), Silk Technologies (spouse-consultant), Topivert (spouse-consultant), TearSolutions (spouse-research), Tearfilm Innovations (spouse-stock/other equity).
     </p>
    </sec>
    <back>
     <ref-list id="bibl0005">
      <title>
       References
      </title>
      <ref id="bib0005">
       <label>
        1
       </label>
       <element-citation id="sbref0005" publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           Miller
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Researchers are tracking another pandemic, too—of coronavirus misinformation
        </article-title>
        <ext-link ext-link-type="uri" id="intr0005" xlink:href="https://www.sciencemag.org/news/2020/03/researchers-are-tracking-another-epidemic-too-misinformation">
         https://www.sciencemag.org/news/2020/03/researchers-are-tracking-another-epidemic-too-misinformation
        </ext-link>
        <year>
         2020
        </year>
        <comment>
         Accessed 24 Mar 2020
        </comment>
       </element-citation>
      </ref>
      <ref id="bib0010">
       <label>
        2
       </label>
       <element-citation id="sbref0010" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Zhong
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Zheng
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods
        </article-title>
        <source>
         Acta Pharmaceutica Sinica B In press
        </source>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib0015">
       <label>
        3
       </label>
       <element-citation id="sbref0015" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Guo
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Pan
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           Z.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Structure analysis of the receptor binding of 2019-nCoV
        </article-title>
        <source>
         Biochem Biophys Res Commun In press
        </source>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib0020">
       <label>
        4
       </label>
       <element-citation id="sbref0020" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Perico
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Benigni
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Remuzzi
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Should COVID-19 Concern Nephrologists? Why and to What Extent? The Emerging Impasse of Angiotensin Blockade
        </article-title>
        <source>
         Nephron
        </source>
        <year>
         2020
        </year>
        <fpage>
         1
        </fpage>
        <lpage>
         9
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib0025">
       <label>
        5
       </label>
       <element-citation id="sbref0025" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Diaz
          </surname>
          <given-names>
           J.H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Hypothesis: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may increase the risk of severe COVID-19
        </article-title>
        <source>
         J Travel Med In press
        </source>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib0030">
       <label>
        6
       </label>
       <element-citation id="sbref0030" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           White
          </surname>
          <given-names>
           A.J.
          </given-names>
         </name>
         <name>
          <surname>
           Cheruvu
          </surname>
          <given-names>
           S.C.
          </given-names>
         </name>
         <name>
          <surname>
           Sarris
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Liyanage
          </surname>
          <given-names>
           S.S.
          </given-names>
         </name>
         <name>
          <surname>
           Lumbers
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Chui
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Wakefield
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           McCluskey
          </surname>
          <given-names>
           P.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Expression of classical components of the renin-angiotensin system in the human eye
        </article-title>
        <source>
         J Renin Angiotensin Aldosterone Syst
        </source>
        <volume>
         16
        </volume>
        <issue>
         1
        </issue>
        <year>
         2015
        </year>
        <fpage>
         59
        </fpage>
        <lpage>
         66
        </lpage>
        <pub-id pub-id-type="pmid">
         25287897
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0035">
       <label>
        7
       </label>
       <element-citation id="sbref0035" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Peng
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           Y.H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Is novel coronavirus disease (COVID-19) transmitted through conjunctiva?
        </article-title>
        <source>
         J Med Virol In press
        </source>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib0040">
       <label>
        8
       </label>
       <element-citation id="sbref0040" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Holappa
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Vapaatalo
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Vaajanen
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Many Faces of Renin-angiotensin System - Focus on Eye
        </article-title>
        <source>
         Open Ophthalmol J
        </source>
        <volume>
         11
        </volume>
        <year>
         2017
        </year>
        <fpage>
         122
        </fpage>
        <lpage>
         142
        </lpage>
        <pub-id pub-id-type="pmid">
         28761566
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0045">
       <label>
        9
       </label>
       <element-citation id="sbref0045" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sharma
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Bettis
          </surname>
          <given-names>
           D.I.
          </given-names>
         </name>
         <name>
          <surname>
           Cowden
          </surname>
          <given-names>
           J.W.
          </given-names>
         </name>
         <name>
          <surname>
           Mohan
          </surname>
          <given-names>
           R.R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Localization of angiotensin converting enzyme in rabbit cornea and its role in controlling corneal angiogenesis in vivo
        </article-title>
        <source>
         Mol Vis
        </source>
        <volume>
         16
        </volume>
        <year>
         2010
        </year>
        <fpage>
         720
        </fpage>
        <lpage>
         728
        </lpage>
        <pub-id pub-id-type="pmid">
         20431722
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0050">
       <label>
        10
       </label>
       <element-citation id="sbref0050" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Seah
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
         <name>
          <surname>
           Agrawal
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Can the Coronavirus Disease 2019 (COVID-19) Affect the Eyes? A Review of Coronaviruses and Ocular Implications in Humans and Animals
        </article-title>
        <source>
         Ocul Immunol Inflamm
        </source>
        <year>
         2020
        </year>
        <fpage>
         1
        </fpage>
        <lpage>
         5
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib0055">
       <label>
        11
       </label>
       <element-citation id="sbref0055" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Steele
          </surname>
          <given-names>
           K.R.
          </given-names>
         </name>
         <name>
          <surname>
           Szczotka-Flynn
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Epidemiology of contact lens-induced infiltrates: an updated review
        </article-title>
        <source>
         Clin Exp Optom
        </source>
        <volume>
         100
        </volume>
        <issue>
         5
        </issue>
        <year>
         2017
        </year>
        <fpage>
         473
        </fpage>
        <lpage>
         481
        </lpage>
        <pub-id pub-id-type="pmid">
         28868803
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0060">
       <label>
        12
       </label>
       <element-citation id="sbref0060" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Stapleton
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Keay
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Edwards
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Holden
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The epidemiology of microbial keratitis with silicone hydrogel contact lenses
        </article-title>
        <source>
         Eye Contact Lens
        </source>
        <volume>
         39
        </volume>
        <issue>
         1
        </issue>
        <year>
         2013
        </year>
        <fpage>
         79
        </fpage>
        <lpage>
         85
        </lpage>
        <pub-id pub-id-type="pmid">
         23172318
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0065">
       <label>
        13
       </label>
       <element-citation id="sbref0065" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Stapleton
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Keay
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Edwards
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Naduvilath
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Dart
          </surname>
          <given-names>
           J.K.
          </given-names>
         </name>
         <name>
          <surname>
           Brian
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Holden
          </surname>
          <given-names>
           B.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The incidence of contact lens-related microbial keratitis in Australia
        </article-title>
        <source>
         Ophthalmology
        </source>
        <volume>
         115
        </volume>
        <issue>
         10
        </issue>
        <year>
         2008
        </year>
        <fpage>
         1655
        </fpage>
        <lpage>
         1662
        </lpage>
        <pub-id pub-id-type="pmid">
         18538404
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0070">
       <label>
        14
       </label>
       <element-citation id="sbref0070" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Dart
          </surname>
          <given-names>
           J.K.
          </given-names>
         </name>
         <name>
          <surname>
           Radford
          </surname>
          <given-names>
           C.F.
          </given-names>
         </name>
         <name>
          <surname>
           Minassian
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Verma
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Stapleton
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Risk factors for microbial keratitis with contemporary contact lenses: a case-control study
        </article-title>
        <source>
         Ophthalmology
        </source>
        <volume>
         115
        </volume>
        <issue>
         10
        </issue>
        <year>
         2008
        </year>
        <fpage>
         1647
        </fpage>
        <lpage>
         1654
        </lpage>
        <comment>
         1654 e1-3
        </comment>
        <pub-id pub-id-type="pmid">
         18597850
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0075">
       <label>
        15
       </label>
       <element-citation id="sbref0075" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cheng
          </surname>
          <given-names>
           K.H.
          </given-names>
         </name>
         <name>
          <surname>
           Leung
          </surname>
          <given-names>
           S.L.
          </given-names>
         </name>
         <name>
          <surname>
           Hoekman
          </surname>
          <given-names>
           H.W.
          </given-names>
         </name>
         <name>
          <surname>
           Beekhuis
          </surname>
          <given-names>
           W.H.
          </given-names>
         </name>
         <name>
          <surname>
           Mulder
          </surname>
          <given-names>
           P.G.
          </given-names>
         </name>
         <name>
          <surname>
           Geerards
          </surname>
          <given-names>
           A.J.
          </given-names>
         </name>
         <name>
          <surname>
           Kijlstra
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Incidence of contact-lens-associated microbial keratitis and its related morbidity
        </article-title>
        <source>
         Lancet
        </source>
        <volume>
         354
        </volume>
        <issue>
         9174
        </issue>
        <year>
         1999
        </year>
        <fpage>
         181
        </fpage>
        <lpage>
         185
        </lpage>
        <pub-id pub-id-type="pmid">
         10421298
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0080">
       <label>
        16
       </label>
       <element-citation id="sbref0080" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Schein
          </surname>
          <given-names>
           O.D.
          </given-names>
         </name>
         <name>
          <surname>
           Glynn
          </surname>
          <given-names>
           R.J.
          </given-names>
         </name>
         <name>
          <surname>
           Poggio
          </surname>
          <given-names>
           E.C.
          </given-names>
         </name>
         <name>
          <surname>
           Seddon
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
         <name>
          <surname>
           Kenyon
          </surname>
          <given-names>
           K.R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The relative risk of ulcerative keratitis among users of daily-wear and extended-wear soft contact lenses. A case-control study. Microbial Keratitis Study Group
        </article-title>
        <source>
         N Engl J Med
        </source>
        <volume>
         321
        </volume>
        <issue>
         12
        </issue>
        <year>
         1989
        </year>
        <fpage>
         773
        </fpage>
        <lpage>
         778
        </lpage>
        <pub-id pub-id-type="pmid">
         2671733
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0085">
       <label>
        17
       </label>
       <element-citation id="sbref0085" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Azari
          </surname>
          <given-names>
           A.A.
          </given-names>
         </name>
         <name>
          <surname>
           Barney
          </surname>
          <given-names>
           N.P.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Conjunctivitis: a systematic review of diagnosis and treatment
        </article-title>
        <source>
         JAMA
        </source>
        <volume>
         310
        </volume>
        <issue>
         16
        </issue>
        <year>
         2013
        </year>
        <fpage>
         1721
        </fpage>
        <lpage>
         1729
        </lpage>
        <pub-id pub-id-type="pmid">
         24150468
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0090">
       <label>
        18
       </label>
       <element-citation id="sbref0090" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Xia
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Tong
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Shen
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Guo
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Evaluation of coronavirus in tears and conjunctival secretions of patients with SARS-CoV-2 infection
        </article-title>
        <source>
         J Med Virol In press
        </source>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib0095">
       <label>
        19
       </label>
       <element-citation id="sbref0095" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Jun
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
         <name>
          <surname>
           Anderson
          </surname>
          <given-names>
           D.E.
          </given-names>
         </name>
         <name>
          <surname>
           Kang
          </surname>
          <given-names>
           A.E.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           L.-F.
          </given-names>
         </name>
         <name>
          <surname>
           Rao
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Young
          </surname>
          <given-names>
           B.E.
          </given-names>
         </name>
         <name>
          <surname>
           Lye
          </surname>
          <given-names>
           D.C.
          </given-names>
         </name>
         <name>
          <surname>
           Agrawal
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Assessing Viral Shedding and Infectivity of Tears in Coronavirus Disease 2019 (COVID-19) Patients
        </article-title>
        <source>
         Ophthalmology In press
        </source>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib0100">
       <label>
        20
       </label>
       <element-citation id="sbref0100" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Guan
          </surname>
          <given-names>
           W.J.
          </given-names>
         </name>
         <name>
          <surname>
           Ni
          </surname>
          <given-names>
           Z.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Hu
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Liang
          </surname>
          <given-names>
           W.H.
          </given-names>
         </name>
         <name>
          <surname>
           Ou
          </surname>
          <given-names>
           C.Q.
          </given-names>
         </name>
         <name>
          <surname>
           He
          </surname>
          <given-names>
           J.X.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Shan
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Lei
          </surname>
          <given-names>
           C.L.
          </given-names>
         </name>
         <name>
          <surname>
           Hui
          </surname>
          <given-names>
           D.S.C.
          </given-names>
         </name>
         <name>
          <surname>
           Du
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           L.J.
          </given-names>
         </name>
         <name>
          <surname>
           Zeng
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Yuen
          </surname>
          <given-names>
           K.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           R.C.
          </given-names>
         </name>
         <name>
          <surname>
           Tang
          </surname>
          <given-names>
           C.L.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           P.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Xiang
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           S.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           J.L.
          </given-names>
         </name>
         <name>
          <surname>
           Liang
          </surname>
          <given-names>
           Z.J.
          </given-names>
         </name>
         <name>
          <surname>
           Peng
          </surname>
          <given-names>
           Y.X.
          </given-names>
         </name>
         <name>
          <surname>
           Wei
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Hu
          </surname>
          <given-names>
           Y.H.
          </given-names>
         </name>
         <name>
          <surname>
           Peng
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           J.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Zheng
          </surname>
          <given-names>
           Z.J.
          </given-names>
         </name>
         <name>
          <surname>
           Qiu
          </surname>
          <given-names>
           S.Q.
          </given-names>
         </name>
         <name>
          <surname>
           Luo
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Ye
          </surname>
          <given-names>
           C.J.
          </given-names>
         </name>
         <name>
          <surname>
           Zhu
          </surname>
          <given-names>
           S.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Zhong
          </surname>
          <given-names>
           N.S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         C. China Medical Treatment Expert Group for, Clinical Characteristics of Coronavirus Disease 2019 in China
        </article-title>
        <source>
         N Engl J Med In press
        </source>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib0105">
       <label>
        21
       </label>
       <element-citation id="sbref0105" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bonn
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         SARS virus in tears?
        </article-title>
        <source>
         Lancet Infect Dis
        </source>
        <volume>
         4
        </volume>
        <issue>
         8
        </issue>
        <year>
         2004
        </year>
        <fpage>
         480
        </fpage>
       </element-citation>
      </ref>
      <ref id="bib0110">
       <label>
        22
       </label>
       <element-citation id="sbref0110" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           W.M.
          </given-names>
         </name>
         <name>
          <surname>
           Yuen
          </surname>
          <given-names>
           K.S.
          </given-names>
         </name>
         <name>
          <surname>
           Fan
          </surname>
          <given-names>
           D.S.
          </given-names>
         </name>
         <name>
          <surname>
           Lam
          </surname>
          <given-names>
           D.S.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           P.K.
          </given-names>
         </name>
         <name>
          <surname>
           Sung
          </surname>
          <given-names>
           J.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Tears and conjunctival scrapings for coronavirus in patients with SARS
        </article-title>
        <source>
         Br J Ophthalmol
        </source>
        <volume>
         88
        </volume>
        <issue>
         7
        </issue>
        <year>
         2004
        </year>
        <fpage>
         968
        </fpage>
        <lpage>
         969
        </lpage>
        <pub-id pub-id-type="pmid">
         15205249
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0115">
       <label>
        23
       </label>
       <element-citation id="sbref0115" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Loon
          </surname>
          <given-names>
           S.C.
          </given-names>
         </name>
         <name>
          <surname>
           Teoh
          </surname>
          <given-names>
           S.C.
          </given-names>
         </name>
         <name>
          <surname>
           Oon
          </surname>
          <given-names>
           L.L.
          </given-names>
         </name>
         <name>
          <surname>
           Se-Thoe
          </surname>
          <given-names>
           S.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Ling
          </surname>
          <given-names>
           A.E.
          </given-names>
         </name>
         <name>
          <surname>
           Leo
          </surname>
          <given-names>
           Y.S.
          </given-names>
         </name>
         <name>
          <surname>
           Leong
          </surname>
          <given-names>
           H.N.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The severe acute respiratory syndrome coronavirus in tears
        </article-title>
        <source>
         Br J Ophthalmol
        </source>
        <volume>
         88
        </volume>
        <issue>
         7
        </issue>
        <year>
         2004
        </year>
        <fpage>
         861
        </fpage>
        <lpage>
         863
        </lpage>
        <pub-id pub-id-type="pmid">
         15205225
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0120">
       <label>
        24
       </label>
       <element-citation id="sbref0120" publication-type="book">
        <source>
         America Academy of Ophthalmology, Alert: Important coronavirus updates for ophthalmologists, AAO Alerts
        </source>
        <year>
         2020
        </year>
        <ext-link ext-link-type="uri" id="intr0010" xlink:href="https://www.aao.org/headline/alert-important-coronavirus-context">
         https://www.aao.org/headline/alert-important-coronavirus-context
        </ext-link>
        <comment>
         Accessed 24 Mar 2020
        </comment>
       </element-citation>
      </ref>
      <ref id="bib0125">
       <label>
        25
       </label>
       <element-citation id="sbref0125" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sun
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Role of the Eye in Transmitting Human Coronavirus: What We Know and What We Do Not Know
        </article-title>
        <source>
         Preprints In press
        </source>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib0130">
       <label>
        26
       </label>
       <element-citation id="sbref0130" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Creager
          </surname>
          <given-names>
           H.M.
          </given-names>
         </name>
         <name>
          <surname>
           Kumar
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Zeng
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Maines
          </surname>
          <given-names>
           T.R.
          </given-names>
         </name>
         <name>
          <surname>
           Tumpey
          </surname>
          <given-names>
           T.M.
          </given-names>
         </name>
         <name>
          <surname>
           Belser
          </surname>
          <given-names>
           J.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Infection and Replication of Influenza Virus at the Ocular Surface
        </article-title>
        <source>
         J Virol
        </source>
        <volume>
         92
        </volume>
        <issue>
         7
        </issue>
        <year>
         2018
        </year>
       </element-citation>
      </ref>
      <ref id="bib0135">
       <label>
        27
       </label>
       <element-citation id="sbref0135" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Nordbo
          </surname>
          <given-names>
           S.A.
          </given-names>
         </name>
         <name>
          <surname>
           Nesbakken
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Skaug
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Rosenlund
          </surname>
          <given-names>
           E.F.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Detection of adenovirus-specific immunoglobulin A in tears from patients with keratoconjunctivitis
        </article-title>
        <source>
         Eur J Clin Microbiol
        </source>
        <volume>
         5
        </volume>
        <issue>
         6
        </issue>
        <year>
         1986
        </year>
        <fpage>
         678
        </fpage>
        <lpage>
         680
        </lpage>
        <pub-id pub-id-type="pmid">
         3026800
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0140">
       <label>
        28
       </label>
       <element-citation id="sbref0140" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ramchandani
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Kong
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Tronstein
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Selke
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Mikhaylova
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Magaret
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           M.L.
          </given-names>
         </name>
         <name>
          <surname>
           Johnston
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Corey
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Wald
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Herpes Simplex Virus Type 1 Shedding in Tears and Nasal and Oral Mucosa of Healthy Adults
        </article-title>
        <source>
         Sex Transm Dis
        </source>
        <volume>
         43
        </volume>
        <issue>
         12
        </issue>
        <year>
         2016
        </year>
        <fpage>
         756
        </fpage>
        <lpage>
         760
        </lpage>
        <pub-id pub-id-type="pmid">
         27835628
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0145">
       <label>
        29
       </label>
       <element-citation id="sbref0145" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tan
          </surname>
          <given-names>
           J.J.L.
          </given-names>
         </name>
         <name>
          <surname>
           Balne
          </surname>
          <given-names>
           P.K.
          </given-names>
         </name>
         <name>
          <surname>
           Leo
          </surname>
          <given-names>
           Y.S.
          </given-names>
         </name>
         <name>
          <surname>
           Tong
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Ng
          </surname>
          <given-names>
           L.F.P.
          </given-names>
         </name>
         <name>
          <surname>
           Agrawal
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Persistence of Zika virus in conjunctival fluid of convalescence patients
        </article-title>
        <source>
         Sci Rep
        </source>
        <volume>
         7
        </volume>
        <issue>
         1
        </issue>
        <year>
         2017
        </year>
        <fpage>
         11194
        </fpage>
        <pub-id pub-id-type="pmid">
         28894118
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0150">
       <label>
        30
       </label>
       <element-citation id="sbref0150" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Jhanji
          </surname>
          <given-names>
           V.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           T.C.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           E.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Agarwal
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Vajpayee
          </surname>
          <given-names>
           R.B.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Adenoviral keratoconjunctivitis
        </article-title>
        <source>
         Surv Ophthalmol
        </source>
        <volume>
         60
        </volume>
        <issue>
         5
        </issue>
        <year>
         2015
        </year>
        <fpage>
         435
        </fpage>
        <lpage>
         443
        </lpage>
        <pub-id pub-id-type="pmid">
         26077630
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0155">
       <label>
        31
       </label>
       <element-citation id="sbref0155" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Garcia-Zalisnak
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Rapuano
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Sheppard
          </surname>
          <given-names>
           J.D.
          </given-names>
         </name>
         <name>
          <surname>
           Davis
          </surname>
          <given-names>
           A.R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Adenovirus Ocular Infections: Prevalence, Pathology, Pitfalls, and Practical Pointers
        </article-title>
        <source>
         Eye Contact Lens
        </source>
        <volume>
         44
        </volume>
        <issue>
         Suppl 1
        </issue>
        <year>
         2018
        </year>
        <fpage>
         S1
        </fpage>
        <lpage>
         S7
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib0160">
       <label>
        32
       </label>
       <element-citation id="sbref0160" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Mueller
          </surname>
          <given-names>
           A.J.
          </given-names>
         </name>
         <name>
          <surname>
           Klauss
          </surname>
          <given-names>
           V.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Main sources of infection in 145 cases of epidemic keratoconjunctivitis
        </article-title>
        <source>
         Ger J Ophthalmol
        </source>
        <volume>
         2
        </volume>
        <issue>
         4-5
        </issue>
        <year>
         1993
        </year>
        <fpage>
         224
        </fpage>
        <lpage>
         227
        </lpage>
        <pub-id pub-id-type="pmid">
         8220103
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0165">
       <label>
        33
       </label>
       <element-citation id="sbref0165" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Doyle
          </surname>
          <given-names>
           T.J.
          </given-names>
         </name>
         <name>
          <surname>
           King
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Cobb
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Miller
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Johnson
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
        </person-group>
        <article-title>
         An outbreak of epidemic keratoconjunctivitis at an outpatient ophthalmology clinic
        </article-title>
        <source>
         Infect Dis Rep
        </source>
        <volume>
         2
        </volume>
        <issue>
         2
        </issue>
        <year>
         2010
        </year>
        <fpage>
         e17
        </fpage>
        <pub-id pub-id-type="pmid">
         24470897
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0170">
       <label>
        34
       </label>
       <element-citation id="sbref0170" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yong
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Killerby
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Pan
          </surname>
          <given-names>
           C.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Huynh
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Green
          </surname>
          <given-names>
           N.M.
          </given-names>
         </name>
         <name>
          <surname>
           Wadford
          </surname>
          <given-names>
           D.A.
          </given-names>
         </name>
         <name>
          <surname>
           Terashita
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Outbreak of Epidemic Keratoconjunctivitis Caused by Human Adenovirus Type D53 in an Eye Care Clinic - Los Angeles County, 2017
        </article-title>
        <source>
         MMWR Morb Mortal Wkly Rep
        </source>
        <volume>
         67
        </volume>
        <issue>
         48
        </issue>
        <year>
         2018
        </year>
        <fpage>
         1347
        </fpage>
        <lpage>
         1349
        </lpage>
        <pub-id pub-id-type="pmid">
         30521501
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0175">
       <label>
        35
       </label>
       <element-citation id="sbref0175" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Muller
          </surname>
          <given-names>
           M.P.
          </given-names>
         </name>
         <name>
          <surname>
           Siddiqui
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Ivancic
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Adenovirus-related epidemic keratoconjunctivitis outbreak at a hospital-affiliated ophthalmology clinic
        </article-title>
        <source>
         Am J Infect Control
        </source>
        <volume>
         46
        </volume>
        <issue>
         5
        </issue>
        <year>
         2018
        </year>
        <fpage>
         581
        </fpage>
        <lpage>
         583
        </lpage>
        <pub-id pub-id-type="pmid">
         29305276
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0180">
       <label>
        36
       </label>
       <element-citation id="sbref0180" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Marinos
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Cabrera-Aguas
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Watson
          </surname>
          <given-names>
           S.L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Viral conjunctivitis: a retrospective study in an Australian hospital
        </article-title>
        <source>
         Cont Lens Anterior Eye
        </source>
        <volume>
         42
        </volume>
        <issue>
         6
        </issue>
        <year>
         2019
        </year>
        <fpage>
         679
        </fpage>
        <lpage>
         684
        </lpage>
        <pub-id pub-id-type="pmid">
         31300283
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0185">
       <label>
        37
       </label>
       <element-citation id="sbref0185" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sammons
          </surname>
          <given-names>
           J.S.
          </given-names>
         </name>
         <name>
          <surname>
           Graf
          </surname>
          <given-names>
           E.H.
          </given-names>
         </name>
         <name>
          <surname>
           Townsend
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Hoegg
          </surname>
          <given-names>
           C.L.
          </given-names>
         </name>
         <name>
          <surname>
           Smathers
          </surname>
          <given-names>
           S.A.
          </given-names>
         </name>
         <name>
          <surname>
           Coffin
          </surname>
          <given-names>
           S.E.
          </given-names>
         </name>
         <name>
          <surname>
           Williams
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Mitchell
          </surname>
          <given-names>
           S.L.
          </given-names>
         </name>
         <name>
          <surname>
           Nawab
          </surname>
          <given-names>
           U.
          </given-names>
         </name>
         <name>
          <surname>
           Munson
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Quinn
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Binenbaum
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Outbreak of Adenovirus in a Neonatal Intensive Care Unit: Critical Importance of Equipment Cleaning During Inpatient Ophthalmologic Examinations
        </article-title>
        <source>
         Ophthalmology
        </source>
        <volume>
         126
        </volume>
        <issue>
         1
        </issue>
        <year>
         2019
        </year>
        <fpage>
         137
        </fpage>
        <lpage>
         143
        </lpage>
        <pub-id pub-id-type="pmid">
         30180976
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0190">
       <label>
        38
       </label>
       <element-citation id="sbref0190" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gottsch
          </surname>
          <given-names>
           J.D.
          </given-names>
         </name>
         <name>
          <surname>
           Froggatt
          </surname>
          <given-names>
           J.W.
          </given-names>
          <suffix>
           3rd
          </suffix>
         </name>
         <name>
          <surname>
           Smith
          </surname>
          <given-names>
           D.M.
          </given-names>
         </name>
         <name>
          <surname>
           Dwyer
          </surname>
          <given-names>
           D.M.
          </given-names>
         </name>
         <name>
          <surname>
           Borenstein
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Karanfil
          </surname>
          <given-names>
           L.V.
          </given-names>
         </name>
         <name>
          <surname>
           Vitale
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Goldberg
          </surname>
          <given-names>
           M.F.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Prevention and control of epidemic keratoconjunctivitis in a teaching eye institute
        </article-title>
        <source>
         Ophthalmic Epidemiol
        </source>
        <volume>
         6
        </volume>
        <issue>
         1
        </issue>
        <year>
         1999
        </year>
        <fpage>
         29
        </fpage>
        <lpage>
         39
        </lpage>
        <pub-id pub-id-type="pmid">
         10384682
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0195">
       <label>
        39
       </label>
       <element-citation id="sbref0195" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ucakhan
          </surname>
          <given-names>
           O.
          </given-names>
         </name>
         <name>
          <surname>
           Yanik
          </surname>
          <given-names>
           O.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The Use of Bandage Contact Lenses in Adenoviral Keratoconjunctivitis
        </article-title>
        <source>
         Eye Contact Lens
        </source>
        <volume>
         42
        </volume>
        <issue>
         6
        </issue>
        <year>
         2016
        </year>
        <fpage>
         388
        </fpage>
        <lpage>
         391
        </lpage>
        <pub-id pub-id-type="pmid">
         26671622
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0200">
       <label>
        40
       </label>
       <element-citation id="sbref0200" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Brandt
          </surname>
          <given-names>
           B.M.
          </given-names>
         </name>
         <name>
          <surname>
           Mandleblatt
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Asbell
          </surname>
          <given-names>
           P.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Risk factors for herpes simplex-induced keratitis: a case-control study
        </article-title>
        <source>
         Ann Ophthalmol
        </source>
        <volume>
         26
        </volume>
        <issue>
         1
        </issue>
        <year>
         1994
        </year>
        <fpage>
         12
        </fpage>
        <lpage>
         16
        </lpage>
        <pub-id pub-id-type="pmid">
         8198362
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0205">
       <label>
        41
       </label>
       <element-citation id="sbref0205" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Mucci
          </surname>
          <given-names>
           J.J.
          </given-names>
         </name>
         <name>
          <surname>
           Utz
          </surname>
          <given-names>
           V.M.
          </given-names>
         </name>
         <name>
          <surname>
           Galor
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Feuer
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Jeng
          </surname>
          <given-names>
           B.H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Recurrence rates of herpes simplex virus keratitis in contact lens and non-contact lens wearers
        </article-title>
        <source>
         Eye Contact Lens
        </source>
        <volume>
         35
        </volume>
        <issue>
         4
        </issue>
        <year>
         2009
        </year>
        <fpage>
         185
        </fpage>
        <lpage>
         187
        </lpage>
        <pub-id pub-id-type="pmid">
         19502988
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0210">
       <label>
        42
       </label>
       <element-citation id="sbref0210" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hamroush
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Welch
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Herpes Simplex epithelial keratitis associated with daily disposable contact lens wear
        </article-title>
        <source>
         Cont Lens Anterior Eye
        </source>
        <volume>
         37
        </volume>
        <issue>
         3
        </issue>
        <year>
         2014
        </year>
        <fpage>
         228
        </fpage>
        <lpage>
         229
        </lpage>
        <pub-id pub-id-type="pmid">
         24333040
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0215">
       <label>
        43
       </label>
       <element-citation id="sbref0215" publication-type="journal">
        <article-title>
         Herpetic Eye Disease Study Group, Psychological stress and other potential triggers for recurrences of herpes simplex virus eye infections
        </article-title>
        <source>
         Herpetic Eye Disease Study Group, Arch Ophthalmol
        </source>
        <volume>
         118
        </volume>
        <issue>
         12
        </issue>
        <year>
         2000
        </year>
        <fpage>
         1617
        </fpage>
        <lpage>
         1625
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib0220">
       <label>
        44
       </label>
       <element-citation id="sbref0220" publication-type="book">
        <source>
         Centers for Disease Control and Prevention, Estimated HIV Incidence and Prevalence in the United States 2010–2016
        </source>
        <year>
         2019
        </year>
        <ext-link ext-link-type="uri" id="intr0015" xlink:href="https://www.cdc.gov/hiv/pdf/library/reports/surveillance/cdc-hiv-surveillance-supplemental-report-vol-24-1.pdf">
         https://www.cdc.gov/hiv/pdf/library/reports/surveillance/cdc-hiv-surveillance-supplemental-report-vol-24-1.pdf
        </ext-link>
        <comment>
         Accessed 24 Mar 2020
        </comment>
       </element-citation>
      </ref>
      <ref id="bib0225">
       <label>
        45
       </label>
       <element-citation id="sbref0225" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ablashi
          </surname>
          <given-names>
           D.V.
          </given-names>
         </name>
         <name>
          <surname>
           Sturzenegger
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Hunter
          </surname>
          <given-names>
           E.A.
          </given-names>
         </name>
         <name>
          <surname>
           Palestine
          </surname>
          <given-names>
           A.G.
          </given-names>
         </name>
         <name>
          <surname>
           Fujikawa
          </surname>
          <given-names>
           L.S.
          </given-names>
         </name>
         <name>
          <surname>
           Kim
          </surname>
          <given-names>
           M.K.
          </given-names>
         </name>
         <name>
          <surname>
           Nussenblatt
          </surname>
          <given-names>
           R.B.
          </given-names>
         </name>
         <name>
          <surname>
           Markham
          </surname>
          <given-names>
           P.D.
          </given-names>
         </name>
         <name>
          <surname>
           Salahuddin
          </surname>
          <given-names>
           S.Z.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Presence of HTLV-III in tears and cells from the eyes of AIDS patients
        </article-title>
        <source>
         J Exp Pathol
        </source>
        <volume>
         3
        </volume>
        <issue>
         4
        </issue>
        <year>
         1987
        </year>
        <fpage>
         693
        </fpage>
        <lpage>
         703
        </lpage>
        <pub-id pub-id-type="pmid">
         3483881
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0230">
       <label>
        46
       </label>
       <element-citation id="sbref0230" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tervo
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Lahdevirta
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Vaheri
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Valle
          </surname>
          <given-names>
           S.L.
          </given-names>
         </name>
         <name>
          <surname>
           Suni
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Recovery of HTLV-III from contact lenses
        </article-title>
        <source>
         Lancet
        </source>
        <volume>
         1
        </volume>
        <issue>
         8477
        </issue>
        <year>
         1986
        </year>
        <fpage>
         379
        </fpage>
        <lpage>
         380
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib0235">
       <label>
        47
       </label>
       <element-citation id="sbref0235" publication-type="book">
        <source>
         Centers for Disease Control and Prevention, HIV Transmission
        </source>
        <year>
         2020
        </year>
        <ext-link ext-link-type="uri" id="intr0020" xlink:href="https://www.cdc.gov/hiv/basics/transmission.html">
         https://www.cdc.gov/hiv/basics/transmission.html
        </ext-link>
        <comment>
         Accessed 24 Mar 2020
        </comment>
       </element-citation>
      </ref>
      <ref id="bib0240">
       <label>
        48
       </label>
       <element-citation id="sbref0240" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Amin
          </surname>
          <given-names>
           R.M.
          </given-names>
         </name>
         <name>
          <surname>
           Dean
          </surname>
          <given-names>
           M.T.
          </given-names>
         </name>
         <name>
          <surname>
           Zaumetzer
          </surname>
          <given-names>
           L.E.
          </given-names>
         </name>
         <name>
          <surname>
           Poiesz
          </surname>
          <given-names>
           B.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Virucidal efficacy of various lens cleaning and disinfecting solutions on HIV-I contaminated contact lenses
        </article-title>
        <source>
         AIDS Res Hum Retroviruses
        </source>
        <volume>
         7
        </volume>
        <issue>
         4
        </issue>
        <year>
         1991
        </year>
        <fpage>
         403
        </fpage>
        <lpage>
         408
        </lpage>
        <pub-id pub-id-type="pmid">
         1906290
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0245">
       <label>
        49
       </label>
       <element-citation id="sbref0245" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Manche
          </surname>
          <given-names>
           E.E.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Trends and Associations in Hospitalizations Due to Corneal Ulcers in the United States, 2002-2012
        </article-title>
        <source>
         Ophthalmic Epidemiol
        </source>
        <volume>
         23
        </volume>
        <issue>
         4
        </issue>
        <year>
         2016
        </year>
        <fpage>
         257
        </fpage>
        <lpage>
         263
        </lpage>
        <pub-id pub-id-type="pmid">
         27348134
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0250">
       <label>
        50
       </label>
       <element-citation id="sbref0250" publication-type="book">
        <source>
         Centers for Disease Control and Prevention, Information from CDC’s division of HIV/AIDS prevention
        </source>
        <year>
         2020
        </year>
        <ext-link ext-link-type="uri" id="intr0025" xlink:href="https://www.cdc.gov/hiv/policies/dear-colleague/dcl/032020.html">
         https://www.cdc.gov/hiv/policies/dear-colleague/dcl/032020.html
        </ext-link>
        <comment>
         Accessed 22 Mar 2020
        </comment>
       </element-citation>
      </ref>
      <ref id="bib0255">
       <label>
        51
       </label>
       <element-citation id="sbref0255" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Seah
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
         <name>
          <surname>
           Su
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Lingam
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Revisiting the dangers of the coronavirus in the ophthalmology practice
        </article-title>
        <source>
         Eye (Lond) In press
        </source>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib0260">
       <label>
        52
       </label>
       <element-citation id="sbref0260" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lu
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Cui
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Qian
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Duan
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Yao
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Song
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Tang
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
        </person-group>
        <article-title>
         On the origin and continuing evolution of SARS-CoV-2
        </article-title>
        <source>
         National Science Review In press
        </source>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib0265">
       <label>
        53
       </label>
       <element-citation id="sbref0265" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Habibzadeh
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Stoneman
          </surname>
          <given-names>
           E.K.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The Novel Coronavirus: A Bird’s Eye View
        </article-title>
        <source>
         Int J Occup Environ Med
        </source>
        <volume>
         11
        </volume>
        <issue>
         2
        </issue>
        <year>
         2020
        </year>
        <fpage>
         65
        </fpage>
        <lpage>
         71
        </lpage>
        <pub-id pub-id-type="pmid">
         32020915
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0270">
       <label>
        54
       </label>
       <element-citation id="sbref0270" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The SARS-CoV-2 outbreak: what we know
        </article-title>
        <source>
         Int J Infect Dis In press
        </source>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib0275">
       <label>
        55
       </label>
       <element-citation id="sbref0275" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Adhikari
          </surname>
          <given-names>
           S.P.
          </given-names>
         </name>
         <name>
          <surname>
           Meng
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           Y.J.
          </given-names>
         </name>
         <name>
          <surname>
           Mao
          </surname>
          <given-names>
           Y.P.
          </given-names>
         </name>
         <name>
          <surname>
           Ye
          </surname>
          <given-names>
           R.X.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           Q.Z.
          </given-names>
         </name>
         <name>
          <surname>
           Sun
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Sylvia
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Rozelle
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Raat
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID-19) during the early outbreak period: a scoping review
        </article-title>
        <source>
         Infect Dis Poverty
        </source>
        <volume>
         9
        </volume>
        <issue>
         1
        </issue>
        <year>
         2020
        </year>
        <fpage>
         29
        </fpage>
        <pub-id pub-id-type="pmid">
         32183901
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0280">
       <label>
        56
       </label>
       <element-citation id="sbref0280" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rothan
          </surname>
          <given-names>
           H.A.
          </given-names>
         </name>
         <name>
          <surname>
           Byrareddy
          </surname>
          <given-names>
           S.N.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak
        </article-title>
        <source>
         J Autoimmun In press
        </source>
        <year>
         2020
        </year>
        <object-id pub-id-type="publisher-id">
         102433
        </object-id>
       </element-citation>
      </ref>
      <ref id="bib0285">
       <label>
        57
       </label>
       <element-citation id="sbref0285" publication-type="book">
        <source>
         World Health Organization, Coronavirus disease (COVID-19) advice for the public
        </source>
        <year>
         2020
        </year>
        <ext-link ext-link-type="uri" id="intr0030" xlink:href="https://www.who.int/emergencies/diseases/novel-coronavirus-2019/advice-for-public">
         https://www.who.int/emergencies/diseases/novel-coronavirus-2019/advice-for-public
        </ext-link>
        <comment>
         Accessed 24 Mar 2020
        </comment>
       </element-citation>
      </ref>
      <ref id="bib0290">
       <label>
        58
       </label>
       <element-citation id="sbref0290" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Fonn
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Jones
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Hand hygiene is linked to microbial keratitis and corneal inflammatory events
        </article-title>
        <source>
         Cont Lens Anterior Eye
        </source>
        <volume>
         42
        </volume>
        <issue>
         2
        </issue>
        <year>
         2019
        </year>
        <fpage>
         132
        </fpage>
        <lpage>
         135
        </lpage>
        <pub-id pub-id-type="pmid">
         30413375
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0295">
       <label>
        59
       </label>
       <element-citation id="sbref0295" publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           Feldman
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         How Ditching Contacts For Glasses Can Protect You From The Coronavirus
        </article-title>
        <ext-link ext-link-type="uri" id="intr0035" xlink:href="https://www.huffingtonpost.ca/entry/how-ditching-contacts-for-glasses-protect-coronavirus_l_5e78e283c5b6f5b7c5489e44">
         https://www.huffingtonpost.ca/entry/how-ditching-contacts-for-glasses-protect-coronavirus_l_5e78e283c5b6f5b7c5489e44
        </ext-link>
        <year>
         2020
        </year>
        <comment>
         Accessed 24 Mar 2020
        </comment>
       </element-citation>
      </ref>
      <ref id="bib0300">
       <label>
        60
       </label>
       <element-citation id="sbref0300" publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           Weiss
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Does wearing glasses help protect you against coronavirus?
        </article-title>
        <ext-link ext-link-type="uri" id="intr0040" xlink:href="https://nypost.com/2020/03/10/does-wearing-glasses-help-protect-you-against-coronavirus/">
         https://nypost.com/2020/03/10/does-wearing-glasses-help-protect-you-against-coronavirus/
        </ext-link>
        <year>
         2020
        </year>
        <comment>
         Accessed 24 Mar 2020
        </comment>
       </element-citation>
      </ref>
      <ref id="bib0305">
       <label>
        61
       </label>
       <element-citation id="sbref0305" publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           Anon
          </surname>
         </name>
        </person-group>
        <article-title>
         Experts do not recommend using contact lenses for coronavirus
        </article-title>
        <ext-link ext-link-type="uri" id="intr0045" xlink:href="https://www.newsmaker.news/a/2020/03/experts-do-not-recommend-using-contact-lenses-for-coronavirus.html">
         https://www.newsmaker.news/a/2020/03/experts-do-not-recommend-using-contact-lenses-for-coronavirus.html
        </ext-link>
        <year>
         2020
        </year>
        <comment>
         Accessed 24 Mar 2020
        </comment>
       </element-citation>
      </ref>
      <ref id="bib0310">
       <label>
        62
       </label>
       <element-citation id="sbref0310" publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           World Health Organization
          </surname>
         </name>
        </person-group>
        <article-title>
         Rational use of personal protective equipment for coronavirus disease 2019 (COVID-19)
        </article-title>
        <ext-link ext-link-type="uri" id="intr0050" xlink:href="https://apps.who.int/iris/bitstream/handle/10665/331215/WHO-2019-nCov-IPCPPE_use-2020.1-eng.pdf">
         https://apps.who.int/iris/bitstream/handle/10665/331215/WHO-2019-nCov-IPCPPE_use-2020.1-eng.pdf
        </ext-link>
        <year>
         2020
        </year>
        <comment>
         Accessed 24 Mar 2020
        </comment>
       </element-citation>
      </ref>
      <ref id="bib0315">
       <label>
        63
       </label>
       <element-citation id="sbref0315" publication-type="book">
        <source>
         Centers for Disease Control and Prevention, Interim Infection Prevention and Control Recommendations for Patients with Suspected or Confirmed Coronavirus Disease 2019 (COVID-19) in Healthcare Settings, COVID-19
        </source>
        <year>
         2020
        </year>
        <ext-link ext-link-type="uri" id="intr0055" xlink:href="https://www.cdc.gov/coronavirus/2019-ncov/infection-control/control-recommendations.html">
         https://www.cdc.gov/coronavirus/2019-ncov/infection-control/control-recommendations.html
        </ext-link>
        <comment>
         Accessed 24 Mar 2020
        </comment>
       </element-citation>
      </ref>
      <ref id="bib0320">
       <label>
        64
       </label>
       <element-citation id="sbref0320" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Warnes
          </surname>
          <given-names>
           S.L.
          </given-names>
         </name>
         <name>
          <surname>
           Little
          </surname>
          <given-names>
           Z.R.
          </given-names>
         </name>
         <name>
          <surname>
           Keevil
          </surname>
          <given-names>
           C.W.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Human Coronavirus 229E Remains Infectious on Common Touch Surface Materials
        </article-title>
        <source>
         mBio
        </source>
        <volume>
         6
        </volume>
        <issue>
         6
        </issue>
        <year>
         2015
        </year>
        <fpage>
         e01697
        </fpage>
        <lpage>
         15
        </lpage>
        <pub-id pub-id-type="pmid">
         26556276
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0325">
       <label>
        65
       </label>
       <element-citation id="sbref0325" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ikonen
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Savolainen-Kopra
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Enstone
          </surname>
          <given-names>
           J.E.
          </given-names>
         </name>
         <name>
          <surname>
           Kulmala
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
         <name>
          <surname>
           Pasanen
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Salmela
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Salo
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Nguyen-Van-Tam
          </surname>
          <given-names>
           J.S.
          </given-names>
         </name>
         <name>
          <surname>
           Ruutu
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
        </person-group>
        <article-title>
         P. consortium, Deposition of respiratory virus pathogens on frequently touched surfaces at airports
        </article-title>
        <source>
         BMC Infect Dis
        </source>
        <volume>
         18
        </volume>
        <issue>
         1
        </issue>
        <year>
         2018
        </year>
        <fpage>
         437
        </fpage>
        <pub-id pub-id-type="pmid">
         30157776
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0330">
       <label>
        66
       </label>
       <element-citation id="sbref0330" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kampf
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Todt
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Pfaender
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Steinmann
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Persistence of coronaviruses on inanimate surfaces and their inactivation with biocidal agents
        </article-title>
        <source>
         J Hosp Infect
        </source>
        <volume>
         104
        </volume>
        <issue>
         3
        </issue>
        <year>
         2020
        </year>
        <fpage>
         246
        </fpage>
        <lpage>
         251
        </lpage>
        <pub-id pub-id-type="pmid">
         32035997
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0335">
       <label>
        67
       </label>
       <element-citation id="sbref0335" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ong
          </surname>
          <given-names>
           S.W.X.
          </given-names>
         </name>
         <name>
          <surname>
           Tan
          </surname>
          <given-names>
           Y.K.
          </given-names>
         </name>
         <name>
          <surname>
           Chia
          </surname>
          <given-names>
           P.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           T.H.
          </given-names>
         </name>
         <name>
          <surname>
           Ng
          </surname>
          <given-names>
           O.T.
          </given-names>
         </name>
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           M.S.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Marimuthu
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Air, Surface Environmental, and Personal Protective Equipment Contamination by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) From a Symptomatic Patient
        </article-title>
        <source>
         JAMA In press
        </source>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib0340">
       <label>
        68
       </label>
       <element-citation id="sbref0340" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Pittet
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Allegranzi
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Sax
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Dharan
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Pessoa-Silva
          </surname>
          <given-names>
           C.L.
          </given-names>
         </name>
         <name>
          <surname>
           Donaldson
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Boyce
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         W.A.f.P.S. Who Global Patient Safety Challenge, Evidence-based model for hand transmission during patient care and the role of improved practices
        </article-title>
        <source>
         Lancet Infect Dis
        </source>
        <volume>
         6
        </volume>
        <issue>
         10
        </issue>
        <year>
         2006
        </year>
        <fpage>
         641
        </fpage>
        <lpage>
         652
        </lpage>
        <pub-id pub-id-type="pmid">
         17008173
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0345">
       <label>
        69
       </label>
       <element-citation id="sbref0345" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Macias
          </surname>
          <given-names>
           A.E.
          </given-names>
         </name>
         <name>
          <surname>
           de la Torre
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Moreno-Espinosa
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Leal
          </surname>
          <given-names>
           P.E.
          </given-names>
         </name>
         <name>
          <surname>
           Bourlon
          </surname>
          <given-names>
           M.T.
          </given-names>
         </name>
         <name>
          <surname>
           Ruiz-Palacios
          </surname>
          <given-names>
           G.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Controlling the novel A (H1N1) influenza virus: don’t touch your face!
        </article-title>
        <source>
         J Hosp Infect
        </source>
        <volume>
         73
        </volume>
        <issue>
         3
        </issue>
        <year>
         2009
        </year>
        <fpage>
         280
        </fpage>
        <lpage>
         281
        </lpage>
        <pub-id pub-id-type="pmid">
         19699011
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0350">
       <label>
        70
       </label>
       <element-citation id="sbref0350" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kwok
          </surname>
          <given-names>
           Y.L.
          </given-names>
         </name>
         <name>
          <surname>
           Gralton
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           McLaws
          </surname>
          <given-names>
           M.L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Face touching: a frequent habit that has implications for hand hygiene
        </article-title>
        <source>
         Am J Infect Control
        </source>
        <volume>
         43
        </volume>
        <issue>
         2
        </issue>
        <year>
         2015
        </year>
        <fpage>
         112
        </fpage>
        <lpage>
         114
        </lpage>
        <pub-id pub-id-type="pmid">
         25637115
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0355">
       <label>
        71
       </label>
       <element-citation id="sbref0355" publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           Khatri
          </surname>
          <given-names>
           U.
          </given-names>
         </name>
         <name>
          <surname>
           Agarwal
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Hey, millennials and Gen Z, this isn’t spring break. It’s a pandemic
        </article-title>
        <ext-link ext-link-type="uri" id="intr0060" xlink:href="https://www.inquirer.com/health/coronavirus/coronavirus-covid-19-millennials-spring-break-social-distancing-20200323.html">
         https://www.inquirer.com/health/coronavirus/coronavirus-covid-19-millennials-spring-break-social-distancing-20200323.html
        </ext-link>
        <year>
         2020
        </year>
        <comment>
         Accessed 24 Mar 2020
        </comment>
       </element-citation>
      </ref>
      <ref id="bib0360">
       <label>
        72
       </label>
       <element-citation id="sbref0360" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zeri
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Naroo
          </surname>
          <given-names>
           S.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Contact lens practice in the time of COVID-19
        </article-title>
        <source>
         Cont Lens Anterior Eye In press
        </source>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib0365">
       <label>
        73
       </label>
       <element-citation id="sbref0365" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chalmers
          </surname>
          <given-names>
           R.L.
          </given-names>
         </name>
         <name>
          <surname>
           Keay
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           McNally
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Kern
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Multicenter case-control study of the role of lens materials and care products on the development of corneal infiltrates
        </article-title>
        <source>
         Optometry and vision science : official publication of the American Academy of Optometry
        </source>
        <volume>
         89
        </volume>
        <issue>
         3
        </issue>
        <year>
         2012
        </year>
        <fpage>
         316
        </fpage>
        <lpage>
         325
        </lpage>
        <pub-id pub-id-type="pmid">
         22227912
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0370">
       <label>
        74
       </label>
       <element-citation id="sbref0370" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           van Doremalen
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Bushmaker
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Morris
          </surname>
          <given-names>
           D.H.
          </given-names>
         </name>
         <name>
          <surname>
           Holbrook
          </surname>
          <given-names>
           M.G.
          </given-names>
         </name>
         <name>
          <surname>
           Gamble
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Williamson
          </surname>
          <given-names>
           B.N.
          </given-names>
         </name>
         <name>
          <surname>
           Tamin
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Harcourt
          </surname>
          <given-names>
           J.L.
          </given-names>
         </name>
         <name>
          <surname>
           Thornburg
          </surname>
          <given-names>
           N.J.
          </given-names>
         </name>
         <name>
          <surname>
           Gerber
          </surname>
          <given-names>
           S.I.
          </given-names>
         </name>
         <name>
          <surname>
           Lloyd-Smith
          </surname>
          <given-names>
           J.O.
          </given-names>
         </name>
         <name>
          <surname>
           de Wit
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Munster
          </surname>
          <given-names>
           V.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1
        </article-title>
        <source>
         N Engl J Med In press
        </source>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib0375">
       <label>
        75
       </label>
       <element-citation id="sbref0375" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Simmons
          </surname>
          <given-names>
           P.A.
          </given-names>
         </name>
         <name>
          <surname>
           Tomlinson
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Seal
          </surname>
          <given-names>
           D.V.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The role of Pseudomonas aeruginosa biofilm in the attachment of Acanthamoeba to four types of hydrogel contact lens materials
        </article-title>
        <source>
         Optometry and vision science : official publication of the American Academy of Optometry
        </source>
        <volume>
         75
        </volume>
        <issue>
         12
        </issue>
        <year>
         1998
        </year>
        <fpage>
         860
        </fpage>
        <lpage>
         866
        </lpage>
        <pub-id pub-id-type="pmid">
         9875990
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0380">
       <label>
        76
       </label>
       <element-citation id="sbref0380" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Subbaraman
          </surname>
          <given-names>
           L.N.
          </given-names>
         </name>
         <name>
          <surname>
           Borazjani
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Zhu
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Jones
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Willcox
          </surname>
          <given-names>
           M.D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Influence of protein deposition on bacterial adhesion to contact lenses
        </article-title>
        <source>
         Optometry and vision science : official publication of the American Academy of Optometry
        </source>
        <volume>
         88
        </volume>
        <issue>
         8
        </issue>
        <year>
         2011
        </year>
        <fpage>
         959
        </fpage>
        <lpage>
         966
        </lpage>
        <pub-id pub-id-type="pmid">
         21602733
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0385">
       <label>
        77
       </label>
       <element-citation id="sbref0385" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Dutta
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Cole
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Willcox
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Factors influencing bacterial adhesion to contact lenses
        </article-title>
        <source>
         Mol Vis
        </source>
        <volume>
         18
        </volume>
        <year>
         2012
        </year>
        <fpage>
         14
        </fpage>
        <lpage>
         21
        </lpage>
        <pub-id pub-id-type="pmid">
         22259220
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0390">
       <label>
        78
       </label>
       <element-citation id="sbref0390" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Willcox
          </surname>
          <given-names>
           M.D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Microbial adhesion to silicone hydrogel lenses: a review
        </article-title>
        <source>
         Eye Contact Lens
        </source>
        <volume>
         39
        </volume>
        <issue>
         1
        </issue>
        <year>
         2013
        </year>
        <fpage>
         61
        </fpage>
        <lpage>
         66
        </lpage>
        <pub-id pub-id-type="pmid">
         23266589
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0395">
       <label>
        79
       </label>
       <element-citation id="sbref0395" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           G.H.
          </given-names>
         </name>
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           J.E.
          </given-names>
         </name>
         <name>
          <surname>
           Park
          </surname>
          <given-names>
           M.K.
          </given-names>
         </name>
         <name>
          <surname>
           Yu
          </surname>
          <given-names>
           H.S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Adhesion of Acanthamoeba on Silicone Hydrogel Contact Lenses
        </article-title>
        <source>
         Cornea
        </source>
        <volume>
         35
        </volume>
        <issue>
         5
        </issue>
        <year>
         2016
        </year>
        <fpage>
         663
        </fpage>
        <lpage>
         668
        </lpage>
        <pub-id pub-id-type="pmid">
         26938330
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0400">
       <label>
        80
       </label>
       <element-citation id="sbref0400" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Dantam
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Subbaraman
          </surname>
          <given-names>
           L.N.
          </given-names>
         </name>
         <name>
          <surname>
           Jones
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Adhesion of Pseudomonas aeruginosa, Achromobacter xylosoxidans, Delftia acidovorans, Stenotrophomonas maltophilia to contact lenses under the influence of an artificial tear solution
        </article-title>
        <source>
         Biofouling
        </source>
        <volume>
         36
        </volume>
        <issue>
         1
        </issue>
        <year>
         2020
        </year>
        <fpage>
         32
        </fpage>
        <lpage>
         43
        </lpage>
        <pub-id pub-id-type="pmid">
         31973583
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0405">
       <label>
        81
       </label>
       <element-citation id="sbref0405" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           K.H.
          </given-names>
         </name>
         <name>
          <surname>
           Peiris
          </surname>
          <given-names>
           J.S.
          </given-names>
         </name>
         <name>
          <surname>
           Lam
          </surname>
          <given-names>
           S.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Poon
          </surname>
          <given-names>
           L.L.
          </given-names>
         </name>
         <name>
          <surname>
           Yuen
          </surname>
          <given-names>
           K.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Seto
          </surname>
          <given-names>
           W.H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The Effects of Temperature and Relative Humidity on the Viability of the SARS Coronavirus
        </article-title>
        <source>
         Adv Virol
        </source>
        <volume>
         2011
        </volume>
        <year>
         2011
        </year>
        <object-id pub-id-type="publisher-id">
         734690
        </object-id>
       </element-citation>
      </ref>
      <ref id="bib0410">
       <label>
        82
       </label>
       <element-citation id="sbref0410" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           van Doremalen
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Bushmaker
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Munster
          </surname>
          <given-names>
           V.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Stability of Middle East respiratory syndrome coronavirus (MERS-CoV) under different environmental conditions
        </article-title>
        <source>
         Euro Surveill
        </source>
        <volume>
         18
        </volume>
        <issue>
         38
        </issue>
        <year>
         2013
        </year>
       </element-citation>
      </ref>
      <ref id="bib0415">
       <label>
        83
       </label>
       <element-citation id="sbref0415" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Teichroeb
          </surname>
          <given-names>
           J.H.
          </given-names>
         </name>
         <name>
          <surname>
           Forrest
          </surname>
          <given-names>
           J.A.
          </given-names>
         </name>
         <name>
          <surname>
           Ngai
          </surname>
          <given-names>
           V.
          </given-names>
         </name>
         <name>
          <surname>
           Martin
          </surname>
          <given-names>
           J.W.
          </given-names>
         </name>
         <name>
          <surname>
           Jones
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Medley
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Imaging protein deposits on contact lens materials
        </article-title>
        <source>
         Optometry and vision science : official publication of the American Academy of Optometry
        </source>
        <volume>
         85
        </volume>
        <issue>
         12
        </issue>
        <year>
         2008
        </year>
        <fpage>
         1151
        </fpage>
        <lpage>
         1164
        </lpage>
        <pub-id pub-id-type="pmid">
         19050470
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0420">
       <label>
        84
       </label>
       <element-citation id="sbref0420" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Mann
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Tighe
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Contact lens interactions with the tear film
        </article-title>
        <source>
         Experimental eye research
        </source>
        <volume>
         117
        </volume>
        <year>
         2013
        </year>
        <fpage>
         88
        </fpage>
        <lpage>
         98
        </lpage>
        <pub-id pub-id-type="pmid">
         23886658
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0425">
       <label>
        85
       </label>
       <element-citation id="sbref0425" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tighe
          </surname>
          <given-names>
           B.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A decade of silicone hydrogel development: surface properties, mechanical properties, and ocular compatibility
        </article-title>
        <source>
         Eye Contact Lens
        </source>
        <volume>
         39
        </volume>
        <issue>
         1
        </issue>
        <year>
         2013
        </year>
        <fpage>
         4
        </fpage>
        <lpage>
         12
        </lpage>
        <pub-id pub-id-type="pmid">
         23292050
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0430">
       <label>
        86
       </label>
       <element-citation id="sbref0430" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Armanious
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Aeppli
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Jacak
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Refardt
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Sigstam
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Kohn
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Sander
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Viruses at Solid–Water Interfaces: A Systematic Assessment of Interactions Driving Adsorption
        </article-title>
        <source>
         Environmental Science &amp; Technology
        </source>
        <volume>
         50
        </volume>
        <issue>
         2
        </issue>
        <year>
         2016
        </year>
        <fpage>
         732
        </fpage>
        <lpage>
         743
        </lpage>
        <pub-id pub-id-type="pmid">
         26636722
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0435">
       <label>
        87
       </label>
       <element-citation id="sbref0435" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kowalski
          </surname>
          <given-names>
           R.P.
          </given-names>
         </name>
         <name>
          <surname>
           Sundar-Raj
          </surname>
          <given-names>
           C.V.
          </given-names>
         </name>
         <name>
          <surname>
           Romanowski
          </surname>
          <given-names>
           E.G.
          </given-names>
         </name>
         <name>
          <surname>
           Gordon
          </surname>
          <given-names>
           Y.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The disinfection of contact lenses contaminated with adenovirus
        </article-title>
        <source>
         Am J Ophthalmol
        </source>
        <volume>
         132
        </volume>
        <issue>
         5
        </issue>
        <year>
         2001
        </year>
        <fpage>
         777
        </fpage>
        <lpage>
         779
        </lpage>
        <pub-id pub-id-type="pmid">
         11704040
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0440">
       <label>
        88
       </label>
       <element-citation id="sbref0440" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Heaselgrave
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Lonnen
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Kilvington
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Santodomingo-Rubido
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Mori
          </surname>
          <given-names>
           O.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The disinfection efficacy of MeniCare soft multipurpose solution against Acanthamoeba and viruses using stand-alone biocidal and regimen testing
        </article-title>
        <source>
         Eye Contact Lens
        </source>
        <volume>
         36
        </volume>
        <issue>
         2
        </issue>
        <year>
         2010
        </year>
        <fpage>
         90
        </fpage>
        <lpage>
         95
        </lpage>
        <pub-id pub-id-type="pmid">
         20107417
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0445">
       <label>
        89
       </label>
       <element-citation id="sbref0445" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rohrer
          </surname>
          <given-names>
           M.D.
          </given-names>
         </name>
         <name>
          <surname>
           Terry
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
         <name>
          <surname>
           Bulard
          </surname>
          <given-names>
           R.A.
          </given-names>
         </name>
         <name>
          <surname>
           Graves
          </surname>
          <given-names>
           D.C.
          </given-names>
         </name>
         <name>
          <surname>
           Taylor
          </surname>
          <given-names>
           E.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Microwave sterilization of hydrophilic contact lenses
        </article-title>
        <source>
         Am J Ophthalmol
        </source>
        <volume>
         101
        </volume>
        <issue>
         1
        </issue>
        <year>
         1986
        </year>
        <fpage>
         49
        </fpage>
        <lpage>
         57
        </lpage>
        <pub-id pub-id-type="pmid">
         3942177
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0450">
       <label>
        90
       </label>
       <element-citation id="sbref0450" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Pepose
          </surname>
          <given-names>
           J.S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Contact lens disinfection to prevent transmission of viral disease, The CLAO journal: official publication of the Contact Lens Association of Ophthalmologists
        </article-title>
        <source>
         Inc
        </source>
        <volume>
         14
        </volume>
        <issue>
         3
        </issue>
        <year>
         1988
        </year>
        <fpage>
         165
        </fpage>
        <lpage>
         168
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib0455">
       <label>
        91
       </label>
       <element-citation id="sbref0455" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lazzaro
          </surname>
          <given-names>
           D.R.
          </given-names>
         </name>
         <name>
          <surname>
           Abulawi
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Hajee
          </surname>
          <given-names>
           M.E.
          </given-names>
         </name>
        </person-group>
        <article-title>
         In vitro cytotoxic effects of benzalkonium chloride on adenovirus
        </article-title>
        <source>
         Eye Contact Lens
        </source>
        <volume>
         35
        </volume>
        <issue>
         6
        </issue>
        <year>
         2009
        </year>
        <fpage>
         329
        </fpage>
        <lpage>
         332
        </lpage>
        <pub-id pub-id-type="pmid">
         19826252
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0460">
       <label>
        92
       </label>
       <element-citation id="sbref0460" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kuc
          </surname>
          <given-names>
           C.J.
          </given-names>
         </name>
         <name>
          <surname>
           Lebow
          </surname>
          <given-names>
           K.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Contact Lens Solutions and Contact Lens Discomfort: Examining the Correlations Between Solution Components, Keratitis, and Contact Lens Discomfort
        </article-title>
        <source>
         Eye Contact Lens
        </source>
        <volume>
         44
        </volume>
        <issue>
         6
        </issue>
        <year>
         2018
        </year>
        <fpage>
         355
        </fpage>
        <lpage>
         366
        </lpage>
        <pub-id pub-id-type="pmid">
         29905583
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0465">
       <label>
        93
       </label>
       <element-citation id="sbref0465" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Abbey
          </surname>
          <given-names>
           A.M.
          </given-names>
         </name>
         <name>
          <surname>
           Gregori
          </surname>
          <given-names>
           N.Z.
          </given-names>
         </name>
         <name>
          <surname>
           Surapaneni
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Miller
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Efficacy of detergent and water versus bleach for disinfection of direct contact ophthalmic lenses
        </article-title>
        <source>
         Cornea
        </source>
        <volume>
         33
        </volume>
        <issue>
         6
        </issue>
        <year>
         2014
        </year>
        <fpage>
         610
        </fpage>
        <lpage>
         613
        </lpage>
        <pub-id pub-id-type="pmid">
         24747806
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0470">
       <label>
        94
       </label>
       <element-citation id="sbref0470" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Smith
          </surname>
          <given-names>
           V.J.
          </given-names>
         </name>
         <name>
          <surname>
           Dyrynda
          </surname>
          <given-names>
           E.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Antimicrobial proteins: From old proteins, new tricks
        </article-title>
        <source>
         Mol Immunol
        </source>
        <volume>
         68
        </volume>
        <issue>
         2 Pt B
        </issue>
        <year>
         2015
        </year>
        <fpage>
         383
        </fpage>
        <lpage>
         398
        </lpage>
        <pub-id pub-id-type="pmid">
         26320628
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0475">
       <label>
        95
       </label>
       <element-citation id="sbref0475" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Malaczewska
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Kaczorek-Lukowska
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Wojcik
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Siwicki
          </surname>
          <given-names>
           A.K.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Antiviral effects of nisin, lysozyme, lactoferrin and their mixtures against bovine viral diarrhoea virus
        </article-title>
        <source>
         BMC Vet Res
        </source>
        <volume>
         15
        </volume>
        <issue>
         1
        </issue>
        <year>
         2019
        </year>
        <fpage>
         318
        </fpage>
        <pub-id pub-id-type="pmid">
         31488163
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0480">
       <label>
        96
       </label>
       <element-citation id="sbref0480" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Flanagan
          </surname>
          <given-names>
           J.L.
          </given-names>
         </name>
         <name>
          <surname>
           Willcox
          </surname>
          <given-names>
           M.D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Role of lactoferrin in the tear film
        </article-title>
        <source>
         Biochimie
        </source>
        <volume>
         91
        </volume>
        <issue>
         1
        </issue>
        <year>
         2009
        </year>
        <fpage>
         35
        </fpage>
        <lpage>
         43
        </lpage>
        <pub-id pub-id-type="pmid">
         18718499
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0485">
       <label>
        97
       </label>
       <element-citation id="sbref0485" publication-type="book">
        <source>
         American Academy of Ophthalmology, Coronavirus eye safety
        </source>
        <year>
         2020
        </year>
        <ext-link ext-link-type="uri" id="intr0065" xlink:href="https://www.aao.org/eye-health/tips-prevention/coronavirus-covid19-eye-infection-pinkeye">
         https://www.aao.org/eye-health/tips-prevention/coronavirus-covid19-eye-infection-pinkeye
        </ext-link>
        <comment>
         Accessed 24 Mar 2020
        </comment>
       </element-citation>
      </ref>
      <ref id="bib0490">
       <label>
        98
       </label>
       <element-citation id="sbref0490" publication-type="book">
        <source>
         General Optical Council, Joint statement and advice for eye care practitioners
        </source>
        <year>
         2020
        </year>
        <ext-link ext-link-type="uri" id="intr0070" xlink:href="https://www.optical.org/en/news_publications/Publications/joint-statement-and-guidance-on-coronavirus-covid19.cfm">
         https://www.optical.org/en/news_publications/Publications/joint-statement-and-guidance-on-coronavirus-covid19.cfm
        </ext-link>
        <comment>
         Accessed 24 Mar 2020
        </comment>
       </element-citation>
      </ref>
      <ref id="bib0495">
       <label>
        99
       </label>
       <element-citation id="sbref0495" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chalmers
          </surname>
          <given-names>
           R.L.
          </given-names>
         </name>
         <name>
          <surname>
           Keay
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Long
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Bergenske
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Giles
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Bullimore
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Risk factors for contact lens complications in US clinical practices
        </article-title>
        <source>
         Optometry and vision science: official publication of the American Academy of Optometry
        </source>
        <volume>
         87
        </volume>
        <issue>
         10
        </issue>
        <year>
         2010
        </year>
        <fpage>
         725
        </fpage>
        <lpage>
         735
        </lpage>
        <pub-id pub-id-type="pmid">
         20729772
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0500">
       <label>
        100
       </label>
       <element-citation id="sbref0500" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chalmers
          </surname>
          <given-names>
           R.L.
          </given-names>
         </name>
         <name>
          <surname>
           Hickson-Curran
          </surname>
          <given-names>
           S.B.
          </given-names>
         </name>
         <name>
          <surname>
           Keay
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Gleason
          </surname>
          <given-names>
           W.J.
          </given-names>
         </name>
         <name>
          <surname>
           Albright
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Rates of adverse events with hydrogel and silicone hydrogel daily disposable lenses in a large postmarket surveillance registry: the TEMPO Registry
        </article-title>
        <source>
         Invest Ophthalmol Vis Sci
        </source>
        <volume>
         56
        </volume>
        <issue>
         1
        </issue>
        <year>
         2015
        </year>
        <fpage>
         654
        </fpage>
        <lpage>
         663
        </lpage>
        <pub-id pub-id-type="pmid">
         25574042
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0505">
       <label>
        101
       </label>
       <element-citation id="sbref0505" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chalmers
          </surname>
          <given-names>
           R.L.
          </given-names>
         </name>
         <name>
          <surname>
           Wagner
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Mitchell
          </surname>
          <given-names>
           G.L.
          </given-names>
         </name>
         <name>
          <surname>
           Lam
          </surname>
          <given-names>
           D.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Kinoshita
          </surname>
          <given-names>
           B.T.
          </given-names>
         </name>
         <name>
          <surname>
           Jansen
          </surname>
          <given-names>
           M.E.
          </given-names>
         </name>
         <name>
          <surname>
           Richdale
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Sorbara
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           McMahon
          </surname>
          <given-names>
           T.T.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Age and other risk factors for corneal infiltrative and inflammatory events in young soft contact lens wearers from the Contact Lens Assessment in Youth (CLAY) study
        </article-title>
        <source>
         Invest Ophthalmol Vis Sci
        </source>
        <volume>
         52
        </volume>
        <issue>
         9
        </issue>
        <year>
         2011
        </year>
        <fpage>
         6690
        </fpage>
        <lpage>
         6696
        </lpage>
        <pub-id pub-id-type="pmid">
         21527379
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0510">
       <label>
        102
       </label>
       <element-citation id="sbref0510" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Morgan
          </surname>
          <given-names>
           P.B.
          </given-names>
         </name>
         <name>
          <surname>
           Efron
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Brennan
          </surname>
          <given-names>
           N.A.
          </given-names>
         </name>
         <name>
          <surname>
           Hill
          </surname>
          <given-names>
           E.A.
          </given-names>
         </name>
         <name>
          <surname>
           Raynor
          </surname>
          <given-names>
           M.K.
          </given-names>
         </name>
         <name>
          <surname>
           Tullo
          </surname>
          <given-names>
           A.B.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Risk factors for the development of corneal infiltrative events associated with contact lens wear
        </article-title>
        <source>
         Invest Ophthalmol Vis Sci
        </source>
        <volume>
         46
        </volume>
        <issue>
         9
        </issue>
        <year>
         2005
        </year>
        <fpage>
         3136
        </fpage>
        <lpage>
         3143
        </lpage>
        <pub-id pub-id-type="pmid">
         16123412
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0515">
       <label>
        103
       </label>
       <element-citation id="sbref0515" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Radford
          </surname>
          <given-names>
           C.F.
          </given-names>
         </name>
         <name>
          <surname>
           Minassian
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Dart
          </surname>
          <given-names>
           J.K.
          </given-names>
         </name>
         <name>
          <surname>
           Stapleton
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Verma
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Risk factors for nonulcerative contact lens complications in an ophthalmic accident and emergency department: a case-control study
        </article-title>
        <source>
         Ophthalmology
        </source>
        <volume>
         116
        </volume>
        <issue>
         3
        </issue>
        <year>
         2009
        </year>
        <fpage>
         385
        </fpage>
        <lpage>
         392
        </lpage>
        <pub-id pub-id-type="pmid">
         19167088
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0520">
       <label>
        104
       </label>
       <element-citation id="sbref0520" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lam
          </surname>
          <given-names>
           D.S.
          </given-names>
         </name>
         <name>
          <surname>
           Houang
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Fan
          </surname>
          <given-names>
           D.S.
          </given-names>
         </name>
         <name>
          <surname>
           Lyon
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Seal
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
        </person-group>
        <article-title>
         G. Hong Kong Microbial Keratitis Study, Incidence and risk factors for microbial keratitis in Hong Kong: comparison with Europe and North America
        </article-title>
        <source>
         Eye (Lond)
        </source>
        <volume>
         16
        </volume>
        <issue>
         5
        </issue>
        <year>
         2002
        </year>
        <fpage>
         608
        </fpage>
        <lpage>
         618
        </lpage>
        <pub-id pub-id-type="pmid">
         12194077
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0525">
       <label>
        105
       </label>
       <element-citation id="sbref0525" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Schein
          </surname>
          <given-names>
           O.D.
          </given-names>
         </name>
         <name>
          <surname>
           McNally
          </surname>
          <given-names>
           J.J.
          </given-names>
         </name>
         <name>
          <surname>
           Katz
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Chalmers
          </surname>
          <given-names>
           R.L.
          </given-names>
         </name>
         <name>
          <surname>
           Tielsch
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
         <name>
          <surname>
           Alfonso
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Bullimore
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           O’Day
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Shovlin
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The incidence of microbial keratitis among wearers of a 30-day silicone hydrogel extended-wear contact lens
        </article-title>
        <source>
         Ophthalmology
        </source>
        <volume>
         112
        </volume>
        <issue>
         12
        </issue>
        <year>
         2005
        </year>
        <fpage>
         2172
        </fpage>
        <lpage>
         2179
        </lpage>
        <pub-id pub-id-type="pmid">
         16325711
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0530">
       <label>
        106
       </label>
       <element-citation id="sbref0530" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Morgan
          </surname>
          <given-names>
           P.B.
          </given-names>
         </name>
         <name>
          <surname>
           Efron
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Hill
          </surname>
          <given-names>
           E.A.
          </given-names>
         </name>
         <name>
          <surname>
           Raynor
          </surname>
          <given-names>
           M.K.
          </given-names>
         </name>
         <name>
          <surname>
           Whiting
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
         <name>
          <surname>
           Tullo
          </surname>
          <given-names>
           A.B.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Incidence of keratitis of varying severity among contact lens wearers
        </article-title>
        <source>
         Br J Ophthalmol
        </source>
        <volume>
         89
        </volume>
        <issue>
         4
        </issue>
        <year>
         2005
        </year>
        <fpage>
         430
        </fpage>
        <lpage>
         436
        </lpage>
        <pub-id pub-id-type="pmid">
         15774919
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0535">
       <label>
        107
       </label>
       <element-citation id="sbref0535" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gielen
          </surname>
          <given-names>
           A.C.
          </given-names>
         </name>
         <name>
          <surname>
           McDonald
          </surname>
          <given-names>
           E.M.
          </given-names>
         </name>
         <name>
          <surname>
           Shields
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Unintentional home injuries across the life span: problems and solutions
        </article-title>
        <source>
         Annu Rev Public Health
        </source>
        <volume>
         36
        </volume>
        <year>
         2015
        </year>
        <fpage>
         231
        </fpage>
        <lpage>
         253
        </lpage>
        <pub-id pub-id-type="pmid">
         25581150
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0540">
       <label>
        108
       </label>
       <element-citation id="sbref0540" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Devroey
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Van Casteren
          </surname>
          <given-names>
           V.
          </given-names>
         </name>
         <name>
          <surname>
           Walckiers
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The added value of the registration of home accidents in general practice
        </article-title>
        <source>
         Scand J Prim Health Care
        </source>
        <volume>
         20
        </volume>
        <issue>
         2
        </issue>
        <year>
         2002
        </year>
        <fpage>
         113
        </fpage>
        <lpage>
         117
        </lpage>
        <pub-id pub-id-type="pmid">
         12184710
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0545">
       <label>
        109
       </label>
       <element-citation id="sbref0545" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Stapleton
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Edwards
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Keay
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Naduvilath
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Dart
          </surname>
          <given-names>
           J.K.
          </given-names>
         </name>
         <name>
          <surname>
           Brian
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Holden
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Risk factors for moderate and severe microbial keratitis in daily wear contact lens users
        </article-title>
        <source>
         Ophthalmology
        </source>
        <volume>
         119
        </volume>
        <issue>
         8
        </issue>
        <year>
         2012
        </year>
        <fpage>
         1516
        </fpage>
        <lpage>
         1521
        </lpage>
        <pub-id pub-id-type="pmid">
         22521083
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0550">
       <label>
        110
       </label>
       <element-citation id="sbref0550" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Arshad
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Carnt
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Tan
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Ekkeshis
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
         <name>
          <surname>
           Stapleton
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Water Exposure and the Risk of Contact Lens-Related Disease
        </article-title>
        <source>
         Cornea
        </source>
        <volume>
         38
        </volume>
        <issue>
         6
        </issue>
        <year>
         2019
        </year>
        <fpage>
         791
        </fpage>
        <lpage>
         797
        </lpage>
        <pub-id pub-id-type="pmid">
         30789440
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0555">
       <label>
        111
       </label>
       <element-citation id="sbref0555" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Stapleton
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Naduvilath
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Keay
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Radford
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Dart
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Edwards
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Carnt
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Minassian
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Holden
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Risk factors and causative organisms in microbial keratitis in daily disposable contact lens wear
        </article-title>
        <source>
         PLoS One
        </source>
        <volume>
         12
        </volume>
        <issue>
         8
        </issue>
        <year>
         2017
        </year>
        <object-id pub-id-type="publisher-id">
         e0181343
        </object-id>
       </element-citation>
      </ref>
      <ref id="bib0560">
       <label>
        112
       </label>
       <element-citation id="sbref0560" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Carnt
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Hoffman
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
         <name>
          <surname>
           Verma
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Hau
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Radford
          </surname>
          <given-names>
           C.F.
          </given-names>
         </name>
         <name>
          <surname>
           Minassian
          </surname>
          <given-names>
           D.C.
          </given-names>
         </name>
         <name>
          <surname>
           Dart
          </surname>
          <given-names>
           J.K.G.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Acanthamoeba keratitis: confirmation of the UK outbreak and a prospective case-control study identifying contributing risk factors
        </article-title>
        <source>
         Br J Ophthalmol
        </source>
        <volume>
         102
        </volume>
        <issue>
         12
        </issue>
        <year>
         2018
        </year>
        <fpage>
         1621
        </fpage>
        <lpage>
         1628
        </lpage>
        <pub-id pub-id-type="pmid">
         30232172
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0565">
       <label>
        113
       </label>
       <element-citation id="sbref0565" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Randag
          </surname>
          <given-names>
           A.C.
          </given-names>
         </name>
         <name>
          <surname>
           van Rooij
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           van Goor
          </surname>
          <given-names>
           A.T.
          </given-names>
         </name>
         <name>
          <surname>
           Verkerk
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Wisse
          </surname>
          <given-names>
           R.P.L.
          </given-names>
         </name>
         <name>
          <surname>
           Saelens
          </surname>
          <given-names>
           I.E.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Stoutenbeek
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           van Dooren
          </surname>
          <given-names>
           B.T.H.
          </given-names>
         </name>
         <name>
          <surname>
           Cheng
          </surname>
          <given-names>
           Y.Y.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Eggink
          </surname>
          <given-names>
           C.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The rising incidence of Acanthamoeba keratitis: A 7-year nationwide survey and clinical assessment of risk factors and functional outcomes
        </article-title>
        <source>
         PLoS One
        </source>
        <volume>
         14
        </volume>
        <issue>
         9
        </issue>
        <year>
         2019
        </year>
        <object-id pub-id-type="publisher-id">
         e0222092
        </object-id>
       </element-citation>
      </ref>
      <ref id="bib0570">
       <label>
        114
       </label>
       <element-citation id="sbref0570" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sankaridurg
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Holden
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Jalbert
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         Adverse events and infections: Which ones and how many?
        </chapter-title>
        <person-group person-group-type="editor">
         <name>
          <surname>
           Sweeney
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
        </person-group>
        <source>
         Silicone hydrogels: Continuous wear contact lenses
        </source>
        <year>
         2004
        </year>
        <publisher-name>
         Butterworth-Heinemann, Oxford
        </publisher-name>
        <fpage>
         217
        </fpage>
        <lpage>
         274
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib0575">
       <label>
        115
       </label>
       <element-citation id="sbref0575" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sweeney
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           du Toit
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Keay
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Jalbert
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
         <name>
          <surname>
           Sankaridurg
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Stern
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Skotnitsky
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Stephensen
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Covey
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Holden
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Rao
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         Clinical performance of silicone hydrogel lenses
        </chapter-title>
        <person-group person-group-type="editor">
         <name>
          <surname>
           Sweeney
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
        </person-group>
        <source>
         Silicone hydrogels: Continuous wear contact lenses
        </source>
        <year>
         2004
        </year>
        <publisher-name>
         Butterworth-Heinemann, Oxford
        </publisher-name>
        <fpage>
         164
        </fpage>
        <lpage>
         216
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib0580">
       <label>
        116
       </label>
       <element-citation id="sbref0580" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Willcox
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Sankaridurg
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Zhu
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Hume
          </surname>
          <given-names>
           E.B.
          </given-names>
         </name>
         <name>
          <surname>
           Cole
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Conibear
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Glasson
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Harmis
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Stapleton
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         Inflammation and infection and the effects of the closed eye
        </chapter-title>
        <person-group person-group-type="editor">
         <name>
          <surname>
           Sweeney
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
        </person-group>
        <source>
         Silicone hydrogels: Continuous wear contact lenses
        </source>
        <year>
         2004
        </year>
        <publisher-name>
         Butterworth-Heinemann, Oxford
        </publisher-name>
        <fpage>
         90
        </fpage>
        <lpage>
         125
        </lpage>
       </element-citation>
      </ref>
     </ref-list>
    </back>
   </article>
   <article article-type="chapter-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <?properties open_access?>
    <front>
     <journal-meta>
      <journal-id journal-id-type="publisher-id">
       978-3-030-03053-7
      </journal-id>
      <journal-id journal-id-type="doi">
       10.1007/978-3-030-03053-7
      </journal-id>
      <journal-id journal-id-type="nlm-ta">
       Defense Against Biological Attacks
      </journal-id>
      <journal-title-group>
       <journal-title>
        Defense Against Biological Attacks
       </journal-title>
       <journal-subtitle>
        Volume I
       </journal-subtitle>
      </journal-title-group>
      <isbn publication-format="print">
       978-3-030-03052-0
      </isbn>
      <isbn publication-format="electronic">
       978-3-030-03053-7
      </isbn>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmc">
       7123648
      </article-id>
      <article-id pub-id-type="publisher-id">
       8
      </article-id>
      <article-id pub-id-type="doi">
       10.1007/978-3-030-03053-7_8
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Article
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        Infection Prevention and Control: A Biodefense Measure
       </article-title>
      </title-group>
      <contrib-group content-type="book editors">
       <contrib contrib-type="editor">
        <name>
         <surname>
          Singh
         </surname>
         <given-names>
          Sunit K.
         </given-names>
        </name>
        <address>
         <phone>
          +9191542-2367936
         </phone>
         <email>
          sunitsingh2000@gmail.com
         </email>
        </address>
        <xref ref-type="aff" rid="Aff1">
         1
        </xref>
       </contrib>
       <contrib contrib-type="editor">
        <name>
         <surname>
          Kuhn
         </surname>
         <given-names>
          Jens H.
         </given-names>
        </name>
        <address>
         <email>
          kuhnjens@mail.nih.gov
         </email>
        </address>
        <xref ref-type="aff" rid="Aff2">
         2
        </xref>
       </contrib>
       <aff id="Aff1">
        <label>
         1
        </label>
        <institution-wrap>
         <institution-id institution-id-type="GRID">
          grid.463154.1
         </institution-id>
         <institution-id institution-id-type="ISNI">
          0000 0004 1768 1906
         </institution-id>
         <institution>
          Molecular Biology Unit,
         </institution>
         <institution>
          Institute of Medical Sciences, Banaras Hindu University,
         </institution>
        </institution-wrap>
        Varanasi, India
       </aff>
       <aff id="Aff2">
        <label>
         2
        </label>
        <institution-wrap>
         <institution-id institution-id-type="GRID">
          grid.419681.3
         </institution-id>
         <institution-id institution-id-type="ISNI">
          0000 0001 2164 9667
         </institution-id>
         <institution>
          NIH/NIAID, Division of Clinical Research,
         </institution>
         <institution>
          Integrated Research Facility at Fort Detrick,
         </institution>
        </institution-wrap>
        Frederick, MD USA
       </aff>
      </contrib-group>
      <contrib-group>
       <contrib contrib-type="author" corresp="yes">
        <name>
         <surname>
          Popescu
         </surname>
         <given-names>
          Saskia
         </given-names>
        </name>
        <degrees>
         MPH, MA, CIC, PhD(c)
        </degrees>
        <address>
         <email>
          spopesc2@gmu.edu
         </email>
        </address>
        <xref ref-type="aff" rid="Aff3">
         3
        </xref>
        <xref ref-type="aff" rid="Aff4">
         4
        </xref>
       </contrib>
       <aff id="Aff3">
        <label>
         3
        </label>
        <institution-wrap>
         <institution-id institution-id-type="GRID">
          grid.22448.38
         </institution-id>
         <institution-id institution-id-type="ISNI">
          0000 0004 1936 8032
         </institution-id>
         <institution>
          George Mason University,
         </institution>
        </institution-wrap>
        Fairfax, VA USA
       </aff>
       <aff id="Aff4">
        <label>
         4
        </label>
        <institution-wrap>
         <institution-id institution-id-type="GRID">
          grid.417276.1
         </institution-id>
         <institution-id institution-id-type="ISNI">
          0000 0001 0381 0779
         </institution-id>
         <institution>
          Phoenix Children’s Hospital,
         </institution>
        </institution-wrap>
        Phoenix, AZ USA
       </aff>
      </contrib-group>
      <pub-date pub-type="epub">
       <day>
        31
       </day>
       <month>
        03
       </month>
       <year>
        2019
       </year>
      </pub-date>
      <fpage>
       145
      </fpage>
      <lpage>
       169
      </lpage>
      <permissions>
       <copyright-statement>
        © Springer Nature Switzerland AG 2019
       </copyright-statement>
       <license>
        <license-p>
         This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
        </license-p>
       </license>
      </permissions>
      <abstract id="Abs1">
       <p id="Par1">
        Infection prevention and control (IPC) is the foundation for preventing the spread of infectious diseases, regardless of source, during medical treatment. Biological attacks will inevitably involve the medical management of sick individuals, which will not only tax the healthcare system, but also highlight the vital importance of infection control. Reducing the capacity for disease transmission will be pivotal in not only the early stages of an outbreak or biological attack, but also during times of crisis. Infection control programs also conduct disease surveillance and reporting to public health departments, which is crucial during an attack or outbreak. Infection control failures, like those in the 2013–2016 Ebola virus disease outbreak and continued Middle East respiratory syndrome (MERS) outbreaks, act as amplifiers for pathogen transmission. In the event of a biological attack, the strength and stamina of a hospital’s infection control program will be critical to early recognition, isolation, treatment, and reducing the spread of infection.
       </p>
      </abstract>
      <kwd-group xml:lang="en">
       <title>
        Keywords
       </title>
       <kwd>
        Infection control
       </kwd>
       <kwd>
        Prevention
       </kwd>
       <kwd>
        Disease
       </kwd>
       <kwd>
        Transmission
       </kwd>
       <kwd>
        Isolation
       </kwd>
       <kwd>
        Infectious
       </kwd>
      </kwd-group>
      <custom-meta-group>
       <custom-meta>
        <meta-name>
         issue-copyright-statement
        </meta-name>
        <meta-value>
         © Springer Nature Switzerland AG 2019
        </meta-value>
       </custom-meta>
      </custom-meta-group>
     </article-meta>
    </front>
    <sec id="Sec1">
     <title>
      Infection Prevention and Control
     </title>
     <p id="Par2">
      Infection prevention and control is a series of practices, processes, and programs within healthcare to reduce the spread of infection among patients and staff. Infection prevention and control (IPC) programs within hospitals and healthcare facilities typically consist of infection preventionists (IPs) who are commonly nurses, epidemiologists, and microbiologists. The duties of the IP and IPC program includes a variety of responsibilities; disease surveillance, case investigation for hospital-associated infections, education, training of staff, policy review, risk assessments for construction in patient care areas, emergency preparedness, reporting of communicable diseases to local health departments, reporting of healthcare-associated infections for reimbursement and federal requirements, etc. Traditionally, the role of the infection prevention program is to focus on reducing healthcare-associated infections (HAIs) however, communicable diseases play a large role in their duties. Properly training and educating staff on the correct use of personal protective equipment (PPE) and ensuring isolation precautions are correctly maintained is a daily responsibility for the IPC department. Aside from ensuring staff compliance to PPE and isolation precautions, IPC works to educate and facilitate compliance among visitors, as they can be a source for disease spread within a healthcare facility. The role of the IPC program and infection preventionists is also as the connective tissue within healthcare facilities to ensure that infectious diseases have the proper response across the healthcare sector, which includes departments like environmental services, security, emergency medicine, facilities, administration, interventional radiology, sterile processing departments, etc. Infection and control programs are the sentinels for underlying issues within the health of the community and healthcare facility.
     </p>
     <sec id="Sec2">
      <title>
       Practitioners
      </title>
      <p id="Par3">
       Infection prevention and control departments are comprised of infection preventionists, who have a variety of backgrounds. Traditionally the IP role has been primarily nurse-driven, but recent years have seen an influx of epidemiologists as the role increasingly involves hospital epidemiology, outbreak investigation, and public health response. The IP, even at the most novice level, must have a rudimentary understanding of microbiology, disease transmission, and public health interventions. IP competencies are built up according the Association for Professionals in Infection Prevention and Epidemiology (APIC) model, which is considered the gold standard. The APIC competency model is based upon a text that includes topics that highlight the range of IP duties—occupational health, sterilization and disinfection, bioterrorism, emergency preparedness, outbreak response, infection prevention in a variety of settings (e.g., behavioral health, correctional facilities, dental services), aseptic technique, infection prevention for specialty care populations (e.g., burns, pediatrics, organ transplants), as well as the environmental components to infection prevention work (e.g., waste management, heating and ventilation, healthcare textiles). The duties and capabilities of the IP are required to be extensive and diverse. Infection preventionists are expected to sit for the Certification in Infection Control (CIC) after 2 years. The CIC is a complex certification which aims to ensure the IP is well-versed in the variety of issues that plague healthcare systems. Since the 2002 severe acute respiratory syndrome (SARS) coronavirus and 2013–2016 Ebola virus disease outbreaks, infection preventionists’ duties have increasingly involved high-consequence pathogens and emergency preparedness. Overall, infection preventionists are responsible for all manner of infectious disease threats within a healthcare facility, regardless of origin.
      </p>
     </sec>
     <sec id="Sec3">
      <title>
       Surveillance and Coordination with Health Departments
      </title>
      <p id="Par4">
       Perhaps one of the most crucial responsibilities of the infection prevention and control program is to perform surveillance and report communicable diseases to local health departments. While IPC programs are frequently responsible for reporting hospital-associated infections within their facility, it is the responsibility for reporting communicable diseases that is relevant to defense against biological attacks. Communicable disease reporting requirements (also known as Infectious Disease Reporting) vary within each state and even county, but overall, there are state laws requiring medical providers to report notifiable disease to local public health departments [
       <xref ref-type="bibr" rid="CR1">
        1
       </xref>
       ]. While there is variation in the lists of notifiable diseases that states require healthcare providers to report, there is a general consistency of common and concerning microorganisms that includes all Category A agents and a majority of those listed within the Center for Disease Control and Prevention’s (CDC) bioterrorism agents page [
       <xref ref-type="bibr" rid="CR2">
        2
       </xref>
       –
       <xref ref-type="bibr" rid="CR5">
        5
       </xref>
       ]. Within hospitals and healthcare facilities, it is generally the IPC program that is responsible for reporting communicable diseases to local public health authorities. While laboratory reporting can and does happen, it is mostly incomplete information and commonly limited to the positive laboratory result and the name of the patient. The legal responsibility of reporting the communicable diseases ultimately tends to fall upon the infection prevention and control program, which must not only report such diseases with complete patient and laboratory information, but also within the required time frame. State reporting laws dictate the list of notifiable diseases and their required reporting time frame. For example, in California, the California Code of Regulations requires a report for West Nile virus infection be submitted by electronic transmission, telephone, or mail within one working day of identification, while a human or animal case of plague requires immediate reporting by phone [
       <xref ref-type="bibr" rid="CR6">
        6
       </xref>
       ]. These lists mirror that of the CDC’s National Notifiable Diseases Surveillance System (NNDSS). In essence, the reporting structure commonly begins with the IP performing surveillance based off laboratory reports and daily reports of admitting diagnoses for newly admitted patients. From this surveillance, reporting is performed to the local health department, which will then report to the state health department, which then reports it to the CDC. In short, national diseases surveillance and reporting frequently starts with hospital IPC programs.
      </p>
      <p id="Par5">
       IPC programs have a critical role in communicable disease reporting, which aids in public health response. The strength of the infection prevention and control program will be seen in their ability to perform more specific surveillance and real-time disease reporting. Poorly supported or minimally staffed IPC programs will likely rely solely on microbiology reports and might be delayed in their surveillance and reporting efforts. Some diseases, like Kawasaki syndrome, cannot be confirmed by laboratory tests, which can be challenging, but is overcome through daily chart review and a strong relationship with physicians and other clinical staff. Moreover, once a case is identified as a communicable disease that must be reported, the skilled IP will not only report the required information (e.g., laboratory results, demographics, contact info) but also relevant medical record information for the condition, which will include a timeline of illness, travel history, physician notes, etc. Such attention to detail facilitates a more rapid and efficient response from public health authorities. Overall, the infection prevention and control program within healthcare facilities is frequently the primary source of communicable disease reporting, which is a vital part of public health response during biological events.
      </p>
     </sec>
     <sec id="Sec4">
      <title>
       Coordination Among Internal Departments
      </title>
      <p id="Par6">
       IPC programs are a connective tissue within the healthcare setting, working across professions and job roles to ensure the response to infectious disease threats is appropriate. It is the responsibility of the IPC program to ensure that clinical staff follow infection control guidelines, but also ancillary staff, which includes but is not limited to environmental services, facilities, sterile processing and disinfection, laboratory, security, or food services. IPC coordinates with these departments to ensure the proper education and compliance is ongoing as interaction with patients is not solely limited to healthcare providers. Aside from ensuring infection control practices are followed, the IPC program must also coordinate with different departments within the healthcare facility/system to ensure the proper expertise are being utilized. Consider the role of construction or facilities maintenance. A relatively simple task, like installing cabling or renovating a new space can bring with it substantial patient safety concerns due to dust, mold, etc. IPC must consider the full spectrum of affected people and departments during biological incidents, for example; during a public health emergency or treatment of a patient in enhanced precautions, IPC must coordinate with environmental services to ensure proper waste disposal is being performed. In the event of a pediatric patient with Ebola virus disease, IPC must ensure that Child Life Services are able to provide recommendations and guidance in regards to the unique needs of pediatric patients. Such unique situations require IPC response and coordination of expert opinions to ensure the most appropriate actions are taken. During an influx of patients with an infectious disease or in the wake of an attack, IPC will be an integral component to hospital response and coordination of efforts. In emergent situations, the Hospital Incident Command System (HICS) may be initiated, of which IPC plays a vital role in providing instructions and expert recommendations.
      </p>
     </sec>
    </sec>
    <sec id="Sec5">
     <title>
      Isolation Precautions and Personal Protective Equipment
     </title>
     <p id="Par7">
      Isolation precautions are singularly one of the most critical components to preventing the spread of infectious diseases during patient care. The rapid isolation and adherence to personal protective equipment guidelines are imperative in daily patient care, but will become even more pertinent during infectious disease crises. Adherence to standard precautions and hand hygiene is fundamental for all patient interactions. However, additional transmission-based precautions may be needed during the medical care of patients with infectious diseases. Transmission-based precautions (isolation precautions) are often required
      <italic>
       in addition
      </italic>
      to standard precautions. Full information on microorganism-specific isolation precautions and detailed PPE directions can be found within several CDC and World Health Organization (WHO) publications. IPC recommendations follow CDC guidelines for isolation precautions and corresponding PPE based upon the identified microorganism (e.g., bacterial, viral, fungal). The recommendations within this chapter serve as broad guidance for utilization and compliance. Reference is made to the patient room, but isolation precautions should be applied to the area in which the patient is present (e.g., treatment room, post-procedural recovery bay).
     </p>
     <sec id="Sec6">
      <title>
       Personal Protective Equipment
      </title>
      <p id="Par8">
       Personal protective equipment (PPE) in the healthcare setting includes gloves, gowns, masks, shoe covers, and eye-protection. These items are the most common and frequently used PPE during patient care, but additional PPE may be recommended in emergent situations. PPE provides a mutual benefit to both patient and healthcare worker as it reduces the spread of diseases between the two parties. Correct utilization of PPE decreases the microbial burden in the environment as well, preventing the spread of disease through cross-contamination. PPE is mutually beneficial within the care process, which should be taught in training to encourage compliance.
      </p>
      <p id="Par9">
       Donning and doffing PPE is a critical component to efficacy. Improper use of PPE is common among healthcare workers, as the time to properly don can be taxing or because it is thought to be easier to continue wearing PPE if only leaving a patient’s room momentarily (e.g., keeping a facemask on while running to the medication room). For PPE to be effective, it must be donned prior to entering the patient room and doffed prior to leaving or upon exiting (depending upon the layout of the care area) to avoid contamination of the hospital unit. PPE should always be changed between patients and should never leave the patient’s room, regardless of how short a simple task may appear. If a patient is in isolation, anyone entering the room should don PPE, regardless of whether the planned task does not involve patient interaction or expected contact with the environment. Once in the patient’s room, one cannot predict what will be needed or if an emergency will occur, meaning that PPE should be worn at all times while caring for a patient in isolation.
      </p>
      <p id="Par10">
       Isolation precautions and the required PPE range from standard precautions to airborne isolation, all of which have different and distinct requirements. Adherence to CDC isolation precaution guidelines and manufacturer recommendations for the PPE are imperative for the treatment of patients with infectious diseases. Regardless of origin, vigilant adherence to proper isolation and PPE guidelines will aid in infection prevention and control efforts, which can halt an outbreak in its tracks. PPE can and should be worn by visitors of the patient however, this is limited to PPE that does not require fit-testing (i.e., respiratory protection for patients with airborne microorganisms, like N-95 masks, should not be worn by visitors or patients as they require special fit-testing to ensure proper sizing). During hospitalization, the room of an contagious patient should have the proper signage on the door indicating which transmission-based precautions are being used so that all staff or visitors entering may wear the necessary PPE.
      </p>
     </sec>
     <sec id="Sec7">
      <title>
       Standard Precautions
      </title>
      <p id="Par11">
       Standard precautions (also referred to Universal Precautions) are basic precautions that should be utilized on all patients as a means of reducing the transmission risk of, for instance, bloodborne pathogens [
       <xref ref-type="bibr" rid="CR37">
        37
       </xref>
       ]. The most basic premise is to use hand hygiene and assess the risk of a potential exposure to blood or other potentially contaminated material (e.g., urine, feces, breast milk) and use the corresponding PPE. Standard precautions encourage the healthcare worker to consider the tasks being performed and apply critical thinking to the risk of potential exposure and then select PPE based upon this assessment. For example, drawing blood typically only calls for gloves, but if the patient is thrashing or aggressive, the healthcare worker should consider eye protection. Another component to standard precautions is respiratory hygiene and cough etiquette. This lesson was developed and became essential during the SARS outbreak and has now become a staple within universal precautions. Respiratory hygiene and cough etiquette highlights the importance of education for healthcare workers, patients, and visitors, to ensure they cover their mouth and nose when coughing or sneezing, perform hand hygiene following exposure to respiratory secretions, and practice spatial separation of febrile persons with respiratory symptoms. The goal of standard precautions is to ensure that, at the most basic level, healthcare workers are protected against blood and other potentially contaminated material through hand hygiene and risk-based PPE utilization. Additional transmission-based precautions, such as contact isolation precautions, build upon standard precautions, meaning that standard precautions will always be used.
      </p>
     </sec>
     <sec id="Sec8">
      <title>
       Hand Hygiene
      </title>
      <p id="Par12">
       The most basic and effective tool in the infection prevention arsenal is hand hygiene. Competent hand hygiene practices can prevent the transmission of diseases, making it the foundation for infection prevention [
       <xref ref-type="bibr" rid="CR32">
        32
       </xref>
       ]. Efforts to maintain compliance can be challenging as healthcare workers are expected to perform hand hygiene before and after patient interaction [
       <xref ref-type="bibr" rid="CR30">
        30
       </xref>
       ,
       <xref ref-type="bibr" rid="CR31">
        31
       </xref>
       ]. The new WHO model for hand hygiene goes beyond the “before and after patient care” practice and emphasizes moments during the patient care process. The Five Moments of Hand Hygiene (frequently called “5 moments”) model emphasizes a broader approach to hand hygiene that encompasses the intricacies of patient care. The WHO’s 5 Moments model is increasingly becoming the standard practice and includes five moments in which hand hygiene should be performed: before patient contact, before aseptic tasks, after body fluid exposure risk, after patient contact, and after contact with patient surroundings [
       <xref ref-type="bibr" rid="CR7">
        7
       </xref>
       ]. Hand hygiene should also be performed after removing gloves. Gloves can easily be seen as a cure-all protective barrier however, hand hygiene should be performed following their removal as leakage during care and cross-contamination during removal is possible [
       <xref ref-type="bibr" rid="CR8">
        8
       </xref>
       ].
      </p>
      <p id="Par13">
       Hand hygiene is performed with either soap and water or alcohol-based hand sanitizer. According to the CDC, washing with soap and water for 15–20 seconds should be performed when hands are visibly soiled, after known exposures to
       <italic>
        Clostridium difficile
       </italic>
       , after known or suspected exposures to patients with diarrhea during a norovirus outbreak, when exposure to
       <italic>
        Bacillus anthracis
       </italic>
       is suspected or proven, before eating, and after using the restroom. If none of those situations are applicable, alcohol-based hand sanitizer is recommended and considered the most effective product. Alcohol-based hand sanitizer (composed of 60–95% alcohol to maintain efficacy) is an easy and effective manner for hand hygiene that takes roughly 20 seconds to dry. Depending upon the situation, alcohol-based hand sanitizer can easily provide staff with an effective and timely method for cleaning their hands, which significantly improves compliance.
      </p>
     </sec>
     <sec id="Sec9">
      <title>
       Contact Precautions
      </title>
      <p id="Par14">
       Contact isolation precautions are used for microorganisms that are transmissible through touch or contact with the patient or a contaminated item (fomite). Contact precautions include wearing a gown and gloves during interaction with the patient or their environment. The most common examples of infections in which contact isolation is used include diarrheal illnesses, methicillin-resistant
       <italic>
        Staphylococcus aureus
       </italic>
       (MRSA), and draining abscesses. Contact precautions should also be taken during the care for patients infected with known or suspected multi-drug resistant microorganisms, Human Parainfluenza virus (HPIV) infection in pediatric patients, poliovirus, vaccinia virus (adverse events following vaccination, like generalized vaccinia or conjunctivitis), etc. Broadly speaking, contact precautions, should be used for patients with diarrhea or draining wounds, and should be considered for children who have respiratory illnesses. The necessary PPE for contact precautions, gown and gloves, should be donned appropriately before entering the room, and removed at the threshold, prior to exiting. Depending on the make of the gown, it is important to follow manufacturers’ recommendations for removal (like pulling away from the body to break any ties in the back.) and wear (i.e., wearing the gown over the shoulders, not hanging down around the elbows). Contact precautions are an effective practice for protecting the healthcare worker against infectious diseases that are spread through touch and fomites.
      </p>
     </sec>
     <sec id="Sec10">
      <title>
       Droplet Precautions
      </title>
      <p id="Par15">
       Droplet isolation precautions are used to help stop the spread of microorganisms that are spread through tiny droplets that are disseminated through sneezing and coughing. The most common causes of droplet precautions are pneumonia, seasonal influenza, pertussis, and bacterial meningitis. Droplet precautions can frequently be confused with airborne precautions, but these precautions focus on those microorganisms that are transmitted via droplets during close proximity interactions [
       <xref ref-type="bibr" rid="CR9">
        9
       </xref>
       ]. To protect against droplet-spread microorganisms, a surgical mask should be worn while in the patient’s room. The mask should be put on prior to entering the room and removed upon exiting the room. While most PPE should not be worn outside of the room, a surgical mask should be discarded in the trash after leaving the room [
       <xref ref-type="bibr" rid="CR10">
        10
       </xref>
       ]. Hand hygiene should be performed after the mask is removed upon exiting of the room. Masks should always be disposed of after leaving the room and should not be re-used for multiple patients as the mask is considered contamination after being touched. In emergent conditions, there have been situations that call for re-using masks if supplies are limited however, these should be evaluated during the event and not a common practice. The Association of Perioperative Registered Nurses (AORN), Food and Drug Administration (FDA), WHO, and CDC all recommend disposal of FDA-approved medical masks after single use and that healthcare workers should don a new mask for each contact with a new patient [
       <xref ref-type="bibr" rid="CR11">
        11
       </xref>
       ]. AORN highlights the hazards of reusing surgical masks by saving them or hanging them around the neck. Droplet precautions are an effective infection control strategy for preventing the spread of infectious diseases that are spread via droplets and close contact.
      </p>
     </sec>
     <sec id="Sec11">
      <title>
       Airborne Precautions
      </title>
      <p id="Par16">
       Airborne isolation precautions are required during the care of patients who have or are suspected of having diseases like tuberculosis, measles, or chickenpox, which are caused by small organisms (&lt;5 μm in diameter) that easily flow on air currents. Patients infected with such pathogens are capable of transmitting disease through respiratory secretions that are aerosolized during coughing, sneezing, suctioning procedures, etc. Airborne precautions are perhaps the most challenging as they require healthcare workers to wear appropriate respirators that have been fit-tested. Adherence to airborne isolation requires healthcare workers to be fit-tested to ensure the National Institute for Occupational Safety and Health (NIOSH)-approved N-95 or higher level respirators maintain a proper seal around the face. These masks should be donned prior to entering the room, removed after exiting the room, and then disposed of.
      </p>
      <p id="Par17">
       One of the most crucial aspects of airborne precautions is that the patient must be in an appropriate negative air pressure room. Negative pressure rooms (also called airborne isolation rooms or AIIR) are designated rooms with the proper engineering controls to ensure that aerosol particles containing microorganisms &lt;5 μm in diameter are kept inside the room. It is vital to maintain negative air pressure, as it ensures that the air flow is from outside into the room, which prevents such microorganisms from being carried into the hallway and adjacent spaces (more information on negative air pressure rooms can be found in the section on environmental infection control). If a patient is suspected of having a disease that requires airborne isolation, it is critical to have them wear a surgical mask until a negative pressure room is available. One of the most common sources for exposures is delay in placing the patient into airborne isolation. Healthcare workers should don N-95 respirators while in the patient’s room and the patient should wear a regular surgical mask during transportation or in an area that is not negative pressure. The use of a surgical mask for patients acts as a protection for those in the rest of the healthcare space.
      </p>
      <p id="Par18">
       Airborne isolation is perhaps the most prudent during bioweapons-related or high-consequence biological events. Patients with high-consequence pathogens, such as monkeypox, SARS, smallpox, viral hemorrhagic fevers, MERS, and influenza, require airborne isolation with some additional isolation precautions. Airborne isolation is the most challenging aspect of dealing with such biological threats as it requires the unique environmental controls that can pose challenging during an influx of patients with infectious diseases or in resource poor areas. A recent WHO report highlighted the role of healthcare facilities and infection control failures in MERS outbreaks, which underscores the consequences of PPE and infection control failures [
       <xref ref-type="bibr" rid="CR12">
        12
       </xref>
       ,
       <xref ref-type="bibr" rid="CR13">
        13
       </xref>
       ]. It is a common practice in healthcare that a patient with a cough/fever has to wear a mask until infectious etiologies can be ruled out. By simply having a potentially sick patient wear a surgical mask during the triage process, healthcare workers and other patients can be protected, regardless whether the patient has an infectious disease that is spread by droplet or airborne mechanisms. Although airborne isolation can be the most taxing in terms of ensuring properly fitted masks are used and negative pressure rooms are available, these are vital components to infection control for high-consequence and highly transmissible diseases.
      </p>
     </sec>
     <sec id="Sec12">
      <title>
       Combination or Enhanced Precautions
      </title>
      <p id="Par19">
       In many cases, combining isolation precautions is most beneficial. As medical care grow is in complexity and more people are involved in patient care, there is a higher risk for spreading microorganisms via aerosol-generating procedures or contaminated surfaces/objects. Additional PPE, like boot/shoe covers, caps, etc., may be utilized in such isolation practices. However, proper PPE donning and doffing practices should always be followed [
       <xref ref-type="bibr" rid="CR33">
        33
       </xref>
       ]. Some microorganisms, like
       <italic>
        Human herpesvirus
       </italic>
       3 (HHV-3, varicella-zoster virus), require a combination of airborne and contact isolation due to the nature of the illness they cause and transmission mechanisms. It is also common in pediatric care to combine contact and droplet isolation during the care of patients with respiratory viruses (e.g., human metapneumonvirus, respiratory syncytial virus, rhinovirus) as children frequently spread such microorganisms through touch. For example, according to CDC guidelines, respiratory infectious diseases (except for influenza, pertussis, etc.) only require standard precautions in adults. However, in infants and young children, standard plus contact isolation is encouraged, which emphasizes the need to assess the patient population when considering isolation precautions during care. Combination precautions are especially beneficial if microorganisms are isolated from multiple sources, such as a patient with Carbapenem-resistant Enterobacteriaceae isolated from both a draining wound and an endotracheal secretion. Typically, contact precautions are sufficient. However, if the microorganism is isolated in respiratory secretions, it is suggested that droplet precautions also be used.
      </p>
      <p id="Par20">
       There is an increasing practice of combining and enhancing isolation precautions for severe, high-consequence, or novel infections as research is ongoing regarding their transmission mechanisms. Enhanced isolation goes beyond just combining transmission based precautions, but adding additional measures and processes [
       <xref ref-type="bibr" rid="CR33">
        33
       </xref>
       ,
       <xref ref-type="bibr" rid="CR34">
        34
       </xref>
       ]. Ebola virus disease, SARS, MERS, and many other diseases require a combination of isolation precautions that include airborne and contact prevention measures, but also enhanced isolation practices that include additional PPE and precautions. Novel or emerging infectious diseases may require an amalgamation of isolation precautions, especially in advanced medical settings. The 2013–2016 Ebola virus disease outbreak highlighted the challenges of managing patients in American hospitals and required substantial revisions to existing PPE and isolation guidelines. At the most rudimentary level, isolation precautions should be designed around the transmission mechanisms of the infectious disease. SARS and MERS coronaviruses are primarily spread through respiratory droplets, which caused significant issues in the early stages of outbreaks due to delayed airborne isolation. On the other hand, Ebola virus disease cases within the United States revealed gaps in isolation guidance and preparedness when responding to patients with emerging infectious diseases. Although aerosol-generating procedures were a topic of concern for SARS and MERS, respiratory precautions were already considered for isolation precautions. The limited experience and knowledge among healthcare workers surrounding Ebola virus disease also posed unique challenges for training on enhanced isolation precautions and PPE during the 2013–2016 outbreak. Overall, enhancing isolation precautions is a helpful strategy for handling a novel or emerging infectious disease, especially if newer or more invasive medical procedures or pediatric patients are involved. One of the most common lessons infection preventionists highlight for clinical staff is that it is always better to quickly initiate isolation precautions and remove them later than find out hours or days into a patient’s care that they were contagious. Patients may voice frustration with being placed in isolation, but delay in isolating a patient who potentially has an infectious disease, runs the risk of furthering disease transmission.
      </p>
     </sec>
     <sec id="Sec13">
      <title>
       Isolation and PPE Compliance in Visitors
      </title>
      <p id="Par21">
       Visitors play a significant role in the well-being of hospitalized patients however, they also can facilitate the transmission of infectious diseases. Healthcare facilities will ultimately need to grapple with balancing patient satisfaction and the potential for visitors to act as amplifiers of disease, especially during outbreaks. Adherence to isolation precautions and hand hygiene is vital among healthcare workers, but the role of visitors has also become a topic of concern. There is substantial evidence for the horizontal transmission of even multi-drug resistant microorganisms involving the hands and attire of healthcare workers. However, consideration must also be given regarding the role of visitors in infection prevention and control [
       <xref ref-type="bibr" rid="CR14">
        14
       </xref>
       ]. While there is no universal recommendation for handling visitor compliance to standard or more advanced precautions, it is encouraged that those visiting a contagious patient should use PPE for their own safety. The Society for Healthcare Epidemiology of America (SHEA) has provided recommendations that highlight the challenges in enforcing visitor compliance, but also notes that it is crucial to consider the infectious microorganism when dealing with visitors who are unwilling to follow precautions. Proper education and guidance on PPE donning and doffing should be given to visitors. However, hand hygiene is perhaps the most important and likely practice to be followed. SHEA notes that “hospital visitors may play a significant role in the ecology of healthcare-associated infections” but few visit more than one patient, which makes the transmission between visitors and multiple patients less likely [
       <xref ref-type="bibr" rid="CR14">
        14
       </xref>
       ]. There is a consistent challenge in enforcing compliance with visitors and little research that has focused solely on their compliance and role within healthcare-associated disease transmission. Several things should be considered to address visitors of patients in isolation for an infection. If the visitor is a household contact and likely to already be exposed the concern then becomes if they are already infected and potentially contagious. If the visitor is a breast-feeding mother who is involved in the care of the patient, it is unlikely isolation precautions can be enforced. Many hospitals within the U.S. also make it a practice to screen visitors during respiratory virus season to prevent symptomatic visitors from exposing patients or staff [
       <xref ref-type="bibr" rid="CR35">
        35
       </xref>
       ]. This practice should be considered for visitors of such patients, especially if they are house-hold or close contacts and may be a source for further transmission.
      </p>
      <p id="Par22">
       Patients with high-consequence diseases, like Ebola virus disease or SARS, may pose a unique challenge for healthcare workers in terms of visitors and isolation precautions and should addressed on a case by case basis. CDC recommendations for visitors of Ebola virus disease patients include that healthcare workers should “avoid entry of visitors into the patient’s room” and that visits should be scheduled and controlled [
       <xref ref-type="bibr" rid="CR15">
        15
       </xref>
       ]. Visitors played a significant role in furthering the spread of SARS and MERS during outbreaks and consideration should be given to restricting the number of visitors during such events. A recent WHO report on MERS found that of the cases between December 2016 and July 2017, 31% were associated with transmission in a healthcare facility, including healthcare workers, patients sharing rooms/wards with MERS patients, and visitors [
       <xref ref-type="bibr" rid="CR12">
        12
       </xref>
       ,
       <xref ref-type="bibr" rid="CR13">
        13
       </xref>
       ]. CDC guidance for infection control during treatment of patients with SARS also encourages limiting visits to those who are necessary for the patient’s emotional well being. Ensuring public health during outbreaks inherently trumps visitation [
       <xref ref-type="bibr" rid="CR16">
        16
       </xref>
       ]. Visitors should be educated and encouraged to wear the necessary PPE when visiting an isolated patient. At the bare minimum, it is prudent to educate and encourage visitors to practice hand hygiene upon entering and exiting the patient’s room.
      </p>
      <p id="Par23">
       Airborne isolations pose a challenge for visitor compliance. Since hospitals can not support fit-testing visitors for N-95 masks or other respirators, each situation should be evaluated on an individual basis. Surgical masks can provide some protection but will not provide a true seal. It is a common practice for many healthcare institutions to allow house-hold contacts to visit a patient in airborne isolation without a mask (or wearing a surgical mask) since exposure has likely already occurred. In this situation, consideration should be given for exposure from that visitor to healthcare workers and others after they have left the negative pressure room. It may be prudent to have visitors in such situations wear a surgical mask upon exiting the patient’s room and wear it until they exit the hospital.
      </p>
      <p id="Par24">
       Visitor adherence to isolation precautions is challenging for even the most common hospitalizations. Staff compliance and vigilance can be a strong role-model and reminder for visitors, especially in regards to hand hygiene. In the event of a bioweapons-related attack or outbreak of a highly infectious disease (i.e., Ebola virus disease), visitor protocols should be established. Unique events and microorganisms can pose a challenge for isolation precaution compliance and recommendations may need to be modified for novel or specific situations (i.e., caring for a pediatric patient and maintaining parent/guardian visitor isolations). Changes to IPC guidelines for such unique situations should be done in conjunction with CDC (and other expert) guidance and discussed in a multidisciplinary setting to ensure support is facility-wide. In these situations, allowance of visitors and PPE recommendations should be made on a case by case basis. Visitors do play a significant role in infection prevention and control within the healthcare environment, which makes their adherence to standard precautions and isolation precautions important and challenging.
      </p>
     </sec>
     <sec id="Sec14">
      <title>
       Discontinuation of Isolation Precautions
      </title>
      <p id="Par25">
       Transmission-based precautions should be maintained until the patient is no longer considered capable of transmitting the disease. The CDC’s Guidelines for Isolation Precautions is an excellent resource for duration of isolation. Consideration should be given for immune status of the patient as immunocompromised patients may need to be isolated for longer periods of time due to lengthier microorganism shedding.
      </p>
     </sec>
    </sec>
    <sec id="Sec15">
     <title>
      Patient Placement and Cohorting
     </title>
     <p id="Par26">
      Patient placement is a vital component to infection control measures, especially during an influx of ill patients. Isolation practices and cohorting (grouping like patients in a shared hospital room or designated unit) plays a significant role in reducing the microbial burden within the healthcare environment. Patient cohorting is a common practice during outbreaks or limited availability of negative pressure rooms however, it is important to consider transmission-based precautions during the assignment of patient rooms and establishing cohorted units.
     </p>
     <sec id="Sec16">
      <title>
       Placement of Patients
      </title>
      <p id="Par27">
       Isolating patients with the appropriate transmission-based precautions is often done during admission. However, if patients are transferred to the healthcare facility and there is already suspicion of an infectious disease, this may also determine where the patient is placed. There is a myriad of components that impact patient placement and such efforts should be performed with IPC in mind.
      </p>
      <p id="Par28">
       Although many healthcare facilities have private rooms, there is always the possibility that patients may have to share rooms. Efforts should be made to place patients with infectious diseases that are transmitted via the contact, droplet, or airborne route, in private rooms. Consideration for route of transmission should always be made during patient admission, which would determine both isolation status and patient placement. Patients needing airborne isolation require rooms that maintain negative pressure, which are typically only a handful of rooms per care area. These patients should be place within private negative pressure rooms. There is an increasingly common practice of requiring private rooms for patients infected with highly resistant microorganisms, such as carbapenem-resistant Enterobacteriaceae (CRE) or multidrug-resistant TB (MDR-TB). Patient placement should be determined with transmission-based precautions in mind and efforts should be made to ensure patients with highly contagious or high consequence pathogens (e.g., Ebola virus, SARS and MERS coronaviruses) are in private isolation rooms per CDC guidelines.
      </p>
     </sec>
     <sec id="Sec17">
      <title>
       Cohorting of Patients and Staff Assignments
      </title>
      <p id="Par29">
       Despite our best efforts, during peak respiratory virus season or an influx of patients, private room availability may be constrained. Cohorting is a common practice during times in which room availability may be scarce. There are two kinds of cohorting; sharing of private rooms or grouping patients within a defined entire hospital unit. If private rooms are not available, patients infected or colonized with the same microorganism (e.g., influenza A virus, MRSA) can be cohorted together to share a room. During respiratory virus season, cohorting based off clinical symptoms is often utilized. While it was necessary to cohort Ebola virus disease patients during the Western African 2013–2016 Ebola virus disease outbreak, CDC guidelines for U.S. hospitals is that patients should be placed in a private room. If there should be an influx of patients with a high consequence pathogen, consideration for cohorting within the same room should be made on a case-by-case basis with infection prevention and control coordinating with the appropriate public health authorities.
      </p>
      <p id="Par30">
       During an outbreak or influx of patients in which hospital bed capacity is strained, cohorting can be utilized for an entire hospital unit or well-defined space. Designated hospital units can be cohorted for infected patients. These units should either be dedicated to patients affected by an outbreak (and the same microorganism) or of all patients in isolation who are cohorted within their rooms based off the previously mentioned criteria. This is an effective practice for segregating the patients and their visitors from healthy/non-infected patients. Cohorting is also an effective strategy for reducing the risk of cross-contamination by staff. The CDC notes that “cohorting healthcare personnel to care only for patients infected or colonized with a single target pathogen limits further transmission to uninfected patients but is difficult to achieve in the face of staff shortages in hospitals and residential healthcare sites. However, if continued transmission is occurring after implementing routine infection control measures and creating patient cohorts, cohorting of healthcare personnel may be beneficial.” [
       <xref ref-type="bibr" rid="CR17">
        17
       </xref>
       ]. Designated staff can be assigned to cohorted patients or units. It is highly encouraged that healthcare workers (especially nurses) caring for cohorted patients, should not also be assigned to patients who are immunocompromised. Cohorting in single rooms or in well-defined units can be an effective mechanism for reducing the spread of infectious diseases during patient care.
      </p>
      <sec id="Sec18">
       <title>
        Designated Staff For Specific Microorganisms
       </title>
       <p id="Par31">
        The Ebola virus disease outbreak in 2013–2016 highlighted the role of healthcare worker transmission, not only between themselves, but also among patients. CDC guidelines encouraged healthcare facilities to minimize staff with direct patient care. It was encouraged that those staff caring for a person under investigation (PUI) or infected with Ebola virus, be dedicated to that patient as to minimize the potential for additional exposure. During the 2011 outbreak of carbapenem-resistant
        <italic>
         Klebsiella pneumonia
        </italic>
        at the National Institute of Health’s Clinical Center, IPC staff adopted a series of control measures that included cohorting, limiting activities of hospital staff exposed to infected patients, and hiring monitors to ensure healthcare providers were wearing appropriate PPE and using hand hygiene [
        <xref ref-type="bibr" rid="CR18">
         18
        </xref>
        ]. Facilities should have policies developed and in place for those staff who may be exposed during their duties. Incidents involving bioweapons, novel or emerging infectious diseases, or high consequence pathogens, will surely require unique guidelines that could test the capacity for hospitals. It behooves healthcare facilities and preparedness efforts to consider staffing and cohorting needs during such challenging situations.
       </p>
      </sec>
     </sec>
    </sec>
    <sec id="Sec19">
     <title>
      Patient Screening and Movement
     </title>
     <p id="Par32">
      The flow of patients from triage to discharge also poses vulnerabilities for infectious disease transmission. The initial screening of patients can be an effective infection control measure for rapid isolation and PPE utilization. Proper communication and triage questions can aid in the rapid identification of patients with increased risk for infectious diseases. Hasty identification of a patient with a potential infection within their first moments within the healthcare facility can substantially decrease the risk for additional exposure. Once admitted to a healthcare facility, patients are frequently transported for diagnostic tests and care. The transportation of a patient can also act as a facilitator for disease transmission if infection control practices are not maintained.
     </p>
     <sec id="Sec20">
      <title>
       Emergency Department Screening and Triage
      </title>
      <p id="Par33">
       The initial interaction a patient within a healthcare facility or urgent care unit is the first opportunity to identify risk for infection. The triage process determines the degree of urgency of the patient’s condition, which then decides the order they are seen. During this process, there are many opportunities to not only identify patients with potentially contagions infections, but also rapidly isolate them to prevent further exposure to staff and other patients. It is encouraged for triage staff to provide patients presenting with a cough, (i.e., a potential respiratory infection) a mask to wear during their time in a waiting room. This simple act can be hugely preventative, whether the patient has influenza, MERS, or TB.
      </p>
      <p id="Par34">
       While the triage process primarily focuses on medical questions, this is also an opportunity for questions regarding international travel and fever. Since the SARS outbreak in 2002, it has become a relatively common practice to incorporate a question within the patient screening/triage process regarding international travel and fever. Travel history is always an important component to the patient’s medical history but we should not forget its significance during triage and patient screening. Presence of fever is a standard part of the medical triage and intake during initial screening and if the patient is febrile, questions regarding travel history become that much more important. There are a mixture of recommendations regarding processes, but it is consistently thought that if a patient with an acute illness (e.g., fever within 2 weeks, diarrhea) has traveled outside the U.S. within the last 21 days, the patient should be isolated. Isolation should be based upon the presenting signs and symptoms but providers should also consider the area of travel and if there are ongoing epidemiologically-significant outbreaks. During outbreaks, like those of SARS and MERS, screening and triage can include questions regarding not just travel, but also exposure or close contact with a sick person who recently traveled to those areas or was infected. The screening and triage process is especially beneficial for early detection and isolation of potentially infectious patients because it can easily be modified. Screening questions can be added or removed based upon healthcare needs. While the standard questions remain the same, questions about specific travel or exposures can be added during times of public health crises. Questions related to travel history should be maintained during all times though and it is encouraged that patients with an acute illness and international travel within 21 days, be placed in a private room until further evaluation by a healthcare provider. Measles and TB are frequent suspected in patients with respiratory symptoms and a recent international travel history. However, the inclusion of travel history in medical triage and screening can also potentially capture cases of avian influenza, MERS, viral hemorrhagic fever, etc.
      </p>
     </sec>
     <sec id="Sec21">
      <title>
       Transportation of Patient Within Hospital
      </title>
      <p id="Par35">
       Patients are frequently transported throughout the hospital during their care, which can make maintaining isolation precautions challenging. It is encouraged for patient transportation to be limited, but there are several recommendations to further reduce the spread of disease during patient movement. Using appropriate barriers is crucial during the transportation of an infectious patient.
      </p>
      <p id="Par36">
       Patients in contact isolation are encouraged to change into a new hospital gown or attire and should be transported on a wheelchair or bed covered with a clean sheet (or other barrier). Infectious skin lesions should be covered. The transporter should wear the appropriate PPE while assisting the patient into or out of the covered wheelchair or bed, which should then be removed upon exiting the room (gown and gloves are not required during the transport of patients in contact precautions). The CDC notes that “when transport or movement in any healthcare setting is necessary, ensure that infected or colonized areas of the patient’s body are contained and covered.” [
       <xref ref-type="bibr" rid="CR17">
        17
       </xref>
       ]. Those patients in droplet or airborne isolation should wear a mask during the transportation process. It is important that notification of the patient’s isolation status be done to the receiving department or healthcare personnel to facilitate the continuation of isolation precautions.
      </p>
     </sec>
     <sec id="Sec22">
      <title>
       Exposure Response
      </title>
      <p id="Par37">
       Despite best efforts, patients are not always isolated or transported appropriately. If a patient with an infectious disease has potentially exposed a considerable number of staff and other patients, infection prevention and control programs may be used to the contain further spread. All exposures are not equal, meaning that MRSA is a common microorganism within the community and an exposure response is often not warranted, whereas exposure to mycobacteria or a more severe illness may require follow-up. These responses should be determined by the IPC program, Occupational Health, and the medical directors associated with these programs in conjunction with hospital administration. Post-exposure prophylaxis may be necessary for staff and patients, but medication distribution should be determined by the appropriate hospital experts. Hospitals and IPC programs should have a functioning process for determining patients with exposure to specific staff or in other patients (i.e., those in the waiting lobby of an emergency department). Commonly, exposure monitoring and notifications are used for patients, visitors, and staff exposed to measles, pertussis, etc., as post-exposure prophylaxis is recommended. IPC programs might monitor admitted patients who were exposed or potentially isolate them during the incubation period. Exposures may also be the result of infectious healthcare staff, which may require patient notification. Overall, these events should be addressed on an individual basis and adequate response measures should be applied to reduce the time between exposure and follow-up.
      </p>
     </sec>
    </sec>
    <sec id="Sec23">
     <title>
      Environmental Infection Control
     </title>
     <p id="Par38">
      Although isolation and PPE utilization are a significant portion of preventing the spread of disease during hospitalization or medical treatment, the role of environmental transmission should not be forgotten. Many diseases can be spread through fomites and poor consideration for the environmental aspects of infection control only fuel transmission. There is considerable literature on the recommendations and guidelines for environmental infection control, specifically by the CDC, OSHA, WHO, and APIC. This section will provide a very high-level overview of these publications. The goal of this section is to raise awareness for environmental mechanisms of transmission and encourage consideration during the development of preparedness and response plans. Healthcare environmental components, such as building design, waste management, disinfection and sterilization, and air monitoring, are critical to reducing the spread of microorganisms, but the ability to make changes may be hindered by high costs and other restraints.
     </p>
     <sec id="Sec24">
      <title>
       Cleaning, Disinfection, and Sterilization
      </title>
      <p id="Par39">
       Cleaning and disinfection of non-critical surfaces is a basic premise of infection control practices, especially standard precautions [
       <xref ref-type="bibr" rid="CR17">
        17
       </xref>
       ]. These practices become even more significant when caring for patients with infectious diseases. Cleaning is the process of removing pathogens, whereas disinfecting kills germs on the surface, and sanitizing lowers the number of pathogens on an object to a safe level. Rutala and Weber provide an extensive outline of such methods for cleaning, which include:
       <list list-type="bullet">
        <list-item>
         <p id="Par40">
          Sterilization: destroys all microorganisms, including bacterial spores
         </p>
        </list-item>
        <list-item>
         <p id="Par41">
          High-level disinfection: destroys all microorganisms except high numbers of bacterial spores
         </p>
        </list-item>
        <list-item>
         <p id="Par42">
          Intermediate level disinfection: destroys vegetative bacterial, mycobacteria, most viruses, most fungi, but not bacterial spores
         </p>
        </list-item>
        <list-item>
         <p id="Par43">
          Low-level disinfection: destroys vegetative bacteria, some fungi and viruses, but not mycobacteria or spores.
         </p>
        </list-item>
       </list>
      </p>
      <p id="Par44">
       Such practices should be closely followed, especially in the event of novel or severe illnesses requiring enhanced precautions. Disinfection recommendations may be revised based upon recommendations from OSHA and the CDC, as was seen during treatment of patients with Ebola virus disease in U.S. hospitals. Environmental contamination can be a significant mechanism for disease transmission during patient care and invasive procedures can increase this substantially. Poorly disinfected or sterilized equipment has been the culprit of many healthcare-associated infections and outbreaks. High-touch surfaces or objects, like sinks and bedrails, require frequent cleaning and disinfection. Frequency and intensity of cleaning and disinfection may also need to be increased depending up on the “degree of environmental contamination” [
       <xref ref-type="bibr" rid="CR17">
        17
       </xref>
       ]. Environmental Protection Agency (EPA)-registered disinfectant should be used to combat the environmental contamination that occurs during patient care. It is important to note that certain pathogens may be resistant to routine disinfectants (e.g., rotaviruses, noroviruses,
       <italic>
        Clostridium difficile
       </italic>
       ,
       <italic>
        Bacillus anthracis
       </italic>
       ), meaning that healthcare workers should ensure the cleaning product they are using is effective against the specific microorganism. Disinfection and sterilization of medical equipment should always follow manufacturer recommendations and be handled with care.
      </p>
      <p id="Par45">
       There are frequently forgotten objects and surfaces that are common culprits for contamination and should be highlighted during routine cleaning. Computer keyboards, stethoscopes, and clinical work stations are all areas that routinely have a high microbial burden and are frequently neglected during cleaning. There is extensive literature on practices for disinfection and sterilization, but at the most basic level, preparedness and response efforts should work to ensure routine cleaning and disinfection is done appropriately and correctly [
       <xref ref-type="bibr" rid="CR36">
        36
       </xref>
       ]. In emergency situations, a quick lesson is always to work “from clean to dirty” and consider all surfaces and objects. Environmental contamination is a continued source for disease transmission in healthcare. These practices should be strengthened during routine care and also refined to meet special needs during public health emergencies and care of patients in enhanced precautions.
      </p>
     </sec>
     <sec id="Sec25">
      <title>
       Ventilation Systems
      </title>
      <p id="Par46">
       Hospital ventilation systems are a critical component to patient safety. These systems maintain negative pressure within airborne isolation rooms and positive pressure in operating/procedure rooms, as well as protective precaution rooms (for severely immunocompromised patients). Negative pressure rooms will become a critical need in outbreaks of microorganisms that require airborne isolation. These rooms should have high-efficiency particulate air (HEPA) and should also follow CDC guidelines for environmental infection control regarding air exchanges per hour (ACH) (i.e. ≥12 ACH for new construction as of 2001; ≥6 ACH for construction before 2001) and be monitored in accordance with engineers’ and manufacturers’ recommendations [
       <xref ref-type="bibr" rid="CR19">
        19
       </xref>
       ]. The negative pressure rooms should maintain air pressure by being properly sealed and are encouraged to have self-sealing doors and ante-rooms. The heating, ventilation, air conditioning (HVAC) systems should also have humidity monitors to ensure the moisture levels are adequate as to discourage microbial growth. The CDC has specific recommendations for air-handling systems in healthcare facilities, which are vital to patient safety and reduction of disease transmission. In the event of a biological attack or outbreak, ensuring that these systems are operational and can maintain proper negative pressure in designated rooms will be of the utmost importance. Although negative pressure rooms are limited on each hospital unit, there is potential to convert entire units to negative pressure through adjustments to the ventilation system and sealing of the unit [
       <xref ref-type="bibr" rid="CR20">
        20
       </xref>
       ].
      </p>
     </sec>
     <sec id="Sec26">
      <title>
       Environmental Services
      </title>
      <p id="Par47">
       Environmental cleaning, waste management, and handling of textiles are all components of environmental service work in healthcare. These duties are especially important upon discharge of the patient when a deep clean of the room is required (commonly called “terminal cleaning”). Within a single day of admission, the composition of a hospital room’s microbes begin to change and mirror that of the patient [
       <xref ref-type="bibr" rid="CR21">
        21
       </xref>
       ]. Combatting the “bacterial communities” that develop within the healthcare environment is an ongoing struggle that emphasizes the important of adequate and consistent environment services. Environmental services staff frequently manage these tasks and should be aware of the patient’s isolation status so that staff utilizes proper PPE and ensures use of proper Environmental Protection Agency (EPA)-registered disinfectants (example:
       <italic>
        Clostridium difficile
       </italic>
       requires the use of bleach products to kill spores). Typically, hospitals have contracts with linen services and waste management companies (for both regular and medical waste). However, practices may change during the care of patients with high consequence pathogens that require enhanced isolation. CDC guidelines regarding medical waste, dishes and eating utensils and textiles all note that these objects have not been implicated in SARS coronavirus transmission and that routine procedures should be utilized [
       <xref ref-type="bibr" rid="CR22">
        22
       </xref>
       ]. In the case of Ebola virus, recommendations were significantly different. For example, despite Ebola virus forming enveloped virions (which are susceptible to a wide range of hospital disinfectants), no EPA-registered disinfectants had labels that specifically cited efficacy against the virus. Consequently, CDC recommendations were changed to encourage use of EPA-registered disinfectants that were effective against viruses that form non-enveloped virions, which are more resistant to hospital germicidal disinfectant cleaning products. CDC recommendations also included discarding of all textiles to avoid staff exposure during the laundering process [
       <xref ref-type="bibr" rid="CR15">
        15
       </xref>
       ]. Many hospitals developed Ebola virus preparedness plans that placed environmental service duties more on the clinical staff caring for a PUI instead of potential exposing additional staff. Environmental services practices should be closely followed during routine patient care but may require modification during the care of patients in enhanced precautions or during outbreaks.
      </p>
      <p id="Par48">
       In the pursuit of more effective and efficient cleaning and disinfecting processes, newer technologies have been utilized, like that of ultraviolet disinfection technology and copper-infused linen. Environmental monitoring to check room cleaning quality is also a frequently used measure to test true cleaning of the space. Overall, environmental infection control by means of environmental services staff, textile care, and waste management are critical components to breaking the chain of infection. The efficacy of these duties and the adherence to transmission-based precautions when working throughout a healthcare facility is a monumental task and becomes even more critical during outbreaks.
      </p>
     </sec>
     <sec id="Sec27">
      <title>
       Water
      </title>
      <p id="Par49">
       There is a considerable amount of literature and regulatory guidance on environmental infection control as it relates to water however, this section will focus on only a handful. Firstly, facilities should consider the mechanisms for preventing the spread of waterborne microorganisms through proper hand hygiene, cleaning of sinks, avoidance of decorative fountains and fish tanks in patient-care areas, and maintaining proper temperatures for hot and cold water [
       <xref ref-type="bibr" rid="CR19">
        19
       </xref>
       ]. Should water disruptions occur, corrective decontamination of the hot water system may be necessary, which can include flushing the water lines and outlets with chlorine and/or superheated water. Hospitals should have contingency plans for water in the event that water disruptions are prolonged due to intrusions or contamination.
      </p>
     </sec>
     <sec id="Sec28">
      <title>
       Construction and Renovation
      </title>
      <p id="Par50">
       Construction, renovation, remediation, repair, and demolition within a healthcare environment can be sources for infection. All work must be reviewed by infection prevention and control to coordinate prevention methods that include containment barriers and post-construction cleaning. Such efforts are necessary as demolition can lead to airborne infections associated with fungal spores in immunocompromised patients. Moreover, if the proper planning is not done, engineering outages can impact negative pressure rooms, which decreases their efficacy. Conversion of spaces to negative pressure wards or specialty isolation units should be planned and tested ahead of time to ensure proper ventilation is possible.
      </p>
     </sec>
    </sec>
    <sec id="Sec29">
     <title>
      Challenges
     </title>
     <sec id="Sec30">
      <title>
       Poor Utilization and Support
      </title>
      <p id="Par51">
       In the day-to-day world of medical care, infection prevention and control practices, like hand hygiene, frequently have poor compliance [
       <xref ref-type="bibr" rid="CR23">
        23
       </xref>
       ]. While there are a multitude of issues that IPC programs face, perhaps the most damning one is internally. Typically, IPC programs are seen as cost centers and not revenue generators, which frequently translates to lackluster support and prioritization [
       <xref ref-type="bibr" rid="CR24">
        24
       </xref>
       ]. Medicine and healthcare are competitive markets, meaning that those programs seen from this light are likely to receive cuts. While there have been studies evaluating the cost of healthcare-associated infections in relation to that of an IPC program, there is a considerable gap within the research regarding IPC programs and response during outbreaks or cases of high-consequence pathogens. Given that a single healthcare-associated infection (HAI), like a surgical-site infection, can cost upwards of $50,000 and preventing just a handful of these infections can pay for the entire budget of an IPC program, it is not unreasonable to think that such cost-saving could be applied to biothreat response within hospitals [
       <xref ref-type="bibr" rid="CR25">
        25
       </xref>
       ]. The cases of Ebola virus disease in Dallas, Texas, in 2014 exposed the lack of preparedness within U.S. hospitals, poor compliance with infection control, and the cost of treating such a severe illness with enhanced precautions. It was estimated that the cost of treating a hospitalized patient with Ebola virus disease in the United States is $30,000 per day [
       <xref ref-type="bibr" rid="CR26">
        26
       </xref>
       ]. Despite spending $60 billion on biodefense since 2001 to prepare for biothreats, a single imported case of Ebola virus disease revealed deep breaks within U.S. preparedness efforts [
       <xref ref-type="bibr" rid="CR27">
        27
       </xref>
       ]. During the 2013–2016 Ebola virus disease outbreak, it frequently fell on the IPC programs to coordinate hospital-wide preparedness and response efforts to ensure facilities were prepared to identify, isolate, and potentially treat a patient. While such events highlight the importance of IPC programs and the diversity of their responsibilities, for many in healthcare the looming threat of Ebola has passed and so has the support. The focus for many IPC programs has gone back to preventing HAIs and Ebola virus disease response plans have been neglected. A 2015 APIC survey found that 92% of IPC program leaders believe they were more prepared than the previously year to receive a patient with a highly infectious disease [
       <xref ref-type="bibr" rid="CR28">
        28
       </xref>
       ]. While this is encouraging, would hospitals and IPC programs feel the same today, several years after the 2013–2016 Ebola virus disease outbreak? There is a substantial need within healthcare to truly support IPC programs for not only day-to-day HAI prevention, but also as a means of establishing an all-hazards approach. Infection prevention and control, as shown within this chapter, involves collaboration with many internal and external partners to ensure patient safety. IPC programs are sentinels within hospitals, alerting internal and external partners of issues, so that they may form a collective response effort. It behooves bio-preparedness efforts to utilize IPC programs and consider IPC practices as a vital resource for disease control, medical countermeasures, and surveillance.
      </p>
     </sec>
     <sec id="Sec31">
      <title>
       Invasive Medical Interventions
      </title>
      <p id="Par52">
       While advances in medicine have given us the capabilities to increasingly counter disease, the invasiveness of certain medical procedures and treatments can pose substantial infection control risks. The treatment of Thomas Duncan, the first Ebola virus-diagnosed patient in the United States, in a seemingly “regular” hospital without specialized training or facilities to handle a patient under enhanced precautions, points to this very dilemma. In the weeks following his hospitalization, there were conversations in hospital around the U.S. as to the safety and ethical considerations for more invasive and riskier medical interventions during the treatment of a patient with such an infectious disease. Medical interventions like invasive surgery, dialysis, insertion of central lines, ventilation, extracorporeal membrane oxygenation (ECMO), or even labor and delivery, all carry inherent risks for the staff performing them. The outbreaks of SARS and MERS coronaviruses, and Ebola virus disease all challenged PPE and isolation recommendations, requiring changes to protect healthcare workers and visitors during treatment, especially those interventions that generate aerosols. These outbreaks have taught vital lessons regarding the life-saving capabilities of modern medicine and technology, but also reveal a lack of preparedness consideration for medical interventions in patients with such severe and uncommon diseases. Future efforts should establish treatment and procedure plans with these diseases in mind, drawing on lessons learned and creating new protocols so that afflicted patients may receive the full range of medical care and healthcare workers can perform such work with minimal risk.
      </p>
     </sec>
     <sec id="Sec32">
      <title>
       Conflicting Guidelines
      </title>
      <p id="Par53">
       Perhaps one of the most challenging aspects of infection prevention during the Ebola virus disease response in American hospitals was the continuous evolution of guidelines for isolation, PPE, disinfection, handling of medical waste, etc. The Blue Ribbon Study Panel on Biodefense highlighted this very issue in its recommendations, pointing to the “need for a standardized process to develop and issue clinical infection control guidance for biological events.” [
       <xref ref-type="bibr" rid="CR29">
        29
       </xref>
       ]. The recommendations from the CDC regarding isolation precautions, specifically the use of negative pressure rooms/airborne isolation and the necessary PPE, were an evolving process in the days following Thomas Duncan’s hospitalization. As an infection preventionist, these days were taxing due to the constant scramble to not only train staff on the appropriate donning and doffing procedures, but even acquire the correct PPE. Novel diseases like SARS and MERS also tax the public health and healthcare response systems in terms of providing adequate recommendations for isolation. While these fluctuations are understandable, in the event of a biological attack, fear and hysteria will likely play a larger role than in naturally occurring outbreaks, which makes the stability of IPC recommendations that much more important. Healthcare workers must feel confident in not only their training, but also the efficacy of their PPE. It is crucial that future efforts include stronger processes to standardize infection control recommendations and guidelines during these critical times.
      </p>
     </sec>
    </sec>
    <sec id="Sec33">
     <title>
      Infection Control in Biodefense Efforts: Minimal Focus Despite Maximum Return
     </title>
     <p id="Par54">
      Biodefense and global health security efforts work to strengthen capacity to respond to infectious disease threats. These efforts are imperative to preventing, detecting, and responding to biological events, whether they are intentional, accidental, or natural. Within these plans, there is often a considerable gap regarding the role of infection prevention and control and the programs within healthcare facilities. There have been several reports and recommendations in recent years to strengthen biodefense efforts. The Health Sector Resilience Checklist for High-Consequence Infectious Diseases from the Johns Hopkins Center for Biosecurity points to the importance of infection control practices and their significance, but there is little overall mention of the programs within hospitals. This checklist focuses on the adherence to infection control practices, like that of the Blue Ribbon Study Panel on Biodefense report, but tends to neglect the role of these programs. The same can be said of more recent pandemic influenza and hospital preparedness plans. Unfortunately, there tends to be a gap in the literature regarding IPC within biodefense efforts and although most focus on larger components (disease surveillance, PPE, medical countermeasures), the utilization of IPC programs should not go ignored. Hospitals already have this tool available and it behooves preparedness efforts to employ it.
     </p>
     <p id="Par55">
      There is a continuous trend of pointing to infection prevention and control processes and neglecting the programs responsible for ensuring they are followed. The systemic gap in preparedness efforts citing infection prevention and control practices but failing to account for the program and role of infection preventionists reveals a fundamental lack of truly understanding the role of these programs and internal hospital operations. Biodefense efforts inherently include infection control practices as they are the foundation for preventing the spread of disease, but this gap regarding the inclusion of IPC programs does them a disservice. Hospitals already struggle with following IPC practices to reduce the spread of infection. Biodefense efforts should strengthen the existing IPC infrastructure and ensure processes are effectively followed. If hospitals are already struggling with hand hygiene and PPE compliance, how will they manage bioterrorism acts or pandemics?
     </p>
     <p id="Par56">
      The problem is twofold: current compliance to infection control processes is often substandard, and the IPC programs are frequently under-utilized and/or -prioritized. Biodefense efforts should seek to increase infection prevention and control efforts and strengthen processes while building upon the existing IPC program infrastructure that can be an effective tool. Infection prevention and control is a significant resource in the biodefense arsenal and should be seen as an independent component, like surveillance and medical countermeasures. These programs are already in place and while they focus on the day-to-day problems of HAIs, they can be utilized to better serve and strengthen the U.S. healthcare infrastructure and thus preparedness. Strengthening IPC programs and processes benefits health security whether it is a local outbreak, an act of bioterrorism, or a pandemic.
     </p>
     <p id="Par57">
      Hospitals are the frontline for biological events and their capacity to adequately detect and respond to such threats can either halt or help the spread of disease. Infection prevention and control practices are existing guidelines and recommendations that seek to combat disease transmission during medical care. IPC programs within hospitals work to ensure staff are educated on and compliant with such practices to protect patients, visitors, and healthcare workers. These programs are also an integral source for infectious disease surveillance and a connective tissue within hospitals, making them a significant contributor to public health surveillance. Outbreaks of SARS, MERS, Ebola virus disease, and multi-drug resistant microorganisms, have all revealed the importance of IPC and the devastating consequences of poor compliance. Continued failure to prioritize IPC programs and practices, as well as the role they serve within outbreaks and growing biological threats, will only serve to weaken preparedness and response efforts. Defense against biological threats requires strong infection control practices, programs, and the ability to adequately employ these efforts prior to and during public health emergencies. Healthcare is a critical infrastructure, meaning that if hospitals are amplifiers for disease transmission and sources for negative patient outcomes, the impact can be devastating. Infection prevention and control is an essential resource against all biological threats, regardless of their origin.
     </p>
    </sec>
    <back>
     <ref-list id="Bib1">
      <title>
       References
      </title>
      <ref id="CR1">
       <label>
        1.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Doyle
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Glynn
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Groseclose
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        <article-title>
         Completeness of notifiable infectious disease reporting in the United States: an analytical literature review
        </article-title>
        <source>
         Am J Epidemiol
        </source>
        <year>
         2002
        </year>
        <volume>
         155
        </volume>
        <issue>
         9
        </issue>
        <fpage>
         866
        </fpage>
        <lpage>
         874
        </lpage>
        <pub-id pub-id-type="doi">
         10.1093/aje/155.9.866
        </pub-id>
        <pub-id pub-id-type="pmid">
         11978592
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR2">
       <label>
        2.
       </label>
       <mixed-citation publication-type="other">
        Centers for Disease Control and Prevention. Bioterrorism agents/diseases. 2017.
        <ext-link ext-link-type="uri" xlink:href="https://emergency.cdc.gov/agent/agentlist.asp">
         https://emergency.cdc.gov/agent/agentlist.asp
        </ext-link>
        . Accessed 7 Apr 2017.
       </mixed-citation>
      </ref>
      <ref id="CR3">
       <label>
        3.
       </label>
       <mixed-citation publication-type="other">
        Centers for Disease Control and Prevention. Clean hands count for healthcare providers. 2017.
        <ext-link ext-link-type="uri" xlink:href="https://www.cdc.gov/handhygiene/providers/index.html">
         https://www.cdc.gov/handhygiene/providers/index.html
        </ext-link>
        . Accessed 19 May 2017.
       </mixed-citation>
      </ref>
      <ref id="CR4">
       <label>
        4.
       </label>
       <mixed-citation publication-type="other">
        Centers for Disease Control and Prevention. Standard precautions for all patient care. 2017.
        <ext-link ext-link-type="uri" xlink:href="https://www.cdc.gov/infectioncontrol/basics/standard-precautions.html">
         https://www.cdc.gov/infectioncontrol/basics/standard-precautions.html
        </ext-link>
        . Accessed 19 May 2017.
       </mixed-citation>
      </ref>
      <ref id="CR5">
       <label>
        5.
       </label>
       <mixed-citation publication-type="other">
        Centers for Disease Control and Prevention. Handwashing: clean hands save lives. 2017.
        <ext-link ext-link-type="uri" xlink:href="https://www.cdc.gov/handwashing/show-me-the-science-hand-sanitizer.html">
         https://www.cdc.gov/handwashing/show-me-the-science-hand-sanitizer.html
        </ext-link>
        . Accessed 16 June 2018.
       </mixed-citation>
      </ref>
      <ref id="CR6">
       <label>
        6.
       </label>
       <mixed-citation publication-type="other">
        California Department of Public Health. Reportable diseases and conditions. 2017.
        <ext-link ext-link-type="uri" xlink:href="https://archive.cdph.ca.gov/HealthInfo/Pages/ReportableDiseases.aspx">
         https://archive.cdph.ca.gov/HealthInfo/Pages/ReportableDiseases.aspx
        </ext-link>
        . Accessed 10 July 2017.
       </mixed-citation>
      </ref>
      <ref id="CR7">
       <label>
        7.
       </label>
       <mixed-citation publication-type="other">
        World Health Organization. Five moments for hand hygiene. 2006.
        <ext-link ext-link-type="uri" xlink:href="http://www.who.int/gpsc/tools/Five_moments/en/">
         http://www.who.int/gpsc/tools/Five_moments/en/
        </ext-link>
        . Accessed 19 May 2017.
       </mixed-citation>
      </ref>
      <ref id="CR8">
       <label>
        8.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Korniewicz
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Kirwin
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Cresci
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Larson
          </surname>
          <given-names>
           E
          </given-names>
         </name>
        </person-group>
        <article-title>
         Leakage of late and vinyl exam gloves in high and low clinical settings
        </article-title>
        <source>
         Am Ind Hyg Assoc J
        </source>
        <year>
         1993
        </year>
        <volume>
         54
        </volume>
        <issue>
         1
        </issue>
        <fpage>
         22
        </fpage>
        <lpage>
         26
        </lpage>
        <pub-id pub-id-type="doi">
         10.1080/15298669391354261
        </pub-id>
        <pub-id pub-id-type="pmid">
         8470620
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR9">
       <label>
        9.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Salath
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         A high-resolution human contact network for infectious disease transmission
        </article-title>
        <source>
         Proc Natl Acad Sci U S A
        </source>
        <year>
         2010
        </year>
        <volume>
         107
        </volume>
        <issue>
         51
        </issue>
        <fpage>
         22020
        </fpage>
        <lpage>
         22025
        </lpage>
        <pub-id pub-id-type="doi">
         10.1073/pnas.1009094108
        </pub-id>
        <pub-id pub-id-type="pmid">
         21149721
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR10">
       <label>
        10.
       </label>
       <mixed-citation publication-type="other">
        Association for Professionals in Infection Control and Epidemiology – APIC. Rules for standard and isolation precautions. 2017.
        <ext-link ext-link-type="uri" xlink:href="http://professionals.site.apic.org/10-ways-to-protect-patients/follow-the-rules-for-isolation-precautions/">
         http://professionals.site.apic.org/10-ways-to-protect-patients/follow-the-rules-for-isolation-precautions/
        </ext-link>
        . Accessed 3 April 2017.
       </mixed-citation>
      </ref>
      <ref id="CR11">
       <label>
        11.
       </label>
       <element-citation publication-type="book">
        <person-group person-group-type="author">
         <collab>
          Committee on the Development of Reusable Facemasks During an Influenza Pandemic, the National Academies
         </collab>
        </person-group>
        <source>
         Reusability of facemasks during an influenza pandemic
        </source>
        <year>
         2006
        </year>
        <publisher-loc>
         Washington, DC
        </publisher-loc>
        <publisher-name>
         The National Academies Press
        </publisher-name>
       </element-citation>
      </ref>
      <ref id="CR12">
       <label>
        12.
       </label>
       <mixed-citation publication-type="other">
        World Health Organization. Evidence of hand hygiene to reduce transmission and infections by multi-drug resistant microorganisms in healthcare settings.
        <ext-link ext-link-type="uri" xlink:href="http://www.who.int/gpsc/tools/Five_moments/en/">
         http://www.who.int/gpsc/tools/Five_moments/en/
        </ext-link>
        . Accessed 19 May 2017.
       </mixed-citation>
      </ref>
      <ref id="CR13">
       <label>
        13.
       </label>
       <mixed-citation publication-type="other">
        World Health Organization. WHO MERS-CoV global summary and assessment of risk. 2017.
        <ext-link ext-link-type="uri" xlink:href="http://www.who.int/emergencies/mers-cov/risk-assessment-july-2017.pdf?ua=1">
         http://www.who.int/emergencies/mers-cov/risk-assessment-july-2017.pdf?ua=1
        </ext-link>
        . Accessed 28 July 2017.
       </mixed-citation>
      </ref>
      <ref id="CR14">
       <label>
        14.
       </label>
       <mixed-citation publication-type="other">
        Munoz-Price I, et al. SHEA expert guidance: isolation precautions for visitors. Infection control &amp; hospital epidemiology. 2015.
        <ext-link ext-link-type="uri" xlink:href="https://shea-online.org/index.php/practice-resources/41-current-guidelines/422-expert-guidance-isolation-precautions-for-visitors">
         https://shea-online.org/index.php/practice-resources/41-current-guidelines/422-expert-guidance-isolation-precautions-for-visitors
        </ext-link>
        . Accessed 2 Aug 2017.
       </mixed-citation>
      </ref>
      <ref id="CR15">
       <label>
        15.
       </label>
       <mixed-citation publication-type="other">
        Centers for Disease Control and Prevention. Infection prevention and control recommendations for hospitalized patients under investigation (PUIs) for Ebola virus disease. 2015.
        <ext-link ext-link-type="uri" xlink:href="https://www.cdc.gov/vhf/ebola/healthcare-us/hospitals/infection-control.html">
         https://www.cdc.gov/vhf/ebola/healthcare-us/hospitals/infection-control.html
        </ext-link>
        . Accessed 4 Feb 2017.
       </mixed-citation>
      </ref>
      <ref id="CR16">
       <label>
        16.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rogers
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        <article-title>
         Why can’t I visit? The ethics of visitation restrictions – lessons learned from SARS
        </article-title>
        <source>
         Crit Care
        </source>
        <year>
         2004
        </year>
        <volume>
         8
        </volume>
        <issue>
         5
        </issue>
        <fpage>
         300
        </fpage>
        <lpage>
         302
        </lpage>
        <pub-id pub-id-type="doi">
         10.1186/cc2930
        </pub-id>
        <pub-id pub-id-type="pmid">
         15469583
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR17">
       <label>
        17.
       </label>
       <mixed-citation publication-type="other">
        Centers for Disease Control and Prevention. Guidelines for isolation precautions: preventing transmission of infectious agents in healthcare settings. 2007.
        <ext-link ext-link-type="uri" xlink:href="https://www.cdc.gov/infectioncontrol/guidelines/isolation/prevention.html">
         https://www.cdc.gov/infectioncontrol/guidelines/isolation/prevention.html
        </ext-link>
        . Accessed 2 May 2017.
       </mixed-citation>
      </ref>
      <ref id="CR18">
       <label>
        18.
       </label>
       <mixed-citation publication-type="other">
        Vastag B. Superbug stalked NIH hospital last year, killing six. The Washington Post. 2012.
        <ext-link ext-link-type="uri" xlink:href="https://www.washingtonpost.com/national/health-science/superbug-stalked-nih-hospital-last-year-killing-six/2012/08/22/5be18b1a-ec66-11e1-9ddc-340d5efb1e9c_story.html">
         https://www.washingtonpost.com/national/health-science/superbug-stalked-nih-hospital-last-year-killing-six/2012/08/22/5be18b1a-ec66-11e1-9ddc-340d5efb1e9c_story.html
        </ext-link>
        . Accessed 28 July 2017.
       </mixed-citation>
      </ref>
      <ref id="CR19">
       <label>
        19.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <collab>
          Centers for Disease Control and Prevention and the Healthcare Infection Control Practices Advisory Committee (HICPAC)
         </collab>
        </person-group>
        <article-title>
         Guidelines for environmental infection control in health-care facilities
        </article-title>
        <source>
         Morb Mortal Wkly Rep
        </source>
        <year>
         2003
        </year>
        <volume>
         52
        </volume>
        <issue>
         RR10
        </issue>
        <fpage>
         1
        </fpage>
        <lpage>
         42
        </lpage>
       </element-citation>
      </ref>
      <ref id="CR20">
       <label>
        20.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Miller
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Implementing a negative-pressure isolation ward for a surge in airborne infectious patients
        </article-title>
        <source>
         Am J Infect Control
        </source>
        <year>
         2017
        </year>
        <volume>
         45
        </volume>
        <issue>
         6
        </issue>
        <fpage>
         652
        </fpage>
        <lpage>
         659
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.ajic.2017.04.104
        </pub-id>
        <pub-id pub-id-type="pmid">
         28330710
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR21">
       <label>
        21.
       </label>
       <mixed-citation publication-type="other">
        Lax S, et al. Bacterial colonization and succession in a newly opened hospital. Sci Transl Med. 2017;9(391) 10.1126/scitranslmed.aah6500.
       </mixed-citation>
      </ref>
      <ref id="CR22">
       <label>
        22.
       </label>
       <mixed-citation publication-type="other">
        Centers for Disease Control and Prevention. SARS, infection control in healthcare facilities. 2005.
        <ext-link ext-link-type="uri" xlink:href="https://www.cdc.gov/sars/guidance/i-infection/healthcare.html">
         https://www.cdc.gov/sars/guidance/i-infection/healthcare.html
        </ext-link>
        . Accessed 14 July 2017.
       </mixed-citation>
      </ref>
      <ref id="CR23">
       <label>
        23.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Erasmus
          </surname>
          <given-names>
           V
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         A qualitative exploration of reasons for poor hand hygiene among hospital workers lack of positive role models and of convincing evidence that hand hygiene prevents cross-infection
        </article-title>
        <source>
         Infect Control Hosp Epidemiol
        </source>
        <year>
         2009
        </year>
        <volume>
         30
        </volume>
        <issue>
         5
        </issue>
        <fpage>
         415
        </fpage>
        <lpage>
         519
        </lpage>
        <pub-id pub-id-type="doi">
         10.1086/596773
        </pub-id>
        <pub-id pub-id-type="pmid">
         19344264
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR24">
       <label>
        24.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Reed
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Kemmerly
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        <article-title>
         Infection control and prevention: a review of hospital-acquired infections and the economic implications
        </article-title>
        <source>
         Ochsner J
        </source>
        <year>
         2009
        </year>
        <volume>
         9
        </volume>
        <issue>
         1
        </issue>
        <fpage>
         27
        </fpage>
        <lpage>
         31
        </lpage>
        <pub-id pub-id-type="pmid">
         21603406
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR25">
       <label>
        25.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Dick
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         A decade of investment in infection prevention: a cost-effectiveness analysis
        </article-title>
        <source>
         Am J Infect Control
        </source>
        <year>
         2015
        </year>
        <volume>
         43
        </volume>
        <issue>
         1
        </issue>
        <fpage>
         4
        </fpage>
        <lpage>
         9
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.ajic.2014.07.014
        </pub-id>
        <pub-id pub-id-type="pmid">
         25564117
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR26">
       <label>
        26.
       </label>
       <mixed-citation publication-type="other">
        Sun L. Cost to treat Ebola in the U.S.: $1.16 million for two patients. The Washington Post. 2014, November 18.
        <ext-link ext-link-type="uri" xlink:href="https://www.washingtonpost.com/news/post-nation/wp/2014/11/18/cost-to-treat-ebola-in-the-u-s-1-16-million-for-2-patients/?utm_term=.e6a9091e93d8">
         https://www.washingtonpost.com/news/post-nation/wp/2014/11/18/cost-to-treat-ebola-in-the-u-s-1-16-million-for-2-patients/?utm_term=.e6a9091e93d8
        </ext-link>
        . Accessed 29 Jan 2017.
       </mixed-citation>
      </ref>
      <ref id="CR27">
       <label>
        27.
       </label>
       <mixed-citation publication-type="other">
        Hayden E. Biodefense since 9/11: the price of protection. Nature. 2011; 477:150–152.
        <ext-link ext-link-type="uri" xlink:href="http://www.nature.com/news/2011/110907/full/477150a.html">
         http://www.nature.com/news/2011/110907/full/477150a.html
        </ext-link>
        . Accessed 30 July 2017.
       </mixed-citation>
      </ref>
      <ref id="CR28">
       <label>
        28.
       </label>
       <mixed-citation publication-type="other">
        Association for Professionals in Infection Control and Epidemiology – APIC. Ebola preparedness one year later: a poll of APIC members. 2015.
        <ext-link ext-link-type="uri" xlink:href="https://apic.org/Resource_/TinyMceFileManager/Topic-specific/APIC_Ebola_Survey_Results_November_2015.pdf">
         https://apic.org/Resource_/TinyMceFileManager/Topic-specific/APIC_Ebola_Survey_Results_November_2015.pdf
        </ext-link>
        . Accessed 15 Aug 2017.
       </mixed-citation>
      </ref>
      <ref id="CR29">
       <label>
        29.
       </label>
       <mixed-citation publication-type="other">
        Blue Ribbon Study Panel on Biodefense. Recommending and promoting changes to U.S. policy and law to strengthen national biodefense while optimizing resource investments. 2015.
        <ext-link ext-link-type="uri" xlink:href="http://www.biodefensestudy.org/">
         http://www.biodefensestudy.org/
        </ext-link>
        . Accessed 8 July 2017.
       </mixed-citation>
      </ref>
      <ref id="CR30">
       <label>
        30.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bloomfield
          </surname>
          <given-names>
           SF
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         The effectiveness of hand hygiene procedures in reducing the risks of infections in home and community settings including handwashing and alcohol-based hand sanitizers
        </article-title>
        <source>
         Am J Infect Control
        </source>
        <year>
         2007
        </year>
        <volume>
         35
        </volume>
        <issue>
         10
        </issue>
        <fpage>
         S27
        </fpage>
        <lpage>
         S64
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.ajic.2007.07.001
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR31">
       <label>
        31.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Boyce
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Pittet
          </surname>
          <given-names>
           D
          </given-names>
         </name>
        </person-group>
        <article-title>
         Guidelines for hand hygiene in health-care settings: recommendations of the healthcare infection control practices advisory committee and the HICPAC/SHEA/APIC/IDSA hand hygiene task force
        </article-title>
        <source>
         Am J Infect Control
        </source>
        <year>
         2002
        </year>
        <volume>
         30
        </volume>
        <issue>
         8
        </issue>
        <fpage>
         S1
        </fpage>
        <lpage>
         46
        </lpage>
        <pub-id pub-id-type="doi">
         10.1067/mic.2002.130391
        </pub-id>
        <pub-id pub-id-type="pmid">
         12461507
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR32">
       <label>
        32.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Grayson
          </surname>
          <given-names>
           ML
          </given-names>
         </name>
         <name>
          <surname>
           Jarvie
          </surname>
          <given-names>
           LJ
          </given-names>
         </name>
         <name>
          <surname>
           Martin
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Johnson
          </surname>
          <given-names>
           PD
          </given-names>
         </name>
         <name>
          <surname>
           Jodoin
          </surname>
          <given-names>
           ME
          </given-names>
         </name>
         <name>
          <surname>
           McMullan
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Significant reductions in methicillin-resistant Staphylococcus aureus bacteraemia and clinical isolates associated with a multisite, hand hygiene culture-change program and subsequent successful statewide roll-out
        </article-title>
        <source>
         Med J Aust
        </source>
        <year>
         2008
        </year>
        <volume>
         188
        </volume>
        <issue>
         11
        </issue>
        <fpage>
         633
        </fpage>
        <lpage>
         640
        </lpage>
        <pub-id pub-id-type="pmid">
         18513171
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR33">
       <label>
        33.
       </label>
       <mixed-citation publication-type="other">
        Johns Hopkins University Center for Health Security. Health sector resilience checklist for high-consequence infectious diseases – informed by the domestic US Ebola response. 2017.
        <ext-link ext-link-type="uri" xlink:href="http://www.centerforhealthsecurity.org/our-work/pubs_archive/pubs-pdfs/2017/HCID_Final_Report_05.23.2017.pdf">
         http://www.centerforhealthsecurity.org/our-work/pubs_archive/pubs-pdfs/2017/HCID_Final_Report_05.23.2017.pdf
        </ext-link>
        . Accessed 22 June 2017.
       </mixed-citation>
      </ref>
      <ref id="CR34">
       <label>
        34.
       </label>
       <mixed-citation publication-type="other">
        Occupational Safety and Health Administration. Ebola: control and prevention.
        <ext-link ext-link-type="uri" xlink:href="https://www.osha.gov/SLTC/ebola/control_prevention.html">
         https://www.osha.gov/SLTC/ebola/control_prevention.html
        </ext-link>
        . Accessed 8 July 2017.
       </mixed-citation>
      </ref>
      <ref id="CR35">
       <label>
        35.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Quinlan
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Loughrey
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Nicklin
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <name>
          <surname>
           Roth
          </surname>
          <given-names>
           V
          </given-names>
         </name>
        </person-group>
        <article-title>
         Restrictive visitor policies: feedback from healthcare workers, patients, and families
        </article-title>
        <source>
         Hosp Q
        </source>
        <year>
         2003
        </year>
        <volume>
         7
        </volume>
        <issue>
         1
        </issue>
        <fpage>
         33
        </fpage>
        <lpage>
         37
        </lpage>
        <pub-id pub-id-type="pmid">
         14674175
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR36">
       <label>
        36.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rutala
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <name>
          <surname>
           Weber
          </surname>
          <given-names>
           D
          </given-names>
         </name>
        </person-group>
        <article-title>
         Disinfection and sterilization: an overview
        </article-title>
        <source>
         AJIC
        </source>
        <year>
         2013
        </year>
        <volume>
         41
        </volume>
        <issue>
         5
        </issue>
        <fpage>
         S2
        </fpage>
        <lpage>
         S5
        </lpage>
       </element-citation>
      </ref>
      <ref id="CR37">
       <label>
        37.
       </label>
       <mixed-citation publication-type="other">
        World Health Organization. Standard precautions in healthcare. 2007.
        <ext-link ext-link-type="uri" xlink:href="http://www.who.int/csr/resources/publications/EPR_AM2_E7.pdf?ua=1">
         http://www.who.int/csr/resources/publications/EPR_AM2_E7.pdf?ua=1
        </ext-link>
        . Accessed 19 May 2017.
       </mixed-citation>
      </ref>
     </ref-list>
    </back>
   </article>
   <article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <?properties open_access?>
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       J Hosp Infect
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       J. Hosp. Infect
      </journal-id>
      <journal-title-group>
       <journal-title>
        The Journal of Hospital Infection
       </journal-title>
      </journal-title-group>
      <issn pub-type="ppub">
       0195-6701
      </issn>
      <issn pub-type="epub">
       1532-2939
      </issn>
      <publisher>
       <publisher-name>
        The Healthcare Infection Society. Published by Elsevier Ltd.
       </publisher-name>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       24330862
      </article-id>
      <article-id pub-id-type="pmc">
       7114876
      </article-id>
      <article-id pub-id-type="publisher-id">
       S0195-6701(13)60012-2
      </article-id>
      <article-id pub-id-type="doi">
       10.1016/S0195-6701(13)60012-2
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Article
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        epic3: National Evidence-Based Guidelines for Preventing Healthcare-Associated Infections in NHS Hospitals in England
       </article-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author" id="au10">
        <name>
         <surname>
          Loveday
         </surname>
         <given-names>
          H.P.
         </given-names>
        </name>
        <email>
         heather.loveday@uwl.ac.uk
        </email>
        <xref ref-type="aff" rid="aff1">
         a
        </xref>
        <xref ref-type="corresp" rid="cor1">
         *
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au20">
        <name>
         <surname>
          Wilson
         </surname>
         <given-names>
          J.A.
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         a
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au30">
        <name>
         <surname>
          Pratt
         </surname>
         <given-names>
          R.J.
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         a
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au40">
        <name>
         <surname>
          Golsorkhi
         </surname>
         <given-names>
          M.
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         a
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au50">
        <name>
         <surname>
          Tingle
         </surname>
         <given-names>
          A.
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         a
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au60">
        <name>
         <surname>
          Bak
         </surname>
         <given-names>
          A.
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         a
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au70">
        <name>
         <surname>
          Browne
         </surname>
         <given-names>
          J.
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         a
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au80">
        <name>
         <surname>
          Prieto
         </surname>
         <given-names>
          J.
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff2">
         b
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au90">
        <name>
         <surname>
          Wilcox
         </surname>
         <given-names>
          M.
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff3">
         c
        </xref>
       </contrib>
      </contrib-group>
      <aff id="aff1">
       <label>
        a
       </label>
       Richard Wells Research Centre, College of Nursing, Midwifery and Healthcare, University of West London (London)
      </aff>
      <aff id="aff2">
       <label>
        b
       </label>
       Faculty of Health Sciences, University of Southampton (Southampton)
      </aff>
      <aff id="aff3">
       <label>
        c
       </label>
       Microbiology and Infection Control, Leeds Teaching Hospitals and University of Leeds (Leeds)
      </aff>
      <author-notes>
       <corresp id="cor1">
        <label>
         *
        </label>
        Corresponding author. Address: Richard Wells Research Centre, College of Nursing, Midwifery and Healthcare, University of West London, Paragon House, Boston Manor Road, Brentford TW8 9GB, UK. Tel.: +44 (0) 20 8209 4110
        <email>
         heather.loveday@uwl.ac.uk
        </email>
       </corresp>
      </author-notes>
      <pub-date pub-type="pmc-release">
       <day>
        10
       </day>
       <month>
        12
       </month>
       <year>
        2013
       </year>
      </pub-date>
      <!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.-->
      <pub-date pub-type="ppub">
       <month>
        1
       </month>
       <year>
        2014
       </year>
      </pub-date>
      <pub-date pub-type="epub">
       <day>
        10
       </day>
       <month>
        12
       </month>
       <year>
        2013
       </year>
      </pub-date>
      <volume>
       86
      </volume>
      <fpage>
       S1
      </fpage>
      <lpage>
       S70
      </lpage>
      <permissions>
       <copyright-statement>
        Copyright © 2014 The Healthcare Infection Society. Published by Elsevier Ltd. All rights reserved.
       </copyright-statement>
       <copyright-year>
        2014
       </copyright-year>
       <copyright-holder>
        The Healthcare Infection Society
       </copyright-holder>
       <license>
        <license-p>
         Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
        </license-p>
       </license>
      </permissions>
      <abstract id="ceab10">
       <title>
        Executive Summary
       </title>
       <p>
        National evidence-based guidelines for preventing healthcare-associated infections (HCAI) in National Health Service (NHS) hospitals in England were originally commissioned by the Department of Health and developed during 1998–2000 by a nurse-led multi-professional team of researchers and specialist clinicians. Following extensive consultation, they were first published in January 2001
        <xref ref-type="bibr" rid="bib1">
         <sup>
          1
         </sup>
        </xref>
        and updated in 2007.
        <xref ref-type="bibr" rid="bib2">
         <sup>
          2
         </sup>
        </xref>
        A cardinal feature of evidence-based guidelines is that they are subject to timely review in order that new research evidence and technological advances can be identified, appraised and, if shown to be effective for the prevention of HCAI, incorporated into amended guidelines. Periodically updating the evidence base and guideline recommendations is essential in order to maintain their validity and authority.
       </p>
       <p>
        The Department of Health commissioned a review of new evidence and we have updated the evidence base for making infection prevention and control recommendations. A critical assessment of the updated evidence indicated that the epic2 guidelines published in 2007 remain robust, relevant and appropriate, but some guideline recommendations required adjustments to enhance clarity and a number of new recommendations were required. These have been clearly identified in the text. In addition, the synopses of evidence underpinning the guideline recommendations have been updated.
       </p>
       <p>
        These guidelines (epic3) provide comprehensive recommendations for preventing HCAI in hospital and other acute care settings based on the best currently available evidence. National evidence-based guidelines are broad principles of best practice that need to be integrated into local practice guidelines and audited to reduce variation in practice and maintain patient safety.
       </p>
       <p>
        Clinically effective infection prevention and control practice is an essential feature of patient protection. By incorporating these guidelines into routine daily clinical practice, patient safety can be enhanced and the risk of patients acquiring an infection during episodes of health care in NHS hospitals in England can be minimised.
       </p>
      </abstract>
     </article-meta>
    </front>
    <p id="para430">
     <fig id="f10">
      <graphic xlink:href="fx1_lrg">
      </graphic>
     </fig>
    </p>
    <p id="para440">
     NICE has accredited the process used by the University of West London to produce its epic3 guidance. Accreditation is valid for 5 years from December 2013.
    </p>
    <p id="para450">
     More information on accreditation can be viewed at:
     <ext-link ext-link-type="uri" id="interrefs10" xlink:href="http://www.nice.org.uk/accreditation">
      www.nice.org.uk/accreditation
     </ext-link>
    </p>
    <p id="para460">
     For full details on our accreditation visit:
     <ext-link ext-link-type="uri" id="interrefs20" xlink:href="http://www.nice.uk/accreditation">
      www.nice.uk/accreditation
     </ext-link>
    </p>
    <sec id="cesec10">
     <label>
      1
     </label>
     <title>
      Introductory Section
     </title>
     <sec id="cesec20">
      <label>
       1.1
      </label>
      <title>
       Guideline Development Team
      </title>
      <p id="para470">
       <list id="celist180" list-type="simple">
        <list-item id="celistitem430">
         <label>
          •
         </label>
         <p id="para480">
          Professor Heather P. Loveday (Project Lead), Professor of Evidence-based Healthcare, College of Nursing, Midwifery and Healthcare, University of West London (London) (HL).
         </p>
        </list-item>
        <list-item id="celistitem440">
         <label>
          •
         </label>
         <p id="para490">
          Ms Jennie A. Wilson, Reader, Healthcare Epidemiology, University of West London (London) (JW).
         </p>
        </list-item>
        <list-item id="celistitem450">
         <label>
          •
         </label>
         <p id="para500">
          Dr Jacqui Prieto, Senior Clinical Academic Research Fellow, University of Southampton (Southampton).
         </p>
        </list-item>
        <list-item id="celistitem460">
         <label>
          •
         </label>
         <p id="para510">
          Professor Mark Wilcox, Professor of Medical Microbiology, University of Leeds (Leeds) (MW).
         </p>
        </list-item>
        <list-item id="celistitem470">
         <label>
          •
         </label>
         <p id="para520">
          Professor Robert J. Pratt CBE, Professor of Nursing, University of West London (London).
         </p>
        </list-item>
        <list-item id="celistitem480">
         <label>
          •
         </label>
         <p id="para530">
          Ms Aggie Bak, Research Assistant, University of West London (London).
         </p>
        </list-item>
        <list-item id="celistitem490">
         <label>
          •
         </label>
         <p id="para540">
          Ms Jessica Browne, Research Assistant, University of West London (London).
         </p>
        </list-item>
        <list-item id="celistitem500">
         <label>
          •
         </label>
         <p id="para550">
          Ms Sharon Elliott, Senior Lecturer (Director Clinical Simulation), University of West London (London).
         </p>
        </list-item>
        <list-item id="celistitem510">
         <label>
          •
         </label>
         <p id="para560">
          Ms Mana Golsorkhi, Research Assistant, University of West London (London).
         </p>
        </list-item>
        <list-item id="celistitem520">
         <label>
          •
         </label>
         <p id="para570">
          Mr Roger King, Lecturer (Operating Department Practice), University of West London (London).
         </p>
        </list-item>
        <list-item id="celistitem530">
         <label>
          •
         </label>
         <p id="para580">
          Ms Caroline Smales, Senior Lecturer (Infectious Diseases), University of West London (London).
         </p>
        </list-item>
        <list-item id="celistitem540">
         <label>
          •
         </label>
         <p id="para590">
          Ms Alison Tingle, Principal Research Programme Officer, University of West London (London).
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <sec id="cesec30">
      <label>
       1.2
      </label>
      <title>
       Guideline Advisory Group
      </title>
      <p id="para600">
       <list id="celist190" list-type="simple">
        <list-item id="celistitem550">
         <label>
          •
         </label>
         <p id="para610">
          Dr Debra Adams, NHS Trust Development Authority (DA)
         </p>
        </list-item>
        <list-item id="celistitem560">
         <label>
          •
         </label>
         <p id="para620">
          Ms Susan Bennett, Lay Member (SB)
         </p>
        </list-item>
        <list-item id="celistitem570">
         <label>
          •
         </label>
         <p id="para630">
          Dr Tim Boswell, Nottingham University Hospitals NHS Trust (TB)
         </p>
        </list-item>
        <list-item id="celistitem580">
         <label>
          •
         </label>
         <p id="para640">
          Ms Maria Cann, Lay Member (MC)
         </p>
        </list-item>
        <list-item id="celistitem590">
         <label>
          •
         </label>
         <p id="para650">
          Ms Tracey Cooper, South London NHS Trust (TC)
         </p>
        </list-item>
        <list-item id="celistitem600">
         <label>
          •
         </label>
         <p id="para660">
          Dr Peter Cowling, Northern Lincolnshire &amp; Goole Hospitals NHS Trust
         </p>
        </list-item>
        <list-item id="celistitem610">
         <label>
          •
         </label>
         <p id="para670">
          Ms Judith Hudson, Association of Healthcare Cleaning Professionals
         </p>
        </list-item>
        <list-item id="celistitem620">
         <label>
          •
         </label>
         <p id="para680">
          Ms Theresa Neale, Urology Nurse Specialist, British Association of Urological Nurses (Consultant)
         </p>
        </list-item>
        <list-item id="celistitem630">
         <label>
          •
         </label>
         <p id="para690">
          Dr Jeff Phillips, Consultant Intensivist and Clinical Lead for Anaesthetics (Consultant) (JPh), Princess Alexandra Hospital Harlow
         </p>
        </list-item>
        <list-item id="celistitem640">
         <label>
          •
         </label>
         <p id="para700">
          Dr Jacqui Prieto, University of Southampton (Infection Prevention Adviser)
         </p>
        </list-item>
        <list-item id="celistitem650">
         <label>
          •
         </label>
         <p id="para710">
          Mr Julian Shah, Consultant Urologist (Consultant), King Edward VII Hospital, London
         </p>
        </list-item>
        <list-item id="celistitem660">
         <label>
          •
         </label>
         <p id="para720">
          Professor Mark Wilcox, Leeds Teaching Hospitals and University of Leeds
         </p>
        </list-item>
        <list-item id="celistitem670">
         <label>
          •
         </label>
         <p id="para730">
          Ms Carole Fry, Department of Health (Observer)
         </p>
        </list-item>
        <list-item id="celistitem680">
         <label>
          •
         </label>
         <p id="para740">
          Professor Brian I. Duerden CBE, Duerden Microbiology Consulting Ltd (Chair of Face-to-Face Meeting)
         </p>
        </list-item>
        <list-item id="celistitem690">
         <label>
          •
         </label>
         <p id="para750">
          Ms Meg Morse, Administrative Officer, University of West London
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <sec id="cesec40">
      <label>
       1.3
      </label>
      <title>
       Acknowledgements
      </title>
      <p id="para760">
       We would like to acknowledge the assistance of the Infection Prevention Society, British Infection Association and the Healthcare Infection Society for their input into the development of these guidelines; and other associations, learned societies, professional organisations, Royal Colleges and patient groups who took an active role in the external review of the guidelines. We would also like to acknowledge the support received from Professor Brian Duerden CBE in chairing the Guideline Development Advisory Group, and Carole Fry in the Chief Medical Officer's Team at the Department of Health (England).
      </p>
     </sec>
     <sec id="cesec50">
      <label>
       1.4
      </label>
      <title>
       Source of Funding
      </title>
      <p id="para770">
       The Department of Health (England).
      </p>
     </sec>
     <sec id="cesec60">
      <label>
       1.5
      </label>
      <title>
       Disclosure of Potential Conflict of Interest
      </title>
      <p id="para780">
       HL: Trustee and Director of the International Clinical Virology Centre and the Infection Prevention Society; educational grant from Care Fusion to attend SHEA conference in April 2010 and consultancy for GAMA Healthcare Ltd in January 2012.
      </p>
      <p id="para790">
       JW: Trustee of the Infection Prevention Society; consultancy for Care Fusion and ICNet.
      </p>
      <p id="para800">
       MW: Research on the use of hydrogen peroxide decontamination supported by Hygiene Solutions (Deprox).
      </p>
      <p id="para810">
       JPh: Sponsored speaker/session chair for Cook Medical.
      </p>
      <p id="para820">
       TC: Consultancy NIHR HTA Programme.
      </p>
      <p id="para830">
       DA: Consultancy and commissioned publications from Sanofi, BD, Smiths-Industry; consultancy from NHS Midlands and East; PhD supported by an education grant from BD and Enturia.
      </p>
      <p id="para840">
       TB: Advisor to Fresenius Medical Care Renal Services and Nottingham Woodthorpe Hospital (Ramsay Healthcare); sponsored speaker for Advanced Sterilisation Products.
      </p>
      <p id="para850">
       SB: Member of NICE Medical Technology Advisory Committee; former trustee of Bladder and Bowel Foundation; sponsorship from a number of urinary catheter manufacturers; Urology Trade Association; Bladder and Bowel Foundation representative on the Urology User Group Coalition.
      </p>
      <p id="para860">
       MC: Trustee of MRSA Action UK; conference attendances sponsored by Mölnlycke Healthcare.
      </p>
      <p id="para870">
       All other authors: no conflicts declared.
      </p>
     </sec>
     <sec id="cesec70">
      <label>
       1.6
      </label>
      <title>
       Relationship of Author(s) with Sponsor
      </title>
      <p id="para880">
       The Department of Health (England) commissioned the authors to update the evidence and guideline recommendations previously developed by them and published as the epic2 guidelines in the
       <italic>
        Journal of Hospital Infection
       </italic>
       in 2007.
      </p>
     </sec>
     <sec id="cesec80">
      <label>
       1.7
      </label>
      <title>
       Responsibility for Guidelines
      </title>
      <p id="para890">
       The views expressed in this publication are those of the authors and, following extensive consultation, have been endorsed by the Department of Health (England).
      </p>
     </sec>
     <sec id="cesec90">
      <label>
       1.8
      </label>
      <title>
       Summary of Guidelines
      </title>
      <sec id="cesec100">
       <title>
        Standard principles for preventing healthcare-associated infections in hospital and other acute care settings
       </title>
       <p id="para900">
        This guidance is based on the best critically appraised evidence currently available. The type and class of supporting evidence explicitly linked to each recommendation is described. Some recommendations from the previous guidelines have been revised to improve clarity; where a new recommendation has been made, this is indicated in the text. These recommendations are not detailed procedural protocols, and need to be incorporated into local guidelines. None are regarded as optional.
       </p>
       <p id="para910">
        Standard infection control precautions need to be applied by all healthcare practitioners to the care of all patients (i.e. adults, children and neonates). The recommendations are divided into five distinct interventions:
        <list id="celist200" list-type="simple">
         <list-item id="celistitem700">
          <label>
           •
          </label>
          <p id="para920">
           hospital environmental hygiene;
          </p>
         </list-item>
         <list-item id="celistitem710">
          <label>
           •
          </label>
          <p id="para930">
           hand hygiene;
          </p>
         </list-item>
         <list-item id="celistitem720">
          <label>
           •
          </label>
          <p id="para940">
           use of personal protective equipment (PPE);
          </p>
         </list-item>
         <list-item id="celistitem730">
          <label>
           •
          </label>
          <p id="para950">
           safe use and disposal of sharps; and
          </p>
         </list-item>
         <list-item id="celistitem740">
          <label>
           •
          </label>
          <p id="para960">
           principles of asepsis.
          </p>
         </list-item>
        </list>
       </p>
       <p id="para970">
        These guidelines do not address the additional infection control requirements of specialist settings, such as the operating department or outbreak situations.
       </p>
      </sec>
      <sec id="cesec110">
       <title>
        Hospital environmental hygiene
       </title>
       <p id="para980">
        <list id="celist210" list-type="simple">
         <list-item id="celistitem750">
          <label>
           SP1
          </label>
          <p id="para990">
           The hospital environment must be visibly clean; free from non-essential items and equipment, dust and dirt; and acceptable to patients, visitors and staff.
          </p>
          <p id="para1000">
           <italic>
            Class D/GPP
           </italic>
          </p>
         </list-item>
         <list-item id="celistitem760">
          <label>
           SP2
          </label>
          <p id="para1010">
           Levels of cleaning should be increased in cases of infection and/or colonisation when a suspected or known pathogen can survive in the environment, and environmental contamination may contribute to the spread of infection.
          </p>
          <p id="para1020">
           <italic>
            Class D/GPP
           </italic>
          </p>
         </list-item>
         <list-item id="celistitem770">
          <label>
           SP3
          </label>
          <p id="para1030">
           The use of disinfectants should be considered for cases of infection and/or colonisation when a suspected or known pathogen can survive in the environment, and environmental contamination may contribute to the spread of infection.
          </p>
          <p id="para1040">
           <italic>
            Class D/GPP
           </italic>
          </p>
         </list-item>
         <list-item id="celistitem780">
          <label>
           SP4
          </label>
          <p id="para1050">
           Shared pieces of equipment used in the delivery of patient care must be cleaned and decontaminated after each use with products recommended by the manufacturer.
          </p>
          <p id="para1060">
           <italic>
            Class D/GPP
           </italic>
          </p>
         </list-item>
         <list-item id="celistitem790">
          <label>
           SP5
          </label>
          <p id="para1070">
           All healthcare workers need to be educated about the importance of maintaining a clean and safe care environment for patients. Every healthcare worker needs to know their specific responsibilities for cleaning and decontaminating the clinical environment and the equipment used in patient care.
          </p>
          <p id="para1080">
           <italic>
            Class D/GPP
           </italic>
          </p>
         </list-item>
        </list>
       </p>
      </sec>
      <sec id="cesec120">
       <title>
        Hand hygiene
       </title>
       <p id="para1090">
        <list id="celist220" list-type="simple">
         <list-item id="celistitem800">
          <label>
           SP6
          </label>
          <p id="para1100">
           Hands must be decontaminated:
           <list id="celist230" list-type="simple">
            <list-item id="celistitem810">
             <label>
              •
             </label>
             <p id="para1110">
              immediately before each episode of direct patient contact or care, including clean/aseptic procedures;
             </p>
            </list-item>
            <list-item id="celistitem820">
             <label>
              •
             </label>
             <p id="para1120">
              immediately after each episode of direct patient contact or care;
             </p>
            </list-item>
            <list-item id="celistitem830">
             <label>
              •
             </label>
             <p id="para1130">
              immediately after contact with body fluids, mucous membranes and non-intact skin;
             </p>
            </list-item>
            <list-item id="celistitem840">
             <label>
              •
             </label>
             <p id="para1140">
              immediately after other activities or contact with objects and equipment in the immediate patient environment that may result in the hands becoming contaminated; and
             </p>
            </list-item>
            <list-item id="celistitem850">
             <label>
              •
             </label>
             <p id="para1150">
              immediately after the removal of gloves.
             </p>
            </list-item>
           </list>
          </p>
          <p id="para1160">
           <italic>
            Class C
           </italic>
          </p>
         </list-item>
         <list-item id="celistitem860">
          <label>
           SP7
          </label>
          <p id="para1170">
           Use an alcohol-based hand rub for decontamination of hands before and after direct patient contact and clinical care, except in the following situations when soap and water must be used:
           <list id="celist240" list-type="simple">
            <list-item id="celistitem870">
             <label>
              •
             </label>
             <p id="para1180">
              when hands are visibly soiled or potentially contaminated with body fluids; and
             </p>
            </list-item>
            <list-item id="celistitem880">
             <label>
              •
             </label>
             <p id="para1190">
              when caring for patients with vomiting or diarrhoeal illness, regardless of whether or not gloves have been worn.
             </p>
            </list-item>
           </list>
          </p>
          <p id="para1200">
           <italic>
            Class A
           </italic>
          </p>
         </list-item>
         <list-item id="celistitem890">
          <label>
           SP8
          </label>
          <p id="para1210">
           Healthcare workers should ensure that their hands can be decontaminated effectively by:
           <list id="celist250" list-type="simple">
            <list-item id="celistitem900">
             <label>
              •
             </label>
             <p id="para1220">
              removing all wrist and hand jewellery;
             </p>
            </list-item>
            <list-item id="celistitem910">
             <label>
              •
             </label>
             <p id="para1230">
              wearing short-sleeved clothing when delivering patient care;
             </p>
            </list-item>
            <list-item id="celistitem920">
             <label>
              •
             </label>
             <p id="para1240">
              making sure that fingernails are short, clean, and free from false nails and nail polish; and
             </p>
            </list-item>
            <list-item id="celistitem930">
             <label>
              •
             </label>
             <p id="para1250">
              covering cuts and abrasions with waterproof dressings.
             </p>
            </list-item>
           </list>
          </p>
          <p id="para1260">
           <italic>
            Class D/GPP
           </italic>
          </p>
         </list-item>
         <list-item id="celistitem940">
          <label>
           SP9
          </label>
          <p id="para1270">
           Effective handwashing technique involves three stages: preparation, washing and rinsing, and drying.
          </p>
          <p id="para1280">
           <list id="celist260" list-type="simple">
            <list-item id="celistitem950">
             <label>
              •
             </label>
             <p id="para1290">
              Preparation: wet hands under tepid running water before applying the recommended amount of liquid soap or an antimicrobial preparation.
             </p>
            </list-item>
            <list-item id="celistitem960">
             <label>
              •
             </label>
             <p id="para1300">
              Washing: the handwash solution must come into contact with all of the surfaces of the hand. The hands should be rubbed together vigorously for a minimum of 10–15 s, paying particular attention to the tips of the fingers, the thumbs and the areas between the fingers. Hands should be rinsed thoroughly.
             </p>
            </list-item>
            <list-item id="celistitem970">
             <label>
              •
             </label>
             <p id="para1310">
              Drying: use good-quality paper towels to dry the hands thoroughly.
             </p>
            </list-item>
           </list>
          </p>
          <p id="para1320">
           <italic>
            Class D/GPP
           </italic>
          </p>
         </list-item>
         <list-item id="celistitem980">
          <label>
           SP10
          </label>
          <p id="para1330">
           When decontaminating hands using an alcohol-based hand rub, hands should be free of dirt and organic material, and:
           <list id="celist270" list-type="simple">
            <list-item id="celistitem990">
             <label>
              •
             </label>
             <p id="para1340">
              hand rub solution must come into contact with all surfaces of the hand; and
             </p>
            </list-item>
            <list-item id="celistitem1000">
             <label>
              •
             </label>
             <p id="para1350">
              hands should be rubbed together vigorously, paying particular attention to the tips of the fingers, the thumbs and the areas between the fingers, until the solution has evaporated and the hands are dry.
             </p>
            </list-item>
           </list>
          </p>
          <p id="para1360">
           <italic>
            Class D/GPP
           </italic>
          </p>
         </list-item>
         <list-item id="celistitem1010">
          <label>
           SP11
          </label>
          <p id="para1370">
           Clinical staff should be made aware of the potentially damaging effects of hand decontamination products, and encouraged to use an emollient hand cream regularly to maintain the integrity of the skin. Consult the occupational health team or a general practitioner if a particular liquid soap, antiseptic handwash or alcohol-based hand rub causes skin irritation.
          </p>
          <p id="para1380">
           <italic>
            Class D/GPP
           </italic>
          </p>
         </list-item>
         <list-item id="celistitem1020">
          <label>
           SP12
          </label>
          <p id="para1390">
           Alcohol-based hand rub should be made available at the point of care in all healthcare facilities.
          </p>
          <p id="para1400">
           <italic>
            Class C
           </italic>
          </p>
         </list-item>
         <list-item id="celistitem1030">
          <label>
           SP13
          </label>
          <p id="para1410">
           Hand hygiene resources and healthcare worker adherence to hand hygiene guidelines should be audited at regular intervals, and the results should be fed back to healthcare workers to improve and sustain high levels of compliance.
          </p>
          <p id="para1420">
           <italic>
            Class C
           </italic>
          </p>
         </list-item>
         <list-item id="celistitem1040">
          <label>
           SP14
          </label>
          <p id="para1430">
           Healthcare organisations must provide regular training in risk assessment, effective hand hygiene and glove use for all healthcare workers.
          </p>
          <p id="para1440">
           <italic>
            Class D/GPP
           </italic>
          </p>
         </list-item>
         <list-item id="celistitem1050">
          <label>
           SP15
          </label>
          <p id="para1450">
           Local programmes of education, social marketing, and audit and feedback should be refreshed regularly and promoted by senior managers and clinicians to maintain focus, engage staff and produce sustainable levels of compliance.
          </p>
          <p id="para1460">
           <bold>
            New recommendation
           </bold>
           <italic>
            Class C
           </italic>
          </p>
         </list-item>
         <list-item id="celistitem1060">
          <label>
           SP16
          </label>
          <p id="para1470">
           Patients and relatives should be provided with information about the need for hand hygiene and how to keep their own hands clean.
          </p>
          <p id="para1480">
           <bold>
            New recommendation
           </bold>
           <italic>
            Class D/GPP
           </italic>
          </p>
         </list-item>
         <list-item id="celistitem1070">
          <label>
           SP17
          </label>
          <p id="para1490">
           Patients should be offered the opportunity to clean their hands before meals; after using the toilet, commode or bedpan/urinal; and at other times as appropriate. Products available should be tailored to patient needs and may include alcohol-based hand rub, hand wipes and access to handwash basins.
          </p>
          <p id="para1500">
           <bold>
            New recommendation
           </bold>
           <italic>
            Class D/GPP
           </italic>
          </p>
         </list-item>
        </list>
       </p>
      </sec>
      <sec id="cesec130">
       <title>
        Use of personal protective equipment
       </title>
       <p id="para1510">
        <list id="celist280" list-type="simple">
         <list-item id="celistitem1080">
          <label>
           SP18
          </label>
          <p id="para1520">
           Selection of personal protective equipment must be based on an assessment of the:
           <list id="celist290" list-type="simple">
            <list-item id="celistitem1090">
             <label>
              •
             </label>
             <p id="para1530">
              risk of transmission of microorganisms to the patient or carer;
             </p>
            </list-item>
            <list-item id="celistitem1100">
             <label>
              •
             </label>
             <p id="para1540">
              risk of contamination of healthcare practitioners' clothing and skin by patients' blood or body fluids; and
             </p>
            </list-item>
            <list-item id="celistitem1110">
             <label>
              •
             </label>
             <p id="para1550">
              suitability of the equipment for proposed use.
             </p>
            </list-item>
           </list>
          </p>
          <p id="para1560">
           <italic>
            Class D/GPP/H&amp;S
           </italic>
          </p>
         </list-item>
         <list-item id="celistitem1120">
          <label>
           SP19
          </label>
          <p id="para1570">
           Healthcare workers should be educated and their competence assessed in the:
           <list id="celist300" list-type="simple">
            <list-item id="celistitem1130">
             <label>
              •
             </label>
             <p id="para1580">
              assessment of risk;
             </p>
            </list-item>
            <list-item id="celistitem1140">
             <label>
              •
             </label>
             <p id="para1590">
              selection and use of personal protective equipment; and
             </p>
            </list-item>
            <list-item id="celistitem1150">
             <label>
              •
             </label>
             <p id="para1600">
              use of standard precautions.
             </p>
            </list-item>
           </list>
          </p>
          <p id="para1610">
           <italic>
            Class D/GPP/H&amp;S
           </italic>
          </p>
         </list-item>
         <list-item id="celistitem1160">
          <label>
           SP20
          </label>
          <p id="para1620">
           Supplies of personal protective equipment should be made available wherever care is delivered and risk assessment indicates a requirement.
          </p>
          <p id="para1630">
           <italic>
            Class D/GPP/H&amp;S
           </italic>
          </p>
         </list-item>
         <list-item id="celistitem1170">
          <label>
           SP21
          </label>
          <p id="para1640">
           Gloves must be worn for:
           <list id="celist310" list-type="simple">
            <list-item id="celistitem1180">
             <label>
              •
             </label>
             <p id="para1650">
              invasive procedures;
             </p>
            </list-item>
            <list-item id="celistitem1190">
             <label>
              •
             </label>
             <p id="para1660">
              contact with sterile sites and non-intact skin or mucous membranes;
             </p>
            </list-item>
            <list-item id="celistitem1200">
             <label>
              •
             </label>
             <p id="para1670">
              all activities that have been assessed as carrying a risk of exposure to blood or body fluids; and
             </p>
            </list-item>
            <list-item id="celistitem1210">
             <label>
              •
             </label>
             <p id="para1680">
              when handling sharps or contaminated devices.
             </p>
            </list-item>
           </list>
          </p>
          <p id="para1690">
           <italic>
            Class D/GPP/H&amp;S
           </italic>
          </p>
         </list-item>
         <list-item id="celistitem1220">
          <label>
           SP22
          </label>
          <p id="para1700">
           Gloves must be:
           <list id="celist320" list-type="simple">
            <list-item id="celistitem1230">
             <label>
              •
             </label>
             <p id="para1710">
              worn as single-use items;
             </p>
            </list-item>
            <list-item id="celistitem1240">
             <label>
              •
             </label>
             <p id="para1720">
              put on immediately before an episode of patient contact or treatment;
             </p>
            </list-item>
            <list-item id="celistitem1250">
             <label>
              •
             </label>
             <p id="para1730">
              removed as soon as the episode is completed;
             </p>
            </list-item>
            <list-item id="celistitem1260">
             <label>
              •
             </label>
             <p id="para1740">
              changed between caring for different patients; and
             </p>
            </list-item>
            <list-item id="celistitem1270">
             <label>
              •
             </label>
             <p id="para1750">
              disposed of into the appropriate waste stream in accordance with local policies for waste management.
             </p>
            </list-item>
           </list>
          </p>
          <p id="para1760">
           <italic>
            Class D/GPP/H&amp;S
           </italic>
          </p>
         </list-item>
         <list-item id="celistitem1280">
          <label>
           SP23
          </label>
          <p id="para1770">
           Hands must be decontaminated immediately after gloves have been removed.
          </p>
          <p id="para1780">
           <italic>
            Class D/GPP/H&amp;S
           </italic>
          </p>
         </list-item>
         <list-item id="celistitem1290">
          <label>
           SP24
          </label>
          <p id="para1790">
           A range of CE-marked medical and protective gloves that are acceptable to healthcare personnel and suitable for the task must be available in all clinical areas.
          </p>
          <p id="para1800">
           <italic>
            Class D/GPP/H&amp;S
           </italic>
          </p>
         </list-item>
         <list-item id="celistitem1300">
          <label>
           SP25
          </label>
          <p id="para1810">
           Sensitivity to natural rubber latex in patients, carers and healthcare workers must be documented, and alternatives to natural rubber latex gloves must be available.
          </p>
          <p id="para1820">
           <italic>
            Class D/GPP/H&amp;S
           </italic>
          </p>
         </list-item>
         <list-item id="celistitem1310">
          <label>
           SP26
          </label>
          <p id="para1830">
           Disposable plastic aprons must be worn when close contact with the patient, materials or equipment pose a risk that clothing may become contaminated with pathogenic microorganisms, blood or body fluids.
          </p>
          <p id="para1840">
           <italic>
            Class D/GPP/H&amp;S
           </italic>
          </p>
         </list-item>
         <list-item id="celistitem1320">
          <label>
           SP27
          </label>
          <p id="para1850">
           Full-body fluid-repellent gowns must be worn where there is a risk of extensive splashing of blood or body fluids on to the skin or clothing of healthcare workers.
          </p>
          <p id="para1860">
           <italic>
            Class D/GPP/H&amp;S
           </italic>
          </p>
         </list-item>
         <list-item id="celistitem1330">
          <label>
           SP28
          </label>
          <p id="para1870">
           Plastic aprons/fluid-repellent gowns should be worn as single-use items for one procedure or episode of patient care, and disposed of into the appropriate waste stream in accordance with local policies for waste management. When used, non-disposable protective clothing should be sent for laundering.
          </p>
          <p id="para1880">
           <italic>
            Class D/GPP/H&amp;S
           </italic>
          </p>
         </list-item>
         <list-item id="celistitem1340">
          <label>
           SP29
          </label>
          <p id="para1890">
           Fluid-repellent surgical face masks and eye protection must be worn where there is a risk of blood or body fluids splashing into the face and eyes.
          </p>
          <p id="para1900">
           <italic>
            Class D/GPP H&amp;S
           </italic>
          </p>
         </list-item>
         <list-item id="celistitem1350">
          <label>
           SP30
          </label>
          <p id="para1910">
           Appropriate respiratory protective equipment should be selected according to a risk assessment that takes account of the infective microorganism, the anticipated activity and the duration of exposure.
          </p>
          <p id="para1920">
           <italic>
            Class D/GPP/H&amp;S
           </italic>
          </p>
         </list-item>
         <list-item id="celistitem1360">
          <label>
           SP31
          </label>
          <p id="para1930">
           Respiratory protective equipment must fit the user correctly and they must be trained in how to use and adjust it in accordance with health and safety regulations.
          </p>
          <p id="para1940">
           <italic>
            Class D/GPP/H&amp;S
           </italic>
          </p>
         </list-item>
         <list-item id="celistitem1370">
          <label>
           SP32
          </label>
          <p id="para1950">
           Personal protective equipment should be removed in the following sequence to minimise the risk of cross/self-contamination:
           <list id="celist330" list-type="simple">
            <list-item id="celistitem1380">
             <label>
              •
             </label>
             <p id="para1960">
              gloves;
             </p>
            </list-item>
            <list-item id="celistitem1390">
             <label>
              •
             </label>
             <p id="para1970">
              apron;
             </p>
            </list-item>
            <list-item id="celistitem1400">
             <label>
              •
             </label>
             <p id="para1980">
              eye protection (when worn); and
             </p>
            </list-item>
            <list-item id="celistitem1410">
             <label>
              •
             </label>
             <p id="para1990">
              mask/respirator (when worn). Hands must be decontaminated following the removal of personal protective equipment.
             </p>
            </list-item>
           </list>
          </p>
          <p id="para2000">
           <bold>
            New recommendation
           </bold>
           <italic>
            Class D/GPP/H&amp;S
           </italic>
          </p>
         </list-item>
        </list>
       </p>
      </sec>
      <sec id="cesec140">
       <title>
        Safe use and disposal of sharps
       </title>
       <p id="para2010">
        <list id="celist340" list-type="simple">
         <list-item id="celistitem1420">
          <label>
           SP33
          </label>
          <p id="para2020">
           Sharps must not be passed directly from hand to hand, and handling should be kept to a minimum.
          </p>
          <p id="para2030">
           <italic>
            Class D/GPP/H&amp;S
           </italic>
          </p>
         </list-item>
         <list-item id="celistitem1430">
          <label>
           SP34
          </label>
          <p id="para2040">
           Needles must not be recapped, bent or disassembled after use.
          </p>
          <p id="para2050">
           <italic>
            Class D/GPP/H&amp;S
           </italic>
          </p>
         </list-item>
         <list-item id="celistitem1440">
          <label>
           SP35
          </label>
          <p id="para2060">
           Used sharps must be discarded at the point of use by the person generating the waste.
          </p>
          <p id="para2070">
           <italic>
            Class D/GPP/H&amp;S
           </italic>
          </p>
         </list-item>
         <list-item id="celistitem1450">
          <label>
           SP36
          </label>
          <p id="para2080">
           All sharps containers must:
           <list id="celist350" list-type="simple">
            <list-item id="celistitem1460">
             <label>
              •
             </label>
             <p id="para2090">
              conform to current national and international standards;
             </p>
            </list-item>
            <list-item id="celistitem1470">
             <label>
              •
             </label>
             <p id="para2100">
              be positioned safely, away from public areas and out of the reach of children, and at a height that enables safe disposal by all members of staff;
             </p>
            </list-item>
            <list-item id="celistitem1480">
             <label>
              •
             </label>
             <p id="para2110">
              be secured to avoid spillage;
             </p>
            </list-item>
            <list-item id="celistitem1490">
             <label>
              •
             </label>
             <p id="para2120">
              be temporarily closed when not in use;
             </p>
            </list-item>
            <list-item id="celistitem1500">
             <label>
              •
             </label>
             <p id="para2130">
              not be filled above the fill line; and
             </p>
            </list-item>
            <list-item id="celistitem1510">
             <label>
              •
             </label>
             <p id="para2140">
              be disposed of when the fill line is reached.
             </p>
            </list-item>
           </list>
          </p>
          <p id="para2150">
           <italic>
            Class D/GPP/H&amp;S
           </italic>
          </p>
         </list-item>
         <list-item id="celistitem1520">
          <label>
           SP37
          </label>
          <p id="para2160">
           All clinical and non-clinical staff must be educated about the safe use and disposal of sharps and the action to be taken in the event of an injury.
          </p>
          <p id="para2170">
           <italic>
            Class D/GPP/H&amp;S
           </italic>
          </p>
         </list-item>
         <list-item id="celistitem1530">
          <label>
           SP38
          </label>
          <p id="para2180">
           Use safer sharps devices where assessment indicates that they will provide safe systems of working for healthcare workers.
          </p>
          <p id="para2190">
           <italic>
            Class C/H&amp;S
           </italic>
          </p>
         </list-item>
         <list-item id="celistitem1540">
          <label>
           SP39
          </label>
          <p id="para2200">
           Organisations should involve end-users in evaluating safer sharps devices to determine their effectiveness, acceptability to practitioners, impact on patient care and cost benefit prior to widespread introduction.
          </p>
          <p id="para2210">
           <italic>
            Class D/GPP/H&amp;S
           </italic>
          </p>
         </list-item>
        </list>
       </p>
      </sec>
      <sec id="cesec150">
       <title>
        Asepsis
       </title>
       <p id="para2220">
        <list id="celist360" list-type="simple">
         <list-item id="celistitem1550">
          <label>
           SP40
          </label>
          <p id="para2230">
           Organisations should provide education to ensure that healthcare workers are trained and competent in performing the aseptic technique.
          </p>
          <p id="para2240">
           <bold>
            New recommendation
           </bold>
           <italic>
            Class D/GPP
           </italic>
          </p>
         </list-item>
         <list-item id="celistitem1560">
          <label>
           SP41
          </label>
          <p id="para2250">
           The aseptic technique should be used for any procedure that breaches the body's natural defences, including:
           <list id="celist370" list-type="simple">
            <list-item id="celistitem1570">
             <label>
              •
             </label>
             <p id="para2260">
              insertion and maintenance of invasive devices;
             </p>
            </list-item>
            <list-item id="celistitem1580">
             <label>
              •
             </label>
             <p id="para2270">
              infusion of sterile fluids and medication; and
             </p>
            </list-item>
            <list-item id="celistitem1590">
             <label>
              •
             </label>
             <p id="para2280">
              care of wounds and surgical incisions.
             </p>
            </list-item>
           </list>
          </p>
          <p id="para2290">
           <bold>
            New recommendation
           </bold>
           <italic>
            Class D/GPP
           </italic>
          </p>
         </list-item>
        </list>
       </p>
      </sec>
      <sec id="cesec160">
       <title>
        Guidelines for preventing infections associated with the use of short-term indwelling urethral catheters
       </title>
       <p id="para2300">
        This guidance is based on the best critically appraised evidence currently available. The type and class of supporting evidence explicitly linked to each recommendation is described. Some recommendations from the previous guidelines have been revised to improve clarity; where a new recommendation has been made, this is indicated in the text. These recommendations are not detailed procedural protocols, and need to be incorporated into local guidelines. None are regarded as optional.
       </p>
       <p id="para2310">
        These guidelines apply to adults and children aged ≥1 year who require a short-term indwelling urethral catheter (≤28 days), and should be read in conjunction with the guidance on Standard Principles. The recommendations are divided into six distinct interventions:
        <list id="celist380" list-type="simple">
         <list-item id="celistitem1600">
          <label>
           •
          </label>
          <p id="para2320">
           assessing the need for catheterisation;
          </p>
         </list-item>
         <list-item id="celistitem1610">
          <label>
           •
          </label>
          <p id="para2330">
           selection of catheter type and system;
          </p>
         </list-item>
         <list-item id="celistitem1620">
          <label>
           •
          </label>
          <p id="para2340">
           catheter insertion;
          </p>
         </list-item>
         <list-item id="celistitem1630">
          <label>
           •
          </label>
          <p id="para2350">
           catheter maintenance;
          </p>
         </list-item>
         <list-item id="celistitem1640">
          <label>
           •
          </label>
          <p id="para2360">
           education of patients, relatives and healthcare workers; and
          </p>
         </list-item>
         <list-item id="celistitem1650">
          <label>
           •
          </label>
          <p id="para2370">
           system interventions for reducing the risk of infection.
          </p>
         </list-item>
        </list>
       </p>
      </sec>
      <sec id="cesec170">
       <title>
        Assessing the need for catheterisation
       </title>
       <p id="para2380">
        <list id="celist390" list-type="simple">
         <list-item id="celistitem1660">
          <label>
           UC1
          </label>
          <p id="para2390">
           Only use a short-term indwelling urethral catheter in patients for whom it is clinically indicated, following assessment of alternative methods and discussion with the patient.
          </p>
          <p id="para2400">
           <italic>
            Class D/GPP
           </italic>
          </p>
         </list-item>
         <list-item id="celistitem1670">
          <label>
           UC2
          </label>
          <p id="para2410">
           Document the clinical indication(s) for catheterisation, date of insertion, expected duration, type of catheter and drainage system, and planned date of removal.
          </p>
          <p id="para2420">
           <italic>
            Class D/GPP
           </italic>
          </p>
         </list-item>
         <list-item id="celistitem1680">
          <label>
           UC3
          </label>
          <p id="para2430">
           Assess and record the reasons for catheterisation every day. Remove the catheter when no longer clinically indicated.
          </p>
          <p id="para2440">
           <italic>
            Class D/GPP
           </italic>
          </p>
         </list-item>
        </list>
       </p>
      </sec>
      <sec id="cesec180">
       <title>
        Selection of catheter type
       </title>
       <p id="para2450">
        <list id="celist400" list-type="simple">
         <list-item id="celistitem1690">
          <label>
           UC4
          </label>
          <p id="para2460">
           Assess patient's needs prior to catheterisation in terms of:
           <list id="celist410" list-type="simple">
            <list-item id="celistitem1700">
             <label>
              •
             </label>
             <p id="para2470">
              latex allergy;
             </p>
            </list-item>
            <list-item id="celistitem1710">
             <label>
              •
             </label>
             <p id="para2480">
              length of catheter (standard, female, paediatric);
             </p>
            </list-item>
            <list-item id="celistitem1720">
             <label>
              •
             </label>
             <p id="para2490">
              type of sterile drainage bag and sampling port (urometer, 2-L bag, leg bag) or catheter valve; and
             </p>
            </list-item>
            <list-item id="celistitem1730">
             <label>
              •
             </label>
             <p id="para2500">
              comfort and dignity.
             </p>
            </list-item>
           </list>
          </p>
          <p id="para2510">
           <bold>
            New recommendation
           </bold>
           <italic>
            Class D/GPP
           </italic>
          </p>
         </list-item>
         <list-item id="celistitem1740">
          <label>
           UC5
          </label>
          <p id="para2520">
           Select a catheter that minimises urethral trauma, irritation and patient discomfort, and is appropriate for the anticipated duration of catheterisation.
          </p>
          <p id="para2530">
           <italic>
            Class D/GPP
           </italic>
          </p>
         </list-item>
         <list-item id="celistitem1750">
          <label>
           UC6
          </label>
          <p id="para2540">
           Select the smallest gauge catheter that will allow urinary outflow and use a 10-mL retention balloon in adults (follow manufacturer's instructions for paediatric catheters). Urological patients may require larger gauge sizes and balloons.
          </p>
          <p id="para2550">
           <italic>
            Class D/GPP
           </italic>
          </p>
         </list-item>
        </list>
       </p>
      </sec>
      <sec id="cesec190">
       <title>
        Catheter insertion
       </title>
       <p id="para2560">
        <list id="celist420" list-type="simple">
         <list-item id="celistitem1760">
          <label>
           UC7
          </label>
          <p id="para2570">
           Catheterisation is an aseptic procedure and should only be undertaken by healthcare workers trained and competent in this procedure.
          </p>
          <p id="para2580">
           <italic>
            Class D/GPP
           </italic>
          </p>
         </list-item>
         <list-item id="celistitem1770">
          <label>
           UC8
          </label>
          <p id="para2590">
           Clean the urethral meatus with sterile, normal saline prior to the insertion of the catheter.
          </p>
          <p id="para2600">
           <italic>
            Class D/GPP
           </italic>
          </p>
         </list-item>
         <list-item id="celistitem1780">
          <label>
           UC9
          </label>
          <p id="para2610">
           Use lubricant from a sterile single-use container to minimise urethral discomfort, trauma and the risk of infection. Ensure the catheter is secured comfortably.
          </p>
          <p id="para2620">
           <italic>
            Class D/GPP
           </italic>
          </p>
         </list-item>
        </list>
       </p>
      </sec>
      <sec id="cesec200">
       <title>
        Catheter maintenance
       </title>
       <p id="para2630">
        <list id="celist430" list-type="simple">
         <list-item id="celistitem1790">
          <label>
           UC10
          </label>
          <p id="para2640">
           Connect a short-term indwelling urethral catheter to a sterile closed urinary drainage system with a sampling port.
          </p>
          <p id="para2650">
           <italic>
            Class A
           </italic>
          </p>
         </list-item>
         <list-item id="celistitem1800">
          <label>
           UC11
          </label>
          <p id="para2660">
           Do not break the connection between the catheter and the urinary drainage system unless clinically indicated.
          </p>
          <p id="para2670">
           <italic>
            Class A
           </italic>
          </p>
         </list-item>
         <list-item id="celistitem1810">
          <label>
           UC12
          </label>
          <p id="para2680">
           Change short-term indwelling urethral catheters and/or drainage bags when clinically indicated and in line with the manufacturer's recommendations.
          </p>
          <p id="para2690">
           <bold>
            New recommendation
           </bold>
           <italic>
            Class D/GPP
           </italic>
          </p>
         </list-item>
         <list-item id="celistitem1820">
          <label>
           UC13
          </label>
          <p id="para2700">
           Decontaminate hands and wear a new pair of clean non-sterile gloves before manipulating each patient's catheter. Decontaminate hands immediately following the removal of gloves.
          </p>
          <p id="para2710">
           <italic>
            Class D/GPP
           </italic>
          </p>
         </list-item>
         <list-item id="celistitem1830">
          <label>
           UC14
          </label>
          <p id="para2720">
           Use the sampling port and the aseptic technique to obtain a catheter sample of urine.
          </p>
          <p id="para2730">
           <italic>
            Class D/GPP
           </italic>
          </p>
         </list-item>
         <list-item id="celistitem1840">
          <label>
           UC15
          </label>
          <p id="para2740">
           Position the urinary drainage bag below the level of the bladder on a stand that prevents contact with the floor.
          </p>
          <p id="para2750">
           <italic>
            Class D/GPP
           </italic>
          </p>
         </list-item>
         <list-item id="celistitem1850">
          <label>
           UC16
          </label>
          <p id="para2760">
           Do not allow the urinary drainage bag to fill beyond three-quarters full.
          </p>
          <p id="para2770">
           <italic>
            Class D/GPP
           </italic>
          </p>
         </list-item>
         <list-item id="celistitem1860">
          <label>
           UC17
          </label>
          <p id="para2780">
           Use a separate, clean container for each patient and avoid contact between the urinary drainage tap and the container when emptying the drainage bag.
          </p>
          <p id="para2790">
           <italic>
            Class D/GPP
           </italic>
          </p>
         </list-item>
         <list-item id="celistitem1870">
          <label>
           UC18
          </label>
          <p id="para2800">
           Do not add antiseptic or antimicrobial solutions to urinary drainage bags.
          </p>
          <p id="para2810">
           <italic>
            Class A
           </italic>
          </p>
         </list-item>
         <list-item id="celistitem1880">
          <label>
           UC19
          </label>
          <p id="para2820">
           Routine daily personal hygiene is all that is required for meatal cleansing.
          </p>
          <p id="para2830">
           <italic>
            Class A
           </italic>
          </p>
         </list-item>
        </list>
       </p>
      </sec>
      <sec id="cesec210">
       <title>
        Education of patients, relatives and healthcare workers
       </title>
       <p id="para2840">
        <list id="celist440" list-type="simple">
         <list-item id="celistitem1890">
          <label>
           UC20
          </label>
          <p id="para2850">
           Do not use bladder maintenance solutions to prevent catheter-associated infection.
          </p>
          <p id="para2860">
           <italic>
            Class A
           </italic>
          </p>
         </list-item>
         <list-item id="celistitem1900">
          <label>
           UC21
          </label>
          <p id="para2870">
           Healthcare workers should be trained and competent in the appropriate use, selection, insertion, maintenance and removal of short-term indwelling urethral catheters.
          </p>
          <p id="para2880">
           <italic>
            Class D/GPP
           </italic>
          </p>
         </list-item>
         <list-item id="celistitem1910">
          <label>
           UC22
          </label>
          <p id="para2890">
           Ensure patients, relatives and carers are given information regarding the reason for the catheter and the plan for review and removal. If discharged with a catheter, the patient should be given written information and shown how to:
           <list id="celist450" list-type="simple">
            <list-item id="celistitem1920">
             <label>
              •
             </label>
             <p id="para2900">
              manage the catheter and drainage system;
             </p>
            </list-item>
            <list-item id="celistitem1930">
             <label>
              •
             </label>
             <p id="para2910">
              minimise the risk of urinary tract infection; and
             </p>
            </list-item>
            <list-item id="celistitem1940">
             <label>
              •
             </label>
             <p id="para2920">
              obtain additional supplies suitable for individual needs.
             </p>
            </list-item>
           </list>
          </p>
          <p id="para2930">
           <italic>
            Class D/GPP
           </italic>
          </p>
         </list-item>
        </list>
       </p>
      </sec>
      <sec id="cesec220">
       <title>
        System interventions for reducing the risk of infection
       </title>
       <p id="para2940">
        <list id="celist460" list-type="simple">
         <list-item id="celistitem1950">
          <label>
           UC23
          </label>
          <p id="para2950">
           Use quality improvement systems to support the appropriate use and management of short-term urethral catheters and ensure their timely removal. These may include:
           <list id="celist470" list-type="simple">
            <list-item id="celistitem1960">
             <label>
              •
             </label>
             <p id="para2960">
              protocols for catheter insertion;
             </p>
            </list-item>
            <list-item id="celistitem1970">
             <label>
              •
             </label>
             <p id="para2970">
              use of bladder ultrasound scanners to assess and manage urinary retention;
             </p>
            </list-item>
            <list-item id="celistitem1980">
             <label>
              •
             </label>
             <p id="para2980">
              reminders to review the continuing use or prompt the removal of catheters;
             </p>
            </list-item>
            <list-item id="celistitem1990">
             <label>
              •
             </label>
             <p id="para2990">
              audit and feedback of compliance with practice guidelines; and
             </p>
            </list-item>
            <list-item id="celistitem2000">
             <label>
              •
             </label>
             <p id="para3000">
              continuing professional education
             </p>
            </list-item>
           </list>
          </p>
          <p id="para3010">
           <bold>
            New recommendation
           </bold>
           <italic>
            Class D/GPP
           </italic>
          </p>
         </list-item>
         <list-item id="celistitem2010">
          <label>
           UC24
          </label>
          <p id="para3020">
           No patient should be discharged or transferred with a short-term indwelling urethral catheter without a plan documenting the:
           <list id="celist480" list-type="simple">
            <list-item id="celistitem2020">
             <label>
              •
             </label>
             <p id="para3030">
              reason for the catheter;
             </p>
            </list-item>
            <list-item id="celistitem2030">
             <label>
              •
             </label>
             <p id="para3040">
              clinical indications for continuing catheterisation; and
             </p>
            </list-item>
            <list-item id="celistitem2040">
             <label>
              •
             </label>
             <p id="para3050">
              date for removal or review by an appropriate clinician overseeing their care.
             </p>
            </list-item>
           </list>
          </p>
          <p id="para3060">
           <bold>
            New recommendation
           </bold>
           <italic>
            Class D/GPP
           </italic>
          </p>
         </list-item>
        </list>
       </p>
      </sec>
      <sec id="cesec230">
       <title>
        Guidelines for preventing infections associated with the use of intravascular access devices
       </title>
       <p id="para3070">
        This guidance is based on the best critically appraised evidence currently available. The type and class of supporting evidence explicitly linked to each recommendation is described. Some recommendations from the previous guidelines have been revised to improve clarity; where a new recommendation has been made, this is indicated in the text. These recommendations are not detailed procedural protocols, and need to be incorporated into local guidelines. None are regarded as optional.
       </p>
      </sec>
      <sec id="cesec240">
       <title>
        Education of healthcare workers and patients
       </title>
       <p id="para3080">
        <list id="celist490" list-type="simple">
         <list-item id="celistitem2050">
          <label>
           IVAD1
          </label>
          <p id="para3090">
           Healthcare workers caring for patients with intravascular catheters should be trained and assessed as competent in using and consistently adhering to practices for the prevention of catheter-related bloodstream infection.
          </p>
          <p id="para3100">
           <italic>
            Class D/GPP
           </italic>
          </p>
         </list-item>
         <list-item id="celistitem2060">
          <label>
           IVAD2
          </label>
          <p id="para3110">
           Healthcare workers should be aware of the manufacturer's advice relating to individual catheters, connection and administration set dwell time, and compatibility with antiseptics and other fluids to ensure the safe use of devices.
          </p>
          <p id="para3120">
           <bold>
            New recommendation
           </bold>
           <italic>
            Class D/GPP
           </italic>
          </p>
         </list-item>
         <list-item id="celistitem2070">
          <label>
           IVAD3
          </label>
          <p id="para3130">
           Before discharge from hospital, patients with intravascular catheters and their carers should be taught any techniques they may need to use to prevent infection and manage their device.
          </p>
          <p id="para3140">
           <italic>
            Class D/GPP
           </italic>
          </p>
         </list-item>
        </list>
       </p>
      </sec>
      <sec id="cesec250">
       <title>
        General asepsis
       </title>
       <p id="para3150">
        <list id="celist500" list-type="simple">
         <list-item id="celistitem2080">
          <label>
           IVAD4
          </label>
          <p id="para3160">
           Hands must be decontaminated, with an alcohol-based hand rub or by washing with liquid soap and water if soiled or potentially contaminated with blood or body fluids, before and after any contact with the intravascular catheter or insertion site.
          </p>
          <p id="para3170">
           <italic>
            Class A
           </italic>
          </p>
         </list-item>
         <list-item id="celistitem2090">
          <label>
           IVAD5
          </label>
          <p id="para3180">
           Use the aseptic technique for the insertion and care of an intravascular access device and when administering intravenous medication.
          </p>
          <p id="para3190">
           <italic>
            Class B
           </italic>
          </p>
         </list-item>
        </list>
       </p>
      </sec>
      <sec id="cesec260">
       <title>
        Selection of catheter type
       </title>
       <p id="para3200">
        <list id="celist510" list-type="simple">
         <list-item id="celistitem2100">
          <label>
           IVAD6
          </label>
          <p id="para3210">
           Use a catheter with the minimum number of ports or lumens essential for management of the patient.
          </p>
          <p id="para3220">
           <italic>
            Class A
           </italic>
          </p>
         </list-item>
         <list-item id="celistitem2110">
          <label>
           IVAD7
          </label>
          <p id="para3230">
           Preferably use a designated single-lumen catheter to administer lipid-containing parenteral nutrition or other lipid-based solutions.
          </p>
          <p id="para3240">
           <italic>
            Class D/GPP
           </italic>
          </p>
         </list-item>
         <list-item id="celistitem2120">
          <label>
           IVAD8
          </label>
          <p id="para3250">
           Use a tunnelled or implanted central venous access device with a subcutaneous port for patients in whom long-term vascular access is required.
          </p>
          <p id="para3260">
           <italic>
            Class A
           </italic>
          </p>
         </list-item>
         <list-item id="celistitem2130">
          <label>
           IVAD9
          </label>
          <p id="para3270">
           Use a peripherally inserted central catheter for patients in whom medium-term intermittent access is required.
          </p>
          <p id="para3280">
           <bold>
            New recommendation
           </bold>
           <italic>
            Class D/GPP
           </italic>
          </p>
         </list-item>
         <list-item id="celistitem2140">
          <label>
           IVAD10
          </label>
          <p id="para3290">
           Use an antimicrobial-impregnated central venous access device for adult patients whose central venous catheter is expected to remain in place for &gt;5 days if catheter-related bloodstream infection rates remain above the locally agreed benchmark, despite the implementation of a comprehensive strategy to reduce catheter-related bloodstream infection.
          </p>
          <p id="para3300">
           <italic>
            Class A
           </italic>
          </p>
         </list-item>
        </list>
       </p>
      </sec>
      <sec id="cesec270">
       <title>
        Selection of catheter insertion site
       </title>
       <p id="para3310">
        <list id="celist520" list-type="simple">
         <list-item id="celistitem2150">
          <label>
           IVAD11
          </label>
          <p id="para3320">
           In selecting an appropriate intravascular insertion site, assess the risks for infection against the risks of mechanical complications and patient comfort.
          </p>
          <p id="para3330">
           <italic>
            Class D/GPP
           </italic>
          </p>
         </list-item>
         <list-item id="celistitem2160">
          <label>
           IVAD12
          </label>
          <p id="para3340">
           Use the upper extremity for non-tunnelled catheter placement unless medically contraindicated.
          </p>
          <p id="para3350">
           <italic>
            Class C
           </italic>
          </p>
         </list-item>
        </list>
       </p>
      </sec>
      <sec id="cesec280">
       <title>
        Maximal sterile barrier precautions during catheter insertion
       </title>
       <p id="para3360">
        <list id="celist530" list-type="simple">
         <list-item id="celistitem2170">
          <label>
           IVAD13
          </label>
          <p id="para3370">
           Use maximal sterile barrier precautions for the insertion of central venous access devices.
          </p>
          <p id="para3380">
           <italic>
            Class C
           </italic>
          </p>
         </list-item>
        </list>
       </p>
      </sec>
      <sec id="cesec290">
       <title>
        Cutaneous antisepsis
       </title>
       <p id="para3390">
        <list id="celist540" list-type="simple">
         <list-item id="celistitem2180">
          <label>
           IVAD14
          </label>
          <p id="para3400">
           Decontaminate the skin at the insertion site with a single-use application of 2% chlorhexidine gluconate in 70% isopropyl alcohol (or povidone iodine in alcohol for patients with sensitivity to chlorhexidine) and allow to dry prior to the insertion of a central venous access device.
          </p>
          <p id="para3410">
           <italic>
            Class A
           </italic>
          </p>
         </list-item>
         <list-item id="celistitem2190">
          <label>
           IVAD15
          </label>
          <p id="para3420">
           Decontaminate the skin at the insertion site with a single-use application of 2% chlorhexidine gluconate in 70% isopropyl alcohol (or povidone iodine in alcohol for patients with sensitivity to chlorhexidine) and allow to dry before inserting a peripheral vascular access device.
          </p>
          <p id="para3430">
           <bold>
            New recommendation
           </bold>
           <italic>
            Class D/GPP
           </italic>
          </p>
         </list-item>
         <list-item id="celistitem2200">
          <label>
           IVAD16
          </label>
          <p id="para3440">
           Do not apply antimicrobial ointment routinely to the catheter placement site prior to insertion to prevent catheter-related bloodstream infection.
          </p>
          <p id="para3450">
           <italic>
            Class D/GPP
           </italic>
          </p>
         </list-item>
        </list>
       </p>
      </sec>
      <sec id="cesec300">
       <title>
        Catheter and catheter site care
       </title>
       <p id="para3460">
        <list id="celist550" list-type="simple">
         <list-item id="celistitem2210">
          <label>
           IVAD17
          </label>
          <p id="para3470">
           Use a sterile, transparent, semi-permeable polyurethane dressing to cover the intravascular insertion site.
          </p>
          <p id="para3480">
           <italic>
            Class D/GPP
           </italic>
          </p>
         </list-item>
         <list-item id="celistitem2220">
          <label>
           IVAD18
          </label>
          <p id="para3490">
           Transparent, semi-permeable polyurethane dressings should be changed every 7 days, or sooner, if they are no longer intact or if moisture collects under the dressing.
          </p>
          <p id="para3500">
           <italic>
            Class D/GPP
           </italic>
          </p>
         </list-item>
         <list-item id="celistitem2230">
          <label>
           IVAD19
          </label>
          <p id="para3510">
           Use a sterile gauze dressing if a patient has profuse perspiration or if the insertion site is bleeding or leaking, and change when inspection of the insertion site is necessary or when the dressing becomes damp, loosened or soiled. Replace with a transparent semi-permeable dressing as soon as possible.
          </p>
          <p id="para3520">
           <italic>
            Class D/GPP
           </italic>
          </p>
         </list-item>
         <list-item id="celistitem2240">
          <label>
           IVAD20
          </label>
          <p id="para3530">
           Consider the use of a chlorhexidine-impregnated sponge dressing in adult patients with a central venous catheter as a strategy to reduce catheter-related bloodstream infection.
          </p>
          <p id="para3540">
           <bold>
            New recommendation
           </bold>
           <italic>
            Class B
           </italic>
          </p>
         </list-item>
         <list-item id="celistitem2250">
          <label>
           IVAD21
          </label>
          <p id="para3550">
           Consider the use of daily cleansing with chlorhexidine in adult patients with a central venous catheter as a strategy to reduce catheter-related bloodstream infection.
          </p>
          <p id="para3560">
           <bold>
            New recommendation
           </bold>
           <italic>
            Class B
           </italic>
          </p>
         </list-item>
         <list-item id="celistitem2260">
          <label>
           IVAD22
          </label>
          <p id="para3570">
           Dressings used on tunnelled or implanted catheter insertion sites should be replaced every 7 days until the insertion site has healed unless there is an indication to change them sooner. A dressing may no longer be required once the insertion site has healed.
          </p>
          <p id="para3580">
           <italic>
            Class D/GPP
           </italic>
          </p>
         </list-item>
         <list-item id="celistitem2270">
          <label>
           IVAD23
          </label>
          <p id="para3590">
           Use a single-use application of 2% chlorhexidine gluconate in 70% isopropyl alcohol (or povidone iodine in alcohol for patients with sensitivity to chlorhexidine) to clean the central catheter insertion site during dressing changes, and allow to air dry.
          </p>
          <p id="para3600">
           <italic>
            Class A
           </italic>
          </p>
         </list-item>
         <list-item id="celistitem2280">
          <label>
           IVAD24
          </label>
          <p id="para3610">
           Use a single-use application of 2% chlorhexidine gluconate in 70% isopropyl alcohol (or povidone iodine in alcohol for patients with sensitivity to chlorhexidine) to clean the peripheral venous catheter insertion site during dressing changes, and allow to air dry.
          </p>
          <p id="para3620">
           <bold>
            New recommendation
           </bold>
           <italic>
            Class D/GPP
           </italic>
          </p>
         </list-item>
         <list-item id="celistitem2290">
          <label>
           IVAD25
          </label>
          <p id="para3630">
           Do not apply antimicrobial ointment to catheter insertion sites as part of routine catheter site care.
          </p>
          <p id="para3640">
           <italic>
            Class D/GPP
           </italic>
          </p>
         </list-item>
        </list>
       </p>
      </sec>
      <sec id="cesec310">
       <title>
        Catheter replacement strategies
       </title>
       <p id="para3650">
        <list id="celist560" list-type="simple">
         <list-item id="celistitem2300">
          <label>
           IVAD26
          </label>
          <p id="para3660">
           Do not routinely replace central venous access devices to prevent catheter-related infection.
          </p>
          <p id="para3670">
           <italic>
            Class A
           </italic>
          </p>
         </list-item>
         <list-item id="celistitem2310">
          <label>
           IVAD27
          </label>
          <p id="para3680">
           Do not use guidewire-assisted catheter exchange for patients with catheter-related bloodstream infection.
          </p>
          <p id="para3690">
           <italic>
            Class A
           </italic>
          </p>
         </list-item>
         <list-item id="celistitem2320">
          <label>
           IVAD28
          </label>
          <p id="para3700">
           Peripheral vascular catheter insertion sites should be inspected at a minimum during each shift, and a Visual Infusion Phlebitis score should be recorded. The catheter should be removed when complications occur or as soon as it is no longer required.
          </p>
          <p id="para3710">
           <bold>
            New recommendation
           </bold>
           <italic>
            Class D/GPP
           </italic>
          </p>
         </list-item>
         <list-item id="celistitem2330">
          <label>
           IVAD29
          </label>
          <p id="para3720">
           Peripheral vascular catheters should be re-sited when clinically indicated and not routinely, unless device-specific recommendations from the manufacturer indicate otherwise.
          </p>
          <p id="para3730">
           <bold>
            New recommendation
           </bold>
           <italic>
            Class B
           </italic>
          </p>
         </list-item>
        </list>
       </p>
      </sec>
      <sec id="cesec320">
       <title>
        General principles for catheter management
       </title>
       <p id="para3740">
        <list id="celist570" list-type="simple">
         <list-item id="celistitem2340">
          <label>
           IVAD30
          </label>
          <p id="para3750">
           A single-use application of 2% chlorhexidine gluconate in 70% isopropyl alcohol (or povidone iodine in alcohol for patients with sensitivity to chlorhexidine) should be used to decontaminate the access port or catheter hub. The hub should be cleaned for a minimum of 15 s and allowed to dry before accessing the system.
          </p>
          <p id="para3760">
           <italic>
            Class D/GPP
           </italic>
          </p>
         </list-item>
         <list-item id="celistitem2350">
          <label>
           IVAD31
          </label>
          <p id="para3770">
           Antimicrobial lock solutions should not be used routinely to prevent catheter-related bloodstream infections.
          </p>
          <p id="para3780">
           <italic>
            Class D/GPP
           </italic>
          </p>
         </list-item>
         <list-item id="celistitem2360">
          <label>
           IVAD32
          </label>
          <p id="para3790">
           Do not routinely administer intranasal or systemic antimicrobials before insertion or during the use of an intravascular device to prevent catheter colonisation or bloodstream infection.
          </p>
          <p id="para3800">
           <italic>
            Class A
           </italic>
          </p>
         </list-item>
         <list-item id="celistitem2370">
          <label>
           IVAD33
          </label>
          <p id="para3810">
           Do not use systemic anticoagulants routinely to prevent catheter-related bloodstream infection.
          </p>
          <p id="para3820">
           <italic>
            Class D/GPP
           </italic>
          </p>
         </list-item>
         <list-item id="celistitem2380">
          <label>
           IVAD34
          </label>
          <p id="para3830">
           Use sterile normal saline for injection to flush and lock catheter lumens that are accessed frequently.
          </p>
          <p id="para3840">
           <italic>
            Class A
           </italic>
          </p>
         </list-item>
         <list-item id="celistitem2390">
          <label>
           IVAD35
          </label>
          <p id="para3850">
           The introduction of new intravascular devices or components should be monitored for an increase in the occurrence of device-associated infection. If an increase in infection rates is suspected, this should be reported to the Medicines and Healthcare Products Regulatory Agency in the UK.
          </p>
          <p id="para3860">
           <italic>
            Class D/GPP
           </italic>
          </p>
         </list-item>
         <list-item id="celistitem2400">
          <label>
           IVAD36
          </label>
          <p id="para3870">
           When safer sharps devices are used, healthcare workers should ensure that all components of the system are compatible and secured to minimise leaks and breaks in the system.
          </p>
          <p id="para3880">
           <italic>
            Class D/GPP
           </italic>
          </p>
         </list-item>
         <list-item id="celistitem2410">
          <label>
           IVAD37
          </label>
          <p id="para3890">
           Administration sets in continuous use do not need to be replaced more frequently than every 96 h, unless device-specific recommendations from the manufacturer indicate otherwise, they become disconnected or the intravascular access device is replaced.
          </p>
          <p id="para3900">
           <italic>
            Class A
           </italic>
          </p>
         </list-item>
         <list-item id="celistitem2420">
          <label>
           IVAD38
          </label>
          <p id="para3910">
           Administration sets for blood and blood components should be changed when the transfusion episode is complete or every 12 h (whichever is sooner).
          </p>
          <p id="para3920">
           <italic>
            Class D/GPP
           </italic>
          </p>
         </list-item>
         <list-item id="celistitem2430">
          <label>
           IVAD39
          </label>
          <p id="para3930">
           Administration sets used for lipid-containing parenteral nutrition should be changed every 24 h.
          </p>
          <p id="para3940">
           <italic>
            Class D/GPP
           </italic>
          </p>
         </list-item>
         <list-item id="celistitem2440">
          <label>
           IVAD40
          </label>
          <p id="para3950">
           Use quality improvement interventions to support the appropriate use and management of intravascular access devices (central and peripheral venous catheters) and ensure their timely removal. These may include:
           <list id="celist580" list-type="simple">
            <list-item id="celistitem2450">
             <label>
              •
             </label>
             <p id="para3960">
              protocols for device insertion and maintenance;
             </p>
            </list-item>
            <list-item id="celistitem2460">
             <label>
              •
             </label>
             <p id="para3970">
              reminders to review the continuing use or prompt the removal of intravascular devices;
             </p>
            </list-item>
            <list-item id="celistitem2470">
             <label>
              •
             </label>
             <p id="para3980">
              audit and feedback of compliance with practice guidelines; and
             </p>
            </list-item>
            <list-item id="celistitem2480">
             <label>
              •
             </label>
             <p id="para3990">
              continuing professional education.
             </p>
            </list-item>
           </list>
          </p>
          <p id="para4000">
           <bold>
            New recommendation
           </bold>
           <italic>
            Class C/GPP
           </italic>
          </p>
         </list-item>
        </list>
       </p>
      </sec>
     </sec>
     <sec id="cesec330">
      <label>
       1.9
      </label>
      <title>
       Introduction – the epic3 Guidelines
      </title>
      <p id="para4010">
       National evidence-based guidelines for preventing HCAI in NHS hospitals were first published in January 2001
       <xref ref-type="bibr" rid="bib1">
        <sup>
         1
        </sup>
       </xref>
       and updated in 2007.
       <xref ref-type="bibr" rid="bib2">
        <sup>
         2
        </sup>
       </xref>
       This second update was commissioned by the Department of Health in 2012 for publication in 2013.
      </p>
      <sec id="cesec340">
       <title>
        What are national evidence-based guidelines?
       </title>
       <p id="para4020">
        These are systematically developed broad statements (principles) of good practice. They are driven by practice need, based on evidence and subject to multi-professional debate, timely and frequent review, and modification. National guidelines are intended to inform the development of detailed operational protocols at local level, and can be used to ensure that these incorporate the most important principles for preventing HCAI in the NHS and other acute healthcare settings.
       </p>
      </sec>
      <sec id="cesec350">
       <title>
        Why do we need national guidelines for preventing healthcare-associated infections?
       </title>
       <p id="para4030">
        During the past two decades, HCAI have become a significant threat to patient safety. The technological advances made in the treatment of many diseases and disorders are often undermined by the transmission of infections within healthcare settings, particularly those caused by antimicrobial-resistant strains of disease-causing microorganisms that are now endemic in many healthcare environments. The financial and personal costs of these infections, in terms of the economic consequences to the NHS and the physical, social and psychological costs to patients and their relatives, have increased both government and public awareness of the risks associated with healthcare interventions, especially the risk of acquiring a new infection.
       </p>
       <p id="para4040">
        Many, although not all, HCAI can be prevented. Clinical effectiveness (i.e. using prevention measures that are based on reliable evidence of efficacy) is a core component of an effective strategy designed to protect patients from the risk of infection, and when combined with quality improvement methods can account for significant reductions in HCAI such as meticillin-resistant
        <italic>
         Staphylococcus aureus
        </italic>
        (MRSA) and
        <italic>
         Clostridium difficile.
        </italic>
       </p>
      </sec>
      <sec id="cesec360">
       <title>
        What is the purpose of the guidelines?
       </title>
       <p id="para4050">
        These guidelines describe clinically effective measures that are used by healthcare workers for preventing infections in hospital and other acute healthcare settings.
       </p>
      </sec>
      <sec id="cesec370">
       <title>
        What is the scope of the guidelines?
       </title>
       <p id="para4060">
        Three sets of guidelines were developed originally and have now been updated. They include:
        <list id="celist590" list-type="simple">
         <list-item id="celistitem2490">
          <label>
           •
          </label>
          <p id="para4070">
           standard infection control principles: including best practice recommendations for hospital environmental hygiene, effective hand hygiene, the appropriate use of PPE, the safe use and disposal of sharps, and the principles of asepsis;
          </p>
         </list-item>
         <list-item id="celistitem2500">
          <label>
           •
          </label>
          <p id="para4080">
           guidelines for preventing infections associated with the use of short-term indwelling urethral catheters; and
          </p>
         </list-item>
         <list-item id="celistitem2510">
          <label>
           •
          </label>
          <p id="para4090">
           guidelines for preventing infections associated with the use of intravascular access devices.
          </p>
         </list-item>
        </list>
       </p>
      </sec>
      <sec id="cesec380">
       <title>
        What is the evidence for these guidelines?
       </title>
       <p id="para4100">
        The evidence for these guidelines was identified by multiple systematic reviews of peer-reviewed research. In addition, evidence from expert opinion as reflected in systematically identified professional, national and international guidelines was considered following formal assessment using a validated appraisal tool.
        <xref ref-type="bibr" rid="bib3">
         <sup>
          3
         </sup>
        </xref>
        All evidence was critically appraised for its methodological rigour and clinical practice applicability, and the best-available evidence influenced the guideline recommendations.
       </p>
      </sec>
      <sec id="cesec390">
       <title>
        Who developed these guidelines?
       </title>
       <p id="para4110">
        A team of specialist infection prevention and control researchers and clinical specialists and a Guideline Development Advisory Group, comprising lay members and specialist clinical practitioners, developed the epic3 guidelines (see Sections 1.1 and 1.2).
       </p>
      </sec>
      <sec id="cesec400">
       <title>
        Who are these guidelines for?
       </title>
       <p id="para4120">
        These guidelines can be appropriately adapted and used by all hospital practitioners. This will inform the development of more detailed local protocols and ensure that important standard principles for infection prevention are incorporated. Consequently, they are aimed at hospital managers, members of hospital infection prevention and control teams, and individual healthcare practitioners. At an individual level, they are intended to influence the quality and clinical effectiveness of infection prevention decision-making. The dissemination of these guidelines will also help patients and carers/relatives to understand the standard infection prevention precautions they can expect all healthcare workers to implement to protect them from HCAI.
       </p>
      </sec>
      <sec id="cesec410">
       <title>
        How are these guidelines structured?
       </title>
       <p id="para4130">
        Each set of guidelines follows an identical format, which consists of:
        <list id="celist600" list-type="simple">
         <list-item id="celistitem2520">
          <label>
           •
          </label>
          <p id="para4140">
           a brief introduction;
          </p>
         </list-item>
         <list-item id="celistitem2530">
          <label>
           •
          </label>
          <p id="para4150">
           the intervention heading;
          </p>
         </list-item>
         <list-item id="celistitem2540">
          <label>
           •
          </label>
          <p id="para4160">
           a headline statement describing the key issues being addressed;
          </p>
         </list-item>
         <list-item id="celistitem2550">
          <label>
           •
          </label>
          <p id="para4170">
           a synthesis of the related evidence; and
          </p>
         </list-item>
         <list-item id="celistitem2560">
          <label>
           •
          </label>
          <p id="para4180">
           guideline recommendation(s) classified according to the strength of the underpinning evidence.
          </p>
         </list-item>
        </list>
       </p>
      </sec>
      <sec id="cesec420">
       <title>
        How frequently are the guidelines reviewed and updated?
       </title>
       <p id="para4190">
        A cardinal feature of evidence-based guidelines is that they are subject to timely review in order that new research evidence and technological advances can be identified, appraised and, if shown to be effective for the prevention of HCAI, incorporated into amended guidelines. The evidence base for these guidelines will be reviewed in 2 years (2015) and the guidelines will be considered for updating approximately 4 years after publication (2017). Following publication the DH will ask the Advisory Group on Antimicrobial Resistance and Healthcare Associated Infection to advise whether the evidence base has progressed significantly to alter the guideline recommendations and warrant an update.
       </p>
      </sec>
      <sec id="cesec430">
       <title>
        How can these guidelines be used to improve your clinical effectiveness?
       </title>
       <p id="para4200">
        In addition to informing the development of detailed local operational protocols, these guidelines can be used as a benchmark for determining appropriate infection prevention decisions and, as part of reflective practice, to assess clinical effectiveness. They also provide a baseline for clinical audit, evaluation and education, and facilitate on-going quality improvements. There are a number of audit tools available locally, nationally and internationally that can be used to audit compliance with guidance including high-impact intervention tools for auditing care bundles.
       </p>
      </sec>
      <sec id="cesec440">
       <title>
        How much will it cost to implement these guidelines?
       </title>
       <p id="para4210">
        Significant additional costs are not anticipated in implementing these guidelines. However, where current equipment or resources do not facilitate the implementation of the guidelines or where staff levels of adherence to current guidance are poor, there may be an associated increase in costs. Given the social and economic costs of HCAI, the consequences associated with not implementing these guidelines would be unacceptable to both patients and healthcare professionals.
       </p>
      </sec>
      <sec id="cesec450">
       <label>
        1.10
       </label>
       <title>
        Guideline Development Methodology
       </title>
       <p id="para4220">
        The guidelines were developed using a systematic review process (
        <xref ref-type="sec" rid="app1">
         Appendix A.1
        </xref>
        ). In each set of guidelines, a summary of the relevant guideline development methodology is provided.
       </p>
       <sec id="cesec460">
        <title>
         Search process
        </title>
        <p id="para4230">
         Electronic databases were searched for national and international guidelines and research studies published during the periods identified for each search question. A two-stage search process was used.
        </p>
       </sec>
       <sec id="cesec470">
        <title>
         Stage 1: Identification of systematic reviews and guidelines
        </title>
        <p id="para4240">
         For each set of epic guidelines, an electronic search was conducted for systematic reviews of randomised controlled trials (RCTs) and current national and international guidelines. International and national guidelines were retrieved and subjected to critical appraisal using the AGREE II Instrument,
         <xref ref-type="bibr" rid="bib3">
          <sup>
           3
          </sup>
         </xref>
         an evaluation method used internationally for assessing the methodological quality of clinical guidelines.
        </p>
        <p id="para4250">
         Following appraisal, accepted guidelines were included as part of the evidence base supporting guideline development and, where appropriate, for delineating search limits. They were also used to verify professional consensus and, in some instances, as the primary source of evidence.
        </p>
       </sec>
       <sec id="cesec480">
        <title>
         Stage 2: Systematic search for additional evidence
        </title>
        <p id="para4260">
         Review questions for the systematic reviews of the literature were developed for each set of epic guideline topics following recommendations from scientific advisors and the Guideline Development Advisory Group.
        </p>
        <p id="para4270">
         Searches were constructed using relevant MeSH (medical subject headings) and free-text terms. The following databases were searched:
         <list id="celist610" list-type="simple">
          <list-item id="celistitem2570">
           <label>
            •
           </label>
           <p id="para4280">
            Medline;
           </p>
          </list-item>
          <list-item id="celistitem2580">
           <label>
            •
           </label>
           <p id="para4290">
            Cumulated Index of Nursing and Allied Health Literature;
           </p>
          </list-item>
          <list-item id="celistitem2590">
           <label>
            •
           </label>
           <p id="para4300">
            Embase;
           </p>
          </list-item>
          <list-item id="celistitem2600">
           <label>
            •
           </label>
           <p id="para4310">
            the Cochrane Library; and
           </p>
          </list-item>
          <list-item id="celistitem2610">
           <label>
            •
           </label>
           <p id="para4320">
            PsycINFO (only searched for hand hygiene).
           </p>
          </list-item>
         </list>
        </p>
       </sec>
       <sec id="cesec490">
        <title>
         Abstract review – identifying studies for appraisal
        </title>
        <p id="para4330">
         Search results were downloaded into a Refworks™ database, and titles and abstracts were printed for review. Titles and abstracts were assessed independently by two reviewers, and studies were retrieved where the title or abstract: addressed one or more of the review questions; identified primary research or systematically conducted secondary research; or indicated a theoretical/clinical/in-use study. Where no abstract was available and the title indicated one or more of the above criteria, the study was retrieved. Due to the limited resources available for this review, foreign language studies were not identified for retrieval.
        </p>
        <p id="para4340">
         Full-text studies were retrieved and read in detail by two experienced reviewers; those meeting the study inclusion criteria were independently quality assessed for inclusion in the systematic review.
        </p>
       </sec>
       <sec id="cesec500">
        <title>
         Quality assessment and data extraction
        </title>
        <p id="para4350">
         Included studies were appraised using tools based on systems developed by the Scottish Intercollegiate Guideline Network (SIGN) for study quality assessment.
         <xref ref-type="bibr" rid="bib4">
          <sup>
           4
          </sup>
         </xref>
         Studies were appraised independently by two reviewers and data were extracted by one experienced reviewer. Any disagreement between reviewers was resolved through discussion. Evidence tables were constructed from the quality assessments, and the studies were summarized in adapted considered judgement forms. The evidence was classified using methods from SIGN, and adapted to include interrupted time series design and controlled before-after studies using criteria developed by the Cochrane Effective Practice and Organisation of Care (EPOC) Group (
         <xref ref-type="table" rid="tbl1">
          Table 1
         </xref>
         ).
         <xref ref-type="bibr" rid="bib4">
          4
         </xref>
         ,
         <xref ref-type="bibr" rid="bib5">
          5
         </xref>
         This system is similar that used in the previous epic guidelines.
         <xref ref-type="bibr" rid="bib2">
          <sup>
           2
          </sup>
         </xref>
         <table-wrap id="tbl1" position="float">
          <label>
           Table 1
          </label>
          <caption>
           <p>
            Levels of evidence for intervention studies
            <xref ref-type="bibr" rid="bib5">
             <sup>
              5
             </sup>
            </xref>
           </p>
          </caption>
          <table frame="hsides" rules="groups">
           <tbody>
            <tr>
             <td align="left">
              1++
             </td>
             <td align="left">
              High-quality meta-analyses, systematic reviews of RCTs or RCTs with a very low risk of bias
             </td>
            </tr>
            <tr>
             <td align="left">
              1+
             </td>
             <td align="left">
              Well-conducted meta-analyses, systematic reviews or RCTs with a low risk of bias
             </td>
            </tr>
            <tr>
             <td align="left">
              1-
             </td>
             <td align="left">
              Meta-analyses, systematic reviews or RCTs with a high risk of bias
              <xref ref-type="table-fn" rid="tbl1fn1">
               *
              </xref>
             </td>
            </tr>
            <tr>
             <td align="left">
              2++
             </td>
             <td align="left">
              <list id="celist10" list-type="simple">
               <list-item id="celistitem10">
                <p id="para10">
                 High-quality systematic reviews of case-control or cohort studies.
                </p>
               </list-item>
               <list-item id="celistitem20">
                <p id="para20">
                 High-quality case-control or cohort studies with a very low risk of confounding or bias and a high probability that the relationship is causal.
                </p>
               </list-item>
               <list-item id="celistitem30">
                <p id="para30">
                 Interrupted time series with a control group: (i) there is a clearly defined point in time when the intervention occurred; and (ii) at least three data points before and three data points after the intervention
                </p>
               </list-item>
              </list>
             </td>
            </tr>
            <tr>
             <td align="left">
              2+
             </td>
             <td align="left">
              <list id="celist20" list-type="simple">
               <list-item id="celistitem40">
                <p id="para40">
                 Well-conducted case-control or cohort studies with a low risk of confounding or bias and a moderate probability that the relationship is causal.
                </p>
               </list-item>
               <list-item id="celistitem50">
                <p id="para50">
                 Controlled before-after studies with two or more intervention and control sites
                </p>
               </list-item>
              </list>
             </td>
            </tr>
            <tr>
             <td align="left">
              2-
             </td>
             <td align="left">
              <list id="celist30" list-type="simple">
               <list-item id="celistitem60">
                <p id="para60">
                 Case-control or cohort studies with a high risk of confounding or bias and a significant risk that the relationship is not causal.
                </p>
               </list-item>
               <list-item id="celistitem70">
                <p id="para70">
                 Interrupted time series without a parallel control group: (i) there is a clearly defined point in time when the intervention occurred; and (ii) at least three data points before and three data points after the intervention.
                </p>
               </list-item>
               <list-item id="celistitem80">
                <p id="para80">
                 Controlled before-after studies with one intervention and one control site
                </p>
               </list-item>
              </list>
             </td>
            </tr>
            <tr>
             <td align="left">
              3
             </td>
             <td align="left">
              Non-analytic studies (e.g. uncontrolled before-after studies, case reports, case series)
             </td>
            </tr>
            <tr>
             <td align="left">
              4
             </td>
             <td align="left">
              Expert opinion. Legislation
             </td>
            </tr>
           </tbody>
          </table>
          <table-wrap-foot>
           <fn>
            <p>
             RCT, randomised controlled trial.
            </p>
           </fn>
          </table-wrap-foot>
          <table-wrap-foot>
           <fn id="tbl1fn1">
            <label>
             *
            </label>
            <p id="cenpara10">
             Studies with an evidence level of ‘1-’ and ‘2-’ should not be used as a basis for making a recommendation.
            </p>
           </fn>
          </table-wrap-foot>
         </table-wrap>
        </p>
        <p id="para4360">
         The evidence tables and considered judgement reports were presented to the Guideline Development Advisory Group for discussion. The guidelines were drafted after extensive discussion.
        </p>
        <p id="para4370">
         Factors influencing the guideline recommendations included:
         <list id="celist620" list-type="simple">
          <list-item id="celistitem2620">
           <label>
            •
           </label>
           <p id="para4380">
            the nature of the evidence;
           </p>
          </list-item>
          <list-item id="celistitem2630">
           <label>
            •
           </label>
           <p id="para4390">
            the applicability of the evidence to practice;
           </p>
          </list-item>
          <list-item id="celistitem2640">
           <label>
            •
           </label>
           <p id="para4400">
            patient preference and acceptability; and
           </p>
          </list-item>
          <list-item id="celistitem2650">
           <label>
            •
           </label>
           <p id="para4410">
            costs and knowledge of healthcare systems.
           </p>
          </list-item>
         </list>
        </p>
        <p id="para4420">
         The classification scheme adopted by SIGN was used to define the strength of recommendation (
         <xref ref-type="table" rid="tbl2">
          Table 2
         </xref>
         ).
         <xref ref-type="bibr" rid="bib4">
          <sup>
           4
          </sup>
         </xref>
         <table-wrap id="tbl2" position="float">
          <label>
           Table 2
          </label>
          <caption>
           <p>
            Classification of recommendations
            <xref ref-type="bibr" rid="bib4">
             <sup>
              4
             </sup>
            </xref>
           </p>
          </caption>
          <table frame="hsides" rules="groups">
           <tbody>
            <tr>
             <td align="left">
              A
             </td>
             <td align="left">
              <list id="celist40" list-type="simple">
               <list-item id="celistitem90">
                <p id="para90">
                 At least one meta-analysis, systematic review or RCT rated as 1++, and directly applicable to the target population; or
                </p>
               </list-item>
               <list-item id="celistitem100">
                <p id="para100">
                 A body of evidence consisting principally of studies rated as 1+, directly applicable to the target population, and demonstrating overall consistency of results
                </p>
               </list-item>
              </list>
             </td>
            </tr>
            <tr>
             <td align="left">
              B
             </td>
             <td align="left">
              <list id="celist50" list-type="simple">
               <list-item id="celistitem110">
                <p id="para110">
                 A body of evidence including studies rated as 2++, directly applicable to the target population, and demonstrating overall consistency of results; or
                </p>
               </list-item>
               <list-item id="celistitem120">
                <p id="para120">
                 Extrapolated evidence from studies rated as 1++ or 1+
                </p>
               </list-item>
              </list>
             </td>
            </tr>
            <tr>
             <td align="left">
              C
             </td>
             <td align="left">
              <list id="celist60" list-type="simple">
               <list-item id="celistitem130">
                <p id="para130">
                 A body of evidence including studies rated as 2+, directly applicable to the target population and demonstrating overall consistency of results; or
                </p>
               </list-item>
               <list-item id="celistitem140">
                <p id="para140">
                 Extrapolated evidence from studies rated as 2++
                </p>
               </list-item>
              </list>
             </td>
            </tr>
            <tr>
             <td align="left">
              D
             </td>
             <td align="left">
              <list id="celist70" list-type="simple">
               <list-item id="celistitem150">
                <p id="para150">
                 Evidence level 3 or 4; or
                </p>
               </list-item>
               <list-item id="celistitem160">
                <p id="para160">
                 Extrapolated evidence from studies rated as 2+
                </p>
               </list-item>
              </list>
             </td>
            </tr>
            <tr>
             <td align="left">
              Good Practice Points IP
             </td>
             <td align="left">
              <list id="celist80" list-type="simple">
               <list-item id="celistitem170">
                <p id="para170">
                 Recommended best practice based on the clinical experience of the Guideline Development Advisory Group and patient preference and experience
                </p>
               </list-item>
               <list-item id="celistitem180">
                <p id="para180">
                 Recommendation from NICE Interventional Procedures guidance
                </p>
               </list-item>
              </list>
             </td>
            </tr>
           </tbody>
          </table>
          <table-wrap-foot>
           <fn>
            <p>
             RCT, randomised controlled trial; NICE, National Institute for Health and Clinical Excellence.
            </p>
           </fn>
          </table-wrap-foot>
         </table-wrap>
        </p>
       </sec>
      </sec>
      <sec id="cesec510">
       <label>
        1.11
       </label>
       <title>
        Consultation Process
       </title>
       <p id="para4430">
        These guidelines have been subject to extensive external consultation with key stakeholders, including Royal Colleges, professional societies and organisations, patients and trade unions (
        <xref ref-type="sec" rid="app2">
         Appendix A.2
        </xref>
        ). Comments were requested on:
        <list id="celist630" list-type="simple">
         <list-item id="celistitem2660">
          <label>
           •
          </label>
          <p id="para4440">
           format;
          </p>
         </list-item>
         <list-item id="celistitem2670">
          <label>
           •
          </label>
          <p id="para4450">
           content;
          </p>
         </list-item>
         <list-item id="celistitem2680">
          <label>
           •
          </label>
          <p id="para4460">
           practice applicability of the guidelines;
          </p>
         </list-item>
         <list-item id="celistitem2690">
          <label>
           •
          </label>
          <p id="para4470">
           patient preference and acceptability; and
          </p>
         </list-item>
         <list-item id="celistitem2700">
          <label>
           •
          </label>
          <p id="para4480">
           specific sections or recommendations.
          </p>
         </list-item>
        </list>
       </p>
       <p id="para4490">
        All the comments were collated and sent to the scientific advisors and the Guideline Development Advisory Group for consideration prior to virtual meetings for discussion and agreement on any changes in the light of comments. Final agreement was sought from the scientific advisors and the Guideline Development Advisory Group following revision.
       </p>
      </sec>
     </sec>
    </sec>
    <sec id="cesec520">
     <label>
      2
     </label>
     <title>
      Standard Principles for Preventing Healthcare-Associated Infections in Hospital and Other Acute Care Settings
     </title>
     <sec id="cesec530">
      <label>
       2.1
      </label>
      <title>
       Introduction
      </title>
      <p id="para4500">
       This guidance is based on the best critically appraised evidence currently available. The type and class of supporting evidence explicitly linked to each recommendation is described. Some recommendations from the previous guidelines have been revised to improve clarity; where a new recommendation has been made, this is indicated in the text. These recommendations are not detailed procedural protocols, and need to be incorporated into local guidelines. None are regarded as optional.
      </p>
      <p id="para4510">
       Standard infection control precautions need to be applied by all healthcare practitioners to the care of all patients (i.e. adults, children and neonates). The recommendations are divided into five distinct interventions:
       <list id="celist640" list-type="simple">
        <list-item id="celistitem2710">
         <label>
          •
         </label>
         <p id="para4520">
          hospital environmental hygiene;
         </p>
        </list-item>
        <list-item id="celistitem2720">
         <label>
          •
         </label>
         <p id="para4530">
          hand hygiene;
         </p>
        </list-item>
        <list-item id="celistitem2730">
         <label>
          •
         </label>
         <p id="para4540">
          use of PPE;
         </p>
        </list-item>
        <list-item id="celistitem2740">
         <label>
          •
         </label>
         <p id="para4550">
          safe use and disposal of sharps; and
         </p>
        </list-item>
        <list-item id="celistitem2750">
         <label>
          •
         </label>
         <p id="para4560">
          principles of asepsis.
         </p>
        </list-item>
       </list>
      </p>
      <p id="para4570">
       These guidelines do not address the additional infection control requirements of specialist settings, such as the operating department or outbreak situations.
      </p>
     </sec>
     <sec id="cesec540">
      <label>
       2.2
      </label>
      <title>
       Hospital Environmental Hygiene
      </title>
      <sec id="cesec550">
       <title>
        Hospital hygiene is important for the prevention of healthcare-associated infections in hospitals
       </title>
       <p id="para4580">
        This section discusses the evidence upon which recommendations for hospital environmental hygiene are based. The evidence identified in the previous systematic review was used as the basis for updating the searches, and searches were conducted for new evidence published since 2006.
        <xref ref-type="bibr" rid="bib2">
         <sup>
          2
         </sup>
        </xref>
        Hospital environmental hygiene encompasses a wide range of routine activities. Guidelines are provided here for:
        <list id="celist650" list-type="simple">
         <list-item id="celistitem2760">
          <label>
           •
          </label>
          <p id="para4590">
           cleaning the general hospital environment;
          </p>
         </list-item>
         <list-item id="celistitem2770">
          <label>
           •
          </label>
          <p id="para4600">
           cleaning items of shared equipment; and
          </p>
         </list-item>
         <list-item id="celistitem2780">
          <label>
           •
          </label>
          <p id="para4610">
           education and training of staff.
          </p>
         </list-item>
        </list>
       </p>
      </sec>
      <sec id="cesec560">
       <title>
        Maintain a clean hospital environment
       </title>
       <p id="para4620">
        Current legislation, regulatory frameworks and quality standards emphasise the importance of the healthcare environment and shared clinical equipment being clean and properly decontaminated to minimise the risk of transmission of HCAI and to maintain public confidence.
        <xref ref-type="bibr" rid="bib6">
         6
        </xref>
        ,
        <xref ref-type="bibr" rid="bib7">
         7
        </xref>
        ,
        <xref ref-type="bibr" rid="bib8">
         8
        </xref>
        ,
        <xref ref-type="bibr" rid="bib9">
         9
        </xref>
        ,
        <xref ref-type="bibr" rid="bib10">
         10
        </xref>
        Patients and their relatives expect the healthcare environment to be clean and infection hazards to be controlled adequately.
        <xref ref-type="bibr" rid="bib9">
         <sup>
          9
         </sup>
        </xref>
       </p>
       <p id="para4630">
        The term ‘cleaning’ is used to describe the physical removal of soil, dirt or dust from surfaces. Conventionally, this is achieved in healthcare settings using cloths and mops. Dust may be removed using dry dust-control mops/cloths. Detergent and water is used for cleaning of soiled or contaminated surfaces, although microfibre cloths and water can also be used for surface cleaning.
        <xref ref-type="bibr" rid="bib9">
         <sup>
          9
         </sup>
        </xref>
       </p>
       <p id="para4640">
        Enhanced cleaning describes the use of methods in addition to standard cleaning specifications. These may include increased cleaning frequency for all or some surfaces, or the use of additional cleaning equipment. Enhanced cleaning may be applied to all areas of the healthcare environment or in specific circumstances, such as cleaning of rooms or bed spaces following the transfer or discharge of patients who are colonised or infected with a pathogenic microorganism. This is sometimes referred to as ‘terminal cleaning’.
       </p>
       <p id="para4650">
        Disinfection is the use of chemical or physical methods to reduce the number of pathogenic microorganisms on surfaces. These methods need to be used in combination with cleaning as they have limited ability to penetrate organic material. The term ‘decontamination’ is used for the process that results in the removal of hazardous substances (e.g. microorganisms, chemicals) and therefore may apply to cleaning or disinfection.
       </p>
       <p id="para4660">
        Research evidence in this field remains largely limited to ecological studies and weak quasi-experimental and observational study designs. There is evidence from outbreak reports and observational research which demonstrates that the hospital environment becomes contaminated with microorganisms responsible for HCAI. Pathogens may be recovered from a variety of surfaces in clinical environments, including those near to the patient that are touched frequently by healthcare workers.
        <xref ref-type="bibr" rid="bib11">
         11
        </xref>
        ,
        <xref ref-type="bibr" rid="bib12">
         12
        </xref>
        ,
        <xref ref-type="bibr" rid="bib13">
         13
        </xref>
        ,
        <xref ref-type="bibr" rid="bib14">
         14
        </xref>
        ,
        <xref ref-type="bibr" rid="bib15">
         15
        </xref>
        ,
        <xref ref-type="bibr" rid="bib16">
         16
        </xref>
        ,
        <xref ref-type="bibr" rid="bib17">
         17
        </xref>
        ,
        <xref ref-type="bibr" rid="bib18">
         18
        </xref>
        ,
        <xref ref-type="bibr" rid="bib19">
         19
        </xref>
        ,
        <xref ref-type="bibr" rid="bib20">
         20
        </xref>
        However, no studies have provided high-quality evidence of direct transmission of the same strain of microorganisms found in the environment to those found in colonised or infected patients.
       </p>
       <p id="para4670">
        We identified one prospective cohort study that found a significant independent association between acquisition of two multi-drug-resistant pathogens and a prior room occupant with the same organism [multi-drug-resistant
        <italic>
         Pseudomonas aeruginosa
        </italic>
        odds ratio (OR) 2.3, 95% confidence interval (CI) 1.2–4.3,
        <italic>
         p
        </italic>
        =0.012; multi-drug-resistant
        <italic>
         Acinetobacter baumanii
        </italic>
        OR 4.2, 95% CI 1.1–1.3,
        <italic>
         p
        </italic>
        =0.04] after adjustment for severity of underlying illness, comorbidities, antimicrobial exposure and some other risk factors.
        <xref ref-type="bibr" rid="bib21">
         <sup>
          21
         </sup>
        </xref>
        A further study reported an association between MRSA and vancomycin-resistant enterococcus (VRE),
        <xref ref-type="bibr" rid="bib22">
         <sup>
          22
         </sup>
        </xref>
        but conclusions that can be drawn from the findings are limited by the retrospective study design and lack of adjustment for severity of underlying illness, colonisation pressure and antibiotic exposure. Similarly, another retrospective cohort study found an association between acquisition of
        <italic>
         C. difficile
        </italic>
        and prior room occupant with the same infection; however, this was based solely on clinical diagnosis rather than active surveillance.
        <xref ref-type="bibr" rid="bib23">
         <sup>
          23
         </sup>
        </xref>
       </p>
       <p id="para4680">
        Many microorganisms recovered from the hospital environment do not cause HCAI. Cleaning will not completely eliminate microorganisms from environmental surfaces, and reductions in their numbers will be transient.
        <xref ref-type="bibr" rid="bib15">
         <sup>
          15
         </sup>
        </xref>
        There is some evidence that enhanced cleaning regimens are associated with the control of outbreaks of HCAI;
        <xref ref-type="bibr" rid="bib24">
         <sup>
          24
         </sup>
        </xref>
        however, these study designs do not provide robust evidence of cause and effect.
       </p>
       <p id="para4690">
        Enhanced cleaning has been recommended, particularly ‘terminal cleaning’, after a bed area has been used by a patient colonised or infected with an HCAI. We searched for robust evidence from studies conducted in the healthcare environment which demonstrated cleaning interventions that were associated with reductions in both environmental contamination and HCAI. A randomised crossover study of daily enhanced cleaning of high-touch surfaces in an intensive care unit (ICU) demonstrated a reduction in the daily number of sites in a bed area contaminated with MRSA (OR 0.59, 95% CI 0.4–0.86,
        <italic>
         p
        </italic>
        =0.006), and the aerobic colony count in communal areas (OR 0.65, 95% CI 0.47–0.92,
        <italic>
         p
        </italic>
        =0.013). Although the reduction in MRSA in the environment was associated with a large reduction in MRSA contaminating doctors' hands (OR 0.26, 95% CI 0.07–0.95,
        <italic>
         p
        </italic>
        =0.025), there was no effect on the incidence of MRSA acquisition by patients (OR 0.98, 95% CI 0.58–1.65,
        <italic>
         p
        </italic>
        =0.93).
        <xref ref-type="bibr" rid="bib25">
         <sup>
          25
         </sup>
        </xref>
       </p>
       <p id="para4700">
        Disinfectants have been recommended for cleaning the hospital environment;
        <xref ref-type="bibr" rid="bib1">
         1
        </xref>
        ,
        <xref ref-type="bibr" rid="bib2">
         2
        </xref>
        however, a systematic review failed to confirm a link between disinfection and the prevention of HCAI, although contamination of detergent and inadequate disinfection strength could have been an important confounder.
        <xref ref-type="bibr" rid="bib26">
         <sup>
          26
         </sup>
        </xref>
        Whilst subsequent studies may have demonstrated a link between disinfection and reduced environmental contamination, and sometimes the acquisition of HCAI, the study designs are weak with no control groups or randomisation of intervention, and/or the introduction of multiple interventions at the same time. This makes it difficult to draw definitive conclusions about the specific effect of disinfection or cleaning.
       </p>
      </sec>
      <sec id="cesec570">
       <title>
        Emerging technology
       </title>
       <p id="para4710">
        New technologies for cleaning and decontaminating the healthcare environment have become available over the past 10 years, including hydrogen peroxide, and others are in the early stages of development. Whilst hydrogen peroxide has been used for decontamination of selected rooms in a US hospital following use by patients with a multi-drug-resistant organism or
        <italic>
         C. difficile
        </italic>
        , this study found that it was not possible to use hydrogen peroxide routinely for this purpose.
        <xref ref-type="bibr" rid="bib27">
         <sup>
          27
         </sup>
        </xref>
        The effectiveness, cost-effectiveness and practicality of this and other new technologies in terms of reducing HCAI and routine use in the variety of facilities in UK hospitals has yet to be demonstrated.
       </p>
       <p id="para4720">
        We identified three studies conducted in patient care environments that provided evidence for the effectiveness of different products, containing chemical or other disinfection agents, on environmental contamination but not reductions in HCAI. A prospective randomised crossover study provided evidence for the effectiveness of daily cleaning of high-touch surfaces with microfibre/copper-impregnated cloths on the reduction of MRSA, as discussed above.
        <xref ref-type="bibr" rid="bib25">
         <sup>
          25
         </sup>
        </xref>
        An RCT demonstrated the efficacy of daily high-touch surface cleaning with peracetic acid on MRSA and
        <italic>
         C. difficile
        </italic>
        contamination of the environment, with a significant reduction in MRSA and
        <italic>
         C. difficile
        </italic>
        isolated from samples taken from surfaces with gloved hands (
        <italic>
         p
        </italic>
        &lt;0.001) and the hands of healthcare workers (3/27 in peractic acid group vs 15/38 in standard cleaning group,
        <italic>
         p
        </italic>
        =0.13).
        <xref ref-type="bibr" rid="bib28">
         <sup>
          28
         </sup>
        </xref>
        A non-randomised controlled trial (NRCT) in two wards at a single hospital provided evidence that an additional cleaner was associated with a 32.5% reduction in environmental microbial contamination of hand-touch sites (95% CI 20.2–42.9,
        <italic>
         p
        </italic>
        &lt;0.0001) and 26.6% reduction in acquisition of MRSA infection (95% CI 7.7–92.3,
        <italic>
         p
        </italic>
        =0.032), although the infection types were not specified.
        <xref ref-type="bibr" rid="bib29">
         <sup>
          29
         </sup>
        </xref>
       </p>
       <p id="para4730">
        Hydrogen peroxide has been used as a method of decontamination of the environment in situations where wards/beds can be closed or left unused for the required period of time
        <xref ref-type="bibr" rid="bib30">
         30
        </xref>
        ,
        <xref ref-type="bibr" rid="bib31">
         31
        </xref>
        ,
        <xref ref-type="bibr" rid="bib32">
         32
        </xref>
        We identified a prospective, randomised before-after study that compared the efficacy of hypochlorite and a hydrogen peroxide decontamination system for terminal cleaning of rooms used by a patient with
        <italic>
         C. difficile
        </italic>
        infection in reducing environmental contamination with
        <italic>
         C. difficile.
        </italic>
        Although both methods reduced environmental contamination significantly compared with cleaning alone, hydrogen peroxide achieved a significantly greater reduction (91% vs 30% decrease in proportion of samples with
        <italic>
         C. difficile, p
        </italic>
        &lt;0.005).
        <xref ref-type="bibr" rid="bib33">
         <sup>
          33
         </sup>
        </xref>
        A prospective cohort study provided evidence for the efficacy of hydrogen peroxide when used for terminal decontamination after standard cleaning in significantly reducing the acquisition of multi-drug-resistant organisms in patients subsequently admitted to the rooms (adjusted incidence rate ratio 0.36, 95% CI 0.19–0.7). However, the effect was mainly driven by reduction in acquisition of VRE, and the results could have been confounded by the concurrent implementation of chlorhexidine baths, incomplete surveillance data and non-random assignment of rooms to the intervention.
        <xref ref-type="bibr" rid="bib34">
         <sup>
          34
         </sup>
        </xref>
       </p>
       <p id="para4740">
        The efficacy of antimicrobial surfaces in the clinical environment in reducing surface contamination and HCAI is an area of emerging research. Four non-randomised, experimental studies, conducted in clinical environments, demonstrated significant reductions in microbial burden of between 80% and 90% on high-touch surfaces coated with metallic copper and/or its alloys compared with similar non-copper surfaces.
        <xref ref-type="bibr" rid="bib35">
         35
        </xref>
        ,
        <xref ref-type="bibr" rid="bib36">
         36
        </xref>
        ,
        <xref ref-type="bibr" rid="bib37">
         37
        </xref>
        ,
        <xref ref-type="bibr" rid="bib38">
         38
        </xref>
        One RCT conducted in three ICUs reported a significantly lower acquisition of HCAI in patients allocated to rooms with six high-touch copper-coated surfaces (3.4% vs 8.1%,
        <italic>
         p
        </italic>
        =0.013). A multi-variate analysis suggested that both severity of underlying illness and room assignment were independently associated with the acquisition of HCAI or colonisation. However, these findings may have been biased by poor discrimination of patients colonised on admission because of limited surveillance cultures, poor agreement in defining cases of HCAI, and incomplete adjustment for confounders in the multi-variate analysis.
        <xref ref-type="bibr" rid="bib39">
         <sup>
          39
         </sup>
        </xref>
        Evidence of the effectiveness and cost-effectiveness of these technologies and their contribution to reductions in HCAI is therefore not currently available.
       </p>
      </sec>
      <sec id="cesec580">
       <title>
        Assessing environmental cleanliness
       </title>
       <p id="para4750">
        Indicators of cleanliness based on levels of microbial or adenosine triphosphate (ATP) contamination have been recommended; however, relationships between ATP and aerobic colony counts are not consistent, and neither method distinguishes normal environmental flora and pathogens responsible for HCAI.
        <xref ref-type="bibr" rid="bib40">
         40
        </xref>
        ,
        <xref ref-type="bibr" rid="bib41">
         41
        </xref>
        Benchmark values of between 250 and 500 relative light units have been proposed as a more objective measure of assessing the efficacy of cleaning than visual assessment, although these are based on arbitrary standards of acceptable contamination that have not been shown to be associated with reductions in HCAI.
        <xref ref-type="bibr" rid="bib42">
         42
        </xref>
        ,
        <xref ref-type="bibr" rid="bib43">
         43
        </xref>
        ,
        <xref ref-type="bibr" rid="bib44">
         44
        </xref>
        We identified a number of uncontrolled before-after studies that used ATP in various forms to highlight the extent of contamination of the healthcare environment. In addition, some studies described the use of ATP monitoring as an intervention to improve cleaning, but the lack of a control group in the study design precluded their inclusion in this review. As cleaning will only have a transient effect on the numbers of microorganisms, regular cleaning or disinfection of hospital surfaces will not guarantee a pathogen-free environment. Preventing the transfer of pathogens from the environment to patients therefore still depends on ensuring that hands are decontaminated prior to patient contact.
       </p>
       <p id="para4760">
        <list id="celist660" list-type="simple">
         <list-item id="celistitem2790">
          <label>
           SP1
          </label>
          <p id="para4770">
           The hospital environment must be visibly clean; free from non-essential items and equipment, dust and dirt; and acceptable to patients, visitors and staff.
          </p>
          <p id="para4780">
           <italic>
            Class D/GPP
           </italic>
          </p>
         </list-item>
         <list-item id="celistitem2800">
          <label>
           SP2
          </label>
          <p id="para4790">
           Levels of cleaning should be increased in cases of infection and/or colonisation when a suspected or known pathogen can survive in the environment, and environmental contamination may contribute to the spread of infection.
          </p>
          <p id="para4800">
           <italic>
            Class D/GPP
           </italic>
          </p>
         </list-item>
         <list-item id="celistitem2810">
          <label>
           SP3
          </label>
          <p id="para4810">
           The use of disinfectants should be considered for cases of infection and/or colonisation when a suspected or known pathogen can survive in the environment, and environmental contamination may contribute to the spread of infection.
          </p>
          <p id="para4820">
           <italic>
            Class D/GPP
           </italic>
          </p>
         </list-item>
        </list>
       </p>
      </sec>
      <sec id="cesec590">
       <title>
        Decontamination of equipment
       </title>
       <p id="para4830">
        Shared clinical equipment used to deliver care in the clinical environment comes into contact with intact skin and is therefore unlikely to introduce infection directly. However, it can act as a vehicle by which microorganisms are transferred between patients, which may subsequently result in infection. Equipment should therefore be cleaned and decontaminated after each use with cleaning agents compatible with the piece of equipment being cleaned. In some outbreak situations, the use of chlorine-releasing agents and detergent should be considered.
        <xref ref-type="bibr" rid="bib6">
         6
        </xref>
        ,
        <xref ref-type="bibr" rid="bib7">
         7
        </xref>
        ,
        <xref ref-type="bibr" rid="bib8">
         8
        </xref>
        ,
        <xref ref-type="bibr" rid="bib9">
         9
        </xref>
       </p>
       <p id="para4840">
        <list id="celist670" list-type="simple">
         <list-item id="celistitem2820">
          <label>
           SP4
          </label>
          <p id="para4850">
           Shared pieces of equipment used in the delivery of patient care must be cleaned and decontaminated after each use with products recommended by the manufacturer.
          </p>
          <p id="para4860">
           <italic>
            Class D/GPP
           </italic>
          </p>
         </list-item>
        </list>
       </p>
      </sec>
      <sec id="cesec600">
       <title>
        Healthcare workers' role in maintaining a clean environment
       </title>
       <p id="para4870">
        In a systematic review of healthcare workers' knowledge about MRSA and/or frequency of cleaning practices, three studies indicated that staff were not using appropriate cleaning practices with sufficient frequency to ensure minimisation of MRSA contamination of personal equipment.
        <xref ref-type="bibr" rid="bib13">
         <sup>
          13
         </sup>
        </xref>
        Staff education was lacking on optimal cleaning practices in the clinical areas. The finding of the review is reinforced by a later observational study, which noted that lapses in adherence to the cleaning protocol were linked with an increase in environmental contamination with isolates of
        <italic>
         A. baumannii.
        </italic>
        <xref ref-type="bibr" rid="bib15">
         <sup>
          15
         </sup>
        </xref>
        A second systematic review of four cohort studies that compared the use of detergents and disinfectants on microbial-contaminated hospital environmental surfaces suggested that a lack of effectiveness was, in many instances, due to inadequate strengths of disinfectants, probably resulting from a lack of knowledge.
        <xref ref-type="bibr" rid="bib26">
         <sup>
          26
         </sup>
        </xref>
       </p>
       <p id="para4880">
        We identified no new, robust research studies of education or system interventions for this review. However, creating a culture of responsibility for maintaining a clean environment and increasing knowledge about how to decontaminate equipment and high-touch surfaces effectively requires education and training of both healthcare cleaning professionals and clinical staff.
       </p>
       <p id="para4890">
        <list id="celist680" list-type="simple">
         <list-item id="celistitem2830">
          <label>
           SP5
          </label>
          <p id="para4900">
           All healthcare workers need to be educated about the importance of maintaining a clean and safe care environment for patients. Every healthcare worker needs to know their specific responsibilities for cleaning and decontaminating the clinical environment and the equipment used in patient care.
          </p>
          <p id="para4910">
           <italic>
            Class D/GPP
           </italic>
          </p>
         </list-item>
        </list>
       </p>
      </sec>
      <sec id="cesec610">
       <title>
        Hospital Hygiene – Systematic Review Process
       </title>
       <p id="para4920">
        <boxed-text id="cetextbox10">
         <sec id="cesec620">
          <title>
           <inline-graphic xlink:href="fx2_lrg.gif">
           </inline-graphic>
           Systematic Review Questions
          </title>
          <p id="para4930">
           <list id="celist690" list-type="simple">
            <list-item id="celistitem2840">
             <label>
              1.
             </label>
             <p id="para4940">
              What is the evidence that the patient environment (including clinical equipment) is a significant factor in the transmission of HCAI?
             </p>
            </list-item>
            <list-item id="celistitem2850">
             <label>
              2.
             </label>
             <p id="para4950">
              What is the effectiveness and cost-effectiveness of conventional cleaning vs enhanced cleaning of the patient bed space in reducing environmental contamination and HCAI?
             </p>
            </list-item>
            <list-item id="celistitem2860">
             <label>
              3.
             </label>
             <p id="para4960">
              What is the effectiveness and cost-effectiveness of antimicrobial surfaces (e.g. silver, copper) in the patient environment in reducing environmental contamination and HCAI?
             </p>
            </list-item>
            <list-item id="celistitem2870">
             <label>
              4.
             </label>
             <p id="para4970">
              What is the effectiveness of education interventions in improving healthcare workers' knowledge and behaviour in maintaining a clean patient environment (including clinical equipment) and in reducing environmental contamination and HCAI?
             </p>
            </list-item>
            <list-item id="celistitem2880">
             <label>
              5.
             </label>
             <p id="para4980">
              What is the effectiveness of system interventions in driving improvements in hospital environmental hygiene and in reducing environmental contamination and HCAI?
             </p>
            </list-item>
           </list>
          </p>
         </sec>
        </boxed-text>
       </p>
       <p id="para4990">
        <boxed-text id="cetextbox20">
         <sec id="cesec630">
          <title>
           <inline-graphic xlink:href="fx2_lrg.gif">
           </inline-graphic>
           Databases and Search Terms Used
          </title>
          <sec id="cesec640">
           <title>
            Databases
           </title>
           <p id="para5000">
            Medline, Cumulative Index to Nursing and Allied Health Literature (CINAHL), Embase, NEHL Guideline Finder, National Institute for Health and Clinical Excellence, the Cochrane Library (CDSR, CCRCT, CMR), US Guideline Clearing House, DARE (NHS Evidence, HTA), Prospero
           </p>
          </sec>
          <sec id="cesec650">
           <title>
            MeSH Terms
           </title>
           <p id="para5010">
            Infection control; cross infection; equipment contamination; disease transmission; disinfection; disinfectants; soaps; anti-infective agents; surface-active agents; hospital housekeeping; hydrogen peroxide; silver
           </p>
          </sec>
          <sec id="cesec660">
           <title>
            Thesaurus and Free-Text Terms
           </title>
           <p id="para5020">
            Hospital hygiene; hospital housekeeper; blood spill; blood exposure; blood splash
           </p>
          </sec>
          <sec id="cesec670">
           <title>
            Search Date
           </title>
           <p id="para5030">
            Jan 2005-Nov 2012
           </p>
          </sec>
         </sec>
        </boxed-text>
       </p>
       <p id="para5040">
        <boxed-text id="cetextbox30">
         <sec id="cesec680">
          <title>
           <inline-graphic xlink:href="fx2_lrg.gif">
           </inline-graphic>
           Search Results
          </title>
          <p id="para5050">
           Total number of articles located = 5944
          </p>
         </sec>
        </boxed-text>
       </p>
       <p id="para5060">
        <boxed-text id="cetextbox40">
         <sec id="cesec690">
          <title>
           <inline-graphic xlink:href="fx2_lrg.gif">
           </inline-graphic>
           Sift 1 Criteria
          </title>
          <p id="para5070">
           <bold>
            Abstract indicates
           </bold>
           that the article: relates to infections associated with hospital hygiene; is written in English; is primary research, a systematic review or a meta-analysis; and appears to inform one or more of the review questions.
          </p>
         </sec>
        </boxed-text>
       </p>
       <p id="para5080">
        <boxed-text id="cetextbox50">
         <sec id="cesec700">
          <title>
           <inline-graphic xlink:href="fx2_lrg.gif">
           </inline-graphic>
           Articles Retrieved
          </title>
          <p id="para5090">
           <bold>
            Total number of articles retrieved from Sift 1 = 164
           </bold>
          </p>
         </sec>
        </boxed-text>
       </p>
       <p id="para5100">
        <boxed-text id="cetextbox60">
         <sec id="cesec710">
          <title>
           <inline-graphic xlink:href="fx2_lrg.gif">
           </inline-graphic>
           Sift 2 Criteria
          </title>
          <p id="para5110">
           <bold>
            Full text confirms
           </bold>
           that the article: relates to infections associated with hospital hygiene; is written in English; is primary research (randomised controlled trials, prospective cohort, interrupted time series, controlled before-after, quasi-experimental, experimental studies answering specific questions), a systematic review or a meta-analysis including the above designs; and informs one or more of the review questions.
          </p>
         </sec>
        </boxed-text>
       </p>
       <p id="para5120">
        <boxed-text id="cetextbox70">
         <sec id="cesec720">
          <title>
           <inline-graphic xlink:href="fx2_lrg.gif">
           </inline-graphic>
           Articles Selected for Appraisal
          </title>
          <p id="para5130">
           <bold>
            Total number of studies selected for appraisal during Sift 2 = 26
           </bold>
          </p>
         </sec>
        </boxed-text>
       </p>
       <p id="para5140">
        <boxed-text id="cetextbox80">
         <sec id="cesec730">
          <title>
           <inline-graphic xlink:href="fx2_lrg.gif">
           </inline-graphic>
           Critical Appraisal
          </title>
          <p id="para5150">
           All articles that described primary research, a systematic review or a meta-analysis and met the Sift 2 criteria were independently critically appraised by two appraisers using SIGN and EPOC criteria. Consensus and grading was achieved through discussion.
          </p>
         </sec>
        </boxed-text>
       </p>
       <p id="para5160">
        <boxed-text id="cetextbox90">
         <sec id="cesec740">
          <title>
           <inline-graphic xlink:href="fx2_lrg.gif">
           </inline-graphic>
           Accepted and Rejected Evidence
          </title>
          <p id="para5170">
           <bold>
            Total number of studies accepted after critical appraisal = 12
           </bold>
          </p>
          <p id="para5180">
           <bold>
            Total number of studies rejected after critical appraisal = 14
           </bold>
          </p>
         </sec>
        </boxed-text>
       </p>
      </sec>
     </sec>
     <sec id="cesec750">
      <label>
       2.3
      </label>
      <title>
       Hand Hygiene
      </title>
      <p id="para5190">
       This section discusses the evidence for recommendations concerning hand hygiene practice. Designing and conducting robust, ethical RCTs in the field of hand hygiene is challenging, meaning that recommendations are based on evidence from NRCTs, quasi-experimental studies, observational studies and laboratory studies with volunteers. In addition, expert opinion derived from systematically retrieved and appraised professional, national and international guidelines is used. The areas discussed in this section include:
       <list id="celist700" list-type="simple">
        <list-item id="celistitem2890">
         <label>
          •
         </label>
         <p id="para5200">
          assessment of the need to decontaminate hands;
         </p>
        </list-item>
        <list-item id="celistitem2900">
         <label>
          •
         </label>
         <p id="para5210">
          efficacy of hand decontamination agents and preparations;
         </p>
        </list-item>
        <list-item id="celistitem2910">
         <label>
          •
         </label>
         <p id="para5220">
          rationale for choice of hand decontamination practice;
         </p>
        </list-item>
        <list-item id="celistitem2920">
         <label>
          •
         </label>
         <p id="para5230">
          technique for hand decontamination;
         </p>
        </list-item>
        <list-item id="celistitem2930">
         <label>
          •
         </label>
         <p id="para5240">
          care required to protect hands from the adverse effects of hand decontamination practice;
         </p>
        </list-item>
        <list-item id="celistitem2940">
         <label>
          •
         </label>
         <p id="para5250">
          promoting adherence to hand hygiene guidelines; and
         </p>
        </list-item>
        <list-item id="celistitem2950">
         <label>
          •
         </label>
         <p id="para5260">
          involving patients and carers in hand hygiene.
         </p>
        </list-item>
       </list>
      </p>
      <sec id="cesec760">
       <title>
        Why is hand decontamination crucial to the prevention of healthcare-associated infection?
       </title>
       <p id="para5270">
        The transfer of organisms between humans can occur directly via hands, or indirectly via an environmental source (e.g. commode or wash basin). Epidemiological evidence indicates that hand-mediated transmission is a major contributing factor in the acquisition and spread of infection in hospitals.
        <xref ref-type="bibr" rid="bib1">
         1
        </xref>
        ,
        <xref ref-type="bibr" rid="bib2">
         2
        </xref>
        ,
        <xref ref-type="bibr" rid="bib45">
         45
        </xref>
       </p>
       <p id="para5280">
        The hands are colonised by two categories of microbial flora. The resident flora are found on the surface, just below the uppermost layer of skin, are adapted to survive in the local conditions and are generally of low pathogenicity, although some, such as
        <italic>
         Stapylococcus epidermidis,
        </italic>
        may cause infection if transferred on to a susceptible site such as an invasive device. The transient flora are made up of microorganisms acquired by touching contaminated surfaces such as the environment, patients or other people, and are readily transferred to the next person or object touched. They may include a range of antimicrobial-resistant pathogens such as MRSA,
        <italic>
         Acinetobacter
        </italic>
        or other multi-resistant Gram-negative bacteria.
        <xref ref-type="bibr" rid="bib1">
         <sup>
          1
         </sup>
        </xref>
        If transferred into susceptible sites such as invasive devices or wounds, these microorganisms can cause life-threatening infections. Transmission to non-vulnerable sites may leave a patient colonised with pathogenic and antibiotic-resistant organisms, which may result in an HCAI at some point in the future.
       </p>
       <p id="para5290">
        Outbreak reports and observational studies of the dynamics of bacterial hand contamination have demonstrated an association between patient care activities that involve direct patient contact and hand contamination.
        <xref ref-type="bibr" rid="bib2">
         2
        </xref>
        ,
        <xref ref-type="bibr" rid="bib45">
         45
        </xref>
        ,
        <xref ref-type="bibr" rid="bib46">
         46
        </xref>
        ,
        <xref ref-type="bibr" rid="bib47">
         47
        </xref>
        ,
        <xref ref-type="bibr" rid="bib48">
         48
        </xref>
        The association between hand decontamination, using liquid soap and water and waterless alcohol-base hand rub (ABHR), and reductions in infection have been confirmed by clinically-based non-randomised trials
        <xref ref-type="bibr" rid="bib49">
         49
        </xref>
        ,
        <xref ref-type="bibr" rid="bib50">
         50
        </xref>
        and observational studies.
        <xref ref-type="bibr" rid="bib51">
         51
        </xref>
        ,
        <xref ref-type="bibr" rid="bib52">
         52
        </xref>
       </p>
       <p id="para5300">
        Current national and international guidance has consistently identified that effective hand decontamination results in significant reductions in the carriage of potential pathogens on the hands, and therefore it is logical that the incidence of preventable HCAI is decreased, leading to a reduction in patient morbidity and mortality.
        <xref ref-type="bibr" rid="bib2">
         2
        </xref>
        ,
        <xref ref-type="bibr" rid="bib45">
         45
        </xref>
        ,
        <xref ref-type="bibr" rid="bib53">
         53
        </xref>
       </p>
      </sec>
      <sec id="cesec770">
       <title>
        When must you decontaminate your hands in relation to patient care?
       </title>
       <p id="para5310">
        Patients are put at risk of developing an HCAI when informal carers or healthcare workers caring for them have contaminated hands. Decontamination refers to a process for the physical removal of dirt, blood and body fluids, and the removal or destruction of microorganisms from the hands.
        <xref ref-type="bibr" rid="bib45">
         <sup>
          45
         </sup>
        </xref>
        The World Health Organization's (WHO) ‘Five Moments for Hand Hygiene’
        <xref ref-type="bibr" rid="bib53">
         <sup>
          53
         </sup>
        </xref>
        provides a framework for training healthcare workers, audit and feedback of hand hygiene practice, and has been adopted without modification in many countries and adapted in others (e.g. Canada).
        <xref ref-type="bibr" rid="bib54">
         <sup>
          54
         </sup>
        </xref>
       </p>
       <p id="para5320">
        Hands must be decontaminated at critical points before, during and after patient care activity to prevent cross-transmission of microorganisms.
        <xref ref-type="bibr" rid="bib1">
         1
        </xref>
        ,
        <xref ref-type="bibr" rid="bib2">
         2
        </xref>
        ,
        <xref ref-type="bibr" rid="bib45">
         45
        </xref>
        ,
        <xref ref-type="bibr" rid="bib55">
         55
        </xref>
        Evidence considered by the National Institute for Health and Clinical Excellence (NICE)
        <xref ref-type="bibr" rid="bib56">
         <sup>
          56
         </sup>
        </xref>
        indicated increases in hand decontamination compliance before and after patient contact associated with implementation of the WHO ‘Five Moments’ and US Centers for Disease Control and Prevention 2002 guidelines, but no difference in compliance after contact with patient surroundings. The following recommendations are derived from the WHO framework and NICE guidelines,
        <xref ref-type="bibr" rid="bib56">
         <sup>
          56
         </sup>
        </xref>
        and include additional points of emphasis.
       </p>
       <p id="para5330">
        <list id="celist710" list-type="simple">
         <list-item id="celistitem2960">
          <label>
           SP6
          </label>
          <p id="para5340">
           Hands must be decontaminated:
           <list id="celist720" list-type="simple">
            <list-item id="celistitem2970">
             <label>
              •
             </label>
             <p id="para5350">
              immediately before each episode of direct patient contact or care, including clean/aseptic procedures;
             </p>
            </list-item>
            <list-item id="celistitem2980">
             <label>
              •
             </label>
             <p id="para5360">
              immediately after each episode of direct patient contact or care;
             </p>
            </list-item>
            <list-item id="celistitem2990">
             <label>
              •
             </label>
             <p id="para5370">
              immediately after contact with body fluids, mucous membranes and non-intact skin;
             </p>
            </list-item>
            <list-item id="celistitem3000">
             <label>
              •
             </label>
             <p id="para5380">
              immediately after other activities or contact with objects and equipment in the immediate patient environment that may result in the hands becoming contaminated; and
             </p>
            </list-item>
            <list-item id="celistitem3010">
             <label>
              •
             </label>
             <p id="para5390">
              immediately after the removal of gloves.
             </p>
            </list-item>
           </list>
          </p>
          <p id="para5400">
           <italic>
            Class C
           </italic>
          </p>
         </list-item>
        </list>
       </p>
      </sec>
      <sec id="cesec780">
       <title>
        Is any one hand-cleaning preparation better than another?
       </title>
       <p id="para5410">
        Current national and international guidelines
        <xref ref-type="bibr" rid="bib2">
         2
        </xref>
        ,
        <xref ref-type="bibr" rid="bib45">
         45
        </xref>
        ,
        <xref ref-type="bibr" rid="bib53">
         53
        </xref>
        consider the efficacy of various preparations for the decontamination of hands using liquid soap and water, antiseptic handwash agents and ABHR in laboratory studies and their effectiveness in clinical use. Overall, there is no compelling evidence to favour the general use of antiseptic handwashing agents over liquid soap or one antiseptic agent over another.
        <xref ref-type="bibr" rid="bib2">
         2
        </xref>
        ,
        <xref ref-type="bibr" rid="bib45">
         45
        </xref>
        ,
        <xref ref-type="bibr" rid="bib53">
         53
        </xref>
        ,
        <xref ref-type="bibr" rid="bib57">
         57
        </xref>
        All hand hygiene products for use in clinical care must comply with current British Standards.
        <xref ref-type="bibr" rid="bib58">
         <sup>
          58
         </sup>
        </xref>
       </p>
       <p id="para5420">
        Many studies have been conducted during the past 15 years to compare hand hygiene preparations, including ABHR and gels, antiseptic handwash and liquid soap.
        <xref ref-type="bibr" rid="bib45">
         <sup>
          45
         </sup>
        </xref>
        RCTs and other quasi-experimental studies have generally demonstrated alcohol-based preparations to be more effective hand hygiene agents than non-medicated soap and antiseptic handwashing agents, although a small number of studies reported no statistically significant difference.
        <xref ref-type="bibr" rid="bib59">
         59
        </xref>
        ,
        <xref ref-type="bibr" rid="bib60">
         60
        </xref>
        ,
        <xref ref-type="bibr" rid="bib61">
         61
        </xref>
        ,
        <xref ref-type="bibr" rid="bib62">
         62
        </xref>
        ,
        <xref ref-type="bibr" rid="bib63">
         63
        </xref>
        ,
        <xref ref-type="bibr" rid="bib64">
         64
        </xref>
        ,
        <xref ref-type="bibr" rid="bib65">
         65
        </xref>
        ,
        <xref ref-type="bibr" rid="bib66">
         66
        </xref>
        ,
        <xref ref-type="bibr" rid="bib67">
         67
        </xref>
        ,
        <xref ref-type="bibr" rid="bib68">
         68
        </xref>
        ,
        <xref ref-type="bibr" rid="bib69">
         69
        </xref>
        ,
        <xref ref-type="bibr" rid="bib70">
         70
        </xref>
        ,
        <xref ref-type="bibr" rid="bib71">
         71
        </xref>
        ,
        <xref ref-type="bibr" rid="bib72">
         72
        </xref>
        ,
        <xref ref-type="bibr" rid="bib73">
         73
        </xref>
        ,
        <xref ref-type="bibr" rid="bib74">
         74
        </xref>
        ,
        <xref ref-type="bibr" rid="bib75">
         75
        </xref>
        ,
        <xref ref-type="bibr" rid="bib76">
         76
        </xref>
        Many of these studies involved the use of ABHR as part of a number of interventions, or multi-modal campaigns, to improve hand hygiene practice, and had methodological flaws that weaken the causal relationship between the introduction of ABHR and reductions in HCAI.
        <xref ref-type="bibr" rid="bib77">
         <sup>
          77
         </sup>
        </xref>
       </p>
       <p id="para5430">
        We identified one multi-variate, interrupted time series which suggested that the amount of ABHR used per patient-day was the only factor associated with a reduction in MRSA incidence density (
        <italic>
         p
        </italic>
        =0.011) in a neonatal ICU in Japan.
        <xref ref-type="bibr" rid="bib78">
         <sup>
          78
         </sup>
        </xref>
        Incidence density fell over a 4-year period from an average of 15 per 1000 patient-days, with a peak of 20 per 1000 patient-days in August 2006, to 0 per 1000 patient-days in October 2008 and was sustained to July 2009 (average incidence density 7.5 per 1000 patient-days). The supporting evidence from laboratory studies of the efficacy of ABHR indicates that these products are highly effective at reducing hand carriage, whilst overcoming some of the recognised barriers to handwashing; most importantly, the ease of use at the point of patient care.
       </p>
       <p id="para5440">
        These studies underpin a continuing trend to adopt ABHR for routine use in clinical practice. However, some studies highlight the need for continued evaluation of the use of ABHR within the clinical environment to ensure staff adherence to guidelines and effective hand decontamination technique.
        <xref ref-type="bibr" rid="bib75">
         75
        </xref>
        ,
        <xref ref-type="bibr" rid="bib76">
         76
        </xref>
       </p>
      </sec>
      <sec id="cesec790">
       <title>
        Choice of decontamination: is it always necessary to wash hands to achieve decontamination?
       </title>
       <p id="para5450">
        Choosing the method of hand decontamination will depend upon the assessment of what is appropriate for the episode of care, the availability of resources at or near the point of care, what is practically possible and, to some degree, personal preferences based on the acceptability of preparations or materials.
       </p>
       <p id="para5460">
        In general, effective handwashing with liquid soap and water or the effective use of ABHR will remove transient microorganisms and render the hands socially clean. The effective use of ABHR will also substantially reduce resident microorganisms. This level of decontamination is sufficient for general social contact and most clinical care activities.
        <xref ref-type="bibr" rid="bib2">
         2
        </xref>
        ,
        <xref ref-type="bibr" rid="bib45">
         45
        </xref>
        ,
        <xref ref-type="bibr" rid="bib53">
         53
        </xref>
        Liquid soap preparations that contain an antiseptic affect both transient microorganisms and resident flora, and some exert a residual effect. The use of preparations containing an antiseptic is required in situations where prolonged reduction in microbial flora on the skin is necessary (e.g. surgery, some invasive procedures or in outbreak situations).
        <xref ref-type="bibr" rid="bib2">
         2
        </xref>
        ,
        <xref ref-type="bibr" rid="bib45">
         45
        </xref>
        ,
        <xref ref-type="bibr" rid="bib53">
         53
        </xref>
       </p>
       <p id="para5470">
        ABHR is not effective against all microorganisms (e.g. some viruses such as Norovirus and spore-forming microorganisms such as
        <italic>
         C. difficile
        </italic>
        ). It will not remove dirt and organic material, and may not be effective in some outbreak situations.
        <xref ref-type="bibr" rid="bib52">
         52
        </xref>
        ,
        <xref ref-type="bibr" rid="bib79">
         79
        </xref>
       </p>
       <p id="para5480">
        We identified two laboratory studies which demonstrated that ABHR was not effective in removing
        <italic>
         C. difficile
        </italic>
        spores from hands.
        <xref ref-type="bibr" rid="bib80">
         80
        </xref>
        ,
        <xref ref-type="bibr" rid="bib81">
         81
        </xref>
        In the first study, a comparison of liquid soap and water, chlorhexidine gluconate (CHG) soap and water, antiseptic hand wipes and ABHR resulted in all the soap and water protocols yielding greater mean colony-forming unit (cfu) reductions, followed by the antiseptic hand wipes, than ABHR. ABHR was equivalent to no intervention (0.06 log
        <sub>
         10
        </sub>
        cfu/mL, 95% CI −0.34 to 0.45 log
        <sub>
         10
        </sub>
        cfu/mL).
        <xref ref-type="bibr" rid="bib80">
         <sup>
          80
         </sup>
        </xref>
        In the second study, three ABHR preparations with a minimum 60% alcohol concentration were compared with antiseptic (CHG) soap and water. Antiseptic soap and water reduced spore counts significantly compared with each of the ABHRs (CHG vs Isagel,
        <italic>
         p
        </italic>
        =0.005; CHG vs Endure,
        <italic>
         p
        </italic>
        =0.010; CHG vs Purell,
        <italic>
         p
        </italic>
        =0.005). In addition, 30% of the residual spores were readily transferred by handshake following the use of ABHR.
        <xref ref-type="bibr" rid="bib81">
         <sup>
          81
         </sup>
        </xref>
        Recent evidence from a laboratory study that compared the efficacy of liquid soap and water and ABHR with and without CHG against H1N1 influenza virus demonstrated that all the hand hygiene protocols were effective in reducing virus copies.
        <xref ref-type="bibr" rid="bib82">
         <sup>
          82
         </sup>
        </xref>
        A further study that compared the use of liquid soap and water and 65% ethanol hand sanitisers for the removal of Rhinovirus indicated that the hand sanitisers were more effective than soap and water.
        <xref ref-type="bibr" rid="bib83">
         <sup>
          83
         </sup>
        </xref>
       </p>
       <p id="para5490">
        Two economic evaluations from the USA, included in recent NICE primary care guidelines, suggest that non-compliance with hand hygiene guidelines results in increased infection-related costs.
        <xref ref-type="bibr" rid="bib56">
         <sup>
          56
         </sup>
        </xref>
        Although compliance increases procurement costs of hand hygiene products, even a small increase in compliance is likely to result in reduced infection costs. We identified a further economic analysis of a hand hygiene programme based on the introduction of point-of-use ABHR and associated implementation materials. This demonstrated a reduction in episodes of HCAI and a saving of $23.7 for every $1 spent on the programme when future costs were considered. Sensitivity analyses showed that the programme remained cost saving in all alternative scenarios.
        <xref ref-type="bibr" rid="bib84">
         <sup>
          84
         </sup>
        </xref>
        ABHR is likely to be less costly and result in greater compliance.
       </p>
       <p id="para5500">
        National and international guidelines suggest that the acceptability of agents and techniques is an essential criterion for the selection of preparations for hand hygiene.
        <xref ref-type="bibr" rid="bib2">
         2
        </xref>
        ,
        <xref ref-type="bibr" rid="bib45">
         45
        </xref>
        ,
        <xref ref-type="bibr" rid="bib53">
         53
        </xref>
        Acceptability of preparations is dependent upon the ease with which the preparation can be used in terms of time and access, together with their dermatological effects.
        <xref ref-type="bibr" rid="bib58">
         <sup>
          58
         </sup>
        </xref>
        ABHR is preferable for routine use due to its efficacy, availability at the point of care and acceptability to healthcare workers.
        <xref ref-type="bibr" rid="bib45">
         <sup>
          45
         </sup>
        </xref>
        However, ABHR does not remove organic matter and is ineffective against some microorganisms; therefore, handwashing is required.
       </p>
       <p id="para5510">
        <list id="celist730" list-type="simple">
         <list-item id="celistitem3020">
          <label>
           SP7
          </label>
          <p id="para5520">
           Use an alcohol-based hand rub for decontamination of hands before and after direct patient contact and clinical care, except in the following situations when soap and water must be used:
           <list id="celist740" list-type="simple">
            <list-item id="celistitem3030">
             <label>
              •
             </label>
             <p id="para5530">
              when hands are visibly soiled or potentially contaminated with body fluids; and
             </p>
            </list-item>
            <list-item id="celistitem3040">
             <label>
              •
             </label>
             <p id="para5540">
              when caring for patients with vomiting or diarrhoeal illness, regardless of whether or not gloves have been worn.
             </p>
            </list-item>
           </list>
          </p>
          <p id="para5550">
           <italic>
            Class A
           </italic>
          </p>
         </list-item>
        </list>
       </p>
      </sec>
      <sec id="cesec800">
       <title>
        Is hand decontamination technique important?
       </title>
       <p id="para5560">
        Investigations of technique for hand decontamination are limited and generally laboratory-based or small-scale observational designs. Hand hygiene technique involves both the preparation and the physical process of decontamination.
        <xref ref-type="bibr" rid="bib2">
         2
        </xref>
        ,
        <xref ref-type="bibr" rid="bib45">
         45
        </xref>
        ,
        <xref ref-type="bibr" rid="bib53">
         53
        </xref>
       </p>
       <p id="para5570">
        Hands and wrists need to be fully exposed to the hand hygiene product and therefore should be free from jewellery and long-sleeved clothing. A number of small-scale observational studies have demonstrated that wearing rings and false nails is associated with increased carriage of microorganisms and, in some cases, linked to the carriage of outbreak strains. Department of Health guidance on uniforms and work wear and NICE guidelines indicate that healthcare workers should remove rings and wrist jewellery, and wear short-sleeved clothing whilst delivering patient care.
        <xref ref-type="bibr" rid="bib56">
         56
        </xref>
        ,
        <xref ref-type="bibr" rid="bib85">
         85
        </xref>
       </p>
       <p id="para5580">
        Evidence for the duration of hand decontamination has been considered in previous systematic reviews underpinning guidelines, and suggests that different durations of handwashing and hand rubbing do not significantly affect the reduction of bacteria.
        <xref ref-type="bibr" rid="bib59">
         59
        </xref>
        ,
        <xref ref-type="bibr" rid="bib76">
         76
        </xref>
        The WHO guidelines indicate that decontamination using ABHR should take 20–30 s for a seven-step process, and that handwashing should take 40–60 s for a nine-step process.
        <xref ref-type="bibr" rid="bib45">
         <sup>
          45
         </sup>
        </xref>
       </p>
       <p id="para5590">
        We identified one recent RCT in a single hospital which demonstrated that allowing staff to decontaminate their hands ‘in no particular order’ took less time and was as effective as using the WHO seven-step technique using ABHR or liquid antimicrobial soap and water (
        <italic>
         p
        </italic>
        =0.04 and
        <italic>
         p
        </italic>
        &lt;0.001, respectively). All three of the protocols tested in this study were effective in reducing hand bacterial load (
        <italic>
         p
        </italic>
        &lt;0.01).
        <xref ref-type="bibr" rid="bib86">
         <sup>
          86
         </sup>
        </xref>
        A similar result was reported by authors of a laboratory study that tested the EN1500 six-step technique against a range of other protocols. They reported that allowing volunteers to use their own ‘responsible application’ or a new five-step technique resulted in better coverage of the hands during hand decontamination.
        <xref ref-type="bibr" rid="bib87">
         <sup>
          87
         </sup>
        </xref>
       </p>
       <p id="para5600">
        A number of laboratory-based studies that investigated methods of hand drying suggested that there is no significant difference in the efficacy of different methods of drying hands, but that good-quality paper towels dry hands efficiently and remove bacteria effectively.
        <xref ref-type="bibr" rid="bib88">
         88
        </xref>
        ,
        <xref ref-type="bibr" rid="bib89">
         89
        </xref>
        Current guidance on infection control in the built environment suggests that air and jet driers are not appropriate for use in clinical areas.
        <xref ref-type="bibr" rid="bib90">
         <sup>
          90
         </sup>
        </xref>
        We identified one systematic review of studies on hand drying that failed to meet the quality criteria for inclusion.
        <xref ref-type="bibr" rid="bib91">
         <sup>
          91
         </sup>
        </xref>
       </p>
       <p id="para5610">
        Due to the methodological limitations of studies, evidence recommendations are based on national and international guidelines which state that the duration of hand decontamination, the exposure of all aspects of the hands and wrists to the preparation being used, the use of vigorous rubbing to create friction, thorough rinsing in the case of handwashing, and ensuring that hands are completely dry are key factors in effective hand hygiene and the maintenance of skin integrity.
        <xref ref-type="bibr" rid="bib2">
         2
        </xref>
        ,
        <xref ref-type="bibr" rid="bib45">
         45
        </xref>
        ,
        <xref ref-type="bibr" rid="bib53">
         53
        </xref>
       </p>
       <p id="para5620">
        <list id="celist750" list-type="simple">
         <list-item id="celistitem3050">
          <label>
           SP8
          </label>
          <p id="para5630">
           Healthcare workers should ensure that their hands can be decontaminated effectively by:
           <list id="celist760" list-type="simple">
            <list-item id="celistitem3060">
             <label>
              •
             </label>
             <p id="para5640">
              removing all wrist and hand jewellery;
             </p>
            </list-item>
            <list-item id="celistitem3070">
             <label>
              •
             </label>
             <p id="para5650">
              wearing short-sleeved clothing when delivering patient care;
             </p>
            </list-item>
            <list-item id="celistitem3080">
             <label>
              •
             </label>
             <p id="para5660">
              making sure that fingernails are short, clean, and free from false nails and nail polish; and
             </p>
            </list-item>
            <list-item id="celistitem3090">
             <label>
              •
             </label>
             <p id="para5670">
              covering cuts and abrasions with waterproof dressings.
             </p>
            </list-item>
           </list>
          </p>
          <p id="para5680">
           <italic>
            Class D/GPP
           </italic>
          </p>
         </list-item>
         <list-item id="celistitem3100">
          <label>
           SP9
          </label>
          <p id="para5690">
           Effective handwashing technique involves three stages: preparation, washing and rinsing, and drying.
          </p>
          <p id="para5700">
           <list id="celist770" list-type="simple">
            <list-item id="celistitem3110">
             <label>
              •
             </label>
             <p id="para5710">
              Preparation: wet hands under tepid running water before applying the recommended amount of liquid soap or an antimicrobial preparation.
             </p>
            </list-item>
            <list-item id="celistitem3120">
             <label>
              •
             </label>
             <p id="para5720">
              Washing: the handwash solution must come into contact with all of the surfaces of the hand. The hands should be rubbed together vigorously for a minimum of 10–15 s, paying particular attention to the tips of the fingers, the thumbs and the areas between the fingers. Hands should be rinsed thoroughly.
             </p>
            </list-item>
            <list-item id="celistitem3130">
             <label>
              •
             </label>
             <p id="para5730">
              Drying: use good-quality paper towels to dry the hands thoroughly.
             </p>
            </list-item>
           </list>
          </p>
          <p id="para5740">
           <italic>
            Class D/GPP
           </italic>
          </p>
         </list-item>
         <list-item id="celistitem3140">
          <label>
           SP10
          </label>
          <p id="para5750">
           When decontaminating hands using an alcohol-based hand rub, hands should be free of dirt and organic material and:
           <list id="celist780" list-type="simple">
            <list-item id="celistitem3150">
             <label>
              •
             </label>
             <p id="para5760">
              hand rub solution must come into contact with all surfaces of the hand; and
             </p>
            </list-item>
            <list-item id="celistitem3160">
             <label>
              •
             </label>
             <p id="para5770">
              hands should be rubbed together vigorously, paying particular attention to the tips of the fingers, the thumbs and the areas between the fingers, until the solution has evaporated and the hands are dry.
             </p>
            </list-item>
           </list>
          </p>
          <p id="para5780">
           <italic>
            Class D/GPP
           </italic>
          </p>
         </list-item>
        </list>
       </p>
      </sec>
      <sec id="cesec810">
       <title>
        Does hand decontamination damage skin?
       </title>
       <p id="para5790">
        Expert opinion suggests that skin damage is generally associated with the detergent base of the preparation and/or poor handwashing technique.
        <xref ref-type="bibr" rid="bib1">
         1
        </xref>
        ,
        <xref ref-type="bibr" rid="bib2">
         2
        </xref>
        ,
        <xref ref-type="bibr" rid="bib45">
         45
        </xref>
        ,
        <xref ref-type="bibr" rid="bib53">
         53
        </xref>
        In addition, the frequent use of some hand hygiene agents may cause damage to the skin and alter normal hand flora. Sore hands are associated with increased colonisation by potentially pathogenic microorganisms and increase the risk of transmission.
        <xref ref-type="bibr" rid="bib1">
         1
        </xref>
        ,
        <xref ref-type="bibr" rid="bib2">
         2
        </xref>
        ,
        <xref ref-type="bibr" rid="bib45">
         45
        </xref>
        ,
        <xref ref-type="bibr" rid="bib53">
         53
        </xref>
        The irritant and drying effects of liquid soap and antiseptic soap preparations have been identified as one of the reasons why healthcare practitioners fail to adhere to hand hygiene guidelines.
        <xref ref-type="bibr" rid="bib1">
         1
        </xref>
        ,
        <xref ref-type="bibr" rid="bib2">
         2
        </xref>
        ,
        <xref ref-type="bibr" rid="bib45">
         45
        </xref>
        ,
        <xref ref-type="bibr" rid="bib53">
         53
        </xref>
        ,
        <xref ref-type="bibr" rid="bib92">
         92
        </xref>
        In addition, washing hands regularly with liquid soap and water before or after the use of ABHR is associated with dermatitis and is not necessary.
        <xref ref-type="bibr" rid="bib45">
         <sup>
          45
         </sup>
        </xref>
       </p>
       <p id="para5800">
        Systematic reviews conducted to underpin national guidelines
        <xref ref-type="bibr" rid="bib1">
         1
        </xref>
        ,
        <xref ref-type="bibr" rid="bib2">
         2
        </xref>
        ,
        <xref ref-type="bibr" rid="bib45">
         45
        </xref>
        ,
        <xref ref-type="bibr" rid="bib53">
         53
        </xref>
        ,
        <xref ref-type="bibr" rid="bib57">
         57
        </xref>
        have identified a range of studies that compared the use of alcohol-based preparations with liquid soap and water using self-assessment of skin condition by nurses. These studies found that ABHR was associated with less skin irritation than liquid soap and water.
        <xref ref-type="bibr" rid="bib60">
         60
        </xref>
        ,
        <xref ref-type="bibr" rid="bib61">
         61
        </xref>
        ,
        <xref ref-type="bibr" rid="bib64">
         64
        </xref>
        ,
        <xref ref-type="bibr" rid="bib67">
         67
        </xref>
        ,
        <xref ref-type="bibr" rid="bib93">
         93
        </xref>
        ,
        <xref ref-type="bibr" rid="bib94">
         94
        </xref>
        ,
        <xref ref-type="bibr" rid="bib95">
         95
        </xref>
        In addition, a longitudinal study of the introduction and subsequent use of ABHR over a 7-year period observed no reports of irritant and contact dermatitis associated with the use of ABHR.
        <xref ref-type="bibr" rid="bib51">
         <sup>
          51
         </sup>
        </xref>
       </p>
       <p id="para5810">
        We identified a recent study which suggested that two ABHR preparations containing a glycerol emollient were more acceptable to staff (
        <italic>
         p
        </italic>
        &lt;0.001).
        <xref ref-type="bibr" rid="bib96">
         <sup>
          96
         </sup>
        </xref>
        Hand moisturisers/emollients that are for shared use are more likely to become contaminated, and have been associated with an outbreak of infection in a neonatal unit.
        <xref ref-type="bibr" rid="bib97">
         <sup>
          97
         </sup>
        </xref>
       </p>
       <p id="para5820">
        Current national and international guidance suggests that skin care, through the appropriate use of hand lotion or moisturisers added to hand hygiene preparations, is an important factor in maintaining skin integrity, encouraging adherence to hand decontamination practices and assuring the health and safety of healthcare practitioners.
        <xref ref-type="bibr" rid="bib2">
         2
        </xref>
        ,
        <xref ref-type="bibr" rid="bib45">
         45
        </xref>
        ,
        <xref ref-type="bibr" rid="bib53">
         53
        </xref>
       </p>
       <p id="para5830">
        <list id="celist790" list-type="simple">
         <list-item id="celistitem3170">
          <label>
           SP11
          </label>
          <p id="para5840">
           Clinical staff should be made aware of the potentially damaging effects of hand decontamination products, and encouraged to use an emollient hand cream regularly to maintain the integrity of the skin. Consult the occupational health team or a general practitioner if a particular liquid soap, antiseptic handwash or alcohol-based hand rub causes skin irritation.
          </p>
          <p id="para5850">
           <italic>
            Class D/GPP
           </italic>
          </p>
         </list-item>
        </list>
       </p>
      </sec>
      <sec id="cesec820">
       <title>
        How can adherence to hand hygiene guidance be promoted?
       </title>
       <p id="para5860">
        National and international guidelines emphasise the importance of adherence to hand hygiene guidance, and provide an overview of the barriers and factors that influence hand hygiene compliance.
        <xref ref-type="bibr" rid="bib1">
         1
        </xref>
        ,
        <xref ref-type="bibr" rid="bib2">
         2
        </xref>
        ,
        <xref ref-type="bibr" rid="bib45">
         45
        </xref>
        ,
        <xref ref-type="bibr" rid="bib53">
         53
        </xref>
       </p>
       <p id="para5870">
        The use of multi-modal approaches to improving hand hygiene practice and behaviour has been advocated for over 10 years. Observational studies have consistently reported an association between multi-modal interventions involving the introduction of near-patient ABHR, audit and feedback, reminders and education, and greater compliance by healthcare staff.
        <xref ref-type="bibr" rid="bib51">
         51
        </xref>
        ,
        <xref ref-type="bibr" rid="bib98">
         98
        </xref>
        ,
        <xref ref-type="bibr" rid="bib99">
         99
        </xref>
        ,
        <xref ref-type="bibr" rid="bib100">
         100
        </xref>
        ,
        <xref ref-type="bibr" rid="bib101">
         101
        </xref>
        ,
        <xref ref-type="bibr" rid="bib102">
         102
        </xref>
        ,
        <xref ref-type="bibr" rid="bib103">
         103
        </xref>
        ,
        <xref ref-type="bibr" rid="bib104">
         104
        </xref>
        ,
        <xref ref-type="bibr" rid="bib105">
         105
        </xref>
        ,
        <xref ref-type="bibr" rid="bib106">
         106
        </xref>
        ,
        <xref ref-type="bibr" rid="bib107">
         107
        </xref>
        ,
        <xref ref-type="bibr" rid="bib108">
         108
        </xref>
        ,
        <xref ref-type="bibr" rid="bib109">
         109
        </xref>
       </p>
       <p id="para5880">
        An early systematic review of 21 studies involving interventions to improve hand hygiene compliance concludes that:
        <list id="celist800" list-type="simple">
         <list-item id="celistitem3180">
          <label>
           •
          </label>
          <p id="para5890">
           single interventions have a short-term influence on hand hygiene;
          </p>
         </list-item>
         <list-item id="celistitem3190">
          <label>
           •
          </label>
          <p id="para5900">
           reminders have a modest but sustained effect;
          </p>
         </list-item>
         <list-item id="celistitem3200">
          <label>
           •
          </label>
          <p id="para5910">
           feedback increases rates of hand hygiene but must be regular;
          </p>
         </list-item>
         <list-item id="celistitem3210">
          <label>
           •
          </label>
          <p id="para5920">
           near-patient alcohol-based preparations improve the frequency with which healthcare workers clean their hands; and
          </p>
         </list-item>
         <list-item id="celistitem3220">
          <label>
           •
          </label>
          <p id="para5930">
           multi-faceted approaches have a more marked effect on hand hygiene and rates of HCAI.
           <xref ref-type="bibr" rid="bib110">
            <sup>
             110
            </sup>
           </xref>
          </p>
         </list-item>
        </list>
       </p>
       <p id="para5940">
        National hand hygiene campaigns have been modelled on the multi-modal approach and implemented across the world.
        <xref ref-type="bibr" rid="bib45">
         45
        </xref>
        ,
        <xref ref-type="bibr" rid="bib51">
         51
        </xref>
        ,
        <xref ref-type="bibr" rid="bib111">
         111
        </xref>
        ,
        <xref ref-type="bibr" rid="bib112">
         112
        </xref>
        In England and Wales, the National Patient Safety Agency's ‘Cleanyourhands Campaign’ was piloted and implemented between 2004 and 2008 with the aim of creating sustainable change in hand hygiene compliance. The campaign comprised the use of near-patient ABHR, national poster materials, audit and feedback, and materials for patient engagement.
       </p>
       <p id="para5950">
        Recent Cochrane reviews of randomised and controlled clinical trials, interrupted time series and controlled before-after studies have suggested that the majority of studies conducted in this field have methodological biases that exclude them from this review.
        <xref ref-type="bibr" rid="bib77">
         77
        </xref>
        ,
        <xref ref-type="bibr" rid="bib113">
         113
        </xref>
        We identified four systematic reviews of interventions to improve hand hygiene compliance.
        <xref ref-type="bibr" rid="bib77">
         77
        </xref>
        ,
        <xref ref-type="bibr" rid="bib114">
         114
        </xref>
        ,
        <xref ref-type="bibr" rid="bib115">
         115
        </xref>
        ,
        <xref ref-type="bibr" rid="bib116">
         116
        </xref>
       </p>
       <p id="para5960">
        The most recent Cochrane review identified 84 studies published after 2006 for potential inclusion, but only four studies (one RCT, two interrupted time series and one controlled before-after study) were included following detailed quality assessment.
        <xref ref-type="bibr" rid="bib77">
         <sup>
          77
         </sup>
        </xref>
        The heterogeneity of interventions and methods precluded the pooling and meta-analysis of results, and it was concluded that multi-faceted campaigns that include social marketing or staff engagement may be more effective than campaigns without these components, and that education or product substitution alone were less effective.
       </p>
       <p id="para5970">
        An integrative systematic review of 35 studies that reported a wide range of interventions, including multi-modal interventions and hand hygiene product changes, only scored nine of the included studies as having limited or no fatal flaws.
        <xref ref-type="bibr" rid="bib114">
         <sup>
          114
         </sup>
        </xref>
        The authors concluded that design limitations made it difficult to generalise the study results or isolate the specific effects of hand hygiene (or other interventions) on reductions in HCAI.
       </p>
       <p id="para5980">
        An earlier systematic review of ‘bundled’ behavioural intervention studies that reported HCAI or rates of colonisation as the primary outcome identified 33 potential studies for inclusion; of these, only four had quality scores &gt;80%. Again, due to the heterogeneity of study interventions and outcomes, the results were narratively synthesised.
        <xref ref-type="bibr" rid="bib115">
         <sup>
          115
         </sup>
        </xref>
        The authors concluded that the formation of multi-disciplinary quality improvement teams and educational interventions might be effective strategies to improve hand hygiene and reduce rates of HCAI.
       </p>
       <p id="para5990">
        The final systematic review focused specifically on educational interventions to improve hand hygiene compliance and competence in hospital settings, and included all study designs that reported at least one outcome measure of hand hygiene competence and had a follow-up of at least 6 months.
        <xref ref-type="bibr" rid="bib116">
         <sup>
          116
         </sup>
        </xref>
        Thirty studies met the inclusion criteria for the review, but it was not possible to separate competence from compliance. Educational interventions taught or re-taught the correct methods for hand hygiene and then assessed compliance. The authors concluded that educational interventions had a greater impact if compliance with hand hygiene was low. Multiple interventions were better than single interventions in sustaining behaviour change, as were continuous, rather than one-off, interventions. However, it was not possible to determine the duration or sustainability of behaviour change in these studies.
       </p>
       <p id="para6000">
        We identified six new studies in our systematic review: one cluster RCT and process evaluation,
        <xref ref-type="bibr" rid="bib117">
         117
        </xref>
        ,
        <xref ref-type="bibr" rid="bib118">
         118
        </xref>
        one step-wedge cluster RCT,
        <xref ref-type="bibr" rid="bib119">
         <sup>
          119
         </sup>
        </xref>
        two interrupted time series studies
        <xref ref-type="bibr" rid="bib84">
         84
        </xref>
        ,
        <xref ref-type="bibr" rid="bib120">
         120
        </xref>
        and one controlled before-after study
        <xref ref-type="bibr" rid="bib121">
         <sup>
          121
         </sup>
        </xref>
        that evaluated multi-modal interventions with varying components. In a cluster RCT that also included a process evaluation, the authors tested a set of core elements in a ‘state-of-the-art strategy’ (SAS) against a team-leader-directed strategy (TDS) at baseline (T1), immediately following the intervention (T2) and 6 months later (T3) to ascertain the additional benefits of leadership and staff engagement components.
        <xref ref-type="bibr" rid="bib117">
         117
        </xref>
        ,
        <xref ref-type="bibr" rid="bib118">
         118
        </xref>
        In the intention-to-treat analysis (ITT), an OR of 1.64 (95% CI 1.33–2.02,
        <italic>
         p
        </italic>
        &lt;0.001) in favour of the TDS between T2 and T3 suggested that engaging ward leadership and the involvement of teams in setting norms and targets resulted in greater compliance with hand hygiene. However, there was no significant difference between the groups' compliance at T3 in the ITT (
        <italic>
         p
        </italic>
        =0.187), with the SAS also having a sustained effect.
        <xref ref-type="bibr" rid="bib117">
         <sup>
          117
         </sup>
        </xref>
        The process evaluation examined the extent to which the content, dosage and coverage of the intervention had been delivered.
        <xref ref-type="bibr" rid="bib118">
         <sup>
          118
         </sup>
        </xref>
        An as-treated analysis demonstrated a greater effect size for the TDS at T3 with a significant difference in hand hygiene compliance (
        <italic>
         p
        </italic>
        &lt;0.01). The process evaluation also suggested that feedback about individual hand hygiene performance at T2 and T3 (
        <italic>
         p
        </italic>
        &lt;0.05 and
        <italic>
         p
        </italic>
        &lt;0.01, respectively), challenging colleagues on undesirable hand hygiene practice (
        <italic>
         p
        </italic>
        &lt;0.01), and support from colleagues in performing hand hygiene (
        <italic>
         p
        </italic>
        &lt;0.01) were positively correlated with changes in nurses' hand hygiene compliance.
        <xref ref-type="bibr" rid="bib118">
         <sup>
          118
         </sup>
        </xref>
       </p>
       <p id="para6010">
        The second cluster RCT used a step-wedge design to assess a behavioural feedback intervention in intensive therapy units (ITUs) and acute care of the elderly (ACE) wards at sites participating in the ‘Cleanyourhands Campaign’.
        <xref ref-type="bibr" rid="bib119">
         <sup>
          119
         </sup>
        </xref>
        The primary and secondary outcome measures were hand hygiene compliance measured by covert direct observation for 1 h every 6 weeks, and soap and ABHR procurement, respectively. Sixty wards were recruited, of which 33 implemented the intervention. The ITT analysis (60 wards) showed a significant effect of the intervention in the ITUs but not the ACE wards, equating to a 7–9% increase in compliance, with estimated OR of 1.44 (95% CI 1.018–1.76,
        <italic>
         p
        </italic>
        =&lt;0.001) in ITUs and estimated OR of 1.06 (95% CI 0.87–1.25,
        <italic>
         p
        </italic>
        =0.5) in ACE wards. The per-protocol analysis (33 wards) showed a significant increase in compliance in both ACE wards and ITUs of 10–13% and 13–18%, respectively, with estimated OR of 1.67 (95% CI 1.26–2.22,
        <italic>
         p
        </italic>
        ≤0.001) in ACE wards and estimated OR of 2.09 (95% CI 1.55–2.81, p≤0.001) in ITUs. The authors concluded that individual feedback and team action planning resulted in moderate but sustained improvements in hand hygiene adherence. The difficulties in implementing this intervention point to the problems that might be faced in a non-trial context.
       </p>
       <p id="para6020">
        Two interrupted time series studies of the 4-year national ‘Cleanyourhands Campaign’ in England and a 4-year hospital-wide programme in Taiwan demonstrated increased hand hygiene compliance (measured by procurement of ABHR and liquid soap) and reductions in HCAI [MRSA and
        <italic>
         C. difficile,
        </italic>
        and MRSA and extensively-drug-resistant
        <italic>
         Acinetobacter
        </italic>
        (XDRAB)].
        <xref ref-type="bibr" rid="bib84">
         84
        </xref>
        ,
        <xref ref-type="bibr" rid="bib120">
         120
        </xref>
        In the national study, increased procurement of soap was independently associated with reductions in
        <italic>
         C. difficile
        </italic>
        infection (adjusted incidence rate ratio for 1-mL increase per patient-bed-day 0.993, 95% CI 0.990–0.996,
        <italic>
         p
        </italic>
        &lt;0.0001) and MRSA in the last four quarters of the study (adjusted incidence rate ratio for 1-mL increase per patient-bed-day 0.990, 95% CI 0.985–0.995,
        <italic>
         p
        </italic>
        &lt;0.0001).
        <xref ref-type="bibr" rid="bib120">
         <sup>
          120
         </sup>
        </xref>
        The ‘Cleanyourhands Campaign’ was not independent of other national programmes to reduce MRSA bloodstream infections and
        <italic>
         C. difficile
        </italic>
        infection. Analysis also identified that the publication of the Health Act and the Department of Health improvement team visits were associated with reductions in MRSA and
        <italic>
         C.difficile.
        </italic>
        In the hospital-wide study,
        <xref ref-type="bibr" rid="bib84">
         <sup>
          84
         </sup>
        </xref>
        the authors demonstrated a decrease in the cumulative incidence of HCAI caused by MRSA (change in level,
        <italic>
         p
        </italic>
        =0.03; change in trend,
        <italic>
         p
        </italic>
        =0.04) and XDRAB (change in level,
        <italic>
         p
        </italic>
        =0.78; change in trend,
        <italic>
         p
        </italic>
        &lt;0.001) during the intervention period. Hand hygiene compliance was significantly correlated with increased consumption of ABHR, and improved overall from 43.3% in 2004 to 95.6% in 2007 (
        <italic>
         p
        </italic>
        &lt;0.001). Hand hygiene compliance was also significantly correlated with professional categories of healthcare workers (
        <italic>
         p
        </italic>
        &lt;0.001) in both general wards and ICUs (
        <italic>
         p
        </italic>
        &lt;0.001).
       </p>
       <p id="para6030">
        The controlled before-after study
        <xref ref-type="bibr" rid="bib121">
         <sup>
          121
         </sup>
        </xref>
        of a range of patient safety interventions in England, including hand hygiene, as measured by ABHR and soap consumption in non-specialist acute hospitals, reported no significant differences in the rate of increase in consumption of ABHR (
        <italic>
         p
        </italic>
        =0.760 favouring controls and
        <italic>
         p
        </italic>
        =0.889 favouring intervention) and non-significant decreases in
        <italic>
         C. difficile
        </italic>
        (
        <italic>
         p
        </italic>
        =0.652) and MRSA (
        <italic>
         p
        </italic>
        =0.693).
       </p>
       <p id="para6040">
        <list id="celist810" list-type="simple">
         <list-item id="celistitem3230">
          <label>
           SP12
          </label>
          <p id="para6050">
           Alcohol-based hand rub should be made available at the point of care in all healthcare facilities.
          </p>
          <p id="para6060">
           <italic>
            Class C
           </italic>
          </p>
         </list-item>
         <list-item id="celistitem3240">
          <label>
           SP13
          </label>
          <p id="para6070">
           Hand hygiene resources and healthcare worker adherence to hand hygiene guidelines should be audited at regular intervals, and the results should be fed back to healthcare workers to improve and sustain high levels of compliance.
          </p>
          <p id="para6080">
           <italic>
            Class C
           </italic>
          </p>
         </list-item>
         <list-item id="celistitem3250">
          <label>
           SP14
          </label>
          <p id="para6090">
           Healthcare organisations must provide regular training in risk assessment, effective hand hygiene and glove use for all healthcare workers.
          </p>
          <p id="para6100">
           <italic>
            Class D/GPP
           </italic>
          </p>
         </list-item>
         <list-item id="celistitem3260">
          <label>
           SP15
          </label>
          <p id="para6110">
           Local programmes of education, social marketing, and audit and feedback should be refreshed regularly and promoted by senior managers and clinicians to maintain focus, engage staff and produce sustainable levels of compliance.
          </p>
          <p id="para6120">
           <bold>
            New recommendation
           </bold>
           <italic>
            Class C
           </italic>
          </p>
         </list-item>
        </list>
       </p>
      </sec>
      <sec id="cesec830">
       <title>
        Patient involvement in hand hygiene
       </title>
       <p id="para6130">
        Patient involvement in multi-modal strategies to improve hand hygiene among healthcare workers is established, and includes making it acceptable for patients and carers to request that healthcare workers clean their hands.
        <xref ref-type="bibr" rid="bib45">
         <sup>
          45
         </sup>
        </xref>
        However, research suggests that many patients and carers do not feel empowered to challenge staff, particularly doctors.
        <xref ref-type="bibr" rid="bib108">
         108
        </xref>
        ,
        <xref ref-type="bibr" rid="bib109">
         109
        </xref>
        ,
        <xref ref-type="bibr" rid="bib122">
         122
        </xref>
        ,
        <xref ref-type="bibr" rid="bib123">
         123
        </xref>
        Many NHS trusts have promoted hand hygiene among visitors by placing ABHR at the entrances to wards and patient rooms, but there is no evidence that this reduces HCAI. Despite being highlighted as an important gap in research, the role of patients' hands in the cross-transmission of microorganisms has not been investigated systematically, other than in ecologic studies that describe hand or skin contamination
        <xref ref-type="bibr" rid="bib124">
         124
        </xref>
        ,
        <xref ref-type="bibr" rid="bib125">
         125
        </xref>
        ,
        <xref ref-type="bibr" rid="bib126">
         126
        </xref>
        or observations of non-use of hand hygiene products.
        <xref ref-type="bibr" rid="bib127">
         <sup>
          127
         </sup>
        </xref>
        Studies of effective interventions to enable patients to clean their hands remain small scale and descriptive in nature.
        <xref ref-type="bibr" rid="bib128">
         128
        </xref>
        ,
        <xref ref-type="bibr" rid="bib129">
         129
        </xref>
        ,
        <xref ref-type="bibr" rid="bib130">
         130
        </xref>
        ,
        <xref ref-type="bibr" rid="bib131">
         131
        </xref>
       </p>
       <p id="para6140">
        We identified three studies that described interventions to improve patient hand hygiene: one in an outbreak situation, one uncontrolled before-after study of parent education in a single paediatric ICU, and one as part of a prospective observational study in a community hospital. None of these studies met the quality criteria for inclusion in this systematic review.
        <xref ref-type="bibr" rid="bib132">
         132
        </xref>
        ,
        <xref ref-type="bibr" rid="bib133">
         133
        </xref>
        ,
        <xref ref-type="bibr" rid="bib134">
         134
        </xref>
        However, all of these studies suggested that improving patient/carer hand hygiene had some effect on cross-transmission of microorganisms and hand hygiene technique. National guidelines indicate that it is important to educate patients and carers about the importance of hand hygiene, and inform them about the availability of hand hygiene facilities and their role in maintaining standards of healthcare workers' hand hygiene.
        <xref ref-type="bibr" rid="bib56">
         <sup>
          56
         </sup>
        </xref>
       </p>
       <p id="para6150">
        <list id="celist820" list-type="simple">
         <list-item id="celistitem3270">
          <label>
           SP16
          </label>
          <p id="para6160">
           Patients and relatives should be provided with information about the need for hand hygiene and how to keep their own hands clean.
          </p>
          <p id="para6170">
           <bold>
            New recommendation
           </bold>
           <italic>
            Class D/GPP
           </italic>
          </p>
         </list-item>
         <list-item id="celistitem3280">
          <label>
           SP17
          </label>
          <p id="para6180">
           Patients should be offered the opportunity to clean their hands before meals; after using the toilet, commode or bedpan/urinal; and at other times as appropriate. Products available should be tailored to patient needs and may include alcohol-based hand rub, hand wipes and access to handwash basins.
          </p>
          <p id="para6190">
           <bold>
            New recommendation
           </bold>
           <italic>
            Class D/GPP
           </italic>
          </p>
         </list-item>
        </list>
       </p>
      </sec>
      <sec id="cesec840">
       <title>
        Hand Hygiene – Systematic Review Process
       </title>
       <p id="para6200">
        <boxed-text id="cetextbox100">
         <sec id="cesec850">
          <title>
           <inline-graphic xlink:href="fx2_lrg.gif">
           </inline-graphic>
           Systematic Review Questions
          </title>
          <p id="para6210">
           <list id="celist830" list-type="simple">
            <list-item id="celistitem3290">
             <label>
              1.
             </label>
             <p id="para6220">
              What is the effectiveness and cost-effectiveness of hand decontamination preparations on hand hygiene compliance among healthcare workers, reductions in HCAI, reductions in transient and/or resident skin microorganisms, and the removal of organic soil?
             </p>
            </list-item>
            <list-item id="celistitem3300">
             <label>
              2.
             </label>
             <p id="para6230">
              What is the most effective hand decontamination technique, including duration, for achieving reductions in transient and/or resident skin microorganisms and the removal of organic soil?
             </p>
            </list-item>
            <list-item id="celistitem3310">
             <label>
              3.
             </label>
             <p id="para6240">
              What is the effectiveness of hand decontamination preparations on user preference and minimising contact dermatitis/allergy in healthcare workers?
             </p>
            </list-item>
            <list-item id="celistitem3320">
             <label>
              4.
             </label>
             <p id="para6250">
              What is the effectiveness of system interventions, electronic monitoring and education programmes in increasing hand hygiene compliance among healthcare workers and reducing infection?
             </p>
            </list-item>
            <list-item id="celistitem3330">
             <label>
              5.
             </label>
             <p id="para6260">
              What is the effectiveness of interventions that provide patients with opportunities to decontaminate their hands while in hospital?
             </p>
            </list-item>
           </list>
          </p>
         </sec>
        </boxed-text>
       </p>
       <p id="para6270">
        <boxed-text id="cetextbox110">
         <sec id="cesec860">
          <title>
           <inline-graphic xlink:href="fx2_lrg.gif">
           </inline-graphic>
           Databases and Search Terms Used
          </title>
          <sec id="cesec870">
           <title>
            Databases
           </title>
           <p id="para6280">
            Medline, Cumulative Index to Nursing and Allied Health Literature (CINAHL), Embase, NEHL Guideline Finder, National Institute for Health and Clinical Excellence, the Cochrane Library (CDSR, CCRCT, CMR), US Guideline
           </p>
           <p id="para6290">
            Clearing House, DARE (NHS Evidence, HTA), Prospero, PsycINFO
           </p>
          </sec>
          <sec id="cesec880">
           <title>
            MeSH TERMS
           </title>
           <p id="para6300">
            Infection control; cross infection; equipment contamination; disease transmission; disinfectants; soaps; anti-infective agents; surface active agents; guideline adherence; consumer satisfaction
           </p>
          </sec>
          <sec id="cesec890">
           <title>
            Thesaurus and Free-Text Terms
           </title>
           <p id="para6310">
            Handwashing; skin; nails; antisepsis; decontamination; WHO Five Moments; multi-modal campaign; patient education; hand hygiene audit; hand hygiene compliance
           </p>
          </sec>
          <sec id="cesec900">
           <title>
            Search Date
           </title>
           <p id="para6320">
            Jan 2006-Jan 2013
           </p>
          </sec>
         </sec>
        </boxed-text>
       </p>
       <p id="para6330">
        <boxed-text id="cetextbox120">
         <sec id="cesec910">
          <title>
           <inline-graphic xlink:href="fx2_lrg.gif">
           </inline-graphic>
           Search Results
          </title>
          <p id="para6340">
           <bold>
            Total number of articles located = 8223
           </bold>
          </p>
         </sec>
        </boxed-text>
       </p>
       <p id="para6350">
        <boxed-text id="cetextbox130">
         <sec id="cesec920">
          <title>
           <inline-graphic xlink:href="fx2_lrg.gif">
           </inline-graphic>
           Sift 1 Criteria
          </title>
          <p id="para6360">
           <bold>
            Abstract indicates
           </bold>
           that the article: relates to infections associated with hand hygiene; is written in English; is primary research, a systematic review or a meta-analysis; and appears to inform one or more of the review questions.
          </p>
         </sec>
        </boxed-text>
       </p>
       <p id="para6370">
        <boxed-text id="cetextbox140">
         <sec id="cesec930">
          <title>
           <inline-graphic xlink:href="fx2_lrg.gif">
           </inline-graphic>
           Articles Retrieved
          </title>
          <p id="para6380">
           <bold>
            Total number of articles retrieved from Sift 1 = 255
           </bold>
          </p>
         </sec>
        </boxed-text>
       </p>
       <p id="para6390">
        <boxed-text id="cetextbox150">
         <sec id="cesec940">
          <title>
           <inline-graphic xlink:href="fx2_lrg.gif">
           </inline-graphic>
           Sift 2 Criteria
          </title>
          <p id="para6400">
           <bold>
            Full text confirms
           </bold>
           that the article: relates to infections associated with hand hygiene; is written in English; is primary research (randomised controlled trials, prospective cohort, interrupted time series, controlled before-after, quasi-experimental, experimental studies answering specific questions), a systematic review or a meta-analysis including the above designs; and informs one or more of the review questions.
          </p>
         </sec>
        </boxed-text>
       </p>
       <p id="para6410">
        <boxed-text id="cetextbox160">
         <sec id="cesec950">
          <title>
           <inline-graphic xlink:href="fx2_lrg.gif">
           </inline-graphic>
           Articles Selected for Appraisal
          </title>
          <p id="para6420">
           <bold>
            Total number of studies selected for appraisal during Sift 2 = 78
           </bold>
          </p>
         </sec>
        </boxed-text>
       </p>
       <p id="para6430">
        <boxed-text id="cetextbox170">
         <sec id="cesec960">
          <title>
           <inline-graphic xlink:href="fx2_lrg.gif">
           </inline-graphic>
           Critical Appraisal
          </title>
          <p id="para6440">
           All articles that described primary research, a systematic review or a meta-analysis and met the Sift 2 criteria were independently critically appraised by two appraisers using SIGN and EPOC criteria. Consensus and grading was achieved through discussion.
          </p>
         </sec>
        </boxed-text>
       </p>
       <p id="para6450">
        <boxed-text id="cetextbox180">
         <sec id="cesec970">
          <title>
           <inline-graphic xlink:href="fx2_lrg.gif">
           </inline-graphic>
           Accepted and Rejected Evidence
          </title>
          <p id="para6460">
           <bold>
            Total number of studies accepted after critical appraisal = 17
           </bold>
          </p>
          <p id="para6470">
           <bold>
            Total number of studies rejected after critical appraisal = 61
           </bold>
          </p>
         </sec>
        </boxed-text>
       </p>
      </sec>
     </sec>
     <sec id="cesec980">
      <label>
       2.4
      </label>
      <title>
       Use of Personal Protective Equipment
      </title>
      <p id="para6480">
       This section discusses the evidence and associated recommendations for the use of PPE by healthcare workers in acute care settings and includes the use of aprons, gowns, gloves, eye protection and face masks/respirators to prevent potential transmission of pathogenic microorganisms to staff, patients and the healthcare environment. The use of gloves for other purposes does not form part of these guidelines. Where health and safety legislation underpins a recommendation, this is indicated by ‘Health &amp; Safety (H&amp;S)’ in addition to the classification of any clinical evidence underpinning the recommendations.
      </p>
      <sec id="cesec990">
       <title>
        Infection prevention and control dress code – protect your patients and yourself
       </title>
       <p id="para6490">
        The primary roles of PPE are to protect staff and reduce opportunities for cross-transmission of microorganisms in hospitals.
        <xref ref-type="bibr" rid="bib1">
         1
        </xref>
        ,
        <xref ref-type="bibr" rid="bib2">
         2
        </xref>
        ,
        <xref ref-type="bibr" rid="bib135">
         135
        </xref>
        There is no evidence that uniforms or work clothing are associated with HCAI. However, there is a public expectation that healthcare workers will wear work and protective clothing to minimise any potential risk to patients and themselves.
        <xref ref-type="bibr" rid="bib85">
         85
        </xref>
        ,
        <xref ref-type="bibr" rid="bib136">
         136
        </xref>
        The decision to use or wear PPE must be based upon an assessment of the level of risk associated with a specific patient care activity or intervention, and take account of current health and safety legislation.
        <xref ref-type="bibr" rid="bib137">
         137
        </xref>
        ,
        <xref ref-type="bibr" rid="bib138">
         138
        </xref>
        ,
        <xref ref-type="bibr" rid="bib139">
         139
        </xref>
        ,
        <xref ref-type="bibr" rid="bib140">
         140
        </xref>
        There is evidence that both a lack of knowledge of guidelines and non-adherence to guideline recommendations are common, and that regular in-service education and training is required.
        <xref ref-type="bibr" rid="bib106">
         106
        </xref>
        ,
        <xref ref-type="bibr" rid="bib141">
         141
        </xref>
        ,
        <xref ref-type="bibr" rid="bib142">
         142
        </xref>
        ,
        <xref ref-type="bibr" rid="bib143">
         143
        </xref>
        ,
        <xref ref-type="bibr" rid="bib144">
         144
        </xref>
       </p>
       <p id="para6500">
        <list id="celist840" list-type="simple">
         <list-item id="celistitem3340">
          <label>
           SP18
          </label>
          <p id="para6510">
           Selection of personal protective equipment must be based on an assessment of the:
           <list id="celist850" list-type="simple">
            <list-item id="celistitem3350">
             <label>
              •
             </label>
             <p id="para6520">
              risk of transmission of microorganisms to the patient or carer;
             </p>
            </list-item>
            <list-item id="celistitem3360">
             <label>
              •
             </label>
             <p id="para6530">
              risk of contamination of healthcare practitioners' clothing and skin by patients' blood or body fluids; and
             </p>
            </list-item>
            <list-item id="celistitem3370">
             <label>
              •
             </label>
             <p id="para6540">
              suitability of the equipment for proposed use.
             </p>
            </list-item>
           </list>
          </p>
          <p id="para6550">
           <italic>
            Class D/GPP/H&amp;S
           </italic>
          </p>
         </list-item>
         <list-item id="celistitem3380">
          <label>
           SP19
          </label>
          <p id="para6560">
           Healthcare workers should be educated and their competence assessed in the:
           <list id="celist860" list-type="simple">
            <list-item id="celistitem3390">
             <label>
              •
             </label>
             <p id="para6570">
              assessment of risk;
             </p>
            </list-item>
            <list-item id="celistitem3400">
             <label>
              •
             </label>
             <p id="para6580">
              selection and use of personal protective equipment; and
             </p>
            </list-item>
            <list-item id="celistitem3410">
             <label>
              •
             </label>
             <p id="para6590">
              use of standard precautions.
             </p>
            </list-item>
           </list>
          </p>
          <p id="para6600">
           <italic>
            Class D/GPP/H&amp;S
           </italic>
          </p>
         </list-item>
         <list-item id="celistitem3420">
          <label>
           SP20
          </label>
          <p id="para6610">
           Supplies of personal protective equipment should be made available wherever care is delivered and risk assessment indicates a requirement.
          </p>
          <p id="para6620">
           <italic>
            Class D/GPP/H&amp;S
           </italic>
          </p>
         </list-item>
        </list>
       </p>
      </sec>
      <sec id="cesec1000">
       <title>
        Gloves: use them appropriately
       </title>
       <p id="para6630">
        The use of gloves as an element of PPE and contact precautions is an everyday part of clinical practice for healthcare workers.
        <xref ref-type="bibr" rid="bib1">
         1
        </xref>
        ,
        <xref ref-type="bibr" rid="bib2">
         2
        </xref>
        ,
        <xref ref-type="bibr" rid="bib135">
         135
        </xref>
        There are other indications unrelated to preventing the cross-transmission of infection that require gloves to be worn (e.g. the use of some chemicals or medications). The two main indications for the use of gloves in the prevention of HCAI
        <xref ref-type="bibr" rid="bib1">
         <sup>
          1
         </sup>
        </xref>
        are:
        <list id="celist870" list-type="simple">
         <list-item id="celistitem3430">
          <label>
           •
          </label>
          <p id="para6640">
           to protect hands from contamination with organic matter and microorganisms; and
          </p>
         </list-item>
         <list-item id="celistitem3440">
          <label>
           •
          </label>
          <p id="para6650">
           to reduce the risk of cross-transmission of microorganisms to staff and patients.
          </p>
         </list-item>
        </list>
       </p>
       <p id="para6660">
        Gloves should be selected on the basis of a risk assessment, and should be suitable for the proposed task and the materials being handled.
        <xref ref-type="bibr" rid="bib138">
         138
        </xref>
        ,
        <xref ref-type="bibr" rid="bib139">
         139
        </xref>
        ,
        <xref ref-type="bibr" rid="bib140">
         140
        </xref>
        Gloves are categorised as medical gloves (examination and surgical) and protective gloves.
        <xref ref-type="bibr" rid="bib145">
         <sup>
          145
         </sup>
        </xref>
        Examination gloves are available as sterile or non-sterile for use by healthcare workers during clinical care to prevent contamination with microorganisms, blood and body fluids. Surgical gloves are available as sterile for use by healthcare workers during surgical and other invasive procedures. Protective gloves are used to protect healthcare workers from chemical hazards.
        <xref ref-type="bibr" rid="bib145">
         <sup>
          145
         </sup>
        </xref>
       </p>
       <p id="para6670">
        Gloves should not be worn as a substitute for hand hygiene. Their prolonged and unnecessary use may cause adverse reactions and skin sensitivity, and may lead to cross-contamination of the patient environment.
        <xref ref-type="bibr" rid="bib1">
         1
        </xref>
        ,
        <xref ref-type="bibr" rid="bib2">
         2
        </xref>
        The need to wear gloves and the selection of appropriate glove materials requires careful assessment of the task to be performed and its related risks to patients and healthcare workers.
        <xref ref-type="bibr" rid="bib1">
         1
        </xref>
        ,
        <xref ref-type="bibr" rid="bib2">
         2
        </xref>
        ,
        <xref ref-type="bibr" rid="bib135">
         135
        </xref>
        ,
        <xref ref-type="bibr" rid="bib146">
         146
        </xref>
        ,
        <xref ref-type="bibr" rid="bib147">
         147
        </xref>
        Risk assessment should include consideration of:
        <list id="celist880" list-type="simple">
         <list-item id="celistitem3450">
          <label>
           •
          </label>
          <p id="para6680">
           who is at risk (patient or healthcare worker) and whether sterile or non-sterile gloves are required;
          </p>
         </list-item>
         <list-item id="celistitem3460">
          <label>
           •
          </label>
          <p id="para6690">
           potential for exposure to blood, body fluids, secretions and excretions;
          </p>
         </list-item>
         <list-item id="celistitem3470">
          <label>
           •
          </label>
          <p id="para6700">
           contact with non-intact skin or mucous membranes during care and invasive procedures; and
          </p>
         </list-item>
         <list-item id="celistitem3480">
          <label>
           •
          </label>
          <p id="para6710">
           healthcare worker and patient sensitivity to glove materials.
          </p>
         </list-item>
        </list>
       </p>
       <p id="para6720">
        We identified four observational studies which suggested that clinical gloves are not used in line with current guidance, and that glove use impacts negatively on hand hygiene.
        <xref ref-type="bibr" rid="bib148">
         148
        </xref>
        ,
        <xref ref-type="bibr" rid="bib149">
         149
        </xref>
        ,
        <xref ref-type="bibr" rid="bib150">
         150
        </xref>
        ,
        <xref ref-type="bibr" rid="bib151">
         151
        </xref>
        In addition, a cluster RCT of screening and enhanced contact precautions for patients colonised with MRSA or VRE found no reduction in transmission, but also found that adherence to contact precautions was less than ideal.
        <xref ref-type="bibr" rid="bib152">
         <sup>
          152
         </sup>
        </xref>
        Gloves must be removed immediately following each care activity for which they have been worn, and hands must be decontaminated in order to prevent the cross-transmission of microorganisms to other susceptible sites in that individual or to other patients. Gloves should not be washed or decontaminated with ABHR as a substitute for changing gloves between care activities.
        <xref ref-type="bibr" rid="bib45">
         <sup>
          45
         </sup>
        </xref>
       </p>
      </sec>
      <sec id="cesec1010">
       <title>
        Gloves are not infallible
       </title>
       <p id="para6730">
        There is evidence that hands become contaminated when clinical gloves are worn, even when the integrity of the glove appears undamaged.
        <xref ref-type="bibr" rid="bib1">
         1
        </xref>
        ,
        <xref ref-type="bibr" rid="bib2">
         2
        </xref>
        ,
        <xref ref-type="bibr" rid="bib135">
         135
        </xref>
        In terms of leakage, gloves made from natural rubber latex (NRL) perform better than vinyl gloves in laboratory test conditions.
        <xref ref-type="bibr" rid="bib1">
         1
        </xref>
        ,
        <xref ref-type="bibr" rid="bib2">
         2
        </xref>
        Standards for the manufacture of medical gloves for single use require gloves to perform to European standards.
        <xref ref-type="bibr" rid="bib153">
         153
        </xref>
        ,
        <xref ref-type="bibr" rid="bib154">
         154
        </xref>
        ,
        <xref ref-type="bibr" rid="bib155">
         155
        </xref>
        ,
        <xref ref-type="bibr" rid="bib156">
         156
        </xref>
        ,
        <xref ref-type="bibr" rid="bib157">
         157
        </xref>
        However, the integrity of gloves cannot be guaranteed, and hands may become contaminated during the removal of gloves.
        <xref ref-type="bibr" rid="bib1">
         1
        </xref>
        ,
        <xref ref-type="bibr" rid="bib2">
         2
        </xref>
        ,
        <xref ref-type="bibr" rid="bib149">
         149
        </xref>
        ,
        <xref ref-type="bibr" rid="bib156">
         156
        </xref>
       </p>
       <p id="para6740">
        The appropriate use of medical gloves provides barrier protection and reduces the risk of hand contamination from blood, body fluids, secretions and excretions, but does not eliminate the risk. Hands cannot be considered to be clean because gloves have been worn, and should be decontaminated following the removal of gloves. Used gloves must be disposed of in accordance with the requirements of current legislation and local policy for waste management.
        <xref ref-type="bibr" rid="bib157">
         <sup>
          157
         </sup>
        </xref>
       </p>
       <p id="para6750">
        <list id="celist890" list-type="simple">
         <list-item id="celistitem3490">
          <label>
           SP21
          </label>
          <p id="para6760">
           Gloves must be worn for:
           <list id="celist900" list-type="simple">
            <list-item id="celistitem3500">
             <label>
              •
             </label>
             <p id="para6770">
              invasive procedures;
             </p>
            </list-item>
            <list-item id="celistitem3510">
             <label>
              •
             </label>
             <p id="para6780">
              contact with sterile sites and non-intact skin or mucous membranes;
             </p>
            </list-item>
            <list-item id="celistitem3520">
             <label>
              •
             </label>
             <p id="para6790">
              all activities that have been assessed as carrying a risk of exposure to blood or body fluids; and
             </p>
            </list-item>
            <list-item id="celistitem3530">
             <label>
              •
             </label>
             <p id="para6800">
              when handling sharps or contaminated devices.
             </p>
            </list-item>
           </list>
          </p>
          <p id="para6810">
           <italic>
            Class D/GPP/H&amp;S
           </italic>
          </p>
         </list-item>
         <list-item id="celistitem3540">
          <label>
           SP22
          </label>
          <p id="para6820">
           Gloves must be:
           <list id="celist910" list-type="simple">
            <list-item id="celistitem3550">
             <label>
              •
             </label>
             <p id="para6830">
              worn as single-use items;
             </p>
            </list-item>
            <list-item id="celistitem3560">
             <label>
              •
             </label>
             <p id="para6840">
              put on immediately before an episode of patient contact or treatment;
             </p>
            </list-item>
            <list-item id="celistitem3570">
             <label>
              •
             </label>
             <p id="para6850">
              removed as soon as the episode is completed;
             </p>
            </list-item>
            <list-item id="celistitem3580">
             <label>
              •
             </label>
             <p id="para6860">
              changed between caring for different patients; and
             </p>
            </list-item>
            <list-item id="celistitem3590">
             <label>
              •
             </label>
             <p id="para6870">
              disposed of into the appropriate waste stream in accordance with local policies for waste management.
             </p>
            </list-item>
           </list>
          </p>
          <p id="para6880">
           <italic>
            Class D/GPP/H&amp;S
           </italic>
          </p>
         </list-item>
         <list-item id="celistitem3600">
          <label>
           SP23
          </label>
          <p id="para6890">
           Hands must be decontaminated immediately after gloves have been removed.
          </p>
          <p id="para6900">
           <italic>
            Class D/GPP/H&amp;S
           </italic>
          </p>
         </list-item>
        </list>
       </p>
      </sec>
      <sec id="cesec1020">
       <title>
        Making choices
       </title>
       <p id="para6910">
        Clinical gloves should be used by healthcare workers to prevent the risk of hand contamination with blood, body fluids, secretions and excretions, and to protect patients from potential cross-contamination of susceptible body sites or invasive devices.
        <xref ref-type="bibr" rid="bib1">
         <sup>
          1
         </sup>
        </xref>
        Having decided that gloves should be used for a healthcare activity, the healthcare worker must make a choice between the use of:
        <list id="celist920" list-type="simple">
         <list-item id="celistitem3610">
          <label>
           •
          </label>
          <p id="para6920">
           sterile or non-sterile gloves, based on contact with susceptible sites or clinical devices; and
          </p>
         </list-item>
         <list-item id="celistitem3620">
          <label>
           •
          </label>
          <p id="para6930">
           surgical or examination gloves, based on the aspect of care or treatment to be undertaken.
          </p>
         </list-item>
        </list>
       </p>
       <p id="para6940">
        Healthcare organisations must provide gloves that conform to European standards (EN455-1, 455–2, 455–3), and which are acceptable to healthcare practitioners.
        <xref ref-type="bibr" rid="bib153">
         153
        </xref>
        ,
        <xref ref-type="bibr" rid="bib154">
         154
        </xref>
        ,
        <xref ref-type="bibr" rid="bib155">
         155
        </xref>
        Medical gloves are available in a range of materials, the most common being NRL, which remains the material of choice due to its efficacy in protecting against bloodborne viruses and properties that enable the wearer to maintain dexterity.
        <xref ref-type="bibr" rid="bib1">
         1
        </xref>
        ,
        <xref ref-type="bibr" rid="bib158">
         158
        </xref>
        Patient or healthcare practitioner sensitivity to NRL proteins must also be taken into account when deciding on glove materials.
        <xref ref-type="bibr" rid="bib146">
         <sup>
          146
         </sup>
        </xref>
       </p>
       <p id="para6950">
        Synthetic gloves are generally more expensive than NRL gloves and may not be suitable for all purposes.
        <xref ref-type="bibr" rid="bib1">
         <sup>
          1
         </sup>
        </xref>
        Nitrile gloves have the same chemical range as NRL gloves and may also lead to sensitivity problems in healthcare workers and patients. Polythene gloves are not suitable for clinical use due to their permeability and tendency to damage easily.
        <xref ref-type="bibr" rid="bib1">
         <sup>
          1
         </sup>
        </xref>
        A study that compared the performance of nitrile, latex, copolymer and vinyl gloves under stressed and unstressed conditions found that nitrile gloves had the lowest failure rate, suggesting that nitrile gloves are a suitable alternative to NRL gloves, provided that there are no sensitivity issues. Importantly, the study noted variation in performance of the same type of glove produced by different manufacturers.
        <xref ref-type="bibr" rid="bib158">
         <sup>
          158
         </sup>
        </xref>
        The Health and Safety Executive (HSE) also provide a guide-to-glove selection for employers.
        <xref ref-type="bibr" rid="bib147">
         <sup>
          147
         </sup>
        </xref>
       </p>
       <p id="para6960">
        <list id="celist930" list-type="simple">
         <list-item id="celistitem3630">
          <label>
           SP24
          </label>
          <p id="para6970">
           A range of CE-marked medical and protective gloves that are acceptable to healthcare personnel and suitable for the task must be available in all clinical areas.
          </p>
          <p id="para6980">
           <italic>
            Class D/GPP/H&amp;S
           </italic>
          </p>
         </list-item>
         <list-item id="celistitem3640">
          <label>
           SP25
          </label>
          <p id="para6990">
           Sensitivity to natural rubber latex in patients, carers and healthcare workers must be documented, and alternatives to natural rubber latex gloves must be available.
          </p>
          <p id="para7000">
           <italic>
            Class D/GPP/H&amp;S
           </italic>
          </p>
         </list-item>
        </list>
       </p>
      </sec>
      <sec id="cesec1030">
       <title>
        Aprons or gowns?
       </title>
       <p id="para7010">
        National and international guidelines recommend that PPE should be worn by all healthcare workers when close contact with the patient, materials or equipment may lead to contamination of uniforms or other clothing with microorganisms, or when there is a risk of contamination with blood or body fluids.
        <xref ref-type="bibr" rid="bib2">
         2
        </xref>
        ,
        <xref ref-type="bibr" rid="bib138">
         138
        </xref>
        ,
        <xref ref-type="bibr" rid="bib159">
         159
        </xref>
        Disposable plastic aprons are recommended for general clinical use.
        <xref ref-type="bibr" rid="bib2">
         <sup>
          2
         </sup>
        </xref>
        Full-body gowns need only be used where there is the possibility of extensive splashing of blood or body fluids, and should be fluid repellent.
        <xref ref-type="bibr" rid="bib2">
         2
        </xref>
        ,
        <xref ref-type="bibr" rid="bib159">
         159
        </xref>
       </p>
       <p id="para7020">
        We identified a systematic review of the evidence that microbial contaminants found on the work clothing of healthcare practitioners are a significant factor in cases of HCAI.
        <xref ref-type="bibr" rid="bib136">
         <sup>
          136
         </sup>
        </xref>
        The reviewers identified seven small-scale studies that described the progressive contamination of work clothing during clinical care, and a further three studies that suggested a link with microbial contamination and infection.
        <xref ref-type="bibr" rid="bib17">
         17
        </xref>
        ,
        <xref ref-type="bibr" rid="bib160">
         160
        </xref>
        ,
        <xref ref-type="bibr" rid="bib161">
         161
        </xref>
        ,
        <xref ref-type="bibr" rid="bib162">
         162
        </xref>
        ,
        <xref ref-type="bibr" rid="bib163">
         163
        </xref>
        ,
        <xref ref-type="bibr" rid="bib164">
         164
        </xref>
        ,
        <xref ref-type="bibr" rid="bib165">
         165
        </xref>
        ,
        <xref ref-type="bibr" rid="bib166">
         166
        </xref>
        ,
        <xref ref-type="bibr" rid="bib167">
         167
        </xref>
        ,
        <xref ref-type="bibr" rid="bib168">
         168
        </xref>
        ,
        <xref ref-type="bibr" rid="bib169">
         169
        </xref>
        One of the three studies was conducted in a simulated scenario and demonstrated that it was possible to transfer
        <italic>
         S. aureus
        </italic>
        from nurses' gowns to patients' bed sheets, but this was not associated with clinical infection.
        <xref ref-type="bibr" rid="bib167">
         <sup>
          167
         </sup>
        </xref>
        A further pair of linked studies, associated with an outbreak of
        <italic>
         Bacillus cereus,
        </italic>
        showed an epidemiological link between contaminated clothing and HCAI, but this occurred when surgical scrub suits became highly contaminated in an industrial laundry, rather than as a result of clinical care.
        <xref ref-type="bibr" rid="bib168">
         168
        </xref>
        ,
        <xref ref-type="bibr" rid="bib169">
         169
        </xref>
        A further study demonstrated high levels of contamination of gowns, gloves and stethoscopes with VRE following examination of patients known to be infected.
        <xref ref-type="bibr" rid="bib170">
         <sup>
          170
         </sup>
        </xref>
       </p>
       <p id="para7030">
        A systematic review of eight studies that assessed the effects of gowning by attendants and visitors found no evidence to suggest that over-gowns are effective in reducing mortality, clinical infection or bacterial colonisation in infants admitted to newborn nurseries.
        <xref ref-type="bibr" rid="bib171">
         <sup>
          171
         </sup>
        </xref>
        One quasi-experimental study investigated the use of gowns and gloves as opposed to gloves alone for prevention of acquisition of VRE in a medical ICU setting.
        <xref ref-type="bibr" rid="bib172">
         <sup>
          172
         </sup>
        </xref>
        A further prospective observational study investigated the use of a similar intervention in a medical ICU.
        <xref ref-type="bibr" rid="bib173">
         <sup>
          173
         </sup>
        </xref>
        These studies suggested that the use of gloves and gowns may minimise the transmission of VRE when colonisation pressure is high.
       </p>
       <p id="para7040">
        <list id="celist940" list-type="simple">
         <list-item id="celistitem3650">
          <label>
           SP26
          </label>
          <p id="para7050">
           Disposable plastic aprons must be worn when close contact with the patient, materials or equipment pose a risk that clothing may become contaminated with pathogenic microorganisms, blood or body fluids.
          </p>
          <p id="para7060">
           <italic>
            Class D/GPP/H&amp;S
           </italic>
          </p>
         </list-item>
         <list-item id="celistitem3660">
          <label>
           SP27
          </label>
          <p id="para7070">
           Full-body fluid-repellent gowns must be worn where there is a risk of extensive splashing of blood or body fluids on to the skin or clothing of healthcare workers.
          </p>
          <p id="para7080">
           <italic>
            Class D/GPP/H&amp;S
           </italic>
          </p>
         </list-item>
         <list-item id="celistitem3670">
          <label>
           SP28
          </label>
          <p id="para7090">
           Plastic aprons/fluid-repellent gowns should worn as single-use items for one procedure or episode of patient care, and disposed of into the appropriate waste stream in accordance with local policies for waste management. When used, non-disposable protective clothing should be sent for laundering.
          </p>
          <p id="para7100">
           <italic>
            Class D/GPP/H&amp;S
           </italic>
          </p>
         </list-item>
        </list>
       </p>
      </sec>
      <sec id="cesec1040">
       <title>
        When are a face mask, respiratory protection and eye protection necessary?
       </title>
       <p id="para7110">
        Healthcare workers (and sometimes patients) may use standard, fluid-repellent surgical face masks to prevent respiratory droplets from the mouth and nose being expelled into the environment. Face masks are also used, often in conjunction with eye protection, to protect the mucous membranes of the wearer from exposure to blood and/or body fluids when splashing may occur. Our previous systematic reviews failed to reveal any robust experimental studies that demonstrated that healthcare workers wearing surgical face masks protected patients from HCAI during routine ward procedures, such as wound dressing or invasive medical procedures.
        <xref ref-type="bibr" rid="bib1">
         1
        </xref>
        ,
        <xref ref-type="bibr" rid="bib2">
         2
        </xref>
       </p>
       <p id="para7120">
        Face masks are also used to protect the wearer from inhaling aerosolised droplet nuclei expelled from the respiratory tract. As surgical face masks are not effective at filtering out such particles, specialised respiratory protective equipment (respirators) may be recommended for the care of patients with certain respiratory diseases [e.g. active multiple drug-resistant pulmonary tuberculosis,
        <xref ref-type="bibr" rid="bib174">
         <sup>
          174
         </sup>
        </xref>
        severe acute respiratory syndrome (SARS) and pandemic influenza].
        <xref ref-type="bibr" rid="bib175">
         <sup>
          175
         </sup>
        </xref>
        The filtration efficiency of these respirators will protect the wearer from inhaling small respiratory particles, but to be effective, they must fit closely to the face to minimise leakage around the mask.
        <xref ref-type="bibr" rid="bib1">
         1
        </xref>
        ,
        <xref ref-type="bibr" rid="bib2">
         2
        </xref>
        ,
        <xref ref-type="bibr" rid="bib176">
         176
        </xref>
       </p>
       <p id="para7130">
        The selection of the most appropriate respiratory protective equipment (RPE) should be based on a suitable risk assessment that includes the task being undertaken, the characteristics of the biological agent to which there is a risk of exposure, as well as the duration of the task and the local environment. Where the activity involves procedures likely to generate aerosols of biological agents transmitted by an airborne route (e.g. intubation), RPE with an assigned protection factor (APF) of 20 (equivalent to FFP3) should be used. In other circumstances, such as where the agent is transmitted via droplet rather than aerosol or where the level of aerosol exposure is low, the risk assessment may conclude that other forms of RPE (e.g. APF10/FFP2) or a physical barrier (e.g. surgical face mask) may be appropriate, such as when caring for patients with influenza. Where RPE is required, it must fit the user properly and the user must be fully trained in how to wear and adjust it.
        <xref ref-type="bibr" rid="bib177">
         <sup>
          177
         </sup>
        </xref>
       </p>
       <p id="para7140">
        We identified four systematic reviews of the use of facial protection, all of which had been undertaken in the aftermath of the SARS outbreak and in response to the H1N1 influenza pandemic. A range of study designs were considered in each of the reviews, including cluster RCTs, RCTs, cohort studies and descriptive before-after studies. Overall, many studies were poorly controlled, with no accounting for confounders, such as poor compliance in the weaker studies. The authors of each of the reviews concluded that there was no strong evidence that masks/respirators alone are effective for the prevention of respiratory viral infections. Masks/respirators should be used together with other protective measures to reduce transmission.
        <xref ref-type="bibr" rid="bib178">
         178
        </xref>
        ,
        <xref ref-type="bibr" rid="bib179">
         179
        </xref>
        ,
        <xref ref-type="bibr" rid="bib180">
         180
        </xref>
        ,
        <xref ref-type="bibr" rid="bib181">
         181
        </xref>
       </p>
       <p id="para7150">
        Our previous systematic review indicated that different protective eyewear offered protection against physical splashing of infected substances into the eyes (although not on all occasions), but that compliance was poor.
        <xref ref-type="bibr" rid="bib1">
         <sup>
          1
         </sup>
        </xref>
        Expert opinion recommends that face and eye protection reduce the risk of occupational exposure of healthcare workers to splashes of blood or body fluids.
        <xref ref-type="bibr" rid="bib1">
         1
        </xref>
        ,
        <xref ref-type="bibr" rid="bib2">
         2
        </xref>
        ,
        <xref ref-type="bibr" rid="bib159">
         159
        </xref>
        ,
        <xref ref-type="bibr" rid="bib182">
         182
        </xref>
       </p>
       <p id="para7160">
        <list id="celist950" list-type="simple">
         <list-item id="celistitem3680">
          <label>
           SP29
          </label>
          <p id="para7170">
           Fluid-repellent surgical face masks and eye protection must be worn where there is a risk of blood or body fluids splashing into the face and eyes.
          </p>
          <p id="para7180">
           <italic>
            Class D/GPP H&amp;S
           </italic>
          </p>
         </list-item>
         <list-item id="celistitem3690">
          <label>
           SP30
          </label>
          <p id="para7190">
           Appropriate respiratory protective equipment should be selected according to a risk assessment that takes account of the infective microorganism, the anticipated activity and the duration of exposure.
          </p>
          <p id="para7200">
           <italic>
            Class D/GPP/H&amp;S
           </italic>
          </p>
         </list-item>
         <list-item id="celistitem3700">
          <label>
           SP31
          </label>
          <p id="para7210">
           Respiratory protective equipment must fit the user correctly and they must be trained in how to use and adjust it in accordance with health and safety regulations.
          </p>
          <p id="para7220">
           <italic>
            Class D/GPP/H&amp;S
           </italic>
          </p>
         </list-item>
         <list-item id="celistitem3710">
          <label>
           SP32
          </label>
          <p id="para7230">
           Personal protective equipment should be removed in the following sequence to minimise the risk of cross/self-contamination:
           <list id="celist960" list-type="simple">
            <list-item id="celistitem3720">
             <label>
              •
             </label>
             <p id="para7240">
              gloves;
             </p>
            </list-item>
            <list-item id="celistitem3730">
             <label>
              •
             </label>
             <p id="para7250">
              apron;
             </p>
            </list-item>
            <list-item id="celistitem3740">
             <label>
              •
             </label>
             <p id="para7260">
              eye protection (when worn); and
             </p>
            </list-item>
            <list-item id="celistitem3750">
             <label>
              •
             </label>
             <p id="para7270">
              mask/respirator (when worn). Hands must be decontaminated following the removal of personal protective equipment.
             </p>
            </list-item>
           </list>
          </p>
          <p id="para7280">
           <bold>
            New recommendation
           </bold>
           <italic>
            Class D/GPP/H&amp;S
           </italic>
          </p>
         </list-item>
        </list>
       </p>
      </sec>
      <sec id="cesec1050">
       <title>
        Personal Protective Equipment – Systematic Review Process
       </title>
       <p id="para7290">
        <boxed-text id="cetextbox190">
         <sec id="cesec1060">
          <title>
           <inline-graphic xlink:href="fx2_lrg.gif">
           </inline-graphic>
           Systematic Review Questions
          </title>
          <p id="para7300">
           <list id="celist970" list-type="simple">
            <list-item id="celistitem3760">
             <label>
              1.
             </label>
             <p id="para7310">
              What is the evidence that healthcare workers' use of clinical gloves is clinically appropriate and cost-effective?
             </p>
            </list-item>
            <list-item id="celistitem3770">
             <label>
              2.
             </label>
             <p id="para7320">
              What is the effect of glove use on hand hygiene compliance?
             </p>
            </list-item>
            <list-item id="celistitem3780">
             <label>
              3.
             </label>
             <p id="para7330">
              What is the effect of glove material (vinyl, latex or nitrile) on user preference and hypersensitivity, protection against bloodborne infections, glove porosity and tears? (adapted from NICE 139)
             </p>
            </list-item>
            <list-item id="celistitem3790">
             <label>
              4.
             </label>
             <p id="para7340">
              What is the evidence that the uniforms/clothes of healthcare workers contribute to the transmission of HCAI?
             </p>
            </list-item>
            <list-item id="celistitem3800">
             <label>
              5.
             </label>
             <p id="para7350">
              What is the evidence that the use of protective clothing reduces the risk of transmission of HCAI?
             </p>
            </list-item>
            <list-item id="celistitem3810">
             <label>
              6.
             </label>
             <p id="para7360">
              What is the effectiveness of PPE (aprons, gloves and mouth/facial protection) in preventing the transmission of bloodborne viruses?
             </p>
            </list-item>
            <list-item id="celistitem3820">
             <label>
              7.
             </label>
             <p id="para7370">
              What is the effectiveness of facial protection (face masks, respirators) in preventing the transmission of respiratory pathogens?
             </p>
            </list-item>
            <list-item id="celistitem3830">
             <label>
              8.
             </label>
             <p id="para7380">
              What is the effectiveness of education interventions in improving healthcare workers' knowledge and behaviour in the appropriate use of PPE and reducing infection?
             </p>
            </list-item>
           </list>
          </p>
         </sec>
        </boxed-text>
       </p>
       <p id="para7390">
        <boxed-text id="cetextbox200">
         <sec id="cesec1070">
          <title>
           <inline-graphic xlink:href="fx2_lrg.gif">
           </inline-graphic>
           Databases and Search Terms Used
          </title>
          <sec id="cesec1080">
           <title>
            Databases
           </title>
           <p id="para7400">
            Medline, Cumulative Index to Nursing and Allied Health Literature (CINAHL), Embase, NEHL Guideline Finder, National Institute for Health and Clinical Excellence, the Cochrane Library (CDSR, CCRCT, CMR), US Guideline Clearing House, DARE (NHS Evidence, HTA), Prospero
           </p>
          </sec>
          <sec id="cesec1090">
           <title>
            MeSH Terms
           </title>
           <p id="para7410">
            Infection control; cross infection; equipment contamination; universal precaution; disease transmission; protective clothing; disposable equipment; masks; gloves, protective; eye protective devices; education; health education, medical education; in-service training; health knowledge
           </p>
          </sec>
          <sec id="cesec1100">
           <title>
            Thesaurus and Free-Text Terms
           </title>
           <p id="para7420">
            Infection; contamination; antisepsis; universal precaution; disease transmission; disinfection; sterilisation; decontamination; disposable equipment; masks; gloves; face shield; goggles; apron; gown; protective clothes; visor; hood; eye protection devices
           </p>
          </sec>
          <sec id="cesec1110">
           <title>
            Search Date
           </title>
           <p id="para7430">
            Apron, gloves (AG): Apr 2011-Feb 2013, facial protection (FP):
           </p>
           <p id="para7440">
            Jan 2006-Jan 2013
           </p>
          </sec>
         </sec>
        </boxed-text>
       </p>
       <p id="para7450">
        <boxed-text id="cetextbox210">
         <sec id="cesec1120">
          <title>
           <inline-graphic xlink:href="fx2_lrg.gif">
           </inline-graphic>
           Search Results
          </title>
          <p id="para7460">
           <bold>
            Total number of articles located = AG (867), FP (8160)
           </bold>
          </p>
         </sec>
        </boxed-text>
       </p>
       <p id="para7470">
        <boxed-text id="cetextbox220">
         <sec id="cesec1130">
          <title>
           <inline-graphic xlink:href="fx2_lrg.gif">
           </inline-graphic>
           Sift 1 Criteria
          </title>
          <p id="para7480">
           <bold>
            Abstract indicates
           </bold>
           that the article: relates to infections associated with protective clothing; is written in English; is primary research, a systematic review or a meta-analysis; and appears to inform one or more of the review questions.
          </p>
         </sec>
        </boxed-text>
       </p>
       <p id="para7490">
        <boxed-text id="cetextbox230">
         <sec id="cesec1140">
          <title>
           <inline-graphic xlink:href="fx2_lrg.gif">
           </inline-graphic>
           Articles Retrieved
          </title>
          <p id="para7500">
           <bold>
            Total number of articles retrieved from Sift 1 = AG (32), FP (25)
           </bold>
          </p>
         </sec>
        </boxed-text>
       </p>
       <p id="para7510">
        <boxed-text id="cetextbox240">
         <sec id="cesec1150">
          <title>
           <inline-graphic xlink:href="fx2_lrg.gif">
           </inline-graphic>
           Sift 2 Criteria
          </title>
          <p id="para7520">
           <bold>
            Full text confirms
           </bold>
           that the article: relates to infections associated with protective clothing; is written in English; is primary research (randomised controlled trials, prospective cohort, interrupted time series, controlled before-after, quasi-experimental), a systematic review or a meta-analysis including the above designs; and informs one or more of the review questions.
          </p>
         </sec>
        </boxed-text>
       </p>
       <p id="para7530">
        <boxed-text id="cetextbox250">
         <sec id="cesec1160">
          <title>
           <inline-graphic xlink:href="fx2_lrg.gif">
           </inline-graphic>
           Articles Selected for Appraisal
          </title>
          <p id="para7540">
           <bold>
            Total number of studies selected for appraisal during Sift 2 =
           </bold>
          </p>
          <p id="para7550">
           <bold>
            AG (6), FP (6)
           </bold>
          </p>
         </sec>
        </boxed-text>
       </p>
       <p id="para7560">
        <boxed-text id="cetextbox260">
         <sec id="cesec1170">
          <title>
           <inline-graphic xlink:href="fx2_lrg.gif">
           </inline-graphic>
           Critical Appraisal
          </title>
          <p id="para7570">
           All articles that described primary research, a systematic review or a meta-analysis and met the Sift 2 criteria were independently critically appraised by two appraisers using SIGN and EPOC criteria. Consensus and grading was achieved through discussion.
          </p>
         </sec>
        </boxed-text>
       </p>
       <p id="para7580">
        <boxed-text id="cetextbox270">
         <sec id="cesec1180">
          <title>
           <inline-graphic xlink:href="fx2_lrg.gif">
           </inline-graphic>
           Accepted and Rejected Evidence
          </title>
          <p id="para7590">
           <bold>
            Total number of studies accepted after critical appraisal = AG (6), FP (4)
           </bold>
          </p>
          <p id="para7600">
           <bold>
            Total number of studies rejected after critical appraisal = AG (0), FP (2)
           </bold>
          </p>
         </sec>
        </boxed-text>
       </p>
      </sec>
     </sec>
     <sec id="cesec1190">
      <label>
       2.5
      </label>
      <title>
       Safe Use and Disposal of Sharps
      </title>
      <p id="para7610">
       This section discusses the evidence and associated recommendations for the safe use and disposal of sharps in general care settings. This includes minimising the potential infection risks associated with sharps use and disposal, and the use of needle protection devices. The use and disposal of sharps is subject to the Health and Safety at Work Act 1974
       <xref ref-type="bibr" rid="bib183">
        <sup>
         183
        </sup>
       </xref>
       and several elements of health and safety legislation including:
       <list id="celist980" list-type="simple">
        <list-item id="celistitem3840">
         <label>
          •
         </label>
         <p id="para7620">
          The Health and Safety (Sharp Instruments in Healthcare) Regulations 2013;
          <xref ref-type="bibr" rid="bib184">
           <sup>
            184
           </sup>
          </xref>
         </p>
        </list-item>
        <list-item id="celistitem3850">
         <label>
          •
         </label>
         <p id="para7630">
          Control of Substances Hazardous to Health Regulations 2002;
          <xref ref-type="bibr" rid="bib139">
           <sup>
            139
           </sup>
          </xref>
         </p>
        </list-item>
        <list-item id="celistitem3860">
         <label>
          •
         </label>
         <p id="para7640">
          Management of Health and Safety at Work Regulations 1999;
          <xref ref-type="bibr" rid="bib137">
           <sup>
            137
           </sup>
          </xref>
         </p>
        </list-item>
        <list-item id="celistitem3870">
         <label>
          •
         </label>
         <p id="para7650">
          The Provision and Use of Work Equipment Regulations 1998;
          <xref ref-type="bibr" rid="bib185">
           <sup>
            185
           </sup>
          </xref>
         </p>
        </list-item>
        <list-item id="celistitem3880">
         <label>
          •
         </label>
         <p id="para7660">
          Reporting of Diseases, Injuries and Dangerous Occurrences Regulations 1995;
          <xref ref-type="bibr" rid="bib186">
           <sup>
            186
           </sup>
          </xref>
         </p>
        </list-item>
        <list-item id="celistitem3890">
         <label>
          •
         </label>
         <p id="para7670">
          The Personal Protective Equipment Regulations 1992;
          <xref ref-type="bibr" rid="bib187">
           <sup>
            187
           </sup>
          </xref>
          and
         </p>
        </list-item>
        <list-item id="celistitem3900">
         <label>
          •
         </label>
         <p id="para7680">
          Health and Safety (First Aid) Regulations 1981.
          <xref ref-type="bibr" rid="bib188">
           <sup>
            188
           </sup>
          </xref>
         </p>
        </list-item>
       </list>
      </p>
      <p id="para7690">
       Where health and safety legislation underpins a recommendation, this is indicated by ‘H&amp;S’ in addition to the classification of any clinical evidence underpinning the recommendations.
      </p>
      <sec id="cesec1200">
       <title>
        Sharps injuries – what's the problem?
       </title>
       <p id="para7700">
        The HSE define a sharp as a needle, blade or other medical instrument capable of cutting or piercing the skin.
        <xref ref-type="bibr" rid="bib184">
         <sup>
          184
         </sup>
        </xref>
        Similarly, a sharps injury is an incident that causes a needle, blade or other medical instrument to penetrate the skin (percutaneous injury). The safe handling and disposal of needles and other sharp instruments forms part of an overall strategy of clinical waste disposal to protect staff, patients and visitors from exposure to bloodborne pathogens.
        <xref ref-type="bibr" rid="bib159">
         <sup>
          159
         </sup>
        </xref>
       </p>
       <p id="para7710">
        The National Audit Office identified that needlestick and sharps injuries ranked alongside moving and handling, falls, trips and exposure to hazardous substances as the main types of accidents experienced by NHS staff.
        <xref ref-type="bibr" rid="bib189">
         <sup>
          189
         </sup>
        </xref>
        A later Royal College of Nursing survey of 4407 nurses found that almost half (48%) had, at some point in their career, sustained a sharps injury from a device that had previously been used on a patient. A similar number (52%) reported fearing sharps injuries, and nearly half (45%) reported that they had not received training from their employer on safe needle use.
        <xref ref-type="bibr" rid="bib190">
         <sup>
          190
         </sup>
        </xref>
        The 2012 ‘Eye of the Needle’ report from the Health Protection Agency confirms that healthcare workers continue to be exposed to bloodborne virus infections, even though such exposures are largely preventable.
        <xref ref-type="bibr" rid="bib191">
         <sup>
          191
         </sup>
        </xref>
        The number of reported occupational exposures almost doubled from 276 in 2002 to 541 in 2011, with almost half of all exposures occurring in nurses. However, in 2011, medical and dental professions reported a similar number of occupational exposures as nursing professions, with exposures in these groups increasing by 131% between 2002 and 2011. The report draws attention to the need for healthcare providers to comply with the European Council Directive 2010/32/EU and adopt safety devices in order to prevent sharps injuries.
       </p>
       <p id="para7720">
        The average risk of transmission of bloodborne viruses following a single percutaneous exposure from an infected person, in the absence of appropriate post-exposure prophylaxis, has been estimated to be:
        <xref ref-type="bibr" rid="bib135">
         135
        </xref>
        ,
        <xref ref-type="bibr" rid="bib191">
         191
        </xref>
        ,
        <xref ref-type="bibr" rid="bib192">
         192
        </xref>
       </p>
       <p id="para7730">
        <list id="celist990" list-type="simple">
         <list-item id="celistitem3910">
          <label>
           •
          </label>
          <p id="para7740">
           hepatitis B virus, one in three;
          </p>
         </list-item>
         <list-item id="celistitem3920">
          <label>
           •
          </label>
          <p id="para7750">
           hepatitis C virus, one in 30; and
          </p>
         </list-item>
         <list-item id="celistitem3930">
          <label>
           •
          </label>
          <p id="para7760">
           human immunodeficiency virus, one in 300.
          </p>
         </list-item>
        </list>
       </p>
      </sec>
      <sec id="cesec1210">
       <title>
        Avoiding sharps injuries is everybody's responsibility
       </title>
       <p id="para7770">
        National and international guidelines are consistent in their recommendations for the safe use and disposal of sharp instruments and needles, and the management of healthcare workers who are exposed to potential infection from bloodborne viruses.
        <xref ref-type="bibr" rid="bib135">
         135
        </xref>
        ,
        <xref ref-type="bibr" rid="bib193">
         193
        </xref>
        ,
        <xref ref-type="bibr" rid="bib194">
         194
        </xref>
        ,
        <xref ref-type="bibr" rid="bib195">
         195
        </xref>
        As with many infection prevention and control policies, the assessment and management of the risks associated with the use of sharps is paramount, and safe systems of work and engineering controls must be in place to minimise any identified risks.
        <xref ref-type="bibr" rid="bib139">
         <sup>
          139
         </sup>
        </xref>
       </p>
       <p id="para7780">
        National
        <xref ref-type="bibr" rid="bib184">
         <sup>
          184
         </sup>
        </xref>
        and European Union
        <xref ref-type="bibr" rid="bib196">
         <sup>
          196
         </sup>
        </xref>
        legislation requires the UK and all EU member states to provide protection for all healthcare workers exposed to the risk of sharps injuries. In summary, the Health and Safety (Sharp Instruments in Healthcare) Regulations 2013 require all employers, under existing health and safety law, to:
        <list id="celist1000" list-type="simple">
         <list-item id="celistitem3940">
          <label>
           •
          </label>
          <p id="para7790">
           conduct risk assessments;
          </p>
         </list-item>
         <list-item id="celistitem3950">
          <label>
           •
          </label>
          <p id="para7800">
           avoid unnecessary use of sharps and, where this is not possible, use safer sharps that incorporate protection mechanisms;
          </p>
         </list-item>
         <list-item id="celistitem3960">
          <label>
           •
          </label>
          <p id="para7810">
           prevent the recapping of needles;
          </p>
         </list-item>
         <list-item id="celistitem3970">
          <label>
           •
          </label>
          <p id="para7820">
           ensure safe disposal by placing secure sharps containers close to the point of use;
          </p>
         </list-item>
         <list-item id="celistitem3980">
          <label>
           •
          </label>
          <p id="para7830">
           provide employees with adequate information and training on the safe use and disposal of sharps, what to do in the event of a sharps injury and the arrangements for testing, immunisation and post-exposure prophylaxis, where appropriate;
          </p>
         </list-item>
         <list-item id="celistitem3990">
          <label>
           •
          </label>
          <p id="para7840">
           record and investigate sharps incidents; and
          </p>
         </list-item>
         <list-item id="celistitem4000">
          <label>
           •
          </label>
          <p id="para7850">
           provide employees who have been injured with access to medical advice, and offer testing, immunisation, post-exposure prophylaxis and counselling, where appropriate.
           <xref ref-type="bibr" rid="bib184">
            184
           </xref>
           ,
           <xref ref-type="bibr" rid="bib193">
            193
           </xref>
          </p>
         </list-item>
        </list>
       </p>
       <p id="para7860">
        Legislation also includes a duty for employees who receive a sharps injury whilst undertaking their work to inform their employer as soon as is practicable.
        <xref ref-type="bibr" rid="bib184">
         184
        </xref>
        ,
        <xref ref-type="bibr" rid="bib193">
         193
        </xref>
        All healthcare workers must be aware of their responsibility in avoiding sharps injuries.
       </p>
       <p id="para7870">
        We identified a systematic review which included studies that focused on education and training interventions to minimise the incidence of occupational injuries involving sharps devices.
        <xref ref-type="bibr" rid="bib197">
         <sup>
          197
         </sup>
        </xref>
        The authors identified five primary before-after studies that demonstrated a consistent reduction in the incidence of percutaneous injuries when other safety initiatives (e.g. training) were implemented before and during the introduction of safer sharps devices.
        <xref ref-type="bibr" rid="bib198">
         198
        </xref>
        ,
        <xref ref-type="bibr" rid="bib199">
         199
        </xref>
        ,
        <xref ref-type="bibr" rid="bib200">
         200
        </xref>
        ,
        <xref ref-type="bibr" rid="bib201">
         201
        </xref>
        ,
        <xref ref-type="bibr" rid="bib202">
         202
        </xref>
        These studies used a range of interventions in one setting and are not generalisable. However, education is essential in ensuring that staff understand safe ways of working and how to use safer sharps devices. This should form a part of induction programmes for new staff and on-going in-service education. The introduction of new devices should include an appropriate training programme as part of staff introduction.
       </p>
       <p id="para7880">
        <list id="celist1010" list-type="simple">
         <list-item id="celistitem4010">
          <label>
           SP33
          </label>
          <p id="para7890">
           Sharps must not be passed directly from hand to hand, and handling should be kept to a minimum.
          </p>
          <p id="para7900">
           <italic>
            Class D/GPP/H&amp;S
           </italic>
          </p>
         </list-item>
         <list-item id="celistitem4020">
          <label>
           SP34
          </label>
          <p id="para7910">
           Needles must not be recapped, bent or disassembled after use.
          </p>
          <p id="para7920">
           <italic>
            Class D/GPP/H&amp;S
           </italic>
          </p>
         </list-item>
         <list-item id="celistitem4030">
          <label>
           SP35
          </label>
          <p id="para7930">
           Used sharps must be discarded at the point of use by the person generating the waste.
          </p>
          <p id="para7940">
           <italic>
            Class D/GPP/H&amp;S
           </italic>
          </p>
         </list-item>
         <list-item id="celistitem4040">
          <label>
           SP36
          </label>
          <p id="para7950">
           All sharps containers must:
           <list id="celist1020" list-type="simple">
            <list-item id="celistitem4050">
             <label>
              •
             </label>
             <p id="para7960">
              conform to current national and international standards;
             </p>
            </list-item>
            <list-item id="celistitem4060">
             <label>
              •
             </label>
             <p id="para7970">
              be positioned safely, away from public areas and out of the reach of children, and at a height that enables safe disposal by all members of staff;
             </p>
            </list-item>
            <list-item id="celistitem4070">
             <label>
              •
             </label>
             <p id="para7980">
              be secured to avoid spillage;
             </p>
            </list-item>
            <list-item id="celistitem4080">
             <label>
              •
             </label>
             <p id="para7990">
              be temporarily closed when not in use;
             </p>
            </list-item>
            <list-item id="celistitem4090">
             <label>
              •
             </label>
             <p id="para8000">
              not be filled above the fill line; and
             </p>
            </list-item>
            <list-item id="celistitem4100">
             <label>
              •
             </label>
             <p id="para8010">
              be disposed of when the fill line is reached.
             </p>
            </list-item>
           </list>
          </p>
          <p id="para8020">
           <italic>
            Class D/GPP/H&amp;S
           </italic>
          </p>
         </list-item>
         <list-item id="celistitem4110">
          <label>
           SP37
          </label>
          <p id="para8030">
           All clinical and non-clinical staff must be educated about the safe use and disposal of sharps and the action to be taken in the event of an injury.
          </p>
          <p id="para8040">
           <italic>
            Class D/GPP/H&amp;S
           </italic>
          </p>
         </list-item>
        </list>
       </p>
      </sec>
      <sec id="cesec1220">
       <title>
        Needle protection devices reduce avoidable injuries
       </title>
       <p id="para8050">
        To improve patient and staff safety, legislation and the Department of Health require healthcare providers and their employees to pursue safer methods of working through risk assessment to eliminate the use of sharps and, where this is not possible, the use of safer sharps.
        <xref ref-type="bibr" rid="bib184">
         184
        </xref>
        ,
        <xref ref-type="bibr" rid="bib203">
         203
        </xref>
        ,
        <xref ref-type="bibr" rid="bib204">
         204
        </xref>
        The incidence of sharps injuries has led to the development of safety devices in many different product groups.
        <xref ref-type="bibr" rid="bib205">
         <sup>
          205
         </sup>
        </xref>
        They are designed to minimise the risk of operator injury during sharps use, as well as ‘downstream’ injuries that occur after disposal, often involving the housekeeping or portering staff responsible for the collection of sharps disposal units.
       </p>
       <p id="para8060">
        The lack of well-designed, controlled intervention studies means that evidence to show whether or not safety devices are effective in reducing rates of infection is limited. However, a small number of studies have shown significant reductions in injuries associated with the use of safety devices
        <xref ref-type="bibr" rid="bib2">
         <sup>
          2
         </sup>
        </xref>
        in cannulation,
        <xref ref-type="bibr" rid="bib206">
         206
        </xref>
        ,
        <xref ref-type="bibr" rid="bib207">
         207
        </xref>
        phlebotomy
        <xref ref-type="bibr" rid="bib208">
         208
        </xref>
        ,
        <xref ref-type="bibr" rid="bib209">
         209
        </xref>
        ,
        <xref ref-type="bibr" rid="bib210">
         210
        </xref>
        and injections.
        <xref ref-type="bibr" rid="bib211">
         <sup>
          211
         </sup>
        </xref>
       </p>
       <p id="para8070">
        It is logical that where needle-free or other safety devices are used, there is a resulting reduction in sharps injuries. A review of needlestick injuries in Scotland suggested that 56% of injuries would ‘probably’ or ‘definitely’ have been prevented if a safety device had been used.
        <xref ref-type="bibr" rid="bib212">
         <sup>
          212
         </sup>
        </xref>
        However, some studies have identified a range of barriers to the expected reduction in injuries, including staff resistance to using new devices, complexity of device operation or improper use, and poor training.
        <xref ref-type="bibr" rid="bib2">
         <sup>
          2
         </sup>
        </xref>
        A comprehensive report and product review conducted in the USA provides background information and guidance on the need for and use of needlestick-prevention devices, but also gives advice on establishing and evaluating a sharps injury prevention programme.
        <xref ref-type="bibr" rid="bib205">
         <sup>
          205
         </sup>
        </xref>
        It reported that all devices have limitations in relation to cost, applicability and/or effectiveness. Some of the devices available are more expensive than standard devices, may not be compatible with existing equipment, and may be associated with an increase in bloodstream infection rates if used incorrectly.
        <xref ref-type="bibr" rid="bib213">
         <sup>
          213
         </sup>
        </xref>
       </p>
       <p id="para8080">
        NICE identified three RCTs that compared safety cannulae with standard cannulae. The studies were all in hospital settings and of low/very-low quality. The quality of evidence for safety needle devices was low, with no RCTs identified and the five before-after implementation studies being of very-low quality. The quality of evidence for training was similarly low, with the type of training varying across the five observational studies identified.
        <xref ref-type="bibr" rid="bib56">
         <sup>
          56
         </sup>
        </xref>
       </p>
       <p id="para8090">
        We identified a systematic review undertaken by the HSE which reviewed 41 studies that provided evidence for reductions in the incidence of occupational sharps injuries associated with use of sharps safety devices, education and training, and the acceptability of sharps safety devices.
        <xref ref-type="bibr" rid="bib197">
         <sup>
          197
         </sup>
        </xref>
        Thirteen studies, predominantly with observational designs, demonstrated that safer sharps devices were associated with a significant reduction in the incidence of healthcare worker needlestick injury.
        <xref ref-type="bibr" rid="bib199">
         199
        </xref>
        ,
        <xref ref-type="bibr" rid="bib201">
         201
        </xref>
        ,
        <xref ref-type="bibr" rid="bib208">
         208
        </xref>
        ,
        <xref ref-type="bibr" rid="bib210">
         210
        </xref>
        ,
        <xref ref-type="bibr" rid="bib214">
         214
        </xref>
        ,
        <xref ref-type="bibr" rid="bib215">
         215
        </xref>
        ,
        <xref ref-type="bibr" rid="bib216">
         216
        </xref>
        ,
        <xref ref-type="bibr" rid="bib217">
         217
        </xref>
        ,
        <xref ref-type="bibr" rid="bib218">
         218
        </xref>
        ,
        <xref ref-type="bibr" rid="bib219">
         219
        </xref>
        ,
        <xref ref-type="bibr" rid="bib220">
         220
        </xref>
        ,
        <xref ref-type="bibr" rid="bib221">
         221
        </xref>
        However, safety devices were not the total solution to reducing occupational injury. The beneficial outcome of consulting with end-users of safer sharps devices before they are introduced was demonstrated in five studies identified in this review.
        <xref ref-type="bibr" rid="bib208">
         208
        </xref>
        ,
        <xref ref-type="bibr" rid="bib211">
         211
        </xref>
        ,
        <xref ref-type="bibr" rid="bib222">
         222
        </xref>
        ,
        <xref ref-type="bibr" rid="bib223">
         223
        </xref>
        ,
        <xref ref-type="bibr" rid="bib224">
         224
        </xref>
        ,
        <xref ref-type="bibr" rid="bib225">
         225
        </xref>
       </p>
       <p id="para8100">
        In the USA, the Occupational Safety Health Administration and the National Institute for Occupational Safety and Health suggest that a thorough evaluation of any device is essential before purchasing decisions are made.
        <xref ref-type="bibr" rid="bib195">
         195
        </xref>
        ,
        <xref ref-type="bibr" rid="bib226">
         226
        </xref>
        Similarly, the HSE suggests that the end-users of any safer sharps device should be involved in the assessment of user acceptability and clinical applicability of any needle safety devices.
        <xref ref-type="bibr" rid="bib184">
         <sup>
          184
         </sup>
        </xref>
        The evaluation should ensure that the safety feature works effectively and reliably, that the device is acceptable to healthcare practitioners and that it does not have an adverse effect on patient care.
       </p>
       <p id="para8110">
        <list id="celist1030" list-type="simple">
         <list-item id="celistitem4120">
          <label>
           SP38
          </label>
          <p id="para8120">
           Use safer sharps devices where assessment indicates that they will provide safe systems of working for healthcare workers.
          </p>
          <p id="para8130">
           <italic>
            Class C/H&amp;S
           </italic>
          </p>
         </list-item>
         <list-item id="celistitem4130">
          <label>
           SP39
          </label>
          <p id="para8140">
           Organisations should involve end-users in evaluating safer sharps devices to determine their effectiveness, acceptability to practitioners, impact on patient care and cost benefit prior to widespread introduction.
          </p>
          <p id="para8150">
           <italic>
            Class D/GPP/H&amp;S
           </italic>
          </p>
         </list-item>
        </list>
       </p>
      </sec>
      <sec id="cesec1230">
       <title>
        Sharps – Systematic Review Process
       </title>
       <p id="para8160">
        <boxed-text id="cetextbox280">
         <sec id="cesec1240">
          <title>
           <inline-graphic xlink:href="fx2_lrg.gif">
           </inline-graphic>
           Systematic Review Questions
          </title>
          <p id="para8170">
           <list id="celist1040" list-type="simple">
            <list-item id="celistitem4140">
             <label>
              1.
             </label>
             <p id="para8180">
              What are the risk factors associated with sharps injuries in secondary health care? (*B)
             </p>
            </list-item>
            <list-item id="celistitem4150">
             <label>
              2.
             </label>
             <p id="para8190">
              What are the changes in legislation in relation to the use and disposal of sharps and the prevention of injuries in healthcare settings? (B)
             </p>
            </list-item>
            <list-item id="celistitem4160">
             <label>
              3.
             </label>
             <p id="para8200">
              What is the effectiveness and cost-effectiveness of using safety needle cannulae vs standard cannulae on healthcare workers' compliance with recommended use and disposal, risk of infection and injury to patients or healthcare workers? (adapted from NICE 139)
              <italic>
               Note: This question may refer to PVC review questions too.
              </italic>
             </p>
            </list-item>
            <list-item id="celistitem4170">
             <label>
              4.
             </label>
             <p id="para8210">
              What is the effectiveness and cost-effectiveness of healthcare workers using safety needle devices (needle-free, retractable needle, safety re-sheathing devices) vs standard needles on healthcare workers' compliance with recommended use and disposal, risk of infection and injury to patients or healthcare workers? (adapted from NICE 139)
             </p>
            </list-item>
            <list-item id="celistitem4180">
             <label>
              5.
             </label>
             <p id="para8220">
              What is the effectiveness of education interventions in improving healthcare workers' knowledge and behaviour in the use and disposal of sharps?
             </p>
            </list-item>
           </list>
          </p>
          <p id="para8230">
           *B: Background question
          </p>
         </sec>
        </boxed-text>
       </p>
       <p id="para8240">
        <boxed-text id="cetextbox290">
         <sec id="cesec1250">
          <title>
           <inline-graphic xlink:href="fx2_lrg.gif">
           </inline-graphic>
           Databases and Search Terms Used
          </title>
          <sec id="cesec1260">
           <title>
            Databases
           </title>
           <p id="para8250">
            Medline, Cumulative Index to Nursing and Allied Health Literature (CINAHL), Embase, NEHL Guideline Finder, National Institute for Health and Clinical Excellence, the Cochrane Library (CDSR, CCRCT, CMR), US Guideline Clearing House, DARE (NHS Evidence, HTA), Prospero
           </p>
          </sec>
          <sec id="cesec1270">
           <title>
            MeSH Terms
           </title>
           <p id="para8260">
            Infection control; cross infection; universal precautions, equipment contamination; disease transmission; needlestick injuries; education; health education; medical education; inservice training; health knowledge
           </p>
          </sec>
          <sec id="cesec1280">
           <title>
            Thesaurus and Free-Text Terms
           </title>
           <p id="para8270">
            Needles; syringes; sharps; resheathing; safe needle; safe lancet; safe cannula, needle retract; needle covered; needle capped; needle fixed; needle uncapped; needleless; needle free
           </p>
          </sec>
          <sec id="cesec1290">
           <title>
            Search Date
           </title>
           <p id="para8280">
            Jan 2005-Feb 2013
           </p>
          </sec>
         </sec>
        </boxed-text>
       </p>
       <p id="para8290">
        <boxed-text id="cetextbox300">
         <sec id="cesec1300">
          <title>
           <inline-graphic xlink:href="fx2_lrg.gif">
           </inline-graphic>
           Search Results
          </title>
          <p id="para8300">
           <bold>
            Total number of articles located = 3989
           </bold>
          </p>
         </sec>
        </boxed-text>
       </p>
       <p id="para8310">
        <boxed-text id="cetextbox310">
         <sec id="cesec1310">
          <title>
           <inline-graphic xlink:href="fx2_lrg.gif">
           </inline-graphic>
           Sift 1 Criteria
          </title>
          <p id="para8320">
           <bold>
            Abstract indicates
           </bold>
           that the article: relates to infections associated with sharps; is written in English, is primary research, a systematic review or a meta-analysis; and appears to inform one or more of the review questions.
          </p>
         </sec>
        </boxed-text>
       </p>
       <p id="para8330">
        <boxed-text id="cetextbox320">
         <sec id="cesec1320">
          <title>
           <inline-graphic xlink:href="fx2_lrg.gif">
           </inline-graphic>
           Articles Retrieved
          </title>
          <p id="para8340">
           <bold>
            Total number of articles retrieved from Sift 1 = 18
           </bold>
          </p>
         </sec>
        </boxed-text>
       </p>
       <p id="para8350">
        <boxed-text id="cetextbox330">
         <sec id="cesec1330">
          <title>
           <inline-graphic xlink:href="fx2_lrg.gif">
           </inline-graphic>
           Sift 2 Criteria
          </title>
          <p id="para8360">
           <bold>
            Full text confirms
           </bold>
           that the article: relates to infections associated with sharps; is written in English; is primary research (randomised controlled trials, prospective cohort, interrupted time series, controlled before-after, quasi-experimental), a systematic review or a meta-analysis including the above designs; and informs one or more of the review questions.
          </p>
         </sec>
        </boxed-text>
       </p>
       <p id="para8370">
        <boxed-text id="cetextbox340">
         <sec id="cesec1340">
          <title>
           <inline-graphic xlink:href="fx2_lrg.gif">
           </inline-graphic>
           Articles Selected for Appraisal
          </title>
          <p id="para8380">
           <bold>
            Total number of studies selected for appraisal during Sift 2 = 2
           </bold>
          </p>
         </sec>
        </boxed-text>
       </p>
       <p id="para8390">
        <boxed-text id="cetextbox350">
         <sec id="cesec1350">
          <title>
           <inline-graphic xlink:href="fx2_lrg.gif">
           </inline-graphic>
           Critical Appraisal
          </title>
          <p id="para8400">
           All articles that described primary research, a systematic review or a meta-analysis and met the Sift 2 criteria were independently critically appraised by two appraisers using SIGN and EPOC criteria. Consensus and grading was achieved through discussion.
          </p>
         </sec>
        </boxed-text>
       </p>
       <p id="para8410">
        <boxed-text id="cetextbox360">
         <sec id="cesec1360">
          <title>
           <inline-graphic xlink:href="fx2_lrg.gif">
           </inline-graphic>
           Accepted and Rejected Evidence
          </title>
          <p id="para8420">
           <bold>
            Total number of studies accepted after critical appraisal = 1
           </bold>
          </p>
          <p id="para8430">
           <bold>
            Total number of studies rejected after critical appraisal = 1
           </bold>
          </p>
         </sec>
        </boxed-text>
       </p>
      </sec>
     </sec>
     <sec id="cesec1370">
      <label>
       2.6
      </label>
      <title>
       Asepsis
      </title>
      <p id="para8440">
       The term ‘asepsis’ means the absence of potentially pathogenic microorganisms.
       <xref ref-type="bibr" rid="bib227">
        <sup>
         227
        </sup>
       </xref>
       Asepsis applies to both medical and surgical procedures. Medical asepsis aims to minimise the risk of contamination by microorganisms, and prevent their transmission by applying standard principles of infection prevention, including decontaminating hands, use of PPE, maintaining an aseptic area, and not touching susceptible sites or the surface of invasive devices.
       <xref ref-type="bibr" rid="bib56">
        <sup>
         56
        </sup>
       </xref>
       Surgical asepsis is a more complex process, including procedures to eliminate microorganisms from an area (thus creating an aseptic environment), and is practised in operating theatres and for invasive procedures, such as the insertion of a central venous catheter (CVC).
       <xref ref-type="bibr" rid="bib56">
        <sup>
         56
        </sup>
       </xref>
       ‘Aseptic technique’ is a term applied to a set of specific practices and procedures used to assure asepsis and prevent the transfer of potentially pathogenic microorganisms to a susceptible site on the body (e.g. an open wound or insertion site for an invasive medical device) or to sterile equipment/devices. It involves ensuring that susceptible body sites and the sterile parts of devices in contact with a susceptible site are not contaminated during the procedure.
      </p>
      <p id="para8450">
       The aseptic technique is an essential element of the prevention of HCAI, particularly when the body's natural defence mechanisms are compromised. However, similar to NICE,
       <xref ref-type="bibr" rid="bib56">
        <sup>
         56
        </sup>
       </xref>
       we identified no clinical or economic evidence that any one approach to the aseptic technique is more clinically or cost-effective than another. Thus, all recommendations here are Class D/GPP.
      </p>
      <sec id="cesec1380">
       <title>
        Improving the practice of the aseptic technique
       </title>
       <p id="para8460">
        No studies that met the inclusion criteria and compared education interventions for improving the aseptic technique generally were identified. We identified one systematic review that assessed education interventions to improve competence in the aseptic insertion and maintenance of CVCs.
        <xref ref-type="bibr" rid="bib228">
         <sup>
          228
         </sup>
        </xref>
        The review included 47 studies of educational interventions that were designed to change staff behaviour related to: general asepsis, maximal sterile barrier (MSB) precautions during insertion, cutaneous antisepsis, and other aspects of insertion and maintenance practice. The studies all described multi-modal education approaches alone or combined with demonstration, simulation, video and self-study. Only one of these studies reported improvements in competence with performing the aseptic technique as a discrete outcome, and nine studies measured overall compliance with the total insertion bundle.
       </p>
       <p id="para8470">
        Variations in terminology are used in the literature to describe the aseptic technique. Inconsistencies in the use of terms and application of the principles of asepsis in clinical practice have been addressed in a framework referred to as ‘aseptic non-touch technique’.
        <xref ref-type="bibr" rid="bib229">
         <sup>
          229
         </sup>
        </xref>
        This provides a practice structure and educational materials aimed at minimising variation and developing competence in practice.
        <xref ref-type="bibr" rid="bib229">
         <sup>
          229
         </sup>
        </xref>
        However, no comparative evidence indicating the efficacy of this approach was identified.
       </p>
       <p id="para8480">
        <list id="celist1050" list-type="simple">
         <list-item id="celistitem4190">
          <label>
           SP40
          </label>
          <p id="para8490">
           Organisations should provide education to ensure that healthcare workers are trained and competent in performing the aseptic technique.
          </p>
          <p id="para8500">
           <bold>
            New recommendation
           </bold>
           <italic>
            Class D/GPP
           </italic>
          </p>
         </list-item>
         <list-item id="celistitem4200">
          <label>
           SP41
          </label>
          <p id="para8510">
           The aseptic technique should be used for any procedure that breaches the body's natural defences, including the:
           <list id="celist1060" list-type="simple">
            <list-item id="celistitem4210">
             <label>
              •
             </label>
             <p id="para8520">
              insertion and maintenance of invasive devices;
             </p>
            </list-item>
            <list-item id="celistitem4220">
             <label>
              •
             </label>
             <p id="para8530">
              infusion of sterile fluids and medication; and
             </p>
            </list-item>
            <list-item id="celistitem4230">
             <label>
              •
             </label>
             <p id="para8540">
              care of wounds and surgical incisions.
             </p>
            </list-item>
           </list>
          </p>
          <p id="para8550">
           <bold>
            New recommendation
           </bold>
           <italic>
            Class D/GPP
           </italic>
          </p>
         </list-item>
        </list>
       </p>
      </sec>
      <sec id="cesec1390">
       <title>
        Asepsis – Systematic Review Process
       </title>
       <p id="para8560">
        <boxed-text id="cetextbox370">
         <sec id="cesec1400">
          <title>
           <inline-graphic xlink:href="fx2_lrg.gif">
           </inline-graphic>
           Systematic Review Questions
          </title>
          <p id="para8570">
           <list id="celist1070" list-type="simple">
            <list-item id="celistitem4240">
             <label>
              1.
             </label>
             <p id="para8580">
              What are the principles of asepsis? (*B)
             </p>
            </list-item>
            <list-item id="celistitem4250">
             <label>
              2.
             </label>
             <p id="para8590">
              When should the principles of asepsis be used in clinical care? (B)
             </p>
            </list-item>
            <list-item id="celistitem4260">
             <label>
              3.
             </label>
             <p id="para8600">
              What is the effectiveness of system interventions and education programmes in increasing healthcare workers' adherence to the principles of the aseptic technique and reducing HCAI?
             </p>
             <p id="para8610">
              *B: Background question
             </p>
            </list-item>
           </list>
          </p>
         </sec>
        </boxed-text>
       </p>
       <p id="para8620">
        <boxed-text id="cetextbox380">
         <sec id="cesec1410">
          <title>
           <inline-graphic xlink:href="fx2_lrg.gif">
           </inline-graphic>
           Databases and Search Terms Used
          </title>
          <sec id="cesec1420">
           <title>
            Databases
           </title>
           <p id="para8630">
            Medline, Cumulative Index to Nursing and Allied Health Literature (CINAHL), Embase, NEHL Guideline Finder, National Institute for Health and Clinical Excellence, the Cochrane Library (CDSR, CCRCT, CMR), US Guideline Clearing House, DARE (NHS Evidence, HTA), Prospero
           </p>
          </sec>
          <sec id="cesec1430">
           <title>
            MeSH Terms
           </title>
           <p id="para8640">
            Healthcare-associated infection, catheter-associated bloodstream infection, catheter-associated urinary tract infection, catheterisation, indwelling catheter, intravascular access device, ANTT, asepsis
           </p>
          </sec>
          <sec id="cesec1440">
           <title>
            Thesaurus and Free-Text Terms
           </title>
           <p id="para8650">
            Non-touch, no touch, aseptic technique, sterile procedure, healthcare workers, education and training
           </p>
          </sec>
          <sec id="cesec1450">
           <title>
            Search Date
           </title>
           <p id="para8660">
            Jan 2011-Apr 2013
           </p>
          </sec>
         </sec>
        </boxed-text>
       </p>
       <p id="para8670">
        <boxed-text id="cetextbox390">
         <sec id="cesec1460">
          <title>
           <inline-graphic xlink:href="fx2_lrg.gif">
           </inline-graphic>
           Search Results
          </title>
          <p id="para8680">
           <bold>
            Total number of articles located = Asepsis-UC (55), Asepsis-IVAD (205)
           </bold>
          </p>
         </sec>
        </boxed-text>
       </p>
       <p id="para8690">
        <boxed-text id="cetextbox400">
         <sec id="cesec1470">
          <title>
           <inline-graphic xlink:href="fx2_lrg.gif">
           </inline-graphic>
           Sift 1 Criteria
          </title>
          <p id="para8700">
           <bold>
            Abstract indicates
           </bold>
           that the article: relates to infections associated with asepsis; is written in English; is primary research, a systematic review or a meta-analysis; and appears to inform one or more of the review questions.
          </p>
         </sec>
        </boxed-text>
       </p>
       <p id="para8710">
        <boxed-text id="cetextbox410">
         <sec id="cesec1480">
          <title>
           <inline-graphic xlink:href="fx2_lrg.gif">
           </inline-graphic>
           Articles Retrieved
          </title>
          <p id="para8720">
           <bold>
            Total number of articles retrieved from Sift 1 = Asepsis-UC (10), Asepsis-IVAD (25)
           </bold>
          </p>
         </sec>
        </boxed-text>
       </p>
       <p id="para8730">
        <boxed-text id="cetextbox420">
         <sec id="cesec1490">
          <title>
           <inline-graphic xlink:href="fx2_lrg.gif">
           </inline-graphic>
           Sift 2 Criteria
          </title>
          <p id="para8740">
           <bold>
            Full text confirms
           </bold>
           that the article: relates to infections associated with asepsis; is written in English; is primary research (randomised controlled trialsRCT), prospective cohort, interrupted time series, controlled before-after, quasi-experimental), a systematic review or a meta-analysis including the above designs; and informs one or more of the review questions.
          </p>
         </sec>
        </boxed-text>
       </p>
       <p id="para8750">
        <boxed-text id="cetextbox430">
         <sec id="cesec1500">
          <title>
           <inline-graphic xlink:href="fx2_lrg.gif">
           </inline-graphic>
           Articles Selected for Appraisal
          </title>
          <p id="para8760">
           <bold>
            Total number of studies selected for appraisal during Sift 2 = 1
           </bold>
          </p>
         </sec>
        </boxed-text>
       </p>
       <p id="para8770">
        <boxed-text id="cetextbox440">
         <sec id="cesec1510">
          <title>
           <inline-graphic xlink:href="fx2_lrg.gif">
           </inline-graphic>
           Critical Appraisal
          </title>
          <p id="para8780">
           All articles that described primary research, a systematic review or a meta-analysis and met the Sift 2 criteria were independently critically appraised by two appraisers using SIGN and EPOC criteria. Consensus and grading was achieved through discussion.
          </p>
         </sec>
        </boxed-text>
       </p>
       <p id="para8790">
        <boxed-text id="cetextbox450">
         <sec id="cesec1520">
          <title>
           <inline-graphic xlink:href="fx2_lrg.gif">
           </inline-graphic>
           Accepted and Rejected Evidence
          </title>
          <p id="para8800">
           <bold>
            Total number of studies accepted after critical appraisal = 0
           </bold>
          </p>
          <p id="para8810">
           <bold>
            Total number of studies rejected after critical appraisal = 1
           </bold>
          </p>
         </sec>
        </boxed-text>
       </p>
       <sec id="cesec1530">
        <label>
         3
        </label>
        <title>
         Guidelines for Preventing Infections Associated with the Use of Short-Term Indwelling Urethral Catheters
        </title>
        <sec id="cesec1540">
         <label>
          3.1
         </label>
         <title>
          Introduction
         </title>
         <p id="para8820">
          This guidance is based on the best critically appraised evidence currently available. The type and class of supporting evidence explicitly linked to each recommendation is described. Evidence identified in the Healthcare Infection Control Practices Advisory Committee (HICPAC) systematic review was used to support the recommendations in these guidelines.
          <xref ref-type="bibr" rid="bib230">
           <sup>
            230
           </sup>
          </xref>
          Some recommendations from the previous guidelines have been revised to improve clarity; where a new recommendation has been made, this is indicated in the text. These recommendations are not detailed procedural protocols, and need to be incorporated into local guidelines. None are regarded as optional.
         </p>
         <p id="para8830">
          These guidelines apply to adults and children aged ≥1 year who require a short-term indwelling urethral catheter (≤28 days), and should be read in conjunction with the guidance on Standard Principles. The recommendations are divided into six distinct interventions:
          <list id="celist1080" list-type="simple">
           <list-item id="celistitem4270">
            <label>
             •
            </label>
            <p id="para8840">
             assessing the need for catheterisation;
            </p>
           </list-item>
           <list-item id="celistitem4280">
            <label>
             •
            </label>
            <p id="para8850">
             selection of catheter type and system;
            </p>
           </list-item>
           <list-item id="celistitem4290">
            <label>
             •
            </label>
            <p id="para8860">
             catheter insertion;
            </p>
           </list-item>
           <list-item id="celistitem4300">
            <label>
             •
            </label>
            <p id="para8870">
             catheter maintenance;
            </p>
           </list-item>
           <list-item id="celistitem4310">
            <label>
             •
            </label>
            <p id="para8880">
             education of patients, relatives and healthcare workers; and
            </p>
           </list-item>
           <list-item id="celistitem4320">
            <label>
             •
            </label>
            <p id="para8890">
             system interventions for reducing the risk of infection.
            </p>
           </list-item>
          </list>
         </p>
        </sec>
        <sec id="cesec1550">
         <label>
          3.2
         </label>
         <title>
          Background and Context of the Guidelines
         </title>
         <p id="para8900">
          Urinary tract infection (UTI) is the most common infection acquired as a result of health care, accounting for 19% of HCAI, with between 43% and 56% of UTIs associated with a urethral catheter.
          <xref ref-type="bibr" rid="bib231">
           231
          </xref>
          ,
          <xref ref-type="bibr" rid="bib232">
           232
          </xref>
          Catheters predispose to infection because microorganisms are able to bypass natural host mechanisms, such as the urethra and micturition, and gain entry to the bladder.
          <xref ref-type="bibr" rid="bib233">
           <sup>
            233
           </sup>
          </xref>
          Most microorganisms causing catheter-associated UTI (CAUTI) gain access to the urinary tract either extraluminally or intraluminally. Extraluminal contamination may occur as the catheter is inserted, by contamination of the catheter from healthcare workers' hands or from the patient's own perineal flora. Extraluminal contamination is also thought to occur from microorganisms ascending from the perineum. Intraluminal contamination occurs by reflux of microorganisms from a contaminated urine drainage bag.
          <xref ref-type="bibr" rid="bib234">
           <sup>
            234
           </sup>
          </xref>
         </p>
         <p id="para8910">
          The bladder is normally sterile; in the non-catheterised patient, a UTI is usually identified from the symptoms of dysuria and frequency of urination. Patients who develop a UTI with a short-term indwelling urethral catheter in place may not experience these symptoms, and diagnosis may be based on other signs, such as fever or suprapubic or loin tenderness.
          <xref ref-type="bibr" rid="bib235">
           <sup>
            235
           </sup>
          </xref>
          After a few days of catheterisation, microorganisms may be isolated from urine and, in the absence of any symptoms of UTI, this is called ‘bacteriuria’.
          <xref ref-type="bibr" rid="bib236">
           <sup>
            236
           </sup>
          </xref>
          The duration of catheterisation is the dominant risk factor for CAUTI, and virtually all catheterised patients develop bacteriuria within 1 month.
          <xref ref-type="bibr" rid="bib230">
           <sup>
            230
           </sup>
          </xref>
          For the purpose of these guidelines, a duration of catheterisation of ≤28 days is considered to be a short-term catheterisation.
          <xref ref-type="bibr" rid="bib234">
           <sup>
            234
           </sup>
          </xref>
         </p>
         <p id="para8920">
          Several factors contribute to the potential development of CAUTI, including the formation of biofilms and encrustation of the catheter. Bacteria on the catheter surface and drainage bag multiply rapidly, adhering to the surface by excreting extracellular polysaccharides and forming a layer known as a ‘biofilm’. Bacteria within the biofilm are morphologically and physiologically different from free-living planktonic bacteria in the urine, and have considerable survival advantages as they are protected from the action of antibiotic therapy.
          <xref ref-type="bibr" rid="bib234">
           <sup>
            234
           </sup>
          </xref>
         </p>
         <p id="para8930">
          Whilst biofilms commonly form on devices inserted into the body, they can cause additional problems on urethral catheters if the bacteria produce the enzyme urease, such as
          <italic>
           Proteus mirabilis.
          </italic>
          <xref ref-type="bibr" rid="bib234">
           <sup>
            234
           </sup>
          </xref>
          This enzyme causes the urine to become alkaline, inducing crystallisation of calcium and magnesium phosphate within the urine. These crystals are incorporated into the biofilm and, over time, result in encrustation of the catheter. Encrustation is generally associated with long-term catheterisation, as it has a direct relationship with the length of catheterisation.
          <xref ref-type="bibr" rid="bib234">
           <sup>
            234
           </sup>
          </xref>
         </p>
         <p id="para8940">
          Urinary catheterisation is a frequent intervention during clinical care in hospital, affecting a significant number of patients. It has been estimated that 15–25% of hospitalised patients have a urinary catheter inserted during their stay.
          <xref ref-type="bibr" rid="bib237">
           237
          </xref>
          ,
          <xref ref-type="bibr" rid="bib238">
           238
          </xref>
          ,
          <xref ref-type="bibr" rid="bib239">
           239
          </xref>
          ,
          <xref ref-type="bibr" rid="bib240">
           240
          </xref>
          This number is much higher in ICUs.
          <xref ref-type="bibr" rid="bib241">
           <sup>
            241
           </sup>
          </xref>
          The risk of infection is associated with the method and duration of catheterisation, the quality of catheter care and patient susceptibility.
          <xref ref-type="bibr" rid="bib242">
           <sup>
            242
           </sup>
          </xref>
          Bacteriuria develops in approximately 30% of catheterised patients after 2–10 days, and 24% (95% CI 23–29%) of these will develop symptoms of CAUTI.
          <xref ref-type="bibr" rid="bib242">
           <sup>
            242
           </sup>
          </xref>
          Approximately 3.6% (95% CI 3.4–3.8%) of those with CAUTI develop life-threatening secondary infections, such as bacteraemia or sepsis, where mortality rates range from 10% to 33%.
          <xref ref-type="bibr" rid="bib243">
           243
          </xref>
          ,
          <xref ref-type="bibr" rid="bib244">
           244
          </xref>
          CAUTI is associated with prolonged hospitalisation, re-admission and increased mortality.
          <xref ref-type="bibr" rid="bib245">
           <sup>
            245
           </sup>
          </xref>
          Patients at particular risk are those who are immunocompromised, the elderly and patients with diabetes.
          <xref ref-type="bibr" rid="bib246">
           <sup>
            246
           </sup>
          </xref>
         </p>
         <p id="para8950">
          Physical and psychological discomfort associated with insertion, removal and the catheter
          <italic>
           in situ
          </italic>
          are common.
          <xref ref-type="bibr" rid="bib247">
           <sup>
            247
           </sup>
          </xref>
          Complications such as inflammation, urethral strictures, mechanical trauma, bladder calculi and other infections of the renal system also occur.
          <xref ref-type="bibr" rid="bib237">
           237
          </xref>
          ,
          <xref ref-type="bibr" rid="bib248">
           248
          </xref>
          ,
          <xref ref-type="bibr" rid="bib249">
           249
          </xref>
          ,
          <xref ref-type="bibr" rid="bib250">
           250
          </xref>
          Urine retention after catheter removal is also a frequent occurrence.
          <xref ref-type="bibr" rid="bib251">
           <sup>
            251
           </sup>
          </xref>
          In some instances, especially in older people, CAUTI may contribute to falls and delirium.
          <xref ref-type="bibr" rid="bib252">
           <sup>
            252
           </sup>
          </xref>
          The treatment of both CAUTI and other infection sequelae contribute to the emerging problem of antibiotic resistance in hospitals, and uropathogens are a major source of infections caused by antimicrobial-resistant organisms.
          <xref ref-type="bibr" rid="bib253">
           <sup>
            253
           </sup>
          </xref>
         </p>
         <p id="para8960">
          CAUTI also increases the cost of health care due to delayed discharge from hospital, antimicrobial treatment and staff resources. The financial burden of CAUTI on the NHS has been estimated as £99 million per year, with an estimated cost per episode of £1968.
          <xref ref-type="bibr" rid="bib254">
           254
          </xref>
          ,
          <xref ref-type="bibr" rid="bib255">
           255
          </xref>
          However, there are no robust economic assessments of the cost of CAUTI.
         </p>
        </sec>
        <sec id="cesec1560">
         <label>
          3.3
         </label>
         <title>
          Assessing the Need for Catheterisation
         </title>
         <sec id="cesec1570">
          <title>
           Catheters place patients at significant risk of acquiring a urinary tract infection. The longer a catheter is in place, the greater the danger
          </title>
          <p id="para8970">
           There is a strong association between the duration of catheterisation and the risk of infection (i.e. the longer the catheter is in place, the higher the incidence of UTI).
           <xref ref-type="bibr" rid="bib242">
            242
           </xref>
           ,
           <xref ref-type="bibr" rid="bib256">
            256
           </xref>
           ,
           <xref ref-type="bibr" rid="bib257">
            257
           </xref>
           In acute care facilities, the risk of developing bacteriuria increases 5% for each day of catheterisation. Approximately 24% of bacteriuric patients will develop CAUTI, and of these, up to 4% develop a severe secondary infection such as bloodstream infection.
           <xref ref-type="bibr" rid="bib242">
            <sup>
             242
            </sup>
           </xref>
          </p>
          <p id="para8980">
           Current best practice emphasises the importance of documenting all procedures involving the catheter or drainage system in the patient's records,
           <xref ref-type="bibr" rid="bib255">
            <sup>
             255
            </sup>
           </xref>
           and providing patients with adequate information in relation to the need for catheterisation, details of the insertion, catheter and drainage system, maintenance procedures and plan for removal of the catheter.
           <xref ref-type="bibr" rid="bib255">
            255
           </xref>
           ,
           <xref ref-type="bibr" rid="bib258">
            258
           </xref>
           There is some evidence to suggest that computer management systems improve documentation and are associated with reduced duration of catheterisation.
           <xref ref-type="bibr" rid="bib259">
            <sup>
             259
            </sup>
           </xref>
          </p>
         </sec>
         <sec id="cesec1580">
          <title>
           What are the indications for using a short-term indwelling urethral catheter?
          </title>
          <p id="para8990">
           Using a short-term indwelling urethral catheter only when necessary after considering alternatives and ensuring the catheter is removed as soon as possible are simple and effective methods to prevent CAUTI. The use of a short-term indwelling urethral catheter may be appropriate in patients with acute urinary retention or obstruction, those who require precise urine output measures to monitor an underlying condition, and patients undergoing certain surgical procedures (especially urological procedures and those of prolonged duration). A short-term indwelling urethral catheter may also be appropriate to minimise discomfort or distress (e.g. during end-of-life care or in the management of open sacral or perineal wounds when the patient is incontinent).
           <xref ref-type="bibr" rid="bib230">
            <sup>
             230
            </sup>
           </xref>
           However, short-term indwelling urethral catheterisation should not be used as a method of managing urinary incontinence.
          </p>
          <p id="para9000">
           While the use of a short-term indwelling urethral catheter is sometimes unavoidable, there is evidence that catheters are inserted without a clear clinical indication, clinicians are not always aware they are
           <italic>
            in situ,
           </italic>
           and they are not removed promptly when no longer required.
           <xref ref-type="bibr" rid="bib238">
            238
           </xref>
           ,
           <xref ref-type="bibr" rid="bib260">
            260
           </xref>
           Interventions that prompt or facilitate the removal of unnecessary catheters may, therefore, reduce the risk of CAUTI. These interventions have been categorised as reminder systems which prompt clinicians that the catheter is in place and removal should be considered, or stop orders, which indicate that catheters should be removed after a set period of time or when defined clinical criteria have been met.
           <xref ref-type="bibr" rid="bib259">
            259
           </xref>
           ,
           <xref ref-type="bibr" rid="bib261">
            261
           </xref>
           ,
           <xref ref-type="bibr" rid="bib262">
            262
           </xref>
           ,
           <xref ref-type="bibr" rid="bib263">
            263
           </xref>
          </p>
          <p id="para9010">
           A systematic review of 14 studies (one RCT, one NRCT, three controlled before-after studies and nine uncontrolled before-after studies) on reminder and stop order systems found that these interventions significantly decreased the rate of CAUTI and did not increase the need for re-catheterisation, although, as some of the studies were not controlled, they were susceptible to bias in favour of the intervention.
           <xref ref-type="bibr" rid="bib261">
            <sup>
             261
            </sup>
           </xref>
          </p>
          <p id="para9020">
           A second systematic review identified a number of uncontrolled before-after studies that used ultrasound bladder scanners to assess for urinary retention and support appropriate catheterisation.
           <xref ref-type="bibr" rid="bib264">
            <sup>
             264
            </sup>
           </xref>
           When used in combination with guidelines,
           <xref ref-type="bibr" rid="bib265">
            <sup>
             265
            </sup>
           </xref>
           insertion checklist/kit, education, audit and feedback,
           <xref ref-type="bibr" rid="bib266">
            <sup>
             266
            </sup>
           </xref>
           and reminder/stop orders,
           <xref ref-type="bibr" rid="bib267">
            <sup>
             267
            </sup>
           </xref>
           ultrasound bladder scanners were found to decrease the use of urethral catheters by 5–15%.
           <xref ref-type="bibr" rid="bib264">
            <sup>
             264
            </sup>
           </xref>
           <list id="celist1090" list-type="simple">
            <list-item id="celistitem4330">
             <label>
              UC1
             </label>
             <p id="para9030">
              Only use a short-term indwelling urethral catheter in patients for whom it is clinically indicated, following assessment of alternative methods and discussion with the patient.
             </p>
             <p id="para9040">
              <italic>
               Class D/GPP
              </italic>
             </p>
            </list-item>
            <list-item id="celistitem4340">
             <label>
              UC2
             </label>
             <p id="para9050">
              Document the clinical indication(s) for catheterisation, date of insertion, expected duration, type of catheter and drainage system, and planned date of removal.
             </p>
             <p id="para9060">
              <italic>
               Class D/GPP
              </italic>
             </p>
            </list-item>
            <list-item id="celistitem4350">
             <label>
              UC3
             </label>
             <p id="para9070">
              Assess and record the reasons for catheterisation every day. Remove the catheter when no longer clinically indicated.
             </p>
             <p id="para9080">
              <italic>
               Class D/GPP
              </italic>
             </p>
            </list-item>
           </list>
          </p>
         </sec>
        </sec>
        <sec id="cesec1590">
         <label>
          3.4
         </label>
         <title>
          Selection of Catheter Type
         </title>
         <sec id="cesec1600">
          <title>
           Is one catheter better than another?
          </title>
          <p id="para9090">
           Evidence from best practice indicates that the incidence of CAUTI in patients catheterised for a short time (up to 1 week) is not influenced by any particular type of catheter material.
           <xref ref-type="bibr" rid="bib268">
            268
           </xref>
           ,
           <xref ref-type="bibr" rid="bib269">
            269
           </xref>
           However, many practitioners have strong preferences for one type of catheter over another. This preference is often based on clinical experience, patient assessment and materials that induce the least allergic response. Smaller gauge catheters with a 10-mL balloon minimise urethral trauma, mucosal irritation and residual urine in the bladder; all factors that predispose to CAUTI.
           <xref ref-type="bibr" rid="bib270">
            270
           </xref>
           ,
           <xref ref-type="bibr" rid="bib271">
            271
           </xref>
           There is also a risk of urethral trauma associated with using a female length catheter in a male patient, and systems should be in place to ensure that this does not occur.
           <xref ref-type="bibr" rid="bib272">
            <sup>
             272
            </sup>
           </xref>
           However, in adults that have recently undergone urological surgery, larger gauge catheters may be indicated to allow for the passage of blood clots. Our previous evidence-based guidelines
           <xref ref-type="bibr" rid="bib1">
            <sup>
             1
            </sup>
           </xref>
           identified three experimental studies that compared the use of latex with silicone catheters, which found no significant difference in the incidence of bacteriuria.
           <xref ref-type="bibr" rid="bib249">
            249
           </xref>
           ,
           <xref ref-type="bibr" rid="bib273">
            273
           </xref>
           ,
           <xref ref-type="bibr" rid="bib274">
            274
           </xref>
          </p>
          <p id="para9100">
           We identified one new systematic review which included three trials that compared different types of standard (non-antiseptic-/non-antimicrobial-impregnated) catheters. These studies did not provide sufficient evidence to suggest that one type of catheter may be more effective than another for the prevention of bacteriuria.
           <xref ref-type="bibr" rid="bib274">
            274
           </xref>
           ,
           <xref ref-type="bibr" rid="bib275">
            275
           </xref>
           ,
           <xref ref-type="bibr" rid="bib276">
            276
           </xref>
           ,
           <xref ref-type="bibr" rid="bib277">
            277
           </xref>
          </p>
          <p id="para9110">
           In our previous systematic review,
           <xref ref-type="bibr" rid="bib278">
            <sup>
             278
            </sup>
           </xref>
           we found evidence related to the efficacy of using short-term indwelling urethral catheters coated or impregnated with antiseptic or antimicrobial agents from four systematic reviews and one meta-analysis. In general, all of these five studies suggested that antiseptic-impregnated or antimicrobial-coated short-term indwelling urethral catheters can significantly prevent or delay the onset of CAUTI compared with standard untreated urinary catheters.
           <xref ref-type="bibr" rid="bib235">
            235
           </xref>
           ,
           <xref ref-type="bibr" rid="bib279">
            279
           </xref>
           ,
           <xref ref-type="bibr" rid="bib280">
            280
           </xref>
           ,
           <xref ref-type="bibr" rid="bib281">
            281
           </xref>
           ,
           <xref ref-type="bibr" rid="bib282">
            282
           </xref>
           The consensus in these five reviews of evidence, however, is that the individual studies reviewed are generally of poor quality; for instance, in one case, only eight studies out of 117 met the inclusion criteria,
           <xref ref-type="bibr" rid="bib280">
            <sup>
             280
            </sup>
           </xref>
           and in another, of the six reports describing seven trials included, only one scored five in the quality assessment. The other five reports only scored one.
           <xref ref-type="bibr" rid="bib282">
            <sup>
             282
            </sup>
           </xref>
           The studies included in these reviews investigated a wide range of coated or impregnated catheters, including catheters coated or impregnated with: silver alloy,
           <xref ref-type="bibr" rid="bib279">
            279
           </xref>
           ,
           <xref ref-type="bibr" rid="bib280">
            280
           </xref>
           ,
           <xref ref-type="bibr" rid="bib282">
            282
           </xref>
           ,
           <xref ref-type="bibr" rid="bib283">
            283
           </xref>
           ,
           <xref ref-type="bibr" rid="bib284">
            284
           </xref>
           ,
           <xref ref-type="bibr" rid="bib285">
            285
           </xref>
           ,
           <xref ref-type="bibr" rid="bib286">
            286
           </xref>
           ,
           <xref ref-type="bibr" rid="bib287">
            287
           </xref>
           ,
           <xref ref-type="bibr" rid="bib288">
            288
           </xref>
           ,
           <xref ref-type="bibr" rid="bib289">
            289
           </xref>
           silver oxide,
           <xref ref-type="bibr" rid="bib280">
            <sup>
             280
            </sup>
           </xref>
           gendine,
           <xref ref-type="bibr" rid="bib290">
            <sup>
             290
            </sup>
           </xref>
           gentamicin,
           <xref ref-type="bibr" rid="bib291">
            <sup>
             291
            </sup>
           </xref>
           silver-hydrogel,
           <xref ref-type="bibr" rid="bib292">
            292
           </xref>
           ,
           <xref ref-type="bibr" rid="bib293">
            293
           </xref>
           ,
           <xref ref-type="bibr" rid="bib294">
            294
           </xref>
           minocycline,
           <xref ref-type="bibr" rid="bib294">
            <sup>
             294
            </sup>
           </xref>
           rifampicin,
           <xref ref-type="bibr" rid="bib295">
            <sup>
             295
            </sup>
           </xref>
           chlorhexidine-silver-sulfadiazine,
           <xref ref-type="bibr" rid="bib294">
            <sup>
             294
            </sup>
           </xref>
           chlorhexideine-sulfadiazine-triclosan,
           <xref ref-type="bibr" rid="bib294">
            <sup>
             294
            </sup>
           </xref>
           nitrofurazone
           <xref ref-type="bibr" rid="bib294">
            <sup>
             294
            </sup>
           </xref>
           and nitrofuroxone.
           <xref ref-type="bibr" rid="bib296">
            <sup>
             296
            </sup>
           </xref>
           Four studies compared the use of silver-coated (silver alloy or silver oxide) catheters with silicone, hydrogel or Teflon® latex.
           <xref ref-type="bibr" rid="bib297">
            297
           </xref>
           ,
           <xref ref-type="bibr" rid="bib298">
            298
           </xref>
           ,
           <xref ref-type="bibr" rid="bib299">
            299
           </xref>
           ,
           <xref ref-type="bibr" rid="bib300">
            300
           </xref>
           A systematic review and meta-analysis of these and other studies found that silver-alloy-coated (but not silver-oxide-coated) catheters were associated with a lower incidence of bacteriuria.
           <xref ref-type="bibr" rid="bib256">
            256
           </xref>
           ,
           <xref ref-type="bibr" rid="bib280">
            280
           </xref>
           Despite their unit cost, these devices may provide a cost-effective option if overall numbers of infections are reduced significantly through their use. However, the few studies that have explored the cost-benefit/cost-effectiveness of using these devices have been inconclusive.
           <xref ref-type="bibr" rid="bib285">
            285
           </xref>
           ,
           <xref ref-type="bibr" rid="bib287">
            287
           </xref>
           ,
           <xref ref-type="bibr" rid="bib289">
            289
           </xref>
           ,
           <xref ref-type="bibr" rid="bib291">
            291
           </xref>
          </p>
          <p id="para9120">
           We identified two new systematic reviews of the efficacy of silver-coated or antimicrobial-impregnated catheters for the prevention of CAUTI.
           <xref ref-type="bibr" rid="bib235">
            235
           </xref>
           ,
           <xref ref-type="bibr" rid="bib275">
            275
           </xref>
           The first systematic review included 22 RCTs, as well as one NRCT, and concluded that silver-coated (alloy or oxide) short-term indwelling urethral catheters reduced the risk of bacteriuria but did not demonstrate an effect on CAUTI.
           <xref ref-type="bibr" rid="bib275">
            <sup>
             275
            </sup>
           </xref>
           Catheters impregnated with antimicrobial agents (minocycline, rifampicin or nitrofurazone) were found to reduce the rate of bacteriuria during the first week of catheterisation, but not for catheter durations exceeding 1 week. Although antimicrobial-impregnated catheters reduced the risk of CAUTI, the number of cases was too small to demonstrate a significant effect. The second systematic review, which included nine RCTs and three quasi-experimental studies, concluded that, compared with standard catheters, both nitrofurazone-impregnated and silver-alloy-coated catheters can prevent and delay the onset of bacteriuria during short-term use. However, there were no data on the risk of CAUTI.
           <xref ref-type="bibr" rid="bib235">
            <sup>
             235
            </sup>
           </xref>
          </p>
          <p id="para9130">
           We identified one multi-centre RCT that compared silver-alloy-coated and nitrofurazone-impregnated catheters with standard Teflon-coated latex for short-term catheterisation.
           <xref ref-type="bibr" rid="bib301">
            <sup>
             301
            </sup>
           </xref>
           Although the nitrofurazone-impregnated and silver-alloy-coated catheters were associated with a reduced risk of CAUTI compared with the Teflon-coated latex, the effect was not considered to be clinically effective (adjusted OR 0.81, 95% CI 0.66–1.01 and adjusted OR 0.96, 95% CI 0.78–1.19, respectively). The nitrofurazone-impregnated catheter, but not the silver-alloy-coated catheter, was associated with a significantly lower incidence of bacteriuria (OR 0.68, 95% CI 0.48–0.99,
           <italic>
            p
           </italic>
           =0.017). However, the nitrofurazone-impregnated catheter was associated with increased discomfort during the period the catheter was in place. A major limitation of this study was that the median duration of catheterisation was 2 days (range 1–3 days) and the risk of CAUTI associated with this short period is correspondingly low. Also, UTIs developing up to 6 weeks post randomisation were included in the outcome measurement, even though they may not have been directly associated with catheterisation. The economic analysis suggested that nitrofurazone-impregnated catheters, but not silver-alloy-coated catheters, may be cost-effective, but the measures of cost were associated with a large amount of uncertainty.
          </p>
          <p id="para9140">
           Overall, the evidence suggests that silver-coated urethral catheters reduce the risk of bacteriuria, but there is insufficient evidence to indicate whether they reduce the risk of CAUTI in short-term catheterised patients.
          </p>
          <p id="para9150">
           <list id="celist1100" list-type="simple">
            <list-item id="celistitem4360">
             <label>
              UC4
             </label>
             <p id="para9160">
              Assess patient's needs prior to catheterisation in terms of:
              <list id="celist1110" list-type="simple">
               <list-item id="celistitem4370">
                <label>
                 •
                </label>
                <p id="para9170">
                 latex allergy;
                </p>
               </list-item>
               <list-item id="celistitem4380">
                <label>
                 •
                </label>
                <p id="para9180">
                 length of catheter (standard, female, paediatric);
                </p>
               </list-item>
               <list-item id="celistitem4390">
                <label>
                 •
                </label>
                <p id="para9190">
                 type of sterile drainage bag and sampling port (urometer, 2-L bag, leg bag) or catheter valve; and
                </p>
               </list-item>
               <list-item id="celistitem4400">
                <label>
                 •
                </label>
                <p id="para9200">
                 comfort and dignity.
                </p>
               </list-item>
              </list>
             </p>
             <p id="para9210">
              <bold>
               New recommendation
              </bold>
              <italic>
               Class D/GPP
              </italic>
             </p>
            </list-item>
            <list-item id="celistitem4410">
             <label>
              UC5
             </label>
             <p id="para9220">
              Select a catheter that minimises urethral trauma, irritation and patient discomfort, and is appropriate for the anticipated duration of catheterisation.
             </p>
             <p id="para9230">
              <italic>
               Class D/GPP
              </italic>
             </p>
            </list-item>
            <list-item id="celistitem4420">
             <label>
              UC6
             </label>
             <p id="para9240">
              Select the smallest gauge catheter that will allow urinary outflow and use a 10-mL retention balloon in adults (follow manufacturer's instructions for paediatric catheters). Urological patients may require larger gauge sizes and balloons.
             </p>
             <p id="para9250">
              <italic>
               Class D/GPP
              </italic>
             </p>
            </list-item>
           </list>
          </p>
         </sec>
        </sec>
        <sec id="cesec1610">
         <label>
          3.5
         </label>
         <title>
          Catheter Insertion
         </title>
         <sec id="cesec1620">
          <title>
           What technique should be used to insert a catheter?
          </title>
          <p id="para9260">
           In our previous review,
           <xref ref-type="bibr" rid="bib2">
            <sup>
             2
            </sup>
           </xref>
           we found evidence from one systematic review which suggested that the use of the aseptic technique has not demonstrated a reduction in the rate of CAUTI.
           <xref ref-type="bibr" rid="bib281">
            <sup>
             281
            </sup>
           </xref>
           However, principles of good practice, clinical guidance
           <xref ref-type="bibr" rid="bib258">
            258
           </xref>
           ,
           <xref ref-type="bibr" rid="bib302">
            302
           </xref>
           and expert opinion,
           <xref ref-type="bibr" rid="bib269">
            269
           </xref>
           ,
           <xref ref-type="bibr" rid="bib270">
            270
           </xref>
           ,
           <xref ref-type="bibr" rid="bib303">
            303
           </xref>
           ,
           <xref ref-type="bibr" rid="bib304">
            304
           </xref>
           ,
           <xref ref-type="bibr" rid="bib305">
            305
           </xref>
           ,
           <xref ref-type="bibr" rid="bib306">
            306
           </xref>
           ,
           <xref ref-type="bibr" rid="bib307">
            307
           </xref>
           together with findings from another systematic review,
           <xref ref-type="bibr" rid="bib256">
            <sup>
             256
            </sup>
           </xref>
           agree that short-term indwelling urethral catheters must be inserted using sterile equipment and the aseptic technique.
          </p>
          <p id="para9270">
           Expert opinion indicates that there is no advantage in using antiseptic preparations for cleansing the urethral meatus prior to catheter insertion.
           <xref ref-type="bibr" rid="bib230">
            230
           </xref>
           ,
           <xref ref-type="bibr" rid="bib258">
            258
           </xref>
           ,
           <xref ref-type="bibr" rid="bib269">
            269
           </xref>
           ,
           <xref ref-type="bibr" rid="bib270">
            270
           </xref>
           Whilst there is low-quality evidence to suggest that pre-lubrication of the catheter decreases the risk of bacteriuria, it is also important to use lubricant or anaesthetic gel in order to minimise urethral trauma and discomfort.
           <xref ref-type="bibr" rid="bib230">
            <sup>
             230
            </sup>
           </xref>
           There is no evidence suggesting a general benefit of securing the catheter in terms of preventing the risk of CAUTI, but it is important in order to minimise patient discomfort.
           <xref ref-type="bibr" rid="bib230">
            <sup>
             230
            </sup>
           </xref>
           Ensuring healthcare practitioners are trained and competent in the insertion of short-term indwelling urethral catheters will minimise trauma, discomfort and the potential for CAUTI.
           <xref ref-type="bibr" rid="bib270">
            270
           </xref>
           ,
           <xref ref-type="bibr" rid="bib302">
            302
           </xref>
           ,
           <xref ref-type="bibr" rid="bib306">
            306
           </xref>
           ,
           <xref ref-type="bibr" rid="bib307">
            307
           </xref>
          </p>
          <p id="para9280">
           Neither we nor HICPAC identified any additional evidence of acceptable quality whilst updating our systematic review.
           <xref ref-type="bibr" rid="bib230">
            <sup>
             230
            </sup>
           </xref>
           <list id="celist1120" list-type="simple">
            <list-item id="celistitem4430">
             <label>
              UC7
             </label>
             <p id="para9290">
              Catheterisation is an aseptic procedure and should only be undertaken by healthcare workers trained and competent in this procedure.
             </p>
             <p id="para9300">
              <italic>
               Class D/GPP
              </italic>
             </p>
            </list-item>
            <list-item id="celistitem4440">
             <label>
              UC8
             </label>
             <p id="para9310">
              Clean the urethral meatus with sterile, normal saline prior to the insertion of the catheter.
             </p>
             <p id="para9320">
              <italic>
               Class D/GPP
              </italic>
             </p>
            </list-item>
            <list-item id="celistitem4450">
             <label>
              UC9
             </label>
             <p id="para9330">
              Use lubricant from a sterile single-use container to minimise urethral discomfort, trauma and the risk of infection. Ensure the catheter is secured comfortably.
             </p>
             <p id="para9340">
              <italic>
               Class D/GPP
              </italic>
             </p>
            </list-item>
           </list>
          </p>
         </sec>
        </sec>
        <sec id="cesec1630">
         <label>
          3.6
         </label>
         <title>
          Catheter Maintenance
         </title>
         <sec id="cesec1640">
          <title>
           How should the drainage system be managed?
          </title>
          <p id="para9350">
           Maintaining a sterile, continuously closed urinary drainage system is central to the prevention of CAUTI.
           <xref ref-type="bibr" rid="bib258">
            258
           </xref>
           ,
           <xref ref-type="bibr" rid="bib270">
            270
           </xref>
           ,
           <xref ref-type="bibr" rid="bib302">
            302
           </xref>
           ,
           <xref ref-type="bibr" rid="bib306">
            306
           </xref>
           ,
           <xref ref-type="bibr" rid="bib308">
            308
           </xref>
           ,
           <xref ref-type="bibr" rid="bib309">
            309
           </xref>
           The risk of infection reduces from 97% with an open system to 8–15% when a sterile closed system is employed.
           <xref ref-type="bibr" rid="bib269">
            269
           </xref>
           ,
           <xref ref-type="bibr" rid="bib307">
            307
           </xref>
           ,
           <xref ref-type="bibr" rid="bib310">
            310
           </xref>
           Breaches in the closed system, such as unnecessary emptying, changing of the urinary drainage bag or taking a urine sample, will increase the risk of CAUTI and therefore should be avoided.
           <xref ref-type="bibr" rid="bib269">
            269
           </xref>
           ,
           <xref ref-type="bibr" rid="bib302">
            302
           </xref>
           ,
           <xref ref-type="bibr" rid="bib311">
            311
           </xref>
           Hands must be decontaminated, and clean and non-sterile gloves should be worn before manipulation of the catheter or the closed system, including drainage taps. A systematic review has suggested that sealed (e.g. taped, pre-sealed) drainage systems contribute to preventing bacteriuria.
           <xref ref-type="bibr" rid="bib281">
            <sup>
             281
            </sup>
           </xref>
           However, there is limited evidence regarding how often catheter bags should be changed. One study showed that higher rates of symptomatic and asymptomatic CAUTI were associated with a 3-day urinary drainage bag change regimen compared with no routine change regimen.
           <xref ref-type="bibr" rid="bib312">
            <sup>
             312
            </sup>
           </xref>
           Best practice suggests that drainage bags should only be changed when necessary (i.e. according either to the manufacturer's recommendations or the patient's clinical need).
           <xref ref-type="bibr" rid="bib258">
            258
           </xref>
           ,
           <xref ref-type="bibr" rid="bib302">
            302
           </xref>
           Reflux of urine is associated with infection and, consequently, drainage bags should be positioned in a way that ensures the free flow of urine and prevents back-flow.
           <xref ref-type="bibr" rid="bib270">
            270
           </xref>
           ,
           <xref ref-type="bibr" rid="bib302">
            302
           </xref>
           It is also recommended that urinary drainage bags should be hung on an appropriate stand that prevents contact with the floor.
           <xref ref-type="bibr" rid="bib269">
            <sup>
             269
            </sup>
           </xref>
          </p>
          <p id="para9360">
           A number of studies have investigated the addition of disinfectants and antimicrobials to drainage bags as a way of preventing CAUTI.
           <xref ref-type="bibr" rid="bib256">
            <sup>
             256
            </sup>
           </xref>
           Three acceptable studies
           <xref ref-type="bibr" rid="bib313">
            313
           </xref>
           ,
           <xref ref-type="bibr" rid="bib314">
            314
           </xref>
           ,
           <xref ref-type="bibr" rid="bib315">
            315
           </xref>
           from our original systematic review
           <xref ref-type="bibr" rid="bib1">
            <sup>
             1
            </sup>
           </xref>
           demonstrated no reduction in the incidence of bacteriuria following the addition of hydrogen peroxide or chlorhexidine to urinary drainage bags. These findings are supported by a further systematic review, which suggested that adding bacterial solutions to drainage bags had no effect on catheter-associated infection.
           <xref ref-type="bibr" rid="bib281">
            <sup>
             281
            </sup>
           </xref>
          </p>
          <p id="para9370">
           Neither we nor HICPAC identified any additional evidence of acceptable quality whilst updating our systematic review.
           <xref ref-type="bibr" rid="bib230">
            <sup>
             230
            </sup>
           </xref>
           <list id="celist1130" list-type="simple">
            <list-item id="celistitem4460">
             <label>
              UC10
             </label>
             <p id="para9380">
              Connect a short-term indwelling urethral catheter to a sterile closed urinary drainage system with a sampling port.
             </p>
             <p id="para9390">
              <italic>
               Class A
              </italic>
             </p>
            </list-item>
            <list-item id="celistitem4470">
             <label>
              UC11
             </label>
             <p id="para9400">
              Do not break the connection between the catheter and the urinary drainage system unless clinically indicated.
             </p>
             <p id="para9410">
              <italic>
               Class A
              </italic>
             </p>
            </list-item>
            <list-item id="celistitem4480">
             <label>
              UC12
             </label>
             <p id="para9420">
              Change short-term indwelling urethral catheters and/or drainage bags when clinically indicated and in line with the manufacturer's recommendations.
             </p>
             <p id="para9430">
              <bold>
               New recommendation
              </bold>
              <italic>
               Class D/GPP
              </italic>
             </p>
            </list-item>
            <list-item id="celistitem4490">
             <label>
              UC13
             </label>
             <p id="para9440">
              Decontaminate hands and wear a new pair of clean non-sterile gloves before manipulating each patient's catheter. Decontaminate hands immediately following the removal of gloves.
             </p>
             <p id="para9450">
              <italic>
               Class D/GPP
              </italic>
             </p>
            </list-item>
            <list-item id="celistitem4500">
             <label>
              UC14
             </label>
             <p id="para9460">
              Use the sampling port and the aseptic technique to obtain a catheter sample of urine.
             </p>
             <p id="para9470">
              <italic>
               Class D/GPP
              </italic>
             </p>
            </list-item>
            <list-item id="celistitem4510">
             <label>
              UC15
             </label>
             <p id="para9480">
              Position the urinary drainage bag below the level of the bladder on a stand that prevents contact with the floor.
             </p>
             <p id="para9490">
              <italic>
               Class D/GPP
              </italic>
             </p>
            </list-item>
            <list-item id="celistitem4520">
             <label>
              UC16
             </label>
             <p id="para9500">
              Do not allow the urinary drainage bag to fill beyond three-quarters full.
             </p>
             <p id="para9510">
              <italic>
               Class D/GPP
              </italic>
             </p>
            </list-item>
            <list-item id="celistitem4530">
             <label>
              UC17
             </label>
             <p id="para9520">
              Use a separate, clean container for each patient and avoid contact between the urinary drainage tap and the container when emptying the drainage bag.
             </p>
             <p id="para9530">
              <italic>
               Class D/GPP
              </italic>
             </p>
            </list-item>
            <list-item id="celistitem4540">
             <label>
              UC18
             </label>
             <p id="para9540">
              Do not add antiseptic or antimicrobial solutions to urinary drainage bags.
             </p>
             <p id="para9550">
              <italic>
               Class A
              </italic>
             </p>
            </list-item>
           </list>
          </p>
         </sec>
         <sec id="cesec1650">
          <title>
           Routine meatal cleansing with antiseptic solutions is unnecessary
          </title>
          <p id="para9560">
           Our previous systematic reviews
           <xref ref-type="bibr" rid="bib1">
            1
           </xref>
           ,
           <xref ref-type="bibr" rid="bib2">
            2
           </xref>
           found eight acceptable studies that compared meatal cleansing with a variety of antiseptic/antimicrobial agents or soap and water. No reduction in bacteriuria was demonstrated when using any of these preparations for meatal/peri-urethral hygiene compared with routine bathing or showering.
           <xref ref-type="bibr" rid="bib281">
            281
           </xref>
           ,
           <xref ref-type="bibr" rid="bib316">
            316
           </xref>
           ,
           <xref ref-type="bibr" rid="bib317">
            317
           </xref>
           ,
           <xref ref-type="bibr" rid="bib318">
            318
           </xref>
           ,
           <xref ref-type="bibr" rid="bib319">
            319
           </xref>
           ,
           <xref ref-type="bibr" rid="bib320">
            320
           </xref>
           ,
           <xref ref-type="bibr" rid="bib321">
            321
           </xref>
           ,
           <xref ref-type="bibr" rid="bib322">
            322
           </xref>
          </p>
          <p id="para9570">
           Expert opinion and other systematic reviews support the view that active meatal cleansing is not necessary and may increase the risk of infection.
           <xref ref-type="bibr" rid="bib56">
            56
           </xref>
           ,
           <xref ref-type="bibr" rid="bib230">
            230
           </xref>
           ,
           <xref ref-type="bibr" rid="bib256">
            256
           </xref>
           ,
           <xref ref-type="bibr" rid="bib258">
            258
           </xref>
           ,
           <xref ref-type="bibr" rid="bib269">
            269
           </xref>
           ,
           <xref ref-type="bibr" rid="bib270">
            270
           </xref>
           Daily routine bathing or showering is all that is needed in order to maintain patient comfort.
          </p>
          <p id="para9580">
           Neither we nor HICPAC identified any additional evidence of acceptable quality whilst updating our systematic review.
           <xref ref-type="bibr" rid="bib230">
            <sup>
             230
            </sup>
           </xref>
           <list id="celist1140" list-type="simple">
            <list-item id="celistitem4550">
             <label>
              UC19
             </label>
             <p id="para9590">
              Routine daily personal hygiene is all that is required for meatal cleansing.
             </p>
             <p id="para9600">
              <italic>
               Class A
              </italic>
             </p>
            </list-item>
           </list>
          </p>
         </sec>
         <sec id="cesec1660">
          <title>
           Irrigation, instillation and washout do not prevent infection
          </title>
          <p id="para9610">
           Evidence from our previous systematic review did not demonstrate any beneficial effect of bladder irrigation, instillation or washout with a variety of antiseptic or antimicrobial agents for the prevention of CAUTI.
           <xref ref-type="bibr" rid="bib1">
            1
           </xref>
           ,
           <xref ref-type="bibr" rid="bib2">
            2
           </xref>
           ,
           <xref ref-type="bibr" rid="bib323">
            323
           </xref>
           ,
           <xref ref-type="bibr" rid="bib324">
            324
           </xref>
           ,
           <xref ref-type="bibr" rid="bib325">
            325
           </xref>
           ,
           <xref ref-type="bibr" rid="bib326">
            326
           </xref>
           ,
           <xref ref-type="bibr" rid="bib327">
            327
           </xref>
           ,
           <xref ref-type="bibr" rid="bib328">
            328
           </xref>
           ,
           <xref ref-type="bibr" rid="bib329">
            329
           </xref>
           ,
           <xref ref-type="bibr" rid="bib330">
            330
           </xref>
           ,
           <xref ref-type="bibr" rid="bib331">
            331
           </xref>
          </p>
          <p id="para9620">
           Evidence from best practice supports these findings of no beneficial effect, and indicates that the introduction of such bladder maintenance solutions may have local toxic effects and contribute to the development of resistant microorganisms. However, continuous or intermittent bladder irrigation may be required for other urological or catheter management indications.
           <xref ref-type="bibr" rid="bib256">
            256
           </xref>
           ,
           <xref ref-type="bibr" rid="bib258">
            258
           </xref>
           ,
           <xref ref-type="bibr" rid="bib269">
            269
           </xref>
           ,
           <xref ref-type="bibr" rid="bib270">
            270
           </xref>
           ,
           <xref ref-type="bibr" rid="bib302">
            302
           </xref>
           <list id="celist1150" list-type="simple">
            <list-item id="celistitem4560">
             <label>
              UC20
             </label>
             <p id="para9630">
              Do not use bladder maintenance solutions to prevent catheter-associated urinary tract infection.
             </p>
             <p id="para9640">
              <italic>
               Class A
              </italic>
             </p>
            </list-item>
           </list>
          </p>
         </sec>
        </sec>
        <sec id="cesec1670">
         <label>
          3.7
         </label>
         <title>
          Education of Patients, Relatives and Healthcare Workers
         </title>
         <p id="para9650">
          Given the frequency of urinary catheterisation in hospital patients and the associated risk of UTI, it is important that patients, their relatives and healthcare workers responsible for catheter insertion and management are educated about infection prevention. All those involved must be aware of the signs and symptoms of UTI and how to access expert help when difficulties arise. Healthcare professionals must be confident and proficient in associated procedures.
         </p>
         <p id="para9660">
          We identified two systematic reviews that reported evidence of the efficacy of healthcare workers' education in reducing the risk of CAUTI within other system interventions.
          <xref ref-type="bibr" rid="bib264">
           264
          </xref>
          ,
          <xref ref-type="bibr" rid="bib332">
           332
          </xref>
          Most of the studies included in these reviews provided low-grade evidence from uncontrolled before-after studies where a combination of different system interventions focusing on reducing the use of urethral catheters and risk of CAUTI were introduced. The first systematic review
          <xref ref-type="bibr" rid="bib264">
           <sup>
            264
           </sup>
          </xref>
          identified one small controlled before-after study
          <xref ref-type="bibr" rid="bib263">
           <sup>
            263
           </sup>
          </xref>
          of an educational intervention with guideline change and posters that was associated with a reduction in use of urethral catheters [relative risk (RR) 0.86, 95% CI 0.68–1.10]. Another systematic review included one controlled before-after study that demonstrated a significant (
          <italic>
           p
          </italic>
          &lt;0.01) increase in adherence to a clinical guideline on the insertion and maintenance of urethral catheters in association with an education programme.
          <xref ref-type="bibr" rid="bib332">
           332
          </xref>
          ,
          <xref ref-type="bibr" rid="bib333">
           333
          </xref>
          A further study reported a reduction in CAUTI and an increase in adherence to protocols for hand hygiene and catheter care in association with an education programme. However, this study did not include a control group.
          <xref ref-type="bibr" rid="bib100">
           <sup>
            100
           </sup>
          </xref>
          <list id="celist1160" list-type="simple">
           <list-item id="celistitem4570">
            <label>
             UC21
            </label>
            <p id="para9670">
             Healthcare workers should be trained and competent in the appropriate use, selection, insertion, maintenance and removal of short-term indwelling urethral catheters.
            </p>
            <p id="para9680">
             <italic>
              Class D/GPP
             </italic>
            </p>
           </list-item>
           <list-item id="celistitem4580">
            <label>
             UC22
            </label>
            <p id="para9690">
             Ensure patients, relatives and carers are given information regarding the reason for the catheter and the plan for review and removal. If discharged with a catheter, the patient should be given written information and shown how to:
             <list id="celist1170" list-type="simple">
              <list-item id="celistitem4590">
               <label>
                •
               </label>
               <p id="para9700">
                manage the catheter and drainage system;
               </p>
              </list-item>
              <list-item id="celistitem4600">
               <label>
                •
               </label>
               <p id="para9710">
                minimise the risk of urinary tract infection; and
               </p>
              </list-item>
              <list-item id="celistitem4610">
               <label>
                •
               </label>
               <p id="para9720">
                obtain additional supplies suitable for individual needs.
               </p>
              </list-item>
             </list>
            </p>
            <p id="para9730">
             <italic>
              Class D/GPP
             </italic>
            </p>
           </list-item>
          </list>
         </p>
        </sec>
        <sec id="cesec1680">
         <label>
          3.8
         </label>
         <title>
          System Interventions for Reducing the Risk of Infection
         </title>
         <p id="para9740">
          A number of studies have reported the effect of quality improvement programmes on the risk of CAUTI.
          <xref ref-type="bibr" rid="bib230">
           <sup>
            230
           </sup>
          </xref>
          The components of these programmes include various combinations of clinical guidelines for catheter insertion and maintenance, education, audit and feedback of compliance with policy, physician/nurse reminder systems (to prompt removal if no longer necessary), automated or nurse-driven removal protocols [where the catheter is removed after a specified period (e.g. 48–72 h) unless countermanded by the physician] and the use of bladder scanners to assess urinary retention and support appropriate catheterisation.
          <xref ref-type="bibr" rid="bib230">
           <sup>
            230
           </sup>
          </xref>
         </p>
         <p id="para9750">
          We identified three systematic reviews relevant to this question.
          <xref ref-type="bibr" rid="bib261">
           261
          </xref>
          ,
          <xref ref-type="bibr" rid="bib264">
           264
          </xref>
          ,
          <xref ref-type="bibr" rid="bib332">
           332
          </xref>
          The first was a review of interventions to remind physicians/nurses to remove unnecessary catheters and the outcome on CAUTI, short-term indwelling urethral catheter use and catheter replacement. It included 14 studies (one RCT, one NRCT, three controlled before-after studies and nine uncontrolled before-after studies).
          <xref ref-type="bibr" rid="bib261">
           <sup>
            261
           </sup>
          </xref>
          Interventions included prewritten or computer-generated stop orders, nurse-generated daily bedside reminders to remove catheters, and daily use of a checklist or protocol to review need for the catheter. Some studies also implemented catheter placement restrictions and education. The meta-analysis suggested that the use of reminder or stop order systems reduced the rate of CAUTI by 52% (
          <italic>
           p
          </italic>
          &lt;0.001) and the mean duration of catheterisation by 37%, with 2.61 fewer days of catheterisation in the intervention group compared with the control group, and no difference in re-catheterisation rates.
         </p>
         <p id="para9760">
          The second systematic review was a review of interventions to minimise the placement of urethral catheters in acute care patients.
          <xref ref-type="bibr" rid="bib264">
           <sup>
            264
           </sup>
          </xref>
          It included one RCT, one NRCT and six uncontrolled before-after studies. Interventions included various combinations of clinician reminders, stop orders and indication checklists, use of bladder scanners and education. The authors concluded that the studies were too small and heterogeneous to draw a definitive conclusion about efficacy in terms of reducing inappropriate catheter placement.
         </p>
         <p id="para9770">
          The third systematic review included three controlled before-after studies and seven uncontrolled before-after studies measuring interventions that increased adherence to catheter care protocols or reduced unnecessary catheter use.
          <xref ref-type="bibr" rid="bib332">
           <sup>
            332
           </sup>
          </xref>
          Interventions included reminders, stop orders, use of bladder scanners, education and catheterisation protocols with audit and feedback on performance. Physician/nurse reminders, particularly automatic stop orders, were found to reduce the duration of catheterisation, although there were insufficient data to determine their effect on CAUTI.
         </p>
         <p id="para9780">
          Many studies in this area are uncontrolled before-after designs and therefore susceptible to bias in favour of the intervention. However, these interventions constitute best practice, and this evidence supports the use of systems to minimise the insertion of catheters and promote timely removal to reduce both the duration of catheterisation and the risk of CAUTI.
         </p>
         <p id="para9790">
          <list id="celist1180" list-type="simple">
           <list-item id="celistitem4620">
            <label>
             UC23
            </label>
            <p id="para9800">
             Use quality improvement systems to support the appropriate use and management of short-term urethral catheters and ensure their timely removal. These may include:
             <list id="celist1190" list-type="simple">
              <list-item id="celistitem4630">
               <label>
                •
               </label>
               <p id="para9810">
                protocols for catheter insertion;
               </p>
              </list-item>
              <list-item id="celistitem4640">
               <label>
                •
               </label>
               <p id="para9820">
                use of bladder ultrasound scanners to assess and manage urinary retention;
               </p>
              </list-item>
              <list-item id="celistitem4650">
               <label>
                •
               </label>
               <p id="para9830">
                reminders to review the continuing use or prompt the removal of catheters;
               </p>
              </list-item>
              <list-item id="celistitem4660">
               <label>
                •
               </label>
               <p id="para9840">
                audit and feedback of compliance with practice guidelines; and
               </p>
              </list-item>
              <list-item id="celistitem4670">
               <label>
                •
               </label>
               <p id="para9850">
                continuing professional education.
               </p>
              </list-item>
             </list>
            </p>
            <p id="para9860">
             <bold>
              New recommendation
             </bold>
             <italic>
              Class D/GPP
             </italic>
            </p>
           </list-item>
           <list-item id="celistitem4680">
            <label>
             UC24
            </label>
            <p id="para9870">
             No patient should be discharged or transferred with a short-term indwelling urethral catheter without a plan documenting the:
             <list id="celist1200" list-type="simple">
              <list-item id="celistitem4690">
               <label>
                •
               </label>
               <p id="para9880">
                reason for the catheter;
               </p>
              </list-item>
              <list-item id="celistitem4700">
               <label>
                •
               </label>
               <p id="para9890">
                clinical indications for continuing catheterisation; and
               </p>
              </list-item>
              <list-item id="celistitem4710">
               <label>
                •
               </label>
               <p id="para9900">
                date for removal or review by an appropriate clinician overseeing their care.
               </p>
              </list-item>
             </list>
            </p>
            <p id="para9910">
             <bold>
              New recommendation
             </bold>
             <italic>
              Class D/GPP
             </italic>
            </p>
           </list-item>
          </list>
         </p>
        </sec>
        <sec id="cesec1690">
         <title>
          Short-term Indwelling Urethral Catheters Systematic Review Process
         </title>
         <p id="para9920">
          <boxed-text id="cetextbox460">
           <sec id="cesec1700">
            <title>
             <inline-graphic xlink:href="fx2_lrg.gif">
             </inline-graphic>
             Systematic Review Questions
            </title>
            <p id="para9930">
             <list id="celist1210" list-type="simple">
              <list-item id="celistitem4720">
               <label>
                1.
               </label>
               <p id="para9940">
                What are the clinical indications for the use of short-term urinary catheters?(*B)
               </p>
              </list-item>
              <list-item id="celistitem4730">
               <label>
                2.
               </label>
               <p id="para9950">
                What is the risk associated with short-term catheterisation in terms of bacteriuria, CAUTI, other morbidities and mortality? (B)
               </p>
              </list-item>
              <list-item id="celistitem4740">
               <label>
                3.
               </label>
               <p id="para9960">
                What is the effectiveness (in terms of patient acceptability and reduced risk of bacteriuria, CAUTI, other morbidities and mortality) and the cost-effectiveness of different types of short-term indwelling urinary catheters (material, coatings and design)?
               </p>
              </list-item>
              <list-item id="celistitem4750">
               <label>
                4.
               </label>
               <p id="para9970">
                What is the most effective catheter insertion technique in terms of patient acceptability and minimisation of urethral trauma, bacteriuria, CAUTI and other morbidities?
               </p>
              </list-item>
              <list-item id="celistitem4760">
               <label>
                5.
               </label>
               <p id="para9980">
                What is the most effective and cost-effective means of maintaining meatal hygiene and a closed drainage system?
               </p>
              </list-item>
              <list-item id="celistitem4770">
               <label>
                6.
               </label>
               <p id="para9990">
                What is the effectiveness of system interventions in reducing the use and duration of short-term urinary catheterisation to minimise the risk of bacteriuria, CAUTI, other morbidities and mortality?
               </p>
              </list-item>
              <list-item id="celistitem4780">
               <label>
                7.
               </label>
               <p id="para10000">
                What is the effectiveness of system interventions in improving healthcare workers knowledge and behaviour relating to the insertion, maintenance and timely removal of indwelling urinary catheters to minimise the risk of bacteriuria, CAUTI, other morbidities and mortality?
               </p>
               <p id="para10010">
                *B: Background question
               </p>
              </list-item>
             </list>
            </p>
           </sec>
          </boxed-text>
         </p>
         <p id="para10020">
          <boxed-text id="cetextbox470">
           <sec id="cesec1710">
            <title>
             <inline-graphic xlink:href="fx2_lrg.gif">
             </inline-graphic>
             Databases and Search Terms Used
            </title>
            <p id="para10030">
             <bold>
              DATABASES
             </bold>
            </p>
            <p id="para10040">
             Medline, Cumulative Index to Nursing and Allied Health Literature (CINAHL), Embase, NEHL Guideline Finder, National Institute for Healthand Clinical Excellence, the Cochrane Library (CDSR, CCRCT, CMR), US Guideline Clearing House, DARE (NHS Evidence, HTA), Prospero
            </p>
            <p id="para10050">
             <bold>
              MeSH TERMS
             </bold>
            </p>
            <p id="para10060">
             Infection control; cross infection; disease transmission; urinary tract infections; urinary catheterisation; indwelling catheters; irrigation; biofilms; hydrogen ion concentration; nursing education; nursing care; inservice training
            </p>
            <p id="para10070">
             <bold>
              THESAURUS AND FREETEXT TERMS
             </bold>
            </p>
            <p id="para10080">
             Urinary catheterisation; urinary tract infection; cross infection; disease transmission; bacteriuria; funguria; encrustation; bladder irrigation; washout; lubrication; urinary dipstick; patient education; quality improvement
            </p>
            <p id="para10090">
             <bold>
              SEARCH DATE
             </bold>
            </p>
            <p id="para10100">
             Jan 2007–Apr 2013
            </p>
           </sec>
          </boxed-text>
         </p>
         <p id="para10110">
          <boxed-text id="cetextbox480">
           <sec id="cesec1720">
            <title>
             <inline-graphic xlink:href="fx2_lrg.gif">
             </inline-graphic>
             Search Results
            </title>
            <p id="para10120">
             Total number of articles located = 7073
            </p>
           </sec>
          </boxed-text>
         </p>
         <p id="para10130">
          <boxed-text id="cetextbox490">
           <sec id="cesec1730">
            <title>
             <inline-graphic xlink:href="fx2_lrg.gif">
             </inline-graphic>
             Sift 1 Criteria
            </title>
            <p id="para10140">
             <bold>
              Abstract indicates
             </bold>
             that the article: relates to infections associated with short-term indwelling urethral catheters; is written in English; is primary research, a systematic review or a meta-analysis; and appears to inform one or more of the review questions.
            </p>
           </sec>
          </boxed-text>
         </p>
         <p id="para10150">
          <boxed-text id="cetextbox500">
           <sec id="cesec1740">
            <title>
             <inline-graphic xlink:href="fx2_lrg.gif">
             </inline-graphic>
             Articles Retrieved
            </title>
            <p id="para10160">
             Total number of articles retrieved from Sift 1 = 54
            </p>
           </sec>
          </boxed-text>
         </p>
         <p id="para10170">
          <boxed-text id="cetextbox510">
           <sec id="cesec1750">
            <title>
             <inline-graphic xlink:href="fx2_lrg.gif">
             </inline-graphic>
             Sift 2 Criteria
            </title>
            <p id="para10180">
             <bold>
              Full text confirms
             </bold>
             that the article: relates to infections associated with short-term indwelling urethral catheters; is written in English; is primary research (randomised controlled trials, prospective cohort, interrupted time series, controlled beforeafter, quasiexperimental), a systematic review or a meta-analysis including the above designs; and informs one or more of the review questions.
            </p>
           </sec>
          </boxed-text>
         </p>
         <p id="para10190">
          <boxed-text id="cetextbox520">
           <sec id="cesec1760">
            <title>
             <inline-graphic xlink:href="fx2_lrg.gif">
             </inline-graphic>
             Articles Selected for Appraisal
            </title>
            <p id="para10200">
             Total number of studies selected for appraisal during Sift 2 = 16
            </p>
           </sec>
          </boxed-text>
         </p>
         <p id="para10210">
          <boxed-text id="cetextbox530">
           <sec id="cesec1770">
            <title>
             <inline-graphic xlink:href="fx2_lrg.gif">
             </inline-graphic>
             Critical Appraisal
            </title>
            <p id="para10220">
             All articles that described primary research, a systematic review or a meta-analysis and met the Sift 2 criteria were independently critically appraised by two appraisers using SIGN and EPOC criteria. Consensus and grading was achieved through discussion.
            </p>
           </sec>
          </boxed-text>
         </p>
         <p id="para10230">
          <boxed-text id="cetextbox540">
           <sec id="cesec1780">
            <title>
             <inline-graphic xlink:href="fx2_lrg.gif">
             </inline-graphic>
             Accepted and Rejected Evidence
            </title>
            <p id="para10240">
             Total number of studies accepted after critical
             <bold>
              appraisal = 6
             </bold>
            </p>
            <p id="para10250">
             Total number of studies rejected after critical
             <bold>
              appraisal = 10
             </bold>
            </p>
           </sec>
          </boxed-text>
         </p>
        </sec>
       </sec>
      </sec>
      <sec id="cesec1790">
       <label>
        4
       </label>
       <title>
        Guidelines for Preventing Infections Associated with the Use of Intravascular Access Devices
       </title>
       <sec id="cesec1800">
        <label>
         4.1
        </label>
        <title>
         Introduction
        </title>
        <p id="para10260">
         This guidance is based on the best critically appraised evidence currently available. The type and class of supporting evidence explicitly linked to each recommendation is described. Evidence identified in the HICPAC systematic review was used to support the recommendations in these guidelines.
         <xref ref-type="bibr" rid="bib334">
          <sup>
           334
          </sup>
         </xref>
         Some recommendations from the previous guidelines have been revised to improve clarity; where a new recommendation has been made, this is indicated in the text. These recommendations are not detailed procedural protocols, and need to be incorporated into local guidelines. None are regarded as optional.
        </p>
       </sec>
       <sec id="cesec1810">
        <title>
         Background and context to the guidelines
        </title>
        <p id="para10270">
         Intravascular access devices, including peripheral, central venous and arterial catheters, are commonly used in the management of patients in acute and chronic care settings. CVCs are frequently used during clinical care and include peripherally inserted, non-tunnelled and tunnelled, and totally implantable CVCs (
         <xref ref-type="table" rid="tbl3">
          Table 3
         </xref>
         ).
         <xref ref-type="bibr" rid="bib334">
          <sup>
           334
          </sup>
         </xref>
         The use of any of these catheters can result in bloodstream infection.
         <table-wrap id="tbl3" position="float">
          <label>
           Table 3
          </label>
          <caption>
           <p>
            Catheters used for venous and arterial access
           </p>
          </caption>
          <table frame="hsides" rules="groups">
           <thead>
            <tr>
             <th align="left">
              Catheter type
             </th>
             <th align="left">
              Features
             </th>
             <th align="left">
              Common use
             </th>
             <th align="left">
              Duration
             </th>
            </tr>
           </thead>
           <tbody>
            <tr>
             <td align="left">
              <bold>
               Peripheral
              </bold>
             </td>
             <td>
             </td>
             <td>
             </td>
             <td>
             </td>
            </tr>
            <tr>
             <td align="left">
              Peripheral venous catheters
             </td>
             <td align="left">
              Peripheral single lumen Inserted in veins of forearm or hand in adults
             </td>
             <td align="left">
              Administration of fluid/blood and medication
             </td>
             <td align="left">
              Short, up to 7–10 days
             </td>
            </tr>
            <tr>
             <td align="left">
              Peripheral arterial catheters
             </td>
             <td align="left">
              <list id="celist90" list-type="simple">
               <list-item id="celistitem190">
                <p id="para190">
                 Single lumen, large calibre
                </p>
               </list-item>
               <list-item id="celistitem200">
                <p id="para200">
                 Most commonly placed in radial artery; alternatives are femoral, axillary, brachial and posterior tibial arteries
                </p>
               </list-item>
              </list>
             </td>
             <td align="left">
              <list id="celist100" list-type="simple">
               <list-item id="celistitem210">
                <p id="para210">
                 Haemodynamic monitoring
                </p>
               </list-item>
               <list-item id="celistitem220">
                <p id="para220">
                 Access/blood draw
                </p>
               </list-item>
               <list-item id="celistitem230">
                <p id="para230">
                 Administration of fluid and medication
                </p>
               </list-item>
              </list>
             </td>
             <td align="left">
              Short, up to 7–10 days
             </td>
            </tr>
            <tr>
             <td align="left">
              Midline catheters
             </td>
             <td align="left">
              Commonly placed in proximal basilic or cephalic veins via the antecubital fossa. Does not enter central veins
             </td>
             <td align="left">
              Administration of fluid, blood and medication
             </td>
             <td align="left">
              Short, 1–4 weeks
             </td>
            </tr>
            <tr>
             <td align="left">
              <bold>
               Central
              </bold>
             </td>
             <td>
             </td>
             <td>
             </td>
             <td>
             </td>
            </tr>
            <tr>
             <td align="left">
              Non-tunnelled central venous catheters
             </td>
             <td align="left">
              <list id="celist110" list-type="simple">
               <list-item id="celistitem240">
                <p id="para240">
                 Single and multiple (up to five) lumens
                </p>
               </list-item>
               <list-item id="celistitem250">
                <p id="para250">
                 Percutaneously inserted into subclavian, internal jugular or femoral veins
                </p>
               </list-item>
              </list>
             </td>
             <td align="left">
              <list id="celist120" list-type="simple">
               <list-item id="celistitem260">
                <p id="para260">
                 Administration of fluid, blood and medication
                </p>
               </list-item>
               <list-item id="celistitem270">
                <p id="para270">
                 Access/blood draw
                </p>
               </list-item>
               <list-item id="celistitem280">
                <p id="para280">
                 Multi-lumen catheters used for administration of parenteral nutrition
                </p>
               </list-item>
              </list>
             </td>
             <td align="left">
              Short, up to 7–10 days
             </td>
            </tr>
            <tr>
             <td align="left">
              Tunnelled central venous catheters
             </td>
             <td align="left">
              <list id="celist130" list-type="simple">
               <list-item id="celistitem290">
                <p id="para290">
                 Image guided or surgical placement
                </p>
               </list-item>
               <list-item id="celistitem300">
                <p id="para300">
                 Implanted into subclavian, internal jugular or femoral veins
                </p>
               </list-item>
              </list>
             </td>
             <td align="left">
              <list id="celist140" list-type="simple">
               <list-item id="celistitem310">
                <p id="para310">
                 Frequent long-term access
                </p>
               </list-item>
               <list-item id="celistitem320">
                <p id="para320">
                 Parenteral nutrition
                </p>
               </list-item>
               <list-item id="celistitem330">
                <p id="para330">
                 Transfusion
                </p>
               </list-item>
               <list-item id="celistitem340">
                <p id="para340">
                 Haemodialysis
                </p>
               </list-item>
               <list-item id="celistitem350">
                <p id="para350">
                 Blood sampling
                </p>
               </list-item>
              </list>
             </td>
             <td align="left">
              Long, months/years
             </td>
            </tr>
            <tr>
             <td align="left">
              Totally implantable catheters
             </td>
             <td align="left">
              <list id="celist150" list-type="simple">
               <list-item id="celistitem360">
                <p id="para360">
                 Image guided or surgical placement
                </p>
               </list-item>
               <list-item id="celistitem370">
                <p id="para370">
                 Tunnelled beneath skin and have a subcutaneous port accessed with a needle
                </p>
               </list-item>
               <list-item id="celistitem380">
                <p id="para380">
                 Implanted into subclavian or internal jugular vein
                </p>
               </list-item>
              </list>
             </td>
             <td align="left">
              <list id="celist160" list-type="simple">
               <list-item id="celistitem390">
                <p id="para390">
                 Single or double lumen
                </p>
               </list-item>
               <list-item id="celistitem400">
                <p id="para400">
                 Infrequent access on a long-term basis
                </p>
               </list-item>
              </list>
             </td>
             <td align="left">
              Long, months/years
             </td>
            </tr>
            <tr>
             <td align="left">
              Peripherally inserted central venous catheters
             </td>
             <td align="left">
              Inserted into basilic, cephalic or brachial veins and enter the superior vena cava
             </td>
             <td align="left">
              <list id="celist170" list-type="simple">
               <list-item id="celistitem410">
                <p id="para410">
                 Administration of fluid and medication including chemotherapy
                </p>
               </list-item>
               <list-item id="celistitem420">
                <p id="para420">
                 Parenteral nutrition Blood sampling
                </p>
               </list-item>
              </list>
             </td>
             <td align="left">
              Medium, 4 weeks to 6 months
             </td>
            </tr>
           </tbody>
          </table>
          <attrib>
           Adapted from O'Grady
           <italic>
            et al. 2011.
           </italic>
           <xref ref-type="bibr" rid="bib334">
            <sup>
             334
            </sup>
           </xref>
          </attrib>
         </table-wrap>
        </p>
        <p id="para10280">
         Catheter-related bloodstream infections (CR-BSI) associated with the insertion and maintenance of CVCs are potentially among the most dangerous complications associated with health care.
         <xref ref-type="bibr" rid="bib231">
          231
         </xref>
         ,
         <xref ref-type="bibr" rid="bib232">
          232
         </xref>
         ,
         <xref ref-type="bibr" rid="bib335">
          335
         </xref>
         In the most recent national prevalence survey, the Health Protection Agency reported that the prevalence of BSI was 0.5%, accounting for 7.3% of the HCAI detected; 64% of BSI occurred in patients with a vascular access device.
         <xref ref-type="bibr" rid="bib231">
          <sup>
           231
          </sup>
         </xref>
         A previous point prevalence survey reported that the prevalence of BSI was 0.85%, accounting for 7% of the HCAI detected; of these, 70% were primary CR-BSI.
         <xref ref-type="bibr" rid="bib232">
          <sup>
           232
          </sup>
         </xref>
         Peripheral venous catheters (PVCs) cause phlebitis in some patients, with studies indicating mean rates of 7–27%,
         <xref ref-type="bibr" rid="bib336">
          336
         </xref>
         ,
         <xref ref-type="bibr" rid="bib337">
          337
         </xref>
         ,
         <xref ref-type="bibr" rid="bib338">
          338
         </xref>
         ,
         <xref ref-type="bibr" rid="bib339">
          339
         </xref>
         but evidence suggests that these devices are less frequently associated with CR-BSI.
         <xref ref-type="bibr" rid="bib334">
          334
         </xref>
         ,
         <xref ref-type="bibr" rid="bib336">
          336
         </xref>
         ,
         <xref ref-type="bibr" rid="bib337">
          337
         </xref>
         ,
         <xref ref-type="bibr" rid="bib338">
          338
         </xref>
         ,
         <xref ref-type="bibr" rid="bib339">
          339
         </xref>
         ,
         <xref ref-type="bibr" rid="bib340">
          340
         </xref>
        </p>
        <p id="para10290">
         CR-BSI involves the presence of systemic infection and evidence implicating the intravascular catheter as its source (i.e. the isolation of the same microorganism from blood cultures as that shown to be significantly colonising the intravascular catheter).
         <xref ref-type="bibr" rid="bib334">
          334
         </xref>
         ,
         <xref ref-type="bibr" rid="bib335">
          335
         </xref>
         Catheter colonisation refers to the growth of microorganisms on either the endoluminal or the external catheter surface beneath the skin in the absence of systemic infection.
         <xref ref-type="bibr" rid="bib334">
          334
         </xref>
         ,
         <xref ref-type="bibr" rid="bib335">
          335
         </xref>
        </p>
        <p id="para10300">
         The microorganisms that colonise catheter hubs and the skin adjacent to the insertion site are the source of most CR-BSI. Coagulase-negative staphylococci, particularly
         <italic>
          Staphylococcus epidermidis
         </italic>
         , are the microorganisms most frequently implicated in CR-BSI. Other microorganisms commonly involved include
         <italic>
          S. aureus, Candida
         </italic>
         species and enterococci.
         <xref ref-type="bibr" rid="bib341">
          341
         </xref>
         ,
         <xref ref-type="bibr" rid="bib342">
          342
         </xref>
         ,
         <xref ref-type="bibr" rid="bib343">
          343
         </xref>
        </p>
        <p id="para10310">
         CR-BSI is generally caused either by skin microorganisms at the insertion site, which contaminate the catheter during insertion and migrate along the cutaneous catheter track after insertion,
         <xref ref-type="bibr" rid="bib344">
          344
         </xref>
         ,
         <xref ref-type="bibr" rid="bib345">
          345
         </xref>
         ,
         <xref ref-type="bibr" rid="bib346">
          346
         </xref>
         or microorganisms from the hands of healthcare workers that contaminate and colonise the catheter hub during care interventions.
         <xref ref-type="bibr" rid="bib347">
          <sup>
           347
          </sup>
         </xref>
         Less commonly, infusate contamination or seeding from a different site of infection in the body via the bloodstream is identified as a cause of CR-BSI.
         <xref ref-type="bibr" rid="bib348">
          348
         </xref>
         ,
         <xref ref-type="bibr" rid="bib349">
          349
         </xref>
        </p>
       </sec>
      </sec>
      <sec id="cesec1820">
       <label>
        4.2
       </label>
       <title>
        What is the Evidence for these Guidelines?
       </title>
       <p id="para10320">
        These guidelines are based upon evidence-based guidelines for preventing intravascular device (IVD)-related infections, developed at the US Centers for Disease Control and Prevention by HICPAC and published in 2011.
        <xref ref-type="bibr" rid="bib334">
         <sup>
          334
         </sup>
        </xref>
        The AGREE II collaboration appraisal instrument was used by four appraisers to review the guidelines independently.
        <xref ref-type="bibr" rid="bib3">
         <sup>
          3
         </sup>
        </xref>
       </p>
       <p id="para10330">
        The appraisal process resulted in the decision that the guideline development processes were valid and that the guidelines were evidence based, categorised to the strength of the evidence examined, reflective of current concepts of best practice. The Guideline Development Advisory Group considered that they were the most authoritative reference guidelines currently available. Following the AGREE process, we systematically searched, retrieved and appraised additional evidence published since the search period identified in the HICPAC technical report.
        <xref ref-type="bibr" rid="bib334">
         <sup>
          334
         </sup>
        </xref>
        Our search period for additional evidence spanned from 2009 to 2012.
       </p>
       <p id="para10340">
        These guidelines apply to caring for all adults and children over the age of 1 year in NHS acute care settings with a CVC or PVC that is being used for the administration of fluids, medications, blood components and/or parenteral nutrition. They should be used in conjunction with the recommendations for Standard Principles for Preventing HCAI, previously described in these guidelines.
       </p>
       <p id="para10350">
        These recommendations describe general principles of best practice that apply to all patients in hospital in whom an intravascular catheter is being used during an acute episode of treatment/care. They do not specifically address the more detailed, technical aspects of the care of infants under 1 year of age, or those children or adults receiving haemodialysis or chemotherapy who will generally have long-term intravascular catheters managed in renal dialysis or outpatient settings.
       </p>
       <p id="para10360">
        The recommendations are divided into nine distinct interventions:
        <list id="celist1220" list-type="simple">
         <list-item id="celistitem4790">
          <label>
           •
          </label>
          <p id="para10370">
           education of healthcare workers and patients;
          </p>
         </list-item>
         <list-item id="celistitem4800">
          <label>
           •
          </label>
          <p id="para10380">
           general asepsis;
          </p>
         </list-item>
         <list-item id="celistitem4810">
          <label>
           •
          </label>
          <p id="para10390">
           selection of type of intravascular catheter;
          </p>
         </list-item>
         <list-item id="celistitem4820">
          <label>
           •
          </label>
          <p id="para10400">
           selection of intravascular catheter insertion site;
          </p>
         </list-item>
         <list-item id="celistitem4830">
          <label>
           •
          </label>
          <p id="para10410">
           MSB precautions during insertion;
          </p>
         </list-item>
         <list-item id="celistitem4840">
          <label>
           •
          </label>
          <p id="para10420">
           cutaneous antisepsis;
          </p>
         </list-item>
         <list-item id="celistitem4850">
          <label>
           •
          </label>
          <p id="para10430">
           catheter and catheter site care;
          </p>
         </list-item>
         <list-item id="celistitem4860">
          <label>
           •
          </label>
          <p id="para10440">
           replacement strategies; and
          </p>
         </list-item>
         <list-item id="celistitem4870">
          <label>
           •
          </label>
          <p id="para10450">
           general principles for catheter management.
          </p>
         </list-item>
        </list>
       </p>
      </sec>
      <sec id="cesec1830">
       <label>
        4.3
       </label>
       <title>
        Education of Healthcare Workers and Patients
       </title>
       <p id="para10460">
        To improve patient outcomes and reduce healthcare costs, it is essential that everyone involved in caring for patients with intravascular catheters is educated about infection prevention. Healthcare workers in hospitals need to be confident and proficient in infection prevention practices, and to be aware of the signs and symptoms of clinical infection. Structured educational programmes that enable healthcare workers to provide, monitor and evaluate care and continually increase their competence are critical to the success of any strategy designed to reduce the risk of infection. Evidence reviewed by HICPAC demonstrates that the risk of infection declines following standardisation of the aseptic technique,
        <xref ref-type="bibr" rid="bib350">
         350
        </xref>
        ,
        <xref ref-type="bibr" rid="bib351">
         351
        </xref>
        ,
        <xref ref-type="bibr" rid="bib352">
         352
        </xref>
        ,
        <xref ref-type="bibr" rid="bib353">
         353
        </xref>
        ,
        <xref ref-type="bibr" rid="bib354">
         354
        </xref>
        ,
        <xref ref-type="bibr" rid="bib355">
         355
        </xref>
        ,
        <xref ref-type="bibr" rid="bib356">
         356
        </xref>
        and increases when the maintenance of intravascular catheters is undertaken by inexperienced healthcare workers.
        <xref ref-type="bibr" rid="bib353">
         353
        </xref>
        ,
        <xref ref-type="bibr" rid="bib357">
         357
        </xref>
       </p>
       <p id="para10470">
        We identified two recent systematic reviews that assessed the effectiveness of education interventions in reducing CR-BSI.
        <xref ref-type="bibr" rid="bib228">
         228
        </xref>
        ,
        <xref ref-type="bibr" rid="bib358">
         358
        </xref>
        The first concluded that current evidence comes predominantly from uncontrolled before-after studies that do not convincingly distinguish intervention effectiveness from secular trends. Clinical practices are addressed by a wide variety of educational strategies that do not draw upon pedagogic, theoretical or conceptual frameworks and consequently do not provide generalisable conclusions about the most effective approaches to education to improve practice.
        <xref ref-type="bibr" rid="bib358">
         <sup>
          358
         </sup>
        </xref>
        The second systematic review concluded first that educational interventions appear to have the most prolonged and profound effect when used in conjunction with audit and feedback, and when availability of clinical equipment is consistent with the content of the education provided. Second, that educational interventions will have a greater impact if baseline compliance with best practice is low. Third, that repeated educational sessions, fed into daily practice, using practical participation, appear to have a small, additional effect on practice change compared with education alone.
        <xref ref-type="bibr" rid="bib228">
         <sup>
          228
         </sup>
        </xref>
       </p>
       <p id="para10480">
        Healthcare workers should be aware of the manufacturers' advice relating to the compatibility of individual devices with antiseptic solutions, dwell time and connections to ensure safe use.
       </p>
       <p id="para10490">
        <list id="celist1230" list-type="simple">
         <list-item id="celistitem4880">
          <label>
           IVAD1
          </label>
          <p id="para10500">
           Healthcare workers caring for patients with intravascular catheters should be trained and assessed as competent in using and consistently adhering to practices for the prevention of catheter-related bloodstream infection.
          </p>
          <p id="para10510">
           <italic>
            Class D/GPP
           </italic>
          </p>
         </list-item>
         <list-item id="celistitem4890">
          <label>
           IVAD2
          </label>
          <p id="para10520">
           Healthcare workers should be aware of the manufacturer's advice relating to individual catheters, connection and administration set dwell time and compatibility with antiseptics and other fluids to ensure the safe use of devices.
          </p>
          <p id="para10530">
           <bold>
            New recommendation
           </bold>
           <italic>
            Class D/GPP
           </italic>
          </p>
         </list-item>
         <list-item id="celistitem4900">
          <label>
           IVAD3
          </label>
          <p id="para10540">
           Before discharge from hospital, patients with intravascular catheters and their carers should be taught any techniques they may need to use to prevent infection and manage their device.
          </p>
          <p id="para10550">
           <italic>
            Class D/GPP
           </italic>
          </p>
         </list-item>
        </list>
       </p>
      </sec>
      <sec id="cesec1840">
       <label>
        4.4
       </label>
       <title>
        General Asepsis
       </title>
       <p id="para10560">
        Hand decontamination and meticulous attention to the aseptic technique are essential during catheter insertion, manipulation, changing catheter site dressings and for accessing the system. Hands should be decontaminated using ABHR or liquid soap and water when hands are visibly soiled or potentially contaminated with organic material, such as blood and other body fluids.
        <xref ref-type="bibr" rid="bib45">
         45
        </xref>
        ,
        <xref ref-type="bibr" rid="bib53">
         53
        </xref>
       </p>
       <p id="para10570">
        The aseptic technique should be used for the insertion and management of IVDs. Structured education should be provided to ensure that healthcare workers are trained and assessed as competent in performing the aseptic technique. Gloves should be worn for procedures involving contact with blood or body fluids. Sterile gloves must be worn for the insertion and dressing of CVCs.
        <xref ref-type="bibr" rid="bib334">
         <sup>
          334
         </sup>
        </xref>
        <list id="celist1240" list-type="simple">
         <list-item id="celistitem4910">
          <label>
           IVAD4
          </label>
          <p id="para10580">
           Hands must be decontaminated, with an alcohol-based hand rub or by washing with liquid soap and water if soiled or potentially contaminated with blood or body fluids, before and after any contact with the intravascular catheter or insertion site.
          </p>
          <p id="para10590">
           <italic>
            Class A
           </italic>
          </p>
         </list-item>
         <list-item id="celistitem4920">
          <label>
           IVAD5
          </label>
          <p id="para10600">
           Use the aseptic technique for the insertion and care of an intravascular access device and when administering intravenous medication.
          </p>
          <p id="para10610">
           <italic>
            Class B
           </italic>
          </p>
         </list-item>
        </list>
       </p>
      </sec>
      <sec id="cesec1850">
       <label>
        4.5
       </label>
       <title>
        Selection of Catheter Type
       </title>
       <p id="para10620">
        The selection of the most appropriate intravascular catheter for each individual patient can reduce the risk of subsequent catheter-related infection.
       </p>
       <sec id="cesec1860">
        <title>
         Catheter material
        </title>
        <p id="para10630">
         Intravascular catheter material may be an important determinant in the development of catheter-related infection. Polytetrafluroethylene (Teflon) and polyurethane catheters have been associated with fewer infections than catheters made of polyvinyl chloride or polyethylene.
         <xref ref-type="bibr" rid="bib359">
          359
         </xref>
         ,
         <xref ref-type="bibr" rid="bib360">
          360
         </xref>
         ,
         <xref ref-type="bibr" rid="bib361">
          361
         </xref>
        </p>
       </sec>
       <sec id="cesec1870">
        <title>
         Number of catheter lumens
        </title>
        <p id="para10640">
         Multi-lumen intravascular access devices may be used because they permit the concurrent administration of fluids and medications, parenteral nutrition and haemodynamic monitoring among critically ill patients.
        </p>
        <p id="para10650">
         Several RCTs and other studies suggest that multi-lumen catheters are associated with a higher risk of infection than single-lumen catheters.
         <xref ref-type="bibr" rid="bib334">
          334
         </xref>
         ,
         <xref ref-type="bibr" rid="bib362">
          362
         </xref>
         ,
         <xref ref-type="bibr" rid="bib363">
          363
         </xref>
         ,
         <xref ref-type="bibr" rid="bib364">
          364
         </xref>
         ,
         <xref ref-type="bibr" rid="bib365">
          365
         </xref>
         ,
         <xref ref-type="bibr" rid="bib366">
          366
         </xref>
         ,
         <xref ref-type="bibr" rid="bib367">
          367
         </xref>
         However, other studies examined by HICPAC failed to demonstrate a difference in the rates of CR-BSI.
         <xref ref-type="bibr" rid="bib368">
          368
         </xref>
         ,
         <xref ref-type="bibr" rid="bib369">
          369
         </xref>
        </p>
        <p id="para10660">
         Multi-lumen catheter insertion sites may be particularly prone to infection because of increased trauma at the insertion site or because multiple ports increase the frequency of CVC manipulation.
         <xref ref-type="bibr" rid="bib364">
          364
         </xref>
         ,
         <xref ref-type="bibr" rid="bib365">
          365
         </xref>
         Patients with multi-lumen catheters tend to be more severely ill, although the increased risk of CR-BSI appears to be independent of underlying illness.
         <xref ref-type="bibr" rid="bib366">
          <sup>
           366
          </sup>
         </xref>
        </p>
       </sec>
       <sec id="cesec1880">
        <title>
         A dedicated catheter lumen is needed for parenteral nutrition
        </title>
        <p id="para10670">
         A prospective epidemiological study in patients receiving parenteral nutrition concluded that either using a single-lumen catheter or a dedicated port in a multi-lumen catheter for parenteral nutrition would reduce the risk of CR-BSI.
         <xref ref-type="bibr" rid="bib359">
          <sup>
           359
          </sup>
         </xref>
         Neither we nor HICPAC identified any additional evidence for this recommendation whilst updating our systematic review, and HICPAC considered this to be a unresolved issue.
         <xref ref-type="bibr" rid="bib334">
          <sup>
           334
          </sup>
         </xref>
        </p>
        <p id="para10680">
         In a systematic review and quantitative meta-analysis focused on determining the risk of CR-BSI and catheter colonisation in multi-lumen catheters compared with single-lumen catheters, the reviewers reported that, although CR-BSI was more common in patients with multi-lumen catheters, when confined to high-quality studies that control for patient differences, there is no significant difference in rates of CR-BSI for the two types of catheter. This analysis suggests that multi-lumen catheters are not a significant risk factor for increased CR-BSI or local catheter colonisation compared with single-lumen CVCs.
         <xref ref-type="bibr" rid="bib370">
          <sup>
           370
          </sup>
         </xref>
        </p>
        <p id="para10690">
         A later systematic review and quantitative meta-analysis tested whether single- vs multi-lumen CVCs had an impact on catheter colonisation and CR-BSI. The study authors concluded that there is some evidence from five RCTs with data on 530 CVCs that for every 20 single-lumen catheters inserted, one CR-BSI (which would have occurred had multi-lumen catheters been used) would be avoided.
         <xref ref-type="bibr" rid="bib371">
          <sup>
           371
          </sup>
         </xref>
        </p>
        <p id="para10700">
         Neither we nor HICPAC identified any additional evidence of acceptable quality whilst updating our systematic reviews.
         <xref ref-type="bibr" rid="bib334">
          <sup>
           334
          </sup>
         </xref>
         <list id="celist1250" list-type="simple">
          <list-item id="celistitem4930">
           <label>
            IVAD6
           </label>
           <p id="para10710">
            Use a catheter with the minimum number of ports or lumens essential for management of the patient.
           </p>
           <p id="para10720">
            <italic>
             Class A
            </italic>
           </p>
          </list-item>
          <list-item id="celistitem4940">
           <label>
            IVAD7
           </label>
           <p id="para10730">
            Preferably use a designated single-lumen catheter to administer lipid-containing parenteral nutrition or other lipid-based solutions.
           </p>
           <p id="para10740">
            <italic>
             Class D/GPP
            </italic>
           </p>
          </list-item>
         </list>
        </p>
       </sec>
       <sec id="cesec1890">
        <title>
         Tunnelled and totally implantable ports
        </title>
        <p id="para10750">
         Surgically implanted (tunnelled) devices (e.g. Hickman® catheters) are commonly used to provide vascular access to patients requiring long-term intravenous therapy. Alternatively, totally implantable intravascular access devices (e.g. Port-A-Cath®) are also tunnelled under the skin, but have a subcutaneous port or reservoir with a self-sealing septum that is accessible by needle puncture through intact skin.
        </p>
        <p id="para10760">
         Multiple studies comparing the incidence of infection associated with long-term tunnelled CVCs and/or totally implantable IVDs with that from percutaneously (non-tunnelled) inserted catheters have been assessed by HICPAC.
         <xref ref-type="bibr" rid="bib372">
          <sup>
           372
          </sup>
         </xref>
         Although most studies reported a lower rate of infection in patients with tunnelled CVCs,
         <xref ref-type="bibr" rid="bib373">
          373
         </xref>
         ,
         <xref ref-type="bibr" rid="bib374">
          374
         </xref>
         ,
         <xref ref-type="bibr" rid="bib375">
          375
         </xref>
         ,
         <xref ref-type="bibr" rid="bib376">
          376
         </xref>
         ,
         <xref ref-type="bibr" rid="bib377">
          377
         </xref>
         ,
         <xref ref-type="bibr" rid="bib378">
          378
         </xref>
         ,
         <xref ref-type="bibr" rid="bib379">
          379
         </xref>
         ,
         <xref ref-type="bibr" rid="bib380">
          380
         </xref>
         ,
         <xref ref-type="bibr" rid="bib381">
          381
         </xref>
         some studies found no significant difference in the rate of infection between tunnelled and non-tunnelled catheters.
         <xref ref-type="bibr" rid="bib382">
          382
         </xref>
         ,
         <xref ref-type="bibr" rid="bib383">
          383
         </xref>
         Additionally, most studies concluded that totally implantable devices had the lowest reported rates of CR-BSI compared with either tunnelled or non-tunnelled CVCs.
         <xref ref-type="bibr" rid="bib384">
          384
         </xref>
         ,
         <xref ref-type="bibr" rid="bib385">
          385
         </xref>
         ,
         <xref ref-type="bibr" rid="bib386">
          386
         </xref>
         ,
         <xref ref-type="bibr" rid="bib387">
          387
         </xref>
         ,
         <xref ref-type="bibr" rid="bib388">
          388
         </xref>
         ,
         <xref ref-type="bibr" rid="bib389">
          389
         </xref>
         ,
         <xref ref-type="bibr" rid="bib390">
          390
         </xref>
         ,
         <xref ref-type="bibr" rid="bib391">
          391
         </xref>
         ,
         <xref ref-type="bibr" rid="bib392">
          392
         </xref>
         ,
         <xref ref-type="bibr" rid="bib393">
          393
         </xref>
         ,
         <xref ref-type="bibr" rid="bib394">
          394
         </xref>
         However, although these devices are less disruptive for patients in terms of daily living, they have a number of disadvantages including the need for needle insertion resulting in increased discomfort.
         <xref ref-type="bibr" rid="bib395">
          <sup>
           395
          </sup>
         </xref>
        </p>
        <p id="para10770">
         Additional evidence was obtained from studies of efficacy of tunnelling to reduce catheter-related infections in patients with short-term CVCs. One RCT demonstrated that subcutaneous tunnelling of short-term CVCs inserted into the internal jugular vein reduced the risk for CR-BSI.
         <xref ref-type="bibr" rid="bib396">
          <sup>
           396
          </sup>
         </xref>
         In a later RCT, the same investigators failed to show a statistically significant difference in the risk for CR-BSI for subcutaneously tunnelled femoral vein catheters.
         <xref ref-type="bibr" rid="bib397">
          <sup>
           397
          </sup>
         </xref>
        </p>
        <p id="para10780">
         An additional meta-analysis of RCTs was focused on the efficacy of tunnelling short-term CVCs to prevent catheter-related infections.
         <xref ref-type="bibr" rid="bib398">
          <sup>
           398
          </sup>
         </xref>
         Data synthesis demonstrated that tunnelling decreased catheter colonisation by 39% and decreased CR-BSI by 44% in comparison with non-tunnelled placement. The majority of the benefit in the decreased rate of catheter sepsis came from one trial of CVCs inserted at the internal jugular site. The reduction in risk was not significant when pooled with data from five subclavian catheter trials. Tunnelling was not associated with increased risk of mechanical complications from placement or technical difficulties during placement. This meta-analysis concluded that tunnelling decreased catheter-related infections; however, a synthesis of the evidence in this meta-analysis does not support routine subcutaneous tunnelling of short-term subclavian venous catheters, and this cannot be recommended unless efficacy is evaluated at different placement sites and relative to other interventions.
        </p>
        <p id="para10790">
         Peripherally inserted central catheters (PICCs) are increasingly used for medium term (6 weeks to 6 months)
         <xref ref-type="bibr" rid="bib395">
          <sup>
           395
          </sup>
         </xref>
         intravascular access, particularly in adults and children requiring antimicrobial treatment, chemotherapy and parenteral nutrition. Evidence examined by HICPAC suggested that PICCs are associated with a lower rate of infection than that associated with other non-tunnelled CVCs.
         <xref ref-type="bibr" rid="bib382">
          382
         </xref>
         ,
         <xref ref-type="bibr" rid="bib398">
          398
         </xref>
         Retrospective studies in outpatient settings indicate that rates of PICC-related bloodstream infection range from 0.4 to 0.8 per 1000 catheter-days.
         <xref ref-type="bibr" rid="bib399">
          399
         </xref>
         ,
         <xref ref-type="bibr" rid="bib400">
          400
         </xref>
         ,
         <xref ref-type="bibr" rid="bib401">
          401
         </xref>
         ,
         <xref ref-type="bibr" rid="bib402">
          402
         </xref>
         ,
         <xref ref-type="bibr" rid="bib403">
          403
         </xref>
         ,
         <xref ref-type="bibr" rid="bib404">
          404
         </xref>
         However, there is little recent robust evidence regarding comparison of rates of CR-BSI in PICCs vs other long-term central venous access devices. A prospective study
         <xref ref-type="bibr" rid="bib405">
          <sup>
           405
          </sup>
         </xref>
         that compared the use of inpatient PICCs indicated a similar rate of CR-BSI to non-tunnelled catheters placed in the internal jugular or subclavian veins and a higher rate than cuffed and tunnelled (CT) catheters (PICC 3.5 CR-BSI per 1000 catheter-days vs non-tunnelled 2.7 CR-BSI per 1000 catheter-days vs cuffed and tunnelled 1.6 CR-BSI per 1000 catheter-days). A systematic review of 200 studies indicated that when used in inpatients, PICCs pose a slightly lower risk of CR-BSI than standard noncuffed and non-medicated CVCs placed in the subclavian or internal jugular vein (2.1 CR-BSI per 1000 catheter-days vs 2.7 CR-BSI per 1000 catheter-days).
         <xref ref-type="bibr" rid="bib340">
          <sup>
           340
          </sup>
         </xref>
        </p>
        <p id="para10800">
         Neither we nor HICPAC identified any additional evidence of acceptable quality whilst updating our systematic review.
         <xref ref-type="bibr" rid="bib334">
          <sup>
           334
          </sup>
         </xref>
         <list id="celist1260" list-type="simple">
          <list-item id="celistitem4950">
           <label>
            IVAD8
           </label>
           <p id="para10810">
            Use a tunnelled or implanted central venous access device with a subcutaneous port for patients in whom long-term vascular access is required.
           </p>
           <p id="para10820">
            <italic>
             Class A
            </italic>
           </p>
          </list-item>
          <list-item id="celistitem4960">
           <label>
            IVAD9
           </label>
           <p id="para10830">
            Use a peripherally inserted central catheter for patients in whom medium-term intermittent access is required.
           </p>
           <p id="para10840">
            <bold>
             New recommendation
            </bold>
            <italic>
             Class D/GPP
            </italic>
           </p>
          </list-item>
         </list>
        </p>
       </sec>
       <sec id="cesec1900">
        <title>
         Antimicrobial impregnated catheters and cuffs
        </title>
        <p id="para10850">
         Some catheters and cuffs are marketed as anti-infective and are coated or impregnated with antimicrobial or antiseptic agents, e.g. chlorhexidine/silver sulfadiazine, minocycline/rifampicin, platinum/silver, and ionic silver in subcutaneous collagen cuffs attached to CVC. Evidence reviewed by HICPAC
         <xref ref-type="bibr" rid="bib406">
          406
         </xref>
         ,
         <xref ref-type="bibr" rid="bib407">
          407
         </xref>
         ,
         <xref ref-type="bibr" rid="bib408">
          408
         </xref>
         ,
         <xref ref-type="bibr" rid="bib409">
          409
         </xref>
         ,
         <xref ref-type="bibr" rid="bib410">
          410
         </xref>
         ,
         <xref ref-type="bibr" rid="bib411">
          411
         </xref>
         ,
         <xref ref-type="bibr" rid="bib412">
          412
         </xref>
         ,
         <xref ref-type="bibr" rid="bib413">
          413
         </xref>
         ,
         <xref ref-type="bibr" rid="bib414">
          414
         </xref>
         ,
         <xref ref-type="bibr" rid="bib415">
          415
         </xref>
         ,
         <xref ref-type="bibr" rid="bib416">
          416
         </xref>
         indicated that the use of antimicrobial or antiseptic-impregnated CVC in adults whose catheter is expected to remain in place for more than five days could decrease the risk for CR-BSI. This may be cost-effective in high-risk patients (intensive care, burn and neutropenic patients) and in other patient populations in whom the rate of CR-BSI exceeds 3.3 per 1,000 catheter days even when there is a comprehensive strategy to reduce rates of CR-BSI.
         <xref ref-type="bibr" rid="bib406">
          <sup>
           406
          </sup>
         </xref>
        </p>
        <p id="para10860">
         A meta-analysis of 23 RCTs published between 1988–1999 included data on 4,660 catheters (2,319 anti-infective and 2,341 control).
         <xref ref-type="bibr" rid="bib417">
          <sup>
           417
          </sup>
         </xref>
         Eleven of the trials in this meta-analysis were conducted in intensive care unit (ICU) settings; four among oncology patients, two among surgical patients; two among patients receiving total parenteral nutrition (TPN) and four among other patient populations. Study authors concluded that antibiotic and chlorhexidine-silver sulfadiazine coatings are anti-infective for short (approximately one week) insertion time. For longer insertion times, there was no data on antibiotic coating, and there is evidence of lack of effect for first generation chlorhexidine-silver sulfadiazine coating. For silver-impregnated collagen cuffs, there is evidence of lack of effect for both short- and long-term insertion.
        </p>
        <p id="para10870">
         Second generation chlorhexidine/silver sulfadiazine catheters with chlorhexidine coating on both the internal and external luminal surfaces are now available. The external surface of these catheters have three times the amount of chlorhexidine and extended release of the surface bound antiseptics than that in the first generation catheters (which are coated with chlorhexidine/silver sulfadiazine only on the external luminal surface). Early studies indicated that the prolonged anti-infective activity associated with the second generation catheters improved efficacy in preventing infections.
         <xref ref-type="bibr" rid="bib418">
          <sup>
           418
          </sup>
         </xref>
        </p>
        <p id="para10880">
         A systematic review and economic evaluation in 2006 concluded that rates of CR-BSI were statistically significantly reduced when an antimicrobial CVC was used. Studies in this review report the best effect when catheters were treated with minocycline/rifampin, or internally and externally treated with silver or chlorhexidine/silver sulfadiazine. A trend to statistical significance was seen in catheters only extraluminally coated. Investigation of other antibiotic treated catheters is limited to single studies with non-significant results.
         <xref ref-type="bibr" rid="bib419">
          <sup>
           419
          </sup>
         </xref>
        </p>
        <p id="para10890">
         We identified two additional systematic reviews and one RCT in our updated search. A recent Cochrane review of studies using impregnation, coating or bonding for reducing central venous catheter-related infections in adults included 56, predominantly unblinded studies, with low or unclear risk of bias. Patients with impregnated catheters had lower rates of CR-BSI (actual risk reduction of 2% (95% CI, 3% to 1%)), and catheter colonisation (actual risk reduction 10% (95% CI, 13% to 7%)). In terms of catheter colonisation sub-group analysis showed that impregnated catheters were more beneficial in studies conducted in intensive care units (RR 0.68 (95% CI, 0.59 to 0.78)) than in studies conducted in haemo-oncology (RR 0.75 (95% CI, 0.51 to 1.11)) or in patients requiring long-term parenteral nutrition RR 0.99 (95% CI, 0.74 to 1.34)). However, sub-group analysis did not identify the same benefit in terms of CR-BSI. There were no statistically significant differences in the overall rates of bloodstream infections or mortality, although these outcomes were less often assessed than CR-BSI and catheter colonisation.
         <xref ref-type="bibr" rid="bib420">
          <sup>
           420
          </sup>
         </xref>
         A collaborative network meta-analysis of CVC use in adults indicated that rifampicin-based impregnated CVC was the only type of impregnated/coated CVC that reduced catheter colonisation and CR-BSI compared with standard CVC.
         <xref ref-type="bibr" rid="bib421">
          <sup>
           421
          </sup>
         </xref>
         In a single blind non-inferiority trial, authors concluded that CVC coated with 5-fluorouracil were non-inferior to chlorhexidine and silver sulfadiazine coated CVCs with respect to the incidence of catheter colonisation (2.9%
         <italic>
          vs
         </italic>
         . 5.3%, respectively).
         <xref ref-type="bibr" rid="bib422">
          <sup>
           422
          </sup>
         </xref>
        </p>
       </sec>
       <sec id="cesec1910">
        <title>
         Be aware of patient sensitivity to chlorhexidine gluconate
        </title>
        <p id="para10900">
         Chlorhexidine is a potential allergenic antiseptic that is present in many products and is widely used in health care for skin antisepsis, insertion of urinary catheters or coating CVCs.
         <xref ref-type="bibr" rid="bib406">
          <sup>
           406
          </sup>
         </xref>
         In susceptible individuals, initial contact will cause a minor hypersensitivity reaction that, although not severe, should not go undocumented as subsequent exposures to chlorhexidine may lead to anaphylaxis.
         <xref ref-type="bibr" rid="bib423">
          423
         </xref>
         ,
         <xref ref-type="bibr" rid="bib424">
          424
         </xref>
         The Medicines and Healthcare Products Regulatory Agency has alerted all healthcare providers in the UK to the risk of chlorhexidine allergy
         <xref ref-type="bibr" rid="bib425">
          <sup>
           425
          </sup>
         </xref>
         and requires them to have systems in place that ensure:
         <list id="celist1270" list-type="simple">
          <list-item id="celistitem4970">
           <label>
            •
           </label>
           <p id="para10910">
            awareness of the potential for an anaphylactic reaction to chlorhexidine;
           </p>
          </list-item>
          <list-item id="celistitem4980">
           <label>
            •
           </label>
           <p id="para10920">
            known allergies are recorded in patient notes;
           </p>
          </list-item>
          <list-item id="celistitem4990">
           <label>
            •
           </label>
           <p id="para10930">
            labels and instructions for use are checked to establish if products contain chlorhexidine prior to use on patients with a known allergy;
           </p>
          </list-item>
          <list-item id="celistitem5000">
           <label>
            •
           </label>
           <p id="para10940">
            if a patient experiences an unexplained reaction, checks are carried out to identify whether chlorhexidine was used or was impregnated in a medical device that was used; and
           </p>
          </list-item>
          <list-item id="celistitem5010">
           <label>
            •
           </label>
           <p id="para10950">
            reporting of allergic reactions to products containing chlorhexidine to the Medicines and Healthcare Products Regulatory Agency.
           </p>
          </list-item>
         </list>
        </p>
        <p id="para10960">
         <list id="celist1280" list-type="simple">
          <list-item id="celistitem5020">
           <label>
            IVAD10
           </label>
           <p id="para10970">
            Use an antimicrobial-impregnated central venous access device for adult patients whose central venous catheter is expected to remain in place for &gt;5 days if catheter-related bloodstream infection rates remain above the locally agreed benchmark, despite the implementation of a comprehensive strategy to reduce catheter-related bloodstream infection.
           </p>
           <p id="para10980">
            <italic>
             Class A
            </italic>
           </p>
          </list-item>
         </list>
        </p>
       </sec>
      </sec>
      <sec id="cesec1920">
       <label>
        4.6
       </label>
       <title>
        Selection of Catheter Insertion Site
       </title>
       <p id="para10990">
        The site at which a vascular access catheter is placed can influence the subsequent risk of CR-BSI because of variation in both the density of local skin flora and the risk of thrombophlebitis. CVCs are generally inserted in the subclavian, jugular or femoral veins, or peripherally inserted into the superior vena cava by way of the major veins of the upper arm (i.e. the cephalic and basilar veins of the antecubital space). PVCs are normally inserted in the upper extremity, although alternatives, such as the foot and scalp, may be used in children and babies.
       </p>
       <sec id="cesec1930">
        <title>
         Subclavian, jugular and femoral placements
        </title>
        <p id="para11000">
         HICPAC examined a number of studies that compared insertion sites and concluded that CVCs inserted into subclavian veins had a lower risk for catheter-related infection than those inserted into either jugular or femoral veins.
         <xref ref-type="bibr" rid="bib345">
          345
         </xref>
         ,
         <xref ref-type="bibr" rid="bib408">
          408
         </xref>
         ,
         <xref ref-type="bibr" rid="bib426">
          426
         </xref>
         ,
         <xref ref-type="bibr" rid="bib427">
          427
         </xref>
         ,
         <xref ref-type="bibr" rid="bib428">
          428
         </xref>
         ,
         <xref ref-type="bibr" rid="bib429">
          429
         </xref>
         ,
         <xref ref-type="bibr" rid="bib430">
          430
         </xref>
         ,
         <xref ref-type="bibr" rid="bib431">
          431
         </xref>
         ,
         <xref ref-type="bibr" rid="bib432">
          432
         </xref>
         ,
         <xref ref-type="bibr" rid="bib433">
          433
         </xref>
         ,
         <xref ref-type="bibr" rid="bib434">
          434
         </xref>
         Guideline developers suggested that internal jugular insertion sites may pose a greater risk for infection because of their proximity to oropharyngeal secretions and because CVCs at this site are difficult to immobilise.
         <xref ref-type="bibr" rid="bib334">
          <sup>
           334
          </sup>
         </xref>
         However, mechanical complications associated with catheterisation might be less common with internal jugular than with subclavian vein insertion.
        </p>
        <p id="para11010">
         Femoral catheters have been demonstrated to have relatively high colonisation rates compared with subclavian and internal jugular sites when used in adults, and current guidelines suggest that the femoral site should be avoided because it is associated with both a higher risk of deep vein thrombosis and catheter-related infection than internal jugular or subclavian catheters.
         <xref ref-type="bibr" rid="bib428">
          428
         </xref>
         ,
         <xref ref-type="bibr" rid="bib432">
          432
         </xref>
         ,
         <xref ref-type="bibr" rid="bib433">
          433
         </xref>
         ,
         <xref ref-type="bibr" rid="bib434">
          434
         </xref>
         ,
         <xref ref-type="bibr" rid="bib435">
          435
         </xref>
         ,
         <xref ref-type="bibr" rid="bib436">
          436
         </xref>
         ,
         <xref ref-type="bibr" rid="bib437">
          437
         </xref>
         One study also found that the risk of infection associated with catheters placed in the femoral vein is accentuated in obese patients.
         <xref ref-type="bibr" rid="bib409">
          <sup>
           409
          </sup>
         </xref>
         Thus, in adult patients, a subclavian site is preferred for preventing infection, although other factors (e.g. the potential for mechanical complications, risk for subclavian vein stenosis and catheter-operator skill) should be considered when deciding where to place the catheter.
        </p>
        <p id="para11020">
         We identified a systematic review and meta-analysis
         <xref ref-type="bibr" rid="bib438">
          <sup>
           438
          </sup>
         </xref>
         in which investigators reviewed two RCTs, eight cohort studies and data from a national HCAI programme. These provided evidence that the selection of device insertion site is not a significant factor for the prevention of CR-BSI. The meta-analysis demonstrated no difference in the risk of CR-BSI between the femoral, subclavian and internal jugular sites, having removed two studies that were statistical outliers. The authors concluded that a pragmatic approach to site selection for central venous access, taking into account underlying disease (e.g. renal disease), the expertise and skill of the operator and the risks associated with placement, should be used.
         <xref ref-type="bibr" rid="bib438">
          <sup>
           438
          </sup>
         </xref>
         Two meta-analyses
         <xref ref-type="bibr" rid="bib439">
          439
         </xref>
         ,
         <xref ref-type="bibr" rid="bib440">
          440
         </xref>
         indicate that the use of real-time two-dimensional ultrasound for the placement of CVCs substantially reduced mechanical complications compared with the standard landmark placement technique. Consequently, the use of ultrasound may indirectly reduce the risk of infection by facilitating mechanically uncomplicated subclavian placement. In the UK, NICE guidelines provide recommendations for two-dimensional ultrasound placement of CVCs.
         <xref ref-type="bibr" rid="bib441">
          <sup>
           441
          </sup>
         </xref>
        </p>
       </sec>
       <sec id="cesec1940">
        <title>
         Upper arm placement
        </title>
        <p id="para11030">
         PICCs may be used as an alternative to subclavian or jugular vein catheterisation. These are inserted into the superior vena cava via the major veins of the upper arm above the antecubital fossa. HICPAC indicated that they are less expensive, associated with fewer mechanical complications (e.g. haemothorax, infiltration and phlebitis) and easier to maintain than short peripheral venous catheters.
         <xref ref-type="bibr" rid="bib334">
          <sup>
           334
          </sup>
         </xref>
         In a prospective cohort study using data from two randomised trials and a systematic review to estimate rates of PICC-related bloodstream infection in hospitalised patients, the author concluded that PICCs used in high-risk hospitalised patients are associated with a rate of CR-BSI similar to conventional CVCs placed in the internal jugular or subclavian veins (two to five per 1000 catheter-days).
         <xref ref-type="bibr" rid="bib441">
          <sup>
           441
          </sup>
         </xref>
        </p>
       </sec>
       <sec id="cesec1950">
        <title>
         Peripheral venous catheters
        </title>
        <p id="para11040">
         To reduce the risk of CR-BSI and phlebitis, it is preferable to use an upper extremity site for inserting a PVC in adults and to replace a device inserted in a lower extremity to a site in the upper extremity as soon as possible.
         <xref ref-type="bibr" rid="bib334">
          <sup>
           334
          </sup>
         </xref>
         In paediatric patients, the upper or lower extremity and the scalp (in young infants) can be used for siting a PVC.
         <xref ref-type="bibr" rid="bib405">
          405
         </xref>
         ,
         <xref ref-type="bibr" rid="bib442">
          442
         </xref>
         <list id="celist1290" list-type="simple">
          <list-item id="celistitem5030">
           <label>
            IVAD11
           </label>
           <p id="para11050">
            In selecting an appropriate intravascular insertion site, assess the risks for infection against the risks of mechanical complications and patient comfort.
           </p>
           <p id="para11060">
            <italic>
             Class D/GPP
            </italic>
           </p>
          </list-item>
          <list-item id="celistitem5040">
           <label>
            IVAD12
           </label>
           <p id="para11070">
            Use the upper extremity for non-tunnelled catheter placement unless medically contraindicated.
           </p>
           <p id="para11080">
            <italic>
             Class C
            </italic>
           </p>
          </list-item>
         </list>
        </p>
       </sec>
      </sec>
      <sec id="cesec1960">
       <label>
        4.7
       </label>
       <title>
        Maximal Sterile Barrier Precautions during Catheter Insertion
       </title>
       <sec id="cesec1970">
        <title>
         Maximal sterile barrier precautions for the insertion of central venous catheters reduces the risk of infection
        </title>
        <p id="para11090">
         The importance of strict adherence to hand decontamination and the aseptic technique as the cornerstone for preventing catheter-related infection is widely accepted. Although this is considered adequate for preventing infections associated with the insertion of short peripheral venous catheters, it is recognised that central venous catheterisation carries a significantly greater risk of infection.
        </p>
        <p id="para11100">
         Studies examined by HICPAC concluded that if MSB precautions were used consistently during CVC insertion, catheter contamination and subsequent catheter-related infections could be reduced significantly.
         <xref ref-type="bibr" rid="bib345">
          345
         </xref>
         ,
         <xref ref-type="bibr" rid="bib352">
          352
         </xref>
         ,
         <xref ref-type="bibr" rid="bib443">
          443
         </xref>
         ,
         <xref ref-type="bibr" rid="bib444">
          444
         </xref>
         A prospective randomised trial that tested the efficacy of MSB precautions to reduce infections associated with long-term, non-tunnelled subclavian silicone catheters, compared with routine procedures, found that they decreased the risk of CR-BSI significantly.
         <xref ref-type="bibr" rid="bib443">
          <sup>
           443
          </sup>
         </xref>
        </p>
        <p id="para11110">
         MSB precautions involve wearing sterile gloves and gown, cap and mask, and using a full-body sterile drape during insertion of the catheter.
         <xref ref-type="bibr" rid="bib334">
          <sup>
           334
          </sup>
         </xref>
         It has been generally assumed that CVCs inserted in the operating theatre pose a lower risk of infection than those inserted on inpatient wards or other patient care areas.
         <xref ref-type="bibr" rid="bib372">
          <sup>
           372
          </sup>
         </xref>
         However, data examined by HICPAC from two prospective studies suggest that the difference in risk of infection depended largely on the magnitude of barrier protection used during catheter insertion, rather than the surrounding environment (i.e. ward vs operating theatre).
         <xref ref-type="bibr" rid="bib345">
          345
         </xref>
         ,
         <xref ref-type="bibr" rid="bib443">
          443
         </xref>
        </p>
        <p id="para11120">
         A systematic review of the value of MSB precautions to prevent CR-BSI defined the components as: the person inserting the catheter should wear a head cap, face mask, sterile body gown and sterile gloves, and use a full-size sterile drape. Their search identified 95 papers discussing the prevention of CR-BSI. The majority of these were narrative reviews or consensus statements. Three primary research studies, differing in design, patient population and clinical settings, that compared infection outcomes using MSB precautions with less stringent barrier techniques, concluded that the use of MSB precautions resulted in a reduction in catheter-related infections. The authors concluded that using MSB precautions appears to decrease transmission of microorganisms, delay colonisation and reduce the rate of HCAI. They also suggested that biological plausibility and the available evidence support using MSB precautions during routine insertion of a CVC to minimise the risk of infection. They recommended that, given the lack of adverse patient reactions, the relatively low cost of MSB precautions and the high cost of CR-BSI, it is probable that MSB precautions will prove to be a cost-effective, or even a cost-saving, intervention.
         <xref ref-type="bibr" rid="bib445">
          <sup>
           445
          </sup>
         </xref>
        </p>
        <p id="para11130">
         Neither we nor HICPAC identified any additional evidence of acceptable quality whilst updating our systematic review.
         <xref ref-type="bibr" rid="bib334">
          <sup>
           334
          </sup>
         </xref>
         <list id="celist1300" list-type="simple">
          <list-item id="celistitem5050">
           <label>
            IVAD13
           </label>
           <p id="para11140">
            Use maximal sterile barrier precautions for the insertion of central venous access devices.
           </p>
           <p id="para11150">
            <italic>
             Class C
            </italic>
           </p>
          </list-item>
         </list>
        </p>
       </sec>
      </sec>
      <sec id="cesec1980">
       <label>
        4.8
       </label>
       <title>
        Cutaneous Antisepsis
       </title>
       <sec id="cesec1990">
        <title>
         Appropriate preparation of the insertion site will reduce the risk of catheter-related infection
        </title>
        <p id="para11160">
         Microorganisms that colonise catheter hubs and the skin surrounding the vascular catheter insertion site are the cause of most CR-BSI.
         <xref ref-type="bibr" rid="bib416">
          416
         </xref>
         ,
         <xref ref-type="bibr" rid="bib446">
          446
         </xref>
         As the risk of infection increases with the density of microorganisms around the insertion site, skin cleansing/antisepsis of the insertion site is one of the most important measures for preventing catheter-related infections.
         <xref ref-type="bibr" rid="bib334">
          <sup>
           334
          </sup>
         </xref>
         Since the early 1990s, research has focused on identifying the most effective antiseptic agent for skin preparation prior to the insertion of IVDs in order to prevent catheter-related infections, especially CR-BSI. In the UK, clinicians principally use alcohol, or either povidone iodine (PVI) or CHG, in various strengths, and the latter two as either aqueous or alcohol-based solutions.
        </p>
        <p id="para11170">
         A prospective randomised trial of agents used for cutaneous antisepsis demonstrated that 2% aqueous CHG was superior to either 10% PVI or 70% alcohol for the prevention of central venous and arterial catheter-related infections.
         <xref ref-type="bibr" rid="bib447">
          <sup>
           447
          </sup>
         </xref>
         A further prospective, randomised trial demonstrated that a 4% alcohol-based solution of 0.25% CHG and 0.025% benzalkonium chloride was more effective for the prevention of central venous or arterial catheter colonisation and infection than 10% PVI.
         <xref ref-type="bibr" rid="bib448">
          <sup>
           448
          </sup>
         </xref>
        </p>
        <p id="para11180">
         The use of 5% PVI solution in 70% ethanol has been shown to be associated with a substantial reduction in catheter-related colonisation and infection compared with 10% aqueous PVI.
         <xref ref-type="bibr" rid="bib449">
          <sup>
           449
          </sup>
         </xref>
         Clinicians may find this useful for those patients for whom alcoholic CHG is contraindicated.
        </p>
        <p id="para11190">
         A meta-analysis
         <xref ref-type="bibr" rid="bib450">
          <sup>
           450
          </sup>
         </xref>
         of studies that compared the risk for CR-BSI following insertion-site skin care with any type of CHG solution vs PVI solution indicated that the use of CHG rather than PVI can reduce the risk for CR-BSI by approximately 49% (RR 0.51, 95% CI 0.27–0.97) in hospitalised patients who require short-term catheterisation (i.e. for every 1000 catheter sites disinfected with CHG rather than PVI, 71 episodes of catheter colonisation and 11 episodes of CR-BSI would be prevented). In this analysis, several types of CHG solution were used in the individual trials, including 0.5% or 1% CHG alcohol solution and 0.5% or 2% CHG aqueous solution. All of these solutions provided a concentration of CHG that is higher than the minimal inhibitory concentration (MIC) for most nosocomial bacteria and yeasts. Subset analysis of aqueous and non-aqueous solutions showed similar effect sizes, but only the subset analysis of the five studies that used alcoholic CHG solution produced a significant reduction in CR-BSI. As few studies used CHG aqueous solution, the lack of a significant difference seen for this solution compared with PVI solution may be a result of inadequate statistical power. Additionally, an economic decision analysis based on available evidence from the same authors suggested that the use of CHG, rather than PVI, for skin care would result in a 1.6% decrease in the incidence of CR-BSI, a 0.23% decrease in mortality, and financial savings per catheter used.
         <xref ref-type="bibr" rid="bib451">
          <sup>
           451
          </sup>
         </xref>
        </p>
        <p id="para11200">
         Several studies were examined that focused on the application of antimicrobial ointments to the catheter site at the time of catheter insertion, or during routine dressing changes, to reduce microbial contamination of catheter insertion sites.
         <xref ref-type="bibr" rid="bib448">
          <sup>
           448
          </sup>
         </xref>
         Reported efficacy of this practice for the prevention of catheter-related infections yielded contradictory findings.
         <xref ref-type="bibr" rid="bib449">
          449
         </xref>
         ,
         <xref ref-type="bibr" rid="bib450">
          450
         </xref>
         ,
         <xref ref-type="bibr" rid="bib451">
          451
         </xref>
         ,
         <xref ref-type="bibr" rid="bib452">
          452
         </xref>
         ,
         <xref ref-type="bibr" rid="bib453">
          453
         </xref>
         ,
         <xref ref-type="bibr" rid="bib454">
          454
         </xref>
         ,
         <xref ref-type="bibr" rid="bib455">
          455
         </xref>
         ,
         <xref ref-type="bibr" rid="bib456">
          456
         </xref>
         ,
         <xref ref-type="bibr" rid="bib457">
          457
         </xref>
         There was also concern that the use of polyantibiotic ointments that were not fungicidal could significantly increase the rate of colonisation of the catheter by
         <italic>
          Candida
         </italic>
         species.
         <xref ref-type="bibr" rid="bib458">
          458
         </xref>
         ,
         <xref ref-type="bibr" rid="bib459">
          459
         </xref>
        </p>
        <p id="para11210">
         NICE
         <xref ref-type="bibr" rid="bib56">
          <sup>
           56
          </sup>
         </xref>
         identified three RCTs that compared the effectiveness of different antiseptic solutions for the insertion of PVCs in hospitalised patients. The evidence from these studies was considered to be of very low quality, and no conclusion could be drawn about the benefits of one particular antiseptic solution over another. However, while there is no evidence comparing different concentrations of CHG, the reviewers indicated that the trend in the evidence suggests that CHG in alcohol may be more effective than PVI in alcohol.
        </p>
        <p id="para11220">
         We identified one recent systematic review of the clinical efficacy and perceived role of CHG in skin antisepsis that included studies about intravascular access.
         <xref ref-type="bibr" rid="bib460">
          <sup>
           460
          </sup>
         </xref>
         The authors suggested a potential source of bias, as many studies have overlooked the importance of alcohol when assessing the efficacy of CHG. The authors assessed the attribution of CHG in each study as correct, incorrect or intermediate. Studies were scored and analysis was performed separately to assess CHG efficiency. The authors concluded that CHG is more efficient than PVI or any other technique alone, but that the presence of alcohol provides additional benefit. The authors suggested that vascular catheters require the immediate antiseptic activity provided by alcohol prior to insertion. They also require a long-lasting antiseptic, as they stay in place for prolonged periods of time.
        </p>
        <p id="para11230">
         <list id="celist1310" list-type="simple">
          <list-item id="celistitem5060">
           <label>
            IVAD14
           </label>
           <p id="para11240">
            Decontaminate the skin at the insertion site with a single-use application of 2% chlorhexidine gluconate in 70% isopropyl alcohol (or povidone iodine in alcohol for patients with sensitivity to chlorhexidine) and allow to dry prior to the insertion of a central venous access device.
           </p>
           <p id="para11250">
            <italic>
             Class A
            </italic>
           </p>
          </list-item>
          <list-item id="celistitem5070">
           <label>
            IVAD15
           </label>
           <p id="para11260">
            Decontaminate the skin at the insertion site with a single-use application of 2% chlorhexidine gluconate in 70% isopropyl alcohol (or povidone iodine in alcohol for patients with sensitivity to chlorhexidine) and allow to dry before inserting a peripheral vascular access device.
           </p>
           <p id="para11270">
            <bold>
             New recommendation
            </bold>
            <italic>
             Class D/GPP
            </italic>
           </p>
          </list-item>
          <list-item id="celistitem5080">
           <label>
            IVAD16
           </label>
           <p id="para11280">
            Do not apply antimicrobial ointment routinely to the catheter placement site prior to insertion to prevent catheter-related bloodstream infection.
           </p>
           <p id="para11290">
            <italic>
             Class D/GPP
            </italic>
           </p>
          </list-item>
         </list>
        </p>
       </sec>
       <sec id="cesec2000">
        <label>
         4.9
        </label>
        <title>
         Catheter and Catheter Site Care
        </title>
        <sec id="cesec2010">
         <title>
          Infections can be minimised by good catheter and insertion site care
         </title>
         <p id="para11300">
          The safe maintenance of an intravascular catheter and appropriate care of the insertion site are essential components of a comprehensive strategy for preventing catheter-related infections. This includes good practice in caring for the patient's catheter hub and connection port, the use of an appropriate intravascular catheter site dressing regimen, and using flush solutions to maintain the patency of the catheter.
         </p>
        </sec>
        <sec id="cesec2020">
         <title>
          Choose the right dressing for insertion sites to minimise infection
         </title>
         <p id="para11310">
          Following placement of a PVC or CVC, a dressing is used to protect the insertion site. As occlusive dressings trap moisture on the skin and provide an ideal environment for the rapid growth of local microflora, dressings for insertion sites must be permeable to water vapour.
          <xref ref-type="bibr" rid="bib446">
           <sup>
            446
           </sup>
          </xref>
          The two most common types of dressings used for insertion sites are sterile, transparent, semi-permeable polyurethane dressings coated with a layer of an acrylic adhesive (‘transparent dressings’) and gauze and tape dressings. Transparent dressings are permeable to water vapour and oxygen, and impermeable to microorganisms.
         </p>
         <p id="para11320">
          HICPAC reviewed the evidence related to which type of dressing provided the greatest protection against infection, including the largest controlled trial of dressing regimens on PVCs,
          <xref ref-type="bibr" rid="bib361">
           <sup>
            361
           </sup>
          </xref>
          a meta-analysis comparing the risk of CR-BSI using transparent vs gauze dressings
          <xref ref-type="bibr" rid="bib461">
           <sup>
            461
           </sup>
          </xref>
          and a Cochrane review.
          <xref ref-type="bibr" rid="bib462">
           <sup>
            462
           </sup>
          </xref>
          All concluded that the choice of dressing can be a matter of preference, but if blood is leaking from the catheter insertion site, a gauze dressing might be preferred to absorb the fluid. We identified an updated Cochrane review which concluded that bloodstream infection was higher in the transparent polyurethane group compared with the gauze and tape group.
          <xref ref-type="bibr" rid="bib463">
           <sup>
            463
           </sup>
          </xref>
          The included trials were graded low quality due to the small sample size and risk of bias. There was additional low-quality evidence that demonstrated no difference between highly permeable polyurethane dressings and other polyurethane dressings in the prevention of CR-BSI.
         </p>
         <p id="para11330">
          HICPAC reviewed the evidence related to impregnated sponge dressings compared with standard dressings and found two RCTs in adults which demonstrated that chlorhexidine-impregnated sponge dressings were associated with a significant reduction in CR-BSI. However, a meta-analysis that included eight RCTs found a reduction in exit site colonisation but no significant reduction in CR-BSI. In paediatric patients, two small RCTs found a reduction in catheter colonisation but not CR-BSI, and evidence of localised contact dermatitis when used for infants of very low birth weight.
          <xref ref-type="bibr" rid="bib334">
           <sup>
            334
           </sup>
          </xref>
         </p>
         <p id="para11340">
          We identified one systematic review and meta-analysis, undertaken as part of a quality improvement collaborative, that synthesised the effects of the routine use of CHG-impregnated sponge dressings in reducing centrally inserted CR-BSI.
          <xref ref-type="bibr" rid="bib464">
           <sup>
            464
           </sup>
          </xref>
          Five studies were included in the analysis; two of the five studies were in patients in haemo/oncological ICUs, and the remaining three studies were in surgical and medical ICUs. Four of the five studies were sponsored by the manufacturer of the product. The reviewers concluded that CHG-impregnated sponge dressings are effective for the prevention of CR-BSI (OR 0.43, 95% CI 0.29–0.64) and catheter colonisation (OR 0.43, 95% CI 0.36–0.51).
         </p>
         <p id="para11350">
          We identified an economic evaluation of the use of CHG sponge dressings and the non-inferiority of dressing changes at 3 and 7 days.
          <xref ref-type="bibr" rid="bib465">
           <sup>
            465
           </sup>
          </xref>
          The authors concluded that the major cost avoided by the use of CHG sponge dressings and 7-day dressing changes rather than 3-day dressing changes was the increased length of stay of 11 days associated with CR-BSI. Chlorhexidine-impregnated sponge dressings remained cost saving for any value where the cost per CR-BSI was &gt;$4400 and the baseline rate of CR-BSI was &gt;0.35%.
          <xref ref-type="bibr" rid="bib465">
           <sup>
            465
           </sup>
          </xref>
         </p>
         <p id="para11360">
          We identified a further RCT of CHG dressings compared with highly adhesive semi-permeable dressings or standard semi-permeable dressings for the prevention of CR-BSI in 1879 patients.
          <xref ref-type="bibr" rid="bib466">
           <sup>
            466
           </sup>
          </xref>
          In the CHG group, the major catheter-related infection rate was 67% lower (0.7 vs 2.1 per 1000 catheter-days, HR 0.328, 95% CI 0.174–0.619,
          <italic>
           p
          </italic>
          =0.0006) and the CR-BSI rate was 60% lower (0.5 vs 1.3 per 1000 catheter-days, HR 0.402, 95% Cl 0.186–0.868,
          <italic>
           p
          </italic>
          =0.02) than with non-chlorhexidine dressings. Decreases were also noted in catheter colonisation and skin colonisation rates at catheter removal. Highly adhesive dressings decreased the detachment rate to 64.3% vs 71.9% (
          <italic>
           p
          </italic>
          &lt;0.0001) and the number of dressings per catheter to two (one to four) vs three (one to five) (
          <italic>
           p
          </italic>
          &lt;0.0001), but increased skin colonisation (
          <italic>
           p
          </italic>
          &lt;0.0001) and catheter colonisation (HR 1.650, 95% Cl 1.21–2.26,
          <italic>
           p
          </italic>
          =0.0016) without influencing CR-BSI rates.
         </p>
         <p id="para11370">
          HICPAC identified three studies that investigated the efficacy of a 2% CHG-impregnated washcloth in reducing the risk of CR-BSI.
          <xref ref-type="bibr" rid="bib334">
           <sup>
            334
           </sup>
          </xref>
          These studies were included in a subsequent systematic review and meta-analysis on the efficacy of either 2% CHG-impregnated cloths or 4% CHG solution for daily skin cleansing in adult acute care settings, mostly ICUs.
          <xref ref-type="bibr" rid="bib467">
           <sup>
            467
           </sup>
          </xref>
          Twelve studies were included: one RCT, one cluster NRCT and 10 controlled interrupted time series. Five studies that reported the insertion technique included the use of CHG. There was a high level of clinical heterogeneity and moderate statistical heterogeneity, which remained following a subgroup analysis by type of CHG formulation. The authors concluded that among ICU patients, daily CHG bathing with CHG liquid (OR 0.47, 95% CI 0.31–0.71) or cloths (OR 0.41, 95% CI 0.25–0.65) reduces the risk of CR-BSI. Similar benefit is obtained regardless of whether CHG cloths or liquid preparation is used (OR 0.44, 95% CI 0.44–0.59). This review was not generalisable to paediatric care.
         </p>
         <p id="para11380">
          Whenever CHG is used for insertion site dressings or skin cleansing, systems should be in place to ensure that it is not used for patients with a history of chlorhexidine sensitivity.
          <xref ref-type="bibr" rid="bib408">
           <sup>
            408
           </sup>
          </xref>
         </p>
         <p id="para11390">
          A single RCT compared the efficacy of two commercially available alcohol-based antiseptic solutions for preparation and care of CVC insertion sites, with and without octenidine dihydrochloride.
          <xref ref-type="bibr" rid="bib468">
           <sup>
            468
           </sup>
          </xref>
          Data were collected from 2002 to 2005 and published in 2010. The authors concluded that octenidine in alcoholic solution is a better option than alcohol alone for the prevention of CVC-associated infections, and may be as effective as CHG in practice but a comparative trial is needed.
         </p>
         <p id="para11400">
          <list id="celist1320" list-type="simple">
           <list-item id="celistitem5090">
            <label>
             IVAD17
            </label>
            <p id="para11410">
             Use a sterile, transparent, semi-permeable polyurethane dressing to cover the intravascular insertion site.
            </p>
            <p id="para11420">
             <italic>
              Class D/GPP
             </italic>
            </p>
           </list-item>
           <list-item id="celistitem5100">
            <label>
             IVAD18
            </label>
            <p id="para11430">
             Transparent, semi-permeable polyurethane dressings should be changed every 7 days, or sooner, if they are no longer intact or if moisture collects under the dressing.
            </p>
            <p id="para11440">
             <italic>
              Class D/GPP
             </italic>
            </p>
           </list-item>
           <list-item id="celistitem5110">
            <label>
             IVAD19
            </label>
            <p id="para11450">
             Use a sterile gauze dressing if a patient has profuse perspiration or if the insertion site is bleeding or leaking, and change when inspection of the insertion site is necessary or when the dressing becomes damp, loosened or soiled. Replace with a transparent semi-permeable dressing as soon as possible.
            </p>
            <p id="para11460">
             <italic>
              Class D/GPP
             </italic>
            </p>
           </list-item>
           <list-item id="celistitem5120">
            <label>
             IVAD20
            </label>
            <p id="para11470">
             Consider the use of a chlorhexidine-impregnated sponge dressing in adult patients with a central venous catheter as a strategy to reduce catheter-related bloodstream infection.
            </p>
            <p id="para11480">
             <bold>
              New recommendation
             </bold>
             <italic>
              Class B
             </italic>
            </p>
           </list-item>
           <list-item id="celistitem5130">
            <label>
             IVAD21
            </label>
            <p id="para11490">
             Consider the use of daily cleansing with chlorhexidine daily in adult patients with a central venous catheter as a strategy to reduce catheter-related bloodstream infection.
            </p>
            <p id="para11500">
             <bold>
              New recommendation
             </bold>
             <italic>
              Class B
             </italic>
            </p>
           </list-item>
           <list-item id="celistitem5140">
            <label>
             IVAD22
            </label>
            <p id="para11510">
             Dressings used on tunnelled or implanted catheter insertion sites should be replaced every 7 days until the insertion site has healed unless there is an indication to change them sooner. A dressing may no longer be required once the insertion site is healed.
            </p>
            <p id="para11520">
             <italic>
              Class D/GPP
             </italic>
            </p>
           </list-item>
          </list>
         </p>
        </sec>
        <sec id="cesec2030">
         <title>
          Use an appropriate antiseptic agent for disinfecting the catheter insertion site during dressing changes
         </title>
         <p id="para11530">
          Research previously described in these guidelines has described the superior effectiveness of CHG to minimise the density of microorganisms around vascular catheter insertion sites.
          <xref ref-type="bibr" rid="bib447">
           447
          </xref>
          ,
          <xref ref-type="bibr" rid="bib448">
           448
          </xref>
          ,
          <xref ref-type="bibr" rid="bib450">
           450
          </xref>
          Consequently, alcoholic CHG is now widely used in the UK for disinfecting the insertion site during dressing changes.
         </p>
         <p id="para11540">
          Studies focused on the use of antimicrobial ointment applied under the dressing to the catheter insertion site to prevent catheter-related infection do not clearly demonstrate efficacy.
          <xref ref-type="bibr" rid="bib454">
           454
          </xref>
          ,
          <xref ref-type="bibr" rid="bib459">
           459
          </xref>
         </p>
         <p id="para11550">
          Most modern intravascular catheters and other catheter materials are not damaged by contact with alcohol. However, alcohol, and other organic solvents and oil-based ointments and creams, may damage some types of polyurethane and silicon catheter tubing (e.g. some catheters used in haemodialysis). The manufacturer's recommendations to only use disinfectants that are compatible with specific catheter materials must therefore be followed.
         </p>
         <p id="para11560">
          <list id="celist1330" list-type="simple">
           <list-item id="celistitem5150">
            <label>
             IVAD23
            </label>
            <p id="para11570">
             Use a single-use application of 2% chlorhexidine gluconate in 70% isopropyl alcohol (or povidone iodine in alcohol for patients with sensitivity to chlorhexidine) to clean the central catheter insertion site during dressing changes, and allow to air dry.
            </p>
            <p id="para11580">
             <italic>
              Class A
             </italic>
            </p>
           </list-item>
           <list-item id="celistitem5160">
            <label>
             IVAD24
            </label>
            <p id="para11590">
             Use a single-use application of 2% chlorhexidine gluconate in 70% isopropyl alcohol (or povidone iodine in alcohol for patients with sensitivity to chlorhexidine) to clean the peripheral venous catheter insertion site during dressing changes, and allow to air dry.
            </p>
            <p id="para11600">
             <bold>
              New recommendation
             </bold>
             <italic>
              Class D/GPP
             </italic>
            </p>
           </list-item>
           <list-item id="celistitem5170">
            <label>
             IVAD25
            </label>
            <p id="para11610">
             Do not apply antimicrobial ointment to catheter insertion sites as part of routine catheter site care.
            </p>
            <p id="para11620">
             <italic>
              Class D/GPP
             </italic>
            </p>
           </list-item>
          </list>
         </p>
        </sec>
       </sec>
       <sec id="cesec2040">
        <label>
         4.10
        </label>
        <title>
         Catheter Replacement Strategies
        </title>
        <sec id="cesec2050">
         <title>
          Replacing intravascular devices routinely does not prevent infection
         </title>
         <p id="para11630">
          Evidence indicates that the routine replacement of CVCs at scheduled time intervals does not reduce rates of CR-BSI. Three randomised trials investigated strategies for replacing CVCs routinely at either 7 days
          <xref ref-type="bibr" rid="bib469">
           469
          </xref>
          ,
          <xref ref-type="bibr" rid="bib470">
           470
          </xref>
          or 3 days
          <xref ref-type="bibr" rid="bib471">
           <sup>
            471
           </sup>
          </xref>
          compared with changing catheters when clinically indicated. Two studies were conducted in adult ICUs
          <xref ref-type="bibr" rid="bib469">
           469
          </xref>
          ,
          <xref ref-type="bibr" rid="bib471">
           471
          </xref>
          and a third study was undertaken in a renal dialysis unit.
          <xref ref-type="bibr" rid="bib470">
           <sup>
            470
           </sup>
          </xref>
          No difference in CR-BSI was observed in patients in the scheduled replacement groups compared with those replaced when clinically indicated.
         </p>
         <p id="para11640">
          Another suggested strategy for the prevention of CR-BSI is the routine scheduling of guidewire exchange of CVCs. A systematic review and meta-analysis
          <xref ref-type="bibr" rid="bib472">
           <sup>
            472
           </sup>
          </xref>
          of 12 RCTs concluded that when compared with insertion at a new site, guidewire exchange was associated with a trend towards increased rates of catheter colonisation (RR 1.26, 95% CI 0.87–1.84), regardless of suspected CR-BSI at the time of replacement. Guidewire exchange was also associated with a trend towards increased rates of catheter exit-site infection (RR 1.52, 95% CI 0.34–6.73) and CR-BSI (RR 1.72, 95% CI 0.89–3.33), but also associated with fewer mechanical complications relative to insertion at a new site.
          <xref ref-type="bibr" rid="bib472">
           <sup>
            472
           </sup>
          </xref>
         </p>
         <p id="para11650">
          Neither we nor HICPAC identified any additional evidence for these recommendations whilst updating our systematic review.
          <xref ref-type="bibr" rid="bib334">
           <sup>
            334
           </sup>
          </xref>
         </p>
        </sec>
        <sec id="cesec2060">
         <title>
          Peripheral vascular devices
         </title>
         <p id="para11660">
          We identified one RCT that compared a routine 3-day re-siting of PVCs compared with a clinically indicated re-siting. IVD-related complication rates were 68 per 1000 IVD-days (clinically indicated) and 66 per 1000 IVD-days (routine replacement) (
          <italic>
           p
          </italic>
          =0.86, hazard ratio 1.03, 95% CI 0.74–1.43). Re-siting a device on clinical indication would allow one in two patients to have a single cannula per course of intravenous treatment, as opposed to one in five patients managed with routine re-siting; overall complication rates appear similar. Clinically indicated re-siting would achieve savings in equipment, staff time and patient discomfort.
          <xref ref-type="bibr" rid="bib473">
           <sup>
            473
           </sup>
          </xref>
         </p>
         <p id="para11670">
          A recent update of a Cochrane review found no evidence to support changing catheters every 72–96 h.
          <xref ref-type="bibr" rid="bib474">
           <sup>
            474
           </sup>
          </xref>
          Consequently, healthcare organisations may consider moving to a policy whereby catheters are changed only if clinically indicated. This would provide cost savings and spare patients the unnecessary pain of routine re-siting of devices in the absence of clinical indications. To minimise peripheral catheter-related complications, the insertion site should be inspected at each shift change and the catheter removed if signs of inflammation, infiltration or blockage are present.
          <xref ref-type="bibr" rid="bib474">
           <sup>
            474
           </sup>
          </xref>
          <list id="celist1340" list-type="simple">
           <list-item id="celistitem5180">
            <label>
             IVAD26
            </label>
            <p id="para11680">
             Do not routinely replace central venous access devices to prevent catheter-related infection.
            </p>
            <p id="para11690">
             <italic>
              Class A
             </italic>
            </p>
           </list-item>
           <list-item id="celistitem5190">
            <label>
             IVAD27
            </label>
            <p id="para11700">
             Do not use guidewire-assisted catheter exchange for patients with catheter-related bloodstream infection.
            </p>
            <p id="para11710">
             <italic>
              Class A
             </italic>
            </p>
           </list-item>
           <list-item id="celistitem5200">
            <label>
             IVAD28
            </label>
            <p id="para11720">
             Peripheral vascular catheter insertion sites should be inspected at a minimum during each shift, and a Visual Infusion Phlebitis score should be recorded. The catheter should be removed when complications occur or as soon as it is no longer required.
            </p>
            <p id="para11730">
             <bold>
              New recommendation
             </bold>
             <italic>
              Class D/GPP
             </italic>
            </p>
           </list-item>
           <list-item id="celistitem5210">
            <label>
             IVAD29
            </label>
            <p id="para11740">
             Peripheral vascular catheters should be re-sited when clinically indicated and not routinely, unless device-specific recommendations from the manufacturer indicate otherwise.
            </p>
            <p id="para11750">
             <bold>
              New recommendation
             </bold>
             <italic>
              Class B
             </italic>
            </p>
           </list-item>
          </list>
         </p>
        </sec>
       </sec>
       <sec id="cesec2070">
        <label>
         4.11
        </label>
        <title>
         General Principles for Catheter Management
        </title>
        <sec id="cesec2080">
         <title>
          Aseptic technique is important when accessing the system
         </title>
         <p id="para11760">
          Evidence demonstrating that contamination of the catheter hub contributes to intraluminal microbial colonisation of catheters, particularly long-term catheters, was considered by HICPAC.
          <xref ref-type="bibr" rid="bib346">
           346
          </xref>
          ,
          <xref ref-type="bibr" rid="bib475">
           475
          </xref>
          ,
          <xref ref-type="bibr" rid="bib476">
           476
          </xref>
          ,
          <xref ref-type="bibr" rid="bib477">
           477
          </xref>
          ,
          <xref ref-type="bibr" rid="bib478">
           478
          </xref>
          ,
          <xref ref-type="bibr" rid="bib479">
           479
          </xref>
          ,
          <xref ref-type="bibr" rid="bib480">
           480
          </xref>
          Catheter hubs are accessed more frequently when catheterisation is prolonged, and this increases the risk of CR-BSI originating from a colonised catheter hub rather than the insertion site.
          <xref ref-type="bibr" rid="bib346">
           <sup>
            346
           </sup>
          </xref>
          Evidence from a prospective cohort study suggested that frequent catheter hub manipulation increases the risk for microbial contamination.
          <xref ref-type="bibr" rid="bib481">
           <sup>
            481
           </sup>
          </xref>
          Additional studies concurred and recommended that hubs and sampling ports should be disinfected using either povidone iodine or chlorhexidine before they are accessed.
          <xref ref-type="bibr" rid="bib406">
           406
          </xref>
          ,
          <xref ref-type="bibr" rid="bib482">
           482
          </xref>
          ,
          <xref ref-type="bibr" rid="bib483">
           483
          </xref>
         </p>
         <p id="para11770">
          A randomised prospective clinical trial investigated the use of needleless connectors or standard caps attached to CVC luer connections. Results suggested that the use of needleless connectors may reduce the microbial contamination rate of CVC luers compared with standard caps. Furthermore, disinfection of needleless connectors with either chlorhexidine/alcohol or PVI significantly reduced external microbial contamination. Both these strategies may reduce the risk of catheter-related infections acquired via the intraluminal route.
          <xref ref-type="bibr" rid="bib484">
           <sup>
            484
           </sup>
          </xref>
         </p>
         <p id="para11780">
          We found no RCT evidence comparing the efficacy of different methods for the decontamination of ports and hubs prior to access. Expert opinion, based on consensus and evidence extrapolated from experimental studies of hub decontamination,
          <xref ref-type="bibr" rid="bib56">
           56
          </xref>
          ,
          <xref ref-type="bibr" rid="bib485">
           485
          </xref>
          ,
          <xref ref-type="bibr" rid="bib486">
           486
          </xref>
          and studies of skin decontamination prior to insertion and during dressing changes, suggests that injection ports or catheter hubs should be decontaminated for a minimum of 15 s using CHG in 70% alcohol before and after accessing the system. Although most intravascular catheters and catheter hub materials are now chemically compatible with alcohol or iodine, some may be incompatible and therefore the manufacturer's recommendations should be followed.
         </p>
         <p id="para11790">
          <list id="celist1350" list-type="simple">
           <list-item id="celistitem5220">
            <label>
             IVAD30
            </label>
            <p id="para11800">
             A single-use application of 2% chlorhexidine gluconate in 70% isopropyl alcohol (or povidone iodine in alcohol for patients with sensitivity to chlorhexidine) should be used to decontaminate the access port or catheter hub. The hub should be cleaned for a minimum of 15 s and allowed to dry before accessing the system.
            </p>
            <p id="para11810">
             <italic>
              Class D/GPP
             </italic>
            </p>
           </list-item>
          </list>
         </p>
        </sec>
       </sec>
       <sec id="cesec2090">
        <title>
         Using lock solutions to prevent infection
        </title>
        <p id="para11820">
         The procedure of flushing and then leaving the lumen of a CVC filled with an antibiotic solution is termed ‘antibiotic lock prophylaxis’ and has been described as a measure to prevent CR-BSI in haemodialysis or a patient who has a history of multiple CR-BSI despite optimal maximal adherence to the aseptic technique. Evidence reviewed by HICPAC
         <xref ref-type="bibr" rid="bib334">
          <sup>
           334
          </sup>
         </xref>
         demonstrated the effectiveness of this type of prophylaxis. However, the majority of the studies were conducted in haemodialysis patients and therefore may not be generalisable.
        </p>
        <p id="para11830">
         We identified a systematic review of RCTs which concluded that the scientific evidence for the effectiveness of the routine use of antibiotic-based lock solutions is weak,
         <xref ref-type="bibr" rid="bib487">
          <sup>
           487
          </sup>
         </xref>
         thus supporting the HICPAC evidence. In addition, there is concern that the use of such solutions could lead to an increase in antimicrobial-resistant microorganisms.
         <xref ref-type="bibr" rid="bib334">
          <sup>
           334
          </sup>
         </xref>
        </p>
        <p id="para11840">
         An additional placebo-RCT of daily ethanol locks to prevent CR-BSI in patients with tunnelled catheters
         <xref ref-type="bibr" rid="bib488">
          <sup>
           488
          </sup>
         </xref>
         found that the reduction in the incidence of endoluminal CR-BSI using preventive ethanol locks was non-significant, although the low incidence of endoluminal CR-BSI precludes definite conclusions, and the low incidence of CR-BSI in the placebo arm meant the study was underpowered in retrospect. Significantly more patients treated with ethanol locks discontinued their prophylactic treatment due to non-severe, ethanol-related adverse effects.
        </p>
        <p id="para11850">
         <list id="celist1360" list-type="simple">
          <list-item id="celistitem5230">
           <label>
            IVAD31
           </label>
           <p id="para11860">
            Antimicrobial lock solutions should not be used routinely to prevent catheter-related bloodstream infections.
           </p>
           <p id="para11870">
            <italic>
             Class D/GPP
            </italic>
           </p>
          </list-item>
         </list>
        </p>
       </sec>
       <sec id="cesec2100">
        <title>
         Antibiotic prophylaxis does not prevent catheter-related bloodstream infection
        </title>
        <p id="para11880">
         HICPAC identified no studies which demonstrated that oral or parenteral antibacterial or antifungal drugs reduced the incidence of CR-BSI among adults. However, among low-birthweight infants, two studies on vancomycin prophylaxis demonstrated a reduction in CR-BSI but no reduction in mortality. As the prophylactic use of vancomycin is an independent risk factor for the acquisition of VRE, it is likely that the risk of acquiring VRE outweighs the benefit of using prophylactic vancomycin.
         <xref ref-type="bibr" rid="bib334">
          334
         </xref>
         ,
         <xref ref-type="bibr" rid="bib489">
          489
         </xref>
        </p>
        <p id="para11890">
         Topical mupirocin is used to suppress
         <italic>
          S. aureus
         </italic>
         in nasal carriers. Some studies have shown that mupirocin applied nasally (or locally to the insertion site) results in reduced risk of CR-BSI.
         <xref ref-type="bibr" rid="bib334">
          <sup>
           334
          </sup>
         </xref>
         However, rates of mupriocin resistance of 12% have been reported in the UK,
         <xref ref-type="bibr" rid="bib490">
          <sup>
           490
          </sup>
         </xref>
         and its incompatibility with polyurethane catheters means that it should not be used routinely.
         <xref ref-type="bibr" rid="bib334">
          <sup>
           334
          </sup>
         </xref>
        </p>
        <p id="para11900">
         Long-term tunnelled CVCs are frequently used for patients with cancer who require intravenous treatments. A Cochrane review published in 2003 concluded that prophylactic antibiotics or catheter flushing with vancomycin and heparin may be of benefit in reducing the risk of catheter-related infections in these high-risk cancer patients.
         <xref ref-type="bibr" rid="bib491">
          <sup>
           491
          </sup>
         </xref>
         However, this practice should not be used routinely in order to minimise the development of antimicrobial resistance.
         <xref ref-type="bibr" rid="bib491">
          <sup>
           491
          </sup>
         </xref>
         <list id="celist1370" list-type="simple">
          <list-item id="celistitem5240">
           <label>
            IVAD32
           </label>
           <p id="para11910">
            Do not routinely administer intranasal or systemic antimicrobials before insertion or during the use of an intravascular device to prevent catheter colonisation or bloodstream infection.
           </p>
           <p id="para11920">
            <italic>
             Class A
            </italic>
           </p>
          </list-item>
         </list>
        </p>
       </sec>
       <sec id="cesec2110">
        <title>
         Maintaining device patency and preventing catheter thrombosis may help prevent infections
        </title>
        <p id="para11930">
         The placement of any CVC or pulmonary artery catheter leads to thrombus formation shortly after insertion, providing a focus for bacterial growth.
         <xref ref-type="bibr" rid="bib492">
          <sup>
           492
          </sup>
         </xref>
         Catheters manufactured from silicone or polyethylene and placed in the subclavian vein are less frequently associated with thrombus formation.
         <xref ref-type="bibr" rid="bib493">
          <sup>
           493
          </sup>
         </xref>
         Between 35% and 65% of patients with long-term CVCs and PICCs develop a thrombosis of the large vessels, and patients are treated with prophylactic heparin to prevent the formation of both deep vein thrombosis and catheter thrombus.
         <xref ref-type="bibr" rid="bib334">
          334
         </xref>
         ,
         <xref ref-type="bibr" rid="bib494">
          494
         </xref>
         ,
         <xref ref-type="bibr" rid="bib495">
          495
         </xref>
         ,
         <xref ref-type="bibr" rid="bib496">
          496
         </xref>
         ,
         <xref ref-type="bibr" rid="bib497">
          497
         </xref>
         ,
         <xref ref-type="bibr" rid="bib498">
          498
         </xref>
         ,
         <xref ref-type="bibr" rid="bib499">
          499
         </xref>
        </p>
       </sec>
       <sec id="cesec2120">
        <title>
         The use of anticoagulants
        </title>
        <p id="para11940">
         Heparin may be administered through several different routes. An early meta-analysis of RCTs compared the effectiveness of heparin administration via an infusion, subcutaneously or intermittent flush for the prevention of thrombus formation and CR-BSI in patients with short-term CVCs.
         <xref ref-type="bibr" rid="bib500">
          <sup>
           500
          </sup>
         </xref>
         Prophylactic heparin infusion was associated with a decrease in catheter thrombus formation, deep vein thrombosis, catheter colonisation and a trend towards reductions in CR-BSI, but this was not statistically significant. HICPAC identified an additional prospective randomised trial that demonstrated a significant decrease in the rate of CR-BSI in patients with non-tunnelled CVCs who received continuous heparin infusion.
         <xref ref-type="bibr" rid="bib501">
          <sup>
           501
          </sup>
         </xref>
         Heparin-bonded (HB) catheters have also been shown to reduce the risk of both thrombus formation and CR-BSI.
         <xref ref-type="bibr" rid="bib502">
          502
         </xref>
         ,
         <xref ref-type="bibr" rid="bib503">
          503
         </xref>
         ,
         <xref ref-type="bibr" rid="bib504">
          504
         </xref>
         ,
         <xref ref-type="bibr" rid="bib505">
          505
         </xref>
        </p>
        <p id="para11950">
         We identified one systematic review of HB CVCs in children.
         <xref ref-type="bibr" rid="bib506">
          <sup>
           506
          </sup>
         </xref>
         The reviewers identified two RCTs of 287 children aged 1 day to 16 years who received either an HB catheter or a standard catheter. There was no significant difference in the median duration of catheter patency in the two groups: 7 days in the HB catheter group and 6 days in the standard catheter group. The authors also reported a trend towards a reduction in the risk of catheter-related thrombosis and catheter occlusion in the HB group. The risks of catheter colonisation and catheter-related infection were significantly reduced in the treatment group, with a delay to infection in the HB catheter group. However, the reviewers considered the need for further studies to confirm the efficacy of HB catheters.
        </p>
        <p id="para11960">
         The use of warfarin has also been shown to reduce the risk of catheter-related thrombosis in some patient groups but not in others, and is generally not associated with a reduction in infection-related complications.
         <xref ref-type="bibr" rid="bib501">
          501
         </xref>
         ,
         <xref ref-type="bibr" rid="bib507">
          507
         </xref>
         ,
         <xref ref-type="bibr" rid="bib508">
          508
         </xref>
         ,
         <xref ref-type="bibr" rid="bib509">
          509
         </xref>
        </p>
       </sec>
       <sec id="cesec2130">
        <title>
         Heparin vs normal saline intermittent flushes
        </title>
        <p id="para11970">
         Systemic heparin, as either an infusion or flush, has a number of side effects that contraindicate its routine use for maintaining the patency of CVCs and preventing thrombus formation; these include thrombocytopenia, allergic reactions and bleeding.
         <xref ref-type="bibr" rid="bib510">
          <sup>
           510
          </sup>
         </xref>
         Normal saline is an alternative to the use of heparin flush.
        </p>
        <p id="para11980">
         HICPAC refer to three systematic reviews, and meta-analysis of RCTs evaluating the effect of heparin on the duration of catheter patency and on the prevention of complications associated with the use of peripheral venous and arterial catheters concluded that heparin at doses of 10 U/mL for intermittent flushing is no more beneficial than flushing with normal saline alone.
         <xref ref-type="bibr" rid="bib511">
          511
         </xref>
         ,
         <xref ref-type="bibr" rid="bib512">
          512
         </xref>
         ,
         <xref ref-type="bibr" rid="bib513">
          513
         </xref>
         ,
         <xref ref-type="bibr" rid="bib514">
          514
         </xref>
         However, manufacturers of implanted ports or opened-ended catheter lumens may recommend heparin flushes for maintaining CVCs that are accessed infrequently.
        </p>
        <p id="para11990">
         We identified one systematic review and two RCTs that compared heparin with normal saline to maintain the patency of CVCs and PVCs, respectively.
         <xref ref-type="bibr" rid="bib515">
          515
         </xref>
         ,
         <xref ref-type="bibr" rid="bib516">
          516
         </xref>
         ,
         <xref ref-type="bibr" rid="bib517">
          517
         </xref>
         A systematic review
         <xref ref-type="bibr" rid="bib515">
          <sup>
           515
          </sup>
         </xref>
         of heparin flushing and other interventions to maintain the patency of CVCs concluded that the evidence base for heparin flushing and other interventions to prevent catheter occlusion is limited and published studies are of low quality. The reviewers concluded that there is no direct evidence of the effectiveness of heparin flushes to prevent CR-BSI or other central line complications.
        </p>
        <p id="para12000">
         In a single-centre RCT
         <xref ref-type="bibr" rid="bib516">
          <sup>
           516
          </sup>
         </xref>
         of newly placed multi-lumen CVCs in patients in medical ICUs and surgical/burn/trauma ICUs, normal saline and heparin flush solutions were found to have similar rates of lumen non-patency. Given potential safety concerns with the use of heparin, normal saline may be the preferred flushing solution for short-term use for CVC maintenance. Secondary outcomes for CR-BSI were non-significant between groups.
        </p>
        <p id="para12010">
         A single-centre cluster RCT
         <xref ref-type="bibr" rid="bib517">
          <sup>
           517
          </sup>
         </xref>
         of 214 medical patients found that twice-daily heparin (100 U/mL) flushes for maintenance of PVCs was more effective than normal saline solution. The number of catheter-related phlebitis/occlusions and the number of catheters per patient was reduced; however, infection outcomes were not measured.
        </p>
        <p id="para12020">
         <list id="celist1380" list-type="simple">
          <list-item id="celistitem5250">
           <label>
            IVAD33
           </label>
           <p id="para12030">
            Do not use systemic anticoagulants routinely to prevent catheter-related bloodstream infection.
           </p>
           <p id="para12040">
            <italic>
             Class D/GPP
            </italic>
           </p>
          </list-item>
          <list-item id="celistitem5260">
           <label>
            IVAD34
           </label>
           <p id="para12050">
            Use sterile normal saline for injection to flush and lock catheter lumens that are accessed frequently.
           </p>
           <p id="para12060">
            <italic>
             Class A
            </italic>
           </p>
          </list-item>
         </list>
        </p>
       </sec>
       <sec id="cesec2140">
        <title>
         Safer sharps devices require vigilance
        </title>
        <p id="para12070">
         Needle-free infusion systems and connection devices have been widely introduced to reduce the incidence of sharps injuries and minimise the risk of transmission of bloodborne pathogens to healthcare workers.
         <xref ref-type="bibr" rid="bib334">
          <sup>
           334
          </sup>
         </xref>
         There is limited evidence that needleless devices or valves reduce the risk of catheter colonisation compared with standard devices.
         <xref ref-type="bibr" rid="bib334">
          <sup>
           334
          </sup>
         </xref>
         In addition, the design features of some of these devices pose a potential risk for contamination, and have been associated with reports of an increase in bloodstream infection rates.
         <xref ref-type="bibr" rid="bib518">
          518
         </xref>
         ,
         <xref ref-type="bibr" rid="bib519">
          519
         </xref>
         ,
         <xref ref-type="bibr" rid="bib520">
          520
         </xref>
         ,
         <xref ref-type="bibr" rid="bib521">
          521
         </xref>
         <list id="celist1390" list-type="simple">
          <list-item id="celistitem5270">
           <label>
            IVAD35
           </label>
           <p id="para12080">
            The introduction of new intravascular devices or components should be monitored for an increase in the occurrence of device-associated infection. If an increase in infection rates is suspected, this should be reported to the Medicines and Healthcare Products Regulatory Agency in the UK.
           </p>
           <p id="para12090">
            <italic>
             Class D/GPP
            </italic>
           </p>
          </list-item>
          <list-item id="celistitem5280">
           <label>
            IVAD36
           </label>
           <p id="para12100">
            When safer sharps devices are used, healthcare workers should ensure that all components of the system are compatible and secured to minimise leaks and breaks in the system.
           </p>
           <p id="para12110">
            <italic>
             Class D/GPP
            </italic>
           </p>
          </list-item>
         </list>
        </p>
       </sec>
       <sec id="cesec2150">
        <title>
         Change intravenous administration sets appropriately
        </title>
        <p id="para12120">
         HICPAC reviewed three well-controlled studies on the optimal interval for the routine replacement of intravenous solution administration sets.
         <xref ref-type="bibr" rid="bib334">
          <sup>
           334
          </sup>
         </xref>
         A Cochrane review
         <xref ref-type="bibr" rid="bib522">
          <sup>
           522
          </sup>
         </xref>
         of 13 RCTs with 4783 patients concluded that there is no evidence that changing intravenous administration sets more often than every 96 h reduces the incidence of bloodstream infection. The reviewers were unable to conclude if changing administration sets less often than every 96 h affects the incidence of infection from the studies. There were no differences between participants with central vs peripheral catheters, nor between participants who did and did not receive parenteral nutrition, or between children and adults. Administration sets that do not contain lipids, blood or blood products may be left in place for intervals of up to 96 h without increasing the incidence of infection. There is no evidence to suggest that administration sets which contain lipids should not be changed every 24 h as currently recommended.
        </p>
        <p id="para12130">
         <list id="celist1400" list-type="simple">
          <list-item id="celistitem5290">
           <label>
            IVAD37
           </label>
           <p id="para12140">
            Administration sets in continuous use do not need to be replaced more frequently than every 96 h, unless device-specific recommendations from the manufacturer indicate otherwise, they become disconnected or the intravascular access device is replaced.
           </p>
           <p id="para12150">
            <italic>
             Class A
            </italic>
           </p>
          </list-item>
          <list-item id="celistitem5300">
           <label>
            IVAD38
           </label>
           <p id="para12160">
            Administration sets for blood and blood components should be changed when the transfusion episode is complete or every 12 h (whichever is sooner).
           </p>
           <p id="para12170">
            <italic>
             Class D/GPP
            </italic>
           </p>
          </list-item>
          <list-item id="celistitem5310">
           <label>
            IVAD39
           </label>
           <p id="para12180">
            Administration sets used for lipid-containing parenteral nutrition should be changed every 24 h.
           </p>
           <p id="para12190">
            <italic>
             Class D/GPP
            </italic>
           </p>
          </list-item>
         </list>
        </p>
       </sec>
       <sec id="cesec2160">
        <title>
         System interventions to reduce catheter-related infection
        </title>
        <p id="para12200">
         Ensuring that patients receive care that is evidence based is an essential element of delivering high-quality health care. In 2005, the Department of Health issued a series of high-impact interventions that were derived from national and international evidence-based guidelines for the prevention of healthcare-associated infection and based on experience from the Institute of Healthcare Improvement 100,000 Lives Campaign focused on reducing patient harm.
         <xref ref-type="bibr" rid="bib523">
          <sup>
           523
          </sup>
         </xref>
         The high-impact interventions focused on increasing the reliability of care and ensuring that recommendations were implemented every time for every patient. The intervention for the prevention of infection associated with the use of IVDs included six key interventions often referred to as a ‘care bundle’, together with audit tools to measure adherence. These six practices included:
         <list id="celist1410" list-type="simple">
          <list-item id="celistitem5320">
           <label>
            •
           </label>
           <p id="para12210">
            aseptic insertion of an appropriate device;
           </p>
          </list-item>
          <list-item id="celistitem5330">
           <label>
            •
           </label>
           <p id="para12220">
            correct siting of the device;
           </p>
          </list-item>
          <list-item id="celistitem5340">
           <label>
            •
           </label>
           <p id="para12230">
            effective cutaneous antisepsis; and for continuing care of the device:
           </p>
          </list-item>
          <list-item id="celistitem5350">
           <label>
            •
           </label>
           <p id="para12240">
            hand decontamination and asepsis for any contact with the device;
           </p>
          </list-item>
          <list-item id="celistitem5360">
           <label>
            •
           </label>
           <p id="para12250">
            daily observation of the insertion site; and
           </p>
          </list-item>
          <list-item id="celistitem5370">
           <label>
            •
           </label>
           <p id="para12260">
            clean, intact dressing.
           </p>
          </list-item>
         </list>
        </p>
        <p id="para12270">
         A small number of well-designed studies
         <xref ref-type="bibr" rid="bib353">
          353
         </xref>
         ,
         <xref ref-type="bibr" rid="bib524">
          524
         </xref>
         have described the use of ‘bundled’ approaches to reducing CR-BSI, and have stimulated individual observational and quality improvement reports of the results of using key evidence-based practices for the prevention of CR-BSI. The most prominent of these was a study conducted in the ICU setting of 108 hospitals in the USA, which was then adopted by other countries including the UK.
         <xref ref-type="bibr" rid="bib525">
          525
         </xref>
         ,
         <xref ref-type="bibr" rid="bib526">
          526
         </xref>
         The authors reported the success of five evidence-based practices combined with system and organisational support, which resulted in a 66% decrease in CR-BSI 18 months after the inception of the programme (incidence rate ratio 0.62, 95% CI 0.47–0.81 to incidence rate ratio 0.34, 95% CI 0.23–0.50) and sustained reductions thereafter.
         <xref ref-type="bibr" rid="bib525">
          <sup>
           525
          </sup>
         </xref>
         The intervention comprised: hand hygiene using ABHR; MSB precautions for insertion; cutaneous antisepsis of the insertion site with 2% CHG; avoiding the femoral site; and removing CVCs as soon as they are no longer clinically indicated. In addition, system changes that prompted the clinician to ‘do the right thing’ included placing all the equipment needed in a cart for ease of access; the use of a checklist; authorising staff to halt procedures if best practice was not being followed; daily rounds to ensure the timely removal of CVCs; feedback of CR-BSI cases to clinical staff; and organisational support to purchase essential equipment and solutions prior to the start of the study.
        </p>
        <p id="para12280">
         Audit and feedback are an essential component of any quality improvement intervention as this promotes a continuous ‘Hawthorne effect’ and enables staff to maintain vigilance and sustain improvement. The use of dashboards and statistical process control charts alerts clinicians to variability outside control limits, and prompts scrutiny of practice and organisational systems, and remedial action to be taken.
         <xref ref-type="bibr" rid="bib527">
          <sup>
           527
          </sup>
         </xref>
        </p>
        <p id="para12290">
         We identified three additional studies that reported ‘bundled interventions’ to reduce CR-BSI.
         <xref ref-type="bibr" rid="bib528">
          528
         </xref>
         ,
         <xref ref-type="bibr" rid="bib529">
          529
         </xref>
         ,
         <xref ref-type="bibr" rid="bib530">
          530
         </xref>
         None were included in the systematic review as they failed to meet study quality criteria. The features of any quality improvement initiative need to be tailored to the local conditions and may include some or all of the following:
         <list id="celist1420" list-type="simple">
          <list-item id="celistitem5380">
           <label>
            •
           </label>
           <p id="para12300">
            hand hygiene, aseptic insertion using MSB precautions (CVC), aseptic technique (PVC), cutaneous antisepsis using 2% CHG in alcohol unless contraindicated, appropriate siting of the CVC or PVC, and prompt removal when no longer indicated;
           </p>
          </list-item>
          <list-item id="celistitem5390">
           <label>
            •
           </label>
           <p id="para12310">
            audit and feedback;
           </p>
          </list-item>
          <list-item id="celistitem5400">
           <label>
            •
           </label>
           <p id="para12320">
            education and training; and
           </p>
          </list-item>
          <list-item id="celistitem5410">
           <label>
            •
           </label>
           <p id="para12330">
            accessibility of equipment and appropriate system changes developed with clinical staff to make best practice the norm.
           </p>
          </list-item>
         </list>
        </p>
        <p id="para12340">
         In one cost-effectiveness study, a Markov decision model was used to evaluate the cost-effectiveness of a care bundle to prevent CR-BSI.
         <xref ref-type="bibr" rid="bib531">
          <sup>
           531
          </sup>
         </xref>
         The care bundle included in the model was based on the bundle advocated by the Institute for Health Improvement 100,000 Lives Campaign,
         <xref ref-type="bibr" rid="bib532">
          <sup>
           532
          </sup>
         </xref>
         comprising optimal hand hygiene, chlorhexidine skin antisepsis, MSB precautions for catheter insertion and insertion equipment kit, optimal insertion site and prompt catheter removal. Costs included monitoring, education and clinical leadership activities. The authors estimated that the bundle would be cost-effective if the costs of implementation were less than AUS$94,559 (£55,817) per ICU.
        </p>
        <p id="para12350">
         <list id="celist1430" list-type="simple">
          <list-item id="celistitem5420">
           <label>
            IVAD40
           </label>
           <p id="para12360">
            Use quality improvement interventions to support the appropriate use and management of intravascular access devices (central and peripheral venous catheters) and ensure their timely removal. These may include:
            <list id="celist1440" list-type="simple">
             <list-item id="celistitem5430">
              <label>
               •
              </label>
              <p id="para12370">
               protocols for device insertion and maintenance;
              </p>
             </list-item>
             <list-item id="celistitem5440">
              <label>
               •
              </label>
              <p id="para12380">
               reminders to review the continuing use or prompt the removal of intravascular devices;
              </p>
             </list-item>
             <list-item id="celistitem5450">
              <label>
               •
              </label>
              <p id="para12390">
               audit and feedback of compliance with practice guidelines; and
              </p>
             </list-item>
             <list-item id="celistitem5460">
              <label>
               •
              </label>
              <p id="para12400">
               continuing professional education.
              </p>
             </list-item>
            </list>
           </p>
           <p id="para12410">
            <bold>
             New recommendation
            </bold>
            <italic>
             Class C/GPP
            </italic>
           </p>
          </list-item>
         </list>
        </p>
       </sec>
      </sec>
      <sec id="cesec2170">
       <title>
        Intravascular Access Devices – Systematic Review Process
       </title>
       <p id="para12420">
        <boxed-text id="cetextbox550">
         <sec id="cesec2180">
          <title>
           <inline-graphic xlink:href="fx2_lrg.gif">
           </inline-graphic>
           Systematic Review Questions
          </title>
          <p id="para12430">
           <list id="celist1450" list-type="simple">
            <list-item id="celistitem5470">
             <label>
              1.
             </label>
             <p id="para12440">
              What types of CVCs (material, coating, antibiotic impregnation, cuffed, tunnelled, midline, PICC) and PVCs (material, coating, antibiotic impregnation) are most effective in reducing the risk of CR-BSI and related complications/adverse events including phlebitis, related mortality, catheter tip colonisation and premature line removal?
             </p>
            </list-item>
            <list-item id="celistitem5480">
             <label>
              2.
             </label>
             <p id="para12450">
              Which CVC/PVC insertion site is associated with the lowest risk of CR-BSI and related complications including phlebitis, related mortality, catheter tip colonisation and premature line removal?
             </p>
            </list-item>
            <list-item id="celistitem5490">
             <label>
              3.
             </label>
             <p id="para12460">
              What is the evidence that additional ports or lumens increase the risk of CR-BSI and related complications/adverse events including phlebitis, mortality, catheter tip colonisation and premature line removal?
             </p>
            </list-item>
            <list-item id="celistitem5500">
             <label>
              4.
             </label>
             <p id="para12470">
              Which infection prevention precautions used for inserting intravascular catheters are most effective in reducing the risk of CR-BSI and related complications/adverse events including phlebitis, catheter tip colonisation, premature line removal and mortality?
             </p>
            </list-item>
            <list-item id="celistitem5510">
             <label>
              5.
             </label>
             <p id="para12480">
              What levels of barrier precautions are most effective in reducing the risk of CR-BSI and related complications/adverse events including phlebitis, catheter tip colonisation, premature line removal and mortality?
             </p>
            </list-item>
            <list-item id="celistitem5520">
             <label>
              6.
             </label>
             <p id="para12490">
              What is the most effective skin antisepsis solution/antiseptic-impregnated product for decontamination of the skin prior to insertion of CVCs and PVCs to reduce the risk of CR-BSI and related complications including phlebitis, catheter tip colonisation, premature line removal and mortality?
             </p>
            </list-item>
            <list-item id="celistitem5530">
             <label>
              7.
             </label>
             <p id="para12500">
              What is the effectiveness of antiseptics vs antiseptic-impregnated products (sponges or cloths) for decontaminating skin at the insertion site or surrounding area whilst a CVC or PVC is
              <italic>
               in situ
              </italic>
              in reducing the risk of CR-BSI and related complications including phlebitis, catheter tip colonisation, premature line removal and mortality?
             </p>
            </list-item>
            <list-item id="celistitem5540">
             <label>
              8.
             </label>
             <p id="para12510">
              What is the evidence for the effectiveness of using antibiotics or antiseptics to lock, flush or clean the catheter hub or entry ports of CVCs and PVCs in reducing the risk of CR-BSI and related complications including phlebitis, catheter tip colonisation, premature line removal and mortality?
             </p>
            </list-item>
            <list-item id="celistitem5550">
             <label>
              9.
             </label>
             <p id="para12520">
              What is the effectiveness of low-dose systemic anticoagulation to reduce the risk of CR-BSI and related complications including phlebitis, catheter tip colonisation, premature line removal and mortality?
             </p>
            </list-item>
            <list-item id="celistitem5560">
             <label>
              10.
             </label>
             <p id="para12530">
              Which dressing type is the most clinically effective in reducing the risk of CR-BSI and related complications including phlebitis, catheter tip colonisation, premature line removal and mortality, and how frequently should dressings be changed?
             </p>
            </list-item>
            <list-item id="celistitem5570">
             <label>
              11.
             </label>
             <p id="para12540">
              What is the optimal frequency to change or re-site PVCs or midline catheters to reduce the risk of CR-BSI and related complications including phlebitis, catheter tip colonisation, premature line removal and mortality?
             </p>
            </list-item>
            <list-item id="celistitem5580">
             <label>
              12.
             </label>
             <p id="para12550">
              What is the evidence for the effectiveness of replacing administration sets to reduce the risk of CR-BSI and related complications including phlebitis, catheter tip colonisation, premature line removal and mortality?
             </p>
            </list-item>
            <list-item id="celistitem5590">
             <label>
              13.
             </label>
             <p id="para12560">
              What is the effectiveness of the prophylactic administration of systemic antimicrobials in reducing the incidence of CR-BSI and related complications including phlebitis, catheter tip colonisation, premature line removal and mortality?
             </p>
            </list-item>
            <list-item id="celistitem5600">
             <label>
              14.
             </label>
             <p id="para12570">
              What is the evidence that the needle-safe devices are associated with increased risk of CR-BSI and related complications including phlebitis, catheter tip colonisation, premature line removal and mortality?
             </p>
            </list-item>
            <list-item id="celistitem5610">
             <label>
              15.
             </label>
             <p id="para12580">
              What is the effectiveness of system interventions in reducing the risk of CR-BSI and related complications including phlebitis, catheter tip colonisation, premature line removal and mortality, and improving healthcare workers' knowledge and behaviour relating to the use of central venous access device (CVAD) and peripheral vascular device (PVD)?
             </p>
            </list-item>
           </list>
          </p>
         </sec>
        </boxed-text>
       </p>
       <p id="para12590">
        <boxed-text id="cetextbox560">
         <sec id="cesec2190">
          <title>
           <inline-graphic xlink:href="fx2_lrg.gif">
           </inline-graphic>
           Databases and Search Terms Used
          </title>
          <p id="para12600">
           <bold>
            DATABASES
           </bold>
          </p>
          <p id="para12610">
           Medline, Cumulative Index to Nursing and Allied Health Literature (CINAHL), Embase, NEHL Guideline Finder, National Institute for Health and Clinical Excellence, the Cochrane Library (CDSR, CCRCT, CMR), US Guideline Clearing House, DARE (NHS Evidence, HTA), Prospero
          </p>
          <p id="para12620">
           <bold>
            MeSH TERMS
           </bold>
          </p>
          <p id="para12630">
           Infection control; cross infection; disease transmission; universal precautions; central venous catheter; bacteremia; chlorhexidine; povidone-iodine; anticoagulants; sepsis; sterilisation; antisepsis; catheterisation; peripheral catheterisation; peripheral catheter
          </p>
          <p id="para12640">
           <bold>
            THESAURUS AND FREE-TEXT TERMS
           </bold>
          </p>
          <p id="para12650">
           PICC; TPN; catheter hub; implantable catheter; catheter port; needle-free devices; needleless connector; intravenous-access; skin preparation; care bundle; Matching Michigan; catheter team, IV team; specialist nurses
          </p>
          <p id="para12660">
           <bold>
            SEARCH DATE
           </bold>
          </p>
          <p id="para12670">
           Jan 2010-Feb 2013
          </p>
         </sec>
        </boxed-text>
       </p>
       <p id="para12680">
        <boxed-text id="cetextbox570">
         <sec id="cesec2200">
          <title>
           <inline-graphic xlink:href="fx2_lrg.gif">
           </inline-graphic>
           Search Results
          </title>
          <p id="para12690">
           Total number of articles located = 8053
          </p>
         </sec>
        </boxed-text>
       </p>
       <p id="para12700">
        <boxed-text id="cetextbox580">
         <sec id="cesec2210">
          <title>
           <inline-graphic xlink:href="fx2_lrg.gif">
           </inline-graphic>
           Sift 1 Criteria
          </title>
          <p id="para12710">
           <bold>
            Abstract indicates
           </bold>
           that the article: relates to infections associated with intravascular access devices; is written in English; is primary research, a systematic review or a meta-analysis; and appears to inform one or more of the review questions.
          </p>
         </sec>
        </boxed-text>
       </p>
       <p id="para12720">
        <boxed-text id="cetextbox590">
         <sec id="cesec2220">
          <title>
           <inline-graphic xlink:href="fx2_lrg.gif">
           </inline-graphic>
           Articles Retrieved
          </title>
          <p id="para12730">
           <bold>
            Total number of articles retrieved from Sift 1 = 96
           </bold>
          </p>
         </sec>
        </boxed-text>
       </p>
       <p id="para12740">
        <boxed-text id="cetextbox600">
         <sec id="cesec2230">
          <title>
           <inline-graphic xlink:href="fx2_lrg.gif">
           </inline-graphic>
           Sift 2 Criteria
          </title>
          <p id="para12750">
           <bold>
            Full text confirms
           </bold>
           that the article: relates to infections associated with intravascular access devices; is written in English; is primary research (randomised controlled trials, prospective cohort, interrupted time series, controlled before-after, quasi-experimental), a systematic review or a meta-analysis including the above designs; and informs one or more of the review questions.
          </p>
         </sec>
        </boxed-text>
       </p>
       <p id="para12760">
        <boxed-text id="cetextbox610">
         <sec id="cesec2240">
          <title>
           <inline-graphic xlink:href="fx2_lrg.gif">
           </inline-graphic>
           Articles Selected for Appraisal
          </title>
          <p id="para12770">
           <bold>
            Total number of studies selected for appraisal during Sift 2 = 30
           </bold>
          </p>
         </sec>
        </boxed-text>
       </p>
       <p id="para12780">
        <boxed-text id="cetextbox620">
         <sec id="cesec2250">
          <title>
           <inline-graphic xlink:href="fx2_lrg.gif">
           </inline-graphic>
           Critical Appraisal
          </title>
          <p id="para12790">
           All articles that described primary research, a systematic review or a meta-analysis and met the Sift 2 criteria were independently critically appraised by two appraisers using SIGN and EPOC criteria. Consensus and grading was achieved through discussion.
          </p>
         </sec>
        </boxed-text>
       </p>
       <p id="para12800">
        <boxed-text id="cetextbox630">
         <sec id="cesec2260">
          <title>
           <inline-graphic xlink:href="fx2_lrg.gif">
           </inline-graphic>
           Accepted and Rejected Evidence
          </title>
          <p id="para12810">
           <bold>
            Total number of studies accepted after critical appraisal = 22
           </bold>
          </p>
          <p id="para12820">
           <bold>
            Total number of studies rejected after critical appraisal = 8
           </bold>
          </p>
         </sec>
        </boxed-text>
       </p>
      </sec>
     </sec>
    </sec>
    <back>
     <ref-list id="bibl10">
      <title>
       References
      </title>
      <ref id="bib1">
       <label>
        1
       </label>
       <element-citation id="sbref10" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Pratt
          </surname>
          <given-names>
           RJ
          </given-names>
         </name>
         <name>
          <surname>
           Pellowe
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Loveday
          </surname>
          <given-names>
           HP
          </given-names>
         </name>
         <name>
          <surname>
           Department of Health (England)
          </surname>
         </name>
        </person-group>
        <article-title>
         The epic project: developing national evidence-based guidelines for preventing healthcare associated infections. Phase I: Guidelines for preventing hospital-acquired infections
        </article-title>
        <source>
         J Hosp Infect
        </source>
        <volume>
         47
        </volume>
        <issue>
         Suppl. l
        </issue>
        <year>
         2001
        </year>
        <fpage>
         S3
        </fpage>
        <lpage>
         S82
        </lpage>
        <pub-id pub-id-type="pmid">
         11161888
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib2">
       <label>
        2
       </label>
       <element-citation id="sbref20" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Pratt
          </surname>
          <given-names>
           RJ
          </given-names>
         </name>
         <name>
          <surname>
           Pellowe
          </surname>
          <given-names>
           CM
          </given-names>
         </name>
         <name>
          <surname>
           Wilson
          </surname>
          <given-names>
           JA
          </given-names>
         </name>
        </person-group>
        <article-title>
         epic2: National evidence-based guidelines for preventing healthcare-associated infections in NHS hospitals in England
        </article-title>
        <source>
         J Hosp Infect
        </source>
        <volume>
         65
        </volume>
        <issue>
         Suppl. 1
        </issue>
        <year>
         2007
        </year>
        <fpage>
         S1
        </fpage>
        <lpage>
         S59
        </lpage>
        <pub-id pub-id-type="pmid">
         17307562
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib3">
       <label>
        3
       </label>
       <element-citation id="sbref30" publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           AGREE II Instrument
          </surname>
         </name>
        </person-group>
        <article-title>
         Appraisal of guidelines for research and evaluation Il
        </article-title>
        <ext-link ext-link-type="uri" id="interrefs30" xlink:href="http://www.agreetrust.org/resource-centre/agree-ii/">
         Available at: http://www.agreetrust.org/resource-centre/agree-ii/
        </ext-link>
        <year>
         2009
        </year>
        <comment>
         Accessed October 5, 2012.
        </comment>
       </element-citation>
      </ref>
      <ref id="bib4">
       <label>
        4
       </label>
       <element-citation id="sbref40" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Scottish Intercollegiate Guidelines Network
          </surname>
         </name>
        </person-group>
        <source>
         SIGN 50: a guideline developer's handbook
        </source>
        <edition>
         Revised edition
        </edition>
        <year>
         2011
        </year>
        <publisher-name>
         Heathcare Improvement Scotland
        </publisher-name>
        <publisher-loc>
         Edinburgh
        </publisher-loc>
        <ext-link ext-link-type="uri" id="interrefs40" xlink:href="http://www.sign.ac.uk/guidelines/fulltext/50/index.html">
         Available at: http://www.sign.ac.uk/guidelines/fulltext/50/index.html
        </ext-link>
        <comment>
         Accessed July 25, 2013
        </comment>
       </element-citation>
      </ref>
      <ref id="bib5">
       <label>
        5
       </label>
       <element-citation id="sbref50" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cochrane Effective Practice and Organisation of Care Review Group
          </surname>
         </name>
        </person-group>
        <source>
         EPOC resources
        </source>
        <year>
         2013
        </year>
        <publisher-name>
         The Cochrane Collaboration
        </publisher-name>
        <ext-link ext-link-type="uri" id="interrefs50" xlink:href="http://epoc.cochrane.org/epoc-resources">
         Available at: http://epoc.cochrane.org/epoc-resources
        </ext-link>
        <comment>
         Accessed 6 August, 2013.
        </comment>
       </element-citation>
      </ref>
      <ref id="bib6">
       <label>
        6
       </label>
       <element-citation id="sbref60" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Department of Health
          </surname>
         </name>
        </person-group>
        <source>
         The Health and Social Care Act 2008: code of practice for the NHS on the prevention and control of healthcare associated infections and related guidance
        </source>
        <year>
         2009
        </year>
        <publisher-name>
         Department of Health
        </publisher-name>
        <publisher-loc>
         London
        </publisher-loc>
       </element-citation>
      </ref>
      <ref id="bib7">
       <label>
        7
       </label>
       <element-citation id="sbref70" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Department of Health
          </surname>
         </name>
        </person-group>
        <source>
         Decontamination of re-usable medical devices in the primary, secondary and tertiary care sectors (NHS and independent providers)
        </source>
        <year>
         2007
        </year>
        <publisher-name>
         Department of Health
        </publisher-name>
        <publisher-loc>
         London
        </publisher-loc>
       </element-citation>
      </ref>
      <ref id="bib8">
       <label>
        8
       </label>
       <element-citation id="sbref80" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Care Quality Commission
          </surname>
         </name>
        </person-group>
        <source>
         Guidance about compliance. Essential standards of quality and safety
        </source>
        <year>
         2010
        </year>
        <publisher-name>
         Care Quality Commission
        </publisher-name>
        <publisher-loc>
         London
        </publisher-loc>
        <ext-link ext-link-type="uri" id="interrefs60" xlink:href="http://www.cqc.org.uk/sites/default/files/media/documents/essential_standards_of_quality_and_safety_march_2010_final_0.pdf">
         Available at: http://www.cqc.org.uk/sites/default/files/media/documents/essential_standards_of_quality_and_safety_march_2010_final_0.pdf
        </ext-link>
        <comment>
         Accessed August 1, 2013.
        </comment>
       </element-citation>
      </ref>
      <ref id="bib9">
       <label>
        9
       </label>
       <element-citation id="sbref90" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           National Patient Safety Agency
          </surname>
         </name>
        </person-group>
        <source>
         The revised healthcare cleaning manual
        </source>
        <year>
         2009
        </year>
        <publisher-name>
         NPSA
        </publisher-name>
        <publisher-loc>
         London
        </publisher-loc>
        <ext-link ext-link-type="uri" id="interrefs70" xlink:href="http://www.nrls.npsa.nhs.uk/EasySiteWeb/getresource.axd?AssetID=61814">
         Available at: http://www.nrls.npsa.nhs.uk/EasySiteWeb/getresource.axd?AssetID=61814
        </ext-link>
        <comment>
         Accessed July 19, 2013.
        </comment>
       </element-citation>
      </ref>
      <ref id="bib10">
       <label>
        10
       </label>
       <element-citation id="sbref100" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           National Institute for Health and Care Excellence
          </surname>
         </name>
        </person-group>
        <source>
         Guidance 36. Prevention and control of healthcare-associated infections. Quality improvement guide
        </source>
        <year>
         2011
        </year>
        <publisher-name>
         National Institute for Health and Care Excellence
        </publisher-name>
        <publisher-loc>
         London
        </publisher-loc>
        <ext-link ext-link-type="uri" id="interrefs80" xlink:href="http://www.nice.org.uk/guidance/PH36">
         Available at: www.nice.org.uk/guidance/PH36
        </ext-link>
        <comment>
         Accessed July 25, 2013.
        </comment>
       </element-citation>
      </ref>
      <ref id="bib11">
       <label>
        11
       </label>
       <element-citation id="sbref110" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Boyce
          </surname>
          <given-names>
           JM
          </given-names>
         </name>
         <name>
          <surname>
           Havill
          </surname>
          <given-names>
           NL
          </given-names>
         </name>
         <name>
          <surname>
           Otter
          </surname>
          <given-names>
           JA
          </given-names>
         </name>
         <name>
          <surname>
           Adams
          </surname>
          <given-names>
           NMT
          </given-names>
         </name>
        </person-group>
        <article-title>
         Widespread environmental contamination associated with patients with diarrhea and methicillin-resistant Staphylococcus aureus colonization of the gastrointestinal tract
        </article-title>
        <source>
         Infect Control Hosp Epidemiol
        </source>
        <volume>
         28
        </volume>
        <year>
         2007
        </year>
        <fpage>
         1142
        </fpage>
        <lpage>
         1147
        </lpage>
        <pub-id pub-id-type="pmid">
         17828690
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib12">
       <label>
        12
       </label>
       <element-citation id="sbref120" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Dancer
          </surname>
          <given-names>
           SJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         Importance of the environment in meticillin-resistant Staphylococcus aureus acquisition: the case for hospital cleaning
        </article-title>
        <source>
         Lancet Infect Dis
        </source>
        <volume>
         8
        </volume>
        <year>
         2008
        </year>
        <fpage>
         101
        </fpage>
        <lpage>
         113
        </lpage>
        <pub-id pub-id-type="pmid">
         17974481
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib13">
       <label>
        13
       </label>
       <element-citation id="sbref130" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Griffiths
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Fernandez
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Halcomb
          </surname>
          <given-names>
           E
          </given-names>
         </name>
        </person-group>
        <article-title>
         Reservoirs of MRSA in the acute hospital setting: a systematic review
        </article-title>
        <source>
         Contemp Nurse
        </source>
        <volume>
         13
        </volume>
        <year>
         2002
        </year>
        <fpage>
         38
        </fpage>
        <lpage>
         49
        </lpage>
        <pub-id pub-id-type="pmid">
         16118969
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib14">
       <label>
        14
       </label>
       <element-citation id="sbref140" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Barker
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Vipond
          </surname>
          <given-names>
           IB
          </given-names>
         </name>
         <name>
          <surname>
           Bloomfield
          </surname>
          <given-names>
           SF
          </given-names>
         </name>
        </person-group>
        <article-title>
         Effects of cleaning and disinfection in reducing the spread of Norovirus contamination via environmental surfaces
        </article-title>
        <source>
         J Hosp Infect
        </source>
        <volume>
         58
        </volume>
        <year>
         2004
        </year>
        <fpage>
         42
        </fpage>
        <lpage>
         49
        </lpage>
        <pub-id pub-id-type="pmid">
         15350713
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib15">
       <label>
        15
       </label>
       <element-citation id="sbref150" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Denton
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Wilcox
          </surname>
          <given-names>
           MH
          </given-names>
         </name>
         <name>
          <surname>
           Parnell
          </surname>
          <given-names>
           P
          </given-names>
         </name>
        </person-group>
        <article-title>
         Role of environmental cleaning in controlling an outbreak of Acinetobacter baumannii on a neurosurgical intensive care unit
        </article-title>
        <source>
         J Hosp Infect
        </source>
        <volume>
         56
        </volume>
        <year>
         2004
        </year>
        <fpage>
         106
        </fpage>
        <lpage>
         110
        </lpage>
        <pub-id pub-id-type="pmid">
         15019221
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib16">
       <label>
        16
       </label>
       <element-citation id="sbref160" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wilcox
          </surname>
          <given-names>
           MH
          </given-names>
         </name>
         <name>
          <surname>
           Fawley
          </surname>
          <given-names>
           WN
          </given-names>
         </name>
         <name>
          <surname>
           Wigglesworth
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Parnell
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Verity
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Freeman
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        <article-title>
         Comparison of the effect of detergent versus hypochlorite cleaning on environmental contamination and incidence of Clostridium difficile infection
        </article-title>
        <source>
         J Hosp Infect
        </source>
        <volume>
         54
        </volume>
        <year>
         2003
        </year>
        <fpage>
         109
        </fpage>
        <lpage>
         114
        </lpage>
        <pub-id pub-id-type="pmid">
         12818583
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib17">
       <label>
        17
       </label>
       <element-citation id="sbref170" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Boyce
          </surname>
          <given-names>
           JM
          </given-names>
         </name>
         <name>
          <surname>
           Potter-Bynoe
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Chenevert
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           King
          </surname>
          <given-names>
           T
          </given-names>
         </name>
        </person-group>
        <article-title>
         Environmental contamination due to methicillin-resistant Staphylococcus aureus: possible infection control implications
        </article-title>
        <source>
         Infect Control Hosp Epidemiol
        </source>
        <volume>
         18
        </volume>
        <year>
         1997
        </year>
        <fpage>
         622
        </fpage>
        <lpage>
         627
        </lpage>
        <pub-id pub-id-type="pmid">
         9309433
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib18">
       <label>
        18
       </label>
       <element-citation id="sbref180" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Oie
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Hosokawa
          </surname>
          <given-names>
           I
          </given-names>
         </name>
         <name>
          <surname>
           Kamiya
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        <article-title>
         Contamination of room door handles by methicillin-sensitive/methicillin-resistant Staphylococcus aureus
        </article-title>
        <source>
         J Hosp Infect
        </source>
        <volume>
         51
        </volume>
        <year>
         2002
        </year>
        <fpage>
         140
        </fpage>
        <lpage>
         143
        </lpage>
        <pub-id pub-id-type="pmid">
         12090803
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib19">
       <label>
        19
       </label>
       <element-citation id="sbref190" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Schultz
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Gill
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Zubairi
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Huber
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Gordin
          </surname>
          <given-names>
           F
          </given-names>
         </name>
        </person-group>
        <article-title>
         Bacterial contamination of computer keyboards in a teaching hospital
        </article-title>
        <source>
         Infect Control Hosp Epidemiol
        </source>
        <volume>
         24
        </volume>
        <year>
         2003
        </year>
        <fpage>
         302
        </fpage>
        <lpage>
         303
        </lpage>
        <pub-id pub-id-type="pmid">
         12725363
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib20">
       <label>
        20
       </label>
       <element-citation id="sbref200" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Brooks
          </surname>
          <given-names>
           SE
          </given-names>
         </name>
         <name>
          <surname>
           Walczak
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
         <name>
          <surname>
           Hameed
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Coonan
          </surname>
          <given-names>
           P
          </given-names>
         </name>
        </person-group>
        <article-title>
         Chlorhexidine resistance in antibiotic-resistant bacteria isolated from the surfaces of dispensers of soap containing chlorhexidine
        </article-title>
        <source>
         Infect Control Hosp Epidemiol
        </source>
        <volume>
         23
        </volume>
        <year>
         2002
        </year>
        <fpage>
         692
        </fpage>
        <lpage>
         695
        </lpage>
        <pub-id pub-id-type="pmid">
         12452299
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib21">
       <label>
        21
       </label>
       <element-citation id="sbref210" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Nseir
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Blazejewski
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Lubret
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Wallet
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Courcol
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Durocher
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        <article-title>
         Risk of acquiring multidrug-resistant Gram-negative bacilli from prior room occupants in the intensive care unit
        </article-title>
        <source>
         Clin Microbiol Infect
        </source>
        <volume>
         17
        </volume>
        <year>
         2011
        </year>
        <fpage>
         1201
        </fpage>
        <lpage>
         1208
        </lpage>
        <pub-id pub-id-type="pmid">
         21054665
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib22">
       <label>
        22
       </label>
       <element-citation id="sbref220" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           SS
          </given-names>
         </name>
         <name>
          <surname>
           Datta
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Platt
          </surname>
          <given-names>
           R
          </given-names>
         </name>
        </person-group>
        <article-title>
         Risk of acquiring antibiotic-resistant bacteria from prior room occupants
        </article-title>
        <source>
         Arch Intern Med
        </source>
        <volume>
         166
        </volume>
        <year>
         2006
        </year>
        <fpage>
         1945
        </fpage>
        <lpage>
         1951
        </lpage>
        <pub-id pub-id-type="pmid">
         17030826
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib23">
       <label>
        23
       </label>
       <element-citation id="sbref230" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Shaughnessy
          </surname>
          <given-names>
           MK
          </given-names>
         </name>
         <name>
          <surname>
           Micielli
          </surname>
          <given-names>
           RL
          </given-names>
         </name>
         <name>
          <surname>
           DePestel
          </surname>
          <given-names>
           DD
          </given-names>
         </name>
        </person-group>
        <article-title>
         Evaluation of hospital room assignment and acquisition of Clostridium difficile infection
        </article-title>
        <source>
         Infect Control Hosp Epidemiol
        </source>
        <volume>
         32
        </volume>
        <year>
         2011
        </year>
        <fpage>
         201
        </fpage>
        <lpage>
         206
        </lpage>
        <pub-id pub-id-type="pmid">
         21460503
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib24">
       <label>
        24
       </label>
       <element-citation id="sbref240" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rampling
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Wiseman
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Davis
          </surname>
          <given-names>
           L
          </given-names>
         </name>
        </person-group>
        <article-title>
         Evidence that hospital hygiene is important in the control of methicillin-resistant Staphylococcus aureus
        </article-title>
        <source>
         J Hosp Infect
        </source>
        <volume>
         49
        </volume>
        <year>
         2001
        </year>
        <fpage>
         109
        </fpage>
        <lpage>
         116
        </lpage>
        <pub-id pub-id-type="pmid">
         11567555
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib25">
       <label>
        25
       </label>
       <element-citation id="sbref250" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wilson
          </surname>
          <given-names>
           AP
          </given-names>
         </name>
         <name>
          <surname>
           Smyth
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Moore
          </surname>
          <given-names>
           G
          </given-names>
         </name>
        </person-group>
        <article-title>
         The impact of enhanced cleaning within the intensive care unit on contamination of the near-patient environment with hospital pathogens: a randomized crossover study in critical care units in two hospitals
        </article-title>
        <source>
         Crit Care Med
        </source>
        <volume>
         39
        </volume>
        <year>
         2011
        </year>
        <fpage>
         651
        </fpage>
        <lpage>
         658
        </lpage>
        <pub-id pub-id-type="pmid">
         21242793
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib26">
       <label>
        26
       </label>
       <element-citation id="sbref260" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Dettenkofer
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Wenzler
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Amthor
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Antes
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Motschall
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Daschner
          </surname>
          <given-names>
           FD
          </given-names>
         </name>
        </person-group>
        <article-title>
         Does disinfection of environmental surfaces influence nosocomial infection rates? A systematic review
        </article-title>
        <source>
         Am J Infect Control
        </source>
        <volume>
         32
        </volume>
        <year>
         2004
        </year>
        <fpage>
         84
        </fpage>
        <lpage>
         89
        </lpage>
        <pub-id pub-id-type="pmid">
         15057199
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib27">
       <label>
        27
       </label>
       <element-citation id="sbref270" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Otter
          </surname>
          <given-names>
           JA
          </given-names>
         </name>
         <name>
          <surname>
           Puchowicz
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Ryan
          </surname>
          <given-names>
           D
          </given-names>
         </name>
        </person-group>
        <article-title>
         Feasibility of routinely using hydrogen peroxide vapor to decontaminate rooms in a busy United States hospital
        </article-title>
        <source>
         Infect Control Hosp Epidemiol
        </source>
        <volume>
         30
        </volume>
        <year>
         2009
        </year>
        <fpage>
         574
        </fpage>
        <lpage>
         577
        </lpage>
        <pub-id pub-id-type="pmid">
         19415969
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib28">
       <label>
        28
       </label>
       <element-citation id="sbref280" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kundrapu
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Sunkesula
          </surname>
          <given-names>
           V
          </given-names>
         </name>
         <name>
          <surname>
           Jury
          </surname>
          <given-names>
           LA
          </given-names>
         </name>
         <name>
          <surname>
           Sitzlar
          </surname>
          <given-names>
           BM
          </given-names>
         </name>
         <name>
          <surname>
           Donskey
          </surname>
          <given-names>
           CJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         Daily disinfection of high-touch surfaces in isolation rooms to reduce contamination of healthcare workers' hands
        </article-title>
        <source>
         Infect Control Hosp Epidemiol
        </source>
        <volume>
         33
        </volume>
        <year>
         2012
        </year>
        <fpage>
         1039
        </fpage>
        <lpage>
         1042
        </lpage>
        <pub-id pub-id-type="pmid">
         22961024
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib29">
       <label>
        29
       </label>
       <element-citation id="sbref290" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Dancer
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           White
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Lamb
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Girvan
          </surname>
          <given-names>
           EK
          </given-names>
         </name>
         <name>
          <surname>
           Robertson
          </surname>
          <given-names>
           C
          </given-names>
         </name>
        </person-group>
        <article-title>
         Measuring the effect of enhanced cleaning in a UK hospital: a prospective cross-over study
        </article-title>
        <source>
         BMC Med
        </source>
        <volume>
         7
        </volume>
        <year>
         2009
        </year>
        <fpage>
         28
        </fpage>
        <pub-id pub-id-type="pmid">
         19505316
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib30">
       <label>
        30
       </label>
       <element-citation id="sbref300" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           French
          </surname>
          <given-names>
           GL
          </given-names>
         </name>
         <name>
          <surname>
           Otter
          </surname>
          <given-names>
           JA
          </given-names>
         </name>
         <name>
          <surname>
           Shannon
          </surname>
          <given-names>
           KP
          </given-names>
         </name>
         <name>
          <surname>
           Adams
          </surname>
          <given-names>
           NMT
          </given-names>
         </name>
         <name>
          <surname>
           Watling
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Parks
          </surname>
          <given-names>
           MJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         Tackling contamination of the hospital environment by methicillin-resistant Staphylococcus aureus (MRSA): a comparison between conventional terminal cleaning and hydrogen peroxide vapour decontamination
        </article-title>
        <source>
         J Hosp Infect
        </source>
        <volume>
         57
        </volume>
        <year>
         2004
        </year>
        <fpage>
         31
        </fpage>
        <lpage>
         37
        </lpage>
        <pub-id pub-id-type="pmid">
         15142713
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib31">
       <label>
        31
       </label>
       <element-citation id="sbref310" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Otter
          </surname>
          <given-names>
           JA
          </given-names>
         </name>
         <name>
          <surname>
           Yezli
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Perl
          </surname>
          <given-names>
           TM
          </given-names>
         </name>
         <name>
          <surname>
           Barbut
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           French
          </surname>
          <given-names>
           GL
          </given-names>
         </name>
        </person-group>
        <article-title>
         The role of ‘no-touch’ automated room disinfection systems in infection prevention and control
        </article-title>
        <source>
         J Hosp Infect
        </source>
        <volume>
         83
        </volume>
        <year>
         2013
        </year>
        <fpage>
         1
        </fpage>
        <lpage>
         13
        </lpage>
        <pub-id pub-id-type="pmid">
         23195691
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib32">
       <label>
        32
       </label>
       <element-citation id="sbref320" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Fu
          </surname>
          <given-names>
           TY
          </given-names>
         </name>
         <name>
          <surname>
           Gent
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Kumar
          </surname>
          <given-names>
           V
          </given-names>
         </name>
        </person-group>
        <article-title>
         Efficacy, efficiency and safety aspects of hydrogen peroxide vapour and aerosolized hydrogen peroxide room disinfection systems
        </article-title>
        <source>
         J Hosp Infect
        </source>
        <volume>
         80
        </volume>
        <year>
         2012
        </year>
        <fpage>
         199
        </fpage>
        <lpage>
         205
        </lpage>
        <pub-id pub-id-type="pmid">
         22306442
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib33">
       <label>
        33
       </label>
       <element-citation id="sbref330" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Barbut
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Menuet
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Verachten
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Girou
          </surname>
          <given-names>
           E
          </given-names>
         </name>
        </person-group>
        <article-title>
         Comparison of the efficacy of a hydrogen peroxide dry-mist disinfection system and sodium hypochlorite solution for eradication of Clostridium difficile spores
        </article-title>
        <source>
         Infect Control Hosp Epidemiol
        </source>
        <volume>
         30
        </volume>
        <year>
         2009
        </year>
        <fpage>
         507
        </fpage>
        <lpage>
         514
        </lpage>
        <pub-id pub-id-type="pmid">
         19379098
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib34">
       <label>
        34
       </label>
       <element-citation id="sbref340" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Passaretti
          </surname>
          <given-names>
           CL
          </given-names>
         </name>
         <name>
          <surname>
           Otter
          </surname>
          <given-names>
           JA
          </given-names>
         </name>
         <name>
          <surname>
           Reich
          </surname>
          <given-names>
           NG
          </given-names>
         </name>
        </person-group>
        <article-title>
         An evaluation of environmental decontamination with hydrogen peroxide vapor for reducing the risk of patient acquisition of multidrug-resistant organisms
        </article-title>
        <source>
         Clin Infect Dis
        </source>
        <volume>
         56
        </volume>
        <year>
         2013
        </year>
        <fpage>
         27
        </fpage>
        <lpage>
         35
        </lpage>
        <pub-id pub-id-type="pmid">
         23042972
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib35">
       <label>
        35
       </label>
       <element-citation id="sbref350" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Schmidt
          </surname>
          <given-names>
           MG
          </given-names>
         </name>
         <name>
          <surname>
           Cantey
          </surname>
          <given-names>
           JR
          </given-names>
         </name>
         <name>
          <surname>
           Freeman
          </surname>
          <given-names>
           KD
          </given-names>
         </name>
        </person-group>
        <article-title>
         Sustained reduction of microbial burden on common hospital surfaces through introduction of copper
        </article-title>
        <source>
         J Clin Microbiol
        </source>
        <volume>
         50
        </volume>
        <year>
         2012
        </year>
        <fpage>
         2217
        </fpage>
        <lpage>
         2223
        </lpage>
        <pub-id pub-id-type="pmid">
         22553242
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib36">
       <label>
        36
       </label>
       <element-citation id="sbref360" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Schmidt
          </surname>
          <given-names>
           MG
          </given-names>
         </name>
         <name>
          <surname>
           Attaway
          </surname>
          <given-names>
           HH
          </given-names>
          <suffix>
           III
          </suffix>
         </name>
         <name>
          <surname>
           Fairey
          </surname>
          <given-names>
           SE
          </given-names>
         </name>
         <name>
          <surname>
           Steed
          </surname>
          <given-names>
           LL
          </given-names>
         </name>
         <name>
          <surname>
           Michels
          </surname>
          <given-names>
           HT
          </given-names>
         </name>
         <name>
          <surname>
           Salgado
          </surname>
          <given-names>
           CD
          </given-names>
         </name>
        </person-group>
        <article-title>
         Copper continuously limits the concentration of bacteria resident on bed rails within the intensive care unit
        </article-title>
        <source>
         Infect Control Hosp Epidemiol
        </source>
        <volume>
         34
        </volume>
        <year>
         2013
        </year>
        <fpage>
         530
        </fpage>
        <lpage>
         533
        </lpage>
        <pub-id pub-id-type="pmid">
         23571374
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib37">
       <label>
        37
       </label>
       <element-citation id="sbref370" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Casey
          </surname>
          <given-names>
           AL
          </given-names>
         </name>
         <name>
          <surname>
           Elliott
          </surname>
          <given-names>
           TSJ
          </given-names>
         </name>
         <name>
          <surname>
           Adams
          </surname>
          <given-names>
           D
          </given-names>
         </name>
        </person-group>
        <article-title>
         Role of copper in reducing hospital environment contamination
        </article-title>
        <source>
         J Hosp Infect
        </source>
        <volume>
         74
        </volume>
        <year>
         2010
        </year>
        <fpage>
         72
        </fpage>
        <lpage>
         77
        </lpage>
        <pub-id pub-id-type="pmid">
         19931938
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib38">
       <label>
        38
       </label>
       <element-citation id="sbref380" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Karpanen
          </surname>
          <given-names>
           TJ
          </given-names>
         </name>
         <name>
          <surname>
           Casey
          </surname>
          <given-names>
           AL
          </given-names>
         </name>
         <name>
          <surname>
           Lambert
          </surname>
          <given-names>
           PA
          </given-names>
         </name>
        </person-group>
        <article-title>
         The antimicrobial efficacy of copper alloy furnishing in the clinical environment: a crossover study
        </article-title>
        <source>
         Infect Control Hosp Epidemiol
        </source>
        <volume>
         33
        </volume>
        <year>
         2012
        </year>
        <fpage>
         3
        </fpage>
        <lpage>
         9
        </lpage>
        <pub-id pub-id-type="pmid">
         22173515
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib39">
       <label>
        39
       </label>
       <element-citation id="sbref390" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Salgado
          </surname>
          <given-names>
           CD
          </given-names>
         </name>
         <name>
          <surname>
           Sepkowitz
          </surname>
          <given-names>
           KA
          </given-names>
         </name>
         <name>
          <surname>
           John
          </surname>
          <given-names>
           JF
          </given-names>
         </name>
        </person-group>
        <article-title>
         Copper surfaces reduce the rate of healthcare-acquired infections in the intensive care unit
        </article-title>
        <source>
         Infect Control Hosp Epidemiol
        </source>
        <volume>
         34
        </volume>
        <year>
         2013
        </year>
        <fpage>
         479
        </fpage>
        <lpage>
         486
        </lpage>
        <pub-id pub-id-type="pmid">
         23571364
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib40">
       <label>
        40
       </label>
       <element-citation id="sbref400" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Mulvey
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Redding
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Robertson
          </surname>
          <given-names>
           C
          </given-names>
         </name>
        </person-group>
        <article-title>
         Finding a benchmark for monitoring hospital cleanliness
        </article-title>
        <source>
         J Hosp Infect
        </source>
        <volume>
         77
        </volume>
        <year>
         2011
        </year>
        <fpage>
         25
        </fpage>
        <lpage>
         30
        </lpage>
        <pub-id pub-id-type="pmid">
         21129820
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib41">
       <label>
        41
       </label>
       <element-citation id="sbref410" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Boyce
          </surname>
          <given-names>
           JM
          </given-names>
         </name>
         <name>
          <surname>
           Havill
          </surname>
          <given-names>
           NL
          </given-names>
         </name>
         <name>
          <surname>
           Dumigan
          </surname>
          <given-names>
           DG
          </given-names>
         </name>
         <name>
          <surname>
           Golebiewski
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Balogun
          </surname>
          <given-names>
           O
          </given-names>
         </name>
         <name>
          <surname>
           Rizvani
          </surname>
          <given-names>
           R
          </given-names>
         </name>
        </person-group>
        <article-title>
         Monitoring the effectiveness of hospital cleaning practices by use of an adenosine triphosphate bioluminescence assay
        </article-title>
        <source>
         Infect Control Hosp Epidemiol
        </source>
        <volume>
         30
        </volume>
        <year>
         2009
        </year>
        <fpage>
         678
        </fpage>
        <lpage>
         684
        </lpage>
        <pub-id pub-id-type="pmid">
         19489715
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib42">
       <label>
        42
       </label>
       <element-citation id="sbref420" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lewis
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Griffith
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Gallo
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Weinbren
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <article-title>
         A modified ATP benchmark for evaluating the cleaning of some hospital environmental surfaces
        </article-title>
        <source>
         J Hosp Infect
        </source>
        <volume>
         69
        </volume>
        <year>
         2008
        </year>
        <fpage>
         156
        </fpage>
        <lpage>
         163
        </lpage>
        <pub-id pub-id-type="pmid">
         18468725
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib43">
       <label>
        43
       </label>
       <element-citation id="sbref430" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Griffith
          </surname>
          <given-names>
           CJ
          </given-names>
         </name>
         <name>
          <surname>
           Obee
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Cooper
          </surname>
          <given-names>
           RA
          </given-names>
         </name>
         <name>
          <surname>
           Burton
          </surname>
          <given-names>
           NF
          </given-names>
         </name>
         <name>
          <surname>
           Lewis
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <article-title>
         The effectiveness of existing and modified cleaning regimens in a Welsh hospital
        </article-title>
        <source>
         J Hosp Infect
        </source>
        <volume>
         66
        </volume>
        <year>
         2007
        </year>
        <fpage>
         352
        </fpage>
        <lpage>
         359
        </lpage>
        <pub-id pub-id-type="pmid">
         17655976
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib44">
       <label>
        44
       </label>
       <element-citation id="sbref440" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Malik
          </surname>
          <given-names>
           RE
          </given-names>
         </name>
         <name>
          <surname>
           Cooper
          </surname>
          <given-names>
           RA
          </given-names>
         </name>
         <name>
          <surname>
           Griffith
          </surname>
          <given-names>
           CJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         Use of audit tools to evaluate the efficacy of cleaning systems in hospitals
        </article-title>
        <source>
         Am J Infect Control
        </source>
        <volume>
         31
        </volume>
        <year>
         2003
        </year>
        <fpage>
         181
        </fpage>
        <lpage>
         187
        </lpage>
        <pub-id pub-id-type="pmid">
         12734526
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib45">
       <label>
        45
       </label>
       <element-citation id="sbref450" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           World Health Organization
          </surname>
         </name>
        </person-group>
        <source>
         WHO Patient Safety. WHO guidelines on hand hygiene in health care
        </source>
        <year>
         2009
        </year>
        <publisher-name>
         World Health Organization
        </publisher-name>
        <publisher-loc>
         Geneva
        </publisher-loc>
       </element-citation>
      </ref>
      <ref id="bib46">
       <label>
        46
       </label>
       <element-citation id="sbref460" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gupta
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Della-Latta
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Todd
          </surname>
          <given-names>
           B
          </given-names>
         </name>
        </person-group>
        <article-title>
         Outbreak of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae in a neonatal intensive care unit linked to artificial nails
        </article-title>
        <source>
         Infect Control Hosp Epidemiol
        </source>
        <volume>
         25
        </volume>
        <year>
         2004
        </year>
        <fpage>
         210
        </fpage>
        <lpage>
         215
        </lpage>
        <pub-id pub-id-type="pmid">
         15061412
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib47">
       <label>
        47
       </label>
       <element-citation id="sbref470" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Pittet
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Dharan
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Touveneau
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Sauvan
          </surname>
          <given-names>
           V
          </given-names>
         </name>
         <name>
          <surname>
           Perneger
          </surname>
          <given-names>
           TV
          </given-names>
         </name>
        </person-group>
        <article-title>
         Bacterial contamination of the hands of hospital staff during routine patient care
        </article-title>
        <source>
         Arch Intern Med
        </source>
        <volume>
         159
        </volume>
        <year>
         1999
        </year>
        <fpage>
         821
        </fpage>
        <lpage>
         826
        </lpage>
        <pub-id pub-id-type="pmid">
         10219927
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib48">
       <label>
        48
       </label>
       <element-citation id="sbref480" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Pessoa-Silva
          </surname>
          <given-names>
           CL
          </given-names>
         </name>
         <name>
          <surname>
           Dharan
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Hugonnet
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        <article-title>
         Dynamics of bacterial hand contamination during routine neonatal care
        </article-title>
        <source>
         Infect Control Hosp Epidemiol
        </source>
        <volume>
         25
        </volume>
        <year>
         2004
        </year>
        <fpage>
         192
        </fpage>
        <lpage>
         197
        </lpage>
        <pub-id pub-id-type="pmid">
         15061408
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib49">
       <label>
        49
       </label>
       <element-citation id="sbref490" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Fendler
          </surname>
          <given-names>
           EJ
          </given-names>
         </name>
         <name>
          <surname>
           Ali
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Hammond
          </surname>
          <given-names>
           BS
          </given-names>
         </name>
         <name>
          <surname>
           Lyons
          </surname>
          <given-names>
           MK
          </given-names>
         </name>
         <name>
          <surname>
           Kelley
          </surname>
          <given-names>
           MB
          </given-names>
         </name>
         <name>
          <surname>
           Vowell
          </surname>
          <given-names>
           NA
          </given-names>
         </name>
        </person-group>
        <article-title>
         The impact of alcohol hand sanitizer use on infection rates in an extended care facility
        </article-title>
        <source>
         Am J Infect Control
        </source>
        <volume>
         30
        </volume>
        <year>
         2002
        </year>
        <fpage>
         226
        </fpage>
        <lpage>
         233
        </lpage>
        <pub-id pub-id-type="pmid">
         12032498
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib50">
       <label>
        50
       </label>
       <element-citation id="sbref500" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ryan
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
         <name>
          <surname>
           Christian
          </surname>
          <given-names>
           RS
          </given-names>
         </name>
         <name>
          <surname>
           Wohlrabe
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        <article-title>
         Handwashing and respiratory illness among young adults in military training
        </article-title>
        <source>
         Am J Prev Med
        </source>
        <volume>
         21
        </volume>
        <year>
         2001
        </year>
        <fpage>
         79
        </fpage>
        <lpage>
         83
        </lpage>
        <pub-id pub-id-type="pmid">
         11457626
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib51">
       <label>
        51
       </label>
       <element-citation id="sbref510" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Pittet
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Hugonnet
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Harbarth
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        <article-title>
         Effectiveness of a hospital-wide programme to improve compliance with hand hygiene
        </article-title>
        <source>
         Lancet
        </source>
        <volume>
         356
        </volume>
        <year>
         2000
        </year>
        <fpage>
         1307
        </fpage>
        <lpage>
         1312
        </lpage>
        <pub-id pub-id-type="pmid">
         11073019
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib52">
       <label>
        52
       </label>
       <element-citation id="sbref520" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gordin
          </surname>
          <given-names>
           FM
          </given-names>
         </name>
         <name>
          <surname>
           Schultz
          </surname>
          <given-names>
           ME
          </given-names>
         </name>
         <name>
          <surname>
           Huber
          </surname>
          <given-names>
           RA
          </given-names>
         </name>
         <name>
          <surname>
           Gill
          </surname>
          <given-names>
           JA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Reduction in nosocomial transmission of drug-resistant bacteria after introduction of an alcohol-based handrub
        </article-title>
        <source>
         Infect Control Hosp Epidemiol
        </source>
        <volume>
         26
        </volume>
        <year>
         2005
        </year>
        <fpage>
         650
        </fpage>
        <lpage>
         653
        </lpage>
        <pub-id pub-id-type="pmid">
         16092747
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib53">
       <label>
        53
       </label>
       <element-citation id="sbref530" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Boyce
          </surname>
          <given-names>
           JM
          </given-names>
         </name>
         <name>
          <surname>
           Pittet
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Healthcare Infection Control Practices Advisory Committee
          </surname>
         </name>
         <name>
          <surname>
           Society for Healthcare Epidemiology of America
          </surname>
         </name>
         <name>
          <surname>
           Association for Professionals in Infection Control
          </surname>
         </name>
         <name>
          <surname>
           Infectious Diseases Society of America Hand Hygiene Task Force
          </surname>
         </name>
        </person-group>
        <article-title>
         Guideline for hand hygiene in health-care settings: recommendations of the Healthcare Infection Control Practices Advisory Committee and the HICPAC/SHEA/APIC/IDSA Hand Hygiene Task Force
        </article-title>
        <source>
         Infect Control Hosp Epidemiol
        </source>
        <volume>
         23
        </volume>
        <issue>
         Suppl. 12
        </issue>
        <year>
         2002
        </year>
        <fpage>
         S3
        </fpage>
        <lpage>
         S40
        </lpage>
        <pub-id pub-id-type="pmid">
         12515399
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib54">
       <label>
        54
       </label>
       <element-citation id="sbref540" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Provincial Infectious Diseases Advisory Committee
          </surname>
         </name>
        </person-group>
        <source>
         Best practices for hand hygiene in all health care settings
        </source>
        <year>
         2010
        </year>
        <publisher-name>
         Ontario Ministry of Health and Long-Term Care/Public Health Division
        </publisher-name>
        <publisher-loc>
         Toronto
        </publisher-loc>
        <ext-link ext-link-type="uri" id="interrefs90" xlink:href="http://www.oahpp.ca/resources/documents/pidac/2010-12%20BP%20Hand%20Hygiene.pdf">
         Available at: http://www.oahpp.ca/resources/documents/pidac/2010-12%20BP%20Hand%20Hygiene.pdf
        </ext-link>
        <comment>
         Accessed July 20, 2013.
        </comment>
       </element-citation>
      </ref>
      <ref id="bib55">
       <label>
        55
       </label>
       <element-citation id="sbref550" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sax
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Allegranzi
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Uçkay
          </surname>
          <given-names>
           I
          </given-names>
         </name>
         <name>
          <surname>
           Larson
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Boyce
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Pittet
          </surname>
          <given-names>
           D
          </given-names>
         </name>
        </person-group>
        <article-title>
         ‘My five moments for hand hygiene’: a user-centred design approach to understand, train, monitor and report hand hygiene
        </article-title>
        <source>
         J Hosp Infect
        </source>
        <volume>
         67
        </volume>
        <year>
         2007
        </year>
        <fpage>
         9
        </fpage>
        <lpage>
         21
        </lpage>
        <pub-id pub-id-type="pmid">
         17719685
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib56">
       <label>
        56
       </label>
       <element-citation id="sbref560" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           National Clinical Guideline Centre
          </surname>
         </name>
        </person-group>
        <source>
         Infection: prevention and control of healthcare-associated infections in primary and community care: partial update of NICE Clinical Guideline 2. NICE Clinical Guidelines, No. 139
        </source>
        <year>
         2012
        </year>
        <publisher-name>
         Royal College of Physicians
        </publisher-name>
        <publisher-loc>
         London
        </publisher-loc>
       </element-citation>
      </ref>
      <ref id="bib57">
       <label>
        57
       </label>
       <element-citation id="sbref570" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Pellowe
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Pratt
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Harper
          </surname>
          <given-names>
           P
          </given-names>
         </name>
        </person-group>
        <article-title>
         Infection control: prevention of healthcare-associated infection in primary and community care
        </article-title>
        <source>
         J Hosp Infect
        </source>
        <volume>
         55
        </volume>
        <issue>
         Suppl. 2
        </issue>
        <year>
         2003
        </year>
        <fpage>
         1
        </fpage>
        <lpage>
         127
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib58">
       <label>
        58
       </label>
       <element-citation id="sbref580" publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           British Standards Institution
          </surname>
         </name>
        </person-group>
        <article-title>
         Chemical disinfectants and antiseptics. Hygienic handrub. Test method and requirements (phase 2/step 2)
        </article-title>
        <ext-link ext-link-type="uri" id="interrefs100" xlink:href="http://www.fda.gov/ohrms/dockets/dailys/03/Sept03/090303/75n-0183h-c000081-09-Tab-04-A-vol161.pdf">
         Available at: http://www.fda.gov/ohrms/dockets/dailys/03/Sept03/090303/75n-0183h-c000081-09-Tab-04-A-vol161.pdf
        </ext-link>
        <year>
         1997
        </year>
        <comment>
         Accessed August 15, 2013.
        </comment>
       </element-citation>
      </ref>
      <ref id="bib59">
       <label>
        59
       </label>
       <element-citation id="sbref590" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lucet
          </surname>
          <given-names>
           JC
          </given-names>
         </name>
         <name>
          <surname>
           Rigaud
          </surname>
          <given-names>
           MP
          </given-names>
         </name>
         <name>
          <surname>
           Mentre
          </surname>
          <given-names>
           F
          </given-names>
         </name>
        </person-group>
        <article-title>
         Hand contamination before and after different hand hygiene techniques: a randomized clinical trial
        </article-title>
        <source>
         J Hosp Infect
        </source>
        <volume>
         50
        </volume>
        <year>
         2002
        </year>
        <fpage>
         276
        </fpage>
        <lpage>
         280
        </lpage>
        <pub-id pub-id-type="pmid">
         12014900
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib60">
       <label>
        60
       </label>
       <element-citation id="sbref600" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Winnefeld
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Richard
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
         <name>
          <surname>
           Drancourt
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Grob
          </surname>
          <given-names>
           JJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         Skin tolerance and effectiveness of two hand decontamination procedures in everyday hospital use
        </article-title>
        <source>
         Br J Dermatol
        </source>
        <volume>
         143
        </volume>
        <year>
         2000
        </year>
        <fpage>
         546
        </fpage>
        <lpage>
         550
        </lpage>
        <pub-id pub-id-type="pmid">
         10971327
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib61">
       <label>
        61
       </label>
       <element-citation id="sbref610" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Larson
          </surname>
          <given-names>
           EL
          </given-names>
         </name>
         <name>
          <surname>
           Aiello
          </surname>
          <given-names>
           AE
          </given-names>
         </name>
         <name>
          <surname>
           Bastyr
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        <article-title>
         Assessment of two hand hygiene regimens for intensive care unit personnel
        </article-title>
        <source>
         Crit Care Med
        </source>
        <volume>
         29
        </volume>
        <year>
         2001
        </year>
        <fpage>
         944
        </fpage>
        <lpage>
         951
        </lpage>
        <pub-id pub-id-type="pmid">
         11378602
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib62">
       <label>
        62
       </label>
       <element-citation id="sbref620" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Girou
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Loyeau
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Legrand
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Oppein
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Brun-Buisson
          </surname>
          <given-names>
           C
          </given-names>
         </name>
        </person-group>
        <article-title>
         Efficacy of handrubbing with alcohol based solution versus standard handwashing with antiseptic soap: randomised clinical trial
        </article-title>
        <source>
         BMJ
        </source>
        <volume>
         325
        </volume>
        <year>
         2002
        </year>
        <fpage>
         362
        </fpage>
        <lpage>
         365
        </lpage>
        <pub-id pub-id-type="pmid">
         12183307
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib63">
       <label>
        63
       </label>
       <element-citation id="sbref630" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zaragoza
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Sallés
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Gomez
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Bayas
          </surname>
          <given-names>
           JM
          </given-names>
         </name>
         <name>
          <surname>
           Trilla
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        <article-title>
         Handwashing with soap or alcoholic solutions? A randomized clinical trial of its effectiveness
        </article-title>
        <source>
         Am J Infect Control
        </source>
        <volume>
         27
        </volume>
        <year>
         1999
        </year>
        <fpage>
         258
        </fpage>
        <lpage>
         261
        </lpage>
        <pub-id pub-id-type="pmid">
         10358229
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib64">
       <label>
        64
       </label>
       <element-citation id="sbref640" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Larson
          </surname>
          <given-names>
           EL
          </given-names>
         </name>
         <name>
          <surname>
           Cimiotti
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Haas
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        <article-title>
         Effect of antiseptic handwashing vs alcohol sanitizer on health care-associated infections in neonatal intensive care units
        </article-title>
        <source>
         Arch Pediatr Adolesc Med
        </source>
        <volume>
         159
        </volume>
        <year>
         2005
        </year>
        <fpage>
         377
        </fpage>
        <lpage>
         383
        </lpage>
        <pub-id pub-id-type="pmid">
         15809394
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib65">
       <label>
        65
       </label>
       <element-citation id="sbref650" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Herruzo-Cabrera
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Garcia-Caballero
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Martin-Moreno
          </surname>
          <given-names>
           JM
          </given-names>
         </name>
         <name>
          <surname>
           Graciani-Perez-Regadera
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
         <name>
          <surname>
           Perez-Rodriguez
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        <article-title>
         Clinical assay of N-duopropenide alcohol solution on hand application in newborn and pediatric intensive care units: control of an outbreak of multiresistant Klebsiella pneumoniae in a newborn intensive care unit with this measure
        </article-title>
        <source>
         Am J Infect Control
        </source>
        <volume>
         29
        </volume>
        <year>
         2001
        </year>
        <fpage>
         162
        </fpage>
        <lpage>
         167
        </lpage>
        <pub-id pub-id-type="pmid">
         11391278
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib66">
       <label>
        66
       </label>
       <element-citation id="sbref660" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Herruzo-Cabrera
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Garcia-Caballero
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Fernandez-Acenero
          </surname>
          <given-names>
           MJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         A new alcohol solution (N-duopropenide) for hygienic (or routine) hand disinfection is more useful than classic handwashing: in vitro and in vivo studies in burn and other intensive care units
        </article-title>
        <source>
         Burns
        </source>
        <volume>
         27
        </volume>
        <year>
         2001
        </year>
        <fpage>
         747
        </fpage>
        <lpage>
         752
        </lpage>
        <pub-id pub-id-type="pmid">
         11600255
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib67">
       <label>
        67
       </label>
       <element-citation id="sbref670" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Larson
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Silberger
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Jakob
          </surname>
          <given-names>
           K
          </given-names>
         </name>
        </person-group>
        <article-title>
         Assessment of alternative hand hygiene regimens to improve skin health among neonatal intensive care unit nurses
        </article-title>
        <source>
         Heart Lung
        </source>
        <volume>
         29
        </volume>
        <year>
         2000
        </year>
        <fpage>
         136
        </fpage>
        <lpage>
         142
        </lpage>
        <pub-id pub-id-type="pmid">
         10739490
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib68">
       <label>
        68
       </label>
       <element-citation id="sbref680" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kramer
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Rudolph
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Kampf
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Pittet
          </surname>
          <given-names>
           D
          </given-names>
         </name>
        </person-group>
        <article-title>
         Limited efficacy of alcohol-based hand gels
        </article-title>
        <source>
         Lancet
        </source>
        <volume>
         359
        </volume>
        <year>
         2002
        </year>
        <fpage>
         1489
        </fpage>
        <lpage>
         1490
        </lpage>
        <pub-id pub-id-type="pmid">
         11988252
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib69">
       <label>
        69
       </label>
       <element-citation id="sbref690" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Moadab
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Rupley
          </surname>
          <given-names>
           KF
          </given-names>
         </name>
         <name>
          <surname>
           Wadhams
          </surname>
          <given-names>
           P
          </given-names>
         </name>
        </person-group>
        <article-title>
         Effectiveness of a nonrinse, alcohol-free antiseptic hand wash
        </article-title>
        <source>
         J Am Podiatr Med Assoc
        </source>
        <volume>
         91
        </volume>
        <year>
         2001
        </year>
        <fpage>
         288
        </fpage>
        <lpage>
         293
        </lpage>
        <pub-id pub-id-type="pmid">
         11420346
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib70">
       <label>
        70
       </label>
       <element-citation id="sbref700" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Guilhermetti
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Hernandes
          </surname>
          <given-names>
           SED
          </given-names>
         </name>
         <name>
          <surname>
           Fukushigue
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Garcia
          </surname>
          <given-names>
           LB
          </given-names>
         </name>
         <name>
          <surname>
           Cardoso
          </surname>
          <given-names>
           CL
          </given-names>
         </name>
        </person-group>
        <article-title>
         Effectiveness of hand-cleansing agents for removing methicillin-resistant Staphylococcus aureus from contaminated hands
        </article-title>
        <source>
         Infect Control Hosp Epidemiol
        </source>
        <volume>
         22
        </volume>
        <year>
         2001
        </year>
        <fpage>
         105
        </fpage>
        <lpage>
         108
        </lpage>
        <pub-id pub-id-type="pmid">
         11232870
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib71">
       <label>
        71
       </label>
       <element-citation id="sbref710" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Paulson
          </surname>
          <given-names>
           DS
          </given-names>
         </name>
         <name>
          <surname>
           Fendler
          </surname>
          <given-names>
           EJ
          </given-names>
         </name>
         <name>
          <surname>
           Dolan
          </surname>
          <given-names>
           MJ
          </given-names>
         </name>
         <name>
          <surname>
           Williams
          </surname>
          <given-names>
           RA
          </given-names>
         </name>
        </person-group>
        <article-title>
         A close look at alcohol gel as an antimicrobial sanitizing agent
        </article-title>
        <source>
         Am J Infect Control
        </source>
        <volume>
         27
        </volume>
        <year>
         1999
        </year>
        <fpage>
         332
        </fpage>
        <lpage>
         338
        </lpage>
        <pub-id pub-id-type="pmid">
         10433672
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib72">
       <label>
        72
       </label>
       <element-citation id="sbref720" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cardoso
          </surname>
          <given-names>
           CL
          </given-names>
         </name>
        </person-group>
        <article-title>
         Effectiveness of hand-cleansing agents for removing Acinetobacter baumannii strain from contaminated hands
        </article-title>
        <source>
         Am J Infect Control
        </source>
        <volume>
         27
        </volume>
        <year>
         1999
        </year>
        <fpage>
         327
        </fpage>
        <lpage>
         331
        </lpage>
        <pub-id pub-id-type="pmid">
         10433671
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib73">
       <label>
        73
       </label>
       <element-citation id="sbref730" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kampf
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Jarosch
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Rüden
          </surname>
          <given-names>
           H
          </given-names>
         </name>
        </person-group>
        <article-title>
         Limited effectiveness of chlorhexidine based hand disinfectants against methicillin-resistant Staphylococcus aureus (MRSA)
        </article-title>
        <source>
         J Hosp Infect
        </source>
        <volume>
         38
        </volume>
        <year>
         1998
        </year>
        <fpage>
         297
        </fpage>
        <lpage>
         303
        </lpage>
        <pub-id pub-id-type="pmid">
         9602978
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib74">
       <label>
        74
       </label>
       <element-citation id="sbref740" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Dyer
          </surname>
          <given-names>
           DL
          </given-names>
         </name>
         <name>
          <surname>
           Gerenratch
          </surname>
          <given-names>
           KB
          </given-names>
         </name>
         <name>
          <surname>
           Wadhams
          </surname>
          <given-names>
           PS
          </given-names>
         </name>
        </person-group>
        <article-title>
         Testing a new alcohol-free hand sanitizer to combat infection
        </article-title>
        <source>
         AORN J
        </source>
        <volume>
         68
        </volume>
        <year>
         1998
        </year>
        <fpage>
         239
        </fpage>
        <lpage>
         241
        </lpage>
        <comment>
         243–244, 247–251.
        </comment>
        <pub-id pub-id-type="pmid">
         9706236
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib75">
       <label>
        75
       </label>
       <element-citation id="sbref750" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Dharan
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Hugonnet
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Sax
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Pittet
          </surname>
          <given-names>
           D
          </given-names>
         </name>
        </person-group>
        <article-title>
         Comparison of waterless hand antisepsis agents at short application times: raising the flag of concern
        </article-title>
        <source>
         Infect Control Hosp Epidemiol
        </source>
        <volume>
         24
        </volume>
        <year>
         2003
        </year>
        <fpage>
         160
        </fpage>
        <lpage>
         164
        </lpage>
        <pub-id pub-id-type="pmid">
         12683505
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib76">
       <label>
        76
       </label>
       <element-citation id="sbref760" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sickbert-Bennett
          </surname>
          <given-names>
           EE
          </given-names>
         </name>
         <name>
          <surname>
           Weber
          </surname>
          <given-names>
           DJ
          </given-names>
         </name>
         <name>
          <surname>
           Gergen-Teague
          </surname>
          <given-names>
           MF
          </given-names>
         </name>
         <name>
          <surname>
           Sobsey
          </surname>
          <given-names>
           MD
          </given-names>
         </name>
         <name>
          <surname>
           Samsa
          </surname>
          <given-names>
           GP
          </given-names>
         </name>
         <name>
          <surname>
           Rutala
          </surname>
          <given-names>
           WA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Comparative efficacy of hand hygiene agents in the reduction of bacteria and viruses
        </article-title>
        <source>
         Am J Infect Control
        </source>
        <volume>
         33
        </volume>
        <year>
         2005
        </year>
        <fpage>
         67
        </fpage>
        <lpage>
         77
        </lpage>
        <pub-id pub-id-type="pmid">
         15761405
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib77">
       <label>
        77
       </label>
       <element-citation id="sbref770" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gould
          </surname>
          <given-names>
           DJ
          </given-names>
         </name>
         <name>
          <surname>
           Moralejo
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Drey
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Chudleigh
          </surname>
          <given-names>
           JH
          </given-names>
         </name>
        </person-group>
        <article-title>
         Interventions to improve hand hygiene compliance in patient care
        </article-title>
        <source>
         Cochrane Database Syst Rev
        </source>
        <volume>
         8
        </volume>
        <year>
         2011
        </year>
        <comment>
         CD005186.
        </comment>
       </element-citation>
      </ref>
      <ref id="bib78">
       <label>
        78
       </label>
       <element-citation id="sbref780" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sakamoto
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Yamada
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Suzuki
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Sugiura
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Tokuda
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
        </person-group>
        <article-title>
         Increased use of alcohol-based hand sanitizers and successful eradication of methicillin-resistant Staphylococcus aureus from a neonatal intensive care unit: a multivariate time series analysis
        </article-title>
        <source>
         Am J Infect Control
        </source>
        <volume>
         38
        </volume>
        <year>
         2010
        </year>
        <fpage>
         529
        </fpage>
        <lpage>
         534
        </lpage>
        <pub-id pub-id-type="pmid">
         20371134
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib79">
       <label>
        79
       </label>
       <element-citation id="sbref790" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Faoagali
          </surname>
          <given-names>
           JL
          </given-names>
         </name>
         <name>
          <surname>
           George
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Fong
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Davy
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Dowser
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <article-title>
         Comparison of the antibacterial efficacy of 4% chlorhexidine gluconate and 1% triclosan handwash products in an acute clinical ward
        </article-title>
        <source>
         Am J Infect Control
        </source>
        <volume>
         27
        </volume>
        <year>
         1999
        </year>
        <fpage>
         320
        </fpage>
        <lpage>
         326
        </lpage>
        <pub-id pub-id-type="pmid">
         10433670
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib80">
       <label>
        80
       </label>
       <element-citation id="sbref800" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Oughton
          </surname>
          <given-names>
           MT
          </given-names>
         </name>
         <name>
          <surname>
           Loo
          </surname>
          <given-names>
           VG
          </given-names>
         </name>
         <name>
          <surname>
           Dendukuri
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Fenn
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Libman
          </surname>
          <given-names>
           MD
          </given-names>
         </name>
        </person-group>
        <article-title>
         Hand hygiene with soap and water is superior to alcohol rub and antiseptic wipes for removal of Clostridium difficile
        </article-title>
        <source>
         Infect Control Hosp Epidemiol
        </source>
        <volume>
         30
        </volume>
        <year>
         2009
        </year>
        <fpage>
         939
        </fpage>
        <lpage>
         944
        </lpage>
        <pub-id pub-id-type="pmid">
         19715426
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib81">
       <label>
        81
       </label>
       <element-citation id="sbref810" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Jabbar
          </surname>
          <given-names>
           U
          </given-names>
         </name>
         <name>
          <surname>
           Leischner
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Kasper
          </surname>
          <given-names>
           D
          </given-names>
         </name>
        </person-group>
        <article-title>
         Effectiveness of alcohol-based hand rubs for removal of Clostridium difficile spores from hands
        </article-title>
        <source>
         Infect Control Hosp Epidemiol
        </source>
        <volume>
         31
        </volume>
        <year>
         2010
        </year>
        <fpage>
         565
        </fpage>
        <lpage>
         570
        </lpage>
        <pub-id pub-id-type="pmid">
         20429659
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib82">
       <label>
        82
       </label>
       <element-citation id="sbref820" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Grayson
          </surname>
          <given-names>
           ML
          </given-names>
         </name>
         <name>
          <surname>
           Melvani
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Druce
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        <article-title>
         Efficacy of soap and water and alcohol-based hand-rub preparations against live H1N1 influenza virus on the hands of human volunteers
        </article-title>
        <source>
         Clin Infect Dis
        </source>
        <volume>
         48
        </volume>
        <year>
         2009
        </year>
        <fpage>
         285
        </fpage>
        <lpage>
         291
        </lpage>
        <pub-id pub-id-type="pmid">
         19115974
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib83">
       <label>
        83
       </label>
       <element-citation id="sbref830" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Turner
          </surname>
          <given-names>
           RB
          </given-names>
         </name>
         <name>
          <surname>
           Fuls
          </surname>
          <given-names>
           JL
          </given-names>
         </name>
         <name>
          <surname>
           Rodgers
          </surname>
          <given-names>
           ND
          </given-names>
         </name>
        </person-group>
        <article-title>
         Effectiveness of hand sanitizers with and without organic acids for removal of rhinovirus from hands
        </article-title>
        <source>
         Antimicrob Agents Chemother
        </source>
        <volume>
         54
        </volume>
        <year>
         2010
        </year>
        <fpage>
         1363
        </fpage>
        <lpage>
         1364
        </lpage>
        <pub-id pub-id-type="pmid">
         20047916
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib84">
       <label>
        84
       </label>
       <element-citation id="sbref840" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Sheng
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        <article-title>
         Effectiveness and limitations of hand hygiene promotion on decreasing healthcare-associated infections
        </article-title>
        <source>
         PLoS One
        </source>
        <volume>
         6
        </volume>
        <year>
         2011
        </year>
        <fpage>
         e27163
        </fpage>
        <pub-id pub-id-type="pmid">
         22110610
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib85">
       <label>
        85
       </label>
       <element-citation id="sbref850" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Department of Health
          </surname>
         </name>
        </person-group>
        <source>
         Uniforms and workwear: guidance on uniform and workwear policies for NHS employers
        </source>
        <year>
         2010
        </year>
        <publisher-name>
         Department of Health
        </publisher-name>
        <publisher-loc>
         London
        </publisher-loc>
       </element-citation>
      </ref>
      <ref id="bib86">
       <label>
        86
       </label>
       <element-citation id="sbref860" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chow
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Arah
          </surname>
          <given-names>
           OA
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        <article-title>
         Alcohol handrubbing and chlorhexidine handwashing protocols for routine hospital practice: a randomized clinical trial of protocol efficacy and time effectiveness
        </article-title>
        <source>
         Am J Infect Control
        </source>
        <volume>
         40
        </volume>
        <year>
         2012
        </year>
        <fpage>
         800
        </fpage>
        <lpage>
         805
        </lpage>
        <pub-id pub-id-type="pmid">
         22325731
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib87">
       <label>
        87
       </label>
       <element-citation id="sbref870" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kampf
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Reichel
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Feil
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Eggerstedt
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Kaulfers
          </surname>
          <given-names>
           P
          </given-names>
         </name>
        </person-group>
        <article-title>
         Influence of rub-in technique on required application time and hand coverage in hygienic hand disinfection
        </article-title>
        <source>
         BMC Infect Dis
        </source>
        <volume>
         8
        </volume>
        <year>
         2008
        </year>
        <fpage>
         149
        </fpage>
        <pub-id pub-id-type="pmid">
         18959788
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib88">
       <label>
        88
       </label>
       <element-citation id="sbref880" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gustafson
          </surname>
          <given-names>
           DR
          </given-names>
         </name>
         <name>
          <surname>
           Vetter
          </surname>
          <given-names>
           EA
          </given-names>
         </name>
         <name>
          <surname>
           Larson
          </surname>
          <given-names>
           DR
          </given-names>
         </name>
        </person-group>
        <article-title>
         Effects of 4 hand-drying methods for removing bacteria from washed hands: a randomized trial
        </article-title>
        <source>
         Mayo Clin Proc
        </source>
        <volume>
         75
        </volume>
        <year>
         2000
        </year>
        <fpage>
         705
        </fpage>
        <lpage>
         708
        </lpage>
        <pub-id pub-id-type="pmid">
         10907386
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib89">
       <label>
        89
       </label>
       <element-citation id="sbref890" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yamamoto
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Ugai
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Takahashi
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
        </person-group>
        <article-title>
         Efficiency of hand drying for removing bacteria from washed hands: comparison of paper towel drying with warm air drying
        </article-title>
        <source>
         Infect Control Hosp Epidemiol
        </source>
        <volume>
         26
        </volume>
        <year>
         2005
        </year>
        <fpage>
         316
        </fpage>
        <lpage>
         320
        </lpage>
        <pub-id pub-id-type="pmid">
         15796287
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib90">
       <label>
        90
       </label>
       <element-citation id="sbref900" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Department of Health
          </surname>
         </name>
        </person-group>
        <source>
         Infection control in the built environment. Health Building Note 00-09
        </source>
        <year>
         2013
        </year>
        <publisher-name>
         Department of Health
        </publisher-name>
        <publisher-loc>
         London
        </publisher-loc>
       </element-citation>
      </ref>
      <ref id="bib91">
       <label>
        91
       </label>
       <element-citation id="sbref910" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Ma
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <name>
          <surname>
           Stack
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        <article-title>
         The hygienic efficacy of different hand-drying methods: a review of the evidence
        </article-title>
        <source>
         Mayo Clin Proc
        </source>
        <volume>
         87
        </volume>
        <year>
         2012
        </year>
        <fpage>
         791
        </fpage>
        <lpage>
         798
        </lpage>
        <pub-id pub-id-type="pmid">
         22656243
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib92">
       <label>
        92
       </label>
       <element-citation id="sbref920" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Pietsch
          </surname>
          <given-names>
           H
          </given-names>
         </name>
        </person-group>
        <article-title>
         Hand antiseptics: rubs versus scrubs, alcoholic solutions versus alcoholic gels
        </article-title>
        <source>
         J Hosp Infect
        </source>
        <volume>
         48
        </volume>
        <issue>
         Suppl. A
        </issue>
        <year>
         2001
        </year>
        <fpage>
         S33
        </fpage>
        <lpage>
         S36
        </lpage>
        <pub-id pub-id-type="pmid">
         11759022
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib93">
       <label>
        93
       </label>
       <element-citation id="sbref930" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Boyce
          </surname>
          <given-names>
           JM
          </given-names>
         </name>
         <name>
          <surname>
           Kelliher
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Vallande
          </surname>
          <given-names>
           N
          </given-names>
         </name>
        </person-group>
        <article-title>
         Skin irritation and dryness associated with two hand-hygiene regimens: soap-and-water hand washing versus hand antisepsis with an alcoholic hand gel
        </article-title>
        <source>
         Infect Control Hosp Epidemiol
        </source>
        <volume>
         21
        </volume>
        <year>
         2000
        </year>
        <fpage>
         442
        </fpage>
        <lpage>
         448
        </lpage>
        <pub-id pub-id-type="pmid">
         10926393
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib94">
       <label>
        94
       </label>
       <element-citation id="sbref940" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Forrester
          </surname>
          <given-names>
           BG
          </given-names>
         </name>
         <name>
          <surname>
           Roth
          </surname>
          <given-names>
           VS
          </given-names>
         </name>
        </person-group>
        <article-title>
         Hand dermatitis in intensive care units
        </article-title>
        <source>
         J Occup Environ Med
        </source>
        <volume>
         40
        </volume>
        <year>
         1998
        </year>
        <fpage>
         881
        </fpage>
        <lpage>
         885
        </lpage>
        <pub-id pub-id-type="pmid">
         9800173
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib95">
       <label>
        95
       </label>
       <element-citation id="sbref950" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kampf
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Muscatiello
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <article-title>
         Dermal tolerance of Sterillium, a propanol-based hand rub
        </article-title>
        <source>
         J Hosp Infect
        </source>
        <volume>
         55
        </volume>
        <year>
         2003
        </year>
        <fpage>
         295
        </fpage>
        <lpage>
         298
        </lpage>
        <pub-id pub-id-type="pmid">
         14629974
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib96">
       <label>
        96
       </label>
       <element-citation id="sbref960" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Pittet
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Allegranzi
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Sax
          </surname>
          <given-names>
           H
          </given-names>
         </name>
        </person-group>
        <article-title>
         Double-blind, randomized, crossover trial of 3 hand rub formulations: fast-track evaluation of tolerability and acceptability
        </article-title>
        <source>
         Infect Control Hosp Epidemiol
        </source>
        <volume>
         28
        </volume>
        <year>
         2007
        </year>
        <fpage>
         1344
        </fpage>
        <lpage>
         1351
        </lpage>
        <pub-id pub-id-type="pmid">
         17994514
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib97">
       <label>
        97
       </label>
       <element-citation id="sbref970" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Becks
          </surname>
          <given-names>
           VE
          </given-names>
         </name>
         <name>
          <surname>
           Lorenzoni
          </surname>
          <given-names>
           NM
          </given-names>
         </name>
        </person-group>
        <article-title>
         Pseudomonas aeruginosa outbreak in a neonatal intensive care unit: a possible link to contaminated hand lotion
        </article-title>
        <source>
         Am J Infect Control
        </source>
        <volume>
         23
        </volume>
        <year>
         1995
        </year>
        <fpage>
         396
        </fpage>
        <lpage>
         398
        </lpage>
        <pub-id pub-id-type="pmid">
         8821117
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib98">
       <label>
        98
       </label>
       <element-citation id="sbref980" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hilburn
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Hammond
          </surname>
          <given-names>
           BS
          </given-names>
         </name>
         <name>
          <surname>
           Fendler
          </surname>
          <given-names>
           EJ
          </given-names>
         </name>
         <name>
          <surname>
           Groziak
          </surname>
          <given-names>
           PA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Use of alcohol hand sanitizer as an infection control strategy in an acute care facility
        </article-title>
        <source>
         Am J Infect Control
        </source>
        <volume>
         31
        </volume>
        <year>
         2003
        </year>
        <fpage>
         109
        </fpage>
        <lpage>
         116
        </lpage>
        <pub-id pub-id-type="pmid">
         12665745
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib99">
       <label>
        99
       </label>
       <element-citation id="sbref990" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rosenthal
          </surname>
          <given-names>
           VD
          </given-names>
         </name>
         <name>
          <surname>
           Guzman
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Safdar
          </surname>
          <given-names>
           N
          </given-names>
         </name>
        </person-group>
        <article-title>
         Reduction in nosocomial infection with improved hand hygiene in intensive care units of a tertiary care hospital in Argentina
        </article-title>
        <source>
         Am J Infect Control
        </source>
        <volume>
         33
        </volume>
        <year>
         2005
        </year>
        <fpage>
         392
        </fpage>
        <lpage>
         397
        </lpage>
        <pub-id pub-id-type="pmid">
         16153485
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib100">
       <label>
        100
       </label>
       <element-citation id="sbref1000" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rosenthal
          </surname>
          <given-names>
           VD
          </given-names>
         </name>
         <name>
          <surname>
           Guzman
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Safdar
          </surname>
          <given-names>
           N
          </given-names>
         </name>
        </person-group>
        <article-title>
         Effect of education and performance feedback on rates of catheter-associated urinary tract infection in intensive care units in Argentina
        </article-title>
        <source>
         Infect Control Hosp Epidemiol
        </source>
        <volume>
         25
        </volume>
        <year>
         2004
        </year>
        <fpage>
         47
        </fpage>
        <lpage>
         50
        </lpage>
        <pub-id pub-id-type="pmid">
         14756219
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib101">
       <label>
        101
       </label>
       <element-citation id="sbref1010" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Won
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Chou
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Hsieh
          </surname>
          <given-names>
           W
          </given-names>
         </name>
        </person-group>
        <article-title>
         Handwashing program for the prevention of nosocomial infections in a neonatal intensive care unit
        </article-title>
        <source>
         Infect Control Hosp Epidemiol
        </source>
        <volume>
         25
        </volume>
        <year>
         2004
        </year>
        <fpage>
         742
        </fpage>
        <lpage>
         746
        </lpage>
        <pub-id pub-id-type="pmid">
         15484798
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib102">
       <label>
        102
       </label>
       <element-citation id="sbref1020" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           MacDonald
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Dinah
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           MacKenzie
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Wilson
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        <article-title>
         Performance feedback of hand hygiene, using alcohol gel as the skin decontaminant, reduces the number of inpatients newly affected by MRSA and antibiotic costs
        </article-title>
        <source>
         J Hosp Infect
        </source>
        <volume>
         56
        </volume>
        <year>
         2004
        </year>
        <fpage>
         56
        </fpage>
        <lpage>
         63
        </lpage>
        <pub-id pub-id-type="pmid">
         14706272
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib103">
       <label>
        103
       </label>
       <element-citation id="sbref1030" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wendt
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Knautz
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           von Baum
          </surname>
          <given-names>
           H
          </given-names>
         </name>
        </person-group>
        <article-title>
         Differences in hand hygiene behavior related to the contamination risk of healthcare activities in different groups of healthcare workers
        </article-title>
        <source>
         Infect Control Hosp Epidemiol
        </source>
        <volume>
         25
        </volume>
        <year>
         2004
        </year>
        <fpage>
         203
        </fpage>
        <lpage>
         206
        </lpage>
        <pub-id pub-id-type="pmid">
         15061410
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib104">
       <label>
        104
       </label>
       <element-citation id="sbref1040" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cohen
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Saiman
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Cimiotti
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Larson
          </surname>
          <given-names>
           E
          </given-names>
         </name>
        </person-group>
        <article-title>
         Factors associated with hand hygiene practices in two neonatal intensive care units
        </article-title>
        <source>
         Pediatr Infect Dis J
        </source>
        <volume>
         22
        </volume>
        <year>
         2003
        </year>
        <fpage>
         494
        </fpage>
        <lpage>
         499
        </lpage>
        <pub-id pub-id-type="pmid">
         12799504
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib105">
       <label>
        105
       </label>
       <element-citation id="sbref1050" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Brown
          </surname>
          <given-names>
           SM
          </given-names>
         </name>
         <name>
          <surname>
           Lubimova
          </surname>
          <given-names>
           AV
          </given-names>
         </name>
         <name>
          <surname>
           Khrustalyeva
          </surname>
          <given-names>
           NM
          </given-names>
         </name>
        </person-group>
        <article-title>
         Use of an alcohol-based hand rub and quality improvement interventions to improve hand hygiene in a Russian neonatal intensive care unit
        </article-title>
        <source>
         Infect Control Hosp Epidemiol
        </source>
        <volume>
         24
        </volume>
        <year>
         2003
        </year>
        <fpage>
         172
        </fpage>
        <lpage>
         179
        </lpage>
        <pub-id pub-id-type="pmid">
         12683507
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib106">
       <label>
        106
       </label>
       <element-citation id="sbref1060" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kuzu
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Özer
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Aydemir
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Yalcin
          </surname>
          <given-names>
           AN
          </given-names>
         </name>
         <name>
          <surname>
           Zencir
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <article-title>
         Compliance with hand hygiene and glove use in a university-affiliated hospital
        </article-title>
        <source>
         Infect Control Hosp Epidemiol
        </source>
        <volume>
         26
        </volume>
        <year>
         2005
        </year>
        <fpage>
         312
        </fpage>
        <lpage>
         315
        </lpage>
        <pub-id pub-id-type="pmid">
         15796286
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib107">
       <label>
        107
       </label>
       <element-citation id="sbref1070" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kim
          </surname>
          <given-names>
           PW
          </given-names>
         </name>
         <name>
          <surname>
           Roghmann
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Perencevich
          </surname>
          <given-names>
           EN
          </given-names>
         </name>
         <name>
          <surname>
           Harris
          </surname>
          <given-names>
           AD
          </given-names>
         </name>
        </person-group>
        <article-title>
         Rates of hand disinfection associated with glove use, patient isolation, and changes between exposure to various body sites
        </article-title>
        <source>
         Am J Infect Control
        </source>
        <volume>
         31
        </volume>
        <year>
         2003
        </year>
        <fpage>
         97
        </fpage>
        <lpage>
         103
        </lpage>
        <pub-id pub-id-type="pmid">
         12665743
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib108">
       <label>
        108
       </label>
       <element-citation id="sbref1080" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           McGuckin
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Taylor
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Martin
          </surname>
          <given-names>
           V
          </given-names>
         </name>
         <name>
          <surname>
           Porten
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Salcido
          </surname>
          <given-names>
           R
          </given-names>
         </name>
        </person-group>
        <article-title>
         Evaluation of a patient education model for increasing hand hygiene compliance in an inpatient rehabilitation unit
        </article-title>
        <source>
         Am J Infect Control
        </source>
        <volume>
         32
        </volume>
        <year>
         2004
        </year>
        <fpage>
         235
        </fpage>
        <lpage>
         238
        </lpage>
        <pub-id pub-id-type="pmid">
         15175621
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib109">
       <label>
        109
       </label>
       <element-citation id="sbref1090" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           McGuckin
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Waterman
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Storr
          </surname>
          <given-names>
           IJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         Evaluation of a patient-empowering hand hygiene programme in the UK
        </article-title>
        <source>
         J Hosp Infect
        </source>
        <volume>
         48
        </volume>
        <year>
         2001
        </year>
        <fpage>
         222
        </fpage>
        <lpage>
         227
        </lpage>
        <pub-id pub-id-type="pmid">
         11439010
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib110">
       <label>
        110
       </label>
       <element-citation id="sbref1100" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Naikoba
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Hayward
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        <article-title>
         The effectiveness of interventions aimed at increasing handwashing in healthcare workers - a systematic review
        </article-title>
        <source>
         J Hosp Infect
        </source>
        <volume>
         47
        </volume>
        <year>
         2001
        </year>
        <fpage>
         173
        </fpage>
        <lpage>
         180
        </lpage>
        <pub-id pub-id-type="pmid">
         11247676
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib111">
       <label>
        111
       </label>
       <element-citation id="sbref1110" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Magiorakos
          </surname>
          <given-names>
           AP
          </given-names>
         </name>
         <name>
          <surname>
           Leens
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Michael
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        <article-title>
         National hand hygiene campaigns in Europe, 2000–2009. Euro surveillance: bulletin Européen sur les maladies transmissibles
        </article-title>
        <source>
         Eur Communic Dis Bull
        </source>
        <volume>
         14
        </volume>
        <year>
         2009
        </year>
        <fpage>
         17
        </fpage>
       </element-citation>
      </ref>
      <ref id="bib112">
       <label>
        112
       </label>
       <element-citation id="sbref1120" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Grayson
          </surname>
          <given-names>
           ML
          </given-names>
         </name>
         <name>
          <surname>
           Russo
          </surname>
          <given-names>
           PL
          </given-names>
         </name>
         <name>
          <surname>
           Cruickshank
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <article-title>
         Outcomes from the first 2 years of the Australian national hand hygiene initiative
        </article-title>
        <source>
         Med J Aust
        </source>
        <volume>
         195
        </volume>
        <year>
         2011
        </year>
        <fpage>
         615
        </fpage>
        <lpage>
         619
        </lpage>
        <pub-id pub-id-type="pmid">
         22107015
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib113">
       <label>
        113
       </label>
       <element-citation id="sbref1130" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gould
          </surname>
          <given-names>
           DJ
          </given-names>
         </name>
         <name>
          <surname>
           Chudleigh
          </surname>
          <given-names>
           JH
          </given-names>
         </name>
         <name>
          <surname>
           Moralejo
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Drey
          </surname>
          <given-names>
           N
          </given-names>
         </name>
        </person-group>
        <article-title>
         Interventions to improve hand hygiene compliance in patient care
        </article-title>
        <source>
         Cochrane Database Syst Rev
        </source>
        <volume>
         18
        </volume>
        <year>
         2007
        </year>
        <comment>
         CD005186.
        </comment>
       </element-citation>
      </ref>
      <ref id="bib114">
       <label>
        114
       </label>
       <element-citation id="sbref1140" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Backman
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Zoutman
          </surname>
          <given-names>
           DE
          </given-names>
         </name>
         <name>
          <surname>
           Marck
          </surname>
          <given-names>
           PB
          </given-names>
         </name>
        </person-group>
        <article-title>
         An integrative review of the current evidence on the relationship between hand hygiene interventions and the incidence of health care-associated infections
        </article-title>
        <source>
         Am J Infect Control
        </source>
        <volume>
         36
        </volume>
        <year>
         2008
        </year>
        <fpage>
         333
        </fpage>
        <lpage>
         348
        </lpage>
        <pub-id pub-id-type="pmid">
         18538700
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib115">
       <label>
        115
       </label>
       <element-citation id="sbref1150" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Aboelela
          </surname>
          <given-names>
           SW
          </given-names>
         </name>
         <name>
          <surname>
           Stone
          </surname>
          <given-names>
           PW
          </given-names>
         </name>
         <name>
          <surname>
           Larson
          </surname>
          <given-names>
           EL
          </given-names>
         </name>
        </person-group>
        <article-title>
         Effectiveness of bundled behavioural interventions to control healthcare-associated infections: a systematic review of the literature
        </article-title>
        <source>
         J Hosp Infect
        </source>
        <volume>
         66
        </volume>
        <year>
         2007
        </year>
        <fpage>
         101
        </fpage>
        <lpage>
         108
        </lpage>
        <pub-id pub-id-type="pmid">
         17320242
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib116">
       <label>
        116
       </label>
       <element-citation id="sbref1160" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cherry
          </surname>
          <given-names>
           MG
          </given-names>
         </name>
         <name>
          <surname>
           Brown
          </surname>
          <given-names>
           JM
          </given-names>
         </name>
         <name>
          <surname>
           Bethell
          </surname>
          <given-names>
           GS
          </given-names>
         </name>
         <name>
          <surname>
           Neal
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Shaw
          </surname>
          <given-names>
           NJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         Features of educational interventions that lead to compliance with hand hygiene in healthcare professionals within a hospital care setting. A BEME systematic review: BEME Guide No. 22
        </article-title>
        <source>
         Med Teach
        </source>
        <volume>
         34
        </volume>
        <year>
         2012
        </year>
        <fpage>
         e406
        </fpage>
        <lpage>
         e420
        </lpage>
        <pub-id pub-id-type="pmid">
         22578050
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib117">
       <label>
        117
       </label>
       <element-citation id="sbref1170" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Huis
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Schoonhoven
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Grol
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Donders
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Hulscher
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           van Achterberg
          </surname>
          <given-names>
           T
          </given-names>
         </name>
        </person-group>
        <article-title>
         Impact of a team and leaders-directed strategy to improve nurses' adherence to hand hygiene guidelines: a cluster randomised trial
        </article-title>
        <source>
         Int J Nurs Stud
        </source>
        <volume>
         50
        </volume>
        <year>
         2013
        </year>
        <fpage>
         464
        </fpage>
        <lpage>
         474
        </lpage>
        <pub-id pub-id-type="pmid">
         22939048
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib118">
       <label>
        118
       </label>
       <element-citation id="sbref1180" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Huis
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Holleman
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           van Achterberg
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Grol
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Schoonhoven
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Hulscher
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <article-title>
         Explaining the effects of two different strategies for promoting hand hygiene in hospital nurses: a process evaluation alongside a cluster randomised controlled trial
        </article-title>
        <source>
         Implement Sci
        </source>
        <volume>
         8
        </volume>
        <year>
         2013
        </year>
        <fpage>
         41
        </fpage>
        <pub-id pub-id-type="pmid">
         23566429
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib119">
       <label>
        119
       </label>
       <element-citation id="sbref1190" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Fuller
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Duckworth
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Jeanes
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        <article-title>
         The Feedback Intervention Trial (FIT) – improving hand-hygiene compliance in UK healthcare workers: a stepped wedge cluster randomised controlled trial
        </article-title>
        <source>
         PLoS One
        </source>
        <volume>
         7
        </volume>
        <year>
         2012
        </year>
        <fpage>
         e41617
        </fpage>
        <pub-id pub-id-type="pmid">
         23110040
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib120">
       <label>
        120
       </label>
       <element-citation id="sbref1200" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Stone
          </surname>
          <given-names>
           SP
          </given-names>
         </name>
         <name>
          <surname>
           Jeanes
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Roberts
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        <article-title>
         Evaluation of the national Cleanyourhands campaign to reduce Staphylococcus aureus bacteraemia and Clostridium difficile infection in hospitals in England and Wales by improved hand hygiene: four year, prospective, ecological, interrupted time series study
        </article-title>
        <source>
         BMJ
        </source>
        <volume>
         3
        </volume>
        <year>
         2012
        </year>
        <fpage>
         e3005
        </fpage>
       </element-citation>
      </ref>
      <ref id="bib121">
       <label>
        121
       </label>
       <element-citation id="sbref1210" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Benning
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Carmalt
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Rudge
          </surname>
          <given-names>
           G
          </given-names>
         </name>
        </person-group>
        <article-title>
         Multiple component patient safety intervention in English hospitals: controlled evaluation of second phase
        </article-title>
        <source>
         BMJ
        </source>
        <volume>
         342
        </volume>
        <year>
         2011
        </year>
        <fpage>
         d199
        </fpage>
        <pub-id pub-id-type="pmid">
         21292720
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib122">
       <label>
        122
       </label>
       <element-citation id="sbref1220" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Longtin
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Sax
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Allegranzi
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Hugonnet
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Pittet
          </surname>
          <given-names>
           D
          </given-names>
         </name>
        </person-group>
        <article-title>
         Patients' beliefs and perceptions of their participation to increase healthcare worker compliance with hand hygiene
        </article-title>
        <source>
         Infect Control Hosp Epidemiol
        </source>
        <volume>
         30
        </volume>
        <year>
         2009
        </year>
        <fpage>
         830
        </fpage>
        <lpage>
         839
        </lpage>
        <pub-id pub-id-type="pmid">
         19642899
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib123">
       <label>
        123
       </label>
       <element-citation id="sbref1230" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lent
          </surname>
          <given-names>
           V
          </given-names>
         </name>
         <name>
          <surname>
           Eckstein
          </surname>
          <given-names>
           BC
          </given-names>
         </name>
         <name>
          <surname>
           Eckstein
          </surname>
          <given-names>
           EC
          </given-names>
         </name>
         <name>
          <surname>
           Cameron
          </surname>
          <given-names>
           AS
          </given-names>
         </name>
         <name>
          <surname>
           Budavich
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Donskey
          </surname>
          <given-names>
           CJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         Evaluation of patient participation in a patient empowerment initiative to improve hand hygiene practices in a veterans affairs medical center
        </article-title>
        <source>
         Am J Infect Control
        </source>
        <volume>
         37
        </volume>
        <year>
         2009
        </year>
        <fpage>
         117
        </fpage>
        <lpage>
         120
        </lpage>
        <pub-id pub-id-type="pmid">
         18834750
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib124">
       <label>
        124
       </label>
       <element-citation id="sbref1240" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sanderson
          </surname>
          <given-names>
           PJ
          </given-names>
         </name>
         <name>
          <surname>
           Weissler
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        <article-title>
         Recovery of coliforms from the hands of nurses and patients: activities leading to contamination
        </article-title>
        <source>
         J Hosp Infect
        </source>
        <volume>
         21
        </volume>
        <year>
         1992
        </year>
        <fpage>
         85
        </fpage>
        <lpage>
         93
        </lpage>
        <pub-id pub-id-type="pmid">
         1353096
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib125">
       <label>
        125
       </label>
       <element-citation id="sbref1250" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Larson
          </surname>
          <given-names>
           EL
          </given-names>
         </name>
         <name>
          <surname>
           Cronquist
          </surname>
          <given-names>
           AB
          </given-names>
         </name>
         <name>
          <surname>
           Whittier
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Lai
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Lyle
          </surname>
          <given-names>
           CT
          </given-names>
         </name>
         <name>
          <surname>
           Latta
          </surname>
          <given-names>
           PD
          </given-names>
         </name>
        </person-group>
        <article-title>
         Differences in skin flora between inpatients and chronically ill outpatients
        </article-title>
        <source>
         Heart Lung
        </source>
        <volume>
         29
        </volume>
        <year>
         2000
        </year>
        <fpage>
         298
        </fpage>
        <lpage>
         305
        </lpage>
        <pub-id pub-id-type="pmid">
         10900068
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib126">
       <label>
        126
       </label>
       <element-citation id="sbref1260" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Banfield
          </surname>
          <given-names>
           KR
          </given-names>
         </name>
         <name>
          <surname>
           Kerr
          </surname>
          <given-names>
           KG
          </given-names>
         </name>
        </person-group>
        <article-title>
         Could hospital patients' hands constitute a missing link?
        </article-title>
        <source>
         J Hosp Infect
        </source>
        <volume>
         61
        </volume>
        <year>
         2005
        </year>
        <fpage>
         183
        </fpage>
        <lpage>
         188
        </lpage>
        <pub-id pub-id-type="pmid">
         16099541
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib127">
       <label>
        127
       </label>
       <element-citation id="sbref1270" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Savage
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Fuller
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Besser
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Stone
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        <article-title>
         Use of alcohol hand rub (AHR) at ward entrances and use of soap and AHR by patients and visitors: a study in 27 wards in nine acute NHS trusts
        </article-title>
        <source>
         J Infect Prev
        </source>
        <volume>
         12
        </volume>
        <year>
         2011
        </year>
        <fpage>
         54
        </fpage>
        <lpage>
         58
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib128">
       <label>
        128
       </label>
       <element-citation id="sbref1280" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lawrence
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <article-title>
         Patient hand hygiene: a clinical inquiry
        </article-title>
        <source>
         Nurs Times
        </source>
        <volume>
         79
        </volume>
        <year>
         1983
        </year>
        <fpage>
         24
        </fpage>
        <lpage>
         25
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib129">
       <label>
        129
       </label>
       <element-citation id="sbref1290" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Duncan
          </surname>
          <given-names>
           C
          </given-names>
         </name>
        </person-group>
        <article-title>
         An exploratory study of patient's feelings about asking healthcare professionals to wash their hands
        </article-title>
        <source>
         J Ren Care
        </source>
        <volume>
         33
        </volume>
        <year>
         2007
        </year>
        <fpage>
         30
        </fpage>
        <lpage>
         34
        </lpage>
        <pub-id pub-id-type="pmid">
         17695559
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib130">
       <label>
        130
       </label>
       <element-citation id="sbref1300" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Burnett
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Kydd
          </surname>
          <given-names>
           P
          </given-names>
         </name>
        </person-group>
        <article-title>
         Hand hygiene: what about our patients?
        </article-title>
        <source>
         Br J Infect Contr
        </source>
        <volume>
         9
        </volume>
        <year>
         2008
        </year>
        <fpage>
         19
        </fpage>
        <lpage>
         24
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib131">
       <label>
        131
       </label>
       <element-citation id="sbref1310" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Burnett
          </surname>
          <given-names>
           E
          </given-names>
         </name>
        </person-group>
        <article-title>
         Perceptions, attitudes, and behavior towards patient hand hygiene
        </article-title>
        <source>
         Am J Infect Control
        </source>
        <volume>
         37
        </volume>
        <year>
         2009
        </year>
        <fpage>
         638
        </fpage>
        <lpage>
         642
        </lpage>
        <pub-id pub-id-type="pmid">
         19628304
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib132">
       <label>
        132
       </label>
       <element-citation id="sbref1320" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cheng
          </surname>
          <given-names>
           VCC
          </given-names>
         </name>
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           AKL
          </given-names>
         </name>
         <name>
          <surname>
           Cheung
          </surname>
          <given-names>
           CHY
          </given-names>
         </name>
        </person-group>
        <article-title>
         Outbreak of human metapneumovirus infection in psychiatric inpatients: implications for directly observed use of alcohol hand rub in prevention of nosocomial outbreaks
        </article-title>
        <source>
         J Hosp Infect
        </source>
        <volume>
         67
        </volume>
        <year>
         2007
        </year>
        <fpage>
         336
        </fpage>
        <lpage>
         343
        </lpage>
        <pub-id pub-id-type="pmid">
         18022285
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib133">
       <label>
        133
       </label>
       <element-citation id="sbref1330" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           YC
          </given-names>
         </name>
         <name>
          <surname>
           Chiang
          </surname>
          <given-names>
           LC
          </given-names>
         </name>
        </person-group>
        <article-title>
         Effectiveness of hand-washing teaching programs for families of children in paediatric intensive care units
        </article-title>
        <source>
         J Clin Nurs
        </source>
        <volume>
         16
        </volume>
        <year>
         2007
        </year>
        <fpage>
         1173
        </fpage>
        <lpage>
         1179
        </lpage>
        <pub-id pub-id-type="pmid">
         17518892
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib134">
       <label>
        134
       </label>
       <element-citation id="sbref1340" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gagné
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Bédard
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Maziade
          </surname>
          <given-names>
           PJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         Systematic patients' hand disinfection: impact on meticillin-resistant Staphylococcus aureus infection rates in a community hospital
        </article-title>
        <source>
         J Hosp Infect
        </source>
        <volume>
         75
        </volume>
        <year>
         2010
        </year>
        <fpage>
         269
        </fpage>
        <lpage>
         272
        </lpage>
        <pub-id pub-id-type="pmid">
         20434796
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib135">
       <label>
        135
       </label>
       <element-citation id="sbref1350" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Expert Advisory Group on AIDS and the Advisory Group on Hepatitis
          </surname>
         </name>
        </person-group>
        <source>
         Guidance for clinical healthcare workers: protection against infection with bloodborne viruses
        </source>
        <year>
         1998
        </year>
        <publisher-name>
         Department of Health
        </publisher-name>
        <publisher-loc>
         London
        </publisher-loc>
       </element-citation>
      </ref>
      <ref id="bib136">
       <label>
        136
       </label>
       <element-citation id="sbref1360" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wilson
          </surname>
          <given-names>
           JA
          </given-names>
         </name>
         <name>
          <surname>
           Loveday
          </surname>
          <given-names>
           HP
          </given-names>
         </name>
         <name>
          <surname>
           Hoffman
          </surname>
          <given-names>
           PN
          </given-names>
         </name>
         <name>
          <surname>
           Pratt
          </surname>
          <given-names>
           RJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         Uniform: an evidence review of the microbiological significance of uniforms and uniform policy in the prevention and control of healthcare-associated infections. Report to the Department of Health (England)
        </article-title>
        <source>
         J Hosp Infect
        </source>
        <volume>
         66
        </volume>
        <year>
         2007
        </year>
        <fpage>
         301
        </fpage>
        <lpage>
         307
        </lpage>
        <pub-id pub-id-type="pmid">
         17602793
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib137">
       <label>
        137
       </label>
       <element-citation id="sbref1370" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Health and Safety Executive
          </surname>
         </name>
        </person-group>
        <source>
         Management of Health and Safety at Work Regulations
        </source>
        <year>
         1999
        </year>
        <publisher-name>
         HSE Books
        </publisher-name>
        <publisher-loc>
         London
        </publisher-loc>
       </element-citation>
      </ref>
      <ref id="bib138">
       <label>
        138
       </label>
       <element-citation id="sbref1380" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Health and Safety Executive
          </surname>
         </name>
        </person-group>
        <source>
         Personal protective equipment at work. Personal Protective Equipment at Work Regulations 1992 (as amended): guidance on regulations
        </source>
        <edition>
         2nd ed.
        </edition>
        <year>
         2005
        </year>
        <publisher-name>
         HSE Books
        </publisher-name>
        <publisher-loc>
         London
        </publisher-loc>
       </element-citation>
      </ref>
      <ref id="bib139">
       <label>
        139
       </label>
       <element-citation id="sbref1390" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Health and Safety Commission
          </surname>
         </name>
        </person-group>
        <source>
         Control of substances hazardous to health. Control of Substances Hazardous to Health Regulations 2002 (as amended). Approved code of practice and guidance
        </source>
        <edition>
         5th ed.
        </edition>
        <year>
         2002
        </year>
        <publisher-name>
         HSE Books
        </publisher-name>
        <publisher-loc>
         London
        </publisher-loc>
       </element-citation>
      </ref>
      <ref id="bib140">
       <label>
        140
       </label>
       <element-citation id="sbref1400" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Health and Safety Executive
          </surname>
         </name>
        </person-group>
        <source>
         Personal protective equipment (PPE) at work: a brief guide. INDG174 (rev2)
        </source>
        <year>
         2013
        </year>
        <publisher-name>
         HSE Books
        </publisher-name>
        <publisher-loc>
         London
        </publisher-loc>
        <ext-link ext-link-type="uri" id="interrefs110" xlink:href="http://www.hse.gov.uk/pubns/indg174.pdf">
         Available at: http://www.hse.gov.uk/pubns/indg174.pdf
        </ext-link>
        <comment>
         Accessed June 5, 2013.
        </comment>
       </element-citation>
      </ref>
      <ref id="bib141">
       <label>
        141
       </label>
       <element-citation id="sbref1410" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sax
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Perneger
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Hugonnet
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Herrault
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Chraïti
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Pittet
          </surname>
          <given-names>
           D
          </given-names>
         </name>
        </person-group>
        <article-title>
         Knowledge of standard and isolation precautions in a large teaching hospital
        </article-title>
        <source>
         Infect Control Hosp Epidemiol
        </source>
        <volume>
         26
        </volume>
        <year>
         2005
        </year>
        <fpage>
         298
        </fpage>
        <lpage>
         304
        </lpage>
        <pub-id pub-id-type="pmid">
         15796284
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib142">
       <label>
        142
       </label>
       <element-citation id="sbref1420" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Trim
          </surname>
          <given-names>
           JC
          </given-names>
         </name>
         <name>
          <surname>
           Adams
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Elliott
          </surname>
          <given-names>
           TSJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         Healthcare workers' knowledge of inoculation injuries and glove use
        </article-title>
        <source>
         Br J Nurs
        </source>
        <volume>
         12
        </volume>
        <year>
         2003
        </year>
        <fpage>
         215
        </fpage>
        <lpage>
         221
        </lpage>
        <pub-id pub-id-type="pmid">
         12671567
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib143">
       <label>
        143
       </label>
       <element-citation id="sbref1430" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ferguson
          </surname>
          <given-names>
           KJ
          </given-names>
         </name>
         <name>
          <surname>
           Waitzkin
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Beekmann
          </surname>
          <given-names>
           SE
          </given-names>
         </name>
         <name>
          <surname>
           Doebbeling
          </surname>
          <given-names>
           BN
          </given-names>
         </name>
        </person-group>
        <article-title>
         Critical incidents of nonadherence with standard precautions guidelines among community hospital-based health care workers
        </article-title>
        <source>
         J Gen Intern Med
        </source>
        <volume>
         19
        </volume>
        <year>
         2004
        </year>
        <fpage>
         726
        </fpage>
        <lpage>
         731
        </lpage>
        <pub-id pub-id-type="pmid">
         15209585
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib144">
       <label>
        144
       </label>
       <element-citation id="sbref1440" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Prieto
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        <article-title>
         Contact precautions for Clostridium diffcile and methicillin-resistant Staphylococcus aureus (MRSA): assessing the impact of a supportive intervention to improve practice
        </article-title>
        <source>
         J Res Nurs
        </source>
        <volume>
         10
        </volume>
        <year>
         2005
        </year>
        <fpage>
         511
        </fpage>
        <lpage>
         526
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib145">
       <label>
        145
       </label>
       <element-citation id="sbref1450" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Royal College of Nursing
          </surname>
         </name>
        </person-group>
        <source>
         Tools of the trade; RCN guidance for healthcare staff on glove use and prevention of contact dermatitis
        </source>
        <year>
         2012
        </year>
        <publisher-name>
         Royal College of Nursing
        </publisher-name>
        <publisher-loc>
         London
        </publisher-loc>
        <ext-link ext-link-type="uri" id="interrefs120" xlink:href="http://www.rcn.org.uk/__data/assets/pdf_file/0003/450507/RCNguidance_glovesdermatitis_WEB2.pdf">
         Available at: http://www.rcn.org.uk/__data/assets/pdf_file/0003/450507/RCNguidance_glovesdermatitis_WEB2.pdf
        </ext-link>
        <comment>
         Accessed July 22, 2013.
        </comment>
       </element-citation>
      </ref>
      <ref id="bib146">
       <label>
        146
       </label>
       <element-citation id="sbref1460" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Health and Safety Executive
          </surname>
         </name>
        </person-group>
        <source>
         Selecting latex gloves
        </source>
        <year>
         2013
        </year>
        <publisher-name>
         HSE Books
        </publisher-name>
        <publisher-loc>
         London
        </publisher-loc>
        <ext-link ext-link-type="uri" id="interrefs130" xlink:href="http://www.hse.gov.uk/skin/employ/latex-gloves.htm">
         Available at: http://www.hse.gov.uk/skin/employ/latex-gloves.htm
        </ext-link>
        <comment>
         Accessed July 25, 2013.
        </comment>
       </element-citation>
      </ref>
      <ref id="bib147">
       <label>
        147
       </label>
       <element-citation id="sbref1470" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Health and Safety Executive
          </surname>
         </name>
        </person-group>
        <source>
         Choosing the right gloves to protect skin: a guide for employers
        </source>
        <year>
         2013
        </year>
        <publisher-name>
         HSE Books
        </publisher-name>
        <publisher-loc>
         London
        </publisher-loc>
        <ext-link ext-link-type="uri" id="interrefs140" xlink:href="http://www.hse.gov.uk/skin/employ/gloves.htm">
         Available at: http://www.hse.gov.uk/skin/employ/gloves.htm
        </ext-link>
        <comment>
         Accessed July 25, 2013.
        </comment>
       </element-citation>
      </ref>
      <ref id="bib148">
       <label>
        148
       </label>
       <element-citation id="sbref1480" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Fuller
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Savage
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Besser
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        <article-title>
         “The dirty hand in the latex glove”: a study of hand hygiene compliance when gloves are worn
        </article-title>
        <source>
         Infect Control Hosp Epidemiol
        </source>
        <volume>
         32
        </volume>
        <year>
         2011
        </year>
        <fpage>
         1194
        </fpage>
        <lpage>
         1199
        </lpage>
        <pub-id pub-id-type="pmid">
         22080658
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib149">
       <label>
        149
       </label>
       <element-citation id="sbref1490" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Eveillard
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Guilloteau
          </surname>
          <given-names>
           V
          </given-names>
         </name>
         <name>
          <surname>
           Kempf
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <article-title>
         Impact of improving glove usage on the hand hygiene compliance
        </article-title>
        <source>
         Am J Infect Control
        </source>
        <volume>
         39
        </volume>
        <year>
         2011
        </year>
        <fpage>
         608
        </fpage>
        <lpage>
         610
        </lpage>
        <pub-id pub-id-type="pmid">
         21514006
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib150">
       <label>
        150
       </label>
       <element-citation id="sbref1500" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Eveillard
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Raymond
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Joly-Guillou
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <article-title>
         Measurement of hand hygiene compliance and gloving practices in different settings for the elderly considering the location of hand hygiene opportunities during patient care
        </article-title>
        <source>
         Am J Infect Control
        </source>
        <volume>
         39
        </volume>
        <year>
         2011
        </year>
        <fpage>
         339
        </fpage>
        <lpage>
         341
        </lpage>
        <pub-id pub-id-type="pmid">
         21531274
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib151">
       <label>
        151
       </label>
       <element-citation id="sbref1510" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Katherason
          </surname>
          <given-names>
           SG
          </given-names>
         </name>
         <name>
          <surname>
           Naing
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Jaalam
          </surname>
          <given-names>
           K
          </given-names>
         </name>
        </person-group>
        <article-title>
         Hand decontamination practices and the appropriate use of gloves in two adult intensive care units in Malaysia
        </article-title>
        <source>
         J Infect Dev Ctries
        </source>
        <volume>
         4
        </volume>
        <year>
         2010
        </year>
        <fpage>
         118
        </fpage>
        <lpage>
         123
        </lpage>
        <pub-id pub-id-type="pmid">
         20212345
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib152">
       <label>
        152
       </label>
       <element-citation id="sbref1520" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Huskins
          </surname>
          <given-names>
           WC
          </given-names>
         </name>
         <name>
          <surname>
           Samore
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Wallace
          </surname>
          <given-names>
           D
          </given-names>
         </name>
        </person-group>
        <article-title>
         Intervention to reduce transmission of resistant bacteria in intensive care
        </article-title>
        <source>
         N Engl J Med
        </source>
        <volume>
         364
        </volume>
        <year>
         2011
        </year>
        <fpage>
         1407
        </fpage>
        <lpage>
         1418
        </lpage>
        <pub-id pub-id-type="pmid">
         21488763
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib153">
       <label>
        153
       </label>
       <element-citation id="sbref1530" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           British Standards Institution
          </surname>
         </name>
        </person-group>
        <source>
         Medical gloves for single use. Part 1: Specification for freedom from holes
        </source>
        <year>
         2000
        </year>
        <publisher-name>
         British Standards Institution
        </publisher-name>
        <publisher-loc>
         London
        </publisher-loc>
        <comment>
         BS-EN 455–1.
        </comment>
       </element-citation>
      </ref>
      <ref id="bib154">
       <label>
        154
       </label>
       <element-citation id="sbref1540" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           British Standards Institution
          </surname>
         </name>
        </person-group>
        <source>
         Medical gloves for single use. Part 2: Specification for physical properties
        </source>
        <year>
         2000
        </year>
        <publisher-name>
         British Standards Institution
        </publisher-name>
        <publisher-loc>
         London
        </publisher-loc>
        <comment>
         BS-EN 455–2.
        </comment>
       </element-citation>
      </ref>
      <ref id="bib155">
       <label>
        155
       </label>
       <element-citation id="sbref1550" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           British Standards Institution
          </surname>
         </name>
        </person-group>
        <source>
         Medical gloves for single use. Part 3: Requirements and testing for biological evaluation
        </source>
        <year>
         2000
        </year>
        <publisher-name>
         British Standards Institution
        </publisher-name>
        <publisher-loc>
         London
        </publisher-loc>
        <comment>
         BS-EN 455–3.
        </comment>
       </element-citation>
      </ref>
      <ref id="bib156">
       <label>
        156
       </label>
       <element-citation id="sbref1560" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tenorio
          </surname>
          <given-names>
           AR
          </given-names>
         </name>
         <name>
          <surname>
           Badri
          </surname>
          <given-names>
           SM
          </given-names>
         </name>
         <name>
          <surname>
           Sahgal
          </surname>
          <given-names>
           NB
          </given-names>
         </name>
        </person-group>
        <article-title>
         Effectiveness of gloves in the prevention of hand carriage of vancomycin-resistant enterococcus species by health care workers after patient care
        </article-title>
        <source>
         Clin Infect Dis
        </source>
        <volume>
         32
        </volume>
        <year>
         2001
        </year>
        <fpage>
         826
        </fpage>
        <lpage>
         829
        </lpage>
        <pub-id pub-id-type="pmid">
         11229854
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib157">
       <label>
        157
       </label>
       <element-citation id="sbref1570" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Department of Health
          </surname>
         </name>
        </person-group>
        <source>
         Health Technical Memorandum 07-01: safe management of healthcare waste
        </source>
        <year>
         2013
        </year>
        <publisher-name>
         Department of Health
        </publisher-name>
        <publisher-loc>
         London
        </publisher-loc>
       </element-citation>
      </ref>
      <ref id="bib158">
       <label>
        158
       </label>
       <element-citation id="sbref1580" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Korniewicz
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           El-Masri
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Broyles
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        <article-title>
         To determine the effects of gloves stress, type of material (vinyl, nitrile, copolymer, latex) and manufacturer on the barrier effectiveness of medical examination gloves
        </article-title>
        <source>
         Am J Infect Control
        </source>
        <volume>
         30
        </volume>
        <year>
         2002
        </year>
        <fpage>
         133
        </fpage>
        <lpage>
         138
        </lpage>
        <pub-id pub-id-type="pmid">
         11944004
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib159">
       <label>
        159
       </label>
       <element-citation id="sbref1590" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Siegel
          </surname>
          <given-names>
           JD
          </given-names>
         </name>
         <name>
          <surname>
           Rhinehart
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Jackson
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Chiarello
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           the Healthcare Infection Control Practices Advisory Committee
          </surname>
         </name>
        </person-group>
        <source>
         2007 Guideline for isolation precautions: preventing transmission of infectious agents in health care settings
        </source>
        <year>
         2007
        </year>
        <publisher-name>
         Mosby, Inc
        </publisher-name>
        <publisher-loc>
         United States
        </publisher-loc>
       </element-citation>
      </ref>
      <ref id="bib160">
       <label>
        160
       </label>
       <element-citation id="sbref1600" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Nye
          </surname>
          <given-names>
           KJ
          </given-names>
         </name>
         <name>
          <surname>
           Leggett
          </surname>
          <given-names>
           VA
          </given-names>
         </name>
         <name>
          <surname>
           Watterson
          </surname>
          <given-names>
           L
          </given-names>
         </name>
        </person-group>
        <article-title>
         Provision and decontamination of uniforms in the NHS
        </article-title>
        <source>
         Nurs Stand
        </source>
        <volume>
         19
        </volume>
        <year>
         2005
        </year>
        <fpage>
         41
        </fpage>
        <lpage>
         45
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib161">
       <label>
        161
       </label>
       <element-citation id="sbref1610" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Speers
          </surname>
          <given-names>
           R
          </given-names>
          <suffix>
           Jr
          </suffix>
         </name>
         <name>
          <surname>
           Shooter
          </surname>
          <given-names>
           RA
          </given-names>
         </name>
         <name>
          <surname>
           Gaya
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Patel
          </surname>
          <given-names>
           N
          </given-names>
         </name>
        </person-group>
        <article-title>
         Contamination of nurses' uniforms with Staphylococcus aureus
        </article-title>
        <source>
         Lancet
        </source>
        <volume>
         2
        </volume>
        <year>
         1969
        </year>
        <fpage>
         233
        </fpage>
        <lpage>
         235
        </lpage>
        <pub-id pub-id-type="pmid">
         4184106
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib162">
       <label>
        162
       </label>
       <element-citation id="sbref1620" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Babb
          </surname>
          <given-names>
           JR
          </given-names>
         </name>
         <name>
          <surname>
           Davies
          </surname>
          <given-names>
           JG
          </given-names>
         </name>
         <name>
          <surname>
           Ayliffe
          </surname>
          <given-names>
           GA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Contamination of protective clothing and nurses' uniforms in an isolation ward
        </article-title>
        <source>
         J Hosp Infect
        </source>
        <volume>
         4
        </volume>
        <year>
         1983
        </year>
        <fpage>
         149
        </fpage>
        <lpage>
         157
        </lpage>
        <pub-id pub-id-type="pmid">
         6195223
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib163">
       <label>
        163
       </label>
       <element-citation id="sbref1630" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Callaghan
          </surname>
          <given-names>
           I
          </given-names>
         </name>
        </person-group>
        <article-title>
         Bacterial contamination of nurses' uniforms: a study
        </article-title>
        <source>
         Nurs Stand
        </source>
        <volume>
         13
        </volume>
        <year>
         1998
        </year>
        <fpage>
         37
        </fpage>
        <lpage>
         42
        </lpage>
        <pub-id pub-id-type="pmid">
         9847772
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib164">
       <label>
        164
       </label>
       <element-citation id="sbref1640" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Perry
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Marshall
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Jones
          </surname>
          <given-names>
           E
          </given-names>
         </name>
        </person-group>
        <article-title>
         Bacterial contamination of uniforms
        </article-title>
        <source>
         J Hosp Infect
        </source>
        <volume>
         48
        </volume>
        <year>
         2001
        </year>
        <fpage>
         238
        </fpage>
        <lpage>
         241
        </lpage>
        <pub-id pub-id-type="pmid">
         11439013
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib165">
       <label>
        165
       </label>
       <element-citation id="sbref1650" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Nye
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Hollis
          </surname>
          <given-names>
           P
          </given-names>
         </name>
        </person-group>
        <article-title>
         Microbial flora on doctors' white coats
        </article-title>
        <source>
         BMJ
        </source>
        <volume>
         303
        </volume>
        <year>
         1991
        </year>
        <fpage>
         1602
        </fpage>
        <lpage>
         1604
        </lpage>
        <pub-id pub-id-type="pmid">
         1773186
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib166">
       <label>
        166
       </label>
       <element-citation id="sbref1660" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Loh
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <name>
          <surname>
           Ng
          </surname>
          <given-names>
           VV
          </given-names>
         </name>
         <name>
          <surname>
           Holton
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        <article-title>
         Bacterial flora on the white coats of medical students
        </article-title>
        <source>
         J Hosp Infect
        </source>
        <volume>
         45
        </volume>
        <year>
         2000
        </year>
        <fpage>
         65
        </fpage>
        <lpage>
         68
        </lpage>
        <pub-id pub-id-type="pmid">
         10833346
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib167">
       <label>
        167
       </label>
       <element-citation id="sbref1670" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hambraeus
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        <article-title>
         Transfer of Staphylococcus aureus via nurses' uniforms
        </article-title>
        <source>
         J Hyg
        </source>
        <volume>
         71
        </volume>
        <year>
         1973
        </year>
        <fpage>
         799
        </fpage>
        <lpage>
         814
        </lpage>
        <pub-id pub-id-type="pmid">
         4520515
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib168">
       <label>
        168
       </label>
       <element-citation id="sbref1680" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Barrie
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Wilson
          </surname>
          <given-names>
           JA
          </given-names>
         </name>
         <name>
          <surname>
           Hoffman
          </surname>
          <given-names>
           PN
          </given-names>
         </name>
         <name>
          <surname>
           Kramer
          </surname>
          <given-names>
           JM
          </given-names>
         </name>
        </person-group>
        <article-title>
         Bacillus cereus meningitis in two neurosurgical patients: an investigation into the source of the organism
        </article-title>
        <source>
         J Infect
        </source>
        <volume>
         25
        </volume>
        <year>
         1992
        </year>
        <fpage>
         291
        </fpage>
        <lpage>
         297
        </lpage>
        <pub-id pub-id-type="pmid">
         1474265
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib169">
       <label>
        169
       </label>
       <element-citation id="sbref1690" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Barrie
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Hoffman
          </surname>
          <given-names>
           PN
          </given-names>
         </name>
         <name>
          <surname>
           Wilson
          </surname>
          <given-names>
           JA
          </given-names>
         </name>
         <name>
          <surname>
           Kramer
          </surname>
          <given-names>
           JM
          </given-names>
         </name>
        </person-group>
        <article-title>
         Contamination of hospital linen by Bacillus cereus
        </article-title>
        <source>
         Epidemiol Infect
        </source>
        <volume>
         113
        </volume>
        <year>
         1994
        </year>
        <fpage>
         297
        </fpage>
        <lpage>
         306
        </lpage>
        <pub-id pub-id-type="pmid">
         7925667
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib170">
       <label>
        170
       </label>
       <element-citation id="sbref1700" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zachary
          </surname>
          <given-names>
           KC
          </given-names>
         </name>
         <name>
          <surname>
           Bayne
          </surname>
          <given-names>
           PS
          </given-names>
         </name>
         <name>
          <surname>
           Morrison
          </surname>
          <given-names>
           VJ
          </given-names>
         </name>
         <name>
          <surname>
           Ford
          </surname>
          <given-names>
           DS
          </given-names>
         </name>
         <name>
          <surname>
           Silver
          </surname>
          <given-names>
           LC
          </given-names>
         </name>
         <name>
          <surname>
           Hooper
          </surname>
          <given-names>
           DC
          </given-names>
         </name>
        </person-group>
        <article-title>
         Contamination of gowns, gloves, and stethoscopes with vancomycin-resistant enterococci
        </article-title>
        <source>
         Infect Control Hosp Epidemiol
        </source>
        <volume>
         22
        </volume>
        <year>
         2001
        </year>
        <fpage>
         560
        </fpage>
        <lpage>
         564
        </lpage>
        <pub-id pub-id-type="pmid">
         11732785
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib171">
       <label>
        171
       </label>
       <element-citation id="sbref1710" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Webster
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Pritchard
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Gowning by attendants and visitors in newborn nurseries for prevention of neonatal morbidity and mortality
        </article-title>
        <source>
         Cochrane Database Syst Rev
        </source>
        <volume>
         3
        </volume>
        <year>
         2003
        </year>
        <comment>
         CD003670.
        </comment>
       </element-citation>
      </ref>
      <ref id="bib172">
       <label>
        172
       </label>
       <element-citation id="sbref1720" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Puzniak
          </surname>
          <given-names>
           LA
          </given-names>
         </name>
         <name>
          <surname>
           Leet
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Mayfield
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Kollef
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Mundy
          </surname>
          <given-names>
           LM
          </given-names>
         </name>
        </person-group>
        <article-title>
         To gown or not to gown: the effect on acquisition of vancomycin-resistant enterococci
        </article-title>
        <source>
         Clin Infect Dis
        </source>
        <volume>
         35
        </volume>
        <year>
         2002
        </year>
        <fpage>
         18
        </fpage>
        <lpage>
         25
        </lpage>
        <pub-id pub-id-type="pmid">
         12060870
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib173">
       <label>
        173
       </label>
       <element-citation id="sbref1730" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Srinivasan
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Song
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <name>
          <surname>
           Ross
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Merz
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <name>
          <surname>
           Brower
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Perl
          </surname>
          <given-names>
           TM
          </given-names>
         </name>
        </person-group>
        <article-title>
         A prospective study to determine whether cover gowns in addition to gloves decrease nosocomial transmission of vancomycin-resistant enterococci in an intensive care unit
        </article-title>
        <source>
         Infect Control Hosp Epidemiol
        </source>
        <volume>
         23
        </volume>
        <year>
         2002
        </year>
        <fpage>
         424
        </fpage>
        <lpage>
         428
        </lpage>
        <pub-id pub-id-type="pmid">
         12186206
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib174">
       <label>
        174
       </label>
       <element-citation id="sbref1740" publication-type="book">
        <person-group person-group-type="author">
         <collab>
          National Collaborating Centre for Chronic Conditions
         </collab>
        </person-group>
        <source>
         Tuberculosis: clinical diagnosis and management of tuberculosis, and measures for its prevention and control
        </source>
        <year>
         2006
        </year>
        <publisher-name>
         Royal College of Physicians
        </publisher-name>
        <publisher-loc>
         London
        </publisher-loc>
       </element-citation>
      </ref>
      <ref id="bib175">
       <label>
        175
       </label>
       <element-citation id="sbref1750" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Department of Health
          </surname>
         </name>
        </person-group>
        <source>
         Pandemic (H1N1) 2009 influenza. A summary of guidance for infection control in healthcare settings
        </source>
        <year>
         2009
        </year>
        <publisher-name>
         Department of Health
        </publisher-name>
        <publisher-loc>
         London
        </publisher-loc>
       </element-citation>
      </ref>
      <ref id="bib176">
       <label>
        176
       </label>
       <element-citation id="sbref1760" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Department of Health
          </surname>
         </name>
        </person-group>
        <source>
         The Interdepartmental Working Group on Tuberculosis: the prevention and control of tuberculosis in the United Kingdom
        </source>
        <year>
         1998
        </year>
        <publisher-name>
         Department of Health
        </publisher-name>
        <publisher-loc>
         London
        </publisher-loc>
       </element-citation>
      </ref>
      <ref id="bib177">
       <label>
        177
       </label>
       <element-citation id="sbref1770" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Health and Safety Executive
          </surname>
         </name>
        </person-group>
        <source>
         Respiratory protective equipment at work: a practical guide
        </source>
        <edition>
         4th ed.
        </edition>
        <year>
         2013
        </year>
        <publisher-name>
         HSE Books
        </publisher-name>
        <publisher-loc>
         London
        </publisher-loc>
        <comment>
         HSG 53.
        </comment>
       </element-citation>
      </ref>
      <ref id="bib178">
       <label>
        178
       </label>
       <element-citation id="sbref1780" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Jefferson
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Del Mar
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Dooley
          </surname>
          <given-names>
           L
          </given-names>
         </name>
        </person-group>
        <article-title>
         Physical interventions to interrupt or reduce the spread of respiratory viruses
        </article-title>
        <source>
         Cochrane Database Syst Rev
        </source>
        <volume>
         1
        </volume>
        <year>
         2010
        </year>
        <comment>
         CD006207.
        </comment>
       </element-citation>
      </ref>
      <ref id="bib179">
       <label>
        179
       </label>
       <element-citation id="sbref1790" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cowling
          </surname>
          <given-names>
           BJ
          </given-names>
         </name>
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Ip
          </surname>
          <given-names>
           DK
          </given-names>
         </name>
         <name>
          <surname>
           Leung
          </surname>
          <given-names>
           GM
          </given-names>
         </name>
         <name>
          <surname>
           Aiello
          </surname>
          <given-names>
           AE
          </given-names>
         </name>
        </person-group>
        <article-title>
         Face masks to prevent transmission of influenza virus: a systematic review
        </article-title>
        <source>
         Epidemiol Infect
        </source>
        <volume>
         138
        </volume>
        <year>
         2010
        </year>
        <fpage>
         449
        </fpage>
        <lpage>
         456
        </lpage>
        <pub-id pub-id-type="pmid">
         20092668
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib180">
       <label>
        180
       </label>
       <element-citation id="sbref1800" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gralton
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           McLaws
          </surname>
          <given-names>
           ML
          </given-names>
         </name>
        </person-group>
        <article-title>
         Protecting healthcare workers from pandemic influenza: N95 or surgical masks?
        </article-title>
        <source>
         Crit Care Med
        </source>
        <volume>
         38
        </volume>
        <year>
         2010
        </year>
        <fpage>
         657
        </fpage>
        <lpage>
         667
        </lpage>
        <pub-id pub-id-type="pmid">
         20095070
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib181">
       <label>
        181
       </label>
       <element-citation id="sbref1810" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bin-Reza
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Lopez Chavarrias
          </surname>
          <given-names>
           V
          </given-names>
         </name>
         <name>
          <surname>
           Nicoll
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Chamberland
          </surname>
          <given-names>
           ME
          </given-names>
         </name>
        </person-group>
        <article-title>
         The use of masks and respirators to prevent transmission of influenza: a systematic review of the scientific evidence
        </article-title>
        <source>
         Influenza Other Respir Viruses
        </source>
        <volume>
         6
        </volume>
        <year>
         2012
        </year>
        <fpage>
         257
        </fpage>
        <lpage>
         267
        </lpage>
        <pub-id pub-id-type="pmid">
         22188875
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib182">
       <label>
        182
       </label>
       <element-citation id="sbref1820" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Health and Safety Commission
          </surname>
         </name>
        </person-group>
        <source>
         Control of Substances Hazardous to Health Regulations. Approved codes of practice
        </source>
        <year>
         1999
        </year>
        <publisher-name>
         HSE Books
        </publisher-name>
        <publisher-loc>
         London
        </publisher-loc>
        <fpage>
         75
        </fpage>
       </element-citation>
      </ref>
      <ref id="bib183">
       <label>
        183
       </label>
       <element-citation id="sbref1830" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Health and Safety Executive
          </surname>
         </name>
        </person-group>
        <source>
         Health and Safety at Work Act 1974
        </source>
        <year>
         1994
        </year>
        <publisher-name>
         HMSO
        </publisher-name>
        <publisher-loc>
         London
        </publisher-loc>
        <ext-link ext-link-type="uri" id="interrefs150" xlink:href="http://www.legislation.gov.uk/ukpga/1974/37/pdfs/ukpga_19740037_en.pdf">
         Available at: http://www.legislation.gov.uk/ukpga/1974/37/pdfs/ukpga_19740037_en.pdf
        </ext-link>
        <comment>
         Accessed August 1, 2013.
        </comment>
       </element-citation>
      </ref>
      <ref id="bib184">
       <label>
        184
       </label>
       <element-citation id="sbref1840" publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           Health and Safety Executive
          </surname>
         </name>
        </person-group>
        <article-title>
         Health and Safety (Sharp Instruments in Healthcare) Regulations 2013. Guidance for employers and employees. Health Services Information Sheet 7
        </article-title>
        <ext-link ext-link-type="uri" id="interrefs160" xlink:href="http://www.hse.gov.uk/pubns/hsis7.htm">
         Available at: www.hse.gov.uk/pubns/hsis7.htm
        </ext-link>
        <year>
         2013
        </year>
        <comment>
         Accessed July 25, 2013.
        </comment>
       </element-citation>
      </ref>
      <ref id="bib185">
       <label>
        185
       </label>
       <element-citation id="sbref1850" publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           Health and Safety Executive
          </surname>
         </name>
        </person-group>
        <article-title>
         The Provision and Use of Work Equipment Regulations
        </article-title>
        <ext-link ext-link-type="uri" id="interrefs170" xlink:href="http://www.hse.gov.uk/work-equipment-machinery/puwer.htm">
         Available at: http://www.hse.gov.uk/work-equipment-machinery/puwer.htm
        </ext-link>
        <year>
         1998
        </year>
        <comment>
         Accessed August 1, 2013.
        </comment>
       </element-citation>
      </ref>
      <ref id="bib186">
       <label>
        186
       </label>
       <element-citation id="sbref1860" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Health and Safety Executive
          </surname>
         </name>
        </person-group>
        <source>
         The Reporting of Injuries, Diseases and Dangerous Occurrences Regulations 1995
        </source>
        <year>
         1995
        </year>
        <publisher-name>
         HSE Books
        </publisher-name>
        <publisher-loc>
         London
        </publisher-loc>
       </element-citation>
      </ref>
      <ref id="bib187">
       <label>
        187
       </label>
       <element-citation id="sbref1870" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Health and Safety Executive
          </surname>
         </name>
        </person-group>
        <source>
         Personal protective equipment at work: Personal Protective Equipment at Work Regulations
        </source>
        <year>
         1992
        </year>
        <publisher-name>
         HMSO
        </publisher-name>
        <publisher-loc>
         London
        </publisher-loc>
       </element-citation>
      </ref>
      <ref id="bib188">
       <label>
        188
       </label>
       <element-citation id="sbref1880" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Health and Safety Executive
          </surname>
         </name>
        </person-group>
        <source>
         The Health and Safety (First-Aid) Regulations 1981. Approved code of practice and guidance
        </source>
        <year>
         1981
        </year>
        <publisher-name>
         HSE Books
        </publisher-name>
        <publisher-loc>
         London
        </publisher-loc>
       </element-citation>
      </ref>
      <ref id="bib189">
       <label>
        189
       </label>
       <element-citation id="sbref1890" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           National Audit Office
          </surname>
         </name>
        </person-group>
        <source>
         A safer place to work: improving the management of health and safety risks to staff in NHS trusts
        </source>
        <year>
         2003
        </year>
        <publisher-name>
         The Stationery Office
        </publisher-name>
        <publisher-loc>
         London
        </publisher-loc>
       </element-citation>
      </ref>
      <ref id="bib190">
       <label>
        190
       </label>
       <element-citation id="sbref1900" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ball
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Pike
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Royal College of Nursing
          </surname>
         </name>
        </person-group>
        <source>
         Needlestick injury in 2008: results from a survey of RCN members
        </source>
        <year>
         2008
        </year>
        <publisher-name>
         Royal College of Nursing
        </publisher-name>
        <publisher-loc>
         London
        </publisher-loc>
       </element-citation>
      </ref>
      <ref id="bib191">
       <label>
        191
       </label>
       <element-citation id="sbref1910" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Health Protection Agency
          </surname>
         </name>
         <name>
          <surname>
           Centre for Infections
          </surname>
         </name>
        </person-group>
        <source>
         Eye of the needle: United Kingdom surveillance of significant occupational exposures to bloodborne viruses in healthcare workers
        </source>
        <year>
         2008
        </year>
        <publisher-name>
         Health Protection Agency
        </publisher-name>
        <publisher-loc>
         London
        </publisher-loc>
       </element-citation>
      </ref>
      <ref id="bib192">
       <label>
        192
       </label>
       <element-citation id="sbref1920" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yazdanpanah
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Domart
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Tarantola
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        <article-title>
         Risk factors for hepatitis C virus transmission to health care workers after occupational exposure: a European case-control study
        </article-title>
        <source>
         Clin Infect Dis
        </source>
        <volume>
         41
        </volume>
        <year>
         2005
        </year>
        <fpage>
         1423
        </fpage>
        <lpage>
         1430
        </lpage>
        <pub-id pub-id-type="pmid">
         16231252
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib193">
       <label>
        193
       </label>
       <element-citation id="sbref1930" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Department of Health
          </surname>
         </name>
        </person-group>
        <source>
         HIV Post-exposure prophylaxis: guidance from the UK Chief Medical Officers' Expert Advisory Group on AIDS
        </source>
        <year>
         2008
        </year>
        <publisher-name>
         Department of Health
        </publisher-name>
        <publisher-loc>
         London
        </publisher-loc>
       </element-citation>
      </ref>
      <ref id="bib194">
       <label>
        194
       </label>
       <element-citation id="sbref1940" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Centers for Disease Control
          </surname>
         </name>
        </person-group>
        <article-title>
         Update. Universal precautions for prevention of transmission of human immunodeficiency virus, hepatitis B virus and other bloodborne pathogens in health care settings
        </article-title>
        <source>
         MMWR
        </source>
        <volume>
         37
        </volume>
        <year>
         1988
        </year>
        <fpage>
         377
        </fpage>
        <lpage>
         382
        </lpage>
        <comment>
         387–388.
        </comment>
        <pub-id pub-id-type="pmid">
         2836717
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib195">
       <label>
        195
       </label>
       <element-citation id="sbref1950" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Occupational Safety and Health Administration
          </surname>
         </name>
        </person-group>
        <source>
         Enforcement procedures for the occupational exposure to bloodborne pathogens. Directive number CPL2–2.44D
        </source>
        <year>
         1999
        </year>
        <publisher-name>
         OSHA
        </publisher-name>
        <publisher-loc>
         Washington DC
        </publisher-loc>
        <ext-link ext-link-type="uri" id="interrefs180" xlink:href="https://www.osha.gov/pls/oshaweb/owadisp.show_document?p_table=DIRECTIVES&amp;p_id=1556">
         Available at: https://www.osha.gov/pls/oshaweb/owadisp.show_document?p_table=DIRECTIVES&amp;p_id=1556
        </ext-link>
        <comment>
         Accessed August 6, 2013.
        </comment>
       </element-citation>
      </ref>
      <ref id="bib196">
       <label>
        196
       </label>
       <element-citation id="sbref1960" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Council Directive 2010/32/EU
          </surname>
         </name>
        </person-group>
        <article-title>
         Implementing the framework agreement on prevention from sharps injuries in the hospital and health care sector. Concluded by HOSPEEM and EPSU
        </article-title>
        <source>
         OJEU
        </source>
        <volume>
         L
        </volume>
        <year>
         2010
        </year>
        <fpage>
         66
        </fpage>
        <lpage>
         72
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib197">
       <label>
        197
       </label>
       <element-citation id="sbref1970" publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           Health and Safety Executive
          </surname>
         </name>
        </person-group>
        <article-title>
         An evaluation of the efficacy of safer sharps devices. Systematic review
        </article-title>
        <ext-link ext-link-type="uri" id="interrefs190" xlink:href="http://www.hse.gov.uk/research/rrpdf/rr914.pdf">
         Available at: http://www.hse.gov.uk/research/rrpdf/rr914.pdf
        </ext-link>
        <year>
         2012
        </year>
        <comment>
         Accessed July 25, 2013.
        </comment>
       </element-citation>
      </ref>
      <ref id="bib198">
       <label>
        198
       </label>
       <element-citation id="sbref1980" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Brusaferro
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Calligaris
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Farneti
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Gubian
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Londero
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Baldo
          </surname>
          <given-names>
           V
          </given-names>
         </name>
        </person-group>
        <article-title>
         Educational programmes and sharps injuries in health care workers
        </article-title>
        <source>
         Occup Med (Lond)
        </source>
        <volume>
         59
        </volume>
        <year>
         2009
        </year>
        <fpage>
         512
        </fpage>
        <lpage>
         514
        </lpage>
        <pub-id pub-id-type="pmid">
         19706644
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib199">
       <label>
        199
       </label>
       <element-citation id="sbref1990" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Valls
          </surname>
          <given-names>
           V
          </given-names>
         </name>
         <name>
          <surname>
           Lozano
          </surname>
          <given-names>
           MS
          </given-names>
         </name>
         <name>
          <surname>
           Yánez
          </surname>
          <given-names>
           R
          </given-names>
         </name>
        </person-group>
        <article-title>
         Use of safety devices and the prevention of percutaneous injuries among healthcare workers
        </article-title>
        <source>
         Infect Control Hosp Epidemiol
        </source>
        <volume>
         28
        </volume>
        <year>
         2007
        </year>
        <fpage>
         1352
        </fpage>
        <lpage>
         1360
        </lpage>
        <pub-id pub-id-type="pmid">
         17994515
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib200">
       <label>
        200
       </label>
       <element-citation id="sbref2000" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Adams
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Elliott
          </surname>
          <given-names>
           TSJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         Impact of safety needle devices on occupationally acquired needlestick injuries: a four-year prospective study
        </article-title>
        <source>
         J Hosp Infect
        </source>
        <volume>
         64
        </volume>
        <year>
         2006
        </year>
        <fpage>
         50
        </fpage>
        <lpage>
         55
        </lpage>
        <pub-id pub-id-type="pmid">
         16822584
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib201">
       <label>
        201
       </label>
       <element-citation id="sbref2010" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zakrzewska
          </surname>
          <given-names>
           JM
          </given-names>
         </name>
         <name>
          <surname>
           Greenwood
          </surname>
          <given-names>
           I
          </given-names>
         </name>
         <name>
          <surname>
           Jackson
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        <article-title>
         Introducing safety syringes into a UK dental school – a controlled study
        </article-title>
        <source>
         Br Dent J
        </source>
        <volume>
         190
        </volume>
        <year>
         2001
        </year>
        <fpage>
         88
        </fpage>
        <lpage>
         92
        </lpage>
        <pub-id pub-id-type="pmid">
         11213339
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib202">
       <label>
        202
       </label>
       <element-citation id="sbref2020" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Liou
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           C
          </given-names>
         </name>
        </person-group>
        <article-title>
         The effectiveness of a training program on reducing needlestick injuries/sharp object injuries among soon graduate vocational nursing school students in Southern Taiwan
        </article-title>
        <source>
         J Occup Health
        </source>
        <volume>
         49
        </volume>
        <year>
         2007
        </year>
        <fpage>
         424
        </fpage>
        <lpage>
         429
        </lpage>
        <pub-id pub-id-type="pmid">
         17951977
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib203">
       <label>
        203
       </label>
       <element-citation id="sbref2030" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Department of Health
          </surname>
         </name>
        </person-group>
        <source>
         An organisation with a memory
        </source>
        <year>
         2000
        </year>
        <publisher-name>
         Stationery Office
        </publisher-name>
        <publisher-loc>
         London
        </publisher-loc>
       </element-citation>
      </ref>
      <ref id="bib204">
       <label>
        204
       </label>
       <element-citation id="sbref2040" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           National Health Service Employees
          </surname>
         </name>
        </person-group>
        <source>
         The management of health safety and welfare: issues for NHS staff
        </source>
        <year>
         2005
        </year>
        <publisher-name>
         Stationery Office
        </publisher-name>
        <publisher-loc>
         London
        </publisher-loc>
       </element-citation>
      </ref>
      <ref id="bib205">
       <label>
        205
       </label>
       <element-citation id="sbref2050" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           ECRI Institute
          </surname>
         </name>
        </person-group>
        <source>
         Sharps safety and needlestick prevention
        </source>
        <edition>
         2nd ed.
        </edition>
        <year>
         2003
        </year>
        <publisher-name>
         ECRI
        </publisher-name>
        <publisher-loc>
         Plymouth
        </publisher-loc>
       </element-citation>
      </ref>
      <ref id="bib206">
       <label>
        206
       </label>
       <element-citation id="sbref2060" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Asai
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Hidaka
          </surname>
          <given-names>
           I
          </given-names>
         </name>
         <name>
          <surname>
           Kawashima
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Miki
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Inada
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Kawachi
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        <article-title>
         Efficacy of catheter needles with safeguard mechanisms
        </article-title>
        <source>
         Anaesthesia
        </source>
        <volume>
         57
        </volume>
        <year>
         2002
        </year>
        <fpage>
         572
        </fpage>
        <lpage>
         577
        </lpage>
        <pub-id pub-id-type="pmid">
         12010273
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib207">
       <label>
        207
       </label>
       <element-citation id="sbref2070" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sohn
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Eagan
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Sepkowitz
          </surname>
          <given-names>
           KA
          </given-names>
         </name>
         <name>
          <surname>
           Zuccotti
          </surname>
          <given-names>
           G
          </given-names>
         </name>
        </person-group>
        <article-title>
         Effect of implementing safety-engineered devices on percutaneous injury epidemiology
        </article-title>
        <source>
         Infect Control Hosp Epidemiol
        </source>
        <volume>
         25
        </volume>
        <year>
         2004
        </year>
        <fpage>
         536
        </fpage>
        <lpage>
         542
        </lpage>
        <pub-id pub-id-type="pmid">
         15301024
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib208">
       <label>
        208
       </label>
       <element-citation id="sbref2080" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Alvarado-Ramy
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Solomon
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Fahrner
          </surname>
          <given-names>
           R
          </given-names>
         </name>
        </person-group>
        <article-title>
         A comprehensive approach to percutaneous injury prevention during phlebotomy: results of a multicenter study, 1993–1995
        </article-title>
        <source>
         Infect Control Hosp Epidemiol
        </source>
        <volume>
         24
        </volume>
        <year>
         2003
        </year>
        <fpage>
         97
        </fpage>
        <lpage>
         104
        </lpage>
        <pub-id pub-id-type="pmid">
         12602691
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib209">
       <label>
        209
       </label>
       <element-citation id="sbref2090" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rogues
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Verdun-Esquer
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Buisson-Valles
          </surname>
          <given-names>
           I
          </given-names>
         </name>
        </person-group>
        <article-title>
         Impact of safety devices for preventing percutaneous injuries related to phlebotomy procedures in health care workers
        </article-title>
        <source>
         Am J Infect Control
        </source>
        <volume>
         32
        </volume>
        <year>
         2004
        </year>
        <fpage>
         441
        </fpage>
        <lpage>
         444
        </lpage>
        <pub-id pub-id-type="pmid">
         15573049
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib210">
       <label>
        210
       </label>
       <element-citation id="sbref2100" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Mendelson
          </surname>
          <given-names>
           MH
          </given-names>
         </name>
         <name>
          <surname>
           Lin-Chen
          </surname>
          <given-names>
           BY
          </given-names>
         </name>
         <name>
          <surname>
           Solomon
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Bailey
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Kogan
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Goldbold
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        <article-title>
         Evaluation of a safety resheathable winged steel needle for prevention of percutaneous injuries associated with intravascular-access procedures among healthcare workers
        </article-title>
        <source>
         Infect Control Hosp Epidemiol
        </source>
        <volume>
         24
        </volume>
        <year>
         2003
        </year>
        <fpage>
         105
        </fpage>
        <lpage>
         112
        </lpage>
        <pub-id pub-id-type="pmid">
         12602692
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib211">
       <label>
        211
       </label>
       <element-citation id="sbref2110" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Adams
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Elliott
          </surname>
          <given-names>
           TSJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         A comparative user evaluation of three needle-protective devices
        </article-title>
        <source>
         Br J Nurs
        </source>
        <volume>
         12
        </volume>
        <year>
         2003
        </year>
        <fpage>
         470
        </fpage>
        <lpage>
         474
        </lpage>
        <pub-id pub-id-type="pmid">
         12743476
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib212">
       <label>
        212
       </label>
       <element-citation id="sbref2120" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cullen
          </surname>
          <given-names>
           BL
          </given-names>
         </name>
         <name>
          <surname>
           Genasi
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Symington
          </surname>
          <given-names>
           I
          </given-names>
         </name>
        </person-group>
        <article-title>
         Potential for reported needlestick injury prevention among healthcare workers through safety device usage and improvement of guideline adherence: expert panel assessment
        </article-title>
        <source>
         J Hosp Infect
        </source>
        <volume>
         63
        </volume>
        <year>
         2006
        </year>
        <fpage>
         445
        </fpage>
        <lpage>
         451
        </lpage>
        <pub-id pub-id-type="pmid">
         16777264
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib213">
       <label>
        213
       </label>
       <element-citation id="sbref2130" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Centers for Disease Control
          </surname>
         </name>
        </person-group>
        <article-title>
         Evaluation of safety devices for preventing percutaneous injuries among health care workers during phlebotomy procedures – Minneapolis-St Paul, New York City and San Francisco, 1993–1995
        </article-title>
        <source>
         MMWR
        </source>
        <volume>
         46
        </volume>
        <year>
         1997
        </year>
        <fpage>
         21
        </fpage>
        <lpage>
         25
        </lpage>
        <pub-id pub-id-type="pmid">
         9011778
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib214">
       <label>
        214
       </label>
       <element-citation id="sbref2140" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sullivan
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Williamson
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Wilson
          </surname>
          <given-names>
           LK
          </given-names>
         </name>
         <name>
          <surname>
           Korte
          </surname>
          <given-names>
           JE
          </given-names>
         </name>
         <name>
          <surname>
           Soper
          </surname>
          <given-names>
           D
          </given-names>
         </name>
        </person-group>
        <article-title>
         Blunt needles for the reduction of needlestick injuries during cesarean delivery: a randomized controlled trial
        </article-title>
        <source>
         Obstet Gynecol
        </source>
        <volume>
         114
        </volume>
        <year>
         2009
        </year>
        <fpage>
         211
        </fpage>
        <pub-id pub-id-type="pmid">
         19622979
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib215">
       <label>
        215
       </label>
       <element-citation id="sbref2150" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hotaling
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <article-title>
         A retractable winged steel (butterfly) needle performance improvement project
        </article-title>
        <source>
         Jt Comm J Qual Patient Saf
        </source>
        <volume>
         35
        </volume>
        <year>
         2009
        </year>
        <fpage>
         100
        </fpage>
        <lpage>
         105
        </lpage>
        <pub-id pub-id-type="pmid">
         19241730
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib216">
       <label>
        216
       </label>
       <element-citation id="sbref2160" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lamontagne
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Abiteboul
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Lolom
          </surname>
          <given-names>
           I
          </given-names>
         </name>
        </person-group>
        <article-title>
         Role of safety-engineered devices in preventing needlestick injuries in 32 French hospitals
        </article-title>
        <source>
         Infect Control Hosp Epidemiol
        </source>
        <volume>
         28
        </volume>
        <year>
         2007
        </year>
        <fpage>
         18
        </fpage>
        <lpage>
         23
        </lpage>
        <pub-id pub-id-type="pmid">
         17230383
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib217">
       <label>
        217
       </label>
       <element-citation id="sbref2170" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Azar-Cavanagh
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Burdt
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Green-McKenzie
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        <article-title>
         Effect of the introduction of an engineered sharps injury prevention device on the percutaneous injury rate in healthcare workers
        </article-title>
        <source>
         Infect Control Hosp Epidemiol
        </source>
        <volume>
         28
        </volume>
        <year>
         2007
        </year>
        <fpage>
         165
        </fpage>
        <lpage>
         170
        </lpage>
        <pub-id pub-id-type="pmid">
         17265397
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib218">
       <label>
        218
       </label>
       <element-citation id="sbref2180" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sohn
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Eagan
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Sepkowitz
          </surname>
          <given-names>
           KA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Safety-engineered device implementation: does it introduce bias in percutaneous injury reporting?
        </article-title>
        <source>
         Infect Control Hosp Epidemiol
        </source>
        <volume>
         25
        </volume>
        <year>
         2004
        </year>
        <fpage>
         543
        </fpage>
        <lpage>
         547
        </lpage>
        <pub-id pub-id-type="pmid">
         15301025
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib219">
       <label>
        219
       </label>
       <element-citation id="sbref2190" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           McCleary
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Caldero
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Adams
          </surname>
          <given-names>
           T
          </given-names>
         </name>
        </person-group>
        <article-title>
         Guarded fistula needle reduces needlestick injuries in hemodialysis
        </article-title>
        <source>
         Nephrol News Issues
        </source>
        <volume>
         16
        </volume>
        <year>
         2002
        </year>
        <fpage>
         66
        </fpage>
        <lpage>
         70
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib220">
       <label>
        220
       </label>
       <element-citation id="sbref2200" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rogers
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Goodno
          </surname>
          <given-names>
           L
          </given-names>
         </name>
        </person-group>
        <article-title>
         Evaluation of interventions to prevent needlestick injuries in health care occupations
        </article-title>
        <source>
         Am J Prev Med
        </source>
        <volume>
         18
        </volume>
        <year>
         2000
        </year>
        <fpage>
         90
        </fpage>
        <lpage>
         98
        </lpage>
        <pub-id pub-id-type="pmid">
         10793285
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib221">
       <label>
        221
       </label>
       <element-citation id="sbref2210" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Reddy
          </surname>
          <given-names>
           SG
          </given-names>
         </name>
         <name>
          <surname>
           Emery
          </surname>
          <given-names>
           RJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         Assessing the effect of long-term availability of engineering controls on needlestick injuries among health care workers: a 3-year preimplementation and postimplementation comparison
        </article-title>
        <source>
         Am J Infect Control
        </source>
        <volume>
         29
        </volume>
        <year>
         2001
        </year>
        <fpage>
         425
        </fpage>
        <lpage>
         427
        </lpage>
        <pub-id pub-id-type="pmid">
         11743491
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib222">
       <label>
        222
       </label>
       <element-citation id="sbref2220" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Prunet
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Meaudre
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Montcriol
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        <article-title>
         A prospective randomized trial of two safety peripheral intravenous catheters
        </article-title>
        <source>
         Anesth Analg
        </source>
        <volume>
         107
        </volume>
        <year>
         2008
        </year>
        <fpage>
         155
        </fpage>
        <lpage>
         158
        </lpage>
        <pub-id pub-id-type="pmid">
         18635482
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib223">
       <label>
        223
       </label>
       <element-citation id="sbref2230" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bamberg
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Rivers
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Moore
          </surname>
          <given-names>
           C
          </given-names>
         </name>
        </person-group>
        <article-title>
         Use of needle safety devices by clinical laboratories in North Carolina hospitals
        </article-title>
        <source>
         Clin Leadersh Manag Rev
        </source>
        <volume>
         17
        </volume>
        <year>
         2003
        </year>
        <fpage>
         21
        </fpage>
        <lpage>
         25
        </lpage>
        <pub-id pub-id-type="pmid">
         12592873
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib224">
       <label>
        224
       </label>
       <element-citation id="sbref2240" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Casey
          </surname>
          <given-names>
           AL
          </given-names>
         </name>
         <name>
          <surname>
           Elliott
          </surname>
          <given-names>
           TS
          </given-names>
         </name>
        </person-group>
        <article-title>
         The usability and acceptability of a needleless connector system
        </article-title>
        <source>
         Br J Nurs
        </source>
        <volume>
         16
        </volume>
        <year>
         2007
        </year>
        <fpage>
         267
        </fpage>
        <lpage>
         271
        </lpage>
        <pub-id pub-id-type="pmid">
         17505370
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib225">
       <label>
        225
       </label>
       <element-citation id="sbref2250" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Clarke
          </surname>
          <given-names>
           SP
          </given-names>
         </name>
         <name>
          <surname>
           Rockett
          </surname>
          <given-names>
           JL
          </given-names>
         </name>
         <name>
          <surname>
           Sloane
          </surname>
          <given-names>
           DM
          </given-names>
         </name>
         <name>
          <surname>
           Aiken
          </surname>
          <given-names>
           LH
          </given-names>
         </name>
        </person-group>
        <article-title>
         Organizational climate, staffing, and safety equipment as predictors of needlestick injuries and near-misses in hospital nurses
        </article-title>
        <source>
         Am J Infect Control
        </source>
        <volume>
         30
        </volume>
        <year>
         2002
        </year>
        <fpage>
         207
        </fpage>
        <lpage>
         216
        </lpage>
        <pub-id pub-id-type="pmid">
         12032495
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib226">
       <label>
        226
       </label>
       <element-citation id="sbref2260" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           National Institute for Occupational Safety and Health
          </surname>
         </name>
        </person-group>
        <source>
         Preventing needlestick injuries in health care settings
        </source>
        <year>
         1999
        </year>
        <publisher-name>
         Department of Health and Human Services
        </publisher-name>
        <publisher-loc>
         Cincinnati
        </publisher-loc>
       </element-citation>
      </ref>
      <ref id="bib227">
       <label>
        227
       </label>
       <element-citation id="sbref2270" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wilson
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        <source>
         Infection control in clinical practices
        </source>
        <year>
         2006
        </year>
        <publisher-name>
         Bailliere Tindall
        </publisher-name>
        <publisher-loc>
         London
        </publisher-loc>
       </element-citation>
      </ref>
      <ref id="bib228">
       <label>
        228
       </label>
       <element-citation id="sbref2280" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cherry
          </surname>
          <given-names>
           MG
          </given-names>
         </name>
         <name>
          <surname>
           Brown
          </surname>
          <given-names>
           JM
          </given-names>
         </name>
         <name>
          <surname>
           Neal
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Ben Shaw
          </surname>
          <given-names>
           N
          </given-names>
         </name>
        </person-group>
        <article-title>
         What features of educational interventions lead to competence in aseptic insertion and maintenance of CV catheters in acute care? BEME Guide No. 15
        </article-title>
        <source>
         Med Teach
        </source>
        <volume>
         32
        </volume>
        <year>
         2010
        </year>
        <fpage>
         198
        </fpage>
        <comment>
         198
        </comment>
        <pub-id pub-id-type="pmid">
         20218835
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib229">
       <label>
        229
       </label>
       <element-citation id="sbref2290" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rowley
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Clare
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Macqueen
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Molyneux
          </surname>
          <given-names>
           R
          </given-names>
         </name>
        </person-group>
        <article-title>
         ANTT v2: an updated practice framework for aseptic technique
        </article-title>
        <source>
         Br J Nurs
        </source>
        <volume>
         19
        </volume>
        <issue>
         Suppl.
        </issue>
        <year>
         2010
        </year>
        <fpage>
         S5
        </fpage>
        <lpage>
         S11
        </lpage>
        <pub-id pub-id-type="pmid">
         20622767
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib230">
       <label>
        230
       </label>
       <element-citation id="sbref2300" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gould
          </surname>
          <given-names>
           CV
          </given-names>
         </name>
         <name>
          <surname>
           Umscheid
          </surname>
          <given-names>
           CA
          </given-names>
         </name>
         <name>
          <surname>
           Agarwal
          </surname>
          <given-names>
           RK
          </given-names>
         </name>
         <name>
          <surname>
           Kuntz
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Pegues
          </surname>
          <given-names>
           DA
          </given-names>
         </name>
         <name>
          <surname>
           Healthcare Infection Control Practices Advisory Committee
          </surname>
         </name>
        </person-group>
        <article-title>
         Guideline for prevention of catheter-associated urinary tract infections
        </article-title>
        <source>
         Infect Control Hosp Epidemiol
        </source>
        <volume>
         31
        </volume>
        <year>
         2010
        </year>
        <fpage>
         319
        </fpage>
        <lpage>
         326
        </lpage>
        <pub-id pub-id-type="pmid">
         20156062
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib231">
       <label>
        231
       </label>
       <element-citation id="sbref2310" publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           Health Protection Agency
          </surname>
         </name>
        </person-group>
        <article-title>
         English national point prevalence survey on healthcare associated infections and antimicrobial use, 2011: preliminary data
        </article-title>
        <ext-link ext-link-type="uri" id="interrefs200" xlink:href="http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1317134305239">
         Available at: http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1317134305239
        </ext-link>
        <year>
         2012
        </year>
        <comment>
         Accessed July 25, 2013.
        </comment>
       </element-citation>
      </ref>
      <ref id="bib232">
       <label>
        232
       </label>
       <element-citation id="sbref2320" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Smyth
          </surname>
          <given-names>
           ETM
          </given-names>
         </name>
         <name>
          <surname>
           McIlvenny
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Enstone
          </surname>
          <given-names>
           JE
          </given-names>
         </name>
        </person-group>
        <article-title>
         Four country healthcare associated infection prevalence survey 2006: overview of the results
        </article-title>
        <source>
         J Hosp Infect
        </source>
        <volume>
         69
        </volume>
        <year>
         2008
        </year>
        <fpage>
         230
        </fpage>
        <lpage>
         248
        </lpage>
        <pub-id pub-id-type="pmid">
         18550218
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib233">
       <label>
        233
       </label>
       <element-citation id="sbref2330" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Department of Health
          </surname>
         </name>
        </person-group>
        <source>
         Urinary catheter care. Essential steps to safe, clean care: reducing healthcare associated infections
        </source>
        <year>
         2006
        </year>
        <publisher-name>
         Department of Health
        </publisher-name>
        <publisher-loc>
         London
        </publisher-loc>
       </element-citation>
      </ref>
      <ref id="bib234">
       <label>
        234
       </label>
       <element-citation id="sbref2340" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chenoweth
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Saint
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        <article-title>
         Preventing catheter-associated urinary tract infections in the intensive care unit
        </article-title>
        <source>
         Crit Care Clin
        </source>
        <volume>
         29
        </volume>
        <year>
         2013
        </year>
        <fpage>
         19
        </fpage>
        <lpage>
         32
        </lpage>
        <pub-id pub-id-type="pmid">
         23182525
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib235">
       <label>
        235
       </label>
       <element-citation id="sbref2350" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Johnson
          </surname>
          <given-names>
           JR
          </given-names>
         </name>
         <name>
          <surname>
           Kuskowski
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
         <name>
          <surname>
           Wilt
          </surname>
          <given-names>
           TJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         Systematic review: antimicrobial urinary catheters to prevent catheter-associated urinary tract infection in hospitalized patients
        </article-title>
        <source>
         Ann Intern Med
        </source>
        <volume>
         144
        </volume>
        <year>
         2006
        </year>
        <fpage>
         116
        </fpage>
        <lpage>
         126
        </lpage>
        <pub-id pub-id-type="pmid">
         16418411
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib236">
       <label>
        236
       </label>
       <element-citation id="sbref2360" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Warren
          </surname>
          <given-names>
           JW
          </given-names>
         </name>
         <name>
          <surname>
           Tenney
          </surname>
          <given-names>
           JH
          </given-names>
         </name>
         <name>
          <surname>
           Hoopes
          </surname>
          <given-names>
           JM
          </given-names>
         </name>
         <name>
          <surname>
           Muncie
          </surname>
          <given-names>
           HL
          </given-names>
         </name>
         <name>
          <surname>
           Anthony
          </surname>
          <given-names>
           WC
          </given-names>
         </name>
        </person-group>
        <article-title>
         A prospective microbiologic study of bacteriuria in patients with chronic indwelling urethral catheters
        </article-title>
        <source>
         J Infect Dis
        </source>
        <volume>
         146
        </volume>
        <year>
         1982
        </year>
        <fpage>
         719
        </fpage>
        <lpage>
         723
        </lpage>
        <pub-id pub-id-type="pmid">
         6815281
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib237">
       <label>
        237
       </label>
       <element-citation id="sbref2370" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Warren
          </surname>
          <given-names>
           JW
          </given-names>
         </name>
        </person-group>
        <article-title>
         Catheter-associated urinary tract infections
        </article-title>
        <source>
         Int J Antimicrob Agents
        </source>
        <volume>
         17
        </volume>
        <year>
         2001
        </year>
        <fpage>
         299
        </fpage>
        <lpage>
         303
        </lpage>
        <pub-id pub-id-type="pmid">
         11295412
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib238">
       <label>
        238
       </label>
       <element-citation id="sbref2380" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Saint
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Wiese
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Amory
          </surname>
          <given-names>
           JK
          </given-names>
         </name>
        </person-group>
        <article-title>
         Are physicians aware of which of their patients have indwelling urinary catheters?
        </article-title>
        <source>
         Am J Med
        </source>
        <volume>
         109
        </volume>
        <year>
         2000
        </year>
        <fpage>
         476
        </fpage>
        <lpage>
         480
        </lpage>
        <pub-id pub-id-type="pmid">
         11042237
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib239">
       <label>
        239
       </label>
       <element-citation id="sbref2390" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Munasinghe
          </surname>
          <given-names>
           RL
          </given-names>
         </name>
         <name>
          <surname>
           Yazdani
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Siddique
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Hafeez
          </surname>
          <given-names>
           W
          </given-names>
         </name>
        </person-group>
        <article-title>
         Appropriateness of use of indwelling urinary catheters in patients admitted to the medical service
        </article-title>
        <source>
         Infect Control Hosp Epidemiol
        </source>
        <volume>
         22
        </volume>
        <year>
         2001
        </year>
        <fpage>
         647
        </fpage>
        <lpage>
         649
        </lpage>
        <pub-id pub-id-type="pmid">
         11776352
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib240">
       <label>
        240
       </label>
       <element-citation id="sbref2400" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Jain
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Parada
          </surname>
          <given-names>
           JP
          </given-names>
         </name>
         <name>
          <surname>
           David
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Smith
          </surname>
          <given-names>
           LG
          </given-names>
         </name>
        </person-group>
        <article-title>
         Overuse of the indwelling urinary tract catheter in hospitalized medical patients
        </article-title>
        <source>
         Arch Intern Med
        </source>
        <volume>
         155
        </volume>
        <year>
         1995
        </year>
        <fpage>
         1425
        </fpage>
        <lpage>
         1429
        </lpage>
        <pub-id pub-id-type="pmid">
         7794092
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib241">
       <label>
        241
       </label>
       <element-citation id="sbref2410" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Burton
          </surname>
          <given-names>
           DC
          </given-names>
         </name>
         <name>
          <surname>
           Edwards
          </surname>
          <given-names>
           JR
          </given-names>
         </name>
         <name>
          <surname>
           Srinivasan
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Fridkin
          </surname>
          <given-names>
           SK
          </given-names>
         </name>
         <name>
          <surname>
           Gould
          </surname>
          <given-names>
           CV
          </given-names>
         </name>
        </person-group>
        <article-title>
         Trends in catheter-associated urinary tract infections in adult intensive care units – United States, 1990–2007
        </article-title>
        <source>
         Infect Control Hosp Epidemiol
        </source>
        <volume>
         32
        </volume>
        <year>
         2011
        </year>
        <fpage>
         748
        </fpage>
        <lpage>
         756
        </lpage>
        <pub-id pub-id-type="pmid">
         21768757
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib242">
       <label>
        242
       </label>
       <element-citation id="sbref2420" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Saint
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        <article-title>
         Clinical and economic consequences of nosocomial catheter-related bacteriuria
        </article-title>
        <source>
         Am J Infect Control
        </source>
        <volume>
         28
        </volume>
        <year>
         2000
        </year>
        <fpage>
         68
        </fpage>
        <lpage>
         75
        </lpage>
        <pub-id pub-id-type="pmid">
         10679141
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib243">
       <label>
        243
       </label>
       <element-citation id="sbref2430" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Shuman
          </surname>
          <given-names>
           EK
          </given-names>
         </name>
         <name>
          <surname>
           Chenoweth
          </surname>
          <given-names>
           CE
          </given-names>
         </name>
        </person-group>
        <article-title>
         Recognition and prevention of healthcare-associated urinary tract infections in the intensive care unit
        </article-title>
        <source>
         Crit Care Med
        </source>
        <volume>
         38
        </volume>
        <issue>
         Suppl.
        </issue>
        <year>
         2010
        </year>
        <fpage>
         S373
        </fpage>
        <lpage>
         S379
        </lpage>
        <pub-id pub-id-type="pmid">
         20647795
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib244">
       <label>
        244
       </label>
       <element-citation id="sbref2440" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chang
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Todd Greene
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Chenoweth
          </surname>
          <given-names>
           CE
          </given-names>
         </name>
        </person-group>
        <article-title>
         Epidemiology of hospital-acquired urinary tract-related bloodstream infection at a university hospital
        </article-title>
        <source>
         Infect Control Hosp Epidemiol
        </source>
        <volume>
         32
        </volume>
        <year>
         2011
        </year>
        <fpage>
         1127
        </fpage>
        <lpage>
         1129
        </lpage>
        <pub-id pub-id-type="pmid">
         22011543
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib245">
       <label>
        245
       </label>
       <element-citation id="sbref2450" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Beattie
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Taylor
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        <article-title>
         Silver alloy vs. uncoated urinary catheters: a systematic review of the literature
        </article-title>
        <source>
         J Clin Nurs
        </source>
        <volume>
         20
        </volume>
        <year>
         2011
        </year>
        <fpage>
         2098
        </fpage>
        <lpage>
         2108
        </lpage>
        <pub-id pub-id-type="pmid">
         21418360
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib246">
       <label>
        246
       </label>
       <element-citation id="sbref2460" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ha
          </surname>
          <given-names>
           U
          </given-names>
         </name>
         <name>
          <surname>
           Cho
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
        </person-group>
        <article-title>
         Catheter-associated urinary tract infections: new aspects of novel urinary catheters
        </article-title>
        <source>
         Int J Antimicrob Agents
        </source>
        <volume>
         28
        </volume>
        <year>
         2006
        </year>
        <fpage>
         485
        </fpage>
        <lpage>
         490
        </lpage>
        <pub-id pub-id-type="pmid">
         17045784
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib247">
       <label>
        247
       </label>
       <element-citation id="sbref2470" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bernard
          </surname>
          <given-names>
           MS
          </given-names>
         </name>
         <name>
          <surname>
           Hunter
          </surname>
          <given-names>
           KF
          </given-names>
         </name>
         <name>
          <surname>
           Moore
          </surname>
          <given-names>
           KN
          </given-names>
         </name>
        </person-group>
        <article-title>
         A review of strategies to decrease the duration of indwelling urethral catheters and potentially reduce the incidence of catheter-associated urinary tract infections
        </article-title>
        <source>
         Urol Nurs
        </source>
        <volume>
         32
        </volume>
        <year>
         2012
        </year>
        <fpage>
         29
        </fpage>
        <lpage>
         37
        </lpage>
        <pub-id pub-id-type="pmid">
         22474863
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib248">
       <label>
        248
       </label>
       <element-citation id="sbref2480" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Saint
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Savel
          </surname>
          <given-names>
           RH
          </given-names>
         </name>
         <name>
          <surname>
           Matthay
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Enhancing the safety of critically ill patients by reducing urinary and central venous catheter-related infections
        </article-title>
        <source>
         Am J Respir Crit Care Med
        </source>
        <volume>
         165
        </volume>
        <year>
         2002
        </year>
        <fpage>
         1475
        </fpage>
        <lpage>
         1479
        </lpage>
        <pub-id pub-id-type="pmid">
         12045119
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib249">
       <label>
        249
       </label>
       <element-citation id="sbref2490" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Talja
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Korpela
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Jarvi
          </surname>
          <given-names>
           K
          </given-names>
         </name>
        </person-group>
        <article-title>
         Comparison of urethral reaction to full silicone, hydrogen-coated and siliconised latex catheters
        </article-title>
        <source>
         Br J Urol
        </source>
        <volume>
         66
        </volume>
        <year>
         1990
        </year>
        <fpage>
         652
        </fpage>
        <lpage>
         657
        </lpage>
        <pub-id pub-id-type="pmid">
         2265339
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib250">
       <label>
        250
       </label>
       <element-citation id="sbref2500" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Robertson
          </surname>
          <given-names>
           GS
          </given-names>
         </name>
         <name>
          <surname>
           Everitt
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Burton
          </surname>
          <given-names>
           PR
          </given-names>
         </name>
         <name>
          <surname>
           Flynn
          </surname>
          <given-names>
           JT
          </given-names>
         </name>
        </person-group>
        <article-title>
         Effect of catheter material on the incidence of urethral strictures
        </article-title>
        <source>
         Br J Urol
        </source>
        <volume>
         68
        </volume>
        <year>
         1991
        </year>
        <fpage>
         612
        </fpage>
        <lpage>
         617
        </lpage>
        <pub-id pub-id-type="pmid">
         1773292
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib251">
       <label>
        251
       </label>
       <element-citation id="sbref2510" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Crowe
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Clift
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Duggan
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Bolton
          </surname>
          <given-names>
           DM
          </given-names>
         </name>
         <name>
          <surname>
           Costello
          </surname>
          <given-names>
           AJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         Randomised study of the effect of midnight versus 0600 removal of urinary catheters
        </article-title>
        <source>
         Br J Urol
        </source>
        <volume>
         71
        </volume>
        <year>
         1993
        </year>
        <fpage>
         306
        </fpage>
        <lpage>
         308
        </lpage>
        <pub-id pub-id-type="pmid">
         8477316
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib252">
       <label>
        252
       </label>
       <element-citation id="sbref2520" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hazelett
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Tsai
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Gareri
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Allen
          </surname>
          <given-names>
           K
          </given-names>
         </name>
        </person-group>
        <article-title>
         The association between indwelling urinary catheter use in the elderly and urinary tract infection in acute care
        </article-title>
        <source>
         BMC Geriatr
        </source>
        <volume>
         6
        </volume>
        <year>
         2006
        </year>
        <fpage>
         15
        </fpage>
        <pub-id pub-id-type="pmid">
         17038177
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib253">
       <label>
        253
       </label>
       <element-citation id="sbref2530" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Curran
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Murdoch
          </surname>
          <given-names>
           H
          </given-names>
         </name>
        </person-group>
        <article-title>
         Aiming to reduce catheter associated urinary tract infections (CAUTI) by adopting a checklist and bundle to achieve sustained system improvements
        </article-title>
        <source>
         J Infect Prev
        </source>
        <volume>
         10
        </volume>
        <year>
         2009
        </year>
        <fpage>
         57
        </fpage>
        <lpage>
         61
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib254">
       <label>
        254
       </label>
       <element-citation id="sbref2540" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Davenport
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Keeley
          </surname>
          <given-names>
           FX
          </given-names>
         </name>
        </person-group>
        <article-title>
         Evidence for the use of silver-alloy-coated urethral catheters
        </article-title>
        <source>
         J Hosp Infect
        </source>
        <volume>
         60
        </volume>
        <year>
         2005
        </year>
        <fpage>
         298
        </fpage>
        <lpage>
         303
        </lpage>
        <pub-id pub-id-type="pmid">
         15936115
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib255">
       <label>
        255
       </label>
       <element-citation id="sbref2550" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ward
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Fenton
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Maher
          </surname>
          <given-names>
           L
          </given-names>
         </name>
        </person-group>
        <article-title>
         The high impact actions for nursing and midwifery 5: protection from infection
        </article-title>
        <source>
         Nurs Times
        </source>
        <volume>
         106
        </volume>
        <year>
         2010
        </year>
        <fpage>
         20
        </fpage>
        <lpage>
         21
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib256">
       <label>
        256
       </label>
       <element-citation id="sbref2560" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Saint
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Lipsky
          </surname>
          <given-names>
           BA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Preventing catheter-related bacteriuria: should we? Can we? How?
        </article-title>
        <source>
         Arch Intern Med
        </source>
        <volume>
         159
        </volume>
        <year>
         1999
        </year>
        <fpage>
         800
        </fpage>
        <lpage>
         808
        </lpage>
        <pub-id pub-id-type="pmid">
         10219925
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib257">
       <label>
        257
       </label>
       <element-citation id="sbref2570" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Foxman
          </surname>
          <given-names>
           B
          </given-names>
         </name>
        </person-group>
        <article-title>
         Epidemiology of urinary tract infections: incidence, morbidity, and economic costs
        </article-title>
        <source>
         Dis Mon
        </source>
        <volume>
         49
        </volume>
        <year>
         2003
        </year>
        <fpage>
         53
        </fpage>
        <lpage>
         70
        </lpage>
        <pub-id pub-id-type="pmid">
         12601337
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib258">
       <label>
        258
       </label>
       <element-citation id="sbref2580" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           ES
          </given-names>
         </name>
        </person-group>
        <article-title>
         Guideline for prevention of catheter-associated urinary tract infections
        </article-title>
        <source>
         Am J Infect Control
        </source>
        <volume>
         11
        </volume>
        <year>
         1983
        </year>
        <fpage>
         28
        </fpage>
        <lpage>
         36
        </lpage>
        <pub-id pub-id-type="pmid">
         6551151
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib259">
       <label>
        259
       </label>
       <element-citation id="sbref2590" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cornia
          </surname>
          <given-names>
           PB
          </given-names>
         </name>
         <name>
          <surname>
           Amory
          </surname>
          <given-names>
           JK
          </given-names>
         </name>
         <name>
          <surname>
           Fraser
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Saint
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Lipsky
          </surname>
          <given-names>
           BA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Computer-based order entry decreases duration of indwelling urinary catheterization in hospitalized patients
        </article-title>
        <source>
         Am J Med
        </source>
        <volume>
         114
        </volume>
        <year>
         2003
        </year>
        <fpage>
         404
        </fpage>
        <lpage>
         407
        </lpage>
        <pub-id pub-id-type="pmid">
         12714131
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib260">
       <label>
        260
       </label>
       <element-citation id="sbref2600" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Fakih
          </surname>
          <given-names>
           MG
          </given-names>
         </name>
         <name>
          <surname>
           Dueweke
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Meisner
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        <article-title>
         Effect of nurse-led multidisciplinary rounds on reducing the unnecessary use of urinary catheterization in hospitalized patients
        </article-title>
        <source>
         Infect Control Hosp Epidemiol
        </source>
        <volume>
         29
        </volume>
        <year>
         2008
        </year>
        <fpage>
         815
        </fpage>
        <lpage>
         819
        </lpage>
        <pub-id pub-id-type="pmid">
         18700831
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib261">
       <label>
        261
       </label>
       <element-citation id="sbref2610" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Meddings
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Rogers
          </surname>
          <given-names>
           MAM
          </given-names>
         </name>
         <name>
          <surname>
           Macy
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Saint
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        <article-title>
         Systematic review and meta-analysis: reminder systems to reduce catheter-associated urinary tract infections and urinary catheter use in hospitalized patients
        </article-title>
        <source>
         Clin Infect Dis
        </source>
        <volume>
         51
        </volume>
        <year>
         2010
        </year>
        <fpage>
         550
        </fpage>
        <lpage>
         560
        </lpage>
        <pub-id pub-id-type="pmid">
         20673003
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib262">
       <label>
        262
       </label>
       <element-citation id="sbref2620" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Loeb
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Hunt
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           O'Halloran
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Carusone
          </surname>
          <given-names>
           SC
          </given-names>
         </name>
         <name>
          <surname>
           Dafoe
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Walter
          </surname>
          <given-names>
           SD
          </given-names>
         </name>
        </person-group>
        <article-title>
         Stop orders to reduce inappropriate urinary catheterization in hospitalized patients: a randomized controlled trial
        </article-title>
        <source>
         J Gen Intern Med
        </source>
        <volume>
         23
        </volume>
        <year>
         2008
        </year>
        <fpage>
         816
        </fpage>
        <lpage>
         820
        </lpage>
        <pub-id pub-id-type="pmid">
         18421507
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib263">
       <label>
        263
       </label>
       <element-citation id="sbref2630" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Stéphan
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Sax
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Wachsmuth
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Hoffmeyer
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Clergue
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Pittet
          </surname>
          <given-names>
           D
          </given-names>
         </name>
        </person-group>
        <article-title>
         Reduction of urinary tract infection and antibiotic use after surgery: a controlled, prospective, before-after intervention study
        </article-title>
        <source>
         Clin Infect Dis
        </source>
        <volume>
         42
        </volume>
        <year>
         2006
        </year>
        <fpage>
         1544
        </fpage>
        <lpage>
         1551
        </lpage>
        <pub-id pub-id-type="pmid">
         16652311
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib264">
       <label>
        264
       </label>
       <element-citation id="sbref2640" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Murphy
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Fader
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Prieto
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        <article-title>
         Interventions to minimise the initial use of indwelling urinary catheters in acute care: a systematic review
        </article-title>
        <source>
         Int J Nurs Stud
        </source>
        <year>
         2013
        </year>
        <comment>
         in press.
        </comment>
       </element-citation>
      </ref>
      <ref id="bib265">
       <label>
        265
       </label>
       <element-citation id="sbref2650" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Slappendel
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Weber
          </surname>
          <given-names>
           EW
          </given-names>
         </name>
        </person-group>
        <article-title>
         Non-invasive measurement of bladder volume as an indication for bladder catheterization after orthopaedic surgery and its effect on urinary tract infections
        </article-title>
        <source>
         Eur J Anaesthesiol
        </source>
        <volume>
         16
        </volume>
        <year>
         1999
        </year>
        <fpage>
         503
        </fpage>
        <lpage>
         506
        </lpage>
        <pub-id pub-id-type="pmid">
         10500936
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib266">
       <label>
        266
       </label>
       <element-citation id="sbref2660" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Patrizzi
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Fasnacht
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Manno
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <article-title>
         A collaborative, nurse-driven initiative to reduce hospital-acquired urinary tract infections
        </article-title>
        <source>
         J Emerg Nurs
        </source>
        <volume>
         35
        </volume>
        <year>
         2009
        </year>
        <fpage>
         536
        </fpage>
        <lpage>
         539
        </lpage>
        <pub-id pub-id-type="pmid">
         19914479
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib267">
       <label>
        267
       </label>
       <element-citation id="sbref2670" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Topal
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Conklin
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Camp
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Morris
          </surname>
          <given-names>
           V
          </given-names>
         </name>
         <name>
          <surname>
           Balcezak
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Herbert
          </surname>
          <given-names>
           P
          </given-names>
         </name>
        </person-group>
        <article-title>
         Prevention of nosocomial catheter-associated urinary tract infections through computerized feedback to physicians and a nurse-directed protocol
        </article-title>
        <source>
         Am J Med Qual
        </source>
        <volume>
         20
        </volume>
        <year>
         2005
        </year>
        <fpage>
         121
        </fpage>
        <lpage>
         126
        </lpage>
        <pub-id pub-id-type="pmid">
         15951517
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib268">
       <label>
        268
       </label>
       <element-citation id="sbref2680" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Pomfret
          </surname>
          <given-names>
           I
          </given-names>
         </name>
        </person-group>
        <article-title>
         Continence clinic. Catheters: design, selection and management
        </article-title>
        <source>
         Br J Nurs
        </source>
        <volume>
         5
        </volume>
        <year>
         1996
        </year>
        <fpage>
         245
        </fpage>
        <lpage>
         251
        </lpage>
        <pub-id pub-id-type="pmid">
         8704456
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib269">
       <label>
        269
       </label>
       <element-citation id="sbref2690" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kunin
          </surname>
          <given-names>
           C
          </given-names>
         </name>
        </person-group>
        <source>
         Urinary tract infections: detection, prevention and management
        </source>
        <edition>
         5th ed.
        </edition>
        <year>
         1997
        </year>
        <publisher-name>
         Williams and Wilkins
        </publisher-name>
        <publisher-loc>
         Baltimore
        </publisher-loc>
       </element-citation>
      </ref>
      <ref id="bib270">
       <label>
        270
       </label>
       <element-citation id="sbref2700" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Dieckhaus
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Garibaldi
          </surname>
          <given-names>
           R
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         Prevention of catheter-associated urinary tract infections
        </chapter-title>
        <person-group person-group-type="editor">
         <name>
          <surname>
           Abrutytn
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Goldmann
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Scheckler
          </surname>
          <given-names>
           W
          </given-names>
         </name>
        </person-group>
        <source>
         Saunders infection control reference service
        </source>
        <year>
         1998
        </year>
        <publisher-name>
         W.B. Saunders Co
        </publisher-name>
        <publisher-loc>
         Philadelphia
        </publisher-loc>
        <fpage>
         169
        </fpage>
        <lpage>
         174
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib271">
       <label>
        271
       </label>
       <element-citation id="sbref2710" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Roe
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Brocklehurst
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        <article-title>
         Study of patients with indwelling catheters
        </article-title>
        <source>
         J Adv Nurs
        </source>
        <volume>
         12
        </volume>
        <year>
         1987
        </year>
        <fpage>
         713
        </fpage>
        <lpage>
         718
        </lpage>
        <pub-id pub-id-type="pmid">
         3693729
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib272">
       <label>
        272
       </label>
       <mixed-citation id="oref10" publication-type="other">
        National Patient Safety Agency.
        <italic>
         Rapid response report: female urinary catheters causing trauma to adult males.
        </italic>
        NSPCA/2009/RRR02. 2009.
       </mixed-citation>
      </ref>
      <ref id="bib273">
       <label>
        273
       </label>
       <element-citation id="sbref2720" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lopez-Lopez
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Pascual
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Martinez-Martinez
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Perea
          </surname>
          <given-names>
           EJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         Effect of a siliconized latex urinary catheter on bacterial adherence and human neutrophil activity
        </article-title>
        <source>
         Diagn Microbiol Infect Dis
        </source>
        <volume>
         14
        </volume>
        <year>
         1991
        </year>
        <fpage>
         1
        </fpage>
        <lpage>
         6
        </lpage>
        <pub-id pub-id-type="pmid">
         1849474
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib274">
       <label>
        274
       </label>
       <element-citation id="sbref2730" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Nickel
          </surname>
          <given-names>
           JC
          </given-names>
         </name>
         <name>
          <surname>
           Feero
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Costerton
          </surname>
          <given-names>
           JW
          </given-names>
         </name>
         <name>
          <surname>
           Wilson
          </surname>
          <given-names>
           E
          </given-names>
         </name>
        </person-group>
        <article-title>
         Incidence and importance of bacteriuria in postoperative, short-term urinary catheterization
        </article-title>
        <source>
         Can J Surg
        </source>
        <volume>
         32
        </volume>
        <year>
         1989
        </year>
        <fpage>
         131
        </fpage>
        <lpage>
         132
        </lpage>
        <pub-id pub-id-type="pmid">
         2920318
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib275">
       <label>
        275
       </label>
       <element-citation id="sbref2740" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Schumm
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Lam
          </surname>
          <given-names>
           T
          </given-names>
         </name>
        </person-group>
        <article-title>
         Types of urethral catheters for management of short-term voiding problems in hospitalized adults: a short version Cochrane Review
        </article-title>
        <source>
         Sri Lanka J Obstet Gynaecol
        </source>
        <volume>
         31
        </volume>
        <year>
         2010
        </year>
        <fpage>
         110
        </fpage>
        <lpage>
         121
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib276">
       <label>
        276
       </label>
       <element-citation id="sbref2750" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chene
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Boulard
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Gachie
          </surname>
          <given-names>
           JP
          </given-names>
         </name>
        </person-group>
        <article-title>
         A controlled trial of a new material for coating urinary catheters
        </article-title>
        <source>
         Agressologie
        </source>
        <volume>
         31
        </volume>
        <year>
         1990
        </year>
        <fpage>
         499
        </fpage>
        <lpage>
         501
        </lpage>
        <pub-id pub-id-type="pmid">
         2089969
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib277">
       <label>
        277
       </label>
       <element-citation id="sbref2760" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tidd
          </surname>
          <given-names>
           MJ
          </given-names>
         </name>
         <name>
          <surname>
           Gow
          </surname>
          <given-names>
           JG
          </given-names>
         </name>
         <name>
          <surname>
           Pennington
          </surname>
          <given-names>
           JH
          </given-names>
         </name>
         <name>
          <surname>
           Shelton
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Scott
          </surname>
          <given-names>
           MR
          </given-names>
         </name>
        </person-group>
        <article-title>
         Comparison of hydrophilic polymer-coated latex, uncoated latex and PVC indwelling balloon catheters in the prevention of urinary infection
        </article-title>
        <source>
         Br J Urol
        </source>
        <volume>
         48
        </volume>
        <year>
         1976
        </year>
        <fpage>
         285
        </fpage>
        <lpage>
         291
        </lpage>
        <pub-id pub-id-type="pmid">
         963410
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib278">
       <label>
        278
       </label>
       <element-citation id="sbref2770" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Pellowe
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Pratt
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Loveday
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Harper
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Robinson
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Jones
          </surname>
          <given-names>
           SRLJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         The epic project: updating the evidence base for national evidence-based guidelines for preventing healthcare-associated infections in NHS hospitals in England. A report with recommendations
        </article-title>
        <source>
         J Hosp Infect
        </source>
        <volume>
         59
        </volume>
        <year>
         2005
        </year>
        <fpage>
         373
        </fpage>
        <lpage>
         374
        </lpage>
        <pub-id pub-id-type="pmid">
         15749329
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib279">
       <label>
        279
       </label>
       <element-citation id="sbref2780" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Brosnahan
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Jull
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Tracy
          </surname>
          <given-names>
           C
          </given-names>
         </name>
        </person-group>
        <article-title>
         Types of urethral catheters for management of short-term voiding problems in hospitalised adults
        </article-title>
        <source>
         Cochrane Database Syst Rev
        </source>
        <volume>
         1
        </volume>
        <year>
         2004
        </year>
        <comment>
         CD004013.
        </comment>
       </element-citation>
      </ref>
      <ref id="bib280">
       <label>
        280
       </label>
       <element-citation id="sbref2790" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Saint
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Elmore
          </surname>
          <given-names>
           JG
          </given-names>
         </name>
         <name>
          <surname>
           Sullivan
          </surname>
          <given-names>
           SD
          </given-names>
         </name>
         <name>
          <surname>
           Emerson
          </surname>
          <given-names>
           SS
          </given-names>
         </name>
         <name>
          <surname>
           Koepsell
          </surname>
          <given-names>
           TD
          </given-names>
         </name>
        </person-group>
        <article-title>
         The efficacy of silver alloy-coated urinary catheters in preventing urinary tract infection: a meta-analysis
        </article-title>
        <source>
         Am J Med
        </source>
        <volume>
         105
        </volume>
        <year>
         1998
        </year>
        <fpage>
         236
        </fpage>
        <lpage>
         241
        </lpage>
        <pub-id pub-id-type="pmid">
         9753027
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib281">
       <label>
        281
       </label>
       <element-citation id="sbref2800" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Dunn
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Pretty
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Reid
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Evans
          </surname>
          <given-names>
           D
          </given-names>
         </name>
        </person-group>
        <article-title>
         Management of short term indwelling urethral catheters to prevent urinary tract infections. A systematic review. Adelaide, S. Australia: Joanna Briggs Institute for Evidence Based Nursing and Midwifery
        </article-title>
        <source>
         Systematic Review
        </source>
        <volume>
         6
        </volume>
        <year>
         2000
        </year>
       </element-citation>
      </ref>
      <ref id="bib282">
       <label>
        282
       </label>
       <element-citation id="sbref2810" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Niël-Weise
          </surname>
          <given-names>
           BS
          </given-names>
         </name>
         <name>
          <surname>
           Arend
          </surname>
          <given-names>
           SM
          </given-names>
         </name>
         <name>
          <surname>
           van den Broek
          </surname>
          <given-names>
           PJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         Is there evidence for recommending silver-coated urinary catheters in guidelines?
        </article-title>
        <source>
         J Hosp Infect
        </source>
        <volume>
         52
        </volume>
        <year>
         2002
        </year>
        <fpage>
         81
        </fpage>
        <lpage>
         87
        </lpage>
        <pub-id pub-id-type="pmid">
         12392898
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib283">
       <label>
        283
       </label>
       <element-citation id="sbref2820" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Verleyen
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           De Ridder
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Van Poppel
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Baert
          </surname>
          <given-names>
           L
          </given-names>
         </name>
        </person-group>
        <article-title>
         Clinical application of the Bardex IC Foley catheter
        </article-title>
        <source>
         Eur Urol
        </source>
        <volume>
         36
        </volume>
        <year>
         1999
        </year>
        <fpage>
         240
        </fpage>
        <lpage>
         246
        </lpage>
        <pub-id pub-id-type="pmid">
         10450010
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib284">
       <label>
        284
       </label>
       <element-citation id="sbref2830" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Karchmer
          </surname>
          <given-names>
           TB
          </given-names>
         </name>
         <name>
          <surname>
           Giannetta
          </surname>
          <given-names>
           ET
          </given-names>
         </name>
         <name>
          <surname>
           Muto
          </surname>
          <given-names>
           CA
          </given-names>
         </name>
         <name>
          <surname>
           Strain
          </surname>
          <given-names>
           BA
          </given-names>
         </name>
         <name>
          <surname>
           Farr
          </surname>
          <given-names>
           BM
          </given-names>
         </name>
        </person-group>
        <article-title>
         A randomized crossover study of silver-coated urinary catheters in hospitalized patients
        </article-title>
        <source>
         Arch Intern Med
        </source>
        <volume>
         160
        </volume>
        <year>
         2000
        </year>
        <fpage>
         3294
        </fpage>
        <lpage>
         3298
        </lpage>
        <pub-id pub-id-type="pmid">
         11088092
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib285">
       <label>
        285
       </label>
       <element-citation id="sbref2840" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Saint
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Veenstra
          </surname>
          <given-names>
           DL
          </given-names>
         </name>
         <name>
          <surname>
           Sullivan
          </surname>
          <given-names>
           SD
          </given-names>
         </name>
         <name>
          <surname>
           Chenoweth
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Fendrick
          </surname>
          <given-names>
           AM
          </given-names>
         </name>
        </person-group>
        <article-title>
         The potential clinical and economic benefits of silver alloy urinary catheters in preventing urinary tract infection
        </article-title>
        <source>
         Arch Intern Med
        </source>
        <volume>
         160
        </volume>
        <year>
         2000
        </year>
        <fpage>
         2670
        </fpage>
        <lpage>
         2675
        </lpage>
        <pub-id pub-id-type="pmid">
         10999983
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib286">
       <label>
        286
       </label>
       <element-citation id="sbref2850" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Newton
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Still
          </surname>
          <given-names>
           JM
          </given-names>
         </name>
         <name>
          <surname>
           Law
          </surname>
          <given-names>
           E
          </given-names>
         </name>
        </person-group>
        <article-title>
         A comparison of the effect of early insertion of standard latex and silver-impregnated latex Foley catheters on urinary tract infections in burn patients
        </article-title>
        <source>
         Infect Control Hosp Epidemiol
        </source>
        <volume>
         23
        </volume>
        <year>
         2002
        </year>
        <fpage>
         217
        </fpage>
        <lpage>
         218
        </lpage>
        <pub-id pub-id-type="pmid">
         12002237
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib287">
       <label>
        287
       </label>
       <element-citation id="sbref2860" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gentry
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Cope
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        <article-title>
         Using silver to reduce catheter-associated urinary tract infections
        </article-title>
        <source>
         Nurs Stand
        </source>
        <volume>
         19
        </volume>
        <year>
         2005
        </year>
        <fpage>
         51
        </fpage>
        <lpage>
         54
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib288">
       <label>
        288
       </label>
       <element-citation id="sbref2870" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Madeo
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Davies
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Johnson
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Owen
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Wadsworth
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Martin
          </surname>
          <given-names>
           C
          </given-names>
         </name>
        </person-group>
        <article-title>
         The impact of using silver alloy urinary catheters in reducing the incidence of urinary tract infections in the critical care setting
        </article-title>
        <source>
         Br J Infect Contr
        </source>
        <volume>
         5
        </volume>
        <year>
         2004
        </year>
        <fpage>
         21
        </fpage>
        <lpage>
         24
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib289">
       <label>
        289
       </label>
       <element-citation id="sbref2880" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rupp
          </surname>
          <given-names>
           ME
          </given-names>
         </name>
         <name>
          <surname>
           Fitzgerald
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Marion
          </surname>
          <given-names>
           N
          </given-names>
         </name>
        </person-group>
        <article-title>
         Effect of silver-coated urinary catheters: efficacy, cost-effectiveness, and antimicrobial resistance
        </article-title>
        <source>
         Am J Infect Control
        </source>
        <volume>
         32
        </volume>
        <year>
         2004
        </year>
        <fpage>
         445
        </fpage>
        <lpage>
         450
        </lpage>
        <pub-id pub-id-type="pmid">
         15573050
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib290">
       <label>
        290
       </label>
       <element-citation id="sbref2890" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chaiban
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Hanna
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Dvorak
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Raad
          </surname>
          <given-names>
           I
          </given-names>
         </name>
        </person-group>
        <article-title>
         A rapid method of impregnating endotracheal tubes and urinary catheters with gendine: a novel antiseptic agent
        </article-title>
        <source>
         J Antimicrob Chemother
        </source>
        <volume>
         55
        </volume>
        <year>
         2005
        </year>
        <fpage>
         51
        </fpage>
        <lpage>
         56
        </lpage>
        <pub-id pub-id-type="pmid">
         15574478
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib291">
       <label>
        291
       </label>
       <element-citation id="sbref2900" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cho
          </surname>
          <given-names>
           YW
          </given-names>
         </name>
         <name>
          <surname>
           Park
          </surname>
          <given-names>
           JH
          </given-names>
         </name>
         <name>
          <surname>
           Kim
          </surname>
          <given-names>
           SH
          </given-names>
         </name>
        </person-group>
        <article-title>
         Gentamicin-releasing urethral catheter for short-term catheterization
        </article-title>
        <source>
         J Biomater Sci Polym Ed
        </source>
        <volume>
         14
        </volume>
        <year>
         2003
        </year>
        <fpage>
         963
        </fpage>
        <lpage>
         972
        </lpage>
        <pub-id pub-id-type="pmid">
         14661873
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib292">
       <label>
        292
       </label>
       <element-citation id="sbref2910" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Thibon
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Le Coutour
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <name>
          <surname>
           Leroyer
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Fabry
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        <article-title>
         Randomized multi-centre trial of the effects of a catheter coated with hydrogel and silver salts on the incidence of hospital-acquired urinary tract infections
        </article-title>
        <source>
         J Hosp Infect
        </source>
        <volume>
         45
        </volume>
        <year>
         2000
        </year>
        <fpage>
         117
        </fpage>
        <lpage>
         124
        </lpage>
        <pub-id pub-id-type="pmid">
         10860688
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib293">
       <label>
        293
       </label>
       <element-citation id="sbref2920" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lai
          </surname>
          <given-names>
           KK
          </given-names>
         </name>
         <name>
          <surname>
           Fontecchio
          </surname>
          <given-names>
           SA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Use of silver-hydrogel urinary catheters on the incidence of catheter-associated urinary tract infections in hospitalized patients
        </article-title>
        <source>
         Am J Infect Control
        </source>
        <volume>
         30
        </volume>
        <year>
         2002
        </year>
        <fpage>
         221
        </fpage>
        <lpage>
         225
        </lpage>
        <pub-id pub-id-type="pmid">
         12032497
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib294">
       <label>
        294
       </label>
       <element-citation id="sbref2930" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gaonkar
          </surname>
          <given-names>
           TA
          </given-names>
         </name>
         <name>
          <surname>
           Sampath
          </surname>
          <given-names>
           LA
          </given-names>
         </name>
         <name>
          <surname>
           Modak
          </surname>
          <given-names>
           SM
          </given-names>
         </name>
        </person-group>
        <article-title>
         Evaluation of the antimicrobial efficacy of urinary catheters impregnated with antiseptics in an in vitro urinary tract model
        </article-title>
        <source>
         Infect Control Hosp Epidemiol
        </source>
        <volume>
         24
        </volume>
        <year>
         2003
        </year>
        <fpage>
         506
        </fpage>
        <lpage>
         513
        </lpage>
        <pub-id pub-id-type="pmid">
         12887239
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib295">
       <label>
        295
       </label>
       <element-citation id="sbref2940" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Darouiche
          </surname>
          <given-names>
           RO
          </given-names>
         </name>
         <name>
          <surname>
           Raad
          </surname>
          <given-names>
           II
          </given-names>
         </name>
         <name>
          <surname>
           Smith
          </surname>
          <given-names>
           JA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Efficacy of antimicrobial-impregnated bladder catheters in reducing catheter-associated bacteriuria: a prospective, randomized, multicenter clinical trial
        </article-title>
        <source>
         Urology
        </source>
        <volume>
         54
        </volume>
        <year>
         1999
        </year>
        <fpage>
         976
        </fpage>
        <lpage>
         981
        </lpage>
        <pub-id pub-id-type="pmid">
         10604693
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib296">
       <label>
        296
       </label>
       <element-citation id="sbref2950" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Al-Habdan
          </surname>
          <given-names>
           I
          </given-names>
         </name>
         <name>
          <surname>
           Sadat-Ali
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Corea
          </surname>
          <given-names>
           JR
          </given-names>
         </name>
         <name>
          <surname>
           Al-Othman
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Kamal
          </surname>
          <given-names>
           BA
          </given-names>
         </name>
         <name>
          <surname>
           Shriyan
          </surname>
          <given-names>
           DS
          </given-names>
         </name>
        </person-group>
        <article-title>
         Assessment of nosocomial urinary tract infections in orthopaedic patients: a prospective and comparative study using two different catheters
        </article-title>
        <source>
         Int Surg
        </source>
        <volume>
         88
        </volume>
        <year>
         2003
        </year>
        <fpage>
         152
        </fpage>
        <lpage>
         154
        </lpage>
        <pub-id pub-id-type="pmid">
         14584770
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib297">
       <label>
        297
       </label>
       <element-citation id="sbref2960" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Riley
          </surname>
          <given-names>
           DK
          </given-names>
         </name>
         <name>
          <surname>
           Classen
          </surname>
          <given-names>
           DC
          </given-names>
         </name>
         <name>
          <surname>
           Stevens
          </surname>
          <given-names>
           LE
          </given-names>
         </name>
         <name>
          <surname>
           Burke
          </surname>
          <given-names>
           JP
          </given-names>
         </name>
        </person-group>
        <article-title>
         A large randomized clinical trial of a silver-impregnated urinary catheter: lack of efficacy and staphylococcal superinfection
        </article-title>
        <source>
         Am J Med
        </source>
        <volume>
         98
        </volume>
        <year>
         1995
        </year>
        <fpage>
         349
        </fpage>
        <lpage>
         356
        </lpage>
        <pub-id pub-id-type="pmid">
         7709947
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib298">
       <label>
        298
       </label>
       <element-citation id="sbref2970" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Johnson
          </surname>
          <given-names>
           JR
          </given-names>
         </name>
         <name>
          <surname>
           Roberts
          </surname>
          <given-names>
           PL
          </given-names>
         </name>
         <name>
          <surname>
           Olsen
          </surname>
          <given-names>
           RJ
          </given-names>
         </name>
         <name>
          <surname>
           Moyer
          </surname>
          <given-names>
           KA
          </given-names>
         </name>
         <name>
          <surname>
           Stamm
          </surname>
          <given-names>
           WE
          </given-names>
         </name>
        </person-group>
        <article-title>
         Prevention of catheter-associated urinary tract infection with a silver oxide-coated urinary catheter: clinical and microbiologic correlates
        </article-title>
        <source>
         J Infect Dis
        </source>
        <volume>
         162
        </volume>
        <year>
         1990
        </year>
        <fpage>
         1145
        </fpage>
        <lpage>
         1150
        </lpage>
        <pub-id pub-id-type="pmid">
         2230239
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib299">
       <label>
        299
       </label>
       <element-citation id="sbref2980" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Liedberg
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Lundeberg
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Ekman
          </surname>
          <given-names>
           P
          </given-names>
         </name>
        </person-group>
        <article-title>
         Refinements in the coating of urethral catheters reduces the incidence of catheter-associated bacteriuria. An experimental and clinical study
        </article-title>
        <source>
         Eur Urol
        </source>
        <volume>
         17
        </volume>
        <year>
         1990
        </year>
        <fpage>
         236
        </fpage>
        <lpage>
         240
        </lpage>
        <pub-id pub-id-type="pmid">
         2190840
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib300">
       <label>
        300
       </label>
       <element-citation id="sbref2990" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Liedberg
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Lundeberg
          </surname>
          <given-names>
           T
          </given-names>
         </name>
        </person-group>
        <article-title>
         Silver alloy coated catheters reduce catheter-associated bacteriuria
        </article-title>
        <source>
         Br J Urol
        </source>
        <volume>
         65
        </volume>
        <year>
         1990
        </year>
        <fpage>
         379
        </fpage>
        <lpage>
         381
        </lpage>
        <pub-id pub-id-type="pmid">
         2187551
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib301">
       <label>
        301
       </label>
       <element-citation id="sbref3000" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Pickard
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Buckley
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Glazener
          </surname>
          <given-names>
           C
          </given-names>
         </name>
        </person-group>
        <article-title>
         Antimicrobial catheters for reduction of symptomatic urinary tract infection in adults requiring short-term catheterisation in hospital: a multicentre randomised controlled trial
        </article-title>
        <source>
         Lancet
        </source>
        <volume>
         380
        </volume>
        <year>
         2012
        </year>
        <fpage>
         1927
        </fpage>
        <lpage>
         1935
        </lpage>
        <pub-id pub-id-type="pmid">
         23134837
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib302">
       <label>
        302
       </label>
       <element-citation id="sbref3010" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ward
          </surname>
          <given-names>
           V
          </given-names>
         </name>
         <name>
          <surname>
           Wilson
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Taylor
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Cookson
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Glynn
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        <source>
         Preventing hospital-acquired infection: clinical guidelines
        </source>
        <year>
         1997
        </year>
        <publisher-name>
         Public Health Laboratory Service
        </publisher-name>
        <publisher-loc>
         London
        </publisher-loc>
       </element-citation>
      </ref>
      <ref id="bib303">
       <label>
        303
       </label>
       <element-citation id="sbref3020" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Stamm
          </surname>
          <given-names>
           W
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         Urinary tract infections
        </chapter-title>
        <person-group person-group-type="editor">
         <name>
          <surname>
           Bennett
          </surname>
          <given-names>
           JBP
          </given-names>
         </name>
        </person-group>
        <source>
         Hospital infection
        </source>
        <edition>
         4th ed.
        </edition>
        <year>
         1998
        </year>
        <publisher-name>
         Lippincott-Raven
        </publisher-name>
        <publisher-loc>
         Philadelphia
        </publisher-loc>
        <fpage>
         477
        </fpage>
        <lpage>
         485
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib304">
       <label>
        304
       </label>
       <element-citation id="sbref3030" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kass
          </surname>
          <given-names>
           EH
          </given-names>
         </name>
         <name>
          <surname>
           Schneiderman
          </surname>
          <given-names>
           LJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         Entry of bacteria into the urinary tracts of patients with inlying catheters
        </article-title>
        <source>
         N Engl J Med
        </source>
        <volume>
         256
        </volume>
        <year>
         1957
        </year>
        <fpage>
         556
        </fpage>
        <lpage>
         557
        </lpage>
        <pub-id pub-id-type="pmid">
         13419041
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib305">
       <label>
        305
       </label>
       <element-citation id="sbref3040" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Desautels
          </surname>
          <given-names>
           RE
          </given-names>
         </name>
         <name>
          <surname>
           Walter
          </surname>
          <given-names>
           CW
          </given-names>
         </name>
         <name>
          <surname>
           Graves
          </surname>
          <given-names>
           RC
          </given-names>
         </name>
         <name>
          <surname>
           Harrison
          </surname>
          <given-names>
           JH
          </given-names>
         </name>
        </person-group>
        <article-title>
         Technical advances in the prevention of urinary tract infection
        </article-title>
        <source>
         J Urol
        </source>
        <volume>
         87
        </volume>
        <year>
         1962
        </year>
        <fpage>
         487
        </fpage>
        <lpage>
         490
        </lpage>
        <pub-id pub-id-type="pmid">
         13885667
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib306">
       <label>
        306
       </label>
       <element-citation id="sbref3050" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kunin
          </surname>
          <given-names>
           CM
          </given-names>
         </name>
         <name>
          <surname>
           McCormack
          </surname>
          <given-names>
           RC
          </given-names>
         </name>
        </person-group>
        <article-title>
         Prevention of catheter-induced urinary-tract infections by sterile closed drainage
        </article-title>
        <source>
         N Engl J Med
        </source>
        <volume>
         274
        </volume>
        <year>
         1966
        </year>
        <fpage>
         1155
        </fpage>
        <lpage>
         1161
        </lpage>
        <pub-id pub-id-type="pmid">
         5934951
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib307">
       <label>
        307
       </label>
       <element-citation id="sbref3060" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Garibaldi
          </surname>
          <given-names>
           RA
          </given-names>
         </name>
         <name>
          <surname>
           Burke
          </surname>
          <given-names>
           JP
          </given-names>
         </name>
         <name>
          <surname>
           Dickman
          </surname>
          <given-names>
           ML
          </given-names>
         </name>
         <name>
          <surname>
           Smith
          </surname>
          <given-names>
           CB
          </given-names>
         </name>
        </person-group>
        <article-title>
         Factors predisposing to bacteriuria during indwelling urethral catheterization
        </article-title>
        <source>
         N Engl J Med
        </source>
        <volume>
         291
        </volume>
        <year>
         1974
        </year>
        <fpage>
         215
        </fpage>
        <lpage>
         219
        </lpage>
        <pub-id pub-id-type="pmid">
         4834750
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib308">
       <label>
        308
       </label>
       <element-citation id="sbref3070" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Thornton
          </surname>
          <given-names>
           GF
          </given-names>
         </name>
         <name>
          <surname>
           Andriole
          </surname>
          <given-names>
           VT
          </given-names>
         </name>
        </person-group>
        <article-title>
         Bacteriuria during indwelling catheter drainage: II. Effect of a closed sterile draining system
        </article-title>
        <source>
         JAMA
        </source>
        <volume>
         214
        </volume>
        <year>
         1970
        </year>
        <fpage>
         339
        </fpage>
        <lpage>
         342
        </lpage>
        <pub-id pub-id-type="pmid">
         4918243
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib309">
       <label>
        309
       </label>
       <element-citation id="sbref3080" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gillespie
          </surname>
          <given-names>
           WA
          </given-names>
         </name>
         <name>
          <surname>
           Simpson
          </surname>
          <given-names>
           RA
          </given-names>
         </name>
         <name>
          <surname>
           Jones
          </surname>
          <given-names>
           JE
          </given-names>
         </name>
         <name>
          <surname>
           Nashef
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Teasdale
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Speller
          </surname>
          <given-names>
           DC
          </given-names>
         </name>
        </person-group>
        <article-title>
         Does the addition of disinfectant to urine drainage bags prevent infection in catheterised patients?
        </article-title>
        <source>
         Lancet
        </source>
        <volume>
         1
        </volume>
        <year>
         1983
        </year>
        <fpage>
         1037
        </fpage>
        <lpage>
         1039
        </lpage>
        <pub-id pub-id-type="pmid">
         6133072
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib310">
       <label>
        310
       </label>
       <element-citation id="sbref3090" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gillespie
          </surname>
          <given-names>
           WA
          </given-names>
         </name>
         <name>
          <surname>
           Lennon
          </surname>
          <given-names>
           GG
          </given-names>
         </name>
         <name>
          <surname>
           Linton
          </surname>
          <given-names>
           KB
          </given-names>
         </name>
         <name>
          <surname>
           Slade
          </surname>
          <given-names>
           N
          </given-names>
         </name>
        </person-group>
        <article-title>
         Prevention of urinary tract infection in gynaecology
        </article-title>
        <source>
         BMJ
        </source>
        <volume>
         2
        </volume>
        <year>
         1964
        </year>
        <fpage>
         423
        </fpage>
        <lpage>
         425
        </lpage>
        <pub-id pub-id-type="pmid">
         14160243
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib311">
       <label>
        311
       </label>
       <element-citation id="sbref3100" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Platt
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Polk
          </surname>
          <given-names>
           BF
          </given-names>
         </name>
         <name>
          <surname>
           Murdock
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Rosner
          </surname>
          <given-names>
           B
          </given-names>
         </name>
        </person-group>
        <article-title>
         Reduction of mortality associated with nosocomial urinary tract infection
        </article-title>
        <source>
         Lancet
        </source>
        <volume>
         1
        </volume>
        <year>
         1983
        </year>
        <fpage>
         893
        </fpage>
        <lpage>
         897
        </lpage>
        <pub-id pub-id-type="pmid">
         6132220
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib312">
       <label>
        312
       </label>
       <element-citation id="sbref3110" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Keerasuntonpong
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Thamlikitkul
          </surname>
          <given-names>
           V
          </given-names>
         </name>
         <name>
          <surname>
           Thearawiboon
          </surname>
          <given-names>
           W
          </given-names>
         </name>
        </person-group>
        <article-title>
         Incidence of urinary tract infections in patients with short-term indwelling urethral catheters: a comparison between a 3-day urinary drainage bag change and no change regimens
        </article-title>
        <source>
         Am J Infect Control
        </source>
        <volume>
         31
        </volume>
        <year>
         2003
        </year>
        <fpage>
         9
        </fpage>
        <lpage>
         12
        </lpage>
        <pub-id pub-id-type="pmid">
         12548251
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib313">
       <label>
        313
       </label>
       <element-citation id="sbref3120" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Maizels
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Schaeffer
          </surname>
          <given-names>
           AJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         Decreased incidence of bacteriuria associated with periodic instillations of hydrogen peroxide into the urethral catheter drainage bag
        </article-title>
        <source>
         J Urol
        </source>
        <volume>
         123
        </volume>
        <year>
         1980
        </year>
        <fpage>
         841
        </fpage>
        <lpage>
         845
        </lpage>
        <pub-id pub-id-type="pmid">
         7381999
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib314">
       <label>
        314
       </label>
       <element-citation id="sbref3130" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sweet
          </surname>
          <given-names>
           DE
          </given-names>
         </name>
         <name>
          <surname>
           Goodpasture
          </surname>
          <given-names>
           HC
          </given-names>
         </name>
         <name>
          <surname>
           Holl
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Smart
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Alexander
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Hedari
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        <article-title>
         Evaluation of H2O2 prophylaxis of bacteriuria in patients with long-term indwelling Foley catheters: a randomized controlled study
        </article-title>
        <source>
         Infect Control
        </source>
        <volume>
         6
        </volume>
        <year>
         1985
        </year>
        <fpage>
         263
        </fpage>
        <lpage>
         266
        </lpage>
        <pub-id pub-id-type="pmid">
         3847401
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib315">
       <label>
        315
       </label>
       <element-citation id="sbref3140" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Thompson
          </surname>
          <given-names>
           RL
          </given-names>
         </name>
         <name>
          <surname>
           Haley
          </surname>
          <given-names>
           CE
          </given-names>
         </name>
         <name>
          <surname>
           Searcy
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Catheter-associated bacteriuria. Failure to reduce attack rates using periodic instillations of a disinfectant into urinary drainage systems
        </article-title>
        <source>
         JAMA
        </source>
        <volume>
         251
        </volume>
        <year>
         1984
        </year>
        <fpage>
         747
        </fpage>
        <lpage>
         751
        </lpage>
        <pub-id pub-id-type="pmid">
         6363727
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib316">
       <label>
        316
       </label>
       <element-citation id="sbref3150" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cleland
          </surname>
          <given-names>
           V
          </given-names>
         </name>
         <name>
          <surname>
           Cox
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Berggren
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Macinnis
          </surname>
          <given-names>
           MR
          </given-names>
         </name>
        </person-group>
        <article-title>
         Prevention of bacteriuria in female patients with indwelling catheters
        </article-title>
        <source>
         Nurs Res
        </source>
        <volume>
         20
        </volume>
        <year>
         1971
        </year>
        <fpage>
         309
        </fpage>
        <lpage>
         318
        </lpage>
        <pub-id pub-id-type="pmid">
         5207134
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib317">
       <label>
        317
       </label>
       <element-citation id="sbref3160" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Burke
          </surname>
          <given-names>
           JP
          </given-names>
         </name>
         <name>
          <surname>
           Garibaldi
          </surname>
          <given-names>
           RA
          </given-names>
         </name>
         <name>
          <surname>
           Britt
          </surname>
          <given-names>
           MR
          </given-names>
         </name>
         <name>
          <surname>
           Jacobson
          </surname>
          <given-names>
           JA
          </given-names>
         </name>
         <name>
          <surname>
           Conti
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Alling
          </surname>
          <given-names>
           DW
          </given-names>
         </name>
        </person-group>
        <article-title>
         Prevention of catheter-associated urinary tract infections. Efficacy of daily meatal care regimens
        </article-title>
        <source>
         Am J Med
        </source>
        <volume>
         70
        </volume>
        <year>
         1981
        </year>
        <fpage>
         655
        </fpage>
        <lpage>
         658
        </lpage>
        <pub-id pub-id-type="pmid">
         7011019
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib318">
       <label>
        318
       </label>
       <element-citation id="sbref3170" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Burke
          </surname>
          <given-names>
           JP
          </given-names>
         </name>
         <name>
          <surname>
           Jacobson
          </surname>
          <given-names>
           JA
          </given-names>
         </name>
         <name>
          <surname>
           Garibaldi
          </surname>
          <given-names>
           RA
          </given-names>
         </name>
         <name>
          <surname>
           Conti
          </surname>
          <given-names>
           MT
          </given-names>
         </name>
         <name>
          <surname>
           Alling
          </surname>
          <given-names>
           DW
          </given-names>
         </name>
        </person-group>
        <article-title>
         Evaluation of daily meatal care with poly-antibiotic ointment in prevention of urinary catheter-associated bacteriuria
        </article-title>
        <source>
         J Urol
        </source>
        <volume>
         129
        </volume>
        <year>
         1983
        </year>
        <fpage>
         331
        </fpage>
        <lpage>
         334
        </lpage>
        <pub-id pub-id-type="pmid">
         6834501
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib319">
       <label>
        319
       </label>
       <element-citation id="sbref3180" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Classen
          </surname>
          <given-names>
           DC
          </given-names>
         </name>
         <name>
          <surname>
           Larsen
          </surname>
          <given-names>
           RA
          </given-names>
         </name>
         <name>
          <surname>
           Burke
          </surname>
          <given-names>
           JP
          </given-names>
         </name>
         <name>
          <surname>
           Stevens
          </surname>
          <given-names>
           LE
          </given-names>
         </name>
        </person-group>
        <article-title>
         Prevention of catheter-associated bacteriuria: clinical trial of methods to block three known pathways of infection
        </article-title>
        <source>
         Am J Infect Control
        </source>
        <volume>
         19
        </volume>
        <year>
         1991
        </year>
        <fpage>
         136
        </fpage>
        <lpage>
         142
        </lpage>
        <pub-id pub-id-type="pmid">
         1863002
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib320">
       <label>
        320
       </label>
       <element-citation id="sbref3190" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Classen
          </surname>
          <given-names>
           DC
          </given-names>
         </name>
         <name>
          <surname>
           Larsen
          </surname>
          <given-names>
           RA
          </given-names>
         </name>
         <name>
          <surname>
           Burke
          </surname>
          <given-names>
           JP
          </given-names>
         </name>
         <name>
          <surname>
           Alling
          </surname>
          <given-names>
           DW
          </given-names>
         </name>
         <name>
          <surname>
           Stevens
          </surname>
          <given-names>
           LE
          </given-names>
         </name>
        </person-group>
        <article-title>
         Daily meatal care for prevention of catheter-associated bacteriuria: results using frequent applications of polyantibiotic cream
        </article-title>
        <source>
         Infect Control Hosp Epidemiol
        </source>
        <volume>
         12
        </volume>
        <year>
         1991
        </year>
        <fpage>
         157
        </fpage>
        <lpage>
         162
        </lpage>
        <pub-id pub-id-type="pmid">
         2022861
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib321">
       <label>
        321
       </label>
       <element-citation id="sbref3200" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Huth
          </surname>
          <given-names>
           TS
          </given-names>
         </name>
         <name>
          <surname>
           Burke
          </surname>
          <given-names>
           JP
          </given-names>
         </name>
         <name>
          <surname>
           Larsen
          </surname>
          <given-names>
           RA
          </given-names>
         </name>
         <name>
          <surname>
           Classen
          </surname>
          <given-names>
           DC
          </given-names>
         </name>
         <name>
          <surname>
           Stevens
          </surname>
          <given-names>
           LE
          </given-names>
         </name>
        </person-group>
        <article-title>
         Randomized trial of meatal care with silver sulfadiazine cream for the prevention of catheter-associated bacteriuria
        </article-title>
        <source>
         J Infect Dis
        </source>
        <volume>
         165
        </volume>
        <year>
         1992
        </year>
        <fpage>
         14
        </fpage>
        <lpage>
         18
        </lpage>
        <pub-id pub-id-type="pmid">
         1727882
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib322">
       <label>
        322
       </label>
       <element-citation id="sbref3210" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Webster
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Hood
          </surname>
          <given-names>
           RH
          </given-names>
         </name>
         <name>
          <surname>
           Burridge
          </surname>
          <given-names>
           CA
          </given-names>
         </name>
         <name>
          <surname>
           Doidge
          </surname>
          <given-names>
           ML
          </given-names>
         </name>
         <name>
          <surname>
           Phillips
          </surname>
          <given-names>
           KM
          </given-names>
         </name>
         <name>
          <surname>
           George
          </surname>
          <given-names>
           N
          </given-names>
         </name>
        </person-group>
        <article-title>
         Water or antiseptic for periurethral cleaning before urinary catheterization: a randomized controlled trial
        </article-title>
        <source>
         Am J Infect Control
        </source>
        <volume>
         29
        </volume>
        <year>
         2001
        </year>
        <fpage>
         389
        </fpage>
        <lpage>
         394
        </lpage>
        <pub-id pub-id-type="pmid">
         11743486
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib323">
       <label>
        323
       </label>
       <element-citation id="sbref3220" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Davies
          </surname>
          <given-names>
           AJ
          </given-names>
         </name>
         <name>
          <surname>
           Desai
          </surname>
          <given-names>
           HN
          </given-names>
         </name>
         <name>
          <surname>
           Turton
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Dyas
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        <article-title>
         Does instillation of chlorhexidine into the bladder of catheterized geriatric patients help reduce bacteriuria?
        </article-title>
        <source>
         J Hosp Infect
        </source>
        <volume>
         9
        </volume>
        <year>
         1987
        </year>
        <fpage>
         72
        </fpage>
        <lpage>
         75
        </lpage>
        <pub-id pub-id-type="pmid">
         2880903
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib324">
       <label>
        324
       </label>
       <element-citation id="sbref3230" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ball
          </surname>
          <given-names>
           AJ
          </given-names>
         </name>
         <name>
          <surname>
           Carr
          </surname>
          <given-names>
           TW
          </given-names>
         </name>
         <name>
          <surname>
           Gillespie
          </surname>
          <given-names>
           WA
          </given-names>
         </name>
         <name>
          <surname>
           Kelly
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Simpson
          </surname>
          <given-names>
           RA
          </given-names>
         </name>
         <name>
          <surname>
           Smith
          </surname>
          <given-names>
           PJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         Bladder irrigation with chlorhexidine for the prevention of urinary infection after transurethral operations: a prospective controlled study
        </article-title>
        <source>
         J Urol
        </source>
        <volume>
         138
        </volume>
        <year>
         1987
        </year>
        <fpage>
         491
        </fpage>
        <lpage>
         494
        </lpage>
        <pub-id pub-id-type="pmid">
         3625846
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib325">
       <label>
        325
       </label>
       <element-citation id="sbref3240" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Jones
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
         <name>
          <surname>
           Hasan
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        <article-title>
         Controlled trial of intravesical noxythiolin in the prevention of infection following outflow tract surgery
        </article-title>
        <source>
         Br J Urol
        </source>
        <volume>
         62
        </volume>
        <year>
         1988
        </year>
        <fpage>
         311
        </fpage>
        <lpage>
         314
        </lpage>
        <pub-id pub-id-type="pmid">
         3142635
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib326">
       <label>
        326
       </label>
       <element-citation id="sbref3250" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Schneeberger
          </surname>
          <given-names>
           PM
          </given-names>
         </name>
         <name>
          <surname>
           Vreede
          </surname>
          <given-names>
           RW
          </given-names>
         </name>
         <name>
          <surname>
           Bogdanowicz
          </surname>
          <given-names>
           JF
          </given-names>
         </name>
         <name>
          <surname>
           van Dijk
          </surname>
          <given-names>
           WC
          </given-names>
         </name>
        </person-group>
        <article-title>
         A randomized study on the effect of bladder irrigation with povidone-iodine before removal of an indwelling catheter
        </article-title>
        <source>
         J Hosp Infect
        </source>
        <volume>
         21
        </volume>
        <year>
         1992
        </year>
        <fpage>
         223
        </fpage>
        <lpage>
         229
        </lpage>
        <pub-id pub-id-type="pmid">
         1353514
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib327">
       <label>
        327
       </label>
       <element-citation id="sbref3260" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Warren
          </surname>
          <given-names>
           JW
          </given-names>
         </name>
         <name>
          <surname>
           Platt
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Thomas
          </surname>
          <given-names>
           RJ
          </given-names>
         </name>
         <name>
          <surname>
           Rosner
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Kass
          </surname>
          <given-names>
           EH
          </given-names>
         </name>
        </person-group>
        <article-title>
         Antibiotic irrigation and catheter-associated urinary-tract infections
        </article-title>
        <source>
         N Engl J Med
        </source>
        <volume>
         299
        </volume>
        <year>
         1978
        </year>
        <fpage>
         570
        </fpage>
        <lpage>
         573
        </lpage>
        <pub-id pub-id-type="pmid">
         210379
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib328">
       <label>
        328
       </label>
       <element-citation id="sbref3270" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Muncie
          </surname>
          <given-names>
           HL
          </given-names>
          <suffix>
           Jr
          </suffix>
         </name>
         <name>
          <surname>
           Hoopes
          </surname>
          <given-names>
           JM
          </given-names>
         </name>
         <name>
          <surname>
           Damron
          </surname>
          <given-names>
           DJ
          </given-names>
         </name>
         <name>
          <surname>
           Tenney
          </surname>
          <given-names>
           JH
          </given-names>
         </name>
         <name>
          <surname>
           Warren
          </surname>
          <given-names>
           JW
          </given-names>
         </name>
        </person-group>
        <article-title>
         Once-daily irrigation of long-term urethral catheters with normal saline. Lack of benefit
        </article-title>
        <source>
         Arch Intern Med
        </source>
        <volume>
         149
        </volume>
        <year>
         1989
        </year>
        <fpage>
         441
        </fpage>
        <lpage>
         443
        </lpage>
        <pub-id pub-id-type="pmid">
         2916889
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib329">
       <label>
        329
       </label>
       <element-citation id="sbref3280" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kennedy
          </surname>
          <given-names>
           AP
          </given-names>
         </name>
         <name>
          <surname>
           Brocklehurst
          </surname>
          <given-names>
           JC
          </given-names>
         </name>
         <name>
          <surname>
           Robinson
          </surname>
          <given-names>
           JM
          </given-names>
         </name>
         <name>
          <surname>
           Faragher
          </surname>
          <given-names>
           EB
          </given-names>
         </name>
        </person-group>
        <article-title>
         Assessment of the use of bladder washouts/instillations in patients with long-term indwelling catheters
        </article-title>
        <source>
         Br J Urol
        </source>
        <volume>
         70
        </volume>
        <year>
         1992
        </year>
        <fpage>
         610
        </fpage>
        <lpage>
         615
        </lpage>
        <pub-id pub-id-type="pmid">
         1486386
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib330">
       <label>
        330
       </label>
       <element-citation id="sbref3290" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cox
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Smith
          </surname>
          <given-names>
           RF
          </given-names>
         </name>
         <name>
          <surname>
           Elliott
          </surname>
          <given-names>
           JP
          </given-names>
         </name>
         <name>
          <surname>
           Quinn
          </surname>
          <given-names>
           EL
          </given-names>
         </name>
        </person-group>
        <article-title>
         Neomycin-polymyxin prophylaxis of urinary-tract infection associated with indwelling catheters
        </article-title>
        <source>
         Antimicrob Agents Chemother
        </source>
        <volume>
         6
        </volume>
        <year>
         1966
        </year>
        <fpage>
         165
        </fpage>
        <lpage>
         168
        </lpage>
        <pub-id pub-id-type="pmid">
         4293647
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib331">
       <label>
        331
       </label>
       <element-citation id="sbref3300" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Getliffe
          </surname>
          <given-names>
           KA
          </given-names>
         </name>
        </person-group>
        <article-title>
         The use of bladder wash-outs to reduce urinary catheter encrustation
        </article-title>
        <source>
         Br J Urol
        </source>
        <volume>
         73
        </volume>
        <year>
         1994
        </year>
        <fpage>
         696
        </fpage>
        <lpage>
         700
        </lpage>
        <pub-id pub-id-type="pmid">
         8032839
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib332">
       <label>
        332
       </label>
       <element-citation id="sbref3310" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ranji
          </surname>
          <given-names>
           SR
          </given-names>
         </name>
         <name>
          <surname>
           Shetty
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Posley
          </surname>
          <given-names>
           KA
          </given-names>
         </name>
        </person-group>
        <source>
         Closing the quality gap: a critical analysis of quality improvement strategies (Vol. 6: Prevention of healthcare-associated infections)
        </source>
        <year>
         2007
        </year>
        <publisher-name>
         Agency for Heathcare Research and Quality (US)
        </publisher-name>
        <publisher-loc>
         Rockville (MD)
        </publisher-loc>
        <comment>
         Jan. Report No.: 04(07)-0051–6.
        </comment>
       </element-citation>
      </ref>
      <ref id="bib333">
       <label>
        333
       </label>
       <element-citation id="sbref3320" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ching
          </surname>
          <given-names>
           TY
          </given-names>
         </name>
         <name>
          <surname>
           Seto
          </surname>
          <given-names>
           WH
          </given-names>
         </name>
        </person-group>
        <article-title>
         Evaluating the efficacy of the infection control liaison nurse in the hospital
        </article-title>
        <source>
         J Adv Nurs
        </source>
        <volume>
         15
        </volume>
        <year>
         1990
        </year>
        <fpage>
         1128
        </fpage>
        <lpage>
         1131
        </lpage>
        <pub-id pub-id-type="pmid">
         2258518
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib334">
       <label>
        334
       </label>
       <element-citation id="sbref3330" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           O'Grady
          </surname>
          <given-names>
           NP
          </given-names>
         </name>
         <name>
          <surname>
           Pearson
          </surname>
          <given-names>
           ML
          </given-names>
         </name>
         <name>
          <surname>
           Raad
          </surname>
          <given-names>
           II
          </given-names>
         </name>
        </person-group>
        <article-title>
         Guidelines for the prevention of intravascular catheter-related infections
        </article-title>
        <source>
         Clin Infect Dis
        </source>
        <volume>
         52
        </volume>
        <year>
         2011
        </year>
        <fpage>
         e162
        </fpage>
        <lpage>
         e193
        </lpage>
        <pub-id pub-id-type="pmid">
         21460264
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib335">
       <label>
        335
       </label>
       <element-citation id="sbref3340" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Pittet
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Tarara
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Wenzel
          </surname>
          <given-names>
           RP
          </given-names>
         </name>
        </person-group>
        <article-title>
         Nosocomial bloodstream infection in critically ill patients. Excess length of stay, extra costs, and attributable mortality
        </article-title>
        <source>
         JAMA
        </source>
        <volume>
         271
        </volume>
        <year>
         1994
        </year>
        <fpage>
         1598
        </fpage>
        <lpage>
         1601
        </lpage>
        <pub-id pub-id-type="pmid">
         8182812
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib336">
       <label>
        336
       </label>
       <element-citation id="sbref3350" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bregenzer
          </surname>
          <given-names>
           TC
          </given-names>
         </name>
         <name>
          <surname>
           Sakmann
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Widmer
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Andreas
          </surname>
          <given-names>
           F
          </given-names>
         </name>
        </person-group>
        <article-title>
         Is routine replacement of peripheral intravenous catheters necessary?
        </article-title>
        <source>
         Arch Intern Med
        </source>
        <volume>
         158
        </volume>
        <year>
         1998
        </year>
        <fpage>
         151
        </fpage>
        <lpage>
         156
        </lpage>
        <pub-id pub-id-type="pmid">
         9448553
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib337">
       <label>
        337
       </label>
       <element-citation id="sbref3360" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cornely
          </surname>
          <given-names>
           OA
          </given-names>
         </name>
         <name>
          <surname>
           Bethe
          </surname>
          <given-names>
           U
          </given-names>
         </name>
         <name>
          <surname>
           Pauls
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Waldschmidt
          </surname>
          <given-names>
           D
          </given-names>
         </name>
        </person-group>
        <article-title>
         Peripheral Teflon catheters: factors determining incidence of phlebitis and duration of cannulation
        </article-title>
        <source>
         Infect Control Hosp Epidemiol
        </source>
        <volume>
         23
        </volume>
        <year>
         2002
        </year>
        <fpage>
         249
        </fpage>
        <lpage>
         253
        </lpage>
        <pub-id pub-id-type="pmid">
         12026149
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib338">
       <label>
        338
       </label>
       <element-citation id="sbref3370" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Grune
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Schrappe
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Basten
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Wenchel
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Tual
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Stutzer
          </surname>
          <given-names>
           H
          </given-names>
         </name>
        </person-group>
        <article-title>
         Phlebitis rate and time kinetics of short peripheral IV catheters
        </article-title>
        <source>
         Infection
        </source>
        <volume>
         32
        </volume>
        <year>
         2004
        </year>
        <fpage>
         30
        </fpage>
        <lpage>
         32
        </lpage>
        <pub-id pub-id-type="pmid">
         15007740
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib339">
       <label>
        339
       </label>
       <element-citation id="sbref3380" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rickard
          </surname>
          <given-names>
           CM
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           McClymont
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        <article-title>
         Routine versus clinically indicated replacement of peripheral intravenous catheters: a randomised controlled equivalence trial
        </article-title>
        <source>
         Lancet
        </source>
        <volume>
         380
        </volume>
        <year>
         2012
        </year>
        <fpage>
         1066
        </fpage>
        <lpage>
         1074
        </lpage>
        <pub-id pub-id-type="pmid">
         22998716
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib340">
       <label>
        340
       </label>
       <element-citation id="sbref3390" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Maki
          </surname>
          <given-names>
           DG
          </given-names>
         </name>
         <name>
          <surname>
           Kluger
          </surname>
          <given-names>
           DM
          </given-names>
         </name>
         <name>
          <surname>
           Crnich
          </surname>
          <given-names>
           CJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         The risk of bloodstream infection in adults with different intravascular devices: a systematic review of 200 published prospective studies
        </article-title>
        <source>
         Mayo Clin Proc
        </source>
        <volume>
         81
        </volume>
        <year>
         2006
        </year>
        <fpage>
         1159
        </fpage>
        <lpage>
         1171
        </lpage>
        <pub-id pub-id-type="pmid">
         16970212
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib341">
       <label>
        341
       </label>
       <element-citation id="sbref3400" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wisplinghoff
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Bischoff
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Tallent
          </surname>
          <given-names>
           SM
          </given-names>
         </name>
         <name>
          <surname>
           Seifert
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Wenzel
          </surname>
          <given-names>
           RP
          </given-names>
         </name>
         <name>
          <surname>
           Edmond
          </surname>
          <given-names>
           MB
          </given-names>
         </name>
        </person-group>
        <article-title>
         Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study
        </article-title>
        <source>
         Clin Infect Dis
        </source>
        <volume>
         39
        </volume>
        <year>
         2004
        </year>
        <fpage>
         309
        </fpage>
        <lpage>
         317
        </lpage>
        <pub-id pub-id-type="pmid">
         15306996
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib342">
       <label>
        342
       </label>
       <element-citation id="sbref3410" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gaynes
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Edwards
          </surname>
          <given-names>
           JR
          </given-names>
         </name>
         <name>
          <surname>
           National Nosocomial Infections Surveillance System
          </surname>
         </name>
        </person-group>
        <article-title>
         Overview of nosocomial infections caused by Gram-negative bacilli
        </article-title>
        <source>
         Clin Infect Dis
        </source>
        <volume>
         41
        </volume>
        <year>
         2005
        </year>
        <fpage>
         848
        </fpage>
        <lpage>
         854
        </lpage>
        <pub-id pub-id-type="pmid">
         16107985
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib343">
       <label>
        343
       </label>
       <element-citation id="sbref3420" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Safdar
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Maki
          </surname>
          <given-names>
           DG
          </given-names>
         </name>
        </person-group>
        <article-title>
         The pathogenesis of catheter-related bloodstream infection with noncuffed short-term central venous catheters
        </article-title>
        <source>
         Intensive Care Med
        </source>
        <volume>
         30
        </volume>
        <year>
         2004
        </year>
        <fpage>
         62
        </fpage>
        <lpage>
         67
        </lpage>
        <pub-id pub-id-type="pmid">
         14647886
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib344">
       <label>
        344
       </label>
       <element-citation id="sbref3430" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Maki
          </surname>
          <given-names>
           DG
          </given-names>
         </name>
         <name>
          <surname>
           Weise
          </surname>
          <given-names>
           CE
          </given-names>
         </name>
         <name>
          <surname>
           Sarafin
          </surname>
          <given-names>
           HW
          </given-names>
         </name>
        </person-group>
        <article-title>
         A semiquantitative culture method for identifying intravenous-catheter-related infection
        </article-title>
        <source>
         N Engl J Med
        </source>
        <volume>
         296
        </volume>
        <year>
         1977
        </year>
        <fpage>
         1305
        </fpage>
        <lpage>
         1309
        </lpage>
        <pub-id pub-id-type="pmid">
         323710
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib345">
       <label>
        345
       </label>
       <element-citation id="sbref3440" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Mermel
          </surname>
          <given-names>
           LA
          </given-names>
         </name>
         <name>
          <surname>
           McCormick
          </surname>
          <given-names>
           RD
          </given-names>
         </name>
         <name>
          <surname>
           Springman
          </surname>
          <given-names>
           SR
          </given-names>
         </name>
         <name>
          <surname>
           Maki
          </surname>
          <given-names>
           DG
          </given-names>
         </name>
        </person-group>
        <article-title>
         The pathogenesis and epidemiology of catheter-related infection with pulmonary artery Swan-Ganz catheters: a prospective study utilizing molecular subtyping
        </article-title>
        <source>
         Am J Med
        </source>
        <volume>
         91
        </volume>
        <year>
         1991
        </year>
        <fpage>
         197S
        </fpage>
        <lpage>
         205S
        </lpage>
        <pub-id pub-id-type="pmid">
         1928165
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib346">
       <label>
        346
       </label>
       <element-citation id="sbref3450" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Raad
          </surname>
          <given-names>
           I
          </given-names>
         </name>
         <name>
          <surname>
           Costerton
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <name>
          <surname>
           Sabharwal
          </surname>
          <given-names>
           U
          </given-names>
         </name>
         <name>
          <surname>
           Sacilowski
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Anaissie
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Bodey
          </surname>
          <given-names>
           GP
          </given-names>
         </name>
        </person-group>
        <article-title>
         Ultrastructural analysis of indwelling vascular catheters: a quantitative relationship between luminal colonization and duration of placement
        </article-title>
        <source>
         J Infect Dis
        </source>
        <volume>
         168
        </volume>
        <year>
         1993
        </year>
        <fpage>
         400
        </fpage>
        <lpage>
         407
        </lpage>
        <pub-id pub-id-type="pmid">
         8335977
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib347">
       <label>
        347
       </label>
       <element-citation id="sbref3460" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Dobbins
          </surname>
          <given-names>
           BM
          </given-names>
         </name>
         <name>
          <surname>
           Kite
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Kindon
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           McMahon
          </surname>
          <given-names>
           MJ
          </given-names>
         </name>
         <name>
          <surname>
           Wilcox
          </surname>
          <given-names>
           MH
          </given-names>
         </name>
        </person-group>
        <article-title>
         DNA fingerprinting analysis of coagulase negative staphylococci implicated in catheter related bloodstream infections
        </article-title>
        <source>
         J Clin Pathol
        </source>
        <volume>
         55
        </volume>
        <year>
         2002
        </year>
        <fpage>
         824
        </fpage>
        <lpage>
         828
        </lpage>
        <pub-id pub-id-type="pmid">
         12401819
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib348">
       <label>
        348
       </label>
       <element-citation id="sbref3470" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Anaissie
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Samonis
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Kontoyiannis
          </surname>
          <given-names>
           D
          </given-names>
         </name>
        </person-group>
        <article-title>
         Role of catheter colonization and infrequent hematogenous seeding in catheter-related infections
        </article-title>
        <source>
         Eur J Clin Microbiol Infect Dis
        </source>
        <volume>
         14
        </volume>
        <year>
         1995
        </year>
        <fpage>
         134
        </fpage>
        <lpage>
         137
        </lpage>
        <pub-id pub-id-type="pmid">
         7758480
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib349">
       <label>
        349
       </label>
       <element-citation id="sbref3480" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Raad
          </surname>
          <given-names>
           I
          </given-names>
         </name>
         <name>
          <surname>
           Mansour
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Hanna
          </surname>
          <given-names>
           HA
          </given-names>
         </name>
         <name>
          <surname>
           Awad
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Alrahwan
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Bivins
          </surname>
          <given-names>
           C
          </given-names>
         </name>
        </person-group>
        <article-title>
         Optimal frequency of changing intravenous administration sets: is it safe to prolong use beyond 72 hours?
        </article-title>
        <source>
         Infect Control Hosp Epidemiol
        </source>
        <volume>
         22
        </volume>
        <year>
         2001
        </year>
        <fpage>
         136
        </fpage>
        <lpage>
         139
        </lpage>
        <pub-id pub-id-type="pmid">
         11310690
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib350">
       <label>
        350
       </label>
       <element-citation id="sbref3490" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yoo
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Ha
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Choi
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Pai
          </surname>
          <given-names>
           H
          </given-names>
         </name>
        </person-group>
        <article-title>
         Effectiveness of surveillance of central catheter-related bloodstream infection in an ICU in Korea
        </article-title>
        <source>
         Infect Control Hosp Epidemiol
        </source>
        <volume>
         22
        </volume>
        <year>
         2001
        </year>
        <fpage>
         433
        </fpage>
        <lpage>
         436
        </lpage>
        <pub-id pub-id-type="pmid">
         11583212
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib351">
       <label>
        351
       </label>
       <element-citation id="sbref3500" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Coopersmith
          </surname>
          <given-names>
           CM
          </given-names>
         </name>
         <name>
          <surname>
           Rebmann
          </surname>
          <given-names>
           TL
          </given-names>
         </name>
         <name>
          <surname>
           Zack
          </surname>
          <given-names>
           JE
          </given-names>
         </name>
        </person-group>
        <article-title>
         Effect of an education program on decreasing catheter-related bloodstream infections in the surgical intensive care unit
        </article-title>
        <source>
         Crit Care Med
        </source>
        <volume>
         30
        </volume>
        <year>
         2002
        </year>
        <fpage>
         59
        </fpage>
        <lpage>
         64
        </lpage>
        <pub-id pub-id-type="pmid">
         11902288
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib352">
       <label>
        352
       </label>
       <element-citation id="sbref3510" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sherertz
          </surname>
          <given-names>
           RJ
          </given-names>
         </name>
         <name>
          <surname>
           Cruz
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Bowton
          </surname>
          <given-names>
           DL
          </given-names>
         </name>
        </person-group>
        <article-title>
         Education of physicians-in-training can decrease the risk for vascular catheter infection
        </article-title>
        <source>
         Ann Intern Med
        </source>
        <volume>
         132
        </volume>
        <year>
         2000
        </year>
        <fpage>
         641
        </fpage>
        <lpage>
         648
        </lpage>
        <pub-id pub-id-type="pmid">
         10766683
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib353">
       <label>
        353
       </label>
       <element-citation id="sbref3520" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Eggimann
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Harbarth
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Constantin
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Touveneau
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Chevrolet
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Pittet
          </surname>
          <given-names>
           D
          </given-names>
         </name>
        </person-group>
        <article-title>
         Impact of a prevention strategy targeted at vascular-access care on incidence of infections acquired in intensive care
        </article-title>
        <source>
         Lancet
        </source>
        <volume>
         355
        </volume>
        <year>
         2000
        </year>
        <fpage>
         1864
        </fpage>
        <lpage>
         1868
        </lpage>
        <pub-id pub-id-type="pmid">
         10866442
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib354">
       <label>
        354
       </label>
       <element-citation id="sbref3530" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sanders
          </surname>
          <given-names>
           RA
          </given-names>
         </name>
         <name>
          <surname>
           Sheldon
          </surname>
          <given-names>
           GF
          </given-names>
         </name>
        </person-group>
        <article-title>
         Septic complications of total parenteral nutrition. A five year experience
        </article-title>
        <source>
         Am J Surg
        </source>
        <volume>
         132
        </volume>
        <year>
         1976
        </year>
        <fpage>
         214
        </fpage>
        <lpage>
         220
        </lpage>
        <pub-id pub-id-type="pmid">
         821351
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib355">
       <label>
        355
       </label>
       <element-citation id="sbref3540" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ryan
          </surname>
          <given-names>
           JA
          </given-names>
          <suffix>
           Jr
          </suffix>
         </name>
         <name>
          <surname>
           Abel
          </surname>
          <given-names>
           RM
          </given-names>
         </name>
         <name>
          <surname>
           Abbott
          </surname>
          <given-names>
           WM
          </given-names>
         </name>
        </person-group>
        <article-title>
         Catheter complications in total parenteral nutrition. A prospective study of 200 consecutive patients
        </article-title>
        <source>
         N Engl J Med
        </source>
        <volume>
         290
        </volume>
        <year>
         1974
        </year>
        <fpage>
         757
        </fpage>
        <lpage>
         761
        </lpage>
        <pub-id pub-id-type="pmid">
         4205578
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib356">
       <label>
        356
       </label>
       <element-citation id="sbref3550" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Murphy
          </surname>
          <given-names>
           LM
          </given-names>
         </name>
         <name>
          <surname>
           Lipman
          </surname>
          <given-names>
           TO
          </given-names>
         </name>
        </person-group>
        <article-title>
         Central venous catheter care in parenteral nutrition: a review
        </article-title>
        <source>
         J Parenter Enteral Nutr
        </source>
        <volume>
         11
        </volume>
        <year>
         1987
        </year>
        <fpage>
         190
        </fpage>
        <lpage>
         201
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib357">
       <label>
        357
       </label>
       <element-citation id="sbref3560" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Armstrong
          </surname>
          <given-names>
           CW
          </given-names>
         </name>
         <name>
          <surname>
           Mayhall
          </surname>
          <given-names>
           CG
          </given-names>
         </name>
         <name>
          <surname>
           Miller
          </surname>
          <given-names>
           KB
          </given-names>
         </name>
        </person-group>
        <article-title>
         Prospective study of catheter replacement and other risk factors for infection of hyperalimentation catheters
        </article-title>
        <source>
         J Infect Dis
        </source>
        <volume>
         154
        </volume>
        <year>
         1986
        </year>
        <fpage>
         808
        </fpage>
        <lpage>
         816
        </lpage>
        <pub-id pub-id-type="pmid">
         3095437
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib358">
       <label>
        358
       </label>
       <mixed-citation id="oref20" publication-type="other">
        Frampton GK, Harris P, Cooper K,
        <italic>
         et al.
        </italic>
        Educational interventions for preventing vascular catheter bloodstream infections in critical care: evidence map, systematic review and economic evaluation. Health Technology Assessment. Project No. 09/01/25.
        <italic>
         Health Technol Assess
        </italic>
        in press.
       </mixed-citation>
      </ref>
      <ref id="bib359">
       <label>
        359
       </label>
       <element-citation id="sbref3570" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Snydman
          </surname>
          <given-names>
           DR
          </given-names>
         </name>
         <name>
          <surname>
           Murray
          </surname>
          <given-names>
           SA
          </given-names>
         </name>
         <name>
          <surname>
           Kornfeld
          </surname>
          <given-names>
           SJ
          </given-names>
         </name>
         <name>
          <surname>
           Majka
          </surname>
          <given-names>
           JA
          </given-names>
         </name>
         <name>
          <surname>
           Ellis
          </surname>
          <given-names>
           CA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Total parenteral nutrition-related infections: prospective epidemiologic study using semiquantitative methods
        </article-title>
        <source>
         Am J Med
        </source>
        <volume>
         73
        </volume>
        <year>
         1982
        </year>
        <fpage>
         695
        </fpage>
        <lpage>
         699
        </lpage>
        <pub-id pub-id-type="pmid">
         6814251
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib360">
       <label>
        360
       </label>
       <element-citation id="sbref3580" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sheth
          </surname>
          <given-names>
           NK
          </given-names>
         </name>
         <name>
          <surname>
           Franson
          </surname>
          <given-names>
           TR
          </given-names>
         </name>
         <name>
          <surname>
           Rose
          </surname>
          <given-names>
           HD
          </given-names>
         </name>
         <name>
          <surname>
           Buckmire
          </surname>
          <given-names>
           FL
          </given-names>
         </name>
         <name>
          <surname>
           Cooper
          </surname>
          <given-names>
           JA
          </given-names>
         </name>
         <name>
          <surname>
           Sohnle
          </surname>
          <given-names>
           PG
          </given-names>
         </name>
        </person-group>
        <article-title>
         Colonization of bacteria on polyvinyl chloride and Teflon intravascular catheters in hospitalized patients
        </article-title>
        <source>
         J Clin Microbiol
        </source>
        <volume>
         18
        </volume>
        <year>
         1983
        </year>
        <fpage>
         1061
        </fpage>
        <lpage>
         1063
        </lpage>
        <pub-id pub-id-type="pmid">
         6643657
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib361">
       <label>
        361
       </label>
       <element-citation id="sbref3590" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Maki
          </surname>
          <given-names>
           DG
          </given-names>
         </name>
         <name>
          <surname>
           Ringer
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <article-title>
         Evaluation of dressing regimens for prevention of infection with peripheral intravenous catheters. Gauze, a transparent polyurethane dressing, and an iodophor-transparent dressing
        </article-title>
        <source>
         JAMA
        </source>
        <volume>
         258
        </volume>
        <year>
         1987
        </year>
        <fpage>
         2396
        </fpage>
        <lpage>
         2403
        </lpage>
        <pub-id pub-id-type="pmid">
         3118061
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib362">
       <label>
        362
       </label>
       <element-citation id="sbref3600" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Pemberton
          </surname>
          <given-names>
           LB
          </given-names>
         </name>
         <name>
          <surname>
           Lyman
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Lander
          </surname>
          <given-names>
           V
          </given-names>
         </name>
         <name>
          <surname>
           Covinsky
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        <article-title>
         Sepsis from triple-vs single-lumen catheters during total parenteral nutrition in surgical or critically ill patients
        </article-title>
        <source>
         Arch Surg
        </source>
        <volume>
         121
        </volume>
        <year>
         1986
        </year>
        <fpage>
         591
        </fpage>
        <lpage>
         594
        </lpage>
        <pub-id pub-id-type="pmid">
         3085637
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib363">
       <label>
        363
       </label>
       <element-citation id="sbref3610" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           McCarthy
          </surname>
          <given-names>
           MC
          </given-names>
         </name>
         <name>
          <surname>
           Shives
          </surname>
          <given-names>
           JK
          </given-names>
         </name>
         <name>
          <surname>
           Robison
          </surname>
          <given-names>
           RJ
          </given-names>
         </name>
         <name>
          <surname>
           Broadie
          </surname>
          <given-names>
           TA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Prospective evaluation of single and triple lumen catheters in total parenteral nutrition
        </article-title>
        <source>
         J Parenter Enteral Nutr
        </source>
        <volume>
         11
        </volume>
        <year>
         1987
        </year>
        <fpage>
         259
        </fpage>
        <lpage>
         262
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib364">
       <label>
        364
       </label>
       <element-citation id="sbref3620" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hilton
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Haslett
          </surname>
          <given-names>
           TM
          </given-names>
         </name>
         <name>
          <surname>
           Borenstein
          </surname>
          <given-names>
           MT
          </given-names>
         </name>
         <name>
          <surname>
           Tucci
          </surname>
          <given-names>
           V
          </given-names>
         </name>
         <name>
          <surname>
           Isenberg
          </surname>
          <given-names>
           HD
          </given-names>
         </name>
         <name>
          <surname>
           Singer
          </surname>
          <given-names>
           C
          </given-names>
         </name>
        </person-group>
        <article-title>
         Central catheter infections: single-versus triple-lumen catheters. Influence of guide wires on infection rates when used for replacement of catheters
        </article-title>
        <source>
         Am J Med
        </source>
        <volume>
         84
        </volume>
        <year>
         1988
        </year>
        <fpage>
         667
        </fpage>
        <lpage>
         672
        </lpage>
        <pub-id pub-id-type="pmid">
         3400662
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib365">
       <label>
        365
       </label>
       <element-citation id="sbref3630" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yeung
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           May
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Hughes
          </surname>
          <given-names>
           R
          </given-names>
         </name>
        </person-group>
        <article-title>
         Infection rate for single lumen v triple lumen subclavian catheters
        </article-title>
        <source>
         Infect Control Hosp Epidemiol
        </source>
        <volume>
         9
        </volume>
        <year>
         1988
        </year>
        <fpage>
         154
        </fpage>
        <lpage>
         158
        </lpage>
        <pub-id pub-id-type="pmid">
         3129491
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib366">
       <label>
        366
       </label>
       <element-citation id="sbref3640" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Clark-Christoff
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Watters
          </surname>
          <given-names>
           VA
          </given-names>
         </name>
         <name>
          <surname>
           Sparks
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <name>
          <surname>
           Snyder
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Grant
          </surname>
          <given-names>
           JP
          </given-names>
         </name>
        </person-group>
        <article-title>
         Use of triple-lumen subclavian catheters for administration of total parenteral nutrition
        </article-title>
        <source>
         J Parenter Enteral Nutr
        </source>
        <volume>
         16
        </volume>
        <year>
         1992
        </year>
        <fpage>
         403
        </fpage>
        <lpage>
         407
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib367">
       <label>
        367
       </label>
       <element-citation id="sbref3650" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Early
          </surname>
          <given-names>
           TF
          </given-names>
         </name>
         <name>
          <surname>
           Gregory
          </surname>
          <given-names>
           RT
          </given-names>
         </name>
         <name>
          <surname>
           Wheeler
          </surname>
          <given-names>
           JR
          </given-names>
         </name>
         <name>
          <surname>
           Snyder
          </surname>
          <given-names>
           SO
          </given-names>
          <suffix>
           Jr
          </suffix>
         </name>
         <name>
          <surname>
           Gayle
          </surname>
          <given-names>
           RG
          </given-names>
         </name>
        </person-group>
        <article-title>
         Increased infection rate in double-lumen versus single-lumen Hickman catheters in cancer patients
        </article-title>
        <source>
         South Med J
        </source>
        <volume>
         83
        </volume>
        <year>
         1990
        </year>
        <fpage>
         34
        </fpage>
        <lpage>
         36
        </lpage>
        <pub-id pub-id-type="pmid">
         2300831
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib368">
       <label>
        368
       </label>
       <element-citation id="sbref3660" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Farkas
          </surname>
          <given-names>
           JC
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Bleriot
          </surname>
          <given-names>
           JP
          </given-names>
         </name>
         <name>
          <surname>
           Chevret
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Goldstein
          </surname>
          <given-names>
           FW
          </given-names>
         </name>
         <name>
          <surname>
           Carlet
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        <article-title>
         Single- versus triple-lumen central catheter-related sepsis: a prospective randomized study in a critically ill population
        </article-title>
        <source>
         Am J Med
        </source>
        <volume>
         93
        </volume>
        <year>
         1992
        </year>
        <fpage>
         277
        </fpage>
        <lpage>
         282
        </lpage>
        <pub-id pub-id-type="pmid">
         1524079
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib369">
       <label>
        369
       </label>
       <element-citation id="sbref3670" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gil
          </surname>
          <given-names>
           RT
          </given-names>
         </name>
         <name>
          <surname>
           Kruse
          </surname>
          <given-names>
           JA
          </given-names>
         </name>
         <name>
          <surname>
           Thill-Baharozian
          </surname>
          <given-names>
           MC
          </given-names>
         </name>
         <name>
          <surname>
           Carlson
          </surname>
          <given-names>
           RW
          </given-names>
         </name>
        </person-group>
        <article-title>
         Triple- vs single-lumen central venous catheters. A prospective study in a critically ill population
        </article-title>
        <source>
         Arch Intern Med
        </source>
        <volume>
         149
        </volume>
        <year>
         1989
        </year>
        <fpage>
         1139
        </fpage>
        <lpage>
         1143
        </lpage>
        <pub-id pub-id-type="pmid">
         2497712
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib370">
       <label>
        370
       </label>
       <element-citation id="sbref3680" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Dezfulian
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Lavelle
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Nallamothu
          </surname>
          <given-names>
           BK
          </given-names>
         </name>
         <name>
          <surname>
           Kaufman
          </surname>
          <given-names>
           SR
          </given-names>
         </name>
         <name>
          <surname>
           Saint
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        <article-title>
         Rates of infection for single-lumen versus multilumen central venous catheters: a meta-analysis
        </article-title>
        <source>
         Crit Care Med
        </source>
        <volume>
         31
        </volume>
        <year>
         2003
        </year>
        <fpage>
         2385
        </fpage>
        <lpage>
         2390
        </lpage>
        <pub-id pub-id-type="pmid">
         14501971
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib371">
       <label>
        371
       </label>
       <element-citation id="sbref3690" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zürcher
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Tramèr
          </surname>
          <given-names>
           MR
          </given-names>
         </name>
         <name>
          <surname>
           Walder
          </surname>
          <given-names>
           B
          </given-names>
         </name>
        </person-group>
        <article-title>
         Colonization and bloodstream infection with single- versus multi-lumen central venous catheters: a quantitative systematic review
        </article-title>
        <source>
         Anesth Analg
        </source>
        <volume>
         99
        </volume>
        <year>
         2004
        </year>
        <fpage>
         177
        </fpage>
        <lpage>
         182
        </lpage>
        <pub-id pub-id-type="pmid">
         15281526
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib372">
       <label>
        372
       </label>
       <element-citation id="sbref3700" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Pearson
          </surname>
          <given-names>
           ML
          </given-names>
         </name>
        </person-group>
        <article-title>
         Guideline for prevention of intravascular device-related infections. Hospital Infection Control Practices Advisory Committee
        </article-title>
        <source>
         Infect Control Hosp Epidemiol
        </source>
        <volume>
         17
        </volume>
        <year>
         1996
        </year>
        <fpage>
         438
        </fpage>
        <lpage>
         473
        </lpage>
        <pub-id pub-id-type="pmid">
         8839803
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib373">
       <label>
        373
       </label>
       <element-citation id="sbref3710" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Abrahm
          </surname>
          <given-names>
           JL
          </given-names>
         </name>
         <name>
          <surname>
           Mullen
          </surname>
          <given-names>
           JL
          </given-names>
         </name>
        </person-group>
        <article-title>
         A prospective study of prolonged central venous access in leukemia
        </article-title>
        <source>
         JAMA
        </source>
        <volume>
         248
        </volume>
        <year>
         1982
        </year>
        <fpage>
         2868
        </fpage>
        <lpage>
         2873
        </lpage>
        <pub-id pub-id-type="pmid">
         7143650
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib374">
       <label>
        374
       </label>
       <element-citation id="sbref3720" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Shapiro
          </surname>
          <given-names>
           ED
          </given-names>
         </name>
         <name>
          <surname>
           Wald
          </surname>
          <given-names>
           ER
          </given-names>
         </name>
         <name>
          <surname>
           Nelson
          </surname>
          <given-names>
           KA
          </given-names>
         </name>
         <name>
          <surname>
           Spiegelman
          </surname>
          <given-names>
           KN
          </given-names>
         </name>
        </person-group>
        <article-title>
         Broviac catheter-related bacteremia in oncology patients
        </article-title>
        <source>
         Am J Dis Child
        </source>
        <volume>
         136
        </volume>
        <year>
         1982
        </year>
        <fpage>
         679
        </fpage>
        <lpage>
         681
        </lpage>
        <pub-id pub-id-type="pmid">
         7102618
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib375">
       <label>
        375
       </label>
       <element-citation id="sbref3730" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Press
          </surname>
          <given-names>
           OW
          </given-names>
         </name>
         <name>
          <surname>
           Ramsey
          </surname>
          <given-names>
           PG
          </given-names>
         </name>
         <name>
          <surname>
           Larson
          </surname>
          <given-names>
           EB
          </given-names>
         </name>
         <name>
          <surname>
           Fefer
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Hickman
          </surname>
          <given-names>
           RO
          </given-names>
         </name>
        </person-group>
        <article-title>
         Hickman catheter infections in patients with malignancies
        </article-title>
        <source>
         Medicine
        </source>
        <volume>
         63
        </volume>
        <year>
         1984
        </year>
        <fpage>
         189
        </fpage>
        <lpage>
         200
        </lpage>
        <pub-id pub-id-type="pmid">
         6377003
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib376">
       <label>
        376
       </label>
       <element-citation id="sbref3740" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Darbyshire
          </surname>
          <given-names>
           PJ
          </given-names>
         </name>
         <name>
          <surname>
           Weightman
          </surname>
          <given-names>
           NC
          </given-names>
         </name>
         <name>
          <surname>
           Speller
          </surname>
          <given-names>
           DC
          </given-names>
         </name>
        </person-group>
        <article-title>
         Problems associated with indwelling central venous catheters
        </article-title>
        <source>
         Arch Dis Child
        </source>
        <volume>
         60
        </volume>
        <year>
         1985
        </year>
        <fpage>
         129
        </fpage>
        <lpage>
         134
        </lpage>
        <pub-id pub-id-type="pmid">
         3977384
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib377">
       <label>
        377
       </label>
       <element-citation id="sbref3750" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Pessa
          </surname>
          <given-names>
           ME
          </given-names>
         </name>
         <name>
          <surname>
           Howard
          </surname>
          <given-names>
           RJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         Complications of Hickman-Broviac catheters
        </article-title>
        <source>
         Surg Gynecol Obstet
        </source>
        <volume>
         161
        </volume>
        <year>
         1985
        </year>
        <fpage>
         257
        </fpage>
        <lpage>
         260
        </lpage>
        <pub-id pub-id-type="pmid">
         3929413
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib378">
       <label>
        378
       </label>
       <element-citation id="sbref3760" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Schuman
          </surname>
          <given-names>
           ES
          </given-names>
         </name>
         <name>
          <surname>
           Winters
          </surname>
          <given-names>
           V
          </given-names>
         </name>
         <name>
          <surname>
           Gross
          </surname>
          <given-names>
           GF
          </given-names>
         </name>
         <name>
          <surname>
           Hayes
          </surname>
          <given-names>
           JF
          </given-names>
         </name>
        </person-group>
        <article-title>
         Management of Hickman catheter sepsis
        </article-title>
        <source>
         Am J Surg
        </source>
        <volume>
         149
        </volume>
        <year>
         1985
        </year>
        <fpage>
         627
        </fpage>
        <lpage>
         628
        </lpage>
        <pub-id pub-id-type="pmid">
         3993842
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib379">
       <label>
        379
       </label>
       <element-citation id="sbref3770" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rannem
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Ladefoged
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Tvede
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Lorentzen
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Jarnum
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        <article-title>
         Catheter-related septicemia in patients receiving home parenteral nutrition
        </article-title>
        <source>
         Scand J Gastroenterol
        </source>
        <volume>
         21
        </volume>
        <year>
         1986
        </year>
        <fpage>
         455
        </fpage>
        <lpage>
         460
        </lpage>
        <pub-id pub-id-type="pmid">
         3088720
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib380">
       <label>
        380
       </label>
       <element-citation id="sbref3780" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Shulman
          </surname>
          <given-names>
           RJ
          </given-names>
         </name>
         <name>
          <surname>
           Smith
          </surname>
          <given-names>
           EO
          </given-names>
         </name>
         <name>
          <surname>
           Rahman
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Gardner
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Reed
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Mahoney
          </surname>
          <given-names>
           D
          </given-names>
         </name>
        </person-group>
        <article-title>
         Single- vs double-lumen central venous catheters in pediatric oncology patients
        </article-title>
        <source>
         Am J Dis Child
        </source>
        <volume>
         142
        </volume>
        <year>
         1988
        </year>
        <fpage>
         893
        </fpage>
        <lpage>
         895
        </lpage>
        <pub-id pub-id-type="pmid">
         3394681
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib381">
       <label>
        381
       </label>
       <element-citation id="sbref3790" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Weightman
          </surname>
          <given-names>
           NC
          </given-names>
         </name>
         <name>
          <surname>
           Simpson
          </surname>
          <given-names>
           EM
          </given-names>
         </name>
         <name>
          <surname>
           Speller
          </surname>
          <given-names>
           DC
          </given-names>
         </name>
         <name>
          <surname>
           Mott
          </surname>
          <given-names>
           MG
          </given-names>
         </name>
         <name>
          <surname>
           Oakhill
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        <article-title>
         Bacteraemia related to indwelling central venous catheters: prevention, diagnosis and treatment
        </article-title>
        <source>
         Eur J Clin Microbiol Infect Dis
        </source>
        <volume>
         7
        </volume>
        <year>
         1988
        </year>
        <fpage>
         125
        </fpage>
        <lpage>
         129
        </lpage>
        <pub-id pub-id-type="pmid">
         3134199
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib382">
       <label>
        382
       </label>
       <element-citation id="sbref3800" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Raad
          </surname>
          <given-names>
           I
          </given-names>
         </name>
         <name>
          <surname>
           Davis
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Becker
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <article-title>
         Low infection rate and long durability of nontunneled silastic catheters. A safe and cost-effective alternative for long-term venous access
        </article-title>
        <source>
         Arch Intern Med
        </source>
        <volume>
         153
        </volume>
        <year>
         1993
        </year>
        <fpage>
         1791
        </fpage>
        <lpage>
         1796
        </lpage>
        <pub-id pub-id-type="pmid">
         8392831
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib383">
       <label>
        383
       </label>
       <element-citation id="sbref3810" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Andrivet
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Bacquer
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Ngoc
          </surname>
          <given-names>
           CV
          </given-names>
         </name>
        </person-group>
        <article-title>
         Lack of clinical benefit from subcutaneous tunnel insertion of central venous catheters in immunocompromised patients
        </article-title>
        <source>
         Clin Infect Dis
        </source>
        <volume>
         18
        </volume>
        <year>
         1994
        </year>
        <fpage>
         199
        </fpage>
        <lpage>
         206
        </lpage>
        <pub-id pub-id-type="pmid">
         8161627
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib384">
       <label>
        384
       </label>
       <element-citation id="sbref3820" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gyves
          </surname>
          <given-names>
           JW
          </given-names>
         </name>
         <name>
          <surname>
           Ensminger
          </surname>
          <given-names>
           WD
          </given-names>
         </name>
         <name>
          <surname>
           Niederhuber
          </surname>
          <given-names>
           JE
          </given-names>
         </name>
        </person-group>
        <article-title>
         A totally implanted injection port system for blood sampling and chemotherapy administration
        </article-title>
        <source>
         JAMA
        </source>
        <volume>
         251
        </volume>
        <year>
         1984
        </year>
        <fpage>
         2538
        </fpage>
        <lpage>
         2541
        </lpage>
        <pub-id pub-id-type="pmid">
         6716582
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib385">
       <label>
        385
       </label>
       <element-citation id="sbref3830" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lokich
          </surname>
          <given-names>
           JJ
          </given-names>
         </name>
         <name>
          <surname>
           Bothe
          </surname>
          <given-names>
           A
          </given-names>
          <suffix>
           Jr
          </suffix>
         </name>
         <name>
          <surname>
           Benotti
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Moore
          </surname>
          <given-names>
           C
          </given-names>
         </name>
        </person-group>
        <article-title>
         Complications and management of implanted venous access catheters
        </article-title>
        <source>
         J Clin Oncol
        </source>
        <volume>
         3
        </volume>
        <year>
         1985
        </year>
        <fpage>
         710
        </fpage>
        <lpage>
         717
        </lpage>
        <pub-id pub-id-type="pmid">
         3923161
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib386">
       <label>
        386
       </label>
       <element-citation id="sbref3840" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Khoury
          </surname>
          <given-names>
           MD
          </given-names>
         </name>
         <name>
          <surname>
           Lloyd
          </surname>
          <given-names>
           LR
          </given-names>
         </name>
         <name>
          <surname>
           Burrows
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Berg
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Yap
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        <article-title>
         A totally implanted venous access system for the delivery of chemotherapy
        </article-title>
        <source>
         Cancer
        </source>
        <volume>
         56
        </volume>
        <year>
         1985
        </year>
        <fpage>
         1231
        </fpage>
        <lpage>
         1234
        </lpage>
        <pub-id pub-id-type="pmid">
         4016711
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib387">
       <label>
        387
       </label>
       <element-citation id="sbref3850" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           McDowell
          </surname>
          <given-names>
           HP
          </given-names>
         </name>
         <name>
          <surname>
           Hart
          </surname>
          <given-names>
           CA
          </given-names>
         </name>
         <name>
          <surname>
           Martin
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        <article-title>
         Implantable subcutaneous venous catheters
        </article-title>
        <source>
         Arch Dis Child
        </source>
        <volume>
         61
        </volume>
        <year>
         1986
        </year>
        <fpage>
         1037
        </fpage>
        <lpage>
         1038
        </lpage>
        <pub-id pub-id-type="pmid">
         3777988
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib388">
       <label>
        388
       </label>
       <element-citation id="sbref3860" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Brincker
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Saeter
          </surname>
          <given-names>
           G
          </given-names>
         </name>
        </person-group>
        <article-title>
         Fifty-five patient years' experience with a totally implanted system for intravenous chemotherapy
        </article-title>
        <source>
         Cancer
        </source>
        <volume>
         57
        </volume>
        <year>
         1986
        </year>
        <fpage>
         1124
        </fpage>
        <lpage>
         1129
        </lpage>
        <pub-id pub-id-type="pmid">
         3943036
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib389">
       <label>
        389
       </label>
       <element-citation id="sbref3870" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wurzel
          </surname>
          <given-names>
           CL
          </given-names>
         </name>
         <name>
          <surname>
           Halom
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Feldman
          </surname>
          <given-names>
           JG
          </given-names>
         </name>
         <name>
          <surname>
           Rubin
          </surname>
          <given-names>
           LG
          </given-names>
         </name>
        </person-group>
        <article-title>
         Infection rates of Broviac-Hickman catheters and implantable venous devices
        </article-title>
        <source>
         Am J Dis Child
        </source>
        <volume>
         142
        </volume>
        <year>
         1988
        </year>
        <fpage>
         536
        </fpage>
        <lpage>
         540
        </lpage>
        <pub-id pub-id-type="pmid">
         3358396
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib390">
       <label>
        390
       </label>
       <element-citation id="sbref3880" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kappers-Klunne
          </surname>
          <given-names>
           MC
          </given-names>
         </name>
         <name>
          <surname>
           Degener
          </surname>
          <given-names>
           JE
          </given-names>
         </name>
         <name>
          <surname>
           Stijnen
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Abels
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        <article-title>
         Complications from long-term indwelling central venous catheters in hematologic patients with special reference to infection
        </article-title>
        <source>
         Cancer
        </source>
        <volume>
         64
        </volume>
        <year>
         1989
        </year>
        <fpage>
         1747
        </fpage>
        <lpage>
         1752
        </lpage>
        <pub-id pub-id-type="pmid">
         2790689
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib391">
       <label>
        391
       </label>
       <element-citation id="sbref3890" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Carde
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Cosset-Delaigue
          </surname>
          <given-names>
           MF
          </given-names>
         </name>
         <name>
          <surname>
           Laplanche
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Chareau
          </surname>
          <given-names>
           I
          </given-names>
         </name>
        </person-group>
        <article-title>
         Classical external indwelling central venous catheter versus totally implanted venous access systems for chemotherapy administration: a randomized trial in 100 patients with solid tumors
        </article-title>
        <source>
         Eur J Cancer Clin Oncol
        </source>
        <volume>
         25
        </volume>
        <year>
         1989
        </year>
        <fpage>
         939
        </fpage>
        <lpage>
         944
        </lpage>
        <pub-id pub-id-type="pmid">
         2666137
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib392">
       <label>
        392
       </label>
       <element-citation id="sbref3900" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Pegues
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Axelrod
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           McClarren
          </surname>
          <given-names>
           C
          </given-names>
         </name>
        </person-group>
        <article-title>
         Comparison of infections in Hickman and implanted port catheters in adult solid tumor patients
        </article-title>
        <source>
         J Surg Oncol
        </source>
        <volume>
         49
        </volume>
        <year>
         1992
        </year>
        <fpage>
         156
        </fpage>
        <lpage>
         162
        </lpage>
        <pub-id pub-id-type="pmid">
         1548889
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib393">
       <label>
        393
       </label>
       <element-citation id="sbref3910" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           van der Pijl
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Frissen
          </surname>
          <given-names>
           PH
          </given-names>
         </name>
        </person-group>
        <article-title>
         Experience with a totally implantable venous access device (Port-A-Cath) in patients with AIDS
        </article-title>
        <source>
         AIDS
        </source>
        <volume>
         6
        </volume>
        <year>
         1992
        </year>
        <fpage>
         709
        </fpage>
        <lpage>
         713
        </lpage>
        <pub-id pub-id-type="pmid">
         1503690
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib394">
       <label>
        394
       </label>
       <element-citation id="sbref3920" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Groeger
          </surname>
          <given-names>
           JS
          </given-names>
         </name>
         <name>
          <surname>
           Lucas
          </surname>
          <given-names>
           AB
          </given-names>
         </name>
         <name>
          <surname>
           Thaler
          </surname>
          <given-names>
           HT
          </given-names>
         </name>
        </person-group>
        <article-title>
         Infectious morbidity associated with long-term use of venous access devices in patients with cancer
        </article-title>
        <source>
         Ann Intern Med
        </source>
        <volume>
         119
        </volume>
        <year>
         1993
        </year>
        <fpage>
         1168
        </fpage>
        <lpage>
         1174
        </lpage>
        <pub-id pub-id-type="pmid">
         8239247
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib395">
       <label>
        395
       </label>
       <element-citation id="sbref3930" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Galloway
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Bodenham
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        <article-title>
         Long-term central venous access
        </article-title>
        <source>
         Br J Anaesth
        </source>
        <volume>
         92
        </volume>
        <year>
         2004
        </year>
        <fpage>
         722
        </fpage>
        <lpage>
         734
        </lpage>
        <pub-id pub-id-type="pmid">
         15003979
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib396">
       <label>
        396
       </label>
       <element-citation id="sbref3940" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Timsit
          </surname>
          <given-names>
           JF
          </given-names>
         </name>
         <name>
          <surname>
           Sebille
          </surname>
          <given-names>
           V
          </given-names>
         </name>
         <name>
          <surname>
           Farkas
          </surname>
          <given-names>
           JC
          </given-names>
         </name>
        </person-group>
        <article-title>
         Effect of subcutaneous tunneling on internal jugular catheter-related sepsis in critically ill patients: a prospective randomized multicenter study
        </article-title>
        <source>
         JAMA
        </source>
        <volume>
         276
        </volume>
        <year>
         1996
        </year>
        <fpage>
         1416
        </fpage>
        <lpage>
         1420
        </lpage>
        <pub-id pub-id-type="pmid">
         8892717
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib397">
       <label>
        397
       </label>
       <element-citation id="sbref3950" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Timsit
          </surname>
          <given-names>
           JF
          </given-names>
         </name>
         <name>
          <surname>
           Carlet
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Bruneel
          </surname>
          <given-names>
           F
          </given-names>
         </name>
        </person-group>
        <article-title>
         Use of tunneled femoral catheters to prevent catheter-related infection. A randomized, controlled trial
        </article-title>
        <source>
         Ann Intern Med
        </source>
        <volume>
         130
        </volume>
        <year>
         1999
        </year>
        <fpage>
         729
        </fpage>
        <lpage>
         735
        </lpage>
        <pub-id pub-id-type="pmid">
         10357691
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib398">
       <label>
        398
       </label>
       <element-citation id="sbref3960" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Randolph
          </surname>
          <given-names>
           AG
          </given-names>
         </name>
         <name>
          <surname>
           Cook
          </surname>
          <given-names>
           DJ
          </given-names>
         </name>
         <name>
          <surname>
           Gonzales
          </surname>
          <given-names>
           CA
          </given-names>
         </name>
         <name>
          <surname>
           Brun-Buisson
          </surname>
          <given-names>
           C
          </given-names>
         </name>
        </person-group>
        <article-title>
         Tunneling short-term central venous catheters to prevent catheter-related infection: a meta-analysis of randomized, controlled trials
        </article-title>
        <source>
         Crit Care Med
        </source>
        <volume>
         26
        </volume>
        <year>
         1998
        </year>
        <fpage>
         1452
        </fpage>
        <lpage>
         1457
        </lpage>
        <pub-id pub-id-type="pmid">
         9710109
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib399">
       <label>
        399
       </label>
       <element-citation id="sbref3970" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ryder
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Peripheral access options
        </article-title>
        <source>
         Surg Oncol Clin N Am
        </source>
        <volume>
         4
        </volume>
        <year>
         1995
        </year>
        <fpage>
         395
        </fpage>
        <lpage>
         427
        </lpage>
        <pub-id pub-id-type="pmid">
         7552784
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib400">
       <label>
        400
       </label>
       <element-citation id="sbref3980" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bottino
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           McCredie
          </surname>
          <given-names>
           KB
          </given-names>
         </name>
         <name>
          <surname>
           Groschel
          </surname>
          <given-names>
           DH
          </given-names>
         </name>
         <name>
          <surname>
           Lawson
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <article-title>
         Long-term intravenous therapy with peripherally inserted silicone elastomer central venous catheters in patients with malignant diseases
        </article-title>
        <source>
         Cancer
        </source>
        <volume>
         43
        </volume>
        <year>
         1979
        </year>
        <fpage>
         1937
        </fpage>
        <lpage>
         1943
        </lpage>
        <pub-id pub-id-type="pmid">
         109182
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib401">
       <label>
        401
       </label>
       <element-citation id="sbref3990" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Graham
          </surname>
          <given-names>
           DR
          </given-names>
         </name>
         <name>
          <surname>
           Keldermans
          </surname>
          <given-names>
           MM
          </given-names>
         </name>
         <name>
          <surname>
           Klemm
          </surname>
          <given-names>
           LW
          </given-names>
         </name>
         <name>
          <surname>
           Semenza
          </surname>
          <given-names>
           NJ
          </given-names>
         </name>
         <name>
          <surname>
           Shafer
          </surname>
          <given-names>
           ML
          </given-names>
         </name>
        </person-group>
        <article-title>
         Infectious complications among patients receiving home intravenous therapy with peripheral, central, or peripherally placed central venous catheters
        </article-title>
        <source>
         Am J Med
        </source>
        <volume>
         91
        </volume>
        <issue>
         Suppl. 2
        </issue>
        <year>
         1991
        </year>
        <fpage>
         S95
        </fpage>
        <lpage>
         S100
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib402">
       <label>
        402
       </label>
       <element-citation id="sbref4000" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Merrell
          </surname>
          <given-names>
           SW
          </given-names>
         </name>
         <name>
          <surname>
           Peatross
          </surname>
          <given-names>
           BG
          </given-names>
         </name>
         <name>
          <surname>
           Grossman
          </surname>
          <given-names>
           MD
          </given-names>
         </name>
         <name>
          <surname>
           Sullivan
          </surname>
          <given-names>
           JJ
          </given-names>
         </name>
         <name>
          <surname>
           Harker
          </surname>
          <given-names>
           WG
          </given-names>
         </name>
        </person-group>
        <article-title>
         Peripherally inserted central venous catheters. Low-risk alternatives for ongoing venous access
        </article-title>
        <source>
         West J Med
        </source>
        <volume>
         160
        </volume>
        <year>
         1994
        </year>
        <fpage>
         25
        </fpage>
        <lpage>
         30
        </lpage>
        <pub-id pub-id-type="pmid">
         8128698
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib403">
       <label>
        403
       </label>
       <element-citation id="sbref4010" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Thiagarajan
          </surname>
          <given-names>
           RR
          </given-names>
         </name>
         <name>
          <surname>
           Ramamoorthy
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Gettmann
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Bratton
          </surname>
          <given-names>
           SL
          </given-names>
         </name>
        </person-group>
        <article-title>
         Survey of the use of peripherally inserted central venous catheters in children
        </article-title>
        <source>
         Pediatrics
        </source>
        <volume>
         99
        </volume>
        <year>
         1997
        </year>
        <fpage>
         e4
        </fpage>
       </element-citation>
      </ref>
      <ref id="bib404">
       <label>
        404
       </label>
       <element-citation id="sbref4020" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Skiest
          </surname>
          <given-names>
           DJ
          </given-names>
         </name>
         <name>
          <surname>
           Abbott
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Keiser
          </surname>
          <given-names>
           P
          </given-names>
         </name>
        </person-group>
        <article-title>
         Peripherally inserted central catheters in patients with AIDS are associated with a low infection rate
        </article-title>
        <source>
         Clin Infect Dis
        </source>
        <volume>
         30
        </volume>
        <year>
         2000
        </year>
        <fpage>
         949
        </fpage>
        <lpage>
         952
        </lpage>
        <pub-id pub-id-type="pmid">
         10880311
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib405">
       <label>
        405
       </label>
       <element-citation id="sbref4030" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Safdar
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Maki
          </surname>
          <given-names>
           DG
          </given-names>
         </name>
        </person-group>
        <article-title>
         Risk of catheter-related bloodstream infection with peripherally inserted central venous catheters used in hospitalized patients
        </article-title>
        <source>
         Chest
        </source>
        <volume>
         128
        </volume>
        <year>
         2005
        </year>
        <fpage>
         489
        </fpage>
        <lpage>
         495
        </lpage>
        <pub-id pub-id-type="pmid">
         16100130
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib406">
       <label>
        406
       </label>
       <element-citation id="sbref4040" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Maki
          </surname>
          <given-names>
           DG
          </given-names>
         </name>
         <name>
          <surname>
           Stolz
          </surname>
          <given-names>
           SM
          </given-names>
         </name>
         <name>
          <surname>
           Wheeler
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Mermel
          </surname>
          <given-names>
           LA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Prevention of central venous catheter-related bloodstream infection by use of an antiseptic-impregnated catheter. A randomized, controlled trial
        </article-title>
        <source>
         Ann Intern Med
        </source>
        <volume>
         127
        </volume>
        <year>
         1997
        </year>
        <fpage>
         257
        </fpage>
        <lpage>
         266
        </lpage>
        <pub-id pub-id-type="pmid">
         9265424
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib407">
       <label>
        407
       </label>
       <element-citation id="sbref4050" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Logghe
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Van Ossel
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           D'Hoore
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <name>
          <surname>
           Ezzedine
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Wauters
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Haxhe
          </surname>
          <given-names>
           JJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         Evaluation of chlorhexidine and silver-sulfadiazine impregnated central venous catheters for the prevention of bloodstream infection in leukaemic patients: a randomized controlled trial
        </article-title>
        <source>
         J Hosp Infect
        </source>
        <volume>
         37
        </volume>
        <year>
         1997
        </year>
        <fpage>
         145
        </fpage>
        <lpage>
         156
        </lpage>
        <pub-id pub-id-type="pmid">
         9364263
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib408">
       <label>
        408
       </label>
       <element-citation id="sbref4060" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Heard
          </surname>
          <given-names>
           SO
          </given-names>
         </name>
         <name>
          <surname>
           Wagle
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Vijayakumar
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           McLean
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Brueggemann
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Napolitano
          </surname>
          <given-names>
           LM
          </given-names>
         </name>
        </person-group>
        <article-title>
         Influence of triple-lumen central venous catheters coated with chlorhexidine and silver sulfadiazine on the incidence of catheter-related bacteremia
        </article-title>
        <source>
         Arch Intern Med
        </source>
        <volume>
         158
        </volume>
        <year>
         1998
        </year>
        <fpage>
         81
        </fpage>
        <lpage>
         87
        </lpage>
        <pub-id pub-id-type="pmid">
         9437382
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib409">
       <label>
        409
       </label>
       <element-citation id="sbref4070" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Haxhe
          </surname>
          <given-names>
           JJ
          </given-names>
         </name>
         <name>
          <surname>
           D'Hoore
          </surname>
          <given-names>
           W
          </given-names>
         </name>
        </person-group>
        <article-title>
         A meta-analysis dealing with the effectiveness of chlorhexidine and silver-sufhadiazine impregnated central venous catheters
        </article-title>
        <source>
         J Hosp Infect
        </source>
        <volume>
         40
        </volume>
        <year>
         1998
        </year>
        <fpage>
         166
        </fpage>
        <lpage>
         168
        </lpage>
        <pub-id pub-id-type="pmid">
         9819700
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib410">
       <label>
        410
       </label>
       <element-citation id="sbref4080" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Oda
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Hamasaki
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Kanda
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Mikami
          </surname>
          <given-names>
           K
          </given-names>
         </name>
        </person-group>
        <article-title>
         Anaphylactic shock induced by an antiseptic-coated central venous [correction of nervous] catheter
        </article-title>
        <source>
         Anesthesiology
        </source>
        <volume>
         87
        </volume>
        <year>
         1997
        </year>
        <fpage>
         1242
        </fpage>
        <lpage>
         1244
        </lpage>
        <pub-id pub-id-type="pmid">
         9366479
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib411">
       <label>
        411
       </label>
       <element-citation id="sbref4090" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Veenstra
          </surname>
          <given-names>
           DL
          </given-names>
         </name>
         <name>
          <surname>
           Saint
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Sullivan
          </surname>
          <given-names>
           SD
          </given-names>
         </name>
        </person-group>
        <article-title>
         Cost-effectiveness of antiseptic-impregnated central venous catheters for the prevention of catheter-related bloodstream infection
        </article-title>
        <source>
         JAMA
        </source>
        <volume>
         282
        </volume>
        <year>
         1999
        </year>
        <fpage>
         554
        </fpage>
        <lpage>
         560
        </lpage>
        <pub-id pub-id-type="pmid">
         10450717
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib412">
       <label>
        412
       </label>
       <element-citation id="sbref4100" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Raad
          </surname>
          <given-names>
           I
          </given-names>
         </name>
         <name>
          <surname>
           Buzaid
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Robertson
          </surname>
          <given-names>
           C
          </given-names>
         </name>
        </person-group>
        <article-title>
         Central venous catheters coated with minocycline and rifampin for the prevention of catheter-related colonization and bloodstream infections. A randomized, double-blind trial. The Texas Medical Center Catheter Study Group
        </article-title>
        <source>
         Ann Intern Med
        </source>
        <volume>
         127
        </volume>
        <year>
         1997
        </year>
        <fpage>
         267
        </fpage>
        <lpage>
         274
        </lpage>
        <pub-id pub-id-type="pmid">
         9265425
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib413">
       <label>
        413
       </label>
       <element-citation id="sbref4110" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Collin
          </surname>
          <given-names>
           GR
          </given-names>
         </name>
        </person-group>
        <article-title>
         Decreasing catheter colonization through the use of an antiseptic-impregnated catheter: a continuous quality improvement project
        </article-title>
        <source>
         Chest
        </source>
        <volume>
         115
        </volume>
        <year>
         1999
        </year>
        <fpage>
         1632
        </fpage>
        <lpage>
         1640
        </lpage>
        <pub-id pub-id-type="pmid">
         10378561
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib414">
       <label>
        414
       </label>
       <element-citation id="sbref4120" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Darouiche
          </surname>
          <given-names>
           RO
          </given-names>
         </name>
         <name>
          <surname>
           Hachem
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Harris
          </surname>
          <given-names>
           RL
          </given-names>
         </name>
         <name>
          <surname>
           Mayhall
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Raad
          </surname>
          <given-names>
           II
          </given-names>
         </name>
         <name>
          <surname>
           Heard
          </surname>
          <given-names>
           SO
          </given-names>
         </name>
        </person-group>
        <article-title>
         A Comparison of Two Antimicrobial-Impregnated Central Venous Catheters
        </article-title>
        <source>
         N Engl J Med
        </source>
        <volume>
         340
        </volume>
        <year>
         1999
        </year>
        <fpage>
         1
        </fpage>
        <lpage>
         8
        </lpage>
        <pub-id pub-id-type="pmid">
         9878638
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib415">
       <label>
        415
       </label>
       <element-citation id="sbref4130" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Veenstra
          </surname>
          <given-names>
           DL
          </given-names>
         </name>
         <name>
          <surname>
           Saint
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Saha
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Lumley
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Sullivan
          </surname>
          <given-names>
           SD
          </given-names>
         </name>
        </person-group>
        <article-title>
         Efficacy of antiseptic-impregnated central venous catheters in preventing catheter-related bloodstream infection: a meta-analysis
        </article-title>
        <source>
         JAMA
        </source>
        <volume>
         281
        </volume>
        <year>
         1999
        </year>
        <fpage>
         261
        </fpage>
        <lpage>
         267
        </lpage>
        <pub-id pub-id-type="pmid">
         9918482
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib416">
       <label>
        416
       </label>
       <element-citation id="sbref4140" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Mermel
          </surname>
          <given-names>
           LA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Prevention of intravascular catheter-related infections
        </article-title>
        <source>
         Ann Intern Med
        </source>
        <volume>
         132
        </volume>
        <year>
         2000
        </year>
        <fpage>
         391
        </fpage>
        <lpage>
         402
        </lpage>
        <pub-id pub-id-type="pmid">
         10691590
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib417">
       <label>
        417
       </label>
       <element-citation id="sbref4150" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Walder
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Pittet
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Tramèr
          </surname>
          <given-names>
           MR
          </given-names>
         </name>
        </person-group>
        <article-title>
         Prevention of bloodstream infections with central venous catheters treated with anti-infective agents depends on catheter type and insertion time: evidence from a meta-analysis
        </article-title>
        <source>
         Infect Control Hosp Epidemiol
        </source>
        <volume>
         23
        </volume>
        <year>
         2002
        </year>
        <fpage>
         748
        </fpage>
        <lpage>
         756
        </lpage>
        <pub-id pub-id-type="pmid">
         12517018
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib418">
       <label>
        418
       </label>
       <element-citation id="sbref4160" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bassetti
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Hu
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           D'Agostino
          </surname>
          <given-names>
           RB
          </given-names>
          <suffix>
           Jr
          </suffix>
         </name>
         <name>
          <surname>
           Sherertz
          </surname>
          <given-names>
           RJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         Prolonged Antimicrobial Activity of a Catheter Containing Chlorhexidine-Silver Sulfadiazine Extends Protection against Catheter Infections In Vivo
        </article-title>
        <source>
         Antimicrob Agents Chemother
        </source>
        <volume>
         45
        </volume>
        <year>
         2001
        </year>
        <fpage>
         1535
        </fpage>
        <lpage>
         1538
        </lpage>
        <pub-id pub-id-type="pmid">
         11302823
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib419">
       <label>
        419
       </label>
       <element-citation id="sbref4170" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hockenhull
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Dwan
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Boland
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Smith
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Bagust
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Dickson
          </surname>
          <given-names>
           R
          </given-names>
         </name>
        </person-group>
        <article-title>
         The clinical effectiveness and cost-effectiveness of central venous catheters treated with anti-infective agents in preventing bloodstream infections: a systematic review and economic evaluation
        </article-title>
        <source>
         Health Technol Assess
        </source>
        <volume>
         12
        </volume>
        <year>
         2008
        </year>
        <fpage>
         1
        </fpage>
        <lpage>
         154
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib420">
       <label>
        420
       </label>
       <element-citation id="sbref4180" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lai
          </surname>
          <given-names>
           NM
          </given-names>
         </name>
         <name>
          <surname>
           Chaiyakunapruk
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Lai
          </surname>
          <given-names>
           NA
          </given-names>
         </name>
         <name>
          <surname>
           O'Riordan
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Pau
          </surname>
          <given-names>
           WS
          </given-names>
         </name>
         <name>
          <surname>
           Saint
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        <article-title>
         Catheter impregnation, coating or bonding for reducing central venous catheter-related infections in adults
        </article-title>
        <source>
         Cochrane Database Syst Rev
        </source>
        <issue>
         6
        </issue>
        <year>
         2013
        </year>
       </element-citation>
      </ref>
      <ref id="bib421">
       <label>
        421
       </label>
       <element-citation id="sbref4190" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Jing
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Jin
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <article-title>
         Effectiveness of different central venous catheters for catheter-related infections: a network meta-analysis
        </article-title>
        <source>
         J Hosp Infect
        </source>
        <volume>
         76
        </volume>
        <year>
         2010
        </year>
        <fpage>
         1
        </fpage>
        <lpage>
         11
        </lpage>
        <pub-id pub-id-type="pmid">
         20638155
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib422">
       <label>
        422
       </label>
       <element-citation id="sbref4200" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Walz
          </surname>
          <given-names>
           JM
          </given-names>
         </name>
         <name>
          <surname>
           Avelar
          </surname>
          <given-names>
           RL
          </given-names>
         </name>
         <name>
          <surname>
           Longtine
          </surname>
          <given-names>
           KJ
          </given-names>
         </name>
         <name>
          <surname>
           Carter
          </surname>
          <given-names>
           KL
          </given-names>
         </name>
         <name>
          <surname>
           Mermel
          </surname>
          <given-names>
           LA
          </given-names>
         </name>
         <name>
          <surname>
           Heard
          </surname>
          <given-names>
           SO
          </given-names>
         </name>
        </person-group>
        <article-title>
         Anti-infective external coating of central venous catheters: a randomized, noninferiority trial comparing 5-fluorouracil with chlorhexidine/silver sulfadiazine in preventing catheter colonization
        </article-title>
        <source>
         Crit Care Med
        </source>
        <volume>
         38
        </volume>
        <year>
         2010
        </year>
        <fpage>
         2095
        </fpage>
        <lpage>
         2102
        </lpage>
        <pub-id pub-id-type="pmid">
         20711070
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib423">
       <label>
        423
       </label>
       <element-citation id="sbref4210" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Nakonechna
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Dorea
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Dixon
          </surname>
          <given-names>
           T
          </given-names>
         </name>
        </person-group>
        <article-title>
         Immediate hypersensitivity to chlorhexidine is increasingly recognised in the United Kingdom
        </article-title>
        <source>
         Allergol Immunopathol
        </source>
        <year>
         2012; Dec19
        </year>
        <comment>
         pii: S0301-0546(12)00262-5. [Epub ahead of print]
        </comment>
       </element-citation>
      </ref>
      <ref id="bib424">
       <label>
        424
       </label>
       <element-citation id="sbref4220" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Guleri
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Kumar
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Morgan
          </surname>
          <given-names>
           RJ
          </given-names>
         </name>
         <name>
          <surname>
           Hartley
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Roberts
          </surname>
          <given-names>
           DH
          </given-names>
         </name>
        </person-group>
        <article-title>
         Anaphylaxis to chlorhexidine-coated central venous catheters: a case series and review of the literature
        </article-title>
        <source>
         Surg Infect
        </source>
        <volume>
         13
        </volume>
        <year>
         2012
        </year>
        <fpage>
         171
        </fpage>
        <lpage>
         174
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib425">
       <label>
        425
       </label>
       <element-citation id="sbref4230" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Medicines and Healthcare Products Regulatory Agency
          </surname>
         </name>
        </person-group>
        <source>
         Medical Device Alert: All medical devices and medicinal products containing chlorhexidine
        </source>
        <year>
         2012
        </year>
        <publisher-name>
         Medicines and Healthcare Products Regulatory Agency
        </publisher-name>
        <publisher-loc>
         London
        </publisher-loc>
        <comment>
         MDA/2012/075.
        </comment>
       </element-citation>
      </ref>
      <ref id="bib426">
       <label>
        426
       </label>
       <element-citation id="sbref4240" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Parienti
          </surname>
          <given-names>
           JJ
          </given-names>
         </name>
         <name>
          <surname>
           Thirion
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Megarbane
          </surname>
          <given-names>
           B
          </given-names>
         </name>
        </person-group>
        <article-title>
         Femoral vs jugular venous catheterization and risk of nosocomial events in adults requiring acute renal replacement therapy: a randomized controlled trial
        </article-title>
        <source>
         JAMA
        </source>
        <volume>
         299
        </volume>
        <year>
         2008
        </year>
        <fpage>
         2413
        </fpage>
        <lpage>
         2422
        </lpage>
        <pub-id pub-id-type="pmid">
         18505951
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib427">
       <label>
        427
       </label>
       <element-citation id="sbref4250" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Moretti
          </surname>
          <given-names>
           EW
          </given-names>
         </name>
         <name>
          <surname>
           Ofstead
          </surname>
          <given-names>
           CL
          </given-names>
         </name>
         <name>
          <surname>
           Kristy
          </surname>
          <given-names>
           RM
          </given-names>
         </name>
         <name>
          <surname>
           Wetzler
          </surname>
          <given-names>
           HP
          </given-names>
         </name>
        </person-group>
        <article-title>
         Impact of central venous catheter type and methods on catheter-related colonization and bacteraemia
        </article-title>
        <source>
         J Hosp Infect
        </source>
        <volume>
         61
        </volume>
        <year>
         2005
        </year>
        <fpage>
         139
        </fpage>
        <lpage>
         145
        </lpage>
        <pub-id pub-id-type="pmid">
         16026898
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib428">
       <label>
        428
       </label>
       <element-citation id="sbref4260" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Nagashima
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Kikuchi
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Tsuyuzaki
          </surname>
          <given-names>
           H
          </given-names>
         </name>
        </person-group>
        <article-title>
         To reduce catheter-related bloodstream infections: is the subclavian route better than the jugular route for central venous catheterization?
        </article-title>
        <source>
         J Infect Chemother
        </source>
        <volume>
         12
        </volume>
        <year>
         2006
        </year>
        <fpage>
         363
        </fpage>
        <lpage>
         365
        </lpage>
        <pub-id pub-id-type="pmid">
         17235641
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib429">
       <label>
        429
       </label>
       <element-citation id="sbref4270" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ruesch
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Walder
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Tramer
          </surname>
          <given-names>
           MR
          </given-names>
         </name>
        </person-group>
        <article-title>
         Complications of central venous catheters: internal jugular versus subclavian access – a systematic review
        </article-title>
        <source>
         Crit Care Med
        </source>
        <volume>
         30
        </volume>
        <year>
         2002
        </year>
        <fpage>
         454
        </fpage>
        <lpage>
         460
        </lpage>
        <pub-id pub-id-type="pmid">
         11889329
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib430">
       <label>
        430
       </label>
       <element-citation id="sbref4280" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sadoyama
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Gontijo Filho
          </surname>
          <given-names>
           PP
          </given-names>
         </name>
        </person-group>
        <article-title>
         Comparison between the jugular and subclavian vein as insertion site for central venous catheters: microbiological aspects and risk factors for colonization and infection
        </article-title>
        <source>
         Braz J Infect Dis
        </source>
        <volume>
         7
        </volume>
        <year>
         2003
        </year>
        <fpage>
         142
        </fpage>
        <lpage>
         148
        </lpage>
        <pub-id pub-id-type="pmid">
         12959686
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib431">
       <label>
        431
       </label>
       <element-citation id="sbref4290" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Richet
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Bouvier
          </surname>
          <given-names>
           AM
          </given-names>
         </name>
         <name>
          <surname>
           Hubert
          </surname>
          <given-names>
           B
          </given-names>
         </name>
        </person-group>
        <article-title>
         Prospective multicenter study of vascular-catheter-related complications and risk factors for positive central-catheter cultures in intensive care unit patients
        </article-title>
        <source>
         J Clin Microbiol
        </source>
        <volume>
         28
        </volume>
        <year>
         1990
        </year>
        <fpage>
         2520
        </fpage>
        <lpage>
         2525
        </lpage>
        <pub-id pub-id-type="pmid">
         2254429
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib432">
       <label>
        432
       </label>
       <element-citation id="sbref4300" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Safdar
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Kluger
          </surname>
          <given-names>
           DM
          </given-names>
         </name>
         <name>
          <surname>
           Maki
          </surname>
          <given-names>
           DG
          </given-names>
         </name>
        </person-group>
        <article-title>
         A review of risk factors for catheter-related bloodstream infection caused by percutaneously inserted, noncuffed central venous catheters: implications for preventive strategies
        </article-title>
        <source>
         Medicine
        </source>
        <volume>
         81
        </volume>
        <year>
         2002
        </year>
        <fpage>
         466
        </fpage>
        <lpage>
         479
        </lpage>
        <pub-id pub-id-type="pmid">
         12441903
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib433">
       <label>
        433
       </label>
       <element-citation id="sbref4310" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lorente
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Jimenez
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Iribarren
          </surname>
          <given-names>
           JL
          </given-names>
         </name>
         <name>
          <surname>
           Jimenez
          </surname>
          <given-names>
           JJ
          </given-names>
         </name>
         <name>
          <surname>
           Martin
          </surname>
          <given-names>
           MM
          </given-names>
         </name>
         <name>
          <surname>
           Mora
          </surname>
          <given-names>
           ML
          </given-names>
         </name>
        </person-group>
        <article-title>
         The micro-organism responsible for central venous catheter related bloodstream infection depends on catheter site
        </article-title>
        <source>
         Intensive Care Med
        </source>
        <volume>
         32
        </volume>
        <year>
         2006
        </year>
        <fpage>
         1449
        </fpage>
        <lpage>
         1450
        </lpage>
        <pub-id pub-id-type="pmid">
         16804728
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib434">
       <label>
        434
       </label>
       <element-citation id="sbref4320" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Traore
          </surname>
          <given-names>
           O
          </given-names>
         </name>
         <name>
          <surname>
           Liotier
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Souweine
          </surname>
          <given-names>
           B
          </given-names>
         </name>
        </person-group>
        <article-title>
         Prospective study of arterial and central venous catheter colonization and of arterial- and central venous catheter-related bacteremia in intensive care units
        </article-title>
        <source>
         Crit Care Med
        </source>
        <volume>
         33
        </volume>
        <year>
         2005
        </year>
        <fpage>
         1276
        </fpage>
        <lpage>
         1280
        </lpage>
        <pub-id pub-id-type="pmid">
         15942344
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib435">
       <label>
        435
       </label>
       <element-citation id="sbref4330" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Merrer
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           De Jonghe
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Golliot
          </surname>
          <given-names>
           F
          </given-names>
         </name>
        </person-group>
        <article-title>
         Complications of femoral and subclavian venous catheterization in critically ill patients: a randomized controlled trial
        </article-title>
        <source>
         JAMA
        </source>
        <volume>
         286
        </volume>
        <year>
         2001
        </year>
        <fpage>
         700
        </fpage>
        <lpage>
         707
        </lpage>
        <pub-id pub-id-type="pmid">
         11495620
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib436">
       <label>
        436
       </label>
       <element-citation id="sbref4340" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Goetz
          </surname>
          <given-names>
           AM
          </given-names>
         </name>
         <name>
          <surname>
           Wagener
          </surname>
          <given-names>
           MM
          </given-names>
         </name>
         <name>
          <surname>
           Miller
          </surname>
          <given-names>
           JM
          </given-names>
         </name>
         <name>
          <surname>
           Muder
          </surname>
          <given-names>
           RR
          </given-names>
         </name>
        </person-group>
        <article-title>
         Risk of infection due to central venous catheters: effect of site of placement and catheter type
        </article-title>
        <source>
         Infect Control Hosp Epidemiol
        </source>
        <volume>
         19
        </volume>
        <year>
         1998
        </year>
        <fpage>
         842
        </fpage>
        <lpage>
         845
        </lpage>
        <pub-id pub-id-type="pmid">
         9831940
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib437">
       <label>
        437
       </label>
       <element-citation id="sbref4350" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Deshpande
          </surname>
          <given-names>
           KS
          </given-names>
         </name>
         <name>
          <surname>
           Hatem
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Ulrich
          </surname>
          <given-names>
           HL
          </given-names>
         </name>
        </person-group>
        <article-title>
         The incidence of infectious complications of central venous catheters at the subclavian, internal jugular, and femoral sites in an intensive care unit population
        </article-title>
        <source>
         Crit Care Med
        </source>
        <volume>
         33
        </volume>
        <year>
         2005
        </year>
        <fpage>
         13
        </fpage>
        <lpage>
         20
        </lpage>
        <pub-id pub-id-type="pmid">
         15644643
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib438">
       <label>
        438
       </label>
       <element-citation id="sbref4360" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Marik
          </surname>
          <given-names>
           PE
          </given-names>
         </name>
         <name>
          <surname>
           Flemmer
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Harrison
          </surname>
          <given-names>
           W
          </given-names>
         </name>
        </person-group>
        <article-title>
         The risk of catheter-related bloodstream infection with femoral venous catheters as compared to subclavian and internal jugular venous catheters: a systematic review of the literature and meta-analysis
        </article-title>
        <source>
         Crit Care Med
        </source>
        <volume>
         40
        </volume>
        <year>
         2012
        </year>
        <fpage>
         2479
        </fpage>
        <lpage>
         2485
        </lpage>
        <pub-id pub-id-type="pmid">
         22809915
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib439">
       <label>
        439
       </label>
       <element-citation id="sbref4370" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Randolph
          </surname>
          <given-names>
           AG
          </given-names>
         </name>
         <name>
          <surname>
           Cook
          </surname>
          <given-names>
           DJ
          </given-names>
         </name>
         <name>
          <surname>
           Gonzales
          </surname>
          <given-names>
           CA
          </given-names>
         </name>
         <name>
          <surname>
           Pribble
          </surname>
          <given-names>
           CG
          </given-names>
         </name>
        </person-group>
        <article-title>
         Ultrasound guidance for placement of central venous catheters: a meta-analysis of the literature
        </article-title>
        <source>
         Crit Care Med
        </source>
        <volume>
         24
        </volume>
        <year>
         1996
        </year>
        <fpage>
         2053
        </fpage>
        <lpage>
         2058
        </lpage>
        <pub-id pub-id-type="pmid">
         8968276
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib440">
       <label>
        440
       </label>
       <element-citation id="sbref4380" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hind
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Calvert
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           McWilliams
          </surname>
          <given-names>
           R
          </given-names>
         </name>
        </person-group>
        <article-title>
         Ultrasonic locating devices for central venous cannulation: meta-analysis
        </article-title>
        <source>
         BMJ
        </source>
        <volume>
         327
        </volume>
        <year>
         2003
        </year>
        <fpage>
         361
        </fpage>
        <lpage>
         364
        </lpage>
        <pub-id pub-id-type="pmid">
         12919984
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib441">
       <label>
        441
       </label>
       <element-citation id="sbref4390" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           National Institute for Health and Care Excellence
          </surname>
         </name>
        </person-group>
        <source>
         Guidance on the use of ultrasound locating devices for placing central venous catheters (No.49)
        </source>
        <year>
         2002
        </year>
        <publisher-name>
         National Insititute for Clinical Excellence
        </publisher-name>
        <publisher-loc>
         London
        </publisher-loc>
        <ext-link ext-link-type="uri" id="interrefs210" xlink:href="http://www.nice.org.uk/nicemedia/live/11474/32461/32461.pdf">
         Available at: http://www.nice.org.uk/nicemedia/live/11474/32461/32461.pdf
        </ext-link>
        <comment>
         Accessed July 25, 2013.
        </comment>
       </element-citation>
      </ref>
      <ref id="bib442">
       <label>
        442
       </label>
       <element-citation id="sbref4400" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Maki
          </surname>
          <given-names>
           DG
          </given-names>
         </name>
         <name>
          <surname>
           Goldman
          </surname>
          <given-names>
           DA
          </given-names>
         </name>
         <name>
          <surname>
           Rhame
          </surname>
          <given-names>
           FS
          </given-names>
         </name>
        </person-group>
        <article-title>
         Infection control in intravenous therapy
        </article-title>
        <source>
         Ann Intern Med
        </source>
        <volume>
         79
        </volume>
        <year>
         1973
        </year>
        <fpage>
         867
        </fpage>
        <lpage>
         887
        </lpage>
        <pub-id pub-id-type="pmid">
         4202639
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib443">
       <label>
        443
       </label>
       <element-citation id="sbref4410" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Raad
          </surname>
          <given-names>
           II
          </given-names>
         </name>
         <name>
          <surname>
           Hohn
          </surname>
          <given-names>
           DC
          </given-names>
         </name>
         <name>
          <surname>
           Gilbreath
          </surname>
          <given-names>
           BJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         Prevention of central venous catheter-related infections by using maximal sterile barrier precautions during insertion
        </article-title>
        <source>
         Infect Control Hosp Epidemiol
        </source>
        <volume>
         15
        </volume>
        <year>
         1994
        </year>
        <fpage>
         231
        </fpage>
        <lpage>
         238
        </lpage>
        <pub-id pub-id-type="pmid">
         8207189
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib444">
       <label>
        444
       </label>
       <element-citation id="sbref4420" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Carrer
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Bocchi
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Bortolotti
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <article-title>
         Effect of different sterile barrier precautions and central venous catheter dressing on the skin colonization around the insertion site
        </article-title>
        <source>
         Minerva Anestesiol
        </source>
        <volume>
         71
        </volume>
        <year>
         2005
        </year>
        <fpage>
         197
        </fpage>
        <lpage>
         206
        </lpage>
        <pub-id pub-id-type="pmid">
         15834348
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib445">
       <label>
        445
       </label>
       <element-citation id="sbref4430" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hu
          </surname>
          <given-names>
           KK
          </given-names>
         </name>
         <name>
          <surname>
           Lipsky
          </surname>
          <given-names>
           BA
          </given-names>
         </name>
         <name>
          <surname>
           Veenstra
          </surname>
          <given-names>
           DL
          </given-names>
         </name>
         <name>
          <surname>
           Saint
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        <article-title>
         Using maximal sterile barriers to prevent central venous catheter-related infection: a systematic evidence-based review
        </article-title>
        <source>
         Am J Infect Control
        </source>
        <volume>
         32
        </volume>
        <year>
         2004
        </year>
        <fpage>
         142
        </fpage>
        <lpage>
         146
        </lpage>
        <pub-id pub-id-type="pmid">
         15153925
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib446">
       <label>
        446
       </label>
       <element-citation id="sbref4440" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Fletcher
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Bodenham
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        <article-title>
         Catheter-related sepsis: an overview -Part 1
        </article-title>
        <source>
         Br J Int Care
        </source>
        <volume>
         9
        </volume>
        <year>
         1999
        </year>
        <fpage>
         46
        </fpage>
        <lpage>
         53
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib447">
       <label>
        447
       </label>
       <element-citation id="sbref4450" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Maki
          </surname>
          <given-names>
           DG
          </given-names>
         </name>
         <name>
          <surname>
           Ringer
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Alvarado
          </surname>
          <given-names>
           CJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         Prospective randomised trial of povidone-iodine, alcohol, and chlorhexidine for prevention of infection associated with central venous and arterial catheters
        </article-title>
        <source>
         Lancet
        </source>
        <volume>
         338
        </volume>
        <year>
         1991
        </year>
        <fpage>
         339
        </fpage>
        <lpage>
         343
        </lpage>
        <pub-id pub-id-type="pmid">
         1677698
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib448">
       <label>
        448
       </label>
       <element-citation id="sbref4460" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Mimoz
          </surname>
          <given-names>
           O
          </given-names>
         </name>
         <name>
          <surname>
           Pieroni
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Lawrence
          </surname>
          <given-names>
           C
          </given-names>
         </name>
        </person-group>
        <article-title>
         Prospective, randomized trial of two antiseptic solutions for prevention of central venous or arterial catheter colonization and infection in intensive care unit patients
        </article-title>
        <source>
         Crit Care Med
        </source>
        <volume>
         24
        </volume>
        <year>
         1996
        </year>
        <fpage>
         1818
        </fpage>
        <lpage>
         1823
        </lpage>
        <pub-id pub-id-type="pmid">
         8917031
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib449">
       <label>
        449
       </label>
       <element-citation id="sbref4470" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Parienti
          </surname>
          <given-names>
           JJ
          </given-names>
         </name>
         <name>
          <surname>
           du Cheyron
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Ramakers
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <article-title>
         Alcoholic povidone-iodine to prevent central venous catheter colonization: a randomized unit-crossover study
        </article-title>
        <source>
         Crit Care Med
        </source>
        <volume>
         32
        </volume>
        <year>
         2004
        </year>
        <fpage>
         708
        </fpage>
        <lpage>
         713
        </lpage>
        <pub-id pub-id-type="pmid">
         15090951
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib450">
       <label>
        450
       </label>
       <element-citation id="sbref4480" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chaiyakunapruk
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Veenstra
          </surname>
          <given-names>
           DL
          </given-names>
         </name>
         <name>
          <surname>
           Lipsky
          </surname>
          <given-names>
           BA
          </given-names>
         </name>
         <name>
          <surname>
           Saint
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        <article-title>
         Chlorhexidine compared with povidone-iodine solution for vascular catheter-site care: a meta-analysis
        </article-title>
        <source>
         Ann Intern Med
        </source>
        <volume>
         136
        </volume>
        <year>
         2002
        </year>
        <fpage>
         792
        </fpage>
        <lpage>
         801
        </lpage>
        <pub-id pub-id-type="pmid">
         12044127
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib451">
       <label>
        451
       </label>
       <element-citation id="sbref4490" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chaiyakunapruk
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Veenstra
          </surname>
          <given-names>
           DL
          </given-names>
         </name>
         <name>
          <surname>
           Lipsky
          </surname>
          <given-names>
           BA
          </given-names>
         </name>
         <name>
          <surname>
           Sullivan
          </surname>
          <given-names>
           SD
          </given-names>
         </name>
         <name>
          <surname>
           Saint
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        <article-title>
         Vascular catheter site care: the clinical and economic benefits of chlorhexidine gluconate compared with povidone iodine
        </article-title>
        <source>
         Clin Infect Dis
        </source>
        <volume>
         37
        </volume>
        <year>
         2003
        </year>
        <fpage>
         764
        </fpage>
        <lpage>
         771
        </lpage>
        <pub-id pub-id-type="pmid">
         12955636
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib452">
       <label>
        452
       </label>
       <element-citation id="sbref4500" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Larson
          </surname>
          <given-names>
           E
          </given-names>
         </name>
        </person-group>
        <article-title>
         Guideline for use of topical antimicrobial agents
        </article-title>
        <source>
         Am J Infect Control
        </source>
        <volume>
         16
        </volume>
        <year>
         1988
        </year>
        <fpage>
         253
        </fpage>
        <lpage>
         266
        </lpage>
        <pub-id pub-id-type="pmid">
         2849888
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib453">
       <label>
        453
       </label>
       <element-citation id="sbref4510" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rannem
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Ladefoged
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Hegnhoj
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Moller
          </surname>
          <given-names>
           EH
          </given-names>
         </name>
         <name>
          <surname>
           Bruun
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Jarnum
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        <article-title>
         Catheter-related sepsis in long-term parenteral nutrition with Broviac catheters. An evaluation of different disinfectants
        </article-title>
        <source>
         Clin Nutr
        </source>
        <volume>
         9
        </volume>
        <year>
         1990
        </year>
        <fpage>
         131
        </fpage>
        <lpage>
         136
        </lpage>
        <pub-id pub-id-type="pmid">
         16837344
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib454">
       <label>
        454
       </label>
       <element-citation id="sbref4520" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Prager
          </surname>
          <given-names>
           RL
          </given-names>
         </name>
         <name>
          <surname>
           Silva
          </surname>
          <given-names>
           J
          </given-names>
          <suffix>
           Jr
          </suffix>
         </name>
        </person-group>
        <article-title>
         Colonization of central venous catheters
        </article-title>
        <source>
         South Med J
        </source>
        <volume>
         77
        </volume>
        <year>
         1984
        </year>
        <fpage>
         458
        </fpage>
        <lpage>
         461
        </lpage>
        <pub-id pub-id-type="pmid">
         6424240
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib455">
       <label>
        455
       </label>
       <element-citation id="sbref4530" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Moran
          </surname>
          <given-names>
           JM
          </given-names>
         </name>
         <name>
          <surname>
           Atwood
          </surname>
          <given-names>
           RP
          </given-names>
         </name>
         <name>
          <surname>
           Rowe
          </surname>
          <given-names>
           MI
          </given-names>
         </name>
        </person-group>
        <article-title>
         A clinical and bacteriologic study of infections associated with venous cutdowns
        </article-title>
        <source>
         N Engl J Med
        </source>
        <volume>
         272
        </volume>
        <year>
         1965
        </year>
        <fpage>
         554
        </fpage>
        <lpage>
         560
        </lpage>
        <pub-id pub-id-type="pmid">
         14248730
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib456">
       <label>
        456
       </label>
       <element-citation id="sbref4540" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Norden
          </surname>
          <given-names>
           CW
          </given-names>
         </name>
        </person-group>
        <article-title>
         Application of antibiotic ointment to the site of venous catheterization – a controlled trial
        </article-title>
        <source>
         J Infect Dis
        </source>
        <volume>
         120
        </volume>
        <year>
         1969
        </year>
        <fpage>
         611
        </fpage>
        <lpage>
         615
        </lpage>
        <pub-id pub-id-type="pmid">
         4310342
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib457">
       <label>
        457
       </label>
       <element-citation id="sbref4550" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zinner
          </surname>
          <given-names>
           SH
          </given-names>
         </name>
         <name>
          <surname>
           Denny-Brown
          </surname>
          <given-names>
           BC
          </given-names>
         </name>
         <name>
          <surname>
           Braun
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Burke
          </surname>
          <given-names>
           JP
          </given-names>
         </name>
         <name>
          <surname>
           Toala
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Kass
          </surname>
          <given-names>
           EH
          </given-names>
         </name>
        </person-group>
        <article-title>
         Risk of infection with intravenous indwelling catheters: effect of application of antibiotic ointment
        </article-title>
        <source>
         J Infect Dis
        </source>
        <volume>
         120
        </volume>
        <year>
         1969
        </year>
        <fpage>
         616
        </fpage>
        <lpage>
         619
        </lpage>
        <pub-id pub-id-type="pmid">
         4310343
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib458">
       <label>
        458
       </label>
       <element-citation id="sbref4560" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Jarrard
          </surname>
          <given-names>
           MM
          </given-names>
         </name>
         <name>
          <surname>
           Freeman
          </surname>
          <given-names>
           JB
          </given-names>
         </name>
        </person-group>
        <article-title>
         The effects of antibiotic ointments and antiseptics on the skin flora beneath subclavian catheter dressings during intravenous hyperalimentation
        </article-title>
        <source>
         J Surg Res
        </source>
        <volume>
         22
        </volume>
        <year>
         1977
        </year>
        <fpage>
         520
        </fpage>
        <lpage>
         526
        </lpage>
        <pub-id pub-id-type="pmid">
         404474
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib459">
       <label>
        459
       </label>
       <element-citation id="sbref4570" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Maki
          </surname>
          <given-names>
           DG
          </given-names>
         </name>
         <name>
          <surname>
           Band
          </surname>
          <given-names>
           JD
          </given-names>
         </name>
        </person-group>
        <article-title>
         A comparative study of polyantibiotic and iodophor ointments in prevention of vascular catheter-related infection
        </article-title>
        <source>
         Am J Med
        </source>
        <volume>
         70
        </volume>
        <year>
         1981
        </year>
        <fpage>
         739
        </fpage>
        <lpage>
         744
        </lpage>
        <pub-id pub-id-type="pmid">
         6259941
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib460">
       <label>
        460
       </label>
       <element-citation id="sbref4580" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Maiwald
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           ESY
          </given-names>
         </name>
        </person-group>
        <article-title>
         The forgotten role of alcohol: a systematic review and meta-analysis of the clinical efficacy and perceived role of chlorhexidine in skin antisepsis
        </article-title>
        <source>
         PLoS One
        </source>
        <volume>
         7
        </volume>
        <year>
         2012
        </year>
        <fpage>
         e44277
        </fpage>
        <pub-id pub-id-type="pmid">
         22984485
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib461">
       <label>
        461
       </label>
       <element-citation id="sbref4590" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hoffmann
          </surname>
          <given-names>
           KK
          </given-names>
         </name>
         <name>
          <surname>
           Weber
          </surname>
          <given-names>
           DJ
          </given-names>
         </name>
         <name>
          <surname>
           Samsa
          </surname>
          <given-names>
           GP
          </given-names>
         </name>
         <name>
          <surname>
           Rutala
          </surname>
          <given-names>
           WA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Transparent polyurethane film as an intravenous catheter dressing. A meta-analysis of the infection risks
        </article-title>
        <source>
         JAMA
        </source>
        <volume>
         267
        </volume>
        <year>
         1992
        </year>
        <fpage>
         2072
        </fpage>
        <lpage>
         2076
        </lpage>
        <pub-id pub-id-type="pmid">
         1532429
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib462">
       <label>
        462
       </label>
       <element-citation id="sbref4600" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gillies
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           O'Riordan
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Carr
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Frost
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Gunning
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           O'Brien
          </surname>
          <given-names>
           I
          </given-names>
         </name>
        </person-group>
        <article-title>
         Gauze and tape and transparent polyurethane dressings for central venous catheters
        </article-title>
        <source>
         Cochrane Database Syst Rev
        </source>
        <volume>
         4
        </volume>
        <year>
         2003
        </year>
        <comment>
         CD003827.
        </comment>
       </element-citation>
      </ref>
      <ref id="bib463">
       <label>
        463
       </label>
       <element-citation id="sbref4610" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Webster
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Gillies
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           O'Riordan
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Sherriff
          </surname>
          <given-names>
           KL
          </given-names>
         </name>
         <name>
          <surname>
           Rickard
          </surname>
          <given-names>
           CM
          </given-names>
         </name>
        </person-group>
        <article-title>
         Gauze and tape and transparent polyurethane dressings for central venous catheters
        </article-title>
        <source>
         Cochrane Database Syst Rev
        </source>
        <volume>
         9
        </volume>
        <year>
         2011
        </year>
        <comment>
         CD003827.
        </comment>
       </element-citation>
      </ref>
      <ref id="bib464">
       <label>
        464
       </label>
       <element-citation id="sbref4620" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Northfield
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Alexander
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Rickard
          </surname>
          <given-names>
           C
          </given-names>
         </name>
        </person-group>
        <article-title>
         Using the collaborative evidence based practice model: a systematic review and uptake of chlorhexidine-impregnated sponge dressings on central venous access devices in a tertiary cancer centre
        </article-title>
        <source>
         Aust J Cancer Nurs
        </source>
        <volume>
         13
        </volume>
        <year>
         2012
        </year>
        <fpage>
         10
        </fpage>
        <lpage>
         15
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib465">
       <label>
        465
       </label>
       <element-citation id="sbref4630" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Schwebel
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Lucet
          </surname>
          <given-names>
           JC
          </given-names>
         </name>
         <name>
          <surname>
           Vesin
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        <article-title>
         Economic evaluation of chlorhexidine-impregnated sponges for preventing catheter-related infections in critically ill adults in the Dressing Study
        </article-title>
        <source>
         Crit Care Med
        </source>
        <volume>
         40
        </volume>
        <year>
         2012
        </year>
        <fpage>
         11
        </fpage>
        <lpage>
         17
        </lpage>
        <pub-id pub-id-type="pmid">
         21926570
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib466">
       <label>
        466
       </label>
       <element-citation id="sbref4640" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Timsit
          </surname>
          <given-names>
           JF
          </given-names>
         </name>
         <name>
          <surname>
           Mimoz
          </surname>
          <given-names>
           O
          </given-names>
         </name>
         <name>
          <surname>
           Mourvillier
          </surname>
          <given-names>
           B
          </given-names>
         </name>
        </person-group>
        <article-title>
         Randomized controlled trial of chlorhexidine dressing and highly adhesive dressing for preventing catheter-related infections in critically ill adults
        </article-title>
        <source>
         Am J Respir Crit Care Med
        </source>
        <volume>
         186
        </volume>
        <year>
         2012
        </year>
        <fpage>
         1272
        </fpage>
        <lpage>
         1278
        </lpage>
        <pub-id pub-id-type="pmid">
         23043083
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib467">
       <label>
        467
       </label>
       <element-citation id="sbref4650" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           O'Horo
          </surname>
          <given-names>
           JC
          </given-names>
         </name>
         <name>
          <surname>
           Silva
          </surname>
          <given-names>
           GL
          </given-names>
         </name>
         <name>
          <surname>
           Munoz-Price
          </surname>
          <given-names>
           LS
          </given-names>
         </name>
         <name>
          <surname>
           Safdar
          </surname>
          <given-names>
           N
          </given-names>
         </name>
        </person-group>
        <article-title>
         The efficacy of daily bathing with chlorhexidine for reducing healthcare-associated bloodstream infections: a meta-analysis
        </article-title>
        <source>
         Infect Control Hosp Epidemiol
        </source>
        <volume>
         33
        </volume>
        <year>
         2012
        </year>
        <fpage>
         257
        </fpage>
        <lpage>
         267
        </lpage>
        <pub-id pub-id-type="pmid">
         22314063
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib468">
       <label>
        468
       </label>
       <element-citation id="sbref4660" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Dettenkofer
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Wilson
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Gratwohl
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        <article-title>
         Skin disinfection with octenidine dihydrochloride for central venous catheter site care: a double-blind, randomized, controlled trial
        </article-title>
        <source>
         Clin Microbiol Infect
        </source>
        <volume>
         16
        </volume>
        <year>
         2010
        </year>
        <fpage>
         600
        </fpage>
        <lpage>
         606
        </lpage>
        <pub-id pub-id-type="pmid">
         19686276
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib469">
       <label>
        469
       </label>
       <element-citation id="sbref4670" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Eyer
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Brummitt
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Crossley
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Siegel
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Cerra
          </surname>
          <given-names>
           F
          </given-names>
         </name>
        </person-group>
        <article-title>
         Catheter-related sepsis: prospective, randomized study of three methods of long-term catheter maintenance
        </article-title>
        <source>
         Crit Care Med
        </source>
        <volume>
         18
        </volume>
        <year>
         1990
        </year>
        <fpage>
         1073
        </fpage>
        <lpage>
         1079
        </lpage>
        <pub-id pub-id-type="pmid">
         2209033
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib470">
       <label>
        470
       </label>
       <element-citation id="sbref4680" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Uldall
          </surname>
          <given-names>
           PR
          </given-names>
         </name>
         <name>
          <surname>
           Merchant
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Woods
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Yarworski
          </surname>
          <given-names>
           U
          </given-names>
         </name>
         <name>
          <surname>
           Vas
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        <article-title>
         Changing subclavian haemodialysis cannulas to reduce infection
        </article-title>
        <source>
         Lancet
        </source>
        <volume>
         317
        </volume>
        <year>
         1981
        </year>
        <fpage>
         1373
        </fpage>
       </element-citation>
      </ref>
      <ref id="bib471">
       <label>
        471
       </label>
       <element-citation id="sbref4690" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cobb
          </surname>
          <given-names>
           DK
          </given-names>
         </name>
         <name>
          <surname>
           High
          </surname>
          <given-names>
           KP
          </given-names>
         </name>
         <name>
          <surname>
           Sawyer
          </surname>
          <given-names>
           RG
          </given-names>
         </name>
        </person-group>
        <article-title>
         A controlled trial of scheduled replacement of central venous and pulmonary-artery catheters
        </article-title>
        <source>
         N Engl J Med
        </source>
        <volume>
         327
        </volume>
        <year>
         1992
        </year>
        <fpage>
         1062
        </fpage>
        <lpage>
         1068
        </lpage>
        <pub-id pub-id-type="pmid">
         1522842
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib472">
       <label>
        472
       </label>
       <element-citation id="sbref4700" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cook
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Randolph
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Kernerman
          </surname>
          <given-names>
           P
          </given-names>
         </name>
        </person-group>
        <article-title>
         Central venous catheter replacement strategies: a systematic review of the literature
        </article-title>
        <source>
         Crit Care Med
        </source>
        <volume>
         25
        </volume>
        <year>
         1997
        </year>
        <fpage>
         1417
        </fpage>
        <lpage>
         1424
        </lpage>
        <pub-id pub-id-type="pmid">
         9267959
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib473">
       <label>
        473
       </label>
       <element-citation id="sbref4710" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rickard
          </surname>
          <given-names>
           CM
          </given-names>
         </name>
         <name>
          <surname>
           McCann
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Munnings
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           McGrail
          </surname>
          <given-names>
           MR
          </given-names>
         </name>
        </person-group>
        <article-title>
         Routine resite of peripheral intravenous devices every 3 days did not reduce complications compared with clinically indicated resite: a randomised controlled trial
        </article-title>
        <source>
         BMC Med
        </source>
        <volume>
         8
        </volume>
        <year>
         2010
        </year>
        <fpage>
         53
        </fpage>
        <pub-id pub-id-type="pmid">
         20831782
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib474">
       <label>
        474
       </label>
       <element-citation id="sbref4720" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Webster
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Osborne
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Rickard
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           New
          </surname>
          <given-names>
           K
          </given-names>
         </name>
        </person-group>
        <article-title>
         Clinically-indicated replacement versus routine replacement of peripheral venous catheters
        </article-title>
        <source>
         Cochrane Database Syst Rev
        </source>
        <volume>
         4
        </volume>
        <year>
         2013
        </year>
        <comment>
         (CD007798).
        </comment>
       </element-citation>
      </ref>
      <ref id="bib475">
       <label>
        475
       </label>
       <element-citation id="sbref4730" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           De Cicco
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Chiaradia
          </surname>
          <given-names>
           V
          </given-names>
         </name>
         <name>
          <surname>
           Veronesi
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        <article-title>
         Source and route of microbial colonisation of parenteral nutrition catheters
        </article-title>
        <source>
         Lancet
        </source>
        <volume>
         334
        </volume>
        <year>
         1989
        </year>
        <fpage>
         1258
        </fpage>
        <lpage>
         1261
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib476">
       <label>
        476
       </label>
       <element-citation id="sbref4740" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Capell
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Linares
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Sitges-Serra
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        <article-title>
         Catheter sepsis due to coagulase-negative staphylococci in patients on total parenteral nutrition
        </article-title>
        <source>
         Eur J Clin Microbiol
        </source>
        <volume>
         5
        </volume>
        <year>
         1986
        </year>
        <fpage>
         40
        </fpage>
        <lpage>
         42
        </lpage>
        <pub-id pub-id-type="pmid">
         3084243
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib477">
       <label>
        477
       </label>
       <element-citation id="sbref4750" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Salzman
          </surname>
          <given-names>
           MB
          </given-names>
         </name>
         <name>
          <surname>
           Isenberg
          </surname>
          <given-names>
           HD
          </given-names>
         </name>
         <name>
          <surname>
           Shapiro
          </surname>
          <given-names>
           JF
          </given-names>
         </name>
         <name>
          <surname>
           Lipsitz
          </surname>
          <given-names>
           PJ
          </given-names>
         </name>
         <name>
          <surname>
           Rubin
          </surname>
          <given-names>
           LG
          </given-names>
         </name>
        </person-group>
        <article-title>
         A prospective study of the catheter hub as the portal of entry for microorganisms causing catheter-related sepsis in neonates
        </article-title>
        <source>
         J Infect Dis
        </source>
        <volume>
         167
        </volume>
        <year>
         1993
        </year>
        <fpage>
         487
        </fpage>
        <lpage>
         490
        </lpage>
        <pub-id pub-id-type="pmid">
         8421188
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib478">
       <label>
        478
       </label>
       <element-citation id="sbref4760" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Peters
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Locci
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Pulverer
          </surname>
          <given-names>
           G
          </given-names>
         </name>
        </person-group>
        <article-title>
         Adherence and growth of coagulase-negative staphylococci on surfaces of intravenous catheters
        </article-title>
        <source>
         J Infect Dis
        </source>
        <volume>
         146
        </volume>
        <year>
         1982
        </year>
        <fpage>
         479
        </fpage>
        <lpage>
         482
        </lpage>
        <pub-id pub-id-type="pmid">
         7119478
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib479">
       <label>
        479
       </label>
       <element-citation id="sbref4770" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Liñares
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Sitges-Serra
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Garau
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Pérez
          </surname>
          <given-names>
           JL
          </given-names>
         </name>
         <name>
          <surname>
           Martín
          </surname>
          <given-names>
           R
          </given-names>
         </name>
        </person-group>
        <article-title>
         Pathogenesis of catheter sepsis: a prospective study with quantitative and semiquantitative cultures of catheter hub and segments
        </article-title>
        <source>
         J Clin Microbiol
        </source>
        <volume>
         21
        </volume>
        <year>
         1985
        </year>
        <fpage>
         357
        </fpage>
        <lpage>
         360
        </lpage>
        <pub-id pub-id-type="pmid">
         3920239
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib480">
       <label>
        480
       </label>
       <element-citation id="sbref4780" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sitges-Serra
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Linares
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Perez
          </surname>
          <given-names>
           JL
          </given-names>
         </name>
         <name>
          <surname>
           Jaurrieta
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Lorente
          </surname>
          <given-names>
           L
          </given-names>
         </name>
        </person-group>
        <article-title>
         A randomized trial on the effect of tubing changes on hub contamination and catheter sepsis during parenteral nutrition
        </article-title>
        <source>
         J Parenter Enteral Nutr
        </source>
        <volume>
         9
        </volume>
        <year>
         1985
        </year>
        <fpage>
         322
        </fpage>
        <lpage>
         325
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib481">
       <label>
        481
       </label>
       <element-citation id="sbref4790" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Weist
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Sperber
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Dietz
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Ruden
          </surname>
          <given-names>
           H
          </given-names>
         </name>
        </person-group>
        <article-title>
         Contamination of stopcocks mounted in administration sets for central venous catheters with replacement at 24 hrs versus 72 hrs: a prospective cohort study
        </article-title>
        <source>
         Infect Control Hosp Epidemiol
        </source>
        <volume>
         18
        </volume>
        <year>
         1997
        </year>
        <fpage>
         24
        </fpage>
        <pub-id pub-id-type="pmid">
         9013242
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib482">
       <label>
        482
       </label>
       <element-citation id="sbref4800" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Salzman
          </surname>
          <given-names>
           MB
          </given-names>
         </name>
         <name>
          <surname>
           Isenberg
          </surname>
          <given-names>
           HD
          </given-names>
         </name>
         <name>
          <surname>
           Rubin
          </surname>
          <given-names>
           LG
          </given-names>
         </name>
        </person-group>
        <article-title>
         Use of disinfectants to reduce microbial contamination of hubs of vascular catheters
        </article-title>
        <source>
         J Clin Microbiol
        </source>
        <volume>
         31
        </volume>
        <year>
         1993
        </year>
        <fpage>
         475
        </fpage>
        <lpage>
         479
        </lpage>
        <pub-id pub-id-type="pmid">
         8458938
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib483">
       <label>
        483
       </label>
       <element-citation id="sbref4810" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ruschman
          </surname>
          <given-names>
           KL
          </given-names>
         </name>
         <name>
          <surname>
           Fulton
          </surname>
          <given-names>
           JS
          </given-names>
         </name>
        </person-group>
        <article-title>
         Effectiveness of disinfectant techniques on intravenous tubing latex injection ports
        </article-title>
        <source>
         J Intraven Nurs
        </source>
        <volume>
         16
        </volume>
        <year>
         1993
        </year>
        <fpage>
         304
        </fpage>
        <lpage>
         308
        </lpage>
        <pub-id pub-id-type="pmid">
         8229434
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib484">
       <label>
        484
       </label>
       <element-citation id="sbref4820" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Casey
          </surname>
          <given-names>
           AL
          </given-names>
         </name>
         <name>
          <surname>
           Worthington
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Lambert
          </surname>
          <given-names>
           PA
          </given-names>
         </name>
         <name>
          <surname>
           Quinn
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Faroqui
          </surname>
          <given-names>
           MH
          </given-names>
         </name>
         <name>
          <surname>
           Elliott
          </surname>
          <given-names>
           TSJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         A randomized, prospective clinical trial to assess the potential infection risk associated with the PosiFlow ® needleless connector
        </article-title>
        <source>
         J Hosp Infect
        </source>
        <volume>
         54
        </volume>
        <year>
         2003
        </year>
        <fpage>
         288
        </fpage>
        <lpage>
         293
        </lpage>
        <pub-id pub-id-type="pmid">
         12919759
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib485">
       <label>
        485
       </label>
       <element-citation id="sbref4830" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Simmons
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Bryson
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Porter
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        <article-title>
         ‘Scrub the hub’: cleaning duration and reduction in bacterial load on central venous catheters
        </article-title>
        <source>
         Crit Care Nurs Q
        </source>
        <volume>
         34
        </volume>
        <year>
         2011
        </year>
        <fpage>
         31
        </fpage>
        <pub-id pub-id-type="pmid">
         21160298
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib486">
       <label>
        486
       </label>
       <element-citation id="sbref4840" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kaler
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <name>
          <surname>
           Chinn
          </surname>
          <given-names>
           R
          </given-names>
         </name>
        </person-group>
        <article-title>
         Successful disinfection of needleless access ports: a matter of time and friction
        </article-title>
        <source>
         JAVA
        </source>
        <volume>
         12
        </volume>
        <year>
         2007
        </year>
        <fpage>
         140
        </fpage>
        <lpage>
         142
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib487">
       <label>
        487
       </label>
       <element-citation id="sbref4850" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Snaterse
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Rüger
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <name>
          <surname>
           Scholte op Reimer
          </surname>
          <given-names>
           WJM
          </given-names>
         </name>
         <name>
          <surname>
           Lucas
          </surname>
          <given-names>
           C
          </given-names>
         </name>
        </person-group>
        <article-title>
         Antibiotic-based catheter lock solutions for prevention of catheter-related bloodstream infection: a systematic review of randomised controlled trials
        </article-title>
        <source>
         J Hosp Infect
        </source>
        <volume>
         75
        </volume>
        <year>
         2010
        </year>
        <fpage>
         1
        </fpage>
        <lpage>
         11
        </lpage>
        <pub-id pub-id-type="pmid">
         20227787
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib488">
       <label>
        488
       </label>
       <element-citation id="sbref4860" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Slobbe
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Doorduijn
          </surname>
          <given-names>
           JK
          </given-names>
         </name>
         <name>
          <surname>
           Lugtenburg
          </surname>
          <given-names>
           PJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         Prevention of catheter-related bacteremia with a daily ethanol lock in patients with tunnelled catheters: a randomized, placebo-controlled trial
        </article-title>
        <source>
         PLoS One
        </source>
        <volume>
         5
        </volume>
        <year>
         2010
        </year>
        <fpage>
         e10840
        </fpage>
        <pub-id pub-id-type="pmid">
         20520776
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib489">
       <label>
        489
       </label>
       <element-citation id="sbref4870" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Centers for Disease Control and Prevention
          </surname>
         </name>
        </person-group>
        <article-title>
         Guidelines for the prevention of intravascular-catheter-related infections
        </article-title>
        <source>
         MMWR
        </source>
        <volume>
         51
        </volume>
        <year>
         2002
        </year>
        <fpage>
         1
        </fpage>
        <lpage>
         29
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib490">
       <label>
        490
       </label>
       <element-citation id="sbref4880" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Morris
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Howard
          </surname>
          <given-names>
           P
          </given-names>
         </name>
        </person-group>
        <article-title>
         Can high-level mupirocin resistance reporting be relied upon to ensure patients are prescribed appropriate treatment?
        </article-title>
        <source>
         ECCMID
        </source>
        <year>
         2012
        </year>
        <fpage>
         2378
        </fpage>
       </element-citation>
      </ref>
      <ref id="bib491">
       <label>
        491
       </label>
       <element-citation id="sbref4890" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           van de Wetering
          </surname>
          <given-names>
           MD
          </given-names>
         </name>
         <name>
          <surname>
           van Woensel
          </surname>
          <given-names>
           JB
          </given-names>
         </name>
        </person-group>
        <article-title>
         Prophylactic antibiotics for preventing early central venous catheter Gram positive infections in oncology patients
        </article-title>
        <source>
         Cochrane Database Syst Rev
        </source>
        <volume>
         2
        </volume>
        <year>
         2003
        </year>
        <comment>
         CD003295.
        </comment>
       </element-citation>
      </ref>
      <ref id="bib492">
       <label>
        492
       </label>
       <element-citation id="sbref4900" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hoar
          </surname>
          <given-names>
           PF
          </given-names>
         </name>
         <name>
          <surname>
           Wilson
          </surname>
          <given-names>
           RM
          </given-names>
         </name>
         <name>
          <surname>
           Mangano
          </surname>
          <given-names>
           DT
          </given-names>
         </name>
         <name>
          <surname>
           Avery
          </surname>
          <given-names>
           GJ
          </given-names>
          <suffix>
           2nd
          </suffix>
         </name>
         <name>
          <surname>
           Szarnicki
          </surname>
          <given-names>
           RJ
          </given-names>
         </name>
         <name>
          <surname>
           Hill
          </surname>
          <given-names>
           JD
          </given-names>
         </name>
        </person-group>
        <article-title>
         Heparin bonding reduces thrombogenicity of pulmonary-artery catheters
        </article-title>
        <source>
         N Engl J Med
        </source>
        <volume>
         305
        </volume>
        <year>
         1981
        </year>
        <fpage>
         993
        </fpage>
        <lpage>
         995
        </lpage>
        <pub-id pub-id-type="pmid">
         7024812
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib493">
       <label>
        493
       </label>
       <element-citation id="sbref4910" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ge
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <name>
          <surname>
           Cavallazzi
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Pan
          </surname>
          <given-names>
           SM
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           YW
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           FL
          </given-names>
         </name>
        </person-group>
        <article-title>
         Central venous access sites for the prevention of venous thrombosis, stenosis and infection
        </article-title>
        <source>
         Cochrane Database Syst Rev
        </source>
        <volume>
         3
        </volume>
        <year>
         2012
        </year>
        <comment>
         CD004084.
        </comment>
       </element-citation>
      </ref>
      <ref id="bib494">
       <label>
        494
       </label>
       <element-citation id="sbref4920" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Raad
          </surname>
          <given-names>
           II
          </given-names>
         </name>
         <name>
          <surname>
           Luna
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Khalil
          </surname>
          <given-names>
           SA
          </given-names>
         </name>
         <name>
          <surname>
           Costerton
          </surname>
          <given-names>
           JW
          </given-names>
         </name>
         <name>
          <surname>
           Lam
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Bodey
          </surname>
          <given-names>
           GP
          </given-names>
         </name>
        </person-group>
        <article-title>
         The relationship between the thrombotic and infectious complications of central venous catheters
        </article-title>
        <source>
         JAMA
        </source>
        <volume>
         271
        </volume>
        <year>
         1994
        </year>
        <fpage>
         1014
        </fpage>
        <lpage>
         1016
        </lpage>
        <pub-id pub-id-type="pmid">
         8139059
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib495">
       <label>
        495
       </label>
       <element-citation id="sbref4930" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chastre
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Cornud
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Bouchama
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Viau
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Benacerraf
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Gibert
          </surname>
          <given-names>
           C
          </given-names>
         </name>
        </person-group>
        <article-title>
         Thrombosis as a complication of pulmonary-artery catheterization via the internal jugular vein: prospective evaluation by phlebography
        </article-title>
        <source>
         N Engl J Med
        </source>
        <volume>
         306
        </volume>
        <year>
         1982
        </year>
        <fpage>
         278
        </fpage>
        <lpage>
         281
        </lpage>
        <pub-id pub-id-type="pmid">
         7054699
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib496">
       <label>
        496
       </label>
       <element-citation id="sbref4940" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Valerio
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Hussey
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Smith
          </surname>
          <given-names>
           F
          </given-names>
         </name>
        </person-group>
        <article-title>
         Central vein thrombosis associated with intravenous feeding – a prospective study
        </article-title>
        <source>
         J Parenter Enteral Nutr
        </source>
        <volume>
         5
        </volume>
        <year>
         1981
        </year>
        <fpage>
         240
        </fpage>
        <lpage>
         242
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib497">
       <label>
        497
       </label>
       <element-citation id="sbref4950" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Andrew
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Marzinotto
          </surname>
          <given-names>
           V
          </given-names>
         </name>
         <name>
          <surname>
           Pencharz
          </surname>
          <given-names>
           P
          </given-names>
         </name>
        </person-group>
        <article-title>
         A cross-sectional study of catheter-related thrombosis in children receiving total parenteral nutrition at home
        </article-title>
        <source>
         J Pediatr
        </source>
        <volume>
         126
        </volume>
        <year>
         1995
        </year>
        <fpage>
         358
        </fpage>
        <lpage>
         363
        </lpage>
        <pub-id pub-id-type="pmid">
         7869192
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib498">
       <label>
        498
       </label>
       <element-citation id="sbref4960" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Krafte-Jacobs
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Sivit
          </surname>
          <given-names>
           CJ
          </given-names>
         </name>
         <name>
          <surname>
           Mejia
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Pollack
          </surname>
          <given-names>
           MM
          </given-names>
         </name>
        </person-group>
        <article-title>
         Catheter-related thrombosis in critically ill children: comparison of catheters with and without heparin bonding
        </article-title>
        <source>
         J Pediatr
        </source>
        <volume>
         126
        </volume>
        <year>
         1995
        </year>
        <fpage>
         50
        </fpage>
        <lpage>
         54
        </lpage>
        <pub-id pub-id-type="pmid">
         7815223
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib499">
       <label>
        499
       </label>
       <element-citation id="sbref4970" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Talbott
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Winters
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <name>
          <surname>
           Bratton
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           O'Rourke
          </surname>
          <given-names>
           P
          </given-names>
         </name>
        </person-group>
        <article-title>
         A prospective study of femoral catheter-related thrombosis in children
        </article-title>
        <source>
         Arch Pediatr Adolesc Med
        </source>
        <volume>
         149
        </volume>
        <year>
         1995
        </year>
        <fpage>
         288
        </fpage>
        <lpage>
         291
        </lpage>
        <pub-id pub-id-type="pmid">
         7858689
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib500">
       <label>
        500
       </label>
       <element-citation id="sbref4980" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Randolph
          </surname>
          <given-names>
           AG
          </given-names>
         </name>
         <name>
          <surname>
           Cook
          </surname>
          <given-names>
           DJ
          </given-names>
         </name>
         <name>
          <surname>
           Gonzales
          </surname>
          <given-names>
           CA
          </given-names>
         </name>
         <name>
          <surname>
           Andrew
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <article-title>
         Benefit of heparin in central venous and pulmonary artery catheters: a meta-analysis of randomized controlled trials
        </article-title>
        <source>
         Chest
        </source>
        <volume>
         113
        </volume>
        <year>
         1998
        </year>
        <fpage>
         165
        </fpage>
        <lpage>
         171
        </lpage>
        <pub-id pub-id-type="pmid">
         9440585
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib501">
       <label>
        501
       </label>
       <element-citation id="sbref4990" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bern
          </surname>
          <given-names>
           MM
          </given-names>
         </name>
         <name>
          <surname>
           Lokich
          </surname>
          <given-names>
           JJ
          </given-names>
         </name>
         <name>
          <surname>
           Wallach
          </surname>
          <given-names>
           SR
          </given-names>
         </name>
        </person-group>
        <article-title>
         Very low doses of warfarin can prevent thrombosis in central venous catheters. A randomized prospective trial
        </article-title>
        <source>
         Ann Intern Med
        </source>
        <volume>
         112
        </volume>
        <year>
         1990
        </year>
        <fpage>
         423
        </fpage>
        <lpage>
         428
        </lpage>
        <pub-id pub-id-type="pmid">
         2178534
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib502">
       <label>
        502
       </label>
       <element-citation id="sbref5000" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Abdelkefi
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Abdeladhim
          </surname>
          <given-names>
           AB
          </given-names>
         </name>
         <name>
          <surname>
           Torjman
          </surname>
          <given-names>
           L
          </given-names>
         </name>
        </person-group>
        <article-title>
         Randomized trial of prevention of catheter-related bloodstream infection by continuous infusion of low-dose unfractionated heparin in patients with hematologic and oncologic disease
        </article-title>
        <source>
         J Clin Oncol
        </source>
        <volume>
         23
        </volume>
        <year>
         2005
        </year>
        <fpage>
         7864
        </fpage>
        <lpage>
         7870
        </lpage>
        <pub-id pub-id-type="pmid">
         16258088
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib503">
       <label>
        503
       </label>
       <element-citation id="sbref5010" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Pierce
          </surname>
          <given-names>
           CM
          </given-names>
         </name>
         <name>
          <surname>
           Wade
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Mok
          </surname>
          <given-names>
           Q
          </given-names>
         </name>
        </person-group>
        <article-title>
         Heparin-bonded central venous lines reduce thrombotic and infective complications in critically ill children
        </article-title>
        <source>
         Intensive Care Med
        </source>
        <volume>
         26
        </volume>
        <year>
         2000
        </year>
        <fpage>
         967
        </fpage>
        <lpage>
         972
        </lpage>
        <pub-id pub-id-type="pmid">
         10990114
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib504">
       <label>
        504
       </label>
       <element-citation id="sbref5020" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Appelgren
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Ransjo
          </surname>
          <given-names>
           U
          </given-names>
         </name>
         <name>
          <surname>
           Bindslev
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Espersen
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Larm
          </surname>
          <given-names>
           O
          </given-names>
         </name>
        </person-group>
        <article-title>
         Surface heparinization of central venous catheters reduces microbial colonization in vitro and in vivo: results from a prospective, randomized trial
        </article-title>
        <source>
         Crit Care Med
        </source>
        <volume>
         24
        </volume>
        <year>
         1996
        </year>
        <fpage>
         1482
        </fpage>
        <lpage>
         1489
        </lpage>
        <pub-id pub-id-type="pmid">
         8797619
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib505">
       <label>
        505
       </label>
       <element-citation id="sbref5030" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Abdelkefi
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Achour
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <name>
          <surname>
           Ben Othman
          </surname>
          <given-names>
           T
          </given-names>
         </name>
        </person-group>
        <article-title>
         Use of heparin-coated central venous lines to prevent catheter-related bloodstream infection
        </article-title>
        <source>
         J Support Oncol
        </source>
        <volume>
         5
        </volume>
        <year>
         2007
        </year>
        <fpage>
         273
        </fpage>
        <lpage>
         278
        </lpage>
        <pub-id pub-id-type="pmid">
         17624052
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib506">
       <label>
        506
       </label>
       <element-citation id="sbref5040" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Shah
          </surname>
          <given-names>
           PS
          </given-names>
         </name>
         <name>
          <surname>
           Shah
          </surname>
          <given-names>
           N
          </given-names>
         </name>
        </person-group>
        <article-title>
         Heparin-bonded catheters for prolonging the patency of central venous catheters in children
        </article-title>
        <source>
         Cochrane Database Syst Rev
        </source>
        <volume>
         4
        </volume>
        <year>
         2007
        </year>
        <comment>
         CD005983.
        </comment>
       </element-citation>
      </ref>
      <ref id="bib507">
       <label>
        507
       </label>
       <element-citation id="sbref5050" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Boraks
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Seale
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Price
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        <article-title>
         Prevention of central venous catheter associated thrombosis using minidose warfarin in patients with haematological malignancies
        </article-title>
        <source>
         Br J Haematol
        </source>
        <volume>
         101
        </volume>
        <year>
         1998
        </year>
        <fpage>
         483
        </fpage>
        <lpage>
         486
        </lpage>
        <pub-id pub-id-type="pmid">
         9633891
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib508">
       <label>
        508
       </label>
       <element-citation id="sbref5060" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Akl
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Karmath
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Yosuico
          </surname>
          <given-names>
           V
          </given-names>
         </name>
        </person-group>
        <article-title>
         Anticoagulation for thrombosis prophylaxis in cancer patients with central venous catheters
        </article-title>
        <source>
         Cochrane Database Syst Rev
        </source>
        <volume>
         18
        </volume>
        <year>
         2007
        </year>
        <comment>
         CD00646.
        </comment>
       </element-citation>
      </ref>
      <ref id="bib509">
       <label>
        509
       </label>
       <element-citation id="sbref5070" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Akl
          </surname>
          <given-names>
           EA
          </given-names>
         </name>
         <name>
          <surname>
           Muti
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Schunemann
          </surname>
          <given-names>
           HJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         Anticoagulation in patients with cancer: an overview of reviews
        </article-title>
        <source>
         Pol Arch Med Wewn
        </source>
        <volume>
         118
        </volume>
        <year>
         2008
        </year>
        <fpage>
         183
        </fpage>
        <lpage>
         193
        </lpage>
        <pub-id pub-id-type="pmid">
         18575417
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib510">
       <label>
        510
       </label>
       <element-citation id="sbref5080" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Klerk
          </surname>
          <given-names>
           CP
          </given-names>
         </name>
         <name>
          <surname>
           Smorenburg
          </surname>
          <given-names>
           SM
          </given-names>
         </name>
         <name>
          <surname>
           Buller
          </surname>
          <given-names>
           HR
          </given-names>
         </name>
        </person-group>
        <article-title>
         Thrombosis prophylaxis in patient populations with a central venous catheter: a systematic review
        </article-title>
        <source>
         Arch Intern Med
        </source>
        <volume>
         163
        </volume>
        <year>
         2003
        </year>
        <fpage>
         1913
        </fpage>
        <lpage>
         1921
        </lpage>
        <pub-id pub-id-type="pmid">
         12963564
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib511">
       <label>
        511
       </label>
       <element-citation id="sbref5090" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Passannante
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Macik
          </surname>
          <given-names>
           BG
          </given-names>
         </name>
        </person-group>
        <article-title>
         The heparin flush syndrome: a cause of iatrogenic hemorrhage
        </article-title>
        <source>
         Am J Med Sci
        </source>
        <volume>
         296
        </volume>
        <year>
         1988
        </year>
        <fpage>
         71
        </fpage>
        <lpage>
         73
        </lpage>
        <pub-id pub-id-type="pmid">
         3407682
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib512">
       <label>
        512
       </label>
       <element-citation id="sbref5100" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Randolph
          </surname>
          <given-names>
           AG
          </given-names>
         </name>
         <name>
          <surname>
           Cook
          </surname>
          <given-names>
           DJ
          </given-names>
         </name>
         <name>
          <surname>
           Gonzales
          </surname>
          <given-names>
           CA
          </given-names>
         </name>
         <name>
          <surname>
           Andrew
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <article-title>
         Benefit of heparin in peripheral venous and arterial catheters: systematic review and meta-analysis of randomised controlled trials
        </article-title>
        <source>
         BMJ
        </source>
        <volume>
         316
        </volume>
        <year>
         1998
        </year>
        <fpage>
         969
        </fpage>
        <lpage>
         975
        </lpage>
        <pub-id pub-id-type="pmid">
         9550955
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib513">
       <label>
        513
       </label>
       <element-citation id="sbref5110" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Goode
          </surname>
          <given-names>
           CJ
          </given-names>
         </name>
         <name>
          <surname>
           Titler
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Rakel
          </surname>
          <given-names>
           B
          </given-names>
         </name>
        </person-group>
        <article-title>
         A meta-analysis of effects of heparin flush and saline flush: quality and cost implications
        </article-title>
        <source>
         Nurs Res
        </source>
        <volume>
         40
        </volume>
        <year>
         1991
        </year>
        <fpage>
         324
        </fpage>
        <lpage>
         330
        </lpage>
        <pub-id pub-id-type="pmid">
         1835537
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib514">
       <label>
        514
       </label>
       <element-citation id="sbref5120" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Peterson
          </surname>
          <given-names>
           FY
          </given-names>
         </name>
         <name>
          <surname>
           Kirchhoff
          </surname>
          <given-names>
           KT
          </given-names>
         </name>
        </person-group>
        <article-title>
         Analysis of the research about heparinized versus nonheparinized intravascular lines
        </article-title>
        <source>
         Heart Lung
        </source>
        <volume>
         20
        </volume>
        <year>
         1991
        </year>
        <fpage>
         631
        </fpage>
        <lpage>
         640
        </lpage>
        <pub-id pub-id-type="pmid">
         1835721
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib515">
       <label>
        515
       </label>
       <element-citation id="sbref5130" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Mitchell
          </surname>
          <given-names>
           MD
          </given-names>
         </name>
         <name>
          <surname>
           Anderson
          </surname>
          <given-names>
           BJ
          </given-names>
         </name>
         <name>
          <surname>
           Williams
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Umscheid
          </surname>
          <given-names>
           CA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Heparin flushing and other interventions to maintain patency of central venous catheters: a systematic review
        </article-title>
        <source>
         J Adv Nurs
        </source>
        <volume>
         65
        </volume>
        <year>
         2009
        </year>
        <fpage>
         2007
        </fpage>
        <lpage>
         2021
        </lpage>
        <pub-id pub-id-type="pmid">
         20568318
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib516">
       <label>
        516
       </label>
       <element-citation id="sbref5140" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Schallom
          </surname>
          <given-names>
           ME
          </given-names>
         </name>
         <name>
          <surname>
           Prentice
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Sona
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Micek
          </surname>
          <given-names>
           ST
          </given-names>
         </name>
         <name>
          <surname>
           Skrupky
          </surname>
          <given-names>
           LP
          </given-names>
         </name>
        </person-group>
        <article-title>
         Heparin or 0.9% sodium chloride to maintain central venous catheter patency: a randomized trial
        </article-title>
        <source>
         Crit Care Med
        </source>
        <volume>
         40
        </volume>
        <year>
         2012
        </year>
        <fpage>
         1820
        </fpage>
        <lpage>
         1826
        </lpage>
        <pub-id pub-id-type="pmid">
         22488006
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib517">
       <label>
        517
       </label>
       <element-citation id="sbref5150" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bertolino
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Pitassi
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Tinelli
          </surname>
          <given-names>
           C
          </given-names>
         </name>
        </person-group>
        <article-title>
         Intermittent flushing with heparin versus saline for maintenance of peripheral intravenous catheters in a medical department: a pragmatic cluster-randomized controlled study
        </article-title>
        <source>
         Worldviews Evid Based Nurs
        </source>
        <volume>
         9
        </volume>
        <year>
         2012
        </year>
        <fpage>
         221
        </fpage>
        <lpage>
         226
        </lpage>
        <pub-id pub-id-type="pmid">
         22390572
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib518">
       <label>
        518
       </label>
       <element-citation id="sbref5160" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rupp
          </surname>
          <given-names>
           ME
          </given-names>
         </name>
         <name>
          <surname>
           Sholtz
          </surname>
          <given-names>
           LA
          </given-names>
         </name>
         <name>
          <surname>
           Jourdan
          </surname>
          <given-names>
           DR
          </given-names>
         </name>
        </person-group>
        <article-title>
         Outbreak of bloodstream infection temporally associated with the use of an intravascular needleless valve
        </article-title>
        <source>
         Clin Infect Dis
        </source>
        <volume>
         44
        </volume>
        <year>
         2007
        </year>
        <fpage>
         1408
        </fpage>
        <lpage>
         1414
        </lpage>
        <pub-id pub-id-type="pmid">
         17479934
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib519">
       <label>
        519
       </label>
       <element-citation id="sbref5170" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Salgado
          </surname>
          <given-names>
           CD
          </given-names>
         </name>
         <name>
          <surname>
           Chinnes
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Paczesny
          </surname>
          <given-names>
           TH
          </given-names>
         </name>
         <name>
          <surname>
           Cantey
          </surname>
          <given-names>
           JR
          </given-names>
         </name>
        </person-group>
        <article-title>
         Increased rate of catheter-related bloodstream infection associated with use of a needleless mechanical valve device at a long-term acute care hospital
        </article-title>
        <source>
         Infect Control Hosp Epidemiol
        </source>
        <volume>
         28
        </volume>
        <year>
         2007
        </year>
        <fpage>
         684
        </fpage>
        <lpage>
         688
        </lpage>
        <pub-id pub-id-type="pmid">
         17520541
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib520">
       <label>
        520
       </label>
       <element-citation id="sbref5180" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Maragakis
          </surname>
          <given-names>
           LL
          </given-names>
         </name>
         <name>
          <surname>
           Bradley
          </surname>
          <given-names>
           KL
          </given-names>
         </name>
         <name>
          <surname>
           Song
          </surname>
          <given-names>
           X
          </given-names>
         </name>
        </person-group>
        <article-title>
         Increased catheter-related bloodstream infection rates after the introduction of a new mechanical valve intravenous access port
        </article-title>
        <source>
         Infect Control Hosp Epidemiol
        </source>
        <volume>
         27
        </volume>
        <year>
         2006
        </year>
        <fpage>
         67
        </fpage>
        <lpage>
         70
        </lpage>
        <pub-id pub-id-type="pmid">
         16418990
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib521">
       <label>
        521
       </label>
       <element-citation id="sbref5190" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Field
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Athan
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           McFarlane
          </surname>
          <given-names>
           C
          </given-names>
         </name>
        </person-group>
        <article-title>
         Incidence of catheter-related bloodstream infection among patients with a needleless, mechanical valve-based intravenous connector in an Australian hematology-oncology unit
        </article-title>
        <source>
         Infect Control Hosp Epidemiol
        </source>
        <volume>
         28
        </volume>
        <year>
         2007
        </year>
        <fpage>
         610
        </fpage>
        <lpage>
         613
        </lpage>
        <pub-id pub-id-type="pmid">
         17464926
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib522">
       <label>
        522
       </label>
       <element-citation id="sbref5200" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gillies
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           O'Riordan
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Wallen
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Morrison
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Rankin
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Nagy
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        <article-title>
         Optimal timing for intravenous administration set replacement
        </article-title>
        <source>
         Cochrane Database Syst Rev
        </source>
        <volume>
         4
        </volume>
        <year>
         2005
        </year>
        <comment>
         CD003588.
        </comment>
       </element-citation>
      </ref>
      <ref id="bib523">
       <label>
        523
       </label>
       <element-citation id="sbref5210" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Department of Health
          </surname>
         </name>
        </person-group>
        <source>
         Saving lives: a delivery programme to reduce healthcare associated infection including MRSA
        </source>
        <year>
         2005
        </year>
        <publisher-name>
         Department of Health
        </publisher-name>
        <publisher-loc>
         London
        </publisher-loc>
       </element-citation>
      </ref>
      <ref id="bib524">
       <label>
        524
       </label>
       <element-citation id="sbref5220" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Berenholtz
          </surname>
          <given-names>
           SM
          </given-names>
         </name>
         <name>
          <surname>
           Pronovost
          </surname>
          <given-names>
           PJ
          </given-names>
         </name>
         <name>
          <surname>
           Lipsett
          </surname>
          <given-names>
           PA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Eliminating catheter-related bloodstream infections in the intensive care unit
        </article-title>
        <source>
         Crit Care Med
        </source>
        <volume>
         32
        </volume>
        <year>
         2004
        </year>
        <fpage>
         2014
        </fpage>
        <lpage>
         2020
        </lpage>
        <pub-id pub-id-type="pmid">
         15483409
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib525">
       <label>
        525
       </label>
       <element-citation id="sbref5230" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Pronovost
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Roth
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Bander
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        <article-title>
         An intervention to decrease catheter-related bloodstream infections in the ICU
        </article-title>
        <source>
         N Engl J Med
        </source>
        <volume>
         355
        </volume>
        <year>
         2006
        </year>
        <fpage>
         2725
        </fpage>
        <lpage>
         2732
        </lpage>
        <pub-id pub-id-type="pmid">
         17192537
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib526">
       <label>
        526
       </label>
       <element-citation id="sbref5240" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Pronovost
          </surname>
          <given-names>
           PJ
          </given-names>
         </name>
         <name>
          <surname>
           Sexton
          </surname>
          <given-names>
           JB
          </given-names>
         </name>
         <name>
          <surname>
           Marsteller
          </surname>
          <given-names>
           JA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Sustaining reductions in catheter related bloodstream infections in Michigan intensive care units: observational study
        </article-title>
        <source>
         BMJ
        </source>
        <volume>
         4
        </volume>
        <year>
         2010
        </year>
        <fpage>
         c309
        </fpage>
       </element-citation>
      </ref>
      <ref id="bib527">
       <label>
        527
       </label>
       <element-citation id="sbref5250" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Curran
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Harper
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Loveday
          </surname>
          <given-names>
           H
          </given-names>
         </name>
        </person-group>
        <article-title>
         Results of a multicentre randomised controlled trial of statistical process control charts and structured diagnostic tools to reduce ward-acquired meticillin-resistant Staphylococcus aureus: the CHART Project
        </article-title>
        <source>
         J Hosp Infect
        </source>
        <volume>
         70
        </volume>
        <year>
         2008
        </year>
        <fpage>
         127
        </fpage>
        <lpage>
         135
        </lpage>
        <pub-id pub-id-type="pmid">
         18723251
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib528">
       <label>
        528
       </label>
       <element-citation id="sbref5260" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Scales
          </surname>
          <given-names>
           DC
          </given-names>
         </name>
         <name>
          <surname>
           Dainty
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Hales
          </surname>
          <given-names>
           B
          </given-names>
         </name>
        </person-group>
        <article-title>
         A multifaceted intervention for quality improvement in a network of intensive care units: a cluster randomized trial
        </article-title>
        <source>
         JAMA
        </source>
        <volume>
         305
        </volume>
        <year>
         2011
        </year>
        <fpage>
         363
        </fpage>
        <lpage>
         372
        </lpage>
        <pub-id pub-id-type="pmid">
         21248161
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib529">
       <label>
        529
       </label>
       <element-citation id="sbref5270" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Munoz-Price
          </surname>
          <given-names>
           LS
          </given-names>
         </name>
         <name>
          <surname>
           Dezfulian
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Wyckoff
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <article-title>
         Effectiveness of stepwise interventions targeted to decrease central catheter-associated bloodstream infections
        </article-title>
        <source>
         Crit Care Med
        </source>
        <volume>
         40
        </volume>
        <year>
         2012
        </year>
        <fpage>
         1464
        </fpage>
        <lpage>
         1469
        </lpage>
        <pub-id pub-id-type="pmid">
         22511128
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib530">
       <label>
        530
       </label>
       <element-citation id="sbref5280" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bion
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Bellingan
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Patten
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <article-title>
         ‘Matching Michigan’: a 2-year stepped interventional programme to minimise central venous catheter-blood stream infections in intensive care units in England
        </article-title>
        <source>
         BMJ
        </source>
        <volume>
         22
        </volume>
        <year>
         2013
        </year>
        <fpage>
         110
        </fpage>
        <lpage>
         123
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib531">
       <label>
        531
       </label>
       <element-citation id="sbref5290" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Halton
          </surname>
          <given-names>
           KA
          </given-names>
         </name>
         <name>
          <surname>
           Cook
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Paterson
          </surname>
          <given-names>
           DL
          </given-names>
         </name>
         <name>
          <surname>
           Safdar
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Graves
          </surname>
          <given-names>
           N
          </given-names>
         </name>
        </person-group>
        <article-title>
         Cost-effectiveness of a central venous catheter care bundle
        </article-title>
        <source>
         PLoS One
        </source>
        <volume>
         5
        </volume>
        <year>
         2010
        </year>
        <fpage>
         e12815
        </fpage>
        <pub-id pub-id-type="pmid">
         20862246
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib532">
       <label>
        532
       </label>
       <element-citation id="sbref5300" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Berwick
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Calkins
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           McCannon
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Hackard
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        <article-title>
         The 100,000 lives campaign: setting a goal and deadline for improving healthcare quality
        </article-title>
        <source>
         JAMA
        </source>
        <volume>
         295
        </volume>
        <year>
         2006
        </year>
        <fpage>
         326
        </fpage>
        <lpage>
         327
        </lpage>
       </element-citation>
      </ref>
     </ref-list>
     <sec id="cesec2270">
      <title>
       Appendices
      </title>
      <sec id="app1">
       <label>
        A.1
       </label>
       <title>
        Systematic Review Process
       </title>
       <p id="para12830">
        <boxed-text id="cetextbox640">
         <sec id="cesec2280">
          <title>
           <inline-graphic xlink:href="fx2_lrg.gif">
           </inline-graphic>
           Initial Search for Published Evidence
          </title>
          <p id="para12840">
           An initial search was made for national and international guidelines and systematic reviews of randomised controlled trials.
          </p>
         </sec>
        </boxed-text>
       </p>
       <p id="para12850">
        <boxed-text id="cetextbox650">
         <sec id="cesec2290">
          <title>
           <inline-graphic xlink:href="fx2_lrg.gif">
           </inline-graphic>
           Systematic Review Questions
          </title>
          <p id="para12860">
           Search questions were based on the scope of the original review and advice from the Guideline Development Group.
          </p>
         </sec>
        </boxed-text>
       </p>
       <p id="para12870">
        <boxed-text id="cetextbox660">
         <sec id="cesec2300">
          <title>
           <inline-graphic xlink:href="fx2_lrg.gif">
           </inline-graphic>
           Literature Search
          </title>
          <p id="para12880">
           Databases to be searched were identified together with search strategy [i.e. relevant medical subject headings (MESH), free-text and thesaurus terms].
          </p>
         </sec>
        </boxed-text>
       </p>
       <p id="para12890">
        <boxed-text id="cetextbox670">
         <sec id="cesec2310">
          <title>
           <inline-graphic xlink:href="fx2_lrg.gif">
           </inline-graphic>
           Sift 1
          </title>
          <p id="para12900">
           <bold>
            Abstracts
           </bold>
           of all articles retrieved from the search were reviewed against pre-determined inclusion criteria (e.g. relevant to a review question, primary research/systematic review/meta-analysis, written in English).
          </p>
         </sec>
        </boxed-text>
       </p>
       <p id="para12910">
        <boxed-text id="cetextbox680">
         <sec id="cesec2320">
          <title>
           <inline-graphic xlink:href="fx2_lrg.gif">
           </inline-graphic>
           Sift 2
          </title>
          <p id="para12920">
           <bold>
            Full text
           </bold>
           of all articles that met the inclusion criteria was reviewed against pre-determined criteria to identify primary research which answers review questions.
          </p>
         </sec>
        </boxed-text>
       </p>
       <p id="para12930">
        <boxed-text id="cetextbox690">
         <sec id="cesec2330">
          <title>
           <inline-graphic xlink:href="fx2_lrg.gif">
           </inline-graphic>
           Critical Appraisal
          </title>
          <p id="para12940">
           All articles that described primary research, a systematic review or a meta-analysis were critically appraised by two experienced appraisers. Consensus and grading was achieved through discussion in the context of pre-determined grading criteria.
          </p>
         </sec>
        </boxed-text>
       </p>
      </sec>
      <sec id="app2">
       <label>
        A.2
       </label>
       <title>
        Consultation Process
       </title>
       <p id="para12950">
        The following organisations were approached for comment:
       </p>
       <p id="para12960">
        Advisory Committee on Antimicrobial Resistance and Healthcare Associated Infection
       </p>
       <p id="para12970">
        Association for Continence Advice
       </p>
       <p id="para12980">
        Association of British Healthcare Industries
       </p>
       <p id="para12990">
        Association of Healthcare Cleaning Professionals
       </p>
       <p id="para13000">
        British Association of Critical Care Nurses
       </p>
       <p id="para13010">
        British Association of Urological Surgeons
       </p>
       <p id="para13020">
        British Association of Urological Nurses
       </p>
       <p id="para13030">
        British Health Care Trades Association
       </p>
       <p id="para13040">
        British Infection Association
       </p>
       <p id="para13050">
        British Medical Association
       </p>
       <p id="para13060">
        British Society for Antimicrobial Chemotherapy
       </p>
       <p id="para13070">
        C-diff Support
       </p>
       <p id="para13080">
        Chartered Society of Physiotherapy
       </p>
       <p id="para13090">
        Foundation Trust Network
       </p>
       <p id="para13100">
        General Medical Council
       </p>
       <p id="para13110">
        Health and Safety Executive
       </p>
       <p id="para13120">
        Health Education England
       </p>
       <p id="para13130">
        Health Professions Council
       </p>
       <p id="para13140">
        Health Protection Scotland
       </p>
       <p id="para13150">
        Healthcare Infection Society
       </p>
       <p id="para13160">
        Healthwatch England
       </p>
       <p id="para13170">
        HPA Scotland
       </p>
       <p id="para13180">
        Infection Prevention Society
       </p>
       <p id="para13190">
        Intensive Care Society
       </p>
       <p id="para13200">
        Medicines and Healthcare Products Regulatory Agency
       </p>
       <p id="para13210">
        MRSA Action UK
       </p>
       <p id="para13220">
        NI Public Health Agency
       </p>
       <p id="para13230">
        NHS Confederation
       </p>
       <p id="para13240">
        NHS Trust Development Authority
       </p>
       <p id="para13250">
        Northern Ireland Executive
       </p>
       <p id="para13260">
        Nursing and Midwifery Council
       </p>
       <p id="para13270">
        Public Health England
       </p>
       <p id="para13280">
        Public Health Wales Health Protection
       </p>
       <p id="para13290">
        Royal College of Anaesthetists
       </p>
       <p id="para13300">
        Royal College of Midwives
       </p>
       <p id="para13310">
        Royal College of Nursing
       </p>
       <p id="para13320">
        Royal College of Pathologists
       </p>
       <p id="para13330">
        Royal College of Physicians
       </p>
       <p id="para13340">
        Royal College of Radiologists
       </p>
       <p id="para13350">
        Royal College of Surgeons of England
       </p>
       <p id="para13360">
        Royal Pharmaceutical Society of Great Britain
       </p>
       <p id="para13370">
        Royal Society of Medicine
       </p>
       <p id="para13380">
        Scottish Government
       </p>
       <p id="para13390">
        Spinal Injury Association
       </p>
       <p id="para13400">
        The Lee Spark Necrotising Fasciitis Foundation
       </p>
       <p id="para13410">
        The Patients Association
       </p>
       <p id="para13420">
        UK Clinical Pharmacists Association
       </p>
       <p id="para13430">
        Unison
       </p>
       <p id="para13440">
        Welsh Assembly Government
       </p>
      </sec>
      <sec id="app3">
       <label>
        A.3
       </label>
       <title>
        Glossary
       </title>
       <p id="para13450">
        <table-wrap id="cetable10" position="anchor">
         <table frame="hsides" rules="groups">
          <tbody>
           <tr>
            <td align="left">
             <bold>
              Adenosine triphosphate (ATP)
             </bold>
            </td>
            <td align="left">
             A chemical compound that contains ‘energy-rich bonds’ and is used by cells to store and deliver energy
            </td>
           </tr>
           <tr>
            <td align="left">
             <bold>
              Aerobic organism
             </bold>
            </td>
            <td align="left">
             An organism that requires free oxygen for life and growth
            </td>
           </tr>
           <tr>
            <td align="left">
             <bold>
              Alcohol-based hand rub
             </bold>
            </td>
            <td align="left">
             A hand decontamination preparation based on alcohol that, for the purposes of these guidelines, encompasses solutions, gels or wipes
            </td>
           </tr>
           <tr>
            <td align="left">
             <bold>
              Antimicrobial
             </bold>
            </td>
            <td align="left">
             A substance that kills or inhibits the growth of microorganisms
            </td>
           </tr>
           <tr>
            <td align="left">
             <bold>
              Asepsis
             </bold>
            </td>
            <td align="left">
             The absence of pathogenic microorganisms
            </td>
           </tr>
           <tr>
            <td align="left">
             <bold>
              Antiseptic
             </bold>
            </td>
            <td align="left">
             A substance that destroys or inhibits the growth of microorganisms and is sufficiently non-toxic to be applied to skin or mucous membranes
            </td>
           </tr>
           <tr>
            <td align="left">
             <bold>
              Aseptic non-touch technique (ANTT)
             </bold>
            </td>
            <td align="left">
             A framework for the aseptic technique based on the concept of defining key parts and key sites to be protected from contamination.
            </td>
           </tr>
           <tr>
            <td align="left">
             <bold>
              Aseptic technique
             </bold>
            </td>
            <td align="left">
             A carefully controlled procedure that aims to prevent contamination by microorganisms
            </td>
           </tr>
           <tr>
            <td align="left">
             <bold>
              Bacteraemia
             </bold>
            </td>
            <td align="left">
             The presence of microorganisms in the bloodstream
            </td>
           </tr>
           <tr>
            <td align="left">
             <bold>
              Bacteriuria
             </bold>
            </td>
            <td align="left">
             The presence of microorganisms in the urine. If there are no symptoms of infection, this is called ‘asymptomatic bacteriuria’
            </td>
           </tr>
           <tr>
            <td align="left">
             <bold>
              Biofilm
             </bold>
            </td>
            <td align="left">
             A complex structure comprising microorganisms and extracellular polymers that forms over surfaces, such as those in contact with water or tissues
            </td>
           </tr>
           <tr>
            <td align="left">
             <bold>
              Bladder irrigation
             </bold>
            </td>
            <td align="left">
             Continuous flow of a solution through the bladder to remove clots or debris
            </td>
           </tr>
           <tr>
            <td align="left">
             <bold>
              Bloodborne virus
             </bold>
            </td>
            <td align="left">
             A viral infection transmitted by exposure to blood and sometimes other bodily fluids. Bloodborne viruses include hepatitis B and C as well as human immunodeficiency virus
            </td>
           </tr>
           <tr>
            <td align="left">
             <bold>
              Bloodstream infection (BSI)
             </bold>
            </td>
            <td align="left">
             The presence of microbes in the blood with symptoms of infection
            </td>
           </tr>
           <tr>
            <td align="left">
             <bold>
              Case-control study
             </bold>
            </td>
            <td align="left">
             An analytical observational study that compares people with the disease of interest with a group of similar ‘control’ people who do not in order to determine potential causes or risk factors
            </td>
           </tr>
           <tr>
            <td align="left">
             <bold>
              Case report
             </bold>
            </td>
            <td align="left">
             A scientific article that describes an individual case in detail
            </td>
           </tr>
           <tr>
            <td align="left">
             <bold>
              Case series
             </bold>
            </td>
            <td align="left">
             A report describing a series of several similar events
            </td>
           </tr>
           <tr>
            <td align="left">
             <bold>
              Catheter-associated urinary tract infection (CAUTI)
             </bold>
            </td>
            <td align="left">
             The presence of symptoms or signs attributable to microorganisms that have invaded the urinary tract, where the patient has, or has recently had, a urinary catheter
            </td>
           </tr>
           <tr>
            <td align="left">
             <bold>
              Catheter colonisation
             </bold>
            </td>
            <td align="left">
             Microorganisms present on a surface of a catheter that could potentially lead to infection
            </td>
           </tr>
           <tr>
            <td align="left">
             <bold>
              Catheter-related bloodstream infection (CR-BSI)
             </bold>
            </td>
            <td align="left">
             An infection of the bloodstream where microorganisms are found in the blood of a patient with a central venous access device, the patient has clinical signs of infection (e.g. fever, chills and hypotension) and there is no other apparent source for the infection. For surveillance purposes, this often refers to bloodstream infections that occur in patients with a central venous access device and where other possible sources of infection have been excluded. A more rigorous definition is where the same microorganism is cultured from the tip of the catheter as grown from the blood; simultaneous quantitative blood cultures with at least a 5:1 ratio of microorganisms cultured from the central venous access device vs peripheral; differential time to positivity of at least 2 h for blood cultures cultured peripherally vs from central venous access device
            </td>
           </tr>
           <tr>
            <td align="left">
             <bold>
              Catheter-related infection
             </bold>
            </td>
            <td align="left">
             Any infection related to a central venous access device, including local (e.g. insertion site) and systemic (e.g. bloodstream) infections
            </td>
           </tr>
           <tr>
            <td align="left">
             <bold>
              Central venous catheter (CVC)
             </bold>
            </td>
            <td align="left">
             A vascular catheter inserted with the tip located in the superior vena cava. Central venous catheters are used for giving multiple infusions, medication or chemotherapy, temporary haemodialysis, monitoring of central venous pressure and frequent blood sampling
            </td>
           </tr>
           <tr>
            <td align="left">
             <bold>
              Chlorhexidine
             </bold>
            </td>
            <td align="left">
             An antiseptic widely used as a solution to disinfect and cleanse the skin, wounds or burns
            </td>
           </tr>
           <tr>
            <td align="left">
             <bold>
              Cleaning
             </bold>
            </td>
            <td align="left">
             Methods that physically remove soil, dust and dirt from surfaces or equipment
            </td>
           </tr>
           <tr>
            <td align="left">
             <bold>
              Clinical waste
             </bold>
            </td>
            <td align="left">
             Waste material that consists wholly or partly of human or animal tissue, blood or body fluids, excretions, drugs or other pharmaceutical products, swabs/dressings, syringes, needles or other sharp instruments
            </td>
           </tr>
           <tr>
            <td align="left">
             <bold>
              Closed urinary drainage system
             </bold>
            </td>
            <td align="left">
             A system where a urinary catheter is connected via tubing to a collecting bag. The system relies on gravity to drain the urine
            </td>
           </tr>
           <tr>
            <td align="left">
             <bold>
              Cohort study
             </bold>
            </td>
            <td align="left">
             A prospective or retrospective follow-up study where groups to be followed-up are defined on the basis of presence or absence of exposure to a risk factor or intervention
            </td>
           </tr>
           <tr>
            <td align="left">
             <bold>
              Colonisation
             </bold>
            </td>
            <td align="left">
             Microorganisms that establish themselves in a particular environment, such as a body surface, without producing disease
            </td>
           </tr>
           <tr>
            <td align="left">
             <bold>
              Colony-forming unit (cfu)
             </bold>
            </td>
            <td align="left">
             An estimate of the number of viable bacterial cells made by counting visible colonies derived from the replication of a single microbial cell
            </td>
           </tr>
           <tr>
            <td align="left">
             <bold>
              Cross-infection
             </bold>
            </td>
            <td align="left">
             Transmission of a pathogenic organism from one person to another
            </td>
           </tr>
           <tr>
            <td align="left">
             <bold>
              Crossover trial
             </bold>
            </td>
            <td align="left">
             A comparison of the outcome between two or more groups of patients that are exposed to different regimens of treatment/intervention where the groups exchange treatment/intervention after a pre-arranged period
            </td>
           </tr>
           <tr>
            <td align="left">
             <bold>
              Decontamination
             </bold>
            </td>
            <td align="left">
             A process that removes hazardous substances, including chemicals or microorganisms
            </td>
           </tr>
           <tr>
            <td align="left">
             <bold>
              Detergent
             </bold>
            </td>
            <td align="left">
             A cleansing agent that removes dirt from a surface by bonding with lipids and other particles
            </td>
           </tr>
           <tr>
            <td align="left">
             <bold>
              Disinfection
             </bold>
            </td>
            <td align="left">
             A process that reduces the number of pathogenic microorganisms to a level at which they are not able to cause harm, but which does not usually destroy spores
            </td>
           </tr>
           <tr>
            <td align="left">
             <bold>
              Droplet nuclei
             </bold>
            </td>
            <td align="left">
             Particles 1–10 μm in diameter comprising the dried residue formed by evaporation of droplets coughed or sneezed from the respiratory tract
            </td>
           </tr>
           <tr>
            <td align="left">
             <bold>
              Dysuria
             </bold>
            </td>
            <td align="left">
             Difficult or painful urination
            </td>
           </tr>
           <tr>
            <td align="left">
             <bold>
              Encrustation
             </bold>
            </td>
            <td align="left">
             Urinary proteins, salts and crystals that adhere to the internal and external surface of a urinary catheter
            </td>
           </tr>
           <tr>
            <td align="left">
             <bold>
              Engineering controls
             </bold>
            </td>
            <td align="left">
             The use of equipment designed to prevent injury to the operator
            </td>
           </tr>
           <tr>
            <td align="left">
             <bold>
              Enteral feeding
             </bold>
            </td>
            <td align="left">
             Administration of nutrients into stomach or other part of the gastrointestinal tract using tubes
            </td>
           </tr>
           <tr>
            <td align="left">
             <bold>
              Exogenous infection
             </bold>
            </td>
            <td align="left">
             Infections caused by microorganisms acquired from another person, animal or the environment
            </td>
           </tr>
           <tr>
            <td align="left">
             <bold>
              Expert opinion
             </bold>
            </td>
            <td align="left">
             Opinion derived from seminal works and appraised national and international guidelines
            </td>
           </tr>
           <tr>
            <td align="left">
             <bold>
              Gram-negative/-positive bacteria
             </bold>
            </td>
            <td align="left">
             The type of bacteria as identified by Gram's staining method. Gram-positive bacteria appear dark blue or purple under a microscope. Such bacteria have a thick layer of peptidoglycan on their cell walls. Gram-negative bacteria appear red under a microscope and have an outer layer of lipoprotein and a thin layer of peptidoglycan
            </td>
           </tr>
           <tr>
            <td align="left">
             <bold>
              Guidewire
             </bold>
            </td>
            <td align="left">
             A wire used to facilitate insertion of the intravascular catheter into the body
            </td>
           </tr>
           <tr>
            <td align="left">
             <bold>
              Haemothorax
             </bold>
            </td>
            <td align="left">
             Blood in the pleural cavity, usually due to injury. If the blood is not drained, it may impair the movement of the lungs or become infected
            </td>
           </tr>
           <tr>
            <td align="left">
             <bold>
              Haematogenous seeding
             </bold>
            </td>
            <td align="left">
             Microorganisms causing infection establish infection at another body site as a result of being transferred in the bloodstream
            </td>
           </tr>
           <tr>
            <td align="left">
             <bold>
              Hand decontamination or hand hygiene
             </bold>
            </td>
            <td align="left">
             The use of soap and water or an antiseptic solution to reduce the number of microorganisms on the hands
            </td>
           </tr>
           <tr>
            <td align="left">
             <bold>
              Hawthorne effect
             </bold>
            </td>
            <td align="left">
             A phenomenon in which the participants change their behaviour or performance in response to being studied
            </td>
           </tr>
           <tr>
            <td align="left">
             <bold>
              Healthcare-associated infection (HCAI)
             </bold>
            </td>
            <td align="left">
             Infection acquired as a result of the delivery of health care either in an acute (hospital) or non-acute setting
            </td>
           </tr>
           <tr>
            <td align="left">
             <bold>
              Healthcare worker
             </bold>
            </td>
            <td align="left">
             Any person employed by a health service, social service, local authority or agency to provide care for sick, disabled or elderly people
            </td>
           </tr>
           <tr>
            <td align="left">
             <bold>
              Heterogeneity
             </bold>
            </td>
            <td align="left">
             Variability, difference
            </td>
           </tr>
           <tr>
            <td align="left">
             <bold>
              Hyperalimentation
             </bold>
            </td>
            <td align="left">
             The administration of nutrients intravenously, usually to individuals who cannot take food via the gastrointestinal tract
            </td>
           </tr>
           <tr>
            <td align="left">
             <bold>
              Hypochlorite
             </bold>
            </td>
            <td align="left">
             A chlorine-based disinfectant
            </td>
           </tr>
           <tr>
            <td align="left">
             <bold>
              Implantable intravascular device
             </bold>
            </td>
            <td align="left">
             A central venous access device that is tunnelled under the skin with a subcutaneous port or reservoir with a self-sealing septum that is accessible by needle puncture through intact skin
            </td>
           </tr>
           <tr>
            <td align="left">
             <bold>
              Incidence
             </bold>
            </td>
            <td align="left">
             The number of new events (e.g. cases of disease) occurring in a population over a defined period of time
            </td>
           </tr>
           <tr>
            <td align="left">
             <bold>
              Indwelling urethral catheter
             </bold>
            </td>
            <td align="left">
             A catheter inserted into the bladder via the urethra and left in place for a period of time
            </td>
           </tr>
           <tr>
            <td align="left">
             <bold>
              Infection
             </bold>
            </td>
            <td align="left">
             Microorganisms that have entered the body and are multiplying in the tissues, typically causing specific symptoms
            </td>
           </tr>
           <tr>
            <td align="left">
             <bold>
              Intention-to-treat analysis
             </bold>
            </td>
            <td align="left">
             An analysis in which the results of the study are based on initial treatment assignment and not on a treatment actually received
            </td>
           </tr>
           <tr>
            <td align="left">
             <bold>
              Interrupted time series
             </bold>
            </td>
            <td align="left">
             A study in which measurements from the group under investigation are taken repeatedly before and after the intervention
            </td>
           </tr>
           <tr>
            <td align="left">
             <bold>
              Intravascular access device (IVAD)
             </bold>
            </td>
            <td align="left">
             A device inserted into a vascular system in order to administer fluids, medicines and nutrients or to obtain blood samples. These include devices inserted peripherally, as well as those inserted into larger veins
            </td>
           </tr>
           <tr>
            <td align="left">
             <bold>
              Invasive device
             </bold>
            </td>
            <td align="left">
             Any device that requires insertion through skin or other normal body defences
            </td>
           </tr>
           <tr>
            <td align="left">
             <bold>
              Luer connector
             </bold>
            </td>
            <td align="left">
             A system of attaching catheters, syringes, tubes and any other components of IVAD to each other
            </td>
           </tr>
           <tr>
            <td align="left">
             <bold>
              Meatus (urethral)
             </bold>
            </td>
            <td align="left">
             External opening of the urethra
            </td>
           </tr>
           <tr>
            <td align="left">
             <bold>
              MeSH
             </bold>
            </td>
            <td align="left">
             Medical subject heading
            </td>
           </tr>
           <tr>
            <td align="left">
             <bold>
              Meta-analysis
             </bold>
            </td>
            <td align="left">
             The combination of data from several studies to produce a single estimate of an effect of a particular intervention
            </td>
           </tr>
           <tr>
            <td align="left">
             <bold>
              Meticillin-resistant
              <italic>
               Staphylococcus aureus
              </italic>
              (MRSA)
             </bold>
            </td>
            <td align="left">
             Strains of
             <italic>
              S. aureus
             </italic>
             that are resistant to many of the antibiotics commonly used to treat infections. Epidemic strains also have a capacity to spread easily from person to person
            </td>
           </tr>
           <tr>
            <td align="left">
             <bold>
              Midline catheter
             </bold>
            </td>
            <td align="left">
             A long peripheral venous catheter inserted in the antecubital vein and advanced to a vein in the upper arm. Designed for short-term (up to 4 weeks) intravenous access
            </td>
           </tr>
           <tr>
            <td align="left">
             <bold>
              Mucosa
             </bold>
            </td>
            <td align="left">
             A membrane lining many tubular structures and cavities such as respiratory tract
            </td>
           </tr>
           <tr>
            <td align="left">
             <bold>
              Needle-free devices (also needleless intravascular catheter connectors)
             </bold>
            </td>
            <td align="left">
             Intravascular connector systems developed to help reduce the incidence of needlestick injury while facilitating medication delivery through intravascular catheters. There are three types of needle-free connectors: blunt cannula (two-piece) systems, one-piece needle-free systems, and one-piece needle-free systems with positive pressure
            </td>
           </tr>
           <tr>
            <td align="left">
             <bold>
              Needle safety device (also needle protection/prevention device)
             </bold>
            </td>
            <td align="left">
             Any device designed to reduce the risk of injury associated with a contaminated needle. This may include needle-free devices or mechanisms on a needle, such as an automated resheathing device, that cover the needle immediately after use
            </td>
           </tr>
           <tr>
            <td align="left">
             <bold>
              Needlestick injury
             </bold>
            </td>
            <td align="left">
             The puncture of skin by a contaminated needle or other sharp medical device
            </td>
           </tr>
           <tr>
            <td align="left">
             <bold>
              Neutropenia
             </bold>
            </td>
            <td align="left">
             Abnormal decrease in the number of neutrophils in peripheral blood, which results in increased susceptibility to infections
            </td>
           </tr>
           <tr>
            <td align="left">
             <bold>
              Nitrile
             </bold>
            </td>
            <td align="left">
             A synthetic rubber made from organic compounds and cyanide
            </td>
           </tr>
           <tr>
            <td align="left">
             <bold>
              Observational study
             </bold>
            </td>
            <td align="left">
             A retrospective or prospective study in which the investigator observes participants, with or without control groups
            </td>
           </tr>
           <tr>
            <td align="left">
             <bold>
              Organic matter
             </bold>
            </td>
            <td align="left">
             Any derivative of a living or once-living organism
            </td>
           </tr>
           <tr>
            <td align="left">
             <bold>
              Outbreak
             </bold>
            </td>
            <td align="left">
             Two or more cases of the same disease where there is evidence of an epidemiological link between them
            </td>
           </tr>
           <tr>
            <td align="left">
             <bold>
              Parenteral feeding (intravenous feeding)
             </bold>
            </td>
            <td align="left">
             Administration of nutrients by an infusion into a vein
            </td>
           </tr>
           <tr>
            <td align="left">
             <bold>
              Particulate filter masks (or respirator masks)
             </bold>
            </td>
            <td align="left">
             Face masks designed to protect the wearer from inhaling airborne particles including microorganisms. They are made to defined performance standards that include filtration efficiency. To be effective, they must be fitted close to the face to minimise leakage
            </td>
           </tr>
           <tr>
            <td align="left">
             <bold>
              Pathogen
             </bold>
            </td>
            <td align="left">
             A microorganism that causes disease
            </td>
           </tr>
           <tr>
            <td align="left">
             <bold>
              Peer-reviewed research
             </bold>
            </td>
            <td align="left">
             An independent assessment or evaluation of the research by a professional with knowledge of the field
            </td>
           </tr>
           <tr>
            <td align="left">
             <bold>
              Percutaneous injury
             </bold>
            </td>
            <td align="left">
             An injury that results in a sharp instrument/object (e.g. needle, scalpel) puncturing the skin
            </td>
           </tr>
           <tr>
            <td align="left">
             <bold>
              Peripheral inserted central venous catheter (PICC)
             </bold>
            </td>
            <td align="left">
             A vascular catheter inserted into the superior vena cava from the basilic or cephalic vein
            </td>
           </tr>
           <tr>
            <td align="left">
             <bold>
              Personal protective equipment (PPE)
             </bold>
            </td>
            <td align="left">
             Specialised clothing or equipment worn to protect against substances or situations that present a hazard to health or safety
            </td>
           </tr>
           <tr>
            <td align="left">
             <bold>
              Phlebitis
             </bold>
            </td>
            <td align="left">
             Inflammation of a vein
            </td>
           </tr>
           <tr>
            <td align="left">
             <bold>
              Post-exposure prophylaxis
             </bold>
            </td>
            <td align="left">
             Drug treatment regimen administered as soon as possible after an occupational exposure to reduce the risk of acquisition of a bloodborne virus
            </td>
           </tr>
           <tr>
            <td align="left">
             <bold>
              Povidone iodine
             </bold>
            </td>
            <td align="left">
             A topical preparation used for antisepsis of the skin in a form of solution or ointment
            </td>
           </tr>
           <tr>
            <td align="left">
             <bold>
              Prevalence
             </bold>
            </td>
            <td align="left">
             The number of events (e.g. cases of disease) present in a defined population at one point in time
            </td>
           </tr>
           <tr>
            <td align="left">
             <bold>
              Prospective study
             </bold>
            </td>
            <td align="left">
             Study in which people are entered into the research and then followed-up over a period of time with events recorded as they happen
            </td>
           </tr>
           <tr>
            <td align="left">
             <bold>
              Peripheral venous catheter (PVC)
             </bold>
            </td>
            <td align="left">
             A small, flexible tube placed into a peripheral vein for the safe infusion of medications, hydration fluids, blood products and nutritional supplements
            </td>
           </tr>
           <tr>
            <td align="left">
             <bold>
              Quasi-experimental study
             </bold>
            </td>
            <td align="left">
             Quasi-experimental research designs specifically lack the element of random assignment of participants (individuals or clinical settings/units) to the treatment or the control group. Randomisation minimises the risk that patients entered into the control and treatment groups will be different
            </td>
           </tr>
           <tr>
            <td align="left">
             <bold>
              Randomised controlled trial (RCT) and non-randomised controlled trial (NRCT)
             </bold>
            </td>
            <td align="left">
             An RCT is a clinical trial where at least two treatment groups are compared, one of them serving as the control group. Allocation to the group uses a random, unbiased method. An NRCT compares a control and treatment group but allocation to each group is not random. Bias is more likely to occur in an NRCT
            </td>
           </tr>
           <tr>
            <td align="left">
             <bold>
              Resident (hand) flora
             </bold>
            </td>
            <td align="left">
             Microorganisms that live in the deeper crevices of skin and hair follicles. These form part of the normal flora of the body and are not readily transferred to other people or objects, or removed by the mechanical action of soap and water. They can be reduced in number with the use of antiseptic soap
            </td>
           </tr>
           <tr>
            <td align="left">
             <bold>
              Respirator
             </bold>
            </td>
            <td align="left">
             See ‘particulate filter masks’
            </td>
           </tr>
           <tr>
            <td align="left">
             <bold>
              Retrospective study
             </bold>
            </td>
            <td align="left">
             A study in which data are captured from historical records of exposures and disease
            </td>
           </tr>
           <tr>
            <td align="left">
             <bold>
              Sepsis
             </bold>
            </td>
            <td align="left">
             A severe, systemic reaction of the immune system to infection that can result in organ failure and death
            </td>
           </tr>
           <tr>
            <td align="left">
             <bold>
              Severe acute respiratory syndrome (SARS)
             </bold>
            </td>
            <td align="left">
             A severe form of pneumonia caused by a coronavirus
            </td>
           </tr>
           <tr>
            <td align="left">
             <bold>
              Sharps
             </bold>
            </td>
            <td align="left">
             Instruments used in delivering health care that can inflict a penetrating injury. Examples include needles, lancets and scalpels
            </td>
           </tr>
           <tr>
            <td align="left">
             <bold>
              Spore
             </bold>
            </td>
            <td align="left">
             A resistant structure produced by microorganisms that enable it to survive adverse conditions
            </td>
           </tr>
           <tr>
            <td align="left">
             <bold>
              Sterilisation
             </bold>
            </td>
            <td align="left">
             A process that removes or destroys all microorganisms including spores
            </td>
           </tr>
           <tr>
            <td align="left">
             <bold>
              Surgical masks
             </bold>
            </td>
            <td align="left">
             A mask that covers the mouth and nose to prevent droplets from the wearer being expelled into the environment. As they are also fluid repellent, they provide some protection for the wearer against exposure of mucous membranes to splashes of blood/body fluid
            </td>
           </tr>
           <tr>
            <td align="left">
             <bold>
              Systematic review
             </bold>
            </td>
            <td align="left">
             Research that summarises the evidence on a clear question according to a defined protocol using explicit and systematic methods to identify, select and appraise relevant studies and extract, collate and report their findings
            </td>
           </tr>
           <tr>
            <td align="left">
             <bold>
              Systemic infection
             </bold>
            </td>
            <td align="left">
             An infection where the pathogen is distributed throughout the body, rather than being concentrated in one area
            </td>
           </tr>
           <tr>
            <td align="left">
             <bold>
              Terminal cleaning
             </bold>
            </td>
            <td align="left">
             The decontamination of a room or patient area after a patient has been transferred or discharged in order to ensure that any dirt, dust or contamination by potentially pathogenic microorganisms is removed before use by another patient
            </td>
           </tr>
           <tr>
            <td align="left">
             <bold>
              Thrombocytopenia
             </bold>
            </td>
            <td align="left">
             A reduction in the number of platelets (thrombocytes) in the blood. This may result in bleeding into the skin, spontaneous bruising or prolonged bleeding after injury
            </td>
           </tr>
           <tr>
            <td align="left">
             <bold>
              Thrombosis
             </bold>
            </td>
            <td align="left">
             A clot in a blood vessel caused by coagulation of blood
            </td>
           </tr>
           <tr>
            <td align="left">
             <bold>
              Thrombophlebitis
             </bold>
            </td>
            <td align="left">
             Phlebitis (vein inflammation) related to a thrombus (blood clot)
            </td>
           </tr>
           <tr>
            <td align="left">
             <bold>
              Transient (hand) flora
             </bold>
            </td>
            <td align="left">
             Microorganisms acquired on the skin through contact with surfaces. The hostile environment of skin means that they can usually only survive for a short time, but they are readily transferred to other surfaces touched. Can be removed by washing with soap and water, and most are destroyed by alcohol-based hand rubs
            </td>
           </tr>
           <tr>
            <td align="left">
             <bold>
              Urinary tract infection (UTI)
             </bold>
            </td>
            <td align="left">
             The invasion of the tissues of the bladder by microorganisms causing symptoms or signs of infection such as dysuria, loin pain, suprapubic tenderness, fever, pyuria and confusion
            </td>
           </tr>
          </tbody>
         </table>
        </table-wrap>
       </p>
      </sec>
     </sec>
    </back>
   </article>
   <article article-type="chapter-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <?properties open_access?>
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       CDC Health Information for International Travel 2010
      </journal-id>
      <journal-title-group>
       <journal-title>
        CDC Health Information for International Travel 2010
       </journal-title>
      </journal-title-group>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmc">
       7150274
      </article-id>
      <article-id pub-id-type="publisher-id">
       B978-0-7020-3481-7.50007-4
      </article-id>
      <article-id pub-id-type="doi">
       10.1016/B978-070203481-7.50007-4
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Article
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        The Pre-Travel Consultation
       </article-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author">
        <collab>
         Managing Editor
        </collab>
       </contrib>
       <contrib contrib-type="editor">
        <name>
         <surname>
          Brunette
         </surname>
         <given-names>
          Gary W.
         </given-names>
        </name>
        <degrees>
         MD, MS
        </degrees>
       </contrib>
      </contrib-group>
      <contrib-group>
       <contrib contrib-type="author">
        <collab>
         Medical Editors
        </collab>
       </contrib>
       <contrib contrib-type="editor">
        <name>
         <surname>
          Kozarsky
         </surname>
         <given-names>
          Phyllis E.
         </given-names>
        </name>
        <degrees>
         MD
        </degrees>
       </contrib>
      </contrib-group>
      <contrib-group>
       <contrib contrib-type="editor">
        <name>
         <surname>
          Magill
         </surname>
         <given-names>
          Alan J.
         </given-names>
        </name>
        <degrees>
         MD
        </degrees>
       </contrib>
      </contrib-group>
      <contrib-group>
       <contrib contrib-type="editor">
        <name>
         <surname>
          Shlim
         </surname>
         <given-names>
          David R.
         </given-names>
        </name>
        <degrees>
         MD
        </degrees>
       </contrib>
      </contrib-group>
      <contrib-group>
       <contrib contrib-type="author">
        <collab>
         Associate Editor
        </collab>
       </contrib>
       <contrib contrib-type="editor">
        <name>
         <surname>
          Whatley
         </surname>
         <given-names>
          Amanda D.
         </given-names>
        </name>
        <degrees>
         MPH
        </degrees>
       </contrib>
      </contrib-group>
      <aff>
       U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, Public Health Service, Centers for Disease Control and Prevention, National Center for Preparedness, Detection, and Control of Infectious Diseases, Division of Global Migration and Quarantine, Atlanta, Georgia
      </aff>
      <pub-date pub-type="pmc-release">
       <day>
        30
       </day>
       <month>
        10
       </month>
       <year>
        2009
       </year>
      </pub-date>
      <!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.-->
      <pub-date pub-type="ppub">
       <year>
        2009
       </year>
      </pub-date>
      <pub-date pub-type="epub">
       <day>
        30
       </day>
       <month>
        10
       </month>
       <year>
        2009
       </year>
      </pub-date>
      <fpage>
       19
      </fpage>
      <lpage>
       241
      </lpage>
      <permissions>
       <copyright-statement>
        Copyright © 2009 Elsevier Inc. All rights reserved.
       </copyright-statement>
       <copyright-year>
        2009
       </copyright-year>
       <copyright-holder>
        Elsevier Inc.
       </copyright-holder>
       <license>
        <license-p>
         Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
        </license-p>
       </license>
      </permissions>
     </article-meta>
    </front>
    <sec id="subchapter1">
     <sec-meta>
      <contrib-group>
       <contrib contrib-type="author" id="au1">
        <name>
         <surname>
          Acosta
         </surname>
         <given-names>
          Rebecca W.
         </given-names>
        </name>
       </contrib>
      </contrib-group>
     </sec-meta>
     <title>
      THE PRE-TRAVEL CONSULTATION
     </title>
     <p id="para125">
      The pre-travel consultation is a risk-based assessment process that provides a guide to prioritizing and customizing pre-travel health care to the traveler's itinerary, risks, and needs. The goal of the pre-travel consultation is the effective and efficient preparation of travelers with the appropriate counseling, vaccinations, and medications to help reduce their risk of illness and injury during travel.
     </p>
     <p id="para126">
      To conduct a risk-based assessment, health-care providers involved in preparing travelers must—
      <list id="celist40" list-type="simple">
       <list-item id="celistitem124">
        <label>
         •
        </label>
        <p id="para127">
         Have a working knowledge of destination-specific disease and health risks and standard recommendations to promote health and prevent illness among travelers. The information and recommendations presented in this publication, the Body of Knowledge in Travel Medicine (as published by the International Society of Travel Medicine [ISTM]), and other authoritative sources (see Appendix B) form the basis for this knowledge.
        </p>
       </list-item>
       <list-item id="celistitem125">
        <label>
         •
        </label>
        <p id="para128">
         Understand the standard for and expectations of conducting a pre-travel consultation and gain expertise in the process. The well-organized and well-executed pre-travel consultation supports consistent, appropriate, and efficient pre-travel health preparation with the following three essential elements:
         <list id="celist41" list-type="simple">
          <list-item id="celistitem126">
           <label>
            1.
           </label>
           <p id="para129">
            Risk Assessment
           </p>
          </list-item>
          <list-item id="celistitem127">
           <label>
            2.
           </label>
           <p id="para130">
            Risk Communication
           </p>
          </list-item>
          <list-item id="celistitem128">
           <label>
            3.
           </label>
           <p id="para131">
            Risk Management
           </p>
          </list-item>
         </list>
        </p>
       </list-item>
      </list>
     </p>
     <sec id="cesec1">
      <title>
       Risk Assessment
      </title>
      <p id="para132">
       The risk assessment provides the foundation for the recommendations given during the consultation. A risk assessment involves gathering pertinent information about the itinerary (“where and when”) and traveler (“who, why, what, and how”) to highlight the traveler's risks and alert the provider to any contraindications and precautions to vaccinations or medications that may be indicated. A questionnaire designed to collect and organize the itinerary and traveler data is an essential tool to help support the risk assessment process and facilitate consistent practice (see Box 1-1).
      </p>
      <p id="para133">
       The most important information to gather includes the following:
       <list id="celist42" list-type="simple">
        <list-item id="celistitem129">
         <label>
          •
         </label>
         <p id="para134">
          <bold>
           Itinerary data
          </bold>
          <list id="celist43" list-type="simple">
           <list-item id="celistitem130">
            <label>
             ○
            </label>
            <p id="para135">
             Countries and regions to be visited; urban versus rural
            </p>
           </list-item>
           <list-item id="celistitem131">
            <label>
             ○
            </label>
            <p id="para136">
             Dates and length of travel
            </p>
           </list-item>
           <list-item id="celistitem132">
            <label>
             ○
            </label>
            <p id="para137">
             Purpose of travel (e.g., business, vacation, visiting friends and relatives)
            </p>
           </list-item>
           <list-item id="celistitem133">
            <label>
             ○
            </label>
            <p id="para138">
             Mode(s) of transportation
            </p>
           </list-item>
           <list-item id="celistitem134">
            <label>
             ○
            </label>
            <p id="para139">
             Planned and possible activities
            </p>
           </list-item>
           <list-item id="celistitem135">
            <label>
             ○
            </label>
            <p id="para140">
             Types of accommodations
            </p>
           </list-item>
          </list>
         </p>
        </list-item>
        <list-item id="celistitem136">
         <label>
          •
         </label>
         <p id="para141">
          <bold>
           Traveler demographic and health/medical history
          </bold>
          <list id="celist44" list-type="simple">
           <list-item id="celistitem137">
            <label>
             ○
            </label>
            <p id="para142">
             Age, sex
            </p>
           </list-item>
           <list-item id="celistitem138">
            <label>
             ○
            </label>
            <p id="para143">
             Vaccination history, including prior adverse events
            </p>
           </list-item>
           <list-item id="celistitem139">
            <label>
             ○
            </label>
            <p id="para144">
             Medical and psychiatric history (past and current)
            </p>
           </list-item>
           <list-item id="celistitem140">
            <label>
             ○
            </label>
            <p id="para145">
             Medications
            </p>
           </list-item>
           <list-item id="celistitem141">
            <label>
             ○
            </label>
            <p id="para146">
             Allergies
            </p>
           </list-item>
           <list-item id="celistitem142">
            <label>
             ○
            </label>
            <p id="para147">
             Pregnancy and breastfeeding status (current status and plans)
            </p>
           </list-item>
          </list>
         </p>
        </list-item>
       </list>
      </p>
      <p id="para148">
       A basic example of using the itinerary and traveler data includes determining if there will be a risk of yellow fever disease or a requirement for yellow fever vaccination based on the itinerary, and if there is a contraindication (e.g., egg allergy) or a precaution (e.g., &gt;60 years of age) to the traveler's receiving the vaccine. Malaria risk is another important consideration. Will the traveler be going to a region endemic for malaria, and what are the appropriate measures to help prevent malaria based on the details of the itinerary and traveler's medical history?
      </p>
      <p id="para149">
       During the risk assessment, the provider must remain alert to other factors about “who” will be traveling. Such factors include the traveler's previous travel experience, perception of risk, cultural background, peer group(s), and possible barriers to care, such as economic issues, attitudes regarding vaccine safety, and fear of vaccines. These factors may greatly affect the traveler's ability and willingness to accept and adhere to the recommendations, and therefore affect the pre-travel consultation.
      </p>
      <p id="para150">
       Anticipating the unique needs of high-risk travelers and preparing them for healthy travel will help prevent illness and injury. The following travelers may be considered high risk:
       <list id="celist45" list-type="simple">
        <list-item id="celistitem143">
         <label>
          •
         </label>
         <p id="para151">
          Travelers visiting friends and relatives (VFRs). These individuals have typically migrated from a less-developed area to a developed area and are now returning to the region of their birth. This is especially important when these individuals are traveling with new family members or children. The traveler returning to his or her country of origin may not understand the dynamics of risk and waning immunity (see the VFR section in Chapter 8).
         </p>
        </list-item>
        <list-item id="celistitem144">
         <label>
          •
         </label>
         <p id="para152">
          The elderly
         </p>
        </list-item>
        <list-item id="celistitem145">
         <label>
          •
         </label>
         <p id="para153">
          Families with young children
         </p>
        </list-item>
        <list-item id="celistitem146">
         <label>
          •
         </label>
         <p id="para154">
          Persons traveling to adopt children abroad
         </p>
        </list-item>
        <list-item id="celistitem147">
         <label>
          •
         </label>
         <p id="para155">
          Persons with weakened immune systems
         </p>
        </list-item>
        <list-item id="celistitem148">
         <label>
          •
         </label>
         <p id="para156">
          Women who are pregnant or breastfeeding
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <sec id="cesec2">
      <title>
       Risk Communication
      </title>
      <p id="para157">
       The next phase of the consultation process is focused on risk communication and includes the presentation of reliable, evidence-based information in a context appropriate for the individual traveler. Time should be allocated for discussion of the risks with the traveler to promote informed decision making about risk avoidance and prevention measures, such as vaccinations and malaria chemoprophylaxis. Risk communication depends heavily upon the risk assessment for the individual traveler, as well as that traveler's perception of risk. For example, three travelers may be going to the same country: one for a week-long, urban-based, business visit; the next on an adventure-seeking, backpack trip to rural areas over several months; and the third is a pregnant VFR traveler. The recommendations and preparation for each of these travelers will vary, even though the destination country is the same.
      </p>
      <p id="para158">
       It is important to give both verbal and written information to the traveler to help guide and focus the discussion and reinforce important issues based on his or her risk assessment. Examples include information pamphlets, malaria risk maps, and vaccine information statements (VISs). Through careful risk assessment and thoughtful risk communication, a risk management plan (i.e., vaccinations, medications, and targeted risk-avoidance education) takes shape.
      </p>
     </sec>
     <sec id="cesec3">
      <title>
       Risk Management
      </title>
      <p id="para159">
       The essential elements of risk management include the following:
       <list id="celist46" list-type="simple">
        <list-item id="celistitem149">
         <label>
          •
         </label>
         <p id="para160">
          Selection, administration, and documentation of vaccinations
          <list id="celist47" list-type="simple">
           <list-item id="celistitem150">
            <label>
             ○
            </label>
            <p id="para161">
             Required, recommended, and routine vaccinations should all be considered (see below)
            </p>
           </list-item>
           <list-item id="celistitem151">
            <label>
             ○
            </label>
            <p id="para162">
             Providers should consider indications, contraindications, precautions, and timing of dosages
            </p>
           </list-item>
          </list>
         </p>
        </list-item>
        <list-item id="celistitem152">
         <label>
          •
         </label>
         <p id="para163">
          Prescribing and advising about preventive medications
          <list id="celist48" list-type="simple">
           <list-item id="celistitem153">
            <label>
             ○
            </label>
            <p id="para164">
             Where appropriate according to risk, antimalarial chemoprophylaxis and medications for travelers' diarrhea, motion sickness, and altitude sickness
            </p>
           </list-item>
          </list>
         </p>
        </list-item>
        <list-item id="celistitem154">
         <label>
          •
         </label>
         <p id="para165">
          Education related to malaria prevention and adherence to chemoprophylaxis (if indicated by the risk assessment)
         </p>
        </list-item>
        <list-item id="celistitem155">
         <label>
          •
         </label>
         <p id="para166">
          Information on risk and prevention of other insect-borne diseases
         </p>
        </list-item>
        <list-item id="celistitem156">
         <label>
          •
         </label>
         <p id="para167">
          Instruction on methods to reduce foodborne and waterborne illness and the self-management of travelers' diarrhea
         </p>
        </list-item>
        <list-item id="celistitem157">
         <label>
          •
         </label>
         <p id="para168">
          Instruction about animal avoidance and rabies
         </p>
        </list-item>
        <list-item id="celistitem158">
         <label>
          •
         </label>
         <p id="para169">
          Information to help reduce the negative effect of
          <list id="celist49" list-type="simple">
           <list-item id="celistitem159">
            <label>
             ○
            </label>
            <p id="para170">
             Other itinerary risks (e.g., altitude, pollution)
            </p>
           </list-item>
           <list-item id="celistitem160">
            <label>
             ○
            </label>
            <p id="para171">
             Activity-specific risks (e.g., diving, rafting, rural road travel)
            </p>
           </list-item>
           <list-item id="celistitem161">
            <label>
             ○
            </label>
            <p id="para172">
             Personal behavior risks (e.g., sexually transmitted diseases)
            </p>
           </list-item>
          </list>
         </p>
        </list-item>
        <list-item id="celistitem162">
         <label>
          •
         </label>
         <p id="para173">
          General guidance on
          <list id="celist50" list-type="simple">
           <list-item id="celistitem163">
            <label>
             ○
            </label>
            <p id="para174">
             Symptoms (e.g., fever, gastrointestinal or dermatologic symptoms) that may require medical attention during or after travel
            </p>
           </list-item>
           <list-item id="celistitem164">
            <label>
             ○
            </label>
            <p id="para175">
             Preparing a travel health kit (see the
             <xref ref-type="sec" rid="subchapter43">
              Travel Health Kits section
             </xref>
             later in this chapter)
            </p>
           </list-item>
           <list-item id="celistitem165">
            <label>
             ○
            </label>
            <p id="para176">
             Accessing medical care abroad and obtaining medical/evacuation insurance
            </p>
           </list-item>
          </list>
         </p>
        </list-item>
       </list>
      </p>
      <p id="para177">
       When considering vaccinations, common terms used include “required,” “recommended,” and “routine.” Required vaccines are those needed when a destination country requires documentation of vaccine administration or some sort of medical waiver. Recommended vaccines are those vaccines that are considered based on the actual disease risk the traveler may encounter during travel. Routine vaccines refer to those vaccines that are recommended in the United States, regardless of travel. These routine vaccines are an important part of pre-travel care because many of the diseases they protect against are more common in countries outside the United States.
      </p>
      <p id="para178">
       Careful documentation of all vaccinations, medications, and specific recommendations given to the traveler helps to complete the care plan record. Providers who are registered to give yellow fever vaccine should be familiar with properly completing the International Certificate of Vaccination or Prophylaxis (ICVP) to ensure that this documentation will be accepted at the borders of destination countries (see the
       <xref ref-type="sec" rid="subchapter6">
        Yellow Fever
       </xref>
       section later in this chapter). Using an electronic record or standardized form facilitates documentation and helps ensure consistency of practice.
      </p>
      <p id="para179">
       Providers should plan to spend an average of 30–45 minutes conducting a complete pre-travel consultation, based on the risk assessment, given the potential complexities in preparing the traveler. Providers with limited knowledge and expertise in travel medicine and the pre-travel consultation should consider referring travelers with complex itineraries or special needs (see Chapters 7 and 8) to a travel medicine clinic or travel medicine specialist through CDC's Travelers' Health website at
       <ext-link ext-link-type="uri" id="interref7" xlink:href="http://www.cdc.gov/travel">
        www.cdc.gov/travel
       </ext-link>
       . References 1–4 can assist those providers interested in gaining a more in-depth perspective on the expectations for providing pre-travel health care and the pre-travel consultation process.
      </p>
     </sec>
     <ref-list id="cebib1">
      <title>
       References
      </title>
      <ref id="bib1">
       <label>
        1
       </label>
       <element-citation id="sbref1" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kozarsky
          </surname>
          <given-names>
           PE
          </given-names>
         </name>
        </person-group>
        <article-title>
         The body of knowledge for the practice of travel medicine
        </article-title>
        <source>
         J Travel Med
        </source>
        <volume>
         13
        </volume>
        <issue>
         5
        </issue>
        <year>
         2006
        </year>
        <fpage>
         251
        </fpage>
        <lpage>
         254
        </lpage>
        <pub-id pub-id-type="pmid">
         16987122
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib2">
       <label>
        2
       </label>
       <element-citation id="sbref2" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hill
          </surname>
          <given-names>
           DR
          </given-names>
         </name>
         <name>
          <surname>
           Ericsson
          </surname>
          <given-names>
           CD
          </given-names>
         </name>
         <name>
          <surname>
           Pearson
          </surname>
          <given-names>
           RD
          </given-names>
         </name>
        </person-group>
        <article-title>
         The practice of travel medicine: guidelines by the Infectious Diseases Society of America
        </article-title>
        <source>
         Clin Infect Dis
        </source>
        <volume>
         43
        </volume>
        <issue>
         12
        </issue>
        <year>
         2006
        </year>
        <fpage>
         1499
        </fpage>
        <lpage>
         1539
        </lpage>
        <pub-id pub-id-type="pmid">
         17109284
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib3">
       <label>
        3
       </label>
       <element-citation id="sbref3" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Spira
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        <article-title>
         Setting the standard
        </article-title>
        <source>
         J Travel Med
        </source>
        <volume>
         10
        </volume>
        <issue>
         1
        </issue>
        <year>
         2003
        </year>
        <fpage>
         1
        </fpage>
        <lpage>
         3
        </lpage>
        <pub-id pub-id-type="pmid">
         12733541
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib4">
       <label>
        4
       </label>
       <element-citation id="sbref4" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Acosta
          </surname>
          <given-names>
           RW
          </given-names>
         </name>
         <name>
          <surname>
           Wolfe
          </surname>
          <given-names>
           MS
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         Structure and organization of the pre-travel consultation and general advice for travelers
        </chapter-title>
        <person-group person-group-type="editor">
         <name>
          <surname>
           Keystone
          </surname>
          <given-names>
           JS
          </given-names>
         </name>
         <name>
          <surname>
           Kozarsky
          </surname>
          <given-names>
           PE
          </given-names>
         </name>
         <name>
          <surname>
           Freedman
          </surname>
          <given-names>
           DO
          </given-names>
         </name>
         <name>
          <surname>
           Nothdurft
          </surname>
          <given-names>
           HD
          </given-names>
         </name>
         <name>
          <surname>
           Connor
          </surname>
          <given-names>
           BA
          </given-names>
         </name>
        </person-group>
        <source>
         Travel medicine
        </source>
        <edition>
         2nd ed.
        </edition>
        <year>
         2008
        </year>
        <publisher-name>
         Mosby
        </publisher-name>
        <publisher-loc>
         Philadelphia
        </publisher-loc>
        <fpage>
         35
        </fpage>
        <lpage>
         45
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib5">
       <label>
        5
       </label>
       <element-citation id="sbref5" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Crockett
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Keystone
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        <article-title>
         “I hate needles” and other factors impacting on travel vaccine uptake
        </article-title>
        <source>
         J Travel Med
        </source>
        <volume>
         12
        </volume>
        <issue>
         Suppl 1
        </issue>
        <year>
         2005
        </year>
        <fpage>
         S41
        </fpage>
        <lpage>
         S46
        </lpage>
        <pub-id pub-id-type="pmid">
         16225805
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib6">
       <label>
        6
       </label>
       <element-citation id="sbref6" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Edwards
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Elwyn
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Mulley
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        <article-title>
         Explaining risks: turning numerical data into meaningful pictures
        </article-title>
        <source>
         BMJ
        </source>
        <volume>
         324
        </volume>
        <year>
         2002
        </year>
        <fpage>
         827
        </fpage>
        <lpage>
         830
        </lpage>
        <pub-id pub-id-type="pmid">
         11934777
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib7">
       <label>
        7
       </label>
       <element-citation id="sbref7" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gherardin
          </surname>
          <given-names>
           T
          </given-names>
         </name>
        </person-group>
        <article-title>
         The pre-travel consultation— an overview
        </article-title>
        <source>
         Australian Fam Phys
        </source>
        <volume>
         36
        </volume>
        <issue>
         5
        </issue>
        <year>
         2007
        </year>
        <fpage>
         300
        </fpage>
        <lpage>
         303
        </lpage>
       </element-citation>
      </ref>
     </ref-list>
    </sec>
    <sec id="subchapter2">
     <sec-meta>
      <contrib-group>
       <contrib contrib-type="author" id="au2">
        <name>
         <surname>
          Atkinson
         </surname>
         <given-names>
          William
         </given-names>
        </name>
       </contrib>
       <contrib contrib-type="author" id="au3">
        <name>
         <surname>
          Kroger
         </surname>
         <given-names>
          Andrew
         </given-names>
        </name>
       </contrib>
      </contrib-group>
     </sec-meta>
     <title>
      GENERAL RECOMMENDATIONS FOR VACCINATION AND IMMUNOPROPHYLAXIS
     </title>
     <p id="para180">
      Recommendations for the use of vaccines and other biologic products (e.g., immune globulin products) in the United States are developed by the Advisory Committee on Immunization Practices (ACIP) and other groups, such as the American Academy of Pediatrics. These recommendations are based on scientific evidence of benefits (immunity to the disease) and risks (vaccine adverse reactions) and, where few or no data are available, on expert opinion. The recommendations include information on general immunization issues and the use of specific vaccines. When these recommendations are issued or revised, they are published in CDC's Morbidity and Mortality Weekly Report (MMWR) (
      <ext-link ext-link-type="uri" id="interref8" xlink:href="http://www.cdc.gov/mmwr">
       www.cdc.gov/mmwr
      </ext-link>
      ). This section is based primarily on the ACIP General Recommendations on Immunization.
     </p>
     <p id="para181">
      Vaccinations against diphtheria, tetanus, pertussis, measles, mumps, rubella, varicella, poliomyelitis, hepatitis A, hepatitis B,
      <italic>
       Haemophilus influenzae
      </italic>
      type b, rotavirus, influenza, human papillomavirus, and pneumococcal and meningococcal invasive disease are routinely administered in the United States, usually in childhood or adolescence. If persons do not have a history of adequate protection against these diseases, immunizations appropriate to their age and previous immunization status should be obtained, whether or not international travel is planned. A visit to a provider for immunizations for travel should be seen as an opportunity to bring an incompletely vaccinated person up-to-date on his or her routine vaccinations.
     </p>
     <p id="para182">
      Both the child and adolescent vaccination schedule and an adult vaccination schedule are published annually in the MMWR. Vaccine providers should obtain the most current schedules from the CDC Vaccines and Immunization website at
      <ext-link ext-link-type="uri" id="interref9" xlink:href="http://www.cdc.gov/vaccines/">
       www.cdc.gov/vaccines/
      </ext-link>
      . The text and
      <xref ref-type="table" rid="cetable1">
       Table 2-1
      </xref>
      ,
      <xref ref-type="table" rid="cetable2">
       Table 2-2
      </xref>
      ,
      <xref ref-type="table" rid="cetable3">
       Table 2-3
      </xref>
      ,
      <xref ref-type="table" rid="cetable4">
       Table 2-4
      </xref>
      ,
      <xref ref-type="table" rid="cetable5">
       Table 2-5
      </xref>
      ,
      <xref ref-type="table" rid="cetable6">
       Table 2-6
      </xref>
      ,
      <xref ref-type="table" rid="cetable7">
       Table 2-7
      </xref>
      ,
      <xref ref-type="table" rid="cetable9">
       2-9
      </xref>
      –
      <xref ref-type="table" rid="cetable10">
       2-10
      </xref>
      ,
      <xref ref-type="table" rid="cetable18">
       2-18
      </xref>
      –
      <xref ref-type="table" rid="cetable19">
       2-19
      </xref>
      ,
      <xref ref-type="table" rid="cetable21">
       2-21
      </xref>
      , 5-2, 7-2,7-3,7-4,7-5, 8-1, 8-7 and 8-8 of this publication present recommendations for the use, number of doses, dose intervals, adverse reactions, precautions, and contraindications for vaccines and toxoids that may be indicated for travelers. For specific vaccines and toxoids, additional details on background, adverse reactions, precautions, and contraindications are found in the respective ACIP statements.
      <table-wrap id="cetable1" position="float">
       <label>
        Table 2-1
       </label>
       <caption>
        <p>
         Revaccination (booster) schedules
        </p>
       </caption>
       <table frame="hsides" rules="groups">
        <thead>
         <tr>
          <th align="left">
           Vaccine
          </th>
          <th align="left">
           Recommendation
          </th>
         </tr>
        </thead>
        <tbody>
         <tr>
          <td align="left">
           Japanese encephalitis
          </td>
          <td align="left">
           Full duration of protection unknown. Neutralizing antibodies may persist at least 2 years after primary immunization.
          </td>
         </tr>
         <tr>
          <td align="left">
           Hepatitis A (HAV)
          </td>
          <td align="left">
           Booster doses not recommended for adults and children who have completed the primary series (2 doses) according to the routine schedule
          </td>
         </tr>
         <tr>
          <td align="left">
           Hepatitis B (HBV)
          </td>
          <td align="left">
           Booster doses not recommended for adults and children who have completed the primary series (3 doses) according to the routine schedule
           <xref ref-type="table-fn" rid="cetablefn1">
            1
           </xref>
          </td>
         </tr>
         <tr>
          <td align="left">
           Influenza
          </td>
          <td align="left">
           1 annual dose (children 6 months to 9 years of age and certain incompletely vaccinated children should receive 2 doses separated by at least 4 weeks the first time that influenza vaccine is administered). Live attenuated influenza vaccine is approved only for healthy nonpregnant persons 2–49 years of age.
          </td>
         </tr>
         <tr>
          <td align="left">
           Measles–mumps–rubella (MMR)
          </td>
          <td align="left">
           2 doses of MMR vaccine separated by at least 4 weeks or other evidence of immunity (e.g., serologic testing) is recommended for persons born after 1956 who travel outside the United States. Revaccination is not recommended.
          </td>
         </tr>
         <tr>
          <td align="left">
           Meningococcal Quadrivalent A,C,Y, W-135
          </td>
          <td align="left">
           Revaccination after 5 years is recommended for persons who received meningococcal polysaccharide vaccine and who remain at increased risk for meningococcal disease (including some international travelers). Revaccination is not recommended after receipt of meningococcal conjugate vaccine.
          </td>
         </tr>
         <tr>
          <td align="left">
           Pneumococcal (polysaccharide)
          </td>
          <td align="left">
           One-time revaccination 5 years after original dose for persons with certain underlying medical conditions (e.g., asplenia) or persons who were first vaccinated at younger than 65 years of age
          </td>
         </tr>
         <tr>
          <td align="left">
           Rotavirus
          </td>
          <td align="left">
           Booster doses not recommended
          </td>
         </tr>
         <tr>
          <td align="left">
           Polio (IPV)
          </td>
          <td align="left">
           A single lifetime booster dose is recommended for adults who have written documentation of having completed a primary series.
          </td>
         </tr>
         <tr>
          <td align="left">
           Rabies pre-exposure vaccine
          </td>
          <td align="left">
           No serologic testing or boosters recommended for travelers. For persons in higher risk groups (e.g., rabies laboratory workers) serologic testing and booster doses are recommended. See
           <xref ref-type="table" rid="cetable17">
            Table 2-17
           </xref>
           .
          </td>
         </tr>
         <tr>
          <td align="left">
           Tetanus/diphtheria, and acellular pertussis (Tdap)
          </td>
          <td align="left">
           Tetanus and diphtheria booster dose is recommended every 10 years. A single dose of adolescent/adult formulation Td that includes acellular pertussis vaccine (Tdap) is recommended to replace one Td booster dose for persons 11–64 years of age. See ACIP statement for details.
          </td>
         </tr>
         <tr>
          <td align="left">
           Typhoid oral
          </td>
          <td align="left">
           Repeat series every 5 years.
          </td>
         </tr>
         <tr>
          <td align="left">
           Typhoid IM
          </td>
          <td align="left">
           Booster dose every 2 years
          </td>
         </tr>
         <tr>
          <td align="left">
           Varicella
          </td>
          <td align="left">
           Revaccination is not recommended.
          </td>
         </tr>
         <tr>
          <td align="left">
           Yellow fever
          </td>
          <td align="left">
           Repeat vaccination every 10 years.
          </td>
         </tr>
        </tbody>
       </table>
       <table-wrap-foot>
        <fn id="cetablefn1">
         <label>
          1
         </label>
         <p id="cenotep2">
          Booster dosing may be appropriate for certain populations, such as hemodialysis patients.
         </p>
        </fn>
       </table-wrap-foot>
      </table-wrap>
      <table-wrap id="cetable2" position="float">
       <label>
        Table 2-2
       </label>
       <caption>
        <p>
         Recommended intervals between administration of antibody-containing products and measles-containing vaccine or varicella-containing vaccine
         <xref ref-type="table-fn" rid="cetablefn2">
          1
         </xref>
        </p>
       </caption>
       <table frame="hsides" rules="groups">
        <thead>
         <tr>
          <th align="left">
           Indication
          </th>
          <th align="left">
           Dose
          </th>
          <th align="left">
           Recommended Interval Before Measles or Varicella Vaccination
          </th>
         </tr>
        </thead>
        <tbody>
         <tr>
          <td align="left">
           Tetanus (TIG)
          </td>
          <td align="left">
           250 units (10 mg IgG/kg) IM
           <xref ref-type="table-fn" rid="cetablefn3">
            2
           </xref>
          </td>
          <td align="left">
           3 months
          </td>
         </tr>
         <tr>
          <td align="left">
           Hepatitis A (IG), duration of international travel
           <list id="celist1" list-type="simple">
            <list-item id="celistitem1">
             <p id="para1">
              &lt;3-month stay
             </p>
            </list-item>
            <list-item id="celistitem2">
             <p id="para2">
              &gt;3-month stay
             </p>
            </list-item>
           </list>
          </td>
          <td align="left">
           <list id="celist2" list-type="simple">
            <list-item id="celistitem3">
             <p id="para3">
             </p>
            </list-item>
            <list-item id="celistitem4">
             <p id="para4">
              0.02 mL/kg (3.3 mg IgG/kg) IM
             </p>
            </list-item>
            <list-item id="celistitem5">
             <p id="para5">
              0.06 mL/kg (10 mg IgG/kg) IM
             </p>
            </list-item>
           </list>
          </td>
          <td align="left">
           <list id="celist3" list-type="simple">
            <list-item id="celistitem6">
             <p id="para6">
             </p>
            </list-item>
            <list-item id="celistitem7">
             <p id="para7">
              3 months
             </p>
            </list-item>
            <list-item id="celistitem8">
             <p id="para8">
              3 months
             </p>
            </list-item>
           </list>
          </td>
         </tr>
         <tr>
          <td align="left">
           Hepatitis B prophylaxis (HBIG)
          </td>
          <td align="left">
           0.06 mL/kg (10 mg IgG/kg) IM
          </td>
          <td align="left">
           3 months
          </td>
         </tr>
         <tr>
          <td align="left">
           Rabies prophylaxis (HRIG)
          </td>
          <td align="left">
           20 IU/kg (22 mg IgG/kg) IM
          </td>
          <td align="left">
           4 months
          </td>
         </tr>
         <tr>
          <td align="left">
           Varicella prophylaxis (VZIG)
          </td>
          <td align="left">
           125 units/10 kg (20–40 mg IgG/kg) IM (maximum 625 units)
          </td>
          <td align="left">
           5 months
          </td>
         </tr>
         <tr>
          <td align="left">
           Measles prophylaxis (IG)
           <list id="celist4" list-type="simple">
            <list-item id="celistitem9">
             <p id="para9">
              Immunocompetent contact
             </p>
            </list-item>
            <list-item id="celistitem10">
             <p id="para10">
              Immunocompromised contact
             </p>
            </list-item>
           </list>
          </td>
          <td align="left">
           <list id="celist5" list-type="simple">
            <list-item id="celistitem11">
             <p id="para11">
             </p>
            </list-item>
            <list-item id="celistitem12">
             <p id="para12">
              0.25 mL/kg (40 mg IgG/kg) IM
             </p>
            </list-item>
            <list-item id="celistitem13">
             <p id="para13">
              0.50 mL/kg (80 mg IgG/kg) IM
             </p>
            </list-item>
           </list>
          </td>
          <td align="left">
           <list id="celist6" list-type="simple">
            <list-item id="celistitem14">
             <p id="para14">
             </p>
            </list-item>
            <list-item id="celistitem15">
             <p id="para15">
              5 months
             </p>
            </list-item>
            <list-item id="celistitem16">
             <p id="para16">
              6 months
             </p>
            </list-item>
           </list>
          </td>
         </tr>
         <tr>
          <td align="left">
           Blood transfusion
           <list id="celist7" list-type="simple">
            <list-item id="celistitem17">
             <p id="para17">
             </p>
            </list-item>
            <list-item id="celistitem18">
             <p id="para18">
              Red blood cells (RBCs), washed
             </p>
            </list-item>
            <list-item id="celistitem19">
             <p id="para19">
              RBCs, adenine-saline added
             </p>
            </list-item>
            <list-item id="celistitem20">
             <p id="para20">
              Packed RBCs (Hct 65%)
              <xref ref-type="table-fn" rid="cetablefn4">
               3
              </xref>
             </p>
            </list-item>
            <list-item id="celistitem21">
             <p id="para21">
              Plasma/platelet products
             </p>
            </list-item>
           </list>
          </td>
          <td align="left">
           <list id="celist8" list-type="simple">
            <list-item id="celistitem22">
             <p id="para22">
             </p>
            </list-item>
            <list-item id="celistitem23">
             <p id="para23">
              10 mL/kg (negligible IgG/kg) IV
             </p>
            </list-item>
            <list-item id="celistitem24">
             <p id="para24">
              10 mL/kg (10 mg IgG/kg) IV
             </p>
            </list-item>
            <list-item id="celistitem25">
             <p id="para25">
              10 mL/kg (60 mg IgG/kg) IV
             </p>
            </list-item>
            <list-item id="celistitem26">
             <p id="para26">
              10 mL/kg (160 mg IgG/kg) IV
             </p>
            </list-item>
           </list>
          </td>
          <td align="left">
           <list id="celist9" list-type="simple">
            <list-item id="celistitem27">
             <p id="para27">
             </p>
            </list-item>
            <list-item id="celistitem28">
             <p id="para28">
              None
             </p>
            </list-item>
            <list-item id="celistitem29">
             <p id="para29">
              3 months
             </p>
            </list-item>
            <list-item id="celistitem30">
             <p id="para30">
              6 months
             </p>
            </list-item>
            <list-item id="celistitem31">
             <p id="para31">
              7 months
             </p>
            </list-item>
           </list>
          </td>
         </tr>
         <tr>
          <td align="left">
           Cytomegalovirus prophylaxis (CMV IGIV)
          </td>
          <td align="left">
           150 mg/kg maximum
          </td>
          <td align="left">
           6 months
          </td>
         </tr>
         <tr>
          <td align="left">
           Respiratory syncytial virus (RSV) monoclonal antibody (Synagis)
           <xref ref-type="table-fn" rid="cetablefn5">
            4
           </xref>
          </td>
          <td align="left">
           15 mg/kg IM
          </td>
          <td align="left">
           None
          </td>
         </tr>
         <tr>
          <td align="left">
           Intravenous immune globulin (IGIV)
           <list id="celist10" list-type="simple">
            <list-item id="celistitem32">
             <p id="para32">
              Replacement therapy
             </p>
            </list-item>
            <list-item id="celistitem33">
             <p id="para33">
              Immune thrombocytopenic purpura (ITP)
             </p>
            </list-item>
            <list-item id="celistitem34">
             <p id="para34">
              ITP
             </p>
            </list-item>
            <list-item id="celistitem35">
             <p id="para35">
              ITP or Kawasaki disease
             </p>
            </list-item>
           </list>
          </td>
          <td align="left">
           <list id="celist11" list-type="simple">
            <list-item id="celistitem36">
             <p id="para36">
             </p>
            </list-item>
            <list-item id="celistitem37">
             <p id="para37">
              300–400 mg/kg IV
             </p>
            </list-item>
            <list-item id="celistitem38">
             <p id="para38">
              400 mg/kg IV
             </p>
            </list-item>
            <list-item id="celistitem39">
             <p id="para39">
              1 gm/kg IV
             </p>
            </list-item>
            <list-item id="celistitem40">
             <p id="para40">
              1.6–2 gm/kg IV
             </p>
            </list-item>
           </list>
          </td>
          <td align="left">
           <list id="celist12" list-type="simple">
            <list-item id="celistitem41">
             <p id="para41">
             </p>
            </list-item>
            <list-item id="celistitem42">
             <p id="para42">
              8 months
             </p>
            </list-item>
            <list-item id="celistitem43">
             <p id="para43">
              8 months
             </p>
            </list-item>
            <list-item id="celistitem44">
             <p id="para44">
              10 months
             </p>
            </list-item>
            <list-item id="celistitem45">
             <p id="para45">
              11 months
             </p>
            </list-item>
           </list>
          </td>
         </tr>
        </tbody>
       </table>
       <table-wrap-foot>
        <fn id="cetablefn2">
         <label>
          1
         </label>
         <p id="cenotep90">
          Adapted from General Recommendations on Immunization, MMWR, 2006. This table is not intended for determining the correct indications and dosage for the use of IG preparations. Unvaccinated people may not be fully protected against measles during the entire recommended interval, and additional doses of immune globulin (IG) or measles vaccine may be indicated after measles exposure. Concentrations of measles antibody in an IG preparation can vary by manufacturer's lot. For example, fourfold or greater variation in the amount of measles antibody titers has been demonstrated in different IG preparations. Rates of antibody clearance after receipt of an IG preparation can also vary. Recommended intervals are extrapolated from an estimated half-life of 30 days for passively acquired antibody and an observed interference with the immune response to measles vaccine for 5 months after a dose of 80 mg IgG/kg.
         </p>
        </fn>
       </table-wrap-foot>
       <table-wrap-foot>
        <fn id="cetablefn3">
         <label>
          2
         </label>
         <p id="cenotep3">
          IG, immune globulin; IM, intramuscular; IV, intravenous.
         </p>
        </fn>
       </table-wrap-foot>
       <table-wrap-foot>
        <fn id="cetablefn4">
         <label>
          3
         </label>
         <p id="cenotep4">
          Assumes a serum IgG concentration of 16 mg/mL.
         </p>
        </fn>
       </table-wrap-foot>
       <table-wrap-foot>
        <fn id="cetablefn5">
         <label>
          4
         </label>
         <p id="cenotep5">
          Contains only antibody to respiratory syncytial virus.
         </p>
        </fn>
       </table-wrap-foot>
      </table-wrap>
      <table-wrap id="cetable3" position="float">
       <label>
        Table 2-3
       </label>
       <caption>
        <p>
         Recommended and minimum ages and intervals between vaccine doses
         <xref ref-type="table-fn" rid="cetablefn6">
          1
         </xref>
        </p>
       </caption>
       <table frame="hsides" rules="groups">
        <thead>
         <tr>
          <th align="left">
           Vaccine and Dose Number
          </th>
          <th align="left">
           Recommended Age for this Dose
          </th>
          <th align="left">
           Minimum Age for this Dose
          </th>
          <th align="left">
           Recommended Interval to Next Dose
          </th>
          <th align="left">
           Minimum Interval to Next Dose
          </th>
         </tr>
        </thead>
        <tbody>
         <tr>
          <td align="left">
           Hepatitis B (HepB)-1
           <xref ref-type="table-fn" rid="cetablefn7">
            2
           </xref>
          </td>
          <td align="left">
           Birth
          </td>
          <td align="left">
           Birth
          </td>
          <td align="left">
           1–4 months
          </td>
          <td align="left">
           4 weeks
          </td>
         </tr>
         <tr>
          <td align="left">
           Hep B-2
          </td>
          <td align="left">
           1–2 months
          </td>
          <td align="left">
           4 weeks
          </td>
          <td align="left">
           2–17 months
          </td>
          <td align="left">
           8 weeks
          </td>
         </tr>
         <tr>
          <td align="left">
           Hep B-3
           <xref ref-type="table-fn" rid="cetablefn8">
            3
           </xref>
          </td>
          <td align="left">
           6–18 months
          </td>
          <td align="left">
           24 weeks
          </td>
          <td align="left">
           NA
          </td>
          <td align="left">
           NA
          </td>
         </tr>
         <tr>
          <td align="left">
           Diphtheria–tetanus–acellular pertussis (DTaP)-1
           <xref ref-type="table-fn" rid="cetablefn7">
            2
           </xref>
          </td>
          <td align="left">
           2 months
          </td>
          <td align="left">
           6 weeks
          </td>
          <td align="left">
           2 months
          </td>
          <td align="left">
           4 weeks
          </td>
         </tr>
         <tr>
          <td align="left">
           DTaP-2
          </td>
          <td align="left">
           4 months
          </td>
          <td align="left">
           10 weeks
          </td>
          <td align="left">
           2 months
          </td>
          <td align="left">
           4 weeks
          </td>
         </tr>
         <tr>
          <td align="left">
           DTaP-3
          </td>
          <td align="left">
           6 months
          </td>
          <td align="left">
           14 weeks
          </td>
          <td align="left">
           6–12 months
          </td>
          <td align="left">
           6 months
           <xref ref-type="table-fn" rid="cetablefn9">
            4
           </xref>
           ,
           <xref ref-type="table-fn" rid="cetablefn10">
            5
           </xref>
          </td>
         </tr>
         <tr>
          <td align="left">
           DTaP-4
          </td>
          <td align="left">
           15–18 months
          </td>
          <td align="left">
           12 months
          </td>
          <td align="left">
           3 years
          </td>
          <td align="left">
           6 months
           <xref ref-type="table-fn" rid="cetablefn9">
            4
           </xref>
          </td>
         </tr>
         <tr>
          <td align="left">
           DTaP-5
          </td>
          <td align="left">
           4–6 years
          </td>
          <td align="left">
           4 years
          </td>
          <td align="left">
           NA
          </td>
          <td align="left">
           NA
          </td>
         </tr>
         <tr>
          <td align="left">
           <italic>
            Haemophilus influenzae
           </italic>
           type b (Hib)-1
           <xref ref-type="table-fn" rid="cetablefn7">
            2
           </xref>
           ,
           <xref ref-type="table-fn" rid="cetablefn11">
            6
           </xref>
          </td>
          <td align="left">
           2 months
          </td>
          <td align="left">
           6 weeks
          </td>
          <td align="left">
           2 months
          </td>
          <td align="left">
           4 weeks
          </td>
         </tr>
         <tr>
          <td align="left">
           Hib-2
          </td>
          <td align="left">
           4 months
          </td>
          <td align="left">
           10 weeks
          </td>
          <td align="left">
           2 months
          </td>
          <td align="left">
           4 weeks
          </td>
         </tr>
         <tr>
          <td align="left">
           Hib-3
           <xref ref-type="table-fn" rid="cetablefn12">
            7
           </xref>
          </td>
          <td align="left">
           6 months
          </td>
          <td align="left">
           14 weeks
          </td>
          <td align="left">
           6–9 months
          </td>
          <td align="left">
           8 weeks
          </td>
         </tr>
         <tr>
          <td align="left">
           Hib-4
          </td>
          <td align="left">
           12–15 months
          </td>
          <td align="left">
           12 months
          </td>
          <td align="left">
           NA
          </td>
          <td align="left">
           NA
          </td>
         </tr>
         <tr>
          <td align="left">
           Inactivated poliovirus (IPV)-1
           <xref ref-type="table-fn" rid="cetablefn7">
            2
           </xref>
          </td>
          <td align="left">
           2 months
          </td>
          <td align="left">
           6 weeks
          </td>
          <td align="left">
           2 months
          </td>
          <td align="left">
           4 weeks
          </td>
         </tr>
         <tr>
          <td align="left">
           IPV-2
          </td>
          <td align="left">
           4 months
          </td>
          <td align="left">
           10 weeks
          </td>
          <td align="left">
           2–14 months
          </td>
          <td align="left">
           4 weeks
          </td>
         </tr>
         <tr>
          <td align="left">
           IPV-3
          </td>
          <td align="left">
           6–18 months
          </td>
          <td align="left">
           14 weeks
          </td>
          <td align="left">
           3–5 years
          </td>
          <td align="left">
           4 weeks
          </td>
         </tr>
         <tr>
          <td align="left">
           IPV-4
          </td>
          <td align="left">
           4–6 years
          </td>
          <td align="left">
           18 weeks
          </td>
          <td align="left">
           NA
          </td>
          <td align="left">
           NA
          </td>
         </tr>
         <tr>
          <td align="left">
           Pneumococcal conjugate (PCV)-1
           <xref ref-type="table-fn" rid="cetablefn11">
            6
           </xref>
          </td>
          <td align="left">
           2 months
          </td>
          <td align="left">
           6 weeks
          </td>
          <td align="left">
           2 months
          </td>
          <td align="left">
           4 weeks
          </td>
         </tr>
         <tr>
          <td align="left">
           PCV-2
          </td>
          <td align="left">
           4 months
          </td>
          <td align="left">
           10 weeks
          </td>
          <td align="left">
           2 months
          </td>
          <td align="left">
           4 weeks
          </td>
         </tr>
         <tr>
          <td align="left">
           PCV-3
          </td>
          <td align="left">
           6 months
          </td>
          <td align="left">
           14 weeks
          </td>
          <td align="left">
           6 months
          </td>
          <td align="left">
           8 weeks
          </td>
         </tr>
         <tr>
          <td align="left">
           PCV-4
          </td>
          <td align="left">
           12–15 months
          </td>
          <td align="left">
           12 months
          </td>
          <td align="left">
           NA
          </td>
          <td align="left">
           NA
          </td>
         </tr>
         <tr>
          <td align="left">
           Measles–mumps–rubella (MMR)-1
           <xref ref-type="table-fn" rid="cetablefn13">
            8
           </xref>
          </td>
          <td align="left">
           12–15 months
          </td>
          <td align="left">
           12 months
          </td>
          <td align="left">
           3–5 years
          </td>
          <td align="left">
           4 weeks
          </td>
         </tr>
         <tr>
          <td align="left">
           MMR-2
           <xref ref-type="table-fn" rid="cetablefn13">
            8
           </xref>
          </td>
          <td align="left">
           4–6 years
          </td>
          <td align="left">
           13 months
          </td>
          <td align="left">
           NA
          </td>
          <td align="left">
           NA
          </td>
         </tr>
         <tr>
          <td align="left">
           Varicella (Var)-1
          </td>
          <td align="left">
           12–15 months
          </td>
          <td align="left">
           12 months
          </td>
          <td align="left">
           3–5 years
          </td>
          <td align="left">
           12 weeks
           <xref ref-type="table-fn" rid="cetablefn14">
            9
           </xref>
          </td>
         </tr>
         <tr>
          <td align="left">
           Var-2
          </td>
          <td align="left">
           4–6 years
          </td>
          <td align="left">
           15 months
          </td>
          <td align="left">
           NA
          </td>
          <td align="left">
           NA
          </td>
         </tr>
         <tr>
          <td align="left">
           Hepatitis A (HepA)-1
          </td>
          <td align="left">
           12–23 months
          </td>
          <td align="left">
           12 months
          </td>
          <td align="left">
           6–18 months
           <xref ref-type="table-fn" rid="cetablefn9">
            4
           </xref>
          </td>
          <td align="left">
           6 months
           <xref ref-type="table-fn" rid="cetablefn9">
            4
           </xref>
          </td>
         </tr>
         <tr>
          <td align="left">
           HepA-2
          </td>
          <td align="left">
           18–41 months
          </td>
          <td align="left">
           18 months
          </td>
          <td align="left">
           NA
          </td>
          <td align="left">
           NA
          </td>
         </tr>
         <tr>
          <td align="left">
           Influenza, inactivated
           <xref ref-type="table-fn" rid="cetablefn15">
            10
           </xref>
          </td>
          <td align="left">
           6–18 years
          </td>
          <td align="left">
           6 months
          </td>
          <td align="left">
           4 weeks
          </td>
          <td align="left">
           4 weeks
          </td>
         </tr>
         <tr>
          <td align="left">
           Influenza, live attenuated
           <xref ref-type="table-fn" rid="cetablefn15">
            10
           </xref>
          </td>
          <td align="left">
           NA
          </td>
          <td align="left">
           2 years
          </td>
          <td align="left">
           4 weeks
          </td>
          <td align="left">
           4weeks
          </td>
         </tr>
         <tr>
          <td align="left">
           Meningococcal conjugate (MCV)
          </td>
          <td align="left">
           11–12 years
          </td>
          <td align="left">
           11 years
          </td>
          <td align="left">
           NA
          </td>
          <td align="left">
           NA
          </td>
         </tr>
         <tr>
          <td align="left">
           Meningococcal polysaccharide (MPSV)-1
          </td>
          <td align="left">
           NA
          </td>
          <td align="left">
           2 years
          </td>
          <td align="left">
           5 years
           <xref ref-type="table-fn" rid="cetablefn16">
            11
           </xref>
          </td>
          <td align="left">
           5 years
           <xref ref-type="table-fn" rid="cetablefn16">
            11
           </xref>
          </td>
         </tr>
         <tr>
          <td align="left">
           MPSV-2
           <xref ref-type="table-fn" rid="cetablefn17">
            12
           </xref>
          </td>
          <td align="left">
           NA
          </td>
          <td align="left">
           7 years
          </td>
          <td align="left">
           NA
          </td>
          <td align="left">
           NA
          </td>
         </tr>
         <tr>
          <td align="left">
           Td
          </td>
          <td align="left">
           11–12 years
          </td>
          <td align="left">
           7 years
          </td>
          <td align="left">
           10 years
          </td>
          <td align="left">
           5 years
          </td>
         </tr>
         <tr>
          <td align="left">
           Tdap
           <xref ref-type="table-fn" rid="cetablefn18">
            13
           </xref>
          </td>
          <td align="left">
           ≥11 years
          </td>
          <td align="left">
           10 years
          </td>
          <td align="left">
           NA
          </td>
          <td align="left">
           NA
          </td>
         </tr>
         <tr>
          <td align="left">
           Pneumococcal polysaccharide (PPV)-1
          </td>
          <td align="left">
           NA
          </td>
          <td align="left">
           2 years
          </td>
          <td align="left">
           5 years
          </td>
          <td align="left">
           5 years
          </td>
         </tr>
         <tr>
          <td align="left">
           PPV-2
           <xref ref-type="table-fn" rid="cetablefn19">
            14
           </xref>
          </td>
          <td align="left">
           NA
          </td>
          <td align="left">
           7 years
          </td>
          <td align="left">
           NA
          </td>
          <td align="left">
           NA
          </td>
         </tr>
         <tr>
          <td align="left">
           Human papillomavirus (HPV)-1
           <xref ref-type="table-fn" rid="cetablefn20">
            15
           </xref>
          </td>
          <td align="left">
           11–12 years
          </td>
          <td align="left">
           9 years
          </td>
          <td align="left">
           2 months
          </td>
          <td align="left">
           4 weeks
          </td>
         </tr>
         <tr>
          <td align="left">
           HPV-2
          </td>
          <td align="left">
           2 months after dose 1
          </td>
          <td align="left">
           9 years, 4 weeks
          </td>
          <td align="left">
           4 months
          </td>
          <td align="left">
           12 weeks
           <xref ref-type="table-fn" rid="cetablefn20">
            15
           </xref>
          </td>
         </tr>
         <tr>
          <td align="left">
           HPV-3
          </td>
          <td align="left">
           6 months after dose 1
          </td>
          <td align="left">
           9 years, 24 weeks
          </td>
          <td align="left">
           NA
          </td>
          <td align="left">
           NA
          </td>
         </tr>
         <tr>
          <td align="left">
           Rotavirus (RV)-1
           <xref ref-type="table-fn" rid="cetablefn21">
            16
           </xref>
          </td>
          <td align="left">
           2 months
          </td>
          <td align="left">
           6 weeks
          </td>
          <td align="left">
           2 months
          </td>
          <td align="left">
           4 weeks
          </td>
         </tr>
         <tr>
          <td align="left">
           RV-2
          </td>
          <td align="left">
           4 months
          </td>
          <td align="left">
           10 weeks
          </td>
          <td align="left">
           2 months
          </td>
          <td align="left">
           4 weeks
          </td>
         </tr>
         <tr>
          <td align="left">
           RV-3
           <xref ref-type="table-fn" rid="cetablefn21">
            16
           </xref>
          </td>
          <td align="left">
           6 months
          </td>
          <td align="left">
           14 weeks
          </td>
          <td align="left">
           NA
          </td>
          <td align="left">
           NA
          </td>
         </tr>
         <tr>
          <td align="left">
           Herpes zoster
           <xref ref-type="table-fn" rid="cetablefn22">
            17
           </xref>
          </td>
          <td align="left">
           60 years
          </td>
          <td align="left">
           60 years
          </td>
          <td align="left">
           NA
          </td>
          <td align="left">
           NA
          </td>
         </tr>
         <tr>
          <td align="left">
           Typhoid, inactivated (ViCPS)
          </td>
          <td align="left">
           ≥2 years
          </td>
          <td align="left">
           ≥2 years
          </td>
          <td align="left">
           NA
          </td>
          <td align="left">
           NA
          </td>
         </tr>
         <tr>
          <td align="left">
           Typhoid, live attenuated (Ty21a)
          </td>
          <td align="left">
           ≥6 years
          </td>
          <td align="left">
           ≥6 years
          </td>
          <td align="left">
           See footnote
           <xref ref-type="table-fn" rid="cetablefn23">
            18
           </xref>
          </td>
          <td align="left">
           See footnote
           <xref ref-type="table-fn" rid="cetablefn23">
            18
           </xref>
          </td>
         </tr>
         <tr>
          <td align="left">
           Yellow Fever
          </td>
          <td align="left">
           &gt;9 months
           <xref ref-type="table-fn" rid="cetablefn24">
            19
           </xref>
          </td>
          <td align="left">
           &gt;9 months
           <xref ref-type="table-fn" rid="cetablefn24">
            19
           </xref>
          </td>
          <td align="left">
           10 years
          </td>
          <td align="left">
           10 years
          </td>
         </tr>
         <tr>
          <td align="left">
           Japanese encephalitis (JE)-1
          </td>
          <td align="left">
           ≥1 year
          </td>
          <td align="left">
           1 year
          </td>
          <td align="left">
           7 days
          </td>
          <td align="left">
           7 days
          </td>
         </tr>
         <tr>
          <td align="left">
           JE-2
          </td>
          <td align="left">
           7 days after dose 1
          </td>
          <td align="left">
           1 year, 7 days
          </td>
          <td align="left">
           30 days
          </td>
          <td align="left">
           14 days
          </td>
         </tr>
         <tr>
          <td align="left">
           JE-3
          </td>
          <td align="left">
           30 days after dose 1
          </td>
          <td align="left">
           1 year, 21 days
          </td>
          <td align="left">
           NA
          </td>
          <td align="left">
           NA
          </td>
         </tr>
         <tr>
          <td align="left">
           Rabies-1 (pre-exposure)
          </td>
          <td align="left">
           See footnote
           <xref ref-type="table-fn" rid="cetablefn25">
            20
           </xref>
          </td>
          <td align="left">
           See footnote
           <xref ref-type="table-fn" rid="cetablefn25">
            20
           </xref>
          </td>
          <td align="left">
           7 days
          </td>
          <td align="left">
           7 days
          </td>
         </tr>
         <tr>
          <td align="left">
           Rabies-2
          </td>
          <td align="left">
           7 days after dose 1
          </td>
          <td align="left">
           7 days after dose 1
          </td>
          <td align="left">
           21 days
          </td>
          <td align="left">
           14 days
          </td>
         </tr>
         <tr>
          <td align="left">
           Rabies-3
          </td>
          <td align="left">
           21 days after dose 1
          </td>
          <td align="left">
           21 days after dose 1
          </td>
          <td align="left">
           NA
          </td>
          <td align="left">
           NA
          </td>
         </tr>
        </tbody>
       </table>
       <table-wrap-foot>
        <fn>
         <p>
          DtaP, diphtheria and tetanus toxoids and acellular pertussis vaccine, pediatric (6 weeks through 6 years); MMR, measles, mumps and rubella; TIV, trivalent (inactivated) influenza vaccine; LAIV, live, attenuated (intranasal) influenza vaccine; Td, tetanus and reduced diphtheria toxoids, Tdap, tetanus toxoid, reduced diphtheria toxoid, and reduced acellular pertussis vaccine.
         </p>
        </fn>
       </table-wrap-foot>
       <table-wrap-foot>
        <fn id="cetablefn6">
         <label>
          1
         </label>
         <p id="cenotep6">
          Combination vaccines are available. Use of licensed combination vaccines is generally preferred over separate injections of their equivalent component vaccines (CDC. Combination vaccines for childhood immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP), the American Academy of Pediatrics (AAP), and the American Academy of Family Physicians (AAFP). MMWR Recomm Rep. 1999;48(RR-5):5). When administering combination vaccines, the minimum age for administration is the oldest age for any of the individual components; the minimum interval between doses is equal to the greatest interval of any of the individual components.
         </p>
        </fn>
       </table-wrap-foot>
       <table-wrap-foot>
        <fn id="cetablefn7">
         <label>
          2
         </label>
         <p id="cenotep7">
          Combination vaccines containing the HepB component are available (HepB-Hib, DTaP-HepB-IPV, HepA-HepB). These vaccines should not be administered to infants younger than 6 weeks of age because of the other components (i.e., Hib, DTaP, IPV). HepA-HepB is not licensed for persons &lt;18 years of age in the United States.
         </p>
        </fn>
       </table-wrap-foot>
       <table-wrap-foot>
        <fn id="cetablefn8">
         <label>
          3
         </label>
         <p id="cenotep8">
          HepB-3 should be administered at least 8 weeks after Hep B-2 and at least 16 weeks after Hep B-1; it should not be administered before age 24 weeks.
         </p>
        </fn>
       </table-wrap-foot>
       <table-wrap-foot>
        <fn id="cetablefn9">
         <label>
          4
         </label>
         <p id="cenotep9">
          Calendar months.
         </p>
        </fn>
       </table-wrap-foot>
       <table-wrap-foot>
        <fn id="cetablefn10">
         <label>
          5
         </label>
         <p id="cenotep10">
          The minimum recommended interval between DTaP-3 and DTaP-4 is 6 months. However, DTaP-4 need not be repeated if administered at least 4 months after DTaP-3. Adapted from
          <xref ref-type="table" rid="cetable1">
           Table 1
          </xref>
          , CDC. General recommendations on immunization. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2006; 55(RR-15):1–48.
         </p>
        </fn>
       </table-wrap-foot>
       <table-wrap-foot>
        <fn id="cetablefn11">
         <label>
          6
         </label>
         <p id="cenotep11">
          For Hib and PCV, children receiving the first dose of vaccine at ≥7 months of age require fewer doses to complete the series (see the current childhood and adolescent immunization schedule at
          <ext-link ext-link-type="uri" id="interref2" xlink:href="http://www.cdc.gov/vaccines/">
           www.cdc.gov/vaccines/
          </ext-link>
          ).
         </p>
        </fn>
       </table-wrap-foot>
       <table-wrap-foot>
        <fn id="cetablefn12">
         <label>
          7
         </label>
         <p id="cenotep12">
          If PRP-OMP (Pedvax-Hib, Merck Vaccine Division) was administered at 2 and 4 months of age, a dose at 6 months of age is not indicated. Adapted from
          <xref ref-type="table" rid="cetable1">
           Table 1
          </xref>
          , CDC. General recommendations on immunization. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2006; 55(RR-15):1–48.
         </p>
        </fn>
       </table-wrap-foot>
       <table-wrap-foot>
        <fn id="cetablefn13">
         <label>
          8
         </label>
         <p id="cenotep13">
          Combination MMR-varicella can be used for children 12 months through 12 years of age. Also see footnote
          <xref ref-type="table-fn" rid="cetablefn14">
           9
          </xref>
          .
         </p>
        </fn>
       </table-wrap-foot>
       <table-wrap-foot>
        <fn id="cetablefn14">
         <label>
          9
         </label>
         <p id="cenotep14">
          The minimum interval from VAR-1 to VAR-2 for persons beginning the series at ≥13 years of age is 4 weeks.
         </p>
        </fn>
       </table-wrap-foot>
       <table-wrap-foot>
        <fn id="cetablefn15">
         <label>
          10
         </label>
         <p id="cenotep15">
          Two doses of influenza vaccine are recommended only for children &lt;9 years of age who are receiving the vaccine for the first time and for certain incompletely vaccinated children. See reference
          <xref ref-type="bibr" rid="bib5">
           5
          </xref>
          .
         </p>
        </fn>
       </table-wrap-foot>
       <table-wrap-foot>
        <fn id="cetablefn16">
         <label>
          11
         </label>
         <p id="cenotep16">
          Some experts recommend that a second dose of MPSV be given 3 years after the first dose for persons at increased risk for meningococcal disease.
         </p>
        </fn>
       </table-wrap-foot>
       <table-wrap-foot>
        <fn id="cetablefn17">
         <label>
          12
         </label>
         <p id="cenotep17">
          A second dose of meningococcal vaccine is recommended for persons previously vaccinated with MPSV who remain at high risk for meningococcal disease. MCV is preferred when revaccinating persons 2–55 years of age (CDC. Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2005;54(RR07);1–21.) Adapted from
          <xref ref-type="table" rid="cetable1">
           Table 1
          </xref>
          , CDC. General recommendations on immunization. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2006; 55(RR-15):1–48.
         </p>
        </fn>
       </table-wrap-foot>
       <table-wrap-foot>
        <fn id="cetablefn18">
         <label>
          13
         </label>
         <p id="cenotep18">
          Only one dose of Tdap is recommended. Subsequent doses should be given as Td. If vaccination to prevent tetanus and/or diphtheria disease is required for children 7–9 years of age, Td should be given (minimum age for Td is 7 years). For one brand of Tdap, the minimum age is 11 years. The preferred interval between Tdap and a previous dose of Td is 5 years, but Tdap may be administered earlier if pertussis immunity is needed. For management of a tetanus-prone wound, the minimum interval after a previous dose of any tetanus-containing vaccine is 5 years.
         </p>
        </fn>
       </table-wrap-foot>
       <table-wrap-foot>
        <fn id="cetablefn19">
         <label>
          14
         </label>
         <p id="cenotep19">
          A second dose of PPV is recommended for persons at highest risk for serious pneumococcal infection and those who are likely to have a rapid decline in pneumococcal antibody concentration. (CDC. Prevention of pneumococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 1997; 46(RR-8):1–24.)
         </p>
        </fn>
       </table-wrap-foot>
       <table-wrap-foot>
        <fn id="cetablefn20">
         <label>
          15
         </label>
         <p id="cenotep20">
          HPV is approved only for females 9–26 years of age. HPV-3 should be administered at least 12 weeks after HPV-2 and at least 24 weeks after HPV-1.
         </p>
        </fn>
       </table-wrap-foot>
       <table-wrap-foot>
        <fn id="cetablefn21">
         <label>
          16
         </label>
         <p id="cenotep21">
          The first dose of RV must be administered by 14 weeks and 6 days of age. The vaccine series should not be started at 15 weeks of age or older. The final dose in the series should be administered by age 8 months 0 days. If Rotarix rotavirus vaccine is administered at 2 and 4 months of age, a dose at 6 months of age is not indicated.
         </p>
        </fn>
       </table-wrap-foot>
       <table-wrap-foot>
        <fn id="cetablefn22">
         <label>
          17
         </label>
         <p id="cenotep22">
          Herpes zoster vaccine is approved as a single dose for persons 60 years of age and older.
         </p>
        </fn>
       </table-wrap-foot>
       <table-wrap-foot>
        <fn id="cetablefn23">
         <label>
          18
         </label>
         <p id="cenotep23">
          Oral typhoid vaccine is recommended to be administered 1 hour before a meal with a cold or lukewarm drink (temperature not to exceed body temperature) (i.e., 98.6° F (37° C)) on alternate days, for a total of 4 doses.
         </p>
        </fn>
       </table-wrap-foot>
       <table-wrap-foot>
        <fn id="cetablefn24">
         <label>
          19
         </label>
         <p id="cenotep24">
          Yellow fever vaccine may be administered to children younger than 9 months of age in certain situations. (CDC. Yellow Fever Vaccine Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2002. MMWR Recomm Rep. 2002;51(RR-17):6–7.)
         </p>
        </fn>
       </table-wrap-foot>
       <table-wrap-foot>
        <fn id="cetablefn25">
         <label>
          20
         </label>
         <p id="cenotep25">
          There is no minimum age for pre-exposure immunization for rabies. (CDC. Human rabies prevention—United States, 2008: recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep. 2008; 57(RR-3):1–28.)
         </p>
        </fn>
       </table-wrap-foot>
       <attrib>
        Adapted from
        <xref ref-type="table" rid="cetable1">
         Table 1
        </xref>
        , CDC. General recommendations on immunization. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2006; 55(RR-15):1–48.
       </attrib>
      </table-wrap>
      <table-wrap id="cetable4" position="float">
       <label>
        Table 2-4
       </label>
       <caption>
        <p>
         Licensed schedule for HAVRIX
         <xref ref-type="table-fn" rid="cetablefn26">
          1
         </xref>
        </p>
       </caption>
       <table frame="hsides" rules="groups">
        <thead>
         <tr>
          <th align="left">
           Age Group (YRS)
          </th>
          <th align="left">
           Dose (EL.U.)
           <xref ref-type="table-fn" rid="cetablefn27">
            2
           </xref>
          </th>
          <th align="left">
           Volume
          </th>
          <th align="left">
           No. of Doses
          </th>
          <th align="left">
           Schedule (Months)
          </th>
         </tr>
        </thead>
        <tbody>
         <tr>
          <td align="left">
           1–18
          </td>
          <td align="left">
           720
          </td>
          <td align="left">
           0.5 mL
          </td>
          <td align="left">
           2
          </td>
          <td align="left">
           0, 6–2
          </td>
         </tr>
         <tr>
          <td align="left">
           ≥19
          </td>
          <td align="left">
           1440
          </td>
          <td align="left">
           1.0 mL
          </td>
          <td align="left">
           2
          </td>
          <td align="left">
           0, 6–12
          </td>
         </tr>
        </tbody>
       </table>
       <table-wrap-foot>
        <fn id="cetablefn26">
         <label>
          1
         </label>
         <p id="cenotep26">
          Hepatitis A vaccine, inactivated, GlaxoSmithKline.
         </p>
        </fn>
       </table-wrap-foot>
       <table-wrap-foot>
        <fn id="cetablefn27">
         <label>
          2
         </label>
         <p id="cenotep27">
          EL.U., enzyme-linked immunosorbent assay (ELISA) units of inactivated hepatitis A virus.
         </p>
        </fn>
       </table-wrap-foot>
      </table-wrap>
      <table-wrap id="cetable5" position="float">
       <label>
        Table 2-5
       </label>
       <caption>
        <p>
         Licensed schedule for VAQTA
         <xref ref-type="table-fn" rid="cetablefn28">
          1
         </xref>
        </p>
       </caption>
       <table frame="hsides" rules="groups">
        <thead>
         <tr>
          <th align="left">
           Age Group (YRS)
          </th>
          <th align="left">
           Dose (U.)
           <xref ref-type="table-fn" rid="cetablefn29">
            2
           </xref>
          </th>
          <th align="left">
           Volume
          </th>
          <th align="left">
           No. of Doses
          </th>
          <th align="left">
           Schedule (Months)
          </th>
         </tr>
        </thead>
        <tbody>
         <tr>
          <td align="left">
           1–18
          </td>
          <td align="left">
           25
          </td>
          <td align="left">
           0.5 mL
          </td>
          <td align="left">
           2
          </td>
          <td align="left">
           0, 6–18
          </td>
         </tr>
         <tr>
          <td align="left">
           ≥19
          </td>
          <td align="left">
           50
          </td>
          <td align="left">
           1.0 mL
          </td>
          <td align="left">
           2
          </td>
          <td align="left">
           0, 6–18
          </td>
         </tr>
        </tbody>
       </table>
       <table-wrap-foot>
        <fn id="cetablefn28">
         <label>
          1
         </label>
         <p id="cenotep28">
          Hepatitis A vaccine, inactivated, Merck &amp; Co., Inc.
         </p>
        </fn>
       </table-wrap-foot>
       <table-wrap-foot>
        <fn id="cetablefn29">
         <label>
          2
         </label>
         <p id="cenotep29">
          U., units of hepatitis A virus antigen.
         </p>
        </fn>
       </table-wrap-foot>
      </table-wrap>
      <table-wrap id="cetable6" position="float">
       <label>
        Table 2-6
       </label>
       <caption>
        <p>
         Licensed schedule for TWINRIX
         <xref ref-type="table-fn" rid="cetablefn30">
          1
         </xref>
        </p>
       </caption>
       <table frame="hsides" rules="groups">
        <thead>
         <tr>
          <th align="left">
           Age Group (YRS)
          </th>
          <th align="left">
           Dose (EL.U./20 mg)
           <xref ref-type="table-fn" rid="cetablefn31">
            2
           </xref>
          </th>
          <th align="left">
           Volume
          </th>
          <th align="left">
           No. of Doses
          </th>
          <th align="left">
           Schedule (Months)
          </th>
         </tr>
        </thead>
        <tbody>
         <tr>
          <td align="left">
           ≥18
          </td>
          <td align="left">
           720
          </td>
          <td align="left">
           1.0 mL
          </td>
          <td align="left">
           3
          </td>
          <td align="left">
           0, 1, 6 months
          </td>
         </tr>
         <tr>
          <td align="left">
           ≥18
          </td>
          <td align="left">
           720
          </td>
          <td align="left">
           1.0 mL
          </td>
          <td align="left">
           4
          </td>
          <td align="left">
           0, 7, 21 days +1 year
          </td>
         </tr>
        </tbody>
       </table>
       <table-wrap-foot>
        <fn id="cetablefn30">
         <label>
          1
         </label>
         <p id="cenotep30">
          Combined hepatitis A and hepatitis B vaccine, GlaxoSmithKline.
         </p>
        </fn>
       </table-wrap-foot>
       <table-wrap-foot>
        <fn id="cetablefn31">
         <label>
          2
         </label>
         <p id="cenotep31">
          EL.U., enzyme-linked immunosorbent assay (ELISA) units of inactivated hepatitis A virus/micrograms hepatitis B surface antigen.
         </p>
        </fn>
       </table-wrap-foot>
      </table-wrap>
      <table-wrap id="cetable7" position="float">
       <label>
        Table 2-7
       </label>
       <caption>
        <p>
         Recommended doses of immune globulin (IG) for protection against hepatitis A
        </p>
       </caption>
       <table frame="hsides" rules="groups">
        <thead>
         <tr>
          <th align="left">
           Setting
          </th>
          <th align="left">
           Duration of Coverage
          </th>
          <th align="left">
           Dose (Ml/Kg)
           <xref ref-type="table-fn" rid="cetablefn32">
            1
           </xref>
          </th>
         </tr>
        </thead>
        <tbody>
         <tr>
          <td align="left">
           Pre-exposure
          </td>
          <td align="left">
           Short-term (1–2 months)
          </td>
          <td align="left">
           0.02
          </td>
         </tr>
         <tr>
          <td>
          </td>
          <td align="left">
           Long-term (3–5 months)
          </td>
          <td align="left">
           0.06
           <xref ref-type="table-fn" rid="cetablefn33">
            2
           </xref>
          </td>
         </tr>
         <tr>
          <td align="left">
           Postexposure
          </td>
          <td align="left">
           NA
          </td>
          <td align="left">
           0.02
          </td>
         </tr>
        </tbody>
       </table>
       <table-wrap-foot>
        <fn id="cetablefn32">
         <label>
          1
         </label>
         <p id="cenotep32">
          IG should be administered by intramuscular injection into either the deltoid or gluteal muscle. For children &lt;12 months of age, IG can be administered in the anterolateral thigh muscle.
         </p>
        </fn>
       </table-wrap-foot>
       <table-wrap-foot>
        <fn id="cetablefn33">
         <label>
          2
         </label>
         <p id="cenotep33">
          Repeat every 5 months if continued exposure to hepatitis A virus occurs.
         </p>
        </fn>
       </table-wrap-foot>
      </table-wrap>
      <table-wrap id="cetable9" position="float">
       <label>
        Table 2-9
       </label>
       <caption>
        <p>
         Recommended doses of currently licensed formulations of hepatitis B vaccine
        </p>
       </caption>
       <table frame="hsides" rules="groups">
        <thead>
         <tr>
          <th align="left">
           Group
           <hr/>
          </th>
          <th align="left" colspan="3">
           Single-Antigen Vaccine
           <hr/>
          </th>
          <th>
           <hr/>
          </th>
          <th align="left" colspan="3">
           Combination Vaccine
           <hr/>
          </th>
          <th>
           <hr/>
          </th>
          <th>
           <hr/>
          </th>
          <th>
           <hr/>
          </th>
         </tr>
         <tr>
          <th>
           <hr/>
          </th>
          <th align="left" colspan="2">
           RECOMBIVAX HB
           <hr/>
          </th>
          <th align="left" colspan="2">
           ENGERIX-B
           <hr/>
          </th>
          <th align="left" colspan="2">
           COMVAX
           <xref ref-type="table-fn" rid="cetablefn43">
            1
           </xref>
           <hr/>
          </th>
          <th align="left" colspan="2">
           PEDIARIX
           <xref ref-type="table-fn" rid="cetablefn44">
            2
           </xref>
           <hr/>
          </th>
          <th align="left" colspan="2">
           TWINRIX
           <xref ref-type="table-fn" rid="cetablefn45">
            3
           </xref>
           <hr/>
          </th>
         </tr>
         <tr>
          <th>
          </th>
          <th align="left">
           Dose (μg)
           <xref ref-type="table-fn" rid="cetablefn46">
            4
           </xref>
          </th>
          <th align="left">
           Volume (ml)
          </th>
          <th align="left">
           Dose (μg)
           <xref ref-type="table-fn" rid="cetablefn46">
            4
           </xref>
          </th>
          <th align="left">
           Volume (ml)
          </th>
          <th align="left">
           Dose (μg)
           <xref ref-type="table-fn" rid="cetablefn46">
            4
           </xref>
          </th>
          <th align="left">
           Volume (ml)
          </th>
          <th align="left">
           Dose (μg)
           <xref ref-type="table-fn" rid="cetablefn46">
            4
           </xref>
          </th>
          <th align="left">
           Volume (ml)
          </th>
          <th align="left">
           Dose (μg)
           <xref ref-type="table-fn" rid="cetablefn46">
            4
           </xref>
          </th>
          <th align="left">
           Volume (ml)
          </th>
         </tr>
        </thead>
        <tbody>
         <tr>
          <td align="left">
           <bold>
            Infants (&lt;1 year)
           </bold>
          </td>
          <td align="left">
           5
           <xref ref-type="table-fn" rid="cetablefn49">
            7
           </xref>
          </td>
          <td align="left">
           0.5
          </td>
          <td align="left">
           10
           <xref ref-type="table-fn" rid="cetablefn49">
            7
           </xref>
          </td>
          <td align="left">
           0.5
          </td>
          <td align="left">
           5
          </td>
          <td align="left">
           0.5
          </td>
          <td align="left">
           10
          </td>
          <td align="left">
           0.5
          </td>
          <td align="left">
           NA
           <xref ref-type="table-fn" rid="cetablefn47">
            5
           </xref>
          </td>
          <td align="left">
           NA
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Children (1–10 years)
           </bold>
          </td>
          <td align="left">
           5
          </td>
          <td align="left">
           0.5
          </td>
          <td align="left">
           10
          </td>
          <td align="left">
           0.5
          </td>
          <td align="left">
           5
          </td>
          <td align="left">
           0.5
          </td>
          <td align="left">
           10
          </td>
          <td align="left">
           0.5
          </td>
          <td align="left">
           NA
          </td>
          <td align="left">
           NA
          </td>
         </tr>
         <tr>
          <td align="left" colspan="11">
           <bold>
            Adolescents
           </bold>
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            11–15 years
           </bold>
          </td>
          <td align="left">
           10
           <xref ref-type="table-fn" rid="cetablefn48">
            6
           </xref>
          </td>
          <td align="left">
           1.0
          </td>
          <td align="left">
           NA
          </td>
          <td align="left">
           NA
          </td>
          <td align="left">
           NA
          </td>
          <td align="left">
           NA
          </td>
          <td align="left">
           NA
          </td>
          <td align="left">
           NA
          </td>
          <td align="left">
           NA
          </td>
          <td align="left">
           NA
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            11–19 years
           </bold>
          </td>
          <td align="left">
           5
          </td>
          <td align="left">
           0.5
          </td>
          <td align="left">
           10
          </td>
          <td align="left">
           0.5
          </td>
          <td align="left">
           NA
          </td>
          <td align="left">
           NA
          </td>
          <td align="left">
           NA
          </td>
          <td align="left">
           NA
          </td>
          <td align="left">
           20
           <xref ref-type="table-fn" rid="cetablefn45">
            3
           </xref>
          </td>
          <td align="left">
           1.0
           <xref ref-type="table-fn" rid="cetablefn45">
            3
           </xref>
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Adults (&gt;20 years)
           </bold>
          </td>
          <td align="left">
           10
          </td>
          <td align="left">
           1.0
          </td>
          <td align="left">
           20
          </td>
          <td align="left">
           1.0
          </td>
          <td align="left">
           NA
          </td>
          <td align="left">
           NA
          </td>
          <td align="left">
           NA
          </td>
          <td align="left">
           NA
          </td>
          <td align="left">
           20
          </td>
          <td align="left">
           1.0
          </td>
         </tr>
         <tr>
          <td align="left" colspan="11">
           <bold>
            Hemodialysis patients and other immunocompromised persons
           </bold>
           <xref ref-type="table-fn" rid="cetablefn49">
            7
           </xref>
          </td>
         </tr>
         <tr>
          <td align="left">
           &lt;20 years
           <xref ref-type="table-fn" rid="cetablefn49">
            7
           </xref>
          </td>
          <td align="left">
           5
          </td>
          <td align="left">
           0.5
          </td>
          <td align="left">
           10
          </td>
          <td align="left">
           0.5
          </td>
          <td align="left">
           NA
          </td>
          <td align="left">
           NA
          </td>
          <td align="left">
           NA
          </td>
          <td align="left">
           NA
          </td>
          <td align="left">
           NA
          </td>
          <td align="left">
           NA
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            ≥20 years
           </bold>
          </td>
          <td align="left">
           40
           <xref ref-type="table-fn" rid="cetablefn50">
            8
           </xref>
          </td>
          <td align="left">
           10
          </td>
          <td align="left">
           40
           <xref ref-type="table-fn" rid="cetablefn51">
            9
           </xref>
          </td>
          <td align="left">
           2.0
          </td>
          <td align="left">
           NA
          </td>
          <td align="left">
           NA
          </td>
          <td align="left">
           NA
          </td>
          <td align="left">
           NA
          </td>
          <td align="left">
           NA
          </td>
          <td align="left">
           NA
          </td>
         </tr>
        </tbody>
       </table>
       <table-wrap-foot>
        <fn id="cetablefn43">
         <label>
          1
         </label>
         <p id="cenotep43">
          Combined hepatitis B–
          <italic>
           Haemophilus influenzae
          </italic>
          type b conjugate vaccine. This vaccine cannot be administered before age 6 weeks or after age 71 months.
         </p>
        </fn>
       </table-wrap-foot>
       <table-wrap-foot>
        <fn id="cetablefn44">
         <label>
          2
         </label>
         <p id="cenotep44">
          Combined hepatitis B–diphtheria, tetanus, pertussis-inactivated poliovirus vaccine. This vaccine cannot be administered at birth, before age 6 weeks, or after age 7 years.
         </p>
        </fn>
       </table-wrap-foot>
       <table-wrap-foot>
        <fn id="cetablefn45">
         <label>
          3
         </label>
         <p id="cenotep45">
          Combined hepatitis A and hepatitis B vaccine. This vaccine is recommended for persons ≥18 years who are at increased risk for both hepatitis A virus and hepatitis B virus infections.
         </p>
        </fn>
       </table-wrap-foot>
       <table-wrap-foot>
        <fn id="cetablefn46">
         <label>
          4
         </label>
         <p id="cenotep46">
          Recombinant hepatitis B surface antigen dose.
         </p>
        </fn>
       </table-wrap-foot>
       <table-wrap-foot>
        <fn id="cetablefn47">
         <label>
          5
         </label>
         <p id="cenotep47">
          Not applicable.
         </p>
        </fn>
       </table-wrap-foot>
       <table-wrap-foot>
        <fn id="cetablefn48">
         <label>
          6
         </label>
         <p id="cenotep48">
          Adult formulation administered on a 2-dose schedule.
         </p>
        </fn>
       </table-wrap-foot>
       <table-wrap-foot>
        <fn id="cetablefn49">
         <label>
          7
         </label>
         <p id="cenotep49">
          Higher doses might be more immunogenic, but no specific recommendations have been made.
         </p>
        </fn>
       </table-wrap-foot>
       <table-wrap-foot>
        <fn id="cetablefn50">
         <label>
          8
         </label>
         <p id="cenotep50">
          Dialysis formulation administered on a 3-dose schedule at 0, 1, and 6 months.
         </p>
        </fn>
       </table-wrap-foot>
       <table-wrap-foot>
        <fn id="cetablefn51">
         <label>
          9
         </label>
         <p id="cenotep51">
          Two 1.0-mL doses administered at one site, on a 4-dose schedule at 0, 1, 2, and 6 months.
         </p>
        </fn>
       </table-wrap-foot>
      </table-wrap>
      <table-wrap id="cetable10" position="float">
       <label>
        Table 2-10
       </label>
       <caption>
        <p>
         Dosage and schedule for typhoid fever vaccination
        </p>
       </caption>
       <table frame="hsides" rules="groups">
        <thead>
         <tr>
          <th align="left">
           Vaccination
          </th>
          <th align="left">
           Age (Years)
          </th>
          <th align="left">
           Dose/Mode of Administration
          </th>
          <th align="left">
           No. of Doses
          </th>
          <th align="left">
           Dosing Interval
          </th>
          <th align="left">
           Boosting Interval
          </th>
         </tr>
        </thead>
        <tbody>
         <tr>
          <td align="left" colspan="6">
           <bold>
            Oral, live, attenuated Ty21a vaccine (Vivotif)
           </bold>
          </td>
         </tr>
         <tr>
          <td align="left">
           Primary series
          </td>
          <td align="left">
           ≥6
          </td>
          <td align="left">
           1 capsule,
           <xref ref-type="table-fn" rid="cetablefn52">
            1
           </xref>
           oral
          </td>
          <td align="left">
           4
          </td>
          <td align="left">
           48 hours
          </td>
          <td align="left">
           Not applicable
          </td>
         </tr>
         <tr>
          <td align="left">
           Booster
          </td>
          <td align="left">
           ≥6
          </td>
          <td align="left">
           1 capsule,
           <xref ref-type="table-fn" rid="cetablefn52">
            1
           </xref>
           oral
          </td>
          <td align="left">
           4
          </td>
          <td align="left">
           48 hours
          </td>
          <td align="left">
           Every 5 years
          </td>
         </tr>
         <tr>
          <td align="left" colspan="6">
           <bold>
            Vi Capsular polysaccharide vaccine (Typhim Vi)
           </bold>
          </td>
         </tr>
         <tr>
          <td align="left">
           Primary series
          </td>
          <td align="left">
           ≥2
          </td>
          <td align="left">
           0.50 mL, intramuscular
          </td>
          <td align="left">
           1
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
         </tr>
         <tr>
          <td align="left">
           Booster
          </td>
          <td align="left">
           ≥2
          </td>
          <td align="left">
           0.50 mL, intramuscular
          </td>
          <td align="left">
           1
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Every 2 years
          </td>
         </tr>
        </tbody>
       </table>
       <table-wrap-foot>
        <fn id="cetablefn52">
         <label>
          1
         </label>
         <p id="cenotep52">
          Administer with cool liquid no warmer than 98.6° F (37° C).
         </p>
        </fn>
       </table-wrap-foot>
      </table-wrap>
      <table-wrap id="cetable18" position="float">
       <label>
        Table 2-18
       </label>
       <caption>
        <p>
         Pre-exposure immunization for rabies
         <xref ref-type="table-fn" rid="cetablefn69">
          1
         </xref>
        </p>
       </caption>
       <table frame="hsides" rules="groups">
        <thead>
         <tr>
          <th align="left">
           Vaccine
          </th>
          <th align="left">
           Dose (Ml)
          </th>
          <th align="left">
           No. of Doses
          </th>
          <th align="left">
           Schedule (Days)
          </th>
          <th align="left">
           Route
          </th>
         </tr>
        </thead>
        <tbody>
         <tr>
          <td align="left">
           HDCV
          </td>
          <td align="left">
           1.0
          </td>
          <td align="left">
           3
          </td>
          <td align="left">
           0, 7, and 21 or 28
          </td>
          <td align="left">
           Intramuscular
          </td>
         </tr>
         <tr>
          <td align="left">
           PCEC
          </td>
          <td align="left">
           1.0
          </td>
          <td align="left">
           3
          </td>
          <td align="left">
           0, 7, and 21 or 28
          </td>
          <td align="left">
           Intramuscular
          </td>
         </tr>
        </tbody>
       </table>
       <table-wrap-foot>
        <fn id="cetablefn69">
         <label>
          1
         </label>
         <p id="cenotep69">
          HDCV, human diploid cell vaccine; PCEC, purified chick embryo cell. Patients who are immunosuppressed by disease or medications should postpone pre-exposure vaccinations and consider avoiding activities for which rabies pre-exposure prophylaxis is indicated. When this course is not possible, immunosuppressed persons who are at risk for rabies should have their antibody titers checked after vaccination.
         </p>
        </fn>
       </table-wrap-foot>
      </table-wrap>
      <table-wrap id="cetable19" position="float">
       <label>
        Table 2-19
       </label>
       <caption>
        <p>
         Postexposure immunization for rabies
         <xref ref-type="table-fn" rid="cetablefn70">
          1
         </xref>
        </p>
       </caption>
       <table frame="hsides" rules="groups">
        <thead>
         <tr>
          <th align="left">
           Immunization Status
          </th>
          <th align="left">
           Vaccine/Product
          </th>
          <th align="left">
           Dose
          </th>
          <th align="left">
           No. of Doses
          </th>
          <th align="left">
           Schedule (Days)
          </th>
          <th align="left">
           Route
          </th>
         </tr>
        </thead>
        <tbody>
         <tr>
          <td align="left">
           Not previously immunized
          </td>
          <td align="left">
           RIG plus
          </td>
          <td align="left">
           20 IU/kg body weight
          </td>
          <td align="left">
           1
          </td>
          <td align="left">
           0
          </td>
          <td align="left">
           Infiltrated at bite site (if possible possible); remainder intramuscular
          </td>
         </tr>
         <tr>
          <td>
          </td>
          <td align="left">
           HDCV or PCEC
          </td>
          <td align="left">
           1.0 mL
          </td>
          <td align="left">
           5
          </td>
          <td align="left">
           0, 3, 7, 14, 28
          </td>
          <td align="left">
           Intramuscular
          </td>
         </tr>
         <tr>
          <td align="left">
           Previously immunized
           <xref ref-type="table-fn" rid="cetablefn71">
            2
           </xref>
           ,
           <xref ref-type="table-fn" rid="cetablefn72">
            3
           </xref>
          </td>
          <td align="left">
           HDCV or PCEC
          </td>
          <td align="left">
           1.0 mL
          </td>
          <td align="left">
           2
          </td>
          <td align="left">
           0, 3
          </td>
          <td align="left">
           Intramuscular
          </td>
         </tr>
        </tbody>
       </table>
       <table-wrap-foot>
        <fn>
         <p>
          RIG, rabies immune globulin; HDCV, human diploid cell (rabies) vaccine; PCEC, purified chick embryo cell.
         </p>
        </fn>
       </table-wrap-foot>
       <table-wrap-foot>
        <fn id="cetablefn70">
         <label>
          1
         </label>
         <p id="cenotep70">
          All postexposure prophylaxis should begin with immediate, thorough cleansing of all wounds with soap and water.
         </p>
        </fn>
       </table-wrap-foot>
       <table-wrap-foot>
        <fn id="cetablefn71">
         <label>
          2
         </label>
         <p id="cenotep71">
          Pre-exposure immunization with HDCV or PCEC, prior postexposure prophylaxis with HDCV or PCEC, or persons previously immunized with any other type of rabies vaccine and a documented history of positive antibody response to the prior vaccination.
         </p>
        </fn>
       </table-wrap-foot>
       <table-wrap-foot>
        <fn id="cetablefn72">
         <label>
          3
         </label>
         <p id="cenotep72">
          RIG should not be administered.
         </p>
        </fn>
       </table-wrap-foot>
      </table-wrap>
      <table-wrap id="cetable21" position="float">
       <label>
        Table 2-21
       </label>
       <caption>
        <p>
         Summary guide to tetanus prophylaxis in routine wound management
         <xref ref-type="table-fn" rid="cetablefn73">
          1
         </xref>
        </p>
       </caption>
       <table frame="hsides" rules="groups">
        <thead>
         <tr>
          <th align="left">
           History of Tetanus Immunization (Doses)
           <hr/>
          </th>
          <th align="left" colspan="2">
           Clean, Minor Wounds
           <hr/>
          </th>
          <th align="left" colspan="2">
           All Other Wounds
           <hr/>
          </th>
         </tr>
         <tr>
          <th>
          </th>
          <th>
           Td
           <xref ref-type="table-fn" rid="cetablefn74">
            2
           </xref>
          </th>
          <th>
           TIG
          </th>
          <th>
           Td
           <xref ref-type="table-fn" rid="cetablefn74">
            2
           </xref>
          </th>
          <th>
           TIG
          </th>
         </tr>
        </thead>
        <tbody>
         <tr>
          <td align="left">
           Uncertain or &lt;3 doses
          </td>
          <td align="left">
           Yes
          </td>
          <td align="left">
           No
          </td>
          <td align="left">
           Yes
          </td>
          <td align="left">
           Yes
          </td>
         </tr>
         <tr>
          <td align="left">
           3 or more doses
          </td>
          <td align="left">
           No
           <xref ref-type="table-fn" rid="cetablefn75">
            3
           </xref>
          </td>
          <td align="left">
           No
          </td>
          <td align="left">
           No
           <xref ref-type="table-fn" rid="cetablefn76">
            4
           </xref>
          </td>
          <td align="left">
           No
          </td>
         </tr>
        </tbody>
       </table>
       <table-wrap-foot>
        <fn id="cetablefn73">
         <label>
          1
         </label>
         <p id="cenotep73">
          Important details in the text.
         </p>
        </fn>
       </table-wrap-foot>
       <table-wrap-foot>
        <fn id="cetablefn74">
         <label>
          2
         </label>
         <p id="cenotep74">
          For children &lt;7 years old, DTaP or DTP (DT, if pertussis vaccine contraindicated) preferred to tetanus toxoid alone. For children ≥7 years of age, Td preferred to tetanus toxoid alone. For adolescents and adults to age 64, tetanus toxoid as Tdap is preferred, if the patient has not previously been vaccinated with Tdap.
         </p>
        </fn>
       </table-wrap-foot>
       <table-wrap-foot>
        <fn id="cetablefn75">
         <label>
          3
         </label>
         <p id="cenotep75">
          Yes, if more than 10 years since last dose.
         </p>
        </fn>
       </table-wrap-foot>
       <table-wrap-foot>
        <fn id="cetablefn76">
         <label>
          4
         </label>
         <p id="cenotep76">
          Yes, if more than 5 years since last dose. More frequent boosters are not needed and can accentuate side effects.
         </p>
        </fn>
       </table-wrap-foot>
      </table-wrap>
     </p>
     <sec id="cesec4">
      <title>
       Spacing of Immunobiologics
      </title>
      <sec id="cesec5">
       <title>
        Simultaneous Administration
       </title>
       <p id="para183">
        All commonly used vaccines can safely and effectively be given simultaneously (i.e., on the same day) at separate sites without impairing antibody responses or increasing rates of adverse reactions. This knowledge is particularly helpful for international travelers, for whom exposure to several infectious diseases might be imminent. Simultaneous administration of all indicated vaccines is encouraged for persons who are the recommended age to receive these vaccines and for whom no contraindications exist. If not administered on the same day, an inactivated vaccine may be given at any time before or after a different inactivated vaccine or a live-virus vaccine.
       </p>
       <p id="para184">
        The immune response to an injected or intranasal live-virus vaccine (e.g., measles, mumps and rubella (MMR); varicella; yellow fever; or live attenuated influenza vaccine) might be impaired if administered within 28 days of another live-virus vaccine. Whenever possible, injected live-virus vaccines administered on different days should be given at least 28 days apart. If two injected or intranasal live-virus vaccines are not administered on the same day but less than 28 days apart, the second vaccine should be readministered at least 4 weeks after the first vaccine was administered.
       </p>
       <p id="para185">
        Live-virus vaccines can interfere with the response to tuberculin testing. Tuberculin testing, if otherwise indicated, can be done either on the day that live-virus vaccines are administered or 4–6 weeks later. Tuberculin skin testing is not a prerequisite for administration of any vaccine.
       </p>
      </sec>
      <sec id="cesec6">
       <title>
        Missed Doses and Boosters
       </title>
       <p id="para186">
        Travelers may forget to return for a follow-up dose of vaccine or booster at the specified time. Occasionally the demand for a vaccine may exceed its supply, and providers may have difficulty obtaining vaccines. (Information on vaccine shortages and recommendations can be found on the CDC Vaccines and Immunization website at
        <ext-link ext-link-type="uri" id="interref10" xlink:href="http://www.cdc.gov/vaccines/vac-gen/shortages/default.htm">
         www.cdc.gov/vaccines/vac-gen/shortages/default.htm
        </ext-link>
        .) It is unnecessary in these cases to restart the interrupted series or to add any extra doses except for oral typhoid. The next scheduled dose should be given when the patient presents. (There are no data for interrupted dosing with oral typhoid vaccine; thus, a travel medicine specialist should be consulted.) Some vaccines require periodic booster doses to maintain protection (
        <xref ref-type="table" rid="cetable1">
         Table 2-1
        </xref>
        ).
       </p>
      </sec>
      <sec id="cesec7">
       <title>
        Antibody-Containing Blood Products
       </title>
       <p id="para187">
        When MMR and varicella vaccines are given shortly before, simultaneously with, or after an antibody-containing blood product, such as immune globulin (IG) or a blood transfusion, response to the vaccine can be diminished. Antibody-containing blood products from the United States do not interfere with the immune response to yellow fever vaccine and are not believed to interfere with the response to live attenuated influenza vaccine or rotavirus vaccine. The duration of inhibition of MMR and varicella vaccines is related to the dose of IG in the product. MMR or its components and varicella vaccines either should be administered at least 2 weeks before receipt of a blood product or should be delayed 3–11 months after receipt of the blood product, depending on the vaccine (
        <xref ref-type="table" rid="cetable2">
         Table 2-2
        </xref>
        ).
       </p>
       <p id="para188">
        Immunoglobulin (IG) administration may become necessary for another indication after MMR or its individual components or varicella vaccines have been given. In such a situation, the IG may interfere with the immune response to the MMR or varicella vaccines. Vaccine virus replication and stimulation of immunity usually occur 2–3 weeks after vaccination. If the interval between administration of one of these vaccines and the subsequent administration of an IG preparation is 14 days or more, the vaccine need not be readministered. If the interval is less than 14 days, the vaccine should be readministered after the interval shown in
        <xref ref-type="table" rid="cetable2">
         Table 2-2
        </xref>
        , unless serologic testing indicates that antibodies have been produced. If administration of IG becomes necessary, MMR or its components or varicella vaccines can be administered simultaneously with IG, with the recognition that vaccine-induced immunity can be compromised. The vaccine should be administered at a body site different from that chosen for the IG injection. Vaccination should be repeated after the interval noted in
        <xref ref-type="table" rid="cetable2">
         Table 2-2
        </xref>
        , unless serologic testing indicates antibodies have been produced.
       </p>
       <p id="para189">
        When IG is given with the first dose of hepatitis A vaccine, the proportion of recipients who develop a protective level of antibody is not affected, but antibody concentrations are lower. Because the final concentrations of antibody are many times higher than those considered protective, this reduced immunogenicity is not expected to be clinically important. IG preparations interact minimally with other inactivated vaccines and toxoids. Other inactivated vaccines may be given simultaneously or at any time interval after or before an antibody-containing blood product is used. However, such vaccines should be administered at different sites from the IG.
       </p>
      </sec>
     </sec>
     <sec id="cesec8">
      <title>
       Vaccination of Persons with Acute Illnesses
      </title>
      <p id="para190">
       Every opportunity should be taken to provide appropriate vaccinations. The decision to delay vaccination because of a current or recent acute illness depends on the severity of the symptoms and their cause. Although a moderate or severe acute illness is sufficient reason to postpone vaccination, minor illnesses (e.g., diarrhea, mild upper respiratory infection with or without low-grade fever, other low-grade febrile illness) are not contraindications to vaccination.
      </p>
      <p id="para191">
       Persons with moderate or severe acute illness, with or without fever, should be vaccinated as soon as the condition has improved. This precaution is to avoid superimposing adverse effects from the vaccine on underlying illness or mistakenly attributing a manifestation of underlying illness to the vaccine. Antimicrobial therapy is not a contraindication to vaccination, with three exceptions. Antibacterial agents may interfere with the response to oral typhoid vaccine. Antiviral agents active against herpesviruses (e.g., acyclovir) may interfere with the response to varicella-containing vaccines (varicella, MMRV, zoster). Antiviral agents active against influenza virus (e.g., zanamivir, oseltamivir) may interfere with the response to live attenuated influenza vaccine.
      </p>
      <p id="para192">
       A physical examination or temperature measurement is not a prerequisite for vaccinating a person who appears to be in good health. Asking if a person is ill, postponing a vaccination for someone with moderate or severe acute illness, and vaccinating someone without contraindications are appropriate procedures for clinic immunizations.
      </p>
     </sec>
     <sec id="cesec9">
      <title>
       Altered Immunocompetence
      </title>
      <p id="para193">
       Altered immunocompetence is a general term that is often used interchangeably with the terms immunosuppression and immunodeficiency. It can be caused either by a disease (e.g., leukemia, HIV infection) or by drugs or other therapies (e.g., cancer chemotherapy, prolonged high dose corticosteroids). It can also include conditions such as asplenia and chronic renal disease.
      </p>
      <p id="para194">
       Determination of altered immunocompetence is important because the incidence or severity of some vaccine-preventable diseases is higher in persons with altered immunocompetence. Therefore, certain vaccines (e.g., inactivated influenza vaccine, pneumococcal vaccines) are recommended specifically for persons with these diseases. Inactivated vaccine may be safely administered to a person with altered immunocompetence, although response to the vaccine may be suboptimal. The vaccine may need to be repeated after immune function has improved.
      </p>
      <p id="para195">
       Persons with altered immunocompetence may be at increased risk for an adverse reaction following administration of live attenuated vaccines because of reduced ability to mount an effective immune response. Live vaccines should generally be deferred until immune function has improved. This is particularly important when planning to give yellow fever vaccine (see the
       <xref ref-type="sec" rid="subchapter6">
        Yellow Fever
       </xref>
       section later in this chapter). MMR and varicella vaccines are recommended for persons with mild or moderate immunosuppression.
      </p>
      <p id="para196">
       For an in-depth discussion, see The Immunocompromised Traveler section in Chapter 8.
      </p>
     </sec>
     <sec id="cesec10">
      <title>
       Vaccination Scheduling for Last-Minute Travelers
      </title>
      <p id="para197">
       As noted in the Simultaneous Administration section, most vaccine products can be given during one visit for persons anticipating imminent travel. Unless the vaccines given are booster doses of those typically given during childhood, vaccines may require a month or more to induce a sufficient immune response, depending on the vaccine and the number of doses in the series.
      </p>
      <p id="para198">
       Some vaccines require more than one dose for best protection. Recommended spacing should be maintained between doses (
       <xref ref-type="table" rid="cetable3">
        Table 2-3
       </xref>
       ). Doses given at less than minimum intervals can lessen the antibody response. Administration of a vaccine earlier than the recommended minimum age or at an interval shorter than the recommended minimum is discouraged.
       <xref ref-type="table" rid="cetable3">
        Table 2-3
       </xref>
       lists the minimum age and minimum interval between doses for vaccines routinely recommended in the United States. Because some travelers visit their health-care providers without ample time for administration of the vaccine doses recommended for optimal protection against certain diseases, studies have been performed and others are ongoing to determine whether accelerated scheduling is adequate. This concern is primarily the case for hepatitis B vaccine or the combined hepatitis A and B vaccine. An accelerated schedule for combined hepatitis A and hepatitis B vaccine has been approved by the U.S. Food and Drug Administration (FDA). It is unclear what level of protection any given traveler will have if a full series of multidose vaccination is not completed.
      </p>
     </sec>
     <sec id="cesec11">
      <title>
       Allergy to Vaccine Components
      </title>
      <p id="para199">
       Vaccine components can cause allergic reactions in some recipients. These reactions can be local or systemic and can include anaphylaxis or anaphylactic-like responses. The vaccine components responsible can include the vaccine antigen, animal proteins, antibiotics, preservatives (e.g., thimerosal), or stabilizers (e.g., gelatin). The most common animal protein allergen is egg protein in vaccines prepared by using embryonated chicken eggs (influenza and yellow fever vaccines). Generally, persons who can eat eggs or egg products safely may receive these vaccines, while those with histories of anaphylactic allergy (e.g., hives, swelling of the mouth and throat, difficulty breathing, hypotension, shock) to eggs or egg proteins ordinarily should not. Screening persons by asking whether they can eat eggs without adverse effects is a reasonable way to identify those who might be at risk from receiving yellow fever and influenza vaccines. Recent studies have indicated that other components in vaccines in addition to egg proteins (e.g., gelatin) may cause allergic reactions, including anaphylaxis in rare instances. Protocols have been developed for testing and vaccinating persons with anaphylactic reactions to egg ingestion.
      </p>
      <p id="para200">
       Some vaccines contain a preservative or trace amounts of antibiotics to which people might be allergic. Those administering the vaccine(s) should carefully review the information provided in the package insert before deciding if the rare person with such an allergy should receive the vaccine. No currently recommended vaccine contains penicillin or penicillin derivatives. Some vaccines (e.g., MMR and its individual component vaccines, inactivated polio vaccine [IPV], varicella, rabies) contain trace amounts of neomycin or other antibiotics; the amount is less than would normally be used for the skin test to determine hypersensitivity. However, persons who have experienced anaphylactic reactions to this antibiotic generally should not receive these vaccines. Most often, neomycin allergy is a contact dermatitis—a manifestation of a delayed-type (cell-mediated) immune response rather than anaphylaxis. A history of delayed-type reactions to neomycin is not a contraindication to receiving these vaccines.
      </p>
      <p id="para201">
       Thimerosal, an organic mercurial compound in use since the 1930s, has been added to certain immunobiologic products as a preservative. Thimerosal is present at preservative concentrations (trace quantities) in multidose vials of some brands of inactivated influenza vaccine, pediatric DT, single-antigen tetanus toxoid, meningococcal polysaccharide vaccine, and Japanese encephalitis vaccine. Receiving thimerosal-containing vaccines has been postulated to lead to induction of allergy. However, there is limited scientific evidence for this assertion. Allergy to thimerosal usually consists of local delayed-type hypersensitivity reactions. Thimerosal elicits positive delayed-type hypersensitivity patch tests in 1%–18% of persons tested, but these tests have limited or no clinical relevance. The majority of persons do not experience reactions to thimerosal administered as a component of vaccines, even when patch or intradermal tests for thimerosal indicate hypersensitivity. A localized or delayed-type hypersensitivity reaction to thimerosal is not a contraindication to receipt of a vaccine that contains thimerosal.
      </p>
      <p id="para202">
       Since mid-2001, vaccines routinely recommended for infants have been manufactured without thimerosal as a preservative. Additional information about thimerosal and the thimerosal content of vaccines is available on the FDA website at
       <ext-link ext-link-type="uri" id="interref11" xlink:href="http://www.fda.gov/cber/vaccine/thimerosal.htm">
        www.fda.gov/cber/vaccine/thimerosal.htm
       </ext-link>
       .
      </p>
     </sec>
     <sec id="cesec12">
      <title>
       Reporting Adverse Events Following Immunization
      </title>
      <p id="para203">
       Modern vaccines are extremely safe and effective. Benefits and risks are associated with the use of all immunobiologics—no vaccine is completely effective or completely free of side effects. Adverse events following immunization have been reported with all vaccines, ranging from frequent, minor, local reactions to extremely rare, severe, systemic illness, such as that associated with yellow fever vaccine (see
       <xref ref-type="sec" rid="subchapter6">
        Yellow Fever
       </xref>
       section later in this chapter). Side effects and adverse events following specific vaccines and toxoids are discussed in detail in each ACIP statement. Health-care providers are required by law to report selected adverse events occurring after vaccination with tetanus vaccine in any combination; pertussis in any combination; measles, mumps or rubella alone or in any combination, oral polio vaccine (OPV), IPV, hepatitis B; varicella;
       <italic>
        Haemophilus influenzae
       </italic>
       type b (conjugate); pneumococcal conjugate; and rotavirus vaccines. In addition, CDC strongly recommends that all vaccine adverse events be reported to the Vaccine Adverse Event Reporting System (VAERS), even if a causal relation to vaccination is not certain. VAERS reporting forms and information are available electronically at
       <ext-link ext-link-type="uri" id="interref12" xlink:href="http://www.vaers.hhs.gov">
        www.vaers.hhs.gov
       </ext-link>
       or may be requested by telephone: 800-822-7967. Health-care providers are encouraged to report electronically at
       <ext-link ext-link-type="uri" id="interref13" xlink:href="https://secure.vaers.org/VaersDataEntryintro.htm">
        https://secure.vaers.org/VaersDataEntryintro.htm
       </ext-link>
       .
      </p>
     </sec>
     <sec id="cesec13">
      <title>
       Injection Route and Injection Site
      </title>
      <p id="para204">
       Injectable vaccines are administered by intramuscular and subcutaneous routes. The method of administration of injectable vaccines depends in part on the presence of an adjuvant in some vaccines. The term adjuvant refers to a vaccine component distinct from the antigen, which enhances the immune response to the antigen. Vaccines containing an adjuvant (i.e., DTaP, DT, human papillomavirus, Td, Tdap, pneumococcal conjugate, Hib, hepatitis A, hepatitis B) should be injected into a muscle mass because administration subcutaneously or intradermally can cause local irritation, induration, skin discoloration, inflammation, and granuloma formation. Routes of administration are recommended by the manufacturer for each immunobiologic. Deviation from the recommended route of administration may reduce vaccine efficacy or increase local adverse reactions. Detailed recommendations on the appropriate route and site for all vaccines have been published in ACIP recommendations; a compiled list of these publications is available on the CDC website at
       <ext-link ext-link-type="uri" id="interref14" xlink:href="http://www.cdc.gov/vaccines/pubs/ACIP-list.htm">
        www.cdc.gov/vaccines/pubs/ACIP-list.htm
       </ext-link>
       (also see Appendix C: Travel Vaccine Summary Table).
      </p>
     </sec>
     <ref-list id="cebib2">
      <title>
       References
      </title>
      <ref id="bib8">
       <label>
        1
       </label>
       <element-citation id="sbref8" publication-type="journal">
        <person-group person-group-type="author">
         <collab>
          CDC
         </collab>
        </person-group>
        <article-title>
         General recommendations on immunization. Recommendations of the Advisory Committee on Immunization Practices (ACIP)
        </article-title>
        <source>
         MMWR Recomm Rep
        </source>
        <volume>
         55
        </volume>
        <issue>
         RR-15
        </issue>
        <year>
         2006
        </year>
        <fpage>
         1
        </fpage>
        <lpage>
         48
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib9">
       <label>
        2
       </label>
       <element-citation id="sbref9" publication-type="journal">
        <person-group person-group-type="author">
         <collab>
          CDC
         </collab>
        </person-group>
        <article-title>
         Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP)
        </article-title>
        <source>
         MMWR Recomm Rep
        </source>
        <volume>
         57
        </volume>
        <issue>
         RR-7
        </issue>
        <year>
         2008
        </year>
        <fpage>
         1
        </fpage>
        <lpage>
         60
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib10">
       <label>
        3
       </label>
       <element-citation id="sbref10" publication-type="journal">
        <person-group person-group-type="author">
         <collab>
          CDC
         </collab>
        </person-group>
        <article-title>
         Measles, mumps, and rubella—vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps. Recommendations of the Advisory Committee on Immunization Practices (ACIP)
        </article-title>
        <source>
         MMWR Recomm Rep
        </source>
        <volume>
         47
        </volume>
        <issue>
         RR-8
        </issue>
        <year>
         1998
        </year>
        <fpage>
         1
        </fpage>
        <lpage>
         57
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib11">
       <label>
        4
       </label>
       <element-citation id="sbref11" publication-type="journal">
        <person-group person-group-type="author">
         <collab>
          CDC
         </collab>
        </person-group>
        <article-title>
         Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP)
        </article-title>
        <source>
         MMWR Recomm Rep
        </source>
        <volume>
         54
        </volume>
        <issue>
         RR07
        </issue>
        <year>
         2005
        </year>
        <fpage>
         1
        </fpage>
        <lpage>
         21
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib12">
       <label>
        5
       </label>
       <element-citation id="sbref12" publication-type="journal">
        <person-group person-group-type="author">
         <collab>
          CDC
         </collab>
        </person-group>
        <article-title>
         Preventing tetanus, diphtheria, and pertussis among adults: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines. Recommendations of the Advisory Committee on Immunization Practices (ACIP)
        </article-title>
        <source>
         MMWR Recomm Rep
        </source>
        <volume>
         55
        </volume>
        <issue>
         RR 17
        </issue>
        <year>
         2006
        </year>
        <fpage>
         1
        </fpage>
        <lpage>
         59
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib13">
       <label>
        6
       </label>
       <element-citation id="sbref13" publication-type="journal">
        <comment>
        </comment>
        <person-group person-group-type="author">
         <name>
          <surname>
           Plotkin
          </surname>
          <given-names>
           SA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Correlates of vaccine-induced immunity
        </article-title>
        <source>
         Clin Infect Dis
        </source>
        <volume>
         47
        </volume>
        <issue>
         3
        </issue>
        <year>
         2008
        </year>
        <fpage>
         401
        </fpage>
        <lpage>
         409
        </lpage>
        <pub-id pub-id-type="pmid">
         18558875
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib14">
       <label>
        7
       </label>
       <element-citation id="sbref14" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Murphy
          </surname>
          <given-names>
           KR
          </given-names>
         </name>
         <name>
          <surname>
           Strunk
          </surname>
          <given-names>
           RC
          </given-names>
         </name>
        </person-group>
        <article-title>
         Safe administration of influenza vaccine in asthmatic children hypersensitive to egg proteins
        </article-title>
        <source>
         J Pediatr
        </source>
        <volume>
         106
        </volume>
        <issue>
         6
        </issue>
        <year>
         1985
        </year>
        <fpage>
         931
        </fpage>
        <lpage>
         933
        </lpage>
        <pub-id pub-id-type="pmid">
         3998949
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib15">
       <label>
        8
       </label>
       <element-citation id="sbref15" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ball
          </surname>
          <given-names>
           LK
          </given-names>
         </name>
         <name>
          <surname>
           Ball
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Pratt
          </surname>
          <given-names>
           RD
          </given-names>
         </name>
        </person-group>
        <article-title>
         An assessment of thimerosal use in childhood vaccines
        </article-title>
        <source>
         Pediatrics
        </source>
        <volume>
         107
        </volume>
        <issue>
         5
        </issue>
        <year>
         2001
        </year>
        <fpage>
         1147
        </fpage>
        <lpage>
         1154
        </lpage>
        <pub-id pub-id-type="pmid">
         11331700
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib16">
       <label>
        9
       </label>
       <element-citation id="sbref16" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Varricchio
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Iskander
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Destefano
          </surname>
          <given-names>
           F
          </given-names>
         </name>
        </person-group>
        <article-title>
         Understanding vaccine safety information from the Vaccine Adverse Event Reporting System
        </article-title>
        <source>
         Pediatr Infect Dis J
        </source>
        <volume>
         23
        </volume>
        <issue>
         4
        </issue>
        <year>
         2004
        </year>
        <fpage>
         287
        </fpage>
        <lpage>
         294
        </lpage>
        <pub-id pub-id-type="pmid">
         15071280
        </pub-id>
       </element-citation>
      </ref>
     </ref-list>
    </sec>
    <sec id="cesec14">
     <title>
     </title>
     <p id="para205">
      Travel-Related Vaccine-Preventable Diseases
     </p>
    </sec>
    <sec id="subchapter3">
     <sec-meta>
      <contrib-group>
       <contrib contrib-type="author" id="au4">
        <name>
         <surname>
          Wiersma
         </surname>
         <given-names>
          Steven T.
         </given-names>
        </name>
       </contrib>
      </contrib-group>
     </sec-meta>
     <title>
      HEPATITIS A
     </title>
     <sec id="cesec15">
      <title>
       Infectious Agent
      </title>
      <p id="para206">
       Hepatitis A virus (HAV), a 27-nm RNA virus classified as a picornavirus.
      </p>
     </sec>
     <sec id="cesec16">
      <title>
       Mode of Transmission
      </title>
      <p id="para207">
       <list id="celist51" list-type="simple">
        <list-item id="celistitem166">
         <label>
          •
         </label>
         <p id="para208">
          Transmission can occur through direct person-to-person contact; through exposure to contaminated water, ice, or shellfish harvested from sewage-contaminated water; or from fruits, vegetables, or other foods that are eaten uncooked and that were contaminated during harvesting or subsequent handling.
         </p>
        </list-item>
        <list-item id="celistitem167">
         <label>
          •
         </label>
         <p id="para209">
          HAV is shed in the feces of persons with HAV infection. The virus reaches peak levels the week or two before onset of symptoms and diminishes rapidly after liver dysfunction or symptoms appear, which is concurrent with the appearance of circulating antibodies to HAV. Infants and children, however, may shed virus for up to 6 months following infection.
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <sec id="cesec17">
      <title>
       Occurrence
      </title>
      <p id="para210">
       <list id="celist52" list-type="simple">
        <list-item id="celistitem168">
         <label>
          •
         </label>
         <p id="para211">
          Worldwide, geographic areas can be characterized by high, intermediate, or low levels of endemicity (
          <xref ref-type="fig" rid="f4">
           Map 2-1
          </xref>
          ). Levels of endemicity are related to hygienic and sanitary conditions in the geographic areas.
          <fig id="f4">
           <label>
            Map 2-1
           </label>
           <caption>
            <p>
             Prevalence of antibody to hepatitis A virus, 2006.
             <xref ref-type="fn" rid="fn1">
              1
             </xref>
            </p>
           </caption>
           <graphic xlink:href="gr21">
           </graphic>
           <attrib>
            <italic>
             (See
            </italic>
            <xref ref-type="fn" rid="fn1">
             note 1
            </xref>
            <italic>
             on opposite page.)
            </italic>
           </attrib>
          </fig>
         </p>
        </list-item>
        <list-item id="celistitem169">
         <label>
          •
         </label>
         <p id="para212">
          HAV infection is common (high or intermediate endemicity) throughout the developing world, where infections most frequently are acquired during early childhood and usually are asymptomatic or mild.
         </p>
        </list-item>
        <list-item id="celistitem170">
         <label>
          •
         </label>
         <p id="para213">
          In areas of high endemicity, adults are usually immune and epidemics of hepatitis A are uncommon.
         </p>
        </list-item>
        <list-item id="celistitem171">
         <label>
          •
         </label>
         <p id="para214">
          In developed countries, HAV infection is less common (low endemicity), but community-wide outbreaks may occur.
         </p>
        </list-item>
        <list-item id="celistitem172">
         <label>
          •
         </label>
         <p id="para215">
          <xref ref-type="fig" rid="f4">
           Map 2-1
          </xref>
          indicates the seroprevalence of antibody to HAV (total anti-HAV) as measured in selected cross-sectional studies among each country's residents. The seroprevalence of anti-HAV provides an estimate of the endemicity of HAV infections, including asymptomatic infections, within a population.
         </p>
        </list-item>
       </list>
      </p>
      <p id="para216">
       <boxed-text id="cetextbox2">
        <label>
         Box 2-1
        </label>
        <caption>
         <title>
          Hepatitis A pre-travel case study
         </title>
        </caption>
        <p id="para217">
         <bold>
          Case study:
         </bold>
         You are a travel medicine professional preparing a group for travel to an eastern European country that is shown in
         <xref ref-type="fig" rid="f4">
          Maps 2-1
         </xref>
         to have an intermediate prevalence of antibody to hepatitis A virus (anti-HAV). You have recommended that all members of the group take precautions to prevent hepatitis A. The leader of the group questions your advice on the basis of an editorial from a major newspaper written by the ambassador to the U.S. from this country. The editorial claims that her country is stigmatized in the U.S. and cites the example of the Yellow Book, which indicates that travelers from the U.S. to this country are at risk for hepatitis A. The editorial states that cases of hepatitis A are at very low levels in this country and seem to be declining over time. How would you respond to the members of the group?
        </p>
        <sec id="cesec18">
         <title>
          Points to consider in your response:
         </title>
         <p id="para218">
          <list id="celist53" list-type="simple">
           <list-item id="celistitem173">
            <label>
             •
            </label>
            <p id="para219">
             In most intermediate and high anti-HAV-endemic countries, many long-term residents are infected as children, at a time when they may not get symptoms. Cases of hepatitis A in the resident population will be very low; however, travelers from low endemic settings such as the United States are at risk for HAV infection and should be protected.
            </p>
           </list-item>
           <list-item id="celistitem174">
            <label>
             •
            </label>
            <p id="para220">
             The determination of risk is based on CDC estimates of prevalence of anti-HAV, a marker of previous HAV infection. This country-level estimate is based on limited data and might not reflect the current prevalence.
            </p>
           </list-item>
           <list-item id="celistitem175">
            <label>
             •
            </label>
            <p id="para221">
             Prevention of hepatitis A in travelers with vaccination should be used liberally because the vaccine is safe and effective and will give long-term benefits that go beyond the risk posed by any specific trip.
            </p>
           </list-item>
          </list>
         </p>
        </sec>
       </boxed-text>
      </p>
     </sec>
     <sec id="cesec19">
      <title>
       Risk for Travelers
      </title>
      <p id="para222">
       <list id="celist54" list-type="simple">
        <list-item id="celistitem176">
         <label>
          •
         </label>
         <p id="para223">
          Hepatitis A is one of the most common vaccine-preventable infections acquired during travel.
         </p>
        </list-item>
        <list-item id="celistitem177">
         <label>
          •
         </label>
         <p id="para224">
          In 2006 in the United States, among cases for which information regarding exposures during the incubation period was collected, the most frequently identified risk factor for hepatitis A was international travel (reported by 15% of case-patients overall).
         </p>
        </list-item>
        <list-item id="celistitem178">
         <label>
          •
         </label>
         <p id="para225">
          As in previous years, most travel-related cases (72%) were associated with travel to Mexico and Central/South America. As HAV transmission in the United States has decreased, cases among travelers to countries in which hepatitis is endemic have accounted for an increased proportion of all cases.
         </p>
        </list-item>
        <list-item id="celistitem179">
         <label>
          •
         </label>
         <p id="para226">
          The risk of acquiring HAV infection for U.S. residents traveling abroad varies with living conditions, length of stay, and the incidence of HAV infection in the area visited. For travelers to other countries, risk for infection increases with duration of travel and is highest for those who live in or visit rural areas, trek in back-country areas, or frequently eat or drink in settings of poor sanitation.
         </p>
        </list-item>
        <list-item id="celistitem180">
         <label>
          •
         </label>
         <p id="para227">
          Nevertheless, many cases of travel-related hepatitis A occur in travelers to developing countries with “standard” tourist itineraries, accommodations, and food consumption behaviors.
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <sec id="cesec20">
      <title>
       Clinical Presentation
      </title>
      <p id="para228">
       <list id="celist55" list-type="simple">
        <list-item id="celistitem181">
         <label>
          •
         </label>
         <p id="para229">
          HAV infection may be asymptomatic, or its clinical manifestations may range in severity from a mild illness lasting 1–2 weeks to a severely disabling disease lasting several months.
         </p>
        </list-item>
        <list-item id="celistitem182">
         <label>
          •
         </label>
         <p id="para230">
          Clinical manifestations of hepatitis A often include the abrupt onset of fever, malaise, anorexia, nausea, and abdominal discomfort, followed within a few days by jaundice.
         </p>
        </list-item>
        <list-item id="celistitem183">
         <label>
          •
         </label>
         <p id="para231">
          The incubation period for hepatitis A averages 28 days (range: 15–50 days).
         </p>
        </list-item>
        <list-item id="celistitem184">
         <label>
          •
         </label>
         <p id="para232">
          The likelihood of having symptoms with HAV infection is related to the infected person's age. In children &lt;6 years of age, most (70%) infections are asymptomatic; if illness does occur, its duration is usually less than 2 months.
         </p>
        </list-item>
        <list-item id="celistitem185">
         <label>
          •
         </label>
         <p id="para233">
          No chronic or long-term infection is associated with hepatitis A, but 10% of infected persons will have prolonged or relapsing symptoms over a 6- to 9-month period.
         </p>
        </list-item>
        <list-item id="celistitem186">
         <label>
          •
         </label>
         <p id="para234">
          The overall case–fatality rate among cases reported to CDC is 0.3%; however, the rate is 1.8% among adults &gt;50 years of age.
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <sec id="cesec21">
      <title>
       Diagnosis
      </title>
      <p id="para235">
       <list id="celist56" list-type="simple">
        <list-item id="celistitem187">
         <label>
          •
         </label>
         <p id="para236">
          Demonstration of IgM antibodies against hepatitis A virus (IgM anti-HAV) in the serum of acutely or recently ill patients establishes the diagnosis.
         </p>
        </list-item>
        <list-item id="celistitem188">
         <label>
          •
         </label>
         <p id="para237">
          IgM anti-HAV becomes detectable 5–10 days after exposure. A fourfold or greater rise in specific antibodies in paired sera, detected by commercially available EIA, also establishes the diagnosis.
         </p>
        </list-item>
        <list-item id="celistitem189">
         <label>
          •
         </label>
         <p id="para238">
          If laboratory tests are not available, epidemiologic evidence may provide support for the diagnosis in a clinically compatible case.
         </p>
        </list-item>
        <list-item id="celistitem190">
         <label>
          •
         </label>
         <p id="para239">
          HAV RNA can be detected in blood and stools of most persons during the acute phase of infection through nucleic acid amplification methods, but these are not generally used for diagnostic purposes.
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <sec id="cesec22">
      <title>
       Treatment
      </title>
      <p id="para240">
       No specific treatment is available for persons with hepatitis A. Treatment is supportive.
      </p>
     </sec>
     <sec id="cesec23">
      <title>
       Preventive Measures for Travelers
      </title>
      <p id="para241">
       <boxed-text id="cetextbox3">
        <p id="para242">
         Health-care providers should administer hepatitis A vaccination for persons traveling for any purpose, frequency, or duration to countries that have high or intermediate endemicity of HAV infection. Providers may also consider its administration to persons for travel to any destination.
        </p>
       </boxed-text>
      </p>
      <sec id="cesec24">
       <title>
        Vaccine and Immune Globulin
       </title>
       <sec id="cesec25">
        <title>
         Monovalent Vaccines
        </title>
        <p id="para243">
         <list id="celist57" list-type="simple">
          <list-item id="celistitem191">
           <label>
            •
           </label>
           <p id="para244">
            Two monovalent hepatitis A vaccines are currently licensed in the United States for persons at least 12 months of age:
            <list id="celist58" list-type="simple">
             <list-item id="celistitem192">
              <label>
               ○
              </label>
              <p id="para245">
               HAVRIX, manufactured by GlaxoSmithKline (
               <xref ref-type="table" rid="cetable4">
                Table 2-4
               </xref>
               ), and
              </p>
             </list-item>
             <list-item id="celistitem193">
              <label>
               ○
              </label>
              <p id="para246">
               VAQTA manufactured by Merck &amp; Co., Inc. (
               <xref ref-type="table" rid="cetable5">
                Table 2-5
               </xref>
               ).
              </p>
             </list-item>
            </list>
           </p>
          </list-item>
          <list-item id="celistitem194">
           <label>
            •
           </label>
           <p id="para247">
            Both vaccines are made of inactivated HAV adsorbed to aluminum hydroxide as an adjuvant. HAVRIX is prepared with 2-phenoxyethanol as a preservative, while VAQTA is formulated without a preservative.
           </p>
          </list-item>
          <list-item id="celistitem195">
           <label>
            •
           </label>
           <p id="para248">
            All hepatitis A vaccines should be administered intramuscularly in the deltoid muscle.
           </p>
          </list-item>
         </list>
        </p>
       </sec>
       <sec id="cesec26">
        <title>
         Combination Vaccine
        </title>
        <p id="para249">
         <list id="celist59" list-type="simple">
          <list-item id="celistitem196">
           <label>
            •
           </label>
           <p id="para250">
            TWINRIX, manufactured by GlaxoSmithKline, is a combined hepatitis A and hepatitis B vaccine licensed for persons Δ18 years of age, containing 720 EL.U. of hepatitis A antigen (50% of the HAVRIX adult dose) and 20 mg of recombinant hepatitis B surface antigen protein (the same as the ENGERIX-B adult dose) (
            <xref ref-type="table" rid="cetable6">
             Table 2-6
            </xref>
            ).
           </p>
          </list-item>
          <list-item id="celistitem197">
           <label>
            •
           </label>
           <p id="para251">
            Primary immunization consists of three doses, given on a 0-, 1-, and 6-month schedule, the same schedule as that commonly used for monovalent hepatitis B vaccine.
           </p>
          </list-item>
          <list-item id="celistitem198">
           <label>
            •
           </label>
           <p id="para252">
            TWINRIX contains aluminum phosphate and aluminum hydroxide as adjuvants and 2-phenoxyethanol as a preservative.
           </p>
          </list-item>
          <list-item id="celistitem199">
           <label>
            •
           </label>
           <p id="para253">
            An accelerated schedule of TWINRIX (i.e., doses at days 0, 7, and 21) for travelers has been approved by the FDA. A booster dose should be given at 1 year.
           </p>
          </list-item>
          <list-item id="celistitem200">
           <label>
            •
           </label>
           <p id="para254">
            The immunogenicity of TWINRIX is equivalent to that of the monovalent hepatitis vaccines when tested after completion of the licensed schedule.
           </p>
          </list-item>
         </list>
        </p>
       </sec>
       <sec id="cesec27">
        <title>
         Vaccination of Travelers
        </title>
        <p id="para255">
         <list id="celist60" list-type="simple">
          <list-item id="celistitem201">
           <label>
            •
           </label>
           <p id="para256">
            All susceptible persons traveling to or working in countries that have high or intermediate hepatitis A endemicity should be vaccinated or receive IG before departure. Hepatitis A vaccine at the age-appropriate dose is preferred to IG. The first dose of hepatitis A vaccine should be administered as soon as travel to countries with high or intermediate endemicity is considered.
           </p>
          </list-item>
          <list-item id="celistitem202">
           <label>
            •
           </label>
           <p id="para257">
            One dose of monovalent hepatitis A vaccine administered at any time before departure can provide adequate protection for most healthy persons &lt;40 years of age.
           </p>
          </list-item>
          <list-item id="celistitem203">
           <label>
            •
           </label>
           <p id="para258">
            Completion of the vaccine series according to the licensed schedule is necessary for long-term protection.
           </p>
          </list-item>
          <list-item id="celistitem204">
           <label>
            •
           </label>
           <p id="para259">
            Many persons will have detectable anti-HAV in response to the monovalent vaccine by 2 weeks after the first vaccine dose. The proportion of persons who develop a detectable antibody response at 2 weeks may be lower when smaller vaccine dosages are used, such as with the use of TWINRIX.
           </p>
          </list-item>
          <list-item id="celistitem205">
           <label>
            •
           </label>
           <p id="para260">
            For optimal protection, older adults, immunocompromised persons, and persons with chronic liver disease or other chronic medical conditions planning to depart to an area in &lt;2 weeks should receive the initial dose of vaccine along with IG (0.02 mL/kg) at a separate anatomic injection site.
           </p>
          </list-item>
          <list-item id="celistitem206">
           <label>
            •
           </label>
           <p id="para261">
            Travelers who receive hepatitis A vaccine less than 2 weeks before traveling to an endemic area and who do not receive IG (either by choice or because of lack of availability) will be at lower risk for infection than those who do not receive hepatitis A vaccine or IG.
           </p>
          </list-item>
          <list-item id="celistitem207">
           <label>
            •
           </label>
           <p id="para262">
            Although vaccination of an immune traveler is not contraindicated and does not increase the risk for adverse effects, screening for total anti-HAV before travel can be useful in some circumstances to determine susceptibility and eliminate unnecessary vaccination or IG prophylaxis of immune travelers. Such serologic screening for susceptibility might be indicated for adult travelers who are &gt;40 years of age and those born in areas of the world with intermediate or high endemicity who are likely to have had prior HAV infection, if the cost of screening (laboratory and office visit) is less than the cost of vaccination or IG prophylaxis and if testing will not delay vaccination and interfere with timely receipt of vaccine or IG before travel. Postvaccination testing for serologic response is not indicated.
           </p>
          </list-item>
          <list-item id="celistitem208">
           <label>
            •
           </label>
           <p id="para263">
            Travelers who are &lt;12 months of age, are allergic to a vaccine component, or who otherwise elect not to receive vaccine should receive a single dose of IG (0.02 mL/kg), which provides effective protection against HAV infection for up to 3 months (
            <xref ref-type="table" rid="cetable7">
             Table 2-7
            </xref>
            ).
           </p>
          </list-item>
          <list-item id="celistitem209">
           <label>
            •
           </label>
           <p id="para264">
            Those who do not receive vaccination and plan to travel for &gt;3 months should receive an IG dose of 0.06 mL/kg, which must be repeated if the duration of travel is &gt;5 months.
           </p>
          </list-item>
          <list-item id="celistitem210">
           <label>
            •
           </label>
           <p id="para265">
            In addition, health-care providers should be alert to opportunities to provide vaccination for all travelers whose plans might include travel at some time in the future to an area of high or intermediate endemicity, including those whose current medical evaluation is for travel to an area where hepatitis A vaccination is not currently recommended.
           </p>
          </list-item>
          <list-item id="celistitem211">
           <label>
            •
           </label>
           <p id="para266">
            Those who refuse vaccine and IG should be advised to closely adhere to prevention tips listed below.
           </p>
          </list-item>
         </list>
        </p>
       </sec>
       <sec id="cesec28">
        <title>
         Other Vaccine Considerations
        </title>
        <p id="para267">
         <list id="celist61" list-type="simple">
          <list-item id="celistitem212">
           <label>
            •
           </label>
           <p id="para268">
            Using the vaccines according to the licensed schedules is preferable. However, an interrupted series does not need to be restarted.
           </p>
          </list-item>
          <list-item id="celistitem213">
           <label>
            •
           </label>
           <p id="para269">
            Given their similar immunogenicity, a series that has been started with one brand of monovalent vaccine (i.e., HAVRIX or VAQTA) may be completed with the other brand.
           </p>
          </list-item>
          <list-item id="celistitem214">
           <label>
            •
           </label>
           <p id="para270">
            Hepatitis A vaccine may be administered at the same time as IG or other commonly used vaccines for travelers, at different injection sites.
           </p>
          </list-item>
          <list-item id="celistitem215">
           <label>
            •
           </label>
           <p id="para271">
            In adults and children who have completed the vaccine series, anti-HAV has been shown to persist for at least 5–12 years after vaccination. Results of mathematical models indicate that, after completion of the vaccination series, anti-HAV will likely persist for 20 years or more. For children and adults who complete the primary series, booster doses of vaccine are not recommended.
           </p>
          </list-item>
         </list>
        </p>
       </sec>
       <sec id="cesec29">
        <title>
         Vaccine Safety and Adverse Reactions
        </title>
        <p id="para272">
         <list id="celist62" list-type="simple">
          <list-item id="celistitem216">
           <label>
            •
           </label>
           <p id="para273">
            Among adults, the most frequently reported side effects occurring 3–5 days after a vaccine dose are tenderness or pain at the injection site (53%–56%) or headache (14%–16%).
           </p>
          </list-item>
          <list-item id="celistitem217">
           <label>
            •
           </label>
           <p id="para274">
            Among children, the most common side effects reported are pain or tenderness at the injection site (15%–19%), feeding problems (8% in one study), or headache (4% in one study).
           </p>
          </list-item>
          <list-item id="celistitem218">
           <label>
            •
           </label>
           <p id="para275">
            No serious adverse events in children or adults that could be definitively attributed to the vaccine or to increases in serious adverse events among vaccinated persons compared with baseline rates have been identified.
           </p>
          </list-item>
          <list-item id="celistitem219">
           <label>
            •
           </label>
           <p id="para276">
            IG for intramuscular administration prepared in the United States has few side effects (primarily soreness at the injection site) and has never been shown to transmit infectious agents (hepatitis B virus, hepatitis C virus [HCV], or HIV).
           </p>
          </list-item>
          <list-item id="celistitem220">
           <label>
            •
           </label>
           <p id="para277">
            Since December 1994, all IG products commercially available in the United States have had to undergo a viral inactivation procedure or be negative for HCV RNA before release.
           </p>
          </list-item>
         </list>
        </p>
       </sec>
       <sec id="cesec30">
        <title>
         Precautions and Contraindications
        </title>
        <p id="para278">
         <list id="celist63" list-type="simple">
          <list-item id="celistitem221">
           <label>
            •
           </label>
           <p id="para279">
            These vaccines should not be administered to travelers with a history of hypersensitivity to any vaccine component.
           </p>
          </list-item>
          <list-item id="celistitem222">
           <label>
            •
           </label>
           <p id="para280">
            HAVRIX or TWINRIX should not be administered to travelers with a history of hypersensitivity reactions to the preservative 2-phenoxyethanol.
           </p>
          </list-item>
          <list-item id="celistitem223">
           <label>
            •
           </label>
           <p id="para281">
            TWINRIX should not be administered to persons with a history of hypersensitivity to yeast.
           </p>
          </list-item>
          <list-item id="celistitem224">
           <label>
            •
           </label>
           <p id="para282">
            Because hepatitis A vaccine consists of inactivated virus and hepatitis B vaccine consists of a recombinant protein, no special precautions need to be taken for vaccination of immunocompromised travelers.
           </p>
          </list-item>
         </list>
        </p>
       </sec>
       <sec id="cesec31">
        <title>
         Pregnancy
        </title>
        <p id="para283">
         <list id="celist64" list-type="simple">
          <list-item id="celistitem225">
           <label>
            •
           </label>
           <p id="para284">
            The safety of hepatitis A vaccine for pregnant women has not been determined.
           </p>
          </list-item>
          <list-item id="celistitem226">
           <label>
            •
           </label>
           <p id="para285">
            However, because hepatitis A vaccine is produced from inactivated HAV, the theoretical risk to either the pregnant woman or the developing fetus is thought to be very low.
           </p>
          </list-item>
          <list-item id="celistitem227">
           <label>
            •
           </label>
           <p id="para286">
            The risk of vaccination should be weighed against the risk of hepatitis A in female travelers who might be at high risk for exposure to HAV.
           </p>
          </list-item>
          <list-item id="celistitem228">
           <label>
            •
           </label>
           <p id="para287">
            Pregnancy is not a contraindication to using IG.
           </p>
          </list-item>
         </list>
        </p>
       </sec>
      </sec>
      <sec id="cesec32">
       <title>
        Other Prevention Tips
       </title>
       <p id="para288">
        <list id="celist65" list-type="simple">
         <list-item id="celistitem229">
          <label>
           •
          </label>
          <p id="para289">
           Boiling or cooking food and beverage items for at least 1 minute to 185° F (85° C) inactivates HAV. Foods and beverages heated to this temperature and for this length of time cannot serve as vehicles for HAV infection unless they become contaminated after heating.
          </p>
         </list-item>
         <list-item id="celistitem230">
          <label>
           •
          </label>
          <p id="para290">
           Adequate chlorination of water as recommended in the United States will inactivate HAV.
          </p>
         </list-item>
         <list-item id="celistitem231">
          <label>
           •
          </label>
          <p id="para291">
           Travelers should be advised that, to minimize their risk of hepatitis A and other enteric diseases in developing countries, they should avoid potentially contaminated water or food.
          </p>
         </list-item>
         <list-item id="celistitem232">
          <label>
           •
          </label>
          <p id="para292">
           Travelers should also be advised to avoid drinking beverages (with or without ice) of unknown purity, eating uncooked shellfish, and eating uncooked fruits or vegetables that are not peeled or prepared by the traveler personally.
          </p>
         </list-item>
        </list>
       </p>
      </sec>
     </sec>
     <ref-list id="cebib3">
      <title>
       References
      </title>
      <ref id="bib17">
       <label>
        1
       </label>
       <element-citation id="sbref17" publication-type="journal">
        <person-group person-group-type="author">
         <collab>
          CDC
         </collab>
        </person-group>
        <article-title>
         Prevention of hepatitis A through active or passive immunization: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
        </article-title>
        <source>
         MMWR Recomm Rep
        </source>
        <volume>
         55
        </volume>
        <issue>
         RR07
        </issue>
        <year>
         2006
        </year>
        <fpage>
         1
        </fpage>
        <lpage>
         23
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib18">
       <label>
        2
       </label>
       <element-citation id="sbref18" publication-type="journal">
        <person-group person-group-type="author">
         <collab>
          CDC
         </collab>
        </person-group>
        <article-title>
         Update: Prevention of hepatitis A after exposure to hepatitis A virus and in international travelers. Updated Recommendations of the Advisory Committee on Immunization Practices (ACIP)
        </article-title>
        <source>
         MMWR Morbid Mortal Wkly Rep
        </source>
        <volume>
         56
        </volume>
        <issue>
         41
        </issue>
        <year>
         2007
        </year>
        <fpage>
         1080
        </fpage>
        <lpage>
         1084
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib19">
       <label>
        3
       </label>
       <element-citation id="sbref19" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bell
          </surname>
          <given-names>
           BP
          </given-names>
         </name>
         <name>
          <surname>
           Feinstone
          </surname>
          <given-names>
           SM
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         Hepatitis A vaccine
        </chapter-title>
        <person-group person-group-type="editor">
         <name>
          <surname>
           Plotkin
          </surname>
          <given-names>
           SA
          </given-names>
         </name>
         <name>
          <surname>
           Orenstein
          </surname>
          <given-names>
           WA
          </given-names>
         </name>
        </person-group>
        <source>
         Vaccines
        </source>
        <edition>
         4th ed.
        </edition>
        <year>
         2004
        </year>
        <publisher-name>
         W.B. Saunders
        </publisher-name>
        <publisher-loc>
         Philadelphia
        </publisher-loc>
        <fpage>
         269
        </fpage>
        <lpage>
         297
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib20">
       <label>
        4
       </label>
       <element-citation id="sbref20" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Mutsch
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Spicher
          </surname>
          <given-names>
           VM
          </given-names>
         </name>
         <name>
          <surname>
           Gut
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Steffen
          </surname>
          <given-names>
           R
          </given-names>
         </name>
        </person-group>
        <article-title>
         Hepatitis A virus infections in travelers, 1988–2004
        </article-title>
        <source>
         Clin Infect Dis
        </source>
        <volume>
         42
        </volume>
        <issue>
         4
        </issue>
        <year>
         2006
        </year>
        <fpage>
         490
        </fpage>
        <lpage>
         497
        </lpage>
        <pub-id pub-id-type="pmid">
         16421793
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib21">
       <label>
        5
       </label>
       <element-citation id="sbref21" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bacaner
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Stauffer
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Boulware
          </surname>
          <given-names>
           DR
          </given-names>
         </name>
        </person-group>
        <article-title>
         Travel medicine considerations for North American immigrants visiting friends and relatives
        </article-title>
        <source>
         JAMA
        </source>
        <volume>
         291
        </volume>
        <issue>
         23
        </issue>
        <year>
         2004
        </year>
        <fpage>
         2856
        </fpage>
        <lpage>
         2864
        </lpage>
        <pub-id pub-id-type="pmid">
         15199037
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib22">
       <label>
        6
       </label>
       <element-citation id="sbref22" publication-type="journal">
        <comment>
        </comment>
        <person-group person-group-type="author">
         <collab>
          CDC
         </collab>
        </person-group>
        <article-title>
         Surveillance for acute viral hepatitis – United States, 2006
        </article-title>
        <source>
         MMWR Surv Summ
        </source>
        <volume>
         57
        </volume>
        <issue>
         SS02
        </issue>
        <year>
         2008
        </year>
        <fpage>
         1
        </fpage>
        <lpage>
         24
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib23">
       <label>
        7
       </label>
       <element-citation id="sbref23" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Van Damme
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Banatvala
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Fay
          </surname>
          <given-names>
           O
          </given-names>
         </name>
        </person-group>
        <article-title>
         Hepatitis A booster vaccination: is there a need?
        </article-title>
        <source>
         Lancet
        </source>
        <volume>
         362
        </volume>
        <issue>
         9389
        </issue>
        <year>
         2003
        </year>
        <fpage>
         1065
        </fpage>
        <lpage>
         1071
        </lpage>
        <pub-id pub-id-type="pmid">
         14522539
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib24">
       <label>
        8
       </label>
       <element-citation id="sbref24" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Winokur
          </surname>
          <given-names>
           PL
          </given-names>
         </name>
         <name>
          <surname>
           Stapleton
          </surname>
          <given-names>
           JT
          </given-names>
         </name>
        </person-group>
        <article-title>
         Immunoglobulin prophylaxis for hepatitis A
        </article-title>
        <source>
         Clin Infect Dis
        </source>
        <volume>
         14
        </volume>
        <issue>
         2
        </issue>
        <year>
         1992
        </year>
        <fpage>
         580
        </fpage>
        <lpage>
         586
        </lpage>
        <pub-id pub-id-type="pmid">
         1554845
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib25">
       <label>
        9
       </label>
       <element-citation id="sbref25" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Fiore
          </surname>
          <given-names>
           AE
          </given-names>
         </name>
        </person-group>
        <article-title>
         Hepatitis A transmitted by food
        </article-title>
        <source>
         Clin Infect Dis
        </source>
        <volume>
         38
        </volume>
        <issue>
         5
        </issue>
        <year>
         2004
        </year>
        <fpage>
         705
        </fpage>
        <lpage>
         715
        </lpage>
        <pub-id pub-id-type="pmid">
         14986256
        </pub-id>
       </element-citation>
      </ref>
     </ref-list>
    </sec>
    <sec id="subchapter4">
     <sec-meta>
      <contrib-group>
       <contrib contrib-type="author" id="au5">
        <name>
         <surname>
          Chaves
         </surname>
         <given-names>
          Sandra S.
         </given-names>
        </name>
       </contrib>
      </contrib-group>
     </sec-meta>
     <title>
      HEPATITIS B
     </title>
     <sec id="cesec33">
      <title>
       Infectious Agent
      </title>
      <p id="para293">
       Hepatitis B is caused by the hepatitis B virus (HBV), a small, circular, partially double-stranded DNA molecule in the
       <italic>
        Hepadnaviridae
       </italic>
       family.
      </p>
     </sec>
     <sec id="cesec34">
      <title>
       Mode of Transmission
      </title>
      <p id="para294">
       HBV is transmitted through activities that involve contact with blood or blood-derived fluids. Such activities include the following:
       <list id="celist66" list-type="simple">
        <list-item id="celistitem233">
         <label>
          •
         </label>
         <p id="para296">
          Unprotected sex with an HBV-infected partner
         </p>
        </list-item>
        <list-item id="celistitem234">
         <label>
          •
         </label>
         <p id="para297">
          Shared needles used for injection of illegal drugs
         </p>
        </list-item>
        <list-item id="celistitem235">
         <label>
          •
         </label>
         <p id="para298">
          Shared glucose-monitoring equipment
         </p>
        </list-item>
        <list-item id="celistitem236">
         <label>
          •
         </label>
         <p id="para299">
          Work in health-care fields (e.g., medical, dental, laboratory) that entails direct exposure to potentially infected human blood
         </p>
        </list-item>
        <list-item id="celistitem237">
         <label>
          •
         </label>
         <p id="para300">
          Transfusions with blood or blood products that have not been screened for HBV
         </p>
        </list-item>
        <list-item id="celistitem238">
         <label>
          •
         </label>
         <p id="para301">
          Dental, medical, or cosmetic (e.g., tattooing, body piercing) procedures with needles or other equipment that are contaminated with HBV
         </p>
        </list-item>
       </list>
      </p>
      <p id="para302">
       In addition, open skin lesions, such as those due to impetigo, scabies, or scratched insect bites, can play a role in HBV transmission if direct exposure to wound exudates from HBV-infected persons occurs.
      </p>
     </sec>
     <sec id="cesec35">
      <title>
       Occurrence
      </title>
      <p id="para303">
       <list id="celist67" list-type="simple">
        <list-item id="celistitem239">
         <label>
          •
         </label>
         <p id="para304">
          The prevalence of chronic HBV infection is low (&lt;2%) in the general population in Northern and Western Europe, North America, Australia, New Zealand, Mexico, and southern South America (
          <xref ref-type="fig" rid="f5">
           Map 2-2
          </xref>
          ).
          <fig id="f5">
           <label>
            Map 2-2
           </label>
           <caption>
            <p>
             Prevalence of chronic infection with hepatitis B virus, 2006.
            </p>
           </caption>
           <graphic xlink:href="gr22">
           </graphic>
          </fig>
         </p>
        </list-item>
        <list-item id="celistitem240">
         <label>
          •
         </label>
         <p id="para305">
          The prevalence of chronic HBV infection is intermediate (2%–7%) in South, Central, and Southwest Asia, Israel, Japan, Eastern and Southern Europe, Russia, most areas surrounding the Amazon River basin, Honduras, and Guatemala (see
          <xref ref-type="fig" rid="f5">
           Maps 2-2
          </xref>
          ).
         </p>
        </list-item>
        <list-item id="celistitem241">
         <label>
          •
         </label>
         <p id="para306">
          The prevalence of chronic HBV infection is high (Δ8%) in all socioeconomic groups in: all of Africa; Southeast Asia, including China, Korea, Indonesia, and the Philippines; the Middle East, except Israel; South and Western Pacific islands; the interior Amazon River basin; and certain parts of the Caribbean (Haiti and the Dominican Republic) (see
          <xref ref-type="fig" rid="f5">
           Maps 2-2
          </xref>
          ).
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <sec id="cesec36">
      <title>
       Risk for Travelers
      </title>
      <p id="para307">
       There are no data with which to assess the risk for HBV infection among U.S. travelers. The risk for HBV infection for international travelers is considered generally low, except for travelers to countries where the prevalence of chronic HBV infection is intermediate or high. Some travelers, such as adventure travelers, Peace Corps volunteers, missionaries, and military personnel, may be at increased risk for infection.
      </p>
      <p id="para308">
       Situations or activities that may carry increased risk for HBV infection for travelers while overseas include the following:
       <list id="celist68" list-type="simple">
        <list-item id="celistitem242">
         <label>
          •
         </label>
         <p id="para310">
          An injury or illness that requires invasive medical attention (e.g., injection, IV drip, transfusion, stitching)
         </p>
        </list-item>
        <list-item id="celistitem243">
         <label>
          •
         </label>
         <p id="para311">
          Dental treatment
         </p>
        </list-item>
        <list-item id="celistitem244">
         <label>
          •
         </label>
         <p id="para312">
          Unprotected sexual contact
         </p>
        </list-item>
        <list-item id="celistitem245">
         <label>
          •
         </label>
         <p id="para313">
          Sharing illegal drug injection equipment
         </p>
        </list-item>
        <list-item id="celistitem246">
         <label>
          •
         </label>
         <p id="para314">
          Skin-perforation practices (e.g., tattooing, ear piercing, acupuncture)
         </p>
        </list-item>
        <list-item id="celistitem247">
         <label>
          •
         </label>
         <p id="para315">
          Cosmetic practices with risk for skin perforation (e.g., manicure/pedicure)
         </p>
        </list-item>
        <list-item id="celistitem248">
         <label>
          •
         </label>
         <p id="para316">
          Sharing personal grooming items (e.g., earrings, toothbrush, razor)
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <sec id="cesec37">
      <title>
       Clinical Presentation
      </title>
      <p id="para317">
       <list id="celist69" list-type="simple">
        <list-item id="celistitem249">
         <label>
          •
         </label>
         <p id="para318">
          Incubation period of hepatitis B is typically 90 days (range: 60–150 days) from exposure to onset of jaundice.
         </p>
        </list-item>
        <list-item id="celistitem250">
         <label>
          •
         </label>
         <p id="para319">
          Constitutional symptoms such as malaise and anorexia may precede jaundice by 1–2 weeks.
         </p>
        </list-item>
        <list-item id="celistitem251">
         <label>
          •
         </label>
         <p id="para320">
          Clinical symptoms and signs include nausea, vomiting, abdominal pain, and jaundice.
         </p>
        </list-item>
        <list-item id="celistitem252">
         <label>
          •
         </label>
         <p id="para321">
          Skin rashes, joint pain, and arthritis may occur.
         </p>
        </list-item>
        <list-item id="celistitem253">
         <label>
          •
         </label>
         <p id="para322">
          Infants, children &lt;5 years of age, and immunosuppressed adults with newly acquired HBV infection typically are asymptomatic.
         </p>
        </list-item>
        <list-item id="celistitem254">
         <label>
          •
         </label>
         <p id="para323">
          Infected persons Δ5 years of age, including immunocompetant adults, 30%–50% have initial clinical signs or symptoms.
         </p>
        </list-item>
        <list-item id="celistitem255">
         <label>
          •
         </label>
         <p id="para324">
          The case–fatality rate of acute hepatitis B is approximately 1%.
         </p>
        </list-item>
        <list-item id="celistitem256">
         <label>
          •
         </label>
         <p id="para325">
          Acute HBV infection causes chronic (long-term) infection in 30%–90% of persons infected as infants or young children and in &lt;5% of adolescents and adults.
         </p>
        </list-item>
        <list-item id="celistitem257">
         <label>
          •
         </label>
         <p id="para326">
          Chronic infection can lead to chronic liver disease, liver scarring (cirrhosis), and liver cancer.
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <sec id="cesec38">
      <title>
       Diagnosis
      </title>
      <p id="para327">
       At least one serologic marker is present during each of the different phases of HBV infection. The serologic markers are typically used to differentiate between acute, resolving, and chronic infection (
       <xref ref-type="table" rid="cetable8">
        Table 2-8
       </xref>
       ).
       <table-wrap id="cetable8" position="float">
        <label>
         Table 2-8
        </label>
        <caption>
         <p>
          Typical interpretation of serologic test results for hepatitis B virus infection
         </p>
        </caption>
        <table frame="hsides" rules="groups">
         <thead>
          <tr>
           <th align="left" colspan="2">
            Serologic Marker
            <hr/>
           </th>
           <th>
            <hr/>
           </th>
           <th>
            <hr/>
           </th>
           <th align="left">
            Interpretation
            <hr/>
           </th>
          </tr>
          <tr>
           <th align="left">
            HBsAg
            <xref ref-type="table-fn" rid="cetablefn34">
             1
            </xref>
           </th>
           <th align="left">
            Total anti-HBc
            <xref ref-type="table-fn" rid="cetablefn35">
             2
            </xref>
           </th>
           <th align="left">
            IgM
            <xref ref-type="table-fn" rid="cetablefn36">
             3
            </xref>
            anti-HBc
           </th>
           <th align="left">
            Anti-HBs
            <xref ref-type="table-fn" rid="cetablefn37">
             4
            </xref>
           </th>
           <th>
           </th>
          </tr>
         </thead>
         <tbody>
          <tr>
           <td align="left">
            –
            <xref ref-type="table-fn" rid="cetablefn38">
             5
            </xref>
           </td>
           <td align="left">
            –
           </td>
           <td align="left">
            –
           </td>
           <td align="left">
            –
           </td>
           <td align="left">
            Never infected
           </td>
          </tr>
          <tr>
           <td align="left">
            +
            <xref ref-type="table-fn" rid="cetablefn39">
             6
            </xref>
            ,
            <xref ref-type="table-fn" rid="cetablefn40">
             7
            </xref>
           </td>
           <td align="left">
            –
           </td>
           <td align="left">
            –
           </td>
           <td align="left">
            –
           </td>
           <td align="left">
            Early acute infection; transient (up to 18 days) after vaccination
           </td>
          </tr>
          <tr>
           <td align="left">
            +
           </td>
           <td align="left">
            +
           </td>
           <td align="left">
            +
           </td>
           <td align="left">
            –
           </td>
           <td align="left">
            Acute infection
           </td>
          </tr>
          <tr>
           <td align="left">
            –
           </td>
           <td align="left">
            +
           </td>
           <td align="left">
            +
           </td>
           <td align="left">
            + or −
           </td>
           <td align="left">
            Acute resolving infection
           </td>
          </tr>
          <tr>
           <td align="left">
            –
           </td>
           <td align="left">
            +
           </td>
           <td align="left">
            –
           </td>
           <td align="left">
            +
           </td>
           <td align="left">
            Recovered from past infection and immune
           </td>
          </tr>
          <tr>
           <td align="left">
            +
           </td>
           <td align="left">
            +
           </td>
           <td align="left">
            –
           </td>
           <td align="left">
            –
           </td>
           <td align="left">
            Chronic infection
           </td>
          </tr>
          <tr>
           <td align="left">
            –
           </td>
           <td align="left">
            +
           </td>
           <td align="left">
            –
           </td>
           <td align="left">
            –
           </td>
           <td align="left">
            False-positive (i.e., susceptible); past infection; “low-level” chronic infection;
            <xref ref-type="table-fn" rid="cetablefn41">
             8
            </xref>
            or passive transfer of anti-HBc to infant born to HBsAg-positive mother
           </td>
          </tr>
          <tr>
           <td align="left">
            –
           </td>
           <td align="left">
            –
           </td>
           <td align="left">
            –
           </td>
           <td align="left">
            +
           </td>
           <td align="left">
            Immune if concentration is ≥10 mIU/mL after vaccine series completion;
            <xref ref-type="table-fn" rid="cetablefn42">
             9
            </xref>
            passive transfer after hepatitis B immune globulin administration
           </td>
          </tr>
         </tbody>
        </table>
        <table-wrap-foot>
         <fn id="cetablefn34">
          <label>
           1
          </label>
          <p id="cenotep34">
           Hepatitis B surface antigen.
          </p>
         </fn>
        </table-wrap-foot>
        <table-wrap-foot>
         <fn id="cetablefn35">
          <label>
           2
          </label>
          <p id="cenotep35">
           IgG antibody to hepatitis B core antigen.
          </p>
         </fn>
        </table-wrap-foot>
        <table-wrap-foot>
         <fn id="cetablefn36">
          <label>
           3
          </label>
          <p id="cenotep36">
           Immunoglobulin M.
          </p>
         </fn>
        </table-wrap-foot>
        <table-wrap-foot>
         <fn id="cetablefn37">
          <label>
           4
          </label>
          <p id="cenotep37">
           Antibody to HBsAg.
          </p>
         </fn>
        </table-wrap-foot>
        <table-wrap-foot>
         <fn id="cetablefn38">
          <label>
           5
          </label>
          <p id="cenotep38">
           Negative test result.
          </p>
         </fn>
        </table-wrap-foot>
        <table-wrap-foot>
         <fn id="cetablefn39">
          <label>
           6
          </label>
          <p id="cenotep39">
           Positive test result.
          </p>
         </fn>
        </table-wrap-foot>
        <table-wrap-foot>
         <fn id="cetablefn40">
          <label>
           7
          </label>
          <p id="cenotep40">
           To ensure that an HBsAg-positive test result is not a false-positive, samples with reactive HBsAg results should be tested with a licensed neutralizing confirmatory test if recommended in the manufacturer's package insert.
          </p>
         </fn>
        </table-wrap-foot>
        <table-wrap-foot>
         <fn id="cetablefn41">
          <label>
           8
          </label>
          <p id="cenotep41">
           Persons positive only for anti-HBc are unlikely to be infectious except under unusual circumstances in which they are the source for direct percutaneous exposure of susceptible recipients to large quantities of virus (e.g., blood transfusion or organ transplant).
          </p>
         </fn>
        </table-wrap-foot>
        <table-wrap-foot>
         <fn id="cetablefn42">
          <label>
           9
          </label>
          <p id="cenotep42">
           Milli-international units per milliliter.
          </p>
         </fn>
        </table-wrap-foot>
        <attrib>
         From CDC. MMWR Recomm Rep. 2006; 55(RR-16):1–25.
        </attrib>
       </table-wrap>
      </p>
     </sec>
     <sec id="cesec39">
      <title>
       Treatment
      </title>
      <p id="para328">
       No specific treatment is available for acute illness caused by hepatitis B. Antiviral drugs are approved for the treatment of chronic hepatitis B.
      </p>
     </sec>
     <sec id="cesec40">
      <title>
       Preventive Measures for Travelers
      </title>
      <sec id="cesec41">
       <title>
        Vaccine
       </title>
       <p id="para329">
        <list id="celist70" list-type="simple">
         <list-item id="celistitem258">
          <label>
           •
          </label>
          <p id="para330">
           Hepatitis B vaccination should be administered to all unvaccinated persons traveling to areas with intermediate to high levels of endemic HBV transmission (i.e., with hepatitis B surface antigen [HBsAg] prevalence Δ2%).
          </p>
         </list-item>
         <list-item id="celistitem259">
          <label>
           •
          </label>
          <p id="para331">
           Hepatitis B vaccination is currently recommended for all U.S. residents who work in health-care fields (e.g., medical, dental, laboratory) that involve potential exposure to human blood.
          </p>
         </list-item>
         <list-item id="celistitem260">
          <label>
           •
          </label>
          <p id="para332">
           All unvaccinated U.S. children and adolescents (&lt;19 years of age) should receive hepatitis B vaccine.
          </p>
         </list-item>
         <list-item id="celistitem261">
          <label>
           •
          </label>
          <p id="para333">
           Unvaccinated persons who have indications for hepatitis B vaccination independent of travel should be vaccinated (e.g., men who have sex with men, injection drug users, anyone who has recently had a sexually transmitted disease or has had more than one sex partner in the previous 6 months).
          </p>
         </list-item>
        </list>
       </p>
       <sec id="cesec42">
        <title>
         Vaccine Dose and Administration
        </title>
        <p id="para334">
         <list id="celist71" list-type="simple">
          <list-item id="celistitem262">
           <label>
            •
           </label>
           <p id="para335">
            The vaccine is usually administered as a three-dose series on a 0-, 1-, and 6-month schedule (see
            <xref ref-type="table" rid="cetable9">
             Table 2-9
            </xref>
            ). The second dose should be given 1 month after the first dose; the third dose should be given at least 2 months after the second dose and at least 4 months after the first dose.
           </p>
          </list-item>
          <list-item id="celistitem263">
           <label>
            •
           </label>
           <p id="para336">
            Alternatively, the vaccine ENGERIX-B, manufactured by GlaxoSmithKline, is also approved for administration on a four-dose schedule at 0, 1, 2, and 12 months.
           </p>
          </list-item>
          <list-item id="celistitem264">
           <label>
            •
           </label>
           <p id="para337">
            There is also a two-dose schedule for RECOMBIVAX HB, a vaccine produced by Merck &amp; Co., Inc., which has been licensed for children and adolescents 11–15 years of age. Using the two-dose schedule, the adult dose of RECOMBIVAX HB is administered, with the second dose given 4–6 months after the first dose.
           </p>
          </list-item>
          <list-item id="celistitem265">
           <label>
            •
           </label>
           <p id="para338">
            A three-dose series that has been started with one brand of vaccine may be completed with the other brand.
           </p>
          </list-item>
          <list-item id="celistitem266">
           <label>
            •
           </label>
           <p id="para339">
            TWINRIX, manufactured by GlaxoSmithKline, is a combined hepatitis A and hepatitis B vaccine licensed for persons 18 years of age or older. Primary immunization consists of three doses, given on a 0-, 1-, and 6-month schedule.
           </p>
          </list-item>
         </list>
        </p>
       </sec>
       <sec id="cesec43">
        <title>
         Special Situations
        </title>
        <p id="para340">
         <list id="celist72" list-type="simple">
          <list-item id="celistitem267">
           <label>
            •
           </label>
           <p id="para341">
            Ideally, vaccination should begin at least 6 months before travel so the full vaccine series can be completed before departure. Because some protection is provided by one or two doses, the vaccine series should be initiated, if indicated, even if it cannot be completed before departure. Optimal protection, however, is not conferred until after the final vaccine dose. Travelers should be advised to return for completion of the vaccine series.
           </p>
          </list-item>
          <list-item id="celistitem268">
           <label>
            •
           </label>
           <p id="para342">
            An accelerated vaccine schedule could be used for those traveling to endemic areas at short notice and facing imminent exposure because of behavioral risks or to emergency responders to disaster areas. The monovalent hepatitis B vaccines can be used at 0, 7, and 14 days. If an accelerated schedule is used, the patient should receive a booster dose at least 6 months after the start of the series to promote long-term immunity.
           </p>
          </list-item>
          <list-item id="celistitem269">
           <label>
            •
           </label>
           <p id="para343">
            An accelerated vaccine schedule with TWINRIX (hepatitis A and hepatitis B vaccine) can also be used (doses at 0, 7, and 21–30 days). In this situation, a booster dose should be given at 12 months to promote long-term immunity.
           </p>
          </list-item>
          <list-item id="celistitem270">
           <label>
            •
           </label>
           <p id="para344">
            For children and adults whose immune status is normal, booster doses of vaccine are not recommended. Serologic testing to assess antibody levels is not necessary for most vaccinees (see the Vaccine Recommendations for Infants and Children section in Chapter 7).
           </p>
          </list-item>
         </list>
        </p>
       </sec>
       <sec id="cesec44">
        <title>
         Vaccine Safety and Adverse Reactions
        </title>
        <p id="para345">
         <list id="celist73" list-type="simple">
          <list-item id="celistitem271">
           <label>
            •
           </label>
           <p id="para346">
            Hepatitis B vaccines have been shown to be safe for persons of all ages. Pain at the injection site (3%–29%) and elevated temperature higher than 37.7° C (99.9° F) (1%–6%) are the most frequently reported side effects among vaccine recipients.
           </p>
          </list-item>
          <list-item id="celistitem272">
           <label>
            •
           </label>
           <p id="para347">
            These vaccines should not be administered to persons with a history of hypersensitivity to any vaccine component, including yeast. The vaccine contains a recombinant protein (HBsAg) that is noninfectious. Limited data indicate that there is no apparent risk of adverse events to the developing fetus when hepatitis B vaccine is administered to pregnant women. HBV infection affecting a pregnant woman can result in serious disease for the mother and chronic infection for the newborn. Neither pregnancy nor lactation should be considered a contraindication for vaccination.
           </p>
          </list-item>
         </list>
        </p>
       </sec>
      </sec>
      <sec id="cesec45">
       <title>
        Other Preventive Measures
       </title>
       <p id="para348">
        <list id="celist74" list-type="simple">
         <list-item id="celistitem273">
          <label>
           •
          </label>
          <p id="para349">
           As part of the pre-travel education process, all travelers should be given information about the risks for hepatitis B and other bloodborne pathogens from contaminated medical equipment, injection drug use, or sexual activity and informed of prevention measures (see below), including hepatitis B vaccination, that can be used to prevent transmission of HBV.
          </p>
         </list-item>
         <list-item id="celistitem274">
          <label>
           •
          </label>
          <p id="para350">
           Regardless of destination, all persons who may engage in practices that put them at risk for HBV infection during travel should receive hepatitis B vaccination if previously unvaccinated.
          </p>
         </list-item>
         <list-item id="celistitem275">
          <label>
           •
          </label>
          <p id="para351">
           Any adult seeking protection from HBV infection should be vaccinated. Acknowledgment of a specific risk factor is not a requirement for vaccination.
          </p>
         </list-item>
         <list-item id="celistitem276">
          <label>
           •
          </label>
          <p id="para352">
           Behavioral preventive measures for HBV infection are similar to those for HIV infection and AIDS.
          </p>
         </list-item>
         <list-item id="celistitem277">
          <label>
           •
          </label>
          <p id="para353">
           When seeking medical or dental care, travelers should be advised to be alert to the use of medical, surgical, and dental equipment that has not been adequately sterilized or disinfected, reuse of contaminated equipment, and unsafe injecting practices (e.g., reuse of disposable needles and syringes).
          </p>
         </list-item>
         <list-item id="celistitem278">
          <label>
           •
          </label>
          <p id="para354">
           HBV and other bloodborne pathogens (e.g., HIV and hepatitis C) can be transmitted if tools are not sterile or if the tattoo artist or piercer does not follow other proper infection-control procedures (e.g., washing hands, using latex gloves, and cleaning and disinfecting surfaces and instruments).
          </p>
         </list-item>
         <list-item id="celistitem279">
          <label>
           •
          </label>
          <p id="para355">
           Travelers should be advised to consider the health risks in deciding to get a tattoo or body piercing in areas where adequate sterilization or disinfection procedures might not be available or practiced.
          </p>
         </list-item>
        </list>
       </p>
      </sec>
     </sec>
     <ref-list id="cebib4">
      <title>
       References
      </title>
      <ref id="bib26">
       <label>
        1
       </label>
       <element-citation id="sbref26" publication-type="journal">
        <person-group person-group-type="author">
         <collab>
          CDC
         </collab>
        </person-group>
        <article-title>
         A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults
        </article-title>
        <source>
         MMWR Recomm Rep
        </source>
        <volume>
         55
        </volume>
        <issue>
         RR-16
        </issue>
        <year>
         2006
        </year>
        <fpage>
         1
        </fpage>
        <lpage>
         25
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib27">
       <label>
        2
       </label>
       <element-citation id="sbref27" publication-type="journal">
        <person-group person-group-type="author">
         <collab>
          CDC
         </collab>
        </person-group>
        <article-title>
         A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part 1: immunization of infants, children, and adolescents
        </article-title>
        <source>
         MMWR Recomm Rep
        </source>
        <volume>
         54
        </volume>
        <issue>
         RR-16
        </issue>
        <year>
         2005
        </year>
        <fpage>
         1
        </fpage>
        <lpage>
         23
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib28">
       <label>
        3
       </label>
       <element-citation id="sbref28" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Mast
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Goldstein
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Ward
          </surname>
          <given-names>
           JL
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         Hepatitis B vaccine
        </chapter-title>
        <person-group person-group-type="editor">
         <name>
          <surname>
           Plotkin
          </surname>
          <given-names>
           SA
          </given-names>
         </name>
         <name>
          <surname>
           Orenstein
          </surname>
          <given-names>
           WA
          </given-names>
         </name>
        </person-group>
        <source>
         Vaccines
        </source>
        <edition>
         5th ed.
        </edition>
        <year>
         2004
        </year>
        <publisher-name>
         W.B. Saunders
        </publisher-name>
        <publisher-loc>
         Philadelphia
        </publisher-loc>
        <fpage>
         299
        </fpage>
        <lpage>
         337
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib29">
       <label>
        4
       </label>
       <element-citation id="sbref29" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Simonsen
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Kane
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Lloyd
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        <article-title>
         Unsafe injections in the developing world and transmission of bloodborne pathogens: a review
        </article-title>
        <source>
         Bull World Health Organ
        </source>
        <volume>
         77
        </volume>
        <issue>
         10
        </issue>
        <year>
         1999
        </year>
        <fpage>
         789
        </fpage>
        <lpage>
         800
        </lpage>
        <pub-id pub-id-type="pmid">
         10593026
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib30">
       <label>
        5
       </label>
       <element-citation id="sbref30" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sagliocca
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Stroffolini
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Amoroso
          </surname>
          <given-names>
           P
          </given-names>
         </name>
        </person-group>
        <article-title>
         Risk factors for acute hepatitis B: a case–control study
        </article-title>
        <source>
         J Viral Hepat
        </source>
        <volume>
         4
        </volume>
        <issue>
         1
        </issue>
        <year>
         1997
        </year>
        <fpage>
         63
        </fpage>
        <lpage>
         66
        </lpage>
        <pub-id pub-id-type="pmid">
         9031067
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib31">
       <label>
        6
       </label>
       <element-citation id="sbref31" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lok
          </surname>
          <given-names>
           AS
          </given-names>
         </name>
         <name>
          <surname>
           McMahon
          </surname>
          <given-names>
           BJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         Practice Guidelines Committee, American Association for the Study of Liver Diseases (AASLD). Chronic hepatitis B: update of recommendations
        </article-title>
        <source>
         Hepatology
        </source>
        <volume>
         39
        </volume>
        <issue>
         3
        </issue>
        <year>
         2004
        </year>
        <fpage>
         857
        </fpage>
        <lpage>
         861
        </lpage>
        <pub-id pub-id-type="pmid">
         14999707
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib32">
       <label>
        7
       </label>
       <element-citation id="sbref32" publication-type="journal">
        <person-group person-group-type="author">
         <collab>
          CDC
         </collab>
        </person-group>
        <article-title>
         Updated U.S. Public Health Service guidelines for the management of occupational exposures to HBV, HCV and HIV and recommendations for postexposure prophylaxis
        </article-title>
        <source>
         MMWR Recomm Rep
        </source>
        <volume>
         50
        </volume>
        <issue>
         RR-11
        </issue>
        <year>
         2001
        </year>
        <fpage>
         1
        </fpage>
        <lpage>
         42
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib33">
       <label>
        8
       </label>
       <element-citation id="sbref33" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bock
          </surname>
          <given-names>
           HL
          </given-names>
         </name>
         <name>
          <surname>
           Loscher
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Scheiermann
          </surname>
          <given-names>
           N
          </given-names>
         </name>
        </person-group>
        <article-title>
         Accelerated schedule for hepatitis B immunization
        </article-title>
        <source>
         J Travel Med
        </source>
        <volume>
         2
        </volume>
        <issue>
         4
        </issue>
        <year>
         1995
        </year>
        <fpage>
         213
        </fpage>
        <lpage>
         217
        </lpage>
        <pub-id pub-id-type="pmid">
         9815393
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib34">
       <label>
        9
       </label>
       <element-citation id="sbref34" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Long
          </surname>
          <given-names>
           GE
          </given-names>
         </name>
         <name>
          <surname>
           Rickman
          </surname>
          <given-names>
           LS
          </given-names>
         </name>
        </person-group>
        <article-title>
         Infectious complications of tattoos
        </article-title>
        <source>
         Clin Infect Dis
        </source>
        <volume>
         18
        </volume>
        <issue>
         4
        </issue>
        <year>
         1994
        </year>
        <fpage>
         610
        </fpage>
        <lpage>
         619
        </lpage>
        <comment>
         Review
        </comment>
        <pub-id pub-id-type="pmid">
         8038318
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib35">
       <label>
        10
       </label>
       <element-citation id="sbref35" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Mariano
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Mele
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Tosti
          </surname>
          <given-names>
           ME
          </given-names>
         </name>
        </person-group>
        <article-title>
         Role of beauty treatment in the spread of parenterally transmitted hepatitis viruses in Italy
        </article-title>
        <source>
         J Med Virol
        </source>
        <volume>
         74
        </volume>
        <issue>
         2
        </issue>
        <year>
         2004
        </year>
        <fpage>
         216
        </fpage>
        <lpage>
         220
        </lpage>
        <pub-id pub-id-type="pmid">
         15332269
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib36">
       <label>
        11
       </label>
       <mixed-citation id="ceotherref1" publication-type="other">
        Provisional Recommendations for Hepatitis B vaccination of adults – October 2005. [cited 2006 Oct 31]. Available from:
        <ext-link ext-link-type="uri" id="interref15" xlink:href="http://www.cdc.gov/nip/recs/provisional_recs/hepB_adult.pdf">
         http://www.cdc.gov/nip/recs/provisional_recs/hepB_adult.pdf
        </ext-link>
        .
       </mixed-citation>
      </ref>
     </ref-list>
    </sec>
    <sec id="subchapter5">
     <sec-meta>
      <contrib-group>
       <contrib contrib-type="author" id="au6">
        <name>
         <surname>
          Mintz
         </surname>
         <given-names>
          Eric
         </given-names>
        </name>
       </contrib>
      </contrib-group>
     </sec-meta>
     <title>
      TYPHOID AND PARATYPHOID FEVER
     </title>
     <sec id="cesec46">
      <title>
       Infectious Agent
      </title>
      <p id="para356">
       Typhoid fever is an acute, life-threatening febrile illness caused by the bacterium
       <italic>
        Salmonella enterica
       </italic>
       serotype Typhi. Paratyphoid fever is a similar illness caused by
       <italic>
        S
       </italic>
       . Paratyphi A, B, or C.
      </p>
     </sec>
     <sec id="cesec47">
      <title>
       Mode of Transmission
      </title>
      <p id="para357">
       <list id="celist75" list-type="simple">
        <list-item id="celistitem280">
         <label>
          •
         </label>
         <p id="para358">
          Humans are the only source. No animal or environmental reservoirs have been identified.
         </p>
        </list-item>
        <list-item id="celistitem281">
         <label>
          •
         </label>
         <p id="para359">
          Typhoid and paratyphoid fever are most often acquired through consumption of water or food that have been contaminated by feces of an acutely infected or convalescent individual or a chronic asymptomatic carrier.
         </p>
        </list-item>
        <list-item id="celistitem282">
         <label>
          •
         </label>
         <p id="para360">
          Transmission through sexual contact, especially among men who have sex with men, has rarely been documented.
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <sec id="cesec48">
      <title>
       Occurrence
      </title>
      <p id="para361">
       <list id="celist76" list-type="simple">
        <list-item id="celistitem283">
         <label>
          •
         </label>
         <p id="para362">
          An estimated 22 million cases of typhoid fever and 200,000 related deaths occur worldwide each year; an additional 6 million cases of paratyphoid fever are estimated to occur annually.
         </p>
        </list-item>
        <list-item id="celistitem284">
         <label>
          •
         </label>
         <p id="para363">
          Approximately 400 cases of typhoid fever and 150 cases of paratyphoid fever are reported to CDC each year among persons with onset of illness in the United States, most of whom are recent travelers.
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <sec id="cesec49">
      <title>
       Risk for Travelers
      </title>
      <p id="para364">
       <list id="celist77" list-type="simple">
        <list-item id="celistitem285">
         <label>
          •
         </label>
         <p id="para365">
          Risk is greatest for travelers to South Asia (6 to 30 times higher than all other destinations). Other areas of risk include East and Southeast Asia, Africa, the Caribbean, and Central and South America.
         </p>
        </list-item>
        <list-item id="celistitem286">
         <label>
          •
         </label>
         <p id="para366">
          Travelers to South Asia are at highest risk for infections that are nalidixic acid-resistant or multidrug-resistant (i.e., resistant to ampicillin, chloramphenicol, and trimethoprim–sulfamethoxazole).
         </p>
        </list-item>
        <list-item id="celistitem287">
         <label>
          •
         </label>
         <p id="para367">
          Travelers who are visiting friends or relatives are at increased risk (see the VFR section in Chapter 8).
         </p>
        </list-item>
        <list-item id="celistitem288">
         <label>
          •
         </label>
         <p id="para368">
          Although the risk of acquiring typhoid or paratyphoid fever increases with the duration of stay, travelers have acquired typhoid fever even during visits of less than 1 week to countries where the disease is endemic.
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <sec id="cesec50">
      <title>
       Clinical Presentation
      </title>
      <p id="para369">
       <list id="celist78" list-type="simple">
        <list-item id="celistitem289">
         <label>
          •
         </label>
         <p id="para370">
          The incubation period of typhoid and paratyphoid infections is 6–30 days. The onset of illness is insidious, with gradually increasing fatigue and a fever that increases daily from low-grade to as high as 102° F–104° F (38.5° C–40° C) by the third to fourth day of illness. Headache, malaise, and anorexia are nearly universal. Hepatosplenomegaly can often be detected. A transient, macular rash of rose-colored spots can occasionally be seen on the trunk.
         </p>
        </list-item>
        <list-item id="celistitem290">
         <label>
          •
         </label>
         <p id="para371">
          Fever is commonly lowest in the morning, reaching a peak in late afternoon or evening. Untreated, the disease can last for a month. The serious complications of typhoid fever generally occur only after 2–3 weeks of illness, mainly intestinal hemorrhage or perforation, which can be life threatening.
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <sec id="cesec51">
      <title>
       Diagnosis
      </title>
      <p id="para372">
       <list id="celist79" list-type="simple">
        <list-item id="celistitem291">
         <label>
          •
         </label>
         <p id="para373">
          Infection with typhoid or paratyphoid fever results in a very low-grade septicemia. Blood culture is usually positive in only half the cases. Stool culture is not usually positive during the acute phase of the disease. Bone-marrow culture increases the diagnostic yield to about 80% of cases.
         </p>
        </list-item>
        <list-item id="celistitem292">
         <label>
          •
         </label>
         <p id="para374">
          The Widal test is an old serologic assay for detecting IgM and IgG antibodies to the O and H antigens of
          <italic>
           Salmonella
          </italic>
          . The test is unreliable, but is widely used in developing countries because of its low cost. Newer serologic assays are somewhat more sensitive and specific than the Widal test, but are infrequently available.
         </p>
        </list-item>
        <list-item id="celistitem293">
         <label>
          •
         </label>
         <p id="para375">
          Because there is no definitive test for typhoid or paratyphoid fever, the diagnosis often has to be made clinically. The combination of a history of being at risk for infection and a gradual onset of fever that increases in severity over several days should raise suspicion of typhoid or paratyphoid fever.
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <sec id="cesec52">
      <title>
       Treatment
      </title>
      <p id="para376">
       <list id="celist80" list-type="simple">
        <list-item id="celistitem294">
         <label>
          •
         </label>
         <p id="para377">
          Specific antimicrobial therapy shortens the clinical course of typhoid fever and reduces the risk for death.
         </p>
        </list-item>
        <list-item id="celistitem295">
         <label>
          •
         </label>
         <p id="para378">
          Empiric treatment of typhoid or paratyphoid fever in most parts of the world would utilize a fluoroquinolone, most often ciprofloxacin. However, resistance to fluoroquinolones is highest in the Indian subcontinent and increasing in other areas. Injectable third-generation cephalosporins are often the empiric drug of choice when the possibility of fluoroquinolone resistance is high.
         </p>
        </list-item>
        <list-item id="celistitem296">
         <label>
          •
         </label>
         <p id="para379">
          Patients treated with an appropriate antibiotic still require 3–5 days to defervesce completely, although the height of the fever decreases each day. Patients may actually feel worse during the time that the fever is starting to go away. If fever does not subside within 5 days, alternative antimicrobial agents or other foci of infection should be considered.
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <sec id="cesec53">
      <title>
       Preventive Measures for Travelers
      </title>
      <sec id="cesec54">
       <title>
        Vaccine
       </title>
       <p id="para380">
        <list id="celist81" list-type="simple">
         <list-item id="celistitem297">
          <label>
           •
          </label>
          <p id="para381">
           CDC recommends typhoid vaccine for travelers to areas where there is a recognized increased risk of exposure to
           <italic>
            S.
           </italic>
           Typhi.
          </p>
         </list-item>
         <list-item id="celistitem298">
          <label>
           •
          </label>
          <p id="para382">
           The typhoid vaccines currently available do not offer protection against
           <italic>
            S.
           </italic>
           Paratyphi infection.
          </p>
         </list-item>
         <list-item id="celistitem299">
          <label>
           •
          </label>
          <p id="para383">
           Travelers should be reminded that typhoid immunization is not 100% effective, and typhoid fever could still occur.
          </p>
         </list-item>
         <list-item id="celistitem300">
          <label>
           •
          </label>
          <p id="para384">
           Two typhoid vaccines are currently available in the United States.
           <list id="celist82" list-type="simple">
            <list-item id="celistitem301">
             <label>
              ○
             </label>
             <p id="para385">
              Oral live, attenuated vaccine (Vivotif Berna vaccine, manufactured from the Ty21a strain of
              <italic>
               S.
              </italic>
              Typhi by the Swiss Serum and Vaccine Institute)
             </p>
            </list-item>
            <list-item id="celistitem302">
             <label>
              ○
             </label>
             <p id="para386">
              Vi capsular polysaccharide vaccine (ViCPS) (Typhim Vi, manufactured by Sanofi Pasteur) for intramuscular use
             </p>
            </list-item>
           </list>
          </p>
         </list-item>
         <list-item id="celistitem303">
          <label>
           •
          </label>
          <p id="para387">
           Both vaccines protect 50%–80% of recipients.
          </p>
         </list-item>
         <list-item id="celistitem304">
          <label>
           •
          </label>
          <p id="para388">
           <xref ref-type="table" rid="cetable10">
            Table 2-10
           </xref>
           provides information on vaccine dosage, administration, and revaccination. The time required for primary vaccination differs for the two vaccines, as do the lower age limits.
          </p>
         </list-item>
         <list-item id="celistitem305">
          <label>
           •
          </label>
          <p id="para389">
           Primary vaccination with oral Ty21a vaccine consists of four capsules, one taken every other day. The capsules should be kept refrigerated (not frozen), and all four doses must be taken to achieve maximum efficacy. Each capsule should be taken with cool liquid no warmer than 37° C (98.6° F), approximately 1 hour before a meal. This regimen should be completed 1 week before potential exposure. The vaccine manufacturer recommends that Ty21a not be administered to infants or children &lt;6 years of age.
          </p>
         </list-item>
         <list-item id="celistitem306">
          <label>
           •
          </label>
          <p id="para390">
           Primary vaccination with ViCPS consists of one 0.5-mL (25-mg) dose administered intramuscularly. One dose of this vaccine should be given at least 2 weeks before expected exposure. The manufacturer does not recommend the vaccine for infants and children &lt;2 years of age.
          </p>
         </list-item>
        </list>
       </p>
       <sec id="cesec55">
        <title>
         Vaccine Safety and Adverse Reactions
        </title>
        <p id="para391">
         Information on adverse reactions is presented in
         <xref ref-type="table" rid="cetable11">
          Table 2-11
         </xref>
         . Information is not available on the safety of these vaccines in pregnancy; it is prudent on theoretical grounds to avoid vaccinating pregnant women. Live, attenuated Ty21a vaccine should not be given to immunocompromised travelers, including those infected with HIV. The intramuscular vaccine presents a theoretically safer alternative for this group. The only contraindication to vaccination with ViCPS vaccine is a history of severe local or systemic reactions after a previous dose. Neither of the available vaccines should be given to persons with an acute febrile illness.
         <table-wrap id="cetable11" position="float">
          <label>
           Table 2-11
          </label>
          <caption>
           <p>
            Common adverse reactions to typhoid fever vaccines
           </p>
          </caption>
          <table frame="hsides" rules="groups">
           <thead>
            <tr>
             <th align="left">
              Vaccine
              <hr/>
             </th>
             <th align="left">
              Reactions
              <hr/>
             </th>
             <th>
              <hr/>
             </th>
             <th>
              <hr/>
             </th>
            </tr>
            <tr>
             <th>
             </th>
             <th align="left">
              Fever
             </th>
             <th align="left">
              Headache
             </th>
             <th align="left">
              Local Reactions
             </th>
            </tr>
           </thead>
           <tbody>
            <tr>
             <td align="left">
              Ty21a
              <xref ref-type="table-fn" rid="cetablefn53">
               1
              </xref>
             </td>
             <td align="left">
              0%–5%
             </td>
             <td align="left">
              0%–5%
             </td>
             <td align="left">
              Not applicable
             </td>
            </tr>
            <tr>
             <td align="left">
              Vi Capsular polysaccharide
             </td>
             <td align="left">
              0%–1%
             </td>
             <td align="left">
              16%–20%
             </td>
             <td align="left">
              7% erythema or induration 1 cm
             </td>
            </tr>
           </tbody>
          </table>
          <table-wrap-foot>
           <fn id="cetablefn53">
            <label>
             1
            </label>
            <p id="cenotep53">
             The side effects of Ty21a are rare and mainly consist of abdominal discomfort, nausea, vomiting, and rash or urticaria.
            </p>
           </fn>
          </table-wrap-foot>
         </table-wrap>
        </p>
       </sec>
       <sec id="cesec56">
        <title>
         Precautions and Contraindications
        </title>
        <p id="para392">
         Theoretical concerns have been raised about the immunogenicity of live, attenuated Ty21a vaccine in persons concurrently receiving antimicrobials (including antimalarial chemoprophylaxis), IG, or viral vaccines. The growth of the live Ty21a strain is inhibited in vitro by various antibacterial agents. Vaccination with Ty21a should be delayed for &gt;72 hours after the administration of any antibacterial agent. Available data do not suggest that simultaneous administration of oral polio or yellow fever vaccine decreases the immunogenicity of Ty21a. If typhoid vaccination is warranted, it should not be delayed because of administration of viral vaccines. Simultaneous administration of Ty21a and IG does not appear to pose a problem.
        </p>
       </sec>
      </sec>
     </sec>
     <ref-list id="cebib5">
      <title>
       References
      </title>
      <ref id="bib37">
       <label>
        1
       </label>
       <element-citation id="sbref36" publication-type="journal">
        <comment>
        </comment>
        <person-group person-group-type="author">
         <name>
          <surname>
           Gupta
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Medalla
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Omondi
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <article-title>
         Laboratory-based surveillance of paratyphoid fever in the United States: travel and antimicrobial resistance
        </article-title>
        <source>
         Clin Infect Dis
        </source>
        <year>
         2008
        </year>
        <comment>
         In press
        </comment>
       </element-citation>
      </ref>
      <ref id="bib38">
       <label>
        2
       </label>
       <element-citation id="sbref37" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ackers
          </surname>
          <given-names>
           ML
          </given-names>
         </name>
         <name>
          <surname>
           Puhr
          </surname>
          <given-names>
           ND
          </given-names>
         </name>
         <name>
          <surname>
           Tauxe
          </surname>
          <given-names>
           RV
          </given-names>
         </name>
        </person-group>
        <article-title>
         Laboratory-based surveillance of
         <italic>
          Salmonella
         </italic>
         serotype Typhi infections in the United States: antimicrobial resistance on the rise
        </article-title>
        <source>
         JAMA
        </source>
        <volume>
         283
        </volume>
        <issue>
         20
        </issue>
        <year>
         2000
        </year>
        <fpage>
         2668
        </fpage>
        <lpage>
         2673
        </lpage>
        <pub-id pub-id-type="pmid">
         10819949
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib39">
       <label>
        3
       </label>
       <element-citation id="sbref38" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Steinberg
          </surname>
          <given-names>
           EB
          </given-names>
         </name>
         <name>
          <surname>
           Bishop
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Haber
          </surname>
          <given-names>
           P
          </given-names>
         </name>
        </person-group>
        <article-title>
         Typhoid fever in travelers: who should be targeted for prevention?
        </article-title>
        <source>
         Clin Infect Dis
        </source>
        <volume>
         39
        </volume>
        <issue>
         2
        </issue>
        <year>
         2004
        </year>
        <fpage>
         186
        </fpage>
        <lpage>
         191
        </lpage>
        <pub-id pub-id-type="pmid">
         15307027
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib40">
       <label>
        4
       </label>
       <element-citation id="sbref39" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Parry
          </surname>
          <given-names>
           CM
          </given-names>
         </name>
         <name>
          <surname>
           Hien
          </surname>
          <given-names>
           TT
          </given-names>
         </name>
         <name>
          <surname>
           Dougan
          </surname>
          <given-names>
           G
          </given-names>
         </name>
        </person-group>
        <article-title>
         Typhoid fever
        </article-title>
        <source>
         N Engl J Med
        </source>
        <volume>
         347
        </volume>
        <issue>
         22
        </issue>
        <year>
         2002
        </year>
        <fpage>
         1770
        </fpage>
        <lpage>
         1782
        </lpage>
        <pub-id pub-id-type="pmid">
         12456854
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib41">
       <label>
        5
       </label>
       <element-citation id="sbref40" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Klugman
          </surname>
          <given-names>
           KP
          </given-names>
         </name>
         <name>
          <surname>
           Gilbertson
          </surname>
          <given-names>
           IT
          </given-names>
         </name>
         <name>
          <surname>
           Koornhof
          </surname>
          <given-names>
           HJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         Protective activity of Vi capsular polysaccharide vaccine against typhoid fever
        </article-title>
        <source>
         Lancet
        </source>
        <volume>
         2
        </volume>
        <issue>
         8569
        </issue>
        <year>
         1987
        </year>
        <fpage>
         1165
        </fpage>
        <lpage>
         1169
        </lpage>
        <pub-id pub-id-type="pmid">
         2890805
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib42">
       <label>
        6
       </label>
       <element-citation id="sbref41" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Simanjuntak
          </surname>
          <given-names>
           CH
          </given-names>
         </name>
         <name>
          <surname>
           Paleologo
          </surname>
          <given-names>
           FP
          </given-names>
         </name>
         <name>
          <surname>
           Punjabi
          </surname>
          <given-names>
           NH
          </given-names>
         </name>
        </person-group>
        <article-title>
         Oral immunisation against typhoid fever in Indonesia with Ty21a vaccine
        </article-title>
        <source>
         Lancet
        </source>
        <volume>
         338
        </volume>
        <issue>
         8774
        </issue>
        <year>
         1991
        </year>
        <fpage>
         1055
        </fpage>
        <lpage>
         1059
        </lpage>
        <pub-id pub-id-type="pmid">
         1681365
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib43">
       <label>
        7
       </label>
       <element-citation id="sbref42" publication-type="journal">
        <person-group person-group-type="author">
         <collab>
          CDC
         </collab>
        </person-group>
        <article-title>
         Typhoid immunization: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
        </article-title>
        <source>
         MMWR Morbid Mortal Wkly Rep
        </source>
        <volume>
         43
        </volume>
        <issue>
         RR-14
        </issue>
        <year>
         1994
        </year>
        <fpage>
         1
        </fpage>
        <lpage>
         7
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib44">
       <label>
        8
       </label>
       <element-citation id="sbref43" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Crump
          </surname>
          <given-names>
           JA
          </given-names>
         </name>
         <name>
          <surname>
           Luby
          </surname>
          <given-names>
           SP
          </given-names>
         </name>
         <name>
          <surname>
           Mintz
          </surname>
          <given-names>
           ED
          </given-names>
         </name>
        </person-group>
        <article-title>
         The global burden of typhoid fever
        </article-title>
        <source>
         Bull World Health Organ
        </source>
        <volume>
         82
        </volume>
        <issue>
         5
        </issue>
        <year>
         2004
        </year>
        <fpage>
         346
        </fpage>
        <lpage>
         353
        </lpage>
        <pub-id pub-id-type="pmid">
         15298225
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib45">
       <label>
        9
       </label>
       <element-citation id="sbref44" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Beeching
          </surname>
          <given-names>
           NJ
          </given-names>
         </name>
         <name>
          <surname>
           Clarke
          </surname>
          <given-names>
           PD
          </given-names>
         </name>
         <name>
          <surname>
           Kitchin
          </surname>
          <given-names>
           NR
          </given-names>
         </name>
        </person-group>
        <article-title>
         Comparison of two combined vaccines against typhoid fever and hepatitis A in healthy adults
        </article-title>
        <source>
         Vaccine
        </source>
        <volume>
         23
        </volume>
        <issue>
         1
        </issue>
        <year>
         2004
        </year>
        <fpage>
         29
        </fpage>
        <lpage>
         35
        </lpage>
        <pub-id pub-id-type="pmid">
         15519704
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib46">
       <label>
        10
       </label>
       <element-citation id="sbref45" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kollaritsch
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Que
          </surname>
          <given-names>
           JU
          </given-names>
         </name>
         <name>
          <surname>
           Kunz
          </surname>
          <given-names>
           C
          </given-names>
         </name>
        </person-group>
        <article-title>
         Safety and immunogenicity of live oral cholera and typhoid vaccines administered alone or in combination with antimalarial drugs, oral polio vaccine, or yellow fever vaccine
        </article-title>
        <source>
         J Infect Dis
        </source>
        <volume>
         175
        </volume>
        <issue>
         4
        </issue>
        <year>
         1997
        </year>
        <fpage>
         871
        </fpage>
        <lpage>
         875
        </lpage>
        <pub-id pub-id-type="pmid">
         9086143
        </pub-id>
       </element-citation>
      </ref>
     </ref-list>
    </sec>
    <sec id="subchapter6">
     <sec-meta>
      <contrib-group>
       <contrib contrib-type="author" id="au7">
        <name>
         <surname>
          Gershman
         </surname>
         <given-names>
          Mark
         </given-names>
        </name>
       </contrib>
       <contrib contrib-type="author" id="au8">
        <name>
         <surname>
          Schroeder
         </surname>
         <given-names>
          Betsy
         </given-names>
        </name>
       </contrib>
       <contrib contrib-type="author" id="au9">
        <name>
         <surname>
          Staples
         </surname>
         <given-names>
          J. Erin
         </given-names>
        </name>
       </contrib>
      </contrib-group>
     </sec-meta>
     <title>
      YELLOW FEVER
     </title>
     <sec id="cesec57">
      <title>
       Infectious Agent
      </title>
      <p id="para393">
       Yellow fever virus (YFV) is a single-stranded RNA virus that belongs to the genus
       <italic>
        Flavivirus
       </italic>
       .
      </p>
     </sec>
     <sec id="cesec58">
      <title>
       Mode of Transmission
      </title>
      <p id="para394">
       <list id="celist83" list-type="simple">
        <list-item id="celistitem307">
         <label>
          •
         </label>
         <p id="para395">
          Vector-borne transmission occurs via the bite of an infected mosquito, primarily
          <italic>
           Aedes
          </italic>
          or
          <italic>
           Haemagogus
          </italic>
          spp.
         </p>
        </list-item>
        <list-item id="celistitem308">
         <label>
          •
         </label>
         <p id="para396">
          Nonhuman and human primates are the main reservoirs of the virus, with anthroponotic (human-to-vector-to-human) transmission occurring.
         </p>
        </list-item>
        <list-item id="celistitem309">
         <label>
          •
         </label>
         <p id="para397">
          There are three transmission cycles for yellow fever: sylvatic (jungle), intermediate (savannah), and urban.
          <list id="celist84" list-type="simple">
           <list-item id="celistitem310">
            <label>
             ○
            </label>
            <p id="para398">
             The sylvatic (jungle) transmission cycle involves transmission of the virus between nonhuman primates and mosquito species found in the forest canopy. The virus is transmitted via mosquitoes from monkeys to humans when the humans encroach into the jungle during occupational or recreational activities.
            </p>
           </list-item>
           <list-item id="celistitem311">
            <label>
             ○
            </label>
            <p id="para399">
             In Africa, an intermediate (savannah) cycle involves transmission of YFV from tree hole-breeding
             <italic>
              Aedes
             </italic>
             spp. to humans living or working in jungle border areas. In this cycle, the virus may be transmitted from monkeys to humans or from human to human via these mosquitoes.
            </p>
           </list-item>
           <list-item id="celistitem312">
            <label>
             ○
            </label>
            <p id="para400">
             The urban transmission cycle involves transmission of the virus between humans and urban mosquitoes, primarily
             <italic>
              Ae. aegypti
             </italic>
             .
            </p>
           </list-item>
          </list>
         </p>
        </list-item>
        <list-item id="celistitem313">
         <label>
          •
         </label>
         <p id="para401">
          Humans infected with YFV experience the highest levels of viremia and can transmit the virus to mosquitoes shortly before onset of fever and for the first 3–5 days of illness.
         </p>
        </list-item>
        <list-item id="celistitem314">
         <label>
          •
         </label>
         <p id="para402">
          Given the high level of viremia attained in humans, bloodborne transmission can also occur (via transfusion, needlestick, and intravenous drug abuse).
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <sec id="cesec59">
      <title>
       Occurrence
      </title>
      <p id="para403">
       <list id="celist85" list-type="simple">
        <list-item id="celistitem315">
         <label>
          •
         </label>
         <p id="para404">
          Yellow fever occurs in sub-Saharan Africa and tropical South America (
          <xref ref-type="fig" rid="f6">
           Maps 2-3
          </xref>
          and
          <xref ref-type="fig" rid="f7">
           2-4
          </xref>
          ), where it is endemic and intermittently epidemic (see
          <xref ref-type="table" rid="cetable12">
           Table 2-12
          </xref>
          for a list of countries with risk of yellow fever transmission).
          <fig id="f6">
           <label>
            Map 2-3
           </label>
           <caption>
            <p>
             Yellow fever-endemic zones in Africa, 2009.
            </p>
           </caption>
           <graphic xlink:href="gr23">
           </graphic>
          </fig>
          <fig id="f7">
           <label>
            Map 2-4
           </label>
           <caption>
            <p>
             Yellow fever-endemic zones in the Americas, 2009.
            </p>
           </caption>
           <graphic xlink:href="gr24">
           </graphic>
          </fig>
          <table-wrap id="cetable12" position="float">
           <label>
            Table 2-12
           </label>
           <caption>
            <p>
             Countries with risk of yellow fever transmission
             <xref ref-type="table-fn" rid="cetablefn54">
              1
             </xref>
            </p>
           </caption>
           <table frame="hsides" rules="groups">
            <thead>
             <tr>
              <th align="left">
               Africa
              </th>
              <th>
              </th>
              <th>
              </th>
              <th align="left">
               Central and South America
              </th>
             </tr>
            </thead>
            <tbody>
             <tr>
              <td align="left">
               Angola
              </td>
              <td align="left">
               Ethiopia
              </td>
              <td align="left">
               Nigeria
              </td>
              <td align="left">
               Argentina
               <xref ref-type="table-fn" rid="cetablefn55">
                2
               </xref>
              </td>
             </tr>
             <tr>
              <td align="left">
               Benin
              </td>
              <td align="left">
               Gabon
              </td>
              <td align="left">
               Rwanda
              </td>
              <td align="left">
               Bolivia
               <xref ref-type="table-fn" rid="cetablefn55">
                2
               </xref>
              </td>
             </tr>
             <tr>
              <td align="left">
               Burkina Faso
              </td>
              <td align="left">
               The Gambia
              </td>
              <td align="left">
               Sierra Leone
              </td>
              <td align="left">
               Brazil
               <xref ref-type="table-fn" rid="cetablefn55">
                2
               </xref>
              </td>
             </tr>
             <tr>
              <td align="left">
               Burundi
              </td>
              <td align="left">
               Ghana
              </td>
              <td align="left">
               São Tomé and Príncipe
              </td>
              <td align="left">
               Colombia
              </td>
             </tr>
             <tr>
              <td align="left">
               Cameroon
              </td>
              <td align="left">
               Guinea
              </td>
              <td align="left">
               Senegal
              </td>
              <td align="left">
               Ecuador
               <xref ref-type="table-fn" rid="cetablefn55">
                2
               </xref>
              </td>
             </tr>
             <tr>
              <td align="left">
               Central African Republic
              </td>
              <td align="left">
               Guinea-Bissau
              </td>
              <td align="left">
               Somalia
              </td>
              <td align="left">
               French Guiana
              </td>
             </tr>
             <tr>
              <td align="left">
               Chad
               <xref ref-type="table-fn" rid="cetablefn55">
                2
               </xref>
              </td>
              <td align="left">
               Kenya
              </td>
              <td align="left">
               Sudan
               <xref ref-type="table-fn" rid="cetablefn55">
                2
               </xref>
              </td>
              <td align="left">
               Guyana
              </td>
             </tr>
             <tr>
              <td align="left">
               Congo, Republic of the
              </td>
              <td align="left">
               Liberia
              </td>
              <td align="left">
               Tanzania
              </td>
              <td align="left">
               Panama
               <xref ref-type="table-fn" rid="cetablefn55">
                2
               </xref>
              </td>
             </tr>
             <tr>
              <td align="left">
               Côte d'Ivoire
              </td>
              <td align="left">
               Mali
               <xref ref-type="table-fn" rid="cetablefn55">
                2
               </xref>
              </td>
              <td align="left">
               Togo
              </td>
              <td align="left">
               Paraguay
              </td>
             </tr>
             <tr>
              <td align="left">
               Democratic Republic of the Congo
              </td>
              <td align="left">
               Mauritania
               <xref ref-type="table-fn" rid="cetablefn55">
                2
               </xref>
              </td>
              <td align="left">
               Uganda
              </td>
              <td align="left">
               Peru
               <xref ref-type="table-fn" rid="cetablefn55">
                2
               </xref>
              </td>
             </tr>
             <tr>
              <td align="left">
               Equatorial Guinea
              </td>
              <td align="left">
               Niger
               <xref ref-type="table-fn" rid="cetablefn55">
                2
               </xref>
              </td>
              <td>
              </td>
              <td align="left">
               Suriname
              </td>
             </tr>
             <tr>
              <td>
              </td>
              <td>
              </td>
              <td>
              </td>
              <td align="left">
               Trinidad and Tobago
               <xref ref-type="table-fn" rid="cetablefn55">
                2
               </xref>
              </td>
             </tr>
             <tr>
              <td>
              </td>
              <td>
              </td>
              <td>
              </td>
              <td align="left">
               Venezuela
               <xref ref-type="table-fn" rid="cetablefn55">
                2
               </xref>
              </td>
             </tr>
            </tbody>
           </table>
           <table-wrap-foot>
            <fn id="cetablefn54">
             <label>
              1
             </label>
             <p id="cenotep54">
              Countries/areas where “a risk of yellow fever transmission is present,” as defined by the World Health Organization, are countries or areas where “yellow fever has been reported currently or in the past, plus vectors and animal reservoirs currently exist” (see
              <ext-link ext-link-type="uri" id="interref3" xlink:href="http://www.who.int/ith/countries/2008_country_list.pdf">
               www.who.int/ith/countries/2008_country_list.pdf
              </ext-link>
              ).
             </p>
            </fn>
           </table-wrap-foot>
           <table-wrap-foot>
            <fn id="cetablefn55">
             <label>
              2
             </label>
             <p id="cenotep55">
              These countries are not holoendemic (i.e., only a portion of the country has risk of yellow fever transmission). Please see
              <xref ref-type="fig" rid="f6">
               Maps 2-3
              </xref>
              and
              <xref ref-type="fig" rid="f7">
               2-4
              </xref>
              and yellow fever vaccine recommendations (
              <xref ref-type="table" rid="cetable14">
               Table 2-14
              </xref>
              ) for details.
             </p>
            </fn>
           </table-wrap-foot>
          </table-wrap>
         </p>
        </list-item>
        <list-item id="celistitem316">
         <label>
          •
         </label>
         <p id="para405">
          In Africa, natural immunity accumulates with age, and thus infants and children are at greatest risk for disease.
         </p>
        </list-item>
        <list-item id="celistitem317">
         <label>
          •
         </label>
         <p id="para406">
          In South America, yellow fever occurs most frequently in unimmunized young men who are exposed to mosquito vectors through their work in forested or transitional areas.
         </p>
        </list-item>
        <list-item id="celistitem318">
         <label>
          •
         </label>
         <p id="para407">
          Most yellow fever disease in humans is due to sylvatic or intermediate transmission cycles. However, urban yellow fever does occur periodically in Africa and sporadically in the Americas.
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <sec id="cesec60">
      <title>
       Risk for Travelers
      </title>
      <sec id="cesec61">
       <title>
        General
       </title>
       <p id="para408">
        A traveler's risk for acquiring yellow fever is determined by various factors, including immunization status, location of travel, season, duration of exposure, occupational and recreational activities while traveling, and local rate of virus transmission at the time of travel. Although reported cases of human disease are the principal indicator of disease risk, case reports may be absent because of a low level of transmission, a high level of immunity in the population (e.g., due to vaccination), or failure of local surveillance systems to detect cases. This “epidemiologic silence” does not equate to absence of risk and should not lead to travel without the protection provided by vaccination.
       </p>
      </sec>
      <sec id="cesec62">
       <title>
        Africa
       </title>
       <p id="para409">
        YFV transmission in rural West Africa is seasonal, with an elevated risk during the end of the rainy season and the beginning of the dry season (usually July–October). However, YFV may be episodically transmitted by
        <italic>
         Ae. aegypti
        </italic>
        even during the dry season in both rural and densely settled urban areas.
       </p>
      </sec>
      <sec id="cesec63">
       <title>
        South America
       </title>
       <p id="para410">
        <list id="celist86" list-type="simple">
         <list-item id="celistitem319">
          <label>
           •
          </label>
          <p id="para411">
           The risk for infection for South America is highest during the rainy season (January–May, with a peak incidence in February and March).
          </p>
         </list-item>
         <list-item id="celistitem320">
          <label>
           •
          </label>
          <p id="para412">
           Given the high level of viremia in humans and the widespread distribution of
           <italic>
            Ae. aegypti
           </italic>
           in many towns and cities, South America is at risk for a large-scale urban epidemic.
          </p>
         </list-item>
        </list>
       </p>
      </sec>
      <sec id="cesec64">
       <title>
        Yellow Fever Cases in Travelers
       </title>
       <p id="para413">
        <list id="celist87" list-type="simple">
         <list-item id="celistitem321">
          <label>
           •
          </label>
          <p id="para414">
           During 1970–2002, a total of nine cases of yellow fever were reported in unvaccinated travelers from the United States and Europe who traveled to West Africa (five cases) or South America (four cases). Eight of these nine travelers died.
          </p>
         </list-item>
         <list-item id="celistitem322">
          <label>
           •
          </label>
          <p id="para415">
           Only one documented case of yellow fever has occurred, which was in a vaccinated traveler from Spain, who visited several West African countries during 1988.
          </p>
         </list-item>
        </list>
       </p>
      </sec>
      <sec id="cesec65">
       <title>
        Risk Estimates for Travelers
       </title>
       <p id="para416">
        <list id="celist88" list-type="simple">
         <list-item id="celistitem323">
          <label>
           •
          </label>
          <p id="para417">
           The risk of acquiring yellow fever is difficult to predict because of variations in ecologic determinants of virus transmission. For a 2-week stay, the risks for illness and death due to yellow fever for an unvaccinated traveler traveling to an endemic area of
           <list id="celist89" list-type="simple">
            <list-item id="celistitem324">
             <label>
              ○
             </label>
             <p id="para418">
              West Africa are 50 per 100,000 and 10 per 100,000, respectively
             </p>
            </list-item>
            <list-item id="celistitem325">
             <label>
              ○
             </label>
             <p id="para419">
              South America are 5 per 100,000 and 1 per 100,000, respectively
             </p>
            </list-item>
           </list>
          </p>
         </list-item>
         <list-item id="celistitem326">
          <label>
           •
          </label>
          <p id="para420">
           These estimates are a rough guideline based on the risk to indigenous populations, often during peak transmission season. Thus, these risk estimates may not accurately reflect the true risk to travelers, who may have a different immunity profile, take precautions against getting bitten by mosquitoes, and have less outdoor exposure.
          </p>
         </list-item>
         <list-item id="celistitem327">
          <label>
           •
          </label>
          <p id="para421">
           The risk of acquiring yellow fever in South America is lower than that in Africa because the mosquitoes that transmit the virus between monkeys in the forest canopy do not often come in contact with humans, and there is a relatively high level of immunity in local residents secondary to vaccine use.
          </p>
         </list-item>
        </list>
       </p>
      </sec>
     </sec>
     <sec id="cesec66">
      <title>
       Clinical Presentation
      </title>
      <p id="para422">
       <list id="celist90" list-type="simple">
        <list-item id="celistitem328">
         <label>
          •
         </label>
         <p id="para423">
          Asymptomatic or clinically inapparent infection is believed to occur in the majority of persons infected with YFV.
         </p>
        </list-item>
        <list-item id="celistitem329">
         <label>
          •
         </label>
         <p id="para424">
          The incubation period is typically 3–6 days.
         </p>
        </list-item>
        <list-item id="celistitem330">
         <label>
          •
         </label>
         <p id="para425">
          The initial illness presents as a nonspecific influenza-like syndrome with sudden onset of fever, chills, headache, backache, myalgias, prostration, nausea, and vomiting. Most patients improve after the initial presentation.
         </p>
        </list-item>
        <list-item id="celistitem331">
         <label>
          •
         </label>
         <p id="para426">
          After a brief remission of hours to a day, approximately 15% of cases progress to develop a more serious or toxic form of the disease characterized by jaundice, hemorrhagic symptoms, and eventually shock and multisystem organ failure.
         </p>
        </list-item>
        <list-item id="celistitem332">
         <label>
          •
         </label>
         <p id="para427">
          The overall case–fatality ratio for cases with jaundice is 20%–50%.
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <sec id="cesec67">
      <title>
       Diagnosis
      </title>
      <p id="para428">
       <list id="celist91" list-type="simple">
        <list-item id="celistitem333">
         <label>
          •
         </label>
         <p id="para429">
          The preliminary diagnosis is based on the patient's clinical features, places and dates of travel, and activities.
         </p>
        </list-item>
        <list-item id="celistitem334">
         <label>
          •
         </label>
         <p id="para430">
          Laboratory diagnosis is generally accomplished by testing serum to detect virus-specific IgM and IgG antibodies by serologic assays. Due to cross-reactivity between antibodies raised against other flaviviruses, more specific antibody testing, such as a neutralization test, should be done to confirm the infection.
         </p>
        </list-item>
        <list-item id="celistitem335">
         <label>
          •
         </label>
         <p id="para431">
          Early in the illness, YFV or yellow fever viral RNA can often be detected in serum samples by virus isolation or nucleic acid amplification tests (NAAT). However, by the time more overt symptoms are recognized, the virus or viral RNA is usually undetectable. Therefore, virus isolation and NAAT should not be used for ruling out a diagnosis of yellow fever.
         </p>
        </list-item>
        <list-item id="celistitem336">
         <label>
          •
         </label>
         <p id="para432">
          Health-care providers should contact their state or local health department or call 800-CDC-INFO (800-232-4636) for assistance with diagnostic testing for yellow fever infections and for questions about antibody response to vaccination.
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <sec id="cesec68">
      <title>
       Treatment
      </title>
      <p id="para433">
       <list id="celist92" list-type="simple">
        <list-item id="celistitem337">
         <label>
          •
         </label>
         <p id="para434">
          No specific treatments have been found to benefit patients with yellow fever.
         </p>
        </list-item>
        <list-item id="celistitem338">
         <label>
          •
         </label>
         <p id="para435">
          Treatment is symptomatic. Rest, fluids, and use of analgesics and antipyretics may relieve symptoms of fever and aching. Care should be taken to avoid certain medications, such as aspirin or other nonsteroidal anti-inflammatory drugs, which may increase the risk for bleeding.
         </p>
        </list-item>
        <list-item id="celistitem339">
         <label>
          •
         </label>
         <p id="para436">
          Infected persons should be protected from further mosquito exposure (staying indoors and/or under a mosquito net) during the first few days of illness, so they do not contribute to the transmission cycle.
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <sec id="cesec69">
      <title>
       Preventive Measures for Travelers
      </title>
      <sec id="cesec70">
       <title>
        Personal Protection Measures
       </title>
       <p id="para437">
        <list id="celist93" list-type="simple">
         <list-item id="celistitem340">
          <label>
           •
          </label>
          <p id="para438">
           No drugs for preventing infection are available.
          </p>
         </list-item>
         <list-item id="celistitem341">
          <label>
           •
          </label>
          <p id="para439">
           The best way to prevent mosquito-borne diseases, including yellow fever, is to avoid mosquito bites (see the
           <xref ref-type="sec" rid="subchapter29">
            Protection Against Mosquitoes, Ticks, and Other Insects and Arthropods
           </xref>
           section later in this chapter):
           <list id="celist94" list-type="simple">
            <list-item id="celistitem342">
             <label>
              ○
             </label>
             <p id="para440">
              Use insect repellent containing DEET, Picaridin, oil of lemon eucalyptus, or IR3535 on exposed skin. Always follow the directions on the package.
             </p>
            </list-item>
            <list-item id="celistitem343">
             <label>
              ○
             </label>
             <p id="para441">
              Wear long sleeves, pants, and socks. If possible, treat clothes with permethrin.
             </p>
            </list-item>
            <list-item id="celistitem344">
             <label>
              ○
             </label>
             <p id="para442">
              Stay in screened or air-conditioned accommodations to keep mosquitoes out.
             </p>
            </list-item>
            <list-item id="celistitem345">
             <label>
              ○
             </label>
             <p id="para443">
              Get rid of mosquito sources by emptying standing water from flowerpots, buckets, car tires and barrels.
             </p>
            </list-item>
           </list>
          </p>
         </list-item>
        </list>
       </p>
      </sec>
      <sec id="cesec71">
       <title>
        Yellow Fever Vaccine
       </title>
       <p id="para444">
        <list id="celist95" list-type="simple">
         <list-item id="celistitem346">
          <label>
           •
          </label>
          <p id="para445">
           Yellow fever is preventable by a relatively safe, effective vaccine.
          </p>
         </list-item>
         <list-item id="celistitem347">
          <label>
           •
          </label>
          <p id="para446">
           All yellow fever vaccines currently manufactured are live attenuated viral vaccines.
          </p>
         </list-item>
         <list-item id="celistitem348">
          <label>
           •
          </label>
          <p id="para447">
           YF-VAX, the only yellow fever vaccine approved for use in the United States, is manufactured by sanofi pasteur.
          </p>
         </list-item>
         <list-item id="celistitem349">
          <label>
           •
          </label>
          <p id="para448">
           Studies comparing the reactogenicity and immunogenicity of various yellow fever vaccines, including those manufactured outside of the United States, suggest that there is no significant difference in the reactogenicity or immune response generated by the various vaccines. Thus, individuals who receive yellow fever vaccines in other countries should be considered protected against yellow fever.
          </p>
         </list-item>
        </list>
       </p>
       <sec id="cesec72">
        <title>
         Recommendations for the Use of Yellow Fever Vaccine for Travelers
        </title>
        <p id="para449">
         <list id="celist96" list-type="simple">
          <list-item id="celistitem350">
           <label>
            •
           </label>
           <p id="para450">
            Persons aged Δ9 months of age who are traveling to or living in areas with risk of yellow fever transmission in South America and Africa should be vaccinated. In addition, some countries require proof of yellow fever vaccination for entry. See the following section in this chapter (
            <xref ref-type="sec" rid="subchapter7">
             Yellow Fever Vaccine Requirements and Recommendations, by Country
            </xref>
            ) for more detailed information on the requirements and recommendations for yellow fever vaccination for specific countries.
           </p>
          </list-item>
          <list-item id="celistitem351">
           <label>
            •
           </label>
           <p id="para451">
            However, because severe adverse events (see below) can follow yellow fever vaccination, physicians should be careful to administer the vaccine only to persons truly at risk of exposure to YFV.
           </p>
          </list-item>
          <list-item id="celistitem352">
           <label>
            •
           </label>
           <p id="para452">
            Refer to Yellow Fever Vaccine Recommendations of the Advisory Committee on Immunization Practices (ACIP) for additional information at
            <ext-link ext-link-type="uri" id="interref16" xlink:href="http://www.cdc.gov/vaccines/pubs/ACIP-list.htm">
             www.cdc.gov/vaccines/pubs/ACIP-list.htm
            </ext-link>
            .
           </p>
          </list-item>
         </list>
        </p>
       </sec>
       <sec id="cesec73">
        <title>
         Vaccine Dose and Administration
        </title>
        <p id="para453">
         <list id="celist97" list-type="simple">
          <list-item id="celistitem353">
           <label>
            •
           </label>
           <p id="para454">
            For all eligible persons, a single injection of 0.5 mL of reconstituted vaccine should be administered subcutaneously.
           </p>
          </list-item>
          <list-item id="celistitem354">
           <label>
            •
           </label>
           <p id="para455">
            The International Health Regulations (IHR) published by WHO require revaccination at 10-year intervals.
           </p>
          </list-item>
         </list>
        </p>
       </sec>
       <sec id="cesec74">
        <title>
         Vaccine Safety and Adverse Reactions
        </title>
        <sec id="cesec75">
         <title>
          Common Adverse Events
         </title>
         <p id="para456">
          <list id="celist98" list-type="simple">
           <list-item id="celistitem355">
            <label>
             •
            </label>
            <p id="para457">
             Reactions to yellow fever vaccine are generally mild, with 10%–30% of vaccinees reporting mild systemic adverse events.
            </p>
           </list-item>
           <list-item id="celistitem356">
            <label>
             •
            </label>
            <p id="para458">
             Reported events typically include low-grade fever, headache, and myalgias that begin within days after vaccination and last 5–10 days.
            </p>
           </list-item>
           <list-item id="celistitem357">
            <label>
             •
            </label>
            <p id="para459">
             Approximately 1% of vaccinees temporarily curtail their regular activities because of these reactions.
            </p>
           </list-item>
          </list>
         </p>
        </sec>
        <sec id="cesec76">
         <title>
          Severe Adverse Events
         </title>
         <sec id="cesec77">
          <title>
           Hypersensitivity
          </title>
          <p id="para460">
           Immediate hypersensitivity reactions, characterized by rash, urticaria, or asthma or a combination of these, are uncommon. Anaphylaxis following yellow fever vaccine is reported to occur at a rate of 1.8 cases per 100,000 doses administered.
          </p>
         </sec>
         <sec id="cesec78">
          <title>
           Yellow Fever Vaccine-Associated Neurologic Disease (YEL-AND)
          </title>
          <p id="para461">
           <list id="celist99" list-type="simple">
            <list-item id="celistitem358">
             <label>
              •
             </label>
             <p id="para462">
              YEL-AND represents a conglomerate of different clinical syndromes, including meningoencephalitis, Guillain–Barré syndrome (GBS), acute disseminated encephalomyelitis (ADEM), bulbar palsy, and Bell's palsy.
             </p>
            </list-item>
            <list-item id="celistitem359">
             <label>
              •
             </label>
             <p id="para463">
              Historically, YEL-AND was seen primarily among infants as encephalitis, but more recent reports have been among persons of all ages.
             </p>
            </list-item>
            <list-item id="celistitem360">
             <label>
              •
             </label>
             <p id="para464">
              The onset of illness for documented cases ranges 3–28 days after vaccination, and almost all cases were in first-time vaccine recipients.
             </p>
            </list-item>
            <list-item id="celistitem361">
             <label>
              •
             </label>
             <p id="para465">
              YEL-AND is rarely fatal.
             </p>
            </list-item>
            <list-item id="celistitem362">
             <label>
              •
             </label>
             <p id="para466">
              The incidence of YEL-AND in the United States is 0.8 per 100,000 doses administered. The rate is higher in persons Δ60 years of age, with a rate of 1.6 per 100,000 doses in persons 60–69 years of age and 2.3 per 100,000 doses in persons Δ70 years of age.
             </p>
            </list-item>
           </list>
          </p>
         </sec>
         <sec id="cesec79">
          <title>
           Yellow Fever Vaccine-Associated Viscerotropic Disease (YEL-AVD)
          </title>
          <p id="para467">
           <list id="celist100" list-type="simple">
            <list-item id="celistitem363">
             <label>
              •
             </label>
             <p id="para468">
              YEL-AVD is a severe illness similar to wild-type disease, with vaccine virus proliferating in multiple organs and often leading to multisystem organ failure and death.
             </p>
            </list-item>
            <list-item id="celistitem364">
             <label>
              •
             </label>
             <p id="para469">
              Since the initial cases of YEL-AVD were published in 2001, more than 40 confirmed and suspected cases have been reported throughout the world.
             </p>
            </list-item>
            <list-item id="celistitem365">
             <label>
              •
             </label>
             <p id="para470">
              The onset of illness for YEL-AVD cases averaged 3.5 days (range: 1–8 days) after vaccination. YEL-AVD appears to occur after the first dose of yellow fever vaccine rather than with booster doses.
             </p>
            </list-item>
            <list-item id="celistitem366">
             <label>
              •
             </label>
             <p id="para471">
              The case–fatality ratio for reported YEL-AVD cases is 53%.
             </p>
            </list-item>
            <list-item id="celistitem367">
             <label>
              •
             </label>
             <p id="para472">
              The incidence of YEL-AVD in the United States is 0.4 cases per 100,000 doses of vaccine administered. The rate is higher for persons Δ60 years of age, with a rate of 1 per 100,000 doses in persons 60–69 years of age and 2.3 per 100,000 doses in persons aged Δ70 years of age.
             </p>
            </list-item>
           </list>
          </p>
         </sec>
        </sec>
       </sec>
       <sec id="cesec80">
        <title>
         Contraindications
        </title>
        <sec id="cesec81">
         <title>
          Infants &lt;9 Months of Age
         </title>
         <p id="para473">
          <list id="celist101" list-type="simple">
           <list-item id="celistitem368">
            <label>
             •
            </label>
            <p id="para474">
             The vaccine is contraindicated for routine use in infants &lt;9 months of age by the manufacturer and the FDA because of the increased risk of postvaccine encephalitis. However, ACIP and WHO recognize that situations occur in which vaccination of an infant 6–8 months of age might be considered, such as residence in or unavoidable travel to a yellow fever endemic or epidemic zone. The decision to immunize infants who are 6–8 months of age must balance the infant's risk for exposure with the risk for vaccine-associated encephalitis.
             <bold>
              YF vaccine should never be administered to infants &lt;6 months of age
             </bold>
             .
            </p>
           </list-item>
           <list-item id="celistitem369">
            <label>
             •
            </label>
            <p id="para475">
             Physicians considering vaccinating infants aged &lt;9 months of age should contact their state health department or call 800-CDC-INFO (800-232-4636) for further advice.
            </p>
           </list-item>
          </list>
         </p>
        </sec>
        <sec id="cesec82">
         <title>
          Hypersensitivity
         </title>
         <p id="para476">
          <list id="celist102" list-type="simple">
           <list-item id="celistitem370">
            <label>
             •
            </label>
            <p id="para477">
             Yellow fever vaccine is contraindicated in anyone with a history of acute hypersensitivity reaction to any of the vaccine components, including gelatin. Because the yellow fever vaccine is produced in chicken embryos, vaccine should not be administered to anyone with a history of acute hypersensitivity to egg or chicken proteins.
            </p>
           </list-item>
           <list-item id="celistitem371">
            <label>
             •
            </label>
            <p id="para478">
             If vaccination of a person with a questionable history of hypersensitivity to one of the vaccine components is considered essential because of a high risk for acquiring yellow fever, desensitizing and vaccinating procedures are described in the vaccine package insert and should be performed under close medical supervision.
            </p>
           </list-item>
          </list>
         </p>
        </sec>
        <sec id="cesec83">
         <title>
          Immunosuppression
         </title>
         <p id="para479">
          <list id="celist103" list-type="simple">
           <list-item id="celistitem372">
            <label>
             •
            </label>
            <p id="para480">
             The vaccine is contraindicated in persons with immunocompromising conditions, including symptomatic HIV infection or AIDS, malignancy, or diseases of the thymus (e.g., thymectomy) or those receiving immunosuppressant therapy (e.g., corticosteroids, alkylating agents, antimetabolites) or radiation therapy.
            </p>
           </list-item>
           <list-item id="celistitem373">
            <label>
             •
            </label>
            <p id="para481">
             Immunosuppressed persons should not be immunized, and travel to yellow fever-endemic areas should be postponed or avoided.
            </p>
           </list-item>
           <list-item id="celistitem374">
            <label>
             •
            </label>
            <p id="para482">
             If travel to yellow fever endemic areas is unavoidable, persons who cannot be immunized because of their immunosuppressive condition should be advised of the risk for acquiring yellow fever disease, instructed in methods for avoiding vector mosquitoes, and, if warranted, issued a medical waiver to fulfill international health regulations (see information in
             <xref ref-type="sec" rid="cesec97">
              Exemption from Vaccination and Waiver Letters
             </xref>
             in this section).
            </p>
           </list-item>
           <list-item id="celistitem375">
            <label>
             •
            </label>
            <p id="para483">
             Physicians considering vaccinating an immunosuppressed individual can contact their state health department or call for more information.
            </p>
           </list-item>
           <list-item id="celistitem376">
            <label>
             •
            </label>
            <p id="para484">
             Family members of immunosuppressed or HIV-infected persons who themselves have no contraindications can receive yellow fever vaccine.
            </p>
           </list-item>
          </list>
         </p>
         <sec id="cesec84">
          <title>
           AIDS or Symptomatic HIV
          </title>
          <p id="para485">
           No large-scale trials have been done to evaluate the safety of the yellow fever vaccine in individuals with HIV or AIDS. However, because yellow fever vaccine is a live, viral vaccine, it is contraindicated in persons with symptomatic HIV infection or AIDS. (For persons with asymptomatic HIV infection, see
           <xref ref-type="sec" rid="cesec87">
            Precautions
           </xref>
           below.)
          </p>
         </sec>
         <sec id="cesec85">
          <title>
           History of Thymus Disease
          </title>
          <p id="para486">
           <list id="celist104" list-type="simple">
            <list-item id="celistitem377">
             <label>
              •
             </label>
             <p id="para487">
              A history of thymus disease is a contraindication to yellow fever vaccine.
             </p>
            </list-item>
            <list-item id="celistitem378">
             <label>
              •
             </label>
             <p id="para488">
              Four persons with a history of thymectomy for a thymoma were noted among the first 23 cases of YEL-AVD, suggesting that compromised thymus function is an independent risk factor for YEL-AVD.
             </p>
            </list-item>
            <list-item id="celistitem379">
             <label>
              •
             </label>
             <p id="para489">
              Health-care providers should be careful to ask about a history of thymus disorder, including myasthenia gravis, thymoma, or prior thymectomy, when screening a patient before administering yellow fever vaccine.
             </p>
            </list-item>
           </list>
          </p>
         </sec>
         <sec id="cesec86">
          <title>
           Immunosuppressive Medication
          </title>
          <p id="para490">
           <list id="celist105" list-type="simple">
            <list-item id="celistitem380">
             <label>
              •
             </label>
             <p id="para491">
              Although no studies have been done to evaluate the safety of yellow fever vaccine in persons receiving immunosuppressive or immunomodulating medicines, the vaccine is contraindicated in those receiving medications that alter the ability to resist viral infections. The vaccine should not be given to individuals who are taking medications with a warning in the package insert against the use of live viral vaccines.
             </p>
            </list-item>
            <list-item id="celistitem381">
             <label>
              •
             </label>
             <p id="para492">
              Low-dose (i.e., 20 mg or less of prednisone or equivalent/day); short-term (i.e., &lt;2 weeks) systemic corticosteroid therapy or intra-articular, bursal, or tendon injections with corticosteroids; and intranasal corticosteroids are not thought to be sufficiently immunosuppressive to constitute an increased hazard to recipients of yellow fever vaccine (see The Immunocompromised Traveler section in Chapter 8).
             </p>
            </list-item>
           </list>
          </p>
         </sec>
        </sec>
       </sec>
       <sec id="cesec87">
        <title>
         Precautions
        </title>
        <sec id="cesec88">
         <title>
          Adults 60 Years of Age or Older
         </title>
         <p id="para493">
          <list id="celist106" list-type="simple">
           <list-item id="celistitem382">
            <label>
             •
            </label>
            <p id="para494">
             Analysis of adverse events passively reported to the Vaccine Adverse Event Reporting System (VAERS) indicate that persons 60 years of age or older may be at increased risk for systemic adverse events following vaccination compared with younger persons.
            </p>
           </list-item>
           <list-item id="celistitem383">
            <label>
             •
            </label>
            <p id="para495">
             The rate of any serious adverse event following vaccination is 1.5 times higher than the average rate for persons 60–69 years of age and 3 times higher for persons 70 years or older.
            </p>
           </list-item>
           <list-item id="celistitem384">
            <label>
             •
            </label>
            <p id="para496">
             To determine if vaccination should be administered to travelers 60 years of age or older, the risks and benefits of vaccination should be weighed against their destination-specific risk for exposure to YFV.
            </p>
           </list-item>
          </list>
         </p>
        </sec>
        <sec id="cesec89">
         <title>
          Asymptomatic HIV
         </title>
         <p id="para497">
          <list id="celist107" list-type="simple">
           <list-item id="celistitem385">
            <label>
             •
            </label>
            <p id="para498">
             Persons who are HIV-infected but who do not have AIDS or other symptomatic manifestations of HIV infection, who have established laboratory verification of adequate immune system function (e.g., CD4+ T cell counts &gt;200/mm
             <sup>
              3
             </sup>
             ), and who cannot avoid potential exposure to YFV should be offered the choice of vaccination.
            </p>
           </list-item>
           <list-item id="celistitem386">
            <label>
             •
            </label>
            <p id="para499">
             If international travel requirements are the only reason to vaccinate an asymptomatic HIV-infected person, rather than an increased risk for acquiring yellow fever, the person should be excused from immunization and issued a medical waiver to fulfill health regulations (see information in
             <xref ref-type="sec" rid="cesec97">
              Exemption from Vaccination and Waiver Letters
             </xref>
             in this section).
            </p>
           </list-item>
           <list-item id="celistitem387">
            <label>
             •
            </label>
            <p id="para500">
             Data are limited regarding seroconversion rates after yellow fever vaccination among asymptomatic HIV-infected persons, but indicate that the seroconversion rate among such persons may be reduced. Because vaccination of asymptomatic HIV-infected persons might be less effective than that of persons not infected with HIV, measurement of the neutralizing antibody response to vaccination should be considered before travel.
            </p>
           </list-item>
          </list>
         </p>
        </sec>
        <sec id="cesec90">
         <title>
          Pregnancy
         </title>
         <p id="para501">
          <list id="celist108" list-type="simple">
           <list-item id="celistitem388">
            <label>
             •
            </label>
            <p id="para502">
             The safety of yellow fever vaccination during pregnancy has not been studied in a large prospective trial. However, a recent study of women who were vaccinated with yellow fever vaccine early in their pregnancies found no major malformations in their infants. There was slight increased risk noted for minor, mostly skin, malformations.
            </p>
           </list-item>
           <list-item id="celistitem389">
            <label>
             •
            </label>
            <p id="para503">
             In a similar study, a higher rate of spontaneous abortions in pregnant women receiving the vaccine was reported but not substantiated.
            </p>
           </list-item>
           <list-item id="celistitem390">
            <label>
             •
            </label>
            <p id="para504">
             The proportion of women vaccinated during pregnancy who develop YF IgG-specific antibodies is variable depending on the study (38.6% or 98.2%) and may be correlated with the trimester in which they received the vaccine. Because pregnancy may affect immunologic function, serologic testing can be considered to document a protective immune response to the vaccine.
            </p>
           </list-item>
           <list-item id="celistitem391">
            <label>
             •
            </label>
            <p id="para505">
             For pregnant women, if travel is unavoidable and the vaccination risks are felt to outweigh the risks of YF exposure, these women should be excused from immunization and, if applicable, issued a medical waiver to fulfill international health regulations (see information in
             <xref ref-type="sec" rid="cesec97">
              Exemption from Vaccination and Waiver Letters
             </xref>
             in this section). Pregnant women who must travel to areas where the risk of yellow fever infection is high should be vaccinated, and their infants should be monitored after birth for evidence of congenital infection and other possible adverse effects resulting from yellow fever vaccination.
            </p>
           </list-item>
           <list-item id="celistitem392">
            <label>
             •
            </label>
            <p id="para506">
             Although there are no specific data, it is recommended that a woman wait 4 weeks after receiving the live virus yellow fever vaccine before conceiving.
            </p>
           </list-item>
          </list>
         </p>
        </sec>
        <sec id="cesec91">
         <title>
          Breastfeeding
         </title>
         <p id="para507">
          <list id="celist109" list-type="simple">
           <list-item id="celistitem393">
            <label>
             •
            </label>
            <p id="para508">
             Whether the yellow fever vaccine is excreted in breast milk is not known.
            </p>
           </list-item>
           <list-item id="celistitem394">
            <label>
             •
            </label>
            <p id="para509">
             One suspect case of YEL-AND has been reported in a 1-month old infant whose mother was vaccinated with yellow fever vaccine and the infant was exclusively breastfed. Testing was unable to determine if the breast milk was the mode of transmission.
            </p>
           </list-item>
           <list-item id="celistitem395">
            <label>
             •
            </label>
            <p id="para510">
             It is recommended that vaccination of nursing mothers should be avoided. However, when travel of nursing mothers to high-risk yellow fever-endemic areas cannot be avoided or postponed, these women should be vaccinated.
            </p>
           </list-item>
          </list>
         </p>
        </sec>
       </sec>
       <sec id="cesec92">
        <title>
         Simultaneous Administration of Other Vaccines and Drugs
        </title>
        <p id="para511">
         <list id="celist110" list-type="simple">
          <list-item id="celistitem396">
           <label>
            •
           </label>
           <p id="para512">
            One study suggested that the immune response to yellow fever vaccine is not inhibited by administration of measles vaccine (also a live, attenuated vaccine) given concurrently or at various intervals of a few days to 1 month prior. However, to minimize the potential risk for interference, injectable or nasally administered live vaccines not administered on the same day should be given at least 4 weeks apart.
           </p>
          </list-item>
          <list-item id="celistitem397">
           <label>
            •
           </label>
           <p id="para513">
            A prospective study of persons given yellow fever vaccine along with 5 mL of commercially available IG showed no alteration of the immunologic response to yellow fever vaccine when compared with controls.
           </p>
          </list-item>
         </list>
        </p>
       </sec>
      </sec>
     </sec>
     <sec id="cesec93">
      <title>
       International Certificate of Vaccination or Prophylaxis (ICVP)
      </title>
      <sec id="cesec94">
       <title>
        Background
       </title>
       <p id="para514">
        <list id="celist111" list-type="simple">
         <list-item id="celistitem398">
          <label>
           •
          </label>
          <p id="para515">
           The International Health Regulations (IHR) allow countries to require proof of yellow fever vaccination for entry and from travelers arriving from certain countries, even if only in transit, to prevent importation and indigenous transmission of YFV.
          </p>
         </list-item>
         <list-item id="celistitem399">
          <label>
           •
          </label>
          <p id="para516">
           Some countries require evidence of vaccination from all entering travelers, which includes direct travel from the United States (
           <xref ref-type="table" rid="cetable13">
            Table 2-13
           </xref>
           ).
           <table-wrap id="cetable13" position="float">
            <label>
             Table 2-13
            </label>
            <caption>
             <p>
              Countries that require proof of yellow fever vaccination for all arriving travelers
              <xref ref-type="table-fn" rid="cetablefn56">
               1
              </xref>
             </p>
            </caption>
            <table frame="hsides" rules="groups">
             <tbody>
              <tr>
               <td align="left">
                Angola
               </td>
               <td align="left">
                French Guiana
               </td>
              </tr>
              <tr>
               <td align="left">
                Benin
               </td>
               <td align="left">
                Gabon
               </td>
              </tr>
              <tr>
               <td align="left">
                Bolivia (or signed affidavit at point of entry)
               </td>
               <td align="left">
                Ghana
               </td>
              </tr>
              <tr>
               <td align="left">
                Burkina Faso
               </td>
               <td align="left">
                Liberia
               </td>
              </tr>
              <tr>
               <td align="left">
                Burundi
               </td>
               <td align="left">
                Mali
               </td>
              </tr>
              <tr>
               <td align="left">
                Cameroon
               </td>
               <td align="left">
                Niger
               </td>
              </tr>
              <tr>
               <td align="left">
                Central African Republic
               </td>
               <td align="left">
                Rwanda
               </td>
              </tr>
              <tr>
               <td align="left">
                Congo, Republic of the
               </td>
               <td align="left">
                São Tomé and Príncipe
               </td>
              </tr>
              <tr>
               <td align="left">
                Côte d'Ivoire
               </td>
               <td align="left">
                Sierra Leone
               </td>
              </tr>
              <tr>
               <td align="left">
                Democratic Republic of the Congo
               </td>
               <td align="left">
                Togo
               </td>
              </tr>
             </tbody>
            </table>
            <table-wrap-foot>
             <fn id="cetablefn56">
              <label>
               1
              </label>
              <p id="cenotep56">
               Country requirements for yellow fever vaccination are subject to change at any time; therefore, CDC encourages travelers to check with the destination country's embassy or consulate before departure.
              </p>
             </fn>
            </table-wrap-foot>
           </table-wrap>
          </p>
         </list-item>
         <list-item id="celistitem400">
          <label>
           •
          </label>
          <p id="para517">
           Travelers who arrive in a country with a yellow fever vaccination entry requirement without proof of yellow fever vaccination may be quarantined up to 6 days.
          </p>
         </list-item>
         <list-item id="celistitem401">
          <label>
           •
          </label>
          <p id="para518">
           Travelers with a specific contraindication to yellow fever vaccine should request a waiver from a physician before traveling to countries requiring vaccination (see below).
          </p>
         </list-item>
        </list>
       </p>
      </sec>
      <sec id="cesec95">
       <title>
        Authorization to Provide Vaccinations and to Validate the ICVP
       </title>
       <p id="para519">
        <list id="celist112" list-type="simple">
         <list-item id="celistitem402">
          <label>
           •
          </label>
          <p id="para520">
           Under the revised IHR (2005), effective December 15, 2007, all state parties (countries) are required to issue a new ICVP. This is intended to replace the former International Certificate of Vaccination against Yellow Fever (ICV).
           <list id="celist113" list-type="simple">
            <list-item id="celistitem403">
             <label>
              ○
             </label>
             <p id="para521">
              Persons who received a yellow fever vaccination after December 15, 2007, must provide proof of vaccination on an ICVP.
             </p>
            </list-item>
            <list-item id="celistitem404">
             <label>
              ○
             </label>
             <p id="para522">
              If the person received the vaccine before December 15, 2007, the original ICV is still valid, provided that the vaccination was given less than 10 years previously.
             </p>
            </list-item>
           </list>
          </p>
         </list-item>
         <list-item id="celistitem405">
          <label>
           •
          </label>
          <p id="para523">
           Vaccinees should receive a completed ICVP (
           <xref ref-type="fig" rid="f1">
            Figure 2-1
           </xref>
           ), validated (stamped and signed) with the center's stamp where the vaccine was given (see below).
           <list id="celist114" list-type="simple">
            <list-item id="celistitem406">
             <label>
              ○
             </label>
             <p id="para524">
              An ICVP must be complete in every detail; if incomplete or inaccurate, it is not valid.
             </p>
            </list-item>
            <list-item id="celistitem407">
             <label>
              ○
             </label>
             <p id="para525">
              Failure to secure validations can cause a traveler to be quarantined, denied entry, or possibly revaccinated at the point of entry to a country. This is not a recommended option for the traveler.
             </p>
            </list-item>
           </list>
           <fig id="f1">
            <label>
             Figure 2-1
            </label>
            <caption>
             <p>
              Example International Certificate of Vaccination or Prophylaxis (ICVP).
             </p>
            </caption>
            <graphic xlink:href="gr1">
            </graphic>
           </fig>
          </p>
         </list-item>
         <list-item id="celistitem408">
          <label>
           •
          </label>
          <p id="para526">
           A copy of the ICVP, CDC 731 (formerly PHS 731) may be purchased from the U.S. Government Printing Office, Washington, D.C.,
           <ext-link ext-link-type="uri" id="interref17" xlink:href="http://bookstore.gpo.gov/,">
            http://bookstore.gpo.gov/,
           </ext-link>
           telephone 866-512-1800. The stock number is 017-001-00567-3 for 25 copies and 017-001-00566-5 for 100 copies.
          </p>
         </list-item>
         <list-item id="celistitem409">
          <label>
           •
          </label>
          <p id="para527">
           This certificate of vaccination is valid for a period of 10 years, beginning 10 days after vaccination. With booster doses of the vaccine, the certificate is considered valid from the day of vaccination.
          </p>
         </list-item>
        </list>
       </p>
      </sec>
      <sec id="cesec96">
       <title>
        Persons Authorized to Sign the Certificate and Designated Yellow Fever Vaccination Centers
       </title>
       <p id="para528">
        <list id="celist115" list-type="simple">
         <list-item id="celistitem410">
          <label>
           •
          </label>
          <p id="para529">
           The ICVP must be signed by a licensed physician or by a health-care worker designated by the physician supervising the administration of the vaccine (
           <xref ref-type="fig" rid="f1">
            Figure 2-1
           </xref>
           ). A signature stamp is not acceptable.
          </p>
         </list-item>
         <list-item id="celistitem411">
          <label>
           •
          </label>
          <p id="para530">
           Yellow fever vaccination must be given at a certified center in possession of an official “Uniform Stamp,” which can be used to validate the ICVP.
          </p>
         </list-item>
         <list-item id="celistitem412">
          <label>
           •
          </label>
          <p id="para531">
           State health departments are responsible for designating nonfederal yellow fever vaccination centers and issuing Uniform Stamps to physicians.
          </p>
         </list-item>
         <list-item id="celistitem413">
          <label>
           •
          </label>
          <p id="para532">
           Information about the location and hours of yellow fever vaccination centers may be obtained by visiting CDC's Travelers' Health website at
           <ext-link ext-link-type="uri" id="interref18" xlink:href="http://wwwn.cdc.gov/travel/yellowfever.aspx">
            wwwn.cdc.gov/travel/yellowfever.aspx
           </ext-link>
           .
          </p>
         </list-item>
        </list>
       </p>
      </sec>
      <sec id="cesec97">
       <title>
        Exemption from Vaccination and Waiver Letters
       </title>
       <p id="para533">
        <list id="celist116" list-type="simple">
         <list-item id="celistitem414">
          <label>
           •
          </label>
          <p id="para534">
           Some countries do not require an ICVP for infants younger than a certain age (e.g., &lt;6 months, &lt;9 months, or &lt;1 year of age, depending on the country). Age requirements for vaccination for individual countries can be found in the Yellow Fever Vaccine Requirements and Recommendations section in this chapter.
          </p>
         </list-item>
         <list-item id="celistitem415">
          <label>
           •
          </label>
          <p id="para535">
           For medical contraindications, a physician who has decided to issue a waiver should fill out and sign the Medical Contraindications to Vaccination section of the ICVP (
           <xref ref-type="fig" rid="f2">
            Figure 2-2
           </xref>
           ). The physician should also—
           <list id="celist117" list-type="simple">
            <list-item id="celistitem416">
             <label>
              ○
             </label>
             <p id="para536">
              Give the traveler a signed and dated exemption letter on the physician's letterhead stationery, clearly stating the contraindications to vaccination and bearing the stamp used by the yellow fever vaccination centers to validate the ICVP.
             </p>
            </list-item>
            <list-item id="celistitem417">
             <label>
              ○
             </label>
             <p id="para537">
              Inform the traveler of any increased risk of yellow fever infection associated with nonvaccination and how to minimize this risk by using mosquito protection measures.
             </p>
            </list-item>
           </list>
           <fig id="f2">
            <label>
             Figure 2-2
            </label>
            <caption>
             <p>
              Example International Certificate of Vaccination or Prophylaxis (ICVP) medical contraindication to vaccination.
             </p>
            </caption>
            <graphic xlink:href="gr2">
            </graphic>
           </fig>
          </p>
         </list-item>
         <list-item id="celistitem418">
          <label>
           •
          </label>
          <p id="para538">
           Reasons other than medical contraindications are not acceptable for exemption from vaccination.
          </p>
         </list-item>
         <list-item id="celistitem419">
          <label>
           •
          </label>
          <p id="para539">
           The traveler should be advised that issuance of a waiver does not guarantee its acceptance by the destination country. On arrival at the destination, the traveler may be faced with quarantine, refusal of entry, or vaccination on site.
          </p>
         </list-item>
         <list-item id="celistitem420">
          <label>
           •
          </label>
          <p id="para540">
           To potentially improve the likelihood of acceptance of a waiver upon arrival at the destination country, the provider can suggest that the traveler take the following additional measures before initiating travel:
           <list id="celist118" list-type="simple">
            <list-item id="celistitem421">
             <label>
              ○
             </label>
             <p id="para541">
              Obtain specific and authoritative advice from the embassy or consulate of the country or countries he or she plans to visit.
             </p>
            </list-item>
            <list-item id="celistitem422">
             <label>
              ○
             </label>
             <p id="para542">
              Request documentation of requirements for waivers from embassies or consulates and retain these along with the completed Medical Contraindication to Vaccination section of the ICVP.
             </p>
            </list-item>
           </list>
          </p>
         </list-item>
        </list>
       </p>
      </sec>
      <sec id="cesec98">
       <title>
        Requirements Versus Recommendations
       </title>
       <p id="para543">
        <list id="celist119" list-type="simple">
         <list-item id="celistitem423">
          <label>
           •
          </label>
          <p id="para544">
           Country entry
           <bold>
            requirements
           </bold>
           for proof of yellow fever vaccination under the IHRs are different from CDC's
           <bold>
            recommendations
           </bold>
           .
          </p>
         </list-item>
         <list-item id="celistitem424">
          <label>
           •
          </label>
          <p id="para545">
           Yellow fever vaccine entry
           <bold>
            requirements
           </bold>
           are established by countries in order to prevent the importation and transmission of YFV, and are allowed under the IHRs. Travelers must comply with these to enter the country, unless they have been issued a medical waiver. Certain countries require vaccination from travelers arriving from all countries, while some countries require vaccination only for travelers coming from “a country with risk of yellow fever transmission” (
           <xref ref-type="table" rid="cetable14">
            Table 2-14
           </xref>
           ). WHO defines those areas “at risk of yellow fever transmission” as countries or areas where yellow fever has been reported currently or in the past, plus where vectors and animal reservoirs currently exist. Country requirements are subject to change at any time; therefore, CDC encourages travelers to check with the appropriate embassy or consulate before departure.
           <table-wrap id="cetable14" position="float">
            <label>
             Table 2-14
            </label>
            <caption>
             <p>
              Yellow fever vaccine requirements and recommendations, by country
             </p>
            </caption>
            <table frame="hsides" rules="groups">
             <thead>
              <tr>
               <th align="left">
                Country
               </th>
               <th align="left">
                Yellow Fever Vaccine Requirements
                <xref ref-type="table-fn" rid="cetablefn57">
                 1
                </xref>
                ,
                <xref ref-type="table-fn" rid="cetablefn58">
                 2
                </xref>
               </th>
               <th align="left">
                CDC Yellow Fever Vaccine Recommendations
                <xref ref-type="table-fn" rid="cetablefn58">
                 2
                </xref>
                ,
                <xref ref-type="table-fn" rid="cetablefn59">
                 3
                </xref>
                ,
                <xref ref-type="table-fn" rid="cetablefn60">
                 4
                </xref>
               </th>
              </tr>
             </thead>
             <tbody>
              <tr>
               <td align="left">
                <bold>
                 Afghanistan
                </bold>
               </td>
               <td align="left">
                If traveling from a country with risk of yellow fever transmission
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Albania
                </bold>
               </td>
               <td align="left">
                If traveling from a country with risk of yellow fever transmission and ≥1 year of age
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Algeria
                </bold>
               </td>
               <td align="left">
                If traveling from a country with risk of yellow fever transmission and ≥1 year of age
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Andorra
                </bold>
               </td>
               <td align="left">
                Not required
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Angola
                </bold>
               </td>
               <td align="left">
                Required upon arrival from all countries if traveler is ≥1 year of age
               </td>
               <td align="left">
                For all travelers ≥9 months of age
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Anguilla
                </bold>
                (U.K.)
               </td>
               <td align="left">
                If traveling from a country with risk of yellow fever transmission and ≥1 year of age
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Antarctica
                </bold>
               </td>
               <td align="left">
                Not required
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Antigua and Barbuda
                </bold>
               </td>
               <td align="left">
                If traveling from a country with risk of yellow fever transmission and ≥1 year of age
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Argentina
                </bold>
               </td>
               <td align="left">
                Not required
               </td>
               <td align="left">
                Yellow fever vaccination is recommended for all travelers ≥9 months of age who are going to the northern and northeastern forested areas of Argentina, including Iguassu Falls and all areas bordering Paraguay and Brazil. These areas include all departments of Misiones and Formosa Provinces; and the Department of Bermejo in Chaco Province; Departments of Berón de Astrada, Capital, General Alvear, General Paz, Ituzaingó, Itatí, Paso de los Libres, San Cosme, San Miguel, San Martín, and Santo Tomé in Corrientes Province; Departments of Valle Grande, Ledesma, Santa Bárbara, and San Pedro in Jujuy Province; and Departments of General José de San Martín, Oran, Rivadavia, and Anta in Salta Province.
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Armenia
                </bold>
               </td>
               <td align="left">
                Not required
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Aruba
                </bold>
               </td>
               <td align="left">
                If traveling from a country with risk of yellow fever transmission and ≥6 months of age
                <xref ref-type="table-fn" rid="cetablefn61">
                 5
                </xref>
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Australia
                </bold>
               </td>
               <td align="left">
                All persons ≥1 year of age who, within 6 days of arrival in Australia, have been in or have passed through a country with risk of yellow fever transmission
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Austria
                </bold>
               </td>
               <td align="left">
                Not required
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Azerbaijan
                </bold>
               </td>
               <td align="left">
                Not required
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Azores
                </bold>
                (Portugal)
               </td>
               <td align="left">
                If traveling from a country with risk of yellow fever transmission and ≥1 year of age
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Bahamas, The
                </bold>
               </td>
               <td align="left">
                If traveling from a country with risk of yellow fever transmission and ≥1 year of age
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Bahrain
                </bold>
               </td>
               <td align="left">
                If traveling from a country with risk of yellow fever transmission and ≥1 year of age
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Bangladesh
                </bold>
               </td>
               <td align="left">
                If traveling from a country with risk of yellow fever transmission and ≥1 year of age
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Barbados
                </bold>
               </td>
               <td align="left">
                If traveling from a country with risk of yellow fever transmission and ≥1 year of age
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Belarus
                </bold>
               </td>
               <td align="left">
                Not required
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Belgium
                </bold>
               </td>
               <td align="left">
                Not required
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Belize
                </bold>
               </td>
               <td align="left">
                If traveling from a country with risk of yellow fever transmission and ≥1 year of age
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Benin
                </bold>
               </td>
               <td align="left">
                Required upon arrival from all countries if traveler is ≥1 year of age
               </td>
               <td align="left">
                For all travelers ≥9 months of age
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Bermuda
                </bold>
                (U.K.)
               </td>
               <td align="left">
                Not required
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Bhutan
                </bold>
               </td>
               <td align="left">
                If traveling from a country with risk of yellow fever transmission
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Bolivia
                </bold>
               </td>
               <td align="left">
                Required for all travelers ≥1 year of age
                <break>
                </break>
                <break>
                </break>
                For U.S. citizens: Medical waivers must be translated into Spanish and accompany the International Certificate of Vaccination or Prophylaxis (ICVP). Travelers who do not have a valid ICVP will still be allowed to enter Bolivia if they agree to sign an affidavit exempting the Bolivian state from any liability in the event the traveler gets sick with yellow fever within the Bolivian territory. This last option may cause delays at the point of entry.
               </td>
               <td align="left">
                For all travelers ≥9 months of age traveling to areas east of the Andes Mountains (see
                <xref ref-type="fig" rid="f7">
                 Map 2-4
                </xref>
                ). Vaccination is NOT recommended for travel only to the cities of La Paz or Sucre.
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Bosnia and Herzegovina
                </bold>
               </td>
               <td align="left">
                Not required
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Botswana
                </bold>
               </td>
               <td align="left">
                If traveling from a country with risk of yellow fever transmission and ≥1 year of age
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Brazil
                </bold>
               </td>
               <td align="left">
                Not required
               </td>
               <td align="left">
                For all travelers ≥9 months of age going to the following areas at risk of yellow fever transmission, including the ENTIRE states of Acre, Amapá, Amazonas, Distrito Federal (including the capital city of Brasilia), Goiás, Maranhão, Mato Grosso, Mato Grosso do Sul, Minas Gerais, Pará, Rondônia, Roraima, and Tocatins; and the designated areas of the following states: northwest and west Bahia, central and west Paraná, southwest Piauí, northwest and west central Rio Grande do Sul, far west Santa Catarina, and north and west São Paulo.
                <break>
                </break>
                <break>
                </break>
                Vaccination is recommended for travelers visiting Iguassu Falls. Vaccination is NOT recommended for travel to the following coastal cities: Rio de Janeiro, São Paulo, Salvador, Recife, and Fortaleza.
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 British Indian Ocean Territory
                </bold>
                includes
                <bold>
                 Diego Garcia
                </bold>
                (U.K.)
               </td>
               <td align="left">
                Not required
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Brunei
                </bold>
               </td>
               <td align="left">
                Required from travelers ≥1 year of age arriving within 6 days from countries with risk of yellow fever transmission or having passed through areas partly or wholly at risk of yellow fever transmission within the preceding 6 days.
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Bulgaria
                </bold>
               </td>
               <td align="left">
                Not required
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Burkina Faso
                </bold>
               </td>
               <td align="left">
                Required upon arrival from all countries if traveler is ≥1 year of age
               </td>
               <td align="left">
                For all travelers ≥9 months of age
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Burma (Myanmar)
                </bold>
               </td>
               <td align="left">
                If traveling from a country with risk of yellow fever transmission. Required also for nationals and residents of Burma (Myanmar) departing for a country with risk of yellow fever transmission
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Burundi
                </bold>
               </td>
               <td align="left">
                Required upon arrival from all countries if traveler is ≥1 year of age
               </td>
               <td align="left">
                For all travelers ≥9 months of age
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Cambodia
                </bold>
               </td>
               <td align="left">
                If traveling from a country with risk of yellow fever transmission
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Cameroon
                </bold>
               </td>
               <td align="left">
                Required upon arrival from all countries if traveler is ≥1 year of age
               </td>
               <td align="left">
                For all travelers ≥9 months of age
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Canada
                </bold>
               </td>
               <td align="left">
                Not required
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Canary Islands
                </bold>
                (Spain)
               </td>
               <td align="left">
                Not required
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Cape Verde
                </bold>
               </td>
               <td align="left">
                If traveling from a country with risk of yellow fever transmission and ≥1 year of age
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Cayman Islands
                </bold>
                (U.K.)
               </td>
               <td align="left">
                Not required
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Central African Republic
                </bold>
               </td>
               <td align="left">
                Required upon arrival from all countries if traveler is ≥1 year of age
               </td>
               <td align="left">
                For all travelers ≥9 months of age
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Chad
                </bold>
               </td>
               <td align="left">
                If traveling from a country with risk of yellow fever transmission
               </td>
               <td align="left">
                For all travelers ≥9 months of age traveling to areas south of the Sahara Desert
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Chile
                </bold>
               </td>
               <td align="left">
                Not required
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 China
                </bold>
               </td>
               <td align="left">
                If traveling from a country with risk of yellow fever transmission
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Christmas Island
                </bold>
                (Australia)
               </td>
               <td align="left">
                All travelers ≥1 year of age, who within the past 6 days have traveled or passed through an endemic area, as listed by WHO
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Cocos (Keeling) Islands
                </bold>
               </td>
               <td align="left">
                All persons ≥1 year of age who, within 6 days of arrival, have been in or have passed through a country with risk of yellow fever transmission
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Colombia
                </bold>
               </td>
               <td align="left">
                Not required
               </td>
               <td align="left">
                For all travelers ≥9 months of age. Travelers whose itinerary is limited to the cities of Bogotá, Cali, or Medellín are at lower risk and may consider foregoing vaccination.
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Comoros
                </bold>
               </td>
               <td align="left">
                Not required
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Congo, Republic of the (Congo-Brazzaville)
                </bold>
               </td>
               <td align="left">
                Required upon arrival from all countries if traveler is ≥1 year of age
               </td>
               <td align="left">
                For all travelers ≥9 months of age
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Cook Islands
                </bold>
                (New Zealand)
               </td>
               <td align="left">
                Not required
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Costa Rica
                </bold>
               </td>
               <td align="left">
                Required from travelers coming from countries with risk of yellow fever transmission. No certificate is required for travelers &lt;9 months of age and ≥60 years of age, pregnant or lactating women, persons with allergy to eggs or gelatin, immunosuppression, thymus disease, a personal or family history of adverse reactions associated with the yellow fever vaccine, or asymptomatic HIV infection with laboratory evidence of satisfactory immune functions.
                <break>
                </break>
                <break>
                </break>
                The following countries are considered at risk of yellow fever transmission:
                <break>
                </break>
                <break>
                </break>
                <italic>
                 South America
                </italic>
                : Boliva, Brazil, Colombia, Ecuador, French Guyana, Peru, Venezuela
                <break>
                </break>
                <break>
                </break>
                <italic>
                 Africa
                </italic>
                : Angola, Benin, Burkina Faso, Cameroon, Gabon, The Gambia, Ghana, Guinea, Liberia, Nigeria, Democratic Republic of the Congo, Sierra Leone, Sudan
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Côte d'Ivoire (Ivory Coast)
                </bold>
               </td>
               <td align="left">
                Required upon arrival from all countries if traveler is ≥1 year of age
               </td>
               <td align="left">
                For all travelers ≥9 months of age
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Croatia
                </bold>
               </td>
               <td align="left">
                Not required
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Cuba
                </bold>
               </td>
               <td align="left">
                Not required
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Cyprus
                </bold>
               </td>
               <td align="left">
                Not required
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Czech Republic
                </bold>
               </td>
               <td align="left">
                Not required
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Democratic Republic of the Congo (Congo-Kinshasa)
                </bold>
               </td>
               <td align="left">
                Required upon arrival from all countries if traveler is ≥1 year of age
               </td>
               <td align="left">
                For all travelers ≥9 months of age
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Denmark
                </bold>
               </td>
               <td align="left">
                Not required
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Djibouti
                </bold>
               </td>
               <td align="left">
                If traveling from a country with risk of yellow fever transmission and ≥1 year of age
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Dominica
                </bold>
               </td>
               <td align="left">
                If traveling from a country with risk of yellow fever transmission and ≥1 year of age
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Dominican Republic
                </bold>
               </td>
               <td align="left">
                Not required
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Easter Island
                </bold>
                (Chile)
               </td>
               <td align="left">
                Required for travelers coming from a country with risk of yellow fever transmission
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Ecuador
                </bold>
                (including the
                <bold>
                 Galápagos Islands
                </bold>
                )
               </td>
               <td align="left">
                Required from travelers ≥1 year of age coming from countries with risk of yellow fever transmission. Nationals and residents of Ecuador are required to possess certificates of vaccination on their departure to an area with risk of yellow fever transmission.
               </td>
               <td align="left">
                For all travelers ≥9 months of age who are traveling to the following provinces in the Amazon Basin: Morona-Santiago, Napo, Orellana, Pastaza, Sucumbíos, and Zamorarisk Chinchipe, and all other areas in the eastern part of the Andes Mountains, NOT including the cities of Quito and Guayaquil or the Galápagos Islands
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Egypt
                </bold>
               </td>
               <td align="left">
                If traveling from countries with risk of yellow fever transmission and ≥1 year of age. Air passengers without a certificate in transit, but coming from these countries or areas, will be detained in the precincts of the airport until they resume their journey. All travelers arriving from Sudan are required to have a vaccination certificate or a location certificate issued by a Sudanese official center, stating that they have not been in Sudan south of 15° N within the previous 6 days.
                <break>
                </break>
                <break>
                </break>
                Required also for travelers arriving or transiting from:
                <break>
                </break>
                <break>
                </break>
                <italic>
                 Africa
                </italic>
                : Angola, Benin, Burkina Faso, Burundi, Cameroon, Central African Republic, Chad, Congo, Côte d'Ivoire, Democratic Republic of the Congo, Equatorial Guinea, Ethiopia, Gabon, The Gambia, Ghana, Guinea, Guinea-Bissau, Kenya, Liberia, Mali, Niger, Nigeria, Rwanda, São Tomé and Príncipe, Senegal, Sierra Leone, Somalia, Sudan (south of 15° N), Tanzania, Togo, Uganda, and Zambia
                <break>
                </break>
                <break>
                </break>
                <italic>
                 Americas
                </italic>
                : Belize, Bolivia, Brazil, Colombia, Costa Rica, Ecuador, French Guiana, Guyana, Panama, Peru, Suriname, Trinidad and Tobago, and Venezuela
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 El Salvador
                </bold>
               </td>
               <td align="left">
                If traveling from a country with risk of yellow fever transmission and ≥6 months of age
                <xref ref-type="table-fn" rid="cetablefn61">
                 5
                </xref>
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Equatorial Guinea
                </bold>
               </td>
               <td align="left">
                If traveling from a country with risk of yellow fever transmission
               </td>
               <td align="left">
                For all travelers ≥9 months of age
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Eritrea
                </bold>
               </td>
               <td align="left">
                If traveling from a country with risk of yellow fever transmission
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Estonia
                </bold>
               </td>
               <td align="left">
                Not required
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Ethiopia
                </bold>
               </td>
               <td align="left">
                If traveling from a country with risk of yellow fever transmission and ≥1 year of age
               </td>
               <td align="left">
                For all travelers ≥9 months of age
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Falkland Islands
                </bold>
                (U.K.)
               </td>
               <td align="left">
                Not required
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Faroe Islands
                </bold>
                (Denmark)
               </td>
               <td align="left">
                Not required
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Fiji
                </bold>
               </td>
               <td align="left">
                If traveling from a country with risk of yellow fever transmission within 10 days of having stayed overnight or longer and ≥1 year of age
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Finland
                </bold>
               </td>
               <td align="left">
                Not required
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 France
                </bold>
               </td>
               <td align="left">
                Not required
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 French Guiana
                </bold>
               </td>
               <td align="left">
                Required upon arrival from all countries if traveler is ≥1 year of age
               </td>
               <td align="left">
                For all travelers ≥9 months of age
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 French Polynesia
                </bold>
                , includes the island groups of
                <bold>
                 Society Islands (Tahiti, Moorea
                </bold>
                , and
                <bold>
                 Bora-Bora), Marquesas Islands (Hiva Oa
                </bold>
                and
                <bold>
                 Ua Huka
                </bold>
                ), and
                <bold>
                 Austral Islands (Tubuai
                </bold>
                and
                <bold>
                 Rurutu
                </bold>
                )
               </td>
               <td align="left">
                If traveling from a country with risk of yellow fever transmission and ≥1 year of age
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Gabon
                </bold>
               </td>
               <td align="left">
                Required upon arrival from all countries if traveler is ≥1 year of age
               </td>
               <td align="left">
                For all travelers ≥9 months of age
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Gambia, The
                </bold>
               </td>
               <td align="left">
                If traveling from a country with risk of yellow fever transmission and ≥1 year of age
               </td>
               <td align="left">
                For all travelers ≥9 months of age
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Georgia
                </bold>
               </td>
               <td align="left">
                Not required
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Germany
                </bold>
               </td>
               <td align="left">
                Not required
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Ghana
                </bold>
               </td>
               <td align="left">
                Required upon arrival from all countries
               </td>
               <td align="left">
                For all travelers ≥9 months of age
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Gibraltar
                </bold>
                (U.K.)
               </td>
               <td align="left">
                Not required
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Greece
                </bold>
               </td>
               <td align="left">
                Not required
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Greenland
                </bold>
                (Denmark)
               </td>
               <td align="left">
                Not required
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Grenada
                </bold>
               </td>
               <td align="left">
                If traveling from a country with risk of yellow fever transmission and ≥1 year of age
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Guadeloupe
                </bold>
                , including
                <bold>
                 St. Barthelemy
                </bold>
                and
                <bold>
                 Saint Martin
                </bold>
                (France)
               </td>
               <td align="left">
                If traveling from a country with risk of yellow fever transmission and ≥1 year of age
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Guam
                </bold>
                (U.S.)
               </td>
               <td align="left">
                Not required
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Guatemala
                </bold>
               </td>
               <td align="left">
                If traveling from a country with risk of yellow fever transmission and ≥1 year of age
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Guinea
                </bold>
               </td>
               <td align="left">
                If traveling from a country with risk of yellow fever transmission and ≥1 year of age
               </td>
               <td align="left">
                For all travelers ≥9 months of age
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Guinea-Bissau
                </bold>
               </td>
               <td align="left">
                If traveling from a country with risk of yellow fever transmission and ≥1 year of age
                <break>
                </break>
                <break>
                </break>
                Required also for travelers arriving from:
                <break>
                </break>
                <break>
                </break>
                <italic>
                 Africa:
                </italic>
                Angola, Benin, Burkina Faso, Burundi, Cape Verde, Central African Republic, Chad, Congo, Côte d'Ivoire, Democratic Republic of the Congo, Djibouti, Equatorial Guinea, Ethiopia, Gabon, The Gambia, Ghana, Guinea, Kenya, Liberia, Madagascar, Mali, Mauritania, Mozambique, Niger, Nigeria, Rwanda, São Tomé and Príncipe, Senegal, Sierra Leone, Somalia, Tanzania, Togo, Uganda, and Zambia
                <break>
                </break>
                <break>
                </break>
                <italic>
                 Americas:
                </italic>
                Bolivia, Brazil, Colombia, Ecuador, French Guiana, Guyana, Panama, Peru, Suriname, and Venezuela
               </td>
               <td align="left">
                For all travelers ≥9 months of age
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Guyana
                </bold>
               </td>
               <td align="left">
                If traveling from a country with risk of yellow fever transmission
                <break>
                </break>
                <break>
                </break>
                Required also for travelers arriving from:
                <break>
                </break>
                <break>
                </break>
                <italic>
                 Africa
                </italic>
                : Angola, Benin, Burkina Faso, Burundi, Cameroon, Central African Republic, Chad, Congo, Côte d'Ivoire, Democratic Republic of the Congo, Equatorial Guinea, Ethiopia, Gabon, The Gambia, Ghana, Guinea, Guinea-Bissau, Kenya, Liberia, Mali, Mauritania, Niger, Nigeria, Rwanda, São Tomé and Príncipe, Senegal, Sierra Leone, Somalia, Sudan, Tanzania, Togo, and Uganda
                <break>
                </break>
                <break>
                </break>
                <italic>
                 Americas
                </italic>
                : Belize, Bolivia, Brazil, Colombia, Ecuador, French Guiana, Guyana, Panama, Peru, Suriname, and Venezuela
               </td>
               <td align="left">
                For all travelers ≥9 months of age
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Haiti
                </bold>
               </td>
               <td align="left">
                If traveling from a country with risk of yellow fever transmission
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Holy See
                </bold>
               </td>
               <td align="left">
                Not required
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Honduras
                </bold>
               </td>
               <td align="left">
                Required from travelers ≥1 year of age coming from countries with risk of yellow fever transmission. The Government of Honduras is also recommending vaccine for travelers coming from Panama.
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Hong Kong SAR
                </bold>
                (China)
               </td>
               <td align="left">
                Not required
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Hungary
                </bold>
               </td>
               <td align="left">
                Not required
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Iceland
                </bold>
               </td>
               <td align="left">
                Not required
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 India
                </bold>
               </td>
               <td align="left">
                Required from travelers ≥6 months of age coming from a country with risk of yellow fever transmission
                <break>
                </break>
                <break>
                </break>
                Specifically, per the Government of India, anyone (except infants ≥6 months old) arriving by air or sea without a certificate is detained in isolation for up to 6 days if that person (i) arrives within 6 days of departure from an area with risk of yellow fever transmission, or (ii) has been in such an area in transit (except those passengers and members of crew who, while in transit through an aiport situated in an area with risk of yellow fever transmission, remained within the airport premises during the period of their entire stay and the Health Officer agrees to such an exemption), or (iii) has come on a ship that started from or touched at any port in a yellow fever area with risk of yellow fever transmission up to 30 days before its arrival into India, unless such a ship has been disinsected in accordance with the procedure laid down by WHO, or (iv) has come by an aircraft which has been in an area with risk of yellow fever transmission and has not been disinsected in accordance with the provisions laid down in the Indian Aircraft Public Health Rules, 1954, or those recommended by WHO.
                <break>
                </break>
                <break>
                </break>
                The following countries and areas are regarded as at risk of yellow fever transmission:
                <break>
                </break>
                <break>
                </break>
                <italic>
                 Africa
                </italic>
                : Angola, Benin, Burkina Faso, Burundi, Cameroon, Central African Republic, Chad, Congo, Côlte d'Ivoire, Democratic Republic of the Congo, Equatorial Guinea, Ethiopia, Gabon, The Gambia, Ghana, Guinea, Guinea-Bissau, Kenya, Liberia, Mali, Niger, Nigeria, Rwanda, São Tomé and Principe, Senegal, Sierra Leone, Somalia, Sudan, Togo, Uganda, Tanzania, and Zambia
                <break>
                </break>
                <break>
                </break>
                <italic>
                 Americas
                </italic>
                : Bolivia, Brazil, Colombia, Ecuador, French Guiana, Guyana, Panama, Peru, Suriname, Trinidad and Tobago, and Venezuela
                <break>
                </break>
                <break>
                </break>
                <italic>
                 Note
                </italic>
                : When a case of yellow fever is reported from any country, that country is regarded by the Government of India as a country with risk of yellow fever and is added to the above list.
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Indonesia
                </bold>
               </td>
               <td align="left">
                If traveling from a country with risk of yellow fever transmission and ≥9 months of age
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Iran
                </bold>
               </td>
               <td align="left">
                If traveling from a country with risk of yellow fever transmission
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Iraq
                </bold>
               </td>
               <td align="left">
                If traveling from a country with risk of yellow fever transmission
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Ireland
                </bold>
               </td>
               <td align="left">
                Not required
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Israel
                </bold>
               </td>
               <td align="left">
                Not required
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Italy
                </bold>
               </td>
               <td align="left">
                Not required
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Jamaica
                </bold>
               </td>
               <td align="left">
                If traveling from a country with risk of yellow fever transmission and ≥1 year of age
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Japan
                </bold>
               </td>
               <td align="left">
                Not required
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Jordan
                </bold>
               </td>
               <td align="left">
                If traveling from a country with risk of yellow fever transmission and ≥1 year of age
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Kazakhstan
                </bold>
               </td>
               <td align="left">
                If traveling from a country with risk of yellow fever transmission
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Kenya
                </bold>
               </td>
               <td align="left">
                If traveling from a country with risk of yellow fever transmission and ≥1 year of age
               </td>
               <td align="left">
                For all travelers ≥9 months of age. The cities of Nairobi and Mombasa have lower risk of transmission than rural areas.
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Kiribati
                </bold>
                (formerly
                <bold>
                 Gilbert Islands
                </bold>
                ), includes
                <bold>
                 Tarawa, Tabuaeran (Fanning Island
                </bold>
                ), and
                <bold>
                 Banaba (Ocean Island)
                </bold>
               </td>
               <td align="left">
                If traveling from a country with risk of yellow fever transmission and ≥1 year of age
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Korea, North
                </bold>
               </td>
               <td align="left">
                If traveling from a country with risk of yellow fever transmission and ≥1 year of age
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Korea, South
                </bold>
               </td>
               <td align="left">
                Not required
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Kosovo
                </bold>
               </td>
               <td align="left">
                Not required
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Kuwait
                </bold>
               </td>
               <td align="left">
                Not required
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Kyrgyzstan
                </bold>
               </td>
               <td align="left">
                Not required
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Laos
                </bold>
               </td>
               <td align="left">
                If traveling from a country with risk of yellow fever transmission
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Latvia
                </bold>
               </td>
               <td align="left">
                Not required
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Lebanon
                </bold>
               </td>
               <td align="left">
                If traveling from a country with risk of yellow fever transmission and ≥6 months of age
                <xref ref-type="table-fn" rid="cetablefn61">
                 5
                </xref>
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Lesotho
                </bold>
               </td>
               <td align="left">
                If traveling from a country with risk of yellow fever transmission
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Liberia
                </bold>
               </td>
               <td align="left">
                Required upon arrival from all countries if traveler is ≥1 year of age
               </td>
               <td align="left">
                For all travelers ≥9 months of age
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Libya
                </bold>
               </td>
               <td align="left">
                If traveling from a country with risk of yellow fever transmission
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Liechtenstein
                </bold>
               </td>
               <td align="left">
                Not required
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Lithuania
                </bold>
               </td>
               <td align="left">
                Not required
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Luxembourg
                </bold>
               </td>
               <td align="left">
                Not required
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Macau SAR
                </bold>
                (China)
               </td>
               <td align="left">
                Not required
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Macedonia
                </bold>
               </td>
               <td align="left">
                Not required
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Madagascar
                </bold>
               </td>
               <td align="left">
                If traveling from a country with risk of yellow fever transmission
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Madeira Islands
                </bold>
                (Portugal)
               </td>
               <td align="left">
                If traveling from a country with risk of yellow fever transmission and ≥1 year of age
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Malawi
                </bold>
               </td>
               <td align="left">
                If traveling from a country with risk of yellow fever transmission
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Malaysia
                </bold>
               </td>
               <td align="left">
                Required from travelers ≥1 year of age arriving within 6 days from countries with risk of yellow fever transmission
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Maldives
                </bold>
               </td>
               <td align="left">
                If traveling from a country with risk of yellow fever transmission
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Mali
                </bold>
               </td>
               <td align="left">
                Required upon arrival from all countries if traveler is ≥1 year of age
               </td>
               <td align="left">
                For all travelers ≥9 months of age going to areas south of the Sahara Desert
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Malta
                </bold>
               </td>
               <td align="left">
                If traveling from a country with risk of yellow fever transmission and ≥9 months of age
                <break>
                </break>
                <break>
                </break>
                If indicated on epidemiological grounds, infants &lt;9 months of age are subject to isolation or surveillance if coming from an area with risk of yellow fever transmission.
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Marshall Islands
                </bold>
               </td>
               <td align="left">
                Not required
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Martinique
                </bold>
                (France)
               </td>
               <td align="left">
                Not required
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Mauritania
                </bold>
               </td>
               <td align="left">
                If traveling from a country with risk of yellow fever transmission and ≥1 year of age
               </td>
               <td align="left">
                For all travelers ≥9 months of age traveling to areas south of the Sahara Desert
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Mauritius
                </bold>
               </td>
               <td align="left">
                If traveling from a country with risk of yellow fever transmission and ≥1 year of age
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Mayotte
                </bold>
                (French territorial collectivity)
               </td>
               <td align="left">
                Not required
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Mexico
                </bold>
               </td>
               <td align="left">
                Not required
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Micronesia Federated States of
                </bold>
                ; includes
                <bold>
                 Yap Islands, Pohnpei, Chuuk
                </bold>
                ,
                <bold>
                 and Kosrae
                </bold>
                ,
               </td>
               <td align="left">
                Not required
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Moldova
                </bold>
               </td>
               <td align="left">
                Not required
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Monaco
                </bold>
               </td>
               <td align="left">
                Not required
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Mongolia
                </bold>
               </td>
               <td align="left">
                Not required
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Montenegro
                </bold>
               </td>
               <td align="left">
                Not required
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Montserrat
                </bold>
                (U.K.)
               </td>
               <td align="left">
                If traveling from a country with risk of yellow fever transmission and ≥1 year of age
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Morocco
                </bold>
               </td>
               <td align="left">
                Not required
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Mozambique
                </bold>
               </td>
               <td align="left">
                If traveling from a country with risk of yellow fever transmission and ≥1 year of age
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Namibia
                </bold>
               </td>
               <td align="left">
                If traveling from a country with risk of yellow fever transmission
                <break>
                </break>
                <break>
                </break>
                The countries, or parts of countries, included in the endemic zones in Africa and South America are regarded as areas with risk of yellow fever transmission. Travelers on scheduled flights that originated outside the countries with risk of yellow fever transmission, but who have been in transit through these areas, are not required to possess a certificate provided that they remained at the scheduled airport or in the adjacent town during transit. All passengers whose flights originated in countries with risk of yellow fever transmission or who have been in transit through these countries on unscheduled flights are required to possess a certificate.
                <break>
                </break>
                <break>
                </break>
                The certificate is not insisted upon in the case of children &lt;1 year of age, but such infants may be subject to surveillance.
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Nauru
                </bold>
               </td>
               <td align="left">
                If traveling from a country with risk of yellow fever transmission and ≥1 year of age
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Nepal
                </bold>
               </td>
               <td align="left">
                If traveling from a country with risk of yellow fever transmission
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Netherlands
                </bold>
               </td>
               <td align="left">
                Not required
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Netherlands Antilles (Bonaire, Curaçao, Saba, St. Eustasius
                </bold>
                , and
                <bold>
                 St. Maarten)
                </bold>
               </td>
               <td align="left">
                If traveling from a country with risk of yellow fever transmission and ≥6 months of age
                <xref ref-type="table-fn" rid="cetablefn61">
                 5
                </xref>
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 New Caledonia
                </bold>
                (France)
               </td>
               <td align="left">
                If traveling from a country with risk of yellow fever transmission and ≥1 year of age
                <break>
                </break>
                <break>
                </break>
                <italic>
                 Note
                </italic>
                : In the event of an epidemic threat to the territory, a specific vaccination certificate may be required.
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 New Zealand
                </bold>
               </td>
               <td align="left">
                Not required
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Nicaragua
                </bold>
               </td>
               <td align="left">
                If traveling from a country with risk of yellow fever transmission and ≥1 year of age
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Niger
                </bold>
               </td>
               <td align="left">
                Required upon arrival from all countries if traveler is ≥1 year of age. The Government of Niger recommends vaccine for travelers leaving Niger.
               </td>
               <td align="left">
                For all travelers ≥9 months of age traveling to areas south of the Sahara Desert
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Nigeria
                </bold>
               </td>
               <td align="left">
                If traveling from a country with risk of yellow fever transmission and ≥1 year of age
               </td>
               <td align="left">
                For all travelers ≥9 months of age
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Niue
                </bold>
                (New Zealand)
               </td>
               <td align="left">
                If traveling from a country with risk of yellow fever transmission and ≥1 year of age
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Norfolk Island
                </bold>
                (Australia)
               </td>
               <td align="left">
                If traveling from a country with risk of yellow fever transmission and ≥1 year of age
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Northern Mariana Islands
                </bold>
                (U.S.), includes
                <bold>
                 Saipan, Tinian
                </bold>
                , and
                <bold>
                 Rota Island
                </bold>
               </td>
               <td align="left">
                Not required
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Norway
                </bold>
               </td>
               <td align="left">
                Not required
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Oman
                </bold>
               </td>
               <td align="left">
                If traveling from a country with risk of yellow fever transmission and ≥1 year of age
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Pakistan
                </bold>
               </td>
               <td align="left">
                Required from travelers coming from any part of a country in which there is a risk of yellow fever transmission; infants &lt;6 months of age are exempt if the mother's vaccination certificate shows that she was vaccinated before the birth of the child.
                <xref ref-type="table-fn" rid="cetablefn61">
                 5
                </xref>
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Palau
                </bold>
               </td>
               <td align="left">
                Required from all travelers ≥1 year of age coming from countries with risk of yellow fever transmission or from countries in any part of which there is a risk of yellow fever transmission
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Panama
                </bold>
               </td>
               <td align="left">
                If traveling from a country with risk of yellow fever transmission
               </td>
               <td align="left">
                For all travelers ≥9 months of age traveling to the provinces of Darien, Kuna Yala (old San Blas), Comarca Emberá, and Panama east of the Canal Zone, EXCLUDING the Canal Zone, Panama City, and San Blas Islands
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Papua New Guinea
                </bold>
               </td>
               <td align="left">
                If traveling from a country with risk of yellow fever transmission and ≥1 year of age
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Paraguay
                </bold>
               </td>
               <td align="left">
                If traveling from a country with risk of yellow fever transmission and ≥1 year of age
               </td>
               <td align="left">
                For all travelers ≥9 months of age
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Peru
                </bold>
               </td>
               <td align="left">
                Not required
               </td>
               <td align="left">
                For all travelers ≥9 months of age traveling to the areas east of the Andes Mountains (see
                <xref ref-type="fig" rid="f7">
                 Map 2-4
                </xref>
                ) and for those who intend to visit any jungle areas of the country &lt;2,300 m (&lt;7,546 ft). Travelers who are limiting travel to the cities of Cuzco and Machu Picchu do NOT need vaccination.
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Philippines
                </bold>
               </td>
               <td align="left">
                If traveling from a country with risk of yellow fever transmission and ≥1 year of age
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Pitcairn Islands
                </bold>
                (U.K.)
               </td>
               <td align="left">
                If traveling from a country with risk of yellow fever transmission and ≥1 year of age
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Poland
                </bold>
               </td>
               <td align="left">
                Not required
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Portugal
                </bold>
               </td>
               <td align="left">
                Required only for travelers ≥1 year of age arriving from a country with risk of yellow fever transmission and destined for the Azores and Madeira. However, no certificate is required for travelers in transit at Funchal, Santa Maria, and Porto Santo.
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Puerto Rico
                </bold>
                (U.S.)
               </td>
               <td align="left">
                Not required
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Qatar
                </bold>
               </td>
               <td align="left">
                Not required
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Réunion
                </bold>
                (France)
               </td>
               <td align="left">
                If traveling from a country with risk of yellow fever transmission and ≥1 year of age
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Romania
                </bold>
               </td>
               <td align="left">
                Not required
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Russia
                </bold>
               </td>
               <td align="left">
                Not required
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Rwanda
                </bold>
               </td>
               <td align="left">
                Required upon arrival from all countries if traveler is ≥1 year of age
               </td>
               <td align="left">
                For all travelers ≥9 months of age
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Saint Helena
                </bold>
                (U.K.)
               </td>
               <td align="left">
                If traveling from a country with risk of yellow fever transmission and ≥1 year of age
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Saint Kitts (Saint Christopher)
                </bold>
                and
                <bold>
                 Nevis
                </bold>
                (U.K.)
               </td>
               <td align="left">
                If traveling from a country with risk of yellow fever transmission and ≥1 year of age
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Saint Lucia
                </bold>
               </td>
               <td align="left">
                If traveling from a country with risk of yellow fever transmission and ≥1 year of age
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Saint Pierre and Miquelon
                </bold>
                (France)
               </td>
               <td align="left">
                Not required
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Saint Vincent and the Grenadines
                </bold>
               </td>
               <td align="left">
                If traveling from a country with risk of yellow fever transmission and ≥1 year of age
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Samoa
                </bold>
                (formerly
                <bold>
                 Western Somoa
                </bold>
                )
               </td>
               <td align="left">
                If traveling from a country with risk of yellow fever transmission and ≥1 year of age
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Samoa, American
                </bold>
                (U.S.)
               </td>
               <td align="left">
                Not required
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 San Marino
                </bold>
               </td>
               <td align="left">
                Not required
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 São Tomé and Príncipe
                </bold>
               </td>
               <td align="left">
                Required upon arrival from all countries if traveler is ≥1 year of age
               </td>
               <td align="left">
                For all travelers ≥9 months of age
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Saudi Arabia
                </bold>
               </td>
               <td align="left">
                If traveling from a country with risk of yellow fever transmission
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Senegal
                </bold>
               </td>
               <td align="left">
                If traveling from a country with risk of yellow fever transmission
               </td>
               <td align="left">
                For all travelers ≥9 months of age
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Serbia
                </bold>
               </td>
               <td align="left">
                Not required
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Seychelles
                </bold>
               </td>
               <td align="left">
                If traveling from a country with risk of yellow fever transmission within the preceding 6 days and ≥1 year of age
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Sierra Leone
                </bold>
               </td>
               <td align="left">
                Required upon arrival from all countries
               </td>
               <td align="left">
                For all travelers ≥9 months of age
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Singapore
                </bold>
               </td>
               <td align="left">
                If traveling from a country with risk of yellow fever transmission within the preceding 6 days and ≥1 year of age
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Slovakia
                </bold>
               </td>
               <td align="left">
                Not required
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Slovenia
                </bold>
               </td>
               <td align="left">
                Not required
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Solomon Islands
                </bold>
               </td>
               <td align="left">
                If traveling from a country with risk of yellow fever transmission
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Somalia
                </bold>
               </td>
               <td align="left">
                If traveling from a country with risk of yellow fever transmission
               </td>
               <td align="left">
                For all travelers ≥9 months of age
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 South Africa
                </bold>
               </td>
               <td align="left">
                If traveling from a country with risk of yellow fever transmission and ≥1 year of age
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 South Georgia
                </bold>
               </td>
               <td align="left">
                Not required
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 South Sandwich Islands
                </bold>
               </td>
               <td align="left">
                Not required
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Spain
                </bold>
               </td>
               <td align="left">
                Not required
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Sri Lanka
                </bold>
               </td>
               <td align="left">
                If traveling from a country with risk of yellow fever transmission and ≥1 year of age
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Sudan
                </bold>
               </td>
               <td align="left">
                If traveling from a country with risk of yellow fever transmission and ≥9 months of age. A certificate may be required for travelers leaving Sudan.
               </td>
               <td align="left">
                For all travelers ≥9 months of age traveling to areas south of the Sahara Desert, EXCLUDING the city of Khartoum
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Suriname
                </bold>
               </td>
               <td align="left">
                If traveling from a country with risk of yellow fever transmission fever transmission and ≥1 year of age
               </td>
               <td align="left">
                For all travelers ≥9 months of age
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Swaziland
                </bold>
               </td>
               <td align="left">
                If traveling from a country with risk of yellow fever transmission
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Sweden
                </bold>
               </td>
               <td align="left">
                Not required
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Switzerland
                </bold>
               </td>
               <td align="left">
                Not required
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Syria
                </bold>
               </td>
               <td align="left">
                If traveling from a country with risk of yellow fever transmission
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Taiwan
                </bold>
               </td>
               <td align="left">
                If traveling from a country with risk of yellow fever transmission
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Tajikistan
                </bold>
               </td>
               <td align="left">
                Not required
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Tanzania
                </bold>
               </td>
               <td align="left">
                If traveling from a country with risk of yellow fever transmission and ≥1 year of age
               </td>
               <td align="left">
                For all travelers ≥9 months of age. The city of Dar es Salaam has a lower risk of transmission than rural areas.
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Thailand
                </bold>
               </td>
               <td align="left">
                If traveling from a country with risk of yellow fever transmission and ≥9 months of age
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Timor-Leste (East Timor)
                </bold>
               </td>
               <td align="left">
                If traveling from a country with risk of yellow fever transmission and ≥1 year of age
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Togo
                </bold>
               </td>
               <td align="left">
                Required upon arrival from all countries if traveler is ≥1 year of age
               </td>
               <td align="left">
                For all travelers ≥9 months of age
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Tokelau
                </bold>
                (New Zealand)
               </td>
               <td align="left">
                Not required
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Tonga
                </bold>
               </td>
               <td align="left">
                If traveling from a country with risk of yellow fever transmission and ≥1 year of age
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Trinidad and Tobago
                </bold>
               </td>
               <td align="left">
                If traveling from a country with risk of yellow fever transmission and ≥1 year of age
               </td>
               <td align="left">
                For all travelers ≥9 months of age whose itinerary includes Trinidad. Port of Spain has lower risk of transmission than rural or forested areas. Cruise ship passengers who do not disembark from the ship or travelers visiting only the urban area of Port of Spain (including passengers in-transit only) may consider foregoing vaccination. Vaccination is NOT recommended for those visiting only Tobago.
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Tunisia
                </bold>
               </td>
               <td align="left">
                If traveling from a country with risk of yellow fever transmission and ≥1 year of age
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Turkey
                </bold>
               </td>
               <td align="left">
                Not required
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Turkmenistan
                </bold>
               </td>
               <td align="left">
                Not required
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Turks and Caicos Islands
                </bold>
                (U.K.)
               </td>
               <td align="left">
                If traveling from a country with risk of yellow fever transmission and ≥1 year of age
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Tuvalu
                </bold>
               </td>
               <td align="left">
                Not required
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Uganda
                </bold>
               </td>
               <td align="left">
                If traveling from a country with risk of yellow fever transmission and ≥1 year of age
               </td>
               <td align="left">
                For all travelers ≥9 months of age
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Ukraine
                </bold>
               </td>
               <td align="left">
                Not required
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 United Arab Emirates
                </bold>
               </td>
               <td align="left">
                Not required
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 United Kingdom
                </bold>
                (with
                <bold>
                 Channel Islands
                </bold>
                and
                <bold>
                 Isle of Man
                </bold>
                )
               </td>
               <td align="left">
                Not required
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 United States
                </bold>
               </td>
               <td align="left">
                Not required
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Uruguay
                </bold>
               </td>
               <td align="left">
                If traveling from a country with risk of yellow fever transmission
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Uzbekistan
                </bold>
               </td>
               <td align="left">
                Not required
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Vanuatu
                </bold>
               </td>
               <td align="left">
                Not required
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Venezuela
                </bold>
               </td>
               <td align="left">
                Not required
               </td>
               <td align="left">
                For all travelers ≥9 months of age traveling to Venezuela, EXCEPT the northern coastal area (see
                <xref ref-type="fig" rid="f7">
                 Map 2-4
                </xref>
                ). The cities of Caracas and Valencia are NOT in the endemic zone.
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Vietnam
                </bold>
               </td>
               <td align="left">
                If traveling from a country with risk of yellow fever transmission and ≥1 year of age
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Virgin Islands British
                </bold>
                ,
               </td>
               <td align="left">
                Not required
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Virgin Islands, U.S.
                </bold>
               </td>
               <td align="left">
                Not required
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Wake Island, U.S.
                </bold>
               </td>
               <td align="left">
                Not required
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Western Sahara
                </bold>
               </td>
               <td align="left">
                Not required
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Yemen
                </bold>
               </td>
               <td align="left">
                If traveling from a country with risk of yellow fever transmission and ≥1 year of age
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Zambia
                </bold>
               </td>
               <td align="left">
                Not required
               </td>
               <td align="left">
                None
               </td>
              </tr>
              <tr>
               <td align="left">
                <bold>
                 Zimbabwe
                </bold>
               </td>
               <td align="left">
                If traveling from a country with risk of yellow fever transmission
               </td>
               <td align="left">
                None
               </td>
              </tr>
             </tbody>
            </table>
            <table-wrap-foot>
             <fn id="cetablefn57">
              <label>
               1
              </label>
              <p id="cenotep57">
               Yellow fever vaccine entry requirements are established by countries to prevent the importation and transmission of yellow fever virus, and are allowed under the International Health Regulations (IHR). Travelers must comply with these to enter the country, unless they have been issued a medical waiver. Certain countries require vaccination from travelers arriving from all countries, while some countries require vaccination only for travelers coming from “a country with risk of yellow fever transmission” (see
               <xref ref-type="table" rid="cetable12">
                Table 2-12
               </xref>
               ). Country requirements are subject to change at any time; therefore, CDC encourages travelers to check with the destination country's embassy or consulate prior to departure.
              </p>
             </fn>
            </table-wrap-foot>
            <table-wrap-foot>
             <fn id="cetablefn58">
              <label>
               2
              </label>
              <p id="cenotep58">
               As a part of an ongoing project, CDC, WHO, and other partners have made every effort to harmonize the listed yellow fever vaccine requirements and recommendations wherever possible. These efforts will continue, and will likely result in further changes to the printed version of this table. Please check the online version of the Yellow Book (
               <ext-link ext-link-type="uri" id="interref5" xlink:href="http://www.cdc.gov/yellowbook">
                www.cdc.gov/yellowbook
               </ext-link>
               ) for the latest information on country requirements and vaccine recommendations.
              </p>
             </fn>
            </table-wrap-foot>
            <table-wrap-foot>
             <fn id="cetablefn59">
              <label>
               3
              </label>
              <p id="cenotep59">
               The information in the section on yellow fever vaccine recommendations is advice given by CDC to prevent yellow fever infections among travelers. Note: CDC recommendations and country requirements may not be the same.
              </p>
             </fn>
            </table-wrap-foot>
            <table-wrap-foot>
             <fn id="cetablefn60">
              <label>
               4
              </label>
              <p id="cenotep60">
               Recommendations are subject to change at any time if disease conditions change; therefore, CDC encourages travelers to check for relevant travel notices on the website (
               <ext-link ext-link-type="uri" id="interref6" xlink:href="http://www.cdc.gov/travel">
                www.cdc.gov/travel
               </ext-link>
               ) prior to departure.
              </p>
             </fn>
            </table-wrap-foot>
            <table-wrap-foot>
             <fn id="cetablefn61">
              <label>
               5
              </label>
              <p id="cenotep61">
               Please note, the U.S. Advisory Committee on Immunization Practices (ACIP) recommends avoiding vaccination of infants &lt;9 months of age.
              </p>
             </fn>
            </table-wrap-foot>
            <attrib>
             <bold>
              Please note:
             </bold>
             Country requirements for yellow fever vaccine are subject to change at any time, and CDC vaccine recommendations are subject to change at any time if disease conditions change; therefore, CDC encourages health-care providers and travelers to check for updates on the CDC website
             <ext-link ext-link-type="uri" id="interref4" xlink:href="http://www.cdc.gov/travel,">
              www.cdc.gov/travel,
             </ext-link>
             and with the destination country's embassy or consulate in sufficient time to receive yellow fever vaccination or to obtain a waiver if recommendations or requirements have changed.
            </attrib>
           </table-wrap>
          </p>
         </list-item>
         <list-item id="celistitem425">
          <label>
           •
          </label>
          <p id="para546">
           The information in the section on yellow fever vaccine
           <bold>
            recommendations
           </bold>
           is advice given by CDC to prevent yellow fever infections among travelers.
           <bold>
            Recommendations
           </bold>
           are subject to change at any time if disease conditions change; therefore, CDC encourages travelers to check for relevant travel notices on the CDC website
           <ext-link ext-link-type="uri" id="interref19" xlink:href="http://www.cdc.gov/travel">
            www.cdc.gov/travel
           </ext-link>
           before departure.
          </p>
         </list-item>
        </list>
       </p>
      </sec>
      <sec id="cesec99">
       <title>
        Vaccination for Travel on Military Orders
       </title>
       <p id="para547">
        Because military requirements may exceed those indicated in this publication, any person who plans to travel on military orders (civilians and military personnel) should be advised to contact the nearest military medical facility to determine the requirements for the trip.
       </p>
      </sec>
     </sec>
     <ref-list id="cebib6">
      <title>
       References
      </title>
      <ref id="bib47">
       <label>
        1
       </label>
       <element-citation id="sbref46" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Monath
          </surname>
          <given-names>
           TP
          </given-names>
         </name>
         <name>
          <surname>
           Teuwen
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Cetron
          </surname>
          <given-names>
           MS
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         Yellow fever vaccine
        </chapter-title>
        <person-group person-group-type="editor">
         <name>
          <surname>
           Plotkin
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Orenstein
          </surname>
          <given-names>
           WA
          </given-names>
         </name>
         <name>
          <surname>
           Offit
          </surname>
          <given-names>
           PA
          </given-names>
         </name>
        </person-group>
        <source>
         Vaccines
        </source>
        <edition>
         5th ed.
        </edition>
        <year>
         2008
        </year>
        <publisher-name>
         W.B. Saunders
        </publisher-name>
        <publisher-loc>
         Philadelphia
        </publisher-loc>
        <fpage>
         959
        </fpage>
        <lpage>
         1055
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib48">
       <label>
        2
       </label>
       <element-citation id="sbref47" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Monath
          </surname>
          <given-names>
           TP
          </given-names>
         </name>
         <name>
          <surname>
           Cetron
          </surname>
          <given-names>
           MS
          </given-names>
         </name>
        </person-group>
        <article-title>
         Prevention of yellow fever in persons traveling to the tropics
        </article-title>
        <source>
         Clin Infect Dis
        </source>
        <volume>
         34
        </volume>
        <issue>
         10
        </issue>
        <year>
         2002
        </year>
        <fpage>
         1369
        </fpage>
        <lpage>
         1378
        </lpage>
        <pub-id pub-id-type="pmid">
         11981733
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib49">
       <label>
        3
       </label>
       <element-citation id="sbref48" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Van der Stuyft
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Gianella
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Pirard
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <article-title>
         Urbanisation of yellow fever in Santa Cruz, Bolivia
        </article-title>
        <source>
         Lancet
        </source>
        <volume>
         353
        </volume>
        <issue>
         9164
        </issue>
        <year>
         1999
        </year>
        <fpage>
         1558
        </fpage>
        <lpage>
         1562
        </lpage>
        <pub-id pub-id-type="pmid">
         10334253
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib50">
       <label>
        4
       </label>
       <mixed-citation id="ceotherref2" publication-type="other">
        Pan American Health Organization. EID Updates: Emerging and Reemerging Infectious Diseases, Region of the Americas. Vol. 5, No. 6 (25 Feb. 2008) Yellow fever in Paraguay: Mobilization continues. [cited 2008 Jun 8]. Available from:
        <ext-link ext-link-type="uri" id="interref20" xlink:href="http://www.paho.org/english/AD/DPC/CD/eid-eer-2008-02-25.htm">
         http://www.paho.org/english/AD/DPC/CD/eid-eer-2008-02-25.htm
        </ext-link>
        .
       </mixed-citation>
      </ref>
      <ref id="bib51">
       <label>
        5
       </label>
       <element-citation id="sbref49" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tomori
          </surname>
          <given-names>
           O
          </given-names>
         </name>
        </person-group>
        <article-title>
         Yellow fever: The recurring plague
        </article-title>
        <source>
         Crit Rev Clin Lab Sci
        </source>
        <volume>
         41
        </volume>
        <issue>
         4
        </issue>
        <year>
         2004
        </year>
        <fpage>
         391
        </fpage>
        <lpage>
         427
        </lpage>
        <pub-id pub-id-type="pmid">
         15487593
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib52">
       <label>
        6
       </label>
       <element-citation id="sbref50" publication-type="journal">
        <person-group person-group-type="author">
         <collab>
          World Health Organization.
         </collab>
        </person-group>
        <article-title>
         Yellow fever vaccine: WHO position paper
        </article-title>
        <source>
         Wkly Epidemiol Rec
        </source>
        <volume>
         40
        </volume>
        <year>
         2003
        </year>
        <fpage>
         349
        </fpage>
        <lpage>
         360
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib53">
       <label>
        7
       </label>
       <element-citation id="sbref51" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Monath
          </surname>
          <given-names>
           TP
          </given-names>
         </name>
         <name>
          <surname>
           Nichols
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Archambault
          </surname>
          <given-names>
           WT
          </given-names>
         </name>
        </person-group>
        <article-title>
         Comparative safety and immunogenicity of two yellow fever 17D vaccines (Arilvax and YF-Vax) in a phase III multicenter, double-blind clinical trial
        </article-title>
        <source>
         Am J Trop Med Hyg
        </source>
        <volume>
         66
        </volume>
        <issue>
         5
        </issue>
        <year>
         2002
        </year>
        <fpage>
         535
        </fpage>
        <lpage>
         541
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib54">
       <label>
        8
       </label>
       <element-citation id="sbref52" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Pfsiter
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Kuersteiner
          </surname>
          <given-names>
           O
          </given-names>
         </name>
         <name>
          <surname>
           Hilfiker
          </surname>
          <given-names>
           H
          </given-names>
         </name>
        </person-group>
        <article-title>
         Immunogenicity and safety of Berna-YF compared with two other 17D yellow fever vaccines in a phase 3 clinical trial
        </article-title>
        <source>
         Am J Trop Med Hyg
        </source>
        <volume>
         72
        </volume>
        <issue>
         3
        </issue>
        <year>
         2005
        </year>
        <fpage>
         339
        </fpage>
        <lpage>
         346
        </lpage>
        <pub-id pub-id-type="pmid">
         15772332
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib55">
       <label>
        9
       </label>
       <element-citation id="sbref53" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ripoll
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Ponce
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Wilson
          </surname>
          <given-names>
           MM
          </given-names>
         </name>
        </person-group>
        <article-title>
         Evaluation of two yellow fever vaccines for routine immunization programs in Argentina
        </article-title>
        <source>
         Hum Vaccin
        </source>
        <volume>
         4
        </volume>
        <issue>
         2
        </issue>
        <year>
         2008
        </year>
        <fpage>
         121
        </fpage>
        <lpage>
         126
        </lpage>
        <pub-id pub-id-type="pmid">
         18382132
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib56">
       <label>
        10
       </label>
       <element-citation id="sbref54" publication-type="journal">
        <person-group person-group-type="author">
         <collab>
          CDC
         </collab>
        </person-group>
        <article-title>
         Yellow fever vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP)
        </article-title>
        <source>
         MMWR Morb Mortal Wkly Rep
        </source>
        <volume>
         51
        </volume>
        <issue>
         RR-17
        </issue>
        <year>
         2002
        </year>
        <fpage>
         1
        </fpage>
        <lpage>
         12
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib57">
       <label>
        11
       </label>
       <mixed-citation id="ceotherref3" publication-type="other">
        World Health Organization. International Health Regulations. 2005. Geneva. [cited 2008 Jun 9]. Available from:
        <ext-link ext-link-type="uri" id="interref21" xlink:href="http://www.who.int/csr/ihr/en/index.html">
         http://www.who.int/csr/ihr/en/index.html
        </ext-link>
        .
       </mixed-citation>
      </ref>
      <ref id="bib58">
       <label>
        12
       </label>
       <element-citation id="sbref55" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lindsey
          </surname>
          <given-names>
           NP
          </given-names>
         </name>
         <name>
          <surname>
           Schroeder
          </surname>
          <given-names>
           BA
          </given-names>
         </name>
         <name>
          <surname>
           Miller
          </surname>
          <given-names>
           ER
          </given-names>
         </name>
        </person-group>
        <article-title>
         Adverse event reports following yellow fever vaccination
        </article-title>
        <source>
         Vaccine
        </source>
        <volume>
         26
        </volume>
        <issue>
         48
        </issue>
        <year>
         2008
        </year>
        <fpage>
         6077
        </fpage>
        <lpage>
         6082
        </lpage>
        <pub-id pub-id-type="pmid">
         18809449
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib59">
       <label>
        13
       </label>
       <element-citation id="sbref56" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           McMahon
          </surname>
          <given-names>
           AW
          </given-names>
         </name>
         <name>
          <surname>
           Eidex
          </surname>
          <given-names>
           RB
          </given-names>
         </name>
         <name>
          <surname>
           Marfin
          </surname>
          <given-names>
           AA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Neurologic disease associated with 17D-204 yellow fever vaccination: a report of 15 cases
        </article-title>
        <source>
         Vaccine
        </source>
        <volume>
         25
        </volume>
        <issue>
         10
        </issue>
        <year>
         2007
        </year>
        <fpage>
         1727
        </fpage>
        <lpage>
         1734
        </lpage>
        <pub-id pub-id-type="pmid">
         17240001
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib60">
       <label>
        14
       </label>
       <element-citation id="sbref57" publication-type="journal">
        <person-group person-group-type="author">
         <collab>
          CDC
         </collab>
        </person-group>
        <article-title>
         Adverse events associated with 17D-derived yellow fever vaccination—United States, 2001–2002
        </article-title>
        <source>
         MMWR Morb Mortal Wkly Rep
        </source>
        <volume>
         51
        </volume>
        <issue>
         44
        </issue>
        <year>
         2002
        </year>
        <fpage>
         989
        </fpage>
        <lpage>
         993
        </lpage>
        <pub-id pub-id-type="pmid">
         12455906
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib61">
       <label>
        15
       </label>
       <element-citation id="sbref58" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Marfin
          </surname>
          <given-names>
           AA
          </given-names>
         </name>
         <name>
          <surname>
           Eidex Barwick
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Monath
          </surname>
          <given-names>
           TP
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         Yellow fever
        </chapter-title>
        <person-group person-group-type="editor">
         <name>
          <surname>
           Guerrant
          </surname>
          <given-names>
           RL
          </given-names>
         </name>
         <name>
          <surname>
           Walker
          </surname>
          <given-names>
           DH
          </given-names>
         </name>
         <name>
          <surname>
           Weller
          </surname>
          <given-names>
           PF
          </given-names>
         </name>
        </person-group>
        <source>
         Tropical infectious diseases: principles, pathogens, &amp; practice
        </source>
        <edition>
         2nd ed.
        </edition>
        <year>
         2005
        </year>
        <publisher-name>
         Mosby Elsevier
        </publisher-name>
        <publisher-loc>
         Philadelphia
        </publisher-loc>
        <fpage>
         797
        </fpage>
        <lpage>
         812
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib62">
       <label>
        16
       </label>
       <element-citation id="sbref59" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hayes
          </surname>
          <given-names>
           EB
          </given-names>
         </name>
        </person-group>
        <article-title>
         Acute viscerotropic disease following vaccination against yellow fever
        </article-title>
        <source>
         Trans R Soc Trop Med Hyg
        </source>
        <volume>
         101
        </volume>
        <issue>
         10
        </issue>
        <year>
         2007
        </year>
        <fpage>
         967
        </fpage>
        <lpage>
         971
        </lpage>
        <pub-id pub-id-type="pmid">
         17669451
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib63">
       <label>
        17
       </label>
       <element-citation id="sbref60" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Muñoz
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Vilella
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Domingo
          </surname>
          <given-names>
           C
          </given-names>
         </name>
        </person-group>
        <article-title>
         Yellow fever-associated viscerotropic disease in Barcelona, Spain
        </article-title>
        <source>
         J Travel Med
        </source>
        <volume>
         15
        </volume>
        <issue>
         3
        </issue>
        <year>
         2008
        </year>
        <fpage>
         202
        </fpage>
        <lpage>
         205
        </lpage>
        <pub-id pub-id-type="pmid">
         18494699
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib64">
       <label>
        18
       </label>
       <element-citation id="sbref61" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Barwick
          </surname>
          <given-names>
           R
          </given-names>
         </name>
        </person-group>
        <article-title>
         History of thymoma and yellow fever vaccination
        </article-title>
        <source>
         Lancet
        </source>
        <volume>
         364
        </volume>
        <issue>
         9438
        </issue>
        <year>
         2004
        </year>
        <fpage>
         936
        </fpage>
        <pub-id pub-id-type="pmid">
         15364184
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib65">
       <label>
        19
       </label>
       <element-citation id="sbref62" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cavalcanti
          </surname>
          <given-names>
           DP
          </given-names>
         </name>
         <name>
          <surname>
           Salomao
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
         <name>
          <surname>
           Lopez-Camelo
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        <article-title>
         Early exposure to yellow fever vaccine during pregnancy
        </article-title>
        <source>
         Trop Med Int Health
        </source>
        <volume>
         12
        </volume>
        <issue>
         7
        </issue>
        <year>
         2007
        </year>
        <fpage>
         833
        </fpage>
        <lpage>
         837
        </lpage>
        <pub-id pub-id-type="pmid">
         17596249
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib66">
       <label>
        20
       </label>
       <element-citation id="sbref63" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Nishioka Sde
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Nunes-Araujo
          </surname>
          <given-names>
           FR F
          </given-names>
         </name>
         <name>
          <surname>
           Pires
          </surname>
          <given-names>
           WP
          </given-names>
         </name>
        </person-group>
        <article-title>
         Yellow fever vaccination during pregnancy and spontaneous abortion: a case–control study
        </article-title>
        <source>
         Trop Med Int Health
        </source>
        <volume>
         3
        </volume>
        <issue>
         1
        </issue>
        <year>
         1998
        </year>
        <fpage>
         29
        </fpage>
        <lpage>
         33
        </lpage>
        <pub-id pub-id-type="pmid">
         9484965
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib67">
       <label>
        21
       </label>
       <element-citation id="sbref64" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Suzano
          </surname>
          <given-names>
           CE
          </given-names>
         </name>
         <name>
          <surname>
           Amaral
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Sato
          </surname>
          <given-names>
           HK
          </given-names>
         </name>
        </person-group>
        <article-title>
         The effects of yellow fever immunization (17DD) inadvertently used in early pregnancy during a mass campaign in Brazil
        </article-title>
        <source>
         Vaccine
        </source>
        <volume>
         24
        </volume>
        <issue>
         9
        </issue>
        <year>
         2006
        </year>
        <fpage>
         1421
        </fpage>
        <lpage>
         1426
        </lpage>
        <pub-id pub-id-type="pmid">
         16236402
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib68">
       <label>
        22
       </label>
       <element-citation id="sbref65" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Nasidi
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Monath
          </surname>
          <given-names>
           TP
          </given-names>
         </name>
         <name>
          <surname>
           Vandenberg
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        <article-title>
         Yellow fever vaccination and pregnancy: a four-year prospective study
        </article-title>
        <source>
         Trans R Soc Trop Med Hyg
        </source>
        <volume>
         87
        </volume>
        <issue>
         3
        </issue>
        <year>
         1993
        </year>
        <fpage>
         337
        </fpage>
        <lpage>
         339
        </lpage>
        <pub-id pub-id-type="pmid">
         8236412
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib69">
       <label>
        23
       </label>
       <element-citation id="sbref66" publication-type="journal">
        <person-group person-group-type="author">
         <collab>
          CDC
         </collab>
        </person-group>
        <article-title>
         General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP)
        </article-title>
        <source>
         MMWR Recomm Rep
        </source>
        <volume>
         55
        </volume>
        <issue>
         RR-15
        </issue>
        <year>
         2006
        </year>
        <fpage>
         1
        </fpage>
        <lpage>
         48
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib70">
       <label>
        24
       </label>
       <element-citation id="sbref67" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kaplan
          </surname>
          <given-names>
           JE
          </given-names>
         </name>
         <name>
          <surname>
           Nelson
          </surname>
          <given-names>
           DB
          </given-names>
         </name>
         <name>
          <surname>
           Schonberger
          </surname>
          <given-names>
           LB
          </given-names>
         </name>
        </person-group>
        <article-title>
         The effect of immune globulin on the response to trivalent oral poliovirus and yellow fever vaccinations
        </article-title>
        <source>
         Bull World Health Organ
        </source>
        <volume>
         62
        </volume>
        <issue>
         4
        </issue>
        <year>
         1984
        </year>
        <fpage>
         585
        </fpage>
        <lpage>
         590
        </lpage>
        <pub-id pub-id-type="pmid">
         6333295
        </pub-id>
       </element-citation>
      </ref>
     </ref-list>
    </sec>
    <sec id="subchapter7">
     <sec-meta>
      <contrib-group>
       <contrib contrib-type="author" id="au10">
        <name>
         <surname>
          Gershman
         </surname>
         <given-names>
          Mark
         </given-names>
        </name>
       </contrib>
       <contrib contrib-type="author" id="au11">
        <name>
         <surname>
          Schroeder
         </surname>
         <given-names>
          Betsy
         </given-names>
        </name>
       </contrib>
       <contrib contrib-type="author" id="au12">
        <name>
         <surname>
          Jentes
         </surname>
         <given-names>
          Emily S.
         </given-names>
        </name>
       </contrib>
       <contrib contrib-type="author" id="au13">
        <name>
         <surname>
          Marano
         </surname>
         <given-names>
          Nina
         </given-names>
        </name>
       </contrib>
      </contrib-group>
     </sec-meta>
     <title>
      YELLOW FEVER VACCINE REQUIREMENTS AND RECOMMENDATIONS, BY COUNTRY
     </title>
     <sec id="cesec100">
      <title>
       JAPANESE ENCEPHALITIS (JE)
      </title>
      <p id="para548">
       <bold>
        Marc Fischer, Anne Griggs, J. Erin Staples
       </bold>
      </p>
      <sec id="cesec101">
       <title>
        Infectious Agent
       </title>
       <p id="para549">
        Japanese encephalitis virus (JEV) is a single-stranded RNA virus that belongs to the genus
        <italic>
         Flavivirus
        </italic>
        and is closely related to West Nile and St. Louis encephalitis viruses.
       </p>
      </sec>
      <sec id="cesec102">
       <title>
        Mode of Transmission
       </title>
       <p id="para550">
        <list id="celist120" list-type="simple">
         <list-item id="celistitem426">
          <label>
           •
          </label>
          <p id="para551">
           JEV is transmitted to humans through the bite of an infected mosquito, primarily
           <italic>
            Culex
           </italic>
           species. Wading birds are the main animal reservoir for the virus, but the presence of pigs greatly amplifies the transmission of JEV.
          </p>
         </list-item>
         <list-item id="celistitem427">
          <label>
           •
          </label>
          <p id="para552">
           Humans are a dead-end host in the JEV transmission cycle.
          </p>
         </list-item>
        </list>
       </p>
      </sec>
      <sec id="cesec103">
       <title>
        Occurrence
       </title>
       <p id="para553">
        <list id="celist121" list-type="simple">
         <list-item id="celistitem428">
          <label>
           •
          </label>
          <p id="para554">
           JEV is the most common cause of encephalitis in Asia, occurring throughout most of Asia and parts of the western Pacific (
           <xref ref-type="fig" rid="f8">
            Map 2-5
           </xref>
           ). JEV has not been locally transmitted in Africa, Europe, or the Americas.
           <fig id="f8">
            <label>
             Map 2-5
            </label>
            <caption>
             <p>
              Geographic distribution of Japanese encephalitis.
             </p>
            </caption>
            <graphic xlink:href="gr25">
            </graphic>
           </fig>
          </p>
         </list-item>
         <list-item id="celistitem429">
          <label>
           •
          </label>
          <p id="para555">
           JEV transmission principally occurs in rural agricultural areas, often associated with rice production and flooding irrigation. In some areas of Asia, these ecologic conditions may occur near or occasionally within urban centers.
          </p>
         </list-item>
         <list-item id="celistitem430">
          <label>
           •
          </label>
          <p id="para556">
           In temperate areas of Asia, transmission is seasonal, and human disease usually peaks in summer and fall. In the subtropics and tropics, seasonal transmission varies with monsoon rains and irrigation practices and may be extended or even occur year-round.
          </p>
         </list-item>
         <list-item id="celistitem431">
          <label>
           •
          </label>
          <p id="para557">
           In endemic countries, JE is primarily a disease of children. However, travel-associated JE can occur among persons of any age.
          </p>
         </list-item>
        </list>
       </p>
      </sec>
      <sec id="cesec104">
       <title>
        Risk for Travelers
       </title>
       <p id="para558">
        <list id="celist122" list-type="simple">
         <list-item id="celistitem432">
          <label>
           •
          </label>
          <p id="para559">
           The risk for JE for most travelers to Asia is extremely low but varies according to season, destination, duration, and activities. Fewer than 40 cases of confirmed JE have been reported in travelers in the last 40 years.
          </p>
         </list-item>
         <list-item id="celistitem433">
          <label>
           •
          </label>
          <p id="para560">
           The overall incidence of JE reported among people from nonendemic countries traveling to Asia is &lt;1 case per 1 million travelers. However, expatriates and travelers staying for prolonged periods in rural areas with active JEV transmission are likely at similar risk as the susceptible resident population (0.1–2 cases per 100,000 persons per week).
          </p>
         </list-item>
         <list-item id="celistitem434">
          <label>
           •
          </label>
          <p id="para561">
           Travelers on even brief trips are probably at increased risk if they have extensive outdoor or nighttime exposure in rural areas, including persons staying in resort areas or with family.
          </p>
         </list-item>
         <list-item id="celistitem435">
          <label>
           •
          </label>
          <p id="para562">
           Short-term travelers whose visits are restricted to major urban areas are at very minimal risk for JE.
          </p>
         </list-item>
         <list-item id="celistitem436">
          <label>
           •
          </label>
          <p id="para563">
           In endemic areas where there are few human cases among residents because of vaccination or natural immunity, JEV is often maintained in an enzootic cycle between animals and mosquitoes. Therefore, susceptible visitors still may be at risk for infection.
          </p>
         </list-item>
        </list>
       </p>
      </sec>
      <sec id="cesec105">
       <title>
        Clinical Presentation
       </title>
       <p id="para564">
        <list id="celist123" list-type="simple">
         <list-item id="celistitem437">
          <label>
           •
          </label>
          <p id="para565">
           Most human infections with JEV are asymptomatic; &lt;1% of people infected with JEV develop clinical disease.
          </p>
         </list-item>
         <list-item id="celistitem438">
          <label>
           •
          </label>
          <p id="para566">
           Acute encephalitis is the most commonly recognized clinical manifestation of JEV infection. Milder forms of disease such as aseptic meningitis or undifferentiated febrile illness can also occur.
          </p>
         </list-item>
         <list-item id="celistitem439">
          <label>
           •
          </label>
          <p id="para567">
           The incubation period is 5–15 days. Illness usually begins with sudden onset of fever, headache, and vomiting. Mental status changes, focal neurologic deficits, generalized weakness, and movement disorders may develop over the next few days.
           <list id="celist124" list-type="simple">
            <list-item id="celistitem440">
             <label>
              ○
             </label>
             <p id="para568">
              A parkinsonian syndrome resulting from extrapyramidal involvement is a very distinctive clinical presentation of JE.
             </p>
            </list-item>
            <list-item id="celistitem441">
             <label>
              ○
             </label>
             <p id="para569">
              Acute flaccid paralysis, with clinical and pathological features similar to poliomyelitis, has also been associated with JEV infection.
             </p>
            </list-item>
            <list-item id="celistitem442">
             <label>
              ○
             </label>
             <p id="para570">
              Seizures are very common, especially among children.
             </p>
            </list-item>
           </list>
          </p>
         </list-item>
         <list-item id="celistitem443">
          <label>
           •
          </label>
          <p id="para571">
           Clinical laboratory findings include moderate leukocytosis, mild anemia, hyponatremia, and cerebrospinal fluid (CSF) pleocytosis with a lymphocytic predominance.
          </p>
         </list-item>
         <list-item id="celistitem444">
          <label>
           •
          </label>
          <p id="para572">
           Case–fatality ratio is approximately 20%–30%. Among survivors, 30%–50% may still have significant neurologic or psychiatric sequelae, even years after their acute illness.
          </p>
         </list-item>
        </list>
       </p>
      </sec>
      <sec id="cesec106">
       <title>
        Diagnosis
       </title>
       <p id="para573">
        <list id="celist125" list-type="simple">
         <list-item id="celistitem445">
          <label>
           •
          </label>
          <p id="para574">
           JE should be suspected in a patient with evidence of a neurologic infection (e.g., encephalitis, meningitis, or acute flaccid paralysis) who has recently traveled or resided in an endemic country in Asia or the western Pacific.
          </p>
         </list-item>
         <list-item id="celistitem446">
          <label>
           •
          </label>
          <p id="para575">
           Laboratory diagnosis of JEV infection should be performed by using JE-specific IgM-capture enzyme-linked immunosorbent assay (ELISA) on CSF or serum. JE-specific IgM antibodies will be present in the CSF or blood of almost all patients by 7 days following onset of symptoms. A fourfold or greater rise in JEV-specific neutralizing antibodies between acute- and convalescent-phase serum specimens may be used to confirm the diagnosis.
          </p>
         </list-item>
         <list-item id="celistitem447">
          <label>
           •
          </label>
          <p id="para576">
           Vaccination history, date of onset of symptoms, and information regarding other flaviviruses known to circulate in the geographic area that may cross-react in serologic assays need to be considered when interpreting results.
          </p>
         </list-item>
         <list-item id="celistitem448">
          <label>
           •
          </label>
          <p id="para577">
           Humans have low levels of transient viremia and usually have neutralizing antibodies by the time distinctive clinical symptoms are recognized. Virus isolation and nucleic-acid amplification tests (NAATs) are insensitive for the detection of JEV or JE viral RNA in blood or CSF and should not be used for ruling out a diagnosis of JE.
          </p>
         </list-item>
         <list-item id="celistitem449">
          <label>
           •
          </label>
          <p id="para578">
           Health-care providers should contact their state or local health department or CDC's Division of Vector Borne Infectious Diseases at 970-221-6400 for assistance with diagnostic testing.
          </p>
         </list-item>
        </list>
       </p>
      </sec>
      <sec id="cesec107">
       <title>
        Treatment
       </title>
       <p id="para579">
        There is no specific antiviral treatment for JE; therapy consists of supportive care and management of complications.
       </p>
      </sec>
      <sec id="cesec108">
       <title>
        Preventive Measures for Travelers
       </title>
       <sec id="cesec109">
        <title>
         Personal Protection Measures
        </title>
        <p id="para580">
         <list id="celist126" list-type="simple">
          <list-item id="celistitem450">
           <label>
            •
           </label>
           <p id="para581">
            No drugs for preventing JEV infection are available.
           </p>
          </list-item>
          <list-item id="celistitem451">
           <label>
            •
           </label>
           <p id="para582">
            The best way to prevent mosquito-borne diseases, including JE, is to avoid mosquito bites (see the
            <xref ref-type="sec" rid="subchapter29">
             Protection Against Mosquitoes, Ticks, and Other Insects and Arthropods
            </xref>
            section later in this chapter).
           </p>
          </list-item>
         </list>
        </p>
       </sec>
       <sec id="cesec110">
        <title>
         JE Vaccines
        </title>
        <p id="para583">
         <list id="celist127" list-type="simple">
          <list-item id="celistitem452">
           <label>
            •
           </label>
           <p id="para584">
            An inactivated mouse brain-derived JE vaccine (JE-VAX, manufactured by sanofi pasteur) has been licensed for use in adult and pediatric travelers (Δ1 year of age) in the United States since 1992. Although production of JE-VAX was discontinued in 2006, stockpiles of the vaccine will be used for U.S. travelers until they are depleted.
           </p>
          </list-item>
          <list-item id="celistitem453">
           <label>
            •
           </label>
           <p id="para585">
            An inactivated cell culture-derived JE vaccine (IXIARO, manufactured by Intercell) was approved for adult travelers (Δ18 years of age) in the United States on March 30, 2009. Recommendations for its use will be available at
            <ext-link ext-link-type="uri" id="interref22" xlink:href="http://www.cdc.gov/travel">
             www.cdc.gov/travel
            </ext-link>
            . Other inactivated and live attenuated JE vaccines are manufactured and used in Asia but not licensed for use in the United States.
           </p>
          </list-item>
         </list>
        </p>
        <sec id="cesec111">
         <title>
          Inactivated Mouse Brain-Derived JE Vaccine (JE-VAX)
         </title>
         <p id="para586">
          <list id="celist128" list-type="simple">
           <list-item id="celistitem454">
            <label>
             •
            </label>
            <p id="para587">
             A randomized controlled trial among 65,000 children in Thailand showed an efficacy of 91% (95% CI 70%–97%) after two doses.
            </p>
           </list-item>
           <list-item id="celistitem455">
            <label>
             •
            </label>
            <p id="para588">
             From 88% to 100% of adults from nonendemic settings developed neutralizing antibodies after receiving three doses of vaccine.
            </p>
           </list-item>
           <list-item id="celistitem456">
            <label>
             •
            </label>
            <p id="para589">
             The duration of protection after primary immunization is unknown, but circulating neutralizing antibodies appear to last for at least 2–3 years.
            </p>
           </list-item>
           <list-item id="celistitem457">
            <label>
             •
            </label>
            <p id="para590">
             Booster doses produce an anamnestic response in neutralizing antibody titers.
            </p>
           </list-item>
          </list>
         </p>
        </sec>
        <sec id="cesec112">
         <title>
          Recommendations for the Use of JE Vaccine for Travelers
         </title>
         <p id="para591">
          <list id="celist129" list-type="simple">
           <list-item id="celistitem458">
            <label>
             •
            </label>
            <p id="para592">
             Decisions regarding the use of JE vaccine for travelers must balance the low risk for disease and the small chance of an adverse event following immunization.
            </p>
           </list-item>
           <list-item id="celistitem459">
            <label>
             •
            </label>
            <p id="para593">
             The U.S. Advisory Committee on Immunization Practices (ACIP) currently recommends JE vaccine for travelers who plan to spend a month or longer in endemic areas or areas with ongoing transmission. Vaccine should also be considered for shorter-term travelers whose itineraries may put them at increased risk for JEV exposure, such as rural stays during the rainy season.
            </p>
           </list-item>
           <list-item id="celistitem460">
            <label>
             •
            </label>
            <p id="para594">
             Evaluation of an individual traveler's risk should take into account itinerary, activities, and best-available information on the current level of JE activity in the travel area (
             <xref ref-type="table" rid="cetable15">
              Table 2-15
             </xref>
             ). Complicating the concept of risk assessment, however, is the fact that sporadic cases of JE have very rarely occurred in travelers whose itineraries would not ordinarily have indicated a risk for JE (e.g., a resort hotel in Bali, a standard tour of China).
             <table-wrap id="cetable15" position="float">
              <label>
               Table 2-15
              </label>
              <caption>
               <p>
                <bold>
                 Risk for Japanese encephalitis, by country
                </bold>
                <xref ref-type="table-fn" rid="cetablefn62">
                 1
                </xref>
               </p>
              </caption>
              <table frame="hsides" rules="groups">
               <thead>
                <tr>
                 <th align="left">
                  Country
                 </th>
                 <th align="left">
                  Affected Areas
                 </th>
                 <th align="left">
                  Transmission Season
                 </th>
                 <th align="left">
                  Comments
                 </th>
                </tr>
               </thead>
               <tbody>
                <tr>
                 <td align="left">
                  <bold>
                   Australia
                  </bold>
                 </td>
                 <td align="left">
                  Outer islands of Torres Strait
                 </td>
                 <td align="left">
                  December to May; all human cases reported from February to April
                 </td>
                 <td align="left">
                  One human case reported from north Queensland mainland
                 </td>
                </tr>
                <tr>
                 <td align="left">
                  <bold>
                   Bangladesh
                  </bold>
                 </td>
                 <td align="left">
                  Limited data; probably widespread
                 </td>
                 <td align="left">
                  Unknown; most human cases reported from May to October
                 </td>
                 <td align="left">
                  One outbreak of human disease reported from Tangail District in 1977. Sentinel surveillance has identified human cases in Chittagong, Khulna, and Rajshahi divisions, and Mymensingh district.
                 </td>
                </tr>
                <tr>
                 <td align="left">
                  <bold>
                   Bhutan
                  </bold>
                 </td>
                 <td align="left">
                  No data
                 </td>
                 <td align="left">
                  No data
                 </td>
                 <td>
                 </td>
                </tr>
                <tr>
                 <td align="left">
                  <bold>
                   Brunei
                  </bold>
                 </td>
                 <td align="left">
                  No data; presumed to be endemic countrywide
                 </td>
                 <td align="left">
                  Unknown; presumed year-round transmission
                 </td>
                 <td>
                 </td>
                </tr>
                <tr>
                 <td align="left">
                  <bold>
                   Burma (Myanmar)
                  </bold>
                 </td>
                 <td align="left">
                  Limited data; presumed be endemic countrywide
                 </td>
                 <td align="left">
                  Unknown; most human cases reported from May to October
                 </td>
                 <td align="left">
                  Outbreaks of human disease documented in Shan State. JEV antibodies documented in animals and humans in other areas
                 </td>
                </tr>
                <tr>
                 <td align="left">
                  <bold>
                   Cambodia
                  </bold>
                 </td>
                 <td align="left">
                  Presumed to be endemic countrywide
                 </td>
                 <td align="left">
                  Probably year round with peaks reported from May to October
                 </td>
                 <td align="left">
                  Sentinel surveillance has identified human cases in at least 14 provinces including Phnom Penh, Takeo, Kampong, Cham, Battambang, Svay Rieng, and Siem Reap.
                 </td>
                </tr>
                <tr>
                 <td align="left">
                  <bold>
                   China
                  </bold>
                 </td>
                 <td align="left">
                  <list id="celist13" list-type="simple">
                   <list-item id="celistitem46">
                    <p id="para46">
                     Human cases reported from all provinces except Xizang (Tibet), Xinjiang, and Qinghai
                    </p>
                   </list-item>
                   <list-item id="celistitem47">
                    <p id="para47">
                     <italic>
                      Hong Kong and Macau:
                     </italic>
                     Not considered endemic. Rare cases reported from the New Territories
                    </p>
                   </list-item>
                  </list>
                 </td>
                 <td align="left">
                  Most human cases reported from April to October
                 </td>
                 <td align="left">
                  <list id="celist14" list-type="simple">
                   <list-item id="celistitem48">
                    <p id="para48">
                     Highest rates reported from the southwest and south central provinces
                    </p>
                   </list-item>
                   <list-item id="celistitem49">
                    <p id="para49">
                     Vaccine not routinely recommended for travel limited to Beijing or other major cities
                    </p>
                   </list-item>
                  </list>
                 </td>
                </tr>
                <tr>
                 <td align="left">
                  <bold>
                   India
                  </bold>
                 </td>
                 <td align="left">
                  Human cases reported from all states except Dadra, Daman, Diu, Gujarat, Himachal, Jammu, Kashmir, Lakshadweep, Meghalaya, Nagar Haveli, Punjab, Rajasthan, and Sikkim
                 </td>
                 <td align="left">
                  Most human cases reported from May to October especially in northern India. The season may be extended or year round in some areas especially in southern India.
                 </td>
                 <td align="left">
                  Highest rates of human disease reported from the states of Andhra Pradesh, Assam, Bihar, Goa, Haryana, Karnataka, Kerala, Tamil Nadu, Uttar Pradesh, and West Bengal
                 </td>
                </tr>
                <tr>
                 <td align="left">
                  <bold>
                   Indonesia
                  </bold>
                 </td>
                 <td align="left">
                  Presumed to be endemic countrywide
                 </td>
                 <td align="left">
                  Human cases reported year round; peak season varies by island
                 </td>
                 <td align="left">
                  Sentinel surveillance has identified human cases in Bali, Kalimantan, Java, Nusa Tenggara, Papua, and Sumatra.
                 </td>
                </tr>
                <tr>
                 <td align="left">
                  <bold>
                   Japan
                  </bold>
                  <xref ref-type="table-fn" rid="cetablefn63">
                   2
                  </xref>
                 </td>
                 <td align="left">
                  Rare sporadic human cases on all islands except Hokkaido. Enzootic activity ongoing
                 </td>
                 <td align="left">
                  Most human cases reported from May to October
                 </td>
                 <td align="left">
                  <list id="celist15" list-type="simple">
                   <list-item id="celistitem50">
                    <p id="para50">
                     Large number of human cases reported until routine JE vaccination introduced in 1968. Most recent small outbreak reported from Chugoku district in 2002. Sporadic cases reported among U.S. military personnel on Okinawa. Enzootic transmission without human cases observed on Hokkaido
                    </p>
                   </list-item>
                   <list-item id="celistitem51">
                    <p id="para51">
                     Vaccine not routinely recommended for travel limited to Tokyo or other major cities
                    </p>
                   </list-item>
                  </list>
                 </td>
                </tr>
                <tr>
                 <td align="left">
                  <bold>
                   Korea, North
                  </bold>
                 </td>
                 <td align="left">
                  No data
                 </td>
                 <td align="left">
                  No data
                 </td>
                 <td>
                 </td>
                </tr>
                <tr>
                 <td align="left">
                  <bold>
                   Korea, South
                  </bold>
                  <xref ref-type="table-fn" rid="cetablefn63">
                   2
                  </xref>
                 </td>
                 <td align="left">
                  Rare sporadic human cases countrywide. Enzootic activity ongoing
                 </td>
                 <td align="left">
                  Most human cases reported from May to October
                 </td>
                 <td align="left">
                  <list id="celist16" list-type="simple">
                   <list-item id="celistitem52">
                    <p id="para52">
                     Large number of human casesreported until routine JE vaccinationintroduced in 1968. Highest rates ofdisease were reported from thesouthern provinces. Last majoroutbreak reported in 1982
                    </p>
                   </list-item>
                   <list-item id="celistitem53">
                    <p id="para53">
                     Vaccine not routinely recommendedfor travel limited to Seoul or othermajor cities
                    </p>
                   </list-item>
                  </list>
                 </td>
                </tr>
                <tr>
                 <td align="left">
                  <bold>
                   Laos
                  </bold>
                 </td>
                 <td align="left">
                  No data; presumed to be endemic countrywide
                 </td>
                 <td align="left">
                  Presumed to be May to October
                 </td>
                 <td>
                 </td>
                </tr>
                <tr>
                 <td align="left">
                  <bold>
                   Malaysia
                  </bold>
                 </td>
                 <td align="left">
                  Endemic in Sarawak; sporadic cases or outbreaks reported from all states of Peninsula, and probably Sabah
                 </td>
                 <td align="left">
                  Year-round transmission
                 </td>
                 <td align="left">
                  <list id="celist17" list-type="simple">
                   <list-item id="celistitem54">
                    <p id="para54">
                     Most human cases reported from Penang and Sarawak
                    </p>
                   </list-item>
                   <list-item id="celistitem55">
                    <p id="para55">
                     Vaccine not routinely recommended for travel limited to Kuala Lumpur or other major cities
                    </p>
                   </list-item>
                  </list>
                 </td>
                </tr>
                <tr>
                 <td align="left">
                  <bold>
                   Mongolia
                  </bold>
                 </td>
                 <td align="left">
                  Not considered endemic
                 </td>
                 <td>
                 </td>
                 <td>
                 </td>
                </tr>
                <tr>
                 <td align="left">
                  <bold>
                   Nepal
                  </bold>
                 </td>
                 <td align="left">
                  Endemic in southern lowlands (Terai). Sporadic cases or outbreaks reported from the Kathmandu valley
                 </td>
                 <td align="left">
                  Most human cases reported from May to November
                 </td>
                 <td align="left">
                  <list id="celist18" list-type="simple">
                   <list-item id="celistitem56">
                    <p id="para56">
                     Highest rates of human disease reported from western Terai districts, including Bankey, Bardia, Dang, and Kailali
                    </p>
                   </list-item>
                   <list-item id="celistitem57">
                    <p id="para57">
                     Vaccine not routinely recommended for travel limited to high-altitude areas
                    </p>
                   </list-item>
                  </list>
                 </td>
                </tr>
                <tr>
                 <td align="left">
                  <bold>
                   Pakistan
                  </bold>
                 </td>
                 <td align="left">
                  Limited data; human cases reported from around Karachi
                 </td>
                 <td align="left">
                  Most human cases reported from May to October
                 </td>
                 <td>
                 </td>
                </tr>
                <tr>
                 <td align="left">
                  <bold>
                   Papua New Guinea
                  </bold>
                 </td>
                 <td align="left">
                  Limited data; sporadic human cases reported from Western, Gulf, and South Highland Provinces
                 </td>
                 <td align="left">
                  Unknown
                 </td>
                 <td align="left">
                  A case of JE was reported from near Port Moresby in 2004. Human cases documented in Papua Indonesia
                 </td>
                </tr>
                <tr>
                 <td align="left">
                  <bold>
                   Philippines
                  </bold>
                 </td>
                 <td align="left">
                  Limited data; presumed to be endemic on all islands
                 </td>
                 <td align="left">
                  Unknown; probably year-round
                 </td>
                 <td align="left">
                  Outbreaks reported in Nueva Ecija, Luzon, and Manila
                 </td>
                </tr>
                <tr>
                 <td align="left">
                  <bold>
                   Russia
                  </bold>
                 </td>
                 <td align="left">
                  Rare human cases reported from the Far Eastern maritime areas south of Khabarousk
                 </td>
                 <td align="left">
                  Most human cases reported from July to September
                 </td>
                 <td>
                 </td>
                </tr>
                <tr>
                 <td align="left">
                  <bold>
                   Singapore
                  </bold>
                 </td>
                 <td align="left">
                  Rare sporadic human cases reported
                 </td>
                 <td align="left">
                  Year-round transmission
                 </td>
                 <td align="left">
                  Vaccine not routinely recommended
                 </td>
                </tr>
                <tr>
                 <td align="left">
                  <bold>
                   Sri Lanka
                  </bold>
                 </td>
                 <td align="left">
                  Endemic countrywide except in mountainous areas
                 </td>
                 <td align="left">
                  Year-round with variable peaks based on monsoon rains
                 </td>
                 <td align="left">
                  Highest rates of human disease reported from Anuradhapura, Gampaha, Kurunegala, Polonnaruwa, and Puttalam districts
                 </td>
                </tr>
                <tr>
                 <td align="left">
                  <bold>
                   Taiwan
                  </bold>
                  <xref ref-type="table-fn" rid="cetablefn63">
                   2
                  </xref>
                 </td>
                 <td align="left">
                  Rare sporadic human cases island-wide
                 </td>
                 <td align="left">
                  Most human cases reported from May to October
                 </td>
                 <td align="left">
                  <list id="celist19" list-type="simple">
                   <list-item id="celistitem58">
                    <p id="para58">
                     Large number of human cases reported until routine JE vaccination introduced in 1968
                    </p>
                   </list-item>
                   <list-item id="celistitem59">
                    <p id="para59">
                     Vaccine not routinely recommended for travel limited to Taipei or other major cities
                    </p>
                   </list-item>
                  </list>
                 </td>
                </tr>
                <tr>
                 <td align="left">
                  <bold>
                   Thailand
                  </bold>
                 </td>
                 <td align="left">
                  Endemic countrywide; seasonal epidemics in the northern provinces
                 </td>
                 <td align="left">
                  Year-round with seasonal peaks from May to October, especially in the north
                 </td>
                 <td align="left">
                  Highest rates of human disease reported from the Chiang Mai Valley. Sporadic human cases reported from Bangkok suburbs
                 </td>
                </tr>
                <tr>
                 <td align="left">
                  <bold>
                   Timor-Leste
                  </bold>
                 </td>
                 <td align="left">
                  Limited data; anecdotal reports of sporadic human cases
                 </td>
                 <td align="left">
                  No data
                 </td>
                 <td>
                 </td>
                </tr>
                <tr>
                 <td align="left">
                  <bold>
                   Vietnam
                  </bold>
                 </td>
                 <td align="left">
                  Endemic countrywide; seasonal epidemics in the northern provinces
                 </td>
                 <td align="left">
                  Year-round with seasonal peaks from May to October, especially in the north
                 </td>
                 <td align="left">
                  Highest rates of disease in the northern provinces around Hanoi and northwestern provinces bordering China
                 </td>
                </tr>
                <tr>
                 <td align="left">
                  <bold>
                   Western Pacific Islands
                  </bold>
                 </td>
                 <td align="left">
                  Outbreaks of human disease reported in Guam in 1947–1948 and Saipan in 1990
                 </td>
                 <td align="left">
                  Unknown; most human cases reported from October to March
                 </td>
                 <td align="left">
                  Enzootic cycle might not be sustainable; outbreaks may follow introductions of JE virus.
                 </td>
                </tr>
               </tbody>
              </table>
              <table-wrap-foot>
               <fn id="cetablefn62">
                <label>
                 1
                </label>
                <p id="cenotep62">
                 Data are based on published reports and personal correspondence. Risk assessments should be performed cautiously because risk can vary within areas and from year to year, and surveillance data regarding human cases and JE virus transmission are incomplete.
                </p>
               </fn>
              </table-wrap-foot>
              <table-wrap-foot>
               <fn id="cetablefn63">
                <label>
                 2
                </label>
                <p id="cenotep63">
                 In some endemic areas, human cases among residents are limited because of vaccination or natural immunity. However, because JE virus is maintained in an enzootic cycle between animals and mosquitoes, susceptible visitors to these areas still may be at risk for infection.
                </p>
               </fn>
              </table-wrap-foot>
             </table-wrap>
            </p>
           </list-item>
          </list>
         </p>
        </sec>
        <sec id="cesec113">
         <title>
          Vaccine Safety and Adverse Events
         </title>
         <p id="para595">
          <list id="celist130" list-type="simple">
           <list-item id="celistitem461">
            <label>
             •
            </label>
            <p id="para596">
             Inactivated mouse brain-derived JE vaccine has been associated with localized erythema, tenderness, and swelling at the injection site in about 20% of recipients.
            </p>
           </list-item>
           <list-item id="celistitem462">
            <label>
             •
            </label>
            <p id="para597">
             Mild systemic side effects (e.g., fever, chills, headache, rash, myalgia, gastrointestinal symptoms) have been reported in approximately 10% of vaccinees.
            </p>
           </list-item>
           <list-item id="celistitem463">
            <label>
             •
            </label>
            <p id="para598">
             Serious allergic hypersensitivity reactions, including generalized urticaria and angioedema of the extremities, face, and oropharynx, have been reported. Accompanying bronchospasm, respiratory distress, and hypotension have been observed in some of these patients, although there have been no fatalities among vaccine recipients with these symptoms.
            </p>
           </list-item>
           <list-item id="celistitem464">
            <label>
             •
            </label>
            <p id="para599">
             Estimates of the frequency of these reactions range from 20 to 600 cases per 100,000 vaccinees and vary by country, year, case definition, surveillance method, and vaccine lot.
            </p>
           </list-item>
           <list-item id="celistitem465">
            <label>
             •
            </label>
            <p id="para600">
             Most hypersensitivity reactions occur within 24–48 hours after the first dose, when they occur following a subsequent dose, the onset of symptoms is often delayed (median: 3 days; range: up to 2 weeks).
            </p>
           </list-item>
           <list-item id="celistitem466">
            <label>
             •
            </label>
            <p id="para601">
             Most reactions can be treated with antihistamines or corticosteroids on an outpatient basis; however, up to 10% of vaccinees with rare severe reactions are hospitalized.
            </p>
           </list-item>
           <list-item id="celistitem467">
            <label>
             •
            </label>
            <p id="para602">
             At least four deaths due to anaphylactic shock temporally associated with receipt of this vaccine have been reported in the world literature, which includes endemic country national vaccine programs. None of these patients had evidence of urticaria or angioedema, and two had received other vaccines simultaneously.
            </p>
           </list-item>
           <list-item id="celistitem468">
            <label>
             •
            </label>
            <p id="para603">
             Moderate to severe neurologic symptoms, including encephalitis, seizures, gait disturbances, and parkinsonian syndrome have been reported, with an incidence of 0.1 to 2 cases per 100,000 vaccinees.
            </p>
           </list-item>
           <list-item id="celistitem469">
            <label>
             •
            </label>
            <p id="para604">
             In addition, there have been case reports of children in Japan and Korea with severe or fatal acute disseminated encephalomyelitis (ADEM) temporally associated with JE vaccination.
            </p>
           </list-item>
          </list>
         </p>
        </sec>
        <sec id="cesec114">
         <title>
          Vaccine Dose and Administration
         </title>
         <p id="para605">
          <list id="celist131" list-type="simple">
           <list-item id="celistitem470">
            <label>
             •
            </label>
            <p id="para606">
             For travelers Δ3 years of age, the recommended primary immunization series for JE-VAX is three doses of 1.0 mL each, administered subcutaneously on days 0, 7, and 30.
            </p>
           </list-item>
           <list-item id="celistitem471">
            <label>
             •
            </label>
            <p id="para607">
             An abbreviated schedule (days 0, 7, and 14) provides similar rates of seroconversion but significantly lower neutralizing antibody titers.
            </p>
           </list-item>
           <list-item id="celistitem472">
            <label>
             •
            </label>
            <p id="para608">
             Immunization routes and schedules for children 1 and 2 years of age are identical except that 0.5-mL doses should be administered.
            </p>
           </list-item>
           <list-item id="celistitem473">
            <label>
             •
            </label>
            <p id="para609">
             Vaccine recipients should be observed for a minimum of 30 minutes after immunization and warned about the possibility of delayed allergic reactions.
            </p>
           </list-item>
           <list-item id="celistitem474">
            <label>
             •
            </label>
            <p id="para610">
             The last dose should be administered at least 10 days before beginning travel to ensure an adequate immune response and access to medical care in the event of any delayed adverse reactions.
            </p>
           </list-item>
           <list-item id="celistitem475">
            <label>
             •
            </label>
            <p id="para611">
             Booster doses may be administered 2–3 years after the primary series. The timing and immune response of subsequent boosters have not been studied in travelers.
            </p>
           </list-item>
          </list>
         </p>
        </sec>
        <sec id="cesec115">
         <title>
          Precautions and Contraindications
         </title>
         <p id="para612">
          <list id="celist132" list-type="simple">
           <list-item id="celistitem476">
            <label>
             •
            </label>
            <p id="para613">
             A history of allergy or hypersensitivity reaction to a previous dose of mouse brain-derived JE vaccine is a contraindication to receiving additional doses.
            </p>
           </list-item>
           <list-item id="celistitem477">
            <label>
             •
            </label>
            <p id="para614">
             Proven or suspected hypersensitivity to thimerosal or proteins of rodent or neural origin is a contraindication to vaccination.
            </p>
           </list-item>
           <list-item id="celistitem478">
            <label>
             •
            </label>
            <p id="para615">
             Persons with a previous history of urticaria are more likely to develop a hypersensitivity reaction following receipt of JE vaccine. This history should be considered when weighing the risks and benefits of the vaccine for an individual patient.
            </p>
           </list-item>
           <list-item id="celistitem479">
            <label>
             •
            </label>
            <p id="para616">
             No specific information is available on the safety of JE vaccine in pregnancy. Therefore, the vaccine should not be routinely administered during pregnancy. Pregnant women who must travel to an area where risk for JE is high should be vaccinated when the theoretical risk for immunization is outweighed by the risk for infection.
            </p>
           </list-item>
           <list-item id="celistitem480">
            <label>
             •
            </label>
            <p id="para617">
             No data are available on vaccine safety and efficacy in infants &lt;1 year of age.
            </p>
           </list-item>
           <list-item id="celistitem481">
            <label>
             •
            </label>
            <p id="para618">
             Two small studies of inactivated JE vaccine in children with underlying medical conditions did not show a change in the adverse reactions or immune response after vaccination.
            </p>
           </list-item>
          </list>
         </p>
        </sec>
       </sec>
      </sec>
     </sec>
     <ref-list id="cebib7">
      <title>
       References
      </title>
      <ref id="bib71">
       <label>
        1
       </label>
       <element-citation id="sbref68" publication-type="journal">
        <person-group person-group-type="author">
         <collab>
          CDC
         </collab>
        </person-group>
        <article-title>
         Inactivated Japanese encephalitis virus vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
        </article-title>
        <source>
         MMWR Recomm Rep
        </source>
        <volume>
         42
        </volume>
        <issue>
         RR-01
        </issue>
        <year>
         1993
        </year>
        <fpage>
         1
        </fpage>
        <lpage>
         16
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib72">
       <label>
        2
       </label>
       <element-citation id="sbref69" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Marfin
          </surname>
          <given-names>
           AA
          </given-names>
         </name>
         <name>
          <surname>
           Eidex
          </surname>
          <given-names>
           RS
          </given-names>
         </name>
         <name>
          <surname>
           Kozarsky
          </surname>
          <given-names>
           PE
          </given-names>
         </name>
        </person-group>
        <article-title>
         Yellow fever and Japanese encephalitis vaccines: indications and complications
        </article-title>
        <source>
         Infect Dis Clin North Am
        </source>
        <volume>
         19
        </volume>
        <issue>
         1
        </issue>
        <year>
         2005
        </year>
        <fpage>
         151
        </fpage>
        <lpage>
         168
        </lpage>
        <pub-id pub-id-type="pmid">
         15701552
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib73">
       <label>
        3
       </label>
       <element-citation id="sbref70" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Shlim
          </surname>
          <given-names>
           DR
          </given-names>
         </name>
         <name>
          <surname>
           Solomon
          </surname>
          <given-names>
           T
          </given-names>
         </name>
        </person-group>
        <article-title>
         Japanese encephalitis vaccine for travelers: exploring the limits of risk
        </article-title>
        <source>
         Clin Infect Dis
        </source>
        <volume>
         35
        </volume>
        <issue>
         2
        </issue>
        <year>
         2002
        </year>
        <fpage>
         183
        </fpage>
        <lpage>
         188
        </lpage>
        <pub-id pub-id-type="pmid">
         12087525
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib74">
       <label>
        4
       </label>
       <element-citation id="sbref71" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Halstead
          </surname>
          <given-names>
           SB
          </given-names>
         </name>
         <name>
          <surname>
           Tsai
          </surname>
          <given-names>
           TF
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         Japanese encephalitis vaccine
        </chapter-title>
        <person-group person-group-type="editor">
         <name>
          <surname>
           Plotkin
          </surname>
          <given-names>
           SA
          </given-names>
         </name>
         <name>
          <surname>
           Orenstein
          </surname>
          <given-names>
           WA
          </given-names>
         </name>
        </person-group>
        <source>
         Vaccines
        </source>
        <edition>
         4th edition.
        </edition>
        <year>
         2004
        </year>
        <publisher-name>
         WB Saunders
        </publisher-name>
        <publisher-loc>
         Philadelphia
        </publisher-loc>
        <fpage>
         919
        </fpage>
        <lpage>
         958
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib75">
       <label>
        5
       </label>
       <element-citation id="sbref72" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Solomon
          </surname>
          <given-names>
           T
          </given-names>
         </name>
        </person-group>
        <article-title>
         Flavivirus encephalitis
        </article-title>
        <source>
         N Engl J Med
        </source>
        <volume>
         351
        </volume>
        <issue>
         4
        </issue>
        <year>
         2004
        </year>
        <fpage>
         370
        </fpage>
        <lpage>
         378
        </lpage>
        <pub-id pub-id-type="pmid">
         15269317
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib76">
       <label>
        6
       </label>
       <element-citation id="sbref73" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tauber
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Kollaritsch
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Korinek
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <article-title>
         Safety and immunogenicity of a Vero-cell-derived, inactivated Japanese encephalitis vaccine: a non-inferiority, phase III, randomised controlled trial
        </article-title>
        <source>
         Lancet
        </source>
        <volume>
         370
        </volume>
        <issue>
         9602
        </issue>
        <year>
         2007
        </year>
        <fpage>
         1847
        </fpage>
        <lpage>
         1853
        </lpage>
        <pub-id pub-id-type="pmid">
         18061060
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib77">
       <label>
        7
       </label>
       <element-citation id="sbref74" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gambel
          </surname>
          <given-names>
           JM
          </given-names>
         </name>
         <name>
          <surname>
           DeFraites
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Hoke
          </surname>
          <given-names>
           C
          </given-names>
         </name>
        </person-group>
        <article-title>
         Japanese encephalitis vaccine: Persistence of antibody up to 3 years after a three-dose primary series
        </article-title>
        <source>
         J Infect Dis
        </source>
        <volume>
         171
        </volume>
        <issue>
         4
        </issue>
        <year>
         1995
        </year>
        <fpage>
         1074
        </fpage>
        <pub-id pub-id-type="pmid">
         7706798
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib78">
       <label>
        8
       </label>
       <element-citation id="sbref75" publication-type="journal">
        <person-group person-group-type="author">
         <collab>
          W.H.O.
         </collab>
        </person-group>
        <article-title>
         Japanese encephalitis vaccines
        </article-title>
        <source>
         weekly Epidemiol Rec
        </source>
        <volume>
         81
        </volume>
        <issue>
         34/35
        </issue>
        <year>
         2006
        </year>
        <fpage>
         331
        </fpage>
        <lpage>
         340
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib79">
       <label>
        9
       </label>
       <element-citation id="sbref76" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Martin
          </surname>
          <given-names>
           DA
          </given-names>
         </name>
         <name>
          <surname>
           Biggerstaff
          </surname>
          <given-names>
           BJ
          </given-names>
         </name>
         <name>
          <surname>
           Allen
          </surname>
          <given-names>
           B
          </given-names>
         </name>
        </person-group>
        <article-title>
         Use of immunoglobulin M cross-reactions in differential diagnosis of human flaviviral encephalitis infections in the United States
        </article-title>
        <source>
         Clin Diag Lab Immunol
        </source>
        <volume>
         9
        </volume>
        <issue>
         3
        </issue>
        <year>
         2002
        </year>
        <fpage>
         544
        </fpage>
        <lpage>
         549
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib80">
       <label>
        10
       </label>
       <element-citation id="sbref77" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Burke
          </surname>
          <given-names>
           DS
          </given-names>
         </name>
         <name>
          <surname>
           Nisalak
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Ussery
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Kinetics of IgM and IgG responses to Japanese encephalitis virus in human serum and cerebrospinal fluid
        </article-title>
        <source>
         J Infect Dis
        </source>
        <volume>
         151
        </volume>
        <issue>
         6
        </issue>
        <year>
         1985
        </year>
        <fpage>
         1093
        </fpage>
        <lpage>
         1099
        </lpage>
        <pub-id pub-id-type="pmid">
         2987367
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib81">
       <label>
        11
       </label>
       <element-citation id="sbref78" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Beasley
          </surname>
          <given-names>
           DW C
          </given-names>
         </name>
         <name>
          <surname>
           Lewthwaite
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Solomon
          </surname>
          <given-names>
           T
          </given-names>
         </name>
        </person-group>
        <article-title>
         Current use and development of vaccines for Japanese encephalitis
        </article-title>
        <source>
         Expert Opin Biol Ther
        </source>
        <volume>
         8
        </volume>
        <issue>
         1
        </issue>
        <year>
         2008
        </year>
        <fpage>
         95
        </fpage>
        <lpage>
         106
        </lpage>
        <pub-id pub-id-type="pmid">
         18081539
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib82">
       <label>
        12
       </label>
       <element-citation id="sbref79" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hoke
          </surname>
          <given-names>
           CH
          </given-names>
         </name>
         <name>
          <surname>
           Nisalak
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Sangawhipa
          </surname>
          <given-names>
           N
          </given-names>
         </name>
        </person-group>
        <article-title>
         Protection against Japanese encephalitis by inactivated vaccines
        </article-title>
        <source>
         N Engl J Med
        </source>
        <volume>
         319
        </volume>
        <issue>
         10
        </issue>
        <year>
         1988
        </year>
        <fpage>
         608
        </fpage>
        <lpage>
         614
        </lpage>
        <pub-id pub-id-type="pmid">
         2842677
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib83">
       <label>
        13
       </label>
       <element-citation id="sbref80" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Defraites
          </surname>
          <given-names>
           RF
          </given-names>
         </name>
         <name>
          <surname>
           Gambel
          </surname>
          <given-names>
           JM
          </given-names>
         </name>
         <name>
          <surname>
           Hoke
          </surname>
          <given-names>
           CH
          </given-names>
          <suffix>
           Jr
          </suffix>
         </name>
        </person-group>
        <article-title>
         Japanese encephalitis vaccine (inactivated, BIKEN) in U.S. soldiers: Immunogenicity and safety of vaccine administered in two dosing regimens
        </article-title>
        <source>
         Am J Trop Med Hyg
        </source>
        <volume>
         61
        </volume>
        <issue>
         2
        </issue>
        <year>
         1999
        </year>
        <fpage>
         288
        </fpage>
        <lpage>
         293
        </lpage>
        <pub-id pub-id-type="pmid">
         10463681
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib84">
       <label>
        14
       </label>
       <element-citation id="sbref81" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Monath
          </surname>
          <given-names>
           TP
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         Japanese encephalitis vaccines: current vaccines and future prospects
        </chapter-title>
        <person-group person-group-type="editor">
         <name>
          <surname>
           Mackenzie
          </surname>
          <given-names>
           JS
          </given-names>
         </name>
         <name>
          <surname>
           Barrett
          </surname>
          <given-names>
           AD
          </given-names>
         </name>
         <name>
          <surname>
           Deubel
          </surname>
          <given-names>
           V
          </given-names>
         </name>
        </person-group>
        <source>
         Current topics in microbiology and immunology: Japanese encephalitis and West Nile virus infections
        </source>
        <year>
         2002
        </year>
        <publisher-name>
         Springer-Verlag
        </publisher-name>
        <publisher-loc>
         Berlin
        </publisher-loc>
        <fpage>
         105
        </fpage>
        <lpage>
         138
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib85">
       <label>
        15
       </label>
       <element-citation id="sbref82" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Plesner
          </surname>
          <given-names>
           AM
          </given-names>
         </name>
        </person-group>
        <article-title>
         Allergic reactions to Japanese encephalitis vaccine
        </article-title>
        <source>
         Immunol Allergy Clin North Am
        </source>
        <volume>
         23
        </volume>
        <issue>
         4
        </issue>
        <year>
         2003
        </year>
        <fpage>
         665
        </fpage>
        <lpage>
         697
        </lpage>
        <pub-id pub-id-type="pmid">
         14753386
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib86">
       <label>
        16
       </label>
       <element-citation id="sbref83" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Takahashi
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Pool
          </surname>
          <given-names>
           V
          </given-names>
         </name>
         <name>
          <surname>
           Tsai
          </surname>
          <given-names>
           T
          </given-names>
         </name>
        </person-group>
        <article-title>
         Adverse events after Japanese encephalitis vaccination: review of post-marketing surveillance data from Japan and the United States. The VAERS Working Group
        </article-title>
        <source>
         Vaccine
        </source>
        <volume>
         18
        </volume>
        <issue>
         26
        </issue>
        <year>
         2000
        </year>
        <fpage>
         2963
        </fpage>
        <lpage>
         2969
        </lpage>
        <pub-id pub-id-type="pmid">
         10825597
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib87">
       <label>
        17
       </label>
       <element-citation id="sbref84" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Berg
          </surname>
          <given-names>
           SW
          </given-names>
         </name>
         <name>
          <surname>
           Mitchell
          </surname>
          <given-names>
           BS
          </given-names>
         </name>
         <name>
          <surname>
           Hanson
          </surname>
          <given-names>
           RK
          </given-names>
         </name>
        </person-group>
        <article-title>
         Systemic reactions in U.S. Marine Corps personnel who received Japanese encephalitis vaccine
        </article-title>
        <source>
         Clin Infect Dis
        </source>
        <volume>
         24
        </volume>
        <issue>
         2
        </issue>
        <year>
         1997
        </year>
        <fpage>
         265
        </fpage>
        <lpage>
         266
        </lpage>
        <pub-id pub-id-type="pmid">
         9114160
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib88">
       <label>
        18
       </label>
       <element-citation id="sbref85" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sohn
          </surname>
          <given-names>
           YM
          </given-names>
         </name>
        </person-group>
        <article-title>
         Japanese encephalitis immunization in Korea: past, present and future
        </article-title>
        <source>
         Emerg Infect Dis
        </source>
        <volume>
         6
        </volume>
        <issue>
         1
        </issue>
        <year>
         2000
        </year>
        <fpage>
         17
        </fpage>
        <lpage>
         24
        </lpage>
        <pub-id pub-id-type="pmid">
         10653564
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib89">
       <label>
        19
       </label>
       <element-citation id="sbref86" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Puthanakit
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Aurpibul
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Yoksan
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        <article-title>
         Japanese encephalitis vaccination in HIV-infected children with immune recovery after highly retroactive antiretroviral therapy
        </article-title>
        <source>
         Vaccine
        </source>
        <volume>
         25
        </volume>
        <issue>
         49
        </issue>
        <year>
         2007
        </year>
        <fpage>
         8257
        </fpage>
        <lpage>
         8261
        </lpage>
        <pub-id pub-id-type="pmid">
         17964009
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib90">
       <label>
        20
       </label>
       <element-citation id="sbref87" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yamada
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Imanishi
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Juang
          </surname>
          <given-names>
           R-F
          </given-names>
         </name>
        </person-group>
        <article-title>
         Trial of inactivated Japanese encephalitis vaccine in children with underlying diseases
        </article-title>
        <source>
         Vaccine
        </source>
        <volume>
         4
        </volume>
        <issue>
         1
        </issue>
        <year>
         1986
        </year>
        <fpage>
         32
        </fpage>
        <lpage>
         34
        </lpage>
        <pub-id pub-id-type="pmid">
         3008460
        </pub-id>
       </element-citation>
      </ref>
     </ref-list>
    </sec>
    <sec id="subchapter8">
     <sec-meta>
      <contrib-group>
       <contrib contrib-type="author" id="au14">
        <name>
         <surname>
          Cohn
         </surname>
         <given-names>
          Amanda
         </given-names>
        </name>
       </contrib>
       <contrib contrib-type="author" id="au15">
        <name>
         <surname>
          Jackson
         </surname>
         <given-names>
          Michael L.
         </given-names>
        </name>
       </contrib>
      </contrib-group>
     </sec-meta>
     <title>
      MENINGOCOCCAL DISEASE
     </title>
     <sec id="cesec116">
      <title>
       Infectious Agent
      </title>
      <p id="para619">
       <list id="celist133" list-type="simple">
        <list-item id="celistitem482">
         <label>
          •
         </label>
         <p id="para620">
          The infectious agent is a gram-negative diplococci,
          <italic>
           Neisseria meningitidis
          </italic>
          . Meningococci are classified into serogroups on the basis of the composition of the capsular polysaccharide.
         </p>
        </list-item>
        <list-item id="celistitem483">
         <label>
          •
         </label>
         <p id="para621">
          The five major meningococcal serogroups associated with disease are A, B, C, Y, and W-135.
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <sec id="cesec117">
      <title>
       Mode of Transmission
      </title>
      <p id="para622">
       Person-to-person transmission occurs by close contact with respiratory secretions or saliva.
      </p>
     </sec>
     <sec id="cesec118">
      <title>
       Occurrence
      </title>
      <p id="para623">
       <list id="celist134" list-type="simple">
        <list-item id="celistitem484">
         <label>
          •
         </label>
         <p id="para624">
          <italic>
           Neisseria meningitidis
          </italic>
          is found worldwide. At any time, 5%–10% of the population may be carriers of
          <italic>
           N. meningitidis
          </italic>
          .
         </p>
        </list-item>
        <list-item id="celistitem485">
         <label>
          •
         </label>
         <p id="para625">
          Invasive disease is much rarer, occurring at a rate of 0.5–10 cases per 100,000 population in nonepidemic areas and up to 1,000 cases per 100,000 population in epidemic regions.
         </p>
        </list-item>
        <list-item id="celistitem486">
         <label>
          •
         </label>
         <p id="para626">
          The incidence of meningococcal disease is highest in the “meningitis belt” of sub-Saharan Africa (
          <xref ref-type="fig" rid="f9">
           Map 2-6
          </xref>
          ). The incidence of meningococcal disease is several times higher in the meningitis belt than in the United States, with periodic epidemics during the dry season (December–June). During nonepidemic periods the rate of meningococcal disease is roughly 5–10 cases per 100,000 population per year. During epidemics the rate can be as high as 1,000 cases per 100,000 population.
          <fig id="f9">
           <label>
            Map 2-6
           </label>
           <caption>
            <p>
             Areas with frequent epidemics of meningococcal meningitis.
            </p>
           </caption>
           <graphic xlink:href="gr26">
           </graphic>
          </fig>
         </p>
        </list-item>
        <list-item id="celistitem487">
         <label>
          •
         </label>
         <p id="para627">
          Serogroup A predominates in the meningitis belt, although serogroups C, X, and W-135 are also found.
         </p>
        </list-item>
        <list-item id="celistitem488">
         <label>
          •
         </label>
         <p id="para628">
          Young children have the highest risk for meningococcal disease.
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <sec id="cesec119">
      <title>
       Risk for Travelers
      </title>
      <p id="para629">
       <list id="celist135" list-type="simple">
        <list-item id="celistitem489">
         <label>
          •
         </label>
         <p id="para630">
          Travelers to the meningitis belt may be at risk for meningococcal disease, particularly during the dry season.
         </p>
        </list-item>
        <list-item id="celistitem490">
         <label>
          •
         </label>
         <p id="para631">
          Risk is likely highest in travelers who will have prolonged contact with local populations in the meningitis belt during an epidemic.
         </p>
        </list-item>
        <list-item id="celistitem491">
         <label>
          •
         </label>
         <p id="para632">
          The incidence of meningococcal disease in international travelers who acquire sporadic disease is very low, estimated at 0.4 per 100,000 in one retrospective study.
         </p>
        </list-item>
        <list-item id="celistitem492">
         <label>
          •
         </label>
         <p id="para633">
          The Hajj pilgrimage to Saudi Arabia has been associated with outbreaks of meningococcal disease in returning pilgrims and their contacts.
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <sec id="cesec120">
      <title>
       Clinical Presentation
      </title>
      <p id="para634">
       <list id="celist136" list-type="simple">
        <list-item id="celistitem493">
         <label>
          •
         </label>
         <p id="para635">
          Meningococcal disease generally occurs 1–14 days after exposure.
         </p>
        </list-item>
        <list-item id="celistitem494">
         <label>
          •
         </label>
         <p id="para636">
          Meningococcal disease presents as meningitis in 50% or more of cases. Meningococcal meningitis is characterized by sudden onset of headache, fever, and stiffness of the neck, sometimes accompanied by nausea, vomiting, photophobia, and/or altered mental status.
         </p>
        </list-item>
        <list-item id="celistitem495">
         <label>
          •
         </label>
         <p id="para637">
          Up to 20% of persons with meningococcal disease present with meningococcal sepsis. Meningococcal sepsis is characterized by an abrupt onset of fever and a
petechial or purpuric rash. The rash may progress to purpura fulminans. Meningococcal sepsis may often involve hypotension, acute adrenal hemorrhage, and multiorgan failure.
         </p>
        </list-item>
        <list-item id="celistitem496">
         <label>
          •
         </label>
         <p id="para638">
          Among infants and children &lt;2 years of age, meningococcal disease may have nonspecific symptoms. Neck stiffness may be absent.
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <sec id="cesec121">
      <title>
       Diagnosis
      </title>
      <p id="para639">
       <list id="celist137" list-type="simple">
        <list-item id="celistitem497">
         <label>
          •
         </label>
         <p id="para640">
          Early diagnosis and treatment are critical.
         </p>
        </list-item>
        <list-item id="celistitem498">
         <label>
          •
         </label>
         <p id="para641">
          If possible, a lumbar puncture should be done before starting antibiotic therapy to ensure that bacteria, if any, can be cultured from cerebrospinal fluid (CSF).
         </p>
        </list-item>
        <list-item id="celistitem499">
         <label>
          •
         </label>
         <p id="para642">
          Diagnosis is generally made isolating
          <italic>
           N. meningitidis
          </italic>
          from blood or CSF, by detecting meningococcal antigen in CSF by latex agglutination, or by evidence of
          <italic>
           N. meningitidis
          </italic>
          DNA by polymerase chain reaction.
         </p>
        </list-item>
        <list-item id="celistitem500">
         <label>
          •
         </label>
         <p id="para643">
          The signs and symptoms of meningococcal meningitis are similar to those of other causes of bacterial meningitis, such as
          <italic>
           Haemophilus influenzae
          </italic>
          and
          <italic>
           Streptococcus pneumoniae
          </italic>
          . Identification of the causative organism is important for selecting the correct antibiotics for treatment and prophylaxis.
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <sec id="cesec122">
      <title>
       Treatment
      </title>
      <p id="para644">
       <list id="celist138" list-type="simple">
        <list-item id="celistitem501">
         <label>
          •
         </label>
         <p id="para645">
          Invasive meningococcal disease is potentially fatal and should always be viewed as a medical emergency.
         </p>
        </list-item>
        <list-item id="celistitem502">
         <label>
          •
         </label>
         <p id="para646">
          Antibiotic treatment must be started early in the course of the disease. Several antibiotic choices are available, including ceftriaxone, chloramphenicol, cefotaxime, and benzylpenicillin.
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <sec id="cesec123">
      <title>
       Preventive Measures for Travelers
      </title>
      <sec id="cesec124">
       <title>
        Vaccine
       </title>
       <p id="para647">
        <list id="celist139" list-type="simple">
         <list-item id="celistitem503">
          <label>
           •
          </label>
          <p id="para648">
           ACIP recommends vaccination against meningococcal disease to persons who travel to or reside in countries where
           <italic>
            N. meningitidis
           </italic>
           is hyperendemic or epidemic, particularly if contact with the local population will be prolonged.
          </p>
         </list-item>
         <list-item id="celistitem504">
          <label>
           •
          </label>
          <p id="para649">
           Vaccination is advised for persons traveling to the meningitis belt of Africa during the dry season (December through June).
          </p>
         </list-item>
         <list-item id="celistitem505">
          <label>
           •
          </label>
          <p id="para650">
           Advisories for travelers to other countries will be issued when epidemics of meningococcal disease caused by vaccine-preventable serogroups are recognized (see the CDC Travelers' Health website at
           <ext-link ext-link-type="uri" id="interref23" xlink:href="http://www.cdc.gov/travel">
            www.cdc.gov/travel
           </ext-link>
           ).
          </p>
         </list-item>
         <list-item id="celistitem506">
          <label>
           •
          </label>
          <p id="para651">
           Quadrivalent meningococcal polysaccharide–protein conjugate vaccine (MCV4) is licensed for use among persons 2–55 years of age.
          </p>
         </list-item>
         <list-item id="celistitem507">
          <label>
           •
          </label>
          <p id="para652">
           Quadrivalent meningococcal polysaccharide vaccine (MPVS4) is licensed for use among persons 2 years of age or older.
          </p>
         </list-item>
         <list-item id="celistitem508">
          <label>
           •
          </label>
          <p id="para653">
           Both vaccines protect against meningococcal disease caused by serogroups A, C, Y, and W-135. Approximately 7–10 days are required following vaccination for development of protective antibody levels.
          </p>
         </list-item>
         <list-item id="celistitem509">
          <label>
           •
          </label>
          <p id="para654">
           MCV4 is the preferred vaccine for persons 2–55 years of age; MPSV4 should be used for persons &gt;55 years of age. There is no licensed vaccine for persons &lt;2 years old, but MPSV4 is safe to give to children &lt;2 years of age who require vaccination before traveling to Mecca for the Hajj pilgrimage.
          </p>
         </list-item>
        </list>
       </p>
       <sec id="cesec125">
        <title>
         Requirement for Travel
        </title>
        <p id="para655">
         Proof of quadrivalent vaccination against meningococcal disease is required for persons traveling to Mecca during the annual Hajj and Umrah pilgrimage.
        </p>
       </sec>
      </sec>
      <sec id="cesec126">
       <title>
        Antibiotic Chemoprophylaxis
       </title>
       <p id="para656">
        <list id="celist140" list-type="simple">
         <list-item id="celistitem510">
          <label>
           •
          </label>
          <p id="para657">
           Antibiotic chemoprophylaxis among close contacts of a patient with invasive meningococcal disease is recommended for prevention of secondary cases in the United States and most industrialized countries.
          </p>
         </list-item>
         <list-item id="celistitem511">
          <label>
           •
          </label>
          <p id="para658">
           Antibiotic regimens for prophylaxis include rifampin, ciprofloxacin, and ceftriaxone. Ceftriaxone is recommended for pregnant women.
          </p>
         </list-item>
        </list>
       </p>
      </sec>
     </sec>
     <ref-list id="cebib8">
      <title>
       References
      </title>
      <ref id="bib91">
       <label>
        1
       </label>
       <element-citation id="sbref88" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Raghunathan
          </surname>
          <given-names>
           PL
          </given-names>
         </name>
         <name>
          <surname>
           Bernhardt
          </surname>
          <given-names>
           SA
          </given-names>
         </name>
         <name>
          <surname>
           Rosenstein
          </surname>
          <given-names>
           NE
          </given-names>
         </name>
        </person-group>
        <article-title>
         Opportunities for control of meningococcal disease in the United States
        </article-title>
        <source>
         Ann Rev Med
        </source>
        <volume>
         55
        </volume>
        <year>
         2004
        </year>
        <fpage>
         333
        </fpage>
        <lpage>
         353
        </lpage>
        <pub-id pub-id-type="pmid">
         14746525
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib92">
       <label>
        2
       </label>
       <element-citation id="sbref89" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rosenstein
          </surname>
          <given-names>
           NE
          </given-names>
         </name>
         <name>
          <surname>
           Perkins
          </surname>
          <given-names>
           BA
          </given-names>
         </name>
         <name>
          <surname>
           Stephens
          </surname>
          <given-names>
           DS
          </given-names>
         </name>
        </person-group>
        <article-title>
         Meningococcal disease
        </article-title>
        <source>
         N Engl J Med
        </source>
        <volume>
         344
        </volume>
        <issue>
         18
        </issue>
        <year>
         2001
        </year>
        <fpage>
         1378
        </fpage>
        <lpage>
         1388
        </lpage>
        <pub-id pub-id-type="pmid">
         11333996
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib93">
       <label>
        3
       </label>
       <element-citation id="sbref90" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Greenwood
          </surname>
          <given-names>
           B
          </given-names>
         </name>
        </person-group>
        <article-title>
         Manson Lecture. Meningococcal meningitis in Africa
        </article-title>
        <source>
         Trans R Soc Trop Med Hyg
        </source>
        <volume>
         93
        </volume>
        <issue>
         4
        </issue>
        <year>
         1999
        </year>
        <fpage>
         341
        </fpage>
        <lpage>
         353
        </lpage>
        <pub-id pub-id-type="pmid">
         10674069
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib94">
       <label>
        4
       </label>
       <element-citation id="sbref91" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Stephens
          </surname>
          <given-names>
           DS
          </given-names>
         </name>
         <name>
          <surname>
           Greenwood
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Brandtzaeg
          </surname>
          <given-names>
           P
          </given-names>
         </name>
        </person-group>
        <article-title>
         Epidemic meningitis, meningococcaemia, and
         <italic>
          Neisseria meningitidis.
         </italic>
        </article-title>
        <source>
         Lancet
        </source>
        <volume>
         369
        </volume>
        <issue>
         9580
        </issue>
        <year>
         2007
        </year>
        <fpage>
         2196
        </fpage>
        <lpage>
         2210
        </lpage>
        <pub-id pub-id-type="pmid">
         17604802
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib95">
       <label>
        5
       </label>
       <mixed-citation id="ceotherref4" publication-type="other">
        American Academy of Pediatrics. Meningococcal infections. In: Pickering LK, ed. Red book: 2003 Report of the Committee on Infectious Disease. 26th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2003. p. 430–6.
       </mixed-citation>
      </ref>
      <ref id="bib96">
       <label>
        6
       </label>
       <element-citation id="sbref92" publication-type="journal">
        <person-group person-group-type="author">
         <collab>
          CDC
         </collab>
        </person-group>
        <article-title>
         Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP)
        </article-title>
        <source>
         MMWR Recomm Rep
        </source>
        <volume>
         54
        </volume>
        <issue>
         RR07
        </issue>
        <year>
         2005
        </year>
        <fpage>
         1
        </fpage>
        <lpage>
         21
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib97">
       <label>
        7
       </label>
       <element-citation id="sbref93" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Koch
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Steffen
          </surname>
          <given-names>
           R
          </given-names>
         </name>
        </person-group>
        <article-title>
         Meningococcal disease in travelers: vaccination recommendations
        </article-title>
        <source>
         J Travel Med
        </source>
        <volume>
         1
        </volume>
        <issue>
         1
        </issue>
        <year>
         1994
        </year>
        <fpage>
         4
        </fpage>
        <lpage>
         7
        </lpage>
        <pub-id pub-id-type="pmid">
         9815300
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib98">
       <label>
        8
       </label>
       <element-citation id="sbref94" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wilder-Smith
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        <article-title>
         Meningococcal disease: risk for international travellers and vaccine strategies
        </article-title>
        <source>
         Travel Med Infect Dis
        </source>
        <volume>
         6
        </volume>
        <issue>
         4
        </issue>
        <year>
         2008
        </year>
        <fpage>
         182
        </fpage>
        <lpage>
         186
        </lpage>
        <pub-id pub-id-type="pmid">
         18571105
        </pub-id>
       </element-citation>
      </ref>
     </ref-list>
    </sec>
    <sec id="subchapter9">
     <sec-meta>
      <contrib-group>
       <contrib contrib-type="author" id="au16">
        <name>
         <surname>
          Rupprecht
         </surname>
         <given-names>
          Charles E.
         </given-names>
        </name>
       </contrib>
       <contrib contrib-type="author" id="au17">
        <name>
         <surname>
          Shlim
         </surname>
         <given-names>
          David R.
         </given-names>
        </name>
       </contrib>
      </contrib-group>
     </sec-meta>
     <title>
      RABIES
     </title>
     <sec id="cesec127">
      <title>
       Infectious Agent
      </title>
      <p id="para659">
       Rabies is an acute, progressive, fatal encephalomyelitis caused by neurotropic viruses in the family
       <italic>
        Rhabdoviridae
       </italic>
       , genus
       <italic>
        Lyssavirus
       </italic>
       . Regardless of the viral variant found throughout the world, all lyssaviruses cause rabies.
      </p>
     </sec>
     <sec id="cesec128">
      <title>
       Mode of Transmission
      </title>
      <p id="para660">
       <list id="celist141" list-type="simple">
        <list-item id="celistitem512">
         <label>
          •
         </label>
         <p id="para661">
          The disease is almost always transmitted by an animal bite that inoculates virus into wounds.
         </p>
        </list-item>
        <list-item id="celistitem513">
         <label>
          •
         </label>
         <p id="para662">
          Very rarely, rabies virus has been transmitted by exposures other than bites that introduce the virus into open wounds or mucous membranes.
         </p>
        </list-item>
        <list-item id="celistitem514">
         <label>
          •
         </label>
         <p id="para663">
          All mammals are believed to be susceptible, but reservoirs are carnivores and bats.
         </p>
        </list-item>
        <list-item id="celistitem515">
         <label>
          •
         </label>
         <p id="para664">
          Although dogs are the main reservoir in developing countries, the epidemiology of the disease differs sufficiently enough from one region or country to another to warrant the medical evaluation of all mammal bites.
         </p>
        </list-item>
        <list-item id="celistitem516">
         <label>
          •
         </label>
         <p id="para665">
          Bat bites anywhere in the world are a cause of concern and an indication for prophylaxis.
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <sec id="cesec129">
      <title>
       Pathophysiology of Rabies
      </title>
      <p id="para666">
       <list id="celist142" list-type="simple">
        <list-item id="celistitem517">
         <label>
          •
         </label>
         <p id="para667">
          Rabies virus is present in the saliva of the biting mammal.
         </p>
        </list-item>
        <list-item id="celistitem518">
         <label>
          •
         </label>
         <p id="para668">
          The virus that is inoculated into the wound does not enter the bloodstream. The virus must be taken up at a nerve synapse to travel to the brain, where it causes a fatal encephalitis. The virus may enter a nerve rapidly, or it may remain at the bite site for an extended period before gaining access to the nervous system. The density of nerve endings in the region of the bite increases the risk of developing rabies encephalitis more rapidly. The hands and face, because of the density of nerve endings, are considered higher-risk exposures.
         </p>
        </list-item>
        <list-item id="celistitem519">
         <label>
          •
         </label>
         <p id="para669">
          Prevention of rabies encephalitis is dependent upon preventing the virus from entering a peripheral nerve. This can be accomplished by wound cleansing and disinfection, instillation of rabies virus neutralizing antibodies into the wound, and stimulating an active immune response with a series of rabies vaccine injections.
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <sec id="cesec130">
      <title>
       Occurrence
      </title>
      <p id="para670">
       <list id="celist143" list-type="simple">
        <list-item id="celistitem520">
         <label>
          •
         </label>
         <p id="para671">
          Rabies is found on all continents except Antarctica.
         </p>
        </list-item>
        <list-item id="celistitem521">
         <label>
          •
         </label>
         <p id="para672">
          In certain areas of the world, canine rabies remains highly endemic, including but not limited to parts of Africa, Asia, and Central and South America.
          <xref ref-type="table" rid="cetable16">
           Table 2-16
          </xref>
          lists countries that have reported no cases of rabies during the most recent period for which information is available (formerly referred to as “rabies-free” countries).
          <table-wrap id="cetable16" position="float">
           <label>
            Table 2-16
           </label>
           <caption>
            <p>
             Countries and political units reporting no indigenous cases of rabies during 2005
             <xref ref-type="table-fn" rid="cetablefn64">
              1
             </xref>
            </p>
           </caption>
           <table frame="hsides" rules="groups">
            <thead>
             <tr>
              <th align="left">
               Region
              </th>
              <th align="left">
               Countries
              </th>
             </tr>
            </thead>
            <tbody>
             <tr>
              <td align="left">
               Africa
              </td>
              <td align="left">
               Cape Verde, Libya, Mauritius, Réunion, São Tomé and Príncipe, and Seychelles
              </td>
             </tr>
             <tr>
              <td align="left">
               Americas
              </td>
              <td align="left">
               North: Bermuda, St. Pierre and Miquelon
               <break>
               </break>
               <break>
               </break>
               <bold>
                Caribbean:
               </bold>
               Antigua and Barbuda, Aruba, Bahamas, Barbados, Cayman Islands, Dominica, Guadeloupe, Jamaica, Martinique, Montserrat, Netherlands Antilles, Saint Kitts (Saint Christopher) and Nevis, Saint Lucia, Saint Martin, Saint Vincent and Grenadines, Turks and Caicos, and Virgin Islands (UK and US)
               <break>
               </break>
               <break>
               </break>
               <bold>
                South:
               </bold>
               Uruguay
              </td>
             </tr>
             <tr>
              <td align="left">
               <bold>
                Asia
               </bold>
              </td>
              <td align="left">
               Hong Kong, Japan, Kuwait, Lebanon, Malaysia (Sabah), Qatar, Singapore, United Arab Emirates
              </td>
             </tr>
             <tr>
              <td align="left">
               <bold>
                Europe
               </bold>
              </td>
              <td align="left">
               Austria, Belgium, Cyprus, Czech Republic,
               <xref ref-type="table-fn" rid="cetablefn65">
                2
               </xref>
               Denmark,
               <xref ref-type="table-fn" rid="cetablefn65">
                2
               </xref>
               Finland, France,
               <xref ref-type="table-fn" rid="cetablefn65">
                2
               </xref>
               Gibraltar, Greece, Iceland, Ireland, Isle of Man, Italy, Luxemburg, Netherlands,
               <xref ref-type="table-fn" rid="cetablefn65">
                2
               </xref>
               Norway, Portugal, Spain
               <xref ref-type="table-fn" rid="cetablefn65">
                2
               </xref>
               (except Ceuta/Melilla), Sweden, Switzerland, and United Kingdom
               <xref ref-type="table-fn" rid="cetablefn65">
                2
               </xref>
              </td>
             </tr>
             <tr>
              <td align="left">
               <bold>
                Oceania
               </bold>
               <xref ref-type="table-fn" rid="cetablefn66">
                3
               </xref>
              </td>
              <td align="left">
               Australia,
               <xref ref-type="table-fn" rid="cetablefn65">
                2
               </xref>
               Northern Mariana Islands, Cook Islands, Fiji, French Polynesia, Guam, Hawaii, Kiribati, Micronesia, New Caledonia, New Zealand, Palau, Papua New Guinea, Samoa, and Vanuatu
              </td>
             </tr>
            </tbody>
           </table>
           <table-wrap-foot>
            <fn id="cetablefn64">
             <label>
              1
             </label>
             <p id="cenotep64">
              Bat rabies may exist in some areas that are reportedly free of rabies in other animals.
             </p>
            </fn>
           </table-wrap-foot>
           <table-wrap-foot>
            <fn id="cetablefn65">
             <label>
              2
             </label>
             <p id="cenotep65">
              Bat lyssaviruses are known to exist in these areas that are reportedly free of rabies in other animals.
             </p>
            </fn>
           </table-wrap-foot>
           <table-wrap-foot>
            <fn id="cetablefn66">
             <label>
              3
             </label>
             <p id="cenotep66">
              Most of Pacific Oceania is reportedly rabies-free.
             </p>
            </fn>
           </table-wrap-foot>
          </table-wrap>
         </p>
        </list-item>
        <list-item id="celistitem522">
         <label>
          •
         </label>
         <p id="para673">
          Additional information about the global occurrence of rabies can be obtained from:
          <list id="celist144" list-type="simple">
           <list-item id="celistitem523">
            <label>
             ○
            </label>
            <p id="para674">
             The World Health Organization (
             <ext-link ext-link-type="uri" id="interref24" xlink:href="http://www.who.int/rabies/rabnet/en/">
              www.who.int/rabies/rabnet/en/
             </ext-link>
             )
            </p>
           </list-item>
           <list-item id="celistitem524">
            <label>
             ○
            </label>
            <p id="para675">
             The Pan American Health Organization (
             <ext-link ext-link-type="uri" id="interref25" xlink:href="http://www.paho.org/english/ad/dpc/vp/rabia.htm">
              www.paho.org/english/ad/dpc/vp/rabia.htm
             </ext-link>
             )
            </p>
           </list-item>
           <list-item id="celistitem525">
            <label>
             ○
            </label>
            <p id="para676">
             The Rabies Bulletin—Europe (
             <ext-link ext-link-type="uri" id="interref26" xlink:href="http://www.rbe.fli.bund.de">
              www.rbe.fli.bund.de
             </ext-link>
             )
            </p>
           </list-item>
           <list-item id="celistitem526">
            <label>
             ○
            </label>
            <p id="para677">
             The World Organization for Animal Health (
             <ext-link ext-link-type="uri" id="interref27" xlink:href="http://www.oie.int/eng/en_index.htm">
              www.oie.int/eng/en_index.htm
             </ext-link>
             )
            </p>
           </list-item>
           <list-item id="celistitem527">
            <label>
             ○
            </label>
            <p id="para678">
             Other sources are local health authorities of the country, the embassy, or the local consulate's office in the United States.
            </p>
           </list-item>
          </list>
         </p>
        </list-item>
       </list>
      </p>
      <p id="para679">
       Lists are provided only as a guide, because up-to-date information may not be available, surveillance standards vary, and reporting status can change suddenly as a result of disease re-introduction or emergence.
      </p>
     </sec>
     <sec id="cesec131">
      <title>
       Risk for Travelers
      </title>
      <p id="para680">
       <list id="celist145" list-type="simple">
        <list-item id="celistitem528">
         <label>
          •
         </label>
         <p id="para681">
          The actual rate of possible rabies exposure in tourists has not been calculated with accuracy. However, studies have found a range of roughly 16 to 200 per 100,000 based on differing criteria.
         </p>
        </list-item>
        <list-item id="celistitem529">
         <label>
          •
         </label>
         <p id="para682">
          Travelers to rabies-endemic countries should be warned about the risk of acquiring rabies and educated in animal bite prevention strategies.
         </p>
        </list-item>
        <list-item id="celistitem530">
         <label>
          •
         </label>
         <p id="para683">
          Street dogs represent the most frequent risk for bite exposure to travelers, followed by monkeys, especially those that live near temples in parts of Asia. Travelers should be instructed not to approach these animals and to be aware of their surroundings so that they do not surprise a dog in a confined space. If a dog is charging at a person, stooping to pick up a rock (or pretending to pick up a rock) can often make the dog turn and run away.
         </p>
        </list-item>
        <list-item id="celistitem531">
         <label>
          •
         </label>
         <p id="para684">
          Monkeys are attracted to food and may jump on travelers' backs if there is food in their backpacks.
         </p>
        </list-item>
        <list-item id="celistitem532">
         <label>
          •
         </label>
         <p id="para685">
          Children are considered to be at high risk from rabies virus exposures because their small stature makes extensive bites more likely, they are attracted to animals, and there is the remote possibility that they may not report a possible exposure.
         </p>
        </list-item>
        <list-item id="celistitem533">
         <label>
          •
         </label>
         <p id="para686">
          Casual exposure to cave air is not a concern, but cavers should be warned not to handle bats. Noncavers can occasionally encounter a bat. Many bats have tiny teeth, and not all wounds may be appreciated compared with the lesions caused by carnivores. Any suspected or documented bite or scratch from a bat should be grounds for seeking postexposure rabies immunoprophylaxis.
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <sec id="cesec132">
      <title>
       Clinical Presentation
      </title>
      <p id="para687">
       <list id="celist146" list-type="simple">
        <list-item id="celistitem534">
         <label>
          •
         </label>
         <p id="para688">
          After infection, the incubation period is highly variable, but lasts approximately 1–3 months.
         </p>
        </list-item>
        <list-item id="celistitem535">
         <label>
          •
         </label>
         <p id="para689">
          The disease progresses from a nonspecific prodromal phase to paresis or paralysis; spasms of swallowing muscles can be stimulated by the sight, sound, or perception of water (hydrophobia); and delirium and convulsions can develop, followed rapidly by coma and death.
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <sec id="cesec133">
      <title>
       Diagnosis
      </title>
      <p id="para690">
       <list id="celist147" list-type="simple">
        <list-item id="celistitem536">
         <label>
          •
         </label>
         <p id="para691">
          Definitive diagnosis can be made by demonstrating the presence of the rabies virus in corneal impressions or nuchal biopsy, either through staining or polymerase chain reaction.
         </p>
        </list-item>
        <list-item id="celistitem537">
         <label>
          •
         </label>
         <p id="para692">
          A serologic response to rabies virus can also prove the diagnosis.
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <sec id="cesec134">
      <title>
       Treatment
      </title>
      <p id="para693">
       No treatment is effective after the development of clinical signs, but the extremely rare case of recovery after extensive medical intervention offers hope that future experimental therapeutics may be developed.
      </p>
     </sec>
     <sec id="cesec135">
      <title>
       Preventive Measures for Travelers
      </title>
      <p id="para694">
       <list id="celist148" list-type="simple">
        <list-item id="celistitem538">
         <label>
          •
         </label>
         <p id="para695">
          Prevention of possible exposures to rabies virus is best accomplished by avoiding bites from mammals (mainly dogs, monkeys, bats, and cats in some countries).
         </p>
        </list-item>
        <list-item id="celistitem539">
         <label>
          •
         </label>
         <p id="para696">
          Although licks from animals to fresh wounds or mucus membranes of humans are a theoretical risk of acquiring rabies and postexposure prophylaxis should be considered, there are no examples of rabies in travelers who were exposed in this way.
         </p>
        </list-item>
        <list-item id="celistitem540">
         <label>
          •
         </label>
         <p id="para697">
          Travelers should be counseled to avoid approaching stray animals, to be aware of their surroundings so that they do not accidentally surprise a stray dog, to avoid contact with bats, and not to carry or eat food while walking among monkeys.
         </p>
        </list-item>
        <list-item id="celistitem541">
         <label>
          •
         </label>
         <p id="para698">
          In addition to avoiding bite exposures, two strategies are available to travelers for the prevention of rabies: vaccination and management of a possible rabies exposure (see sections below for more specific details).
         </p>
        </list-item>
        <list-item id="celistitem542">
         <label>
          •
         </label>
         <p id="para699">
          For certain international travelers, pre-exposure rabies vaccine may be recommended, based on the local incidence of rabies in the country to be visited, the availability of appropriate anti-rabies biologicals, and the intended activity and duration of stay of the traveler.
          <list id="celist149" list-type="simple">
           <list-item id="celistitem543">
            <label>
             ○
            </label>
            <p id="para700">
             A decision to receive pre-exposure rabies immunization may also be based on the likelihood of repeat travel to at-risk destinations over time or taking up residence in a high-risk destination.
            </p>
           </list-item>
           <list-item id="celistitem544">
            <label>
             ○
            </label>
            <p id="para701">
             Pre-exposure vaccination may be recommended for veterinarians, animal handlers, field biologists, cavers, missionaries, and certain laboratory workers.
             <xref ref-type="table" rid="cetable17">
              Table 2-17
             </xref>
             provides criteria for pre-exposure vaccination.
             <table-wrap id="cetable17" position="float">
              <label>
               Table 2-17
              </label>
              <caption>
               <p>
                Criteria for pre-exposure immunization for rabies
               </p>
              </caption>
              <table frame="hsides" rules="groups">
               <thead>
                <tr>
                 <th align="left">
                  Risk Category
                 </th>
                 <th align="left">
                  Nature of Risk
                 </th>
                 <th align="left">
                  Typical Populations
                 </th>
                 <th align="left">
                  Pre-exposure Regimen
                 </th>
                </tr>
               </thead>
               <tbody>
                <tr>
                 <td align="left">
                  Continuous
                 </td>
                 <td align="left">
                  Virus present continuously, often in high concentrations
                  <break>
                  </break>
                  <break>
                  </break>
                  Specific exposures likely to go unrecognized
                  <break>
                  </break>
                  <break>
                  </break>
                  Bite, nonbite, or aerosol exposure
                 </td>
                 <td align="left">
                  Rabies research laboratory workers,
                  <xref ref-type="table-fn" rid="cetablefn67">
                   1
                  </xref>
                  rabies biologics production workers
                 </td>
                 <td align="left">
                  Primary course: serologic testing every 6 months; booster vaccination if antibody titer is below acceptable level
                  <xref ref-type="table-fn" rid="cetablefn68">
                   2
                  </xref>
                 </td>
                </tr>
                <tr>
                 <td align="left">
                  Frequent
                 </td>
                 <td align="left">
                  Exposure usually episodic with source recognized, but exposure might also be unrecognized
                  <break>
                  </break>
                  <break>
                  </break>
                  Bite, nonbite, or aerosol exposure possible
                 </td>
                 <td align="left">
                  Rabies diagnostic laboratory workers
                  <xref ref-type="table-fn" rid="cetablefn67">
                   1
                  </xref>
                  , cavers, veterinarians and staff, and animal control and wildlife workers in rabies-epizootic areas
                 </td>
                 <td align="left">
                  Primary course: serologic testing every 2 years; booster vaccination if antibody titer is below acceptable level
                  <xref ref-type="table-fn" rid="cetablefn68">
                   2
                  </xref>
                 </td>
                </tr>
                <tr>
                 <td align="left">
                  Infrequent (greater than general population)
                 </td>
                 <td align="left">
                  Exposure nearly always episodic with source recognized
                  <break>
                  </break>
                  <break>
                  </break>
                  Bite or nonbite exposure
                 </td>
                 <td align="left">
                  Veterinarians, animal control and wildlife workers in areas with low rabies rates; veterinary students; and travelers visiting areas where rabies is enzootic and immediate access to appropriate medical care, including biologics, is limited
                 </td>
                 <td align="left">
                  Primary course: no serologic testing or booster vaccination
                 </td>
                </tr>
                <tr>
                 <td align="left">
                  Rare (general population)
                 </td>
                 <td align="left">
                  Exposure always episodic, with source recognized
                 </td>
                 <td align="left">
                  U.S. population at large, including individuals in rabies-epizootic areas
                 </td>
                 <td align="left">
                  No pre-exposure immunization necessary
                 </td>
                </tr>
               </tbody>
              </table>
              <table-wrap-foot>
               <fn id="cetablefn67">
                <label>
                 1
                </label>
                <p id="cenotep67">
                 Judgment of relative risk and extra monitoring of vaccination status of laboratory workers is the responsibility of the laboratory supervisor (see U.S. Department of Health and Human Services' Biosafety in Microbiological and Biomedical Laboratories, 1999)
                </p>
               </fn>
              </table-wrap-foot>
              <table-wrap-foot>
               <fn id="cetablefn68">
                <label>
                 2
                </label>
                <p id="cenotep68">
                 Pre-exposure booster immunization consists of one dose of human diploid cell (rabies) vaccine (HDCV) or purified chick embryo cell (PCEC) vaccine, 1.0-mL dose, intramuscular (IM) (deltoid area). Minimum acceptable antibody level is complete virus neutralization at a 1:5 serum dilution by the rapid fluorescent focus inhibition test. A booster dose should be administered if titer falls below this level.
                </p>
               </fn>
              </table-wrap-foot>
             </table-wrap>
            </p>
           </list-item>
          </list>
         </p>
        </list-item>
        <list-item id="celistitem545">
         <label>
          •
         </label>
         <p id="para702">
          Immediate and adequate medical care after an animal bite is critical to preventing rabies (see
          <xref ref-type="sec" rid="cesec139">
           Management of a Possible Rabies Exposure
          </xref>
          below). Regardless of whether or not pre-exposure vaccine is administered, travelers going to areas with a high risk for rabies should be especially encouraged to purchase medical evacuation insurance (see the
          <xref ref-type="sec" rid="subchapter45">
           Travel Insurance and Evacuation Insurance
          </xref>
          section later in this chapter).
         </p>
        </list-item>
       </list>
      </p>
      <sec id="cesec136">
       <title>
        Vaccine
       </title>
       <sec id="cesec137">
        <title>
         Pre-Exposure Vaccination
        </title>
        <p id="para703">
         <list id="celist150" list-type="simple">
          <list-item id="celistitem546">
           <label>
            •
           </label>
           <p id="para704">
            In the United States, pre-exposure vaccination consists of a series of three injections with human diploid cell rabies vaccine (HDCV) or purified chick embryo cell (PCEC) vaccine.
           </p>
          </list-item>
          <list-item id="celistitem547">
           <label>
            •
           </label>
           <p id="para705">
            The schedule for this series in given in
            <xref ref-type="table" rid="cetable18">
             Table 2-18
            </xref>
            .
           </p>
          </list-item>
          <list-item id="celistitem548">
           <label>
            •
           </label>
           <p id="para706">
            In the event of a possible rabies exposure in someone who has received pre-exposure rabies immunization, rabies immune globulin (RIG) is not given, and two boosters of an acceptable rabies vaccine are given on days 0 and 3. The booster doses need to be modern cell culture vaccines, but they do not need to be the same brand as the vaccine given in the pre-exposure immunization series.
           </p>
          </list-item>
          <list-item id="celistitem549">
           <label>
            •
           </label>
           <p id="para707">
            Pre-exposure immunization does not eliminate the need for additional medical attention after a rabies exposure, but it greatly simplifies postexposure prophylaxis.
           </p>
          </list-item>
          <list-item id="celistitem550">
           <label>
            •
           </label>
           <p id="para708">
            Pre-exposure vaccination may also provide some degree of protection when there is an unapparent or unrecognized exposure to rabies virus and when postexposure prophylaxis might be delayed.
           </p>
          </list-item>
          <list-item id="celistitem551">
           <label>
            •
           </label>
           <p id="para709">
            Travelers should receive all three pre-exposure immunizations before travel. If three doses of rabies vaccine cannot be completed prior to travel, the traveler should not start the series, as it would be problematic to plan postexposure prophylaxis after a partial immunization series.
           </p>
          </list-item>
         </list>
        </p>
        <p id="para710">
         Beginning in 2007 and anticipated to continue through 2009, the United States has experienced a limitation in supply of rabies vaccine. As a result, during this time, pre-exposure rabies vaccination has not been available to international travelers, except under special circumstances. The existing supplies of rabies vaccine are being reserved for postexposure prophylaxis.
        </p>
       </sec>
       <sec id="cesec138">
        <title>
         Postexposure Vaccination
        </title>
        <p id="para711">
         <list id="celist151" list-type="simple">
          <list-item id="celistitem552">
           <label>
            •
           </label>
           <p id="para712">
            If pre-exposure rabies immunization is not given, the traveler will need to obtain full postexposure rabies prophylaxis in the event of a possible rabies virus exposure. This consists of injections of RIG (20 IU/kg) and a series of five injections of rabies vaccine over a 1-month period.
           </p>
          </list-item>
          <list-item id="celistitem553">
           <label>
            •
           </label>
           <p id="para713">
            Because RIG or rabies vaccine may not be available in the destination country, travelers should have a strategy in place before travel as to how to respond to a possible exposure. This strategy may require the traveler to fly to a different country to obtain the appropriate prophylaxis.
           </p>
          </list-item>
          <list-item id="celistitem554">
           <label>
            •
           </label>
           <p id="para714">
            Different postexposure vaccine schedules, alternative routes of administration and other rabies vaccines besides HDCV and PCEC may be found abroad. Although not approved for sale in the United States, purified vero cell rabies vaccine and purified chick embryo cell vaccine (manufactured abroad) are acceptable alternatives if available in a destination country.
           </p>
          </list-item>
          <list-item id="celistitem555">
           <label>
            •
           </label>
           <p id="para715">
            Historically, rabies vaccine was once manufactured from viruses grown in animal brains, and some of these vaccines are still in use in developing countries. The brain-derived vaccines can be identified if the traveler is offered a large injection (5 mL) daily for 14–21 days. The traveler should not accept these vaccines, but rather travel to where acceptable vaccines and immune globulin are available.
           </p>
          </list-item>
         </list>
        </p>
       </sec>
      </sec>
      <sec id="cesec139">
       <title>
        Management of a Possible Rabies Exposure
       </title>
       <p id="para716">
        <list id="celist152" list-type="simple">
         <list-item id="celistitem556">
          <label>
           •
          </label>
          <p id="para717">
           Travelers should be advised that any animal bite or scratch should receive prompt local first aid by thorough cleansing of the wound with copious amounts of soap and water and povidone iodine, if available. This local care will substantially reduce the risk for rabies.
          </p>
         </list-item>
         <list-item id="celistitem557">
          <label>
           •
          </label>
          <p id="para718">
           Wounds that might require suturing should have the suturing delayed for a few days. If suturing is necessary for control of bleeding or for functional or cosmetic reasons, RIG should be administered into the wound before closing the wound. The use of local anesthetic is not contraindicated in wound management.
          </p>
         </list-item>
         <list-item id="celistitem558">
          <label>
           •
          </label>
          <p id="para719">
           Human rabies immune globulin (HRIG) is manufactured by plasmaphoresis of hyperimmunized volunteers. The manufactured quantity of HRIG falls short of world-wide requirements, and the substance is not available in many developing countries. Equine rabies immune globulin (ERIG) or purified fractions of ERIG have been used effectively in some developing countries where HRIG might not be available. If necessary, such heterologous products are preferable to no RIG administration in human rabies postexposure prophylaxis.
          </p>
         </list-item>
         <list-item id="celistitem559">
          <label>
           •
          </label>
          <p id="para720">
           The incidence of adverse reactions after the use of these products has been low (0.8%–6.0%), and most of those reactions were minor. However, such products are neither evaluated by U.S. standards nor regulated by the FDA, and their use cannot be unequivocally recommended at this time. In addition, unpurified antirabies serum of equine origin might still be used in some countries where neither HRIG nor ERIG is available. The use of this antirabies serum is associated with higher rates of serious adverse reactions, including anaphylaxis.
          </p>
         </list-item>
         <list-item id="celistitem560">
          <label>
           •
          </label>
          <p id="para721">
           After wound cleansing, as much of the calculated amount of RIG (see
           <xref ref-type="table" rid="cetable19">
            Table 2-19
           </xref>
           ) as is anatomically feasible is infiltrated around the wound. The dose injected around the wound may be as small as 0.5 mL if the wound is small or on a finger. If the wounds are extensive, the calculated dose of RIG must not be exceeded. If the calculated dose is inadequate to inject all the wounds, the RIG should be diluted with normal saline to extend the number of wounds that can be injected. This is a particular issue in children, whose body weight may be small in relation to the size and number of wounds.
          </p>
         </list-item>
         <list-item id="celistitem561">
          <label>
           •
          </label>
          <p id="para722">
           The remainder of the RIG dose, if any, should be injected intramuscularly. Care should be taken to guarantee that this remaining amount of RIG is deposited in a muscle and not injected subcutaneously, which may decrease its effectiveness. The remaining RIG can be given in the deltoid muscle, on the opposite side of the initial vaccine dose. The anterior thigh is also an alternative site.
          </p>
         </list-item>
         <list-item id="celistitem562">
          <label>
           •
          </label>
          <p id="para723">
           RIG should not be given more than 7 days after the start of the postexposure vaccine series. This 7-day period does not relate to the time of the bite exposure itself.
          </p>
         </list-item>
         <list-item id="celistitem563">
          <label>
           •
          </label>
          <p id="para724">
           Postexposure prophylaxis, including RIG, should be initiated after a possible bite exposure even if there has been a considerable delay between the exposure and the traveler presenting for evaluation.
          </p>
         </list-item>
         <list-item id="celistitem564">
          <label>
           •
          </label>
          <p id="para725">
           Travelers who have completed a three-dose pre-exposure rabies immunization series or have received the full postexposure prophylaxis are considered pre-immunized and do not require routine boosters, except after a possible rabies exposure.
          </p>
         </list-item>
         <list-item id="celistitem565">
          <label>
           •
          </label>
          <p id="para726">
           Periodic serum testing for rabies antibody is not necessary in routine international travelers.
          </p>
         </list-item>
        </list>
       </p>
      </sec>
      <sec id="cesec140">
       <title>
        Vaccine Safety and Adverse Reactions
       </title>
       <p id="para727">
        <list id="celist153" list-type="simple">
         <list-item id="celistitem566">
          <label>
           •
          </label>
          <p id="para728">
           Travelers should be advised that they may experience local reactions after vaccination, such as pain, erythema, swelling, or itching at the injection site, or mild systemic reactions, such as headache, nausea, abdominal pain, muscle aches, and dizziness.
          </p>
         </list-item>
         <list-item id="celistitem567">
          <label>
           •
          </label>
          <p id="para729">
           Approximately 6% of persons receiving booster vaccinations with HDCV may experience an immune complex-like reaction characterized by urticaria, pruritus, and malaise. The likelihood of these reactions is less with PCECV.
          </p>
         </list-item>
         <list-item id="celistitem568">
          <label>
           •
          </label>
          <p id="para730">
           Once initiated, rabies postexposure prophylaxis should not be interrupted or discontinued because of local or mild systemic reactions to rabies vaccine.
          </p>
         </list-item>
        </list>
       </p>
      </sec>
      <sec id="cesec141">
       <title>
        Precautions and Contraindications
       </title>
       <p id="para731">
        <list id="celist154" list-type="simple">
         <list-item id="celistitem569">
          <label>
           •
          </label>
          <p id="para732">
           Pregnancy is not a contraindication to postexposure prophylaxis.
          </p>
         </list-item>
         <list-item id="celistitem570">
          <label>
           •
          </label>
          <p id="para733">
           In infants and children, the dose of HDCV or PCEC for pre-exposure or postexposure prophylaxis is the same as that recommended for adults. The dose of RIG for postexposure prophylaxis is based on body weight (
           <xref ref-type="table" rid="cetable19">
            Table 2-19
           </xref>
           ).
          </p>
         </list-item>
        </list>
       </p>
      </sec>
     </sec>
     <ref-list id="cebib9">
      <title>
       References
      </title>
      <ref id="bib99">
       <label>
        1
       </label>
       <element-citation id="sbref95" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Warrell
          </surname>
          <given-names>
           MJ
          </given-names>
         </name>
         <name>
          <surname>
           Warrell
          </surname>
          <given-names>
           DA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Rabies and other lyssavirus diseases
        </article-title>
        <source>
         Lancet
        </source>
        <volume>
         363
        </volume>
        <issue>
         9413
        </issue>
        <year>
         2004
        </year>
        <fpage>
         959
        </fpage>
        <lpage>
         969
        </lpage>
        <pub-id pub-id-type="pmid">
         15043965
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib100">
       <label>
        2
       </label>
       <element-citation id="sbref96" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Strauss
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Granz
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Wassermann-Neuhold
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <article-title>
         A human case of travel-related rabies in Austria, September 2004
        </article-title>
        <source>
         Euro Surveill
        </source>
        <volume>
         10
        </volume>
        <issue>
         11
        </issue>
        <year>
         2005
        </year>
        <fpage>
         225
        </fpage>
        <lpage>
         226
        </lpage>
        <pub-id pub-id-type="pmid">
         16371686
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib101">
       <label>
        3
       </label>
       <element-citation id="sbref97" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Smith
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Petrovic
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Solomon
          </surname>
          <given-names>
           T
          </given-names>
         </name>
        </person-group>
        <article-title>
         Death from rabies in a UK traveller returning from India
        </article-title>
        <source>
         Euro Surveill
        </source>
        <volume>
         10
        </volume>
        <issue>
         30
        </issue>
        <year>
         2005
        </year>
        <fpage>
         2761
        </fpage>
       </element-citation>
      </ref>
      <ref id="bib102">
       <label>
        4
       </label>
       <element-citation id="sbref98" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Jackson
          </surname>
          <given-names>
           AC
          </given-names>
         </name>
         <name>
          <surname>
           Warrell
          </surname>
          <given-names>
           MJ
          </given-names>
         </name>
         <name>
          <surname>
           Rupprecht
          </surname>
          <given-names>
           CE
          </given-names>
         </name>
        </person-group>
        <article-title>
         Management of rabies in humans
        </article-title>
        <source>
         Clin Infect Dis
        </source>
        <volume>
         36
        </volume>
        <issue>
         1
        </issue>
        <year>
         2003
        </year>
        <fpage>
         60
        </fpage>
        <lpage>
         63
        </lpage>
        <pub-id pub-id-type="pmid">
         12491203
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib103">
       <label>
        5
       </label>
       <element-citation id="sbref99" publication-type="journal">
        <person-group person-group-type="author">
         <collab>
          CDC
         </collab>
        </person-group>
        <article-title>
         Human Rabies Prevention—United States, 2008: Recommendations of the Advisory Committee on Immunization Practices
        </article-title>
        <source>
         MMWR Recomm Rep
        </source>
        <volume>
         57
        </volume>
        <issue>
         RR-03
        </issue>
        <year>
         2008
        </year>
        <fpage>
         1
        </fpage>
        <lpage>
         28
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib104">
       <label>
        6
       </label>
       <element-citation id="sbref100" publication-type="journal">
        <person-group person-group-type="author">
         <collab>
          World Health Organization Expert Consultation on Rabies.
         </collab>
        </person-group>
        <source>
         World Health Organ Tech Rep Ser
        </source>
        <volume>
         931
        </volume>
        <year>
         2005
        </year>
        <fpage>
         1
        </fpage>
        <lpage>
         88
        </lpage>
        <pub-id pub-id-type="pmid">
         16485446
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib105">
       <label>
        7
       </label>
       <element-citation id="sbref101" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rupprecht
          </surname>
          <given-names>
           CE
          </given-names>
         </name>
         <name>
          <surname>
           Gibbons
          </surname>
          <given-names>
           RV
          </given-names>
         </name>
        </person-group>
        <source>
         Clinical practice. Prophylaxis against rabies. N Engl J Med
        </source>
        <volume>
         351
        </volume>
        <issue>
         26
        </issue>
        <year>
         2004
        </year>
        <fpage>
         2626
        </fpage>
        <lpage>
         2635
        </lpage>
       </element-citation>
      </ref>
     </ref-list>
    </sec>
    <sec id="cesec142">
     <title>
     </title>
     <p id="para734">
      Routine Vaccine-Preventable Diseases
     </p>
    </sec>
    <sec id="subchapter10">
     <sec-meta>
      <contrib-group>
       <contrib contrib-type="author" id="au18">
        <name>
         <surname>
          Tiwari
         </surname>
         <given-names>
          Tejpratap S.P.
         </given-names>
        </name>
       </contrib>
      </contrib-group>
     </sec-meta>
     <title>
      DIPHTHERIA
     </title>
     <sec id="cesec143">
      <title>
       Infectious Agent
      </title>
      <p id="para735">
       <list id="celist155" list-type="simple">
        <list-item id="celistitem571">
         <label>
          •
         </label>
         <p id="para736">
          Diphtheria is caused by toxigenic strains of
          <italic>
           Corynebacterium diphtheriae
          </italic>
          biotype mitis, gravis, intermedius, or belfanti.
         </p>
        </list-item>
        <list-item id="celistitem572">
         <label>
          •
         </label>
         <p id="para737">
          The bacteria produce an exotoxin which, if absorbed in the bloodstream, may damage organs such as the heart, kidneys, and nerves.
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <sec id="cesec144">
      <title>
       Mode of Transmission
      </title>
      <p id="para738">
       <list id="celist156" list-type="simple">
        <list-item id="celistitem573">
         <label>
          •
         </label>
         <p id="para739">
          Humans are the only known reservoir of
          <italic>
           C. diphtheriae
          </italic>
          .
         </p>
        </list-item>
        <list-item id="celistitem574">
         <label>
          •
         </label>
         <p id="para740">
          Person-to-person transmission occurs through oral or respiratory droplets, close physical contact, and rarely by fomites.
         </p>
        </list-item>
        <list-item id="celistitem575">
         <label>
          •
         </label>
         <p id="para741">
          Cutaneous diphtheria is common in tropical countries, and contact with discharge from skin lesions may play an important role in transmission of infection in these environments.
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <sec id="cesec145">
      <title>
       Occurrence
      </title>
      <p id="para742">
       <list id="celist157" list-type="simple">
        <list-item id="celistitem576">
         <label>
          •
         </label>
         <p id="para743">
          Diphtheria is found worldwide. Countries with endemic diphtheria are shown in
          <xref ref-type="table" rid="cetable20">
           Table 2-20
          </xref>
          .
          <table-wrap id="cetable20" position="float">
           <label>
            Table 2-20
           </label>
           <caption>
            <p>
             Countries with endemic diphtheria
            </p>
           </caption>
           <table frame="hsides" rules="groups">
            <thead>
             <tr>
              <th align="left">
               Regions
              </th>
              <th align="left">
               Countries
              </th>
             </tr>
            </thead>
            <tbody>
             <tr>
              <td align="left">
               <bold>
                Africa
               </bold>
              </td>
              <td align="left">
               Algeria, Angola, Egypt, Niger, Nigeria, Sudan, and sub-Saharan countries
              </td>
             </tr>
             <tr>
              <td align="left">
               <bold>
                Americas
               </bold>
              </td>
              <td align="left">
               Bolivia, Brazil, Colombia, Dominican Republic, Ecuador, Haiti, and Paraguay
              </td>
             </tr>
             <tr>
              <td align="left">
               <bold>
                Asia/South Pacific
               </bold>
              </td>
              <td align="left">
               Afghanistan, Bangladesh, Bhutan, Burma (Myanmar), Cambodia, China, India, Indonesia, Laos, Malaysia, Mongolia, Nepal, Pakistan, Papua New Guinea, Philippines, Thailand, and Vietnam
              </td>
             </tr>
             <tr>
              <td align="left">
               <bold>
                Middle East
               </bold>
              </td>
              <td align="left">
               Iran, Iraq, Saudi Arabia, Syria, Turkey, and Yemen
              </td>
             </tr>
             <tr>
              <td align="left">
               <bold>
                Europe
               </bold>
              </td>
              <td align="left">
               Albania, Russia, and countries of the former Soviet Union
              </td>
             </tr>
            </tbody>
           </table>
          </table-wrap>
         </p>
        </list-item>
        <list-item id="celistitem577">
         <label>
          •
         </label>
         <p id="para744">
          Diphtheria causes significant morbidity and mortality in developing countries where vaccination coverage is low.
         </p>
        </list-item>
        <list-item id="celistitem578">
         <label>
          •
         </label>
         <p id="para745">
          During the 1990s, large epidemics occurred in the newly independent states of the former Soviet Union. More recently in the Americas, diphtheria outbreaks occurred in Paraguay, the Dominican Republic, and Haiti.
         </p>
        </list-item>
        <list-item id="celistitem579">
         <label>
          •
         </label>
         <p id="para746">
          Diphtheria is uncommon in industrialized countries because of long-standing routine use of DTP (diphtheria and tetanus toxoids and pertussis vaccine). Diphtheria is uncommon in the United States; and the last case occurred in an elderly traveler returning from Haiti in 2003.
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <sec id="cesec146">
      <title>
       Risk for Travelers
      </title>
      <p id="para747">
       <list id="celist158" list-type="simple">
        <list-item id="celistitem580">
         <label>
          •
         </label>
         <p id="para748">
          Symptomatic infection is extremely rare in adequately immunized persons, although active immunization with diphtheria toxoid does not prevent colonization or transient carriage of
          <italic>
           C. diphtheriae
          </italic>
          .
         </p>
        </list-item>
        <list-item id="celistitem581">
         <label>
          •
         </label>
         <p id="para749">
          Exposure and higher risk of acquiring disease and potentially life-threatening complications are possible in inadequately immunized or unimmunized travelers to countries with endemic diphtheria.
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <sec id="cesec147">
      <title>
       Clinical Presentation
      </title>
      <p id="para750">
       <list id="celist159" list-type="simple">
        <list-item id="celistitem582">
         <label>
          •
         </label>
         <p id="para751">
          The incubation period is 2–5 days (range 1–10 days).
         </p>
        </list-item>
        <list-item id="celistitem583">
         <label>
          •
         </label>
         <p id="para752">
          Nasal diphtheria can be asymptomatic or mild, with a blood-tinged discharge.
         </p>
        </list-item>
        <list-item id="celistitem584">
         <label>
          •
         </label>
         <p id="para753">
          Affected anatomic sites include the mucous membrane of the upper respiratory tract (nose, pharynx, tonsils, larynx, and trachea [respiratory diphtheria]), skin (cutaneous diphtheria), or rarely, mucous membranes at other sites (eye, ear, vulva).
         </p>
        </list-item>
        <list-item id="celistitem585">
         <label>
          •
         </label>
         <p id="para754">
          Respiratory diphtheria has a gradual onset and is characterized by a mild fever (rarely &gt;101° F or &gt;38.3° C), sore throat, difficulty in swallowing, malaise, loss of appetite, and if the larynx is involved, hoarseness may occur.
         </p>
        </list-item>
        <list-item id="celistitem586">
         <label>
          •
         </label>
         <p id="para755">
          The hallmark of respiratory diphtheria is the presence of a membrane that appears within 2–3 days of illness over the mucous membrane of the tonsils, pharynx, larynx, or nares, and which can extend into the trachea. The membrane is firm, fleshy, grey, and adherent, and bleeds following attempts to remove or dislodge it.
         </p>
        </list-item>
        <list-item id="celistitem587">
         <label>
          •
         </label>
         <p id="para756">
          Local complications such as life-threatening or fatal airway obstruction can result from extension of the membrane or dislodgement of a piece of the membrane into the larynx or trachea.
         </p>
        </list-item>
        <list-item id="celistitem588">
         <label>
          •
         </label>
         <p id="para757">
          In severe respiratory diphtheria, cervical lymphadenopathy and soft-tissue swelling in the neck give rise to a “bull-neck” appearance.
         </p>
        </list-item>
        <list-item id="celistitem589">
         <label>
          •
         </label>
         <p id="para758">
          The case–fatality rate of respiratory diphtheria is 5%–10%.
         </p>
        </list-item>
        <list-item id="celistitem590">
         <label>
          •
         </label>
         <p id="para759">
          Systemic complications, including myocarditis, and polyneuropathies, can result from absorption of diphtheria toxin from the infection site. However, cutaneous and nasal diphtheria are localized and rarely associated with systemic toxicity.
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <sec id="cesec148">
      <title>
       Diagnosis
      </title>
      <p id="para760">
       <list id="celist160" list-type="simple">
        <list-item id="celistitem591">
         <label>
          •
         </label>
         <p id="para761">
          A presumptive diagnosis is usually based on clinical features.
         </p>
        </list-item>
        <list-item id="celistitem592">
         <label>
          •
         </label>
         <p id="para762">
          A confirmed diagnosis is made by isolation of
          <italic>
           C. diphtheriae
          </italic>
          from culture of nasal or throat swabs, or membrane tissue.
         </p>
        </list-item>
        <list-item id="celistitem593">
         <label>
          •
         </label>
         <p id="para763">
          Toxin production is confirmed by performing a modified Elek test.
         </p>
        </list-item>
        <list-item id="celistitem594">
         <label>
          •
         </label>
         <p id="para764">
          Polymerase chain reaction assays can also be performed on isolates, swabs, or membrane specimens to rapidly confirm the presence of tox gene responsible for production of diphtheria toxin, but the test is available only in research or reference laboratories.
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <sec id="cesec149">
      <title>
       Treatment
      </title>
      <p id="para765">
       <list id="celist161" list-type="simple">
        <list-item id="celistitem595">
         <label>
          •
         </label>
         <p id="para766">
          Patients with respiratory diphtheria require hospitalization to monitor response to treatment and manage complications.
         </p>
        </list-item>
        <list-item id="celistitem596">
         <label>
          •
         </label>
         <p id="para767">
          Equine diphtheria antitoxin (DAT) is the mainstay of treatment and is administered after sensitivity testing, without waiting for laboratory confirmation. In the United States, DAT is available to physicians under an FDA-approved Investigational New Drug protocol by contacting CDC at 770-488-7100.
         </p>
        </list-item>
        <list-item id="celistitem597">
         <label>
          •
         </label>
         <p id="para768">
          An appropriate antibiotic (erythromycin or penicillin) to eliminate the causative organisms, stop exotoxin production, and reduce communicability.
         </p>
        </list-item>
        <list-item id="celistitem598">
         <label>
          •
         </label>
         <p id="para769">
          Supportive care (airway, cardiac monitoring) is required.
         </p>
        </list-item>
        <list-item id="celistitem599">
         <label>
          •
         </label>
         <p id="para770">
          Antimicrobial prophylaxis (erythromycin or penicillin) is recommended for close contacts of patients.
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <sec id="cesec150">
      <title>
       Preventive Measures for Travelers
      </title>
      <sec id="cesec151">
       <title>
        Vaccine
       </title>
       <p id="para771">
        <list id="celist162" list-type="simple">
         <list-item id="celistitem600">
          <label>
           •
          </label>
          <p id="para772">
           For protection against diphtheria, all travelers should be up-to-date with diphtheria toxoid vaccine before departure. Diphtheria toxoid is not manufactured as a monovalent vaccine but is available in pediatric (D) and adult formulations (d) that are combined with other vaccines such as tetanus toxoid (DT, Td), or tetanus toxoid and acellular or whole-cell pertussis antigens (DTaP, DTwP, Tdap), or as a DTwP/DTaP combination with other antigens (e.g., hepatitis B, inactivated poliovirus vaccines, or Hib vaccine).
          </p>
         </list-item>
         <list-item id="celistitem601">
          <label>
           •
          </label>
          <p id="para773">
           In the United States, infants and children &lt;7 years of age are vaccinated with diphtheria toxoid in combination with tetanus toxoid and acellular pertussis vaccine (DTaP) according to a routine childhood immunization schedule as recommended by the ACIP (see the Vaccine Recommendations for Infants and Children section in Chapter 7).
          </p>
         </list-item>
         <list-item id="celistitem602">
          <label>
           •
          </label>
          <p id="para774">
           Immunization for infants and children &lt;7 years of age consists of five doses of DTaP vaccine. The first three doses are usually given at ages 2, 4, and 6 months, followed by booster doses at ages 12–18 months and 4–6 years (see Table 7-2).
          </p>
         </list-item>
         <list-item id="celistitem603">
          <label>
           •
          </label>
          <p id="para775">
           Adolescents 11–18 years of age should receive a dose of Tdap instead of Td for booster immunization against tetanus, diphtheria, and pertussis if they have completed the recommended childhood DTwP/DTaP vaccination series (see Table 7-3).
          </p>
         </list-item>
         <list-item id="celistitem604">
          <label>
           •
          </label>
          <p id="para776">
           Adults 19–64 years of age should receive a single dose of age-appropriate Tdap to replace a single dose of Td for active booster immunization against tetanus, diphtheria and pertussis. Thereafter, routine booster doses with Td should be given every 10 years to maintain seroprotection against diphtheria as well as tetanus. This booster is particularly important for travelers who will live or work with local populations in countries where diphtheria is endemic.
          </p>
         </list-item>
         <list-item id="celistitem605">
          <label>
           •
          </label>
          <p id="para777">
           Adults &gt;65 years of age should receive Td; Tdap is not licensed for this age group.
          </p>
         </list-item>
         <list-item id="celistitem606">
          <label>
           •
          </label>
          <p id="para778">
           Persons &gt;7 years of age and with uncertain vaccination history or who have never been vaccinated against tetanus, diphtheria, or pertussis should receive three doses of an age-appropriate tetanus and diphtheria toxoid-containing vaccine. If a person is 10–65 years old, a single dose of Tdap may be substituted for one Td dose for added protection against pertussis.
          </p>
         </list-item>
        </list>
       </p>
      </sec>
     </sec>
     <ref-list id="cebib10">
      <title>
       References
      </title>
      <ref id="bib106">
       <label>
        1
       </label>
       <mixed-citation id="ceotherref5" publication-type="other">
        American Academy of Pediatrics. Diphtheria. In: Pickering LK, Baker CJ, Long SS, McMillan JA, editors. Red book: 2006 Report of the Committee on Infectious Diseases. 27th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2006:p.277–81.
       </mixed-citation>
      </ref>
      <ref id="bib107">
       <label>
        2
       </label>
       <mixed-citation id="ceotherref6" publication-type="other">
        World Health Organization. WHO vaccine-preventable diseases monitoring system: 2005 global summary. Geneva, Switzerland: World Health Organization; 2005 Dec. 333 p. Report No.: WHO/IVB/2005.
       </mixed-citation>
      </ref>
      <ref id="bib108">
       <label>
        3
       </label>
       <element-citation id="sbref102" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Galazka
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        <article-title>
         The changing epidemiology of diphtheria in the vaccine era
        </article-title>
        <source>
         J Infect Dis
        </source>
        <volume>
         181
        </volume>
        <issue>
         Suppl 1
        </issue>
        <year>
         2000
        </year>
        <fpage>
         S2
        </fpage>
        <lpage>
         S9
        </lpage>
        <pub-id pub-id-type="pmid">
         10657184
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib109">
       <label>
        4
       </label>
       <element-citation id="sbref103" publication-type="journal">
        <person-group person-group-type="author">
         <collab>
          CDC
         </collab>
        </person-group>
        <article-title>
         Fatal respiratory diphtheria in a U.S. traveler to Haiti—Pennsylvania, 2003
        </article-title>
        <source>
         MMWR Morbid Mortal Wkly Rep
        </source>
        <volume>
         52
        </volume>
        <issue>
         53
        </issue>
        <year>
         2004
        </year>
        <fpage>
         1285
        </fpage>
        <lpage>
         1286
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib110">
       <label>
        5
       </label>
       <element-citation id="sbref104" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wharton
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Vitek
          </surname>
          <given-names>
           CR
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         Diphtheria toxoid
        </chapter-title>
        <person-group person-group-type="editor">
         <name>
          <surname>
           Plotkin
          </surname>
          <given-names>
           SA
          </given-names>
         </name>
         <name>
          <surname>
           Orenstein
          </surname>
          <given-names>
           WA
          </given-names>
         </name>
        </person-group>
        <source>
         Vaccines
        </source>
        <edition>
         4th ed.
        </edition>
        <year>
         2004
        </year>
        <publisher-name>
         W.B. Saunders
        </publisher-name>
        <publisher-loc>
         Philadelphia
        </publisher-loc>
        <fpage>
         211
        </fpage>
        <lpage>
         228
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib111">
       <label>
        6
       </label>
       <element-citation id="sbref105" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bisgard
          </surname>
          <given-names>
           KM
          </given-names>
         </name>
         <name>
          <surname>
           Hardy
          </surname>
          <given-names>
           IR B
          </given-names>
         </name>
         <name>
          <surname>
           Popovic
          </surname>
          <given-names>
           T
          </given-names>
         </name>
        </person-group>
        <article-title>
         Respiratory diphtheria in the United States, 1980 through 1995
        </article-title>
        <source>
         Am J Public Health
        </source>
        <volume>
         88
        </volume>
        <issue>
         5
        </issue>
        <year>
         1998
        </year>
        <fpage>
         787
        </fpage>
        <lpage>
         791
        </lpage>
        <pub-id pub-id-type="pmid">
         9585746
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib112">
       <label>
        7
       </label>
       <element-citation id="sbref106" publication-type="journal">
        <person-group person-group-type="author">
         <collab>
          CDC
         </collab>
        </person-group>
        <article-title>
         Diphtheria acquired by U.S. citizens in the Russian Federation and Ukraine—1994
        </article-title>
        <source>
         MMWR Morbid Mortal Wkly Rep
        </source>
        <volume>
         44
        </volume>
        <issue>
         12
        </issue>
        <year>
         1995
        </year>
        <fpage>
         237
        </fpage>
        <comment>
         243–4
        </comment>
       </element-citation>
      </ref>
      <ref id="bib113">
       <label>
        8
       </label>
       <element-citation id="sbref107" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Farizo
          </surname>
          <given-names>
           KM
          </given-names>
         </name>
         <name>
          <surname>
           Strebel
          </surname>
          <given-names>
           PM
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           RT
          </given-names>
         </name>
        </person-group>
        <article-title>
         Fatal respiratory disease due to
         <italic>
          Corynebacterium diphtheriae
         </italic>
         : case report and review of guidelines for management, investigation, and control
        </article-title>
        <source>
         Clin Infect Dis
        </source>
        <volume>
         16
        </volume>
        <issue>
         1
        </issue>
        <year>
         1993
        </year>
        <fpage>
         59
        </fpage>
        <lpage>
         68
        </lpage>
        <pub-id pub-id-type="pmid">
         8448320
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib114">
       <label>
        9
       </label>
       <element-citation id="sbref108" publication-type="journal">
        <person-group person-group-type="author">
         <collab>
          CDC
         </collab>
        </person-group>
        <article-title>
         Availability of diphtheria antitoxin through an Investigational New Drug protocol
        </article-title>
        <source>
         MMWR Morb Mortal Wkly Rep
        </source>
        <volume>
         53
        </volume>
        <issue>
         19
        </issue>
        <year>
         2004
        </year>
        <fpage>
         413
        </fpage>
       </element-citation>
      </ref>
      <ref id="bib115">
       <label>
        10
       </label>
       <element-citation id="sbref109" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kretsinger
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Broder
          </surname>
          <given-names>
           KR
          </given-names>
         </name>
         <name>
          <surname>
           Cortese
          </surname>
          <given-names>
           MM
          </given-names>
         </name>
        </person-group>
        <article-title>
         Preventing tetanus, diphtheria, and pertussis among adults: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP) and recommendation of ACIP, supported by the Healthcare Infection Control Practices Advisory Committee (HICPAC) for use of Tdap among health-care personnel
        </article-title>
        <source>
         MMWR Recomm. Rep
        </source>
        <volume>
         55
        </volume>
        <issue>
         RR-17
        </issue>
        <year>
         2006
        </year>
        <fpage>
         1
        </fpage>
        <lpage>
         37
        </lpage>
       </element-citation>
      </ref>
     </ref-list>
    </sec>
    <sec id="subchapter11">
     <sec-meta>
      <contrib-group>
       <contrib contrib-type="author" id="au19">
        <name>
         <surname>
          Dunne
         </surname>
         <given-names>
          Eileen F.
         </given-names>
        </name>
       </contrib>
      </contrib-group>
     </sec-meta>
     <title>
      HUMAN PAPILLOMAVIRUS (HPV)
     </title>
     <sec id="cesec152">
      <title>
       Infectious Agent
      </title>
      <p id="para779">
       <list id="celist163" list-type="simple">
        <list-item id="celistitem607">
         <label>
          •
         </label>
         <p id="para780">
          Human papillomavirus (HPV) is in the family Papillomaviridae, a family of DNA viruses that has a double-stranded, closed, circular genome of ∼8 kb and a nonenveloped icosahedral capsid.
         </p>
        </list-item>
        <list-item id="celistitem608">
         <label>
          •
         </label>
         <p id="para781">
          Infection with human papillomavirus is specific to humans.
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <sec id="cesec153">
      <title>
       Mode of Transmission
      </title>
      <p id="para782">
       <list id="celist164" list-type="simple">
        <list-item id="celistitem609">
         <label>
          •
         </label>
         <p id="para783">
          There are more than 100 HPV types. Some types cause infection on the skin and others cause infection on the mucosa. More than 40 mucosal HPV types are commonly found on the genitals and are transmitted primarily by sexual contact, most commonly sexual intercourse.
         </p>
        </list-item>
        <list-item id="celistitem610">
         <label>
          •
         </label>
         <p id="para784">
          Sometimes transmission of genital HPV types occurs by other routes (e.g., mother-to-child transmission).
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <sec id="cesec154">
      <title>
       Occurrence
      </title>
      <p id="para785">
       <list id="celist165" list-type="simple">
        <list-item id="celistitem611">
         <label>
          •
         </label>
         <p id="para786">
          HPV is common worldwide.
         </p>
        </list-item>
        <list-item id="celistitem612">
         <label>
          •
         </label>
         <p id="para787">
          Studies in multiple countries demonstrate prevalence of HPV from 3% to 70%.
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <sec id="cesec155">
      <title>
       Risk for Travelers
      </title>
      <p id="para788">
       There are no inherent risks for travelers. HPV is ubiquitous and common worldwide. Risk depends on the behavior of the traveler.
      </p>
     </sec>
     <sec id="cesec156">
      <title>
       Clinical Presentation
      </title>
      <p id="para789">
       <list id="celist166" list-type="simple">
        <list-item id="celistitem613">
         <label>
          •
         </label>
         <p id="para790">
          HPV infection is usually subclinical and asymptomatic.
         </p>
        </list-item>
        <list-item id="celistitem614">
         <label>
          •
         </label>
         <p id="para791">
          HPV infection with cutaneous types can cause the common skin wart.
         </p>
        </list-item>
        <list-item id="celistitem615">
         <label>
          •
         </label>
         <p id="para792">
          HPV infection with mucosal types is presumed when anogenital warts or cervical cell changes are detected in screening.
         </p>
        </list-item>
        <list-item id="celistitem616">
         <label>
          •
         </label>
         <p id="para793">
          HPV rarely causes recurrent respiratory papillomatosis (RRP); anogenital cancers such as vaginal, vulvar, anal, penile cancers; and some oral cancers.
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <sec id="cesec157">
      <title>
       Diagnosis
      </title>
      <p id="para794">
       <list id="celist167" list-type="simple">
        <list-item id="celistitem617">
         <label>
          •
         </label>
         <p id="para795">
          Infection is most commonly asymptomatic and transient.
         </p>
        </list-item>
        <list-item id="celistitem618">
         <label>
          •
         </label>
         <p id="para796">
          When clinical disease occurs, diagnosis is usually made by detection of the lesion by visual inspection, and in women by a Papanicolaou test (Pap test), HPV test (done in similar fashion to a Pap test), or by colposcopy. Definitive diagnosis is made by biopsy.
         </p>
        </list-item>
        <list-item id="celistitem619">
         <label>
          •
         </label>
         <p id="para797">
          Laboratory diagnosis of HPV in the clinical setting can be made by using the Digene hybrid capture 2 test (hc2); this test is recommended only in the setting of cervical cancer screening. Other DNA and serologic tests are available in research settings.
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <sec id="cesec158">
      <title>
       Treatment
      </title>
      <p id="para798">
       There is no treatment for HPV, but there are treatments for HPV-associated conditions such as genital warts and cervical cell changes.
      </p>
     </sec>
     <sec id="cesec159">
      <title>
       Preventive Measures for Travelers
      </title>
      <p id="para799">
       <list id="celist168" list-type="simple">
        <list-item id="celistitem620">
         <label>
          •
         </label>
         <p id="para800">
          There are no recommendations for preventive measures for travelers beyond abstinence or engaging in safe sexual behaviors.
         </p>
        </list-item>
        <list-item id="celistitem621">
         <label>
          •
         </label>
         <p id="para801">
          The quadrivalent HPV vaccine prevents four HPV types (types 6, 11, 16, 18) commonly associated with genital warts and cervical cancers. Cervical cancer screening with the Pap test should be continued because the vaccine does not prevent all types associated with cancers.
         </p>
        </list-item>
        <list-item id="celistitem622">
         <label>
          •
         </label>
         <p id="para802">
          ACIP recommendations for HPV vaccine are that 11- and 12-year-old girls should be routinely vaccinated, and the vaccine series can be started as young as 9 years of age. Girls and young women 13–26 years of age should be vaccinated if they have not received the vaccine or have not completed the series.
         </p>
        </list-item>
        <list-item id="celistitem623">
         <label>
          •
         </label>
         <p id="para803">
          Vaccination consists of three intramuscular doses, on day 0, at 2 months, and 6 months; see product insert for some variability in administration timing. The vaccine is generally well tolerated, although pain at the injection site is common.
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <ref-list id="cebib11">
      <title>
       References
      </title>
      <ref id="bib116">
       <label>
        1
       </label>
       <element-citation id="sbref110" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Franceschi
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Herrero
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Clifford
          </surname>
          <given-names>
           GM
          </given-names>
         </name>
        </person-group>
        <article-title>
         Variations in the age-specific curves of human papillomavirus prevalence in women worldwide
        </article-title>
        <source>
         Int J Cancer
        </source>
        <volume>
         119
        </volume>
        <issue>
         11
        </issue>
        <year>
         2006
        </year>
        <fpage>
         2677
        </fpage>
        <lpage>
         2684
        </lpage>
        <pub-id pub-id-type="pmid">
         16991121
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib117">
       <label>
        2
       </label>
       <element-citation id="sbref111" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Markowitz
          </surname>
          <given-names>
           LE
          </given-names>
         </name>
         <name>
          <surname>
           Dunne
          </surname>
          <given-names>
           EF
          </given-names>
         </name>
         <name>
          <surname>
           Saraiya
          </surname>
          <given-names>
           MD
          </given-names>
         </name>
        </person-group>
        <article-title>
         Quadrivalent human papillomavirus vaccine: Recommendations of the Advisory Committee for Immunization Practices (ACIP)
        </article-title>
        <source>
         MMWR Morbid Mortal Wkly Rep
        </source>
        <volume>
         56
        </volume>
        <issue>
         RR-2
        </issue>
        <year>
         2007
        </year>
        <fpage>
         1
        </fpage>
        <lpage>
         24
        </lpage>
       </element-citation>
      </ref>
     </ref-list>
    </sec>
    <sec id="subchapter12">
     <sec-meta>
      <contrib-group>
       <contrib contrib-type="author" id="au20">
        <name>
         <surname>
          McCarron
         </surname>
         <given-names>
          Margaret
         </given-names>
        </name>
       </contrib>
       <contrib contrib-type="author" id="au21">
        <name>
         <surname>
          Shay
         </surname>
         <given-names>
          David K.
         </given-names>
        </name>
       </contrib>
      </contrib-group>
     </sec-meta>
     <title>
      INFLUENZA (SEASONAL, AVIAN, AND PANDEMIC)
     </title>
     <sec id="cesec160">
      <title>
       Infectious Agent
      </title>
      <p id="para804">
       <list id="celist169" list-type="simple">
        <list-item id="celistitem624">
         <label>
          •
         </label>
         <p id="para805">
          Influenza is caused by infection with influenza viruses.
         </p>
        </list-item>
        <list-item id="celistitem625">
         <label>
          •
         </label>
         <p id="para806">
          Human influenza viruses can be divided into three types: A, B, and C. Only types A and B cause widespread illness in humans.
         </p>
        </list-item>
        <list-item id="celistitem626">
         <label>
          •
         </label>
         <p id="para807">
          Influenza A viruses are further classified into subtypes on the basis of two surface proteins: hemagglutinin (H) and neuraminidase (N). There are 16 different hemagglutinin subtypes and 9 different neuraminidase subtypes.
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <sec id="cesec161">
      <title>
       Mode of Transmission
      </title>
      <p id="para808">
       <list id="celist170" list-type="simple">
        <list-item id="celistitem627">
         <label>
          •
         </label>
         <p id="para809">
          Person-to-person transmission results from respiratory droplets of coughs and sneezes.
          <list id="celist171" list-type="simple">
           <list-item id="celistitem628">
            <label>
             ○
            </label>
            <p id="para810">
             Most healthy adults can infect others beginning 1 day before symptoms develop and up to 5 days after becoming sick.
            </p>
           </list-item>
           <list-item id="celistitem629">
            <label>
             ○
            </label>
            <p id="para811">
             Children can pass the virus for longer than 7 days.
            </p>
           </list-item>
           <list-item id="celistitem630">
            <label>
             ○
            </label>
            <p id="para812">
             Fomite transmission is also possible.
            </p>
           </list-item>
          </list>
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <sec id="cesec162">
      <title>
       Occurrence
      </title>
      <sec id="cesec163">
       <title>
        Seasonal Influenza
       </title>
       <p id="para813">
        <list id="celist172" list-type="simple">
         <list-item id="celistitem631">
          <label>
           •
          </label>
          <p id="para814">
           Infection with seasonal influenza viruses is common.
          </p>
         </list-item>
         <list-item id="celistitem632">
          <label>
           •
          </label>
          <p id="para815">
           In temperate climates in the Northern Hemisphere, annual seasonal epidemics of influenza generally occur during the winter months, while in the temperate regions of the Southern Hemisphere most activity occurs from April through September.
          </p>
         </list-item>
         <list-item id="celistitem633">
          <label>
           •
          </label>
          <p id="para816">
           In tropical and subtropical areas, influenza can occur throughout the year.
          </p>
         </list-item>
         <list-item id="celistitem634">
          <label>
           •
          </label>
          <p id="para817">
           CDC has estimated that U.S. epidemics during the 1990s were associated with an annual average of 36,000 influenza-related deaths.
          </p>
         </list-item>
         <list-item id="celistitem635">
          <label>
           •
          </label>
          <p id="para818">
           Influenza virus infections cause disease in all age groups. Rates of infection are highest among infants and children, but rates of serious morbidity and mortality are highest among persons Δ65 years of age and persons of any age who have medical conditions (e.g., chronic cardiopulmonary disease) that place them at increased risk for complications from influenza. Children &lt;2 years of age have rates of influenza-related hospitalization that are as high as those in the elderly.
          </p>
         </list-item>
        </list>
       </p>
      </sec>
      <sec id="cesec164">
       <title>
        Avian Influenza
       </title>
       <p id="para819">
        <list id="celist173" list-type="simple">
         <list-item id="celistitem636">
          <label>
           •
          </label>
          <p id="para820">
           Avian influenza refers to influenza A viruses usually found in birds. Influenza A viruses infect a broad range of avian species and several mammalian species, including humans, swine, and horses.
           <list id="celist174" list-type="simple">
            <list-item id="celistitem637">
             <label>
              ○
             </label>
             <p id="para821">
              Most cases of avian influenza infection in humans have resulted from contact with infected poultry (e.g., domesticated chickens, ducks, and turkeys) or surfaces contaminated with secretions or excretions from infected birds.
             </p>
            </list-item>
            <list-item id="celistitem638">
             <label>
              ○
             </label>
             <p id="para822">
              The spread of avian influenza viruses from one ill person to another has been reported very rarely and has thus far been limited, inefficient, and unsustained.
             </p>
            </list-item>
           </list>
          </p>
         </list-item>
         <list-item id="celistitem639">
          <label>
           •
          </label>
          <p id="para823">
           H5N1 is an influenza A virus, which is a type characterized by the ability to constantly undergo change. H5N1 virus has caused serious disease among wild birds and poultry on multiple continents. Human cases of H5N1 are very rare but have occurred in countries in Asia, Africa, Eastern Europe, and the Middle East since 2003. As of June 2008, only 385 human cases of H5N1 infection have been reported worldwide. These cases, however, are a concern because the mortality rate is high. There is a concern that H5N1 may gain the ability to spread easily between people. Vigilant monitoring for human infection and person-to-person transmission has become an important component of pandemic preparedness. For a current list of countries reporting outbreaks of H5N1 among birds, see the World Organization for Animal Health (OIE) website at
           <ext-link ext-link-type="uri" id="interref28" xlink:href="http://www.oie.int/">
            www.oie.int/
           </ext-link>
           .
          </p>
         </list-item>
         <list-item id="celistitem640">
          <label>
           •
          </label>
          <p id="para824">
           The global influenza research community conducts surveillance for novel influenza viruses in travelers. In a 2007 review of returned U.S. travelers suspected of having H5N1 infection, no evidence of infection with novel viruses was reported. Surveillance continues for human infection with H5N1 in travelers.
          </p>
         </list-item>
         <list-item id="celistitem641">
          <label>
           •
          </label>
          <p id="para825">
           For current, continuously updated information, see CDC's Avian Influenza website (
           <ext-link ext-link-type="uri" id="interref29" xlink:href="http://www.cdc.gov/flu/avian/index.htm">
            www.cdc.gov/flu/avian/index.htm
           </ext-link>
           ).
          </p>
         </list-item>
        </list>
       </p>
      </sec>
      <sec id="cesec165">
       <title>
        Pandemic Influenza
       </title>
       <p id="para826">
        <list id="celist175" list-type="simple">
         <list-item id="celistitem642">
          <label>
           •
          </label>
          <p id="para827">
           The emergence of a novel human influenza A virus could lead to a global pandemic, during which rates of morbidity and mortality from influenza-related complications could increase dramatically. The public health threat of a pandemic arising from novel influenza A viruses, including influenza A (H5N1), becomes imminent only if the virus gains the ability to spread efficiently from one human to another.
          </p>
         </list-item>
         <list-item id="celistitem643">
          <label>
           •
          </label>
          <p id="para828">
           Such transmission has not yet been observed with the currently circulating A (H5N1) viruses. Although a few cases of limited person-to-person spread of H5N1 viruses have been reported as of June 2008, no instances of transmission continuing beyond one person are thought to have occurred.
          </p>
         </list-item>
         <list-item id="celistitem644">
          <label>
           •
          </label>
          <p id="para829">
           Because the situation has and may continue to evolve, for current information see the official U.S. government website for pandemic influenza (
           <ext-link ext-link-type="uri" id="interref30" xlink:href="http://www.pandemicflu.gov/">
            www.pandemicflu.gov/
           </ext-link>
           ).
          </p>
         </list-item>
        </list>
       </p>
      </sec>
     </sec>
     <sec id="cesec166">
      <title>
       Risk for Travelers
      </title>
      <sec id="cesec167">
       <title>
        Seasonal Influenza
       </title>
       <p id="para830">
        <list id="celist176" list-type="simple">
         <list-item id="celistitem645">
          <label>
           •
          </label>
          <p id="para831">
           The risk for exposure to seasonal influenza during international travel depends on the time of year and destination. In the tropics, influenza can occur throughout the year, while in the temperate regions of the Southern Hemisphere most activity occurs from April through September.
          </p>
         </list-item>
         <list-item id="celistitem646">
          <label>
           •
          </label>
          <p id="para832">
           In temperate climates, travelers can also be exposed to influenza during the summer, especially when traveling as part of large tourist groups with travelers from areas of the world where influenza viruses are circulating.
          </p>
         </list-item>
        </list>
       </p>
      </sec>
      <sec id="cesec168">
       <title>
        Avian Influenza
       </title>
       <p id="para833">
        <list id="celist177" list-type="simple">
         <list-item id="celistitem647">
          <label>
           •
          </label>
          <p id="para834">
           In those countries where H5N1 has occurred most people become infected through direct contact with birds (e.g., domesticated chickens, ducks, and turkeys) that were carrying the H5N1 virus or from surfaces contaminated with secretions or excretions from these birds. Direct contact could happen during activities such as—
           <list id="celist178" list-type="simple">
            <list-item id="celistitem648">
             <label>
              ○
             </label>
             <p id="para835">
              Visiting poultry farms
             </p>
            </list-item>
            <list-item id="celistitem649">
             <label>
              ○
             </label>
             <p id="para836">
              Visiting live bird or poultry markets
             </p>
            </list-item>
            <list-item id="celistitem650">
             <label>
              ○
             </label>
             <p id="para837">
              Preparing or consuming uncooked or undercooked bird products (such as meat, eggs, or blood).
             </p>
            </list-item>
           </list>
          </p>
         </list-item>
         <list-item id="celistitem651">
          <label>
           •
          </label>
          <p id="para838">
           Because the situation has and may continue to evolve, travelers can stay abreast of new developments by checking the following websites that are updated regularly:
           <list id="celist179" list-type="simple">
            <list-item id="celistitem652">
             <label>
              ○
             </label>
             <p id="para839">
              U.S. government website for pandemic influenza (
              <ext-link ext-link-type="uri" id="interref31" xlink:href="http://www.pandemicflu.gov/">
               www.pandemicflu.gov/
              </ext-link>
              )
             </p>
            </list-item>
            <list-item id="celistitem653">
             <label>
              ○
             </label>
             <p id="para840">
              CDC's Travelers' Health website (
              <ext-link ext-link-type="uri" id="interref32" xlink:href="http://wwwn.cdc.gov/travel/contentAvianFluInformation.aspx">
               wwwn.cdc.gov/travel/contentAvianFluInformation.aspx
              </ext-link>
              )
             </p>
            </list-item>
            <list-item id="celistitem654">
             <label>
              ○
             </label>
             <p id="para841">
              CDC's Avian Influenza website (
              <ext-link ext-link-type="uri" id="interref33" xlink:href="http://www.cdc.gov/flu/avian/">
               www.cdc.gov/flu/avian/
              </ext-link>
              )
             </p>
            </list-item>
            <list-item id="celistitem655">
             <label>
              ○
             </label>
             <p id="para842">
              WHO website (
              <ext-link ext-link-type="uri" id="interref34" xlink:href="http://www.who.int/csr/disease/avian_influenza/en/index.html">
               www.who.int/csr/disease/avian_influenza/en/index.html
              </ext-link>
              ).
             </p>
            </list-item>
           </list>
          </p>
         </list-item>
        </list>
       </p>
      </sec>
     </sec>
     <sec id="cesec169">
      <title>
       Clinical Presentation
      </title>
      <p id="para843">
       <list id="celist180" list-type="simple">
        <list-item id="celistitem656">
         <label>
          •
         </label>
         <p id="para844">
          Onset of symptoms typically occurs 1–4 days after infection.
         </p>
        </list-item>
        <list-item id="celistitem657">
         <label>
          •
         </label>
         <p id="para845">
          Uncomplicated influenza illness is characterized by the abrupt onset of constitutional and respiratory signs and symptoms (e.g., fever, myalgia, headache, malaise, nonproductive cough, sore throat, and rhinitis). Among children, otitis media, nausea, and vomiting are also commonly reported with influenza illness.
         </p>
        </list-item>
        <list-item id="celistitem658">
         <label>
          •
         </label>
         <p id="para846">
          Influenza illness typically resolves within 1 week for most persons, although cough and malaise can persist for &gt;2 weeks. However, influenza virus infections can cause primary influenza viral pneumonia; exacerbate underlying medical conditions (e.g., pulmonary or cardiac disease); lead to secondary bacterial pneumonia, sinusitis, or otitis; or contribute to co-infections with other viral or bacterial pathogens. Influenza-related deaths can result from primary illnesses, secondary bacterial pneumonia, or exacerbations of chronic cardiac or pulmonary conditions.
         </p>
        </list-item>
        <list-item id="celistitem659">
         <label>
          •
         </label>
         <p id="para847">
          Young children with influenza virus infection may have initial symptoms mimicking bacterial sepsis with high fevers, and febrile seizures have been reported in 6%–20% of children hospitalized with influenza virus infection. Population-based studies among hospitalized children with laboratory-confirmed influenza have demonstrated that, although the majority of hospitalizations are brief (2 days or less), 4%–11% of children hospitalized with laboratory-confirmed influenza required treatment in the intensive-care unit and 3% required mechanical ventilation. Among 1,308 hospitalized children in one study, 80% were &lt;5 years of age and 27% were &lt;6 months of age. Influenza virus infection also has been uncommonly associated with encephalopathy, transverse myelitis, myositis, myocarditis, pericarditis, and Reye syndrome.
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <sec id="cesec170">
      <title>
       Diagnosis
      </title>
      <p id="para848">
       <list id="celist181" list-type="simple">
        <list-item id="celistitem660">
         <label>
          •
         </label>
         <p id="para849">
          Respiratory illnesses caused by influenza virus infection are difficult to distinguish from illnesses caused by other respiratory pathogens on the basis of signs and symptoms alone. Sensitivity and predictive value of clinical definitions can vary, depending on the degree of circulation of other respiratory pathogens and the level of influenza activity. Among studies conducted with children and adults, the positive predictive value of clinical signs and symptoms for laboratory-confirmed influenza virus infection has ranged from 30% to 88%.
         </p>
        </list-item>
        <list-item id="celistitem661">
         <label>
          •
         </label>
         <p id="para850">
          Laboratory testing can aid in diagnosis. Diagnostic tests available for influenza include viral culture, serology, rapid antigen testing, polymerase chain reaction, and immunofluorescence assays.
         </p>
        </list-item>
        <list-item id="celistitem662">
         <label>
          •
         </label>
         <p id="para851">
          Respiratory specimens obtained via nasopharyngeal swabs typically yield better detection of influenza than specimens obtained via oropharyngeal swabs.
         </p>
        </list-item>
        <list-item id="celistitem663">
         <label>
          •
         </label>
         <p id="para852">
          Commercial rapid diagnostic tests are available that can detect influenza viruses within 30 minutes. Some tests are approved for use in any outpatient setting, whereas others must be used in a moderately complex clinical laboratory. These rapid tests differ in the types of influenza viruses they can detect and whether they can distinguish between influenza types. Some tests can detect only influenza A viruses, some detect both influenza A and B viruses, but cannot distinguish between the two types, and some detect both influenza A and B and can distinguish between the two.
         </p>
        </list-item>
        <list-item id="celistitem664">
         <label>
          •
         </label>
         <p id="para853">
          None of the commercially available rapid tests provides any information about influenza A subtypes. The types of specimens acceptable for use (i.e., throat, nasopharyngeal, or nasal aspirates, swabs, or washes) also vary by test. The specificity and, in particular, the sensitivity of rapid tests are lower than for viral culture and vary by test. Because of the lower sensitivity of the rapid tests, physicians should consider confirming negative tests with viral culture or other means because of the possibility of false-negative rapid test results.
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <sec id="cesec171">
      <title>
       Treatment
      </title>
      <p id="para854">
       <list id="celist182" list-type="simple">
        <list-item id="celistitem665">
         <label>
          •
         </label>
         <p id="para855">
          Influenza-specific antiviral drugs for chemoprophylaxis of influenza are important adjuncts to the influenza vaccine.
         </p>
        </list-item>
        <list-item id="celistitem666">
         <label>
          •
         </label>
         <p id="para856">
          The four currently licensed U.S. antiviral agents are amantadine, rimantadine, zanamivir, and oseltamivir. Amantadine and rimantadine have a mechanism of action effective only against influenza A viruses, while the neuraminidase inhibitors oseltamivir and zanamivir are effective against both influenza A and B viruses.
         </p>
        </list-item>
        <list-item id="celistitem667">
         <label>
          •
         </label>
         <p id="para857">
          Antiviral drug testing results conducted at CDC during the 2005–2006 influenza season, indicated 79% resistance among influenza A H3N2 viruses and 10% among H1N1. CDC recommends that neither amantadine nor rimantadine be used for the treatment or chemoprophylaxis of influenza A in the United States until susceptibility to these antiviral medications has been re-established among circulating influenza A viruses.
         </p>
        </list-item>
        <list-item id="celistitem668">
         <label>
          •
         </label>
         <p id="para858">
          Oseltamivir or zanamivir can be prescribed if antiviral treatment of influenza is indicated. Oseltamivir is approved for treatment of persons aged Δ1 year, and zanamivir is approved for treatment of persons Δ7 years of age. Oseltamivir and zanamivir can be used for chemoprophylaxis of influenza; oseltamivir is licensed for use in persons Δ1 year of age, and zanamivir is licensed for use in persons Δ5 years of age. These two drugs differ in dosing, approved age groups for use, side effects, and cost. The package inserts should be consulted for more information.
         </p>
        </list-item>
       </list>
      </p>
      <sec id="cesec172">
       <title>
        Antiviral Resistance
       </title>
       <p id="para859">
        <list id="celist183" list-type="simple">
         <list-item id="celistitem669">
          <label>
           •
          </label>
          <p id="para860">
           In the winter of 2007–2008, oseltamivir-resistant influenza A (H1N1) viruses were found to be circulating in several countries, including the United States, but the highest rates of resistance were found in Northern Europe. Oseltamivir resistance appears to be geographically variable, both within Europe and globally. In the United States, approximately 12% of H1N1 viruses from the 2007–2008 season were resistant to oseltamivir, resistance was highest in Europe at 26%, and overall global resistance was approximately 16%. The oseltamivir-resistant H1N1 viruses remained sensitive to amantadine and rimantadine. This strain of oseltamivir-resistant influenza A (H1N1) may continue to circulate in future seasons or may spread geographically. Oseltamivir and zanamivir remain the preferred antiviral drugs to be used in the treatment of influenza virus infection, given their relatively low levels of resistance compared with the high resistance found to amantadine and rimantadine among currently circulating influenza A viruses.
          </p>
         </list-item>
         <list-item id="celistitem670">
          <label>
           •
          </label>
          <p id="para861">
           Some H5N1 viruses currently infecting birds and humans are resistant to amantadine and rimantadine. Most of the H5N1 viruses tested have been susceptible to the antiviral medications oseltamivir and zanamivir, but resistance has been reported. The effectiveness of antivirals for treating H5N1 virus infections is unknown. For more information about influenza antiviral drugs, see
           <ext-link ext-link-type="uri" id="interref35" xlink:href="http://www.cdc.gov/flu/avian/gen-info/avian-flu-humans.htm#antiviral">
            www.cdc.gov/flu/avian/gen-info/avian-flu-humans.htm#antiviral
           </ext-link>
           .
          </p>
         </list-item>
         <list-item id="celistitem671">
          <label>
           •
          </label>
          <p id="para862">
           For more detailed information on influenza vaccines, treatment, and general prevention and control, please refer to “Prevention and Control of Influenza: Recommendations of the Advisory Committee on Immunization Practices (ACIP)” (the most recent version is available at:
           <ext-link ext-link-type="uri" id="interref36" xlink:href="http://www.cdc.gov/vaccines/pubs/ACIP-list.htm">
            www.cdc.gov/vaccines/pubs/ACIP-list.htm
           </ext-link>
           ).
          </p>
         </list-item>
        </list>
       </p>
      </sec>
     </sec>
     <sec id="cesec173">
      <title>
       Preventive Measures for Travelers
      </title>
      <p id="para863">
       <list id="celist184" list-type="simple">
        <list-item id="celistitem672">
         <label>
          •
         </label>
         <p id="para864">
          Handwashing and cough hygiene can play important roles in limiting person-to-person transmission of influenza. Where handwashing is not available, use of hand sanitizing gels containing greater than 60% alcohol can be used.
         </p>
        </list-item>
        <list-item id="celistitem673">
         <label>
          •
         </label>
         <p id="para865">
          Annual vaccination of persons at high risk for complications and vaccination of health-care workers and close contacts of high risk persons before the influenza season are the most effective measure for preventing seasonal influenza and associated complications.
         </p>
        </list-item>
        <list-item id="celistitem674">
         <label>
          •
         </label>
         <p id="para866">
          Vaccination of travelers is recommended when the vaccine is available and if there are no contraindications.
         </p>
        </list-item>
       </list>
      </p>
      <sec id="cesec174">
       <title>
        Vaccine
       </title>
       <p id="para867">
        <list id="celist185" list-type="simple">
         <list-item id="celistitem675">
          <label>
           •
          </label>
          <p id="para868">
           Two types of influenza vaccines are currently available for use in the United States: trivalent inactivated vaccine (TIV), administered by intramuscular injection; and live, attenuated influenza vaccine (LAIV), administered by nasal spray. LAIV is approved currently for use only in healthy persons 2–49 years of age who are not pregnant.
          </p>
         </list-item>
         <list-item id="celistitem676">
          <label>
           •
          </label>
          <p id="para869">
           In the United States, annual influenza vaccination is recommended by CDC and ACIP for certain groups of people, primarily those who are at high risk of having serious flu complications or those who live with or care for those at high risk for serious complications. Annual recommendations are published by CDC and ACIP, including information about the season's vaccine composition, dosage and administration, and recommendations for specific populations. The current version of these routine recommendations is available at
           <ext-link ext-link-type="uri" id="interref37" xlink:href="http://www.cdc.gov/vaccines/pubs/ACIP-list.htm">
            www.cdc.gov/vaccines/pubs/ACIP-list.htm
           </ext-link>
           .
          </p>
         </list-item>
         <list-item id="celistitem677">
          <label>
           •
          </label>
          <p id="para870">
           The influenza vaccine must be administered annually to optimize protection because vaccine-derived immunity declines over time and because the vaccine strains must be updated regularly to reflect ongoing antigenic changes among circulating influenza viruses.
          </p>
         </list-item>
         <list-item id="celistitem678">
          <label>
           •
          </label>
          <p id="para871">
           Dosages differ according to age group and type of vaccine used. For inactivated vaccines, two doses administered at least 1 month apart are required for previously unvaccinated infants and children through 8 years of age. In adults, studies have indicated little or no improvement in antibody response when a second dose of inactivated vaccine is administered during the same season; therefore, a booster is not recommended. Inactivated vaccine should be administered in infants and young children in the anterolateral aspect of the thigh; all other recipients should be vaccinated in the deltoid muscle.
          </p>
         </list-item>
         <list-item id="celistitem679">
          <label>
           •
          </label>
          <p id="para872">
           The age groups for which influenza and pneumococcal vaccination are recommended overlap considerably. For travelers at high risk who have not previously been vaccinated with pneumococcal vaccine, health-care providers should strongly consider administering pneumococcal and influenza vaccines concurrently. Both vaccines can be administered at the same time at different sites without increasing side effects. Infants and children can receive influenza vaccine at the same time they receive other routine vaccinations.
          </p>
         </list-item>
         <list-item id="celistitem680">
          <label>
           •
          </label>
          <p id="para873">
           Both influenza vaccines contain three strains of influenza viruses. Viruses in inactivated vaccines are killed, while those in LAIV are live. These live viruses are attenuated and do not cause influenza illnesses. The viruses used in both vaccines are representative of viruses likely to circulate in the upcoming season, and usually one or more vaccine strains are updated annually. Because the vaccine is grown in hen eggs, the vaccine may contain small amounts of egg protein. The package insert should be consulted regarding the use of other compounds to inactivate the viruses or to limit bacterial contamination.
          </p>
         </list-item>
        </list>
       </p>
      </sec>
      <sec id="cesec175">
       <title>
        Avian Influenza
       </title>
       <p id="para874">
        <list id="celist186" list-type="simple">
         <list-item id="celistitem681">
          <label>
           •
          </label>
          <p id="para875">
           H5N1 infections in humans, though rare, can cause serious disease and death.
          </p>
         </list-item>
         <list-item id="celistitem682">
          <label>
           •
          </label>
          <p id="para876">
           CDC advises travelers to countries with known outbreaks of H5N1 to avoid—
           <list id="celist187" list-type="simple">
            <list-item id="celistitem683">
             <label>
              ○
             </label>
             <p id="para877">
              Poultry farms
             </p>
            </list-item>
            <list-item id="celistitem684">
             <label>
              ○
             </label>
             <p id="para878">
              All poultry, whether or not symptomatic, and especially contact with sick or dead poultry
             </p>
            </list-item>
            <list-item id="celistitem685">
             <label>
              ○
             </label>
             <p id="para879">
              Contact with surfaces that may have been contaminated by poultry feces or secretions
             </p>
            </list-item>
            <list-item id="celistitem686">
             <label>
              ○
             </label>
             <p id="para880">
              Contact with animals in live food markets
             </p>
            </list-item>
           </list>
          </p>
         </list-item>
         <list-item id="celistitem687">
          <label>
           •
          </label>
          <p id="para881">
           Since transmission of H5N1 viruses to two persons through consumption of uncooked duck blood may have occurred in Vietnam in 2005, uncooked poultry or poultry products, including blood, should not be consumed. Care should be taken when preparing these foods.
          </p>
         </list-item>
         <list-item id="celistitem688">
          <label>
           •
          </label>
          <p id="para882">
           For more information, see Human Infection with Avian Influenza A (H5N1) Virus Advice for Travelers (
           <ext-link ext-link-type="uri" id="interref38" xlink:href="http://wwwn.cdc.gov/travel/contentAvianFluAsia.aspx">
            wwwn.cdc.gov/travel/contentAvianFluAsia.aspx
           </ext-link>
           ) and the WHO Avian Influenza Fact Sheet (
           <ext-link ext-link-type="uri" id="interref39" xlink:href="http://www.who.int/mediacentre/factsheets/avian_influenza/en/index.html#humans">
            www.who.int/mediacentre/factsheets/avian_influenza/en/index.html#humans
           </ext-link>
           ).
          </p>
         </list-item>
         <list-item id="celistitem689">
          <label>
           •
          </label>
          <p id="para883">
           A vaccine to protect humans against influenza A (H5N1) is not yet available commercially, but candidate vaccines are undergoing human clinical trials in the United States, with one vaccine currently licensed in the United States. This vaccine is approved by the U.S. FDA for stockpiling purposes only.
          </p>
         </list-item>
        </list>
       </p>
      </sec>
     </sec>
     <ref-list id="cebib12">
      <title>
       References
      </title>
      <ref id="bib118">
       <label>
        1
       </label>
       <element-citation id="sbref112" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Fiore
          </surname>
          <given-names>
           AE S
          </given-names>
         </name>
         <name>
          <surname>
           Shay
          </surname>
          <given-names>
           DK
          </given-names>
         </name>
         <name>
          <surname>
           Broder
          </surname>
          <given-names>
           K
          </given-names>
         </name>
        </person-group>
        <article-title>
         Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2008
        </article-title>
        <source>
         MMWR Morbid Mortal Wkly Rep
        </source>
        <volume>
         57
        </volume>
        <issue>
         RR-7
        </issue>
        <year>
         2008
        </year>
        <fpage>
         1
        </fpage>
        <lpage>
         60
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib119">
       <label>
        2
       </label>
       <element-citation id="sbref113" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ortiz
          </surname>
          <given-names>
           JR
          </given-names>
         </name>
         <name>
          <surname>
           Wallis
          </surname>
          <given-names>
           TR
          </given-names>
         </name>
         <name>
          <surname>
           Katz
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
        </person-group>
        <article-title>
         No evidence of avian influenza A (H5N1) among returning US travelers
        </article-title>
        <source>
         Emerg Infect Dis
        </source>
        <volume>
         13
        </volume>
        <issue>
         2
        </issue>
        <year>
         2007
        </year>
        <fpage>
         294
        </fpage>
        <lpage>
         297
        </lpage>
        <pub-id pub-id-type="pmid">
         17479895
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib120">
       <label>
        3
       </label>
       <element-citation id="sbref114" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Uyeki
          </surname>
          <given-names>
           TM
          </given-names>
         </name>
         <name>
          <surname>
           Zane
          </surname>
          <given-names>
           SB
          </given-names>
         </name>
         <name>
          <surname>
           Bodnar
          </surname>
          <given-names>
           UR
          </given-names>
         </name>
        </person-group>
        <article-title>
         Large summertime influenza A outbreak among tourists in Alaska and the Yukon Territory
        </article-title>
        <source>
         Clin Infect Dis
        </source>
        <volume>
         36
        </volume>
        <issue>
         9
        </issue>
        <year>
         2003
        </year>
        <fpage>
         1095
        </fpage>
        <lpage>
         1102
        </lpage>
        <pub-id pub-id-type="pmid">
         12715302
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib121">
       <label>
        4
       </label>
       <element-citation id="sbref115" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Juurlink
          </surname>
          <given-names>
           DN
          </given-names>
         </name>
         <name>
          <surname>
           Stukel
          </surname>
          <given-names>
           TA
          </given-names>
         </name>
         <name>
          <surname>
           Kwong
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        <article-title>
         Guillain–Barré syndrome after influenza vaccination in adults: a population-based study
        </article-title>
        <source>
         Arch Intern Med
        </source>
        <volume>
         166
        </volume>
        <issue>
         20
        </issue>
        <year>
         2006
        </year>
        <fpage>
         2217
        </fpage>
        <lpage>
         2221
        </lpage>
        <pub-id pub-id-type="pmid">
         17101939
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib122">
       <label>
        5
       </label>
       <element-citation id="sbref116" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Naleway
          </surname>
          <given-names>
           AL
          </given-names>
         </name>
         <name>
          <surname>
           Smith
          </surname>
          <given-names>
           WJ
          </given-names>
         </name>
         <name>
          <surname>
           Mullooly
          </surname>
          <given-names>
           JP
          </given-names>
         </name>
        </person-group>
        <article-title>
         Delivering influenza vaccine to pregnant women
        </article-title>
        <source>
         Epidemiol Rev
        </source>
        <volume>
         28
        </volume>
        <year>
         2006
        </year>
        <fpage>
         47
        </fpage>
        <lpage>
         53
        </lpage>
        <pub-id pub-id-type="pmid">
         16731574
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib123">
       <label>
        6
       </label>
       <element-citation id="sbref117" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kroon
          </surname>
          <given-names>
           FP
          </given-names>
         </name>
         <name>
          <surname>
           van Dissel
          </surname>
          <given-names>
           JT
          </given-names>
         </name>
         <name>
          <surname>
           de Jong
          </surname>
          <given-names>
           JC
          </given-names>
         </name>
        </person-group>
        <article-title>
         Antibody response after influenza vaccination in HIV-infected individuals: a consecutive 3-year study
        </article-title>
        <source>
         Vaccine
        </source>
        <volume>
         18
        </volume>
        <issue>
         26
        </issue>
        <year>
         2000
        </year>
        <fpage>
         3040
        </fpage>
        <lpage>
         3049
        </lpage>
        <pub-id pub-id-type="pmid">
         10825608
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib124">
       <label>
        7
       </label>
       <mixed-citation id="ceotherref7" publication-type="other">
        Avian Influenza A virus infections of humans [Internet]. Atlanta: Centers for Disease Control and Prevention. [updated 2008 May 23; cited 2008 Nov 30]. Available from:
        <ext-link ext-link-type="uri" id="interref40" xlink:href="http://www.cdc.gov/flu/avian/gen-info/avian-flu-humans.htm">
         http://www.cdc.gov/flu/avian/gen-info/avian-flu-humans.htm
        </ext-link>
        .
       </mixed-citation>
      </ref>
      <ref id="bib125">
       <label>
        8
       </label>
       <mixed-citation id="ceotherref8" publication-type="other">
        Diganosis: clinical signs and symptoms of influenza [Internet]. Atlanta: Centers for Disease Control and Prevention. [updated 2008 Sep 12; cited 2008 Jul 28]. Available from:
        <ext-link ext-link-type="uri" id="interref41" xlink:href="http://www.cdc.gov/flu/professionals/acip/clinical.htm">
         http://www.cdc.gov/flu/professionals/acip/clinical.htm
        </ext-link>
        .
       </mixed-citation>
      </ref>
      <ref id="bib126">
       <label>
        9
       </label>
       <element-citation id="sbref118" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Heinonen
          </surname>
          <given-names>
           OS
          </given-names>
         </name>
         <name>
          <surname>
           Shapiro
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Monson
          </surname>
          <given-names>
           RR
          </given-names>
         </name>
        </person-group>
        <article-title>
         Immunization during pregnancy against poliomyelitis and influenza in relation to childhood malignancy
        </article-title>
        <source>
         Int J Epidemiol
        </source>
        <volume>
         2
        </volume>
        <issue>
         3
        </issue>
        <year>
         1973
        </year>
        <fpage>
         229
        </fpage>
        <lpage>
         235
        </lpage>
        <pub-id pub-id-type="pmid">
         4359832
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib127">
       <label>
        10
       </label>
       <mixed-citation id="ceotherref9" publication-type="other">
        NIH, CDC, HIVMA/IDSA. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents [Internet]. Rockville (MD): AIDS
        <italic>
         Info
        </italic>
        ; 2008. [cited 25 Jul 2008]. Available from:
        <ext-link ext-link-type="uri" id="interref42" xlink:href="http://www.aidsinfo.nih.gov/contentfiles/Adult_OI.pdf">
         http://www.aidsinfo.nih.gov/contentfiles/Adult_OI.pdf
        </ext-link>
       </mixed-citation>
      </ref>
      <ref id="bib128">
       <label>
        11
       </label>
       <element-citation id="sbref119" publication-type="journal">
        <comment>
        </comment>
        <person-group person-group-type="author">
         <name>
          <surname>
           Lin
          </surname>
          <given-names>
           JC
          </given-names>
         </name>
         <name>
          <surname>
           Nichol
          </surname>
          <given-names>
           KL
          </given-names>
         </name>
        </person-group>
        <article-title>
         Excess mortality due to pneumonia or influenza during influenza seasons among persons with acquired immunodeficiency syndrome
        </article-title>
        <source>
         Arch Intern Med
        </source>
        <volume>
         161
        </volume>
        <year>
         2001
        </year>
        <fpage>
         441
        </fpage>
        <lpage>
         446
        </lpage>
        <pub-id pub-id-type="pmid">
         11176770
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib129">
       <label>
        12
       </label>
       <element-citation id="sbref120" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Miotti
          </surname>
          <given-names>
           PG
          </given-names>
         </name>
        </person-group>
        <article-title>
         Nelson KE, Dallabetta GA, et al. The influence of HIV infection on antibody responses to a two-dose regimen of influenza vaccine
        </article-title>
        <source>
         JAMA
        </source>
        <volume>
         262
        </volume>
        <issue>
         6
        </issue>
        <year>
         1989
        </year>
        <fpage>
         779
        </fpage>
        <lpage>
         783
        </lpage>
        <pub-id pub-id-type="pmid">
         2787416
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib130">
       <label>
        13
       </label>
       <element-citation id="sbref121" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bright
          </surname>
          <given-names>
           RA
          </given-names>
         </name>
         <name>
          <surname>
           Shay
          </surname>
          <given-names>
           DK
          </given-names>
         </name>
         <name>
          <surname>
           Shu
          </surname>
          <given-names>
           B
          </given-names>
         </name>
        </person-group>
        <article-title>
         Adamantane resistance among influenza A viruses isolated early during the 2005–2006 influenza season in the United States
        </article-title>
        <source>
         JAMA
        </source>
        <volume>
         295
        </volume>
        <issue>
         8
        </issue>
        <year>
         2006
        </year>
        <fpage>
         891
        </fpage>
        <lpage>
         894
        </lpage>
        <pub-id pub-id-type="pmid">
         16456087
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib131">
       <label>
        14
       </label>
       <element-citation id="sbref122" publication-type="book">
        <person-group person-group-type="author">
         <collab>
          W.H.O.
         </collab>
        </person-group>
        <source>
         Influenza A(H1N1) virus resistance to oseltamivir—2008 influenza season, southern hemisphere [Internet]
        </source>
        <year>
         2008
        </year>
        <publisher-name>
         World Health Organization
        </publisher-name>
        <publisher-loc>
         Geneva
        </publisher-loc>
        <comment>
         [cited 2008 Nov 30]. Available from:
         <ext-link ext-link-type="uri" id="interref43" xlink:href="http://www.who.int/csr/disease/influenza/H1N1webupdate20082008_kf.pdf">
          http://www.who.int/csr/disease/influenza/H1N1webupdate20082008_kf.pdf
         </ext-link>
        </comment>
       </element-citation>
      </ref>
      <ref id="bib132">
       <label>
        15
       </label>
       <mixed-citation id="ceotherref10" publication-type="other">
        CDC. Questions &amp; answers: Influenza antiviral drug resistance [Internet]. Atlanta: Centers for Disease Control and Prevention. [updated 2008 Jul 17; cited 2008 Nov 30]. Available from:
        <ext-link ext-link-type="uri" id="interref44" xlink:href="http://www.cdc.gov/flu/about/qa/antiviralresistance.htm">
         http://www.cdc.gov/flu/about/qa/antiviralresistance.htm
        </ext-link>
        .
       </mixed-citation>
      </ref>
      <ref id="bib133">
       <label>
        16
       </label>
       <element-citation id="sbref123" publication-type="book">
        <person-group person-group-type="author">
         <collab>
          European Centre for Disease Prevention and Control (ECDC)
         </collab>
        </person-group>
        <source>
         Antivirals and antiviral resistant influenza [Internet]
        </source>
        <year>
         2008
        </year>
        <publisher-name>
         ECDC
        </publisher-name>
        <publisher-loc>
         Stockholm
        </publisher-loc>
        <comment>
         [cited 2008 Nov 30]; Available from:
         <ext-link ext-link-type="uri" id="interref45" xlink:href="http://ecdc.europa.eu/Health%5Ftopics/influenza/antivirals.html">
          http://ecdc.europa.eu/Health%5Ftopics/influenza/antivirals.html
         </ext-link>
        </comment>
       </element-citation>
      </ref>
      <ref id="bib134">
       <label>
        17
       </label>
       <element-citation id="sbref124" publication-type="book">
        <person-group person-group-type="author">
         <collab>
          W.H.O.
         </collab>
        </person-group>
        <source>
         WHO/ECDC frequently asked questions for Oseltamivir resistance [Internet]
        </source>
        <year>
         2008
        </year>
        <publisher-name>
         WHO
        </publisher-name>
        <publisher-loc>
         Geneva
        </publisher-loc>
        <comment>
         [cited 2008 Nov 30]. Available from:
         <ext-link ext-link-type="uri" id="interref46" xlink:href="http://www.who.int/csr/disease/influenza/oseltamivir_faqs/en/index.html">
          http://www.who.int/csr/disease/influenza/oseltamivir_faqs/en/index.html
         </ext-link>
        </comment>
       </element-citation>
      </ref>
     </ref-list>
    </sec>
    <sec id="subchapter13">
     <sec-meta>
      <contrib-group>
       <contrib contrib-type="author" id="au22">
        <name>
         <surname>
          Parker
         </surname>
         <given-names>
          Amy A.
         </given-names>
        </name>
       </contrib>
       <contrib contrib-type="author" id="au23">
        <name>
         <surname>
          Uzicanin
         </surname>
         <given-names>
          Amra
         </given-names>
        </name>
       </contrib>
      </contrib-group>
     </sec-meta>
     <title>
      MEASLES (RUBEOLA)
     </title>
     <sec id="cesec176">
      <title>
       Infectious Agent
      </title>
      <p id="para884">
       <list id="celist188" list-type="simple">
        <list-item id="celistitem690">
         <label>
          •
         </label>
         <p id="para885">
          Measles virus is a member of the genus
          <italic>
           Morbillivirus
          </italic>
          of the family Paramyxoviridae.
         </p>
        </list-item>
        <list-item id="celistitem691">
         <label>
          •
         </label>
         <p id="para886">
          Humans are the only known natural host for the measles virus.
         </p>
        </list-item>
        <list-item id="celistitem692">
         <label>
          •
         </label>
         <p id="para887">
          Measles, also known as rubeola, is one of the most highly communicable infectious diseases.
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <sec id="cesec177">
      <title>
       Mode of Transmission
      </title>
      <p id="para888">
       <list id="celist189" list-type="simple">
        <list-item id="celistitem693">
         <label>
          •
         </label>
         <p id="para889">
          Measles spreads by airborne droplets.
         </p>
        </list-item>
        <list-item id="celistitem694">
         <label>
          •
         </label>
         <p id="para890">
          Direct contact with nasal or throat secretions of infected persons.
         </p>
        </list-item>
        <list-item id="celistitem695">
         <label>
          •
         </label>
         <p id="para891">
          Less commonly it is spread by articles freshly soiled with nose and throat secretions.
         </p>
        </list-item>
        <list-item id="celistitem696">
         <label>
          •
         </label>
         <p id="para892">
          Infected persons are usually contagious from 4 days before onset of signs or symptoms, and until 4 days after the onset of signs or symptoms.
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <sec id="cesec178">
      <title>
       Occurrence
      </title>
      <p id="para893">
       <list id="celist190" list-type="simple">
        <list-item id="celistitem697">
         <label>
          •
         </label>
         <p id="para894">
          An estimated 20 million measles cases still occur globally every year, and travelers could be exposed in almost any country they visit. However, the risks are greater in countries where measles remains endemic or where large outbreaks are occurring.
         </p>
        </list-item>
        <list-item id="celistitem698">
         <label>
          •
         </label>
         <p id="para895">
          In the Americas, indigenous measles circulation was interrupted in 2002, but risk of measles due to virus importations from other parts of the world still remains.
         </p>
        </list-item>
        <list-item id="celistitem699">
         <label>
          •
         </label>
         <p id="para896">
          The number of reported measles cases in the United States has declined from 894,134 in 1941 to fewer than 150 cases each year since 1997. However, from January 1 through April 25, 2008, a total of 64 confirmed measles cases were reported to CDC, which is the largest number of cases reported in the United States for the corresponding period for any year since 2001. Ten of these cases were acquired abroad by unvaccinated travelers (five in visitors to the United States and five in U.S. residents) and the remaining cases were considered to be associated with these importations of measles.
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <sec id="cesec179">
      <title>
       Risk for Travelers
      </title>
      <p id="para897">
       <list id="celist191" list-type="simple">
        <list-item id="celistitem700">
         <label>
          •
         </label>
         <p id="para898">
          All persons who do not have evidence of measles immunity are at risk for contracting measles during international travel.
         </p>
        </list-item>
        <list-item id="celistitem701">
         <label>
          •
         </label>
         <p id="para899">
          Acceptable presumptive evidence of immunity to measles for international travelers includes—
          <list id="celist192" list-type="simple">
           <list-item id="celistitem702">
            <label>
             ○
            </label>
            <p id="para900">
             For infants 6–11 months of age, documented administration of one dose of live measles-containing vaccine
             <xref ref-type="fn" rid="fn4">
              1
             </xref>
             and, for persons Δ12 months of age, two doses of MMR
             <xref ref-type="fn" rid="fn5">
              2
             </xref>
             vaccine at least 28 days apart, on or after the first birthday
            </p>
           </list-item>
           <list-item id="celistitem703">
            <label>
             ○
            </label>
            <p id="para901">
             Laboratory evidence of immunity
            </p>
           </list-item>
           <list-item id="celistitem704">
            <label>
             ○
            </label>
            <p id="para902">
             Birth before 1957
            </p>
           </list-item>
           <list-item id="celistitem705">
            <label>
             ○
            </label>
            <p id="para903">
             Documented physician-diagnosed measles
            </p>
           </list-item>
          </list>
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <sec id="cesec180">
      <title>
       Clinical Presentation
      </title>
      <p id="para904">
       <list id="celist193" list-type="simple">
        <list-item id="celistitem706">
         <label>
          •
         </label>
         <p id="para905">
          Incubation period is ∼10 days (range 7–18 days) from exposure to onset of fever, usually 14 days before appearance of rash.
         </p>
        </list-item>
        <list-item id="celistitem707">
         <label>
          •
         </label>
         <p id="para906">
          Symptoms include prodromal fever, conjunctivitis, coryza, cough, and small spots with white or bluish white centers on an erythematous base on the buccal mucosa (Koplik spots).
         </p>
        </list-item>
        <list-item id="celistitem708">
         <label>
          •
         </label>
         <p id="para907">
          Characteristic red, blotchy (maculopapular) rash appears on third to seventh day that begins on the face, becomes generalized, and lasts 4–7 days.
         </p>
        </list-item>
        <list-item id="celistitem709">
         <label>
          •
         </label>
         <p id="para908">
          Complications include diarrhea (8%), middle ear infection (7%–9%), and pneumonia (1%–6%). Encephalitis, frequently resulting in permanent brain damage, occurs in approximately 1 per 1,000–2,000 cases of measles. Subacute sclerosing panencephalitis (SSPE), a rare but serious degenerative central nervous system disease, is thought to occur in 1 per 100,000 cases, although a risk of 22 cases of SSPE per 100,000 measles cases was found during the 1989–1991 measles resurgence in the United States. SSPE, which is caused by a persistent infection with a defective measles virus, is manifested by mental and motor deterioration that starts an average of 7 years after measles virus infection (most frequently in children &lt;2 years of age), progressing to coma and death.
         </p>
        </list-item>
        <list-item id="celistitem710">
         <label>
          •
         </label>
         <p id="para909">
          The risk of serious complications and death is highest for children £5 years of age and adults Δ20 years of age. It is also higher in populations with poor nutritional status.
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <sec id="cesec181">
      <title>
       Diagnosis
      </title>
      <p id="para910">
       <list id="celist194" list-type="simple">
        <list-item id="celistitem711">
         <label>
          •
         </label>
         <p id="para911">
          A clinical case of measles illness is characterized by all of the following:
          <list id="celist195" list-type="simple">
           <list-item id="celistitem712">
            <label>
             ○
            </label>
            <p id="para912">
             Generalized maculopapular rash lasting Δ3 days
            </p>
           </list-item>
           <list-item id="celistitem713">
            <label>
             ○
            </label>
            <p id="para913">
             Temperature Δ101° F (Δ38.3° C)
            </p>
           </list-item>
           <list-item id="celistitem714">
            <label>
             ○
            </label>
            <p id="para914">
             Cough, coryza, or conjunctivitis
            </p>
           </list-item>
          </list>
         </p>
        </list-item>
        <list-item id="celistitem715">
         <label>
          •
         </label>
         <p id="para915">
          Laboratory criteria for diagnosis is a positive serologic test for measles immunoglobulin M (IgM) antibody, seroconversion or significant rise in measles IgG antibody level by any standard serologic assay, or isolation of measles virus or identification by PCR of measles virus RNA from a clinical specimen.
         </p>
        </list-item>
        <list-item id="celistitem716">
         <label>
          •
         </label>
         <p id="para916">
          A confirmed case is either laboratory confirmed or meets the clinical case definition and is epidemiologically linked to a confirmed case. A laboratory-confirmed case does not need to meet the clinical case definition.
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <sec id="cesec182">
      <title>
       Treatment
      </title>
      <p id="para917">
       <list id="celist196" list-type="simple">
        <list-item id="celistitem717">
         <label>
          •
         </label>
         <p id="para918">
          There is no specific antiviral therapy or treatment for measles.
         </p>
        </list-item>
        <list-item id="celistitem718">
         <label>
          •
         </label>
         <p id="para919">
          Supportive therapy includes hydration, antipyretics, and treating complications such as pneumonia.
         </p>
        </list-item>
        <list-item id="celistitem719">
         <label>
          •
         </label>
         <p id="para920">
          The WHO currently recommends vitamin A for all children with acute measles, regardless of their country of residence, to reduce morbidity and mortality. Vitamin A is administered once a day for 2 days, at the following doses:
          <list id="celist197" list-type="simple">
           <list-item id="celistitem720">
            <label>
             ○
            </label>
            <p id="para921">
             50,000 IU for infants &lt;6 months of age
            </p>
           </list-item>
           <list-item id="celistitem721">
            <label>
             ○
            </label>
            <p id="para922">
             100,000 IU for infants 6–11months of age
            </p>
           </list-item>
           <list-item id="celistitem722">
            <label>
             ○
            </label>
            <p id="para923">
             200,000 IU for children ages 12 months or older
            </p>
           </list-item>
          </list>
         </p>
        </list-item>
        <list-item id="celistitem723">
         <label>
          •
         </label>
         <p id="para924">
          A third age-specific dose of vitamin A is to be given 2–4 weeks later to case-patients with clinical signs and symptoms of vitamin A deficiency. Parenteral and oral formulations of vitamin A are available in the United States.
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <sec id="cesec183">
      <title>
       Preventive Measures for Travelers
      </title>
      <sec id="cesec184">
       <title>
        Vaccine
       </title>
       <p id="para925">
        <list id="celist198" list-type="simple">
         <list-item id="celistitem724">
          <label>
           •
          </label>
          <p id="para926">
           Measles vaccine contains live, attenuated measles virus. It is available as a monovalent formulation and in combination formulations, such as measles–rubella (MR), measles–mumps–rubella (MMR), and measles–mumps–rubella–varicella (MMRV).
          </p>
         </list-item>
         <list-item id="celistitem725">
          <label>
           •
          </label>
          <p id="para927">
           Ensure that all travelers who do not have evidence of measles immunity (see
           <xref ref-type="sec" rid="cesec179">
            Risk for Travelers
           </xref>
           earlier in this section) are up to date on measles vaccination prior to departure.
           <list id="celist199" list-type="simple">
            <list-item id="celistitem726">
             <label>
              ○
             </label>
             <p id="para928">
              Infants 6–11 months of age should have at least one dose of measles-containing vaccine.
              <xref ref-type="fn" rid="fn4">
               1
              </xref>
             </p>
            </list-item>
            <list-item id="celistitem727">
             <label>
              ○
             </label>
             <p id="para929">
              Preschool children Δ12 months of age should have two doses of MMR
              <xref ref-type="fn" rid="fn5">
               2
              </xref>
              vaccine separated by at least 28 days.
             </p>
            </list-item>
            <list-item id="celistitem728">
             <label>
              ○
             </label>
             <p id="para930">
              School-age children should have two doses of MMR.
              <xref ref-type="fn" rid="fn5">
               2
              </xref>
             </p>
            </list-item>
            <list-item id="celistitem729">
             <label>
              ○
             </label>
             <p id="para931">
              Adults born in or after 1957 should have two doses of measles-containing vaccine.
             </p>
            </list-item>
            <list-item id="celistitem730">
             <label>
              ○
             </label>
             <p id="para932">
              If administered at Δ12 months of age, one dose of measles-containing vaccine or MMR is 95% effective in preventing measles disease and two doses are 99% effective. One dose of measles-containing vaccine or MMR is approximately 85% effective if administered at 9 months of age.
             </p>
            </list-item>
           </list>
          </p>
         </list-item>
         <list-item id="celistitem731">
          <label>
           •
          </label>
          <p id="para933">
           For persons Δ12 months of age, combined MMR vaccine is recommended whenever one or more of the individual components is indicated to provide optimal protection against mumps and rubella. For infants &lt;12 months of age, measles vaccine alone is recommended if it is available; otherwise MMR should be used.
          </p>
         </list-item>
         <list-item id="celistitem732">
          <label>
           •
          </label>
          <p id="para934">
           MMR vaccine, if administered within 72 hours of initial measles exposure, may provide some protection. If the exposure does not result in infection, the vaccine should induce protection against subsequent measles virus infection.
          </p>
         </list-item>
         <list-item id="celistitem733">
          <label>
           •
          </label>
          <p id="para935">
           Immune globulin (IG) can be used to prevent or mitigate measles in a susceptible person when administered within 6 days of exposure. However, any immunity conferred is temporary unless modified or typical measles occurs, and the person should receive measles-containing vaccine 5–6 months after IG administration.
          </p>
         </list-item>
        </list>
       </p>
      </sec>
      <sec id="cesec185">
       <title>
        Adverse Reactions, Precautions, and Contraindications to Measles Vaccine
       </title>
       <sec id="cesec186">
        <title>
         Allergy
        </title>
        <p id="para936">
         Persons with severe allergy (i.e., hives, swelling of the mouth or throat, difficulty breathing, hypotension, and shock) to gelatin or neomycin or who have had a severe allergic reaction to a prior dose of MMR or MMRV should not be revaccinated except with extreme caution. MMR or MMRV vaccines may be administered to egg-allergic persons without prior routine skin testing or the use of special protocols.
        </p>
       </sec>
       <sec id="cesec187">
        <title>
         Immunosuppression
        </title>
        <p id="para937">
         Replication of vaccine viruses can be potentiated in persons who have immune deficiency disorders. Death related to vaccine-associated measles infection has been reported among severely immunocompromised persons. Therefore, severely immunosuppressed individuals should not be vaccinated with MMR or MMRV vaccines
         <list id="celist200" list-type="simple">
          <list-item id="celistitem734">
           <label>
            •
           </label>
           <p id="para938">
            MMR or MMRV should be avoided for at least 1 month after cessation of high-dose corticosteroid therapy. Some experts, however, recommend waiting only 2 weeks after completion of therapy among individuals receiving high doses of systemic corticosteroids daily or on alternate days even if they were receiving therapy for less than 14 days.
           </p>
          </list-item>
          <list-item id="celistitem735">
           <label>
            •
           </label>
           <p id="para939">
            Other immunosuppressive therapy: MMR or MMRV vaccines in general should be withheld for at least 3 months. This interval is based on the assumption that the immunologic responsiveness will have been restored in 3 months and the underlying disease for which the therapy was given is in remission.
           </p>
          </list-item>
         </list>
        </p>
       </sec>
       <sec id="cesec188">
        <title>
         Thrombocytopenia
        </title>
        <p id="para940">
         The benefits of primary immunization are usually greater than the potential risks. However, avoiding a subsequent dose of MMR or MMRV vaccine may be prudent if an episode of thrombocytopenia occurred within approximately 6 weeks after a previous dose of vaccine.
        </p>
       </sec>
      </sec>
     </sec>
     <ref-list id="cebib13">
      <title>
       References
      </title>
      <ref id="bib135">
       <label>
        1
       </label>
       <mixed-citation id="ceotherref11" publication-type="other">
        American Academy of Pediatrics. Measles. In: Pickering LK, Baker CJ, Long SS, McMillan JA, editors. Red book: 2006 report of the Committee on Infectious Diseases. 27th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2006. p. 441–52.
       </mixed-citation>
      </ref>
      <ref id="bib136">
       <label>
        2
       </label>
       <mixed-citation id="ceotherref12" publication-type="other">
        Measles fact sheet. 2007 Nov [cited 2008 Nov 25] Available from:
        <ext-link ext-link-type="uri" id="interref47" xlink:href="http://www.who.int/mediacentre/factsheets/fs286/en/">
         http://www.who.int/mediacentre/factsheets/fs286/en/
        </ext-link>
        .
       </mixed-citation>
      </ref>
      <ref id="bib137">
       <label>
        3
       </label>
       <element-citation id="sbref125" publication-type="journal">
        <person-group person-group-type="author">
         <collab>
          CDC
         </collab>
        </person-group>
        <article-title>
         Progress toward measles elimination—Region of the Americas, 2002–2003. MMWR
        </article-title>
        <source>
         Morbid Mortal Wkly Rep
        </source>
        <volume>
         53
        </volume>
        <issue>
         14
        </issue>
        <year>
         2004
        </year>
        <fpage>
         304
        </fpage>
        <lpage>
         306
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib138">
       <label>
        4
       </label>
       <element-citation id="sbref126" publication-type="journal">
        <person-group person-group-type="author">
         <collab>
          CDC
         </collab>
        </person-group>
        <article-title>
         Measles—United States, January 1-April 25, 2008
        </article-title>
        <source>
         MMWR Morb Mortal Wkly Rep
        </source>
        <volume>
         57
        </volume>
        <year>
         2008
        </year>
        <fpage>
         1
        </fpage>
        <lpage>
         4
        </lpage>
        <pub-id pub-id-type="pmid">
         18185492
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib139">
       <label>
        5
       </label>
       <element-citation id="sbref127" publication-type="journal">
        <person-group person-group-type="author">
         <collab>
          CDC
         </collab>
        </person-group>
        <article-title>
         Measles, mumps, and rubella-vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
        </article-title>
        <source>
         MMWR Morbid Mortal Wkly Rep
        </source>
        <volume>
         47
        </volume>
        <issue>
         RR-8
        </issue>
        <year>
         1998
        </year>
        <fpage>
         1
        </fpage>
        <lpage>
         57
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib140">
       <label>
        6
       </label>
       <element-citation id="sbref128" publication-type="journal">
        <person-group person-group-type="author">
         <collab>
          CDC
         </collab>
        </person-group>
        <article-title>
         Update: recommendations from the Advisory Committee on Immunization Practices (ACIP) regarding administration of combination MMRV vaccine
        </article-title>
        <source>
         MMWR Morbid Mortal Wkly Rep
        </source>
        <volume>
         57
        </volume>
        <issue>
         10
        </issue>
        <year>
         2008
        </year>
        <fpage>
         258
        </fpage>
        <lpage>
         260
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib141">
       <label>
        7
       </label>
       <element-citation id="sbref129" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Strebel
          </surname>
          <given-names>
           PM
          </given-names>
         </name>
         <name>
          <surname>
           Papania
          </surname>
          <given-names>
           MJ
          </given-names>
         </name>
         <name>
          <surname>
           dayan
          </surname>
          <given-names>
           GH
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         Measles vaccine
        </chapter-title>
        <person-group person-group-type="editor">
         <name>
          <surname>
           Plotkin
          </surname>
          <given-names>
           SA
          </given-names>
         </name>
         <name>
          <surname>
           Orenstein
          </surname>
          <given-names>
           WA
          </given-names>
         </name>
         <name>
          <surname>
           Offit
          </surname>
          <given-names>
           PA
          </given-names>
         </name>
        </person-group>
        <source>
         Vaccines
        </source>
        <edition>
         5th ed.
        </edition>
        <year>
         2008
        </year>
        <publisher-name>
         Saunders Elsevier
        </publisher-name>
        <publisher-loc>
         Philadelphia
        </publisher-loc>
        <fpage>
         353
        </fpage>
        <lpage>
         398
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib142">
       <label>
        8
       </label>
       <element-citation id="sbref130" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bellini
          </surname>
          <given-names>
           WJ
          </given-names>
         </name>
         <name>
          <surname>
           Rota
          </surname>
          <given-names>
           JS
          </given-names>
         </name>
         <name>
          <surname>
           Lowe
          </surname>
          <given-names>
           LE
          </given-names>
         </name>
        </person-group>
        <article-title>
         Subacute sclerosing panencephalitis: more cases of this fatal disease are prevented by measles immunization than was previously recognized
        </article-title>
        <source>
         J Infect Dis
        </source>
        <volume>
         192
        </volume>
        <issue>
         10
        </issue>
        <year>
         2005
        </year>
        <fpage>
         1686
        </fpage>
        <lpage>
         1693
        </lpage>
        <pub-id pub-id-type="pmid">
         16235165
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib143">
       <label>
        9
       </label>
       <element-citation id="sbref131" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Perry
          </surname>
          <given-names>
           RT
          </given-names>
         </name>
         <name>
          <surname>
           Halsey
          </surname>
          <given-names>
           NA
          </given-names>
         </name>
        </person-group>
        <article-title>
         The clinical significance of measles: a review
        </article-title>
        <source>
         J Infect Dis
        </source>
        <volume>
         189
        </volume>
        <issue>
         Suppl 1
        </issue>
        <year>
         2004
        </year>
        <fpage>
         S4
        </fpage>
        <lpage>
         16
        </lpage>
        <pub-id pub-id-type="pmid">
         15106083
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib144">
       <label>
        10
       </label>
       <mixed-citation id="ceotherref13" publication-type="other">
        Measles (rubeola) 2007 case definition. 2008 Jan 9 [cited 2008 Nov 25]. Available from:
        <ext-link ext-link-type="uri" id="interref48" xlink:href="http://www.cdc.gov/ncphi/disss/nndss/casedef/measles_current.htm">
         http://www.cdc.gov/ncphi/disss/nndss/casedef/measles_current.htm
        </ext-link>
        .
       </mixed-citation>
      </ref>
      <ref id="bib145">
       <label>
        11
       </label>
       <mixed-citation id="ceotherref14" publication-type="other">
        American Academy of Pediatrics. Measles. In: Pickering LK, Baker CJ, Long SL, Kimberlin DW, editors. Red book: 2006 report of the Committee on Infectious Diseases. 27th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2006.
       </mixed-citation>
      </ref>
      <ref id="bib146">
       <label>
        12
       </label>
       <element-citation id="sbref132" publication-type="journal">
        <person-group person-group-type="author">
         <collab>
          CDC
         </collab>
        </person-group>
        <article-title>
         Recommended childhood and adolescent immunization schedule—United States, 2006
        </article-title>
        <source>
         MMWR Morb Mortal Wkly Rep
        </source>
        <volume>
         54
        </volume>
        <issue>
         52
        </issue>
        <year>
         2006
        </year>
        <fpage>
         Q1
        </fpage>
        <lpage>
         Q4
        </lpage>
       </element-citation>
      </ref>
     </ref-list>
    </sec>
    <sec id="subchapter14">
     <sec-meta>
      <contrib-group>
       <contrib contrib-type="author" id="au24">
        <name>
         <surname>
          Kutty
         </surname>
         <given-names>
          Preeta K.
         </given-names>
        </name>
       </contrib>
       <contrib contrib-type="author" id="au25">
        <name>
         <surname>
          Barskey
         </surname>
         <given-names>
          Albert E.
         </given-names>
         <suffix>
          IV
         </suffix>
        </name>
       </contrib>
       <contrib contrib-type="author" id="au26">
        <name>
         <surname>
          Gallagher
         </surname>
         <given-names>
          Kathleen M.
         </given-names>
        </name>
       </contrib>
      </contrib-group>
     </sec-meta>
     <title>
      MUMPS
     </title>
     <sec id="cesec190">
      <title>
       Infectious Agent
      </title>
      <p id="para943">
       <list id="celist201" list-type="simple">
        <list-item id="celistitem736">
         <label>
          •
         </label>
         <p id="para944">
          Mumps virus is an enveloped, negative-strand RNA virus, a member of the genus
          <italic>
           Rubulavirus
          </italic>
          .
         </p>
        </list-item>
        <list-item id="celistitem737">
         <label>
          •
         </label>
         <p id="para945">
          Humans are the only known natural host for mumps virus.
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <sec id="cesec191">
      <title>
       Mode of Transmission
      </title>
      <p id="para946">
       <list id="celist202" list-type="simple">
        <list-item id="celistitem738">
         <label>
          •
         </label>
         <p id="para947">
          Transmission is by respiratory droplets, saliva, or contact with contaminated fomites.
         </p>
        </list-item>
        <list-item id="celistitem739">
         <label>
          •
         </label>
         <p id="para948">
          Patients are usually contagious 1–2 days (occasionally as long as 7 days) before symptom onset until 5 days afterward.
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <sec id="cesec192">
      <title>
       Occurrence
      </title>
      <p id="para949">
       <list id="celist203" list-type="simple">
        <list-item id="celistitem740">
         <label>
          •
         </label>
         <p id="para950">
          With the exception of the multistate outbreak in 2006, mumps is an uncommon disease in the United States because of a successful vaccination program.
         </p>
        </list-item>
        <list-item id="celistitem741">
         <label>
          •
         </label>
         <p id="para951">
          Mumps virus remains endemic in many countries throughout the world because mumps vaccine is used in only 57% of the World Health Organization member countries.
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <sec id="cesec193">
      <title>
       Risk for Travelers
      </title>
      <p id="para952">
       <list id="celist204" list-type="simple">
        <list-item id="celistitem742">
         <label>
          •
         </label>
         <p id="para953">
          The risk of exposure to mumps among travelers can be high in most countries of the world, especially for travelers &gt;12 months of age who do not have evidence of mumps immunity (see
          <xref ref-type="sec" rid="cesec197">
           Preventive Measures for Travelers
          </xref>
          later in this section). Although some countries have had variable successes with a national vaccination program—including Finland, which has declared elimination—the risk of contacting imported mumps in these countries is still a concern.
         </p>
        </list-item>
        <list-item id="celistitem743">
         <label>
          •
         </label>
         <p id="para954">
          Acceptable presumptive evidence of immunity to mumps for international travelers includes—
          <list id="celist205" list-type="simple">
           <list-item id="celistitem744">
            <label>
             ○
            </label>
            <p id="para955">
             Documented administration of two doses of live mumps virus vaccine at least 28 days apart, on or after the first birthday
            </p>
           </list-item>
           <list-item id="celistitem745">
            <label>
             ○
            </label>
            <p id="para956">
             Laboratory evidence of immunity
            </p>
           </list-item>
           <list-item id="celistitem746">
            <label>
             ○
            </label>
            <p id="para957">
             Birth before 1957
            </p>
           </list-item>
           <list-item id="celistitem747">
            <label>
             ○
            </label>
            <p id="para958">
             Documentation of physician-diagnosed mumps
            </p>
           </list-item>
          </list>
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <sec id="cesec194">
      <title>
       Clinical Presentation
      </title>
      <p id="para959">
       <list id="celist206" list-type="simple">
        <list-item id="celistitem748">
         <label>
          •
         </label>
         <p id="para960">
          Incubation period from exposure to onset of symptoms is generally 16–18 days (range 12–25 days).
         </p>
        </list-item>
        <list-item id="celistitem749">
         <label>
          •
         </label>
         <p id="para961">
          Onset of illness is usually nonspecific, with symptoms of fever, headache, malaise, myalgia, and anorexia.
         </p>
        </list-item>
        <list-item id="celistitem750">
         <label>
          •
         </label>
         <p id="para962">
          Mumps is characterized by parotitis, either unilateral or bilateral.
         </p>
        </list-item>
        <list-item id="celistitem751">
         <label>
          •
         </label>
         <p id="para963">
          Although mumps is generally a mild and self-limited disease, complications of mumps infection can include deafness; orchitis, oophoritis, or mastitis (inflammation of the testicles, ovaries or breasts, respectively); pancreatitis; and meningitis or encephalitis. With the exception of deafness, these complications are more frequent in adults than in children.
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <sec id="cesec195">
      <title>
       Diagnosis
      </title>
      <p id="para964">
       <list id="celist207" list-type="simple">
        <list-item id="celistitem752">
         <label>
          •
         </label>
         <p id="para965">
          Mumps may occur in epidemics; mumps virus is the only cause of epidemic parotitis.
         </p>
        </list-item>
        <list-item id="celistitem753">
         <label>
          •
         </label>
         <p id="para966">
          Diagnosis is usually clinical, based on the presence of parotitis and associated signs, symptoms, or complications.
         </p>
        </list-item>
        <list-item id="celistitem754">
         <label>
          •
         </label>
         <p id="para967">
          Clinical case definition: An illness with acute onset of unilateral or bilateral tender, self-limited swelling of the parotid glands, other salivary gland(s), or both, lasting at least 2 days, and without other apparent cause.
         </p>
        </list-item>
        <list-item id="celistitem755">
         <label>
          •
         </label>
         <p id="para968">
          Laboratory criteria include—
          <list id="celist208" list-type="simple">
           <list-item id="celistitem756">
            <label>
             ○
            </label>
            <p id="para969">
             Isolation of mumps virus from clinical specimen
            </p>
           </list-item>
           <list-item id="celistitem757">
            <label>
             ○
            </label>
            <p id="para970">
             Detection of mumps nucleic acid (e.g., standard or real-time RT-PCR assays)
            </p>
           </list-item>
           <list-item id="celistitem758">
            <label>
             ○
            </label>
            <p id="para971">
             Detection of mumps IgM antibody
            </p>
           </list-item>
           <list-item id="celistitem759">
            <label>
             ○
            </label>
            <p id="para972">
             Demonstration of specific mumps antibody response in the absence of recent vaccination, either a fourfold increase in IgG titer as measured by quantitative assays, or seroconversion from negative to positive by using a standard serologic assay of paired acute- and convalescent-phase serum specimens
            </p>
           </list-item>
          </list>
         </p>
        </list-item>
        <list-item id="celistitem760">
         <label>
          •
         </label>
         <p id="para973">
          Laboratory specimens that can be collected are serum for serology (IgM, IgG) and a buccal swab (or a throat swab) for viral specimens. For more information see
          <ext-link ext-link-type="uri" id="interref49" xlink:href="http://www.cdc.gov/vaccines/vpd-vac/mumps/outbreak/faqs-lab-spec-collect.htm">
           www.cdc.gov/vaccines/vpd-vac/mumps/outbreak/faqs-lab-spec-collect.htm
          </ext-link>
          .
         </p>
        </list-item>
        <list-item id="celistitem761">
         <label>
          •
         </label>
         <p id="para974">
          Laboratory confirmation is more challenging in highly vaccinated populations. Serologic tests should be interpreted with caution. A negative laboratory test should not rule out a clinically compatible case, especially in a two-dose vaccine recipient.
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <sec id="cesec196">
      <title>
       Treatment
      </title>
      <p id="para975">
       There is no specific antiviral therapy for mumps, and the basic treatment consists of supportive care.
      </p>
     </sec>
     <sec id="cesec197">
      <title>
       Preventive Measures for Travelers
      </title>
      <sec id="cesec198">
       <title>
        Vaccine
       </title>
       <p id="para976">
        <list id="celist209" list-type="simple">
         <list-item id="celistitem762">
          <label>
           •
          </label>
          <p id="para977">
           Although vaccination against mumps is not a requirement for entry into any country (including the United States), travelers leaving the United States or living abroad should ensure they are immune to mumps.
          </p>
         </list-item>
         <list-item id="celistitem763">
          <label>
           •
          </label>
          <p id="para978">
           Mumps vaccine contains live, attenuated mumps virus. It is available as a monovalent formulation and in combination formulations, such as MMR. Combined MMR vaccine is recommended whenever one or more of the individual components is indicated to provide optimal protection against measles and rubella. Mumps vaccine is highly, but not 100%, effective in preventing mumps. One dose of mumps vaccine is approximately 80%–85% effective in preventing clinical mumps with parotitis, and two doses are approximately 90% effective.
          </p>
         </list-item>
         <list-item id="celistitem764">
          <label>
           •
          </label>
          <p id="para979">
           Mumps vaccine has not been demonstrated to be effective in preventing infection after exposure; however, it can be administered postexposure to provide protection against subsequent exposures. Immune globulin is not effective in preventing mumps infection following an exposure and is not recommended.
          </p>
         </list-item>
        </list>
       </p>
      </sec>
      <sec id="cesec199">
       <title>
        Adverse Reactions, Precautions, and Contraindications to Mumps Vaccine
       </title>
       <p id="para980">
        <list id="celist210" list-type="simple">
         <list-item id="celistitem765">
          <label>
           •
          </label>
          <p id="para981">
           Refer to the Measles (Rubeola) section earlier in this chapter for information on reactions following MMR vaccine and additional precautions and contraindications.
          </p>
         </list-item>
        </list>
       </p>
       <sec id="cesec200">
        <title>
         General Vaccine Recommendations, Pediatric and Catch-Up Schedules, and Recommendations for Special Populations
        </title>
        <p id="para982">
         <list id="celist211" list-type="simple">
          <list-item id="celistitem766">
           <label>
            •
           </label>
           <p id="para983">
            Refer to Chapters 7 and 8.
           </p>
          </list-item>
         </list>
        </p>
       </sec>
      </sec>
     </sec>
     <ref-list id="cebib14">
      <title>
       References
      </title>
      <ref id="bib147">
       <label>
        1
       </label>
       <mixed-citation id="ceotherref15" publication-type="other">
        American Academy of Pediatrics. Mumps. In: Pickering LK, Baker CJ, Long SS, McMillan JA, editors. Red book: 2006 report of the Committee on Infectious Diseases. 27th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2003. p. 464–8.
       </mixed-citation>
      </ref>
      <ref id="bib148">
       <label>
        2
       </label>
       <element-citation id="sbref133" publication-type="journal">
        <comment>
        </comment>
        <person-group person-group-type="author">
         <collab>
          CDC
         </collab>
        </person-group>
        <article-title>
         Updated recommendations for isolation of persons with mumps
        </article-title>
        <source>
         MMWR Morbid Mortal Wkly Rep
        </source>
        <volume>
         57
        </volume>
        <issue>
         40
        </issue>
        <year>
         2008
        </year>
        <fpage>
         1103
        </fpage>
        <lpage>
         1105
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib149">
       <label>
        3
       </label>
       <element-citation id="sbref134" publication-type="journal">
        <person-group person-group-type="author">
         <collab>
          World Health Organization.
         </collab>
        </person-group>
        <article-title>
         Global status of mumps immunization and surveillance
        </article-title>
        <source>
         Wkly Epidemiol Rec
        </source>
        <volume>
         80
        </volume>
        <issue>
         48
        </issue>
        <year>
         2005
        </year>
        <fpage>
         417
        </fpage>
        <lpage>
         424
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib150">
       <label>
        4
       </label>
       <element-citation id="sbref135" publication-type="journal">
        <person-group person-group-type="author">
         <collab>
          CDC
         </collab>
        </person-group>
        <article-title>
         Measles, mumps, and rubella-vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps. Recommendations of the Advisory Committee on Immunization Practices (ACIP)
        </article-title>
        <source>
         MMWR Morbid Mortal Wkly Rep
        </source>
        <volume>
         47
        </volume>
        <issue>
         RR-8
        </issue>
        <year>
         1998
        </year>
        <fpage>
         1
        </fpage>
        <lpage>
         57
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib151">
       <label>
        5
       </label>
       <element-citation id="sbref136" publication-type="journal">
        <person-group person-group-type="author">
         <collab>
          CDC
         </collab>
        </person-group>
        <article-title>
         Notice to readers: Updated recommendations of the Advisory Committee on Immunization Practices (ACIP) for the control and elimination of mumps
        </article-title>
        <source>
         MMWR Morbid Mortal Wkly Rep
        </source>
        <volume>
         55
        </volume>
        <issue>
         22
        </issue>
        <year>
         2006
        </year>
        <fpage>
         629
        </fpage>
        <lpage>
         630
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib152">
       <label>
        6
       </label>
       <element-citation id="sbref137" publication-type="journal">
        <person-group person-group-type="author">
         <collab>
          CDC
         </collab>
        </person-group>
        <article-title>
         Measles prevention: recommendations of the Immunization Practices Advisory Committee on Infectious Diseases (ACIP)
        </article-title>
        <source>
         MMWR Morbid Mortal Wkly Rep
        </source>
        <volume>
         38
        </volume>
        <issue>
         No. S-9
        </issue>
        <year>
         1989
        </year>
        <fpage>
         1
        </fpage>
        <lpage>
         18
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib153">
       <label>
        7
       </label>
       <element-citation id="sbref138" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Plotkin
          </surname>
          <given-names>
           SA
          </given-names>
         </name>
         <name>
          <surname>
           Rubin
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         Mumps Vaccine
        </chapter-title>
        <person-group person-group-type="editor">
         <name>
          <surname>
           Plotkin
          </surname>
          <given-names>
           SA
          </given-names>
         </name>
         <name>
          <surname>
           Orenstein
          </surname>
          <given-names>
           WA
          </given-names>
         </name>
         <name>
          <surname>
           Offit
          </surname>
          <given-names>
           PA
          </given-names>
         </name>
        </person-group>
        <source>
         Vaccines
        </source>
        <edition>
         5th ed.
        </edition>
        <year>
         2008
        </year>
        <publisher-name>
         Elsevier Saunders
        </publisher-name>
        <publisher-loc>
         Philadelphia
        </publisher-loc>
        <fpage>
         436
        </fpage>
        <lpage>
         465
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib154">
       <label>
        8
       </label>
       <element-citation id="sbref139" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Watson
          </surname>
          <given-names>
           JC
          </given-names>
         </name>
         <name>
          <surname>
           Hadler
          </surname>
          <given-names>
           SC
          </given-names>
         </name>
         <name>
          <surname>
           Dykewicz
          </surname>
          <given-names>
           CA
          </given-names>
         </name>
        </person-group>
        <article-title>
         CDC. Measles, mumps and rubella vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: recommendations of the Advisory Committee on Immunization Practices (ACIP)
        </article-title>
        <source>
         MMWR Morbid Mortal Wkly Rep
        </source>
        <volume>
         47
        </volume>
        <issue>
         RR-8
        </issue>
        <year>
         1998
        </year>
        <fpage>
         1
        </fpage>
        <lpage>
         57
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib155">
       <label>
        9
       </label>
       <mixed-citation id="ceotherref16" publication-type="other">
        Council of State and Territorial Epidemiologists. Infectious Disease Committee. Revision of the surveillance case definition for mumps. [cited 2008 Nov 25] Available from:
        <ext-link ext-link-type="uri" id="interref50" xlink:href="http://www.cste.org/PS/2007ps/2007psfinal/ID/07-ID-02.pdf">
         http://www.cste.org/PS/2007ps/2007psfinal/ID/07-ID-02.pdf
        </ext-link>
        .
       </mixed-citation>
      </ref>
      <ref id="bib156">
       <label>
        10
       </label>
       <element-citation id="sbref140" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Harling
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           White
          </surname>
          <given-names>
           JM
          </given-names>
         </name>
         <name>
          <surname>
           Ramsay
          </surname>
          <given-names>
           ME
          </given-names>
         </name>
        </person-group>
        <article-title>
         The effectiveness of the mumps component of the MMR vaccine: a case control study
        </article-title>
        <source>
         Vaccine
        </source>
        <volume>
         23
        </volume>
        <issue>
         31
        </issue>
        <year>
         2005
        </year>
        <fpage>
         4070
        </fpage>
        <lpage>
         4074
        </lpage>
        <pub-id pub-id-type="pmid">
         15950329
        </pub-id>
       </element-citation>
      </ref>
     </ref-list>
    </sec>
    <sec id="subchapter15">
     <sec-meta>
      <contrib-group>
       <contrib contrib-type="author" id="au27">
        <name>
         <surname>
          Skoff
         </surname>
         <given-names>
          Tami H.
         </given-names>
        </name>
       </contrib>
       <contrib contrib-type="author" id="au28">
        <name>
         <surname>
          Thomas
         </surname>
         <given-names>
          Cynthia G.
         </given-names>
        </name>
       </contrib>
      </contrib-group>
     </sec-meta>
     <title>
      PERTUSSIS
     </title>
     <sec id="cesec201">
      <title>
       Infectious Agent
      </title>
      <p id="para984">
       Pertussis is caused by fastidious gram-negative coccobacillus,
       <italic>
        Bordetella pertussis.
       </italic>
      </p>
     </sec>
     <sec id="cesec202">
      <title>
       Mode of Transmission
      </title>
      <p id="para985">
       It is spread by person-to-person transmission via aerosolized respiratory droplets or by direct contact with respiratory secretions.
      </p>
     </sec>
     <sec id="cesec203">
      <title>
       Occurrence
      </title>
      <p id="para986">
       <list id="celist212" list-type="simple">
        <list-item id="celistitem767">
         <label>
          •
         </label>
         <p id="para987">
          <italic>
           B. pertussis
          </italic>
          circulates worldwide, but disease rates are highest among young children in countries where vaccination coverage is low, which is primarily in the developing world.
         </p>
        </list-item>
        <list-item id="celistitem768">
         <label>
          •
         </label>
         <p id="para988">
          In developed countries, the incidence of pertussis is highest among unvaccinated infants and increases again among adolescents.
         </p>
        </list-item>
        <list-item id="celistitem769">
         <label>
          •
         </label>
         <p id="para989">
          Immunity from childhood vaccination and natural disease wanes with time; therefore, adolescents and adults who have not received a Tdap booster vaccination can become infected or re-infected.
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <sec id="cesec204">
      <title>
       Risk for Travelers
      </title>
      <p id="para990">
       <list id="celist213" list-type="simple">
        <list-item id="celistitem770">
         <label>
          •
         </label>
         <p id="para991">
          Pertussis remains endemic worldwide, even in areas with high vaccination rates.
         </p>
        </list-item>
        <list-item id="celistitem771">
         <label>
          •
         </label>
         <p id="para992">
          Travelers who come in close contact with infected persons are at risk for disease. Infants too young to be protected by a complete vaccination series are at greatest risk for severe pertussis requiring hospitalization.
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <sec id="cesec205">
      <title>
       Clinical Presentation
      </title>
      <p id="para993">
       <list id="celist214" list-type="simple">
        <list-item id="celistitem772">
         <label>
          •
         </label>
         <p id="para994">
          In classic disease, mild upper respiratory tract symptoms begin 7–10 days (range 6–21 days) after exposure, followed by a cough that becomes paroxysmal. Coughing paroxysms may be frequent or relatively infrequent and are often followed by vomiting. Fever is absent or minimal. The CDC/Council of State and Territorial Epidemiologists' clinical case definition for pertussis includes cough for Δ2 weeks with paroxysms, whoop, and/or post-tussive vomiting.
         </p>
        </list-item>
        <list-item id="celistitem773">
         <label>
          •
         </label>
         <p id="para995">
          Disease in infants &lt;6 months of age can be atypical with a short catarrhal stage, gagging, gasping, or apnea as early manifestations; among infants &lt;2 months of age, the case–fatality rate is approximately 1%.
         </p>
        </list-item>
        <list-item id="celistitem774">
         <label>
          •
         </label>
         <p id="para996">
          Recently immunized children may have mild cough illness; older children and adults may have prolonged cough with or without paroxysms. The cough gradually wanes over several weeks to months.
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <sec id="cesec206">
      <title>
       Diagnosis
      </title>
      <p id="para997">
       <list id="celist215" list-type="simple">
        <list-item id="celistitem775">
         <label>
          •
         </label>
         <p id="para998">
          Factors such as prior vaccination status, stage of disease, antibiotic use, specimen collection and transport conditions, and nonstandardized tests may affect the sensitivity, specificity, and interpretation of available diagnostic tests for
          <italic>
           B. pertussis
          </italic>
          .
         </p>
        </list-item>
        <list-item id="celistitem776">
         <label>
          •
         </label>
         <p id="para999">
          Current CDC guidelines for the laboratory confirmation of pertussis cases include culture and PCR (when the above clinical case definition is met); serology and direct fluorescent antibody (DFA) tests are not confirmatory tests included in the case definition.
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <sec id="cesec207">
      <title>
       Treatment
      </title>
      <p id="para1000">
       <list id="celist216" list-type="simple">
        <list-item id="celistitem777">
         <label>
          •
         </label>
         <p id="para1001">
          Macrolide antibiotics (azithromycin, clarithromycin, and erythromycin) are recommended for the treatment of pertussis in persons Δ1 month of age; for infants &lt;1 month of age, azithromycin is the preferred antibiotic.
         </p>
        </list-item>
        <list-item id="celistitem778">
         <label>
          •
         </label>
         <p id="para1002">
          Antimicrobial therapy with a macrolide antibiotic administered &lt;3 weeks after cough onset can limit transmission to others.
         </p>
        </list-item>
        <list-item id="celistitem779">
         <label>
          •
         </label>
         <p id="para1003">
          Postexposure prophylaxis is recommended for close contacts of cases and for individuals at high risk of developing severe disease. The recommended agents and dosing regimens for prophylaxis are the same as those indicated for the treatment of pertussis.
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <sec id="cesec208">
      <title>
       Preventive Measures for Travelers
      </title>
      <sec id="cesec209">
       <title>
        Vaccine
       </title>
       <p id="para1004">
        <list id="celist217" list-type="simple">
         <list-item id="celistitem780">
          <label>
           •
          </label>
          <p id="para1005">
           Travelers should be up to date with pertussis vaccinations prior to departure.
          </p>
         </list-item>
         <list-item id="celistitem781">
          <label>
           •
          </label>
          <p id="para1006">
           Complete vaccination of children &lt;7 years of age with five doses of acellular pertussis vaccine in combination with diphtheria and tetanus toxoids (DTaP) is recommended; an accelerated schedule of doses may be used to complete the DTaP series.
          </p>
         </list-item>
         <list-item id="celistitem782">
          <label>
           •
          </label>
          <p id="para1007">
           There is no pertussis-containing vaccine licensed for children 7–9 years of age. If a child turns 10 years old during the vaccination series with Td (tetanus and diphtheria toxoids vaccine), a single dose of Tdap may be substituted for one of the Td doses.
          </p>
         </list-item>
         <list-item id="celistitem783">
          <label>
           •
          </label>
          <p id="para1008">
           Adolescents aged 11–18 years should receive a single dose of Tdap instead of Td for booster immunization against tetanus, diphtheria, and pertussis if they have completed the recommended childhood DTwP/DTaP vaccination series. Adolescents who received their last Td (tetanus and diphtheria toxoids vaccine) 5 years or more previously should also receive a single dose of Tdap.
          </p>
         </list-item>
         <list-item id="celistitem784">
          <label>
           •
          </label>
          <p id="para1009">
           Adults 19–64 years of age should receive a single dose of Tdap to replace a single dose of Td for booster immunization against tetanus, diphtheria, and pertussis if their last tetanus toxoid-containing vaccine (e.g., Td) was administered 10 years or more prior. Tdap is not licensed for adults 65 years of age or older.
          </p>
         </list-item>
         <list-item id="celistitem785">
          <label>
           •
          </label>
          <p id="para1010">
           Tdap can be given in intervals &lt;10 years from the last Td to provide pertussis protection prior to travel, except in those individuals with a contraindication to vaccination.
          </p>
         </list-item>
         <list-item id="celistitem786">
          <label>
           •
          </label>
          <p id="para1011">
           Adolescents and adults who have never been immunized against pertussis, tetanus, or diphtheria, have incomplete immunization, or whose immunity is uncertain should follow the catch-up schedule established for Td/Tdap. Tdap can be substituted for any one of the Td doses in the series.
          </p>
         </list-item>
        </list>
       </p>
      </sec>
     </sec>
     <ref-list id="cebib15">
      <title>
       References
      </title>
      <ref id="bib157">
       <label>
        1
       </label>
       <element-citation id="sbref141" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Edwards
          </surname>
          <given-names>
           KM
          </given-names>
         </name>
         <name>
          <surname>
           Decker
          </surname>
          <given-names>
           MD
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         Pertussis vaccines
        </chapter-title>
        <person-group person-group-type="editor">
         <name>
          <surname>
           Plotkin
          </surname>
          <given-names>
           SA
          </given-names>
         </name>
         <name>
          <surname>
           Orenstein
          </surname>
          <given-names>
           WA
          </given-names>
         </name>
        </person-group>
        <source>
         Vaccines
        </source>
        <edition>
         4th ed.
        </edition>
        <year>
         2004
        </year>
        <publisher-name>
         W.B. Saunders
        </publisher-name>
        <publisher-loc>
         Philadelphia
        </publisher-loc>
        <fpage>
         471
        </fpage>
        <lpage>
         528
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib158">
       <label>
        2
       </label>
       <element-citation id="sbref142" publication-type="journal">
        <person-group person-group-type="author">
         <collab>
          CDC
         </collab>
        </person-group>
        <article-title>
         Preventing tetanus, diphtheria, and pertussis among adolescents: Use of tetanus toxoid, reduced diptheria toxoid and acellular pertussis vaccines. Recommendations of the Advisory Committee on Immunization Practices (ACIP)
        </article-title>
        <source>
         MMWR Recomm Rep
        </source>
        <volume>
         55
        </volume>
        <issue>
         RR-17
        </issue>
        <year>
         2006
        </year>
        <fpage>
         1
        </fpage>
        <lpage>
         37
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib159">
       <label>
        3
       </label>
       <mixed-citation id="ceotherref17" publication-type="other">
        American Academy of Pediatrics. Pertussis. In: Pickering LK, Baker CJ, Long SS, McMillan JA, editors. Red book: 2006 report of the Committee on Infectious Diseases. 27th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2006. p. 498–520.
       </mixed-citation>
      </ref>
      <ref id="bib160">
       <label>
        4
       </label>
       <element-citation id="sbref143" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tiwari
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Murphy
          </surname>
          <given-names>
           TV
          </given-names>
         </name>
         <name>
          <surname>
           Moran
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        <article-title>
         Recommended antimicrobial agents for the treatment and postexposure prophylaxis of pertussis: 2005 CDC guidelines
        </article-title>
        <source>
         MMWR Recomm Rep
        </source>
        <volume>
         54
        </volume>
        <issue>
         RR-14
        </issue>
        <year>
         2005
        </year>
        <fpage>
         1
        </fpage>
        <lpage>
         16
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib161">
       <label>
        5
       </label>
       <element-citation id="sbref144" publication-type="journal">
        <person-group person-group-type="author">
         <collab>
          CDC
         </collab>
        </person-group>
        <article-title>
         Pertussis vaccination: Use of acellular pertussis vaccines among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP)
        </article-title>
        <source>
         MMWR Recomm Rep
        </source>
        <volume>
         46
        </volume>
        <issue>
         RR-7
        </issue>
        <year>
         1997
        </year>
        <fpage>
         1
        </fpage>
        <lpage>
         25
        </lpage>
       </element-citation>
      </ref>
     </ref-list>
    </sec>
    <sec id="subchapter16">
     <sec-meta>
      <contrib-group>
       <contrib contrib-type="author" id="au29">
        <name>
         <surname>
          Nuorti
         </surname>
         <given-names>
          J. Pekka
         </given-names>
        </name>
       </contrib>
      </contrib-group>
     </sec-meta>
     <title>
      PNEUMOCOCCAL DISEASE (
      <italic>
       STREPTOCOCCUS PNEUMONIAE
      </italic>
      )
     </title>
     <sec id="cesec210">
      <title>
       Infectious Agent
      </title>
      <p id="para1012">
       <list id="celist218" list-type="simple">
        <list-item id="celistitem787">
         <label>
          •
         </label>
         <p id="para1013">
          <italic>
           Streptococcus pneumoniae
          </italic>
          (pneumococcus) is a bacterium that frequently colonizes the nasopharynx of healthy persons, particularly young children, without causing illness.
         </p>
        </list-item>
        <list-item id="celistitem788">
         <label>
          •
         </label>
         <p id="para1014">
          There are 91 known pneumococcal serotypes.
         </p>
        </list-item>
        <list-item id="celistitem789">
         <label>
          •
         </label>
         <p id="para1015">
          The major clinical syndromes include life-threatening infections such as meningitis, bacteremia, and pneumonia.
         </p>
        </list-item>
        <list-item id="celistitem790">
         <label>
          •
         </label>
         <p id="para1016">
          Pneumococcus is the most commonly identified cause of community-acquired pneumonia. It is also a major cause of milder but more common illnesses, such as sinusitis and otitis media.
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <sec id="cesec211">
      <title>
       Mode of Transmission
      </title>
      <p id="para1017">
       <list id="celist219" list-type="simple">
        <list-item id="celistitem791">
         <label>
          •
         </label>
         <p id="para1018">
          Direct person-to-person transmission is through close contact via respiratory droplets.
         </p>
        </list-item>
        <list-item id="celistitem792">
         <label>
          •
         </label>
         <p id="para1019">
          Transmission is thought to be common, but clinical illness occurs infrequently among casual contacts.
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <sec id="cesec212">
      <title>
       Occurrence
      </title>
      <p id="para1020">
       <list id="celist220" list-type="simple">
        <list-item id="celistitem793">
         <label>
          •
         </label>
         <p id="para1021">
          Pneumococcal disease occurs worldwide, and the reported incidence varies by geographic region.
         </p>
        </list-item>
        <list-item id="celistitem794">
         <label>
          •
         </label>
         <p id="para1022">
          Rates are higher in developing countries than in industrialized countries.
         </p>
        </list-item>
        <list-item id="celistitem795">
         <label>
          •
         </label>
         <p id="para1023">
          Pneumococcal disease is more common during winter and early spring, when respiratory viruses such as influenza are circulating. Most illnesses are sporadic.
         </p>
        </list-item>
        <list-item id="celistitem796">
         <label>
          •
         </label>
         <p id="para1024">
          Outbreaks of pneumococcal disease are uncommon but may occur in closed populations such as nursing homes, childcare centers or other institutions.
         </p>
        </list-item>
        <list-item id="celistitem797">
         <label>
          •
         </label>
         <p id="para1025">
          In the United States, most deaths from pneumococcal disease occur in older adults, although in developing countries, many children die of pneumococcal pneumonia.
         </p>
        </list-item>
        <list-item id="celistitem798">
         <label>
          •
         </label>
         <p id="para1026">
          Routine use of the 7-valent pneumococcal conjugate vaccine (PCV7) in the United States since 2000 has dramatically reduced the incidence of pneumococcal disease in both children and adults. Because the vaccine interrupts transmission of vaccine-type pneumococci, rates of pneumococcal disease in unvaccinated older children and adults have also decreased.
         </p>
        </list-item>
        <list-item id="celistitem799">
         <label>
          •
         </label>
         <p id="para1027">
          As of 2008, 18 industrialized countries are routinely using pneumococcal conjugate vaccines, including Canada, Australia, the United Kingdom, and other Western European and Middle Eastern countries.
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <sec id="cesec213">
      <title>
       Risk for Travelers
      </title>
      <p id="para1028">
       <list id="celist221" list-type="simple">
        <list-item id="celistitem800">
         <label>
          •
         </label>
         <p id="para1029">
          The risk for pneumococcal disease is generally highest among young children, the elderly, and persons of any age who have chronic medical conditions, such as heart disease, lung disease, diabetes or asplenia, or conditions that suppress the immune system, such as HIV.
         </p>
        </list-item>
        <list-item id="celistitem801">
         <label>
          •
         </label>
         <p id="para1030">
          Cigarette smokers are also at increased risk.
         </p>
        </list-item>
        <list-item id="celistitem802">
         <label>
          •
         </label>
         <p id="para1031">
          Most travelers, however, are not in these categories. It is important to recognize that healthy travelers in their twenties or thirties have developed pneumococcal pneumonia while traveling in developing countries.
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <sec id="cesec214">
      <title>
       Clinical Presentation
      </title>
      <p id="para1032">
       <list id="celist222" list-type="simple">
        <list-item id="celistitem803">
         <label>
          •
         </label>
         <p id="para1033">
          Sudden onset with fever and malaise are typical symptoms for all forms of pneumococcal infections and may be the only symptoms in young children with bacteremia.
         </p>
        </list-item>
        <list-item id="celistitem804">
         <label>
          •
         </label>
         <p id="para1034">
          In pneumococcal pneumonia, fever may precede the usual symptoms of cough, pleuritic chest pain, and the production of purulent or blood-tinged sputum.
         </p>
        </list-item>
        <list-item id="celistitem805">
         <label>
          •
         </label>
         <p id="para1035">
          In elderly persons, the onset of pneumococcal pneumonia may be less abrupt, with fever, shortness of breath, or altered mental status as the initial symptoms; sputum production may be absent.
         </p>
        </list-item>
        <list-item id="celistitem806">
         <label>
          •
         </label>
         <p id="para1036">
          Pneumococcal meningitis may present with a stiff neck, headache, lethargy, or seizures; otitis media or sinusitis typically cause pain in the ears or sinuses.
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <sec id="cesec215">
      <title>
       Diagnosis
      </title>
      <p id="para1037">
       <list id="celist223" list-type="simple">
        <list-item id="celistitem807">
         <label>
          •
         </label>
         <p id="para1038">
          A definitive diagnosis of pneumococcal infection can be made by isolation of the bacterium from blood or other normally sterile body sites, such as cerebrospinal fluid. Most patients with pneumococcal pneumonia, however, do not have detectable bacteremia.
         </p>
        </list-item>
        <list-item id="celistitem808">
         <label>
          •
         </label>
         <p id="para1039">
          The diagnosis of pneumococcal pneumonia can be suspected if on microscopy a sputum specimen contains many gram-stain positive diplococci and polymorphonuclear leukocytes and very few epithelial cells.
         </p>
        </list-item>
        <list-item id="celistitem809">
         <label>
          •
         </label>
         <p id="para1040">
          Typical chest radiography may show lobar, segmental, or multilobar consolidation.
         </p>
        </list-item>
        <list-item id="celistitem810">
         <label>
          •
         </label>
         <p id="para1041">
          Pneumococcal pneumonia is usually, but not always, associated with a high white blood cell count. High white blood cell counts should raise suspicion for this diagnosis, since other serious travel-related diseases causing fever, such as hepatitis, typhoid fever, malaria, dengue fever, or typhus, all have normal or low white blood cell counts.
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <sec id="cesec216">
      <title>
       Treatment
      </title>
      <p id="para1042">
       <list id="celist224" list-type="simple">
        <list-item id="celistitem811">
         <label>
          •
         </label>
         <p id="para1043">
          All types of pneumococcal infections are usually treated with antibiotics.
         </p>
        </list-item>
        <list-item id="celistitem812">
         <label>
          •
         </label>
         <p id="para1044">
          Worldwide, many strains are increasingly resistant to penicillin, cephalosporin, and macrolides, and some are resistant to multiple classes of drugs, complicating treatment choices. Antimicrobial susceptibility of strains isolated from blood and cerebrospinal fluid should be determined, and treatment should be targeted based on the susceptibility results.
         </p>
        </list-item>
        <list-item id="celistitem813">
         <label>
          •
         </label>
         <p id="para1045">
          In 2008, the Clinical and Laboratory Standards Institute adopted new susceptibility breakpoints for penicillin treatment of nonmeningitis cases of pneumococcal disease. However, empiric antibiotic therapy should not be delayed and should begin before microbiological confirmation of etiology.
         </p>
        </list-item>
        <list-item id="celistitem814">
         <label>
          •
         </label>
         <p id="para1046">
          In the United States and other countries where beta-lactam resistance among pneumococcal isolates is common, the initial regimen for suspected pneumococcal meningitis should include vancomycin until the antimicrobial susceptibility pattern of the organism is available.
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <sec id="cesec217">
      <title>
       Preventive Measures for Travelers
      </title>
      <sec id="cesec218">
       <title>
        Vaccine
       </title>
       <p id="para1047">
        <list id="celist225" list-type="simple">
         <list-item id="celistitem815">
          <label>
           •
          </label>
          <p id="para1048">
           No specific recommendations for the use of pneumococcal vaccines in travelers have been formulated.
          </p>
         </list-item>
         <list-item id="celistitem816">
          <label>
           •
          </label>
          <p id="para1049">
           Currently, two vaccines are available for prevention of pneumococcal disease in the United States.
           <list id="celist226" list-type="simple">
            <list-item id="celistitem817">
             <label>
              ○
             </label>
             <p id="para1050">
              <bold>
               <italic>
                Pneumococcal conjugate vaccine
               </italic>
              </bold>
              —The 7-valent pneumococcal conjugate vaccine (PCV7) (Prevnar, Wyeth Vaccines) is mainly used in children. It is part of the routine infant immunization schedule in the United States and is now recommended for all children &lt;5 years of age (see the Vaccine Recommendations for Infants and Children section in Chapter 7). The infant schedule consists of a three-dose primary series at ages 2, 4, and 6 months and a booster dose at 12–15 months of age. Fewer doses are required for children who begin the series after 7 months of age.
             </p>
            </list-item>
            <list-item id="celistitem818">
             <label>
              ○
             </label>
             <p id="para1051">
              <bold>
               <italic>
                Pneumococcal polysaccharaide vaccine
               </italic>
              </bold>
              —A 23-valent pneumococcal polysaccharide vaccine (PPV23) (Pneumovax, Merck) is mainly used in older adults and persons with underlying medical conditions. PPV23 is recommended for all adults Δ65 years of age and for persons 2–64 years of age with underlying medical conditions at the time the condition is recognized. In 2006, only about 57% of adults aged Δ65 years of age had received the vaccine. Children 2–4 years of age who have underlying medical conditions that are indications for PPV23 should also receive polysaccharide vaccine after receiving the conjugate vaccine series.
             </p>
            </list-item>
           </list>
          </p>
         </list-item>
         <list-item id="celistitem819">
          <label>
           •
          </label>
          <p id="para1052">
           Both vaccines induce antibodies to the specific types of pneumococcal capsule and have been shown to be effective against invasive disease.
          </p>
         </list-item>
         <list-item id="celistitem820">
          <label>
           •
          </label>
          <p id="para1053">
           Additional pneumococcal conjugate vaccine formulations are expected to be licensed soon. The WHO recommends that inclusion of pneumococcal conjugate vaccines in all national immunization programs should be a priority.
          </p>
         </list-item>
         <list-item id="celistitem821">
          <label>
           •
          </label>
          <p id="para1054">
           Routine revaccination is not recommended for most people. A second dose of PPV23 is recommended 5 years after the first dose for the following groups:
           <list id="celist227" list-type="simple">
            <list-item id="celistitem822">
             <label>
              ○
             </label>
             <p id="para1055">
              Persons with sickle cell disease, asplenia, renal disease, hematologic or generalized malignancy, or other immunocompromising condition
             </p>
            </list-item>
            <list-item id="celistitem823">
             <label>
              ○
             </label>
             <p id="para1056">
              Persons Δ65 years of age who received PPV23 before age 65 years for an underlying medical condition, if at least 5 years have passed since their previous dose
             </p>
            </list-item>
           </list>
          </p>
         </list-item>
         <list-item id="celistitem824">
          <label>
           •
          </label>
          <p id="para1057">
           Because of limited data regarding the duration of protection provided by PPV23 and the safety of multiple doses, only a single revaccination is recommended. Persons should receive one dose if they have an indication for polysaccharide vaccine and their vaccination history is unknown.
          </p>
         </list-item>
        </list>
       </p>
       <sec id="cesec219">
        <title>
         Safety and Side Effects
        </title>
        <p id="para1058">
         <list id="celist228" list-type="simple">
          <list-item id="celistitem825">
           <label>
            •
           </label>
           <p id="para1059">
            After receipt of PCV7, mild local reactions, such as redness, swelling, or tenderness, occur in 10%–23% of infants. Larger areas of redness or swelling or limitations in arm movement may occur in 1%–9% of infants. Low-grade fever can occur in up to 24% and fever higher than 102.2° F may occur in up to 2.5% of vaccinees.
           </p>
          </list-item>
          <list-item id="celistitem826">
           <label>
            •
           </label>
           <p id="para1060">
            After receipt of PPV23, self-limiting local side effects occur in approximately half of vaccine recipients and are more common after revaccination than with first dose. These reactions usually resolve within 48 hours. More severe local reactions and systemic symptoms, including myalgias and fever, are rare.
           </p>
          </list-item>
         </list>
        </p>
       </sec>
       <sec id="cesec220">
        <title>
         Precautions and Contraindications
        </title>
        <p id="para1061">
         <list id="celist229" list-type="simple">
          <list-item id="celistitem827">
           <label>
            •
           </label>
           <p id="para1062">
            PCV7 is contraindicated for children known to have hypersensitivity to any component of the vaccine.
           </p>
          </list-item>
          <list-item id="celistitem828">
           <label>
            •
           </label>
           <p id="para1063">
            Health-care providers may delay vaccination of children with moderate or severe illness until the child has recovered, although minor illnesses, such as mild upper-respiratory tract infection with or without low-grade fever, are not contraindications.
           </p>
          </list-item>
          <list-item id="celistitem829">
           <label>
            •
           </label>
           <p id="para1064">
            Revaccination with PPV23 is contraindicated for persons who had a severe reaction (e.g., anaphylactic reaction or localized arthus-type reaction) to the initial dose.
           </p>
          </list-item>
         </list>
        </p>
       </sec>
      </sec>
      <sec id="cesec221">
       <title>
        Additional Preventive Measures
       </title>
       <p id="para1065">
        <list id="celist230" list-type="simple">
         <list-item id="celistitem830">
          <label>
           •
          </label>
          <p id="para1066">
           The following may reduce the risk of pneumococcal disease:
           <list id="celist231" list-type="simple">
            <list-item id="celistitem831">
             <label>
              ○
             </label>
             <p id="para1067">
              improving control of chronic conditions that predispose to pneumococcal disease, such as diabetes and HIV,
             </p>
            </list-item>
            <list-item id="celistitem832">
             <label>
              ○
             </label>
             <p id="para1068">
              stopping smoking, and
             </p>
            </list-item>
            <list-item id="celistitem833">
             <label>
              ○
             </label>
             <p id="para1069">
              avoiding crowded living conditions.
             </p>
            </list-item>
           </list>
          </p>
         </list-item>
         <list-item id="celistitem834">
          <label>
           •
          </label>
          <p id="para1070">
           Chemoprophylaxis is not routinely recommended for close contacts of pneumococcal meningitis or other cases of invasive disease or for travelers unless otherwise recommended by the health-care practitioner supervising their care.
          </p>
         </list-item>
        </list>
       </p>
      </sec>
     </sec>
     <ref-list id="cebib16">
      <title>
       References
      </title>
      <ref id="bib162">
       <label>
        1
       </label>
       <element-citation id="sbref145" publication-type="journal">
        <person-group person-group-type="author">
         <collab>
          CDC
         </collab>
        </person-group>
        <article-title>
         Prevention of pneumococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP)
        </article-title>
        <source>
         MMWR Morbid Mortal Wkly Rep
        </source>
        <volume>
         46
        </volume>
        <issue>
         RR-8
        </issue>
        <year>
         1997
        </year>
        <fpage>
         1
        </fpage>
        <lpage>
         24
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib163">
       <label>
        2
       </label>
       <element-citation id="sbref146" publication-type="journal">
        <person-group person-group-type="author">
         <collab>
          CDC
         </collab>
        </person-group>
        <article-title>
         Preventing pneumococcal disease among infants and young children: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
        </article-title>
        <source>
         MMWR Recomm Rep
        </source>
        <volume>
         49
        </volume>
        <issue>
         No. RR-9
        </issue>
        <year>
         2000
        </year>
        <fpage>
         1
        </fpage>
        <lpage>
         38
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib164">
       <label>
        3
       </label>
       <mixed-citation id="ceotherref18" publication-type="other">
        American Academy of Pediatrics. Pneumococcal infections. In: Pickering LK, Baker CJ, Long SS, McMillan JA, editors. Red book: 2006 Report of the Committee on Infectious Diseases. Elk Grove Village, IL: American Academy of Pediatrics; 2006. p. 525–37.
       </mixed-citation>
      </ref>
      <ref id="bib165">
       <label>
        4
       </label>
       <element-citation id="sbref147" publication-type="journal">
        <person-group person-group-type="author">
         <collab>
          CDC
         </collab>
        </person-group>
        <article-title>
         Invasive pneumococcal disease in children 5 years after routine conjugate vaccine introduction—eight states, 1998–2005
        </article-title>
        <source>
         MMWR Morb Mortal Wkly Rep
        </source>
        <volume>
         57
        </volume>
        <issue>
         6
        </issue>
        <year>
         2008
        </year>
        <fpage>
         144
        </fpage>
        <lpage>
         148
        </lpage>
        <pub-id pub-id-type="pmid">
         18272956
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib166">
       <label>
        5
       </label>
       <element-citation id="sbref148" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Fedson
          </surname>
          <given-names>
           DS
          </given-names>
         </name>
         <name>
          <surname>
           Scott
          </surname>
          <given-names>
           JA G
          </given-names>
         </name>
        </person-group>
        <article-title>
         The burden of pneumococcal disease among adults in developed and developing countries: what is and is not known
        </article-title>
        <source>
         Vaccine
        </source>
        <volume>
         17
        </volume>
        <issue>
         Supplement 1
        </issue>
        <year>
         1999
        </year>
        <fpage>
         S11
        </fpage>
        <lpage>
         S18
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib167">
       <label>
        6
       </label>
       <element-citation id="sbref149" publication-type="journal">
        <person-group person-group-type="author">
         <collab>
          W.H.O.
         </collab>
        </person-group>
        <article-title>
         Pneumococcal conjugate vaccine for childhood immunisation—WHO position paper
        </article-title>
        <source>
         Wkly Epidemiol Rec
        </source>
        <volume>
         82
        </volume>
        <issue>
         12
        </issue>
        <year>
         2007
        </year>
        <fpage>
         93
        </fpage>
        <lpage>
         104
        </lpage>
        <pub-id pub-id-type="pmid">
         17380597
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib168">
       <label>
        7
       </label>
       <element-citation id="sbref150" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Whitney
          </surname>
          <given-names>
           CG
          </given-names>
         </name>
         <name>
          <surname>
           Farley
          </surname>
          <given-names>
           MM
          </given-names>
         </name>
         <name>
          <surname>
           Hadler
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        <article-title>
         Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine
        </article-title>
        <source>
         N Engl J Med
        </source>
        <volume>
         348
        </volume>
        <issue>
         18
        </issue>
        <year>
         2003
        </year>
        <fpage>
         1737
        </fpage>
        <lpage>
         1746
        </lpage>
        <pub-id pub-id-type="pmid">
         12724479
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib169">
       <label>
        8
       </label>
       <element-citation id="sbref151" publication-type="journal">
        <comment>
        </comment>
        <person-group person-group-type="author">
         <name>
          <surname>
           Greenwood
          </surname>
          <given-names>
           B
          </given-names>
         </name>
        </person-group>
        <article-title>
         The epidemiology of pneumococcal infection in children in the developing world
        </article-title>
        <source>
         Phil Trans R Soc Lond B Biol Sci
        </source>
        <volume>
         354
        </volume>
        <issue>
         1384
        </issue>
        <year>
         1999
        </year>
        <fpage>
         777
        </fpage>
        <lpage>
         785
        </lpage>
        <pub-id pub-id-type="pmid">
         10365403
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib170">
       <label>
        9
       </label>
       <element-citation id="sbref152" publication-type="book">
        <person-group person-group-type="author">
         <collab>
          Clinical and Laboratory Standards Institute.
         </collab>
        </person-group>
        <source>
         Performance standards for antimicrobial susceptibility testing; eighteenth informational supplement
        </source>
        <year>
         2008
        </year>
        <publisher-name>
         Clinical and Laboratory Standards Institute
        </publisher-name>
        <publisher-loc>
         Wayne, PA
        </publisher-loc>
        <comment>
         CLSI Document M100-S18
        </comment>
       </element-citation>
      </ref>
      <ref id="bib171">
       <label>
        10
       </label>
       <element-citation id="sbref153" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tunkel
          </surname>
          <given-names>
           AR
          </given-names>
         </name>
         <name>
          <surname>
           Hartman
          </surname>
          <given-names>
           BJ
          </given-names>
         </name>
         <name>
          <surname>
           Kaplan
          </surname>
          <given-names>
           SL
          </given-names>
         </name>
        </person-group>
        <article-title>
         Practice guidelines for the management of bacterial meningitis
        </article-title>
        <source>
         Clin Infect Dis
        </source>
        <volume>
         39
        </volume>
        <issue>
         9
        </issue>
        <year>
         2004
        </year>
        <fpage>
         1267
        </fpage>
        <lpage>
         1284
        </lpage>
        <pub-id pub-id-type="pmid">
         15494903
        </pub-id>
       </element-citation>
      </ref>
     </ref-list>
    </sec>
    <sec id="subchapter17">
     <sec-meta>
      <contrib-group>
       <contrib contrib-type="author" id="au30">
        <name>
         <surname>
          Alexander
         </surname>
         <given-names>
          James P.
         </given-names>
        </name>
       </contrib>
       <contrib contrib-type="author" id="au31">
        <name>
         <surname>
          Wassilak
         </surname>
         <given-names>
          Steven
         </given-names>
        </name>
       </contrib>
      </contrib-group>
     </sec-meta>
     <title>
      POLIOMYELITIS
     </title>
     <sec id="cesec222">
      <title>
       Infectious Agent
      </title>
      <p id="para1071">
       <list id="celist232" list-type="simple">
        <list-item id="celistitem835">
         <label>
          •
         </label>
         <p id="para1072">
          The infectious agent is poliovirus (genus Enterovirus) types 1, 2, and 3.
         </p>
        </list-item>
        <list-item id="celistitem836">
         <label>
          •
         </label>
         <p id="para1073">
          Polioviruses are small (27–30 nm), nonenveloped viruses with capsids enclosing a single-stranded, positive-sense RNA genome about 7,500 nucleotides long.
         </p>
        </list-item>
        <list-item id="celistitem837">
         <label>
          •
         </label>
         <p id="para1074">
          Most of the properties of polioviruses are shared with the other enteroviruses.
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <sec id="cesec223">
      <title>
       Mode of Transmission
      </title>
      <p id="para1075">
       Fecal–oral or oral transmission. Acute infection involves the gastrointestinal tract and occasionally the central nervous system.
      </p>
     </sec>
     <sec id="cesec224">
      <title>
       Occurrence
      </title>
      <p id="para1076">
       <list id="celist233" list-type="simple">
        <list-item id="celistitem838">
         <label>
          •
         </label>
         <p id="para1077">
          In the prevaccine era, infection with poliovirus was common worldwide, with seasonal peaks and epidemics in the summer and fall in temperate areas.
         </p>
        </list-item>
        <list-item id="celistitem839">
         <label>
          •
         </label>
         <p id="para1078">
          The incidence of poliomyelitis in the United States declined rapidly after the licensure of inactivated polio vaccine (IPV) in 1955 and live oral polio vaccine (OPV) in the 1960s. The last cases of indigenously acquired polio in the United States occurred in 1979.
         </p>
        </list-item>
        <list-item id="celistitem840">
         <label>
          •
         </label>
         <p id="para1079">
          The Global Polio Eradication Initiative (GPEI) subsequently led to elimination of polio in the Americas, where the last wild poliovirus (WPV)-associated polio case was detected in 1991.
         </p>
        </list-item>
        <list-item id="celistitem841">
         <label>
          •
         </label>
         <p id="para1080">
          In 1999, a change in vaccination policy in the United States from use of OPV to exclusive use of IPV resulted in the elimination of the 8–10 vaccine-associated paralytic poliomyelitis (VAPP) cases that had occurred annually since the introduction of OPV in the 1960s.
         </p>
        </list-item>
        <list-item id="celistitem842">
         <label>
          •
         </label>
         <p id="para1081">
          In the United States, two events that occurred in 2005 highlighted the continuing but low risk for poliovirus infection for unvaccinated persons, whether residing in the United States or traveling.
          <list id="celist234" list-type="simple">
           <list-item id="celistitem843">
            <label>
             ○
            </label>
            <p id="para1082">
             A case of imported VAPP occurred in an unvaccinated U.S. adult who had traveled abroad, likely from contact with an infant recently vaccinated with OPV.
            </p>
           </list-item>
           <list-item id="celistitem844">
            <label>
             ○
            </label>
            <p id="para1083">
             An unvaccinated immunocompromised infant and four children in two other families in the same small rural community were found to be asymptomatically infected with a vaccine-derived poliovirus, presumably originating outside the United States in a country that uses OPV.
            </p>
           </list-item>
          </list>
         </p>
        </list-item>
        <list-item id="celistitem845">
         <label>
          •
         </label>
         <p id="para1084">
          The GPEI has built upon the success in the Americas and made great progress in eradicating wild polioviruses. There are only four countries where wild poliovirus circulation has never been interrupted: Afghanistan, India, Nigeria, and Pakistan. WPV type 2 has not been detected since October 1999.
         </p>
        </list-item>
        <list-item id="celistitem846">
         <label>
          •
         </label>
         <p id="para1085">
          During 2002–2006, 22 previously polio-free countries were affected by importations of WPV type 1 from the remaining polio-endemic countries, primarily Nigeria. In 2007–2008, polio cases occurred in 12 countries following importations of WPV originating from Nigeria or India.
         </p>
        </list-item>
        <list-item id="celistitem847">
         <label>
          •
         </label>
         <p id="para1086">
          In spite of recent WPV outbreaks and continued circulation in the four countries where WPV circulation has never been interrupted, the GPEI has reduced the number of reported polio cases worldwide by more than 99% since the mid-1980s. With intensified efforts, worldwide eradication of polio appears feasible in the future.
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <sec id="cesec225">
      <title>
       Risk for Travelers
      </title>
      <p id="para1087">
       <list id="celist235" list-type="simple">
        <list-item id="celistitem848">
         <label>
          •
         </label>
         <p id="para1088">
          Because of polio eradication efforts, the number of countries where travelers are at risk for polio has decreased dramatically.
         </p>
        </list-item>
        <list-item id="celistitem849">
         <label>
          •
         </label>
         <p id="para1089">
          At the time of publication, most of the world's population resides in areas considered free of WPV circulation, including the Western Hemisphere, the Western Pacific region (which encompasses China), and the European region.
         </p>
        </list-item>
        <list-item id="celistitem850">
         <label>
          •
         </label>
         <p id="para1090">
          Vaccination is recommended for all travelers to polio-endemic or epidemic areas, including countries with recent proven WPV circulation and neighboring countries. As of September 2008, these areas include some but not all countries in Africa, South Asia, Southeast Asia, and the Middle East. For current information on the status of polio eradication efforts and vaccine recommendations, consult the Travel Notices on the CDC Travelers' Health website (
          <ext-link ext-link-type="uri" id="interref51" xlink:href="http://www.cdc.gov/travel/">
           www.cdc.gov/travel/
          </ext-link>
          ) or the GPEI website (
          <ext-link ext-link-type="uri" id="interref52" xlink:href="http://www.polioeradication.org/">
           www.polioeradication.org/
          </ext-link>
          ).
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <sec id="cesec226">
      <title>
       Clinical Presentation
      </title>
      <p id="para1091">
       Clinical manifestations of poliovirus infection range from asymptomatic (most infections) to symptomatic, including acute flaccid paralysis of a single limb to quadriplegia, respiratory failure, and, rarely, death.
      </p>
     </sec>
     <sec id="cesec227">
      <title>
       Diagnosis
      </title>
      <p id="para1092">
       The diagnosis is made by the identification of poliovirus in clinical specimens (usually stool) obtained from an acutely ill patient. Poliovirus may be detected from stool specimens for up to 4 weeks after onset of illness.
      </p>
     </sec>
     <sec id="cesec228">
      <title>
       Treatment
      </title>
      <p id="para1093">
       Only symptomatic treatment is available, ranging from pain and fever relief to intubation and mechanical ventilation for those with respiratory insufficiency.
      </p>
     </sec>
     <sec id="cesec229">
      <title>
       Preventive Measures for Travelers
      </title>
      <p id="para1094">
       <list id="celist236" list-type="simple">
        <list-item id="celistitem851">
         <label>
          •
         </label>
         <p id="para1095">
          A person is considered to be fully immunized if he or she has received a primary series of at least three doses of IPV, three doses of OPV, or four doses of any combination of IPV and OPV.
         </p>
        </list-item>
        <list-item id="celistitem852">
         <label>
          •
         </label>
         <p id="para1096">
          To eliminate the risk for VAPP, OPV has not been recommended for routine immunization in the United States since January 1, 2000, and is no longer available in this country.
         </p>
        </list-item>
        <list-item id="celistitem853">
         <label>
          •
         </label>
         <p id="para1097">
          OPV continues to be used in the majority of countries and for global polio eradication activities.
         </p>
        </list-item>
       </list>
      </p>
      <sec id="cesec230">
       <title>
        Vaccine
       </title>
       <sec id="cesec231">
        <title>
         Infants and Children
        </title>
        <p id="para1098">
         <list id="celist237" list-type="simple">
          <list-item id="celistitem854">
           <label>
            •
           </label>
           <p id="para1099">
            Because OPV is no longer recommended for routine immunization in the United States, all infants and children should receive four doses of IPV at 2, 4, and 6–18 months and 4–6 years of age. The fourth (booster) dose is not needed if the third dose of the primary series is administered on or after the fourth birthday.
           </p>
          </list-item>
          <list-item id="celistitem855">
           <label>
            •
           </label>
           <p id="para1100">
            If accelerated protection is needed, the minimum interval between doses is 4 weeks, although the preferred interval between the second and third doses is 2 months.
           </p>
          </list-item>
          <list-item id="celistitem856">
           <label>
            •
           </label>
           <p id="para1101">
            The minimum age for IPV administration is 6 weeks. Infants and children who have initiated the poliovirus vaccination series with one or more doses of OPV should receive IPV to complete the series.
           </p>
          </list-item>
         </list>
        </p>
       </sec>
       <sec id="cesec232">
        <title>
         Adults
        </title>
        <p id="para1102">
         <list id="celist238" list-type="simple">
          <list-item id="celistitem857">
           <label>
            •
           </label>
           <p id="para1103">
            Adults who are traveling to areas where poliomyelitis cases are still occurring and who are unvaccinated, incompletely vaccinated, or whose vaccination status is unknown should receive two doses of IPV administered at an interval of 4–8 weeks; a third dose should be administered 6–12 months after the second.
           </p>
          </list-item>
          <list-item id="celistitem858">
           <label>
            •
           </label>
           <p id="para1104">
            If three doses of IPV cannot be administered within the recommended intervals before protection is needed, the following alternatives are recommended:
            <list id="celist239" list-type="simple">
             <list-item id="celistitem859">
              <label>
               ○
              </label>
              <p id="para1105">
               If &gt;8 weeks is available before protection is needed, three doses of IPV should be administered at least 4 weeks apart.
              </p>
             </list-item>
             <list-item id="celistitem860">
              <label>
               ○
              </label>
              <p id="para1106">
               If &lt;8 weeks but &gt;4 weeks is available before protection is needed, two doses of IPV should be administered at least 4 weeks apart.
              </p>
             </list-item>
             <list-item id="celistitem861">
              <label>
               ○
              </label>
              <p id="para1107">
               If &lt;4 weeks is available before protection is needed, a single dose of IPV is recommended.
              </p>
             </list-item>
            </list>
           </p>
          </list-item>
          <list-item id="celistitem862">
           <label>
            •
           </label>
           <p id="para1108">
            If fewer than three doses are administered, the remaining IPV doses to complete a three-dose series should be administered when feasible, at the intervals recommended above, if the person remains at increased risk for poliovirus exposure.
           </p>
          </list-item>
          <list-item id="celistitem863">
           <label>
            •
           </label>
           <p id="para1109">
            Adults (Δ18 years of age) who are traveling to areas where poliomyelitis cases are occurring and who have received a primary series with either IPV or OPV in childhood should receive another dose of IPV before departure.
           </p>
          </list-item>
          <list-item id="celistitem864">
           <label>
            •
           </label>
           <p id="para1110">
            For adults, available data do not indicate the need for more than a single lifetime booster dose with IPV.
           </p>
          </list-item>
         </list>
        </p>
       </sec>
       <sec id="cesec233">
        <title>
         Allergy to Vaccine
        </title>
        <p id="para1111">
         <list id="celist240" list-type="simple">
          <list-item id="celistitem865">
           <label>
            •
           </label>
           <p id="para1112">
            Minor local reactions (pain and redness) can occur following IPV. No serious adverse reactions to IPV have been documented.
           </p>
          </list-item>
          <list-item id="celistitem866">
           <label>
            •
           </label>
           <p id="para1113">
            IPV should not be administered to persons who have experienced a severe allergic (anaphylactic) reaction after a previous dose of IPV or after receiving streptomycin, polymyxin B, or neomycin which IPV contains in trace amounts; hypersensitivity reactions can occur following IPV among persons sensitive to these three antibiotics.
           </p>
          </list-item>
         </list>
        </p>
       </sec>
       <sec id="cesec234">
        <title>
         Pregnancy and Breastfeeding
        </title>
        <p id="para1114">
         <list id="celist241" list-type="simple">
          <list-item id="celistitem867">
           <label>
            •
           </label>
           <p id="para1115">
            If a pregnant woman is unvaccinated or incompletely vaccinated and requires immediate protection against polio because of planned travel to a country or area where polio cases are occurring, IPV can be administered as recommended for adults.
           </p>
          </list-item>
          <list-item id="celistitem868">
           <label>
            •
           </label>
           <p id="para1116">
            Breastfeeding is not a contraindication to immunization of an infant or mother against polio.
           </p>
          </list-item>
         </list>
        </p>
       </sec>
       <sec id="cesec235">
        <title>
         Precautions and Contraindications
        </title>
        <p id="para1117">
         <list id="celist242" list-type="simple">
          <list-item id="celistitem869">
           <label>
            •
           </label>
           <p id="para1118">
            IPV may be administered to persons with diarrhea.
           </p>
          </list-item>
          <list-item id="celistitem870">
           <label>
            •
           </label>
           <p id="para1119">
            Minor upper respiratory illnesses with or without fever, mild to moderate local reactions to a previous dose of IPV, current antimicrobial therapy, and the convalescent phase of acute illness are not contraindications for vaccination.
           </p>
          </list-item>
         </list>
        </p>
       </sec>
       <sec id="cesec236">
        <title>
         Immunosuppression
        </title>
        <p id="para1120">
         <list id="celist243" list-type="simple">
          <list-item id="celistitem871">
           <label>
            •
           </label>
           <p id="para1121">
            IPV may be administered safely to immunodeficient travelers and their household contacts. Although a protective immune response cannot be ensured, IPV might confer some protection to the immunodeficient person.
           </p>
          </list-item>
          <list-item id="celistitem872">
           <label>
            •
           </label>
           <p id="para1122">
            Persons with certain primary immunodeficiency diseases should avoid contact with excreted OPV virus (e.g., exposure to a child vaccinated with OPV within the previous 6 weeks); however, this situation no longer occurs in the United States unless a child receives OPV overseas.
           </p>
          </list-item>
         </list>
        </p>
       </sec>
      </sec>
     </sec>
     <ref-list id="cebib17">
      <title>
       References
      </title>
      <ref id="bib172">
       <label>
        1
       </label>
       <element-citation id="sbref154" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sutter
          </surname>
          <given-names>
           RW
          </given-names>
         </name>
         <name>
          <surname>
           Kew
          </surname>
          <given-names>
           OM
          </given-names>
         </name>
         <name>
          <surname>
           Cochi
          </surname>
          <given-names>
           SL
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         Poliovirus vaccine—live
        </chapter-title>
        <person-group person-group-type="editor">
         <name>
          <surname>
           Plotkin
          </surname>
          <given-names>
           SA
          </given-names>
         </name>
         <name>
          <surname>
           Orenstein
          </surname>
          <given-names>
           WA
          </given-names>
         </name>
         <name>
          <surname>
           Offit
          </surname>
          <given-names>
           PA
          </given-names>
         </name>
        </person-group>
        <source>
         Vaccines
        </source>
        <edition>
         5th ed.
        </edition>
        <year>
         2008
        </year>
        <publisher-name>
         Saunders Elsevier
        </publisher-name>
        <publisher-loc>
         Philadelphia
        </publisher-loc>
        <fpage>
         631
        </fpage>
        <lpage>
         686
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib173">
       <label>
        2
       </label>
       <element-citation id="sbref155" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Plotkin
          </surname>
          <given-names>
           SA
          </given-names>
         </name>
         <name>
          <surname>
           Vidor
          </surname>
          <given-names>
           E
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         Poliovirus Vaccine—Inactivated
        </chapter-title>
        <person-group person-group-type="editor">
         <name>
          <surname>
           Plotkin
          </surname>
          <given-names>
           SA
          </given-names>
         </name>
         <name>
          <surname>
           Orenstein
          </surname>
          <given-names>
           WA
          </given-names>
         </name>
         <name>
          <surname>
           Offit
          </surname>
          <given-names>
           PA
          </given-names>
         </name>
        </person-group>
        <source>
         Vaccines
        </source>
        <edition>
         5th ed.
        </edition>
        <year>
         2008
        </year>
        <publisher-name>
         Saunders Elsevier
        </publisher-name>
        <publisher-loc>
         Philadelphia
        </publisher-loc>
        <fpage>
         605
        </fpage>
        <lpage>
         630
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib174">
       <label>
        3
       </label>
       <element-citation id="sbref156" publication-type="book">
        <person-group person-group-type="author">
         <collab>
          CDC
         </collab>
        </person-group>
        <chapter-title>
         Poliomyelitis
        </chapter-title>
        <person-group person-group-type="editor">
         <name>
          <surname>
           Atkinson
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <name>
          <surname>
           Hamborsky
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           McIntyre
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Wolfe
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        <source>
         Epidemiology and prevention of vaccine-preventable diseases
        </source>
        <edition>
         9th ed.
        </edition>
        <year>
         2006
        </year>
        <publisher-name>
         Public Health Foundation
        </publisher-name>
        <publisher-loc>
         Washington, DC
        </publisher-loc>
        <fpage>
         97
        </fpage>
        <lpage>
         110
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib175">
       <label>
        4
       </label>
       <element-citation id="sbref157" publication-type="journal">
        <person-group person-group-type="author">
         <collab>
          CDC
         </collab>
        </person-group>
        <article-title>
         Progress toward interruption of wild poliovirus transmission-worldwide, January 2007–April 2008
        </article-title>
        <source>
         MMWR Morbid Mortal Wkly Rep
        </source>
        <volume>
         57
        </volume>
        <issue>
         18
        </issue>
        <year>
         2008
        </year>
        <fpage>
         489
        </fpage>
        <lpage>
         494
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib176">
       <label>
        5
       </label>
       <element-citation id="sbref158" publication-type="journal">
        <person-group person-group-type="author">
         <collab>
          CDC
         </collab>
        </person-group>
        <article-title>
         Resurgence of wild poliovirus type 1 transmission and consequences of importation—21 countries, 2002–2005
        </article-title>
        <source>
         MMWR Morbid Mortal Wkly Rep
        </source>
        <volume>
         55
        </volume>
        <issue>
         6
        </issue>
        <year>
         2006
        </year>
        <fpage>
         145
        </fpage>
        <lpage>
         150
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib177">
       <label>
        6
       </label>
       <mixed-citation id="ceotherref19" publication-type="other">
        Global case count. [cited 2008 Sept 16]. Available from:
        <ext-link ext-link-type="uri" id="interref53" xlink:href="http://www.polioeradication">
         http://www.polioeradication
        </ext-link>
        . org/casecount.asp.
       </mixed-citation>
      </ref>
      <ref id="bib178">
       <label>
        7
       </label>
       <element-citation id="sbref159" publication-type="journal">
        <person-group person-group-type="author">
         <collab>
          CDC
         </collab>
        </person-group>
        <article-title>
         Poliomyelitis prevention in the United States—updated recommendations of the Advisory Committee on Immunization Practices (ACIP)
        </article-title>
        <source>
         MMWR Recomm Rep
        </source>
        <volume>
         49
        </volume>
        <issue>
         RR-5
        </issue>
        <year>
         2000
        </year>
        <fpage>
         1
        </fpage>
        <lpage>
         22
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib179">
       <label>
        8
       </label>
       <element-citation id="sbref160" publication-type="journal">
        <person-group person-group-type="author">
         <collab>
          CDC
         </collab>
        </person-group>
        <article-title>
         Poliomyelitis—United States, 1975–1984
        </article-title>
        <source>
         MMWR Morbid Mortal Wkly Rep
        </source>
        <volume>
         35
        </volume>
        <issue>
         11
        </issue>
        <year>
         1986
        </year>
        <fpage>
         180
        </fpage>
        <lpage>
         182
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib180">
       <label>
        9
       </label>
       <element-citation id="sbref161" publication-type="journal">
        <person-group person-group-type="author">
         <collab>
          CDC
         </collab>
        </person-group>
        <article-title>
         International Notes: Certification of poliomyelitis eradication—the Americas, 1994
        </article-title>
        <source>
         MMWR Morbid Mortal Wkly Rep
        </source>
        <volume>
         43
        </volume>
        <issue>
         39
        </issue>
        <year>
         1994
        </year>
        <fpage>
         720
        </fpage>
        <lpage>
         722
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib181">
       <label>
        10
       </label>
       <element-citation id="sbref162" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Alexander
          </surname>
          <given-names>
           LN
          </given-names>
         </name>
         <name>
          <surname>
           Seward
          </surname>
          <given-names>
           JF
          </given-names>
         </name>
         <name>
          <surname>
           Santibanez
          </surname>
          <given-names>
           TA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Vaccine policy changes and epidemiology of polio in the United States
        </article-title>
        <source>
         JAMA
        </source>
        <volume>
         292
        </volume>
        <issue>
         14
        </issue>
        <year>
         2004
        </year>
        <fpage>
         1696
        </fpage>
        <lpage>
         1701
        </lpage>
        <pub-id pub-id-type="pmid">
         15479934
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib182">
       <label>
        11
       </label>
       <element-citation id="sbref163" publication-type="journal">
        <person-group person-group-type="author">
         <collab>
          CDC
         </collab>
        </person-group>
        <article-title>
         Imported vaccine-associated paralytic poliomyelitis—United States, 2005
        </article-title>
        <source>
         MMWR Morbid Mortal Wkly Rep
        </source>
        <volume>
         55
        </volume>
        <issue>
         4
        </issue>
        <year>
         2006
        </year>
        <fpage>
         97
        </fpage>
        <lpage>
         99
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib183">
       <label>
        12
       </label>
       <element-citation id="sbref164" publication-type="journal">
        <person-group person-group-type="author">
         <collab>
          CDC
         </collab>
        </person-group>
        <article-title>
         Poliovirus infections in four unvaccinated children—Minnesota, August–October, 2005
        </article-title>
        <source>
         MMWR Morbid Mortal Wkly Rep
        </source>
        <volume>
         54
        </volume>
        <issue>
         41
        </issue>
        <year>
         2005
        </year>
        <fpage>
         1053
        </fpage>
        <lpage>
         1055
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib184">
       <label>
        13
       </label>
       <element-citation id="sbref165" publication-type="journal">
        <person-group person-group-type="author">
         <collab>
          CDC
         </collab>
        </person-group>
        <article-title>
         Laboratory surveillance for wild and vaccine-derived polioviruses
        </article-title>
        <source>
         MMWR Morbid Mortal Wkly Rep
        </source>
        <volume>
         57
        </volume>
        <issue>
         35
        </issue>
        <year>
         2008
        </year>
        <fpage>
         967
        </fpage>
        <lpage>
         970
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib185">
       <label>
        14
       </label>
       <element-citation id="sbref166" publication-type="journal">
        <person-group person-group-type="author">
         <collab>
          World Health Organization.
         </collab>
        </person-group>
        <article-title>
         Conclusions and recommendations of the Advisory Committee on Poliomyelitis Eradication, Geneva 27–28 November 2007
        </article-title>
        <source>
         Wkly Epidemiol Rec
        </source>
        <volume>
         83
        </volume>
        <issue>
         3
        </issue>
        <year>
         2008
        </year>
        <fpage>
         25
        </fpage>
        <lpage>
         35
        </lpage>
        <pub-id pub-id-type="pmid">
         18203406
        </pub-id>
       </element-citation>
      </ref>
     </ref-list>
    </sec>
    <sec id="subchapter18">
     <sec-meta>
      <contrib-group>
       <contrib contrib-type="author" id="au32">
        <name>
         <surname>
          Reef
         </surname>
         <given-names>
          Susan E.
         </given-names>
        </name>
       </contrib>
      </contrib-group>
     </sec-meta>
     <title>
      RUBELLA
     </title>
     <sec id="cesec237">
      <title>
       Infectious Agent
      </title>
      <p id="para1123">
       Rubella virus is a member of
       <italic>
        Togaviridae
       </italic>
       family and the only member of the genus
       <italic>
        Rubivirus.
       </italic>
      </p>
     </sec>
     <sec id="cesec238">
      <title>
       Mode of Transmission
      </title>
      <p id="para1124">
       <list id="celist244" list-type="simple">
        <list-item id="celistitem873">
         <label>
          •
         </label>
         <p id="para1125">
          Rubella virus is transmitted through person-to-person contact or droplets shed from the respiratory secretions of infected persons.
         </p>
        </list-item>
        <list-item id="celistitem874">
         <label>
          •
         </label>
         <p id="para1126">
          If a woman with rubella is infected during pregnancy, the virus can cross the placenta and infect the fetus.
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <sec id="cesec239">
      <title>
       Occurrence
      </title>
      <p id="para1127">
       <list id="celist245" list-type="simple">
        <list-item id="celistitem875">
         <label>
          •
         </label>
         <p id="para1128">
          Rubella occurs worldwide.
         </p>
        </list-item>
        <list-item id="celistitem876">
         <label>
          •
         </label>
         <p id="para1129">
          In the United States, endemic rubella has been eliminated. However, since 2005, an average of 10 cases is reported each year. Of these cases, approximately 33% are imported or linked to importations.
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <sec id="cesec240">
      <title>
       Risk for Travelers
      </title>
      <p id="para1130">
       <list id="celist246" list-type="simple">
        <list-item id="celistitem877">
         <label>
          •
         </label>
         <p id="para1131">
          All susceptible persons are at risk for infection from exposure to rubella during travel outside the United States.
         </p>
        </list-item>
        <list-item id="celistitem878">
         <label>
          •
         </label>
         <p id="para1132">
          Because asymptomatic rubella infections are common, travelers may be unaware that they have been in contact with an infected person.
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <sec id="cesec241">
      <title>
       Clinical Presentation
      </title>
      <p id="para1133">
       <list id="celist247" list-type="simple">
        <list-item id="celistitem879">
         <label>
          •
         </label>
         <p id="para1134">
          The average incubation period is 14 days, with a range of 12–23 days.
         </p>
        </list-item>
        <list-item id="celistitem880">
         <label>
          •
         </label>
         <p id="para1135">
          Rubella usually presents as a nonspecific, maculopapular, generalized rash lasting 3 days or fewer (hence the term “3-day measles”) with generalized lymphadenopathy, particularly of the posterior auricular, suboccipital and posterior cervical lymph nodes.
         </p>
        </list-item>
        <list-item id="celistitem881">
         <label>
          •
         </label>
         <p id="para1136">
          Asymptomatic rubella virus infections are common, and up to 50% of infections occur without rash.
         </p>
        </list-item>
        <list-item id="celistitem882">
         <label>
          •
         </label>
         <p id="para1137">
          In adults and adolescents, the rash may be preceded by a 1- to 5-day prodrome of low-grade fever, malaise, anorexia, mild conjunctivitis, coryza, sore throat, and lymphadenopathy.
         </p>
        </list-item>
        <list-item id="celistitem883">
         <label>
          •
         </label>
         <p id="para1138">
          The most important and serious consequence of rubella is infection during early pregnancy. These consequences may include miscarriages, fetal deaths/stillbirths, and an infant born with constellation of severe birth defects known as congenital rubella syndrome (CRS). The most common congenital defects are cataracts, heart defects, and hearing impairment.
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <sec id="cesec242">
      <title>
       Diagnosis
      </title>
      <p id="para1139">
       <list id="celist248" list-type="simple">
        <list-item id="celistitem884">
         <label>
          •
         </label>
         <p id="para1140">
          Many illnesses can mimic rubella, and up to 50% of rubella infections are asymptomatic. Therefore, the only reliable evidence of acute rubella virus infection is laboratory diagnosis.
         </p>
        </list-item>
        <list-item id="celistitem885">
         <label>
          •
         </label>
         <p id="para1141">
          Serologic testing for rubella-specific IgM antibody is the most commonly used for diagnosis of rubella.
         </p>
        </list-item>
        <list-item id="celistitem886">
         <label>
          •
         </label>
         <p id="para1142">
          Diagnosis can also be made by demonstration of seroconversion of rubella-specific IgG antibody titers and by detection of virus either through virus culture or PCR.
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <sec id="cesec243">
      <title>
       Treatment
      </title>
      <p id="para1143">
       There is no specific antiviral therapy for rubella; basic treatment consists of supportive care.
      </p>
     </sec>
     <sec id="cesec244">
      <title>
       Preventive Measures for Travelers
      </title>
      <sec id="cesec245">
       <title>
        Vaccine
       </title>
       <p id="para1144">
        <list id="celist249" list-type="simple">
         <list-item id="celistitem887">
          <label>
           •
          </label>
          <p id="para1145">
           Before international travel, persons should be immune to rubella.
          </p>
         </list-item>
         <list-item id="celistitem888">
          <label>
           •
          </label>
          <p id="para1146">
           Acceptable presumptive evidence of immunity to rubella for international travelers includes—
           <list id="celist250" list-type="simple">
            <list-item id="celistitem889">
             <label>
              ○
             </label>
             <p id="para1147">
              Documentation of receipt of one or more doses of rubella-containing vaccine on or after the first birthday
             </p>
            </list-item>
            <list-item id="celistitem890">
             <label>
              ○
             </label>
             <p id="para1148">
              Laboratory evidence of rubella immunity (a positive serologic test for rubella-specific IgG antibody)
             </p>
            </list-item>
           </list>
          </p>
         </list-item>
        </list>
       </p>
       <sec id="cesec246">
        <title>
         Adverse Reactions, Precautions, and Contraindications to Rubella Vaccine
        </title>
        <p id="para1149">
         <list id="celist251" list-type="simple">
          <list-item id="celistitem891">
           <label>
            •
           </label>
           <p id="para1150">
            Refer to the Measles (Rubeola) section earlier in this chapter for information on reactions following MMR vaccine and additional precautions and contraindications.
           </p>
          </list-item>
         </list>
        </p>
       </sec>
      </sec>
     </sec>
     <ref-list id="cebib18">
      <title>
       References
      </title>
      <ref id="bib186">
       <label>
        1
       </label>
       <element-citation id="sbref167" publication-type="book">
        <person-group person-group-type="author">
         <collab>
          CDC
         </collab>
        </person-group>
        <chapter-title>
         Rubella
        </chapter-title>
        <person-group person-group-type="editor">
         <name>
          <surname>
           Atkinson
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <name>
          <surname>
           Hamborsky
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           McIntyre
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Wolfe
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        <source>
         Epidemiology and prevention of vaccine-preventable diseases
        </source>
        <edition>
         10th ed.
        </edition>
        <year>
         2008
        </year>
        <publisher-name>
         Public Health Foundation
        </publisher-name>
        <publisher-loc>
         Washington (DC)
        </publisher-loc>
        <fpage>
         159
        </fpage>
        <lpage>
         174
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib187">
       <label>
        2
       </label>
       <element-citation id="sbref168" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Reef
          </surname>
          <given-names>
           SE
          </given-names>
         </name>
         <name>
          <surname>
           Redd
          </surname>
          <given-names>
           SB
          </given-names>
         </name>
         <name>
          <surname>
           Abernathy
          </surname>
          <given-names>
           E
          </given-names>
         </name>
        </person-group>
        <article-title>
         The epidemiological profile of rubella and congenital rubella syndrome in the United States, 1998–2004: the evidence for absence of endemic transmission
        </article-title>
        <source>
         Clin Infect Dis
        </source>
        <volume>
         43
        </volume>
        <issue>
         Suppl 3
        </issue>
        <year>
         2006
        </year>
        <fpage>
         S126
        </fpage>
        <lpage>
         S132
        </lpage>
        <pub-id pub-id-type="pmid">
         16998771
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib188">
       <label>
        3
       </label>
       <element-citation id="sbref169" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Plotkin
          </surname>
          <given-names>
           SA
          </given-names>
         </name>
         <name>
          <surname>
           Reef
          </surname>
          <given-names>
           SE
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         Rubella vaccine
        </chapter-title>
        <person-group person-group-type="editor">
         <name>
          <surname>
           Plotkin
          </surname>
          <given-names>
           SA
          </given-names>
         </name>
         <name>
          <surname>
           Orenstein
          </surname>
          <given-names>
           WA
          </given-names>
         </name>
         <name>
          <surname>
           Offit
          </surname>
          <given-names>
           PA
          </given-names>
         </name>
        </person-group>
        <source>
         Vaccines
        </source>
        <edition>
         5th ed.
        </edition>
        <year>
         2008
        </year>
        <publisher-name>
         Saunders Elsevier
        </publisher-name>
        <publisher-loc>
         Philadelphia
        </publisher-loc>
        <fpage>
         735
        </fpage>
        <lpage>
         771
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib189">
       <label>
        4
       </label>
       <element-citation id="sbref170" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Reef
          </surname>
          <given-names>
           SE
          </given-names>
         </name>
         <name>
          <surname>
           Cochi
          </surname>
          <given-names>
           SL
          </given-names>
         </name>
        </person-group>
        <article-title>
         The evidence for the elimination of rubella and congenital rubella syndrome in the United States: a public health achievement
        </article-title>
        <source>
         Clin Infect Dis
        </source>
        <volume>
         43
        </volume>
        <issue>
         Suppl 3
        </issue>
        <year>
         2006
        </year>
        <fpage>
         S123
        </fpage>
        <lpage>
         S125
        </lpage>
        <pub-id pub-id-type="pmid">
         16998770
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib190">
       <label>
        5
       </label>
       <element-citation id="sbref171" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Meissner
          </surname>
          <given-names>
           HC
          </given-names>
         </name>
         <name>
          <surname>
           Reef
          </surname>
          <given-names>
           SE
          </given-names>
         </name>
         <name>
          <surname>
           Cochi
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        <article-title>
         Elimination of rubella from the United States: a milestone on the road to global elimination
        </article-title>
        <source>
         Pediatrics
        </source>
        <volume>
         117
        </volume>
        <issue>
         3
        </issue>
        <year>
         2006
        </year>
        <fpage>
         933
        </fpage>
        <lpage>
         935
        </lpage>
        <pub-id pub-id-type="pmid">
         16510677
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib191">
       <label>
        6
       </label>
       <element-citation id="sbref172" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Robertson
          </surname>
          <given-names>
           SE
          </given-names>
         </name>
         <name>
          <surname>
           Featherstone
          </surname>
          <given-names>
           DA
          </given-names>
         </name>
         <name>
          <surname>
           Gacic-Dobo
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <article-title>
         Rubella and congenital rubella syndrome: global update
        </article-title>
        <source>
         Rev Panam Salud Publica
        </source>
        <volume>
         14
        </volume>
        <issue>
         5
        </issue>
        <year>
         2003
        </year>
        <fpage>
         306
        </fpage>
        <lpage>
         315
        </lpage>
        <pub-id pub-id-type="pmid">
         14870758
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib192">
       <label>
        7
       </label>
       <element-citation id="sbref173" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Plotinsky
          </surname>
          <given-names>
           RN
          </given-names>
         </name>
         <name>
          <surname>
           Talbot
          </surname>
          <given-names>
           EA
          </given-names>
         </name>
         <name>
          <surname>
           Kellenberg
          </surname>
          <given-names>
           JE
          </given-names>
         </name>
        </person-group>
        <article-title>
         Congenital rubella syndrome in a child born to Liberian refugees: clinical and public health perspectives
        </article-title>
        <source>
         Clin Pediatr (Phila)
        </source>
        <volume>
         46
        </volume>
        <issue>
         4
        </issue>
        <year>
         2007
        </year>
        <fpage>
         349
        </fpage>
        <lpage>
         355
        </lpage>
        <pub-id pub-id-type="pmid">
         17475995
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib193">
       <label>
        8
       </label>
       <element-citation id="sbref174" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Watson
          </surname>
          <given-names>
           JC
          </given-names>
         </name>
         <name>
          <surname>
           Hadler
          </surname>
          <given-names>
           SC
          </given-names>
         </name>
         <name>
          <surname>
           Dykewicz
          </surname>
          <given-names>
           CA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Measles, mumps, and rubella-vaccine use and strategies for elimination of measles, rubella, congenital rubella syndrome and control of mumps: recommendations of the Advisory Committee on Immunization Practices (ACIP)
        </article-title>
        <source>
         MMWR Recomm Rep
        </source>
        <volume>
         47
        </volume>
        <issue>
         RR-8
        </issue>
        <year>
         1998
        </year>
        <fpage>
         1
        </fpage>
        <lpage>
         57
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib194">
       <label>
        9
       </label>
       <element-citation id="sbref175" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kroger
          </surname>
          <given-names>
           AT
          </given-names>
         </name>
         <name>
          <surname>
           Atkinson
          </surname>
          <given-names>
           WL
          </given-names>
         </name>
         <name>
          <surname>
           Marcuse
          </surname>
          <given-names>
           EK
          </given-names>
         </name>
        </person-group>
        <article-title>
         CDC. General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP)
        </article-title>
        <source>
         MMWR Recomm Rep
        </source>
        <volume>
         55
        </volume>
        <issue>
         RR-15
        </issue>
        <year>
         2006
        </year>
        <fpage>
         1
        </fpage>
        <lpage>
         48
        </lpage>
       </element-citation>
      </ref>
     </ref-list>
    </sec>
    <sec id="subchapter19">
     <sec-meta>
      <contrib-group>
       <contrib contrib-type="author" id="au33">
        <name>
         <surname>
          Joyce
         </surname>
         <given-names>
          M. Patricia
         </given-names>
        </name>
       </contrib>
      </contrib-group>
     </sec-meta>
     <title>
      TETANUS
     </title>
     <sec id="cesec247">
      <title>
       Infectious Agent
      </title>
      <p id="para1151">
       <list id="celist252" list-type="simple">
        <list-item id="celistitem892">
         <label>
          •
         </label>
         <p id="para1152">
          <italic>
           Clostridium tetani
          </italic>
          , the tetanus bacillus, is a spore-forming, anaerobic gram-positive bacterium.
         </p>
        </list-item>
        <list-item id="celistitem893">
         <label>
          •
         </label>
         <p id="para1153">
          Clinical disease is caused by a neurotoxin produced by anaerobic tetanus bacilli growing in contaminated wounds.
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <sec id="cesec248">
      <title>
       Mode of Transmission
      </title>
      <p id="para1154">
       <list id="celist253" list-type="simple">
        <list-item id="celistitem894">
         <label>
          •
         </label>
         <p id="para1155">
          Tetanus is a global health problem because
          <italic>
           C. tetani
          </italic>
          spores are ubiquitous in the environment.
         </p>
        </list-item>
        <list-item id="celistitem895">
         <label>
          •
         </label>
         <p id="para1156">
          Lesions that are considered “tetanus prone” are wounds contaminated with dirt, feces, or saliva, deep wounds, burns, crush injuries, or those with necrotic tissue.
         </p>
        </list-item>
        <list-item id="celistitem896">
         <label>
          •
         </label>
         <p id="para1157">
          Tetanus has also been associated with apparently clean superficial wounds, surgical procedures, insect bites, dental infections, chronic sores and infections, and intravenous drug use.
         </p>
        </list-item>
        <list-item id="celistitem897">
         <label>
          •
         </label>
         <p id="para1158">
          A reservoir of tetanus bacteria exists in the intestines of horses and other animals, including humans, in which the organism is a harmless normal inhabitant. Soil or fomites contaminated with animal and human feces propagate transmission.
         </p>
        </list-item>
        <list-item id="celistitem898">
         <label>
          •
         </label>
         <p id="para1159">
          Tetanus has no direct person-to-person transmission.
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <sec id="cesec249">
      <title>
       Occurrence
      </title>
      <p id="para1160">
       <list id="celist254" list-type="simple">
        <list-item id="celistitem899">
         <label>
          •
         </label>
         <p id="para1161">
          In 2006, an estimated 290,000 people worldwide died of tetanus, most of them in Asia, Africa, and South America.
         </p>
        </list-item>
        <list-item id="celistitem900">
         <label>
          •
         </label>
         <p id="para1162">
          The disease occurs almost exclusively in persons who are inadequately immunized.
         </p>
        </list-item>
        <list-item id="celistitem901">
         <label>
          •
         </label>
         <p id="para1163">
          Worldwide, the disease is more common in agricultural regions and in areas where contact with animal excreta is more likely and immunization is inadequate.
         </p>
        </list-item>
        <list-item id="celistitem902">
         <label>
          •
         </label>
         <p id="para1164">
          In developing countries, tetanus in neonates born to unvaccinated mothers (neonatal tetanus) is the most common form of the disease.
         </p>
        </list-item>
        <list-item id="celistitem903">
         <label>
          •
         </label>
         <p id="para1165">
          In 10% of reported cases in the United States, no antecedent wound was identified.
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <sec id="cesec250">
      <title>
       Risk for Travelers
      </title>
      <p id="para1166">
       Tetanus can occur anywhere in the world in inadequately vaccinated persons.
      </p>
     </sec>
     <sec id="cesec251">
      <title>
       Clinical Presentation
      </title>
      <p id="para1167">
       <list id="celist255" list-type="simple">
        <list-item id="celistitem904">
         <label>
          •
         </label>
         <p id="para1168">
          Acute manifestations of tetanus are characterized by muscle rigidity and painful spasms, often starting in the muscles of the jaw and neck. Severe tetanus can lead to respiratory failure and death.
         </p>
        </list-item>
        <list-item id="celistitem905">
         <label>
          •
         </label>
         <p id="para1169">
          The incubation period is usually 3–21 days (average 10 days), although it may range from 1 day to several months, depending on the character, extent, and location of the wound. Most cases occur within 14 days. In general, shorter incubation periods are associated with more heavily contaminated wounds, more severe disease, and a worse prognosis.
         </p>
        </list-item>
       </list>
      </p>
      <sec id="cesec252">
       <title>
        Clinical Syndromes
       </title>
       <sec id="cesec253">
        <title>
         Generalized Tetanus
        </title>
        <p id="para1170">
         <list id="celist256" list-type="simple">
          <list-item id="celistitem906">
           <label>
            •
           </label>
           <p id="para1171">
            Generalized tetanus is the most common form, accounting for more than 80% of cases.
           </p>
          </list-item>
          <list-item id="celistitem907">
           <label>
            •
           </label>
           <p id="para1172">
            Neonatal tetanus is generalized tetanus in neonates, usually due to umbilical stump infections.
           </p>
          </list-item>
          <list-item id="celistitem908">
           <label>
            •
           </label>
           <p id="para1173">
            The average incubation period from injury to symptom onset is 7–8 days (range 3 days–3 weeks).
           </p>
          </list-item>
          <list-item id="celistitem909">
           <label>
            •
           </label>
           <p id="para1174">
            The most common initial sign is trismus (spasm of the muscles of mastication or “lockjaw”). Trismus may be followed by painful spasms in other muscle groups in the neck, trunk, and extremities and by generalized, tonic, seizure-like activity or frank convulsions in severe cases.
           </p>
          </list-item>
          <list-item id="celistitem910">
           <label>
            •
           </label>
           <p id="para1175">
            Generalized tetanus can be accompanied by autonomic nervous system abnormalities, as well as a variety of complications related to severe spasm and prolonged hospitalization.
           </p>
          </list-item>
          <list-item id="celistitem911">
           <label>
            •
           </label>
           <p id="para1176">
            The clinical course of generalized tetanus is variable and depends on the degree of prior immunity, the amount of toxin present, and the age and general health of the patient.
           </p>
          </list-item>
          <list-item id="celistitem912">
           <label>
            •
           </label>
           <p id="para1177">
            Even with modern intensive care, generalized tetanus is associated with mortality rates of 10%–20%.
           </p>
          </list-item>
         </list>
        </p>
       </sec>
       <sec id="cesec254">
        <title>
         Localized Tetanus
        </title>
        <p id="para1178">
         <list id="celist257" list-type="simple">
          <list-item id="celistitem913">
           <label>
            •
           </label>
           <p id="para1179">
            Localized tetanus is an unusual form of the disease consisting of spasm of muscles in a confined area close to the site of the injury.
           </p>
          </list-item>
          <list-item id="celistitem914">
           <label>
            •
           </label>
           <p id="para1180">
            Although localized tetanus often occurs in persons with partial immunity and is usually mild, progression to generalized tetanus can occur.
           </p>
          </list-item>
         </list>
        </p>
       </sec>
       <sec id="cesec255">
        <title>
         Cephalic Tetanus
        </title>
        <p id="para1181">
         <list id="celist258" list-type="simple">
          <list-item id="celistitem915">
           <label>
            •
           </label>
           <p id="para1182">
            The rarest form, cephalic tetanus, is associated with lesions of the head or face and has been described in association with ear infections (i.e., otitis media).
           </p>
          </list-item>
          <list-item id="celistitem916">
           <label>
            •
           </label>
           <p id="para1183">
            The incubation period is short, usually 1–2 days.
           </p>
          </list-item>
          <list-item id="celistitem917">
           <label>
            •
           </label>
           <p id="para1184">
            Unlike generalized and localized tetanus, cephalic tetanus results in flaccid cranial nerve palsies rather than spasm. Trismus may also be present. Like localized tetanus, cephalic tetanus can progress to the generalized form.
           </p>
          </list-item>
         </list>
        </p>
       </sec>
      </sec>
     </sec>
     <sec id="cesec256">
      <title>
       Diagnosis
      </title>
      <p id="para1185">
       <list id="celist259" list-type="simple">
        <list-item id="celistitem918">
         <label>
          •
         </label>
         <p id="para1186">
          The diagnosis is almost always made clinically.
         </p>
        </list-item>
        <list-item id="celistitem919">
         <label>
          •
         </label>
         <p id="para1187">
          The disease is characterized by painful muscular contractions, primarily of the masseter and neck muscles, secondarily of trunk muscles.
         </p>
        </list-item>
        <list-item id="celistitem920">
         <label>
          •
         </label>
         <p id="para1188">
          A common first sign suggestive of tetanus in older children and adults is abdominal rigidity, though rigidity is sometimes confined to the region of injury.
         </p>
        </list-item>
        <list-item id="celistitem921">
         <label>
          •
         </label>
         <p id="para1189">
          Generalized spasms occur, frequently induced by sensory stimuli; typical features of the tetanic spasm are the position of opisthotonos and the facial expression known as “risus sardonicus.”
         </p>
        </list-item>
        <list-item id="celistitem922">
         <label>
          •
         </label>
         <p id="para1190">
          History of an injury or apparent portal of entry may be lacking.
         </p>
        </list-item>
        <list-item id="celistitem923">
         <label>
          •
         </label>
         <p id="para1191">
          The organism is rarely recovered from the site of infection, and usually there is no detectable antibody response.
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <sec id="cesec257">
      <title>
       Treatment
      </title>
      <p id="para1192">
       <list id="celist260" list-type="simple">
        <list-item id="celistitem924">
         <label>
          •
         </label>
         <p id="para1193">
          Tetanus is a medical emergency requiring hospitalization, immediate treatment with human tetanus immune globulin (TIG) (or equine antitoxin if human immune globulin is not available), a tetanus toxoid booster, agents to control muscle spasm, and, if indicated, aggressive wound care and antibiotics.
          <list id="celist261" list-type="simple">
           <list-item id="celistitem925">
            <label>
             ○
            </label>
            <p id="para1194">
             Specific treatment: TIG administered intramuscularly in doses of 3000–6000 IU. If immunoglobulin is not available, tetanus antitoxin (equine origin) in a single large dose should be given intravenously, following testing for hypersensitivity.
            </p>
           </list-item>
          </list>
         </p>
        </list-item>
        <list-item id="celistitem926">
         <label>
          •
         </label>
         <p id="para1195">
          Metronidazole is the most appropriate antibiotic. It is associated with the shortest recovery time and lowest case–fatality rate. It should be given for 7–14 days in large doses; this also allows for a reduction in the amount of muscle relaxants and sedatives required.
         </p>
        </list-item>
        <list-item id="celistitem927">
         <label>
          •
         </label>
         <p id="para1196">
          The wound should be debrided widely and excised if possible. Wide debridement of the umbilical stump in neonates is not indicated.
         </p>
        </list-item>
        <list-item id="celistitem928">
         <label>
          •
         </label>
         <p id="para1197">
          Depending on the severity of disease, mechanical ventilation and agents to control autonomic nervous system instability may be required.
         </p>
        </list-item>
        <list-item id="celistitem929">
         <label>
          •
         </label>
         <p id="para1198">
          An adequate airway should be maintained, and sedation should be used as indicated; muscle relaxant drugs, together with tracheostomy or nasotracheal intubation and mechanically assisted respiration, may be lifesaving.
         </p>
        </list-item>
        <list-item id="celistitem930">
         <label>
          •
         </label>
         <p id="para1199">
          Active immunization should be initiated concurrently with treatment.
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <sec id="cesec258">
      <title>
       Preventive Measures for Travelers
      </title>
      <p id="para1200">
       <list id="celist262" list-type="simple">
        <list-item id="celistitem931">
         <label>
          •
         </label>
         <p id="para1201">
          Travelers should ensure they have adequate immunity to tetanus.
          <list id="celist263" list-type="simple">
           <list-item id="celistitem932">
            <label>
             ○
            </label>
            <p id="para1202">
             Active immunity is induced by tetanus toxoid and persists for at least 10 years after full immunization; transient passive immunity follows injection of TIG or tetanus antitoxin (equine origin).
            </p>
           </list-item>
           <list-item id="celistitem933">
            <label>
             ○
            </label>
            <p id="para1203">
             Infants of actively immunized mothers acquire passive immunity that protects them from neonatal tetanus.
            </p>
           </list-item>
           <list-item id="celistitem934">
            <label>
             ○
            </label>
            <p id="para1204">
             Recovery from tetanus may not result in immunity; second attacks can occur, and primary immunization is indicated after recovery.
            </p>
           </list-item>
          </list>
         </p>
        </list-item>
        <list-item id="celistitem935">
         <label>
          •
         </label>
         <p id="para1205">
          Wounded travelers who received their most recent tetanus toxoid-containing vaccine more than 5 years previously or who have not received at least three doses of tetanus toxoid-containing vaccines may require a dose of tetanus toxoid-containing vaccine (Tdap, Td, or DTaP), depending on the nature of the wound.
         </p>
        </list-item>
        <list-item id="celistitem936">
         <label>
          •
         </label>
         <p id="para1206">
          Human tetanus immune globulin (TIG) is indicated in travelers with tetanus-prone wounds who have an unknown or incomplete history of primary tetanus vaccination.
         </p>
        </list-item>
       </list>
      </p>
      <sec id="cesec259">
       <title>
        General Preventive Measures
       </title>
       <p id="para1207">
        <list id="celist264" list-type="simple">
         <list-item id="celistitem937">
          <label>
           •
          </label>
          <p id="para1208">
           Universal active immunization with adsorbed tetanus toxoid, gives durable protection for at least 10 years; after the initial basic series has been completed, single booster doses elicit high levels of immunity.
          </p>
         </list-item>
         <list-item id="celistitem938">
          <label>
           •
          </label>
          <p id="para1209">
           In children &lt;7 years of age, the toxoid is generally administered together with diphtheria toxoid and pertussis vaccine as a triple (DTP or DTaP) antigen, or as a double (DT) antigen when contraindications to pertussis vaccine exist.
          </p>
         </list-item>
         <list-item id="celistitem939">
          <label>
           •
          </label>
          <p id="para1210">
           Td is used for children &gt;7 years of age.
          </p>
         </list-item>
         <list-item id="celistitem940">
          <label>
           •
          </label>
          <p id="para1211">
           For adolescents 11–12 years of age, a single dose of Tdap is recommended for routine booster, and for adolescents and adults 13–64 years of age, a single dose of Tdap is recommended to replace the next decennial Td booster or when indicated as part of wound prophylaxis.
          </p>
         </list-item>
         <list-item id="celistitem941">
          <label>
           •
          </label>
          <p id="para1212">
           In countries with incomplete immunization programs for children, all pregnant women should receive two doses of tetanus toxoid in the first pregnancy, with an interval of at least 1 month, and with the second dose at least 2 weeks prior to childbirth.
          </p>
         </list-item>
         <list-item id="celistitem942">
          <label>
           •
          </label>
          <p id="para1213">
           Vaccine-induced maternal immunity is important in preventing maternal and neonatal tetanus. Active protection should be maintained by administering booster doses of Td every 10 years, preferably before or between pregnancies.
          </p>
         </list-item>
         <list-item id="celistitem943">
          <label>
           •
          </label>
          <p id="para1214">
           For children and adults who are severely immunocompromised or infected with HIV, tetanus toxoid is indicated in the same schedule and dose as for immunocompetent persons even though the immune response may be suboptimal.
          </p>
         </list-item>
         <list-item id="celistitem944">
          <label>
           •
          </label>
          <p id="para1215">
           Minor local reactions following tetanus toxoid injections are relatively frequent; severe local and systemic reactions are infrequent but do occur, particularly after excessive numbers of prior doses have been given.
          </p>
         </list-item>
        </list>
       </p>
      </sec>
      <sec id="cesec260">
       <title>
        Prophylaxis in Wound Management (see
        <xref ref-type="table" rid="cetable21">
         Table 2-21
        </xref>
        )
       </title>
       <p id="para1216">
        <list id="celist265" list-type="simple">
         <list-item id="celistitem945">
          <label>
           •
          </label>
          <p id="para1217">
           Tetanus prophylaxis in patients with wounds is based on careful assessment of whether the wound is clean or contaminated, the immunization status of the patient, proper use of tetanus toxoid and/or TIG, wound cleaning and, where required, surgical debridement and the proper use of antibiotics.
          </p>
         </list-item>
         <list-item id="celistitem946">
          <label>
           •
          </label>
          <p id="para1218">
           Those who have been completely immunized and who sustain minor and uncontaminated wounds require a booster dose of toxoid only if more than 10 years have elapsed since the last dose was given. For major or contaminated wounds, a single booster injection of tetanus toxoid (preferably as Td or Tdap) should be administered promptly on the day of injury if the patient has not received tetanus toxoid within the preceding 5 years.
          </p>
         </list-item>
         <list-item id="celistitem947">
          <label>
           •
          </label>
          <p id="para1219">
           Persons who have not completed a full primary series of tetanus toxoid require a dose of toxoid as soon as possible following the wound and may require passive immunization with human TIG if the wound is major or if it is contaminated with soil containing animal excreta. DTP/DTaP, DT, or Td, as determined by the age of the patient and previous immunization history, should be used at the time of the wound and ultimately to complete the primary series.
          </p>
         </list-item>
         <list-item id="celistitem948">
          <label>
           •
          </label>
          <p id="para1220">
           Passive immunization with at least 250 IU of TIG intramuscularly (or 1,500 to 5,000 IU of antitoxin of animal origin, if globulin is not available), regardless of the patient's age, is indicated for patients with other than clean, minor wounds and a history of no, unknown, or fewer than three previous tetanus toxoid doses. When tetanus toxoid and TIG or antitoxin are given concurrently, separate syringes and separate sites must be used.
          </p>
         </list-item>
        </list>
       </p>
      </sec>
     </sec>
     <ref-list id="cebib19">
      <title>
       References
      </title>
      <ref id="bib195">
       <label>
        1
       </label>
       <element-citation id="sbref176" publication-type="journal">
        <comment>
        </comment>
        <person-group person-group-type="author">
         <name>
          <surname>
           Kretsinger
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Broder
          </surname>
          <given-names>
           KR
          </given-names>
         </name>
         <name>
          <surname>
           Cortese
          </surname>
          <given-names>
           MM
          </given-names>
         </name>
        </person-group>
        <article-title>
         Preventing tetanus, diphtheria, and pertussis among adults: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP), supported by the Healthcare Infection Control Practices Advisory Committee (HICPAC), for use of Tdap among health-care personnel
        </article-title>
        <source>
         MMWR Recomm Rep
        </source>
        <volume>
         55
        </volume>
        <issue>
         RR-17
        </issue>
        <year>
         2006
        </year>
        <fpage>
         1
        </fpage>
        <lpage>
         37
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib196">
       <label>
        2
       </label>
       <element-citation id="sbref177" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Broder
          </surname>
          <given-names>
           KR
          </given-names>
         </name>
         <name>
          <surname>
           Cortese
          </surname>
          <given-names>
           MM
          </given-names>
         </name>
         <name>
          <surname>
           Iskander
          </surname>
          <given-names>
           JK
          </given-names>
         </name>
        </person-group>
        <article-title>
         Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines. Recommendations of the Advisory Committee on Immunization Practices (ACIP)
        </article-title>
        <source>
         MMWR Recomm Rep
        </source>
        <volume>
         55
        </volume>
        <issue>
         RR-3
        </issue>
        <year>
         2006
        </year>
        <fpage>
         1
        </fpage>
        <lpage>
         34
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib197">
       <label>
        3
       </label>
       <element-citation id="sbref178" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Roper
          </surname>
          <given-names>
           MH
          </given-names>
         </name>
         <name>
          <surname>
           Vandelaer
          </surname>
          <given-names>
           JH
          </given-names>
         </name>
         <name>
          <surname>
           Gasse
          </surname>
          <given-names>
           FL
          </given-names>
         </name>
        </person-group>
        <article-title>
         Maternal and neonatal tetanus
        </article-title>
        <source>
         Lancet
        </source>
        <volume>
         370
        </volume>
        <issue>
         9603
        </issue>
        <year>
         2007
        </year>
        <fpage>
         1947
        </fpage>
        <lpage>
         1959
        </lpage>
        <pub-id pub-id-type="pmid">
         17854885
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib198">
       <label>
        4
       </label>
       <element-citation id="sbref179" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wassilak
          </surname>
          <given-names>
           SG F
          </given-names>
         </name>
         <name>
          <surname>
           Roper
          </surname>
          <given-names>
           MH
          </given-names>
         </name>
         <name>
          <surname>
           Kretsinger
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Orenstein
          </surname>
          <given-names>
           WA
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         Tetanus toxoid
        </chapter-title>
        <person-group person-group-type="editor">
         <name>
          <surname>
           Plotkin
          </surname>
          <given-names>
           SA
          </given-names>
         </name>
         <name>
          <surname>
           Orenstein
          </surname>
          <given-names>
           WA
          </given-names>
         </name>
         <name>
          <surname>
           Offit
          </surname>
          <given-names>
           PA
          </given-names>
         </name>
        </person-group>
        <source>
         Vaccines
        </source>
        <edition>
         5th ed.
        </edition>
        <year>
         2008
        </year>
        <publisher-name>
         Saunders Elsevier
        </publisher-name>
        <publisher-loc>
         Philadelphia
        </publisher-loc>
        <fpage>
         805
        </fpage>
        <lpage>
         839
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib199">
       <label>
        5
       </label>
       <element-citation id="sbref180" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Vandelaer
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Birmingham
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Gasse
          </surname>
          <given-names>
           F
          </given-names>
         </name>
        </person-group>
        <article-title>
         Tetanus in developing countries: an update on the Maternal and Neonatal Tetanus Elimination Initiative
        </article-title>
        <source>
         Vaccine
        </source>
        <volume>
         21
        </volume>
        <issue>
         24
        </issue>
        <year>
         2003
        </year>
        <fpage>
         3442
        </fpage>
        <lpage>
         3445
        </lpage>
        <pub-id pub-id-type="pmid">
         12850356
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib200">
       <label>
        6
       </label>
       <element-citation id="sbref181" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Murphy
          </surname>
          <given-names>
           TV
          </given-names>
         </name>
         <name>
          <surname>
           Slade
          </surname>
          <given-names>
           BA
          </given-names>
         </name>
         <name>
          <surname>
           Broder
          </surname>
          <given-names>
           KR
          </given-names>
         </name>
        </person-group>
        <article-title>
         Prevention of pertussis, tetanus, and diphtheria among pregnant and postpartum women and their infants. Recommendations of the Advisory Committee on Immunization. Practices (ACIP)
        </article-title>
        <source>
         MMWR Recomm Rep
        </source>
        <volume>
         57
        </volume>
        <issue>
         RR-4
        </issue>
        <year>
         2008
        </year>
        <fpage>
         1
        </fpage>
        <lpage>
         51
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib201">
       <label>
        7
       </label>
       <element-citation id="sbref182" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hsu
          </surname>
          <given-names>
           SS
          </given-names>
         </name>
         <name>
          <surname>
           Groleau
          </surname>
          <given-names>
           G
          </given-names>
         </name>
        </person-group>
        <article-title>
         Tetanus in the emergency department: a current review
        </article-title>
        <source>
         J Emerg Med
        </source>
        <volume>
         20
        </volume>
        <issue>
         4
        </issue>
        <year>
         2001
        </year>
        <fpage>
         357
        </fpage>
        <lpage>
         365
        </lpage>
        <pub-id pub-id-type="pmid">
         11348815
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib202">
       <label>
        8
       </label>
       <element-citation id="sbref183" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Pascual
          </surname>
          <given-names>
           FB
          </given-names>
         </name>
         <name>
          <surname>
           McGinley
          </surname>
          <given-names>
           EL
          </given-names>
         </name>
         <name>
          <surname>
           Zanardi
          </surname>
          <given-names>
           LR
          </given-names>
         </name>
        </person-group>
        <article-title>
         Tetanus surveillance—United States, 1998–2000
        </article-title>
        <source>
         MMWR Surveill Summ
        </source>
        <volume>
         52
        </volume>
        <issue>
         3
        </issue>
        <year>
         2003
        </year>
        <fpage>
         1
        </fpage>
        <lpage>
         8
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib203">
       <label>
        9
       </label>
       <element-citation id="sbref184" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Farrar
          </surname>
          <given-names>
           JJ
          </given-names>
         </name>
         <name>
          <surname>
           Yen
          </surname>
          <given-names>
           LM
          </given-names>
         </name>
         <name>
          <surname>
           Cook
          </surname>
          <given-names>
           T
          </given-names>
         </name>
        </person-group>
        <article-title>
         Tetanus
        </article-title>
        <source>
         J Neurol Neurosurg Psychiatry
        </source>
        <volume>
         69
        </volume>
        <issue>
         3
        </issue>
        <year>
         2000
        </year>
        <fpage>
         292
        </fpage>
        <lpage>
         301
        </lpage>
        <pub-id pub-id-type="pmid">
         10945801
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib204">
       <label>
        10
       </label>
       <mixed-citation id="ceotherref20" publication-type="other">
        American Academy of Pediatrics. Tetanus (lockjaw). In: Pickering LK, Baker CH, Long SS, McMillan JA, editors. Red Book: 2006 Report of the Committee on Infectious Diseases. 27th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2006: p. 648–53.
       </mixed-citation>
      </ref>
     </ref-list>
    </sec>
    <sec id="subchapter20">
     <sec-meta>
      <contrib-group>
       <contrib contrib-type="author" id="au34">
        <name>
         <surname>
          Harriman
         </surname>
         <given-names>
          Kathleen H.
         </given-names>
        </name>
       </contrib>
       <contrib contrib-type="author" id="au35">
        <name>
         <surname>
          Chavez
         </surname>
         <given-names>
          Gilberto F.
         </given-names>
        </name>
       </contrib>
      </contrib-group>
     </sec-meta>
     <title>
      VARICELLA (CHICKENPOX)
     </title>
     <sec id="cesec261">
      <title>
       Infectious Agent
      </title>
      <p id="para1221">
       <list id="celist266" list-type="simple">
        <list-item id="celistitem949">
         <label>
          •
         </label>
         <p id="para1222">
          Varicella-zoster virus (VZV) is a member of the herpesvirus family.
         </p>
        </list-item>
        <list-item id="celistitem950">
         <label>
          •
         </label>
         <p id="para1223">
          Humans are the only reservoir of the virus, and disease occurs only in humans.
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <sec id="cesec262">
      <title>
       Mode of Transmission
      </title>
      <p id="para1224">
       <list id="celist267" list-type="simple">
        <list-item id="celistitem951">
         <label>
          •
         </label>
         <p id="para1225">
          VZV is transmitted from person to person by direct contact, inhalation of aerosols from vesicular fluid of skin lesions of acute varicella or zoster, or infected respiratory tract secretions that might also be aerosolized.
         </p>
        </list-item>
        <list-item id="celistitem952">
         <label>
          •
         </label>
         <p id="para1226">
          The virus enters the host through the upper respiratory tract or the conjunctiva.
         </p>
        </list-item>
        <list-item id="celistitem953">
         <label>
          •
         </label>
         <p id="para1227">
          In utero infection can also occur as a result of transplacental passage of virus during maternal varicella infection.
         </p>
        </list-item>
        <list-item id="celistitem954">
         <label>
          •
         </label>
         <p id="para1228">
          The period of contagiousness is estimated to begin 1–2 days before the onset of rash and to end when all lesions are crusted, typically 4–7 days after onset of rash in immunocompetent persons, but this period may be longer in immunocompromised persons.
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <sec id="cesec263">
      <title>
       Occurrence
      </title>
      <p id="para1229">
       <list id="celist268" list-type="simple">
        <list-item id="celistitem955">
         <label>
          •
         </label>
         <p id="para1230">
          Varicella occurs worldwide. In temperate climates, varicella tends to be a childhood disease, with peak incidence during late winter and early spring. In tropical climates, infection tends to occur at older ages, resulting in higher susceptibility among adults than in temperate climates.
         </p>
        </list-item>
        <list-item id="celistitem956">
         <label>
          •
         </label>
         <p id="para1231">
          Before introduction of varicella vaccine in the United States in 1995, varicella was endemic, and virtually all persons were infected by adulthood. Since implementation of the varicella vaccination program, the epidemiology and clinical characteristics of varicella have changed, with substantial declines in morbidity and mortality. The incidence of varicella has steadily declined in all age groups, with the greatest decline among children 1–4 years of age.
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <sec id="cesec264">
      <title>
       Risk for Travelers
      </title>
      <p id="para1232">
       <list id="celist269" list-type="simple">
        <list-item id="celistitem957">
         <label>
          •
         </label>
         <p id="para1233">
          Varicella vaccine is routinely used for vaccination of healthy children in only some countries, including the United States, Uruguay, Qatar, Australia, Canada, Costa Rica, Germany, and South Korea.
         </p>
        </list-item>
        <list-item id="celistitem958">
         <label>
          •
         </label>
         <p id="para1234">
          The risk for varicella infection is higher for people traveling to most other parts of the world than it is in the United States. However, VZV is still widely circulating in the United States. Additionally, exposure to herpes zoster (shingles), while less common than varicella, poses a risk for varicella infection in susceptible travelers.
         </p>
        </list-item>
        <list-item id="celistitem959">
         <label>
          •
         </label>
         <p id="para1235">
          Travelers at highest risk for severe varicella disease are immunocompromised persons or pregnant women without a history of varicella disease or vaccination.
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <sec id="cesec265">
      <title>
       Clinical Presentation
      </title>
      <p id="para1236">
       <list id="celist270" list-type="simple">
        <list-item id="celistitem960">
         <label>
          •
         </label>
         <p id="para1237">
          Varicella is generally a mild disease in children. It usually lasts 4–7 days and is characterized by a short (1- to 2-day) or absent prodromal period (low-grade fever, malaise) and by a pruritic rash consisting of crops of macules, papules, and vesicles (on average 250–500 lesions), which appear in three or more successive waves and resolve by crusting.
         </p>
        </list-item>
        <list-item id="celistitem961">
         <label>
          •
         </label>
         <p id="para1238">
          Serious complications are the exception but can occur, mainly in infants, adolescents, adults, and immunocompromised persons. They include secondary bacterial infections of skin lesions, pneumonia, cerebellar ataxia, and encephalitis.
         </p>
        </list-item>
        <list-item id="celistitem962">
         <label>
          •
         </label>
         <p id="para1239">
          The average incubation period for varicella is 14–16 days (range 10–21 days).
         </p>
        </list-item>
        <list-item id="celistitem963">
         <label>
          •
         </label>
         <p id="para1240">
          A modified varicella, known as breakthrough disease, can occur in some vaccinated persons, because the vaccine is 70%–90% effective in preventing disease. Breakthrough varicella is most commonly (∼70%–80% of cases) mild, with &lt;50 skin lesions, less fever, and shorter duration of rash. The rash may be atypical in appearance with fewer vesicles and predominance of maculopapular lesions. Nevertheless, breakthrough varicella is infectious (although less than varicella in unvaccinated persons). Persons with breakthrough varicella should be isolated for as long as lesions persist.
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <sec id="cesec266">
      <title>
       Diagnosis
      </title>
      <p id="para1241">
       <list id="celist271" list-type="simple">
        <list-item id="celistitem964">
         <label>
          •
         </label>
         <p id="para1242">
          Skin lesions are the preferred specimen for laboratory confirmation of varicella disease.
          <list id="celist272" list-type="simple">
           <list-item id="celistitem965">
            <label>
             ○
            </label>
            <p id="para1243">
             Vesicular fluid or a scab can be used to identify VZV by using polymerase chain reaction (PCR). Rapid diagnostic tests (PCR, direct fluorescent antibody) are the methods of choice.
            </p>
           </list-item>
           <list-item id="celistitem966">
            <label>
             ○
            </label>
            <p id="para1244">
             VZV can also be isolated from scrapings of a vesicle base during the first 3–4 days of the eruption.
            </p>
           </list-item>
           <list-item id="celistitem967">
            <label>
             ○
            </label>
            <p id="para1245">
             Collecting skin lesion specimens from breakthrough cases can be challenging because the rash is often maculopapular with few or no vesicles. If lesions are not present, scraping of the lesion is recommended.
            </p>
           </list-item>
          </list>
         </p>
        </list-item>
        <list-item id="celistitem968">
         <label>
          •
         </label>
         <p id="para1246">
          Serologic tests for confirmation of disease:
          <list id="celist273" list-type="simple">
           <list-item id="celistitem969">
            <label>
             ○
            </label>
            <p id="para1247">
             A significant rise in serum varicella IgG antibody from acute- and convalescent-phase samples by any standard serologic assay can confirm a diagnosis retrospectively, but may not be reliable in immunocompromised people.
            </p>
           </list-item>
           <list-item id="celistitem970">
            <label>
             ○
            </label>
            <p id="para1248">
             Commercially available tests are not sufficiently sensitive to reliably demonstrate vaccine-induced immunity.
            </p>
           </list-item>
          </list>
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <sec id="cesec267">
      <title>
       Postexposure Prophylaxis
      </title>
      <sec id="cesec268">
       <title>
        Vaccine
       </title>
       <p id="para1249">
        <list id="celist274" list-type="simple">
         <list-item id="celistitem971">
          <label>
           •
          </label>
          <p id="para1250">
           Varicella vaccine is recommended for postexposure administration for healthy unvaccinated persons without other evidence of immunity.
          </p>
         </list-item>
         <list-item id="celistitem972">
          <label>
           •
          </label>
          <p id="para1251">
           Administration of varicella vaccine to exposed susceptible persons Δ12 months of age, as soon as possible within 72 hours and possibly up to 120 hours after exposure, may prevent or modify disease and is recommended if there are no contraindications to use. In several studies, protective efficacy was reported as Δ90% when children were vaccinated within 3 days of exposure.
          </p>
         </list-item>
        </list>
       </p>
      </sec>
      <sec id="cesec269">
       <title>
        Use of Varicella Zoster Immune Globulin (VZIG)
       </title>
       <p id="para1252">
        <list id="celist275" list-type="simple">
         <list-item id="celistitem973">
          <label>
           •
          </label>
          <p id="para1253">
           In certain circumstances, postexposure prophylaxis with VZIG is recommended.
          </p>
         </list-item>
         <list-item id="celistitem974">
          <label>
           •
          </label>
          <p id="para1254">
           The decision to administer VZIG to a person exposed to varicella should be based on 1) whether the person is susceptible, 2) whether the exposure is likely to result in infection, and 3) whether the person is at greater risk for complications than the general population.
          </p>
         </list-item>
         <list-item id="celistitem975">
          <label>
           •
          </label>
          <p id="para1255">
           Persons at greater risk for severe complications who are not candidates for varicella vaccination who may benefit from postexposure prophylaxis with VZIG include:
           <list id="celist276" list-type="simple">
            <list-item id="celistitem976">
             <label>
              ○
             </label>
             <p id="para1256">
              susceptible immunocompromised persons (including people being treated with chronic corticosteroids Δ2 mg/kg of body weight or a total of 20 mg/day of prednisone or equivalent)
             </p>
            </list-item>
            <list-item id="celistitem977">
             <label>
              ○
             </label>
             <p id="para1257">
              susceptible pregnant women
             </p>
            </list-item>
            <list-item id="celistitem978">
             <label>
              ○
             </label>
             <p id="para1258">
              newborns whose mothers had onset of varicella within 5 days before and 2 days after delivery
             </p>
            </list-item>
            <list-item id="celistitem979">
             <label>
              ○
             </label>
             <p id="para1259">
              preterm infants at Δ28 weeks gestation whose mothers are susceptible to varicella
             </p>
            </list-item>
            <list-item id="celistitem980">
             <label>
              ○
             </label>
             <p id="para1260">
              preterm infants at &lt;28 weeks gestation or £1,000 g birth weight, regardless of maternal history or serostatus.
             </p>
            </list-item>
           </list>
          </p>
         </list-item>
         <list-item id="celistitem981">
          <label>
           •
          </label>
          <p id="para1261">
           VZIG provides maximum benefit when administered as soon as possible after exposure, but may be effective if administered as late as 96 hours after exposure.
          </p>
         </list-item>
         <list-item id="celistitem982">
          <label>
           •
          </label>
          <p id="para1262">
           The product currently in use in the United States, VariZIG, is available under an Investigational New Drug protocol and can be obtained from the sole authorized U.S. distributor, FFF enterprises (Temecula, California) (24-hour telephone, 800-843-7477 or
           <ext-link ext-link-type="uri" id="interref54" xlink:href="http://www.fffenterprises.com">
            www.fffenterprises.com
           </ext-link>
           ).
          </p>
         </list-item>
         <list-item id="celistitem983">
          <label>
           •
          </label>
          <p id="para1263">
           If administration of VariZIG does not appear possible within 96 hours of exposure, administration of immune globulin intravenous (IGIV) should be considered as an alternative (IGIV should also be administered within 96 hours of exposure).
          </p>
         </list-item>
        </list>
       </p>
      </sec>
     </sec>
     <sec id="cesec270">
      <title>
       Treatment
      </title>
      <p id="para1264">
       <list id="celist277" list-type="simple">
        <list-item id="celistitem984">
         <label>
          •
         </label>
         <p id="para1265">
          Oral acyclovir is not recommended for routine use in healthy children with varicella but should be considered for otherwise healthy people at increased risk for moderate to severe disease, e.g.: persons aged &gt;12 years; people with chronic cutaneous or pulmonary disorders; receiving long-term salicylate therapy; and receiving short, intermittent or aerosolized courses of corticosteroids.
         </p>
        </list-item>
        <list-item id="celistitem985">
         <label>
          •
         </label>
         <p id="para1266">
          Intravenous antiviral therapy, when administered within 24 hours of onset of rash is recommended for immunocompromised persons, including patients being treated with chronic corticosteroids.
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <sec id="cesec271">
      <title>
       Preventive Measures for Travelers
      </title>
      <p id="para1267">
       Although vaccination against varicella is not a requirement for entry into any country (including the United States), persons traveling or living abroad should ensure that they are immune.
      </p>
      <sec id="cesec272">
       <title>
        Vaccine
       </title>
       <p id="para1268">
        <list id="celist278" list-type="simple">
         <list-item id="celistitem986">
          <label>
           •
          </label>
          <p id="para1269">
           Varicella vaccine contains live, attenuated VZV. It is available as a monovalent formulation and in combination formulation, as measles–mumps–rubella–varicella (MMRV) vaccine, which is licensed in the United States for children 1–12 years only.
          </p>
         </list-item>
         <list-item id="celistitem987">
          <label>
           •
          </label>
          <p id="para1270">
           Two doses of varicella-containing vaccine are now recommended for all susceptible persons older than one year without contraindications. The first dose should be administered at 12–15 months of age and the second dose at 4–6 years of age. A second catch-up dose of varicella vaccination is recommended for children, adolescents and adults who previously have received one dose. The minimum interval for children younger than 13 years is 3 months. The ACIP now recommends that all others at least 13 years of age without evidence of immunity be vaccinated with two doses of varicella vaccine at an interval of 4–8 weeks. In case of uncertainty, prior varicella disease is not a contraindication to varicella vaccination.
          </p>
         </list-item>
         <list-item id="celistitem988">
          <label>
           •
          </label>
          <p id="para1271">
           Evidence of immunity to varicella includes any of the following:
           <list id="celist279" list-type="simple">
            <list-item id="celistitem989">
             <label>
              ○
             </label>
             <p id="para1272">
              Documentation of age-appropriate vaccination:
              <list id="celist280" list-type="simple">
               <list-item id="celistitem990">
                <label>
                 □
                </label>
                <p id="para1273">
                 Preschool-age children aged Δ12 months: 1 dose
                </p>
               </list-item>
               <list-item id="celistitem991">
                <label>
                 □
                </label>
                <p id="para1274">
                 School-age children, adolescents, and adults: 2 doses
                </p>
               </list-item>
              </list>
             </p>
            </list-item>
            <list-item id="celistitem992">
             <label>
              ○
             </label>
             <p id="para1275">
              Laboratory evidence of immunity or laboratory confirmation of disease
             </p>
            </list-item>
            <list-item id="celistitem993">
             <label>
              ○
             </label>
             <p id="para1276">
              Birth in the United States before 1980 (not a criterion for health-care personnel, pregnant women, and immunocompromised persons)
             </p>
            </list-item>
            <list-item id="celistitem994">
             <label>
              ○
             </label>
             <p id="para1277">
              A health-care provider diagnosis of varicella or a health-care provider verification of a history of varicella disease
             </p>
            </list-item>
            <list-item id="celistitem995">
             <label>
              ○
             </label>
             <p id="para1278">
              A health-care provider diagnosis of herpes zoster or a health-care provider verification of a history of herpes zoster disease
             </p>
            </list-item>
           </list>
          </p>
         </list-item>
        </list>
       </p>
       <sec id="cesec273">
        <title>
         Adverse Reactions
        </title>
        <p id="para1279">
         <list id="celist281" list-type="simple">
          <list-item id="celistitem996">
           <label>
            •
           </label>
           <p id="para1280">
            The most common adverse reactions following varicella vaccine are injection site complaints (pain, soreness, redness, and swelling) that are self-limited. Fever was reported in uncontrolled trials in 15% of children and 10% of adolescents and adults. A macular or vaccine rash usually consisting of a few lesions at the injection site was reported in 3% and 1% of persons receiving the first and second dose, respectively. A generalized rash with a small number of lesions may rarely occur, within 3 weeks of vaccination.
           </p>
          </list-item>
          <list-item id="celistitem997">
           <label>
            •
           </label>
           <p id="para1281">
            Varicella vaccine is a live-virus vaccine that induces latent infection similar to that caused by wild VZV. Consequently, zoster caused by vaccine virus has been reported. This appears to occur at a lower rate than following natural infection but longer term follow-up is needed.
           </p>
          </list-item>
         </list>
        </p>
       </sec>
       <sec id="cesec274">
        <title>
         Contraindications
        </title>
        <sec id="cesec275">
         <title>
          Allergy
         </title>
         <p id="para1282">
          <list id="celist282" list-type="simple">
           <list-item id="celistitem998">
            <label>
             •
            </label>
            <p id="para1283">
             Persons with severe allergy (hives, swelling of the mouth or throat, difficulty breathing, hypotension, and shock) to gelatin or neomycin or who have had a severe allergic reaction to a prior dose of vaccine should not be vaccinated.
            </p>
           </list-item>
           <list-item id="celistitem999">
            <label>
             •
            </label>
            <p id="para1284">
             Single-antigen varicella vaccine does not contain egg protein or preservative. For the combination MMRV vaccine, live measles and live mumps vaccine are produced in chick embryo culture. However, the risk for serious allergic reactions after administration of measles- or mumps-containing vaccines in persons who are allergic to eggs is low.
            </p>
           </list-item>
          </list>
         </p>
        </sec>
        <sec id="cesec276">
         <title>
          Altered Immunity
         </title>
         <p id="para1285">
          Persons with immunosuppression of cellular immune function resulting from leukemia, lymphomas of any type, generalized malignancy, immunodeficiency disease, or immunosuppressive therapy should not be vaccinated. Treatment with low-dose prednisone (e.g., &lt;2 mg/kg of body weight/day or &lt;20 mg/day) or aerosolized steroid preparations is not a contraindication to varicella vaccination. Persons whose immunosuppressive therapy with steroids has been stopped for 1 month (3 months for chemotherapy) may be vaccinated. In addition, persons with impaired humoral immunity may now be vaccinated. Because children infected with HIV are at greater risk for morbidity from varicella and herpes zoster than are healthy children, the ACIP recommends that varicella vaccine should be considered for HIV-infected children at least 12 months of age with CD4+ T-lymphocyte percentages Δ15% and without evidence of varicella immunity. Eligible children should receive two doses of single-antigen varicella vaccine, with a minimum 3-month interval between doses. Vaccination (two doses, administered 3 months apart) may be considered for HIV-infected older children, adolescents and adults with CD4+ T-lymphocyte count Δ200 cells/mL, after weighing the risks and benefits.
         </p>
        </sec>
        <sec id="cesec277">
         <title>
          Pregnancy
         </title>
         <p id="para1286">
          Women known to be pregnant or attempting to become pregnant should not receive varicella vaccine. Pregnancy should be avoided for 1 month following varicella vaccination. Breastfeeding is not a contraindication to the varicella vaccination.
         </p>
        </sec>
       </sec>
       <sec id="cesec278">
        <title>
         Precautions
        </title>
        <sec id="cesec279">
         <title>
          Illness
         </title>
         <p id="para1287">
          Vaccination of persons who have acute severe illness, including untreated, active tuberculosis, should be postponed until recovery.
         </p>
        </sec>
        <sec id="cesec280">
         <title>
          Recent Administration of Blood, Plasma, or Immune Globulin
         </title>
         <p id="para1288">
          The effect of the administration of immune globulin (IG) on the response to varicella virus vaccine is unknown. Because of the potential inhibition of the antibody response by passively transferred antibodies, varicella vaccines should not be administered for 3–11 months, depending on the dosage, after administration of blood (except washed red cells), plasma, or IG.
         </p>
        </sec>
        <sec id="cesec281">
         <title>
          Use of Salicylates
         </title>
         <p id="para1289">
          No adverse events following varicella vaccination related to the use of salicylates (e.g., aspirin) have been reported to date. However, the manufacturer recommends that vaccine recipients avoid the use of salicylates for 6 weeks after receiving varicella vaccine because of the association between aspirin use and Reye syndrome following varicella.
         </p>
        </sec>
       </sec>
      </sec>
     </sec>
     <ref-list id="cebib20">
      <title>
       References
      </title>
      <ref id="bib205">
       <label>
        1
       </label>
       <element-citation id="sbref185" publication-type="journal">
        <person-group person-group-type="author">
         <collab>
          CDC
         </collab>
        </person-group>
        <article-title>
         Prevention of varicella. Recommendations of the Advisory Committee on Immunization Practices (ACIP)
        </article-title>
        <source>
         MMWR Morbid Mortal Wkly Rep
        </source>
        <volume>
         56
        </volume>
        <issue>
         RR-4
        </issue>
        <year>
         2007
        </year>
        <fpage>
         1
        </fpage>
        <lpage>
         40
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib206">
       <label>
        2
       </label>
       <element-citation id="sbref186" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gershon
          </surname>
          <given-names>
           AA
          </given-names>
         </name>
         <name>
          <surname>
           Takahasi
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Seward
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         Varicella vaccine
        </chapter-title>
        <person-group person-group-type="editor">
         <name>
          <surname>
           Plotkin
          </surname>
          <given-names>
           SA
          </given-names>
         </name>
         <name>
          <surname>
           Orenstein
          </surname>
          <given-names>
           WA
          </given-names>
         </name>
        </person-group>
        <source>
         Vaccines
        </source>
        <edition>
         4th ed.
        </edition>
        <year>
         2004
        </year>
        <publisher-name>
         W.B. Saunders
        </publisher-name>
        <publisher-loc>
         Philadelphia
        </publisher-loc>
        <fpage>
         783
        </fpage>
        <lpage>
         823
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib207">
       <label>
        3
       </label>
       <element-citation id="sbref187" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Seward
          </surname>
          <given-names>
           JF
          </given-names>
         </name>
         <name>
          <surname>
           Watson
          </surname>
          <given-names>
           BM
          </given-names>
         </name>
         <name>
          <surname>
           Peterson
          </surname>
          <given-names>
           CL
          </given-names>
         </name>
        </person-group>
        <article-title>
         Varicella disease after introduction of varicella vaccine in the United States, 1995–2000
        </article-title>
        <source>
         JAMA
        </source>
        <volume>
         287
        </volume>
        <issue>
         5
        </issue>
        <year>
         2002
        </year>
        <fpage>
         606
        </fpage>
        <lpage>
         611
        </lpage>
        <pub-id pub-id-type="pmid">
         11829699
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib208">
       <label>
        4
       </label>
       <element-citation id="sbref188" publication-type="journal">
        <comment>
        </comment>
        <person-group person-group-type="author">
         <collab>
          CDC
         </collab>
        </person-group>
        <article-title>
         Decline in annual incidence of varicella-selected states, 1990–2001
        </article-title>
        <source>
         MMWR Morbid Mortal Wkly Rep
        </source>
        <volume>
         52
        </volume>
        <issue>
         37
        </issue>
        <year>
         2003
        </year>
        <fpage>
         884
        </fpage>
        <lpage>
         885
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib209">
       <label>
        5
       </label>
       <element-citation id="sbref189" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Guris
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Jumaan
          </surname>
          <given-names>
           AO
          </given-names>
         </name>
         <name>
          <surname>
           Mascola
          </surname>
          <given-names>
           L
          </given-names>
         </name>
        </person-group>
        <article-title>
         Changing varicella epidemiology in active surveillance sites—United States, 1995–2005
        </article-title>
        <source>
         J Infect Dis
        </source>
        <volume>
         197
        </volume>
        <issue>
         Suppl 2
        </issue>
        <year>
         2008
        </year>
        <fpage>
         S71
        </fpage>
        <lpage>
         S75
        </lpage>
        <pub-id pub-id-type="pmid">
         18419413
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib210">
       <label>
        6
       </label>
       <mixed-citation id="ceotherref21" publication-type="other">
        Immunization summary: The 2007 edition. [cited 2008 April 14]. Available from:
        <ext-link ext-link-type="uri" id="interref55" xlink:href="http://www.unicef.org/publications/files/Immunization_Summary_2007.pdf">
         http://www.unicef.org/publications/files/Immunization_Summary_2007.pdf
        </ext-link>
       </mixed-citation>
      </ref>
      <ref id="bib211">
       <label>
        7
       </label>
       <element-citation id="sbref190" publication-type="journal">
        <person-group person-group-type="author">
         <collab>
          CDC
         </collab>
        </person-group>
        <article-title>
         A new product (VariZIG) for postexposure prophylaxis of varicella available under an Investigational New Drug application expanded access protocol
        </article-title>
        <source>
         MMWR Morbid Mortal Wkly Rep
        </source>
        <volume>
         55
        </volume>
        <year>
         2006
        </year>
        <fpage>
         1
        </fpage>
        <lpage>
         2
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib212">
       <label>
        8
       </label>
       <element-citation id="sbref191" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kuter
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Matthews
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Shinefield
          </surname>
          <given-names>
           H
          </given-names>
         </name>
        </person-group>
        <article-title>
         Ten year follow-up of healthy children who received one or two injections of varicella vaccine
        </article-title>
        <source>
         Pediatr Infect Dis J
        </source>
        <volume>
         23
        </volume>
        <issue>
         2
        </issue>
        <year>
         2004
        </year>
        <fpage>
         132
        </fpage>
        <lpage>
         137
        </lpage>
        <pub-id pub-id-type="pmid">
         14872179
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib213">
       <label>
        9
       </label>
       <element-citation id="sbref192" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Seward
          </surname>
          <given-names>
           JF
          </given-names>
         </name>
        </person-group>
        <article-title>
         Update on varicella
        </article-title>
        <source>
         Pediatr Infect Dis J
        </source>
        <volume>
         20
        </volume>
        <issue>
         6
        </issue>
        <year>
         2001
        </year>
        <fpage>
         19
        </fpage>
        <lpage>
         21
        </lpage>
        <pub-id pub-id-type="pmid">
         11176562
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib214">
       <label>
        10
       </label>
       <element-citation id="sbref193" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Harpaz
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Ortega-Sanchez
          </surname>
          <given-names>
           IR
          </given-names>
         </name>
         <name>
          <surname>
           Seward
          </surname>
          <given-names>
           JF
          </given-names>
         </name>
        </person-group>
        <article-title>
         Prevention of herpes zoster. Recommendations of the Advisory Committee on Immunization Practices (ACIP)
        </article-title>
        <source>
         MMWR Recomm Rep
        </source>
        <volume>
         57
        </volume>
        <issue>
         RR-05
        </issue>
        <year>
         2008
        </year>
        <fpage>
         1
        </fpage>
        <lpage>
         30
        </lpage>
       </element-citation>
      </ref>
     </ref-list>
    </sec>
    <sec id="cesec282">
     <title>
     </title>
     <p id="para1290">
      Malaria
     </p>
    </sec>
    <sec id="subchapter21">
     <sec-meta>
      <contrib-group>
       <contrib contrib-type="author" id="au36">
        <name>
         <surname>
          Arguin
         </surname>
         <given-names>
          Paul M.
         </given-names>
        </name>
       </contrib>
       <contrib contrib-type="author" id="au37">
        <name>
         <surname>
          Steele
         </surname>
         <given-names>
          Stefanie F.
         </given-names>
        </name>
       </contrib>
      </contrib-group>
     </sec-meta>
     <title>
      MALARIA
     </title>
     <sec id="cesec283">
      <title>
       Infectious Agent
      </title>
      <p id="para1291">
       Malaria in humans is caused by one of four protozoan species of the genus
       <italic>
        Plasmodium
       </italic>
       :
       <italic>
        P. falciparum, P. vivax, P. ovale
       </italic>
       , or
       <italic>
        P. malariae
       </italic>
       . Recently,
       <italic>
        P. knowlesi
       </italic>
       , a parasite of Old World monkeys, has been documented as a cause of human infections and some fatalities in Southeast Asia. Investigations are ongoing to determine the extent of its transmission to humans.
      </p>
     </sec>
     <sec id="cesec284">
      <title>
       Mode of Transmission
      </title>
      <p id="para1292">
       All species are transmitted by the bite of an infected female
       <italic>
        Anopheles
       </italic>
       mosquito. Occasionally, transmission occurs by blood transfusion, organ transplantation, needle sharing, or congenitally from mother to fetus.
      </p>
     </sec>
     <sec id="cesec285">
      <title>
       Occurrence
      </title>
      <p id="para1293">
       <list id="celist283" list-type="simple">
        <list-item id="celistitem1000">
         <label>
          •
         </label>
         <p id="para1294">
          Each year malaria causes 350–500 million infections worldwide and approximately 1 million deaths.
         </p>
        </list-item>
        <list-item id="celistitem1001">
         <label>
          •
         </label>
         <p id="para1295">
          Transmission occurs in large areas of Central and South America, parts of the Caribbean, Africa, Asia (including South Asia, Southeast Asia, and the Middle East), Eastern Europe, and the South Pacific (
          <xref ref-type="fig" rid="f10">
           Maps 2-7
          </xref>
          and
          <xref ref-type="fig" rid="f11">
           2-8
          </xref>
          ).
          <fig id="f10">
           <label>
            Map 2-7
           </label>
           <caption>
            <p>
             Malaria-endemic countries in the Western Hemisphere.
            </p>
           </caption>
           <graphic xlink:href="gr27">
           </graphic>
          </fig>
          <fig id="f11">
           <label>
            Map 2-8
           </label>
           <caption>
            <p>
             Malaria-endemic countries in the Eastern Hemisphere.
            </p>
           </caption>
           <graphic xlink:href="gr28">
           </graphic>
          </fig>
         </p>
        </list-item>
        <list-item id="celistitem1002">
         <label>
          •
         </label>
         <p id="para1296">
          Information about malaria transmission in specific countries (see the
          <xref ref-type="sec" rid="subchapter22">
           Malaria Risk Information and Prophylaxis, by Country
          </xref>
          , section later in this chapter) is derived from various sources, including WHO.
         </p>
        </list-item>
        <list-item id="celistitem1003">
         <label>
          •
         </label>
         <p id="para1297">
          Tools such as the interactive malaria map can assist in locating more unusual destinations and determining if malaria transmission occurs there (see
          <ext-link ext-link-type="uri" id="interref56" xlink:href="http://www.cdc.gov/malaria/risk_map/">
           www.cdc.gov/malaria/risk_map/
          </ext-link>
          ).
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <sec id="cesec286">
      <title>
       Risk for Travelers
      </title>
      <p id="para1298">
       <list id="celist284" list-type="simple">
        <list-item id="celistitem1004">
         <label>
          •
         </label>
         <p id="para1299">
          The risk for a traveler acquiring malaria differs substantially from region to region and from traveler to traveler, even within a single country.
         </p>
        </list-item>
        <list-item id="celistitem1005">
         <label>
          •
         </label>
         <p id="para1300">
          From 1997 through 2006, 10,745 cases of malaria among U.S. residents were reported to CDC. Of these, 6,376 (59.3%) were acquired in sub-Saharan Africa; 1,498 (13.9%) in Asia; 1,427 (13.3%) in the Caribbean and Central and South America; and 278 (0.03%) in Oceania. During this period, 54 fatal malaria infections occurred among U.S. residents; 46 (85.2%) were caused by
          <italic>
           P. falciparum
          </italic>
          , of which 33 (71.1%) were acquired in sub-Saharan Africa.
         </p>
        </list-item>
        <list-item id="celistitem1006">
         <label>
          •
         </label>
         <p id="para1301">
          These absolute numbers of cases should be considered within the context of the volume of travel to these locations. Regions with the highest estimated relative risk for infection for travelers are West Africa and Oceania. Regions with moderate estimated relative risk for infection are the other parts of Africa, South Asia, and South America. Regions with lower estimated relative risk are Central America and other parts of Asia. There is considerable country-by-country variation, as well as variable transmission within countries and sometimes seasonal variation.
         </p>
        </list-item>
        <list-item id="celistitem1007">
         <label>
          •
         </label>
         <p id="para1302">
          Prevention of malaria involves striking a balance between ensuring that all people who will be at risk for infection use the appropriate prevention measures, while preventing adverse effects of those interventions among people using them unnecessarily. An individual risk assessment should be conducted for every traveler, taking into account not only the destination country, but also the detailed itinerary, including specific cities, types of accommodation, season, and style of travel. In addition, conditions such as pregnancy or the presence of antimalarial drug resistance at the destination may modify the risk assessment.
         </p>
        </list-item>
        <list-item id="celistitem1008">
         <label>
          •
         </label>
         <p id="para1303">
          Depending on level of risk, it may be appropriate to recommend no specific interventions, mosquito avoidance measures only, or mosquito avoidance measures plus chemoprophylaxis.
         </p>
        </list-item>
        <list-item id="celistitem1009">
         <label>
          •
         </label>
         <p id="para1304">
          For areas of intense transmission, such as West Africa, exposure for even short periods of time can result in transmission, so this area should be considered high risk.
         </p>
        </list-item>
        <list-item id="celistitem1010">
         <label>
          •
         </label>
         <p id="para1305">
          Malaria risk is not distributed homogeneously throughout all countries. Some destinations have malaria transmission occurring throughout the whole country, while in others it occurs in defined pockets. If travelers are going to the high-risk pockets during peak transmission times, even though the country as a whole may be low risk, this destination for this individual may be high risk.
         </p>
        </list-item>
        <list-item id="celistitem1011">
         <label>
          •
         </label>
         <p id="para1306">
          Geography is just one part of determining a traveler's risk for infection. Risk can differ substantially for different travelers if their behaviors and circumstances differ. For example, travelers staying in air-conditioned hotels may be at lower risk than backpackers or adventure travelers. Similarly, long-term residents living in screened and air-conditioned housing are less likely to be exposed than are persons living without such amenities.
         </p>
        </list-item>
        <list-item id="celistitem1012">
         <label>
          •
         </label>
         <p id="para1307">
          The highest risk is associated with first- and second-generation immigrants living in nonendemic countries who return to their countries of origin to visit friends and relatives (VFRs). VFR travelers often consider themselves to be at no risk because they grew up in a malarious country and consider themselves immune. However, acquired immunity is lost very quickly, and VFRs should be considered as having the same risk as otherwise nonimmune travelers.
         </p>
        </list-item>
        <list-item id="celistitem1013">
         <label>
          •
         </label>
         <p id="para1308">
          Travelers should also be reminded that even if one has had malaria before, one can get it again and preventive measures are still necessary. All travelers going to malaria-endemic countries, even for short periods of time, such as cruise ship passengers, may be at risk for becoming infected with malaria.
         </p>
        </list-item>
        <list-item id="celistitem1014">
         <label>
          •
         </label>
         <p id="para1309">
          Persons who have been in an area where malaria transmission occurs, either during daytime or nighttime hours, are not permitted to donate blood in the United States for a period of time after returning from the malarious area. Persons who are residents of nonmalarious countries are not permitted to donate blood for 1 year after they have returned from a malarious area. Persons who are residents of malarious countries are not permitted to donate blood for 3 years after leaving a malarious area. Persons who have had malaria are not allowed to donate blood for 3 years after treatment for malaria.
         </p>
        </list-item>
        <list-item id="celistitem1015">
         <label>
          •
         </label>
         <p id="para1310">
          Risk assessments may differ between travel medicine providers and blood banks. A travel medicine provider advising a traveler going to a relatively low-risk country for a short period of time and engaging in behaviors that place them at lower risk for exposure may choose insect avoidance only and no chemoprophylaxis for the traveler. However, upon the traveler's return, a blood bank may still choose to defer that traveler for 1 year because of the travel to an area where transmission occurs.
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <sec id="cesec287">
      <title>
       Clinical Presentation
      </title>
      <p id="para1311">
       <list id="celist285" list-type="simple">
        <list-item id="celistitem1016">
         <label>
          •
         </label>
         <p id="para1312">
          Malaria is characterized by fever and influenza-like symptoms, including chills, headache, myalgias, and malaise; these symptoms can occur at intervals.
         </p>
        </list-item>
        <list-item id="celistitem1017">
         <label>
          •
         </label>
         <p id="para1313">
          Uncomplicated disease may be associated with anemia and jaundice. In severe disease, most commonly caused by
          <italic>
           P. falciparum
          </italic>
          , seizures, mental confusion, kidney failure, acute respiratory disease syndrome (ARDS), coma, and death may occur.
         </p>
        </list-item>
        <list-item id="celistitem1018">
         <label>
          •
         </label>
         <p id="para1314">
          Malaria symptoms can develop as early as 7 days (usually at least 14 days) after initial exposure in a malaria-endemic area and as late as several months or more after departure.
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <sec id="cesec288">
      <title>
       Diagnosis
      </title>
      <p id="para1315">
       <list id="celist286" list-type="simple">
        <list-item id="celistitem1019">
         <label>
          •
         </label>
         <p id="para1316">
          Travelers who have symptoms of malaria should be advised to seek medical evaluation
          <bold>
           as soon as possible
          </bold>
          .
         </p>
        </list-item>
        <list-item id="celistitem1020">
         <label>
          •
         </label>
         <p id="para1317">
          Smear microscopy remains the gold standard for malaria diagnosis. Microscopy can also be used to determine the species of malaria parasite and quantify the parasitemia—both of which are necessary pieces of information for providing the most appropriate treatment.
         </p>
        </list-item>
        <list-item id="celistitem1021">
         <label>
          •
         </label>
         <p id="para1318">
          Various test kits are available to detect antigens derived from malaria parasites. Such immunologic (immunochromatographic) tests most often use a dipstick or cassette format and provide results in 2–15 minutes. These rapid diagnostic tests (RDTs) offer a useful alternative to microscopy in situations where reliable microscopic diagnosis is not available. The U.S. Food and Drug Administration (FDA) has approved one RDT for use in the United States by hospital and commercial laboratories, not by individual clinicians or by patients themselves. This RDT, called BinaxNOW Malaria test, is produced by Inverness Medical Professional Diagnostics, located in Scarborough, Maine.
         </p>
        </list-item>
        <list-item id="celistitem1022">
         <label>
          •
         </label>
         <p id="para1319">
          Polymerase chain reaction (PCR) tests are also available for detecting malaria parasites; however, none are FDA-approved. Although these tests are slightly more sensitive than routine microscopy, results are not usually available as quickly as microscopy results should be, thus limiting the clinical utility of this test. PCR testing can be used to determine the species of the parasite if the microscopic results are ambiguous.
         </p>
        </list-item>
        <list-item id="celistitem1023">
         <label>
          •
         </label>
         <p id="para1320">
          In sub-Saharan Africa, the rate of false-positive blood films for malaria may be very high. Travelers to this region should be warned they may be diagnosed with malaria incorrectly, even though they are taking a reliable antimalarial regimen. In such cases, acutely ill travelers should be advised to seek the best available medical services and follow the treatment offered locally (except the use of halofantrine which is not recommended; see below), but
          <bold>
           not
          </bold>
          to stop their chemoprophylaxis regimen.
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <sec id="cesec289">
      <title>
       Treatment
      </title>
      <p id="para1321">
       <list id="celist287" list-type="simple">
        <list-item id="celistitem1024">
         <label>
          •
         </label>
         <p id="para1322">
          Malaria can be treated effectively early in the course of the disease, but delay of appropriate therapy can have serious or even fatal consequences.
         </p>
        </list-item>
        <list-item id="celistitem1025">
         <label>
          •
         </label>
         <p id="para1323">
          Travelers who have symptoms of malaria should be advised to seek medical evaluation
          <bold>
           as soon as possible
          </bold>
          .
         </p>
        </list-item>
        <list-item id="celistitem1026">
         <label>
          •
         </label>
         <p id="para1324">
          Specific treatment options depend on the species of malaria, the likelihood of drug resistance (based on the location of acquisition of infection), the age of the patient, pregnancy status, and the severity of infection. If possible, it is advisable to consult with a provider who has specialized travel/tropical medicine expertise or with an infectious disease physician.
         </p>
        </list-item>
        <list-item id="celistitem1027">
         <label>
          •
         </label>
         <p id="para1325">
          CDC recommendations for malaria treatment can be found at
          <ext-link ext-link-type="uri" id="interref57" xlink:href="http://www.cdc.gov/malaria/diagnosis_treatment/treatment.htm">
           www.cdc.gov/malaria/diagnosis_treatment/treatment.htm
          </ext-link>
          .
         </p>
        </list-item>
        <list-item id="celistitem1028">
         <label>
          •
         </label>
         <p id="para1326">
          Medications that are not used in the United States for the treatment of malaria, such as halofantrine (Halfan), are widely available overseas. CDC does not recommend halofantrine for treatment because of cardiac adverse events, including deaths, which have been documented following treatment doses. These adverse events have occurred in persons with and without pre-existing cardiac problems and both in the presence and absence of other antimalarial drugs (e.g., mefloquine).
         </p>
        </list-item>
       </list>
      </p>
      <sec id="cesec290">
       <title>
        Self-Treatment (
        <xref ref-type="table" rid="cetable22">
         Table 2-22
        </xref>
        )
       </title>
       <p id="para1327">
        <list id="celist288" list-type="simple">
         <list-item id="celistitem1029">
          <label>
           •
          </label>
          <p id="para1328">
           Travelers who reject the advice to take prophylaxis, who choose a suboptimal drug regimen (e.g., chloroquine in an area with chloroquine-resistant
           <italic>
            P. falciparum
           </italic>
           ), or who require a less-than-optimal drug regimen for medical reasons are at greater risk for acquiring malaria and needing prompt treatment.
          </p>
         </list-item>
         <list-item id="celistitem1030">
          <label>
           •
          </label>
          <p id="para1329">
           Travelers who are taking effective prophylaxis but who will be in very remote areas may decide, in consultation with their health-care provider, to take along a full course of an approved malaria treatment regimen for self-treatment. This should occur very rarely.
          </p>
         </list-item>
         <list-item id="celistitem1031">
          <label>
           •
          </label>
          <p id="para1330">
           Travelers should be advised to take their presumptive self-treatment promptly if they have fever, chills, or other influenza-like illness and if professional medical care is not available within 24 hours.
           <bold>
            Travelers should be advised that this self-treatment of a possible malarial infection is only a temporary measure and that prompt medical evaluation is imperative
           </bold>
           .
          </p>
         </list-item>
         <list-item id="celistitem1032">
          <label>
           •
          </label>
          <p id="para1331">
           Atovaquone/proguanil may be used for presumptive self-treatment for travelers NOT taking atovaquone/proguanil for prophylaxis. If taking atovaquone/proguanil for prophylaxis, the use of the same drug at therapeutic doses is not recommended to empirically treat fever (suspected malaria). The CDC Malaria Branch (Malaria Hotline 770-488-7788) can provide consultation to health-care providers on other potential options for self-treatment if atovaquone/proguanil cannot be used.
          </p>
         </list-item>
        </list>
        <table-wrap id="cetable22" position="float">
         <label>
          Table 2-22
         </label>
         <caption>
          <p>
           Presumptive self-treatment of malaria
          </p>
         </caption>
         <table frame="hsides" rules="groups">
          <thead>
           <tr>
            <th align="left">
             Drug
            </th>
            <th align="left">
             Adult Dose
            </th>
            <th align="left">
             Pediatric Dose
            </th>
            <th align="left">
             Comments
            </th>
           </tr>
          </thead>
          <tbody>
           <tr>
            <td align="left">
             Atovaquone/proguanil (Malarone). Self-treatment drug to be used if professional medical care is not available within 24 hours. Medical care should be sought immediately after treatment.
            </td>
            <td align="left">
             4 tablets (each dose contains 1,000 mg atovaquone and 400 mg proguanil) orally as a single daily dose for 3 consecutive days
            </td>
            <td align="left">
             Daily dose to be taken for 3 consecutive days: 5–8 kg: 2 pediatric tablets; 9–10 kg: 3 pediatric tablets; 11–20 kg: 1 adult tablet; 21–30 kg: 2 adult tablets; 31–40 kg: 3 adult tablets; &gt;41 kg: 4 adult tablets
            </td>
            <td align="left">
             Contraindicated in persons with severe renal impairment (creatinine clearance &lt;30 mL/min). Not recommended for self-treatment in persons on atovaquone/proguanil prophylaxis. Not currently recommended for children &lt;5 kg, pregnant women, and women breastfeeding infants weighing &lt;5 kg
            </td>
           </tr>
          </tbody>
         </table>
        </table-wrap>
       </p>
      </sec>
      <sec id="cesec291">
       <title>
        Malaria Hotline
       </title>
       <p id="para1332">
        <list id="celist289" list-type="simple">
         <list-item id="celistitem1033">
          <label>
           •
          </label>
          <p id="para1333">
           Health-care professionals who require assistance with the diagnosis or treatment of malaria should call the CDC Malaria Hotline (770-488-7788) from 8:00 am to 4:30 pm Eastern time. After hours or on weekends and holidays, health-care providers requiring assistance should call the CDC Emergency Operations Center at 770-488-7100 and ask the operator to page the person on call for the Malaria Branch.
          </p>
         </list-item>
         <list-item id="celistitem1034">
          <label>
           •
          </label>
          <p id="para1334">
           Information on diagnosis and treatment is available at
           <ext-link ext-link-type="uri" id="interref58" xlink:href="http://www.cdc.gov/malaria">
            www.cdc.gov/malaria
           </ext-link>
           .
          </p>
         </list-item>
        </list>
       </p>
      </sec>
     </sec>
     <sec id="cesec292">
      <title>
       Preventive Measures for Travelers
      </title>
      <p id="para1335">
       Malaria prevention consists of a combination of mosquito avoidance measures and chemoprophylaxis. Although very efficacious, none of the recommended interventions are 100% effective.
      </p>
      <sec id="cesec293">
       <title>
        Mosquito Avoidance Measures
       </title>
       <p id="para1336">
        <list id="celist290" list-type="simple">
         <list-item id="celistitem1035">
          <label>
           •
          </label>
          <p id="para1337">
           Because of the nocturnal feeding habits of
           <italic>
            Anopheles
           </italic>
           mosquitoes, malaria transmission occurs primarily between dusk and dawn.
          </p>
         </list-item>
         <list-item id="celistitem1036">
          <label>
           •
          </label>
          <p id="para1338">
           Contact with mosquitoes can be reduced by remaining in well-screened areas, using mosquito bed nets (preferably insecticide-treated nets), using a pyrethroid-containing flying-insect spray in living and sleeping areas during evening and nighttime hours, and wearing clothes that cover most of the body.
          </p>
         </list-item>
         <list-item id="celistitem1037">
          <label>
           •
          </label>
          <p id="para1339">
           All travelers should use an effective mosquito repellent.
          </p>
         </list-item>
         <list-item id="celistitem1038">
          <label>
           •
          </label>
          <p id="para1340">
           The most effective repellent against a wide range of vectors is DEET (
           <italic>
            N
           </italic>
           ,
           <italic>
            N
           </italic>
           -diethylmetatoluamide), an ingredient in many commercially available insect repellents. The actual concentration of DEET varies widely among repellents. DEET formulations as high as 50% are recommended for both adults and children older than 2 months of age (see the
           <xref ref-type="sec" rid="subchapter29">
            Protection Against Mosquitoes, Ticks, and Other Insects and Arthropods
           </xref>
           section later in this chapter). DEET should be applied to the exposed parts of the skin when mosquitoes are likely to be present.
          </p>
         </list-item>
         <list-item id="celistitem1039">
          <label>
           •
          </label>
          <p id="para1341">
           In addition to using a topical insect repellent, a permethrin-containing product may be applied to bed nets and clothing for additional protection against mosquitoes.
          </p>
         </list-item>
        </list>
       </p>
      </sec>
      <sec id="cesec294">
       <title>
        Chemoprophylaxis
       </title>
       <p id="para1342">
        <list id="celist291" list-type="simple">
         <list-item id="celistitem1040">
          <label>
           •
          </label>
          <p id="para1343">
           All currently recommended primary chemoprophylaxis regimens involve taking a medicine before travel, during travel, and for a period of time after leaving the malaria endemic area. Beginning the drug before travel allows the antimalarial agent to be in the blood before the traveler is exposed to malaria parasites.
          </p>
         </list-item>
         <list-item id="celistitem1041">
          <label>
           •
          </label>
          <p id="para1344">
           Presumptive antirelapse therapy (also known as terminal prophylaxis) uses a medication towards the end of the exposure period (or immediately thereafter) to prevent relapses or delayed-onset clinical presentations of malaria caused by hypnozoites (dormant liver stages) of
           <italic>
            P. vivax
           </italic>
           or
           <italic>
            P. ovale
           </italic>
           . Because most malarious areas of the world (except the Caribbean) have at least one species of relapsing malaria, travelers to these areas have some risk for acquiring either
           <italic>
            P. vivax
           </italic>
           or
           <italic>
            P. ovale
           </italic>
           , although the actual risk for an individual traveler is difficult to define. Presumptive anti-relapse therapy is generally indicated only for persons who have had prolonged exposure in malaria-endemic areas (e.g., missionaries, volunteers).
          </p>
         </list-item>
         <list-item id="celistitem1042">
          <label>
           •
          </label>
          <p id="para1345">
           In choosing an appropriate chemoprophylactic regimen before travel, the traveler and the health-care provider should consider several factors. The travel itinerary should be reviewed in detail and compared with the information on where malaria transmission occurs within a given country (see the
           <xref ref-type="sec" rid="subchapter22">
            Malaria Risk Information and Prophylaxis, by Country
           </xref>
           , section later in this chapter) to determine whether the traveler will actually be traveling in a part of the country where malaria occurs and if significant antimalarial drug resistance has been reported in that location.
          </p>
         </list-item>
         <list-item id="celistitem1043">
          <label>
           •
          </label>
          <p id="para1346">
           The resistance of
           <italic>
            P. falciparum
           </italic>
           to chloroquine has been confirmed in all areas with
           <italic>
            P. falciparum
           </italic>
           malaria except the Caribbean, Central America west of the Panama Canal, and some countries in the Middle East. In addition, resistance to sulfadoxine–pyrimethamine (e.g., Fansidar) is widespread in the Amazon River Basin area of South America, much of Southeast Asia, other parts of Asia, and in large parts of Africa. Resistance to mefloquine has been confirmed on the borders of Thailand with Burma (Myanmar) and Cambodia, in the western provinces of Cambodia, in the eastern states of Burma (Myanmar), on the border between Burma and China, along the borders of Laos and Burma, and the adjacent parts of the Thailand–Cambodia border, as well as in southern Vietnam (
           <xref ref-type="fig" rid="f12">
            Map 2-9
           </xref>
           ).
           <fig id="f12">
            <label>
             Map 2-9
            </label>
            <caption>
             <p>
              Geographic distribution of mefloquine-resistant malaria.
             </p>
            </caption>
            <graphic xlink:href="gr29">
            </graphic>
           </fig>
          </p>
         </list-item>
         <list-item id="celistitem1044">
          <label>
           •
          </label>
          <p id="para1347">
           Additional factors to consider are the patient's other medical conditions, medications being taken (to assess potential drug–drug interactions), the cost of the medicines, and the potential side effects.
          </p>
         </list-item>
         <list-item id="celistitem1045">
          <label>
           •
          </label>
          <p id="para1348">
           The medications recommended for chemoprophylaxis of malaria may also be available at overseas destinations. However, combinations of these medications and additional drugs that are not recommended may be commonly prescribed and used in other countries. Travelers should be strongly discouraged from obtaining chemoprophylactic medications while abroad. The quality of these products is not known, and they may not be protective and may be dangerous. These medications may have been produced by substandard manufacturing practices, may be counterfeit, or may contain contaminants. Additional information on this topic can be found in
           <italic>
            Perspectives:
           </italic>
           Counterfeit Drugs later in this chapter and in an FDA document Purchasing Medications Outside the United States (
           <ext-link ext-link-type="uri" id="interref59" xlink:href="http://www.fda.gov/ora/import/purchasing_medications.htm">
            www.fda.gov/ora/import/purchasing_medications.htm
           </ext-link>
           ).
          </p>
         </list-item>
        </list>
       </p>
       <sec id="cesec295">
        <title>
         Medications Used for Chemoprophylaxis
        </title>
        <sec id="cesec296">
         <title>
          Atovaquone/Proguanil (Malarone)
         </title>
         <p id="para1349">
          <list id="celist292" list-type="simple">
           <list-item id="celistitem1046">
            <label>
             •
            </label>
            <p id="para1350">
             Atovaquone/proguanil is a fixed combination of the two drugs, atovaquone and proguanil.
            </p>
           </list-item>
           <list-item id="celistitem1047">
            <label>
             •
            </label>
            <p id="para1351">
             Prophylaxis should begin 1–2 days before travel to malarious areas and should be taken daily, at the same time each day, while in the malarious areas, and daily for 7 days after leaving the area (see
             <xref ref-type="table" rid="cetable23">
              Table 2-23
             </xref>
             for recommended dosages).
             <table-wrap id="cetable23" position="float">
              <label>
               Table 2-23
              </label>
              <caption>
               <p>
                Drugs used in the prophylaxis of malaria
               </p>
              </caption>
              <table frame="hsides" rules="groups">
               <thead>
                <tr>
                 <th align="left">
                  Drug
                 </th>
                 <th align="left">
                  Usage
                 </th>
                 <th align="left">
                  Adult Dose
                 </th>
                 <th align="left">
                  Pediatric Dose
                 </th>
                 <th align="left">
                  Comments
                 </th>
                </tr>
               </thead>
               <tbody>
                <tr>
                 <td align="left">
                  Atovaquone/proguanil (Malarone)
                 </td>
                 <td align="left">
                  Prophylaxis in all areas
                 </td>
                 <td align="left">
                  Adult tablets contain 250 mg atovaquone and 100 mg proguanil hydrochloride. 1 adult tablet orally, daily
                 </td>
                 <td align="left">
                  Pediatric tablets contain 62.5 mg atovaquone and 25 mg proguanil hydrochloride. 5-8 kg: frac12; pediatric tablet daily; &gt;8–10 kg: frac34; pediatric tablet daily; &gt;10-20 kg: 1 pediatric tablet daily; &gt;20-30 kg: 2 pediatric tablets daily; &gt;30-40 kg: 3 pediatric tablets daily; &gt;40 kg: 1 adult tablet daily
                 </td>
                 <td align="left">
                  Begin 1-2 days before travel to malarious areas. Take daily at the same time each day while in the malarious area and for 7 days after leaving such areas. Contraindicated in persons with severe renal impairment (creatinine clearance &lt;30 mL/min). Atovaquone/proguanil should be taken with food or a milky drink. Not recommended for prophylaxis for children &lt;5 kg, pregnant women, and women breastfeeding infants weighing &lt;5 kg. Partial tablet dosages may need to be prepared by a pharmacist and dispensed in individual capsules, as described in the text.
                 </td>
                </tr>
                <tr>
                 <td align="left">
                  Chloroquine phosphate (Aralen and generic)
                 </td>
                 <td align="left">
                  Prophylaxis only in areas with chloroquine-sensitive malaria
                 </td>
                 <td align="left">
                  300 mg base (500 mg salt) orally, once/week
                 </td>
                 <td align="left">
                  <list id="celist20" list-type="simple">
                   <list-item id="celistitem60">
                    <p id="para60">
                     5 mg/kg base (8.3 mg/kg salt) orally,
                    </p>
                   </list-item>
                   <list-item id="celistitem61">
                    <p id="para61">
                     once/week, up to maximum adult dose of 300 mg base
                    </p>
                   </list-item>
                  </list>
                 </td>
                 <td align="left">
                  Begin 1-2 weeks before travel to malarious areas. Take weekly on the same day of the week while in the malarious area and for 4 weeks after leaving such areas. May exacerbate psoriasis
                 </td>
                </tr>
                <tr>
                 <td align="left">
                  Doxycycline (many brand names and generic)
                 </td>
                 <td align="left">
                  Prophylaxis in all areas
                 </td>
                 <td align="left">
                  100 mg orally, daily
                 </td>
                 <td align="left">
                  &gt;8 years of age: 2 mg/kg up to adult dose of 100 mg/day
                 </td>
                 <td align="left">
                  Begin 1-2 days before travel to malarious areas. Take daily at the same time each day while in the malarious area and for 4 weeks after leaving such areas. Contraindicated in children &lt;8 years of age and pregnant women
                 </td>
                </tr>
                <tr>
                 <td align="left">
                  Hydroxychloroquine sulfate (Plaquenil)
                 </td>
                 <td align="left">
                  An alternative to chloroquine for prophylaxis only in areas with chloroquine-sensitive malaria
                 </td>
                 <td align="left">
                  310 mg base (400 mg salt) orally, once/week
                 </td>
                 <td align="left">
                  <list id="celist21" list-type="simple">
                   <list-item id="celistitem62">
                    <p id="para62">
                     5 mg/kg base (6.5 mg/kg salt) orally,
                    </p>
                   </list-item>
                   <list-item id="celistitem63">
                    <p id="para63">
                     once/week, up to maximum adult dose of 310 mg base
                    </p>
                   </list-item>
                  </list>
                 </td>
                 <td align="left">
                  Begin 1-2 weeks before travel to malarious areas. Take weekly on the same day of the week while in the malarious area and for 4 weeks after leaving such areas.
                 </td>
                </tr>
                <tr>
                 <td align="left">
                  Mefloquine (Lariam and generic)
                 </td>
                 <td align="left">
                  Prophylaxis in areas with mefloquine-sensitive malaria
                 </td>
                 <td align="left">
                  228 mg base (250 mg salt) orally, once/week
                 </td>
                 <td align="left">
                  &lt;9 kg: 4.6 mg/kg base (5 mg/kg salt) orally, once/week; &gt;9–19 kg: frac14; tablet once/week; &gt;19-30 kg: frac12; tablet once/week;
                 </td>
                 <td align="left">
                  Begin 1-2 weeks before travel to malarious areas. Take weekly on the same day of the week while in the malarious area and for 4 weeks after leaving such areas. Contraindicated in persons allergic to mefloquine or related compounds (e.g., quinine, quinidine) and in persons with active depression, a recent history of depression, generalized anxiety disorder,
                 </td>
                </tr>
                <tr>
                 <td align="left">
                  Mefloquine (Lariam and generic)
                 </td>
                 <td>
                 </td>
                 <td>
                 </td>
                 <td align="left">
                  &gt;31–45 kg: frac34; tablet once/week; &gt;45 kg: 1 tablet once/week
                 </td>
                 <td align="left">
                  psychosis, schizophrenia, other major psychiatric disorders, or seizures. Use with caution in persons with psychiatric disturbances or a previous history of depression. Not recommended for persons with cardiac conduction abnormalities
                 </td>
                </tr>
                <tr>
                 <td align="left">
                  Primaquine
                 </td>
                 <td align="left">
                  Prophylaxis for short-duration travel to areas with principally
                  <italic>
                   P. vivax
                  </italic>
                 </td>
                 <td align="left">
                  30 mg base (52.6 mg salt) orally, daily
                 </td>
                 <td align="left">
                  0.5 mg/kg base (0.8 mg/kg salt) up to adult dose orally, daily
                 </td>
                 <td align="left">
                  <list id="celist22" list-type="simple">
                   <list-item id="celistitem64">
                    <p id="para64">
                     Begin 1-2 days before travel to malarious areas. Take daily at the same time each day while in the malarious area and for 7 days after leaving such areas.
                    </p>
                   </list-item>
                   <list-item id="celistitem65">
                    <p id="para65">
                     Contraindicated in persons with G6PD deficiency. Also contraindicated during pregnancy and lactation unless the infant being breastfed has a documented normal G6PD level
                    </p>
                   </list-item>
                  </list>
                 </td>
                </tr>
                <tr>
                 <td align="left">
                  Primaquine
                 </td>
                 <td align="left">
                  Used for presumptive antirelapse therapy (terminal prophylaxis) to decrease the risk for relapses of
                  <italic>
                   P. vivax and P. ovale
                  </italic>
                 </td>
                 <td align="left">
                  30 mg base (52.6 mg salt) orally, once/day for 14 days after departure from the malarious area
                 </td>
                 <td align="left">
                  0.5 mg/kg base (0.8 mg/kg salt) up to adult dose orally, once/day for 14 days after departure from the malarious area
                 </td>
                 <td align="left">
                  Indicated for persons who have had prolonged exposure to
                  <italic>
                   P. vivax
                  </italic>
                  and
                  <italic>
                   P. ovale
                  </italic>
                  or both. Contraindicated in persons with G6PD deficiency. Also contraindicated during pregnancy and lactation unless the infant being breastfed has a documented normal G6PD level
                 </td>
                </tr>
               </tbody>
              </table>
              <table-wrap-foot>
               <fn>
                <p>
                 1 Glucose-6-phosphate dehydrogenase. All persons who take primaquine should have a documented normal G6PD level before starting the medication.
                </p>
               </fn>
              </table-wrap-foot>
             </table-wrap>
            </p>
           </list-item>
           <list-item id="celistitem1048">
            <label>
             •
            </label>
            <p id="para1352">
             Malarone is very well tolerated, and side effects are rare. The most common adverse effects reported in persons using atovaquone/proguanil for prophylaxis or treatment are abdominal pain, nausea, vomiting, and headache. Malarone should not be used for prophylaxis in children weighing &lt;5 kg, pregnant women, or patients with severe renal impairment (creatinine clearance &lt;30 mL/min). It should be used with caution by patients taking coumadin (warfarin) for anticoagulation.
            </p>
           </list-item>
          </list>
         </p>
        </sec>
        <sec id="cesec297">
         <title>
          Chloroquine (Aralen) and Hydroxychloroquine (Plaquenil)
         </title>
         <p id="para1353">
          <list id="celist293" list-type="simple">
           <list-item id="celistitem1049">
            <label>
             •
            </label>
            <p id="para1354">
             Chloroquine phosphate or hydroxychloroquine sulfate can be used for prevention of malaria only in destinations where chloroquine resistance is not present (see
             <xref ref-type="fig" rid="f10">
              Maps 2-7
             </xref>
             and
             <xref ref-type="fig" rid="f11">
              2-8
             </xref>
             or the next section in this chapter,
             <xref ref-type="sec" rid="subchapter22">
              Malaria Risk Information and Prophylaxis, by Country
             </xref>
             ).
            </p>
           </list-item>
           <list-item id="celistitem1050">
            <label>
             •
            </label>
            <p id="para1355">
             Prophylaxis should begin 1–2 weeks before travel to malarious areas. It should be continued by taking the drug once a week, on the same day of the week, during travel in malarious areas and for 4 weeks after a traveler leaves these areas (see
             <xref ref-type="table" rid="cetable23">
              Table 2-23
             </xref>
             for recommended dosages).
            </p>
           </list-item>
           <list-item id="celistitem1051">
            <label>
             •
            </label>
            <p id="para1356">
             Reported side effects include gastrointestinal disturbance, headache, dizziness, blurred vision, insomnia, and pruritus, but generally these effects do not require that the drug be discontinued. High doses of chloroquine, such as those used to treat rheumatoid arthritis, have been associated with retinopathy; this serious side effect appears to be extremely unlikely when chloroquine is used for routine weekly malaria prophylaxis. Chloroquine and related compounds have been reported to exacerbate psoriasis. Persons who experience uncomfortable side effects after taking chloroquine may tolerate the drug better by taking it with meals. As an alternative, the related compound hydroxychloroquine sulfate may be better tolerated.
            </p>
           </list-item>
          </list>
         </p>
         <p id="para1357">
          <boxed-text id="cetextbox4">
           <label>
            Box 2-2
           </label>
           <caption>
            <title>
             Clinical pearls
            </title>
           </caption>
           <p id="para1358">
            <list id="celist294" list-type="simple">
             <list-item id="celistitem1052">
              <label>
               •
              </label>
              <p id="para1359">
               Overdose of antimalarial drugs, particularly chloroquine, can be fatal. Medication should be stored in childproof containers out of the reach of infants and children.
              </p>
             </list-item>
             <list-item id="celistitem1053">
              <label>
               •
              </label>
              <p id="para1360">
               Chemoprophylaxis can be started earlier if there are particular concerns about tolerating one of the medications. For example, mefloquine can be started 3–4 weeks in advance to allow potential adverse events to occur before travel. If unacceptable side effects develop, there would be time to change the medication before the traveler's departure.
              </p>
             </list-item>
             <list-item id="celistitem1054">
              <label>
               •
              </label>
              <p id="para1361">
               The drugs used for antimalarial chemoprophylaxis are generally well tolerated. However, side effects can occur. Minor side effects usually do not require stopping the drug. Travelers who have serious side effects should see a health-care provider who can determine if their symptoms are related to the medicine and make an appropriate medication change.
              </p>
             </list-item>
             <list-item id="celistitem1055">
              <label>
               •
              </label>
              <p id="para1362">
               In comparison with drugs with short half-lives, which are taken daily, drugs with longer half-lives, which are taken weekly, offer the advantage of a wider margin of error if the traveler is late with a dose. For example, if a traveler is 1–2 days late with a weekly drug, prophylactic blood levels can remain adequate; if the traveler is 1–2 days late with a daily drug, protective blood levels are less likely to be maintained.
              </p>
             </list-item>
             <list-item id="celistitem1056">
              <label>
               •
              </label>
              <p id="para1363">
               In those who are G6PD deficient, primaquine can cause hemolysis, which can be fatal. Be sure to document a normal G6PD level before prescribing primaquine.
              </p>
             </list-item>
             <list-item id="celistitem1057">
              <label>
               •
              </label>
              <p id="para1364">
               Travelers should be informed that malaria can be fatal if treatment is delayed. Medical help should be sought promptly if malaria is suspected, and a blood sample should be taken and examined for malaria parasites on one or more occasions.
              </p>
             </list-item>
             <list-item id="celistitem1058">
              <label>
               •
              </label>
              <p id="para1365">
               Malaria smear results or an RDT test must be available immediately. Sending specimens to offsite laboratories where results are not available for extended periods of time (days) is not acceptable. If a patient has an illness suggestive of severe malaria and a compatible travel history in an area where malaria transmission occurs, it is advisable to start treatment as soon as possible, even before the diagnosis is established. CDC recommendations for malaria treatment can be found at
               <ext-link ext-link-type="uri" id="interref60" xlink:href="http://www.cdc.gov/malaria/diagnosis_treatment/treatment.htm">
                www.cdc.gov/malaria/diagnosis_treatment/treatment.htm
               </ext-link>
               .
              </p>
             </list-item>
            </list>
           </p>
          </boxed-text>
         </p>
        </sec>
        <sec id="cesec298">
         <title>
          Doxycycline (Many Brand Names and Generic)
         </title>
         <p id="para1366">
          <list id="celist295" list-type="simple">
           <list-item id="celistitem1059">
            <label>
             •
            </label>
            <p id="para1367">
             Doxycycline prophylaxis should begin 1–2 days before travel to malarious areas. It should be continued once a day, at the same time each day, during travel in malarious areas and daily for 4 weeks after the traveler leaves such areas.
            </p>
           </list-item>
           <list-item id="celistitem1060">
            <label>
             •
            </label>
            <p id="para1368">
             Insufficient data exist on the antimalarial prophylactic efficacy of related compounds such as minocycline (commonly prescribed for the treatment of acne). Persons on a long-term regimen of minocycline who are in need of malaria prophylaxis should stop taking minocycline 1–2 days before travel and start doxycycline instead. The minocycline can be restarted after the full course of doxycycline is completed (see
             <xref ref-type="table" rid="cetable23">
              Table 2-23
             </xref>
             for recommended dosages).
            </p>
           </list-item>
           <list-item id="celistitem1061">
            <label>
             •
            </label>
            <p id="para1369">
             Doxycycline can cause photosensitivity, usually manifested as an exaggerated sunburn reaction. The risk for such a reaction can be minimized by avoiding prolonged, direct exposure to the sun and by using sunscreens. In addition, doxycycline use is associated with an increased frequency of vaginal yeast infections. Gastrointestinal side effects (nausea or vomiting) may be minimized by taking the drug with a meal. To reduce the risk for esophagitis, travelers should be advised not to take doxycycline before going to bed. Doxycycline is contraindicated in persons with an allergy to tetracyclines, during pregnancy, and in infants and children &lt;8 years of age.
            </p>
           </list-item>
           <list-item id="celistitem1062">
            <label>
             •
            </label>
            <p id="para1370">
             Vaccination with the oral typhoid vaccine Ty21a should be delayed for at least 24 hours after taking a dose of doxycycline.
            </p>
           </list-item>
          </list>
         </p>
        </sec>
        <sec id="cesec299">
         <title>
          Mefloquine (Lariam)
         </title>
         <p id="para1371">
          <list id="celist296" list-type="simple">
           <list-item id="celistitem1063">
            <label>
             •
            </label>
            <p id="para1372">
             Mefloquine prophylaxis should begin 1–2 weeks before travel to malarious areas. It should be continued once a week, on the same day of the week, during travel in malarious areas and for 4 weeks after a traveler leaves such areas (see
             <xref ref-type="table" rid="cetable23">
              Table 2-23
             </xref>
             for recommended dosages).
            </p>
           </list-item>
           <list-item id="celistitem1064">
            <label>
             •
            </label>
            <p id="para1373">
             Mefloquine has been associated with rare serious adverse reactions (e.g., psychoses, seizures) at prophylactic doses; these reactions are more frequent with the higher doses used for treatment. Other side effects that have occurred in chemoprophylaxis studies include gastrointestinal disturbance, headache, insomnia, abnormal dreams, visual disturbances, depression, anxiety disorder, and dizziness. Other more severe neuropsychiatric disorders occasionally reported during postmarketing surveillance include sensory and motor neuropathies (including paresthesia, tremor, and ataxia), agitation or restlessness, mood changes, panic attacks, forgetfulness, confusion, hallucinations, aggression, paranoia, and encephalopathy. On occasion, psychiatric symptoms have been reported to continue long after mefloquine has been stopped. Mefloquine is contraindicated for use by travelers with a known hypersensitivity to mefloquine or related compounds (e.g., quinine, quinidine) and in persons with active depression, a recent history of depression, generalized anxiety disorder, psychosis, schizophrenia, other major psychiatric disorders, or seizures. It should be used with caution in persons with psychiatric disturbances or a previous history of depression. A review of available data suggests that mefloquine may be used in persons concurrently on beta blockers, if they have no underlying arrhythmia. However, mefloquine is not recommended for persons with cardiac conduction abnormalities.
            </p>
           </list-item>
           <list-item id="celistitem1065">
            <label>
             •
            </label>
            <p id="para1374">
             Any traveler receiving a prescription for mefloquine must also receive a copy of the FDA Medication Guide, which can be found at the following website:
             <ext-link ext-link-type="uri" id="interref61" xlink:href="http://www.fda.gov/cder/foi/label/2003/19591s19lbl_Lariam.pdf">
              www.fda.gov/cder/foi/label/2003/19591s19lbl_Lariam.pdf
             </ext-link>
             .
            </p>
           </list-item>
          </list>
         </p>
        </sec>
        <sec id="cesec300">
         <title>
          Primaquine
         </title>
         <p id="para1375">
          <list id="celist297" list-type="simple">
           <list-item id="celistitem1066">
            <label>
             •
            </label>
            <p id="para1376">
             Primaquine phosphate has two distinct uses for malaria prevention: primary prophylaxis and presumptive antirelapse therapy (also called terminal prophylaxis).
            </p>
           </list-item>
           <list-item id="celistitem1067">
            <label>
             •
            </label>
            <p id="para1377">
             When taken for primary prophylaxis, primaquine should be taken 1–2 days before travel to malarious areas, daily, at the same time each day, while in the malarious areas, and daily for 7 days after leaving the areas (see
             <xref ref-type="table" rid="cetable23">
              Table 2-23
             </xref>
             for recommended dosages). Primary prophylaxis with primaquine obviates the need for presumptive antirelapse therapy.
            </p>
           </list-item>
           <list-item id="celistitem1068">
            <label>
             •
            </label>
            <p id="para1378">
             When used for presumptive antirelapse therapy, primaquine is administered for 14 days after the traveler has left a malarious area. When chloroquine, doxycycline, or mefloquine is used for primary prophylaxis, primaquine is usually taken during the last 2 weeks of postexposure prophylaxis. When atovaquone/proguanil is used for prophylaxis, primaquine may be taken during the final 7 days of atovaquone/proguanil, and then for an additional 7 days. It is preferable that primaquine be given concurrently with the primary prophylaxis medication. However, if that is not feasible, the primaquine course should still be administered after the primary prophylaxis medication has been completed.
            </p>
           </list-item>
           <list-item id="celistitem1069">
            <label>
             •
            </label>
            <p id="para1379">
             The most common adverse event in glucose-6-phosphate dehydrogenase (G6PD) in normal persons is gastrointestinal upset if primaquine is taken on an empty stomach. This problem is minimized or eliminated if primaquine is taken with food.
            </p>
           </list-item>
           <list-item id="celistitem1070">
            <label>
             •
            </label>
            <p id="para1380">
             In G6PD-deficient persons, primaquine can cause hemolysis that can be fatal.
             <bold>
              Before primaquine is used, G6PD deficiency MUST be ruled out by appropriate laboratory testing
             </bold>
             .
            </p>
           </list-item>
          </list>
         </p>
        </sec>
       </sec>
       <sec id="cesec301">
        <title>
         Travel to Areas with Limited Malaria Transmission
        </title>
        <p id="para1381">
         For destinations (see the next section in this chapter,
         <xref ref-type="sec" rid="subchapter22">
          Malaria Risk Information and Prophylaxis, by Country
         </xref>
         ) where malaria cases occur sporadically and risk for infection to travelers is assessed as being very low, it is recommended that travelers use mosquito avoidance measures only, and no chemoprophylaxis should be prescribed.
        </p>
       </sec>
       <sec id="cesec302">
        <title>
         Travel to Areas with Mainly P. vivax
         <italic>
          Malaria
         </italic>
        </title>
        <p id="para1382">
         <list id="celist298" list-type="simple">
          <list-item id="celistitem1071">
           <label>
            •
           </label>
           <p id="para1383">
            For destinations where the main species of malaria present is
            <italic>
             P. vivax
            </italic>
            , in addition to mosquito avoidance measures, primaquine is a good choice for primary prophylaxis for travelers who are not G6PD-deficient. Its use for this indication is considered off-label use in the United States.
           </p>
          </list-item>
          <list-item id="celistitem1072">
           <label>
            •
           </label>
           <p id="para1384">
            The predominant species of malaria and the recommended chemoprohylaxis medicines are listed in the following section in this chapter,
            <xref ref-type="sec" rid="subchapter22">
             Malaria Risk Information and Prophylaxis, by Country
            </xref>
            .
           </p>
          </list-item>
          <list-item id="celistitem1073">
           <label>
            •
           </label>
           <p id="para1385">
            For persons unable to take primaquine, other drugs can be used as described below, depending on the presence of antimalarial drug resistance.
           </p>
          </list-item>
         </list>
        </p>
       </sec>
       <sec id="cesec303">
        <title>
         Travel to Areas with Chloroquine-Sensitive Malaria
        </title>
        <p id="para1386">
         <list id="celist299" list-type="simple">
          <list-item id="celistitem1074">
           <label>
            •
           </label>
           <p id="para1387">
            For destinations where chloroquine-sensitive malaria is present, in addition to mosquito avoidance measures, the many effective chemoprophylaxis alternatives include chloroquine, atovaquone/proguanil, doxycycline, mefloquine, and in some instances primaquine for travelers who are not G6PD-deficient.
           </p>
          </list-item>
          <list-item id="celistitem1075">
           <label>
            •
           </label>
           <p id="para1388">
            Longer-term travelers may prefer the convenience of weekly chloroquine, while shorter-term travelers may prefer the shorter course of atovaquone/proguanil or primaquine.
           </p>
          </list-item>
         </list>
        </p>
       </sec>
       <sec id="cesec304">
        <title>
         Travel to Areas with Chloroquine-Resistant Malaria
        </title>
        <p id="para1389">
         For destinations where chloroquine-resistant malaria is present, in addition to mosquito avoidance measures, chemoprophylaxis options are limited to atovaquone/proguanil, doxycycline, and mefloquine.
        </p>
       </sec>
       <sec id="cesec305">
        <title>
         Travel to Areas with Mefloquine-Resistant Malaria
        </title>
        <p id="para1390">
         For destinations where mefloquine-resistant malaria is present, in addition to mosquito avoidance measures, chemoprophylaxis options are reduced to either atovaquone/proguanil or doxycycline.
        </p>
       </sec>
       <sec id="cesec306">
        <title>
         Chemoprophylaxis for Infants, Children, and Adolescents
        </title>
        <p id="para1391">
         <list id="celist300" list-type="simple">
          <list-item id="celistitem1076">
           <label>
            •
           </label>
           <p id="para1392">
            Infants of any age or weight or children and adolescents of any age can contract malaria. Therefore, all children traveling to malaria-risk areas should take an antimalarial drug.
           </p>
          </list-item>
          <list-item id="celistitem1077">
           <label>
            •
           </label>
           <p id="para1393">
            In the United States, antimalarial drugs are available only in tablet form and may taste quite bitter. Pediatric dosages should be carefully calculated according to body weight but should never exceed adult dosage. Pharmacists can pulverize tablets and prepare gelatin capsules for each measured dose. If the child is unable to swallow the capsules or tablets, parents should prepare the child's dose of medication by breaking open the gelatin capsule and mixing the drug with a small amount of something sweet, such as applesauce, chocolate syrup, or jelly, to ensure the entire dose is delivered to the child. Giving the dose on a full stomach may minimize stomach upset and vomiting.
           </p>
          </list-item>
          <list-item id="celistitem1078">
           <label>
            •
           </label>
           <p id="para1394">
            Chloroquine and mefloquine are options for use in infants and children of all ages and weights, depending on the presence of drug resistance at their destination.
           </p>
          </list-item>
          <list-item id="celistitem1079">
           <label>
            •
           </label>
           <p id="para1395">
            Primaquine can be used for children who are not G6PD-deficient traveling to areas with principally
            <italic>
             P. vivax
            </italic>
            .
           </p>
          </list-item>
          <list-item id="celistitem1080">
           <label>
            •
           </label>
           <p id="para1396">
            Doxycycline may be used for children who are at least 8 years of age.
           </p>
          </list-item>
          <list-item id="celistitem1081">
           <label>
            •
           </label>
           <p id="para1397">
            Atovaquone/proguanil may be used for prophylaxis for infants and children weighing at least 5 kg (11 lbs). Providers should note that this prophylactic dosing for children weighing &lt;11 kg constitutes off-label use in the United States.
           </p>
          </list-item>
          <list-item id="celistitem1082">
           <label>
            •
           </label>
           <p id="para1398">
            Pediatric dosing regimens are contained in
            <xref ref-type="table" rid="cetable23">
             Table 2-23
            </xref>
            .
           </p>
          </list-item>
         </list>
        </p>
       </sec>
       <sec id="cesec307">
        <title>
         Chemoprophylaxis during Pregnancy and Breastfeeding
        </title>
        <p id="para1399">
         <list id="celist301" list-type="simple">
          <list-item id="celistitem1083">
           <label>
            •
           </label>
           <p id="para1400">
            Malaria infection in pregnant women can be more severe than in nonpregnant women. Malaria can increase the risk for adverse pregnancy outcomes, including prematurity, abortion, and stillbirth. For these reasons, and because no chemoprophylactic regimen is completely effective, women who are pregnant or likely to become pregnant should be advised to avoid travel to areas with malaria transmission if possible (see the Traveling while Pregnant section in Chapter 8). If travel to a malarious area cannot be deferred, use of an effective chemoprophylaxis regimen is essential.
           </p>
          </list-item>
          <list-item id="celistitem1084">
           <label>
            •
           </label>
           <p id="para1401">
            Pregnant women traveling to areas where chloroquine-resistant
            <italic>
             P. falciparum
            </italic>
            has not been reported may take chloroquine prophylaxis. Chloroquine has not been found to have any harmful effects on the fetus when used in the recommended doses for malaria prophylaxis; therefore, pregnancy is not a contraindication for malaria prophylaxis with chloroquine phosphate or hydroxychloroquine sulfate.
           </p>
          </list-item>
          <list-item id="celistitem1085">
           <label>
            •
           </label>
           <p id="para1402">
            For travel to areas where chloroquine resistance is present, mefloquine is currently the only medication recommended for malaria chemoprophylaxis during pregnancy. A review of mefloquine use in pregnancy from clinical trials and reports of inadvertent use of mefloquine during pregnancy suggests that its use at prophylactic doses during the second and third trimesters of pregnancy is not associated with adverse fetal or pregnancy outcomes. More limited data suggest it is also safe to use during the first trimester.
           </p>
          </list-item>
          <list-item id="celistitem1086">
           <label>
            •
           </label>
           <p id="para1403">
            Because of insufficient data regarding the use during pregnancy, atovaquone/proguanil is not currently recommended for the prevention of malaria in pregnant women.
           </p>
          </list-item>
          <list-item id="celistitem1087">
           <label>
            •
           </label>
           <p id="para1404">
            Doxycycline is contraindicated for malaria prophylaxis during pregnancy because of the risk for adverse effects seen with tetracycline, a related drug, on the fetus, which include discoloration and dysplasia of the teeth and inhibition of bone growth.
           </p>
          </list-item>
          <list-item id="celistitem1088">
           <label>
            •
           </label>
           <p id="para1405">
            Primaquine should not be used during pregnancy because the drug may be passed transplacentally to a G6PD-deficient fetus and cause hemolytic anemia in utero.
           </p>
          </list-item>
          <list-item id="celistitem1089">
           <label>
            •
           </label>
           <p id="para1406">
            Health-care professionals who require additional assistance with the management of pregnant travelers who are unable to take mefloquine chemoprophylaxis should call the CDC Malaria Hotline (770-488-7788).
           </p>
          </list-item>
          <list-item id="celistitem1090">
           <label>
            •
           </label>
           <p id="para1407">
            Very small amounts of antimalarial drugs are excreted in the breast milk of lactating women. Because the quantity of antimalarial drugs transferred in breast milk is insufficient to provide adequate protection against malaria, infants who require chemoprophylaxis must receive the recommended dosages of antimalarial drugs listed in
            <xref ref-type="table" rid="cetable23">
             Table 2-23
            </xref>
            .
           </p>
          </list-item>
          <list-item id="celistitem1091">
           <label>
            •
           </label>
           <p id="para1408">
            Because chloroquine and mefloquine may be safely prescribed to infants, it is also safe for infants to be exposed to the small amounts excreted in breast milk.
           </p>
          </list-item>
          <list-item id="celistitem1092">
           <label>
            •
           </label>
           <p id="para1409">
            Although data are very limited about the use of doxycycline in lactating women, most experts consider the theoretical possibility of adverse events to the infant to be remote.
           </p>
          </list-item>
          <list-item id="celistitem1093">
           <label>
            •
           </label>
           <p id="para1410">
            Although no information is available on the amount of primaquine that enters human breast milk, the mother and infant should be tested for G6PD deficiency before primaquine is given to a woman who is breastfeeding.
           </p>
          </list-item>
          <list-item id="celistitem1094">
           <label>
            •
           </label>
           <p id="para1411">
            Because data are not yet available on the safety of atovaquone/proguanil prophylaxis in infants weighing &lt;5 kg (&lt;11 lbs), CDC does not currently recommend it for the prevention of malaria in women breastfeeding infants weighing &lt;5 kg. However, it can be used for treatment of women who are breastfeeding infants of any weight when the potential benefit outweighs the potential risk to the infant (e.g., treating a breastfeeding woman who has acquired
            <italic>
             P. falciparum
            </italic>
            malaria in an area of multidrug-resistant strains and who cannot tolerate other treatment options).
           </p>
          </list-item>
         </list>
        </p>
       </sec>
       <sec id="cesec308">
        <title>
         Changing Medications during Chemoprophylaxis as a Result of Side Effects
        </title>
        <p id="para1412">
         <list id="celist302" list-type="simple">
          <list-item id="celistitem1095">
           <label>
            •
           </label>
           <p id="para1413">
            Medications recommended for prophylaxis against malaria have different modes of action that affect the parasites at different stages of the life cycle. Thus, if the medication needs to be changed because of side effects before a full course has been completed, there are some special considerations.
           </p>
          </list-item>
          <list-item id="celistitem1096">
           <label>
            •
           </label>
           <p id="para1414">
            If a traveler starts prophylaxis with a medication such as mefloquine or doxycycline and then changes to atovaquone/proguanil during or after travel, the standard duration of prophylaxis for atovaquone/proguanil would be insufficient.
           </p>
          </list-item>
          <list-item id="celistitem1097">
           <label>
            •
           </label>
           <p id="para1415">
            If the switch occurs 3 weeks or more before departure from the risk area, atovaquone/proguanil should be taken for the remainder of the stay in the risk area and for 1 week thereafter.
           </p>
          </list-item>
          <list-item id="celistitem1098">
           <label>
            •
           </label>
           <p id="para1416">
            If the switch occurs &lt;3 weeks before departure from the risk area, atovaquone/proguanil should be taken for 4 weeks after the switch.
           </p>
          </list-item>
          <list-item id="celistitem1099">
           <label>
            •
           </label>
           <p id="para1417">
            If the switch occurs following departure from the risk area, atovaquone/proguanil should be continued until 4 weeks after the date of departure from the risk area.
           </p>
          </list-item>
          <list-item id="celistitem1100">
           <label>
            •
           </label>
           <p id="para1418">
            Due to their pharmacokinetics, switching from a daily medicine such as doxycycline to a weekly medicine such as mefloquine should be avoided.
           </p>
          </list-item>
          <list-item id="celistitem1101">
           <label>
            •
           </label>
           <p id="para1419">
            Health-care professionals who require additional assistance with the management of travelers who need to change medications during prophylaxis should call the CDC Malaria Hotline (770-488-7788).
           </p>
          </list-item>
         </list>
        </p>
       </sec>
      </sec>
     </sec>
     <ref-list id="cebib21">
      <title>
       References
      </title>
      <ref id="bib215">
       <label>
        1
       </label>
       <mixed-citation id="ceotherref22" publication-type="other">
        Malaria map application. [cited 2008 Nov 26]. Available from:
        <ext-link ext-link-type="uri" id="interref62" xlink:href="http://www.cdc.gov/malaria/risk_map/">
         http://www.cdc.gov/malaria/risk_map/
        </ext-link>
        .
       </mixed-citation>
      </ref>
      <ref id="bib216">
       <label>
        2
       </label>
       <mixed-citation id="ceotherref23" publication-type="other">
        Malaria website. [cited 2008 Nov 26]. Available from:
        <ext-link ext-link-type="uri" id="interref63" xlink:href="http://www.cdc.gov/malaria/">
         http://www.cdc.gov/malaria/
        </ext-link>
        .
       </mixed-citation>
      </ref>
      <ref id="bib217">
       <label>
        3
       </label>
       <element-citation id="sbref194" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cox-Singh
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Davis
          </surname>
          <given-names>
           TM
          </given-names>
         </name>
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           KS
          </given-names>
         </name>
        </person-group>
        <article-title>
         <italic>
          Plasmodium knowlesi
         </italic>
         malaria in humans is widely distributed and potentially life threatening
        </article-title>
        <source>
         Clin Infect Dis
        </source>
        <volume>
         46
        </volume>
        <issue>
         2
        </issue>
        <year>
         2008
        </year>
        <fpage>
         165
        </fpage>
        <lpage>
         171
        </lpage>
        <pub-id pub-id-type="pmid">
         18171245
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib218">
       <label>
        4
       </label>
       <element-citation id="sbref195" publication-type="journal">
        <comment>
        </comment>
        <person-group person-group-type="author">
         <name>
          <surname>
           Guinovart
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Navia
          </surname>
          <given-names>
           MM
          </given-names>
         </name>
         <name>
          <surname>
           Tanner
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <article-title>
         Malaria: burden of disease
        </article-title>
        <source>
         Curr Mol Med
        </source>
        <volume>
         6
        </volume>
        <issue>
         2
        </issue>
        <year>
         2006
        </year>
        <fpage>
         137
        </fpage>
        <lpage>
         140
        </lpage>
        <pub-id pub-id-type="pmid">
         16515506
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib219">
       <label>
        5
       </label>
       <element-citation id="sbref196" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Mali
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Steele
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Slutsker
          </surname>
          <given-names>
           L
          </given-names>
         </name>
        </person-group>
        <article-title>
         Malaria surveillance—United States, 2006
        </article-title>
        <source>
         MMWR Surveill Summ
        </source>
        <volume>
         57
        </volume>
        <issue>
         5
        </issue>
        <year>
         2008
        </year>
        <fpage>
         24
        </fpage>
        <lpage>
         39
        </lpage>
        <pub-id pub-id-type="pmid">
         18566568
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib220">
       <label>
        6
       </label>
       <element-citation id="sbref197" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Newman
          </surname>
          <given-names>
           RD
          </given-names>
         </name>
         <name>
          <surname>
           Parise
          </surname>
          <given-names>
           ME
          </given-names>
         </name>
         <name>
          <surname>
           Barber
          </surname>
          <given-names>
           AM
          </given-names>
         </name>
        </person-group>
        <article-title>
         Malaria-related deaths among U.S. travelers, 1963–2001
        </article-title>
        <source>
         Ann Intern Med
        </source>
        <volume>
         141
        </volume>
        <issue>
         7
        </issue>
        <year>
         2004
        </year>
        <fpage>
         547
        </fpage>
        <lpage>
         555
        </lpage>
        <pub-id pub-id-type="pmid">
         15466772
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib221">
       <label>
        7
       </label>
       <element-citation id="sbref198" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Leder
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Black
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           O'Brien
          </surname>
          <given-names>
           D
          </given-names>
         </name>
        </person-group>
        <article-title>
         Malaria in travelers: a review of the GeoSentinel surveillance network
        </article-title>
        <source>
         Clin Infect Dis
        </source>
        <volume>
         39
        </volume>
        <issue>
         8
        </issue>
        <year>
         2004
        </year>
        <fpage>
         1104
        </fpage>
        <lpage>
         1112
        </lpage>
        <pub-id pub-id-type="pmid">
         15486832
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib222">
       <label>
        8
       </label>
       <element-citation id="sbref199" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Leder
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Tong
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Weld
          </surname>
          <given-names>
           L
          </given-names>
         </name>
        </person-group>
        <article-title>
         Illness in travelers visiting friends and relatives: a review of the GeoSentinel surveillance network
        </article-title>
        <source>
         Clin Infect Dis
        </source>
        <volume>
         43
        </volume>
        <year>
         2006
        </year>
        <fpage>
         1185
        </fpage>
        <lpage>
         1193
        </lpage>
        <pub-id pub-id-type="pmid">
         17029140
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib223">
       <label>
        9
       </label>
       <element-citation id="sbref200" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kitchen
          </surname>
          <given-names>
           AD
          </given-names>
         </name>
         <name>
          <surname>
           Chiodini
          </surname>
          <given-names>
           PL
          </given-names>
         </name>
        </person-group>
        <article-title>
         Malaria and blood transfusion
        </article-title>
        <source>
         Vox Sanguin
        </source>
        <volume>
         90
        </volume>
        <issue>
         2
        </issue>
        <year>
         2006
        </year>
        <fpage>
         77
        </fpage>
        <lpage>
         84
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib224">
       <label>
        10
       </label>
       <element-citation id="sbref201" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Parise
          </surname>
          <given-names>
           ME
          </given-names>
         </name>
         <name>
          <surname>
           Lewis
          </surname>
          <given-names>
           LS
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         Severe malaria: North American perspective
        </chapter-title>
        <person-group person-group-type="editor">
         <name>
          <surname>
           Feldman
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Sarosi
          </surname>
          <given-names>
           GA
          </given-names>
         </name>
        </person-group>
        <source>
         Tropical and parasitic infections in the ICU
        </source>
        <year>
         2005
        </year>
        <publisher-name>
         Springer Science+ Buisness Media, Inc.
        </publisher-name>
        <publisher-loc>
         New York
        </publisher-loc>
        <fpage>
         17
        </fpage>
        <lpage>
         38
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib225">
       <label>
        11
       </label>
       <element-citation id="sbref202" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kochar
          </surname>
          <given-names>
           DK
          </given-names>
         </name>
         <name>
          <surname>
           Saxena
          </surname>
          <given-names>
           V
          </given-names>
         </name>
         <name>
          <surname>
           Singh
          </surname>
          <given-names>
           N
          </given-names>
         </name>
        </person-group>
        <article-title>
         <italic>
          Plasmodium vivax
         </italic>
         malaria
        </article-title>
        <source>
         Emerg Infect Dis
        </source>
        <volume>
         11
        </volume>
        <issue>
         1
        </issue>
        <year>
         2005
        </year>
        <fpage>
         132
        </fpage>
        <lpage>
         134
        </lpage>
        <pub-id pub-id-type="pmid">
         15705338
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib226">
       <label>
        12
       </label>
       <element-citation id="sbref203" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Reyburn
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Mbatia
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Drakeley
          </surname>
          <given-names>
           C
          </given-names>
         </name>
        </person-group>
        <article-title>
         Overdiagnosis of malaria in patients with severe febrile illness in Tanzania: a prospective study
        </article-title>
        <source>
         BMJ
        </source>
        <volume>
         329
        </volume>
        <issue>
         7476
        </issue>
        <year>
         2004
        </year>
        <fpage>
         1212
        </fpage>
        <pub-id pub-id-type="pmid">
         15542534
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib227">
       <label>
        13
       </label>
       <element-citation id="sbref204" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hill
          </surname>
          <given-names>
           DR
          </given-names>
         </name>
         <name>
          <surname>
           Ericsson
          </surname>
          <given-names>
           CD
          </given-names>
         </name>
         <name>
          <surname>
           Pearson
          </surname>
          <given-names>
           RD
          </given-names>
         </name>
        </person-group>
        <article-title>
         The practice of travel medicine: guidelines by the Infectious Diseases Society of America
        </article-title>
        <source>
         Clin Infect Dis
        </source>
        <volume>
         43
        </volume>
        <issue>
         12
        </issue>
        <year>
         2006
        </year>
        <fpage>
         1499
        </fpage>
        <lpage>
         1539
        </lpage>
        <pub-id pub-id-type="pmid">
         17109284
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib228">
       <label>
        14
       </label>
       <element-citation id="sbref205" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Fradin
          </surname>
          <given-names>
           MS
          </given-names>
         </name>
         <name>
          <surname>
           day
          </surname>
          <given-names>
           JF
          </given-names>
         </name>
        </person-group>
        <article-title>
         Comparative efficacy of insect repellents against mosquito bites
        </article-title>
        <source>
         N Engl J Med
        </source>
        <volume>
         347
        </volume>
        <issue>
         1
        </issue>
        <year>
         2002
        </year>
        <fpage>
         13
        </fpage>
        <lpage>
         18
        </lpage>
        <pub-id pub-id-type="pmid">
         12097535
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib229">
       <label>
        15
       </label>
       <element-citation id="sbref206" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Boggild
          </surname>
          <given-names>
           AK
          </given-names>
         </name>
         <name>
          <surname>
           Parise
          </surname>
          <given-names>
           ME
          </given-names>
         </name>
         <name>
          <surname>
           Lewis
          </surname>
          <given-names>
           LS
          </given-names>
         </name>
        </person-group>
        <article-title>
         Atovaquone-proguanil: report from the CDC expert meeting on malaria chemoprophylaxis (II)
        </article-title>
        <source>
         Am J Trop Med Hyg
        </source>
        <volume>
         76
        </volume>
        <issue>
         2
        </issue>
        <year>
         2007
        </year>
        <fpage>
         208
        </fpage>
        <lpage>
         223
        </lpage>
        <pub-id pub-id-type="pmid">
         17297027
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib230">
       <label>
        16
       </label>
       <element-citation id="sbref207" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Baird
          </surname>
          <given-names>
           JK
          </given-names>
         </name>
         <name>
          <surname>
           Fryauff
          </surname>
          <given-names>
           DJ
          </given-names>
         </name>
         <name>
          <surname>
           Hoffman
          </surname>
          <given-names>
           SL
          </given-names>
         </name>
        </person-group>
        <article-title>
         Primaquine for prevention of malaria in travelers
        </article-title>
        <source>
         Clin Infect Dis
        </source>
        <volume>
         37
        </volume>
        <issue>
         12
        </issue>
        <year>
         2003
        </year>
        <fpage>
         1659
        </fpage>
        <lpage>
         1667
        </lpage>
        <pub-id pub-id-type="pmid">
         14689349
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib231">
       <label>
        17
       </label>
       <element-citation id="sbref208" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hill
          </surname>
          <given-names>
           DR
          </given-names>
         </name>
         <name>
          <surname>
           Baird
          </surname>
          <given-names>
           JK
          </given-names>
         </name>
         <name>
          <surname>
           Parise
          </surname>
          <given-names>
           ME
          </given-names>
         </name>
        </person-group>
        <article-title>
         Primaquine: report from CDC expert meeting on malaria chemoprophylaxis I
        </article-title>
        <source>
         Am J Trop Med Hyg
        </source>
        <volume>
         75
        </volume>
        <issue>
         3
        </issue>
        <year>
         2006
        </year>
        <fpage>
         402
        </fpage>
        <lpage>
         415
        </lpage>
        <pub-id pub-id-type="pmid">
         16968913
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib232">
       <label>
        18
       </label>
       <element-citation id="sbref209" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Schwartz
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Parise
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Kozarsky
          </surname>
          <given-names>
           P
          </given-names>
         </name>
        </person-group>
        <article-title>
         Delayed onset of malaria-implications for chemoprophylaxis in travelers
        </article-title>
        <source>
         N Engl J Med
        </source>
        <volume>
         349
        </volume>
        <issue>
         16
        </issue>
        <year>
         2003
        </year>
        <fpage>
         1510
        </fpage>
        <lpage>
         1516
        </lpage>
        <pub-id pub-id-type="pmid">
         14561793
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib233">
       <label>
        19
       </label>
       <element-citation id="sbref210" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Whitty
          </surname>
          <given-names>
           CJ M
          </given-names>
         </name>
         <name>
          <surname>
           Edmonds
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Mutabingwa
          </surname>
          <given-names>
           TK
          </given-names>
         </name>
        </person-group>
        <article-title>
         Malaria in pregnancy
        </article-title>
        <source>
         BJOG
        </source>
        <volume>
         112
        </volume>
        <issue>
         9
        </issue>
        <year>
         2005
        </year>
        <fpage>
         1189
        </fpage>
        <lpage>
         1195
        </lpage>
        <pub-id pub-id-type="pmid">
         16101595
        </pub-id>
       </element-citation>
      </ref>
     </ref-list>
    </sec>
    <sec id="subchapter22">
     <sec-meta>
      <contrib-group>
       <contrib contrib-type="author" id="au38">
        <name>
         <surname>
          Tan
         </surname>
         <given-names>
          Kathrine R.
         </given-names>
        </name>
       </contrib>
       <contrib contrib-type="author" id="au39">
        <name>
         <surname>
          Mali
         </surname>
         <given-names>
          Sonja
         </given-names>
        </name>
       </contrib>
       <contrib contrib-type="author" id="au40">
        <name>
         <surname>
          Arguin
         </surname>
         <given-names>
          Paul M.
         </given-names>
        </name>
       </contrib>
      </contrib-group>
     </sec-meta>
     <title>
      MALARIA RISK INFORMATION AND PROPHYLAXIS, BY COUNTRY
     </title>
     <p id="para1420">
      <table-wrap id="cetable30" position="float">
       <label>
        Table 2-24
       </label>
       <caption>
        <p>
         <bold>
          Malaria risk information and prophylaxis, by country
         </bold>
         <xref ref-type="table-fn" rid="cetablefn80">
          1
         </xref>
        </p>
       </caption>
       <table frame="hsides" rules="groups">
        <thead>
         <tr>
          <th align="left">
           Country
          </th>
          <th align="left">
           Areas with Malaria
          </th>
          <th align="left">
           Drug Resistance
           <xref ref-type="table-fn" rid="cetablefn81">
            2
           </xref>
          </th>
          <th align="left">
           Malaria Species
           <xref ref-type="table-fn" rid="cetablefn82">
            3
           </xref>
          </th>
          <th align="left">
           Recommended Chemoprophylaxis
           <xref ref-type="table-fn" rid="cetablefn83">
            4
           </xref>
          </th>
         </tr>
        </thead>
        <tbody>
         <tr>
          <td align="left">
           <bold>
            Afghanistan
           </bold>
          </td>
          <td align="left">
           April–December in all areas at altitudes &lt;2,000 m (&lt;6,561 ft)
          </td>
          <td align="left">
           Chloroquine
          </td>
          <td align="left">
           <italic>
            P. vivax
           </italic>
           80%–90%
           <break>
           </break>
           <italic>
            P. falciparum
           </italic>
           10%–20%
          </td>
          <td align="left">
           Atovaquone/proguanil, doxycycline, or mefloquine
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Albania
           </bold>
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Algeria
           </bold>
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Andorra
           </bold>
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Angola
           </bold>
          </td>
          <td align="left">
           All
          </td>
          <td align="left">
           Chloroquine
          </td>
          <td align="left">
           <italic>
            P. falciparum
           </italic>
           90%
           <break>
           </break>
           <italic>
            P. ovale
           </italic>
           5%
           <break>
           </break>
           <italic>
            P. vivax
           </italic>
           5%
          </td>
          <td align="left">
           Atovaquone/proguanil, doxycycline, or mefloquine
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Anguilla
           </bold>
           (U.K.)
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Antarctica
           </bold>
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Antigua and Barbuda
           </bold>
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Argentina
           </bold>
          </td>
          <td align="left">
           Rural areas of Salta and Jujuy provinces (along Bolivian border) and Misiones and Corrientes provinces (along border of Paraguay). Malaria present in Iguassu Falls
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           <italic>
            P. vivax
           </italic>
           100%
          </td>
          <td align="left">
           Atovaquone/proguanil, chloroquine, doxycycline, mefloquine, or primaquine
           <xref ref-type="table-fn" rid="cetablefn84">
            5
           </xref>
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Armenia
           </bold>
          </td>
          <td align="left">
           Previously limited to the Ararat Valley in the Ararat and Artashat regions and Masis district. No cases reported since 2006
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           Historically
           <italic>
            P. vivax
           </italic>
           100%
          </td>
          <td align="left">
           Mosquito avoidance only
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Aruba
           </bold>
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Australia
           </bold>
           , including
           <bold>
            Cocos
           </bold>
           (
           <bold>
            Keeling
           </bold>
           )
           <bold>
            Islands
           </bold>
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Austria
           </bold>
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Azerbaijan
           </bold>
          </td>
          <td align="left">
           Rural areas &lt;1,500 m (4,921 ft). None in Baku
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           <italic>
            P. vivax
           </italic>
           100%
          </td>
          <td align="left">
           Atovaquone/proguanil, chloroquine, doxycycline, mefloquine, or primaquine
           <xref ref-type="table-fn" rid="cetablefn84">
            5
           </xref>
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Azores
           </bold>
           (Portugal)
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Bahamas, The
           </bold>
          </td>
          <td align="left">
           Present only in Great Exuma Island
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           <italic>
            P. falciparum
           </italic>
           100%
          </td>
          <td align="left">
           Atovaquone/proguanil, chloroquine, doxycycline, or mefloquine
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Bahrain
           </bold>
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Bangladesh
           </bold>
          </td>
          <td align="left">
           All areas, except in city of Dhaka
          </td>
          <td align="left">
           Chloroquine
          </td>
          <td align="left">
           <italic>
            P. falciparum
           </italic>
           77%
           <break>
           </break>
           <italic>
            P. vivax
           </italic>
           23%
          </td>
          <td align="left">
           Atovaquone/proguanil, doxycycline, or mefloquine
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Barbados
           </bold>
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Belarus
           </bold>
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Belgium
           </bold>
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Belize
           </bold>
          </td>
          <td align="left">
           All areas, except in Belize City
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           <italic>
            P. vivax
           </italic>
           95%
           <break>
           </break>
           <italic>
            P. falciparum
           </italic>
           5%
          </td>
          <td align="left">
           Atovaquone/proguanil, chloroquine, doxycycline, mefloquine, or primaquine
           <xref ref-type="table-fn" rid="cetablefn84">
            5
           </xref>
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Benin
           </bold>
          </td>
          <td align="left">
           All
          </td>
          <td align="left">
           Chloroquine
          </td>
          <td align="left">
           <italic>
            P. falciparum
           </italic>
           85%
           <break>
           </break>
           <italic>
            P. ovale
           </italic>
           5%–10%
           <break>
           </break>
           <italic>
            P. vivax
           </italic>
           rare
          </td>
          <td align="left">
           Atovaquone/proguanil, doxycycline, or mefloquine
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Bermuda
           </bold>
           (U.K.)
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Bhutan
           </bold>
          </td>
          <td align="left">
           Rural areas &lt;1,700 m (&lt;5,577 ft) of the southern belt districts along the border with India: Chirang, Geylegphug, Samchi, Samdrup Jongkhar, Sarpang and Shemgang
          </td>
          <td align="left">
           Chloroquine
          </td>
          <td align="left">
           <italic>
            P. falciparum
           </italic>
           50%
           <break>
           </break>
           <italic>
            P. vivax
           </italic>
           50%
          </td>
          <td align="left">
           Atovaquone/proguanil, doxycycline, or mefloquine
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Bolivia
           </bold>
          </td>
          <td align="left">
           All areas &lt;2,500 m (&lt;8,202 ft) in the following departments: Beni, Chuquisaca, Cochabamba, La Paz, Pando, Santa Cruz, and Tarija. None in city of La Paz
          </td>
          <td align="left">
           Chloroquine
          </td>
          <td align="left">
           <italic>
            P. vivax
           </italic>
           70%-95%
           <break>
           </break>
           <italic>
            P. falciparum
           </italic>
           5%-30%
          </td>
          <td align="left">
           Atovaquone/proguanil, doxycycline, or mefloquine
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Bosnia and Herzegovina
           </bold>
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Botswana
           </bold>
          </td>
          <td align="left">
           North of 22° S in the northern provinces of Central, Chobe, Ghanzi, and Ngamiland, including safaris to the Okavango Delta area. None in the city of Gaborone
          </td>
          <td align="left">
           Chloroquine
          </td>
          <td align="left">
           <italic>
            P. falciparum
           </italic>
           90%
           <break>
           </break>
           <italic>
            P. vivax
           </italic>
           5%
           <break>
           </break>
           <italic>
            P. ovale
           </italic>
           5%
          </td>
          <td align="left">
           Atovaquone/proguanil, doxycycline, or mefloquine
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Brazil
           </bold>
          </td>
          <td align="left">
           <list id="celist303" list-type="simple">
            <list-item id="celistitem1102">
             <p id="para1421">
              States of Acre, Rondônia, Amapá, Amazonas, Roraima, and Tocantins. Parts of states of Maranhaõ (western part), Mato Grosso (northern part), and Pará (except Belem City). Also present in urban areas, including large cities such as Porto Velho, Boa Vista, Macapa, Manaus, Santarem, and Maraba, where the transmission occurs on the periphery of these cities
             </p>
            </list-item>
            <list-item id="celistitem1103">
             <p id="para1422">
              Malaria in Iguassu Falls
             </p>
            </list-item>
           </list>
          </td>
          <td align="left">
           Chloroquine
          </td>
          <td align="left">
           <italic>
            P. vivax
           </italic>
           75%
           <break>
           </break>
           <italic>
            P. falciparum
           </italic>
           25%
          </td>
          <td align="left">
           Atovaquone/proguanil, doxycycline, or mefloquine
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            British Indian Ocean Territory
           </bold>
           , includes
           <bold>
            Diego Garcia
           </bold>
           (U.K.)
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Brunei
           </bold>
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Bulgaria
           </bold>
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Burkina Faso
           </bold>
          </td>
          <td align="left">
           All
          </td>
          <td align="left">
           Chloroquine
          </td>
          <td align="left">
           <italic>
            P. falciparum
           </italic>
           80%
           <break>
           </break>
           <italic>
            P. ovale
           </italic>
           5%-10%
           <break>
           </break>
           <italic>
            P. vivax
           </italic>
           rare
          </td>
          <td align="left">
           Atovaquone/proguanil, doxycycline, or mefloquine
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Burma (Myanmar)
           </bold>
          </td>
          <td align="left">
           Rural areas throughout the country at altitudes &lt;1,000 m (&lt;3,281 ft). None in cities of Rangoon (Yangon) and Mandalay
          </td>
          <td align="left">
           Chloroquine Mefloquine (see
           <xref ref-type="fig" rid="f12">
            Map 2-9
           </xref>
           )
          </td>
          <td align="left">
           <italic>
            P. falciparum
           </italic>
           80%
           <break>
           </break>
           <italic>
            P. vivax
           </italic>
           20%
          </td>
          <td align="left">
           <list id="celist304" list-type="simple">
            <list-item id="celistitem1104">
             <p id="para1423">
              In the provinces of Bago, Kayah, Kachin, Kayin, Shan, and Tanintharyi: Atovaquone/proguanil or doxycycline
             </p>
            </list-item>
            <list-item id="celistitem1105">
             <p id="para1424">
              All other areas: Atovaquone/proguanil, doxycycline, or mefloquine
             </p>
            </list-item>
           </list>
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Burundi
           </bold>
          </td>
          <td align="left">
           All
          </td>
          <td align="left">
           Chloroquine
          </td>
          <td align="left">
           <italic>
            P. falciparum
           </italic>
           &gt;85%
           <break>
           </break>
           <italic>
            P. malariae, P. ovale,
           </italic>
           and
           <italic>
            P. vivax &lt;15%
           </italic>
          </td>
          <td align="left">
           Atovaquone/proguanil, doxycycline, or mefloquine
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Cambodia
           </bold>
          </td>
          <td align="left">
           Present throughout country, including the temple complex at Angkor Wat, except none in Phnom Penh and around Lake Tonle Sap
          </td>
          <td align="left">
           Chloroquine Mefloquine (see
           <xref ref-type="fig" rid="f12">
            Map 2-9
           </xref>
           )
          </td>
          <td align="left">
           <italic>
            P. falciparum
           </italic>
           86%
           <break>
           </break>
           <italic>
            P. vivax
           </italic>
           12%
           <break>
           </break>
           <italic>
            P. malariae 2%
           </italic>
          </td>
          <td align="left">
           <list id="celist305" list-type="simple">
            <list-item id="celistitem1106">
             <p id="para1425">
              In the provinces of Preah Vihear, Siemreap, Oddar Meanchey, Banteay Meanchey, Battambang, Pailin, Kampot, Koh Kong, and Pursat bordering Thailand:
              <list id="celist306" list-type="simple">
               <list-item id="celistitem1107">
                <p id="para1426">
                 Atovaquone/proguanil or doxycycline
                </p>
               </list-item>
               <list-item id="celistitem1108">
                <p id="para1427">
                 All other areas: Atovaquone/proguanil, doxycycline, or mefloquine
                </p>
               </list-item>
              </list>
             </p>
            </list-item>
           </list>
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Cameroon
           </bold>
          </td>
          <td align="left">
           All
          </td>
          <td align="left">
           Chloroquine
          </td>
          <td align="left">
           <italic>
            P. falciparum
           </italic>
           80%
           <break>
           </break>
           <italic>
            P. ovale
           </italic>
           5%–10%
           <break>
           </break>
           <italic>
            P. vivax
           </italic>
           rare
          </td>
          <td align="left">
           Atovaquone/proguanil, doxycycline, or mefloquine
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Canada
           </bold>
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Canary Islands
           </bold>
           (Spain)
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Cape Verde
           </bold>
          </td>
          <td align="left">
           Limited to Sao Tiago Island
          </td>
          <td align="left">
           Chloroquine
          </td>
          <td align="left">
           <italic>
            P. falciparum primarily
           </italic>
          </td>
          <td align="left">
           Atovaquone/proguanil, doxycycline, or mefloquine
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Cayman Islands
           </bold>
           (U.K.)
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Central African Republic
           </bold>
          </td>
          <td align="left">
           All
          </td>
          <td align="left">
           Chloroquine
          </td>
          <td align="left">
           <italic>
            P. falciparum
           </italic>
           85%
           <break>
           </break>
           <italic>
            P. malariae, P. ovale,
           </italic>
           and
           <italic>
            P. vivax
           </italic>
           15%
          </td>
          <td align="left">
           Atovaquone/proguanil, doxycycline, or mefloquine
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Chad
           </bold>
          </td>
          <td align="left">
           All
          </td>
          <td align="left">
           Chloroquine
          </td>
          <td align="left">
           <italic>
            P. falciparum
           </italic>
           85%
           <break>
           </break>
           <italic>
            P. malariae, P. ovale,
           </italic>
           and
           <italic>
            P. vivax
           </italic>
           15%
          </td>
          <td align="left">
           Atovaquone/proguanil, doxycycline, or mefloquine
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Chile
           </bold>
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            China
           </bold>
          </td>
          <td align="left">
           Rural parts of Anhui, Yunnan, Hainan provinces. Rare cases occur in other rural parts of the country &lt;1,500m(&lt;4,921 ft) during May-December. None in major river cruises and urban areas
          </td>
          <td align="left">
           Chloroguine (Vlefloguine (see
           <xref ref-type="fig" rid="f12">
            Map 2-9
           </xref>
           )
          </td>
          <td align="left">
           <italic>
            P. falciparum
           </italic>
           primarily in Hainan and Yunnan.
           <break>
           </break>
           <italic>
            P. vivax
           </italic>
           primarily elsewhere
          </td>
          <td align="left">
           <list id="celist307" list-type="simple">
            <list-item id="celistitem1109">
             <p id="para1428">
              Along China-Burma border in the western part of Yunnan province:
              <list id="celist308" list-type="simple">
               <list-item id="celistitem1110">
                <p id="para1429">
                 Atovaguone/proguanil or doxycycline
                </p>
               </list-item>
               <list-item id="celistitem1111">
                <p id="para1430">
                 Hainan and the other parts of Yunnan province:
                 <list id="celist309" list-type="simple">
                  <list-item id="celistitem1112">
                   <p id="para1431">
                    Atovaguone/proguanil, doxycycline or mefloguine
                   </p>
                  </list-item>
                  <list-item id="celistitem1113">
                   <p id="para1432">
                    Anhui province: Atovaguone/proguanil, chloroguine, doxycycline, or mefloguine
                   </p>
                  </list-item>
                  <list-item id="celistitem1114">
                   <p id="para1433">
                    All other areas with malaria transmission: Mosguito avoidance
                   </p>
                  </list-item>
                 </list>
                </p>
               </list-item>
              </list>
             </p>
            </list-item>
           </list>
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Christmas Island
           </bold>
           (Australia)
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Colombia
           </bold>
          </td>
          <td align="left">
           All rural areas at altitudes &lt; 1,800 m (&lt;5,906 ft). None in Bogota and Cartagena
          </td>
          <td align="left">
           Chloroguine
          </td>
          <td align="left">
           <italic>
            P. falciparum
           </italic>
           50%
           <italic>
            P. vivax
           </italic>
           50%
          </td>
          <td align="left">
           Atovaguone/proguanil, doxycycline, or mefloguine
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Comoros
           </bold>
          </td>
          <td align="left">
           All
          </td>
          <td align="left">
           Chloroguine
          </td>
          <td align="left">
           <italic>
            P. falciparum
           </italic>
           primarily
          </td>
          <td align="left">
           Atovaguone/proguanil, doxycycline, or mefloguine
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Congo, Republic of the (Congo-Brazzavi1le)
           </bold>
          </td>
          <td align="left">
           All
          </td>
          <td align="left">
           Chloroguine
          </td>
          <td align="left">
           <italic>
            P. falciparum
           </italic>
           primarily
          </td>
          <td align="left">
           Atovaguone/proguanil, doxycycline, or mefloguine
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Cook Islands
           </bold>
           (New Zealand)
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Costa Rica
           </bold>
          </td>
          <td align="left">
           Limon province, but not in Limon city (Puerto Limon). Rare cases in Puntarenas, Alajuela, Guanacaste, and Heredia provinces
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           <italic>
            P. vivax
           </italic>
           90%
           <break>
           </break>
           <italic>
            P. falciparum
           </italic>
           10%
          </td>
          <td align="left">
           <list id="celist310" list-type="simple">
            <list-item id="celistitem1115">
             <p id="para1434">
              Limon province: Atovaguone/proguanil, chloroguine, doxycycline, mefloguine, or primaquine
              <xref ref-type="table-fn" rid="cetablefn84">
               5
              </xref>
             </p>
            </list-item>
            <list-item id="celistitem1116">
             <p id="para1435">
              All other areas with malaria transmission: Mosguito avoidance
             </p>
            </list-item>
           </list>
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Côte d'Ivoire (Ivory Coast)
           </bold>
          </td>
          <td align="left">
           All
          </td>
          <td align="left">
           Chloroguine
          </td>
          <td align="left">
           <italic>
            P. falciparum
           </italic>
           85%
           <italic>
            P. ovale 5%-10%
           </italic>
           <break>
           </break>
           <italic>
            P. vivax
           </italic>
           rare
          </td>
          <td align="left">
           Atovaguone/proguanil, doxycycline, or mefloguine
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Croatia
           </bold>
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Cuba
           </bold>
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Cyprus
           </bold>
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Czech Republic
           </bold>
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Democratic Republic of the Congo (Congo-Kinshasa)
           </bold>
          </td>
          <td align="left">
           All
          </td>
          <td align="left">
           Chloroguine
          </td>
          <td align="left">
           <italic>
            P. falciparum
           </italic>
           90%
           <break>
           </break>
           <italic>
            P. ovale
           </italic>
           5%
           <italic>
            P. vivax
           </italic>
           rare
          </td>
          <td align="left">
           Atovaguone/proguanil, doxycycline, or mefloguine
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Denmark
           </bold>
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Djibouti
           </bold>
          </td>
          <td align="left">
           All
          </td>
          <td align="left">
           Chloroguine
          </td>
          <td align="left">
           <italic>
            P. falciparum
           </italic>
           90%
           <break>
           </break>
           <italic>
            P. vivax
           </italic>
           5%-10%
          </td>
          <td align="left">
           Atovaguone/proguanil, doxycycline, or mefloguine
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Dominica
           </bold>
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Dominican Republic
           </bold>
          </td>
          <td align="left">
           All areas (including resort areas), except not present in the cities of Santo Domingo and Santiago
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           <italic>
            P. falciparum
           </italic>
           100%
          </td>
          <td align="left">
           Atovaguone/proguanil, chloroguine, doxycycline, or mefloguine
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Easter Island
           </bold>
           (Chile)
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Ecuador,
           </bold>
           including the
           <bold>
            Galapagos Islands
           </bold>
          </td>
          <td align="left">
           All areas at altitudes &lt;1,500m(&lt;4,921 ft). Not present in the cities of Guayaguil, Quito, and the Galapagos Islands
          </td>
          <td align="left">
           Chloroguine
          </td>
          <td align="left">
           <italic>
            P. vivax
           </italic>
           75%
           <break>
           </break>
           <italic>
            P. falciparum
           </italic>
           25%
          </td>
          <td align="left">
           Atovaguone/proguanil, doxycycline, or mefloguine
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Egypt
           </bold>
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            El Salvador
           </bold>
          </td>
          <td align="left">
           Rural areas of Santa Ana, Ahuachapãn, La Paz, and La Union departments
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           <italic>
            P. vivax
           </italic>
           99%
           <italic>
            P. falciparum &lt;
           </italic>
           1 %
          </td>
          <td align="left">
           Atovaguone/proguanil, chloroguine, doxycycline, mefloguine or primaquine
           <xref ref-type="table-fn" rid="cetablefn84">
            5
           </xref>
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Equatorial Guinea
           </bold>
          </td>
          <td align="left">
           All
          </td>
          <td align="left">
           Chloroguine
          </td>
          <td align="left">
           <italic>
            P. falciparum
           </italic>
           85%
           <italic>
            P. malariae, P. ovale,
           </italic>
           and
           <italic>
            P. vivax
           </italic>
           15%
          </td>
          <td align="left">
           Atovaguone/proguanil, doxycycline, or mefloguine
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Eritrea
           </bold>
          </td>
          <td align="left">
           All areas at altitudes &lt;2,200m(&lt;7,218ft). None in Asmara
          </td>
          <td align="left">
           Chloroguine
          </td>
          <td align="left">
           <italic>
            P. falciparum
           </italic>
           85%
           <italic>
            P.
           </italic>
           vivax 10%-15%
           <italic>
            P. ovale
           </italic>
           rare
          </td>
          <td align="left">
           Atovaguone/proguanil, doxycycline, or mefloguine
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Estonia
           </bold>
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Ethiopia
           </bold>
          </td>
          <td align="left">
           All areas at altitudes &lt;2,500m (&lt;8,202 ft), except none in Addis Ababa
          </td>
          <td align="left">
           Chloroguine
          </td>
          <td align="left">
           <italic>
            P. falciparum
           </italic>
           85%
           <italic>
            P
           </italic>
           vivax 10%-15%
           <break>
           </break>
           <italic>
            P. malariae
           </italic>
           and
           <italic>
            P. ovale
           </italic>
           &lt;5%
          </td>
          <td align="left">
           Atovaguone/proguanil, doxycycline, or mefloguine
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Falkland, South Georgia &amp; South Sandwich Islands (U.K.)
           </bold>
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Faroe Islands
           </bold>
           (Denmark)
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Fiji
           </bold>
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Finland
           </bold>
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            France
           </bold>
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            French Guiana
           </bold>
          </td>
          <td align="left">
           All areas, except none in city of Cayenne or Devil's Island (Ile du Diable)
          </td>
          <td align="left">
           Chloroguine
          </td>
          <td align="left">
           <italic>
            P. falciparum
           </italic>
           &gt;50%
           <italic>
            P. vivax,
           </italic>
           &lt;50%
          </td>
          <td align="left">
           Atovaguone/proguanil, doxycycline, or mefloguine
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            French Polynesia,
           </bold>
           includes the island groups of
           <bold>
            Society Islands (Tahiti, Moorea,
           </bold>
           and
           <bold>
            Bora-Bora), Marquesas Islands (Hiva Oa
           </bold>
           and
           <bold>
            Ua Huka),
           </bold>
           and
           <bold>
            Austral Islands (Tubuai
           </bold>
           and
           <bold>
            Rurutu)
           </bold>
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Gabon
           </bold>
          </td>
          <td align="left">
           All
          </td>
          <td align="left">
           Chloroguine
          </td>
          <td align="left">
           <italic>
            P. falciparum
           </italic>
           95%
           <break>
           </break>
           <italic>
            P. malariae, P. ovale, P. vivax
           </italic>
           5%
          </td>
          <td align="left">
           Atovaguone/proguanil, doxycycline, or mefloguine
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Gambia, The
           </bold>
          </td>
          <td align="left">
           All
          </td>
          <td align="left">
           Chloroguine
          </td>
          <td align="left">
           <italic>
            P. falciparum
           </italic>
           85%
           <italic>
            P. malariae, P. ovale, P. vivax 15%
           </italic>
          </td>
          <td align="left">
           Atovaguone/proguanil, doxycycline, or mefloguine
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Georgia
           </bold>
          </td>
          <td align="left">
           Present in the southeastern part of the country near the Azerbaijan border, mainly in the Kakheti and Kveno Kartli regions. None in Tblisi
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           <italic>
            P. vivax 100%
           </italic>
          </td>
          <td align="left">
           Atovaguone/proguanil, chloroguine, doxycycline, mefloguine, or primaquine
           <xref ref-type="table-fn" rid="cetablefn84">
            5
           </xref>
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Germany
           </bold>
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Ghana
           </bold>
          </td>
          <td align="left">
           All
          </td>
          <td align="left">
           Chloroguine
          </td>
          <td align="left">
           <italic>
            P. falciparum
           </italic>
           85%
           <italic>
            P. ovale 5%-10%
           </italic>
           <break>
           </break>
           <italic>
            P. vivax
           </italic>
           rare
          </td>
          <td align="left">
           Atovaguone/proguanil, doxycycline, or mefloguine
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Gibraltar (U.K.)
           </bold>
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Greece
           </bold>
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Greenland
           </bold>
           (Denmark)
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Grenada
           </bold>
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Guadeloupe
           </bold>
           (France)
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Guam (U.S.)
           </bold>
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Guatemala
           </bold>
          </td>
          <td align="left">
           Rural areas only at altitudes &lt; 1,500 m (&lt;4,921ft). None in Guatemala City, Antigua or Lake Atitlán
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           <italic>
            P. vivax
           </italic>
           97%
           <break>
           </break>
           <italic>
            P. falciparum
           </italic>
           3%
          </td>
          <td align="left">
           Atovaguone/proguanil, chloroguine, doxycycline, mefloguine, or primaquine
           <xref ref-type="table-fn" rid="cetablefn84">
            5
           </xref>
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Guinea
           </bold>
          </td>
          <td align="left">
           All
          </td>
          <td align="left">
           Chloroguine
          </td>
          <td align="left">
           <italic>
            P. falciparum
           </italic>
           85%
           <italic>
            P. ovale 5%-10%
           </italic>
           <break>
           </break>
           <italic>
            P. vivax
           </italic>
           rare
          </td>
          <td align="left">
           Atovaguone/proguanil, doxycycline, or mefloquine
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Guinea-Bissau
           </bold>
          </td>
          <td align="left">
           All
          </td>
          <td align="left">
           Chloroguine
          </td>
          <td align="left">
           <italic>
            P. falciparum
           </italic>
           85%
           <italic>
            P. ovale 5%-10%
           </italic>
           <break>
           </break>
           <italic>
            P. vivax
           </italic>
           rare
          </td>
          <td align="left">
           Atovaguone/proguanil, doxycycline, or mefloquine
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Guyana
           </bold>
          </td>
          <td align="left">
           All rural areas &lt;900 m (&lt;2,953 ft)
          </td>
          <td align="left">
           Chloroguine
          </td>
          <td align="left">
           <italic>
            P. falciparum
           </italic>
           60%
           <italic>
            P. vivax 40% P. malariae &lt;
           </italic>
           1 %
          </td>
          <td align="left">
           Atovaguone/proguanil, doxycycline, or mefloquine
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Haiti
           </bold>
          </td>
          <td align="left">
           All (including Port Labadee)
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           <italic>
            P. falciparum
           </italic>
           100%
          </td>
          <td align="left">
           Atovaguone/proguanil, chloroguine, doxycycline, or mefloguine
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Holy See
           </bold>
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Honduras
           </bold>
          </td>
          <td align="left">
           Present throughout the country at altitudes &lt;1000m(&lt;3,281 ft) and in Roatãn and other Bay Island. None in Tegucigalpa and San Pedro Sula
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           <italic>
            P. vivax
           </italic>
           50%-95%
           <break>
           </break>
           <italic>
            P. falciparum
           </italic>
           5%-50%
          </td>
          <td align="left">
           Atovaguone/proguanil, chloroguine, doxycycline, or mefloquine
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Hong Kong SAR
           </bold>
           (China)
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Hungary
           </bold>
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Iceland
           </bold>
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            India
           </bold>
          </td>
          <td align="left">
           All areas throughout country
           <bold>
            except
           </bold>
           no malaria in areas &gt;2,000 m (&gt;6,561 ft) in Himachal Pradesh, Jammu, Kashmir, and Sikkim. Present in cities of Delhi and Bombay (Mumbai)
          </td>
          <td align="left">
           Chloroguine
          </td>
          <td align="left">
           <italic>
            P. vivax
           </italic>
           40%
           <break>
           </break>
           <italic>
            P. falciparum
           </italic>
           20%-40%
           <break>
           </break>
           <italic>
            P. malariae
           </italic>
           and
           <italic>
            P. ovale
           </italic>
           20%-40%
          </td>
          <td align="left">
           Atovaguone/proguanil, doxycycline, or mefloquine
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Indonesia
           </bold>
          </td>
          <td align="left">
           <list id="celist311" list-type="simple">
            <list-item id="celistitem1117">
             <p id="para1436">
              Present in rural areas of Sumatra, Sulawesi, Kalimantan (Borneo) and Nusa Tenggara Barat (includes the island of Lombok)
             </p>
            </list-item>
            <list-item id="celistitem1118">
             <p id="para1437">
              All areas of eastern Indonesia (provinces of Papua Indonesia, Irian Jaya Barat, Nusa Tenggara Timur, Maluku, and Maluku Utara)
             </p>
            </list-item>
            <list-item id="celistitem1119">
             <p id="para1438">
              None in Jakarta, resort areas of Bali and the island of Java, except for the Menoreh Hills in central Java. None in urban areas in Sumatra, Kalimantan, Nusa Tenggara Barat and Sulawesi
             </p>
            </list-item>
           </list>
          </td>
          <td align="left">
           Chloroguine
          </td>
          <td align="left">
           <italic>
            P. falciparum
           </italic>
           66%
           <break>
           </break>
           <italic>
            P. vivax
           </italic>
           34%
          </td>
          <td align="left">
           Atovaguone/proguanil, doxycycline, or mefloquine
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Iran
           </bold>
          </td>
          <td align="left">
           <list id="celist312" list-type="simple">
            <list-item id="celistitem1120">
             <p id="para1439">
              Rural areas of Sistan-1 Baluchestan, the southern tropical part of Kerman, and Hormozgan province
             </p>
            </list-item>
            <list-item id="celistitem1121">
             <p id="para1440">
              Ardebil and East Azerbijan provinces north of the Zagros mountains during March through November
             </p>
            </list-item>
           </list>
          </td>
          <td align="left">
           Chloroguine
          </td>
          <td align="left">
           <italic>
            P. vivax
           </italic>
           88%
           <italic>
            P. falciparum
           </italic>
           11 %
          </td>
          <td align="left">
           Atovaguone/proguanil, doxycycline, or mefloquine
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Iraq
           </bold>
          </td>
          <td align="left">
           Present in areas at altitudes &lt; 1,500 m (&lt;4,921 ft) in provinces of Duhok, Erbil, Ninawa, Sulaimaninya, and Ta'mim. None in Baghdad, Tikrit, and Ramadi
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           <italic>
            P. vivax 100%
           </italic>
          </td>
          <td align="left">
           Atovaguone/proguanil, chloroguine, doxycycline, mefloguine, or primaquine
           <xref ref-type="table-fn" rid="cetablefn84">
            5
           </xref>
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Ireland
           </bold>
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Israel
           </bold>
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Italy
           </bold>
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Jamaica
           </bold>
          </td>
          <td align="left">
           Rare local cases in Kingston
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           <italic>
            P. falciparum
           </italic>
           100%
          </td>
          <td align="left">
           (Mosquito avoidance only)
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Japan
           </bold>
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Jordan
           </bold>
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Kazakhstan
           </bold>
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Kenya
           </bold>
          </td>
          <td align="left">
           Present in all areas (including game parks) at altitudes &lt;2,500 m (&lt;8,202 ft). None in Nairobi
          </td>
          <td align="left">
           Chloroguine
          </td>
          <td align="left">
           <italic>
            P. falciparum
           </italic>
           85%
           <italic>
            P. vivax5%-10% P. ovale
           </italic>
           up to 5%
          </td>
          <td align="left">
           Atovaguone/proguanil, doxycycline, or mefloquine
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Kiribati
           </bold>
           (formerly
           <bold>
            Gilbert Islands),
           </bold>
           includes
           <bold>
            Tarawa, Tabuaeran (Fanning Island),
           </bold>
           and
           <bold>
            Banaba (Ocean Island)
           </bold>
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Korea, North
           </bold>
          </td>
          <td align="left">
           Present in southern provinces
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           Presumed to be
           <italic>
            P. vivax 100%
           </italic>
          </td>
          <td align="left">
           Atovaguone/proguanil, chloroguine, doxycycline, mefloguine, or primaquine
           <xref ref-type="table-fn" rid="cetablefn84">
            5
           </xref>
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Korea, South
           </bold>
          </td>
          <td align="left">
           Limited to rural areas in the northern parts of Kyonggi and Kangwon provinces including the demilitarized zone (DMZ)
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           <italic>
            P. vivax 100%
           </italic>
          </td>
          <td align="left">
           Atovaguone/proguanil, chloroguine, doxycycline, mefloguine, or primaquine
           <xref ref-type="table-fn" rid="cetablefn84">
            5
           </xref>
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Kosovo
           </bold>
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Kuwait
           </bold>
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Kyrgyzstan
           </bold>
          </td>
          <td align="left">
           Frequent border crossings between neighboring countries with malaria poses a small risk of malaria transmission in the southern and western parts of the country along the borders of Tajikistan and Uzbekistan No malaria transmission reported in Bishkek
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           <italic>
            P. vivax
           </italic>
           99%
           <italic>
            P. falciparum
           </italic>
           rare imported cases
          </td>
          <td align="left">
           Mosquito avoidance only
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Laos
           </bold>
          </td>
          <td align="left">
           All, except none in the city of Vientiane
          </td>
          <td align="left">
           Chloroquine (Vlefloquine (see
           <xref ref-type="fig" rid="f12">
            Map 2-9
           </xref>
           )
          </td>
          <td align="left">
           <italic>
            P. falciparum
           </italic>
           95%
           <break>
           </break>
           <italic>
            P. vivax
           </italic>
           4%
           <break>
           </break>
           <italic>
            P. malariae
           </italic>
           and
           <italic>
            P. ovale 1%
           </italic>
          </td>
          <td align="left">
           <list id="celist313" list-type="simple">
            <list-item id="celistitem1122">
             <p id="para1441">
              Along the Laos-Burma border in the provinces of Bokéoand Louang Namtha and along the Laos-Thailand border in the province of Saravane and Champassack: Atovaquone/proguanil or doxycycline
             </p>
            </list-item>
            <list-item id="celistitem1123">
             <p id="para1442">
              All other areas: Atovaquone/proguanil, doxycycline, or mefloquine
             </p>
            </list-item>
           </list>
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Latvia
           </bold>
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Lebanon
           </bold>
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Lesotho
           </bold>
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Liberia
           </bold>
          </td>
          <td align="left">
           All
          </td>
          <td align="left">
           Chloroquine
          </td>
          <td align="left">
           <italic>
            P. falciparum
           </italic>
           85%
           <break>
           </break>
           <italic>
            P. ovale
           </italic>
           5%-10%
           <break>
           </break>
           <italic>
            P. vivax
           </italic>
           rare
          </td>
          <td align="left">
           Atovaquone/proguanil, doxycycline, or mefloquine
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Libya
           </bold>
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Liechtenstein
           </bold>
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Lithuania
           </bold>
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Luxembourg
           </bold>
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Macau SAR
           </bold>
           (China)
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Macedonia
           </bold>
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Madagascar
           </bold>
          </td>
          <td align="left">
           All
          </td>
          <td align="left">
           Chloroquine
          </td>
          <td align="left">
           <italic>
            P. falciparum
           </italic>
           85%
           <break>
           </break>
           <italic>
            P. vivax
           </italic>
           5%-10%
           <break>
           </break>
           <italic>
            P. ovale
           </italic>
           5%
          </td>
          <td align="left">
           Atovaquone/proguanil, doxycycline, or mefloquine
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Madeira Islands
           </bold>
           (Portugal)
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Malawi
           </bold>
          </td>
          <td align="left">
           All
          </td>
          <td align="left">
           Chloroquine
          </td>
          <td align="left">
           <italic>
            P. falciparum
           </italic>
           90%
           <break>
           </break>
           <italic>
            P. malariae, P. ovale,
           </italic>
           a nd
           <italic>
            P. vivax
           </italic>
           10%
          </td>
          <td align="left">
           Atovaquone/proguanil, doxycycline, or mefloquine
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Malaysia
           </bold>
          </td>
          <td align="left">
           Present in rural areas of Malaysian Borneo, and to a lesser extent in rural areas of peninsular Malaysia
          </td>
          <td align="left">
           Chloroquine
          </td>
          <td align="left">
           <italic>
            P. falciparum
           </italic>
           40%
           <break>
           </break>
           <italic>
            P. vivax
           </italic>
           50%
           <italic>
            IP ovale &lt;1% P. knowlesi
           </italic>
           reported to cause some human infections here
          </td>
          <td align="left">
           Atovaquone/proguanil, doxycycline, or mefloquine
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Maldives
           </bold>
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Mali
           </bold>
          </td>
          <td align="left">
           All
          </td>
          <td align="left">
           Chloroquine
          </td>
          <td align="left">
           <italic>
            P. falciparum
           </italic>
           85%
           <break>
           </break>
           <italic>
            P. ovale
           </italic>
           5%-10%
           <italic>
            P. vivax
           </italic>
           rare
          </td>
          <td align="left">
           Atovaquone/proguanil, doxycycline, or mefloquine
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Malta
           </bold>
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Marshall Islands
           </bold>
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Martinique
           </bold>
           (France)
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Mauritania
           </bold>
          </td>
          <td align="left">
           Present in southern provinces. None in Dakhlet-Nouadhibou, Inchiri, Adrar and Tiris-Zemmour regions
          </td>
          <td align="left">
           Chloroquine
          </td>
          <td align="left">
           <italic>
            P. falciparum
           </italic>
           85%
           <break>
           </break>
           <italic>
            P. ovale
           </italic>
           5%-10%
           <italic>
            P. vivax
           </italic>
           rare
          </td>
          <td align="left">
           Atovaquone/proguanil, doxycycline, or mefloquine
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Mauritius
           </bold>
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Mayotte
           </bold>
           (French territorial collectivity)
          </td>
          <td align="left">
           All
          </td>
          <td align="left">
           Chloroquine
          </td>
          <td align="left">
           <italic>
            P. falciparum
           </italic>
           40%-50%
           <break>
           </break>
           <italic>
            P. vivax
           </italic>
           35%-40%
           <italic>
            P ovale &lt;1%
           </italic>
          </td>
          <td align="left">
           Atovaquone/proguanil, doxycycline, or mefloquine
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Mexico
           </bold>
          </td>
          <td align="left">
           Limited to areas infrequently visited by travelers, including small foci along the Guatemala and Belize borders in the states of Chiapas, Quintana Roo, and Tabasco; rural areas in the states of Nayarit, Oaxaca, and Sinaloa; and in an area between 24° N and 28° N latitude, and 106°W and 110°W longitude, which lies in parts of Sonora, Chihuahua, and Durango. No malaria along the United States-Mexico border and in the major resorts along the Pacific and Gulf coasts
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           <italic>
            P. vivax
           </italic>
           99%
           <break>
           </break>
           <italic>
            P. falciparum
           </italic>
           1 %
          </td>
          <td align="left">
           Atovaquone/proguanil, chloroquine, doxycycline, mefloquine, or primaquine
           <xref ref-type="table-fn" rid="cetablefn84">
            5
           </xref>
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Micronesia, Federated States of;
           </bold>
           includes
           <bold>
            Yap Islands, Pohnpei, Chuuk,
           </bold>
           and
           <bold>
            Kosrae
           </bold>
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Moldova
           </bold>
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Monaco
           </bold>
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Mongolia
           </bold>
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Montenegro
           </bold>
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Montserrat (U.K.)
           </bold>
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Morocco
           </bold>
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Mozambique
           </bold>
          </td>
          <td align="left">
           All
          </td>
          <td align="left">
           Chloroguine
          </td>
          <td align="left">
           <italic>
            P. falciparum
           </italic>
           95%
           <break>
           </break>
           <italic>
            P. malariae
           </italic>
           and
           <italic>
            P. ovale
           </italic>
           5%
           <break>
           </break>
           <italic>
            P. vivax
           </italic>
           rare
          </td>
          <td align="left">
           Atovaguone/proguanil, doxycycline, or mefloquine
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Namibia
           </bold>
          </td>
          <td align="left">
           Present in the provinces of Kunene, Ohangwena, Okavango, Omaheke, Omusati, Oshana. Oshikoto, Otjozondjupa, and the Caprivi Strip
          </td>
          <td align="left">
           Chloroguine
          </td>
          <td align="left">
           <italic>
            P. falciparum
           </italic>
           90%
           <break>
           </break>
           <italic>
            P. malariae, P. ovale,
           </italic>
           and
           <italic>
            P. vivax
           </italic>
           10%
          </td>
          <td align="left">
           Atovaguone/proguanil, doxycycline, or mefloquine
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Nauru
           </bold>
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Nepal
           </bold>
          </td>
          <td align="left">
           Present throughout country at altitudes &lt;1,200m(&lt;3,937ft). None in Kathmandu and on typical Himalayan treks
          </td>
          <td align="left">
           Chloroguine
          </td>
          <td align="left">
           <italic>
            P. vivax
           </italic>
           88%
           <italic>
            P. falciparum
           </italic>
           12%
          </td>
          <td align="left">
           Atovaguone/proguanil, doxycycline, or mefloquine
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Netherlands
           </bold>
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Netherlands Antilles (Bonaire, Curaçao, Saba, St. Eustasius,
           </bold>
           and
           <bold>
            St. Maarten)
           </bold>
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            New Caledonia
           </bold>
           (France)
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            New Zealand
           </bold>
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Nicaragua
           </bold>
          </td>
          <td align="left">
           Present in rural areas. None in Managua
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           <italic>
            P. vivax
           </italic>
           95%
           <break>
           </break>
           <italic>
            P. falciparum
           </italic>
           5%
          </td>
          <td align="left">
           Atovaguone/proguanil, chloroguine, doxycycline, mefloguine, or primaquine
           <xref ref-type="table-fn" rid="cetablefn84">
            5
           </xref>
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Niger
           </bold>
          </td>
          <td align="left">
           All
          </td>
          <td align="left">
           Chloroguine
          </td>
          <td align="left">
           <italic>
            P. falciparum
           </italic>
           85%
           <italic>
            P. ovale 5%-10% P. vivax
           </italic>
           rare
          </td>
          <td align="left">
           Atovaguone/proguanil, doxycycline, or mefloquine
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Nigeria
           </bold>
          </td>
          <td align="left">
           All
          </td>
          <td align="left">
           Chloroguine
          </td>
          <td align="left">
           <italic>
            P. falciparum
           </italic>
           85%
           <italic>
            P. ovale 5%-10% P. vivax
           </italic>
           rare
          </td>
          <td align="left">
           Atovaguone/proguanil, doxycycline, or mefloquine
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Niue
           </bold>
           (New Zealand)
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Norfolk Island
           </bold>
           (Australia)
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Northern Mariana Islands
           </bold>
           (U.S.), includes
           <bold>
            Saipan, Tinian,
           </bold>
           and
           <bold>
            Rota Island
           </bold>
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Norway
           </bold>
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Oman
           </bold>
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Pakistan
           </bold>
          </td>
          <td align="left">
           All areas (including all cities) at altitudes &lt;2,500 m (&lt;8202 ft)
          </td>
          <td align="left">
           Chloroguine
          </td>
          <td align="left">
           <italic>
            P. falciparum
           </italic>
           70%
           <break>
           </break>
           <italic>
            P. vivax
           </italic>
           30%
          </td>
          <td align="left">
           Atovaguone/proguanil, doxycycline, or mefloquine
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Palau
           </bold>
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Panama
           </bold>
          </td>
          <td align="left">
           Present in rural areas of the provinces of Bocas Del Toro, Darién, Veragaus, San Blas and San Blas Islands. None in Panama City or in the former Canal Zone
          </td>
          <td align="left">
           Chloroguine
          </td>
          <td align="left">
           <italic>
            P. vivax
           </italic>
           90%-95%
           <break>
           </break>
           <italic>
            P. falciparum
           </italic>
           5%-10%
          </td>
          <td align="left">
           <list id="celist314" list-type="simple">
            <list-item id="celistitem1124">
             <p id="para1443">
              Bocas Del Toro: Atovaguone/proguanil, chloroguine, doxycycline, mefloguine, or primaquine
              <xref ref-type="table-fn" rid="cetablefn84">
               5
              </xref>
             </p>
            </list-item>
            <list-item id="celistitem1125">
             <p id="para1444">
              Darién, San Bias, and Veragaus provinces: Atovaguone/proguanil, doxycycline, mefloguine, or primaquine
              <xref ref-type="table-fn" rid="cetablefn84">
               5
              </xref>
             </p>
            </list-item>
           </list>
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Papua New Guinea
           </bold>
          </td>
          <td align="left">
           Present throughout at altitudes &lt; 1,800 m (&lt;5,906 ft)
          </td>
          <td align="left">
           Chloroguine (both
           <italic>
            P. falciparum
           </italic>
           and
           <italic>
            P. vivax)
           </italic>
          </td>
          <td align="left">
           <italic>
            P. falciparum
           </italic>
           65%-80%
           <italic>
            P. vivax 10%-30% P. malariae
           </italic>
           and
           <italic>
            P. ovale
           </italic>
           rare
          </td>
          <td align="left">
           Atovaguone/proguanil, doxycycline, or mefloquine
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Paraguay
           </bold>
          </td>
          <td align="left">
           Present in the departments of Alto Parana, Caaguazu, and Canendiyu
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           <italic>
            P. vivax
           </italic>
           95%
           <break>
           </break>
           <italic>
            P. falciparum
           </italic>
           5%
          </td>
          <td align="left">
           Atovaguone/proguanil, chloroguine, doxycycline, mefloguine, or primaquine
           <xref ref-type="table-fn" rid="cetablefn84">
            5
           </xref>
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Peru
           </bold>
          </td>
          <td align="left">
           All departments &lt;2000 m (6,561 ft) except none in Areguipa, (Vloguegua), Puno, and Tacna. Present in Puerto (Vlaldonado)
          </td>
          <td align="left">
           Chloroguine
          </td>
          <td align="left">
           <italic>
            P. vivax
           </italic>
           70%
           <break>
           </break>
           <italic>
            P. falciparum
           </italic>
           30%
           <break>
           </break>
           <italic>
            P. malariae &lt;
           </italic>
           1 %
          </td>
          <td align="left">
           <list id="celist315" list-type="simple">
            <list-item id="celistitem1126">
             <p id="para1445">
              Lima, coastal areas south of Lima, or the highland tourist areas (Cuzco, (Vlachu Picchu, and LakeTiticaca): (Mosquito avoidance only)
             </p>
            </list-item>
            <list-item id="celistitem1127">
             <p id="para1446">
              Other areas: Atovaguone/proguanil, doxycycline, or mefloquine
             </p>
            </list-item>
           </list>
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Philippines
           </bold>
          </td>
          <td align="left">
           Present in rural areas &lt;600 m (1,969 ft), on islands of Luzon, Palawan, and Mindanao. None in urban areas
          </td>
          <td align="left">
           Chloroguine
          </td>
          <td align="left">
           <italic>
            P. falciparum
           </italic>
           70%-80%
           <break>
           </break>
           <italic>
            P. vivax
           </italic>
           20%-30%
          </td>
          <td align="left">
           Atovaguone/proguanil, doxycycline, or mefloquine
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Pitcairn Islands (U.K.)
           </bold>
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Poland
           </bold>
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Portugal
           </bold>
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Puerto Rico (U.S.)
           </bold>
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Qatar
           </bold>
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Réunion
           </bold>
           (France)
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Romania
           </bold>
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Russia
           </bold>
          </td>
          <td align="left">
           Rare local cases by border with Azerbaijan
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           <italic>
            P. vivax 100%
           </italic>
          </td>
          <td align="left">
           By border with Azerbaijan: Mosguito avoidance only
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Rwanda
           </bold>
          </td>
          <td align="left">
           All
          </td>
          <td align="left">
           Chloroguine
          </td>
          <td align="left">
           <italic>
            P. falciparum
           </italic>
           &gt;85%
           <break>
           </break>
           <italic>
            P. vivax
           </italic>
           5%
           <break>
           </break>
           <italic>
            P. ovale
           </italic>
           5%
          </td>
          <td align="left">
           Atovaguone/proguanil, doxycycline, or mefloquine
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Saint Barthélémy
           </bold>
           (France)
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Saint Helena (U.K.)
           </bold>
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Saint Kitts (Saint Christopher) and Nevis (U.K.)
           </bold>
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Saint Lucia
           </bold>
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Saint Martin
           </bold>
           (France)
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Saint Pierre
           </bold>
           and
           <bold>
            Miquelon
           </bold>
           (France)
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Saint Vincent and the Grenadines
           </bold>
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Samoa
           </bold>
           (formerly
           <bold>
            Western Samoa)
           </bold>
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Samoa, American (U.S.)
           </bold>
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            San Marino
           </bold>
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            São Tomé and Principé
           </bold>
          </td>
          <td align="left">
           All
          </td>
          <td align="left">
           Chloroguine
          </td>
          <td align="left">
           <italic>
            P. falciparum
           </italic>
           85%
           <break>
           </break>
           <italic>
            P. malariae, P. ovale
           </italic>
           5%
           <break>
           </break>
           <italic>
            P. vivax
           </italic>
           rare
          </td>
          <td align="left">
           Atovaguone/proguanil, doxycycline, or mefloquine
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Saudi Arabia
           </bold>
          </td>
          <td align="left">
           Provinces of AI (Vladinah, Asir (excluding high-altitude areas &gt;2,000 m), Jazan, and Mecca. None in cities of Jeddah, Mecca, Medina, Riyadh, and Ta'if
          </td>
          <td align="left">
           Chloroguine
          </td>
          <td align="left">
           <italic>
            P. falciparum
           </italic>
           predominantly
           <italic>
            P. vivax
           </italic>
           rare
          </td>
          <td align="left">
           Atovaguone/proguanil, doxycycline, or mefloquine
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Senegal
           </bold>
          </td>
          <td align="left">
           All
          </td>
          <td align="left">
           Chloroguine
          </td>
          <td align="left">
           <italic>
            P. falciparum
           </italic>
           &gt;85%
           <italic>
            P. ovale 5%-10% P. vivax
           </italic>
           rare
          </td>
          <td align="left">
           Atovaguone/proguanil, doxycycline, or mefloquine
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Serbia
           </bold>
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Seychelles
           </bold>
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Sierra Leone
           </bold>
          </td>
          <td align="left">
           All
          </td>
          <td align="left">
           Chloroguine
          </td>
          <td align="left">
           <italic>
            P. falciparum
           </italic>
           85%
           <break>
           </break>
           <italic>
            P. malariae, P. ovale,
           </italic>
           and
           <italic>
            P. vivax
           </italic>
           5%
          </td>
          <td align="left">
           Atovaguone/proguanil, doxycycline, or mefloquine
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Singapore
           </bold>
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Slovakia
           </bold>
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Slovenia
           </bold>
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Solomon Islands
           </bold>
          </td>
          <td align="left">
           All
          </td>
          <td align="left">
           Chloroguine
          </td>
          <td align="left">
           <italic>
            P. falciparum
           </italic>
           60%
           <break>
           </break>
           <italic>
            P. vivax
           </italic>
           35%-40%
           <italic>
            P. ovale &lt;1%
           </italic>
          </td>
          <td align="left">
           Atovaguone/proguanil, doxycycline, or mefloquine
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Somalia
           </bold>
          </td>
          <td align="left">
           All
          </td>
          <td align="left">
           Chloroguine
          </td>
          <td align="left">
           <italic>
            P. falciparum
           </italic>
           95%
           <italic>
            P. vivax, P. malariae,
           </italic>
           and
           <italic>
            P. ovale
           </italic>
           5%
          </td>
          <td align="left">
           Atovaguone/proguanil, doxycycline, or mefloquine
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            South Africa
           </bold>
          </td>
          <td align="left">
           Present in the (Vlpumalanga Province, Limpopo (Northern) Province, and northeastern KwaZulu-Natal as far south as the Tugela River. Present in Kruger National Park
          </td>
          <td align="left">
           Chloroguine
          </td>
          <td align="left">
           <italic>
            P. falciparum
           </italic>
           90%
           <break>
           </break>
           <italic>
            P. vivax
           </italic>
           5%
           <break>
           </break>
           <italic>
            P. ovale
           </italic>
           5%
          </td>
          <td align="left">
           Atovaguone/proguanil, doxycycline, or mefloquine
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Spain
           </bold>
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Sri Lanka
           </bold>
          </td>
          <td align="left">
           All areas, except none in the districts of Colombo, Galle, Gampaha, Kalutara, (Vlatara, and Nuvvara Eliya)
          </td>
          <td align="left">
           Chloroguine
          </td>
          <td align="left">
           <italic>
            P. vivax
           </italic>
           88%
           <break>
           </break>
           <italic>
            P. falciparum
           </italic>
           12%
          </td>
          <td align="left">
           Atovaguone/proguanil, doxycycline, or mefloquine
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Sudan
           </bold>
          </td>
          <td align="left">
           All
          </td>
          <td align="left">
           Chloroguine
          </td>
          <td align="left">
           <italic>
            P. falciparum
           </italic>
           90%
           <break>
           </break>
           <italic>
            P. malariae, P. vivax,
           </italic>
           and
           <italic>
            P. ovale
           </italic>
           10%
          </td>
          <td align="left">
           Atovaguone/proguanil, doxycycline, or mefloquine
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Suriname
           </bold>
          </td>
          <td align="left">
           All areas, except none in Paramaribo
          </td>
          <td align="left">
           Chloroguine
          </td>
          <td align="left">
           <italic>
            P. falciparum
           </italic>
           70%
           <italic>
            P. vivax 15%-20%
           </italic>
          </td>
          <td align="left">
           Atovaguone/proguanil, doxycycline, or mefloquine
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Swaziland
           </bold>
          </td>
          <td align="left">
           Present in the northern and eastern areas bordering (Vlozambigue and Zimbabwe, including all of Lubombo district)
          </td>
          <td align="left">
           Chloroguine
          </td>
          <td align="left">
           <italic>
            P. falciparum
           </italic>
           90%
           <break>
           </break>
           <italic>
            P. vivax
           </italic>
           5%
           <break>
           </break>
           <italic>
            P. ovale
           </italic>
           5%
          </td>
          <td align="left">
           Atovaguone/proguanil, doxycycline, or mefloquine
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Sweden
           </bold>
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Switzerland
           </bold>
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Syria
           </bold>
          </td>
          <td align="left">
           Rare cases in the northern border in El Hassaka province
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           <italic>
            P. vivax
           </italic>
           predominantly
          </td>
          <td align="left">
           (Mosquito avoidance only)
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Taiwan
           </bold>
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Tajikistan
           </bold>
          </td>
          <td align="left">
           All areas &lt;2,000 m (6562 ft)
          </td>
          <td align="left">
           Chloroguine
          </td>
          <td align="left">
           <italic>
            P. vivax
           </italic>
           90%
           <break>
           </break>
           <italic>
            P. falciparum
           </italic>
           10%
          </td>
          <td align="left">
           Atovaguone/proguanil, doxycycline, mefloguine, or primaguine
           <xref ref-type="table-fn" rid="cetablefn84">
            5
           </xref>
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Tanzania
           </bold>
          </td>
          <td align="left">
           All areas at altitudes &lt;1,800m(&lt;5,906ft)
          </td>
          <td align="left">
           Chloroguine
          </td>
          <td align="left">
           <italic>
            P. falciparum
           </italic>
           &gt;85%
           <break>
           </break>
           <italic>
            P. malariae,
           </italic>
           and
           <italic>
            P. ovale &gt;
           </italic>
           10%
           <break>
           </break>
           <italic>
            P. vivax
           </italic>
           rare
          </td>
          <td align="left">
           Atovaguone/proguanil, doxycycline, or mefloquine
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Thailand
           </bold>
          </td>
          <td align="left">
           Rural, forested areas that border Cambodia, Laos, and Myanmar (Burma). Rare local cases in Phang Nga and Phuket. None in cities and in major tourist resorts. None in cities of Bangkok, Chiang Mai, Chiang Rai, Pattaya, Koh Samui, and Koh Phangan
          </td>
          <td align="left">
           Chloroguine Mefloguine (see
           <xref ref-type="fig" rid="f12">
            Map 2-9
           </xref>
           )
          </td>
          <td align="left">
           <italic>
            P. falciparum
           </italic>
           50% (up to 75% some areas)
           <break>
           </break>
           <italic>
            P. vivax
           </italic>
           50% (up to 60% some areas)
           <break>
           </break>
           <italic>
            P. ovale,
           </italic>
           rare
          </td>
          <td align="left">
           <list id="celist316" list-type="simple">
            <list-item id="celistitem1128">
             <p id="para1447">
              Phang Nga and Phuket: Mosguito avoidance only
             </p>
            </list-item>
            <list-item id="celistitem1129">
             <p id="para1448">
              All other areas: Atovaguone/proguanil or doxycycline
             </p>
            </list-item>
           </list>
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Timor-Leste (East Timor)
           </bold>
          </td>
          <td align="left">
           All
          </td>
          <td align="left">
           Chloroguine
          </td>
          <td align="left">
           <italic>
            P. falciparum
           </italic>
           50%
           <break>
           </break>
           <italic>
            P. vivax
           </italic>
           50%
           <italic>
            P. ovale &lt;1% P. malariae &lt;
           </italic>
           1 %
          </td>
          <td align="left">
           Atovaguone/proguanil, doxycycline, or mefloquine
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Togo
           </bold>
          </td>
          <td align="left">
           All
          </td>
          <td align="left">
           Chloroguine
          </td>
          <td align="left">
           <italic>
            P. falciparum
           </italic>
           85%
           <italic>
            P. ovale 5%-10% P. vivax
           </italic>
           rare
          </td>
          <td align="left">
           Atovaguone/proguanil, doxycycline, or mefloquine
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Tokelau
           </bold>
           (NewZealand)
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Tonga
           </bold>
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Trinidad and Tobago
           </bold>
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Tunisia
           </bold>
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Turkey
           </bold>
          </td>
          <td align="left">
           Present by border with Syria. None on the Incerlik U.S. Air Force base and on typical cruise itineraries
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           P. v/Vaxand
           <italic>
            P. falciparum
           </italic>
           present
          </td>
          <td align="left">
           Atovaguone/proguanil, chloroguine, doxycycline, or mefloquine
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Turkmenistan
           </bold>
          </td>
          <td align="left">
           Rare local cases by Afghanistan border
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           <italic>
            P. vivax 100%
           </italic>
          </td>
          <td align="left">
           Mosguito avoidance only
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Turks and Caicos Islands (U.K.)
           </bold>
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Tuvalu
           </bold>
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Uganda
           </bold>
          </td>
          <td align="left">
           All
          </td>
          <td align="left">
           Chloroguine
          </td>
          <td align="left">
           <italic>
            P. falciparum
           </italic>
           &gt;85%
           <break>
           </break>
           <italic>
            P. malariae, P. ovale,
           </italic>
           and
           <italic>
            P. vivax
           </italic>
           &lt;15%
          </td>
          <td align="left">
           Atovaguone/proguanil, doxycycline, or mefloquine
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Ukraine
           </bold>
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            United Arab Emirates
           </bold>
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            United Kingdom
           </bold>
           (with
           <bold>
            Channel Islands
           </bold>
           and
           <bold>
            Isle of Man)
           </bold>
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            United States
           </bold>
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Uruguay
           </bold>
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Uzbekistan
           </bold>
          </td>
          <td align="left">
           Rare cases along the Afghanistan and Tajikistan border
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           P
           <italic>
            vivax 100%
           </italic>
          </td>
          <td align="left">
           Mosguito avoidance only
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Vanuatu
           </bold>
          </td>
          <td align="left">
           All
          </td>
          <td align="left">
           Chloroguine
          </td>
          <td align="left">
           <italic>
            P. falciparum
           </italic>
           60%
           <break>
           </break>
           <italic>
            P. vivax
           </italic>
           35%-40%
           <italic>
            P. ovale &lt;1%
           </italic>
          </td>
          <td align="left">
           Atovaguone/proguanil, doxycycline, or mefloquine
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Venezuela
           </bold>
          </td>
          <td align="left">
           Rural areas of the following states: Apure, Amazonas, Barinas, Bolivar, Sucre, Tachira, and Delta Amacuro. Present in Angel Falls. None in Margarita Island
          </td>
          <td align="left">
           Chloroguine
          </td>
          <td align="left">
           <italic>
            P. vivax
           </italic>
           80%-90%
           <break>
           </break>
           <italic>
            P. falciparum
           </italic>
           10%-20%
          </td>
          <td align="left">
           Atovaguone/proguanil, doxycycline, or mefloquine
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Vietnam
           </bold>
          </td>
          <td align="left">
           Rural, forested areas,
           <bold>
            except
           </bold>
           none in the Red River delta and the coast north of Nha Trang. None in Can Tho, Da Nang, Haiphong, Hanoi, Ho Chi Minh City (Saigon), Hue, Nha Trang, and Qui Nhon
          </td>
          <td align="left">
           Chloroguine (Vlefloguine (see
           <xref ref-type="fig" rid="f12">
            Map 2-9
           </xref>
           )
          </td>
          <td align="left">
           <italic>
            P. falciparum
           </italic>
           50%-80%
           <break>
           </break>
           <italic>
            P. vivax
           </italic>
           20%-50%
          </td>
          <td align="left">
           <list id="celist317" list-type="simple">
            <list-item id="celistitem1130">
             <p id="para1449">
              Southern part of the country in the provinces of Dae Lac, Gia Lai, Khan h Hoa, Kon Turn, Lam Dong, Ninh Thuan, Song Be, Tay Ninh: Atovaguone/proguanil or doxycycline
             </p>
            </list-item>
            <list-item id="celistitem1131">
             <p id="para1450">
              All other areas: Atovaguone/proguanil, doxycycline, or mefloquine
             </p>
            </list-item>
           </list>
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Virgin Islands, British
           </bold>
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Virgin Islands, U.S.
           </bold>
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
          <td align="left">
           Not applicable
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Western Sahara
           </bold>
          </td>
          <td align="left">
           Rare cases
          </td>
          <td align="left">
           None
          </td>
          <td align="left">
           Unknown
          </td>
          <td align="left">
           Mosguito avoidance only
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Yemen
           </bold>
          </td>
          <td align="left">
           All areas at altitudes &lt;2,000 m (&lt;6,561 ft). None in Sana'a
          </td>
          <td align="left">
           Chloroguine
          </td>
          <td align="left">
           <italic>
            P. falciparum
           </italic>
           95%
           <break>
           </break>
           <italic>
            P. malariae, P. vivax,
           </italic>
           and
           <italic>
            P. ovale 5%
           </italic>
          </td>
          <td align="left">
           Atovaguone/proguanil, doxycycline, or mefloquine
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Zambia
           </bold>
          </td>
          <td align="left">
           All
          </td>
          <td align="left">
           Chloroguine
          </td>
          <td align="left">
           <italic>
            P. falciparum
           </italic>
           &gt;90%
           <italic>
            P. vivax
           </italic>
           up to 5%
           <break>
           </break>
           <italic>
            P. ovale
           </italic>
           up to 5 %
          </td>
          <td align="left">
           Atovaguone/proguanil, doxycycline, or mefloquine
          </td>
         </tr>
         <tr>
          <td align="left">
           <bold>
            Zimbabwe
           </bold>
          </td>
          <td align="left">
           All
          </td>
          <td align="left">
           Chloroguine
          </td>
          <td align="left">
           <italic>
            P. falciparum
           </italic>
           &gt;90%
           <break>
           </break>
           <italic>
            P. vivax
           </italic>
           up to 5%
           <break>
           </break>
           <italic>
            P. ovale
           </italic>
           up to 5 %
          </td>
          <td align="left">
           Atovaguone/proguanil, doxycycline, or mefloquine
          </td>
         </tr>
        </tbody>
       </table>
       <table-wrap-foot>
        <fn id="cetablefn80">
         <label>
          1
         </label>
         <p id="cenotep80">
          The information presented herein was accurate at the time of publication; however, factors that can change rapidly and from year to year, such as local weather conditions, mosquito vector density, and prevalence of infection, can markedly affect local malaria transmission patterns. Updated information may be found on the CDC Travelers' Health website at
          <ext-link ext-link-type="uri" id="interref64" xlink:href="http://www.cdc.gov/travel">
           www.cdc.gov/travel
          </ext-link>
          .
         </p>
        </fn>
       </table-wrap-foot>
       <table-wrap-foot>
        <fn id="cetablefn81">
         <label>
          2
         </label>
         <p id="cenotep81">
          Refers to
          <italic>
           P. falciparum
          </italic>
          malaria.
         </p>
        </fn>
       </table-wrap-foot>
       <table-wrap-foot>
        <fn id="cetablefn82">
         <label>
          3
         </label>
         <p id="cenotep82">
          Estimates of malaria species are based on best available data from multiple sources.
         </p>
        </fn>
       </table-wrap-foot>
       <table-wrap-foot>
        <fn id="cetablefn83">
         <label>
          4
         </label>
         <p id="cenotep83">
          Several medications are available for chemoprophylaxis. When deciding which drug to use, consider specific itinerary, length of trip, cost of drug, previous adverse reactions to antimalarials, drug allergies, and current medical history. All travelers should seek medical attention in the event of fever during or after return from travel to areas with malaria.
         </p>
        </fn>
       </table-wrap-foot>
       <table-wrap-foot>
        <fn id="cetablefn84">
         <label>
          5
         </label>
         <p id="cenotep84">
          Primaquine can cause hemolytic anemia in persons with G6PD deficiency. Patients must be tested and documented to have a normal level of G6PD activity prior to starting primaquine.
         </p>
        </fn>
       </table-wrap-foot>
      </table-wrap>
     </p>
     <sec id="cesec309">
      <title>
      </title>
      <p id="para1451">
       Self-Treatable Diseases
      </p>
     </sec>
     <sec id="cesec310">
      <title>
       SELF-TREATABLE DISEASES
      </title>
      <p id="para1452">
       <bold>
        Alan J. Magill
       </bold>
      </p>
      <p id="para1453">
       Despite our best efforts at helping to prevent illness, travelers will often become ill while traveling. Obtaining reliable and timely medical care can be problematic in many destinations. As a result, prescribing certain medications in advance can empower the traveler to self-diagnose and treat common health problems. During an activity in a remote setting, such as trekking, the only alternative to self-treatment would be no treatment. In some developing countries, appropriate pre-travel counseling may result in a more accurate diagnosis and treatment than relying on local medical care. In addition, the increasing awareness of counterfeit drugs in pharmacies in the developing world (as many as 20%–30% of the drugs on the shelves) makes it more important for travelers to carry reliable drugs from their own country.
      </p>
      <p id="para1454">
       Providing education and prescriptions is part of the pre-travel consultation. The key aspect to this strategy is to recognize which travelers may be at risk and to educate them as to the diagnosis and treatment of the particular illness. The keys to successful self-treatment strategies are providing a simple disease definition, providing one choice of treatment, and educating the traveler about the expected outcome of treatment. Using travelers' diarrhea as an example, one could provide the following advice:
       <list id="celist318" list-type="simple">
        <list-item id="celistitem1132">
         <label>
          •
         </label>
         <p id="para1455">
          Travelers' diarrhea is defined as “the sudden onset of relatively uncomfortable diarrhea.”
         </p>
        </list-item>
        <list-item id="celistitem1133">
         <label>
          •
         </label>
         <p id="para1456">
          The treatment is ciprofloxacin 500 mg every 12 hours for 1 day (two doses).
         </p>
        </list-item>
        <list-item id="celistitem1134">
         <label>
          •
         </label>
         <p id="para1457">
          The traveler should feel better within 6 to 24 hours.
         </p>
        </list-item>
       </list>
      </p>
      <p id="para1458">
       To minimize the potential negative effects of a self-treatment strategy, the recommendations should follow a few key points:
       <list id="celist319" list-type="simple">
        <list-item id="celistitem1135">
         <label>
          •
         </label>
         <p id="para1459">
          Drugs used must be safe, well tolerated, and effective for use as self-treatment.
         </p>
        </list-item>
        <list-item id="celistitem1136">
         <label>
          •
         </label>
         <p id="para1460">
          A drug's toxicity or potential for harm, if used incorrectly or in an overdose situation, should be minimal.
         </p>
        </list-item>
        <list-item id="celistitem1137">
         <label>
          •
         </label>
         <p id="para1461">
          Good directions are critical. Consider providing simple but clear handouts describing how to use the drugs. Keeping the directions simple will greatly increase the effectiveness of the strategy.
         </p>
        </list-item>
       </list>
      </p>
      <p id="para1462">
       Following are some of the most common situations in which people would find self-treatment useful. The extent of self-treatment recommendations offered to the traveler should reflect the remoteness and difficulty of travel and the availability of reliable medical care at the particular destination. The recommended self-treatment options for each disease are provided in the designated section of the Yellow Book.
      </p>
      <p id="para1463">
       <bold>
        Travelers' diarrhea (TD)
       </bold>
       is perhaps most frequent indication for self-treatment. The success of this strategy is based on the epidemiologic evidence that bacterial pathogens account for more than 90% of TD in short-term travelers. The recognition of antibiotic resistance for certain organisms in specific destinations has made the empiric choice of treatment somewhat more problematic in recent times (see the
       <xref ref-type="sec" rid="cesec311">
        Travelers' Diarrhea section
       </xref>
       next in this chapter).
      </p>
      <p id="para1464">
       <bold>
        Altitude illness
       </bold>
       or acute mountain sickness (AMS) is a risk for travelers who ascend rapidly to altitudes &gt;8,000 ft (2,440 m). Certain common travel destinations, such as Cuzco, Peru, or Lhasa, Tibet, involve flying to altitudes of 11,300 ft (3,445 m) or 12,700 ft (3,870 m). The symptoms of headache, anorexia, nausea, fatigue, lassitude, and poor sleep can largely be prevented or treated with acetazolamide (see the
       <xref ref-type="sec" rid="subchapter24">
        Altitude Illness
       </xref>
       section later in this chapter).
      </p>
      <p id="para1465">
       <bold>
        Jet lag
       </bold>
       affects almost everyone who crosses three or more time zones. There is no consensus on the optimal pharmacologic treatment or prevention of the symptoms of jet lag, but sleeping medication taken at the destination may help regularize sleep patterns (see the
       <xref ref-type="sec" rid="subchapter25">
        Jet Lag
       </xref>
       section later in this chapter).
      </p>
      <p id="para1466">
       <bold>
        Motion sickness
       </bold>
       can be a major deterent to enjoyment for any susceptible person on a boat or a winding road. Premedication may help alleviate or ameliorate this bothersome syndrome (see the
       <xref ref-type="sec" rid="subchapter26">
        Motion Sickness
       </xref>
       section later in this chapter).
      </p>
      <p id="para1467">
       The self-treatment of suspected
       <bold>
        respiratory infections
       </bold>
       with empiric antibiotics is controversial. Almost all upper respiratory tract infections are initially caused by viruses. However, these viral infections, under the stress of travel, can lead to bacterial sinusitis, bronchitis or pneumonia. Respiratory infections that last longer than a week without signs of improvement may require empiric antibiotics for recovery. Prolonged respiratory infections may have more of a negative impact on a trip than diarrheal disease (see the
       <xref ref-type="sec" rid="subchapter27">
        Respiratory Infections
       </xref>
       section later in this chapter).
      </p>
      <p id="para1468">
       <bold>
        Bacterial skin infections
       </bold>
       are not common among travelers, but when they occur, they can be particularly distressing. Bacterial abscesses or cellulitis can worsen rapidly and be very painful. If the traveler is in a remote area or even more than a day's travel from medical care, the use of empiric antibiotic treatment can be extremely beneficial (see the Skin and Soft Tissue Infections in Returned Travelers section in Chapter 4).
      </p>
      <p id="para1469">
       <bold>
        Urinary tract infections
       </bold>
       are common among many women, and carrying an antibiotic for empiric treatment of this condition may be valuable in many circumstances.
      </p>
      <p id="para1470">
       <bold>
        Vaginal yeast infections
       </bold>
       in women can be a very annoying and debilitating problem. For women who know they are prone to infections, all sexually active women, and those who may be receiving antibiotics for other reasons, including doxycycline for antimalarial prophylaxis, a self-treatment course of their preferred antifungal medication can be prescribed.
      </p>
      <p id="para1471">
       <bold>
        Occupational/HIV needlestick
       </bold>
       is a particular risk to those participating in medical-related activities. Every year thousands of such individuals are now working in areas of sub-Saharan Africa, where the HIV prevalence may be higher than 15%–20%. A significant needlestick in this setting should prompt immediate wound care and the possible use of antiretroviral medications (see the
       <xref ref-type="sec" rid="subchapter28">
        Occupational Exposure to HIV
       </xref>
       section later in this chapter).
      </p>
      <p id="para1472">
       <bold>
        Malaria self-treatment
       </bold>
       is often referred to as stand-by emergency treatment (SBET). This strategy asks the traveler to use a therapeutic dose of an appropriate antimalarial drug when the traveler has a significant fever accompanied by systemic illness, and then proceed to reliable medical care within 24 hours. The goal is to prevent death or severe malaria. Since most travelers at risk of malaria should be advised to use prophylactic medication, this strategy is usually discouraged and reserved for a specific type of traveler under certain defined circumstances (see the
       <xref ref-type="sec" rid="subchapter21">
        Malaria
       </xref>
       section earlier in this chapter).
      </p>
     </sec>
     <sec id="cesec311">
      <title>
       TRAVELERS' DIARRHEA
      </title>
      <p id="para1473">
       <bold>
        Bradley A. Connor
       </bold>
      </p>
      <sec id="cesec312">
       <title>
        Description
       </title>
       <p id="para1474">
        Travelers' diarrhea (TD) is the most predictable travel-related illness. Attack rates range from 30% to 70% of travelers, depending on the destination. Traditionally, it was thought that TD could be prevented by following eating rules, but studies have found that people who follow the rules still get ill. Poor hygiene practice in local restaurants is likely the largest contributor to the risk for TD.
       </p>
       <p id="para1475">
        TD itself is a clinical syndrome that can result from a variety of intestinal pathogens. Bacterial pathogens are the predominant risk, thought to account for 80%–90% of TD. Intestinal viruses have been isolated in studies of TD, but they usually account for 5%–8% of illnesses. Protozoal pathogens are slower to manifest symptoms, and collectively account for about 10% of diagnoses in longer-term travelers. What is commonly known as “food poisoning” involves the ingestion of preformed toxins in food. In this syndrome, vomiting and diarrhea may both be present, but symptoms usually resolve spontaneously within 12 hours.
       </p>
      </sec>
      <sec id="cesec313">
       <title>
        Infectious Agent
       </title>
       <p id="para1476">
        <list id="celist320" list-type="simple">
         <list-item id="celistitem1138">
          <label>
           •
          </label>
          <p id="para1477">
           Bacteria are the most common cause of TD. The most common pathogen is enterotoxigenic
           <italic>
            Escherichia coli
           </italic>
           , followed by
           <italic>
            Campylobacter jejuni
           </italic>
           ,
           <italic>
            Shigella
           </italic>
           sp., and
           <italic>
            Salmonella
           </italic>
           sp. Enteroadherent and other
           <italic>
            E. coli
           </italic>
           species have been found to also be common pathogens in bacterial diarrhea.
          </p>
         </list-item>
         <list-item id="celistitem1139">
          <label>
           •
          </label>
          <p id="para1478">
           Viral diarrhea can be caused by a number of viral pathogens, including norovirus, rotavirus, and astrovirus.
          </p>
         </list-item>
         <list-item id="celistitem1140">
          <label>
           •
          </label>
          <p id="para1479">
           <italic>
            Giardia
           </italic>
           is the main protozoal pathogen found in travelers.
           <italic>
            Entamoeba histolytica
           </italic>
           is a relatively uncommon pathogen in travelers.
           <italic>
            Cryptosporidium
           </italic>
           is also relatively uncommon. The risk for
           <italic>
            Cyclospora
           </italic>
           is highly geographic and seasonal, with the most well-known risks in Nepal, Peru, Haiti, and Guatemala.
           <italic>
            Dientamoeba fragilis
           </italic>
           is a low-grade but persisent pathogen that is occasionally diagnosed in travelers.
          </p>
         </list-item>
         <list-item id="celistitem1141">
          <label>
           •
          </label>
          <p id="para1480">
           The individual pathogens are each discussed in their own sections in Chapter 5, and persistent diarrhea is discussed in Chapter 4.
          </p>
         </list-item>
        </list>
       </p>
      </sec>
      <sec id="cesec314">
       <title>
        Occurrence
       </title>
       <p id="para1481">
        <list id="celist321" list-type="simple">
         <list-item id="celistitem1142">
          <label>
           •
          </label>
          <p id="para1482">
           The most important determinant of risk is travel destination, and there are regional differences in both the risk for and etiology of diarrhea.
          </p>
         </list-item>
         <list-item id="celistitem1143">
          <label>
           •
          </label>
          <p id="para1483">
           The world is generally divided into three grades of risk: low, intermediate, and high.
           <list id="celist322" list-type="simple">
            <list-item id="celistitem1144">
             <label>
              ○
             </label>
             <p id="para1484">
              Low-risk countries include the United States, Canada, Australia, New Zealand, Japan, and countries in Northern and Western Europe.
             </p>
            </list-item>
            <list-item id="celistitem1145">
             <label>
              ○
             </label>
             <p id="para1485">
              Intermediate-risk countries include those in Eastern Europe, South Africa, and some of the Caribbean islands.
             </p>
            </list-item>
            <list-item id="celistitem1146">
             <label>
              ○
             </label>
             <p id="para1486">
              High-risk areas include most of Asia, the Middle East, Africa, Mexico, and Central and South America.
             </p>
            </list-item>
           </list>
          </p>
         </list-item>
        </list>
       </p>
      </sec>
      <sec id="cesec315">
       <title>
        Risk for Travelers
       </title>
       <p id="para1487">
        Travelers' diarrhea occurs equally in male and female travelers and is more common in young adults than in older people. In short-term travelers, bouts of TD do not appear to protect against future attacks, and more than one episode of TD may occur during a single trip. A cohort of expatriates taking up residence in Kathmandu, Nepal, experienced an average of 3.2 episodes of TD per person in their first year. In more temperate regions, there may be seasonal variations in diarrhea risk. In South Asia, for example, during the hot months preceding the monsoon, much higher TD attack rates are commonly reported.
       </p>
       <p id="para1488">
        In environments where large numbers of people do not have access to plumbing or outhouses, the amount of stool contamination in the environment will be higher and more accessible to flies. Inadequate electrical capacity may lead to frequent blackouts or poorly functioning refrigeration, which can result in unsafe food storage and an increased risk for disease. Inadequate water supplies can lead to the absence of sinks for handwashing by restaurant staff. Poor training in handling and preparation of food may lead to cross-contamination from meat and inadequate sterilization of food preparation surfaces and utensils. In destinations in which effective food handling courses have been provided, the risk for TD has been demonstrated to decrease. It should be noted, however, that pathogens that cause TD are not unique to developing countries. The risk of TD is associated with the hygiene practices in specific destinations and the handling and preparation of food in restaurants in developed countries as well.
       </p>
      </sec>
      <sec id="cesec316">
       <title>
        Clinical Presentation
       </title>
       <p id="para1489">
        <list id="celist323" list-type="simple">
         <list-item id="celistitem1147">
          <label>
           •
          </label>
          <p id="para1490">
           Bacterial diarrhea presents with the sudden onset of bothersome symptoms that can range from mild cramps and urgent loose stools, to severe abdominal pain, fever, vomiting, and bloody diarrhea.
          </p>
         </list-item>
         <list-item id="celistitem1148">
          <label>
           •
          </label>
          <p id="para1491">
           Viral enteropathogens present in a similar fashion to bacterial pathogens, although with norovirus vomiting may be more prominent.
          </p>
         </list-item>
         <list-item id="celistitem1149">
          <label>
           •
          </label>
          <p id="para1492">
           Protozoal diarrhea, such as that caused by
           <italic>
            Giardia intestinalis
           </italic>
           , or
           <italic>
            Entamoeba histolytica
           </italic>
           , generally has a more gradual onset of low-grade symptoms, with 2–5 loose stools per day.
          </p>
         </list-item>
         <list-item id="celistitem1150">
          <label>
           •
          </label>
          <p id="para1493">
           The incubation period of the pathogens can be a clue to the etiology of TD.
           <list id="celist324" list-type="simple">
            <list-item id="celistitem1151">
             <label>
              ○
             </label>
             <p id="para1494">
              Bacterial and viral pathogens have an incubation period of 6–48 hours.
             </p>
            </list-item>
            <list-item id="celistitem1152">
             <label>
              ○
             </label>
             <p id="para1495">
              Protozoal pathogens generally have an incubation period of 1–2 weeks and rarely present in the first few weeks of travel. An exception can be
              <italic>
               Cyclospora cayetanensis
              </italic>
              , which can present quickly in areas of high risk.
             </p>
            </list-item>
           </list>
          </p>
         </list-item>
         <list-item id="celistitem1153">
          <label>
           •
          </label>
          <p id="para1496">
           Untreated bacterial diarrhea lasts 3–5 days. Viral diarrhea lasts 2–3 days. Protozoal diarrhea can persist for weeks to months without treatment.
          </p>
         </list-item>
         <list-item id="celistitem1154">
          <label>
           •
          </label>
          <p id="para1497">
           An acute bout of gastroenteritis can lead to persistent gastrointestinal symptoms, even in the absence of continued infection (see the Persistent Travelers' Diarrhea section in Chapter 4). Other postinfectious sequelae include reactive arthritis and Guillain–Barré syndrome.
          </p>
         </list-item>
        </list>
       </p>
      </sec>
      <sec id="cesec317">
       <title>
        Preventive Measures for Travelers
       </title>
       <p id="para1498">
        <list id="celist325" list-type="simple">
         <list-item id="celistitem1155">
          <label>
           •
          </label>
          <p id="para1499">
           For travelers to high-risk areas, several approaches may be recommended that can reduce but never completely eliminate the risk for TD. These include—
           <list id="celist326" list-type="simple">
            <list-item id="celistitem1156">
             <label>
              ○
             </label>
             <p id="para1500">
              Instruction regarding food and beverage selection
             </p>
            </list-item>
            <list-item id="celistitem1157">
             <label>
              ○
             </label>
             <p id="para1501">
              Use of agents other than antimicrobial drugs for prophylaxis
             </p>
            </list-item>
            <list-item id="celistitem1158">
             <label>
              ○
             </label>
             <p id="para1502">
              Use of prophylactic antibiotics
             </p>
            </list-item>
           </list>
          </p>
         </list-item>
         <list-item id="celistitem1159">
          <label>
           •
          </label>
          <p id="para1503">
           Carrying small containers of hand-sanitizing solutions or gels (containing at least 60% alcohol) may make it easier for travelers to clean their hands before eating.
          </p>
         </list-item>
        </list>
       </p>
       <sec id="cesec318">
        <title>
         Food and Beverage Selection
        </title>
        <p id="para1504">
         Care in selecting food and beverages for consumption might minimize the risk for acquiring TD. Travelers should be advised that foods that are freshly cooked and served piping hot are safer than foods that may have been sitting for some time in the kitchen or in a buffet. Care should be taken to avoid beverages diluted with nonpotable water (reconstituted fruit juices, ice, and milk) and foods washed in nonpotable water, such as salads. Other risky foods include raw or undercooked meat and seafood, and unpeeled raw fruits and vegetables. Safe beverages include those that are bottled and sealed, or carbonated. Boiled beverages and those appropriately treated with iodine or chlorine may also be safely consumed. Although food and water precautions continue to be recommended, travelers may not always be able to always adhere to the advice. Furthermore, many of the factors that ensure food safety, such as restaurant hygiene, are out of the traveler's control.
        </p>
       </sec>
       <sec id="cesec319">
        <title>
         Nonantimicrobial Drugs for Prophylaxis
        </title>
        <p id="para1505">
         The primary agent studied for prevention of TD, other than antimicrobial drugs, is bismuth subsalicylate (BSS), which is the active ingredient in Pepto-Bismol. Studies from Mexico have shown this agent (taken daily as either 2 oz of liquid or two chewable tablets four times per day) reduces the incidence of TD from 40% to 14%. BSS commonly causes blackening of the tongue and stool and may cause nausea, constipation, and rarely tinnitus. BSS should be avoided by travelers with aspirin allergy, renal insufficiency, and gout, and by those taking anticoagulants, probenecid, or methotrexate. In travelers taking aspirin or salicylates for other reasons, the use of BSS may result in salicylate toxicity. Caution should be used in administering BSS to children with viral infections, such as varicella or influenza, because of the risk for Reye syndrome. BSS is not recommended for children &lt;3 years of age. Studies have not established the safety of BSS use for periods &gt;3 weeks.
        </p>
        <p id="para1506">
         The use of probiotics, such as Lactobacillus GG and
         <italic>
          Saccharomyces boulardii
         </italic>
         , has been studied in the prevention of TD in limited numbers of subjects. Results are inconclusive, partially because standardized preparations of these bacteria are not reliably available.
        </p>
       </sec>
       <sec id="cesec320">
        <title>
         Prophylactic Antibiotics
        </title>
        <p id="para1507">
         Prophylactic antibiotics have been demonstrated to be quite effective in the prevention of TD. Controlled studies have shown that diarrhea attack rates are reduced from 40% to 4% by the use of antibiotics. The prophylactic antibiotic of choice has changed over the past few decades as resistance patterns have evolved. Agents such as trimethoprim-sulfamethoxazole and doxycycline are no longer considered effective antimicrobial agents against enteric bacterial pathogens. The fluoroquinolones have been the most effective antibiotics for the prophylaxis and treatment of bacterial TD pathogens, but increasing resistance to these agents, mainly among
         <italic>
          Campylobacter
         </italic>
         species, may limit their benefit in the future. A nonabsorbable antibiotic, rifaximin, is being investigated for its potential use in TD prophylaxis. In the only study published to date, rifaximin reduced the risk for TD in travelers to Mexico by 77%. At this time, prophylactic antibiotics should not be recommended for most travelers. In addition to affording no protection against nonbacterial pathogens, the use of antibiotics may be associated with allergic or adverse reactions in a certain percentage of travelers. The use of prophylactic antibiotics should be weighed against the result of using prompt, early self-treatment with antibiotics when TD occurs, which can limit the duration of illness to 6–24 hours in most cases.
        </p>
        <p id="para1508">
         Prophylactic antibiotics may be considered for short-term travelers who are high-risk hosts (such as those who are immunosuppressed) or are taking critical trips during which even a short bout of diarrhea could impact the purpose of the trip.
        </p>
       </sec>
      </sec>
      <sec id="cesec321">
       <title>
        Treatment
       </title>
       <p id="para1509">
        Antibiotics are the principal element in the treatment of TD. Adjunctive agents used for symptomatic control may also be recommended.
       </p>
       <sec id="cesec322">
        <title>
         Antibiotics
        </title>
        <p id="para1510">
         As bacterial causes of TD far outnumber other microbial etiologies, empiric treatment with an antibiotic directed at enteric bacterial pathogens remains the best therapy for TD. The benefit of treatment of TD with antibiotics has been proven in numerous studies. The effectiveness of a particular antimicrobial depends on the etiologic agent and its antibiotic sensitivity. Both as empiric therapy or for treatment of a specific bacterial pathogen, first-line antibiotics include those of the fluoroquinolone class, such as ciprofloxacin or levofloxacin. Increasing microbial resistance to the fluoroquinolones, especially among
         <italic>
          Campylobacter
         </italic>
         isolates, may limit their usefulness in some destinations such as Thailand, where
         <italic>
          Campylobacter
         </italic>
         is prevalent. Isolated anecdotal case reports of resistant
         <italic>
          Campylobacter
         </italic>
         diarrhea occur periodically from other destinations. An alternative to the fluoroquinolones in this situation is azithromycin. Rifaximin has been approved for the treatment of TD caused by noninvasive strains of
         <italic>
          E. coli
         </italic>
         . However, since it is often difficult for travelers to distinguish between invasive and noninvasive diarrhea and since they would have to carry a back-up drug in the event of invasive diarrhea, the overall usefulness of rifaximin as empiric self-treatment remains to be determined.
        </p>
        <p id="para1511">
         Single-dose or 1-day therapy for TD with a fluoroquinolone is well established, both by clinical trials and clinical experience. The best regimen for azithromycin treatment is not yet established. One study used a single dose of 1,000 mg, but side effects (mainly nausea) may limit the acceptability of this large dose. Azithromycin, 500 mg per day for 1–2 days, appears to be effective in most cases of TD.
        </p>
       </sec>
       <sec id="cesec323">
        <title>
         Antimotility Agents
        </title>
        <p id="para1512">
         Antimotility agents provide symptomatic relief and serve as useful adjuncts to antibiotic therapy in TD. Synthetic opiates, such as loperamide and diphenoxylate, can reduce bowel movement frequency and enable travelers to ride on an airplane or bus while awaiting the effects of antibiotics. Loperamide appears to have antisecretory properties as well. The safety of loperamide when used along with an appropriate antibiotic has been well established, even in cases of invasive pathogens. Loperamide can be used in children, and liquid formulations are available. In practice, however, these drugs are rarely given to small children.
        </p>
       </sec>
       <sec id="cesec324">
        <title>
         Oral Rehydration Therapy
        </title>
        <p id="para1513">
         Fluids and electrolytes are lost in cases of TD, and replenishment is important, especially in young children or adults with chronic medical illness. In adult travelers who are otherwise healthy, severe dehydration resulting from TD is unusual unless prolonged vomiting is present. Nonetheless, replacement of fluid losses remains an important adjunct to other therapy and helps the traveler feel better more quickly. Travelers should remember to use only beverages that are sealed or carbonated, or otherwise known to be purified. For more severe fluid loss, replacement is best accomplished with oral rehydration solutions (ORS), such as the WHO ORS solutions, which are widely available at stores and pharmacies in most developing countries (see
         <xref ref-type="table" rid="cetable24">
          Table 2-25
         </xref>
         for details). ORS is prepared by adding one packet to the appropriate volume of boiled or treated water. Travelers may find most ORS formulations to be relatively unpalatable, due to their saltiness. In most cases, rehydration can be maintained with any palatable liquid.
         <table-wrap id="cetable24" position="float">
          <label>
           Table 2-25
          </label>
          <caption>
           <p>
            Composition of WHO oral rehydration solution (ORS) for diarrheal illness
           </p>
          </caption>
          <table frame="hsides" rules="groups">
           <thead>
            <tr>
             <th align="left">
              Ingredient
             </th>
             <th align="left">
              Amount
             </th>
             <th align="left">
              Measurement
             </th>
            </tr>
           </thead>
           <tbody>
            <tr>
             <td align="left">
              Sodium chloride
             </td>
             <td align="left">
              3.5 g/L
             </td>
             <td align="left">
              ½ tsp
             </td>
            </tr>
            <tr>
             <td align="left">
              Potassium chloride
             </td>
             <td align="left">
              1.5 g/L
             </td>
             <td align="left">
              1¼ tsp
             </td>
            </tr>
            <tr>
             <td align="left">
              Glucose
             </td>
             <td align="left">
              20.0 g/L
             </td>
             <td align="left">
              2 tbsp
             </td>
            </tr>
            <tr>
             <td align="left">
              Trisodium citrate (or sodium bicarbonate)
             </td>
             <td align="left">
              2.9 g/L (or 2.5 g/L)
             </td>
             <td align="left">
              ½ tsp
             </td>
            </tr>
            <tr>
             <td align="left">
              Water
             </td>
             <td align="left">
              1,000 g
             </td>
             <td align="left">
              1 liter
             </td>
            </tr>
           </tbody>
          </table>
         </table-wrap>
        </p>
       </sec>
       <sec id="cesec325">
        <title>
         Treatment of TD Caused by Protozoa
        </title>
        <p id="para1514">
         The most common parasitic cause of TD is
         <italic>
          Giardia intestinalis
         </italic>
         , and treatment options include metronidazole, tinidazole, and nitazoxanide. Although cryptosporidiosis is usually a self-limited illness in immunocompetent persons, nitazoxanide can be considered as a treatment option. Cyclosporiasis is treated with trimethoprim–sulfamethoxazole. Treatment of amebiasis is with metronidazole or tinidazole, followed by treatment with a luminal agent such as paromomycin.
        </p>
       </sec>
       <sec id="cesec326">
        <title>
         Treatment for Children
        </title>
        <p id="para1515">
         Children who accompany their parents on trips to high-risk destinations may be expected to have TD as well. There is no reason to withhold antibiotics from children who contract TD. In older children and teenagers, treatment recommendations for TD follow those for adults, with possible adjustments in the dose of medication. Macrolides such as azithromycin are considered first-line antibiotic therapy in children, although some experts now use short-course fluoroquinolone therapy for travelers &lt;18 years of age. Rifaximin is approved for use starting at 12 years of age.
        </p>
        <p id="para1516">
         Infants and younger children are at higher risk for developing dehydration from TD, which is best prevented by the early use of ORS solutions. Breastfed infants should continue to nurse on demand, and bottle-fed infants can continue to drink their formula. Older infants and children may eat a regular diet, depending on the level of their appetite while they are ill. Infants in diapers are at risk for developing a painful, ecxematous rash on their buttocks in response to the liquid stool. Hydrocortisone cream will quickly improve this rash. More information about diarrhea and dehydration are discussed in the Traveling Safely with Infants and Children section in Chapter 7.
        </p>
       </sec>
      </sec>
     </sec>
     <ref-list id="cebib22">
      <title>
       References
      </title>
      <ref id="bib234">
       <label>
        1
       </label>
       <element-citation id="sbref211" publication-type="journal">
        <comment>
        </comment>
        <person-group person-group-type="author">
         <name>
          <surname>
           Steffen
          </surname>
          <given-names>
           R
          </given-names>
         </name>
        </person-group>
        <article-title>
         Epidemiology of travellers' diarrhoea
        </article-title>
        <source>
         Scand J Gastroenterol Suppl
        </source>
        <volume>
         84
        </volume>
        <year>
         1983
        </year>
        <fpage>
         5
        </fpage>
        <lpage>
         17
        </lpage>
        <pub-id pub-id-type="pmid">
         6579635
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib235">
       <label>
        2
       </label>
       <element-citation id="sbref212" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Black
          </surname>
          <given-names>
           RE
          </given-names>
         </name>
        </person-group>
        <article-title>
         Epidemiology of travelers' diarrhea and relative importance of various pathogens
        </article-title>
        <source>
         Rev Infect Dis
        </source>
        <volume>
         12
        </volume>
        <issue>
         Suppl 1
        </issue>
        <year>
         1990
        </year>
        <fpage>
         S73
        </fpage>
        <lpage>
         S79
        </lpage>
        <pub-id pub-id-type="pmid">
         2406860
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib236">
       <label>
        3
       </label>
       <element-citation id="sbref213" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Adachi
          </surname>
          <given-names>
           JA
          </given-names>
         </name>
         <name>
          <surname>
           Jiang
          </surname>
          <given-names>
           ZD
          </given-names>
         </name>
         <name>
          <surname>
           Mathewson
          </surname>
          <given-names>
           JJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         Enteroaggregative
         <italic>
          Escherichia coli
         </italic>
         as a major etiologic agent in traveler's diarrhea in 3 regions of the world
        </article-title>
        <source>
         Clin Infect Dis
        </source>
        <volume>
         32
        </volume>
        <issue>
         12
        </issue>
        <year>
         2001
        </year>
        <fpage>
         1706
        </fpage>
        <lpage>
         1709
        </lpage>
        <pub-id pub-id-type="pmid">
         11360211
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib237">
       <label>
        4
       </label>
       <element-citation id="sbref214" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           von Sonnenburg
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Tornieporth
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Waiyaki
          </surname>
          <given-names>
           P
          </given-names>
         </name>
        </person-group>
        <article-title>
         Risk and aetiology of diarrhoea at various tourist destinations
        </article-title>
        <source>
         Lancet
        </source>
        <volume>
         356
        </volume>
        <issue>
         9224
        </issue>
        <year>
         2000
        </year>
        <fpage>
         133
        </fpage>
        <lpage>
         134
        </lpage>
        <pub-id pub-id-type="pmid">
         10963251
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib238">
       <label>
        5
       </label>
       <element-citation id="sbref215" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Shlim
          </surname>
          <given-names>
           DR
          </given-names>
         </name>
        </person-group>
        <article-title>
         Update in traveler's diarrhea
        </article-title>
        <source>
         Infect Dis Clin North Am
        </source>
        <volume>
         19
        </volume>
        <issue>
         1
        </issue>
        <year>
         2005
        </year>
        <fpage>
         137
        </fpage>
        <lpage>
         149
        </lpage>
        <pub-id pub-id-type="pmid">
         15701551
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib239">
       <label>
        6
       </label>
       <element-citation id="sbref216" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           DuPont
          </surname>
          <given-names>
           HL
          </given-names>
         </name>
         <name>
          <surname>
           Ericsson
          </surname>
          <given-names>
           CD
          </given-names>
         </name>
        </person-group>
        <article-title>
         Prevention and treatment of traveler's diarrhea
        </article-title>
        <source>
         N Engl J Med
        </source>
        <volume>
         328
        </volume>
        <issue>
         25
        </issue>
        <year>
         1993
        </year>
        <fpage>
         1821
        </fpage>
        <lpage>
         1827
        </lpage>
        <pub-id pub-id-type="pmid">
         8502272
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib240">
       <label>
        7
       </label>
       <element-citation id="sbref217" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Connor
          </surname>
          <given-names>
           BA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Sequelae of traveler's diarrhea: focus on postinfectious irritable bowel syndrome
        </article-title>
        <source>
         Clin Infect Dis
        </source>
        <volume>
         41
        </volume>
        <issue>
         Suppl 8
        </issue>
        <year>
         2005
        </year>
        <fpage>
         S577
        </fpage>
        <lpage>
         S586
        </lpage>
        <pub-id pub-id-type="pmid">
         16267722
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib241">
       <label>
        8
       </label>
       <element-citation id="sbref218" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hoge
          </surname>
          <given-names>
           CW
          </given-names>
         </name>
         <name>
          <surname>
           Gambel
          </surname>
          <given-names>
           JM
          </given-names>
         </name>
         <name>
          <surname>
           Srijan
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        <article-title>
         Trends in antimicrobial resistance among diarrheal pathogens isolated in Thailand over 15 years
        </article-title>
        <source>
         Clin Infect Dis
        </source>
        <volume>
         26
        </volume>
        <year>
         1998
        </year>
        <fpage>
         341
        </fpage>
        <lpage>
         345
        </lpage>
        <pub-id pub-id-type="pmid">
         9502453
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib242">
       <label>
        9
       </label>
       <element-citation id="sbref219" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           DuPont
          </surname>
          <given-names>
           HL
          </given-names>
         </name>
         <name>
          <surname>
           Jiang
          </surname>
          <given-names>
           ZD
          </given-names>
         </name>
         <name>
          <surname>
           Ericsson
          </surname>
          <given-names>
           CD
          </given-names>
         </name>
        </person-group>
        <article-title>
         Rifaximin versus ciprofloxacin for the treatment of traveler's diarrhea: a randomized double blind clinical trial
        </article-title>
        <source>
         Clin Infect Dis
        </source>
        <volume>
         33
        </volume>
        <issue>
         11
        </issue>
        <year>
         2001
        </year>
        <fpage>
         1807
        </fpage>
        <lpage>
         1815
        </lpage>
        <pub-id pub-id-type="pmid">
         11692292
        </pub-id>
       </element-citation>
      </ref>
     </ref-list>
    </sec>
    <sec id="subchapter23">
     <sec-meta>
      <contrib-group>
       <contrib contrib-type="author" id="au41">
        <name>
         <surname>
          Pawlowski
         </surname>
         <given-names>
          Sean W.
         </given-names>
        </name>
       </contrib>
       <contrib contrib-type="author" id="au42">
        <name>
         <surname>
          Guerrant
         </surname>
         <given-names>
          Richard L.
         </given-names>
        </name>
       </contrib>
      </contrib-group>
     </sec-meta>
     <title>
      <italic>
       PERSPECTIVES:
      </italic>
      GLOBAL IMPACT OF DIARRHEAL DISEASE
     </title>
     <p id="para1517">
      Travelers frequently acquire the enteric pathogens that are present in food and water at their destinations and develop travelers' diarrhea. Mercifully, this is usually a nonfatal nuisance for travelers from developed nations, who, due to their well-nourished state, lack of other co-morbidities, antibiotic availability, and lack of repetitive infections, recover from their illness (more often than not) with few lasting effects.
     </p>
     <p id="para1518">
      In the short term, for those living in developing countries, infections due to enteric organisms are potentially life threatening, particularly in children and when combined with other illnesses, such as measles. Oral rehydration is the mainstay of treatment, but children suffering repeated, malnourishing illnesses at weaning require critical nutrient and micronutrient therapy as well.
     </p>
     <p id="para1519">
      While those traveling to aid in humanitarian efforts, including missionaries and volunteers, may feel they are well prepared to meet the challenges they face, many may not fully understand the profound impact that the lack of availability of clean water and sanitation has on indigenous populations. Travel health advisors, as well, should understand the serious implications and consequences of the global burden of these diarrheal illnesses as their occurrence is centered in the destinations of many U.S. travelers. Recent figures estimate 1.6 million deaths per year worldwide in children &lt;5 years of age in these areas. Fortunately, this rate is dramatically down from 4.6 million per year (estimates from 1955 to 1979), in large part due to the implementation of oral rehydration therapy. However, the morbidity rates either have not fallen or have slightly increased. In addition, as the AIDS pandemic continues to spread, complications associated with endemic enteric pathogens will likely increase both mortality and morbidity.
     </p>
     <p id="para1520">
      More difficult to quantify is the global burden of repeated or persistent diarrheal illnesses. Unfortunately, these contribute significantly to the impairment of physical and cognitive development of children and to long-term disability, which ultimately result in substantial national economic losses.
     </p>
     <ref-list id="cebib23">
      <title>
       References
      </title>
      <ref id="bib243">
       <label>
        1
       </label>
       <mixed-citation id="ceotherref24" publication-type="other">
        The state of the world's children 2008. [cited 2008 Nov 26]. Available from:
        <ext-link ext-link-type="uri" id="interref65" xlink:href="http://www.unicef.org/sowc08/">
         http://www.unicef.org/sowc08/
        </ext-link>
        .
       </mixed-citation>
      </ref>
      <ref id="bib244">
       <label>
        2
       </label>
       <element-citation id="sbref220" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kosek
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Bern
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Guerrant
          </surname>
          <given-names>
           R
          </given-names>
         </name>
        </person-group>
        <article-title>
         The global burden of diarrhoeal disease, as estimated from studies published between 1992 and 2000
        </article-title>
        <source>
         Bull WHO
        </source>
        <volume>
         81
        </volume>
        <issue>
         3
        </issue>
        <year>
         2003
        </year>
        <fpage>
         197
        </fpage>
        <lpage>
         204
        </lpage>
        <pub-id pub-id-type="pmid">
         12764516
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib245">
       <label>
        3
       </label>
       <element-citation id="sbref221" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Guerrant
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Oria
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Bushen
          </surname>
          <given-names>
           OY
          </given-names>
         </name>
        </person-group>
        <article-title>
         Global impact of diarrheal diseases that are sampled by travelers: the rest of the hippopotamus
        </article-title>
        <source>
         Clin Infect Dis
        </source>
        <volume>
         41
        </volume>
        <issue>
         Suppl 8
        </issue>
        <year>
         2005
        </year>
        <fpage>
         S524
        </fpage>
        <lpage>
         S530
        </lpage>
        <pub-id pub-id-type="pmid">
         16267713
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib246">
       <label>
        4
       </label>
       <element-citation id="sbref222" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Guerrant
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Kosek
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Moore
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        <article-title>
         Magnitude and impact of diarrheal diseases
        </article-title>
        <source>
         Arch Med Res
        </source>
        <volume>
         33
        </volume>
        <issue>
         4
        </issue>
        <year>
         2002
        </year>
        <fpage>
         351
        </fpage>
        <lpage>
         355
        </lpage>
        <pub-id pub-id-type="pmid">
         12234524
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib247">
       <label>
        5
       </label>
       <element-citation id="sbref223" publication-type="journal">
        <comment>
        </comment>
        <person-group person-group-type="author">
         <name>
          <surname>
           Guerrant
          </surname>
          <given-names>
           RL
          </given-names>
         </name>
         <name>
          <surname>
           Oriá
          </surname>
          <given-names>
           RB
          </given-names>
         </name>
         <name>
          <surname>
           Moore
          </surname>
          <given-names>
           SR
          </given-names>
         </name>
        </person-group>
        <article-title>
         Malnutrition as an enteric infectious disease, with long-term effects on child development
        </article-title>
        <source>
         Nutr Rev
        </source>
        <volume>
         66
        </volume>
        <issue>
         9
        </issue>
        <year>
         2008
        </year>
        <fpage>
         487
        </fpage>
        <lpage>
         505
        </lpage>
        <pub-id pub-id-type="pmid">
         18752473
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib248">
       <label>
        6
       </label>
       <element-citation id="sbref224" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Checkley
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <name>
          <surname>
           Buckley
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Gilman
          </surname>
          <given-names>
           RH
          </given-names>
         </name>
        </person-group>
        <article-title>
         The Childhood Malnutrition and Diarrhea Network. Multi-country analysis of the effects of diarrhea on childhood stunting
        </article-title>
        <source>
         Internat J Epidemiol
        </source>
        <volume>
         37
        </volume>
        <issue>
         4
        </issue>
        <year>
         2008
        </year>
        <fpage>
         816
        </fpage>
        <lpage>
         830
        </lpage>
       </element-citation>
      </ref>
     </ref-list>
    </sec>
    <sec id="subchapter24">
     <sec-meta>
      <contrib-group>
       <contrib contrib-type="author" id="au43">
        <name>
         <surname>
          Hackett
         </surname>
         <given-names>
          Peter H.
         </given-names>
        </name>
       </contrib>
       <contrib contrib-type="author" id="au44">
        <name>
         <surname>
          Shlim
         </surname>
         <given-names>
          David R.
         </given-names>
        </name>
       </contrib>
      </contrib-group>
     </sec-meta>
     <title>
      ALTITUDE ILLNESS
     </title>
     <sec id="cesec327">
      <title>
       Occurrence
      </title>
      <p id="para1521">
       The stresses of the high-altitude environment include cold, low humidity, increased ultraviolet (UV) radiation, and decreased air pressure, all of which can cause problems for travelers. The greatest concern, however, is hypoxia. At 10,000 ft (3,000 m), for example, the inspired PO
       <sub>
        2
       </sub>
       is only 69% of sea-level value. The degree of hypoxic stress depends upon altitude, rate of ascent, and duration of exposure. Sleeping at high altitude produces the greatest hypoxia; day trips to high altitude with return to low altitude are much less stressful on the body.
      </p>
     </sec>
     <sec id="cesec328">
      <title>
       Acclimatization
      </title>
      <p id="para1522">
       The human body adjusts very well to moderate hypoxia, but requires time to do so (
       <xref ref-type="boxed-text" rid="cetextbox1">
        Box 2-3
       </xref>
       ). The process of acute acclimatization to high altitude takes 3–5 days; therefore, acclimatizing for a few days at 8,000–9,000 ft before proceeding to higher altitude is ideal. Acclimatization prevents altitude illness, improves sleep, and increases comfort and well-being, although exercise performance will always be reduced compared with low altitude. Increase in ventilation is the most important factor in acute acclimatization; therefore, respiratory depressants must be avoided. Increased red-cell production does not play a role in acute acclimatization.
       <boxed-text id="cetextbox1">
        <label>
         Box 2-3
        </label>
        <caption>
         <title>
          Tips for acclimatization
         </title>
        </caption>
        <p id="para118">
         The following are helpful tips for people traveling to high altitude destinations.
         <list id="celist39" list-type="simple">
          <list-item id="celistitem118">
           <label>
            •
           </label>
           <p id="para119">
            Ascend gradually, if possible. Try not to go directly from low altitude to &gt;9,000 ft (2,750 m) sleeping altitude in one day.
           </p>
          </list-item>
          <list-item id="celistitem119">
           <label>
            •
           </label>
           <p id="para120">
            Consider using acetazolamide (Diamox) to speed acclimatization if abrupt ascent is unavoidable.
           </p>
          </list-item>
          <list-item id="celistitem120">
           <label>
            •
           </label>
           <p id="para121">
            Avoid alcohol for the first 48 hours.
           </p>
          </list-item>
          <list-item id="celistitem121">
           <label>
            •
           </label>
           <p id="para122">
            Participate in only mild exercise for the first 48 hours.
           </p>
          </list-item>
          <list-item id="celistitem122">
           <label>
            •
           </label>
           <p id="para123">
            Having a high-altitude exposure at &gt;9,000 ft (2,750 m), for 2 nights or more within 30 days prior to the trip is useful.
           </p>
          </list-item>
          <list-item id="celistitem123">
           <label>
            •
           </label>
           <p id="para124">
            Treat an altitude headache with simple analgesics.
           </p>
          </list-item>
         </list>
        </p>
       </boxed-text>
      </p>
     </sec>
     <sec id="cesec329">
      <title>
       Risk for Travelers
      </title>
      <p id="para1523">
       Inadequate acclimatization may lead to altitude illness in any traveler going to 8,000 ft (2,500 m) or higher. Susceptibility and resistance to altitude illness are genetic traits, and no screening tests are available to predict risk. Risk is not affected by training or physical fitness. Children are equally susceptible as adults; persons &gt;50 years of age have slightly lower risk. How a traveler has responded to high altitude previously is the most reliable guide for future trips but is not infallible. However, given certain baseline susceptibility, risk is greatly influenced by rate of ascent and exertion.
      </p>
      <p id="para1524">
       Determining an itinerary that will avoid any occurrence of altitude illness is difficult because of variations in individual susceptibility, as well as in starting points and terrain. Itineraries with a high risk for altitude illness include flying directly to &gt;9,000 ft or rapid hiking ascents, such as climbing Mt. Kilimanjaro. It is best to average no more than 1,000 ft (300 m) ft per day in altitude gain above 12,000 ft (3,660 m).
      </p>
      <p id="para1525">
       Examples of high-altitude cities with airports are Cuzco, Peru (11,000 ft; 3,326 m); La Paz, Bolivia (12,000 ft; 3,660 m); and Lhasa, Tibet (12,500 ft; 3,810 m). Travelers flying into these locations may require a period of acclimatization before proceeding higher, and drug prophylaxis may be indicated.
      </p>
     </sec>
     <sec id="cesec330">
      <title>
       Clinical Presentation
      </title>
      <p id="para1526">
       Altitude illness is divided into three syndromes:
       <list id="celist327" list-type="simple">
        <list-item id="celistitem1160">
         <label>
          •
         </label>
         <p id="para1527">
          Acute mountain sickness (AMS)
         </p>
        </list-item>
        <list-item id="celistitem1161">
         <label>
          •
         </label>
         <p id="para1528">
          High-altitude cerebral edema (HACE)
         </p>
        </list-item>
        <list-item id="celistitem1162">
         <label>
          •
         </label>
         <p id="para1529">
          High-altitude pulmonary edema (HAPE)
         </p>
        </list-item>
       </list>
      </p>
      <sec id="cesec331">
       <title>
        Acute Mountain Sickness (AMS)
       </title>
       <p id="para1530">
        AMS is the most common form of altitude illness, striking, for example, 25% of all visitors sleeping above 8,000 ft (2,500 m) in Colorado. Symptoms are those of an alcohol hangover: headache is the cardinal symptom, sometimes accompanied by fatigue, loss of appetite, nausea, and, occasionally, vomiting. Headache onset is usually 2–12 hours after arrival at a higher altitude, and often during or after the first night. Preverbal children may develop loss of appetite, irritability, and pallor. AMS generally resolves with 24–72 hours of acclimatization.
       </p>
      </sec>
      <sec id="cesec332">
       <title>
        High-Altitude Cerebral Edema (HACE)
       </title>
       <p id="para1531">
        HACE is a severe progression of AMS and is rare; it is most often associated with pulmonary edema. In addition to AMS symptoms, lethargy becomes profound, with drowsiness, confusion, and ataxia on tandem gait test. A person with HACE requires immediate descent; death from HACE can ensue within 24 hours of developing ataxia if the person fails to descend.
       </p>
      </sec>
      <sec id="cesec333">
       <title>
        High-Altitude Pulmonary Edema (HAPE)
       </title>
       <p id="para1532">
        HAPE can occur by itself or in conjunction with AMS and HACE; incidence is 1/10,000 skiers in Colorado and up to 1 of 100 climbers at &gt;14,000 ft (4,270 m). Initial symptoms are increased breathlessness with exertion, and eventually increased breathlessness at rest, associated with weakness and cough. Oxygen or descent of 1,000 m or more is life-saving. HAPE can be more rapidly fatal than HACE.
       </p>
      </sec>
      <sec id="cesec334">
       <title>
        Pre-Existing Medical Problems
       </title>
       <p id="para1533">
        <list id="celist328" list-type="simple">
         <list-item id="celistitem1163">
          <label>
           •
          </label>
          <p id="para1534">
           Travelers with medical conditions, such as heart failure, myocardial ischemia (angina), sickle cell disease, or any form of pulmonary insufficiency, should be advised to consult a physician familiar with high-altitude medical issues before undertaking high-altitude travel.
          </p>
         </list-item>
         <list-item id="celistitem1164">
          <label>
           •
          </label>
          <p id="para1535">
           The risk for new ischemic heart disease in previously healthy travelers does not appear to be increased at high altitudes.
          </p>
         </list-item>
         <list-item id="celistitem1165">
          <label>
           •
          </label>
          <p id="para1536">
           Diabetics can travel safely to high altitude, but they must be accustomed to exercise and carefully monitor their blood glucose. Diabetic ketoacidosis may be triggered by altitude illness and may be more difficult to treat in those on acetazolamide. Not all glucose meters may read accurately at high altitudes.
          </p>
         </list-item>
         <list-item id="celistitem1166">
          <label>
           •
          </label>
          <p id="para1537">
           Most people do not have visual problems at high altitude. However, at very high altitudes some persons who have had radial keratotomy may develop acute farsightedness and be unable to climb by themselves. LASIK and other newer procedures may produce only minor visual disturbances at high altitudes.
          </p>
         </list-item>
         <list-item id="celistitem1167">
          <label>
           •
          </label>
          <p id="para1538">
           There are no studies or case reports of harm to a fetus if the mother travels briefly to high altitude during pregnancy. However, it may be prudent to recommend that pregnant women stay at sleeping altitudes of 12,000 ft (3,658 m) if possible. The dangers of having a pregnancy complication in remote, mountainous terrain should also be discussed.
          </p>
         </list-item>
        </list>
       </p>
      </sec>
     </sec>
     <sec id="cesec335">
      <title>
       Treatment
      </title>
      <sec id="cesec336">
       <title>
        Acetazolamide
       </title>
       <p id="para1539">
        Acetazolamide (Diamox) prevents AMS when taken before ascent and can speed recovery if taken after symptoms have developed. The drug works by acidifying the blood, which causes an increase in respiration and thus aids acclimatization. An effective dose that minimizes the common side effects of increased urination and paresthesias of the fingers and toes is 125 mg every 12 hours, beginning the day before ascent and continuing the first 2 days at altitude, or longer if ascent continues. Allergic reactions to acetazolamide are uncommon, but the drug is related to sulfonamides and should not be used by sulfa-allergic persons with history of anaphylaxis. A trial dose taken in a safe environment before travel may be useful for those with a more mild allergic history to sulfonamides. People with history of severe penicillin allergy have occasionally had allergic reactions to acetazolamide.
       </p>
      </sec>
      <sec id="cesec337">
       <title>
        Dexamethasone
       </title>
       <p id="para1540">
        Dexamethasone is very effective for prevention and treatment of AMS and HACE, and perhaps HAPE as well. Unlike acetazolamide, rebound can occur if the drug is discontinued at altitude prior to acclimatization. Acetazolamide is preferable to prevent AMS while ascending, with dexamethasone reserved for treatment during descent. Adult dosage is 4 mg every 6 hours.
       </p>
       <p id="para1541">
        HAPE is always associated with increased pulmonary artery pressure, and pulmonary vasodilators are useful for preventing and treating HAPE.
       </p>
      </sec>
      <sec id="cesec338">
       <title>
        Nifedipine
       </title>
       <p id="para1542">
        Nifedipine prevents and ameliorates HAPE in persons who are particularly susceptible to the condition. The adult dosage is 20 mg of extended release every 8–12 hours. PDE-5 inhibitors can also selectively lower pulmonary artery pressure, with less effect on systemic blood pressure.
       </p>
      </sec>
      <sec id="cesec339">
       <title>
        Other Medications
       </title>
       <p id="para1543">
        Tadalafil (Cialis), 10 mg twice a day, during ascent can prevent HAPE and is being studied for treatment. When taken before ascent, gingko biloba, 100–120 mg twice daily, was shown to reduce AMS in adults in some trials, but it was not effective in others, probably due to variation in ingredients. Gingko biloba has not yet been compared directly with acetazolamide.
       </p>
      </sec>
     </sec>
     <sec id="cesec340">
      <title>
       Preventive Measures for Travelers
      </title>
      <p id="para1544">
       The main point of instructing travelers about altitude illness is not to prevent any possibility of altitude illness, but to prevent death from altitude illness. The onset of symptoms and clinical course is sufficiently slow and predictable that there is no reason for someone to die from altitude illness unless trapped by weather or geography in a situation in which descent is impossible. The three rules that travelers should be made aware of to prevent death from altitude illness are—
       <list id="celist329" list-type="simple">
        <list-item id="celistitem1168">
         <label>
          •
         </label>
         <p id="para1545">
          Know the early symptoms of altitude illness and be willing to acknowledge when they are present.
         </p>
        </list-item>
        <list-item id="celistitem1169">
         <label>
          •
         </label>
         <p id="para1546">
          Never ascend to sleep at a higher altitude when experiencing symptoms of altitude illness, no matter how minor they seem.
         </p>
        </list-item>
        <list-item id="celistitem1170">
         <label>
          •
         </label>
         <p id="para1547">
          Descend if the symptoms become worse while resting at the same altitude.
         </p>
        </list-item>
       </list>
      </p>
      <p id="para1548">
       For trekking groups and expeditions going into remote high-altitude areas, where descent to a lower altitude could be problematic, a pressurization bag (such as the Gamow bag) can prove extremely beneficial. A foot pump produces an increased pressure of 2 lbs. per in
       <xref ref-type="bibr" rid="bib250">
        <sup>
         2
        </sup>
       </xref>
       , mimicking a descent of 5,000–6,000 ft (1,500–1,800 m), depending on the starting altitude. The total packed weight of bag and pump is 6.5 kg.
      </p>
      <p id="para1549">
       For most travelers, the best way to avoid altitude illness is by gradual ascent, with extra rest days at intermediate altitudes every 3,000 ft (900 m) or less. If ascent must be rapid, acetazolamide may be used prophylactically, and dexamethasone and pulmonary artery pressure-lowering drugs, such as nifedipine or sildenafil, may be carried for emergencies.
      </p>
     </sec>
     <ref-list id="cebib24">
      <title>
       References
      </title>
      <ref id="bib249">
       <label>
        1
       </label>
       <element-citation id="sbref225" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hackett
          </surname>
          <given-names>
           PH
          </given-names>
         </name>
         <name>
          <surname>
           Roach
          </surname>
          <given-names>
           RC
          </given-names>
         </name>
        </person-group>
        <article-title>
         High-altitude illness
        </article-title>
        <source>
         N Engl J Med
        </source>
        <volume>
         345
        </volume>
        <issue>
         2
        </issue>
        <year>
         2001
        </year>
        <fpage>
         107
        </fpage>
        <lpage>
         114
        </lpage>
        <pub-id pub-id-type="pmid">
         11450659
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib250">
       <label>
        2
       </label>
       <element-citation id="sbref226" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hackett
          </surname>
          <given-names>
           PH
          </given-names>
         </name>
         <name>
          <surname>
           Roach
          </surname>
          <given-names>
           RC
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         High-altitude medicine
        </chapter-title>
        <person-group person-group-type="editor">
         <name>
          <surname>
           Auerbach
          </surname>
          <given-names>
           PS
          </given-names>
         </name>
        </person-group>
        <source>
         Wilderness medicine
        </source>
        <edition>
         5th ed.
        </edition>
        <year>
         2007
        </year>
        <publisher-name>
         Mosby Elsevier
        </publisher-name>
        <publisher-loc>
         Philadelphia
        </publisher-loc>
       </element-citation>
      </ref>
      <ref id="bib251">
       <label>
        3
       </label>
       <element-citation id="sbref227" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Pollard
          </surname>
          <given-names>
           AJ
          </given-names>
         </name>
         <name>
          <surname>
           Murdoch
          </surname>
          <given-names>
           DR
          </given-names>
         </name>
        </person-group>
        <source>
         The high altitude medicine handbook
        </source>
        <edition>
         3rd ed.
        </edition>
        <year>
         2003
        </year>
        <publisher-name>
         Radcliffe Medical Press
        </publisher-name>
        <publisher-loc>
         Abingdon, UK
        </publisher-loc>
       </element-citation>
      </ref>
      <ref id="bib252">
       <label>
        4
       </label>
       <element-citation id="sbref228" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hackett
          </surname>
          <given-names>
           PH
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         High altitude and common medical conditions
        </chapter-title>
        <person-group person-group-type="editor">
         <name>
          <surname>
           Hornbein
          </surname>
          <given-names>
           TF
          </given-names>
         </name>
         <name>
          <surname>
           Schoene
          </surname>
          <given-names>
           RB
          </given-names>
         </name>
        </person-group>
        <source>
         High altitude: an exploration of human adaptation
        </source>
        <year>
         2001
        </year>
        <publisher-name>
         Marcel Dekker, Inc.
        </publisher-name>
        <publisher-loc>
         New York
        </publisher-loc>
        <fpage>
         839
        </fpage>
        <lpage>
         885
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib253">
       <label>
        5
       </label>
       <element-citation id="sbref229" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Strom
          </surname>
          <given-names>
           BL
          </given-names>
         </name>
         <name>
          <surname>
           Schinnar
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Apter
          </surname>
          <given-names>
           AJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         Absence of cross-reactivity between sulfonamide antibiotics and sulfonamide nonantibiotics
        </article-title>
        <source>
         N Engl J Med
        </source>
        <volume>
         349
        </volume>
        <issue>
         17
        </issue>
        <year>
         2003
        </year>
        <fpage>
         1628
        </fpage>
        <lpage>
         1635
        </lpage>
        <pub-id pub-id-type="pmid">
         14573734
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib254">
       <label>
        6
       </label>
       <element-citation id="sbref230" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Johnson
          </surname>
          <given-names>
           TS
          </given-names>
         </name>
         <name>
          <surname>
           Rock
          </surname>
          <given-names>
           PB
          </given-names>
         </name>
         <name>
          <surname>
           Fulco
          </surname>
          <given-names>
           CS
          </given-names>
         </name>
        </person-group>
        <article-title>
         Prevention of acute mountain sickness by dexamethasone
        </article-title>
        <source>
         N Engl J Med
        </source>
        <volume>
         310
        </volume>
        <issue>
         11
        </issue>
        <year>
         1984
        </year>
        <fpage>
         683
        </fpage>
        <lpage>
         686
        </lpage>
        <pub-id pub-id-type="pmid">
         6700643
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib255">
       <label>
        7
       </label>
       <element-citation id="sbref231" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Maggiorini
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Brunner-La Rocca
          </surname>
          <given-names>
           HP
          </given-names>
         </name>
         <name>
          <surname>
           Peth
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        <article-title>
         Both tadalafil and dexamethasone may reduce the incidence of high-altitude pulmonary edema: a randomized trial
        </article-title>
        <source>
         Ann Intern Med
        </source>
        <volume>
         145
        </volume>
        <issue>
         7
        </issue>
        <year>
         2006
        </year>
        <fpage>
         497
        </fpage>
        <lpage>
         506
        </lpage>
        <pub-id pub-id-type="pmid">
         17015867
        </pub-id>
       </element-citation>
      </ref>
     </ref-list>
    </sec>
    <sec id="subchapter25">
     <sec-meta>
      <contrib-group>
       <contrib contrib-type="author" id="au45">
        <name>
         <surname>
          Yanni
         </surname>
         <given-names>
          Emad
         </given-names>
        </name>
       </contrib>
      </contrib-group>
     </sec-meta>
     <title>
      JET LAG
     </title>
     <sec id="cesec341">
      <title>
       Description
      </title>
      <p id="para1550">
       Jet lag is a temporary disorder among air travelers who rapidly travel across three or more time zones. Jet lag results from the slow adjustment of the body clock to the destination time, so that daily rhythms and the internal drive for sleep and wakefulness are out of synchrony with the new environment.
      </p>
      <p id="para1551">
       The intrinsic body clock resides in the suprachiasmatic nuclei at the base of the hypothalamus, which contains melatonin receptors. The body clock receives information about light from the eyes and is also thought to receive input via the intergeniculate leaflet that carries information about physical activities and general excitement. Melatonin is manufactured in the pineal gland from tryptophan, and its synthesis and release are stimulated by darkness and suppressed by light; consequently, the secretion of melatonin is responsible for setting our sleep–wake cycle. The body clock is adjusted to the solar day by rhythmic cues in the environment known as zeitgebers (time-givers). The main zeitgebers are the light–dark cycle and this rhythmic secretion of melatonin. Exercise might also exert a weaker effect on the body clock than other zeitgebers. Although incompletely understood, the body clock is partly responsible for the daily rhythms in core temperature and plasma hormone concentrations as well.
      </p>
     </sec>
     <sec id="cesec342">
      <title>
       Occurrence
      </title>
      <p id="para1552">
       <list id="celist330" list-type="simple">
        <list-item id="celistitem1171">
         <label>
          •
         </label>
         <p id="para1553">
          Eastward travel is associated with difficulty in falling asleep at the destination bedtime and difficulty arising in the morning.
         </p>
        </list-item>
        <list-item id="celistitem1172">
         <label>
          •
         </label>
         <p id="para1554">
          Westward travel is associated with early evening sleepiness and predawn awakening.
         </p>
        </list-item>
        <list-item id="celistitem1173">
         <label>
          •
         </label>
         <p id="para1555">
          Travelers flying within the same time zone typically experience the fewest problems.
         </p>
        </list-item>
        <list-item id="celistitem1174">
         <label>
          •
         </label>
         <p id="para1556">
          Crossing more time zones or traveling eastward generally increases the time required for adaptation.
         </p>
        </list-item>
        <list-item id="celistitem1175">
         <label>
          •
         </label>
         <p id="para1557">
          Jet lag lasts for several days, roughly equal to two-thirds the number of time zones crossed for eastward flights, and about half the number of time zones crossed after westward flights.
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <sec id="cesec343">
      <title>
       Risk for Travelers
      </title>
      <p id="para1558">
       <list id="celist331" list-type="simple">
        <list-item id="celistitem1176">
         <label>
          •
         </label>
         <p id="para1559">
          Individual responses to crossing time zones and the ability to adapt to new time zones vary. The intensity and duration of jet lag are related to the following:
          <list id="celist332" list-type="simple">
           <list-item id="celistitem1177">
            <label>
             ○
            </label>
            <p id="para1560">
             Number of time zones crossed
            </p>
           </list-item>
           <list-item id="celistitem1178">
            <label>
             ○
            </label>
            <p id="para1561">
             Direction of travel
            </p>
           </list-item>
           <list-item id="celistitem1179">
            <label>
             ○
            </label>
            <p id="para1562">
             Ability to sleep while traveling
            </p>
           </list-item>
           <list-item id="celistitem1180">
            <label>
             ○
            </label>
            <p id="para1563">
             Availability and intensity of local circadian time cues at the destination
            </p>
           </list-item>
           <list-item id="celistitem1181">
            <label>
             ○
            </label>
            <p id="para1564">
             Individual differences in phase tolerance
            </p>
           </list-item>
          </list>
         </p>
        </list-item>
        <list-item id="celistitem1182">
         <label>
          •
         </label>
         <p id="para1565">
          Although more data are needed, risk factors cited by the American Academy of Sleep Medicine include the following:
          <list id="celist333" list-type="simple">
           <list-item id="celistitem1183">
            <label>
             ○
            </label>
            <p id="para1566">
             Older individuals tend to experience fewer jet lag symptoms than those who are younger.
            </p>
           </list-item>
           <list-item id="celistitem1184">
            <label>
             ○
            </label>
            <p id="para1567">
             Exposure to local (natural) light–dark cycle usually accelerates adaptation after jet travel over 2 to 10 time zones
            </p>
           </list-item>
          </list>
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <sec id="cesec344">
      <title>
       Clinical Presentation
      </title>
      <p id="para1568">
       Signs of jet lag include the following:
       <list id="celist334" list-type="simple">
        <list-item id="celistitem1185">
         <label>
          •
         </label>
         <p id="para1569">
          Poor sleep, including delayed sleep onset (after eastward flight), early awakening (after westward flight), and fractionated sleep (after flights in either direction).
         </p>
        </list-item>
        <list-item id="celistitem1186">
         <label>
          •
         </label>
         <p id="para1570">
          Poor performance in both physical and mental tasks during the new daytime.
         </p>
        </list-item>
        <list-item id="celistitem1187">
         <label>
          •
         </label>
         <p id="para1571">
          Negative subjective changes, such as increased fatigue, frequency of headaches and irritability, and decreased ability to concentrate.
         </p>
        </list-item>
        <list-item id="celistitem1188">
         <label>
          •
         </label>
         <p id="para1572">
          Gastrointestinal disturbances (indigestion, frequency of defecation, and the altered consistency of stools) and decreased interest in and enjoyment of meals.
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <sec id="cesec345">
      <title>
       Preventive Measures for Travelers
      </title>
      <sec id="cesec346">
       <title>
        Prior to Travel
       </title>
       <p id="para1573">
        <list id="celist335" list-type="simple">
         <list-item id="celistitem1189">
          <label>
           •
          </label>
          <p id="para1574">
           Stay healthy by continuing to exercise, eating a nutritious diet, and getting plenty of rest.
          </p>
         </list-item>
         <list-item id="celistitem1190">
          <label>
           •
          </label>
          <p id="para1575">
           Consider timed bright light exposure prior to and during travel (although it requires high motivation and strict compliance with the prescribed light–dark schedules).
          </p>
         </list-item>
         <list-item id="celistitem1191">
          <label>
           •
          </label>
          <p id="para1576">
           Break up the journey with a stop-over.
          </p>
         </list-item>
        </list>
       </p>
       <p id="para1577">
        <bold>
         <italic>
          Note:
         </italic>
        </bold>
        The use of the nutritional supplement melatonin is controversial for the prevention of jet lag. Some clinicians advocate the use of 0.5 mg to 5 mg of melatonin during the first few days of travel, and there are data to suggest its efficacy. However, the quality control of its production is not regulated by the U.S. Food and Drug Administration, and contaminants have been found in commercially available products.
       </p>
       <p id="para1578">
        Current information does not support the use of special diets to ameliorate jet lag.
       </p>
      </sec>
      <sec id="cesec347">
       <title>
        During Travel
       </title>
       <p id="para1579">
        Travelers should be advised to—
        <list id="celist336" list-type="simple">
         <list-item id="celistitem1192">
          <label>
           •
          </label>
          <p id="para1580">
           Avoid large meals, alcohol, and caffeine.
          </p>
         </list-item>
         <list-item id="celistitem1193">
          <label>
           •
          </label>
          <p id="para1581">
           Drink plenty of water.
          </p>
         </list-item>
         <list-item id="celistitem1194">
          <label>
           •
          </label>
          <p id="para1582">
           Move around on the plane to promote mental and physical acuity.
          </p>
         </list-item>
         <list-item id="celistitem1195">
          <label>
           •
          </label>
          <p id="para1583">
           Wear comfortable shoes and clothing.
          </p>
         </list-item>
         <list-item id="celistitem1196">
          <label>
           •
          </label>
          <p id="para1584">
           Sleep, if possible, during long flights.
          </p>
         </list-item>
        </list>
       </p>
      </sec>
      <sec id="cesec348">
       <title>
        On Arrival at the Destination
       </title>
       <p id="para1585">
        Travelers should be advised to—
        <list id="celist337" list-type="simple">
         <list-item id="celistitem1197">
          <label>
           •
          </label>
          <p id="para1586">
           Avoid situations requiring critical decision-making, such as important meetings, on the first day after arrival.
          </p>
         </list-item>
         <list-item id="celistitem1198">
          <label>
           •
          </label>
          <p id="para1587">
           Adapt to the local schedule as soon as possible. However, if the travel period is 2 days or less, travelers should remain on home time.
          </p>
         </list-item>
         <list-item id="celistitem1199">
          <label>
           •
          </label>
          <p id="para1588">
           Optimize exposure to sunlight following arrival in either direction.
          </p>
         </list-item>
         <list-item id="celistitem1200">
          <label>
           •
          </label>
          <p id="para1589">
           Eat meals appropriate to the local time.
          </p>
         </list-item>
        </list>
       </p>
      </sec>
     </sec>
     <sec id="cesec349">
      <title>
       Treatment
      </title>
      <p id="para1590">
       <list id="celist338" list-type="simple">
        <list-item id="celistitem1201">
         <label>
          •
         </label>
         <p id="para1591">
          The 2008 American Academy of Sleep Medicine (AASD) recommendations include promoting sleep with hypnotic medication, although the effects of hypnotics on daytime symptoms of jet lag have not been well studied.
         </p>
        </list-item>
        <list-item id="celistitem1202">
         <label>
          •
         </label>
         <p id="para1592">
          The prescription of nonaddictive sedative hypnotics (nonbenzodiazepines), such as zolpidem, has been shown in some studies to promote longer periods of high-quality sleep. If a benzodiazepine is preferred, a short-acting one, such as temazepam, is recommended to minimize oversedation the following day.
         </p>
        </list-item>
        <list-item id="celistitem1203">
         <label>
          •
         </label>
         <p id="para1593">
          Because alcohol intake is often high during international travel, the risk for interaction with hypnotics should be emphasized with patients.
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <ref-list id="cebib25">
      <title>
       References
      </title>
      <ref id="bib256">
       <label>
        1
       </label>
       <element-citation id="sbref232" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Waterhouse
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Reilly
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Atkinson
          </surname>
          <given-names>
           G
          </given-names>
         </name>
        </person-group>
        <article-title>
         Jet lag: trends and coping strategies
        </article-title>
        <source>
         Lancet
        </source>
        <volume>
         369
        </volume>
        <issue>
         9567
        </issue>
        <year>
         2007
        </year>
        <fpage>
         1117
        </fpage>
        <lpage>
         1129
        </lpage>
        <pub-id pub-id-type="pmid">
         17398311
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib257">
       <label>
        2
       </label>
       <element-citation id="sbref233" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Dubocovich
          </surname>
          <given-names>
           ML
          </given-names>
         </name>
         <name>
          <surname>
           Markowska
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <article-title>
         Functional MT1 and MT2 melatonin receptors in mammals
        </article-title>
        <source>
         Endocrines
        </source>
        <volume>
         27
        </volume>
        <issue>
         2
        </issue>
        <year>
         2005
        </year>
        <fpage>
         101
        </fpage>
        <lpage>
         110
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib258">
       <label>
        3
       </label>
       <element-citation id="sbref234" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Reid
          </surname>
          <given-names>
           KJ
          </given-names>
         </name>
         <name>
          <surname>
           Chang
          </surname>
          <given-names>
           AM
          </given-names>
         </name>
         <name>
          <surname>
           Zee
          </surname>
          <given-names>
           PC
          </given-names>
         </name>
        </person-group>
        <article-title>
         Circadian rhythm sleep disorders
        </article-title>
        <source>
         Med Clin North Am
        </source>
        <volume>
         88
        </volume>
        <issue>
         3
        </issue>
        <year>
         2004
        </year>
        <fpage>
         631
        </fpage>
        <lpage>
         651
        </lpage>
        <pub-id pub-id-type="pmid">
         15087208
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib259">
       <label>
        4
       </label>
       <element-citation id="sbref235" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Waterhouse
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Edward
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Nevill
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        <article-title>
         Do subjective symptoms predict our perception of jet lag?
        </article-title>
        <source>
         Ergonomics
        </source>
        <volume>
         43
        </volume>
        <issue>
         10
        </issue>
        <year>
         2000
        </year>
        <fpage>
         1514
        </fpage>
        <lpage>
         1527
        </lpage>
        <pub-id pub-id-type="pmid">
         11083132
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib260">
       <label>
        5
       </label>
       <element-citation id="sbref236" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sack
          </surname>
          <given-names>
           RL
          </given-names>
         </name>
         <name>
          <surname>
           Auckley
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Auger
          </surname>
          <given-names>
           RR
          </given-names>
         </name>
        </person-group>
        <article-title>
         Circadian rhythm sleep disorders: part 1, basic principles, shift work and jet lag disorders: An American Academy of Sleep Medicine Review
        </article-title>
        <source>
         Sleep
        </source>
        <volume>
         30
        </volume>
        <issue>
         11
        </issue>
        <year>
         2007
        </year>
        <fpage>
         1460
        </fpage>
        <lpage>
         1483
        </lpage>
        <pub-id pub-id-type="pmid">
         18041480
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib261">
       <label>
        6
       </label>
       <element-citation id="sbref237" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Jamieson
          </surname>
          <given-names>
           AO
          </given-names>
         </name>
         <name>
          <surname>
           Zammit
          </surname>
          <given-names>
           GK
          </given-names>
         </name>
         <name>
          <surname>
           Rosenberg
          </surname>
          <given-names>
           RS
          </given-names>
         </name>
        </person-group>
        <article-title>
         Zolpidem reduces the sleep disturbance of jet lag
        </article-title>
        <source>
         Sleep Med
        </source>
        <volume>
         2
        </volume>
        <issue>
         5
        </issue>
        <year>
         2001
        </year>
        <fpage>
         423
        </fpage>
        <lpage>
         430
        </lpage>
        <pub-id pub-id-type="pmid">
         14592392
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib262">
       <label>
        7
       </label>
       <element-citation id="sbref238" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Daurat
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Benoit
          </surname>
          <given-names>
           O
          </given-names>
         </name>
         <name>
          <surname>
           Buguet
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        <article-title>
         Effects of zopiclone on the rest/activity rhythm after a westward flight across five time zones
        </article-title>
        <source>
         Psychopharmacology
        </source>
        <volume>
         149
        </volume>
        <issue>
         3
        </issue>
        <year>
         2000
        </year>
        <fpage>
         241
        </fpage>
        <lpage>
         245
        </lpage>
        <pub-id pub-id-type="pmid">
         10823404
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib263">
       <label>
        8
       </label>
       <element-citation id="sbref239" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Reilly
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Waterhouse
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Edwards
          </surname>
          <given-names>
           B
          </given-names>
         </name>
        </person-group>
        <article-title>
         Jet lag and air travel: implications for performance
        </article-title>
        <source>
         Clin Sports Med
        </source>
        <volume>
         24
        </volume>
        <issue>
         2
        </issue>
        <year>
         2005
        </year>
        <fpage>
         367
        </fpage>
        <lpage>
         380
        </lpage>
        <pub-id pub-id-type="pmid">
         15892930
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib264">
       <label>
        9
       </label>
       <element-citation id="sbref240" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Herxheimer
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        <article-title>
         Jet lag
        </article-title>
        <source>
         Clin Evid
        </source>
        <volume>
         13
        </volume>
        <year>
         2005
        </year>
        <fpage>
         2178
        </fpage>
        <lpage>
         2183
        </lpage>
       </element-citation>
      </ref>
     </ref-list>
    </sec>
    <sec id="subchapter26">
     <sec-meta>
      <contrib-group>
       <contrib contrib-type="author" id="au46">
        <name>
         <surname>
          Carroll
         </surname>
         <given-names>
          I. Dale
         </given-names>
        </name>
       </contrib>
      </contrib-group>
     </sec-meta>
     <title>
      MOTION SICKNESS
     </title>
     <sec id="cesec350">
      <title>
       Occurrence
      </title>
      <p id="para1594">
       Motion sickness is the result of a conflict between the various senses in regard to motion. The semicircular canals and otoliths in the inner ear sense angular and vertical motion, while the eyes and the proprioceptors determine the body's position in space. When signals received by the eyes or the proprioceptors do not match those being transmitted by the inner ear, motion sickness occurs. It can occur in either the presence or absence of actual motion, such as when viewing a slide through a microscope. Symptoms include nausea, vomiting, pallor, sweating, and often a sense of impending doom. Motion sickness is likely to occur when there is movement simultaneously in multiple planes, such as on amusement rides, on board ships, or during air travel.
      </p>
     </sec>
     <sec id="cesec351">
      <title>
       Risk for Travelers
      </title>
      <p id="para1595">
       <list id="celist339" list-type="simple">
        <list-item id="celistitem1204">
         <label>
          •
         </label>
         <p id="para1596">
          All individuals, given sufficient stimulus, will develop motion sickness.
         </p>
        </list-item>
        <list-item id="celistitem1205">
         <label>
          •
         </label>
         <p id="para1597">
          Children 2–12 years of age are especially susceptible, while infants and toddlers seem relatively immune.
         </p>
        </list-item>
        <list-item id="celistitem1206">
         <label>
          •
         </label>
         <p id="para1598">
          Women, especially when pregnant, menstruating, or on hormones, are more likely to have motion sickness.
         </p>
        </list-item>
        <list-item id="celistitem1207">
         <label>
          •
         </label>
         <p id="para1599">
          Persons with migraine are more prone to either migraine or motion sickness at the same time as the other malady.
         </p>
        </list-item>
        <list-item id="celistitem1208">
         <label>
          •
         </label>
         <p id="para1600">
          Those who expect to be sick are more apt to experience symptoms.
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <sec id="cesec352">
      <title>
       Treatment
      </title>
      <p id="para1601">
       There are both nonpharmacologic and pharmacologic interventions for the prevention or management of motion sickness. None are ideal, and the medications typically cause drowsiness or similar adverse effects. Some feel that permitting continued exposure to motions that induce motion sickness will decondition the response and diminish the symptoms; however, most persons traveling for a limited time will understandably not be willing to endure the symptoms in the hope of deconditioning and will instead want to avail themselves of some of the suggestions that follow or the medications listed in
       <xref ref-type="table" rid="cetable25">
        Table 2-26
       </xref>
       .
       <table-wrap id="cetable25" position="float">
        <label>
         Table 2-26
        </label>
        <caption>
         <p>
          Pharmacologic interventions for motion sickness (adult dosing)
         </p>
        </caption>
        <table frame="hsides" rules="groups">
         <thead>
          <tr>
           <th align="left">
            Medication
           </th>
           <th align="left">
            Dose
           </th>
           <th align="left">
            Caution/Safety Information
           </th>
           <th align="left">
            Adverse Effects
           </th>
           <th align="left">
            Drug Interactions
           </th>
          </tr>
         </thead>
         <tbody>
          <tr>
           <td align="left">
            <bold>
             Vitamin supplements
            </bold>
            Vitamin B
            <sub>
             6
            </sub>
           </td>
           <td align="left">
            Various
           </td>
           <td>
           </td>
           <td>
           </td>
           <td>
           </td>
          </tr>
          <tr>
           <td align="left">
            <bold>
             Pyridoxine-doxylamine
            </bold>
            (Example of brand: Diclectin)
           </td>
           <td align="left">
            Fixed combination available by Rx. in Canada. Sold separately in U.S.
           </td>
           <td align="left">
            More than 200,000 participants in controlled studies of nausea in pregnancy
           </td>
           <td>
           </td>
           <td>
           </td>
          </tr>
          <tr>
           <td align="left">
            <bold>
             Anticholinergic
            </bold>
            Scopolamine (Examples of brands: Scopace, Transderm-scop)
           </td>
           <td align="left">
            <list id="celist23" list-type="simple">
             <list-item id="celistitem66">
              <p id="para66">
               Patch: 1.5 mg q 3 days, apply behind ear at least 4 hrs before travel
              </p>
             </list-item>
             <list-item id="celistitem67">
              <p id="para67">
               Oral: 0.4-0.8 mg q 8 hrs beginning 1 hr before travel
              </p>
             </list-item>
            </list>
           </td>
           <td align="left">
            <list id="celist24" list-type="simple">
             <list-item id="celistitem68">
              <p id="para68">
               Contraindicated in narrow-angle glaucoma, urinary retention, Gl obstruction, myasthenia gravis. Wash hands after patch application to prevent transfer to eyes.
              </p>
             </list-item>
             <list-item id="celistitem69">
              <p id="para69">
               Caution in hot environment or with thyroid, cardiopulmonary, GE reflux, liver, or kidney disease, seizure or psychotic disorder
              </p>
             </list-item>
            </list>
           </td>
           <td align="left">
            <list id="celist25" list-type="simple">
             <list-item id="celistitem70">
              <p id="para70">
               <italic>
                Common:
               </italic>
               dry mouth/nose/throat, blurred vision, drowsiness
              </p>
             </list-item>
             <list-item id="celistitem71">
              <p id="para71">
               <italic>
                Less common:
               </italic>
               palpitations, urinary retention, bloating, constipation, headache, confusion, hyperexcitability, insomnia, toxic psychosis
              </p>
             </list-item>
            </list>
           </td>
           <td align="left">
            Additive effects with alcohol and other CNS depressants. Antacids impair absorption of oral scopolamine. May impair Gl motility when used with antidiarrheal drugs. May impair absorption of oral medications
           </td>
          </tr>
          <tr>
           <td align="left">
            <bold>
             Antihistamines
            </bold>
            Dimenhydrinate (Examples of brands: Calm X, Dramamine, Triptone)
           </td>
           <td align="left">
            Tablets 50 mg, syrup 12.5 mg/5 ml_. Take 30 min before travel. Adults 50-100 mg q 4-6 hours
           </td>
           <td align="left">
            Caution in glaucoma, urinary retention, GI obstruction, liver or kidney disease, chronic obstructive pulmonary disease (COPD), seizure disorder. Should not be used in children &lt;2 yrs. Take with food or milk to reduce nausea.
           </td>
           <td align="left">
            <list id="celist26" list-type="simple">
             <list-item id="celistitem72">
              <p id="para72">
               <italic>
                Common:
               </italic>
               drowsiness, anticholinergic symptoms (dry mouth/nose/throat, blurred vision, urinary retention), thick respiratory secretions
              </p>
             </list-item>
             <list-item id="celistitem73">
              <p id="para73">
               <italic>
                Less common:
               </italic>
               dizziness, weakness, hypotension or hypertension, cardiac arrhythmia, wheezing, sweating, nausea, vomiting, bloating, diarrhea, constipation, jaundice, anorexia, headache, confusion, tinnitus, paradoxical hyperexcitability, seizures, psychosis, acute dystonic reaction, paresthesias, photosensitivity, anaphylaxis
              </p>
             </list-item>
            </list>
           </td>
           <td align="left">
            Additive effects with alcohol and other CNS depressants. Antihistamine effects may be potentiated by monamine oxidase inhibitors. Antacids may impair absorption.
           </td>
          </tr>
          <tr>
           <td align="left">
            <bold>
             Diphenhydramine
            </bold>
            (Brands: multiple)
           </td>
           <td align="left">
            Available in oral capsules and tablets (25 mg, 50 mg),
           </td>
           <td align="left">
            As above
           </td>
           <td align="left">
            As above
           </td>
           <td align="left">
            As above
           </td>
          </tr>
          <tr>
           <td align="left">
            <bold>
             Diphenhydramine
            </bold>
           </td>
           <td align="left">
            elixir (12.5 mg/5 mL). Adults 10-50 mg q 4-6 hours 12.5 mg, 25 mg, 50 mg
           </td>
           <td>
           </td>
           <td>
           </td>
           <td>
           </td>
          </tr>
          <tr>
           <td align="left">
            <bold>
             Meclizine
            </bold>
            (Brands: Antivert [Rx], Bonine [OTC], Dramamine II [OTC], Meclicot [Rx], Medivert [Rx])
           </td>
           <td align="left">
            Adult dose 25-50 mg q 24 hours
           </td>
           <td align="left">
            As above
           </td>
           <td align="left">
            As above
           </td>
           <td align="left">
            As above
           </td>
          </tr>
          <tr>
           <td align="left">
            <bold>
             Cyclizine
            </bold>
            (Brand: Marezine [OTC])
           </td>
           <td align="left">
            50 mg tablets. Adult dose 50 mg q 4-6 hrs
           </td>
           <td align="left">
            As above
           </td>
           <td align="left">
            As above
           </td>
           <td align="left">
            As above
           </td>
          </tr>
          <tr>
           <td align="left">
            <bold>
             Antidopaminergic
            </bold>
            Promethazine (Brands: Phenergan, Promacot)
           </td>
           <td align="left">
            Available in oral tablets (12.5 mg, 25 mg, 50 mg), syrup (6.25 mg/5 mL, 25 mg/5 mL), rectal suppositories, and intramuscular injection. Adults: 25 mg every 8-12 hrs 5 mg and 10 mg tablets
           </td>
           <td align="left">
            Caution in sulfite allergy (some formulations contain sulfite), cardiovascular disease, peptic ulcer disease
           </td>
           <td align="left">
            Pronounced sedation, postural hypotension, skin rash, body temperature dysregulation, extrapyramidal symptoms, delirium, neuroleptic malignant syndrome
           </td>
           <td align="left">
            May interact with other neurologic drugs
           </td>
          </tr>
          <tr>
           <td align="left">
            <bold>
             Metoclopramide
            </bold>
            (Brands: Reglan)
           </td>
           <td align="left">
            Adults: 10-15 mg q 6 hrs
           </td>
           <td align="left">
            Unproven benefit as antinausea agent with motion sickness, but may help by hastening gastric emptying
           </td>
           <td align="left">
            Sedation, insomnia, extrapyramidal symptoms
           </td>
           <td align="left">
            May decrease absorption of medications from stomach while increasing absorption from intestine. May necessitate change in insulin dose or timing in diabetics
           </td>
          </tr>
          <tr>
           <td align="left">
            <bold>
             Sympathomimetics
            </bold>
            Pseudoephedrine
           </td>
           <td align="left">
            Adults: 60 mg q 6 hours
           </td>
           <td align="left">
            Sometimes used to counteract sedating effect of other medications
           </td>
           <td align="left">
            Difficult urination, dry mouth, restlessness, headache
           </td>
           <td>
           </td>
          </tr>
          <tr>
           <td align="left">
            <bold>
             Benzodiazepines
            </bold>
            Diazepam (Brand: Valium)
           </td>
           <td align="left">
            2 mg, 5 mg and 10 mg tablets. Adult dose 2-10 mg q 6 hrs
           </td>
           <td align="left">
            Very sedating; perhaps of value when added to other medications
           </td>
           <td>
           </td>
           <td>
           </td>
          </tr>
          <tr>
           <td align="left">
            <bold>
             Other antiemetics
            </bold>
            Prochlorperazine (Brand: Compazine)
           </td>
           <td align="left">
            5 mg and 10 mg tablets. Adult dose 5-10 mg q 6 hrs
           </td>
           <td align="left">
            Effective against nausea but not specific for motion sickness.
           </td>
           <td align="left">
            May cause photosensitization, extrapyramidal symptoms
           </td>
           <td>
           </td>
          </tr>
          <tr>
           <td align="left">
            <bold>
             Ondansetron
            </bold>
            (Brand: Zofran)
           </td>
           <td align="left">
            4 mg and 8 mg tablets; Adult dose 4-8 mg q 8-12 hrs
           </td>
           <td align="left">
            Orally disintegrating tablets contain phenylalanine
           </td>
           <td align="left">
            Contraindicated with apomorphine. Effect may be decreased with some anticonvulsants (carbamazepine, phenytoin) and rifamycin (rifampin, rifabutin)
           </td>
           <td>
           </td>
          </tr>
         </tbody>
        </table>
       </table-wrap>
      </p>
      <sec id="cesec353">
       <title>
        Medications
       </title>
       <p id="para1602">
        <list id="celist340" list-type="simple">
         <list-item id="celistitem1209">
          <label>
           •
          </label>
          <p id="para1603">
           Antihistamines are the most commonly used and available medications, although nonsedating ones appear to be the least effective.
          </p>
         </list-item>
         <list-item id="celistitem1210">
          <label>
           •
          </label>
          <p id="para1604">
           Pyridoxine hydrochloride (vitamin B
           <sub>
            6
           </sub>
           ) plus doxylamine succinate (an antihistamine) is prescribed under the brand name of Diclectin in Canada and often recommended in their separate forms by clinicians in the United States.
          </p>
         </list-item>
         <list-item id="celistitem1211">
          <label>
           •
          </label>
          <p id="para1605">
           Sedation is the primary side effect of all the efficacious drugs.
           <list id="celist341" list-type="simple">
            <list-item id="celistitem1212">
             <label>
              ○
             </label>
             <p id="para1606">
              Sedation is problematic when treating patients who perform essential tasks such as flying a plane or acting as crew on a ship, or in travelers who wish to participate in activities such as scuba diving or hang gliding.
             </p>
            </list-item>
           </list>
          </p>
         </list-item>
         <list-item id="celistitem1213">
          <label>
           •
          </label>
          <p id="para1607">
           Some common prescription medications used by travelers may aggravate the nausea of motion sickness (see
           <xref ref-type="table" rid="cetable26">
            Table 2-27
           </xref>
           ).
           <table-wrap id="cetable26" position="float">
            <label>
             Table 2-27
            </label>
            <caption>
             <p>
              Medications that may increase nausea
             </p>
            </caption>
            <table frame="hsides" rules="groups">
             <thead>
              <tr>
               <th align="left">
                Medication Class
               </th>
               <th align="left">
                Examples
               </th>
              </tr>
             </thead>
             <tbody>
              <tr>
               <td align="left">
                Antibiotics
               </td>
               <td align="left">
                Azithromycin, metronidazole, erythromycin, trimethoprim-sulfamethoxazole
               </td>
              </tr>
              <tr>
               <td align="left">
                Antiparasitics
               </td>
               <td align="left">
                Albendazole, thiabendazole, iodoquinol, chloroquine, mefloquine
               </td>
              </tr>
              <tr>
               <td align="left">
                Estrogens
               </td>
               <td align="left">
                Oral contraceptives, estradiol
               </td>
              </tr>
              <tr>
               <td align="left">
                Cardiovascular
               </td>
               <td align="left">
                Digoxin, levodopa
               </td>
              </tr>
              <tr>
               <td align="left">
                Narcotic analgesics
               </td>
               <td align="left">
                Codeine, morphine, meperidine
               </td>
              </tr>
              <tr>
               <td align="left">
                Nonsteroidal analgesics
               </td>
               <td align="left">
                Ibuprophen, naproxen, indomethacin
               </td>
              </tr>
              <tr>
               <td align="left">
                Antidepressants
               </td>
               <td align="left">
                Fluoxetine, paroxitene, sertraline
               </td>
              </tr>
              <tr>
               <td align="left">
                Asthma medication
               </td>
               <td align="left">
                Aminophylline
               </td>
              </tr>
              <tr>
               <td align="left">
                Bisphosphonates
               </td>
               <td align="left">
                Alendronate sodium, ibandronate sodium, risedronate sodium
               </td>
              </tr>
             </tbody>
            </table>
           </table-wrap>
          </p>
         </list-item>
        </list>
       </p>
       <sec id="cesec354">
        <title>
         Medications in Children
        </title>
        <p id="para1608">
         <list id="celist342" list-type="simple">
          <list-item id="celistitem1214">
           <label>
            •
           </label>
           <p id="para1609">
            For symptomatic treatment of children 2–12 years of age, dimenhydrinate, 1–1.5 mg/kg per dose, or diphenhydramine, 0.5–1 mg/kg per dose up to 25 mg, can be given 1 hour before travel and every 6 hours during the trip.
           </p>
          </list-item>
          <list-item id="celistitem1215">
           <label>
            •
           </label>
           <p id="para1610">
            Because some children have paradoxical agitation with these medicines, a test dose should be given at home before departure.
           </p>
          </list-item>
          <list-item id="celistitem1216">
           <label>
            •
           </label>
           <p id="para1611">
            Scopalamine causes potentially dangerous adverse effects in children and should not be used; prochlorperazine and metoclopramide should be used with caution in children.
           </p>
          </list-item>
          <list-item id="celistitem1217">
           <label>
            •
           </label>
           <p id="para1612">
            Antihistamines are not FDA approved for use for the prevention or treatment of motion sickness in children. Caregivers should be reminded to always ask a
physician, pharmacist, or other health-care professional if they have any questions about how to use or dose antihistamines in children before they administer the medication. Oversedation of young children with antihistamines can lead to life-threatening side effects.
           </p>
          </list-item>
         </list>
        </p>
       </sec>
       <sec id="cesec355">
        <title>
         Medications in Pregnancy
        </title>
        <p id="para1613">
         <list id="celist343" list-type="simple">
          <list-item id="celistitem1218">
           <label>
            •
           </label>
           <p id="para1614">
            Drugs with the most safety data regarding the treatment of the nausea of pregnancy would seem to be the logical first choice.
           </p>
          </list-item>
          <list-item id="celistitem1219">
           <label>
            •
           </label>
           <p id="para1615">
            Letter scoring of the safety of medications in pregnancy may not be helpful, and practitioners should review the actual safety data or call the patient's obstetrical provider for suggestions.
           </p>
          </list-item>
          <list-item id="celistitem1220">
           <label>
            •
           </label>
           <p id="para1616">
            Web-based information may be found at
            <ext-link ext-link-type="uri" id="interref66" xlink:href="http://www.Motherisk.org">
             www.Motherisk.org
            </ext-link>
            and
            <ext-link ext-link-type="uri" id="interref67" xlink:href="http://www.Reprotox.org">
             www.Reprotox.org
            </ext-link>
            .
           </p>
          </list-item>
         </list>
        </p>
       </sec>
      </sec>
     </sec>
     <sec id="cesec356">
      <title>
       Preventive Measures for Travelers
      </title>
      <p id="para1617">
       Nonpharmacologic interventions include—
       <list id="celist344" list-type="simple">
        <list-item id="celistitem1221">
         <label>
          •
         </label>
         <p id="para1618">
          Being aware of those situations which tend to trigger symptoms.
         </p>
        </list-item>
        <list-item id="celistitem1222">
         <label>
          •
         </label>
         <p id="para1619">
          <bold>
           Optimizing positioning
          </bold>
          —Driving a vehicle instead of riding in it, as well as sitting in the front seat of a car or bus, sitting over the wing of an aircraft or being in the central cabin on a ship can help reduce symptoms.
         </p>
        </list-item>
        <list-item id="celistitem1223">
         <label>
          •
         </label>
         <p id="para1620">
          <bold>
           Eating or drinking
          </bold>
          —Eating before the onset of symptoms may hasten gastric emptying, but in some individuals, can aggravate motion sickness. Drinking caffeinated beverages along with taking one of the medications suggested can help manage motion sickness.
         </p>
        </list-item>
        <list-item id="celistitem1224">
         <label>
          •
         </label>
         <p id="para1621">
          <bold>
           Reducing sensory input
          </bold>
          —The reduction of aggravating stimuli (e.g., lying prone, looking at the horizon, or shutting eyes) can help alleviate symptoms.
         </p>
        </list-item>
        <list-item id="celistitem1225">
         <label>
          •
         </label>
         <p id="para1622">
          <bold>
           Adding distractions
          </bold>
          —Aromatherapy using mint, lavender, or ginger (oral) helps some; flavored lozenges may help as well. They may function as placebos or, in the case of oral ginger, may hasten gastric emptying.
         </p>
        </list-item>
        <list-item id="celistitem1226">
         <label>
          •
         </label>
         <p id="para1623">
          <bold>
           Using acupressure or magnets
          </bold>
          —Advocated by some to prevent or treat nausea (not specifically for motion sickness), although scientific data are lacking.
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <ref-list id="cebib26">
      <title>
       References
      </title>
      <ref id="bib265">
       <label>
        1
       </label>
       <element-citation id="sbref241" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Priesol
          </surname>
          <given-names>
           AJ
          </given-names>
         </name>
        </person-group>
        <person-group person-group-type="editor">
         <name>
          <surname>
           Rose
          </surname>
          <given-names>
           BD
          </given-names>
         </name>
        </person-group>
        <source>
         Motion Sickness
        </source>
        <year>
         2008
        </year>
        <publisher-name>
         UpToDate
        </publisher-name>
        <publisher-loc>
         Waltham MA
        </publisher-loc>
       </element-citation>
      </ref>
      <ref id="bib266">
       <label>
        2
       </label>
       <element-citation id="sbref242" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Takeda
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Morita
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Horii
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        <article-title>
         Neural mechanisms of motion sickness
        </article-title>
        <source>
         J Med Invest
        </source>
        <volume>
         48
        </volume>
        <issue>
         1–2
        </issue>
        <year>
         2001
        </year>
        <fpage>
         44
        </fpage>
        <lpage>
         59
        </lpage>
        <pub-id pub-id-type="pmid">
         11286016
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib267">
       <label>
        3
       </label>
       <element-citation id="sbref243" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Benline
          </surname>
          <given-names>
           TA
          </given-names>
         </name>
         <name>
          <surname>
           French
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Poole
          </surname>
          <given-names>
           E
          </given-names>
         </name>
        </person-group>
        <article-title>
         Anti-emetic drug effects on pilot performance: granisetron vs. ondansetron
        </article-title>
        <source>
         Aviat Space Environ Med
        </source>
        <volume>
         68
        </volume>
        <issue>
         11
        </issue>
        <year>
         1997
        </year>
        <fpage>
         998
        </fpage>
        <lpage>
         1005
        </lpage>
        <pub-id pub-id-type="pmid">
         9383499
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib268">
       <label>
        4
       </label>
       <mixed-citation id="ceotherref25" publication-type="other">
        FDA. Pregnancy and lactation labeling. 2008 [cited 2008 Oct 8]. Available from:
        <ext-link ext-link-type="uri" id="interref68" xlink:href="http://www.fda.gov/cder/regulatory/pregnancy_labeling">
         www.fda.gov/cder/regulatory/pregnancy_labeling
        </ext-link>
        .
       </mixed-citation>
      </ref>
     </ref-list>
    </sec>
    <sec id="subchapter27">
     <sec-meta>
      <contrib-group>
       <contrib contrib-type="author" id="au47">
        <name>
         <surname>
          LaRocque
         </surname>
         <given-names>
          Regina C.
         </given-names>
        </name>
       </contrib>
       <contrib contrib-type="author" id="au48">
        <name>
         <surname>
          Ryan
         </surname>
         <given-names>
          Edward T.
         </given-names>
        </name>
       </contrib>
      </contrib-group>
     </sec-meta>
     <title>
      RESPIRATORY INFECTIONS
     </title>
     <p id="para1624">
      Respiratory infections are an underappreciated risk for travel. Respiratory infection is a leading cause of seeking medical care in returning travelers and has been reported to occur in up to 20% of all travelers. Thus, respiratory infections may be almost as common as travelers' diarrhea. Upper respiratory infection is more common than lower respiratory infection. In general, the types of respiratory infections that affect travelers are similar to those in nontravelers, and exotic causes are rare. Travelers may be exposed to respiratory tract pathogens while in transit, while in close contact with other individuals, and while at their final destination.
     </p>
     <sec id="cesec357">
      <title>
       Infectious Agent
      </title>
      <p id="para1625">
       <list id="celist345" list-type="simple">
        <list-item id="celistitem1227">
         <label>
          •
         </label>
         <p id="para1626">
          Viral pathogens are the most common cause of respiratory infection in travelers; causative agents include coronavirus, adenovirus, rhinovirus, influenza virus, parainfluenza virus, human metapneumovirus, and respiratory syncytial virus.
         </p>
        </list-item>
        <list-item id="celistitem1228">
         <label>
          •
         </label>
         <p id="para1627">
          Bacterial pathogens are less common but include
          <italic>
           Streptococcus pneumoniae
          </italic>
          ,
          <italic>
           Mycoplasma pneumoniae
          </italic>
          ,
          <italic>
           Haemophilus influenzae
          </italic>
          ,
          <italic>
           Chlamydophila pneumoniae
          </italic>
          , and
          <italic>
           Legionella
          </italic>
          species. Viral pathogens may set the stage for subsequent bacterial sinusitis or bronchitis.
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <sec id="cesec358">
      <title>
       Occurrence
      </title>
      <p id="para1628">
       <list id="celist346" list-type="simple">
        <list-item id="celistitem1229">
         <label>
          •
         </label>
         <p id="para1629">
          Outbreaks are usually associated with common exposure in hotels and cruise ships or among tour groups.
         </p>
        </list-item>
        <list-item id="celistitem1230">
         <label>
          •
         </label>
         <p id="para1630">
          A few specific pathogens have been associated with outbreaks in travelers, including influenza,
          <italic>
           Legionella pneumophila
          </italic>
          , severe acute respiratory syndrome (SARS), and histoplasmosis.
         </p>
        </list-item>
        <list-item id="celistitem1231">
         <label>
          •
         </label>
         <p id="para1631">
          The peak influenza season in the temperate northern hemisphere is December through February. In the temperate southern hemisphere, the peak influenza season is June through August. Travelers to tropical zones are at risk year round.
         </p>
        </list-item>
        <list-item id="celistitem1232">
         <label>
          •
         </label>
         <p id="para1632">
          Exposure to an infected individual from another hemisphere, such as on a cruise ship or package tour, can lead to an outbreak of influenza at any time or place.
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <sec id="cesec359">
      <title>
       Risk for Travelers
      </title>
      <p id="para1633">
       Factors contributing to respiratory infection in travelers include—
       <list id="celist347" list-type="simple">
        <list-item id="celistitem1233">
         <label>
          •
         </label>
         <p id="para1634">
          Air-pressure changes during ascent and descent of aircraft. These baropressure changes can facilitate the development of sinusitis and otitis media.
         </p>
        </list-item>
        <list-item id="celistitem1234">
         <label>
          •
         </label>
         <p id="para1635">
          Intermingling of large numbers of people in airports, travel hubs, transport vehicles, cruise ships, and hotels can facilitate transmission.
         </p>
        </list-item>
        <list-item id="celistitem1235">
         <label>
          •
         </label>
         <p id="para1636">
          Direct air-borne transmission of respiratory tract pathogens aboard aircraft is unusual because of frequent air recirculation and filtration, although sporadic cases of SARS, influenza, tuberculosis, and other agents have occurred in modern aircraft. Transmission of infection may occur between passengers who are seated in proximity to one another, usually through direct contact or droplets.
         </p>
        </list-item>
        <list-item id="celistitem1236">
         <label>
          •
         </label>
         <p id="para1637">
          Air quality at many travel destinations may not be optimal, and exposure to sulfur dioxide, nitrogen dioxide, carbon monoxide, ozone, and particulate matter in air is associated with a number of health risks, including increased risk for respiratory tract inflammation, exacerbations of asthma and chronic obstructive pulmonary disease, and increased risks of bronchitis and pneumonia.
         </p>
        </list-item>
        <list-item id="celistitem1237">
         <label>
          •
         </label>
         <p id="para1638">
          Certain epidemiologic characteristics of travelers that have been associated with a higher risk for respiratory tract infection include children, the elderly, and individuals with co-morbid pulmonary conditions, such as asthma and chronic obstructive pulmonary disease.
         </p>
        </list-item>
        <list-item id="celistitem1238">
         <label>
          •
         </label>
         <p id="para1639">
          The risk for tuberculosis among travelers is very low (see the Tuberculosis section in Chapter 5).
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <sec id="cesec360">
      <title>
       Clinical Presentation
      </title>
      <p id="para1640">
       <list id="celist348" list-type="simple">
        <list-item id="celistitem1239">
         <label>
          •
         </label>
         <p id="para1641">
          Most respiratory tract infections, especially those of the upper respiratory tract, are mild and not incapacitating.
         </p>
        </list-item>
        <list-item id="celistitem1240">
         <label>
          •
         </label>
         <p id="para1642">
          Lower respiratory tract infections, particularly pneumonia, can be more severe.
         </p>
        </list-item>
        <list-item id="celistitem1241">
         <label>
          •
         </label>
         <p id="para1643">
          Individuals with influenza commonly have acute onset of fever, myalgia, headache, and cough.
         </p>
        </list-item>
        <list-item id="celistitem1242">
         <label>
          •
         </label>
         <p id="para1644">
          Travelers with a viral upper respiratory infection may have persistent symptoms and should consider the possibility of subsequent bacterial sinusitis or bronchitis with symptoms that worsen after one week.
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <sec id="cesec361">
      <title>
       Diagnosis
      </title>
      <p id="para1645">
       <list id="celist349" list-type="simple">
        <list-item id="celistitem1243">
         <label>
          •
         </label>
         <p id="para1646">
          Identifying a specific etiologic agent, especially in the absence of pneumonia, is often difficult and not clinically necessary.
         </p>
        </list-item>
        <list-item id="celistitem1244">
         <label>
          •
         </label>
         <p id="para1647">
          If indicated, the following methods of diagnosis can be used:
          <list id="celist350" list-type="simple">
           <list-item id="celistitem1245">
            <label>
             ○
            </label>
            <p id="para1648">
             Molecular methods are available for the diagnosis of a number of respiratory viruses, including influenza virus, parainfluenza virus, adenovirus, human metapneumovirus, and respiratory syncytial virus, and for certain nonviral pathogens such as
             <italic>
              Legionella pneumophila
             </italic>
             .
            </p>
           </list-item>
           <list-item id="celistitem1246">
            <label>
             ○
            </label>
            <p id="para1649">
             Rapid tests are also available for detecting group A streptococcal pharyngitis.
            </p>
           </list-item>
           <list-item id="celistitem1247">
            <label>
             ○
            </label>
            <p id="para1650">
             Microbiologic culturing of sputum and blood, although insensitive, can assist in identifying a causative respiratory pathogen in persons with pneumonia.
            </p>
           </list-item>
          </list>
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <sec id="cesec362">
      <title>
       Treatment
      </title>
      <p id="para1651">
       <list id="celist351" list-type="simple">
        <list-item id="celistitem1248">
         <label>
          •
         </label>
         <p id="para1652">
          Affected travelers are usually managed similarly to nontravelers, although travelers with progressive or severe illness should be evaluated for illnesses specific to their travel destinations and exposure history.
         </p>
        </list-item>
        <list-item id="celistitem1249">
         <label>
          •
         </label>
         <p id="para1653">
          Most respiratory infections of travelers are due to viruses, are mild, and do not require specific treatment or antibiotics. No systematic study of self-treatment of travelers with respiratory infections has been reported.
         </p>
        </list-item>
        <list-item id="celistitem1250">
         <label>
          •
         </label>
         <p id="para1654">
          Self-treatment usually involves supportive measures and may include the use of analgesics, decongestants, increased fluid intake, and inhaled moisture.
         </p>
        </list-item>
        <list-item id="celistitem1251">
         <label>
          •
         </label>
         <p id="para1655">
          Self-treatment with antibiotics can be considered for upper respiratory infections that are worsening after 7 days of symptoms, particularly if specific symptoms of sinusitis or bronchitis are present. A respiratory-spectrum fluoroquinolone such as levofloxacin or a macrolide such as azithromycin may be prescribed to the traveler for this purpose prior to travel.
         </p>
        </list-item>
        <list-item id="celistitem1252">
         <label>
          •
         </label>
         <p id="para1656">
          The rate of influenza infection among travelers is not known. The difficulty in self-diagnosing influenza makes it problematic to decide whether to provide travelers with a self-treatment dose of a neuraminidase inhibitor. This practice should probably be limited to travelers with a specific underlying condition that may predispose them to severe influenza.
         </p>
        </list-item>
       </list>
      </p>
      <sec id="cesec363">
       <title>
        Medical Interventions
       </title>
       <p id="para1657">
        Specific situations that may require medical intervention include—
        <list id="celist352" list-type="simple">
         <list-item id="celistitem1253">
          <label>
           •
          </label>
          <p id="para1658">
           Pharyngitis without rhinorrhea, cough, or other symptoms that may indicate infection with group A streptococcus.
          </p>
         </list-item>
         <list-item id="celistitem1254">
          <label>
           •
          </label>
          <p id="para1659">
           Sudden onset of cough, chest pain, and fever that may indicate pneumonia, resulting in a situation where the traveler may be sick enough to seek medical care right away.
          </p>
         </list-item>
         <list-item id="celistitem1255">
          <label>
           •
          </label>
          <p id="para1660">
           Travelers with underlying medical conditions, such as asthma, pulmonary disease, or heart disease, who may need to seek medical care earlier than otherwise healthy travelers.
          </p>
         </list-item>
        </list>
       </p>
      </sec>
     </sec>
     <sec id="cesec364">
      <title>
       Preventive Measures for Travelers
      </title>
      <p id="para1661">
       <list id="celist353" list-type="simple">
        <list-item id="celistitem1256">
         <label>
          •
         </label>
         <p id="para1662">
          Vaccines are available for the prevention of a number of respiratory tract pathogens, including influenza,
          <italic>
           S. pneumoniae
          </italic>
          ,
          <italic>
           H. influenzae
          </italic>
          type B (in young children), pertussis, diphtheria, varicella, and measles. Unless contraindicated, travelers should be vaccinated against influenza.
         </p>
        </list-item>
        <list-item id="celistitem1257">
         <label>
          •
         </label>
         <p id="para1663">
          The prevention of respiratory illness while traveling may not be possible, but common-sense preventive measures include—
          <list id="celist354" list-type="simple">
           <list-item id="celistitem1258">
            <label>
             ○
            </label>
            <p id="para1664">
             Trying to minimize close contact with persons who are coughing and sneezing
            </p>
           </list-item>
           <list-item id="celistitem1259">
            <label>
             ○
            </label>
            <p id="para1665">
             Frequent handwashing, either with soap and water or alcohol-based hand sanitizers (containing at least 60% alcohol)
            </p>
           </list-item>
           <list-item id="celistitem1260">
            <label>
             ○
            </label>
            <p id="para1666">
             Using a vasoconstricting nasal spray immediately prior to air travel, if the traveler has a pre-existing eustachean tube dysfunction.
            </p>
           </list-item>
          </list>
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <ref-list id="cebib27">
      <title>
       References
      </title>
      <ref id="bib269">
       <label>
        1
       </label>
       <element-citation id="sbref244" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ansart
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Pajot
          </surname>
          <given-names>
           O
          </given-names>
         </name>
         <name>
          <surname>
           Grivois
          </surname>
          <given-names>
           JP
          </given-names>
         </name>
        </person-group>
        <article-title>
         Pneumonia among travelers returning from abroad
        </article-title>
        <source>
         J Travel Med
        </source>
        <volume>
         11
        </volume>
        <issue>
         2
        </issue>
        <year>
         2004
        </year>
        <fpage>
         87
        </fpage>
        <lpage>
         91
        </lpage>
        <pub-id pub-id-type="pmid">
         15109472
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib270">
       <label>
        2
       </label>
       <element-citation id="sbref245" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Leder
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Sundararajan
          </surname>
          <given-names>
           V
          </given-names>
         </name>
         <name>
          <surname>
           Weld
          </surname>
          <given-names>
           L
          </given-names>
         </name>
        </person-group>
        <article-title>
         Respiratory tract infections in travelers: a review of the GeoSentinel surveillance network
        </article-title>
        <source>
         Clin Infect Dis
        </source>
        <volume>
         36
        </volume>
        <issue>
         4
        </issue>
        <year>
         2003
        </year>
        <fpage>
         399
        </fpage>
        <lpage>
         406
        </lpage>
        <pub-id pub-id-type="pmid">
         12567296
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib271">
       <label>
        3
       </label>
       <element-citation id="sbref246" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Freedman
          </surname>
          <given-names>
           DO
          </given-names>
         </name>
         <name>
          <surname>
           Weld
          </surname>
          <given-names>
           LH
          </given-names>
         </name>
         <name>
          <surname>
           Kozarsky
          </surname>
          <given-names>
           PE
          </given-names>
         </name>
        </person-group>
        <article-title>
         Spectrum of disease and relation to place of exposure among ill returned travelers
        </article-title>
        <source>
         N Engl J Med
        </source>
        <volume>
         354
        </volume>
        <issue>
         2
        </issue>
        <year>
         2006
        </year>
        <fpage>
         119
        </fpage>
        <lpage>
         130
        </lpage>
        <pub-id pub-id-type="pmid">
         16407507
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib272">
       <label>
        4
       </label>
       <element-citation id="sbref247" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Miller
          </surname>
          <given-names>
           JM
          </given-names>
         </name>
         <name>
          <surname>
           Tam
          </surname>
          <given-names>
           TW
          </given-names>
         </name>
         <name>
          <surname>
           Maloney
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        <article-title>
         Cruise ships: high-risk passengers and the global spread of new influenza viruses
        </article-title>
        <source>
         Clin Infect Dis
        </source>
        <volume>
         31
        </volume>
        <issue>
         2
        </issue>
        <year>
         2000
        </year>
        <fpage>
         433
        </fpage>
        <lpage>
         438
        </lpage>
        <pub-id pub-id-type="pmid">
         10987701
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib273">
       <label>
        5
       </label>
       <element-citation id="sbref248" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Weitzel
          </surname>
          <given-names>
           EK
          </given-names>
         </name>
         <name>
          <surname>
           McMains
          </surname>
          <given-names>
           KC
          </given-names>
         </name>
         <name>
          <surname>
           Rajapaksa
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        <article-title>
         Aerosinusitis: pathophysiology, prophylaxis, and management in passengers and aircrew
        </article-title>
        <source>
         Aviat Space Environ Med
        </source>
        <volume>
         79
        </volume>
        <issue>
         1
        </issue>
        <year>
         2008
        </year>
        <fpage>
         50
        </fpage>
        <lpage>
         53
        </lpage>
        <pub-id pub-id-type="pmid">
         18225779
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib274">
       <label>
        6
       </label>
       <element-citation id="sbref249" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zitter
          </surname>
          <given-names>
           JN
          </given-names>
         </name>
         <name>
          <surname>
           Mazonson
          </surname>
          <given-names>
           PD
          </given-names>
         </name>
         <name>
          <surname>
           Miller
          </surname>
          <given-names>
           DP
          </given-names>
         </name>
        </person-group>
        <article-title>
         Aircraft cabin air recirculation and symptoms of the common cold
        </article-title>
        <source>
         JAMA
        </source>
        <volume>
         288
        </volume>
        <issue>
         4
        </issue>
        <year>
         2002
        </year>
        <fpage>
         483
        </fpage>
        <lpage>
         486
        </lpage>
        <pub-id pub-id-type="pmid">
         12132979
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib275">
       <label>
        7
       </label>
       <element-citation id="sbref250" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Schwela
          </surname>
          <given-names>
           D
          </given-names>
         </name>
        </person-group>
        <article-title>
         Air pollution and health in urban areas
        </article-title>
        <source>
         Rev Environ Health
        </source>
        <volume>
         15
        </volume>
        <issue>
         1–2
        </issue>
        <year>
         2000
        </year>
        <fpage>
         13
        </fpage>
        <lpage>
         42
        </lpage>
        <pub-id pub-id-type="pmid">
         10939084
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib276">
       <label>
        8
       </label>
       <element-citation id="sbref251" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Luna
          </surname>
          <given-names>
           LK
          </given-names>
         </name>
         <name>
          <surname>
           Panning
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Grywna
          </surname>
          <given-names>
           K
          </given-names>
         </name>
        </person-group>
        <article-title>
         Spectrum of viruses and atypical bacteria in intercontinental air travelers with symptoms of acute respiratory infection
        </article-title>
        <source>
         J Infect Dis
        </source>
        <volume>
         195
        </volume>
        <issue>
         5
        </issue>
        <year>
         2007
        </year>
        <fpage>
         675
        </fpage>
        <lpage>
         679
        </lpage>
        <pub-id pub-id-type="pmid">
         17262708
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib277">
       <label>
        9
       </label>
       <element-citation id="sbref252" publication-type="journal">
        <comment>
        </comment>
        <person-group person-group-type="author">
         <name>
          <surname>
           Camps
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Vilella
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Marcos
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Incidence of respiratory viruses among travelers with a febrile syndrome returning from tropical and subtropical areas
        </article-title>
        <source>
         J Med Virol
        </source>
        <volume>
         80
        </volume>
        <issue>
         4
        </issue>
        <year>
         2008
        </year>
        <fpage>
         711
        </fpage>
        <lpage>
         715
        </lpage>
        <pub-id pub-id-type="pmid">
         18297697
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib278">
       <label>
        10
       </label>
       <element-citation id="sbref253" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Redman
          </surname>
          <given-names>
           CA
          </given-names>
         </name>
         <name>
          <surname>
           Maclennan
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Wilson
          </surname>
          <given-names>
           E
          </given-names>
         </name>
        </person-group>
        <article-title>
         Diarrhea and respiratory symptoms among travelers to Asia, Africa, and South and Central America from Scotland
        </article-title>
        <source>
         J Travel Med
        </source>
        <volume>
         13
        </volume>
        <issue>
         4
        </issue>
        <year>
         2006
        </year>
        <fpage>
         203
        </fpage>
        <lpage>
         211
        </lpage>
        <pub-id pub-id-type="pmid">
         16884402
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib279">
       <label>
        11
       </label>
       <element-citation id="sbref254" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rack
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Wichmann
          </surname>
          <given-names>
           O
          </given-names>
         </name>
         <name>
          <surname>
           Kamara
          </surname>
          <given-names>
           B
          </given-names>
         </name>
        </person-group>
        <article-title>
         Risk and spectrum of diseases in travelers to popular tourist destinations
        </article-title>
        <source>
         J Travel Med
        </source>
        <volume>
         12
        </volume>
        <issue>
         5
        </issue>
        <year>
         2005
        </year>
        <fpage>
         248
        </fpage>
        <lpage>
         253
        </lpage>
        <pub-id pub-id-type="pmid">
         16256047
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib280">
       <label>
        12
       </label>
       <element-citation id="sbref255" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Morgan
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Cano
          </surname>
          <given-names>
           MV
          </given-names>
         </name>
         <name>
          <surname>
           Feikin
          </surname>
          <given-names>
           DR
          </given-names>
         </name>
        </person-group>
        <article-title>
         A large outbreak of histoplasmosis among American travelers associated with a hotel in Acapulco, Mexico, spring 2001
        </article-title>
        <source>
         Am J Trop Med Hyg
        </source>
        <volume>
         69
        </volume>
        <issue>
         6
        </issue>
        <year>
         2003
        </year>
        <fpage>
         663
        </fpage>
        <lpage>
         669
        </lpage>
        <pub-id pub-id-type="pmid">
         14740886
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib281">
       <label>
        13
       </label>
       <element-citation id="sbref256" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Leder
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Newman
          </surname>
          <given-names>
           D
          </given-names>
         </name>
        </person-group>
        <article-title>
         Respiratory infections during air travel
        </article-title>
        <source>
         Intern Med J
        </source>
        <volume>
         35
        </volume>
        <issue>
         1
        </issue>
        <year>
         2005
        </year>
        <fpage>
         50
        </fpage>
        <lpage>
         55
        </lpage>
        <pub-id pub-id-type="pmid">
         15667469
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib282">
       <label>
        14
       </label>
       <element-citation id="sbref257" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Medina-Ramon
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Zanobetti
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Schwartz
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        <article-title>
         The effect of ozone and PM10 on hospital admissions for pneumonia and chronic obstructive pulmonary disease: a national multicity study
        </article-title>
        <source>
         Am J Epidemiol
        </source>
        <volume>
         163
        </volume>
        <issue>
         6
        </issue>
        <year>
         2006
        </year>
        <fpage>
         579
        </fpage>
        <lpage>
         588
        </lpage>
        <pub-id pub-id-type="pmid">
         16443803
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib283">
       <label>
        15
       </label>
       <element-citation id="sbref258" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Farhat
          </surname>
          <given-names>
           SC
          </given-names>
         </name>
         <name>
          <surname>
           Paulo
          </surname>
          <given-names>
           RL
          </given-names>
         </name>
         <name>
          <surname>
           Shimoda
          </surname>
          <given-names>
           TM
          </given-names>
         </name>
        </person-group>
        <article-title>
         Effect of air pollution on pediatric respiratory emergency room visits and hospital admissions
        </article-title>
        <source>
         Braz J Med Biol Res
        </source>
        <volume>
         38
        </volume>
        <issue>
         2
        </issue>
        <year>
         2005
        </year>
        <fpage>
         227
        </fpage>
        <lpage>
         235
        </lpage>
        <pub-id pub-id-type="pmid">
         15785834
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib284">
       <label>
        16
       </label>
       <element-citation id="sbref259" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Leder
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Tong
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Weld
          </surname>
          <given-names>
           L
          </given-names>
         </name>
        </person-group>
        <article-title>
         Illness in travelers visiting friends and relatives: a review of the GeoSentinel Surveillance Network
        </article-title>
        <source>
         Clin Infect Dis
        </source>
        <volume>
         43
        </volume>
        <issue>
         9
        </issue>
        <year>
         2006
        </year>
        <fpage>
         1185
        </fpage>
        <lpage>
         1193
        </lpage>
        <pub-id pub-id-type="pmid">
         17029140
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib285">
       <label>
        17
       </label>
       <element-citation id="sbref260" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cobelens
          </surname>
          <given-names>
           FG
          </given-names>
         </name>
         <name>
          <surname>
           van Deutekom
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Draayer-Jansen
          </surname>
          <given-names>
           IW
          </given-names>
         </name>
        </person-group>
        <article-title>
         Risk of infection with
         <italic>
          Mycobacterium tuberculosis
         </italic>
         in travellers to areas of high tuberculosis endemicity
        </article-title>
        <source>
         Lancet
        </source>
        <volume>
         356
        </volume>
        <issue>
         9228
        </issue>
        <year>
         2000
        </year>
        <fpage>
         461
        </fpage>
        <lpage>
         465
        </lpage>
        <pub-id pub-id-type="pmid">
         10981889
        </pub-id>
       </element-citation>
      </ref>
     </ref-list>
    </sec>
    <sec id="subchapter28">
     <sec-meta>
      <contrib-group>
       <contrib contrib-type="author" id="au49">
        <name>
         <surname>
          Warnock
         </surname>
         <given-names>
          Eli W.
         </given-names>
         <suffix>
          III
         </suffix>
        </name>
       </contrib>
       <contrib contrib-type="author" id="au50">
        <name>
         <surname>
          Chosewood
         </surname>
         <given-names>
          L. Casey
         </given-names>
        </name>
       </contrib>
      </contrib-group>
     </sec-meta>
     <title>
      OCCUPATIONAL EXPOSURE TO HIV
     </title>
     <sec id="cesec365">
      <title>
       Risk for Health-Care Workers in International Locations
      </title>
      <p id="para1667">
       The safety practices and facility standards in health-care settings of developing countries may be less stringent than those in developed settings. The health-care resources and training of health-care workers in these settings may also be limited. These conditions have the potential to increase the risk for occupational HIV exposure to visiting health-care workers in developing countries. Lack of access to personal protective equipment may also increase risk.
      </p>
      <p id="para1668">
       Additionally, the prevalence of HIV infection in some developing countries is higher than that in the United States. Due to limited access to adequate treatment, infected source material in some developing countries may have higher viral loads than source material in the United States. Occupational exposure to source material with higher viral loads increases the risk for acquiring HIV occupationally.
      </p>
     </sec>
     <sec id="cesec366">
      <title>
       Infectious Agent
      </title>
      <p id="para1669">
       Human immunodeficiency virus (HIV) is one of the pathogens, along with hepatitis C virus (HCV) and hepatitis B virus (HBV), that may be transmitted occupationally to health-care workers.
      </p>
     </sec>
     <sec id="cesec367">
      <title>
       Mode of Transmission
      </title>
      <p id="para1670">
       Occupational transmission of HIV and transmission of other blood-borne pathogens typically occur via percutaneous exposure to contaminated sharps, including needles, lancets, scalpels, and broken glass. It can also occur when mucous membranes or nonintact skin comes into contact with infected blood or other body fluids.
      </p>
     </sec>
     <sec id="cesec368">
      <title>
       Occurrence
      </title>
      <p id="para1671">
       <list id="celist355" list-type="simple">
        <list-item id="celistitem1261">
         <label>
          •
         </label>
         <p id="para1672">
          The estimated annual number of health-care workers worldwide exposed to sharps injuries contaminated with HIV was 327,000 in 2005.
         </p>
        </list-item>
        <list-item id="celistitem1262">
         <label>
          •
         </label>
         <p id="para1673">
          The risk of HIV infection following percutaneous exposure with a contaminated sharp is estimated to be 0.3%, or approximately 3 infections per 1,000 exposures.
         </p>
        </list-item>
        <list-item id="celistitem1263">
         <label>
          •
         </label>
         <p id="para1674">
          Worldwide, the total number of HIV infections attributable to sharps injuries has been estimated to be 1,000 (range 200–5,000).
         </p>
        </list-item>
        <list-item id="celistitem1264">
         <label>
          •
         </label>
         <p id="para1675">
          A 2005 study estimated that these infections would result in the worldwide premature deaths of 736 (range 129–3,578) health-care workers during the years 2000 to 2030.
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <sec id="cesec369">
      <title>
       Preventive Measures for Travelers
      </title>
      <p id="para1676">
       Health-care providers working internationally who will be engaging in high-risk occupational activities, such as drawing blood or the other use of sharps during patient care, should—
       <list id="celist356" list-type="simple">
        <list-item id="celistitem1265">
         <label>
          •
         </label>
         <p id="para1677">
          Consistently follow standard precautions to reduce the risk of occupational exposure to HIV and other blood-borne pathogens. Standard precautions involve the use of protective barriers such as gloves, gowns, aprons, masks, or protective eyewear, which can reduce the risk of exposure of the health-care worker's skin or mucous membranes to potentially infective materials. Additional information about occupational health and safety standards for blood-borne pathogens can be found on the Occupational Safety and Health Administration (OSHA) website at
          <ext-link ext-link-type="uri" id="interref69" xlink:href="http://www.osha.gov/pls/oshaweb/owadisp.show_document?p_table=STANDARDS&amp;p_id=10051">
           www.osha.gov/pls/oshaweb/owadisp.show_document?p_table=STANDARDS&amp;p_id=10051
          </ext-link>
          .
         </p>
        </list-item>
        <list-item id="celistitem1266">
         <label>
          •
         </label>
         <p id="para1678">
          Always be mindful of the hazards posed by sharps injuries.
         </p>
        </list-item>
        <list-item id="celistitem1267">
         <label>
          •
         </label>
         <p id="para1679">
          Maintain strict safety standards while working in environments that may have less stringent standards.
         </p>
        </list-item>
        <list-item id="celistitem1268">
         <label>
          •
         </label>
         <p id="para1680">
          Use devices with safety features and improved work practices as recommended by the National Institute for Occupational Safety and Health (NIOSH) to prevent injuries caused by needles, scalpels, and other sharp instruments or devices. Additional information about preventing needlestick injuries in health-care settings can be found on the NIOSH website:
          <ext-link ext-link-type="uri" id="interref70" xlink:href="http://www.cdc.gov/niosh/2000-108.html#8">
           www.cdc.gov/niosh/2000-108.html#8
          </ext-link>
          .
         </p>
        </list-item>
        <list-item id="celistitem1269">
         <label>
          •
         </label>
         <p id="para1681">
          Consider bringing their own protective equipment if they are unsure of its availability at their destination.
         </p>
        </list-item>
        <list-item id="celistitem1270">
         <label>
          •
         </label>
         <p id="para1682">
          Consider bringing postexposure prophylaxis (PEP) for HIV with them for use in the event that they experience a sharps injury with a contaminated or potentially contaminated needle.
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <sec id="cesec370">
      <title>
       Postexposure Management
      </title>
      <p id="para1683">
       Health-care providers who have been occupationally exposed to HIV or have been exposed to potentially infectious material from a source person who is likely to be infected with HIV should immediately—
       <list id="celist357" list-type="simple">
        <list-item id="celistitem1271">
         <label>
          •
         </label>
         <p id="para1684">
          Wash the exposed area with soap and water thoroughly. If mucous membrane exposure has occurred, flush the area with copious amounts of water or saline.
         </p>
        </list-item>
        <list-item id="celistitem1272">
         <label>
          •
         </label>
         <p id="para1685">
          Seek qualified medical evaluation as soon as possible to guide decisions on postexposure treatment and testing.
         </p>
        </list-item>
        <list-item id="celistitem1273">
         <label>
          •
         </label>
         <p id="para1686">
          Contact the National Clinicians' Postexposure Prophylaxis Hotline (PEPline) at 1-888-448-4911 (24 hours/7 days a week) for assistance in assessing risk and advice on managing occupational exposures to HIV, hepatitis, and other blood-borne pathogens. Additional information about PEPline can be found on the National HIV/AIDS Clinicians' Consultation Center website at
          <ext-link ext-link-type="uri" id="interref71" xlink:href="http://www.ucsf.edu/hivcntr/Hotlines/PEPline.html">
           www.ucsf.edu/hivcntr/Hotlines/PEPline.html
          </ext-link>
          .
         </p>
        </list-item>
        <list-item id="celistitem1274">
         <label>
          •
         </label>
         <p id="para1687">
          Consider beginning postexposure prophylaxis (PEP) for HIV.
         </p>
        </list-item>
       </list>
      </p>
      <sec id="cesec371">
       <title>
        Postexposure Prophylaxis
       </title>
       <p id="para1688">
        <list id="celist358" list-type="simple">
         <list-item id="celistitem1275">
          <label>
           •
          </label>
          <p id="para1689">
           A number of medication combinations are available for PEP.
          </p>
         </list-item>
         <list-item id="celistitem1276">
          <label>
           •
          </label>
          <p id="para1690">
           Refer to MMWR's Updated U.S. Public Health Service Guidelines for the Management of Occupational Exposures to HIV, Recommendations for Postexposure Prophylaxis, Updated Information Regarding Antiretroviral Agents Used as HIV Postexposure Prophylaxis for Occupational HIV Exposures (
           <ext-link ext-link-type="uri" id="interref72" xlink:href="http://www.aidsinfo.nih.gov/Guidelines/GuidelineDetail.aspx?MenuItem=Guidelines&amp;Search=Off&amp;GuidelineID=10&amp;ClassID=3">
            www.aidsinfo.nih.gov/Guidelines/GuidelineDetail.aspx?MenuItem=Guidelines&amp;Search=Off&amp;GuidelineID=10&amp;ClassID=3
           </ext-link>
           ) and the PEPline for more information about PEP recommendations.
          </p>
         </list-item>
         <list-item id="celistitem1277">
          <label>
           •
          </label>
          <p id="para1691">
           Specific regimens should be individually determined for those travelers at risk by health-care providers familiar with the medications and the traveler's medical history.
          </p>
         </list-item>
         <list-item id="celistitem1278">
          <label>
           •
          </label>
          <p id="para1692">
           If the exposed person chooses to initiate PEP, they must do so within hours, as delays lead to a significant decline in PEP effectiveness.
          </p>
         </list-item>
         <list-item id="celistitem1279">
          <label>
           •
          </label>
          <p id="para1693">
           If indicated, arrange for procurement or shipment of additional postexposure prophylaxis from a credible source to complete the recommended 4-week course of treatment.
          </p>
         </list-item>
         <list-item id="celistitem1280">
          <label>
           •
          </label>
          <p id="para1694">
           Consider other potential infectious disease exposures from the source material as well, to include HBV or HCV, and manage if appropriate.
          </p>
         </list-item>
        </list>
       </p>
      </sec>
     </sec>
     <sec id="cesec372">
      <title>
       Postexposure Testing
      </title>
      <p id="para1695">
       <list id="celist359" list-type="simple">
        <list-item id="celistitem1281">
         <label>
          •
         </label>
         <p id="para1696">
          Persons with occupational exposure to HIV should receive baseline postexposure HIV-antibody testing by enzyme immunoassay, postexposure counseling, and medical evaluation, whether or not they receive PEP. In addition to baseline HIV-antibody testing, persons occupationally exposed should receive follow-up HIV-antibody testing by enzyme immunoassay for 6 months following exposure, at 6 weeks, 12 weeks, and 6 months (aidsinfo.nih.gov/contentfiles/HealthCareOccupExpoGL.pdf).
         </p>
        </list-item>
        <list-item id="celistitem1282">
         <label>
          •
         </label>
         <p id="para1697">
          The U.S. Public Health Service also recommends that health-care workers occupationally exposed to a source co-infected with HIV and HCV and who acquire HCV infection receive extended HIV postexposure surveillance for up to 12 months following exposure.
         </p>
        </list-item>
        <list-item id="celistitem1283">
         <label>
          •
         </label>
         <p id="para1698">
          Exposed health-care providers should be advised to use precautions (e.g., avoid blood or tissue donations, breastfeeding, or pregnancy) to prevent secondary transmission, especially during the first 6–12 weeks postexposure.
         </p>
        </list-item>
        <list-item id="celistitem1284">
         <label>
          •
         </label>
         <p id="para1699">
          For exposures for which PEP is prescribed, health-care providers should be informed about—
          <list id="celist360" list-type="simple">
           <list-item id="celistitem1285">
            <label>
             ○
            </label>
            <p id="para1700">
             possible drug toxicities and the need for monitoring
            </p>
           </list-item>
           <list-item id="celistitem1286">
            <label>
             ○
            </label>
            <p id="para1701">
             possible drug interactions
            </p>
           </list-item>
           <list-item id="celistitem1287">
            <label>
             ○
            </label>
            <p id="para1702">
             the need for adherence to PEP regimens
            </p>
           </list-item>
          </list>
         </p>
        </list-item>
        <list-item id="celistitem1288">
         <label>
          •
         </label>
         <p id="para1703">
          Consider re-evaluation of exposed health-care providers, if possible, 72 hours postexposure, especially after additional information about the exposure or source person becomes available and when adverse events of any medication can be assessed.
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <ref-list id="cebib28">
      <title>
       References
      </title>
      <ref id="bib286">
       <label>
        1
       </label>
       <mixed-citation id="ceotherref26" publication-type="other">
        Regulations (Standards—29 CFR): Bloodborne pathogens—1910.1030. [cited 2008 Apr 1]. Available from:
        <ext-link ext-link-type="uri" id="interref145" xlink:href="http://www.osha.gov/pls/oshaweb/owadisp.show_document?p_table=STANDARDS&amp;p_id=10051">
         http://www.osha.gov/pls/oshaweb/owadisp.show_document?p_table=STANDARDS&amp;p_id=10051
        </ext-link>
        .
       </mixed-citation>
      </ref>
      <ref id="bib287">
       <label>
        2
       </label>
       <mixed-citation id="ceotherref27" publication-type="other">
        Preventing needlestick injuries in health care settings. [cited 2008 Apr 10]. Available from:
        <ext-link ext-link-type="uri" id="interref73" xlink:href="http://www.cdc.gov/niosh/2000-108.html#8">
         http://www.cdc.gov/niosh/2000–108.html#8
        </ext-link>
        .
       </mixed-citation>
      </ref>
      <ref id="bib288">
       <label>
        3
       </label>
       <mixed-citation id="ceotherref28" publication-type="other">
        National Clinicians' Post-Exposure Prophylaxis Hotline (PEPline). [cited 2007 Dec 20]. Available from:
        <ext-link ext-link-type="uri" id="interref74" xlink:href="http://www.ucsf.edu/hivcntr/PEPline/index.html">
         http://www.ucsf.edu/hivcntr/PEPline/index.html
        </ext-link>
        .
       </mixed-citation>
      </ref>
      <ref id="bib289">
       <label>
        4
       </label>
       <element-citation id="sbref261" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sepkowitz
          </surname>
          <given-names>
           KA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Occupationally acquired infections in health care workers. Part II
        </article-title>
        <source>
         Ann Intern Med
        </source>
        <volume>
         125
        </volume>
        <issue>
         11
        </issue>
        <year>
         1996
        </year>
        <fpage>
         917
        </fpage>
        <lpage>
         928
        </lpage>
        <pub-id pub-id-type="pmid">
         8967673
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib290">
       <label>
        5
       </label>
       <element-citation id="sbref262" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Romea
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Alkiza
          </surname>
          <given-names>
           ME
          </given-names>
         </name>
         <name>
          <surname>
           Ramon
          </surname>
          <given-names>
           JM
          </given-names>
         </name>
        </person-group>
        <article-title>
         Risk of occupational transmission of HIV infection among health care workers. Study in a Spanish hospital
        </article-title>
        <source>
         Eur J Epidemiol
        </source>
        <volume>
         11
        </volume>
        <issue>
         2
        </issue>
        <year>
         1995
        </year>
        <fpage>
         225
        </fpage>
        <lpage>
         229
        </lpage>
        <pub-id pub-id-type="pmid">
         7672081
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib291">
       <label>
        6
       </label>
       <mixed-citation id="ceotherref29" publication-type="other">
        EPINet—Exposure Prevention Information Network. Uniform needle stick and sharp object injury report. International Health Care Worker Safety Center, University of Virginia, USA. 1998. [2008 Nov 26]. Available from:
        <ext-link ext-link-type="uri" id="interref75" xlink:href="http://www.healthsystem.virginia.edu/internet/epinet/home.cfm">
         http://www.healthsystem.virginia.edu/internet/epinet/home.cfm
        </ext-link>
       </mixed-citation>
      </ref>
      <ref id="bib292">
       <label>
        7
       </label>
       <mixed-citation id="ceotherref30" publication-type="other">
        Canadian Center for Occupational Health and Safety. Needlestick injuries. 2000. [cited 2007 Dec]. Available from:
        <ext-link ext-link-type="uri" id="interref76" xlink:href="http://www.ccohs.ca/oshanswers/diseases/needlestick_injuries.html">
         http://www.ccohs.ca/oshanswers/diseases/needlestick_injuries.html
        </ext-link>
        .
       </mixed-citation>
      </ref>
      <ref id="bib293">
       <label>
        8
       </label>
       <element-citation id="sbref263" publication-type="journal">
        <comment>
        </comment>
        <person-group person-group-type="author">
         <name>
          <surname>
           Puro
          </surname>
          <given-names>
           V
          </given-names>
         </name>
         <name>
          <surname>
           De Carli
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Petrosillo
          </surname>
          <given-names>
           N
          </given-names>
         </name>
        </person-group>
        <article-title>
         Risk of exposure to blood borne infection for Italian healthcare workers, by job category and work area. Studio Italiano Rischio Occupazionale da HIV Group
        </article-title>
        <source>
         Infect Control Hosp Epidemiol
        </source>
        <volume>
         22
        </volume>
        <issue>
         4
        </issue>
        <year>
         2001
        </year>
        <fpage>
         206
        </fpage>
        <lpage>
         210
        </lpage>
        <pub-id pub-id-type="pmid">
         11379710
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib294">
       <label>
        9
       </label>
       <element-citation id="sbref264" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Prüss-Üstün
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Rapiti
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Hutin
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
        </person-group>
        <article-title>
         Estimation of the global burden of disease attributable to contaminated sharps injuries among health-care workers
        </article-title>
        <source>
         Am J Industr Med
        </source>
        <volume>
         48
        </volume>
        <issue>
         6
        </issue>
        <year>
         2005
        </year>
        <fpage>
         482
        </fpage>
        <lpage>
         490
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib295">
       <label>
        10
       </label>
       <element-citation id="sbref265" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bell
          </surname>
          <given-names>
           DM
          </given-names>
         </name>
        </person-group>
        <article-title>
         Occupational risk of human immunodeficiency virus infection in health care workers: an overview
        </article-title>
        <source>
         Am J Med
        </source>
        <volume>
         102
        </volume>
        <issue>
         5B
        </issue>
        <year>
         1997
        </year>
        <fpage>
         9
        </fpage>
        <lpage>
         15
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib296">
       <label>
        11
       </label>
       <element-citation id="sbref266" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sagoe-Moses
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Pearson
          </surname>
          <given-names>
           RD
          </given-names>
         </name>
         <name>
          <surname>
           Perry
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        <article-title>
         Risks to health care workers in developing countries
        </article-title>
        <source>
         N Engl J Med
        </source>
        <volume>
         345
        </volume>
        <issue>
         7
        </issue>
        <year>
         2001
        </year>
        <fpage>
         538
        </fpage>
        <lpage>
         541
        </lpage>
        <pub-id pub-id-type="pmid">
         11519511
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib297">
       <label>
        12
       </label>
       <element-citation id="sbref267" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Panlilio
          </surname>
          <given-names>
           AL
          </given-names>
         </name>
         <name>
          <surname>
           Cardo
          </surname>
          <given-names>
           DM
          </given-names>
         </name>
         <name>
          <surname>
           Grohskopf
          </surname>
          <given-names>
           LA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Updated U.S. Public Health Service guidelines for the management of occupational exposures to HIV and recommendations for Postexposure Prophylaxis
        </article-title>
        <source>
         MMWR Recomm Rep
        </source>
        <volume>
         54
        </volume>
        <issue>
         RR-9
        </issue>
        <year>
         2005
        </year>
        <fpage>
         1
        </fpage>
        <lpage>
         17
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib298">
       <label>
        13
       </label>
       <element-citation id="sbref268" publication-type="journal">
        <person-group person-group-type="author">
         <collab>
          CDC
         </collab>
        </person-group>
        <article-title>
         Updated information regarding antiretroviral agents used as HIV postexposure prophylaxis for occupational HIV exposures
        </article-title>
        <source>
         MMWR Morb Mortal Wkly Rep
        </source>
        <volume>
         56
        </volume>
        <issue>
         49
        </issue>
        <year>
         2007
        </year>
        <fpage>
         1291
        </fpage>
        <lpage>
         1292
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib299">
       <label>
        14
       </label>
       <element-citation id="sbref269" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Uslan
          </surname>
          <given-names>
           DZ
          </given-names>
         </name>
         <name>
          <surname>
           Verk
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        <article-title>
         Postexposure chemoprophylaxis for occupational exposure to Human Immunodeficiency Virus in traveling health care workers
        </article-title>
        <source>
         J Travel Med
        </source>
        <volume>
         12
        </volume>
        <issue>
         1
        </issue>
        <year>
         2005
        </year>
        <fpage>
         14
        </fpage>
        <lpage>
         18
        </lpage>
        <pub-id pub-id-type="pmid">
         15996462
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib300">
       <label>
        15
       </label>
       <element-citation id="sbref270" publication-type="journal">
        <person-group person-group-type="author">
         <collab>
          CDC
         </collab>
        </person-group>
        <article-title>
         Updated U.S. Public Health Service guidelines for the management of occupational exposures to HBV, HCV, and HIV and recommendations for postexposure prophylaxis
        </article-title>
        <source>
         MMWR Recomm Rep
        </source>
        <volume>
         50
        </volume>
        <issue>
         RR-11
        </issue>
        <year>
         2001
        </year>
        <fpage>
         1
        </fpage>
        <lpage>
         42
        </lpage>
       </element-citation>
      </ref>
     </ref-list>
    </sec>
    <sec id="cesec373">
     <title>
     </title>
     <p id="para1704">
      Counseling and Advice for Travelers
     </p>
    </sec>
    <sec id="subchapter29">
     <sec-meta>
      <contrib-group>
       <contrib contrib-type="author" id="au51">
        <name>
         <surname>
          Zielinski-Gutierrez
         </surname>
         <given-names>
          Emily
         </given-names>
        </name>
       </contrib>
       <contrib contrib-type="author" id="au52">
        <name>
         <surname>
          Wirtz
         </surname>
         <given-names>
          Robert A.
         </given-names>
        </name>
       </contrib>
       <contrib contrib-type="author" id="au53">
        <name>
         <surname>
          Nasci
         </surname>
         <given-names>
          Roger S.
         </given-names>
        </name>
       </contrib>
      </contrib-group>
     </sec-meta>
     <title>
      PROTECTION AGAINST MOSQUITOES, TICKS, AND OTHER INSECTS AND ARTHROPODS
     </title>
     <p id="para1705">
      Although vaccines or chemoprophylactic drugs are available to protect against some important vector-borne diseases such as yellow fever and malaria, travelers still should be advised to use repellents and other general protective measures against biting arthropods. The effectiveness of malaria chemoprophylaxis is variable, depending on patterns of drug resistance, bio-availability, and compliance with medication, and no similar preventive measures exist for other mosquito-borne diseases such as dengue or chikungunya.
     </p>
     <p id="para1706">
      CDC recommends the use of products containing active ingredients that have been registered by the U.S. Environmental Protection Agency (EPA) for use as repellents applied to skin and clothing (see below). EPA registration of active ingredients indicates the materials have been reviewed and approved for efficacy and human safety when applied according to the instructions on the label.
     </p>
     <sec id="cesec374">
      <title>
       General Protective Measures
      </title>
      <p id="para1707">
       <list id="celist361" list-type="simple">
        <list-item id="celistitem1289">
         <label>
          •
         </label>
         <p id="para1708">
          <bold>
           Avoid outbreaks:
          </bold>
          To the extent possible, travelers should avoid known foci of epidemic disease transmission. The CDC Travelers' Health webpage provides alerts and information on regional disease transmission patterns and outbreak alerts (
          <ext-link ext-link-type="uri" id="interref77" xlink:href="http://www.cdc.gov/travel">
           www.cdc.gov/travel
          </ext-link>
          ).
         </p>
        </list-item>
        <list-item id="celistitem1290">
         <label>
          •
         </label>
         <p id="para1709">
          <bold>
           Be aware of peak exposure times and places:
          </bold>
          Exposure to arthropod bites may be reduced if travelers modify their patterns of activity or behavior. Although mosquitoes may bite at any time of day, peak biting activity for vectors of some diseases (e.g., dengue, chikungunya) is during daylight hours. Vectors of other diseases (e.g., malaria) are most active in twilight periods (i.e., dawn and dusk) or in the evening after dark. Avoiding the outdoors or focusing preventive actions during peak hours may reduce risk. Place also matters; ticks are often found in grasses and other vegetated areas. Local health officials or guides may be able to point out areas with greater arthropod activity.
         </p>
        </list-item>
        <list-item id="celistitem1291">
         <label>
          •
         </label>
         <p id="para1710">
          <bold>
           Wear appropriate clothing:
          </bold>
          Travelers can minimize areas of exposed skin by wearing long-sleeved shirts, long pants, boots, and hats. Tucking in shirts and wearing socks and closed shoes instead of sandals may reduce risk. Repellents or insecticides such as permethrin can be applied to clothing and gear for added protection; this measure is discussed in detail below.
         </p>
        </list-item>
        <list-item id="celistitem1292">
         <label>
          •
         </label>
         <p id="para1711">
          <bold>
           Check for ticks:
          </bold>
          Travelers should be advised to inspect themselves and their clothing for ticks during outdoor activity and at the end of the day. Prompt removal of attached ticks can prevent some infections.
         </p>
        </list-item>
        <list-item id="celistitem1293">
         <label>
          •
         </label>
         <p id="para1712">
          <bold>
           Bed nets:
          </bold>
          When accommodations are not adequately screened or air conditioned, bed nets are essential to provide protection and to reduce discomfort caused by biting insects. If bed nets do not reach the floor, they should be tucked under mattresses. Bed nets are most effective when they are treated with an insecticide or repellent such as permethrin. Pretreated, long-lasting bed nets can be purchased prior to traveling, or nets can be treated after purchase. The permethrin will be effective for several months if the bed net is not washed. (Long-lasting pretreated nets may be effective for much longer.)
         </p>
        </list-item>
        <list-item id="celistitem1294">
         <label>
          •
         </label>
         <p id="para1713">
          <bold>
           Insecticides:
          </bold>
          Aerosol insecticides, vaporizing mats and mosquito coils can help to clear rooms or areas of mosquitoes; however, some products available internationally may contain pesticides that are not registered in the United States. Insecticides should always be used with caution, avoiding direct inhalation of spray or smoke.
         </p>
        </list-item>
       </list>
      </p>
      <p id="para1714">
       <bold>
        Optimum protection can be provided by applying the repellents described in the following sections to clothing and to exposed skin
       </bold>
       .
      </p>
     </sec>
     <sec id="cesec375">
      <title>
       Repellents for Use on Skin and Clothing
      </title>
      <p id="para1715">
       CDC has evaluated information published in peer-reviewed scientific literature and data available from EPA to identify several EPA-registered products that provide repellent activity sufficient to help people avoid the bites of disease-carrying mosquitoes. Products containing the following active ingredients typically provide reasonably long-lasting protection:
       <list id="celist362" list-type="simple">
        <list-item id="celistitem1295">
         <label>
          •
         </label>
         <p id="para1716">
          <bold>
           DEET
          </bold>
          (chemical name:
          <italic>
           N
          </italic>
          ,
          <italic>
           N
          </italic>
          -diethyl-
          <italic>
           m
          </italic>
          -toluamide or
          <italic>
           N
          </italic>
          ,
          <italic>
           N
          </italic>
          -diethly-3-methyl-benzamide). Products containing DEET include but are not limited to Off!, Cutter, Sawyer, and Ultrathon.
         </p>
        </list-item>
        <list-item id="celistitem1296">
         <label>
          •
         </label>
         <p id="para1717">
          <bold>
           Picaridin
          </bold>
          (KBR 3023, aka Bayrepel, and icaridin outside the United States; chemical name 2-(2-hydroxyethyl)-1-piperidinecarboxylic acid 1-methylpropyl ester). Products containing picaridin include but are not limited to Cutter Advanced, Skin So Soft Bug Guard Plus and Autan (outside the United States).
         </p>
        </list-item>
        <list-item id="celistitem1297">
         <label>
          •
         </label>
         <p id="para1718">
          <bold>
           Oil of lemon eucalyptus
          </bold>
          <xref ref-type="fn" rid="fn2">
           *
          </xref>
          or
          <bold>
           PMD
          </bold>
          (chemical name:
          <italic>
           para
          </italic>
          -menthane-3,8-diol) the synthesized version of oil of lemon eucalyptus. Products containing OLE and PMD include but are not limited to Repel.
         </p>
        </list-item>
        <list-item id="celistitem1298">
         <label>
          •
         </label>
         <p id="para1719">
          <bold>
           IR3535
          </bold>
          (chemical name: 3-[
          <italic>
           N
          </italic>
          -butyl-
          <italic>
           N
          </italic>
          -acetyl]-aminopropionic acid, ethyl ester) Products containing IR3535 include but are not limited to Skin so Soft Bug Guard Plus Expedition.
         </p>
        </list-item>
       </list>
      </p>
      <p id="para1720">
       EPA characterizes the active ingredients DEET and picaridin as “conventional repellents” and oil of lemon eucalyptus, PMD, and IR3535 as “biopesticide repellents,” which are derived from natural materials.
      </p>
      <sec id="cesec376">
       <title>
        Repellent Efficacy
       </title>
       <p id="para1721">
        <list id="celist363" list-type="simple">
         <list-item id="celistitem1299">
          <label>
           •
          </label>
          <p id="para1722">
           Published data indicate that repellent efficacy and duration of protection vary considerably among products and among mosquito species.
          </p>
         </list-item>
         <list-item id="celistitem1300">
          <label>
           •
          </label>
          <p id="para1723">
           Product efficacy and duration of protection are also markedly affected by ambient temperature, amount of perspiration, exposure to water, abrasive removal, and other factors.
          </p>
         </list-item>
         <list-item id="celistitem1301">
          <label>
           •
          </label>
          <p id="para1724">
           In general,
           <bold>
            higher concentrations of active ingredient provide longer duration of protection
           </bold>
           , regardless of the active ingredient. Products with £10% active ingredient may offer only limited protection, often from 1–2 hours.
          </p>
         </list-item>
         <list-item id="celistitem1302">
          <label>
           •
          </label>
          <p id="para1725">
           Products that offer
           <bold>
            sustained release or controlled release (i.e., micro-encapsulated) formulations, even with lower active ingredient concentrations, may provide longer protection times
           </bold>
           .
          </p>
         </list-item>
         <list-item id="celistitem1303">
          <label>
           •
          </label>
          <p id="para1726">
           Studies suggest that concentrations of DEET above ∼50% do not offer a marked increase in protection time against mosquitoes (i.e., DEET efficacy tends to plateau at around 50%).
          </p>
         </list-item>
         <list-item id="celistitem1304">
          <label>
           •
          </label>
          <p id="para1727">
           Regardless of what product is used, if travelers start to get mosquito bites they should reapply the repellent according to the label instructions or leave the area with biting insects if possible.
          </p>
         </list-item>
        </list>
       </p>
       <p id="para1728">
        Repellents should be purchased before traveling and can be found in hardware stores, drug stores and supermarkets. A wider variety of repellents can be found in camping, sporting goods, and military surplus stores. When purchasing repellents overseas, look for the EPA-registered active ingredients on the product labels; some names of products available internationally have been specified above.
       </p>
      </sec>
      <sec id="cesec377">
       <title>
        Repellents and Sunscreen
       </title>
       <p id="para1729">
        Repellents that are applied according to label instructions may be used with sunscreen with no reduction in repellent activity. Products that combine sunscreen and repellent are not recommended, because sunscreen may need to be reapplied with greater frequency and in greater amounts than are needed to provide protection from biting insects.
        <bold>
         In general, the recommendation is to apply sunscreen first, before applying the repellent
        </bold>
        .
       </p>
      </sec>
     </sec>
     <sec id="cesec378">
      <title>
       Repellents/Insecticides for Use On Clothing
      </title>
      <p id="para1730">
       <list id="celist364" list-type="simple">
        <list-item id="celistitem1305">
         <label>
          •
         </label>
         <p id="para1731">
          <bold>
           Clothing, shoes, bed nets, mesh jackets, and camping gear can be treated with permethrin for added protection
          </bold>
          .
         </p>
        </list-item>
        <list-item id="celistitem1306">
         <label>
          •
         </label>
         <p id="para1732">
          Products such as Permanone and Sawyer permethrin are registered with EPA specifically for this use.
         </p>
        </list-item>
        <list-item id="celistitem1307">
         <label>
          •
         </label>
         <p id="para1733">
          Permethrin is a highly effective insecticide and repellent. Permethrin-treated clothing repels and kills ticks, mosquitoes, and other arthropods. Clothing and other items must be treated several days in advance of travel to allow them to dry. As with all pesticides, follow the label instructions when using permethrin clothing treatments. Alternatively, clothing pretreated with permethrin is commercially available (e.g., products from Buzz Off/Insect Shield).
         </p>
        </list-item>
        <list-item id="celistitem1308">
         <label>
          •
         </label>
         <p id="para1734">
          Permethrin-treated materials retain repellency/insecticidal activity after repeated laundering but should be retreated as described on the product label to provide continued protection. Clothing treated with the other repellent products described above (e.g., DEET) provides protection from biting arthropods but will not last through washing and will require more frequent reapplications.
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <sec id="cesec379">
      <title>
       Precautions when Using Insect Repellents
      </title>
      <p id="para1735">
       <list id="celist365" list-type="simple">
        <list-item id="celistitem1309">
         <label>
          •
         </label>
         <p id="para1736">
          Apply repellents only to exposed skin and/or clothing, as directed on the product label. Do not use repellents under clothing.
         </p>
        </list-item>
        <list-item id="celistitem1310">
         <label>
          •
         </label>
         <p id="para1737">
          Never use repellents over cuts, wounds or irritated skin.
         </p>
        </list-item>
        <list-item id="celistitem1311">
         <label>
          •
         </label>
         <p id="para1738">
          Do not apply repellents to eyes or mouth, and apply sparingly around ears. When using sprays, do not spray directly on face-spray on hands first and then apply to face. Wash hands after application to avoid accidental exposure to eyes.
         </p>
        </list-item>
        <list-item id="celistitem1312">
         <label>
          •
         </label>
         <p id="para1739">
          Do not allow children to handle repellents. When using on children, adults should apply repellents to their hands first, and then put it on the child. It may be advisable to avoid applying to children's hands.
         </p>
        </list-item>
        <list-item id="celistitem1313">
         <label>
          •
         </label>
         <p id="para1740">
          Use just enough repellent to cover exposed skin and/or clothing. Heavy application and saturation are generally unnecessary for effectiveness. If biting insects do not respond to a thin film of repellent, apply a bit more.
         </p>
        </list-item>
        <list-item id="celistitem1314">
         <label>
          •
         </label>
         <p id="para1741">
          After returning indoors, wash treated skin with soap and water or bathe. This is particularly important when repellents are used repeatedly in a day or on consecutive days. Also, wash treated clothing before wearing it again. (This precaution may vary with different repellents—check the product label.)
         </p>
        </list-item>
        <list-item id="celistitem1315">
         <label>
          •
         </label>
         <p id="para1742">
          If anyone experiences a rash or other bad reaction from an insect repellent, the repellent use should be discontinued, the repellent should be washed off with mild soap and water, and a local poison control center should be called for further guidance. If seeking health care because of the repellent, take the repellent to the doctor's office and show the doctor.
         </p>
        </list-item>
        <list-item id="celistitem1316">
         <label>
          •
         </label>
         <p id="para1743">
          Permethrin should never be applied to skin, but only to clothing, bed nets, or other fabrics as directed on the product label.
         </p>
        </list-item>
       </list>
      </p>
      <sec id="cesec380">
       <title>
        Children
       </title>
       <p id="para1744">
        <list id="celist366" list-type="simple">
         <list-item id="celistitem1317">
          <label>
           •
          </label>
          <p id="para1745">
           Most repellents can be used on children &gt;2 months of age.
          </p>
         </list-item>
         <list-item id="celistitem1318">
          <label>
           •
          </label>
          <p id="para1746">
           Protect infants &lt;2 months of age from biting mosquitoes by using an infant carrier draped with mosquito netting with an elastic edge for a tight fit.
          </p>
         </list-item>
         <list-item id="celistitem1319">
          <label>
           •
          </label>
          <p id="para1747">
           Products containing oil of lemon eucalyptus specify that they should not be used on children &lt;3 years of age.
          </p>
         </list-item>
         <list-item id="celistitem1320">
          <label>
           •
          </label>
          <p id="para1748">
           Other than the safety tips listed above, EPA does not recommend any additional precautions for using registered repellents on children or on pregnant or lactating women.
          </p>
         </list-item>
        </list>
       </p>
      </sec>
     </sec>
     <sec id="cesec381">
      <title>
       Useful Links
      </title>
      <p id="para1749">
       <list id="celist367" list-type="simple">
        <list-item id="celistitem1321">
         <label>
          •
         </label>
         <p id="para1750">
          U.S. Environmental Protection Agency. How to Use Insect Repellents Safely; [updated 2007 July 5; cited 2008 Nov 29]. Available from:
          <ext-link ext-link-type="uri" id="interref78" xlink:href="http://www.epa.gov/pesticides/health/mosquitoes/insectrp.htm">
           www.epa.gov/pesticides/health/mosquitoes/insectrp.htm
          </ext-link>
          .
         </p>
        </list-item>
        <list-item id="celistitem1322">
         <label>
          •
         </label>
         <p id="para1751">
          Centers for Disease Control and Prevention. Insect Repellent Use and Safety; [updated 2008 May 14; cited 2008 Nov 29]. Available from:
          <ext-link ext-link-type="uri" id="interref79" xlink:href="http://www.cdc.gov/ncidod/dvbid/westnile/qa/insect_repellent.htm">
           www.cdc.gov/ncidod/dvbid/westnile/qa/insect_repellent.htm
          </ext-link>
          .
         </p>
        </list-item>
        <list-item id="celistitem1323">
         <label>
          •
         </label>
         <p id="para1752">
          Health Canada's Pest Management Regulatory Agency. Safety Tips on Using Personal Insect Repellents; [updated 2004 September 17; cited 2008 Nov 29]. Available from:
          <ext-link ext-link-type="uri" id="interref80" xlink:href="http://www.pmra-arla.gc.ca/english/consum/insectrepellents-e.html">
           www.pmra-arla.gc.ca/english/consum/insectrepellents-e.html
          </ext-link>
          .
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <ref-list id="cebib29">
      <title>
       References
      </title>
      <ref id="bib301">
       <label>
        1
       </label>
       <element-citation id="sbref271" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Barnard
          </surname>
          <given-names>
           DR
          </given-names>
         </name>
         <name>
          <surname>
           Xue
          </surname>
          <given-names>
           RD
          </given-names>
         </name>
        </person-group>
        <article-title>
         Laboratory evaluation of mosquito repellents against
         <italic>
          Aedes albopictus, Culex nigripalpus
         </italic>
         and
         <italic>
          Ochlerotatus triseriatus
         </italic>
         (Diptera: Culicidae)
        </article-title>
        <source>
         J Med Entomol
        </source>
        <volume>
         41
        </volume>
        <issue>
         4
        </issue>
        <year>
         2004
        </year>
        <fpage>
         726
        </fpage>
        <lpage>
         730
        </lpage>
        <pub-id pub-id-type="pmid">
         15311467
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib302">
       <label>
        2
       </label>
       <element-citation id="sbref272" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Barnard
          </surname>
          <given-names>
           DR
          </given-names>
         </name>
         <name>
          <surname>
           Bernier
          </surname>
          <given-names>
           UR
          </given-names>
         </name>
         <name>
          <surname>
           Posey
          </surname>
          <given-names>
           KH
          </given-names>
         </name>
        </person-group>
        <article-title>
         Repellency of IR3535, KBR3023,
         <italic>
          para
         </italic>
         -menthane-3,8-diol, and deet to Black Salt Marsh mosquitoes (Diptera: Culicidae) in the Everglades National Park
        </article-title>
        <source>
         J Med Entomol
        </source>
        <volume>
         39
        </volume>
        <issue>
         6
        </issue>
        <year>
         2002
        </year>
        <fpage>
         895
        </fpage>
        <lpage>
         899
        </lpage>
        <pub-id pub-id-type="pmid">
         12495189
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib303">
       <label>
        3
       </label>
       <element-citation id="sbref273" publication-type="journal">
        <comment>
        </comment>
        <person-group person-group-type="author">
         <name>
          <surname>
           Fradin
          </surname>
          <given-names>
           MS
          </given-names>
         </name>
         <name>
          <surname>
           Day
          </surname>
          <given-names>
           JF
          </given-names>
         </name>
        </person-group>
        <article-title>
         Comparative efficacy of insect repellents against mosquito bites
        </article-title>
        <source>
         N Engl J Med
        </source>
        <volume>
         347
        </volume>
        <issue>
         1
        </issue>
        <year>
         2002
        </year>
        <fpage>
         13
        </fpage>
        <lpage>
         18
        </lpage>
        <pub-id pub-id-type="pmid">
         12097535
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib304">
       <label>
        4
       </label>
       <element-citation id="sbref274" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Murphy
          </surname>
          <given-names>
           ME
          </given-names>
         </name>
         <name>
          <surname>
           Montemarano
          </surname>
          <given-names>
           AD
          </given-names>
         </name>
         <name>
          <surname>
           Debboun
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <article-title>
         The effect of sunscreen on the efficacy of insect repellent: a clinical trial
        </article-title>
        <source>
         J Am Acad Dermatol
        </source>
        <volume>
         43
        </volume>
        <issue>
         2 Pt 1
        </issue>
        <year>
         2000
        </year>
        <fpage>
         219
        </fpage>
        <lpage>
         222
        </lpage>
        <pub-id pub-id-type="pmid">
         10906641
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib305">
       <label>
        5
       </label>
       <element-citation id="sbref275" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Thavara
          </surname>
          <given-names>
           U
          </given-names>
         </name>
         <name>
          <surname>
           Tawatsin
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Chompoosri
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        <article-title>
         Laboratory and field evaluations of the insect repellent 3535 (ethyl butylacetylaminopropionate) and deet against mosquito vectors in Thailand
        </article-title>
        <source>
         J Am Mosq Control Assoc
        </source>
        <volume>
         17
        </volume>
        <issue>
         3
        </issue>
        <year>
         2001
        </year>
        <fpage>
         190
        </fpage>
        <lpage>
         195
        </lpage>
        <pub-id pub-id-type="pmid">
         14529087
        </pub-id>
       </element-citation>
      </ref>
     </ref-list>
    </sec>
    <sec id="subchapter30">
     <sec-meta>
      <contrib-group>
       <contrib contrib-type="author" id="au54">
        <name>
         <surname>
          Backer
         </surname>
         <given-names>
          Howard D.
         </given-names>
        </name>
       </contrib>
      </contrib-group>
     </sec-meta>
     <title>
      WATER DISINFECTION FOR TRAVELERS
     </title>
     <sec id="cesec382">
      <title>
       Risk for Travelers
      </title>
      <p id="para1753">
       Waterborne disease is a risk for international travelers who visit countries that have poor hygiene and inadequate sanitation, and for wilderness users relying on surface water in any country, including the United States. Worldwide, more than one billion people have no access to potable water and 2.4 billion do not have adequate sanitation. In developing countries, the influence of high-density population and rampant pollution, along with absent, overwhelmed, or insufficient sanitation and water treatment systems, means that surface water may be highly polluted with human waste and even urban tap water may become contaminated. Primarily humans, but also animals, are the source of microorganisms that contaminate water sources and cause intestinal infections.
      </p>
      <p id="para1754">
       The list of potential waterborne pathogens is extensive and includes bacteria, viruses, protozoa, and parasitic helminths. Most of the organisms that can cause travelers' diarrhea can be waterborne, although the majority of travelers' intestinal infections are probably transmitted by food. Microorganisms with small infectious doses can even cause illness through recreational water exposure, via inadvertent water ingestion.
      </p>
      <p id="para1755">
       Bottled water has become the convenient solution for most travelers, but in some places, it may not be superior to tap water. Moreover, the plastic bottles create a huge ecological problem, since most developing countries do not recycle plastic bottles. All international travelers, especially long-term travelers or expatriates, should become familiar with and utilize simple methods to ensure safe drinking water. Disinfection, the desired result of field water treatment, means the removal or destruction of harmful microorganisms. The goal of disinfection is to reduce the risk of gastrointestinal infection and diarrheal illness.
       <xref ref-type="table" rid="cetable27">
        Table 2-28
       </xref>
       compares benefits and limitations of different methods.
       <table-wrap id="cetable27" position="float">
        <label>
         Table 2-28
        </label>
        <caption>
         <p>
          Comparison of water disinfection techniques
         </p>
        </caption>
        <table frame="hsides" rules="groups">
         <thead>
          <tr>
           <th align="left">
            Technique
           </th>
           <th align="left">
            Advantages
           </th>
           <th align="left">
            Disadvantages
           </th>
          </tr>
         </thead>
         <tbody>
          <tr>
           <td align="left">
            Heat
           </td>
           <td align="left">
            <list id="celist27" list-type="simple">
             <list-item id="celistitem74">
              <p id="para74">
               • Does not impart additional taste or color
              </p>
             </list-item>
             <list-item id="celistitem75">
              <p id="para75">
               • Single step that inactivates all enteric pathogens
              </p>
             </list-item>
             <list-item id="celistitem76">
              <p id="para76">
               • Efficacy is not compromised by contaminants or particles in the water as for halogenation and filtratino
              </p>
             </list-item>
            </list>
           </td>
           <td align="left">
            <list id="celist28" list-type="simple">
             <list-item id="celistitem77">
              <p id="para77">
               • Does not improve taste, smell or appearance of poor quality water
              </p>
             </list-item>
             <list-item id="celistitem78">
              <p id="para78">
               • Fuel sources may be scarce, expensive or unavailable
              </p>
             </list-item>
             <list-item id="celistitem79">
              <p id="para79">
               • Does not prevent recontamination during storage
              </p>
             </list-item>
            </list>
           </td>
          </tr>
          <tr>
           <td align="left">
            Filtration
           </td>
           <td align="left">
            <list id="celist29" list-type="simple">
             <list-item id="celistitem80">
              <p id="para80">
               • Simple to operate
              </p>
             </list-item>
             <list-item id="celistitem81">
              <p id="para81">
               • Requires no holding time for treatment
              </p>
             </list-item>
             <list-item id="celistitem82">
              <p id="para82">
               • Large choice of commercial products
              </p>
             </list-item>
             <list-item id="celistitem83">
              <p id="para83">
               • Adds no unpleasant taste and often improves taste and appearance of water
              </p>
             </list-item>
             <list-item id="celistitem84">
              <p id="para84">
               • Rationally combined with halogens for removal or destruction of all pathogenic waterborne microbes
              </p>
             </list-item>
            </list>
           </td>
           <td align="left">
            <list id="celist30" list-type="simple">
             <list-item id="celistitem85">
              <p id="para85">
               • Adds bulk and weight to baggage
              </p>
             </list-item>
             <list-item id="celistitem86">
              <p id="para86">
               • Many are not reliable for removal of viruses
              </p>
             </list-item>
             <list-item id="celistitem87">
              <p id="para87">
               • Channeling of water or high pressure can force microorganisms through the filter
              </p>
             </list-item>
             <list-item id="celistitem88">
              <p id="para88">
               • Relatively expensive, compared to chemical treatment
              </p>
             </list-item>
             <list-item id="celistitem89">
              <p id="para89">
               • Eventually clogs from suspended particulate matter and may require some maintenance or repair in the field
              </p>
             </list-item>
            </list>
           </td>
          </tr>
          <tr>
           <td align="left">
            Halogens
           </td>
           <td align="left">
            <list id="celist31" list-type="simple">
             <list-item id="celistitem90">
              <p id="para90">
               • Inexpensive and widely available in liquid or tablet forms
              </p>
             </list-item>
             <list-item id="celistitem91">
              <p id="para91">
               • Taste can be removed by several techniques
              </p>
             </list-item>
             <list-item id="celistitem92">
              <p id="para92">
               • Flexible dosing
              </p>
             </list-item>
             <list-item id="celistitem93">
              <p id="para93">
               • Equally easy to treat large and small volumes
              </p>
             </list-item>
            </list>
           </td>
           <td align="left">
            <list id="celist32" list-type="simple">
             <list-item id="celistitem94">
              <p id="para94">
               • Corrosive and stains clothing
              </p>
             </list-item>
             <list-item id="celistitem95">
              <p id="para95">
               • Imparts taste and odor to water
              </p>
             </list-item>
             <list-item id="celistitem96">
              <p id="para96">
               • Flexibility requires understanding of principles
              </p>
             </list-item>
             <list-item id="celistitem97">
              <p id="para97">
               • Iodine is physiologically active, with potential adverse effects
              </p>
             </list-item>
             <list-item id="celistitem98">
              <p id="para98">
               • Not readily effective against
               <italic>
                Cryptosporidium
               </italic>
               oocysts
              </p>
             </list-item>
             <list-item id="celistitem99">
              <p id="para99">
               • Efficacy decreases with low water temperature and decreasing water clarity
              </p>
             </list-item>
            </list>
           </td>
          </tr>
          <tr>
           <td align="left">
            Chlorine Dioxide
           </td>
           <td align="left">
            <list id="celist33" list-type="simple">
             <list-item id="celistitem100">
              <p id="para100">
               • Low doses have no taste or color
              </p>
             </list-item>
             <list-item id="celistitem101">
              <p id="para101">
               • Simple to use and available in liquid or tablet form
              </p>
             </list-item>
             <list-item id="celistitem102">
              <p id="para102">
               • More potent than equivalent doses of chlorine
              </p>
             </list-item>
             <list-item id="celistitem103">
              <p id="para103">
               • Effective against all waterborne pathogens
              </p>
             </list-item>
            </list>
           </td>
           <td align="left">
            <list id="celist34" list-type="simple">
             <list-item id="celistitem104">
              <p id="para104">
               • Volatile and sensitive to sunlight: do not expose tablets to air and use generated solutions rapidly
              </p>
             </list-item>
             <list-item id="celistitem105">
              <p id="para105">
               • No persistent residual, so does not prevent recontamination during storage
              </p>
             </list-item>
            </list>
           </td>
          </tr>
          <tr>
           <td align="left">
            Ultraviolet
           </td>
           <td align="left">
            <list id="celist35" list-type="simple">
             <list-item id="celistitem106">
              <p id="para106">
               • Imparts no taste
              </p>
             </list-item>
             <list-item id="celistitem107">
              <p id="para107">
               • Portable devices now available
              </p>
             </list-item>
             <list-item id="celistitem108">
              <p id="para108">
               • Effective against all waterborne pathogens
              </p>
             </list-item>
            </list>
           </td>
           <td align="left">
            <list id="celist36" list-type="simple">
             <list-item id="celistitem109">
              <p id="para109">
               • Requires clear water
              </p>
             </list-item>
             <list-item id="celistitem110">
              <p id="para110">
               • Does not improve taste or appearance of water
              </p>
             </list-item>
             <list-item id="celistitem111">
              <p id="para111">
               • Relatively expensive
              </p>
             </list-item>
             <list-item id="celistitem112">
              <p id="para112">
               • Requires batteries or power source
              </p>
             </list-item>
             <list-item id="celistitem113">
              <p id="para113">
               • Difficult to know if devices are delivering required UV doses
              </p>
             </list-item>
            </list>
           </td>
          </tr>
         </tbody>
        </table>
       </table-wrap>
      </p>
     </sec>
     <sec id="cesec383">
      <title>
       Field Techniques for Water Treatment
      </title>
      <sec id="cesec384">
       <title>
        Heat
       </title>
       <p id="para1756">
        Common intestinal pathogens are readily inactivated by heat. Microorganisms are killed in a shorter time at higher temperatures, whereas temperatures as low as 140° F (60° C) are effective with a longer contact time. Pasteurization uses this principle to kill food-borne enteric pathogens and spoiling organisms at temperatures between 140° F (60° C) and 158° F (70° C), well below the boiling point of water (212° F; 100° C).
       </p>
       <p id="para1757">
        Although attaining boiling temperature is not necessary for inactivation of common intestinal pathogens, it is the only easily recognizable endpoint without using a thermometer. Microorganisms begin to die as water is heated on a stove or fire from 150° F (65° C) to boiling. All organisms except bacterial spores, which are not usually waterborne enteric pathogens, are killed within seconds at boiling temperature. Therefore, any water brought to a boil should be adequately disinfected. CDC and the Environmental Protection Agency recommend boiling for 1 minute to allow for a margin of safety and so users are clear that the water is truly boiling. Because the boiling point decreases with increasing altitude, CDC advises boiling water for 3 minutes at altitudes greater than 6,562 feet (&gt;2000 m).
       </p>
       <p id="para1758">
        If no other means of water treatment is available, a potential alternative to boiling is to use tap water that is too hot to touch, which is probably at a temperature between 131° F (55° C) and 140° F (60° C). This temperature may be adequate to kill pathogens if the water has been kept hot in the tank for some time. However, because one cannot know for certain that this temperature has been maintained for long enough to kill all waterborne pathogens, boiling is still advisable if possible. Travelers with access to electricity can bring a small electric heating coil or a lightweight beverage warmer to boil water.
       </p>
      </sec>
      <sec id="cesec385">
       <title>
        Filtration
       </title>
       <p id="para1759">
        Filter pore size is the primary determinant of a filter's effectiveness, but microorganisms also adhere to filter media by electrochemical reactions. Microfilters with “absolute” pore sizes of 0.1–0.4 mm are usually effective for removal of cysts and bacteria but may not adequately remove viruses, which are a major concern in water with high levels of fecal contamination (
        <xref ref-type="table" rid="cetable28">
         Table 2-29
        </xref>
        ). Environmental Protection Agency (EPA) designation of water “purifier” indicates that company-sponsored testing has substantiated claims for removing 10
        <sup>
         4
        </sup>
        (9,999 of 10,000) viruses although EPA does not independently test the validity of these claims.
        <table-wrap id="cetable28" position="float">
         <label>
          Table 2-29
         </label>
         <caption>
          <p>
           Microorganism size and susceptibility to filtration
          </p>
         </caption>
         <table frame="hsides" rules="groups">
          <thead>
           <tr>
            <th align="left">
             Organism
            </th>
            <th align="left">
             Average Size (μm)
            </th>
            <th align="left">
             Maximum recommended filter rating (μm Absolute)
             <xref ref-type="table-fn" rid="cetablefn77">
              1
             </xref>
            </th>
           </tr>
          </thead>
          <tbody>
           <tr>
            <td align="left">
             Viruses
            </td>
            <td align="left">
             0.03
            </td>
            <td align="left">
             Not specified
            </td>
           </tr>
           <tr>
            <td align="left">
             Enteric bacteria (
             <italic>
              E. coli
             </italic>
             )
            </td>
            <td align="left">
             0.5 × 3.0–8.0
            </td>
            <td align="left">
             0.2–0.4
            </td>
           </tr>
           <tr>
            <td align="left">
             <italic>
              Cryptosporidium
             </italic>
             oocyst
            </td>
            <td align="left">
             4–6
            </td>
            <td align="left">
             1
            </td>
           </tr>
           <tr>
            <td align="left">
             <italic>
              Giardia
             </italic>
             cyst
            </td>
            <td align="left">
             6.0–10.0 × 8.0–15.0
            </td>
            <td align="left">
             3.0–5.0
            </td>
           </tr>
          </tbody>
         </table>
         <table-wrap-foot>
          <fn id="cetablefn77">
           <label>
            1
           </label>
           <p id="cenotep77">
            NSF 53 rating on a filter certifies for cyst/oocyst removal.
           </p>
          </fn>
         </table-wrap-foot>
        </table-wrap>
       </p>
       <p id="para1760">
        Reverse osmosis filtration can both remove microbiologic contamination and desalinate water. The high price and slow output of small hand-pump reverse-osmosis units currently prohibit use by land-based travelers; however, they are important survival aids for ocean voyagers.
       </p>
       <p id="para1761">
        If the water supply is suspected of being heavily contaminated with biologic wastes and additional assurance is needed, then a second step with chemical treatment of the water before filtration can kill viruses. Many filters contain a charcoal stage that will remove the taste of added chlorine or iodine.
       </p>
      </sec>
      <sec id="cesec386">
       <title>
        Chemical Disinfection
       </title>
       <p id="para1762">
        The most common chemical water disinfectants are chlorine and iodine (halogens). Worldwide, chemical disinfection with chlorine is the most commonly used method for improving and maintaining microbiologic quality of drinking water. Sodium hypochlorite, common household bleach, is the primary disinfectant promoted by CDC and the WHO Safe Water System for individual household use in the developing world.
       </p>
       <p id="para1763">
        Primary factors that determine the rate and proportion of microorganisms killed are the concentration of halogen (measured in mg/L or parts per million) and the length of time microorganisms are exposed to the halogen (contact time, measured in minutes). Given adequate concentrations and contact times, both chlorine and iodine have similar activity and are effective against many bacteria. Due to many uncontrolled factors in the field, extending the contact time adds a margin of safety. Cloudy water contains material that will use added disinfectant so it will require higher concentrations or contact times. However, some common waterborne parasites such as
        <italic>
         Cryptosporidium
        </italic>
        , are poorly inactivated by halogen disinfection, even at practical extended contact times. Therefore, chemical disinfection should be supplemented with adequate filtration to remove these disease-causing microorganisms from drinking water.
       </p>
       <p id="para1764">
        Both chlorine and iodine are available in liquid and tablet form (
        <xref ref-type="table" rid="cetable29">
         Table 2-30
        </xref>
        ). Iodine has physiologic activity (it is used by the thyroid), so WHO recommends limiting iodine water disinfection to a few weeks of emergency use. It is not recommended in persons with unstable thyroid disease, known iodine allergy, or pregnancy (because of the potential effect on the fetal thyroid).
        <table-wrap id="cetable29" position="float">
         <label>
          Table 2-30
         </label>
         <caption>
          <p>
           Iodine and chlorine formulations and doses
          </p>
         </caption>
         <table frame="hsides" rules="groups">
          <thead>
           <tr>
            <th align="left">
             Iodination Techniques added to 1 liter or quart of water
            </th>
            <th align="left">
             Yield 4 mg/L Contact (Wait) Time 45 min at 30° C 180 min at 5° C
             <xref ref-type="table-fn" rid="cetablefn78">
              1
             </xref>
            </th>
            <th align="left">
             Yield 8 mg/L Contact (Wait) Time 15 min at 30° C 60 min at 5° C
             <xref ref-type="table-fn" rid="cetablefn78">
              1
             </xref>
            </th>
           </tr>
          </thead>
          <tbody>
           <tr>
            <td align="left">
             Iodine tablets (tetraglycine hydroperiodide) (e.g., Potable Aqua, Globaline)
            </td>
            <td align="left">
             ½ tablet
            </td>
            <td align="left">
             1 tablet
            </td>
           </tr>
           <tr>
            <td align="left">
             2% iodine solution (tincture)
            </td>
            <td align="left">
             <list id="celist37" list-type="simple">
              <list-item id="celistitem114">
               <p id="para114">
                0.2 mL
               </p>
              </list-item>
              <list-item id="celistitem115">
               <p id="para115">
                5 gtts
                <xref ref-type="table-fn" rid="cetablefn79">
                 2
                </xref>
               </p>
              </list-item>
             </list>
            </td>
            <td align="left">
             <list id="celist38" list-type="simple">
              <list-item id="celistitem116">
               <p id="para116">
                0.4 mL
               </p>
              </list-item>
              <list-item id="celistitem117">
               <p id="para117">
                10 gtts
                <xref ref-type="table-fn" rid="cetablefn79">
                 2
                </xref>
               </p>
              </list-item>
             </list>
            </td>
           </tr>
           <tr>
            <td align="left">
             Saturated solution: iodine crystals in water (e.g., Polar Pure)
            </td>
            <td align="left">
             13.0 mL
            </td>
            <td align="left">
             26.0 mL
            </td>
           </tr>
           <tr>
            <td align="left">
             <bold>
              Chlorination techniques
             </bold>
            </td>
            <td align="left">
             <bold>
              Yield 5 mg/L
             </bold>
            </td>
            <td align="left">
             <bold>
              Yield 10 mg/L
             </bold>
            </td>
           </tr>
           <tr>
            <td align="left">
             Sodium hypochlorite
            </td>
            <td align="left">
             0.1 mL
            </td>
            <td align="left">
             0.2 mL
            </td>
           </tr>
           <tr>
            <td align="left">
             Household bleach 5%
            </td>
            <td align="left">
             2 drops
            </td>
            <td align="left">
             4 drops
            </td>
           </tr>
           <tr>
            <td align="left">
             Sodium dichloroisocyanurate (e.g., AquaClear)
            </td>
            <td>
            </td>
            <td align="left">
             1 tablet
            </td>
           </tr>
           <tr>
            <td align="left">
             Chlorine plus flocculating agent (e.g., Chlor-floc)
            </td>
            <td>
            </td>
            <td align="left">
             1 tablet
            </td>
           </tr>
          </tbody>
         </table>
         <table-wrap-foot>
          <fn id="cetablefn78">
           <label>
            1
           </label>
           <p id="cenotep78">
            Very cold water requires prolonged contact time with iodine or chlorine to kill
            <italic>
             Giardia
            </italic>
            cysts. These contact times have been extended from the usual recommendations in cold water to account for this and for the uncertainty of residual concentration.
           </p>
          </fn>
         </table-wrap-foot>
         <table-wrap-foot>
          <fn id="cetablefn79">
           <label>
            2
           </label>
           <p id="cenotep79">
            Drops per minute.
           </p>
          </fn>
         </table-wrap-foot>
        </table-wrap>
       </p>
       <p id="para1765">
        The taste of halogens in water can be improved by several means:
        <list id="celist368" list-type="simple">
         <list-item id="celistitem1324">
          <label>
           •
          </label>
          <p id="para1766">
           Reduce concentration and increase contact time.
          </p>
         </list-item>
         <list-item id="celistitem1325">
          <label>
           •
          </label>
          <p id="para1767">
           Use a filter that contains activated carbon after contact time.
          </p>
         </list-item>
         <list-item id="celistitem1326">
          <label>
           •
          </label>
          <p id="para1768">
           Add a tiny pinch of ascorbic acid (vitamin C, available in powder or crystal form and an ingredient in most flavored drink mixes) after the required contact time to remove the taste of halogens. (This works by converting iodine to iodide or chlorine to chloride, which have no taste or color.)
          </p>
         </list-item>
        </list>
       </p>
      </sec>
      <sec id="cesec387">
       <title>
        Iodine Resins
       </title>
       <p id="para1769">
        Iodine resins transfer iodine to microorganisms that come into contact with the resin, but leave little iodine dissolved in the water. The resins have been incorporated into many different filter designs available for field use. Most contain a 1-mm cyst filter, which should effectively remove protozoan cysts (it should say 1-mm or 1 micron “absolute”). Few models are sold in the United States because of inconsistent test results, but some models are still available for international use.
       </p>
      </sec>
      <sec id="cesec388">
       <title>
        Salt (Sodium Chloride) Electrolysis
       </title>
       <p id="para1770">
        Passing a current through a simple brine salt solution generates mixed oxidants, primarily chlorine, which can be used for disinfection of microbes. See the discussion on chlorine above. The process was recently designed in a pocket-sized instrument that uses salt, water and electrical current generated from camera batteries to produce a disinfectant solution that is added to water.
       </p>
      </sec>
      <sec id="cesec389">
       <title>
        Chlorine Dioxide
       </title>
       <p id="para1771">
        Chlorine dioxide (ClO
        <sub>
         2
        </sub>
        ) is capable of inactivating most water-borne pathogens, including
        <italic>
         Cryptosporidium
        </italic>
        oocysts, at practical doses and contact times. There are several new chemical methods for generating chlorine dioxide in the field for small-quantity water treatment.
       </p>
      </sec>
      <sec id="cesec390">
       <title>
        Ultraviolet (UV) Light
       </title>
       <p id="para1772">
        UV light can be used as a pathogen reduction method against microorganisms. The technology requires effective pre-filtering due to its dependence on low water turbidity (cloudiness), the correct power delivery, and correct contact times to achieve maximum pathogen reduction. UV might be an effective method in pathogen reduction in backcountry water. However, there is a lack of independent testing data available on specific systems.
       </p>
      </sec>
      <sec id="cesec391">
       <title>
        Solar Irradiation and Heating
       </title>
       <p id="para1773">
        UV irradiation by sunlight in the UVA range can substantially improve the microbiologic quality of water. Recent work has confirmed the efficacy and optimal procedures of the solar disinfection (SODIS) technique. Transparent bottles (e.g., clear plastic beverage bottles), preferably lying on a dark surface, are exposed to sunlight for a minimum of 4 hours. UV and thermal inactivation are synergistic for solar disinfection of drinking water. Use of a simple reflector or solar cooker can achieve temperatures of 149° F (65° C), which will pasteurize the water after 4 hours. In emergency situations such as refugee camps and disaster areas, where strong sunshine is available, solar disinfection of drinking water can improve water quality.
       </p>
      </sec>
      <sec id="cesec392">
       <title>
        Silver and Other Products
       </title>
       <p id="para1774">
        Silver ion has bactericidal effects in low doses and some attractive features, including absence of color, taste, and odor. The use of silver as a drinking water disinfectant is popular in Europe, but it is not approved for this purpose in the United States because silver concentration in water is strongly affected by adsorption onto the surface of the container and there has been limited testing on viruses and cysts.
       </p>
       <p id="para1775">
        Several other common products have known antibacterial effects in water and are marketed in commercial products for travelers, including hydrogen peroxide, citrus juice, and potassium permanganate. None have sufficient data to recommend them for water disinfection in the field.
       </p>
       <p id="para1776">
        Granular activated carbon (GAC) removes organic and inorganic chemicals (including chemical disinfectants) through adsorption onto carbon particles, thereby improving odor and taste. GAC may trap but does not kill microorganisms. GAC is a common component of field filters.
       </p>
       <p id="para1777">
        Coagulation–flocculation (CF) removes suspended particles that cause a cloudy appearance and bad taste and do not settle by gravity; this process removes many but not all microorganisms. Alum, or one of several other substances, is added to the water, stirred well, allowed to settle, then poured through a simple coffee filter or fine cloth to remove the sediment. CF is an ancient technique that is still used routinely in municipal water treatment in conjunction with other treatment methods, such as disinfection, filtration, UV radiation, and ozonation.
       </p>
      </sec>
      <sec id="cesec393">
       <title>
        The Preferred Technique
       </title>
       <p id="para1778">
        The optimal technique for an individual or group depends on personal preference, size of the group, water source, and the style of travel. Boiling is most effective but may not be practical in all situations. Unfortunately, alternative treatment may require a two-step process of 1) coagulation–flocculation and/or filtration and 2) halogenation. It is best to filter first and then add the halogen. On long-distance, oceangoing boats where water must be desalinated during the voyage, only reverse-osmosis membrane filters are adequate.
       </p>
       <p id="para1779">
        When the water will be stored for a period of time, such as on a boat, motor home, or a home with rainwater collection, halogens should be used to prevent the water from becoming recontaminated. A tightly sealed container is best to decrease risk of contamination. A minimum residual of 3–4 mg/L of hypochlorite should be maintained in the stored water. For short-term home storage, narrow-mouth jars or containers with water spigots prevent contamination from repeated contact with hands or utensils.
       </p>
      </sec>
     </sec>
     <ref-list id="cebib30">
      <title>
       References
      </title>
      <ref id="bib306">
       <label>
        1
       </label>
       <element-citation id="sbref276" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Backer
          </surname>
          <given-names>
           HD
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         Field water disinfection
        </chapter-title>
        <person-group person-group-type="editor">
         <name>
          <surname>
           Auerbach
          </surname>
          <given-names>
           PS
          </given-names>
         </name>
        </person-group>
        <source>
         Wilderness medicine
        </source>
        <edition>
         5th ed.
        </edition>
        <year>
         2007
        </year>
        <publisher-name>
         Mosby
        </publisher-name>
        <publisher-loc>
         Philadelphia
        </publisher-loc>
        <fpage>
         1368
        </fpage>
        <lpage>
         1417
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib307">
       <label>
        2
       </label>
       <element-citation id="sbref277" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Backer
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Hollowell
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        <article-title>
         Use of iodine for water disinfection: iodine toxicity and maximum recommended dose
        </article-title>
        <source>
         Environ Health Perspect
        </source>
        <volume>
         108
        </volume>
        <issue>
         8
        </issue>
        <year>
         2000
        </year>
        <fpage>
         679
        </fpage>
        <lpage>
         684
        </lpage>
        <pub-id pub-id-type="pmid">
         10964787
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib308">
       <label>
        3
       </label>
       <element-citation id="sbref278" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Groh
          </surname>
          <given-names>
           CD
          </given-names>
         </name>
         <name>
          <surname>
           MacPherson
          </surname>
          <given-names>
           DW
          </given-names>
         </name>
         <name>
          <surname>
           Groves
          </surname>
          <given-names>
           DJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         Effect of heat on the sterilization of artificially contaminated water
        </article-title>
        <source>
         J Travel Med
        </source>
        <volume>
         3
        </volume>
        <issue>
         1
        </issue>
        <year>
         1996
        </year>
        <fpage>
         11
        </fpage>
        <lpage>
         13
        </lpage>
        <pub-id pub-id-type="pmid">
         9815415
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib309">
       <label>
        4
       </label>
       <element-citation id="sbref279" publication-type="journal">
        <comment>
        </comment>
        <person-group person-group-type="author">
         <name>
          <surname>
           Joyce
          </surname>
          <given-names>
           TM
          </given-names>
         </name>
         <name>
          <surname>
           McGuigan
          </surname>
          <given-names>
           KG
          </given-names>
         </name>
         <name>
          <surname>
           Elmore-Meegan
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <article-title>
         Inactivation of fecal bacteria in drinking water by solar heating
        </article-title>
        <source>
         Appl Environ Microbiol
        </source>
        <volume>
         62
        </volume>
        <issue>
         2
        </issue>
        <year>
         1996
        </year>
        <fpage>
         399
        </fpage>
        <lpage>
         402
        </lpage>
        <pub-id pub-id-type="pmid">
         8593045
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib310">
       <label>
        5
       </label>
       <element-citation id="sbref280" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Korich
          </surname>
          <given-names>
           DG
          </given-names>
         </name>
         <name>
          <surname>
           Mead
          </surname>
          <given-names>
           JR
          </given-names>
         </name>
         <name>
          <surname>
           Madore
          </surname>
          <given-names>
           MS
          </given-names>
         </name>
        </person-group>
        <article-title>
         Effects of ozone, chlorine dioxide, chlorine, and monochloramine on
         <italic>
          Cryptosporidium parvum
         </italic>
         oocyst viability
        </article-title>
        <source>
         Appl Environ Microbiol
        </source>
        <volume>
         56
        </volume>
        <issue>
         5
        </issue>
        <year>
         1990
        </year>
        <fpage>
         1423
        </fpage>
        <lpage>
         1428
        </lpage>
        <pub-id pub-id-type="pmid">
         2339894
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib311">
       <label>
        6
       </label>
       <element-citation id="sbref281" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           McGuigan
          </surname>
          <given-names>
           KG
          </given-names>
         </name>
         <name>
          <surname>
           Joyce
          </surname>
          <given-names>
           TM
          </given-names>
         </name>
         <name>
          <surname>
           Conroy
          </surname>
          <given-names>
           RM
          </given-names>
         </name>
        </person-group>
        <article-title>
         Solar disinfection of drinking water contained in transparent plastic bottles: characterizing the bacterial inactivation process
        </article-title>
        <source>
         J Appl Microbiol
        </source>
        <volume>
         84
        </volume>
        <issue>
         6
        </issue>
        <year>
         1998
        </year>
        <fpage>
         1138
        </fpage>
        <lpage>
         1148
        </lpage>
        <pub-id pub-id-type="pmid">
         9717300
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib312">
       <label>
        7
       </label>
       <element-citation id="sbref282" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Marchin
          </surname>
          <given-names>
           GL
          </given-names>
         </name>
         <name>
          <surname>
           Fina
          </surname>
          <given-names>
           LR
          </given-names>
         </name>
        </person-group>
        <article-title>
         Contact and demand-release disinfectants
        </article-title>
        <source>
         Crit Rev Environ Contr
        </source>
        <volume>
         19
        </volume>
        <issue>
         4
        </issue>
        <year>
         1989
        </year>
        <fpage>
         227
        </fpage>
        <lpage>
         290
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib313">
       <label>
        8
       </label>
       <mixed-citation id="ceotherref31" publication-type="other">
        Sobsey MD. Managing water in the home: accelerated health gains from improved water supply. Geneva: World Health Organization, 2002. [cited 6 Feb 2007]. Available from:
        <ext-link ext-link-type="uri" id="interref81" xlink:href="http://www.who.int/water_sanitation_health/dwq/wsh0207/en/index.html">
         http://www.who.int/water_sanitation_health/dwq/wsh0207/en/index.html
        </ext-link>
        .
       </mixed-citation>
      </ref>
      <ref id="bib314">
       <label>
        9
       </label>
       <mixed-citation id="ceotherref32" publication-type="other">
        World Health Organization and United Nations Children's Fund. The global water supply and sanitation assessment 2000 report. 2000. [cited 6 Feb 2007]. Available from:
        <ext-link ext-link-type="uri" id="interref82" xlink:href="http://www.who.int/water_sanitation_health/monitoring/globalassess/en/">
         http://www.who.int/water_sanitation_health/monitoring/globalassess/en/
        </ext-link>
        .
       </mixed-citation>
      </ref>
     </ref-list>
    </sec>
    <sec id="subchapter31">
     <sec-meta>
      <contrib-group>
       <contrib contrib-type="author" id="au55">
        <name>
         <surname>
          Ansdell
         </surname>
         <given-names>
          Vernon E.
         </given-names>
        </name>
       </contrib>
      </contrib-group>
     </sec-meta>
     <title>
      SUNBURN
     </title>
     <sec id="cesec394">
      <title>
       Description
      </title>
      <p id="para1780">
       <list id="celist369" list-type="simple">
        <list-item id="celistitem1327">
         <label>
          •
         </label>
         <p id="para1781">
          Travelers to the tropics and subtropics are at increased risk of overexposure to the sun. Important consequences include sunburn, premature aging of the skin, wrinkling, and skin cancer, including melanoma.
         </p>
        </list-item>
        <list-item id="celistitem1328">
         <label>
          •
         </label>
         <p id="para1782">
          Sunlight consists of ultraviolet (UV) rays (i.e., UVA, UVB, and UVC).
          <list id="celist370" list-type="simple">
           <list-item id="celistitem1329">
            <label>
             ○
            </label>
            <p id="para1783">
             UVA rays are present throughout the day and are the most important cause of premature aging of the skin. In addition, UVA rays are responsible for photosensitivity reactions and also contribute to skin cancer.
            </p>
           </list-item>
           <list-item id="celistitem1330">
            <label>
             ○
            </label>
            <p id="para1784">
             UVB rays are intense from 10 am to 4 pm and are most responsible for sunburn and skin cancer development.
            </p>
           </list-item>
           <list-item id="celistitem1331">
            <label>
             ○
            </label>
            <p id="para1785">
             UVC rays are filtered by the ozone layer and do not reach the earth's surface.
            </p>
           </list-item>
          </list>
         </p>
        </list-item>
        <list-item id="celistitem1332">
         <label>
          •
         </label>
         <p id="para1786">
          The benefits of UV radiation include vitamin D protection, which is important for calcium absorption.
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <sec id="cesec395">
      <title>
       Occurrence and Risk For Travelers
      </title>
      <p id="para1787">
       Increased exposure to UV radiation occurs nearer the equator, during summer months, at higher elevation and between 10 am and 4 pm. Reflection from the snow, sand, and water increases exposure, a particularly important consideration for beach activities, skiing, swimming, and sailing.
      </p>
      <sec id="cesec396">
       <title>
        Commonly Used Medications that May Cause Photosensitivity Reactions
       </title>
       <sec id="cesec397">
        <title>
         Antimicrobials
        </title>
        <p id="para1788">
         Fluoroquinolones, sulfonamides, and tetracyclines (especially demeclocycline); less frequently, doxycycline, oxytetracycline, and tetracycline; rarely, minocycline.
        </p>
       </sec>
       <sec id="cesec398">
        <title>
         Antimalarials
        </title>
        <p id="para1789">
         Doxycycline.
        </p>
       </sec>
       <sec id="cesec399">
        <title>
         Others
        </title>
        <p id="para1790">
         Nonsteroidal anti-inflammatory drugs, thiazide diuretics, furosemide, amiodarone, sulfonylureas, acetazolamide (Diamox), phenothiazines.
        </p>
       </sec>
      </sec>
     </sec>
     <sec id="cesec400">
      <title>
       Clinical Presentation
      </title>
      <p id="para1791">
       <list id="celist371" list-type="simple">
        <list-item id="celistitem1333">
         <label>
          •
         </label>
         <p id="para1792">
          Symptoms from sunburn appear 3–5 hours after overexposure, worsen over the next 24–36 hours, and resolve in 3–5 days.
         </p>
        </list-item>
        <list-item id="celistitem1334">
         <label>
          •
         </label>
         <p id="para1793">
          Serious burns are painful, and the skin may be tender, swollen and blistered. There may be fever, headache, itching, and malaise. Skin peeling occurs 3–8 days after excessive sun exposure.
         </p>
        </list-item>
        <list-item id="celistitem1335">
         <label>
          •
         </label>
         <p id="para1794">
          Overexposure to the sun over several years leads to premature aging of the skin, wrinkling, age spots, and an increased risk for skin cancer, including melanoma.
         </p>
        </list-item>
        <list-item id="celistitem1336">
         <label>
          •
         </label>
         <p id="para1795">
          Overexposure to the sun can cause red, dry painful eyes. Repeated exposure to sunlight results in pterygium formation and important causes of blindness such as cataracts and macular degeneration.
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <sec id="cesec401">
      <title>
       Preventive Measures for Travelers
      </title>
      <sec id="cesec402">
       <title>
        Sun Protection Factor (SPF)
       </title>
       <p id="para1796">
        SPF defines the extra protection against UVB rays that an individual will get by using a sunscreen. For example, if a person using SPF 15 sunscreen normally acquires a sunburn within 20 minutes without protection, the benefit will be 20 × 15 minutes extra protection with sunscreen (i.e., 300 minutes = 5 hours). SPF does not refer to protection against UVA rays. Products containing Mexoryl, Parsol 1789, titanium dioxide, zinc oxide, or avobenzone block UVA rays.
       </p>
      </sec>
      <sec id="cesec403">
       <title>
        UV Index
       </title>
       <p id="para1797">
        The UV index provides travelers with an indication of the risk of UV radiation. Information is often available on the Internet or in local newspapers. The UV index ranges from 1 (low) to 11 or higher (extremely high).
       </p>
      </sec>
      <sec id="cesec404">
       <title>
        Sun Avoidance
       </title>
       <p id="para1798">
        Staying indoors or seeking shade between 10 am and 4 pm is very important in limiting exposure to UV rays, particularly UVB rays. Be aware that sunburn and sun damage can occur even on cloudy days.
       </p>
      </sec>
      <sec id="cesec405">
       <title>
        Protective Clothing
       </title>
       <p id="para1799">
        <list id="celist372" list-type="simple">
         <list-item id="celistitem1337">
          <label>
           •
          </label>
          <p id="para1800">
           Wide-brimmed hats and long sleeves and pants provide important protection against UV rays.
          </p>
         </list-item>
         <list-item id="celistitem1338">
          <label>
           •
          </label>
          <p id="para1801">
           Tightly woven clothing and darker fabrics provide additional protection.
          </p>
         </list-item>
         <list-item id="celistitem1339">
          <label>
           •
          </label>
          <p id="para1802">
           High SPF sun-protective clothing is recommended for those at increased risk of sunburn or with a history of skin cancer. This type of clothing contains colorless compounds, fluorescent brighteners, or specifically treated resins that absorb UV rays and often provides an SPF of 30 or higher.
          </p>
         </list-item>
         <list-item id="celistitem1340">
          <label>
           •
          </label>
          <p id="para1803">
           Sunglasses that provide 100% protection against UV radiation are strongly recommended.
          </p>
         </list-item>
        </list>
       </p>
      </sec>
      <sec id="cesec406">
       <title>
        Sunscreens
       </title>
       <p id="para1804">
        Sunscreens protect the skin by absorbing or reflecting UV radiation.
       </p>
       <p id="para1805">
        <bold>
         <italic>
          Physical Sunscreens
         </italic>
        </bold>
        contain large particulate substances such as titanium dioxide and zinc oxide, which act to reflect and scatter both visible and UV light. They are effective sunscreens but are less popular because of aesthetically unappealing characteristics such as opaqueness and tendency to stain clothing. They are recommended for those who burn easily or who take medications that may cause photosensitivity reactions.
       </p>
       <p id="para1806">
        <bold>
         <italic>
          Chemical Sunscreens
         </italic>
        </bold>
        absorb rather than reflect UV radiation. A combination of agents is recommended to provide broad-spectrum protection against UVA and UVB rays.
       </p>
       <sec id="cesec407">
        <title>
         Key Points Regarding Sunscreens
        </title>
        <p id="para1807">
         <list id="celist373" list-type="simple">
          <list-item id="celistitem1341">
           <label>
            •
           </label>
           <p id="para1808">
            Choose a sunscreen with at least 15 SPF.
           </p>
          </list-item>
          <list-item id="celistitem1342">
           <label>
            •
           </label>
           <p id="para1809">
            Select a water- and sweat-resistant product that provides protection against both UVA and UVB rays.
           </p>
          </list-item>
          <list-item id="celistitem1343">
           <label>
            •
           </label>
           <p id="para1810">
            Look for a sunscreen with at least three different active ingredients to provide broad-spectrum UVA and UVB ray protection. These ingredients generally include PABA derivatives, salicylates (homosalate, octyl salicylate), or cinnamates (octyll methoxycinnamate and cinoxate) for UVB ray absorption; benzophenones (oxybenzone, dioxybenzone, sulisobenzone) for shorter-wavelength UVA ray protection; and avobenzone (Parsol1789), ecamsule (Mexoryl), titanium dioxide, or zinc oxide for the remaining UVA spectrum.
           </p>
          </list-item>
          <list-item id="celistitem1344">
           <label>
            •
           </label>
           <p id="para1811">
            Apply 30 minutes before exposure to the sun.
           </p>
          </list-item>
          <list-item id="celistitem1345">
           <label>
            •
           </label>
           <p id="para1812">
            At least 1 oz of sunscreen is needed for total body application (i.e., quarter of a 4-oz bottle).
           </p>
          </list-item>
          <list-item id="celistitem1346">
           <label>
            •
           </label>
           <p id="para1813">
            Apply to all exposed areas, especially the ears, scalp, lips, back of the neck, tops of the feet, and backs of the hands.
           </p>
          </list-item>
          <list-item id="celistitem1347">
           <label>
            •
           </label>
           <p id="para1814">
            Reapply after 1–2 hours and after sweating, swimming, or toweling (even on cloudy days).
           </p>
          </list-item>
          <list-item id="celistitem1348">
           <label>
            •
           </label>
           <p id="para1815">
            Many sunscreens lose potency after 1–2 years.
           </p>
          </list-item>
          <list-item id="celistitem1349">
           <label>
            •
           </label>
           <p id="para1816">
            Sunscreens should be applied to the skin before insect repellents.
           </p>
          </list-item>
          <list-item id="celistitem1350">
           <label>
            •
           </label>
           <p id="para1817">
            Avoid products that contain sunscreens and insect repellents. (DEET-containing insect repellents may decrease the effectiveness of sunscreens and may increase absorption of DEET through the skin.)
           </p>
          </list-item>
         </list>
        </p>
       </sec>
      </sec>
     </sec>
     <sec id="cesec408">
      <title>
       Treatment
      </title>
      <p id="para1818">
       <list id="celist374" list-type="simple">
        <list-item id="celistitem1351">
         <label>
          •
         </label>
         <p id="para1819">
          Hydration and staying in a cool, shaded, or indoor environment
         </p>
        </list-item>
        <list-item id="celistitem1352">
         <label>
          •
         </label>
         <p id="para1820">
          Topical and oral nonsteroidal anti-inflammatory drugs decrease erythema if used before or soon after exposure to UVB rays and may relieve symptoms such as headache, fever, and local pain. Topical steroids are of limited benefit, and systemic steroids appear to be ineffective.
         </p>
        </list-item>
        <list-item id="celistitem1353">
         <label>
          •
         </label>
         <p id="para1821">
          Moisturizing creams, aloe vera, and diphenhydramine may help to relieve symptoms.
         </p>
        </list-item>
        <list-item id="celistitem1354">
         <label>
          •
         </label>
         <p id="para1822">
          In severe cases, narcotic analgesics may be indicated to relieve pain.
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <ref-list id="cebib31">
      <title>
       References
      </title>
      <ref id="bib315">
       <label>
        1
       </label>
       <element-citation id="sbref283" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kaplan
          </surname>
          <given-names>
           LA
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         Exposure to radiation from the sun
        </chapter-title>
        <person-group person-group-type="editor">
         <name>
          <surname>
           Auerbach
          </surname>
          <given-names>
           PS
          </given-names>
         </name>
        </person-group>
        <source>
         Wilderness medicine
        </source>
        <edition>
         5th ed.
        </edition>
        <year>
         2007
        </year>
        <publisher-name>
         Mosby
        </publisher-name>
        <publisher-loc>
         Philadelphia
        </publisher-loc>
        <fpage>
         351
        </fpage>
        <lpage>
         371
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib316">
       <label>
        2
       </label>
       <element-citation id="sbref284" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           McClean
          </surname>
          <given-names>
           DI
          </given-names>
         </name>
         <name>
          <surname>
           Gallagher
          </surname>
          <given-names>
           R
          </given-names>
         </name>
        </person-group>
        <article-title>
         Sunscreens. Use and misuse
        </article-title>
        <source>
         Dermatol Clin
        </source>
        <volume>
         16
        </volume>
        <issue>
         2
        </issue>
        <year>
         1998
        </year>
        <fpage>
         219
        </fpage>
        <lpage>
         226
        </lpage>
        <pub-id pub-id-type="pmid">
         9589195
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib317">
       <label>
        3
       </label>
       <element-citation id="sbref285" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Diffey
          </surname>
          <given-names>
           BL
          </given-names>
         </name>
         <name>
          <surname>
           Grice
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        <article-title>
         The influence of sunscreen type on photoprotection
        </article-title>
        <source>
         Br J Dermatol
        </source>
        <volume>
         137
        </volume>
        <issue>
         1
        </issue>
        <year>
         1997
        </year>
        <fpage>
         103
        </fpage>
        <lpage>
         105
        </lpage>
        <pub-id pub-id-type="pmid">
         9274634
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib318">
       <label>
        4
       </label>
       <element-citation id="sbref286" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Murphy
          </surname>
          <given-names>
           ME
          </given-names>
         </name>
         <name>
          <surname>
           Montemarano
          </surname>
          <given-names>
           AD
          </given-names>
         </name>
         <name>
          <surname>
           Debboun
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <article-title>
         The effect of sunscreen on the efficacy of insect repellent: a chemical trial
        </article-title>
        <source>
         J Am Acad Dermatol
        </source>
        <volume>
         43
        </volume>
        <year>
         2000
        </year>
        <fpage>
         219
        </fpage>
        <lpage>
         222
        </lpage>
        <pub-id pub-id-type="pmid">
         10906641
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib319">
       <label>
        5
       </label>
       <element-citation id="sbref287" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gu
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Collins
          </surname>
          <given-names>
           DM
          </given-names>
         </name>
        </person-group>
        <article-title>
         In vitro evaluation of concurrent use of commercially available insect repellent and sunscreen preparations
        </article-title>
        <source>
         Br J Dermatol
        </source>
        <volume>
         152
        </volume>
        <issue>
         6
        </issue>
        <year>
         2005
        </year>
        <fpage>
         1263
        </fpage>
        <lpage>
         1267
        </lpage>
        <pub-id pub-id-type="pmid">
         15948991
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib320">
       <label>
        6
       </label>
       <element-citation id="sbref288" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Han
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Maibach
          </surname>
          <given-names>
           HI
          </given-names>
         </name>
        </person-group>
        <article-title>
         Management of acute sunburn
        </article-title>
        <source>
         Am J Clin Dermatol
        </source>
        <volume>
         5
        </volume>
        <issue>
         1
        </issue>
        <year>
         2004
        </year>
        <fpage>
         39
        </fpage>
        <lpage>
         47
        </lpage>
        <pub-id pub-id-type="pmid">
         14979742
        </pub-id>
       </element-citation>
      </ref>
     </ref-list>
    </sec>
    <sec id="subchapter32">
     <sec-meta>
      <contrib-group>
       <contrib contrib-type="author" id="au56">
        <name>
         <surname>
          Backer
         </surname>
         <given-names>
          Howard D.
         </given-names>
        </name>
       </contrib>
       <contrib contrib-type="author" id="au57">
        <name>
         <surname>
          Shlim
         </surname>
         <given-names>
          David R.
         </given-names>
        </name>
       </contrib>
      </contrib-group>
     </sec-meta>
     <title>
      PROBLEMS WITH HEAT AND COLD
     </title>
     <sec id="cesec409">
      <title>
       Background
      </title>
      <p id="para1823">
       Foreign travel involves heading into new environments, and climate is one of the most important factors to consider. Travelers may encounter temperature and weather extremes that are either much hotter or colder than they are used to, and either extreme can have health consequences.
      </p>
      <p id="para1824">
       Travelers should try to determine the likely climate extremes that they will face during their journey and to prepare with proper clothing, knowledge, and equipment. This section gives a brief overview of the topic.
      </p>
     </sec>
     <sec id="cesec410">
      <title>
       Problems Associated with a Hot Climate
      </title>
      <sec id="cesec411">
       <title>
        Risk for Travelers
       </title>
       <p id="para1825">
        Many of the most popular travel destinations are tropical or desert areas. Travelers who sit on the beach or by the pool and do only short walking tours incur minimal risk of heat illness. Those who do strenuous hiking or biking in the heat may have significant risk, especially travelers coming from cool or temperate climates who are not in good physical condition and unacclimatized to the heat.
       </p>
      </sec>
      <sec id="cesec412">
       <title>
        Clinical Presentations
       </title>
       <sec id="cesec413">
        <title>
         Physiology of Heat Injuries
        </title>
        <p id="para1826">
         Tolerance to heat depends primarily on physiologic factors, unlike cold environments where adaptive behaviors are more important. The major means of heat dissipation are radiation at rest and evaporation of sweat during exercise, both of which become minimal with air temperatures above 95° F (35° C) and high humidity.
        </p>
        <p id="para1827">
         The major organs involved in temperature regulation are the skin, where sweating and heat exchange take place, and the cardiovascular system, which must greatly increase blood flow to shunt heat from the core to the surface while meeting the metabolic demands of exercise. Cardiovascular status and conditioning are the major physiologic variables affecting the response to heat stress at all ages. Dehydration is the most important predisposing factor in heat illness; temperature and heart rate increase in direct proportion to the level of dehydration. Sweat is a hypotonic fluid containing sodium and chloride. Sweat rates commonly reach 1–2 L/hr, which may result in significant fluid and sodium loss.
        </p>
       </sec>
       <sec id="cesec414">
        <title>
         Minor Heat Disorders
        </title>
        <p id="para1828">
         <bold>
          Heat cramps
         </bold>
         are painful muscle contractions following exercise in heat. They begin an hour or more after stopping exercise, most often involving heavily used muscles in the calves, thighs, and abdomen. If rest and passive stretching of the muscle do not resolve cramps, an oral salt solution, as in rehydration solutions, will rapidly relieve symptoms.
        </p>
        <p id="para1829">
         <bold>
          Heat syncope
         </bold>
         is sudden fainting in heat that occurs in unacclimatized people while standing or after 15–20 minutes of exercise. Consciousness rapidly returns to normal when the patient is supine. Rest, relief from heat, and oral fluids are sufficient treatments.
        </p>
        <p id="para1830">
         <bold>
          Heat edema
         </bold>
         is mild swelling of the hands and feet, which is more frequent in women during the first few days of heat exposure. It resolves spontaneously and should not be treated with diuretics, which may delay acclimatization and cause dehydration.
        </p>
        <p id="para1831">
         <bold>
          Prickly heat
         </bold>
         (e.g., miliaria, heat rash) manifests as small, red, pruritic lesions on the skin caused by obstruction of the sweat ducts. It is best prevented by wearing light, loose clothing and avoiding heavy, continuous sweating.
        </p>
       </sec>
       <sec id="cesec415">
        <title>
         Major Heat Disorders
        </title>
        <sec id="cesec416">
         <title>
          Heat Exhaustion
         </title>
         <p id="para1832">
          <list id="celist375" list-type="simple">
           <list-item id="celistitem1355">
            <label>
             •
            </label>
            <p id="para1833">
             Most people who experience acute collapse or other symptoms associated with exercise in the heat are suffering from heat exhaustion, simply defined as the inability to continue exertion in the heat.
            </p>
           </list-item>
           <list-item id="celistitem1356">
            <label>
             •
            </label>
            <p id="para1834">
             The presumed cause of heat exhaustion is loss of fluid and electrolytes, but there are no objective markers to define the syndrome, which is a spectrum ranging from minor complaints to a vague boundary shared with heat stroke.
            </p>
           </list-item>
           <list-item id="celistitem1357">
            <label>
             •
            </label>
            <p id="para1835">
             Transient mental changes, such as irritability, confusion, or irrational behavior, may be present, but neurologic signs, such as seizures or coma, would indicate heat stroke or hyponatremia.
            </p>
           </list-item>
           <list-item id="celistitem1358">
            <label>
             •
            </label>
            <p id="para1836">
             Body temperature may be normal or elevated.
            </p>
           </list-item>
           <list-item id="celistitem1359">
            <label>
             •
            </label>
            <p id="para1837">
             Most cases can be treated with supine rest in a cool place and oral water or fluids containing glucose and salt. Spontaneous cooling occurs, and patients recover within hours, preventing progression to more serious illness. An oral solution for treating minor heat disorders or for fluid and electrolyte replacement can be made by adding ¼ teaspoon or two l-gm salt tablets to l liter of water, plus 4–8 tsp of sugar if desired for taste.
            </p>
           </list-item>
           <list-item id="celistitem1360">
            <label>
             •
            </label>
            <p id="para1838">
             Subacute heat exhaustion may develop over several days and is often misdiagnosed as “summer flu” because of findings of weakness, fatigue, headache, dizziness, anorexia, nausea, vomiting, and diarrhea. Treatment is as described for acute heat exhaustion.
            </p>
           </list-item>
          </list>
         </p>
        </sec>
        <sec id="cesec417">
         <title>
          Exercise-Induced Hyponatremia
         </title>
         <p id="para1839">
          <list id="celist376" list-type="simple">
           <list-item id="celistitem1361">
            <label>
             •
            </label>
            <p id="para1840">
             Some travelers are so concerned about preventing heat illness and dehydration that they adopt the attitude that “you can't drink too much.” Sadly, this attitude can lead to tragic outcomes.
            </p>
           </list-item>
           <list-item id="celistitem1362">
            <label>
             •
            </label>
            <p id="para1841">
             Hyponatremia due to excessive water intake occurs in both endurance athletes and recreational hikers, particularly if the person is replacing sodium loss through sweating with plain water.
            </p>
           </list-item>
           <list-item id="celistitem1363">
            <label>
             •
            </label>
            <p id="para1842">
             In the field setting, altered mental status with normal body temperature and a history of large volumes of water intake are highly suggestive of hyponatremia. The vague and nonspecific symptoms are the same as those described for hyponatremia in other settings (e.g., anorexia, nausea, emesis, headache, muscle weakness, lethargy, confusion, and seizures).
            </p>
           </list-item>
           <list-item id="celistitem1364">
            <label>
             •
            </label>
            <p id="para1843">
             Until clinically apparent alterations in mental status appear, heat exhaustion is difficult to distinguish from early hyponatremia.
            </p>
           </list-item>
           <list-item id="celistitem1365">
            <label>
             •
            </label>
            <p id="para1844">
             A delay before onset of major symptoms or deterioration after cessation of exercise and heat exposure are unique aspects of hyponatremia.
            </p>
           </list-item>
           <list-item id="celistitem1366">
            <label>
             •
            </label>
            <p id="para1845">
             Prevention includes sodium supplementation with prolonged exercise or heat exposure. For hikers and wilderness users, food is the most efficient vehicle for salt replacement. Trail snacks should include salty foods (e.g., trail mix, crackers, pretzels, jerky), and not just sweets.
            </p>
           </list-item>
          </list>
         </p>
        </sec>
        <sec id="cesec418">
         <title>
          Heat Stroke
         </title>
         <p id="para1846">
          <list id="celist377" list-type="simple">
           <list-item id="celistitem1367">
            <label>
             •
            </label>
            <p id="para1847">
             Heat stroke is an extreme medical emergency requiring aggressive cooling measures and hospitalization for support.
            </p>
           </list-item>
           <list-item id="celistitem1368">
            <label>
             •
            </label>
            <p id="para1848">
             Heat stroke is the only form of heat illness in which the mechanisms for thermal homeostasis have failed. As a result of uncontrolled fever and circulatory collapse, organ damage can occur in the brain, liver, kidneys, and heart.
            </p>
           </list-item>
           <list-item id="celistitem1369">
            <label>
             •
            </label>
            <p id="para1849">
             The onset of heat stroke may be acute (exertional heat stroke) or gradual (nonexertional heat stroke, also referred to as classic or epidemic).
            </p>
           </list-item>
           <list-item id="celistitem1370">
            <label>
             •
            </label>
            <p id="para1850">
             A presumptive diagnosis of heatstroke is made when patients have hyperpyrexia and marked alteration of mental status.
            </p>
           </list-item>
           <list-item id="celistitem1371">
            <label>
             •
            </label>
            <p id="para1851">
             Body temperatures in excess of 106° F (41° C) can be observed; even without a thermometer, these patients will feel hot to touch. If a thermometer is available, a rectal temperature is the safest and most reliable way to check the temperature in someone who may have heatstroke.
            </p>
           </list-item>
           <list-item id="celistitem1372">
            <label>
             •
            </label>
            <p id="para1852">
             In the field, institute evaporative cooling by maximizing skin exposure, spraying tepid water on the skin, and maintaining air movement over the body by fans. If ice is available, apply cold packs to the neck, axillas, and groin and massage the skin with ice. Immersion in a nearby pool or natural body of water can initiate cooling.
            </p>
           </list-item>
           <list-item id="celistitem1373">
            <label>
             •
            </label>
            <p id="para1853">
             Unless the recovery is very rapid, the person should be evacuated to a hospital. If that is not possible, encourage rehydration, if the person is able to take oral fluids, and monitor closely for several hours.
            </p>
           </list-item>
          </list>
         </p>
        </sec>
       </sec>
      </sec>
      <sec id="cesec419">
       <title>
        Prevention of Heat Disorders
       </title>
       <sec id="cesec420">
        <title>
         Heat Acclimatization
        </title>
        <p id="para1854">
         Heat acclimatization is a process of physiologic adaptation to a hot environment that occurs in both residents and visitors. The result of acclimatization is an increase in sweating, and decreased energy expenditure with lower rise in body temperature for a given workload. Only partial adaptation occurs by passive exposure to heat. Full acclimatization, especially cardiovascular response, requires 1–2 hours of exercise in the heat each day. Most acclimatization changes occur within 10 days, provided a suitable amount of exercise is taken each day in the heat. After this time, only increased physical fitness will result in further exercise tolerance. Decay of acclimatization occurs within days to weeks if there is no heat exposure.
        </p>
       </sec>
       <sec id="cesec421">
        <title>
         Physical Conditioning and Acclimatization
        </title>
        <p id="para1855">
         Higher levels of physical fitness improve exercise tolerance and capacity in heat, but not as much as acclimatization. If possible, travelers should acclimatize before leaving by exercising at least 1 hour daily in the heat. If this is not possible before departing, exercise in heat during the first week of travel should be limited in intensity and duration (30- to 90-minute periods) with rest in between. It is a good idea to conform to the local practice in most hot regions and avoid strenuous activity during the hottest part of the day.
        </p>
       </sec>
       <sec id="cesec422">
        <title>
         Clothing
        </title>
        <p id="para1856">
         Clothing should be lightweight, loose, and light-colored to allow maximum air circulation for evaporation yet give protection from the sun. A wide-brimmed hat markedly reduces radiant heat exposure.
        </p>
       </sec>
       <sec id="cesec423">
        <title>
         Fluid and Electrolyte Replacement
        </title>
        <p id="para1857">
         During exertion, fluid intake improves performance and decreases the likelihood of illness. Reliance on thirst alone is not sufficient to prevent significant dehydration. During mild to moderate exertion, electrolyte replacement offers no advantage over plain water. However, for those exercising many hours in heat, a weak solution similar to commercial electrolyte drinks is recommended. Salty snacks or light salting of mealtime food or fluids is the most efficient way to replace salt losses. Salt tablets, when swallowed whole, may cause gastrointestinal irritation and vomiting, but two tablets can be dissolved in one liter of water. Urine volume and color are a readily available means to monitor fluid needs.
        </p>
       </sec>
      </sec>
     </sec>
     <sec id="cesec424">
      <title>
       Problems Associated with a Cold Climate
      </title>
      <sec id="cesec425">
       <title>
        Risk for Travelers
       </title>
       <p id="para1858">
        Travelers do not have to be in an arctic or high-altitude environment to encounter problems with the cold. Humidity, rain, and wind can produce hypothermia even with temperatures around 50° F (12° C–14° C). Reports of severe hypothermia in international travelers are rare. Many high-altitude destinations are not wilderness areas, and villages offer an escape from extreme weather. In Nepal, trekkers almost never experience hypothermia except in the rare instance in which they may get lost in a storm. Even in a temperate climate, the traveler in a small boat that overturns in very cold water can rapidly become hypothermic.
       </p>
      </sec>
      <sec id="cesec426">
       <title>
        Clinical Presentations
       </title>
       <sec id="cesec427">
        <title>
         Hypothermia
        </title>
        <p id="para1859">
         Hypothermia can be defined, in general terms, as having a core body temperature of &lt;95° F (35° C). When persons are faced with an environment in which they cannot keep warm, they first feel chilled, then begin to shiver, and eventually stop shivering as their metabolic reserves are exhausted. At that point, body temperature continues to decrease, dependent upon the ambient temperatures. As the core temperature falls, neurologic functioning decreases until almost all hypothermic people with a core temperature of £86° F (30° C) are comatose. The record low core body temperature in an adult who survived is 56° F (13° C). Travelers headed to a cold climate should be encouraged to ask questions and research appropriate clothing and equipment.
        </p>
        <p id="para1860">
         Travelers who will be recreating or working around cold water face a different sort of risk. Immersion hypothermia can render a person unable to swim or keep floating within 30–60 minutes. In these cases, a personal flotation device is critical, as is knowledge about self-rescue and righting a capsized boat.
        </p>
        <p id="para1861">
         The other medical conditions associated with cold affect mainly the skin and the extremities. These can be divided into nonfreezing cold injuries and freezing injuries (frostbite).
        </p>
       </sec>
       <sec id="cesec428">
        <title>
         Nonfreezing Cold Injury
        </title>
        <p id="para1862">
         The nonfreezing cold injuries are—
         <list id="celist378" list-type="simple">
          <list-item id="celistitem1374">
           <label>
            •
           </label>
           <p id="para1863">
            <bold>
             Trench foot
            </bold>
            (immersion foot): This condition is caused by prolonged immersion of the feet in cold water (32° F–59° F, 0° C–15° C). The damage is mainly to nerves and blood vessels, and the result is pain that is aggravated by heat and a dependent position of the limb. Severe cases can take months to resolve. Unlike the treatment for frostbite, immersion foot should not be rapidly rewarmed, which can make the damage much worse.
           </p>
          </list-item>
          <list-item id="celistitem1375">
           <label>
            •
           </label>
           <p id="para1864">
            <bold>
             Pernio
            </bold>
            (chilblains): Pernio are localized, inflammatory lesions that occur mainly on the hands of susceptible individuals. They can occur with exposure to only moderately cold weather. The bluish-red lesions are thought to be caused by prolonged, cold-induced vasoconstriction. As with trench foot, rapid rewarming should be avoided, as it makes the pain worse. Nifedipine may be an effective treatment.
           </p>
          </list-item>
          <list-item id="celistitem1376">
           <label>
            •
           </label>
           <p id="para1865">
            <bold>
             Cold urticaria
            </bold>
            : This condition involves the formation of localized or general wheals and itching after exposure to cold. It is not the absolute temperature that induces this form of urticara, but the rate of change of temperature in the skin.
           </p>
          </list-item>
         </list>
        </p>
       </sec>
       <sec id="cesec429">
        <title>
         Freezing Cold Injury
        </title>
        <sec id="cesec430">
         <title>
          Categories of Frostbite
         </title>
         <p id="para1866">
          <list id="celist379" list-type="simple">
           <list-item id="celistitem1377">
            <label>
             •
            </label>
            <p id="para1867">
             Frostbite is the term that is used to describe tissue damage from direct freezing of the skin.
            </p>
           </list-item>
           <list-item id="celistitem1378">
            <label>
             •
            </label>
            <p id="para1868">
             Modern equipment and clothing have greatly decreased the risk of frostbite in most adventurous tourist destinations, and frostbite occurs mainly during an accident, severe unexpected weather, or as a result of poor planning.
            </p>
           </list-item>
           <list-item id="celistitem1379">
            <label>
             •
            </label>
            <p id="para1869">
             Once frostbite injury has occurred, little can be done to reverse the changes. Therefore, taking great care to prevent frostbite is crucial.
            </p>
           </list-item>
           <list-item id="celistitem1380">
            <label>
             •
            </label>
            <p id="para1870">
             Frostbite is usually graded like burns.
             <list id="celist380" list-type="simple">
              <list-item id="celistitem1381">
               <label>
                ○
               </label>
               <p id="para1871">
                First-degree frostbite involves reddening of the skin without deeper damage. The prognosis for complete healing is virtually 100%.
               </p>
              </list-item>
              <list-item id="celistitem1382">
               <label>
                ○
               </label>
               <p id="para1872">
                Second-degree frostbite involves blister formation. Blisters filled with clear fluid have a better prognosis than blood-tinged blisters.
               </p>
              </list-item>
              <list-item id="celistitem1383">
               <label>
                ○
               </label>
               <p id="para1873">
                Third-degree frostbite represents full-thickness injury to the skin, and possibly the underlying tissues. No blister forms, the skin darkens over time and may turn black, and if the tissue is completely devascularized, amputation will be necessary.
               </p>
              </list-item>
             </list>
            </p>
           </list-item>
          </list>
         </p>
        </sec>
        <sec id="cesec431">
         <title>
          Management of Frostbite
         </title>
         <p id="para1874">
          Frostbitten skin is numb and appears whitish or waxy. The generally accepted method for treating a frozen digit or limb is through rapid rewarming in water heated to 104° F–108° F (40° C–42° C). The frozen area should be completely immersed in the warm water. A thermometer is needed to maintain the water at the correct temperature. Rewarming can be associated with severe pain, and analgesics can be given if needed. Once the area is rewarmed, it must be safeguarded against freezing again. It is thought to be better to keep digits frozen a little longer and rapidly rewarm them, than to allow them to thaw out slowly or to thaw and refreeze. A cycle of freeze–thaw–refreeze is devastating to tissue and leads more directly to the need for amputation.
         </p>
         <p id="para1875">
          Once the area has rewarmed, it can be examined. If blisters are present, it is important to note whether they extend to the end of the digit. Proximal blisters usually mean that the tissue distal to the blister has suffered full-thickness damage. Treatment consists of avoiding further mechanical trauma to the area and preventing infection. Reasonable field treatment consists of washing the area thoroughly with a disinfectant such as povidone–iodine, putting dressings between the toes or fingers to prevent maceration, using fluffs (expanded gauze sponges) for padding, and covering with a roller gauze bandage. These dressings can safely be left on for up to 3 days at a time. By leaving the dressings on longer, the traveler can preserve what may be limited supplies of bandages. Prophylactic antibiotics are not needed in most situations.
         </p>
         <p id="para1876">
          Once the patient has reached a definitive medical setting, there should be no rush to do surgery. The usual time from injury to surgery is 4–5 weeks. By that time the dead tissue has begun to separate from viable tissue, and the surgeon can plan surgery that maximizes the remaining digits.
         </p>
        </sec>
       </sec>
      </sec>
     </sec>
     <ref-list id="cebib32">
      <title>
       References
      </title>
      <ref id="bib321">
       <label>
        1
       </label>
       <element-citation id="sbref289" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Moran
          </surname>
          <given-names>
           DS
          </given-names>
         </name>
         <name>
          <surname>
           Gaffin
          </surname>
          <given-names>
           SL
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         Clinical management of heat-related illnesses
        </chapter-title>
        <person-group person-group-type="editor">
         <name>
          <surname>
           Auerbach
          </surname>
          <given-names>
           PS
          </given-names>
         </name>
        </person-group>
        <source>
         Wilderness medicine
        </source>
        <edition>
         5th ed.
        </edition>
        <year>
         2007
        </year>
        <publisher-name>
         Mosby
        </publisher-name>
        <publisher-loc>
         Philadelphia
        </publisher-loc>
       </element-citation>
      </ref>
      <ref id="bib322">
       <label>
        2
       </label>
       <element-citation id="sbref290" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Epstein
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Moran
          </surname>
          <given-names>
           DS
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         Extremes of temperature and hydration
        </chapter-title>
        <person-group person-group-type="editor">
         <name>
          <surname>
           Keystone
          </surname>
          <given-names>
           JS
          </given-names>
         </name>
         <name>
          <surname>
           Kozarsky
          </surname>
          <given-names>
           PE
          </given-names>
         </name>
         <name>
          <surname>
           Freedman
          </surname>
          <given-names>
           DO
          </given-names>
         </name>
         <name>
          <surname>
           Nothdurft
          </surname>
          <given-names>
           HD
          </given-names>
         </name>
         <name>
          <surname>
           Connor
          </surname>
          <given-names>
           BA
          </given-names>
         </name>
        </person-group>
        <source>
         Travel medicine
        </source>
        <edition>
         2nd ed.
        </edition>
        <year>
         2008
        </year>
        <publisher-name>
         Mosby
        </publisher-name>
        <publisher-loc>
         Philadelphia
        </publisher-loc>
        <fpage>
         413
        </fpage>
        <lpage>
         422
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib323">
       <label>
        3
       </label>
       <element-citation id="sbref291" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Noakes
          </surname>
          <given-names>
           TD
          </given-names>
         </name>
        </person-group>
        <article-title>
         The hyponatremia of exercise
        </article-title>
        <source>
         Int J Sport Nutr
        </source>
        <volume>
         2
        </volume>
        <issue>
         3
        </issue>
        <year>
         1992
        </year>
        <fpage>
         205
        </fpage>
        <lpage>
         228
        </lpage>
        <pub-id pub-id-type="pmid">
         1299494
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib324">
       <label>
        4
       </label>
       <element-citation id="sbref292" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Backer
          </surname>
          <given-names>
           HD
          </given-names>
         </name>
         <name>
          <surname>
           Shopes
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Collins
          </surname>
          <given-names>
           SL
          </given-names>
         </name>
        </person-group>
        <article-title>
         Exertional heat illness and hyponatremia in hikers
        </article-title>
        <source>
         Am J Emerg Med
        </source>
        <volume>
         17
        </volume>
        <issue>
         6
        </issue>
        <year>
         1999
        </year>
        <fpage>
         532
        </fpage>
        <lpage>
         539
        </lpage>
        <pub-id pub-id-type="pmid">
         10530529
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib325">
       <label>
        5
       </label>
       <element-citation id="sbref293" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           McCauley
          </surname>
          <given-names>
           RL
          </given-names>
         </name>
         <name>
          <surname>
           Killyon
          </surname>
          <given-names>
           GW
          </given-names>
         </name>
         <name>
          <surname>
           Smith
          </surname>
          <given-names>
           DJ
          </given-names>
          <suffix>
           Jr
          </suffix>
         </name>
        </person-group>
        <chapter-title>
         Frostbite
        </chapter-title>
        <person-group person-group-type="editor">
         <name>
          <surname>
           Auerbach
          </surname>
          <given-names>
           PS
          </given-names>
         </name>
        </person-group>
        <source>
         Wilderness medicine
        </source>
        <edition>
         5th ed.
        </edition>
        <year>
         2007
        </year>
        <publisher-name>
         Mosby
        </publisher-name>
        <publisher-loc>
         Philadelphia
        </publisher-loc>
       </element-citation>
      </ref>
     </ref-list>
    </sec>
    <sec id="subchapter33">
     <sec-meta>
      <contrib-group>
       <contrib contrib-type="author" id="au58">
        <name>
         <surname>
          Ansdell
         </surname>
         <given-names>
          Vernon E.
         </given-names>
        </name>
       </contrib>
      </contrib-group>
     </sec-meta>
     <title>
      FOOD POISONING FROM MARINE TOXINS
     </title>
     <sec id="cesec432">
      <title>
       Description
      </title>
      <p id="para1877">
       <list id="celist381" list-type="simple">
        <list-item id="celistitem1384">
         <label>
          •
         </label>
         <p id="para1878">
          Seafood poisoning from marine toxins is an underrecognized hazard for travelers, particularly in the tropics and subtropics. Furthermore, the risk is increasing as a result of multiple factors such as global warming, coral reef damage, and spread of toxic algal blooms.
         </p>
        </list-item>
        <list-item id="celistitem1385">
         <label>
          •
         </label>
         <p id="para1879">
          <bold>
           Ciguatera fish poisoning
          </bold>
          and shellfish poisoning are caused by potent toxins that originate in small marine organisms (dinoflagellates and diatoms).
         </p>
        </list-item>
        <list-item id="celistitem1386">
         <label>
          •
         </label>
         <p id="para1880">
          <bold>
           Scombroid
          </bold>
          poisoning is caused by eating improperly chilled fish that contains large quantities of histamine.
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <sec id="cesec433">
      <title>
       Ciguatera Fish Poisoning
      </title>
      <p id="para1881">
       Ciguatera fish poisoning occurs after eating reef fish contaminated with toxins such as ciguatoxin or maitotoxin. These potent toxins originate from small marine organisms (dinoflagellates) that grow on and around coral reefs. Dinoflagellates are ingested by herbivorous fish, and the toxins are concentrated as they pass up the food chain to large (usually &gt;6 pounds) carnivorous fish and finally to humans. Toxin in fish is concentrated in the liver, intestinal tract, roe, and head.
      </p>
      <p id="para1882">
       <italic>
        Gambierdiscus toxicus
       </italic>
       , which produces ciguatoxin, tends to proliferate on dead coral reefs. The risk of ciguatera is likely to increase as more coral reefs die as a result of factors such as global warming, construction, and nutrient runoff.
      </p>
      <sec id="cesec434">
       <title>
        Risk for Travelers
       </title>
       <p id="para1883">
        <list id="celist382" list-type="simple">
         <list-item id="celistitem1387">
          <label>
           •
          </label>
          <p id="para1884">
           Over 50,000 cases of ciguatera poisoning occur every year.
          </p>
         </list-item>
         <list-item id="celistitem1388">
          <label>
           •
          </label>
          <p id="para1885">
           The incidence in travelers to endemic areas has been estimated as high as 3/100.
          </p>
         </list-item>
         <list-item id="celistitem1389">
          <label>
           •
          </label>
          <p id="para1886">
           Ciguatera is widespread in tropical and subtropical waters, usually between the latitudes of 35 degrees north and 35 degrees south; it is particularly common in the Pacific and Indian Oceans and the Caribbean Sea.
          </p>
         </list-item>
         <list-item id="celistitem1390">
          <label>
           •
          </label>
          <p id="para1887">
           Fish that are most likely to cause ciguatera poisoning are carnivorous reef fish, including barracuda, grouper, moray eel, amberjack, sea bass, or sturgeon. Omnivorous and herbivorous fish such as parrot fish, surgeon fish, and red snapper can also be a risk.
          </p>
         </list-item>
        </list>
       </p>
      </sec>
      <sec id="cesec435">
       <title>
        Clinical Presentation
       </title>
       <p id="para1888">
        <list id="celist383" list-type="simple">
         <list-item id="celistitem1391">
          <label>
           •
          </label>
          <p id="para1889">
           Typical ciguatera poisoning results in a gastrointestinal illness, followed by neurologic symptoms and, very rarely, cardiovascular collapse.
          </p>
         </list-item>
         <list-item id="celistitem1392">
          <label>
           •
          </label>
          <p id="para1890">
           The first symptoms usually appear 1–3 hours after eating contaminated fish and include nausea, vomiting, diarrhea, and abdominal pain.
          </p>
         </list-item>
         <list-item id="celistitem1393">
          <label>
           •
          </label>
          <p id="para1891">
           Neurologic symptoms appear 3–72 hours after the meal and include paresthesias, pain in the teeth or the sensation that the teeth are loose, itching, metallic taste, blurred vision, or even transient blindness. Temperature reversal (hot objects feel cold and cold objects feel hot) is very characteristic. Neurologic symptoms usually last a few days to several weeks.
          </p>
         </list-item>
         <list-item id="celistitem1394">
          <label>
           •
          </label>
          <p id="para1892">
           Chronic neuropsychiatric symptoms resembling chronic fatigue syndrome may be very disabling, last several months, and include malaise, depression, headaches, myalgias, and fatigue. Cardiac manifestations include bradycardia, other arrythmias, and hypotension.
          </p>
         </list-item>
         <list-item id="celistitem1395">
          <label>
           •
          </label>
          <p id="para1893">
           Overall mortality from ciguatera poisoning is about 0.1% but varies due to the toxin dose absorbed and availability of adequate medical care to deal with serious complications such as cardiovascular collapse or respiratory failure.
          </p>
         </list-item>
         <list-item id="celistitem1396">
          <label>
           •
          </label>
          <p id="para1894">
           The diagnosis of ciguatera poisoning is based on the clinical signs and symptoms and a history of eating fish that are known to carry ciguatera toxin. Commercial kits are available to test for ciguatera in fish, but there is no test for ciguatera in humans.
          </p>
         </list-item>
        </list>
       </p>
      </sec>
      <sec id="cesec436">
       <title>
        Preventive Measures for Travelers
       </title>
       <p id="para1895">
        <list id="celist384" list-type="simple">
         <list-item id="celistitem1397">
          <label>
           •
          </label>
          <p id="para1896">
           Avoid or limit consumption of the reef fish listed above, particularly when the individual fish weighs 6 pounds or more.
          </p>
         </list-item>
         <list-item id="celistitem1398">
          <label>
           •
          </label>
          <p id="para1897">
           Never eat high-risk fish such as barracuda or moray eel.
          </p>
         </list-item>
         <list-item id="celistitem1399">
          <label>
           •
          </label>
          <p id="para1898">
           Avoid the parts of the fish that concentrate ciguatera toxin, such as liver, intestines, roe, and head.
          </p>
         </list-item>
         <list-item id="celistitem1400">
          <label>
           •
          </label>
          <p id="para1899">
           Remember that ciguatera toxins do not affect the texture, taste or smell of fish, and they are not destroyed by gastric acid, cooking, smoking, freezing, canning, salting, or pickling.
          </p>
         </list-item>
         <list-item id="celistitem1401">
          <label>
           •
          </label>
          <p id="para1900">
           Commercial kits (if available) can be used to check if the fish is safe to eat.
          </p>
         </list-item>
        </list>
       </p>
      </sec>
      <sec id="cesec437">
       <title>
        Treatment
       </title>
       <p id="para1901">
        <list id="celist385" list-type="simple">
         <list-item id="celistitem1402">
          <label>
           •
          </label>
          <p id="para1902">
           There is no specific antidote for ciguatoxin or maitotoxin.
          </p>
         </list-item>
         <list-item id="celistitem1403">
          <label>
           •
          </label>
          <p id="para1903">
           Treatment is generally symptomatic and supportive.
          </p>
         </list-item>
         <list-item id="celistitem1404">
          <label>
           •
          </label>
          <p id="para1904">
           Intravenous mannitol has been reported to reduce the severity and duration of neurologic symptoms, particularly if given early.
          </p>
         </list-item>
        </list>
       </p>
      </sec>
     </sec>
     <sec id="cesec438">
      <title>
       Scombroid
      </title>
      <p id="para1905">
       Scombroid, one of the commonest fish poisonings, occurs worldwide in both temperate and tropical waters. The illness occurs after eating improperly refrigerated or preserved fish containing high levels of histamine and often resembles a moderate to severe IgE-mediated allergic reaction.
      </p>
      <p id="para1906">
       Fish that cause scombroid have naturally high levels of histidine in the flesh and include tuna, mackerel, mahimahi (dolphin fish), sardine, anchovy, herring, bluefish, amberjack, and marlin. Histidine is converted to histamine by bacterial overgrowth in fish that has been improperly stored (over 20° C) after capture. Histamine and other scombrotoxins are resistant to cooking, smoking, canning, or freezing.
      </p>
      <p id="para1907">
       Scombroid fish poisoning occurs worldwide in both temperate and tropical waters.
      </p>
      <sec id="cesec439">
       <title>
        Clinical Presentation
       </title>
       <p id="para1908">
        <list id="celist386" list-type="simple">
         <list-item id="celistitem1405">
          <label>
           •
          </label>
          <p id="para1909">
           Symptoms of scombroid poisoning resemble an acute allergic reaction and usually appear 10–60 minutes after eating contaminated fish. They include flushing of the face and upper body (resembling sunburn), severe headache, palpitations, itching, blurred vision, abdominal cramps, and diarrhea.
          </p>
         </list-item>
         <list-item id="celistitem1406">
          <label>
           •
          </label>
          <p id="para1910">
           Untreated, symptoms usually resolve within 12 hours. Rarely, there may be respiratory compromise, malignant arrythmias, and hypotension requiring hospitalization.
          </p>
         </list-item>
         <list-item id="celistitem1407">
          <label>
           •
          </label>
          <p id="para1911">
           Diagnosis is usually clinical. A clustering of cases helps to exclude the possibility of fish allergy.
          </p>
         </list-item>
        </list>
       </p>
      </sec>
      <sec id="cesec440">
       <title>
        Preventive Measures for Travelers
       </title>
       <p id="para1912">
        <list id="celist387" list-type="simple">
         <list-item id="celistitem1408">
          <label>
           •
          </label>
          <p id="para1913">
           Fish contaminated with histamine may have a peppery, sharp, salty, or bubbly taste, but may also look, smell, and taste normal.
          </p>
         </list-item>
         <list-item id="celistitem1409">
          <label>
           •
          </label>
          <p id="para1914">
           The key to prevention is to make sure that the fish is promptly chilled (below 15° C–20° C) after capture.
          </p>
         </list-item>
         <list-item id="celistitem1410">
          <label>
           •
          </label>
          <p id="para1915">
           Cooking, smoking, canning, or freezing will not destroy histamine in contaminated fish.
          </p>
         </list-item>
        </list>
       </p>
      </sec>
      <sec id="cesec441">
       <title>
        Treatment
       </title>
       <p id="para1916">
        <list id="celist388" list-type="simple">
         <list-item id="celistitem1411">
          <label>
           •
          </label>
          <p id="para1917">
           Scombroid poisoning usually responds well to H1 antihistamines.
          </p>
         </list-item>
         <list-item id="celistitem1412">
          <label>
           •
          </label>
          <p id="para1918">
           H2 antihistamines may also be of benefit.
          </p>
         </list-item>
        </list>
       </p>
      </sec>
     </sec>
     <sec id="cesec442">
      <title>
       Shellfish Poisoning
      </title>
      <p id="para1919">
       There are several forms of shellfish poisoning. All occur after ingesting filter-feeding bivalve mollusks, such as mussels, oysters, clams, scallops, and cockles containing potent toxins. The toxins originate in small marine organisms (dinoflagellates or diatoms) that are ingested and concentrated by shellfish.
      </p>
      <sec id="cesec443">
       <title>
        Risk for Travelers
       </title>
       <p id="para1920">
        Contaminated shellfish may be found in temperate and tropical waters, typically during or after dinoflagellate blooms or “red tides.”
       </p>
      </sec>
      <sec id="cesec444">
       <title>
        Clinical Presentation
       </title>
       <p id="para1921">
        Poisoning results in gastrointestinal and neurologic illness of varying severity. Symptoms typically appear 30–60 minutes after ingesting toxic shellfish but can be delayed for several hours. Diagnosis is usually made clinically together with a history of recent shellfish ingestion.
       </p>
       <sec id="cesec445">
        <title>
         Paralytic Shellfish Poisoning
        </title>
        <p id="para1922">
         This is the most common and most severe form of shellfish poisoning. Symptoms usually appear 30–60 minutes after eating toxic shellfish and include numbness and tingling of the face, lips, tongue, arms, and legs. There may be headache, nausea, vomiting, and diarrhea. Severe cases are associated with ingestion of large doses of toxin and clinical features such as ataxia, dysphagia, mental status changes, flaccid paralysis, and respiratory failure. The case–fatality rate averages 6% and may be particularly high in children.
        </p>
       </sec>
       <sec id="cesec446">
        <title>
         Neurotoxic Shellfish Poisoning
        </title>
        <p id="para1923">
         Usually presents as gastroenteritis accompanied by minor neurologic symptoms, resembling mild ciguatera poisoning or mild paralytic shellfish poisoning. Inhalation of aerosolized toxin in the sea spray associated with a red tide may cause an acute respiratory illness, rhinorrhea, and bronchoconstriction.
        </p>
       </sec>
       <sec id="cesec447">
        <title>
         Diarrheic Shellfish Poisoning
        </title>
        <p id="para1924">
         This produces chills, nausea, vomiting, abdominal cramps, and diarrhea. No fatalities have been reported.
        </p>
       </sec>
       <sec id="cesec448">
        <title>
         Amnesic Shellfish Poisoning
        </title>
        <p id="para1925">
         This is a rare form of shellfish poisoning that produces a gastroenteritis that may be accompanied by headache, confusion, and permanent short-term memory loss. In severe cases, seizures, paralysis, and death may occur.
        </p>
       </sec>
      </sec>
      <sec id="cesec449">
       <title>
        Preventive Measures for Travelers
       </title>
       <p id="para1926">
        <list id="celist389" list-type="simple">
         <list-item id="celistitem1413">
          <label>
           •
          </label>
          <p id="para1927">
           Shellfish poisoning can be prevented by avoiding potentially contaminated bivalve molluscs. This is particularly important in areas during or shortly after “red tides.”
          </p>
         </list-item>
         <list-item id="celistitem1414">
          <label>
           •
          </label>
          <p id="para1928">
           Travelers to developing countries should avoid eating all shellfish, because they carry a high risk of viral and bacterial infections.
          </p>
         </list-item>
         <list-item id="celistitem1415">
          <label>
           •
          </label>
          <p id="para1929">
           Marine shellfish toxins cannot be destroyed by cooking or freezing.
          </p>
         </list-item>
        </list>
       </p>
      </sec>
      <sec id="cesec450">
       <title>
        Treatment
       </title>
       <p id="para1930">
        <list id="celist390" list-type="simple">
         <list-item id="celistitem1416">
          <label>
           •
          </label>
          <p id="para1931">
           Treatment is symptomatic and supportive.
          </p>
         </list-item>
         <list-item id="celistitem1417">
          <label>
           •
          </label>
          <p id="para1932">
           Severe cases of paralytic shellfish poisoning may require mechanical ventilation.
          </p>
         </list-item>
        </list>
       </p>
      </sec>
     </sec>
     <ref-list id="cebib33">
      <title>
       References
      </title>
      <ref id="bib326">
       <label>
        1
       </label>
       <element-citation id="sbref294" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ansdell
          </surname>
          <given-names>
           V
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         Food-borne illness
        </chapter-title>
        <person-group person-group-type="editor">
         <name>
          <surname>
           Keystone
          </surname>
          <given-names>
           JS
          </given-names>
         </name>
         <name>
          <surname>
           Kozarsky
          </surname>
          <given-names>
           PE
          </given-names>
         </name>
         <name>
          <surname>
           Freedman
          </surname>
          <given-names>
           DO
          </given-names>
         </name>
         <name>
          <surname>
           Nothdurft
          </surname>
          <given-names>
           HD
          </given-names>
         </name>
         <name>
          <surname>
           Connor
          </surname>
          <given-names>
           BA
          </given-names>
         </name>
        </person-group>
        <source>
         Travel medicine
        </source>
        <edition>
         2nd ed.
        </edition>
        <year>
         2008
        </year>
        <publisher-name>
         Mosby
        </publisher-name>
        <publisher-loc>
         Philadelphia
        </publisher-loc>
        <fpage>
         475
        </fpage>
        <lpage>
         484
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib327">
       <label>
        2
       </label>
       <element-citation id="sbref295" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Isbister
          </surname>
          <given-names>
           GK
          </given-names>
         </name>
         <name>
          <surname>
           Kiernan
          </surname>
          <given-names>
           MC
          </given-names>
         </name>
        </person-group>
        <article-title>
         Neurotoxic marine poisoning
        </article-title>
        <source>
         Lancet Neurol
        </source>
        <volume>
         4
        </volume>
        <issue>
         4
        </issue>
        <year>
         2005
        </year>
        <fpage>
         219
        </fpage>
        <lpage>
         228
        </lpage>
        <pub-id pub-id-type="pmid">
         15778101
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib328">
       <label>
        3
       </label>
       <element-citation id="sbref296" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sobel
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Painter
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        <article-title>
         Illnesses caused by marine toxins
        </article-title>
        <source>
         Clin Infect Dis
        </source>
        <volume>
         41
        </volume>
        <issue>
         9
        </issue>
        <year>
         2005
        </year>
        <fpage>
         1290
        </fpage>
        <lpage>
         1296
        </lpage>
        <pub-id pub-id-type="pmid">
         16206104
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib329">
       <label>
        4
       </label>
       <element-citation id="sbref297" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Palafox
          </surname>
          <given-names>
           NA
          </given-names>
         </name>
         <name>
          <surname>
           Jain
          </surname>
          <given-names>
           LG
          </given-names>
         </name>
         <name>
          <surname>
           Pinano
          </surname>
          <given-names>
           AZ
          </given-names>
         </name>
        </person-group>
        <article-title>
         Successful treatment of ciguatera fish poisoning with intravenous mannitol
        </article-title>
        <source>
         JAMA
        </source>
        <volume>
         259
        </volume>
        <issue>
         18
        </issue>
        <year>
         1988
        </year>
        <fpage>
         2740
        </fpage>
        <lpage>
         2742
        </lpage>
        <pub-id pub-id-type="pmid">
         3128666
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib330">
       <label>
        5
       </label>
       <element-citation id="sbref298" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Schnorf
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Taurarii
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Cundy
          </surname>
          <given-names>
           T
          </given-names>
         </name>
        </person-group>
        <article-title>
         Ciguatera fish poisoning: a double-blind randomized trial of mannitol therapy
        </article-title>
        <source>
         Neurology
        </source>
        <volume>
         58
        </volume>
        <issue>
         6
        </issue>
        <year>
         2002
        </year>
        <fpage>
         873
        </fpage>
        <lpage>
         880
        </lpage>
        <pub-id pub-id-type="pmid">
         11914401
        </pub-id>
       </element-citation>
      </ref>
     </ref-list>
    </sec>
    <sec id="subchapter34">
     <sec-meta>
      <contrib-group>
       <contrib contrib-type="author" id="au59">
        <name>
         <surname>
          Marano
         </surname>
         <given-names>
          Nina
         </given-names>
        </name>
       </contrib>
       <contrib contrib-type="author" id="au60">
        <name>
         <surname>
          Galland
         </surname>
         <given-names>
          G. Gale
         </given-names>
        </name>
       </contrib>
      </contrib-group>
     </sec-meta>
     <title>
      ANIMAL-ASSOCIATED HAZARDS
     </title>
     <sec id="cesec451">
      <title>
       Human Interaction with Animals: A Risk Factor for Injury
      </title>
      <p id="para1933">
       Animals in general tend to avoid human beings, but they can attack if they perceive threat, are protecting their young or territory, or are injured or ill. Although attacks by wild animals are more dramatic, attacks by domestic animals are far more common. Animals cause injury through bites, kicks, or blunt trauma, or by the use of horns or claws. Further damage can occur if injuries become secondarily infected, as these infections may result in serious systemic disease. In addition, animals can transmit zoonotic infections such as rabies. A recent 10-year retrospective review of dog bites in Austria showed that 75% of the bites were preventable because the person intentionally interacted with the dog.
      </p>
     </sec>
     <sec id="cesec452">
      <title>
       Bite Wounds
      </title>
      <sec id="cesec453">
       <title>
        Prevention
       </title>
       <p id="para1934">
        <list id="celist391" list-type="simple">
         <list-item id="celistitem1418">
          <label>
           •
          </label>
          <p id="para1935">
           Before departure, travelers should have a current tetanus vaccination or should have documentation of receiving a booster vaccination within the prior 5–10 years. An assessment of the traveler's need for pre-exposure rabies immunization should be made according to guidelines in
           <xref ref-type="table" rid="cetable17">
            Table 2-17
           </xref>
           .
          </p>
         </list-item>
         <list-item id="celistitem1419">
          <label>
           •
          </label>
          <p id="para1936">
           During travel, travelers should never try to pet, handle, or feed unfamiliar animals, domestic or wild, particularly in areas of endemic rabies. Young children are more likely to be bitten by animals and sustain more severe injuries from animal bites.
          </p>
         </list-item>
        </list>
       </p>
      </sec>
      <sec id="cesec454">
       <title>
        Management
       </title>
       <p id="para1937">
        <list id="celist392" list-type="simple">
         <list-item id="celistitem1420">
          <label>
           •
          </label>
          <p id="para1938">
           All wounds should receive prompt local treatment by thorough cleansing and debridement of the wound if necrotic tissue or dirt is present to prevent infection and illness, especially tetanus or rabies-prone wounds (see the
           <xref ref-type="sec" rid="subchapter9">
            Rabies
           </xref>
           and
           <xref ref-type="sec" rid="subchapter19">
            Tetanus
           </xref>
           sections earlier in this chapter).
          </p>
         </list-item>
         <list-item id="celistitem1421">
          <label>
           •
          </label>
          <p id="para1939">
           Any animal bite should be evaluated by a health-care provider as soon as possible, after cleaning the wound. Travelers who might have been exposed to rabies should contact a reliable health practitioner for advice about rabies postexposure prophylaxis (see the
           <xref ref-type="sec" rid="subchapter9">
            Rabies
           </xref>
           section earlier in this chapter). Since rabies immune globulin or rabies vaccine may not be available in the destination country, travelers should have a strategy in place prior to travel as to how to respond to a possible rabies exposure. This strategy may require the traveler to fly to a different country to obtain the appropriate treatment.
           <list id="celist393" list-type="simple">
            <list-item id="celistitem1422">
             <label>
              ○
             </label>
             <p id="para1940">
              Travelers who have purchased medical evacuation insurance should contact their insurance provider for guidance on seeking medical care.
             </p>
            </list-item>
            <list-item id="celistitem1423">
             <label>
              ○
             </label>
             <p id="para1941">
              U.S. citizens can contact the local U.S. Embassy or Consulate in the country they are visiting for assistance in locating a health-care professional at their destination. Consular personnel at U.S. Embassies and Consulates abroad and in the United States are available 24 hours a day, 7 days a week, to provide emergency assistance to U.S. citizens. To contact the U.S. Department of State's Overseas Citizens Services:
              <list id="celist394" list-type="simple">
               <list-item id="celistitem1424">
                <label>
                 □
                </label>
                <p id="para1942">
                 Dial: 888-407-4747 if calling from the U.S. or Canada
                </p>
               </list-item>
               <list-item id="celistitem1425">
                <label>
                 □
                </label>
                <p id="para1943">
                 Dial: 202-501-4444 if calling from overseas
                </p>
               </list-item>
              </list>
             </p>
            </list-item>
           </list>
          </p>
         </list-item>
         <list-item id="celistitem1426">
          <label>
           •
          </label>
          <p id="para1944">
           Travelers who received their most recent tetanus toxoid-containing vaccine &gt;5 years previously or who have not received at least three doses of tetanus toxoid-containing vaccines may require a dose of tetanus toxoid-containing vaccine (Tdap, Td, or DTaP), according to the guidelines in
           <xref ref-type="table" rid="cetable21">
            Table 2-21
           </xref>
           .
          </p>
         </list-item>
        </list>
       </p>
       <p id="para1945">
        A wide variety of animals and insects can cause illness and injury to travelers; a short synopsis of risks by species is provided below.
       </p>
      </sec>
     </sec>
     <sec id="cesec455">
      <title>
       Monkeys
      </title>
      <p id="para1946">
       <list id="celist395" list-type="simple">
        <list-item id="celistitem1427">
         <label>
          •
         </label>
         <p id="para1947">
          Macaques, a type of monkey, pose a threat for rabies and herpes B virus. Macaques are native to Asia and Northern Africa. They are also housed in research facilities, zoos, wildlife or amusement parks, and are kept as pets in private homes throughout the world. Monkey bites occasionally occur in certain urban sites, such as temples in Nepal or India.
         </p>
        </list-item>
        <list-item id="celistitem1428">
         <label>
          •
         </label>
         <p id="para1948">
          Herpes B virus is related to the herpes simplex viruses, which cause oral and genital ulcers. Herpes B virus was discovered in 1933, and since that time approximately 50 cases have been reported in humans, with an 80% mortality rate. Herpes B infection is rare in humans, and most documented cases have resulted from occupational exposures. No cases of herpes B infection have been reported in travelers or others exposed to monkeys in the wild. However, travelers to areas where free-ranging macaques exist should be aware of the potential risk. An infected monkey may appear completely healthy.
         </p>
        </list-item>
        <list-item id="celistitem1429">
         <label>
          •
         </label>
         <p id="para1949">
          Documented routes of human infection include animal bites and scratches, exposure to infected tissue or body fluids from splashes, and, in one instance, human-to-human spread. Even minor scratches or bites should be considered potential exposures as, experimentally, herpes B virus has been isolated from surfaces for up to 2 weeks after it was applied (unpublished data, National Institutes of Health B Virus Reference Laboratory).
         </p>
        </list-item>
        <list-item id="celistitem1430">
         <label>
          •
         </label>
         <p id="para1950">
          The incubation period for herpes B may be less than 1 week to a month or longer.
         </p>
        </list-item>
        <list-item id="celistitem1431">
         <label>
          •
         </label>
         <p id="para1951">
          Neurologic symptoms develop as the virus infects the central nervous system and may lead to ascending paralysis and respiratory failure.
         </p>
        </list-item>
        <list-item id="celistitem1432">
         <label>
          •
         </label>
         <p id="para1952">
          Increased public and physician awareness about the risks associated with an injury from a macaque, improved first aid postexposure, the availability of better diagnostic tests, and improved anti-viral therapeutics have decreased the mortality rate to 20% in treated individuals. As a result, from 1987 to 2004 there have been only five fatal infections.
         </p>
        </list-item>
       </list>
      </p>
      <sec id="cesec456">
       <title>
        Prevention
       </title>
       <p id="para1953">
        Travelers should never attempt to feed, pet, or otherwise handle any monkeys.
       </p>
      </sec>
      <sec id="cesec457">
       <title>
        Management
       </title>
       <p id="para1954">
        <list id="celist396" list-type="simple">
         <list-item id="celistitem1433">
          <label>
           •
          </label>
          <p id="para1955">
           Travelers should seek first aid immediately after being bitten or scratched by a monkey. The wound should be thoroughly cleaned, and travelers should seek health care immediately.
          </p>
         </list-item>
         <list-item id="celistitem1434">
          <label>
           •
          </label>
          <p id="para1956">
           If the history is strongly suggestive of exposure to herpes B through contact with monkeys, there are published guidelines for the prevention of herpes B infection after exposure and for the treatment of established infection. These guidelines have recommendations for serologic tests and postexposure prophylaxis. When potentially exposed travelers return home, they should follow up with their health-care providers for care. Additional information and photos of macaques can be found at the website for the National B Virus Resource Center at the Georgia State University Viral Immunology Center:
           <ext-link ext-link-type="uri" id="interref83" xlink:href="http://www2.gsu.edu/~wwwvir/">
            www2.gsu.edu/∼wwwvir/
           </ext-link>
           .
          </p>
         </list-item>
        </list>
       </p>
      </sec>
     </sec>
     <sec id="cesec458">
      <title>
       Snakes
      </title>
      <p id="para1957">
       <list id="celist397" list-type="simple">
        <list-item id="celistitem1435">
         <label>
          •
         </label>
         <p id="para1958">
          Poisonous snakes are hazards in many locations, although deaths from snakebites are rare. Snakebites usually occur in areas where dense human populations coexist with dense snake populations (e.g., Southeast Asia, sub-Saharan Africa, and tropical America).
         </p>
        </list-item>
        <list-item id="celistitem1436">
         <label>
          •
         </label>
         <p id="para1959">
          Common sense is the best precaution. Most snakebites are the direct result of startling, handling, or harassing snakes. Therefore, all snakes should be left alone. Travelers should maintain awareness of their surroundings, especially at night and during warm weather when snakes tend to be more active. For extra precaution, when practical, travelers should wear heavy, ankle high or higher boots, and long pants when walking outdoors at night in areas possibly inhabited by venomous snakes.
         </p>
        </list-item>
       </list>
      </p>
      <sec id="cesec459">
       <title>
        Management
       </title>
       <p id="para1960">
        <list id="celist398" list-type="simple">
         <list-item id="celistitem1437">
          <label>
           •
          </label>
          <p id="para1961">
           Travelers should be advised to seek immediate medical attention any time a bite wound breaks the skin, or when snake venom is ejected into their eyes or mucous membranes.
          </p>
         </list-item>
         <list-item id="celistitem1438">
          <label>
           •
          </label>
          <p id="para1962">
           Immobilization of the affected limb and application of a pressure bandage that does not restrict blood flow are recommended first-aid measures while the victim is moved as quickly as possible to a medical facility.
          </p>
         </list-item>
         <list-item id="celistitem1439">
          <label>
           •
          </label>
          <p id="para1963">
           Incision of the bite site and tourniquets that restrict blood flow to the affected limb are not recommended.
          </p>
         </list-item>
         <list-item id="celistitem1440">
          <label>
           •
          </label>
          <p id="para1964">
           Specific therapy for snakebites is controversial and should be left to the judgment of local emergency medical personnel. Specific antivenins are available for some snakes in some areas, so trying to ascertain the species of snake that bit the victim may be critical.
          </p>
         </list-item>
        </list>
       </p>
      </sec>
     </sec>
     <sec id="cesec460">
      <title>
       Insects
      </title>
      <p id="para1965">
       Bites and stings from insects such as spiders and scorpions can be painful and can result in significant morbidity and mortality, particularly among infants and children. Many insects can transmit communicable diseases, even without the traveler's awareness of the bite. This is particularly true when camping or staying in rustic accommodations.
      </p>
      <sec id="cesec461">
       <title>
        Prevention
       </title>
       <p id="para1966">
        Exposure to insect bites and scorpion envenomations can be avoided by wearing long sleeves and pants while hiking, sleeping under mosquito nets, and shaking clothing and shoes before putting them on.
       </p>
      </sec>
      <sec id="cesec462">
       <title>
        Management
       </title>
       <p id="para1967">
        Travelers should be advised to seek medical attention if an insect bite or sting causes redness, swelling, bruising, or persistent pain. Those who have a history of severe allergic reactions to insect bites or stings should also ask their physician to evaluate them for the need to carry an epinephrine autoinjector (EpiPen) to use in case of recurrence (both in general and especially while traveling).
       </p>
      </sec>
     </sec>
     <sec id="cesec463">
      <title>
       Bats
      </title>
      <p id="para1968">
       <list id="celist399" list-type="simple">
        <list-item id="celistitem1441">
         <label>
          •
         </label>
         <p id="para1969">
          Bats can be found almost anywhere in the world except the polar regions and extreme deserts. Bats are reservoir hosts for viruses that can cross species barriers to infect humans and other domestic and wild mammals. Viruses such as rabies virus can be transmitted directly from bats to people.
         </p>
        </list-item>
        <list-item id="celistitem1442">
         <label>
          •
         </label>
         <p id="para1970">
          It is not possible to tell if a bat has rabies; however, any bat that is active by day, is found in a place where bats are not usually seen (for example, indoors or outdoors in areas in close proximity to humans), or is unable to fly is far more likely than others to be rabid.
         </p>
        </list-item>
        <list-item id="celistitem1443">
         <label>
          •
         </label>
         <p id="para1971">
          Human exposure to bats can occur during adventure activities such as caving. Exposure can include bites, scratches, and mucosal or cutaneous exposure to bat saliva. Like any other wild animal, any bat, whether it is sick or healthy, will bite in self-defense if handled.
         </p>
        </list-item>
       </list>
      </p>
      <sec id="cesec464">
       <title>
        Prevention
       </title>
       <p id="para1972">
        Bats should never be handled. Travelers should be discouraged from going into caves that have a large bat infestation. Depending on the country being visited, pre-exposure rabies vaccination may be recommended for persons engaged in outdoor activities such as caving and spelunking.
       </p>
      </sec>
      <sec id="cesec465">
       <title>
        Management
       </title>
       <p id="para1973">
        <list id="celist400" list-type="simple">
         <list-item id="celistitem1444">
          <label>
           •
          </label>
          <p id="para1974">
           If a bite occurs or if infectious material (such as saliva) from a bat gets into the eyes, nose, mouth, or a wound, the traveler should wash the affected area thoroughly and get medical advice immediately. Any suspected or documented bite or scratch from a bat should be grounds for seeking postexposure rabies immunoprophylaxis.
          </p>
         </list-item>
         <list-item id="celistitem1445">
          <label>
           •
          </label>
          <p id="para1975">
           People usually know when they have been bitten by a bat. However, bats have tiny teeth and not all wounds may be apparent. There are situations in which travelers should seek medical advice even in the absence of an obvious bite wound, such as upon awakening and finding a bat in the room or seeing a bat in the room of a child.
          </p>
         </list-item>
        </list>
       </p>
      </sec>
     </sec>
     <sec id="cesec466">
      <title>
       Marine Animals
      </title>
      <p id="para1976">
       <list id="celist401" list-type="simple">
        <list-item id="celistitem1446">
         <label>
          •
         </label>
         <p id="para1977">
          Venomous injuries from marine fish and invertebrates are increasing with the popularity of surfing, scuba diving, and snorkeling. The majority of species responsible for human injuries and envenomation reside in tropical coastal waters and include stingrays, jellyfish, stonefish, and scorpionfish.
         </p>
        </list-item>
        <list-item id="celistitem1447">
         <label>
          •
         </label>
         <p id="para1978">
          Travelers should be advised to use protective footwear and maintain vigilance while engaging in recreational water activities. Traumatic injury, envenomation and wound infection are common sequelae. Identification of the species involved is helpful in determining the best course of treatment.
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <sec id="cesec467">
      <title>
       Birds
      </title>
      <p id="para1979">
       <list id="celist402" list-type="simple">
        <list-item id="celistitem1448">
         <label>
          •
         </label>
         <p id="para1980">
          When traveling in an area that is experiencing an outbreak of avian influenza (
          <ext-link ext-link-type="uri" id="interref84" xlink:href="http://www.cdc.gov/flu/avian/outbreaks/current.htm">
           www.cdc.gov/flu/avian/outbreaks/current.htm
          </ext-link>
          ), travelers should avoid all contact with poultry (e.g., chickens, ducks, geese, pigeons, turkeys, and quail) or any wild birds, and avoid settings where H5N1-infected poultry may be present, such as commercial or backyard poultry farms and live poultry markets.
         </p>
        </list-item>
        <list-item id="celistitem1449">
         <label>
          •
         </label>
         <p id="para1981">
          Travelers should not eat uncooked or undercooked poultry or poultry products, including dishes made with uncooked poultry blood.
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <ref-list id="cebib34">
      <title>
       References
      </title>
      <ref id="bib331">
       <label>
        1
       </label>
       <element-citation id="sbref299" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Callahan
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         Bites, stings, and envenoming injuries
        </chapter-title>
        <person-group person-group-type="editor">
         <name>
          <surname>
           Keystone
          </surname>
          <given-names>
           JS
          </given-names>
         </name>
         <name>
          <surname>
           Kozarsky
          </surname>
          <given-names>
           PE
          </given-names>
         </name>
         <name>
          <surname>
           Freedman
          </surname>
          <given-names>
           DO
          </given-names>
         </name>
         <name>
          <surname>
           Nothdurft
          </surname>
          <given-names>
           HD
          </given-names>
         </name>
         <name>
          <surname>
           Connor
          </surname>
          <given-names>
           BA
          </given-names>
         </name>
        </person-group>
        <source>
         Travel medicine
        </source>
        <edition>
         2nd ed.
        </edition>
        <year>
         2008
        </year>
        <publisher-name>
         Mosby
        </publisher-name>
        <publisher-loc>
         Philadelphia
        </publisher-loc>
        <fpage>
         463
        </fpage>
        <lpage>
         474
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib332">
       <label>
        2
       </label>
       <element-citation id="sbref300" publication-type="book">
        <person-group person-group-type="author">
         <collab>
          Anonymous.
         </collab>
        </person-group>
        <chapter-title>
         Rabies
        </chapter-title>
        <person-group person-group-type="editor">
         <name>
          <surname>
           Acha
          </surname>
          <given-names>
           PN
          </given-names>
         </name>
         <name>
          <surname>
           Szyfres
          </surname>
          <given-names>
           B
          </given-names>
         </name>
        </person-group>
        <edition>
         3rd ed.
        </edition>
        <series>
         Zoonoses and communicable diseases common to man and animals
        </series>
        <volume>
         2
        </volume>
        <year>
         2003
        </year>
        <publisher-name>
         PAHO
        </publisher-name>
        <publisher-loc>
         Washington (DC)
        </publisher-loc>
        <fpage>
         246
        </fpage>
        <lpage>
         276
        </lpage>
        <comment>
         Chlamydioses, rickettsioses, and viruses.
        </comment>
       </element-citation>
      </ref>
      <ref id="bib333">
       <label>
        3
       </label>
       <element-citation id="sbref301" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Schalamon
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Ainoedhofer
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Singer
          </surname>
          <given-names>
           G
          </given-names>
         </name>
        </person-group>
        <article-title>
         Analysis of dog bites in children who are younger than 17 years
        </article-title>
        <source>
         Pediatrics
        </source>
        <volume>
         117
        </volume>
        <issue>
         3
        </issue>
        <year>
         2006
        </year>
        <fpage>
         e374
        </fpage>
        <lpage>
         e379
        </lpage>
        <pub-id pub-id-type="pmid">
         16510617
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib334">
       <label>
        4
       </label>
       <element-citation id="sbref302" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Huff
          </surname>
          <given-names>
           JL
          </given-names>
         </name>
         <name>
          <surname>
           Barry
          </surname>
          <given-names>
           PA
          </given-names>
         </name>
        </person-group>
        <article-title>
         B-virus (Cercopithecine herpesvirus 1) infection in humans and macaques: potential for zoonotic disease
        </article-title>
        <source>
         Emerg Infect Dis
        </source>
        <volume>
         9
        </volume>
        <issue>
         2
        </issue>
        <year>
         2003
        </year>
        <fpage>
         246
        </fpage>
        <lpage>
         250
        </lpage>
        <pub-id pub-id-type="pmid">
         12603998
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib335">
       <label>
        5
       </label>
       <element-citation id="sbref303" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cohen
          </surname>
          <given-names>
           JI
          </given-names>
         </name>
         <name>
          <surname>
           Davenport
          </surname>
          <given-names>
           DS
          </given-names>
         </name>
         <name>
          <surname>
           Stewart
          </surname>
          <given-names>
           JA
          </given-names>
         </name>
        </person-group>
        <article-title>
         B Virus Working Group. Recommendations for prevention of and therapy for exposure to B virus (Cercopithecine Herpesvirus 1)
        </article-title>
        <source>
         Clin Infect Dis
        </source>
        <volume>
         35
        </volume>
        <issue>
         10
        </issue>
        <year>
         2002
        </year>
        <fpage>
         1191
        </fpage>
        <lpage>
         1203
        </lpage>
        <pub-id pub-id-type="pmid">
         12410479
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib336">
       <label>
        6
       </label>
       <element-citation id="sbref304" publication-type="journal">
        <comment>
        </comment>
        <person-group person-group-type="author">
         <name>
          <surname>
           Gold
          </surname>
          <given-names>
           BS
          </given-names>
         </name>
         <name>
          <surname>
           Dart
          </surname>
          <given-names>
           RC
          </given-names>
         </name>
         <name>
          <surname>
           Barish
          </surname>
          <given-names>
           RA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Bites of venomous snakes
        </article-title>
        <source>
         N Engl J Med
        </source>
        <volume>
         347
        </volume>
        <issue>
         5
        </issue>
        <year>
         2002
        </year>
        <fpage>
         347
        </fpage>
        <lpage>
         356
        </lpage>
        <pub-id pub-id-type="pmid">
         12151473
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib337">
       <label>
        7
       </label>
       <element-citation id="sbref305" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Warrell
          </surname>
          <given-names>
           DA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Treatment of bites by adders and exotic venomous snakes
        </article-title>
        <source>
         BMJ
        </source>
        <volume>
         331
        </volume>
        <issue>
         7527
        </issue>
        <year>
         2005
        </year>
        <fpage>
         1244
        </fpage>
        <lpage>
         1247
        </lpage>
        <pub-id pub-id-type="pmid">
         16308385
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib338">
       <label>
        8
       </label>
       <element-citation id="sbref306" publication-type="journal">
        <person-group person-group-type="author">
         <collab>
          CDC
         </collab>
        </person-group>
        <article-title>
         Nonfatal dog bite-related injuries treated in hospital emergency departments—United States, 2001
        </article-title>
        <source>
         MMWR Morb Mortal Wkly Rep
        </source>
        <volume>
         52
        </volume>
        <issue>
         26
        </issue>
        <year>
         2003
        </year>
        <fpage>
         605
        </fpage>
        <lpage>
         610
        </lpage>
        <pub-id pub-id-type="pmid">
         12844076
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib339">
       <label>
        9
       </label>
       <element-citation id="sbref307" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Löe
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Röskaft
          </surname>
          <given-names>
           E
          </given-names>
         </name>
        </person-group>
        <article-title>
         Large carnivores and human safety: a review
        </article-title>
        <source>
         Ambio
        </source>
        <volume>
         33
        </volume>
        <issue>
         6
        </issue>
        <year>
         2004
        </year>
        <fpage>
         283
        </fpage>
        <lpage>
         288
        </lpage>
        <pub-id pub-id-type="pmid">
         15387060
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib340">
       <label>
        10
       </label>
       <element-citation id="sbref308" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Schalamon
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Ainoedhofer
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Singer
          </surname>
          <given-names>
           G
          </given-names>
         </name>
        </person-group>
        <article-title>
         Analysis of dog bites in children who are younger than 17 years
        </article-title>
        <source>
         Pediatrics
        </source>
        <volume>
         117
        </volume>
        <issue>
         3
        </issue>
        <year>
         2006
        </year>
        <fpage>
         e374
        </fpage>
        <lpage>
         e379
        </lpage>
        <pub-id pub-id-type="pmid">
         16510617
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib341">
       <label>
        11
       </label>
       <element-citation id="sbref309" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Feldman
          </surname>
          <given-names>
           KA
          </given-names>
         </name>
         <name>
          <surname>
           Trent
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Jay
          </surname>
          <given-names>
           MT
          </given-names>
         </name>
        </person-group>
        <article-title>
         Epidemiology of hospitalizations resulting from dog bites in California, 1991–1998
        </article-title>
        <source>
         Am J Public Health
        </source>
        <volume>
         94
        </volume>
        <issue>
         11
        </issue>
        <year>
         2004
        </year>
        <fpage>
         1940
        </fpage>
        <lpage>
         1941
        </lpage>
        <pub-id pub-id-type="pmid">
         15514233
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib342">
       <label>
        12
       </label>
       <element-citation id="sbref310" publication-type="journal">
        <person-group person-group-type="author">
         <collab>
          CDC
         </collab>
        </person-group>
        <article-title>
         Dog-bite-related fatalities—United States, 1995–1996
        </article-title>
        <source>
         MMWR Morb Mortal Wkly Rep
        </source>
        <volume>
         46
        </volume>
        <issue>
         21
        </issue>
        <year>
         1997
        </year>
        <fpage>
         463
        </fpage>
        <lpage>
         467
        </lpage>
        <pub-id pub-id-type="pmid">
         9182209
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib343">
       <label>
        13
       </label>
       <element-citation id="sbref311" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Diaz
          </surname>
          <given-names>
           JH
          </given-names>
         </name>
        </person-group>
        <article-title>
         The global epidemiology, syndromic classification, management, and prevention of spider bites
        </article-title>
        <source>
         Am J Trop Med Hyg
        </source>
        <volume>
         71
        </volume>
        <issue>
         2
        </issue>
        <year>
         2004
        </year>
        <fpage>
         239
        </fpage>
        <lpage>
         250
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib344">
       <label>
        14
       </label>
       <element-citation id="sbref312" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gibbons
          </surname>
          <given-names>
           RV
          </given-names>
         </name>
        </person-group>
        <article-title>
         Cryptogenic rabies, bats, and the question of aerosol transmission
        </article-title>
        <source>
         Ann Emerg Med
        </source>
        <volume>
         39
        </volume>
        <issue>
         5
        </issue>
        <year>
         2002
        </year>
        <fpage>
         528
        </fpage>
        <lpage>
         536
        </lpage>
        <pub-id pub-id-type="pmid">
         11973559
        </pub-id>
       </element-citation>
      </ref>
     </ref-list>
    </sec>
    <sec id="subchapter35">
     <sec-meta>
      <contrib-group>
       <contrib contrib-type="author" id="au61">
        <name>
         <surname>
          Barbeau
         </surname>
         <given-names>
          Deborah Nicolls
         </given-names>
        </name>
       </contrib>
      </contrib-group>
     </sec-meta>
     <title>
      DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM
     </title>
     <sec id="cesec468">
      <title>
       Background
      </title>
      <p id="para1982">
       Venous thromboembolism (VTE) consists of two related conditions: 1) deep vein thrombosis (DVT) and 2) pulmonary embolism (PE). DVT occurs when there is a partial or complete blockage of a deep vein by a blood clot, most commonly in the legs. The clot may break off and travel to the vessels in the lung, causing a life-threatening PE.
      </p>
      <p id="para1983">
       VTE associated with air travel was first described in the early 1950s. Previous studies have shown a two- to four-fold increased risk of VTE following air travel. In 2001, the World Health Organization set up the WHO Research into Global Hazards of Travel (WRIGHT) Project, a large collaborative research study to confirm the association between VTE and air travel. The goals of this project are to determine the magnitude of the risk of VTE due to air travel, to determine the effect of other factors on the association, and to study the effect of preventive measures on risk. The results of Phase I of the project were published recently. Phase II will address the effect of preventive measures.
      </p>
     </sec>
     <sec id="cesec469">
      <title>
       Risk for Travelers
      </title>
      <p id="para1984">
       Several factors have been associated with an increased risk for developing VTE (
       <xref ref-type="fig" rid="f13">
        Box 2-4
       </xref>
       ).
       <fig id="f13">
        <label>
         Box 2-4
        </label>
        <caption>
         <p>
          Risk factors for venous thromboembolism (VTE)
         </p>
         <p>
          Rights were not granted to include this box in electronic media. Please refer to the printed publication.
         </p>
        </caption>
        <graphic xlink:href="box4">
        </graphic>
        <permissions>
         <copyright-statement>
          © 2009 American Heart Association
         </copyright-statement>
         <copyright-year>
          2009
         </copyright-year>
         <license>
          <license-p>
           Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
          </license-p>
         </license>
        </permissions>
       </fig>
      </p>
      <p id="para1985">
       Combined effects have been observed between these established risk factors and different forms of travel. A population-based case–control study of adults receiving treatment for their first VTE found that long-distance travel (Δ4 hours) doubled the risk of VTE. The effect was greatest in the first week after travel but remained elevated for 2 months. Travel by air increased the risk to the same extent as travel by bus, train, or car, suggesting that the increased risk of air travel is due primarily to prolonged immobility. Synergistic effects were noted with factor V Leiden mutations, women who used oral contraceptives, BMI &gt;30 kg/m
       <sup>
        2
       </sup>
       , and height &gt;1.9 m (approximately 6 ft 3 in). Some of these effects were greatest following air travel. Furthermore, people shorter than 1.6 m (approximately 5 ft 3 in) had an increased risk of VTE only after prolonged air travel. These findings suggest that additional factors related to air travel may be involved in the increased risk for VTE.
      </p>
     </sec>
     <sec id="cesec470">
      <title>
       Occurrence
      </title>
      <p id="para1986">
       Two recent retrospective cohort studies address the issue of air travel-associated VTE incidence. The first was a cohort of 2,499 healthy Dutch commercial pilots. The incidence of VTE in this group was 0.3 per 1,000 person-years. When the data were adjusted for age and sex, the rate was not different from that in the general Dutch population. There was no association between the number of hours flown.
      </p>
      <p id="para1987">
       The second study was among 8,755 employees of several international organizations. The overall incidence of VTE following flights &gt;4 hours was 1.4 per 1,000 person-years. The absolute risk of VTE was 1 per 4,656 flights. The rates of VTE were higher in women, especially those using oral contraceptives. Incidence was also higher in employees with a BMI &gt;25 kg/m
       <sup>
        2
       </sup>
       and those with height &lt;1.65 m (5 ft 5 in) or &gt;1.85 m (6 ft 1 in). The risk of VTE increased with flight duration and with the number of times the employee flew during an 8-week period; the risk of VTE tripled in employees who went on five or more long-haul (Δ4 hours) flights. Each extra flight increased the risk of VTE 1.4-fold. The risk of VTE was highest in the first 2 weeks after a long-haul flight and gradually decreased to baseline after 8 weeks.
      </p>
      <p id="para1988">
       Both these studies were performed among populations that are younger (mean age 35–40 years) and healthier than the general population and are not, therefore, generalizable to a higher-risk population.
      </p>
     </sec>
     <sec id="cesec471">
      <title>
       Clinical Presentation
      </title>
      <p id="para1989">
       Symptoms of DVT include swelling, redness, pain, or tenderness, and increased warmth over the skin. It may be difficult to distinguish from muscle strain, injury, or skin infection.
      </p>
      <p id="para1990">
       Symptoms of PE range from mild and nonspecific to acute, resembling heart attack or stroke. Once a clot has traveled to the lungs, common symptoms of PE are chest pain and shortness of breath. Other symptoms include dizziness, fainting, anxiety, and malaise. PE can occur in the absence of overt signs of DVT.
      </p>
     </sec>
     <sec id="cesec472">
      <title>
       Diagnosis
      </title>
      <p id="para1991">
       Specialized imaging tests (e.g., duplex venous ultrasound, venography, computed tomography (CT) scans, and magnetic resonance imaging) are needed to make a definitive diagnosis of DVT. Helical CT or ventilation–perfusion scans are commonly used to diagnose PE.
      </p>
     </sec>
     <sec id="cesec473">
      <title>
       Preventive Measures for Travelers
      </title>
      <p id="para1992">
       Several randomized, controlled trials have been performed to assess the effect of prophylactic measures on VTE risk after air travel. All studies examined the risk of asymptomatic DVT in travelers making flights Δ7 hours. All travelers were encouraged to do regular exercises and to drink nonalcoholic beverages during the flight. DVT was diagnosed by venous ultrasound from 90 minutes to 48 hours after the flight. Interventions that were studied include compression stockings, aspirin, low-molecular weight heparin, and various natural extracts with anticoagulant properties. No significant effect was seen in any of the pharmacologic interventions. Compression stockings (10–20 mm Hg and 20–30 mm Hg) were shown to significantly reduce the risk of asymptomatic DVT; however, four travelers wearing compression stockings in one study developed superficial thrombophlebitis. Symptomatic DVT and PE were not observed in any of the travelers enrolled in the studies.
      </p>
      <p id="para1993">
       All travelers should keep hydrated, wear loose-fitting clothing, and make efforts to walk and stretch at regular intervals during long-distance travel. Compression stockings may be beneficial to travelers with other risk factors for VTE. Currently no convincing data suggest that pharmacologic interventions reduce the risk of significant VTE during travel.
      </p>
      <p id="para1994">
       The American College of Chest Physicians published the 8th edition of their Antithrombotic and Thrombolytic Therapy Evidence-Based Clinical Practice Guidelines in a June 2008 Supplement to Chest. Recommendations for long-distance travel associated VTE are the following:
       <list id="celist403" list-type="simple">
        <list-item id="celistitem1450">
         <label>
          •
         </label>
         <p id="para1995">
          For travelers who are taking flights &gt;8 hours, the following general measures are recommended: avoidance of constrictive clothing around the lower extremities or waist, maintenance of adequate hydration, and frequent calf muscle contraction (Grade 1C).
         </p>
        </list-item>
        <list-item id="celistitem1451">
         <label>
          •
         </label>
         <p id="para1996">
          For long-distance travelers with additional risk factors for VTE, we recommend the general measures listed above. If active thromboprophylaxis is considered because of a perceived high risk of VTE, we suggest the use of properly fitted, below-knee graduated compression stockings (GCS), providing 15–30 mm Hg of pressure at the ankle (Grade 2C), or a single prophylactic dose of low-molecular-weight heparin (LMWH), injected prior to departure (Grade 2C).
         </p>
        </list-item>
        <list-item id="celistitem1452">
         <label>
          •
         </label>
         <p id="para1997">
          For long-distance travelers, we recommend against the use of aspirin for VTE prevention (Grade 1B).
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <ref-list id="cebib35">
      <title>
       References
      </title>
      <ref id="bib345">
       <label>
        1
       </label>
       <element-citation id="sbref313" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Anderson
          </surname>
          <given-names>
           FA
          </given-names>
          <suffix>
           Jr
          </suffix>
         </name>
         <name>
          <surname>
           Spencer
          </surname>
          <given-names>
           FA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Risk factors for venous thromboembolism
        </article-title>
        <source>
         Circulation
        </source>
        <volume>
         107
        </volume>
        <issue>
         23 Suppl 1
        </issue>
        <year>
         2003
        </year>
        <fpage>
         I9
        </fpage>
        <lpage>
         16
        </lpage>
        <pub-id pub-id-type="pmid">
         12814980
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib346">
       <label>
        2
       </label>
       <mixed-citation id="ceotherref33" publication-type="other">
        World Health Organization. WHO Research into Global Hazards of Travel (WRIGHT) project: Final Report of Phase I. Geneva (Switzerland): World Health Organization; 2007 [cited 2008 May 30]. Available from:
        <ext-link ext-link-type="uri" id="interref85" xlink:href="http://www.who.int/cardiovascular_diseases/wright_project/en">
         http://www.who.int/cardiovascular_diseases/wright_project/en
        </ext-link>
        .
       </mixed-citation>
      </ref>
      <ref id="bib347">
       <label>
        3
       </label>
       <element-citation id="sbref314" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kuipers
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Cannegieter
          </surname>
          <given-names>
           SC
          </given-names>
         </name>
         <name>
          <surname>
           Middeldorp
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        <article-title>
         The absolute risk of venous thrombosis after air travel: a cohort study of 8,755 employees of international organisations
        </article-title>
        <source>
         PLoS Med
        </source>
        <volume>
         4
        </volume>
        <issue>
         9
        </issue>
        <year>
         2007
        </year>
        <fpage>
         e290
        </fpage>
        <pub-id pub-id-type="pmid">
         17896862
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib348">
       <label>
        4
       </label>
       <element-citation id="sbref315" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Goodacre
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Sutton
          </surname>
          <given-names>
           AJ
          </given-names>
         </name>
         <name>
          <surname>
           Sampson
          </surname>
          <given-names>
           FC
          </given-names>
         </name>
        </person-group>
        <article-title>
         Meta-analysis: the value of clinical assessment in the diagnosis of deep venous thrombosis
        </article-title>
        <source>
         Ann Intern Med
        </source>
        <volume>
         143
        </volume>
        <issue>
         2
        </issue>
        <year>
         2005
        </year>
        <fpage>
         129
        </fpage>
        <lpage>
         139
        </lpage>
        <pub-id pub-id-type="pmid">
         16027455
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib349">
       <label>
        5
       </label>
       <element-citation id="sbref316" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kuipers
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Schreijer
          </surname>
          <given-names>
           AJ
          </given-names>
         </name>
         <name>
          <surname>
           Cannegieter
          </surname>
          <given-names>
           SC
          </given-names>
         </name>
        </person-group>
        <article-title>
         Travel and venous thrombosis: a systematic review
        </article-title>
        <source>
         J Intern Med
        </source>
        <volume>
         262
        </volume>
        <issue>
         6
        </issue>
        <year>
         2007
        </year>
        <fpage>
         615
        </fpage>
        <lpage>
         634
        </lpage>
        <pub-id pub-id-type="pmid">
         18028182
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib350">
       <label>
        6
       </label>
       <element-citation id="sbref317" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Geerts
          </surname>
          <given-names>
           WH
          </given-names>
         </name>
         <name>
          <surname>
           Bergqvist
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Pineo
          </surname>
          <given-names>
           GF
          </given-names>
         </name>
        </person-group>
        <article-title>
         American College of Chest Physicians. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
        </article-title>
        <source>
         Chest
        </source>
        <volume>
         133
        </volume>
        <issue>
         6 Suppl
        </issue>
        <year>
         2008
        </year>
        <fpage>
         381S
        </fpage>
        <lpage>
         453S
        </lpage>
        <pub-id pub-id-type="pmid">
         18574271
        </pub-id>
       </element-citation>
      </ref>
     </ref-list>
    </sec>
    <sec id="subchapter36">
     <sec-meta>
      <contrib-group>
       <contrib contrib-type="author" id="au62">
        <name>
         <surname>
          Sleet
         </surname>
         <given-names>
          David A.
         </given-names>
        </name>
       </contrib>
       <contrib contrib-type="author" id="au63">
        <name>
         <surname>
          Wallace
         </surname>
         <given-names>
          L.J. David
         </given-names>
        </name>
       </contrib>
       <contrib contrib-type="author" id="au64">
        <name>
         <surname>
          Shlim
         </surname>
         <given-names>
          David R.
         </given-names>
        </name>
       </contrib>
      </contrib-group>
     </sec-meta>
     <title>
      INJURIES AND SAFETY
     </title>
     <sec id="cesec474">
      <title>
       Overview
      </title>
      <p id="para1998">
       According to the World Health Organization, injuries are among the leading causes of death and disability in the world, and they are the leading cause of preventable death in travelers. Of the approximately five million people killed due to injuries in the world, approximately 1.2 million people died of road traffic incidents, 815,000 from suicide and 520,000 from homicides. In addition to the considerable number of deaths, millions more are wounded or suffer other nonfatal health consequences. Worldwide, among persons aged 5–44 years, injuries account for 6 of the 15 leading causes of death.
      </p>
      <p id="para1999">
       In 2007, just over 64 million Americans traveled outside the United States. The vast majority of these trips occurred without any serious health problems, but fatal and serious injuries occur to Americans every year while traveling internationally. Among travelers abroad, injuries are one of the leading causes of death. Compared with injuries, infectious diseases, for example, only account for a small proportion (2%) of deaths to overseas travelers.
      </p>
      <p id="para2000">
       The U.S. Department of State collects data on U.S. citizens who die in a foreign country from non-natural causes for the most recent 3-year period and makes these data available on the Department of State website. These deaths are categorized by location where the death occurred, date of death, and cause of death. These deaths should be considered a conservative estimate of the true number of U.S. citizens who die in foreign countries, as some deaths may not be reported to the Department of State. We analyzed these data and found that from 2003 to 2005 an estimated 2,276 U.S. citizens died from injuries and violence while in foreign countries (excluding deaths occurring in Iraq and Afghanistan). Road traffic crashes headed the list of causes (34%), followed by homicide (17%), and drowning (13%) (
       <xref ref-type="fig" rid="f3">
        Figure 2-3
       </xref>
       ). By comparison to U.S. injury fatalities in 2003, road traffic crashes accounted for 27%, homicide 11%, and drowning 2% of all injury deaths.
       <fig id="f3">
        <label>
         Figure 2-3
        </label>
        <caption>
         <p>
          Leading causes of injury death of U.S. citizens in foreign countries, 2003–2005.
         </p>
        </caption>
        <graphic xlink:href="gr3">
        </graphic>
        <attrib>
         (From U.S. Department of State. U.S. citizen deaths from non-natural causes. Washington D.C.: U.S. Department of State. Available from:
         <ext-link ext-link-type="uri" id="interref1" xlink:href="http://travel.state.gov/law/family_issues/death/death_600.html">
          http://travel.state.gov/law/family_issues/death/death_600.html
         </ext-link>
         .)
        </attrib>
       </fig>
      </p>
      <p id="para2001">
       Depending on travel destination, duration, and planned activities, other common injury and safety concerns include natural hazards and disasters, civil unrest, terrorism, hate crimes against Americans, falls, burns, poisoning, drug-related overdose, and suicide. If seriously injured, emergency care may not be available or acceptable by U.S. standards. Trauma centers which are capable of providing optimal trauma care are uncommon outside urban areas.
      </p>
      <p id="para2002">
       Males, compared with females, are more likely to die from injury causes while traveling internationally. Acquaintance rape and sexual assault are among the important risks to women travelers. Travelers should be aware of the increased risk of certain injuries while traveling abroad, particularly in low-income countries, and be prepared to take preventive steps to avoid them.
      </p>
     </sec>
     <sec id="cesec475">
      <title>
       Road Traffic Injuries
      </title>
      <p id="para2003">
       Road traffic injuries are the leading cause of injury-related deaths worldwide. An estimated 3,000 people are killed each day around the world in road traffic crashes involving cars, buses, motorcycles, bicycles, trucks, or pedestrians. Each year another 20 to 50 million are seriously injured. In response to this crisis, in 2008 the United Nations General Assembly, passed resolution 62/244 ‘Improving global road safety” to strength international cooperation to develop policies and practices to reduce crash risks around the world.
      </p>
      <p id="para2004">
       According to U.S. Department of State data, road traffic crashes are also the leading cause of injury death to U.S. citizens while traveling internationally (see
       <xref ref-type="fig" rid="f3">
        Figure 2-3
       </xref>
       ). An estimated 768 Americans were killed in road traffic crashes in the period from 2003 to 2005. Approximately 13% of these road traffic deaths involved motorcycles and 7% were pedestrians. A study from Bermuda reported that tourists sustain a much higher rate of motorbike injuries than the local population, with the highest rate in persons aged 50–59 years. Loss of vehicular control, unfamiliar equipment, and inexperience with motorized two-wheelers contributed to crashes and injuries, even when traveling at speeds less than 30 mph. Road traffic crashes are also a leading cause of nonfatal injury among U.S. citizens requiring emergency transport back to the United States.
      </p>
      <p id="para2005">
       Road traffic crashes are common in foreign tourists for a number of reasons: lack of familiarity with the roads, driving on the opposite side of the road than in one's home country, poorly made or maintained vehicles, travel fatigue, poor road surfaces without shoulders, unprotected curves and cliffs, and poor visibility due to lack of adequate lighting, both on the road and on the vehicle. In many low-income areas of the world, unsafe roads and vehicles and an inadequate transportation infrastructure contribute to the traffic injury problem. A safety concern in low-income countries is the mixing of motor vehicles with vulnerable road users such as pedestrians, bicyclists, and motorbike users. It is common in low-income countries to have cars, buses, and large trucks all sharing the same road with pedestrians, motorbikes, bicycles, rickshaws and even animals. This mixing of road users all in the same travel lane increases the risk for crashes and injuries.
      </p>
      <p id="para2006">
       Sometimes travelers have few options in getting to remote areas, but if there are choices, they should look for better-maintained vehicles, daytime travel, seatbelts and a trained and licensed or hired driver.
      </p>
      <sec id="cesec476">
       <title>
        Prevention of Road Traffic Injuries
       </title>
       <p id="para2007">
        Health advisors should counsel the traveler to:
        <list id="celist404" list-type="simple">
         <list-item id="celistitem1453">
          <label>
           •
          </label>
          <p id="para2008">
           Use safety belts and child safety seats whenever possible. Safety belts reduce the risk of death in a crash by 45%–60%, child safety seats by 54% and infant seats by 70%. When traveling, rent newer vehicles with safety belts and airbags and bring a child safety seat from home.
          </p>
         </list-item>
         <list-item id="celistitem1454">
          <label>
           •
          </label>
          <p id="para2009">
           Rent larger vehicles if possible, because they provide more protection in a crash.
          </p>
         </list-item>
         <list-item id="celistitem1455">
          <label>
           •
          </label>
          <p id="para2010">
           Try to ride only in taxis with functional safety belts and ride in the rear seat.
          </p>
         </list-item>
         <list-item id="celistitem1456">
          <label>
           •
          </label>
          <p id="para2011">
           Wear helmets when riding motorcycles, motorbikes, and bicycles. If helmets are likely to be unavailable at the destination, they should be brought from home.
          </p>
         </list-item>
         <list-item id="celistitem1457">
          <label>
           •
          </label>
          <p id="para2012">
           Avoid drinking alcohol and driving or biking. U.S. data show that an alcohol-impaired driver has a 17 times greater risk of being involved in a fatal crash.
          </p>
         </list-item>
         <list-item id="celistitem1458">
          <label>
           •
          </label>
          <p id="para2013">
           Visit the websites of the Association for International Road Travel (ASIRT) (
           <ext-link ext-link-type="uri" id="interref86" xlink:href="http://www.asirt.org">
            www.asirt.org
           </ext-link>
           ) and Make Roads Safe (
           <ext-link ext-link-type="uri" id="interref87" xlink:href="http://www.makeroadssafe.org">
            www.makeroadssafe.org
           </ext-link>
           ), both NGOs, which have useful safety tips for international travelers, including road safety checklists and country specific driving risks.
          </p>
         </list-item>
         <list-item id="celistitem1459">
          <label>
           •
          </label>
          <p id="para2014">
           Check the safety and security information from the U.S. Department of State (
           <ext-link ext-link-type="uri" id="interref88" xlink:href="http://www.travel.state.gov">
            www.travel.state.gov
           </ext-link>
           ).
          </p>
         </list-item>
         <list-item id="celistitem1460">
          <label>
           •
          </label>
          <p id="para2015">
           Consider hiring a driver familiar with the destination, the language and an expert in maneuvering through local traffic.
          </p>
         </list-item>
         <list-item id="celistitem1461">
          <label>
           •
          </label>
          <p id="para2016">
           Avoid riding on overcrowded, overweight, top heavy busses, or minivans, or riding with any driver who has consumed alcohol.
          </p>
         </list-item>
         <list-item id="celistitem1462">
          <label>
           •
          </label>
          <p id="para2017">
           Be aware of pedestrians and be aware as a pedestrian of the dangers. Walk with a friend, rather than alone, as this helps with safety.
          </p>
         </list-item>
        </list>
       </p>
      </sec>
     </sec>
     <sec id="cesec477">
      <title>
       Water Injuries
      </title>
      <p id="para2018">
       Drowning accounts for 13% of deaths of Americans abroad. The risk factors have not been clearly defined, but are suspected to be related to unfamiliarity with local water currents and water conditions. Drowning was the leading cause of injury death to Americans visiting countries where exposure to water recreation was a major activity such as Fiji, Dutch Antilles, Aruba, and Costa Rica. Studies have found that young men are particularly at risk of head and spinal cord injuries from diving into shallow water, with alcohol a factor in some cases. In 2000, approximately 449,000 people drowned worldwide; the exact number of travelers who suffer from nonfatal drowning is not precisely known.
      </p>
      <p id="para2019">
       Alcohol is also a suspected contributing factor to both drowning and boating mishaps.
      </p>
      <p id="para2020">
       Scuba diving is a frequent pursuit of travelers in ocean destinations. Travelers should either be experienced divers, or dive with a reliable dive shop and instructors. They should be reminded not to dive on the same day they arrive by airplane. The fatality rate among all divers, worldwide, is thought to be 15 to 20 deaths per 100,000 divers per year.
      </p>
     </sec>
     <sec id="cesec478">
      <title>
       Other Unintentional Injuries
      </title>
      <p id="para2021">
       From 2003 to 2005, other than drowning, airplane crashes, natural disasters, and other unintentional injuries accounted for over a third of all injury deaths to Americans in foreign countries (see
       <xref ref-type="fig" rid="f3">
        Figure 2-3
       </xref>
       ). Fires can be a substantial risk in low-income countries where building codes are not present or enforced, where there's an absence of smoke alarms, where there is no emergency access to 9-1-1 services, and where the fire department focus is on putting out fires rather than on fire prevention or victim rescue.
      </p>
      <sec id="cesec479">
       <title>
        Preventing Other Unintentional Injuries
       </title>
       <p id="para2022">
        Health advisors should counsel the traveler on the following:
        <list id="celist405" list-type="simple">
         <list-item id="celistitem1463">
          <label>
           •
          </label>
          <p id="para2023">
           Travelers should consider purchasing special health and evacuation insurance if their destinations include countries where there may not be access to good medical care.
          </p>
         </list-item>
         <list-item id="celistitem1464">
          <label>
           •
          </label>
          <p id="para2024">
           Because trauma care is poor in many countries, victims of injuries can die before ever reaching a hospital, and there may be no coordinated ambulance services. In remote areas, medical assistance, drugs and medicines may be unavailable and travel can take a long time to the nearest medical facility.
          </p>
         </list-item>
         <list-item id="celistitem1465">
          <label>
           •
          </label>
          <p id="para2025">
           Where possible avoid using local unscheduled small aircraft. If available choose larger aircraft (greater than 30 seats) as they have undergone more strict and regular safety inspections. Larger aircraft also provide more protection in the event of a crash. From 2003 to 2005 an estimated 83 Americans were killed in airplane crashes in foreign countries (see
           <xref ref-type="fig" rid="f3">
            Figure 2-3
           </xref>
           ). For country-specific airline crash events, see
           <ext-link ext-link-type="uri" id="interref89" xlink:href="http://www.airsafe.com">
            www.airsafe.com
           </ext-link>
           .
          </p>
         </list-item>
         <list-item id="celistitem1466">
          <label>
           •
          </label>
          <p id="para2026">
           To prevent fire-related injuries, select accommodations on the 6th floor or below (fire ladders generally cannot reach above the 6th). If possible, stay in hotels with smoke alarms and preferably sprinkler systems. Be alert for improperly vented heating devices which may cause poisoning from carbon monoxide (CO), a colorless odorless gas and by-product of all fossil fuel combustions. Some travelers choose to carry a personal CO detector. Travelers should identify two escape routes from buildings and remember to escape a fire by crawling low under smoke and by covering one's mouth with a wet cloth.
          </p>
         </list-item>
        </list>
       </p>
      </sec>
     </sec>
     <sec id="cesec480">
      <title>
       Violence-Related Injuries
      </title>
      <p id="para2027">
       Violence is a leading worldwide public health problem and a growing concern of travelers. In 2000, about 1.6 million persons lost their lives to violence and only one-fifth were casualties of armed conflicts. Rates of violent deaths in low- to middle-income countries are more than 3 times those in higher-income countries, although there are great variations within countries, depending on regional demographic differences.
      </p>
      <p id="para2028">
       Homicide was the second leading cause of injury death among American travelers in foreign countries accounting for almost 400 deaths from 2003 to 2005 (see
       <xref ref-type="fig" rid="f3">
        Figure 2-3
       </xref>
       ). For some low-income countries such as Honduras, Colombia, Guatemala, and Haiti homicide was the leading cause of injury death for Americans accounting for 43%–65% of all injury deaths.
      </p>
      <p id="para2029">
       Terrorism-related deaths among Americans in foreign countries, while alarming, are still relatively rare events and accounted for only 2% of all injury deaths (see
       <xref ref-type="fig" rid="f3">
        Figure 2-3
       </xref>
       ). The vast majority of terrorism deaths among Americans occurred in countries of the Middle East. According to data from the State Department, 2003–2005, 82% of the injury deaths among Americans in Saudi Arabia and 55% of injury deaths in Israel/West Bank/Gaza were from terrorism.
      </p>
      <p id="para2030">
       Suicide is the fourth leading cause of injury death to U.S. citizens traveling abroad (see
       <xref ref-type="fig" rid="f3">
        Figure 2-3
       </xref>
       ). Factors contributing to homicide and suicide may be different while traveling than at home. Unfamiliarity with a destination, not being vigilant to one's surroundings, and alcohol involvement may increase risk of assault and homicide. For longer-term travelers (e.g., missionaries and volunteers), social isolation and substance abuse, particularly in the face of living in areas of poverty and rigid gender roles, may increase the risk of depression and suicide.
      </p>
      <p id="para2031">
       If a traveler is the victim of a crime overseas, the nearest U.S. embassy, consulate, or consular agency for assistance should be contacted at
       <ext-link ext-link-type="uri" id="interref90" xlink:href="http://www.travel.state.gov">
        www.travel.state.gov
       </ext-link>
       .
      </p>
      <sec id="cesec481">
       <title>
        Prevention of Violence
       </title>
       <p id="para2032">
        U.S. travelers are viewed by many criminals as wealthy, naïve targets, who are inexperienced and unfamiliar with the culture and inept at seeking assistance once victimized. Traveling in high poverty areas, civil unrest, alcohol or drug use, and traveling in unfamiliar environments at night increase the likelihood that a U.S. traveler will be the victim of planned or random violence.
       </p>
       <p id="para2033">
        To avoid violence while traveling, limit travel at night, travel with a companion, and vary the routine travel habits. Travelers should wear locally available accessories that are more typical of a country-savvy expatriate community and avoid expensive or provocative clothing, or accessories. Accommodations on the ground floor of hotels or immediately next to the stairwell should be avoided. Criminals are less likely to victimize upper level floors. All doors and windows should be locked. Some carry a door intruder alarm, a smoke alarm, and a rubber door stop that can be used as a supplemental door lock. Persons unknown to the traveler should not be invited into one's accommodations as this can be misinterpreted or against local laws and customs.
       </p>
       <p id="para2034">
        The U.S. Department of State website (
        <ext-link ext-link-type="uri" id="interref91" xlink:href="http://www.travel.state.gov">
         www.travel.state.gov
        </ext-link>
        ) has useful information regarding safety and security.
       </p>
      </sec>
     </sec>
     <sec id="cesec482">
      <title>
       Summary
      </title>
      <p id="para2035">
       Injuries and violence are as much a public health problem to travelers overseas as are infectious and chronic diseases—and they are in many ways more deadly. Injuries are still the most frequent cause of death abroad in developing countries. Effective prevention strategies are available, particularly for travelers who find themselves in new environments and who may be more likely to be unaware of risks or complacent in exotic surroundings. Despite greater understanding and increased research efforts in this field, data on the magnitude and severity of injuries is still incomplete or unreliable in many countries. Existing data indicate that injury and violence are among the most important causes of premature death and ill-health to U.S. travelers overseas. Travel health advisors and other health-care providers should alert the public to the known risks and especially about simple and effective preventive measures to implement during international travel.
      </p>
     </sec>
     <ref-list id="cebib36">
      <title>
       References
      </title>
      <ref id="bib351">
       <label>
        1
       </label>
       <mixed-citation id="ceotherref34" publication-type="other">
        Peden M, McGee K, Sharma G. The injury chart book: a graphical overview of the global burden of injuries [Internet]. [cited 2008 Nov 25] Geneva (Switzerland): World Health Organization; 2002. Available from:
        <ext-link ext-link-type="uri" id="interref92" xlink:href="http://www.who.int/violence_injury_prevention/publications/other_injury/chartb/en/">
         http://www.who.int/violence_injury_prevention/publications/other_injury/chartb/en/
        </ext-link>
       </mixed-citation>
      </ref>
      <ref id="bib352">
       <label>
        2
       </label>
       <mixed-citation id="ceotherref35" publication-type="other">
        U.S. Department of Commerce. The Office of Travel and Tourism Industries. 2007 United States resident travel abroad [cited 2008 Nov 25]. Available from:
        <ext-link ext-link-type="uri" id="interref93" xlink:href="http://tinet.ita.doc.gov/outreachpages/outbound.general_information">
         http://tinet.ita.doc.gov/outreachpages/outbound.general_information
        </ext-link>
        . outbound_overview.html.
       </mixed-citation>
      </ref>
      <ref id="bib353">
       <label>
        3
       </label>
       <element-citation id="sbref318" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           McInnes
          </surname>
          <given-names>
           RJ
          </given-names>
         </name>
         <name>
          <surname>
           Williamson
          </surname>
          <given-names>
           LM
          </given-names>
         </name>
         <name>
          <surname>
           Morrison
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        <article-title>
         Unintentional injury during foreign travel: a review
        </article-title>
        <source>
         J Travel Med
        </source>
        <volume>
         9
        </volume>
        <issue>
         6
        </issue>
        <year>
         2002
        </year>
        <fpage>
         297
        </fpage>
        <lpage>
         307
        </lpage>
        <pub-id pub-id-type="pmid">
         12962584
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib354">
       <label>
        4
       </label>
       <mixed-citation id="ceotherref36" publication-type="other">
        U.S. Department of State. U.S. citizen deaths from non-natural causes by foreign country [cited 2006 June]. Available from:
        <ext-link ext-link-type="uri" id="interref94" xlink:href="http://travel.state.gov/law/family_issues/death/death_600.html">
         http://travel.state.gov/law/family_issues/death/death_600.html
        </ext-link>
       </mixed-citation>
      </ref>
      <ref id="bib355">
       <label>
        5
       </label>
       <mixed-citation id="ceotherref37" publication-type="other">
        Web-based Injury Statistics Query and Reporting System (WISQARS) [cited 2008 June]. Available from:
        <ext-link ext-link-type="uri" id="interref95" xlink:href="http://www.cdc.gov/ncipc/wisqars">
         www.cdc.gov/ncipc/wisqars
        </ext-link>
       </mixed-citation>
      </ref>
      <ref id="bib356">
       <label>
        6
       </label>
       <element-citation id="sbref319" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           MacPherson
          </surname>
          <given-names>
           DW
          </given-names>
         </name>
         <name>
          <surname>
           Guérillot
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Streiner
          </surname>
          <given-names>
           DL
          </given-names>
         </name>
        </person-group>
        <article-title>
         Death and dying abroad: the Canadian experience
        </article-title>
        <source>
         J Travel Med
        </source>
        <volume>
         7
        </volume>
        <issue>
         5
        </issue>
        <year>
         2000
        </year>
        <fpage>
         227
        </fpage>
        <lpage>
         233
        </lpage>
        <pub-id pub-id-type="pmid">
         11231205
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib357">
       <label>
        7
       </label>
       <element-citation id="sbref320" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hargarten
          </surname>
          <given-names>
           SW
          </given-names>
         </name>
         <name>
          <surname>
           Baker
          </surname>
          <given-names>
           TD
          </given-names>
         </name>
         <name>
          <surname>
           Guptill
          </surname>
          <given-names>
           K
          </given-names>
         </name>
        </person-group>
        <article-title>
         Overseas fatalities of United States citizen travelers: an analysis of deaths related to international travel
        </article-title>
        <source>
         Ann Emerg Med
        </source>
        <volume>
         20
        </volume>
        <issue>
         6
        </issue>
        <year>
         1991
        </year>
        <fpage>
         622
        </fpage>
        <lpage>
         626
        </lpage>
        <pub-id pub-id-type="pmid">
         2039100
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib358">
       <label>
        8
       </label>
       <mixed-citation id="ceotherref38" publication-type="other">
        Peden M, Scurfield R, Sleet D, et al., editors. World report on road traffic injury prevention. Geneva (Switzerland): World Health Organization; 2004. [cited 2008 Nov 25]. Available from:
        <ext-link ext-link-type="uri" id="interref146" xlink:href="http://www.who.int/violence_injury_prevention/publications/road_traffic/world_report/en/">
         http://www.who.int/violence_injury_prevention/publications/road_traffic/world_report/en/
        </ext-link>
        .
       </mixed-citation>
      </ref>
      <ref id="bib359">
       <label>
        9
       </label>
       <element-citation id="sbref321" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sleet
          </surname>
          <given-names>
           DA
          </given-names>
         </name>
         <name>
          <surname>
           Branche
          </surname>
          <given-names>
           CM
          </given-names>
         </name>
        </person-group>
        <article-title>
         Road safety is no accident
        </article-title>
        <source>
         J Safety Res
        </source>
        <volume>
         35
        </volume>
        <issue>
         2
        </issue>
        <year>
         2004
        </year>
        <fpage>
         173
        </fpage>
        <lpage>
         174
        </lpage>
        <pub-id pub-id-type="pmid">
         15178235
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib360">
       <label>
        10
       </label>
       <element-citation id="sbref322" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Carey
          </surname>
          <given-names>
           MJ
          </given-names>
         </name>
         <name>
          <surname>
           Aitken
          </surname>
          <given-names>
           ME
          </given-names>
         </name>
        </person-group>
        <article-title>
         Motorbike injuries in Bermuda: a risk for tourists
        </article-title>
        <source>
         Ann Emerg Med
        </source>
        <volume>
         28
        </volume>
        <issue>
         4
        </issue>
        <year>
         1996
        </year>
        <fpage>
         424
        </fpage>
        <lpage>
         429
        </lpage>
        <pub-id pub-id-type="pmid">
         8839529
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib361">
       <label>
        11
       </label>
       <element-citation id="sbref323" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hargarten
          </surname>
          <given-names>
           SW
          </given-names>
         </name>
         <name>
          <surname>
           Bouc
          </surname>
          <given-names>
           GT
          </given-names>
         </name>
        </person-group>
        <article-title>
         Emergency air medical transport of U.S.-citizen tourists: 1988 to 1990
        </article-title>
        <source>
         Air Med J
        </source>
        <volume>
         12
        </volume>
        <issue>
         10
        </issue>
        <year>
         1993
        </year>
        <fpage>
         398
        </fpage>
        <lpage>
         402
        </lpage>
        <pub-id pub-id-type="pmid">
         10129574
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib362">
       <label>
        12
       </label>
       <element-citation id="sbref324" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Barss
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Smith
          </surname>
          <given-names>
           GS
          </given-names>
         </name>
         <name>
          <surname>
           Baker
          </surname>
          <given-names>
           SP
          </given-names>
         </name>
        </person-group>
        <source>
         Injury prevention: an international perspective
        </source>
        <year>
         1998
        </year>
        <publisher-name>
         Oxford University Press
        </publisher-name>
        <publisher-loc>
         New York
        </publisher-loc>
       </element-citation>
      </ref>
      <ref id="bib363">
       <label>
        13
       </label>
       <element-citation id="sbref325" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zaza
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Sleet
          </surname>
          <given-names>
           DA
          </given-names>
         </name>
         <name>
          <surname>
           Shults
          </surname>
          <given-names>
           RA
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         Reducing injuries to motor vehicle occupants
        </chapter-title>
        <person-group person-group-type="editor">
         <name>
          <surname>
           Zaza
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Briss
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Harris
          </surname>
          <given-names>
           K
          </given-names>
         </name>
        </person-group>
        <source>
         The guide to community preventive services: what works to promote health?
        </source>
        <year>
         2005
        </year>
        <publisher-name>
         Oxford University Press
        </publisher-name>
        <publisher-loc>
         New York
        </publisher-loc>
        <fpage>
         329
        </fpage>
        <lpage>
         384
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib364">
       <label>
        14
       </label>
       <mixed-citation id="ceotherref39" publication-type="other">
        The Association for International Road Travel. [cited 2008 Nov 25]. Available from:
        <ext-link ext-link-type="uri" id="interref96" xlink:href="http://www.asirt.org">
         www.asirt.org
        </ext-link>
       </mixed-citation>
      </ref>
      <ref id="bib365">
       <label>
        15
       </label>
       <mixed-citation id="ceotherref40" publication-type="other">
        Commission for Global Road Safety. Make Roads Safe. [cited 2008 Nov 25] Available from:
        <ext-link ext-link-type="uri" id="interref97" xlink:href="http://www.makeroadssafe.org">
         www.makeroadssafe.org
        </ext-link>
       </mixed-citation>
      </ref>
      <ref id="bib366">
       <label>
        16
       </label>
       <mixed-citation id="ceotherref41" publication-type="other">
        U.S. Department of State. Bureau of Consular Affairs [cited 2008 Nov 25]. Available from:
        <ext-link ext-link-type="uri" id="interref98" xlink:href="http://travel.state.gov/travel/travel_1744.html">
         http://travel.state.gov/travel/travel_1744.html
        </ext-link>
        .
       </mixed-citation>
      </ref>
      <ref id="bib367">
       <label>
        17
       </label>
       <mixed-citation id="ceotherref42" publication-type="other">
        Krug EG, Dahlberg LL, Mercy JA, et al. World report on violence and health. Geneva (Switzerland): World Health Organization; 2002. [cited 2008 Nov 25]. Available from:
        <ext-link ext-link-type="uri" id="interref99" xlink:href="http://www.who.int/violence_injury_prevention/violence/world_report/en">
         www.who.int/violence_injury_prevention/violence/world_report/en
        </ext-link>
       </mixed-citation>
      </ref>
      <ref id="bib368">
       <label>
        18
       </label>
       <element-citation id="sbref326" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Jeannel
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Allain-Ioos
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Bonmarin
          </surname>
          <given-names>
           I
          </given-names>
         </name>
        </person-group>
        <article-title>
         Les décès de français lors d'un séjour à l’étranger et leurs causes
        </article-title>
        <source>
         Bull Epid Heb
        </source>
        <issue>
         23–4
        </issue>
        <year>
         2006
        </year>
        <fpage>
         166
        </fpage>
        <lpage>
         168
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib369">
       <label>
        19
       </label>
       <element-citation id="sbref327" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ball
          </surname>
          <given-names>
           DJ
          </given-names>
         </name>
         <name>
          <surname>
           Machin
          </surname>
          <given-names>
           N
          </given-names>
         </name>
        </person-group>
        <article-title>
         Foreign travel and the risk of harm
        </article-title>
        <source>
         Int J Inj Contr Saf Promot
        </source>
        <volume>
         13
        </volume>
        <issue>
         2
        </issue>
        <year>
         2006
        </year>
        <fpage>
         107
        </fpage>
        <lpage>
         115
        </lpage>
        <pub-id pub-id-type="pmid">
         16707347
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib370">
       <label>
        20
       </label>
       <element-citation id="sbref328" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cortés
          </surname>
          <given-names>
           LM
          </given-names>
         </name>
         <name>
          <surname>
           Hargarten
          </surname>
          <given-names>
           SW
          </given-names>
         </name>
         <name>
          <surname>
           Hennes
          </surname>
          <given-names>
           HM
          </given-names>
         </name>
        </person-group>
        <article-title>
         Recommendations for water safety and drowning prevention for travelers
        </article-title>
        <source>
         J Travel Med
        </source>
        <volume>
         13
        </volume>
        <issue>
         1
        </issue>
        <year>
         2006
        </year>
        <fpage>
         21
        </fpage>
        <lpage>
         34
        </lpage>
        <pub-id pub-id-type="pmid">
         16412106
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib371">
       <label>
        21
       </label>
       <mixed-citation id="ceotherref43" publication-type="other">
        United Nations General Assembly. Resolution A/RES/62/244 Improving global road safety. Sixty-second session, agenda item 46. 87th Plenary meeting, 2008 March 31. Passed 2008 April.
       </mixed-citation>
      </ref>
     </ref-list>
    </sec>
    <sec id="subchapter37">
     <sec-meta>
      <contrib-group>
       <contrib contrib-type="author" id="au65">
        <name>
         <surname>
          Malilay
         </surname>
         <given-names>
          Josephine
         </given-names>
        </name>
       </contrib>
       <contrib contrib-type="author" id="au66">
        <name>
         <surname>
          Batts
         </surname>
         <given-names>
          Dahna
         </given-names>
        </name>
       </contrib>
       <contrib contrib-type="author" id="au67">
        <name>
         <surname>
          Ansari
         </surname>
         <given-names>
          Armin
         </given-names>
        </name>
       </contrib>
       <contrib contrib-type="author" id="au68">
        <name>
         <surname>
          Miller
         </surname>
         <given-names>
          Charles W.
         </given-names>
        </name>
       </contrib>
       <contrib contrib-type="author" id="au69">
        <name>
         <surname>
          Brown
         </surname>
         <given-names>
          Clive M.
         </given-names>
        </name>
       </contrib>
      </contrib-group>
     </sec-meta>
     <title>
      NATURAL DISASTERS AND ENVIRONMENTAL HAZARDS
     </title>
     <sec id="cesec483">
      <title>
       Natural Disasters
      </title>
      <p id="para2036">
       Travelers should be aware of the potential for natural phenomena such as hurricanes, tornadoes, or earthquakes. Natural disasters can contribute to the transmission of some diseases, especially since water supplies and sewage systems may be disrupted, sanitation and hygiene compromised by population displacement and overcrowding, and normal public health services interrupted.
      </p>
      <sec id="cesec484">
       <title>
        Disease Risks
       </title>
       <p id="para2037">
        <list id="celist406" list-type="simple">
         <list-item id="celistitem1467">
          <label>
           •
          </label>
          <p id="para2038">
           The risk for infectious diseases is minimal unless a disease is endemic in an area prior to the disaster event, since transmission cannot take place unless the causative agent is present.
           <list id="celist407" list-type="simple">
            <list-item id="celistitem1468">
             <label>
              ○
             </label>
             <p id="para2039">
              Although typhoid can be endemic in developing countries, natural disasters have seldom led to epidemic levels of disease.
             </p>
            </list-item>
            <list-item id="celistitem1469">
             <label>
              ○
             </label>
             <p id="para2040">
              Floods have been known to prompt outbreaks of leptospirosis in areas where the organism is found in water sources (see the Leptospirosis section in Chapter 5).
             </p>
            </list-item>
           </list>
          </p>
         </list-item>
         <list-item id="celistitem1470">
          <label>
           •
          </label>
          <p id="para2041">
           When water and sewage systems have been disrupted, safe water and food supplies are of great importance in preventing enteric disease transmission. If contamination is suspected, water should be boiled and appropriately disinfected (see the
           <xref ref-type="sec" rid="subchapter30">
            Water Disinfection for Travelers
           </xref>
           section earlier in this chapter).
          </p>
         </list-item>
         <list-item id="celistitem1471">
          <label>
           •
          </label>
          <p id="para2042">
           Travelers who are injured during a natural disaster should have a medical evaluation to determine what additional care may be required for wounds potentially contaminated with feces, soil, or saliva or that have been exposed to fresh or sea water that may contain parasites or bacteria.
          </p>
         </list-item>
         <list-item id="celistitem1472">
          <label>
           •
          </label>
          <p id="para2043">
           Tetanus booster status should always be kept current.
          </p>
         </list-item>
        </list>
       </p>
      </sec>
      <sec id="cesec485">
       <title>
        Injuries
       </title>
       <p id="para2044">
        <list id="celist408" list-type="simple">
         <list-item id="celistitem1473">
          <label>
           •
          </label>
          <p id="para2045">
           When arriving at a destination, travelers should be familiar with local risks for seismic, flood-related, landslide-related, tsunami-related, and other hazards, as well as warning systems, evacuation routes, and shelters in areas of high risk.
          </p>
         </list-item>
         <list-item id="celistitem1474">
          <label>
           •
          </label>
          <p id="para2046">
           After natural disasters, deaths are rarely due to infectious diseases but most often to blunt trauma, crush-related injuries, or drowning. Travelers should thus be aware of the risks for injury before, during, and after a natural disaster.
          </p>
         </list-item>
         <list-item id="celistitem1475">
          <label>
           •
          </label>
          <p id="para2047">
           In floods, people should avoid driving through swiftly moving water.
          </p>
         </list-item>
         <list-item id="celistitem1476">
          <label>
           •
          </label>
          <p id="para2048">
           Travelers should exercise caution during clean-up, particularly when encountering downed power lines, water-affected electrical outlets, interrupted gas lines, and stray or frightened animals.
          </p>
         </list-item>
         <list-item id="celistitem1477">
          <label>
           •
          </label>
          <p id="para2049">
           During natural disasters, technological malfunctions may release hazardous materials (e.g., release of toxic chemicals from a point source displaced by strong winds, seismic motion, or rapidly moving water).
          </p>
         </list-item>
        </list>
       </p>
      </sec>
      <sec id="cesec486">
       <title>
        Environmental Risks
       </title>
       <p id="para2050">
        <list id="celist409" list-type="simple">
         <list-item id="celistitem1478">
          <label>
           •
          </label>
          <p id="para2051">
           Natural disasters often lead to wide-ranging air pollution in large cities. Uncontrolled forest fires have caused widespread pollution over vast expanses of the world.
          </p>
         </list-item>
         <list-item id="celistitem1479">
          <label>
           •
          </label>
          <p id="para2052">
           Natural or manmade disasters resulting in massive structural collapse or dust clouds can cause the release of chemical or biologic contaminants (e.g., asbestos or the arthrospores that lead to coccidioidomycosis).
          </p>
         </list-item>
         <list-item id="celistitem1480">
          <label>
           •
          </label>
          <p id="para2053">
           Health risks associated with these environmental occurrences have not been fully studied.
          </p>
         </list-item>
         <list-item id="celistitem1481">
          <label>
           •
          </label>
          <p id="para2054">
           Travelers with chronic pulmonary disease may be more susceptible to adverse effects from these exposures.
          </p>
         </list-item>
        </list>
       </p>
      </sec>
      <sec id="cesec487">
       <title>
        Event-Specific Information
       </title>
       <p id="para2055">
        Typically, following natural disasters of a magnitude that may impact travelers, current information about the disaster, as well as travel health information specific to those needing entry into such regions, is provided on the CDC Travelers' Health website (
        <ext-link ext-link-type="uri" id="interref100" xlink:href="http://www.cdc.gov/travel">
         www.cdc.gov/travel
        </ext-link>
        ). Recommendations may include specific immunizations or cautions regarding unique hazards in the affected area.
       </p>
      </sec>
     </sec>
     <sec id="cesec488">
      <title>
       Environmental Hazards
      </title>
      <sec id="cesec489">
       <title>
        Air
       </title>
       <p id="para2056">
        <list id="celist410" list-type="simple">
         <list-item id="celistitem1482">
          <label>
           •
          </label>
          <p id="para2057">
           Air pollution may be found in large cities throughout the world; its sources are often attributed to automobile exhaust and industrial emissions and may be aggravated by climate and geography.
          </p>
         </list-item>
         <list-item id="celistitem1483">
          <label>
           •
          </label>
          <p id="para2058">
           The harmful effects of air pollution are difficult to avoid when visiting some cities; limiting strenuous activity and not smoking can help.
          </p>
         </list-item>
         <list-item id="celistitem1484">
          <label>
           •
          </label>
          <p id="para2059">
           Any risk to healthy short-term travelers to such areas is probably small, but persons with pre-existing health conditions (e.g., asthma or chronic obstructive pulmonary disease) could be more susceptible.
          </p>
         </list-item>
         <list-item id="celistitem1485">
          <label>
           •
          </label>
          <p id="para2060">
           Avoidance of dust clouds and areas of heavy dust or haze may be wise.
          </p>
         </list-item>
        </list>
       </p>
      </sec>
      <sec id="cesec490">
       <title>
        Water
       </title>
       <p id="para2061">
        <list id="celist411" list-type="simple">
         <list-item id="celistitem1486">
          <label>
           •
          </label>
          <p id="para2062">
           Rivers, lakes, and the ocean may be contaminated with—
           <list id="celist412" list-type="simple">
            <list-item id="celistitem1487">
             <label>
              ○
             </label>
             <p id="para2063">
              organic or inorganic chemical compounds (e.g., heavy metals or other toxins);
             </p>
            </list-item>
            <list-item id="celistitem1488">
             <label>
              ○
             </label>
             <p id="para2064">
              harmful algal blooms (i.e., cyanobacteria) that can be toxic both to fish and to people who eat the fish or who swim or bathe in the water; and
             </p>
            </list-item>
            <list-item id="celistitem1489">
             <label>
              ○
             </label>
             <p id="para2065">
              pathogens from human and animal waste that may cause disease in swimmers.
             </p>
            </list-item>
           </list>
          </p>
         </list-item>
         <list-item id="celistitem1490">
          <label>
           •
          </label>
          <p id="para2066">
           Such hazards may not be immediately apparent in a body of water.
          </p>
         </list-item>
         <list-item id="celistitem1491">
          <label>
           •
          </label>
          <p id="para2067">
           Extensive water damage after major hurricanes and floods increases the likelihood of mold contamination in buildings. U.S. residents may visit flooded areas overseas as part of emergency, medical, or humanitarian missions. Mold is a greater hazard for persons with conditions such as impaired host defenses or mold allergies. To prevent exposure that could result in adverse health effects from disturbed mold, persons should—
           <list id="celist413" list-type="simple">
            <list-item id="celistitem1492">
             <label>
              ○
             </label>
             <p id="para2068">
              Avoid areas where mold contamination is obvious.
             </p>
            </list-item>
            <list-item id="celistitem1493">
             <label>
              ○
             </label>
             <p id="para2069">
              Use personal protective equipment (PPE) (e.g. gloves, goggles, tight-fitting NIOSH-approved N-95 respirator). Travelers should take sufficient PPE with them, as these may be scarce in the countries visited.
             </p>
            </list-item>
            <list-item id="celistitem1494">
             <label>
              ○
             </label>
             <p id="para2070">
              Keep hands, skin, and clothing clean and free from mold-contaminated dust.
             </p>
            </list-item>
            <list-item id="celistitem1495">
             <label>
              ○
             </label>
             <p id="para2071">
              The CDC MMWR guidance, “Mold Prevention Strategies and Possible Health Effects in the Aftermath of Hurricanes and Major Floods,” provides recommendations for dealing with mold in these settings.
             </p>
            </list-item>
           </list>
          </p>
         </list-item>
        </list>
       </p>
      </sec>
      <sec id="cesec491">
       <title>
        Radiation
       </title>
       <p id="para2072">
        <list id="celist414" list-type="simple">
         <list-item id="celistitem1496">
          <label>
           •
          </label>
          <p id="para2073">
           Natural background radiation levels can vary substantially from region to region, but these natural variations are not a health concern for either the traveler or resident population.
          </p>
         </list-item>
         <list-item id="celistitem1497">
          <label>
           •
          </label>
          <p id="para2074">
           Travelers should be aware of regions known to have been contaminated with radioactive materials, such as the area surrounding the Chernobyl nuclear power station, 100 km (62 miles) northwest of Kiev, Ukraine. This unprecedented radiation emergency and subsequent contamination primarily affected regions in three republics—Ukraine, Belarus, and Russia—with the highest radioactive ground contamination within 30 km (19 miles) of Chernobyl.
          </p>
         </list-item>
         <list-item id="celistitem1498">
          <label>
           •
          </label>
          <p id="para2075">
           In most countries, known areas of radioactive contamination are fenced or marked with signs. These areas should not be trespassed.
          </p>
         </list-item>
         <list-item id="celistitem1499">
          <label>
           •
          </label>
          <p id="para2076">
           Any traveler seeking long-term (more than a few months) residence near a known or suspected contaminated area should consult with staff of the nearest U.S. Embassy and inquire about any applicable advisories in that area regarding drinking water quality or purchase of meat, fruit, and vegetables from local farmers.
          </p>
         </list-item>
         <list-item id="celistitem1500">
          <label>
           •
          </label>
          <p id="para2077">
           Radiation emergencies are rare events. In case of such an emergency, however, travelers should:
           <list id="celist415" list-type="simple">
            <list-item id="celistitem1501">
             <label>
              ○
             </label>
             <p id="para2078">
              Follow instructions provided by local emergency and public health authorities.
             </p>
            </list-item>
            <list-item id="celistitem1502">
             <label>
              ○
             </label>
             <p id="para2079">
              If such information is not forthcoming, U.S. travelers should immediately seek advice from the nearest U.S. embassy.
             </p>
            </list-item>
           </list>
          </p>
         </list-item>
         <list-item id="celistitem1503">
          <label>
           •
          </label>
          <p id="para2080">
           Natural disasters (such as floods) may also result in displacement of industrial or clinical radioactive sources. In all circumstances, travelers should exercise caution when they encounter unknown objects or equipment, especially if they bear the radioactive symbol. If a questionable object is encountered, appropriate authorities should be notified.
          </p>
         </list-item>
        </list>
       </p>
      </sec>
     </sec>
     <ref-list id="cebib37">
      <title>
       References
      </title>
      <ref id="bib372">
       <label>
        1
       </label>
       <element-citation id="sbref329" publication-type="book">
        <person-group person-group-type="author">
         <collab>
          Pan American Health Organization.
         </collab>
        </person-group>
        <source>
         Natural disasters: protecting the public's health
        </source>
        <year>
         2000
        </year>
        <publisher-name>
         Pan American Health Organization
        </publisher-name>
        <publisher-loc>
         Washington (DC)
        </publisher-loc>
        <comment>
         [cited 2006 Jun 21]. Available from:
         <ext-link ext-link-type="uri" id="interref101" xlink:href="http://www.paho.org/English/dd/ped/SP575.htm">
          http://www.paho.org/English/dd/ped/SP575.htm
         </ext-link>
        </comment>
       </element-citation>
      </ref>
      <ref id="bib373">
       <label>
        2
       </label>
       <element-citation id="sbref330" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Watson
          </surname>
          <given-names>
           JT
          </given-names>
         </name>
         <name>
          <surname>
           Gayer
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Connolly
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Epidemics after natural disasters
        </article-title>
        <source>
         Emerg Infect Dis
        </source>
        <volume>
         13
        </volume>
        <issue>
         1
        </issue>
        <year>
         2007
        </year>
        <fpage>
         1
        </fpage>
        <lpage>
         5
        </lpage>
        <pub-id pub-id-type="pmid">
         17370508
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib374">
       <label>
        3
       </label>
       <element-citation id="sbref331" publication-type="book">
        <person-group person-group-type="editor">
         <name>
          <surname>
           Noji
          </surname>
          <given-names>
           EK
          </given-names>
         </name>
        </person-group>
        <source>
         The public health consequences of disasters
        </source>
        <year>
         1997
        </year>
        <publisher-name>
         Oxford University Press
        </publisher-name>
        <publisher-loc>
         New York
        </publisher-loc>
       </element-citation>
      </ref>
      <ref id="bib375">
       <label>
        4
       </label>
       <element-citation id="sbref332" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Young
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Balluz
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Malilay
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        <article-title>
         Natural and technologic hazardous material releases during and after natural disasters: a review
        </article-title>
        <source>
         Sci Total Environ
        </source>
        <volume>
         322
        </volume>
        <issue>
         1–3
        </issue>
        <year>
         2004
        </year>
        <fpage>
         3
        </fpage>
        <lpage>
         20
        </lpage>
        <pub-id pub-id-type="pmid">
         15081734
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib376">
       <label>
        5
       </label>
       <element-citation id="sbref333" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Nukushina
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        <article-title>
         Japanese earthquake victims are being exposed to high density of asbestos. We need protective masks desperately
        </article-title>
        <source>
         Epidemiol Prev
        </source>
        <volume>
         19
        </volume>
        <issue>
         63
        </issue>
        <year>
         1995
        </year>
        <fpage>
         226
        </fpage>
        <lpage>
         227
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib377">
       <label>
        6
       </label>
       <element-citation id="sbref334" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Schneider
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Hajjeh
          </surname>
          <given-names>
           RA
          </given-names>
         </name>
         <name>
          <surname>
           Spiegel
          </surname>
          <given-names>
           RA
          </given-names>
         </name>
        </person-group>
        <article-title>
         A coccidioidomycosis outbreak following the Northridge, Calif, earthquake
        </article-title>
        <source>
         JAMA
        </source>
        <volume>
         277
        </volume>
        <issue>
         11
        </issue>
        <year>
         1997
        </year>
        <fpage>
         904
        </fpage>
        <lpage>
         908
        </lpage>
        <pub-id pub-id-type="pmid">
         9062329
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib378">
       <label>
        7
       </label>
       <element-citation id="sbref335" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Brant
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Brown
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Burkhart
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        <article-title>
         CDC. Mold prevention strategies and possible health effects in the aftermath of hurricanes and major floods
        </article-title>
        <source>
         MMWR Recomm Rep
        </source>
        <volume>
         55
        </volume>
        <issue>
         RR-8
        </issue>
        <year>
         2006
        </year>
        <fpage>
         1
        </fpage>
        <lpage>
         27
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib379">
       <label>
        8
       </label>
       <mixed-citation id="ceotherref44" publication-type="other">
        National Council on Radiation Protection and Measurements. Exposure of the population in the United States and Canada from natural background radiation. Report No 94. Bethesda (Md); 1987.
       </mixed-citation>
      </ref>
      <ref id="bib380">
       <label>
        9
       </label>
       <element-citation id="sbref336" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Eisenbud
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Gessel
          </surname>
          <given-names>
           T
          </given-names>
         </name>
        </person-group>
        <source>
         Environmental radioactivity from natural, industrial, and military sources
        </source>
        <edition>
         4th ed.
        </edition>
        <year>
         1997
        </year>
        <publisher-name>
         Academic Press
        </publisher-name>
        <publisher-loc>
         San Diego
        </publisher-loc>
       </element-citation>
      </ref>
      <ref id="bib381">
       <label>
        10
       </label>
       <mixed-citation id="ceotherref45" publication-type="other">
        United Nations Scientific Committee on the Effects of Atomic Radiation. Annex J: Exposures and effects of the Chernobyl accident. In: Sources and effects of ionizing radiation; United Nations Scientific Committee on the Effects of Atomic Radiation. UNSCEAR 2000 Report to the General Assembly with Scientific Annexes. Volume II: Effects. New York: United Nations; 2000. p. 451–556.
       </mixed-citation>
      </ref>
      <ref id="bib382">
       <label>
        11
       </label>
       <element-citation id="sbref337" publication-type="book">
        <person-group person-group-type="author">
         <collab>
          U.S. Food and Drug Administration, Center for Devices and Radiological Health
         </collab>
        </person-group>
        <source>
         Accidental radioactive contamination of human food and animal feeds: recommendations for state and local agencies
        </source>
        <year>
         1998
        </year>
        <publisher-name>
         U.S. Food and Drug Administration
        </publisher-name>
        <publisher-loc>
         Rockville (MD)
        </publisher-loc>
        <comment>
         [cited 2006 Jun 22]. Available from:
         <ext-link ext-link-type="uri" id="interref102" xlink:href="http://www.fda.gov/cdrh/dmqrp/84.html">
          http://www.fda.gov/cdrh/dmqrp/84.html
         </ext-link>
        </comment>
       </element-citation>
      </ref>
     </ref-list>
    </sec>
    <sec id="subchapter38">
     <sec-meta>
      <contrib-group>
       <contrib contrib-type="author" id="au70">
        <name>
         <surname>
          Nord
         </surname>
         <given-names>
          Daniel A.
         </given-names>
        </name>
       </contrib>
      </contrib-group>
     </sec-meta>
     <title>
      SCUBA DIVING
     </title>
     <p id="para2081">
      Scuba diving can present a variety of unique medical challenges for the traveling diver. Because diving injuries are generally rare, few health-care providers are trained in their diagnosis and treatment. Thus, the recreational diver must be able to recognize the signs of injury and ensure the availability of dive medicine help when needed.
     </p>
     <sec id="cesec492">
      <title>
       Fitness to Dive
      </title>
      <p id="para2082">
       Planning for dive-related travel should take into account any changes in health status, recent injuries, or surgery. In general, respiratory disorders, as well as any disorders affecting higher function and consciousness (e.g., diabetes mellitus or seizures), respiratory function (e.g., asthma), psychological problems (e.g., anxiety), and pregnancy raise special concerns about diving fitness.
      </p>
     </sec>
     <sec id="cesec493">
      <title>
       Diving Disorders
      </title>
      <sec id="cesec494">
       <title>
        Barotrauma
       </title>
       <sec id="cesec495">
        <title>
         Ear and Sinus
        </title>
        <p id="para2083">
         Ear barotrauma is the most common injury in divers. On descent, failure to equalize pressure changes within the middle ear space creates a pressure gradient across the eardrum, which can cause bleeding or fluid accumulation in the middle ear, as well as stretching or rupture of the eardrum and the membranes covering the windows of the inner ear. Symptoms can include—
         <list id="celist416" list-type="simple">
          <list-item id="celistitem1504">
           <label>
            •
           </label>
           <p id="para2084">
            pain
           </p>
          </list-item>
          <list-item id="celistitem1505">
           <label>
            •
           </label>
           <p id="para2085">
            tinnitus (ringing in the ears)
           </p>
          </list-item>
          <list-item id="celistitem1506">
           <label>
            •
           </label>
           <p id="para2086">
            vertigo (dizziness or sensation of spinning)
           </p>
          </list-item>
          <list-item id="celistitem1507">
           <label>
            •
           </label>
           <p id="para2087">
            sensation of fullness
           </p>
          </list-item>
          <list-item id="celistitem1508">
           <label>
            •
           </label>
           <p id="para2088">
            effusion (fluid accumulation in the ear)
           </p>
          </list-item>
          <list-item id="celistitem1509">
           <label>
            •
           </label>
           <p id="para2089">
            decreased hearing
           </p>
          </list-item>
         </list>
        </p>
        <p id="para2090">
         Paranasal sinuses, because of their relatively narrow connecting passageways, are uniquely susceptible to barotraumas, generally on descent. With small changes in pressure (depth), symptoms are usually mild and short lived, but can be exacerbated by continued diving. Larger pressure changes, especially with forceful attempts at equilibration (e.g., valsalva maneuver), can be more injurious. Additional risk factors for ear and sinus barotrauma include—
         <list id="celist417" list-type="simple">
          <list-item id="celistitem1510">
           <label>
            •
           </label>
           <p id="para2091">
            earplugs
           </p>
          </list-item>
          <list-item id="celistitem1511">
           <label>
            •
           </label>
           <p id="para2092">
            medications
           </p>
          </list-item>
          <list-item id="celistitem1512">
           <label>
            •
           </label>
           <p id="para2093">
            ear and/or sinus surgery
           </p>
          </list-item>
          <list-item id="celistitem1513">
           <label>
            •
           </label>
           <p id="para2094">
            nasal deformity
           </p>
          </list-item>
          <list-item id="celistitem1514">
           <label>
            •
           </label>
           <p id="para2095">
            disease
           </p>
          </list-item>
         </list>
        </p>
        <p id="para2096">
         A diver who may have sustained ear or sinus barotrauma should discontinue diving and seek medical attention.
        </p>
       </sec>
       <sec id="cesec496">
        <title>
         Pulmonary
        </title>
        <p id="para2097">
         It is critical for a scuba diver to exhale (or breathe normally) while ascending slowly. Overinflation of the lungs, which usually happens when a novice diver panics, can result as a scuba diver ascends toward the surface without exhaling. During ascent, compressed gas trapped in the lung increases in volume until the expansion exceeds the elastic limit of lung tissue, causing damage and allowing gas bubbles to escape into one or more of three possible locations, as follows:
         <list id="celist418" list-type="simple">
          <list-item id="celistitem1515">
           <label>
            •
           </label>
           <p id="para2098">
            Gas entering the pleural space can cause lung collapse or pneumothorax.
           </p>
          </list-item>
          <list-item id="celistitem1516">
           <label>
            •
           </label>
           <p id="para2099">
            Gas entering the mediastinum (space around the heart, trachea and esophagus) causes mediastinal emphysema and frequently tracks under the skin (subcutaneous emphysema) or into the tissue around the larynx, sometimes precipitating a change in the voice characteristics.
           </p>
          </list-item>
          <list-item id="celistitem1517">
           <label>
            •
           </label>
           <p id="para2100">
            Gas rupturing the alveolar walls can dissect into the pulmonary capillaries and pass via the pulmonary veins to the left side of the heart, where it is distributed according to relative blood flow, resulting in arterial gas embolism (AGE).
           </p>
          </list-item>
         </list>
        </p>
        <p id="para2101">
         While mediastinal or subcutaneous emphysema usually resolves spontaneously, pneumothorax generally requires specific treatment to remove the air and reinflate the lung. AGE is a medical emergency requiring appropriate intervention, which includes recompression treatment with hyperbaric oxygen.
        </p>
        <p id="para2102">
         Lung overinflation injuries from scuba diving can range from dramatic and life threatening to mild symptoms of chest pain and dyspnea. Although pulmonary barotrauma is relatively uncommon in divers, prompt medical evaluation is necessary, and evidence for this condition should always be considered in the presence of respiratory or neurologic symptoms following a dive.
        </p>
       </sec>
      </sec>
      <sec id="cesec497">
       <title>
        Decompression Illness
       </title>
       <p id="para2103">
        Decompression illness (DCI) is an all-inclusive term that describes the dysbaric injuries, AGE, and decompression sickness (DCS). Because the two diseases are considered to result from separate causes, they are described here separately. However, from a clinical and practical standpoint, distinguishing between them in the field may be impossible—and unnecessary, since the initial treatment is the same for both. DCI can occur even in divers who have carefully followed the standard decompression tables and the principles of safe diving.
       </p>
      </sec>
      <sec id="cesec498">
       <title>
        Arterial Gas Embolism (AGE)
       </title>
       <p id="para2104">
        Gas entering the arterial blood through ruptured pulmonary vessels can distribute bubbles into the body tissues, including the heart and brain, where they disrupt circulation. AGE may cause minimal neurologic symptoms or dramatic symptoms that require immediate attention. These signs and symptoms include—
        <list id="celist419" list-type="simple">
         <list-item id="celistitem1518">
          <label>
           •
          </label>
          <p id="para2105">
           numbness
          </p>
         </list-item>
         <list-item id="celistitem1519">
          <label>
           •
          </label>
          <p id="para2106">
           weakness
          </p>
         </list-item>
         <list-item id="celistitem1520">
          <label>
           •
          </label>
          <p id="para2107">
           tingling
          </p>
         </list-item>
         <list-item id="celistitem1521">
          <label>
           •
          </label>
          <p id="para2108">
           dizziness
          </p>
         </list-item>
         <list-item id="celistitem1522">
          <label>
           •
          </label>
          <p id="para2109">
           visual blurring
          </p>
         </list-item>
         <list-item id="celistitem1523">
          <label>
           •
          </label>
          <p id="para2110">
           chest pain
          </p>
         </list-item>
         <list-item id="celistitem1524">
          <label>
           •
          </label>
          <p id="para2111">
           personality change
          </p>
         </list-item>
         <list-item id="celistitem1525">
          <label>
           •
          </label>
          <p id="para2112">
           paralysis or seizures
          </p>
         </list-item>
         <list-item id="celistitem1526">
          <label>
           •
          </label>
          <p id="para2113">
           loss of consciousness
          </p>
         </list-item>
         <list-item id="celistitem1527">
          <label>
           •
          </label>
          <p id="para2114">
           death
          </p>
         </list-item>
        </list>
       </p>
       <p id="para2115">
        In general, any scuba diver who surfaces unconscious or loses consciousness within 10 minutes after surfacing should be assumed to have AGE. Intervention with basic life support is indicated, including the administration of 100% oxygen, followed by rapid evacuation to a hyperbaric oxygen treatment facility.
       </p>
      </sec>
      <sec id="cesec499">
       <title>
        Decompression Sickness
       </title>
       <p id="para2116">
        Breathing air under pressure causes excess inert gas (usually nitrogen) to dissolve in body tissues. The amount dissolved is proportional to and increases with depth and time. As the diver ascends to the surface, the excess dissolved gas must be cleared through respiration via the bloodstream. Depending on the amount dissolved and the rate of ascent, some gas can supersaturate tissues, where it separates from solution to form bubbles, interfering with blood flow and tissue oxygenation and causing signs and symptoms of decompression sickness. These symptoms include—
        <list id="celist420" list-type="simple">
         <list-item id="celistitem1528">
          <label>
           •
          </label>
          <p id="para2117">
           joint aches or pain
          </p>
         </list-item>
         <list-item id="celistitem1529">
          <label>
           •
          </label>
          <p id="para2118">
           numbness and/or tingling
          </p>
         </list-item>
         <list-item id="celistitem1530">
          <label>
           •
          </label>
          <p id="para2119">
           mottling or marbling of skin
          </p>
         </list-item>
         <list-item id="celistitem1531">
          <label>
           •
          </label>
          <p id="para2120">
           coughing spasms or shortness of breath
          </p>
         </list-item>
         <list-item id="celistitem1532">
          <label>
           •
          </label>
          <p id="para2121">
           itching
          </p>
         </list-item>
         <list-item id="celistitem1533">
          <label>
           •
          </label>
          <p id="para2122">
           unusual fatigue
          </p>
         </list-item>
         <list-item id="celistitem1534">
          <label>
           •
          </label>
          <p id="para2123">
           dizziness
          </p>
         </list-item>
         <list-item id="celistitem1535">
          <label>
           •
          </label>
          <p id="para2124">
           weakness
          </p>
         </list-item>
         <list-item id="celistitem1536">
          <label>
           •
          </label>
          <p id="para2125">
           personality changes
          </p>
         </list-item>
         <list-item id="celistitem1537">
          <label>
           •
          </label>
          <p id="para2126">
           loss of bowel or bladder function
          </p>
         </list-item>
         <list-item id="celistitem1538">
          <label>
           •
          </label>
          <p id="para2127">
           staggering, loss of coordination, and/or tremors
          </p>
         </list-item>
         <list-item id="celistitem1539">
          <label>
           •
          </label>
          <p id="para2128">
           paralysis
          </p>
         </list-item>
         <list-item id="celistitem1540">
          <label>
           •
          </label>
          <p id="para2129">
           collapse or unconsciousness
          </p>
         </list-item>
        </list>
       </p>
       <p id="para2130">
        Serious permanent injury may result from either AGE or DCS.
       </p>
      </sec>
     </sec>
     <sec id="cesec500">
      <title>
       Flying after Diving
      </title>
      <p id="para2131">
       The risk of developing decompression sickness is increased when divers are exposed to increased altitude too soon following a dive. The cabin pressure of commercial aircraft may be the equivalent of 8,000 ft (2,438 m). Thus, divers should avoid flying or an altitude exposure &gt;2,000 ft (610 m) for—
       <list id="celist421" list-type="simple">
        <list-item id="celistitem1541">
         <label>
          •
         </label>
         <p id="para2132">
          a minimum of 12 hours after surfacing from a single no-decompression dive, or
         </p>
        </list-item>
        <list-item id="celistitem1542">
         <label>
          •
         </label>
         <p id="para2133">
          after repetitive dives and/or multiple days of diving, wait a minimum of 18 hours before ascending to altitude, to reduce the risk of decompression sickness.
         </p>
        </list-item>
       </list>
      </p>
      <p id="para2134">
       These recommended preflight surface intervals do not guarantee avoidance of DCS. Longer surface intervals will further reduce DCS risk.
      </p>
     </sec>
     <sec id="cesec501">
      <title>
       Prevention of Diving Disorders
      </title>
      <p id="para2135">
       Recreational divers should dive conservatively and well within the limits of their dive tables or computers. Risk factors for DCI are primarily dive depth and bottom time; however, factors such as rapid ascent, repetitive dives, strenuous exercise, dives &gt;60 feet, altitude exposure soon after a dive, and physiological variability also increase risk. Divers should be cautioned to stay well hydrated and rested, dive within the limits of their training, and follow established guidelines for dives unique to their travel destination. Diving is a skill that requires appropriate training and certification and should be done with a companion.
      </p>
     </sec>
     <sec id="cesec502">
      <title>
       Treatment of Diving Disorders
      </title>
      <p id="para2136">
       Definitive treatment of DCI begins with early recognition of symptoms, followed by recompression with hyperbaric oxygen. A high concentration (100%) of supplemental oxygen is considered effective first aid in relieving the signs and symptoms of decompression illness and should be administered as soon as possible. Divers are often dehydrated, either because of incidental causes, immersion, or DCI itself, which can cause a capillary leak. Administration of isotonic glucose-free intravenous fluid is recommended in most cases. Oral rehydration fluids may also be helpful, provided they can be safely administered (e.g., if the diver is conscious). The definitive treatment of DCI is recompression and oxygen administration in a hyperbaric chamber.
      </p>
      <p id="para2137">
       The Divers Alert Network (DAN) maintains a 24-hour emergency consultation and evacuation assistance at 919-684-8111 or 919-684-4326 (collect calls are accepted). DAN will provide assistance with management of the injured diver, help in deciding if recompression is needed, the location of the closest recompression facility, and assistance in arranging patient transport. DAN can also be contacted for routine nonemergency consultation by telephone at 919-684-2948, ext. 222, or by accessing the website
       <ext-link ext-link-type="uri" id="interref103" xlink:href="http://www.diversalertnetwork.org">
        www.diversalertnetwork.org
       </ext-link>
       .
      </p>
      <p id="para2138">
       Travelers who plan to scuba dive may want to ascertain whether there are recompression facilities at their destination prior to embarking on their trip.
      </p>
     </sec>
     <ref-list id="cebib38">
      <title>
       References
      </title>
      <ref id="bib383">
       <label>
        1
       </label>
       <element-citation id="sbref338" publication-type="book">
        <person-group person-group-type="editor">
         <name>
          <surname>
           Brubakk
          </surname>
          <given-names>
           AO
          </given-names>
         </name>
         <name>
          <surname>
           Neuman
          </surname>
          <given-names>
           TS
          </given-names>
         </name>
        </person-group>
        <source>
         Bennett and Elliot's physiology and medicine of diving
        </source>
        <edition>
         5th ed.
        </edition>
        <year>
         2003
        </year>
        <publisher-name>
         Saunders Ltd.
        </publisher-name>
        <publisher-loc>
         London
        </publisher-loc>
       </element-citation>
      </ref>
      <ref id="bib384">
       <label>
        2
       </label>
       <element-citation id="sbref339" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Moon
          </surname>
          <given-names>
           RE
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         Treatment of decompression illness
        </chapter-title>
        <person-group person-group-type="editor">
         <name>
          <surname>
           Bove
          </surname>
          <given-names>
           AA
          </given-names>
         </name>
         <name>
          <surname>
           Davis
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        <source>
         Diving medicine
        </source>
        <edition>
         4th ed.
        </edition>
        <year>
         2004
        </year>
        <publisher-name>
         Saunders
        </publisher-name>
        <publisher-loc>
         London
        </publisher-loc>
        <fpage>
         195
        </fpage>
        <lpage>
         223
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib385">
       <label>
        3
       </label>
       <mixed-citation id="ceotherref46" publication-type="other">
        Sheffield PJ, Vann RD. Flying after recreational diving: workshop proceedings. Divers Alert Network. 2004 [cited 2008 Nov 25]. Available from:
        <ext-link ext-link-type="uri" id="interref104" xlink:href="http://www.diversalertnetwork.org/research/projects/fad/workshop/">
         http://www.diversalertnetwork.org/research/projects/fad/workshop/
        </ext-link>
        .
       </mixed-citation>
      </ref>
      <ref id="bib386">
       <label>
        4
       </label>
       <element-citation id="sbref340" publication-type="book">
        <comment>
        </comment>
        <person-group person-group-type="author">
         <name>
          <surname>
           Thalmann
          </surname>
          <given-names>
           ED
          </given-names>
         </name>
        </person-group>
        <source>
         DAN dive and travel medical guide
        </source>
        <edition>
         rev. ed.
        </edition>
        <year>
         2003
        </year>
        <publisher-name>
         Divers Alert Network
        </publisher-name>
        <publisher-loc>
         Durham, NC
        </publisher-loc>
       </element-citation>
      </ref>
     </ref-list>
    </sec>
    <sec id="subchapter39">
     <sec-meta>
      <contrib-group>
       <contrib contrib-type="author" id="au71">
        <name>
         <surname>
          Reed
         </surname>
         <given-names>
          Christie M.
         </given-names>
        </name>
       </contrib>
      </contrib-group>
     </sec-meta>
     <title>
      MEDICAL TOURISM
     </title>
     <sec id="cesec503">
      <title>
       Introduction
      </title>
      <p id="para2139">
       Travel for the purpose of obtaining health care abroad has received a great deal of attention in the popular media recently—even Wikipedia has recently devoted a section to the practice (
       <ext-link ext-link-type="uri" id="interref147" xlink:href="http://en.wikipedia.org/wiki/Medical_tourism">
        http://en.wikipedia.org/wiki/Medical_tourism
       </ext-link>
       ). However, it is not the only form of “medical tourism.” The term has also been applied to travel by health-care professionals for the purpose of providing health care. The extent of either form of travel is not well characterized, but the overarching issues for both types of travelers, their primary health-care providers, and travel medicine providers are outlined below.
      </p>
     </sec>
     <sec id="cesec504">
      <title>
       Travel to Obtain Care
      </title>
      <p id="para2140">
       Data from the annual U.S. Department of Commerce in-flight survey during 2003–2006 show an overall annual increase in the number of trips taken by U.S. residents for which at least one purpose was health care. In 2006, there were approximately half a million overseas trips in which health treatment was at least one purpose of travel. Common cited procedures include:
       <list id="celist422" list-type="simple">
        <list-item id="celistitem1543">
         <label>
          •
         </label>
         <p id="para2141">
          Dentistry
         </p>
        </list-item>
        <list-item id="celistitem1544">
         <label>
          •
         </label>
         <p id="para2142">
          Reproductive procedures
         </p>
        </list-item>
        <list-item id="celistitem1545">
         <label>
          •
         </label>
         <p id="para2143">
          Surgeries (cosmetic, joint replacement, and cardiac)
         </p>
        </list-item>
       </list>
      </p>
      <p id="para2144">
       Lower cost is often mentioned as the motivation for this type of medical tourism, and an entire industry has grown up around this phenomenon. One can search for a provider and research accreditation status of the facility online, opt for an online concierge service that will make all the arrangements or, more recently, find that health insurance coverage may include the option of “outsourced” health care.
      </p>
      <p id="para2145">
       The dynamic nature of the field was described in a recent roundtable discussion in Merrell et al.,
       <disp-quote>
        <p>
         <italic>
          In recent years, standards have been rising in other parts of the world even faster than prices have surged in the U.S. Many physicians abroad trained in the U.S. and the Joint Commission International (JCI) applies strict standards to accreditation of offshore facilities. Those facilities use the same implants, supplies, and drugs as their U.S. counterparts. However, a heart bypass in Thailand costs $11,000 compared to as much as $130,000 in the U.S. Spinal fusion surgery in India at $5,500 compares to over $60,000 in the U.S.
         </italic>
        </p>
       </disp-quote>
      </p>
      <p id="para2147">
       However, the quality of facilities, assistance services, and care is neither uniform nor regulated; thus, in most instances, responsibility for assessing suitability of an individual program or facility lies solely with the traveler.
      </p>
      <sec id="cesec505">
       <title>
        Guidelines for Travelers Seeking Care Abroad
       </title>
       <p id="para2148">
        Potential patients should consider that, whatever procedure is being contemplated, travelers undergoing medical treatment outside their accustomed environment are almost always at a disadvantage, particularly if there are complications. Concerns are—
        <list id="celist423" list-type="simple">
         <list-item id="celistitem1546">
          <label>
           •
          </label>
          <p id="para2149">
           Resolution of financial issues if costs escalate, such as in the case of complications.
          </p>
         </list-item>
         <list-item id="celistitem1547">
          <label>
           •
          </label>
          <p id="para2150">
           Language and cultural differences may impede accurate interpretation of both verbal and nonverbal communication.
          </p>
         </list-item>
         <list-item id="celistitem1548">
          <label>
           •
          </label>
          <p id="para2151">
           Religious and ethical differences may be encountered over issues such as heroic efforts to preserve life or limb or in care of the terminally ill.
          </p>
         </list-item>
         <list-item id="celistitem1549">
          <label>
           •
          </label>
          <p id="para2152">
           Lack of familiarity with the local medical system, limited access to past medical history, unfamiliar drugs and medicines.
          </p>
         </list-item>
         <list-item id="celistitem1550">
          <label>
           •
          </label>
          <p id="para2153">
           Legal recourse may be fairly limited, difficult to obtain, or nonexistent.
          </p>
         </list-item>
         <list-item id="celistitem1551">
          <label>
           •
          </label>
          <p id="para2154">
           Follow-up care back in the United States may be more difficult to arrange and may be fraught with problems, should there be complications.
          </p>
         </list-item>
        </list>
       </p>
       <p id="para2155">
        Potential patients should consider the guiding principles developed by the American Medical Association for employers, insurance companies, and other entities that facilitate or offer incentives for care outside the United States, although in some circumstances it is unclear how realistic they may be (see
        <ext-link ext-link-type="uri" id="interref105" xlink:href="http://www.ama-assn.org/ama1/pub/upload/mm/31/medicaltourism.pdf">
         www.ama-assn.org/ama1/pub/upload/mm/31/medicaltourism.pdf
        </ext-link>
        ). These principles stipulate that international care must be voluntary and provided by accredited institutions; financial incentives should not inappropriately limit or restrict patient options; there should be continuity of care, including coverage of costs upon return; patients should be informed of their rights and legal recourse before travel; patients should have access to licensing, outcome, and accrediting information when seeking care; medical record transfers should comply with Health Insurance Portability and Accountability Act (HIPAA) guidelines; and patients should be informed of potential risks of combining surgical procedures with long flights and vacation activities. The American Society for Plastic Surgery emphasizes plastic surgery is “real” surgery and outlines the issues every patient undergoing surgery should consider, whether at home or abroad, on their website at
        <ext-link ext-link-type="uri" id="interref106" xlink:href="http://www.plasticsurgery.org/patients_consumers/patient_safety/Medical-Tourism.cfm">
         www.plasticsurgery.org/patients_consumers/patient_safety/Medical-Tourism.cfm
        </ext-link>
        . Several clusters of mycobacterial wound infections in travelers returning from cosmetic procedures abroad have been published. Similarly, the American Dental Association provides informational documents, including: “Traveler's Guide to Safe Dental Care” through the Global Dental Safety Organization for Safety and Asepsis Procedures at
        <ext-link ext-link-type="uri" id="interref107" xlink:href="http://www.osap.org">
         www.osap.org
        </ext-link>
        and “Dental Care Away from Home” at
        <ext-link ext-link-type="uri" id="interref108" xlink:href="http://www.ada.org/public/manage/care/index.asp">
         www.ada.org/public/manage/care/index.asp
        </ext-link>
        .
       </p>
       <p id="para2156">
        Individuals researching accreditation status should note that, although facilities may be part of a chain, they are surveyed and accredited individually. They should also check the duration of the accreditation and validate that the information is current by consulting the public portion of the appropriate accrediting agency website (see
        <xref ref-type="sec" rid="cebib39">
         references
        </xref>
        below).
       </p>
      </sec>
      <sec id="cesec506">
       <title>
        Pre-Travel Advice for the Medical Tourist
       </title>
       <p id="para2157">
        As discussed in the Planning for Healthy Travel section in Chapter 1, patients who do elect to travel should consult a travel health-care practitioner for advice tailored to individual health needs, preferably at least 4–6 weeks in advance of travel. This is particularly true for patients considering invasive procedures, who should consult as soon as travel is considered to allow for assessment of hepatitis B vaccination status (see the
        <xref ref-type="sec" rid="subchapter4">
         Hepatitis B
        </xref>
        section earlier in this chapter). Hepatitis B and C viruses and HIV are examples of blood-borne infections that can be transmitted via contaminated equipment, from infected health-care providers during invasive procedures, via transfusion of blood or blood products, or through transplantation of tissue or organs that have not been properly screened. Prevalence rates of these viruses vary considerably around the world and are generally higher in developing parts of the world than in the United States. U.S. policies address hepatitis B vaccination status of health-care workers, but these policies are not uniform worldwide and there are no currently licensed vaccines for hepatitis C and HIV. Blood transfusion programs in the United States and other developed areas rely on voluntary, nonremunerated donors; screen the donated blood for a variety of potentially blood-borne pathogens; and are closely regulated. Standards in other parts of the world vary. Based on data from 2000–2001, the latest available on the WHO Global Database on Blood Safety (
        <ext-link ext-link-type="uri" id="interref109" xlink:href="http://www.who.int/bloodsafety/global_database/en/">
         www.who.int/bloodsafety/global_database/en/
        </ext-link>
        ), 70 countries did not test all donated blood for the three major blood-borne viruses, HIV and hepatitis B and C.
       </p>
      </sec>
      <sec id="cesec507">
       <title>
        Organ Transplantation
       </title>
       <p id="para2158">
        Organ transplantation in the United States is also a voluntary, closely monitored process coordinated by the United Network for Organ Sharing (
        <ext-link ext-link-type="uri" id="interref110" xlink:href="http://www.optn.org">
         www.optn.org
        </ext-link>
        ). The need for transplantable organs, however, far exceeds the available supply worldwide. Travel to a country with less rigorous methods of distribution for the purpose of obtaining a transplant has been termed “transplant tourism” or “organ trafficking.” Recently, there have been reports in the media of investigations and arrests associated with “rings” that use unscrupulous methods to obtain organs. In 2004, the World Health Assembly Resolution 57.18 encouraged member countries to protect vulnerable populations. Some countries have begun experimenting with controlled programs to relieve the shortage, support the health of the donor, and remove incentives for clandestine operations. A revised set of eleven WHO Guiding Principles on Human Cell, Tissue and Organ Transplantation will be presented to the World Health Assembly in 2009 (
        <ext-link ext-link-type="uri" id="interref111" xlink:href="http://www.who.int/transplantation/">
         www.who.int/transplantation/
        </ext-link>
        ).
       </p>
      </sec>
     </sec>
     <sec id="cesec508">
      <title>
       Travel for the Purpose of Delivering Health Care
      </title>
      <p id="para2159">
       There are many structured opportunities for health-care professionals, students, or trainees to participate in established programs in developing areas of the world that are mutually beneficial to both the local population and the traveler. Travel by health-care workers in their professional capacity should be governed by the principle of
       <italic>
        Primum non nocere
       </italic>
       , or “first, do no harm.” The traveling health-care worker should have sufficient experience or be at a stage in training to be able to contribute labor, knowledge, and skills to the host community. Benefits to the traveling health-care worker include exposure to patients with tropical diseases and conditions that are not commonly seen or are at a more advanced stage than in the country of residence; local diagnostic skills which are often less dependent on technology; and new cultures and new ways of thinking, in addition to any personal gratification. Many medical schools and universities have established reciprocal relationships with institutions in developing areas in which there is an exchange of students and faculty. A variety of organizations match volunteers with local needs for skills-building or to address specific problems. Doctors Without Borders/Médecins Sans Frontières (MSF), which received the Nobel Peace Prize in 1999 for humanitarian efforts around the world, requires a minimum 6-month commitment from physicians and a shorter commitment for surgeons. Interventional programs such as dentistry or surgery simultaneously provide reparative or reconstructive services to the population and train local staff to perform the procedures and provide follow-up care, often donating excess supplies. Other ongoing volunteer relationships exist between faith-based or service organizations and local communities. The involvement of the local health establishment is key to determining needs and maximizing benefit to the local population, as well as educating the visitors on local customs and medical issues and providing translation, if needed, to adequately assess the patients, obtain consent, and advise on postprocedure care.
      </p>
      <p id="para2160">
       These forms of international capacity-building should be differentiated from—
       <list id="celist424" list-type="simple">
        <list-item id="celistitem1552">
         <label>
          •
         </label>
         <p id="para2161">
          medicine that is practiced on local populations ad hoc by independent travelers to areas that seem to have no system of health care,
         </p>
        </list-item>
        <list-item id="celistitem1553">
         <label>
          •
         </label>
         <p id="para2162">
          the development of adventure holidays sold to groups of doctors specifically for the purposes of research or providing health care in the absence of prior consultation, and
         </p>
        </list-item>
        <list-item id="celistitem1554">
         <label>
          •
         </label>
         <p id="para2163">
          students or trainees who travel to “gain practical experience” beyond their training with minimal supervision or absence of structured learning, or practitioners performing outside the area of their expertise.
         </p>
        </list-item>
       </list>
      </p>
      <p id="para2164">
       The acts performed in a life-threatening emergency are justified, but if a local health-care system exists there should still be follow-up with the nearest local provider. Health-care professionals contemplating an international clinical experience should also consult the Humanitarian Aid Workers section in Chapter 8 for a discussion of emotional and physical fitness to participate, preparation, and after-care issues.
      </p>
     </sec>
     <sec id="cesec509">
      <title>
       The Primary Health-Care Provider
      </title>
      <p id="para2165">
       Primary health-care providers play a crucial role in several aspects of medical tourism. For un- or under-insured patients who cannot afford their prescribed course of treatment, the primary care provider may be asked to provide counsel regarding international treatment options, assist with vetting available options, optimize patient status prior to travel, or coordinate care on return. Each provider will need to assess individually his or her ability to address travel health issues or refer to a travel medicine provider.
      </p>
      <p id="para2166">
       Clinicians who care for immigrant populations should also be aware that the majority of health-seeking travelers in 2004 were current U.S. citizens born outside the United States, followed by non-U.S. citizens. Health-care needs, such as dentistry, are often included in visits home, due to familiarity with care in the country of origin, the high cost of health care in the United States, and lack of insurance coverage in these populations. There are also recent reports that patients on transplant waiting lists may also travel abroad for the procedure and return to the developed country of residence for continued care, often requiring immediate hospitalization and intense initial management with little documentation. Options for dialysis care are also increasing in developing areas; thus patients requiring this level of care may return home for visits and obtain local care. Acute hepatitis B infections have been diagnosed in patients returning to developed countries from both scenarios. Clinicians providing care to immigrant populations should consider routinely inquiring about future or recent travel home to visit friends and relatives, whether health care will be sought or occurred during travel and advise accordingly (see the VFR section in Chapter 8).
      </p>
     </sec>
     <sec id="cesec510">
      <title>
       Travel Medicine Providers
      </title>
      <p id="para2167">
       Patients who plan to seek medical care abroad may not divulge this activity during the consultation. The desire for anonymity may be a reason for seeking procedures, such as cosmetic surgery or sex-change operations, abroad. As previously mentioned, cost is often an issue, and patients may be uncomfortable self-disclosing. Clinicians may find that routine discussion of hepatitis B vaccination with all patients in the context of risk due to tattoo, sex, emergency medical care, and invasive procedures offers an environment for patients to initiate further discussion.
      </p>
      <p id="para2168">
       Health-care providers may also find that the medical industry and associated resources that are rapidly expanding in the developing world related to medical tourism intersect directly with the medical care options for patients with pre-existing illness who travel, emergency care for travelers, and health-care options for expatriates (see the
       <xref ref-type="sec" rid="subchapter44">
        Obtaining Health Care Abroad for the Ill Traveler
       </xref>
       section later in this chapter).
      </p>
     </sec>
     <sec id="cesec511">
      <title>
       Additional Resources for Medical Tourism and Accredidation
      </title>
      <p id="para2169">
       <list id="celist425" list-type="simple">
        <list-item id="celistitem1555">
         <label>
          •
         </label>
         <p id="para2170">
          Joint Commission International (jointcommissioninternational.org/)
         </p>
        </list-item>
        <list-item id="celistitem1556">
         <label>
          •
         </label>
         <p id="para2171">
          Trent International Accreditation Scheme (trentaccreditationscheme.org/)
         </p>
        </list-item>
        <list-item id="celistitem1557">
         <label>
          •
         </label>
         <p id="para2172">
          Australian Council for Healthcare Standards International (
          <ext-link ext-link-type="uri" id="interref112" xlink:href="http://www.achs.org.au/ACHSI/">
           www.achs.org.au/ACHSI/
          </ext-link>
          )
         </p>
        </list-item>
        <list-item id="celistitem1558">
         <label>
          •
         </label>
         <p id="para2173">
          Canadian Council on Health Services (
          <ext-link ext-link-type="uri" id="interref113" xlink:href="http://www.cchsa.ca/">
           www.cchsa.ca/
          </ext-link>
          )
         </p>
        </list-item>
        <list-item id="celistitem1559">
         <label>
          •
         </label>
         <p id="para2174">
          International Society of Plastic Surgery also certifies international surgeons who meet U.S. standards (
          <ext-link ext-link-type="uri" id="interref114" xlink:href="http://www.isaps.org">
           www.isaps.org
          </ext-link>
          )
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <ref-list id="cebib39">
      <title>
       References
      </title>
      <ref id="bib387">
       <label>
        1
       </label>
       <mixed-citation id="ceotherref47" publication-type="other">
        U.S. Department of Commerce. Office of Travel and Tourism Industries survey of international air travelers US to overseas and Mexico 2006 report, 2006 January–December. 2007.
       </mixed-citation>
      </ref>
      <ref id="bib388">
       <label>
        2
       </label>
       <mixed-citation id="ceotherref48" publication-type="other">
        U.S. Department of Commerce. Office of Travel and Tourism Industries survey of international air travelers US to overseas and Mexico by birth and citizenship. 2004 report, 2004 January–December. 2005.
       </mixed-citation>
      </ref>
      <ref id="bib389">
       <label>
        3
       </label>
       <mixed-citation id="ceotherref49" publication-type="other">
        U.S. Department of Commerce. Office of Travel and Tourism Industries survey of international air travelers US to overseas and Mexico 2005 report, 2005 January–December. 2006.
       </mixed-citation>
      </ref>
      <ref id="bib390">
       <label>
        4
       </label>
       <mixed-citation id="ceotherref50" publication-type="other">
        U.S. Department of Commerce. Office of Travel and Tourism Industries survey of international air travelers US to overseas and Mexico by birth and citizenship. 2003 report, 2003 January–December. 2005.
       </mixed-citation>
      </ref>
      <ref id="bib391">
       <label>
        5
       </label>
       <element-citation id="sbref341" publication-type="book">
        <comment>
        </comment>
        <person-group person-group-type="author">
         <name>
          <surname>
           Reed
          </surname>
          <given-names>
           CM
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         The health-seeking traveler
        </chapter-title>
        <person-group person-group-type="editor">
         <name>
          <surname>
           Keystone
          </surname>
          <given-names>
           JS
          </given-names>
         </name>
         <name>
          <surname>
           Kozarsky
          </surname>
          <given-names>
           PE
          </given-names>
         </name>
         <name>
          <surname>
           Freedman
          </surname>
          <given-names>
           DO
          </given-names>
         </name>
         <name>
          <surname>
           Nothdurft
          </surname>
          <given-names>
           HD
          </given-names>
         </name>
         <name>
          <surname>
           Connor
          </surname>
          <given-names>
           BA
          </given-names>
         </name>
        </person-group>
        <source>
         Travel medicine
        </source>
        <edition>
         2nd ed.
        </edition>
        <year>
         2008
        </year>
        <publisher-name>
         Mosby
        </publisher-name>
        <publisher-loc>
         Philadelphia
        </publisher-loc>
        <fpage>
         343
        </fpage>
        <lpage>
         350
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib392">
       <label>
        6
       </label>
       <element-citation id="sbref342" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Merrell
          </surname>
          <given-names>
           RC
          </given-names>
         </name>
         <name>
          <surname>
           Boucher
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Carabello
          </surname>
          <given-names>
           L
          </given-names>
         </name>
        </person-group>
        <article-title>
         Medical tourism
        </article-title>
        <source>
         Telemed J E Health
        </source>
        <volume>
         14
        </volume>
        <issue>
         1
        </issue>
        <year>
         2008
        </year>
        <fpage>
         14
        </fpage>
        <lpage>
         20
        </lpage>
        <pub-id pub-id-type="pmid">
         18328021
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib393">
       <label>
        7
       </label>
       <element-citation id="sbref343" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wapner
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        <article-title>
         American Medical Association provides guidance on medical tourism
        </article-title>
        <source>
         BMJ
        </source>
        <volume>
         337
        </volume>
        <year>
         2008
        </year>
        <fpage>
         a575
        </fpage>
        <pub-id pub-id-type="pmid">
         18595942
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib394">
       <label>
        8
       </label>
       <element-citation id="sbref344" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Furuya
          </surname>
          <given-names>
           EY
          </given-names>
         </name>
         <name>
          <surname>
           Paez
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Srinivasan
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        <article-title>
         Outbreak of
         <italic>
          Mycobacterium abscessus
         </italic>
         wound infections among “lipotourists” from the United States who underwent abdominoplasty in the Dominican Republic
        </article-title>
        <source>
         Clin Infect Dis
        </source>
        <volume>
         46
        </volume>
        <issue>
         8
        </issue>
        <year>
         2008
        </year>
        <fpage>
         1181
        </fpage>
        <lpage>
         1188
        </lpage>
        <pub-id pub-id-type="pmid">
         18444853
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib395">
       <label>
        9
       </label>
       <mixed-citation id="ceotherref51" publication-type="other">
        Oleksyn V. Top transplant surgeons involved in organ trafficking, expert says. The Associated Press [updated 2008 Feb 14]. Available from:
        <ext-link ext-link-type="uri" id="interref115" xlink:href="http://www.bookrags.com/news/top-transplant-surgeons-involved-in-moc/">
         http://www.bookrags.com/news/top-transplant-surgeons-involved-in-moc/
        </ext-link>
       </mixed-citation>
      </ref>
      <ref id="bib396">
       <label>
        10
       </label>
       <mixed-citation id="ceotherref52" publication-type="other">
        U.S. Health Resources and Services Administration, Healthcare Systems Bureau, Division of Transplantation. 2007 Annual Report of the U.S. Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients: Transplant Data 1997–2006. Rockville (MD): 2007. [cited 2008 Jul 22]. Available from:
        <ext-link ext-link-type="uri" id="interref116" xlink:href="http://www.ustransplant.org/annual_reports/current/">
         http://www.ustransplant.org/annual_reports/current/
        </ext-link>
       </mixed-citation>
      </ref>
      <ref id="bib397">
       <label>
        11
       </label>
       <element-citation id="sbref345" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bishop
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Litch
          </surname>
          <given-names>
           JA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Medical tourism can do harm
        </article-title>
        <source>
         BMJ
        </source>
        <volume>
         320
        </volume>
        <issue>
         7240
        </issue>
        <year>
         2000
        </year>
        <fpage>
         1017
        </fpage>
        <pub-id pub-id-type="pmid">
         10753174
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib398">
       <label>
        12
       </label>
       <element-citation id="sbref346" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           O'Leary
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        <article-title>
         Working vacation
        </article-title>
        <source>
         Yale Alumni Magazine
        </source>
        <volume>
         71
        </volume>
        <issue>
         5
        </issue>
        <year>
         2008
        </year>
        <comment>
         [cited 2008 Oct 13]. Available from:
         <ext-link ext-link-type="uri" id="interref148" xlink:href="http://www.yalealumnimagazine.com/issues/2008_05/notebook.html">
          http://www.yalealumnimagazine.com/issues/2008_05/notebook.html
         </ext-link>
        </comment>
       </element-citation>
      </ref>
      <ref id="bib399">
       <label>
        13
       </label>
       <mixed-citation id="ceotherref53" publication-type="other">
        U.S. Department of Commerce. Office of Travel and Tourism Industries survey of international air travelers US to overseas and Mexico by birth and citizenship. 2004 report, 2004 January–December. 2005.
       </mixed-citation>
      </ref>
      <ref id="bib400">
       <label>
        14
       </label>
       <element-citation id="sbref347" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Merion
          </surname>
          <given-names>
           RM
          </given-names>
         </name>
         <name>
          <surname>
           Barnes
          </surname>
          <given-names>
           AD
          </given-names>
         </name>
         <name>
          <surname>
           Lin
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <article-title>
         Transplants in foreign countries among patients removed from the US transplant waiting list
        </article-title>
        <source>
         Am J Transplant
        </source>
        <volume>
         8
        </volume>
        <issue>
         4 Pt 2
        </issue>
        <year>
         2008
        </year>
        <fpage>
         988
        </fpage>
        <lpage>
         996
        </lpage>
        <pub-id pub-id-type="pmid">
         18336701
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib401">
       <label>
        15
       </label>
       <element-citation id="sbref348" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Harling
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Turbitt
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Millar
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <article-title>
         Passage from India: an outbreak of hepatitis B linked to a patient who acquired infection from health care overseas
        </article-title>
        <source>
         Public Health
        </source>
        <volume>
         121
        </volume>
        <issue>
         10
        </issue>
        <year>
         2007
        </year>
        <fpage>
         734
        </fpage>
        <lpage>
         741
        </lpage>
        <pub-id pub-id-type="pmid">
         17573083
        </pub-id>
       </element-citation>
      </ref>
     </ref-list>
    </sec>
    <sec id="subchapter40">
     <sec-meta>
      <contrib-group>
       <contrib contrib-type="author" id="au72">
        <name>
         <surname>
          Green
         </surname>
         <given-names>
          Michael D.
         </given-names>
        </name>
       </contrib>
      </contrib-group>
     </sec-meta>
     <title>
      <italic>
       PERSPECTIVES:
      </italic>
      COUNTERFEIT DRUGS
     </title>
     <sec id="cesec512">
      <title>
       GENERAL INFORMATION
      </title>
      <p id="para2175">
       Counterfeit and substandard drugs are an international problem contributing to morbidity, mortality, toxicity, and drug resistance. A counterfeit medicine is a compound that is not made by an authorized manufacturer but is presented to the consumer as if it were. Overall, global estimates of drug counterfeiting are somewhat ambiguous, depending on geographic region, but proportions range from 1% of sales in developed countries to &gt;10% in developing countries. In specific regions in Africa, Asia, and Latin America, chances of purchasing a counterfeit drug may be higher than 30%. Although the availability of fake drugs is a worldwide occurrence, developing countries lacking adequate resources to effectively monitor and maintain good drug quality are most susceptible. These conditions allow for the proliferation of counterfeit as well as substandard medicines.
      </p>
      <p id="para2176">
       Since counterfeit drugs are not made by the legitimate manufacturer and are produced under unlawful circumstances, contaminants or lack of proper ingredients may result in serious harm to one's health. For example, the active pharmaceutical ingredient (API) may be completely lacking, present in small quantities, or substituted by another less-effective compound. In addition, the wrong inactive ingredients (excipients) can contribute to poor drug dissolution and bioavailability. As a result, a patient may not respond to treatment, or they may exhibit adverse reactions to unknown substituted ingredients.
      </p>
      <p id="para2177">
       Prior to international departure, travel clinics should alert travelers of the dangers of counterfeit and substandard drugs and provide suggestions on how to avoid them. Listed are main points of which to be aware.
      </p>
     </sec>
     <sec id="cesec513">
      <title>
       HOW TO AVOID COUNTERFEIT DRUGS WHEN TRAVELING
      </title>
      <p id="para2178">
       The best way to avoid counterfeit drugs is to reduce the need to purchase medications abroad. Anticipated amounts of medications for chronic conditions such as hypertension, sinusitis, arthritis, hay fever, etc., medications for gastroenteritis (travelers' diarrhea), and prophylactic medications for infectious diseases such as malaria (depending on the destinations) should all be purchased at home prior to traveling.
      </p>
      <sec id="cesec514">
       <title>
        To do before you leave:
       </title>
       <p id="para2179">
        <list id="celist426" list-type="simple">
         <list-item id="celistitem1560">
          <label>
           ¢
          </label>
          <p id="para2180">
           <bold>
            Make sure you have all your vaccinations before embarking
           </bold>
           . Immunizations provide the best protection against many serious diseases.
          </p>
         </list-item>
         <list-item id="celistitem1561">
          <label>
           ¢
          </label>
          <p id="para2181">
           <bold>
            Purchase in advance, in your home country, all the medicines you will need for the entire trip
           </bold>
           . Prescriptions from your doctor usually cannot be filled overseas, and over-the-counter medicines may not be available in many foreign countries. Checked baggage can get lost; therefore pack as much as possible in a carry-on bag. Bring along extra in case of travel delays.
          </p>
         </list-item>
         <list-item id="celistitem1562">
          <label>
           ¢
          </label>
          <p id="para2182">
           <bold>
            Make sure your medicines are in their original containers
           </bold>
           . If the drug is a prescription, make sure your name and dosage requirements are on the container.
          </p>
         </list-item>
         <list-item id="celistitem1563">
          <label>
           ¢
          </label>
          <p id="para2183">
           <bold>
            Bring your “Patient Prescription Information” sheet
           </bold>
           . This sheet provides information on common generic and brand names, usage, side effects, precautions, and drug interactions.
          </p>
         </list-item>
        </list>
       </p>
      </sec>
      <sec id="cesec515">
       <title>
        What to do if you run out and require additional medications:
       </title>
       <p id="para2184">
        <list id="celist427" list-type="simple">
         <list-item id="celistitem1564">
          <label>
           ¢
          </label>
          <p id="para2185">
           <bold>
            Purchase medicines from a legitimate pharmacy
           </bold>
           . In some places, it is difficult to know if a pharmacy has a genuine license. Your chances of receiving a counterfeit drug are less if you avoid buying from open markets, street vendors, or suspicious-looking pharmacies. Request a receipt when making the purchase. The U.S. Embassy may be able to assist you in finding a legitimate pharmacy in the area.
          </p>
         </list-item>
         <list-item id="celistitem1565">
          <label>
           ¢
          </label>
          <p id="para2186">
           <bold>
            Do not buy medicines that are significantly cheaper than the typical price
           </bold>
           . Although generics are usually less expensive, many counterfeited brand names are sold at prices significantly below the normal price for that particular brand.
          </p>
         </list-item>
         <list-item id="celistitem1566">
          <label>
           ¢
          </label>
          <p id="para2187">
           <bold>
            Make sure the medicines you purchase are in their original packages or containers
           </bold>
           . Many times medicines are sold to the pharmacy in bulk and the pharmacist will dispense the required amount of medicine into another container. If you receive medicines as loose tablets or capsules supplied in a plastic bag or envelope, ask the pharmacist to see the container from which it was originally dispensed. Record the brand, batch number, and expiration date. Sometimes a wary consumer will prompt the seller into making sure he or she supplies you with quality medicine.
          </p>
         </list-item>
         <list-item id="celistitem1567">
          <label>
           ¢
          </label>
          <p id="para2188">
           <bold>
            Be familiar with your medications
           </bold>
           . The size, shape, color, and taste of counterfeit medicines may be different from the authentic. Discoloration, splits, cracks, spots, and stickiness of the tablets or capsules are indications of a possible counterfeit. Keep examples of authentic medications available for comparison if you purchase the same brand.
          </p>
         </list-item>
         <list-item id="celistitem1568">
          <label>
           ¢
          </label>
          <p id="para2189">
           <bold>
            Be familiar with the packaging
           </bold>
           . Different color inks, poor-quality print or packaging material, and misspelled words are clues to counterfeit material. Also, keep an example of packaging for comparison. Observe the expiration date to make sure the medicine has not expired and the package contains the drug insert.
          </p>
         </list-item>
        </list>
       </p>
      </sec>
     </sec>
     <sec id="cesec516">
      <title>
       USEFUL WEBSITES ON COUNTERFEITS
      </title>
      <p id="para2190">
       <list id="celist428" list-type="simple">
        <list-item id="celistitem1569">
         <label>
          ¢
         </label>
         <p id="para2191">
          General Information:
          <list id="celist429" list-type="simple">
           <list-item id="celistitem1570">
            <label>
             ○
            </label>
            <p id="para2192">
             CDC:
             <list id="celist430" list-type="simple">
              <list-item id="celistitem1571">
               <label>
                □
               </label>
               <p id="para2193">
                <ext-link ext-link-type="uri" id="interref117" xlink:href="http://wwwn.cdc.gov/travel/contentCounterfeitDrugs.aspx">
                 wwwn.cdc.gov/travel/contentCounterfeitDrugs.aspx
                </ext-link>
               </p>
              </list-item>
              <list-item id="celistitem1572">
               <label>
                □
               </label>
               <p id="para2194">
                <ext-link ext-link-type="uri" id="interref118" xlink:href="http://www.cdc.gov/malaria/travel/counterfeit_drugs.htm">
                 www.cdc.gov/malaria/travel/counterfeit_drugs.htm
                </ext-link>
               </p>
              </list-item>
             </list>
            </p>
           </list-item>
           <list-item id="celistitem1573">
            <label>
             ○
            </label>
            <p id="para2195">
             World Health Organization: who.int/mediacentre/factsheets/fs275/en
            </p>
           </list-item>
          </list>
         </p>
        </list-item>
        <list-item id="celistitem1574">
         <label>
          ¢
         </label>
         <p id="para2196">
          U.S. Food and Drug Administration:
          <ext-link ext-link-type="uri" id="interref119" xlink:href="http://www.fda.gov/counterfeit/">
           www.fda.gov/counterfeit/
          </ext-link>
         </p>
        </list-item>
        <list-item id="celistitem1575">
         <label>
          ¢
         </label>
         <p id="para2197">
          U.S. Pharmacopeia:
          <ext-link ext-link-type="uri" id="interref120" xlink:href="http://www.usp.org/worldwide/dqi/drugQuality.html">
           www.usp.org/worldwide/dqi/drugQuality.html
          </ext-link>
         </p>
        </list-item>
        <list-item id="celistitem1576">
         <label>
          ¢
         </label>
         <p id="para2198">
          Warnings and alerts:
          <ext-link ext-link-type="uri" id="interref121" xlink:href="http://www.safemedicines.org/in_the_news/drug_alerts.php">
           www.safemedicines.org/in_the_news/drug_alerts.php
          </ext-link>
         </p>
        </list-item>
        <list-item id="celistitem1577">
         <label>
          ¢
         </label>
         <p id="para2199">
          What can you pack in your luggage (for travelers with disabilities and medical conditions):
          <list id="celist431" list-type="simple">
           <list-item id="celistitem1578">
            <label>
             ○
            </label>
            <p id="para2200">
             Transportation Security Administration:
             <ext-link ext-link-type="uri" id="interref122" xlink:href="http://www.tsa.gov/travelers/airtravel/specialneeds/editorial_1059.shtm">
              www.tsa.gov/travelers/airtravel/specialneeds/editorial_1059.shtm
             </ext-link>
            </p>
           </list-item>
          </list>
         </p>
        </list-item>
        <list-item id="celistitem1579">
         <label>
          ¢
         </label>
         <p id="para2201">
          What can you bring back:
          <list id="celist432" list-type="simple">
           <list-item id="celistitem1580">
            <label>
             ○
            </label>
            <p id="para2202">
             U.S. Customs and Border Protection:
             <ext-link ext-link-type="uri" id="interref123" xlink:href="http://www.cbp.gov/xp/cgov/travel/clearing/restricted/medication_drugs.xml">
              www.cbp.gov/xp/cgov/travel/clearing/restricted/medication_drugs.xml
             </ext-link>
            </p>
           </list-item>
          </list>
         </p>
        </list-item>
        <list-item id="celistitem1581">
         <label>
          ¢
         </label>
         <p id="para2203">
          Reporting counterfeit cases:
          <ext-link ext-link-type="uri" id="interref124" xlink:href="http://www.who.int/medicines/services/counterfeit/report/en/">
           www.who.int/medicines/services/counterfeit/report/en/
          </ext-link>
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <ref-list id="cebib40">
      <title>
       References
      </title>
      <ref id="bib402">
       <label>
        1
       </label>
       <element-citation id="sbref349" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Newton
          </surname>
          <given-names>
           PN
          </given-names>
         </name>
         <name>
          <surname>
           Green
          </surname>
          <given-names>
           MD
          </given-names>
         </name>
         <name>
          <surname>
           Fernández
          </surname>
          <given-names>
           FM
          </given-names>
         </name>
        </person-group>
        <article-title>
         Counterfeit anti-infective drugs
        </article-title>
        <source>
         Lancet Infect Dis
        </source>
        <volume>
         6
        </volume>
        <issue>
         9
        </issue>
        <year>
         2006
        </year>
        <fpage>
         602
        </fpage>
        <lpage>
         613
        </lpage>
        <pub-id pub-id-type="pmid">
         16931411
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib403">
       <label>
        2
       </label>
       <mixed-citation id="ceotherref54" publication-type="other">
        World Health Organization. Counterfeit medicines. Fact sheet no. 275. Nov. 2006 [updated 2006 Nov 14; cited 2008 Jun 6]. Available from:
        <ext-link ext-link-type="uri" id="interref125" xlink:href="http://who.int/mediacentre/factsheets/fs275/en">
         http://who.int/mediacentre/factsheets/fs275/en
        </ext-link>
        .
       </mixed-citation>
      </ref>
      <ref id="bib404">
       <label>
        3
       </label>
       <element-citation id="sbref350" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Newton
          </surname>
          <given-names>
           PN
          </given-names>
         </name>
         <name>
          <surname>
           Fernandez
          </surname>
          <given-names>
           FM
          </given-names>
         </name>
         <name>
          <surname>
           Green
          </surname>
          <given-names>
           MD
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         Counterfeit and substandard antimalarial drugs
        </chapter-title>
        <person-group person-group-type="editor">
         <name>
          <surname>
           Schlagenhauf-Lawlor
          </surname>
          <given-names>
           P
          </given-names>
         </name>
        </person-group>
        <source>
         Travelers' malaria
        </source>
        <edition>
         2nd ed.
        </edition>
        <year>
         2008
        </year>
        <publisher-name>
         BC Decker, Inc.
        </publisher-name>
        <publisher-loc>
         Hamilton (Canada)
        </publisher-loc>
        <fpage>
         331
        </fpage>
        <lpage>
         342
        </lpage>
       </element-citation>
      </ref>
     </ref-list>
    </sec>
    <sec id="subchapter41">
     <sec-meta>
      <contrib-group>
       <contrib contrib-type="author" id="au73">
        <name>
         <surname>
          Barnett
         </surname>
         <given-names>
          Elizabeth D.
         </given-names>
        </name>
       </contrib>
      </contrib-group>
     </sec-meta>
     <title>
      DRUG–VACCINE AND DRUG–DRUG INTERACTIONS
     </title>
     <p id="para2204">
      The pre-travel travel medicine visit potentially exposes people to a number of different vaccines, prophylactic medications, and therapeutic drugs. In addition, the traveler may already be taking one or more medications on a regular basis. Travel medicine practitioners need to think about the possible interactions between all these products. Although a comprehensive list of interactions is beyond the scope of this section, some of the more significant interactions of commonly used vaccines and medications are discussed here.
     </p>
     <sec id="cesec517">
      <title>
       Interactions between Travel Vaccines and Drugs
      </title>
      <sec id="cesec518">
       <title>
        Oral Typhoid Vaccine
       </title>
       <p id="para2205">
        There is a concern that antibiotics or anti-malarials with antibiotic activity should not be taken at the same time as the oral typhoid vaccine (a live-bacteria vaccine) as they may be active against the vaccine strain and prevent an adequate immune response to the vaccine. These issues should be addressed separately.
       </p>
       <p id="para2206">
        Sulfonamides and antibiotics taken orally should not be taken at the same time as oral typhoid vaccine. Parenteral typhoid vaccine is a more appropriate choice for individuals taking antibiotics.
       </p>
       <p id="para2207">
        The current mefloquine (Lariam) product insert recommends vaccinations with attenuated live bacteria be completed at least 3 days before the first dose of Lariam. However, one study in humans failed to show any decrease in immunogenicity when the vaccine was given to those on mefloquine prophylaxis. Mefloquine can be given concurrently with the oral typhoid vaccine. Although the antibody response to oral typhoid vaccine was reduced by higher dose proguanil in one study examining the effects of concomitant use of oral typhoid vaccine and chloroquine, mefloquine, and proguanil, a second study using approved prophylaxis doses of atovaquone–proguanil showed no decrease in immunogenicity. Atovaquone–proguanil at prophylaxis doses can be given concurrently with the oral typhoid vaccine. However, since the oral typhoid vaccine should be completed 14 days prior to traveling, there should be no opportunity for concomitant administration with atovaquone/proguanil in most travelers. This same study also showed no decrease in immunogenicity with chloroquine. Chloroquine can be given concurrently with the oral typhoid vaccine.
       </p>
       <p id="para2208">
        Doxycycline is an antibiotic with both antibacterial and antimalarial activity. Thus it should not be given concurrently with oral typhoid vaccine. However, since the oral typhoid vaccine should be completed 14 days prior to traveling, there should be no opportunity for interaction with doxycycline in most travelers.
       </p>
      </sec>
      <sec id="cesec519">
       <title>
        Rabies Vaccine
       </title>
       <p id="para2209">
        Concomitant use of chloroquine may reduce antibody response to intradermal rabies vaccine administered for pre-exposure prophylaxis. The intramuscular route should be used for persons taking chloroquine concurrently (the intradermal route is currently not approved for use in the United States); ideally, the rabies pre-exposure prophylaxis series should be completed before beginning chloroquine.
       </p>
       <p id="para2210">
        Corticosteroids and other immunosuppressive agents may interfere with response to rabies immunization; when these are used concurrently with rabies vaccine for postexposure prophylaxis, testing should be done to ensure adequate antibody response.
       </p>
      </sec>
     </sec>
     <sec id="cesec520">
      <title>
       Interactions between Antimalarials and Other Drugs
      </title>
      <sec id="cesec521">
       <title>
        Mefloquine
       </title>
       <p id="para2211">
        Mefloquine may interact with several categories of drugs, including other antimalarials, drugs that alter cardiac conduction, and anticonvulsants. Although the antimalarial halofantrine is not available in the United States, potentially fatal prolongation of the QTc interval of the electrocardiogram may occur if halofantrine is given after mefloquine. Halofantrine should not be given with or after mefloquine. If halofantrine is given for treatment of malaria, mefloquine for prophylaxis should not be resumed until at least 12 hours after the last halofantrine dose. However, no conclusive data are available with regard to coadministration of mefloquine and other drugs that may theoretically have an impact on cardiac conduction. These include anti-arrhythmic or beta-blocking agents, calcium-channel blockers, antihistamines, H1-blocking agents, tricyclic antidepressant, or phenothiazines. Use of these drugs along with mefloquine should be avoided, if possible.
       </p>
       <p id="para2212">
        Mefloquine used with the anticonvulsants valproic acid, carbamazepine, phenobarbital, or phenytoin may lower anticonvulsant plasma levels, thus lowering seizure threshold. Monitoring anticonvulsant levels would be appropriate in persons for whom mefloquine must be used concomitantly with these drugs.
       </p>
      </sec>
      <sec id="cesec522">
       <title>
        Chloroquine
       </title>
       <p id="para2213">
        Chloroquine absorption may be reduced by antacids or kaolin; at least 4 hours should elapse between doses of these medications. Concomitant use of cimetidine and chloroquine should be avoided, as cimetidine can inhibit the metabolism of chloroquine and may increase drug levels. Chloroquine inhibits bioavailability of ampicillin; 2 hours should elapse between doses.
       </p>
      </sec>
      <sec id="cesec523">
       <title>
        Atovaquone–Proguanil
       </title>
       <p id="para2214">
        Tetracycline, rifampin, and rifabutin may reduce plasma concentrations of atovaquone and should not be used concurrently with atovaquone–proguanil. Metaclopramide may reduce bioavailability of atovaquone; unless no other antiemetics are available, this antiemetic should not be used for treatment of the vomiting that may accompany use of atovaquone at treatment doses. Atovaquone–proguanil should not be used with other proguanil-containing medications. Patients on anticoagulants may need to reduce their anticoagulant doses or more closely monitor their prothrombin time while taking atovaquone proguanil.
       </p>
      </sec>
      <sec id="cesec524">
       <title>
        Doxycycline
       </title>
       <p id="para2215">
        Doxycycline use theoretically may lead to decreased efficacy of oral contraceptives, although it has been difficult to quantify this effect in a way that is useful for counseling travelers. Changes in hormone levels in women taking oral contraceptives concurrently with doxycycline have not been demonstrated. Phenytoin, carbamazepine, and barbiturates may decrease the half-life of doxycycline. Patients on anticoagulants may need to reduce their anticoagulant doses while taking doxycycline because of its ability to depress plasma prothrombin activity. Absorption of tetracyclines may be impaired by bismuth subsalicyclate, iron-containing preparations, and antacids containing calcium, magnesium, or aluminum; these preparations should not be taken within 1–3 hours of doxycycline. Doxycycline absorption is not markedly affected by food or milk taken concurrently. Doxycyline may interfere with the bactericidal activity of penicillin, and these drugs should not be taken concurrently.
       </p>
      </sec>
     </sec>
     <sec id="cesec525">
      <title>
       Interactions with Antidiarrheal Drugs
      </title>
      <sec id="cesec526">
       <title>
        Fluoroquinolones
       </title>
       <p id="para2216">
        Increase in the international normalized ratio (INR) has been reported when levofloxacin and warfarin are used concurrently. Concurrent administration of ciprofloxacin and magnesium or aluminum hydroxide containing antacids may reduce bioavailability of ciprofloxacin significantly. Ciprofloxacin decreases clearance of theophylline and caffeine; theophylline levels should be monitored when ciprofloxacin is used concurrently. Ciprofloxacin should not be used with tazanidine.
       </p>
      </sec>
      <sec id="cesec527">
       <title>
        Azithromycin
       </title>
       <p id="para2217">
        Close monitoring for side effects of azithromycin is recommended when azithromycin is used with nelfinavir. Increased anticoagulant effects have been noted when azithromycin is used with warfarin; monitoring of prothrombin time is recommended for such individuals.
       </p>
      </sec>
      <sec id="cesec528">
       <title>
        Rifaximin
       </title>
       <p id="para2218">
        No clinically significant drug interactions have been reported to date with rifaximin. Although the drug induces cytochrome P450 3A4 (CYP3A4), studies of concurrent administration of rifaximin with midazolam and with a single dose of the oral contraceptive ethinyl etradiol and norestironate did not show changes in the pharmacokinetics of these drugs.
       </p>
      </sec>
     </sec>
     <sec id="cesec529">
      <title>
       Interactions with Drugs Used for Travel to High Altitude
      </title>
      <sec id="cesec530">
       <title>
        Acetazolamide
       </title>
       <p id="para2219">
        Acetazolamide produces alkaline urine that can increase the rate of excretion of barbiturates and salicylates and may potentiate salicylate toxicity. Decreased excretion of dextroamphetamine, anticholinergics, mecamylamine, ephedrine, mexiletine, or quinide may also occur. Hypokalemia caused by corticosteroids may be potentiated by concurrent use of acetazolamide.
       </p>
      </sec>
      <sec id="cesec531">
       <title>
        Dexamethasone
       </title>
       <p id="para2220">
        Dexamethasone interacts with multiple classes of drugs. Use of this drug for treatment of altitude illness may, however, be lifesaving. Interactions may occur with the following drugs and drug classes: macrolide antibiotics, anticholinesterases, anticoagulants, hypoglycemic agents, isoniazid, digitalis preparations, oral contraceptives, and phenytoin.
       </p>
      </sec>
     </sec>
     <ref-list id="cebib41">
      <title>
       References
      </title>
      <ref id="bib405">
       <label>
        1
       </label>
       <element-citation id="sbref351" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kollaritsch
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Que
          </surname>
          <given-names>
           JU
          </given-names>
         </name>
         <name>
          <surname>
           Kunz
          </surname>
          <given-names>
           C
          </given-names>
         </name>
        </person-group>
        <article-title>
         Safety and immunogenicity of live oral chlorera and typhoid vaccines administered alone or in combination with antimalarial drugs, oral polio vaccine, or yellow fever vaccine
        </article-title>
        <source>
         J Infect Dis
        </source>
        <volume>
         175
        </volume>
        <issue>
         4
        </issue>
        <year>
         1997
        </year>
        <fpage>
         871
        </fpage>
        <lpage>
         875
        </lpage>
        <pub-id pub-id-type="pmid">
         9086143
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib406">
       <label>
        2
       </label>
       <element-citation id="sbref352" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Horowitz
          </surname>
          <given-names>
           H
          </given-names>
         </name>
        </person-group>
        <article-title>
         Carbonaro CA. Inhibition of the
         <italic>
          Salmonella
         </italic>
         Typhi oral vaccine strain, Ty21a, by mefloquine and chloroquine
        </article-title>
        <source>
         J Infect Dis
        </source>
        <volume>
         166
        </volume>
        <issue>
         6
        </issue>
        <year>
         1992
        </year>
        <fpage>
         1462
        </fpage>
        <lpage>
         1464
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib407">
       <label>
        3
       </label>
       <element-citation id="sbref353" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Brachman
          </surname>
          <given-names>
           PS
          </given-names>
          <suffix>
           Jr
          </suffix>
         </name>
         <name>
          <surname>
           Metchock
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Kozarsky
          </surname>
          <given-names>
           PE
          </given-names>
         </name>
        </person-group>
        <article-title>
         Effects of antimalarial chemoprophylactic agents on the viability of the Ty21a vaccine strain
        </article-title>
        <source>
         Clin Infect Dis
        </source>
        <volume>
         15
        </volume>
        <issue>
         6
        </issue>
        <year>
         1992
        </year>
        <fpage>
         1057
        </fpage>
        <lpage>
         1058
        </lpage>
        <pub-id pub-id-type="pmid">
         1457647
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib408">
       <label>
        4
       </label>
       <element-citation id="sbref354" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Pappaioanou
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Fishbein
          </surname>
          <given-names>
           DB
          </given-names>
         </name>
         <name>
          <surname>
           Dreesen
          </surname>
          <given-names>
           DW
          </given-names>
         </name>
        </person-group>
        <article-title>
         Antibody response to preexposure human diploid-cell rabies vaccine given concurrently with chloroquine
        </article-title>
        <source>
         N Engl J Med
        </source>
        <volume>
         314
        </volume>
        <issue>
         5
        </issue>
        <year>
         1986
        </year>
        <fpage>
         280
        </fpage>
        <lpage>
         284
        </lpage>
        <pub-id pub-id-type="pmid">
         3510393
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib409">
       <label>
        5
       </label>
       <element-citation id="sbref355" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Matson
          </surname>
          <given-names>
           PA
          </given-names>
         </name>
         <name>
          <surname>
           Luby
          </surname>
          <given-names>
           SP
          </given-names>
         </name>
         <name>
          <surname>
           Redd
          </surname>
          <given-names>
           SC
          </given-names>
         </name>
        </person-group>
        <article-title>
         Cardiac effects of standard-dose halofantrine therapy
        </article-title>
        <source>
         Am J Trop Med Hyg
        </source>
        <volume>
         54
        </volume>
        <issue>
         3
        </issue>
        <year>
         1996
        </year>
        <fpage>
         229
        </fpage>
        <lpage>
         231
        </lpage>
        <pub-id pub-id-type="pmid">
         8600755
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib410">
       <label>
        6
       </label>
       <mixed-citation id="ceotherref55" publication-type="other">
        CDC. Sudden death in a traveler following halofantrine administration—Togo, 2000. MMWR Morb Mortal Wkly Rep. 2001;50(9):169–70, 179.
       </mixed-citation>
      </ref>
      <ref id="bib411">
       <label>
        7
       </label>
       <element-citation id="sbref356" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Neely
          </surname>
          <given-names>
           JL
          </given-names>
         </name>
         <name>
          <surname>
           Abate
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Swinker
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <article-title>
         The effect of doxycycline on serum levels of ethinyl estradiol, norethindrone, and endogenous progesterone
        </article-title>
        <source>
         Obstet Gynecol
        </source>
        <volume>
         77
        </volume>
        <issue>
         3
        </issue>
        <year>
         1991
        </year>
        <fpage>
         416
        </fpage>
        <lpage>
         420
        </lpage>
        <pub-id pub-id-type="pmid">
         1992409
        </pub-id>
       </element-citation>
      </ref>
     </ref-list>
    </sec>
    <sec id="subchapter42">
     <sec-meta>
      <contrib-group>
       <contrib contrib-type="author" id="au74">
        <name>
         <surname>
          LoBue
         </surname>
         <given-names>
          Philip
         </given-names>
        </name>
       </contrib>
      </contrib-group>
     </sec-meta>
     <title>
      <italic>
       PERSPECTIVES:
      </italic>
      PPD TESTING OF TRAVELERS
     </title>
     <p id="para2221">
      Screening travelers for asymptomatic tuberculosis (TB) infections should only be carried out among travelers who will be at significant risk of acquiring TB (see the TB section in Chapter 5). Screening with a tuberculin skin test (TST) in a very low-risk population may result in a false-positive test, leading to unnecessary further screening or unnecessary therapeutic treatment. Using even highly sensitive and specific tests in very low-prevalence populations will produce more false positives than true positives.
     </p>
     <p id="para2222">
      Therefore, the TST should be considered only for travelers anticipating an extended stay over a period of years in a country with a high risk of TB or for those who could be expected to come in contact routinely with hospital, prison, or homeless shelter populations. The general recommendation is that persons at low risk for TB, which includes the vast majority of travelers, do not need to be screened before or after travel.
     </p>
     <p id="para2223">
      For travelers who anticipate a long stay or contact with a high-risk population, careful pre-travel screening should be carried out. The two-step TST is recommended in this population, for the following reasons:
      <list id="celist433" list-type="simple">
       <list-item id="celistitem1582">
        <label>
         ¢
        </label>
        <p id="para2224">
         The use of two-step testing can reduce the number of positive TSTs that would otherwise be misclassified as recent skin test conversions during future periodic screenings.
        </p>
       </list-item>
       <list-item id="celistitem1583">
        <label>
         ¢
        </label>
        <p id="para2225">
         Certain persons who were infected with
         <italic>
          Mycobacterium tuberculosis
         </italic>
         years earlier exhibit waning delayed-type hypersensitivity to tuberculin. When they are skin tested years after infection, they might have a false-negative TST result (even though they are truly infected). However, this first skin test years after the infection might stimulate the ability to react to subsequent tests, resulting in a “booster” reaction. When the test is repeated, the reaction might be misinterpreted as a new infection (recent conversion) rather than a boosted reaction.
        </p>
       </list-item>
       <list-item id="celistitem1584">
        <label>
         ¢
        </label>
        <p id="para2226">
         For two-step testing, persons whose baseline TSTs yield a negative result are retested 1–3 weeks after the initial test. If the second test result is negative, they are considered not infected. If the second test result is positive, they are classified as having had previous TB infection.
        </p>
       </list-item>
       <list-item id="celistitem1585">
        <label>
         ¢
        </label>
        <p id="para2227">
         Two-step testing should be considered for the baseline testing of persons who report no history of a recent TST and who will receive repeated TSTs as part of an ongoing monitoring of whether they have been exposed to TB.
        </p>
       </list-item>
       <list-item id="celistitem1586">
        <label>
         ¢
        </label>
        <p id="para2228">
         If the two-step TST result is negative, the traveler should have a repeat TST 8–10 weeks after returning from their trip, or as part of a periodic screening examination for those who remain at high risk.
        </p>
       </list-item>
      </list>
     </p>
     <p id="para2229">
      Two-step testing is particularly important for travelers who will have potential prolonged TB exposure; it is particularly important among those going to areas where drug resistance is very high. Two-step testing prior to travel will detect boosting and potentially prevent “false conversions”-positive TST results that appear to be indicative of infection acquired during travel, but which are really the result of previous TB infection. This is particularly important if the traveler is going to a country where XDR TB is rampant. It would be critical to know whether the person's skin test had actually been positive before the travel.
     </p>
     <p id="para2230">
      Persons having repeat TSTs must be tested with the same commercial antigen, as switching antigens can also lead to false TST conversions.
     </p>
     <p id="para2231">
      An alternative to two-step TST is a single FDA-approved interferon-gamma release assay (IGRA), such as the QuantiFERON TB test (Gold or Gold In-Tube versions). IGRAs are about equally specific as TST in non-BCG-vaccinated populations and much more specific in BCG-vaccinated populations. For a traveler whose time before departure is short, a single-step TST would be an acceptable alternative if there were insufficient time for the two-step TST and the IGRA were not available.
     </p>
     <p id="para2232">
      In general it is best not to mix tests. There is about 15% discordance between TST and IGRA, usually with the TST positive and the IGRA negative. There are multiple reasons for the discordance, and in any individual it is often difficult to be confident about the reason for discordance. However, if the health-care provider decides to mix tests, it is better to go from TST to IGRA than the other way around, because the likelihood of having a discordant result, with the TST negative and the IGRA positive, is much lower. Such discordant results may become unavoidable as more medical establishments switch from TSTs to IGRAs.
     </p>
     <p id="para2233">
      The use of TST among those visiting friends and relatives in TB-endemic areas should take into account the high rate of TST positivity in this population. In a study among 53,000 adults in Tennessee, the prevalence of a positive TST among the foreign born was 10 times that of the U.S. born (34.2% vs. 3.2%). Confirming TST status prior to travel would prevent the conclusion that a positive TST after travel was due to recent conversion.
     </p>
     <ref-list id="cebib42">
      <title>
       References
      </title>
      <ref id="bib412">
       <label>
        1
       </label>
       <element-citation id="sbref357" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Leder
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Tong
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Weld
          </surname>
          <given-names>
           L
          </given-names>
         </name>
        </person-group>
        <article-title>
         Illness in travelers visiting friends and relatives: a review of the GeoSentinel Surveillance Network
        </article-title>
        <source>
         Clin Infect Dis
        </source>
        <volume>
         43
        </volume>
        <issue>
         9
        </issue>
        <year>
         2006
        </year>
        <fpage>
         1185
        </fpage>
        <lpage>
         1193
        </lpage>
        <pub-id pub-id-type="pmid">
         17029140
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib413">
       <label>
        2
       </label>
       <element-citation id="sbref358" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Jung
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Banks
          </surname>
          <given-names>
           RH
          </given-names>
         </name>
        </person-group>
        <article-title>
         Tuberculosis risk in US Peace Corps volunteers, 1996 to 2005
        </article-title>
        <source>
         J Travel Med
        </source>
        <volume>
         15
        </volume>
        <issue>
         2
        </issue>
        <year>
         2008
        </year>
        <fpage>
         87
        </fpage>
        <lpage>
         94
        </lpage>
        <pub-id pub-id-type="pmid">
         18346241
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib414">
       <label>
        3
       </label>
       <element-citation id="sbref359" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cobelens
          </surname>
          <given-names>
           FG
          </given-names>
         </name>
         <name>
          <surname>
           van Deutekom
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Draayer-Jansen
          </surname>
          <given-names>
           IW
          </given-names>
         </name>
        </person-group>
        <article-title>
         Risk of infection with
         <italic>
          Mycobacterium tuberculosis
         </italic>
         in travellers to areas of high tuberculosis endemicity
        </article-title>
        <source>
         Lancet
        </source>
        <volume>
         356
        </volume>
        <issue>
         9228
        </issue>
        <year>
         2000
        </year>
        <fpage>
         461
        </fpage>
        <lpage>
         465
        </lpage>
        <pub-id pub-id-type="pmid">
         10981889
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib415">
       <label>
        4
       </label>
       <element-citation id="sbref360" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Haley
          </surname>
          <given-names>
           CA
          </given-names>
         </name>
         <name>
          <surname>
           Cain
          </surname>
          <given-names>
           KP
          </given-names>
         </name>
         <name>
          <surname>
           Yu
          </surname>
          <given-names>
           C
          </given-names>
         </name>
        </person-group>
        <article-title>
         Risk-based screening for latent tuberculosis infection
        </article-title>
        <source>
         South Med J
        </source>
        <volume>
         101
        </volume>
        <issue>
         2
        </issue>
        <year>
         2008
        </year>
        <fpage>
         142
        </fpage>
        <lpage>
         149
        </lpage>
        <pub-id pub-id-type="pmid">
         18364613
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib416">
       <label>
        5
       </label>
       <element-citation id="sbref361" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Al-Jahdali
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Memish
          </surname>
          <given-names>
           ZA
          </given-names>
         </name>
         <name>
          <surname>
           Menzies
          </surname>
          <given-names>
           D
          </given-names>
         </name>
        </person-group>
        <article-title>
         Tuberculosis in association with travel
        </article-title>
        <source>
         Int J Antimicrob Agents
        </source>
        <volume>
         21
        </volume>
        <issue>
         2
        </issue>
        <year>
         2003
        </year>
        <fpage>
         125
        </fpage>
        <lpage>
         130
        </lpage>
        <pub-id pub-id-type="pmid">
         12615375
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib417">
       <label>
        6
       </label>
       <element-citation id="sbref362" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Johnston
          </surname>
          <given-names>
           VJ
          </given-names>
         </name>
         <name>
          <surname>
           Grant
          </surname>
          <given-names>
           AD
          </given-names>
         </name>
        </person-group>
        <article-title>
         Tuberculosis in travellers
        </article-title>
        <source>
         Travel Med Infect Dis
        </source>
        <volume>
         1
        </volume>
        <issue>
         4
        </issue>
        <year>
         2003
        </year>
        <fpage>
         205
        </fpage>
        <lpage>
         212
        </lpage>
        <pub-id pub-id-type="pmid">
         17291919
        </pub-id>
       </element-citation>
      </ref>
     </ref-list>
    </sec>
    <sec id="subchapter43">
     <sec-meta>
      <contrib-group>
       <contrib contrib-type="author" id="au75">
        <name>
         <surname>
          Whatley
         </surname>
         <given-names>
          Amanda D.
         </given-names>
        </name>
       </contrib>
       <contrib contrib-type="author" id="au76">
        <name>
         <surname>
          Barbeau
         </surname>
         <given-names>
          Deborah Nicolls
         </given-names>
        </name>
       </contrib>
      </contrib-group>
     </sec-meta>
     <title>
      TRAVEL HEALTH KITS
     </title>
     <p id="para2234">
      The purpose of packing a travel health jit is to ensure travelers have supplies they need to—
      <list id="celist434" list-type="simple">
       <list-item id="celistitem1587">
        <label>
         •
        </label>
        <p id="para2235">
         manage pre-existing medical conditions and treat any exacerbations of these conditions,
        </p>
       </list-item>
       <list-item id="celistitem1588">
        <label>
         •
        </label>
        <p id="para2236">
         prevent illness related to traveling, and
        </p>
       </list-item>
       <list-item id="celistitem1589">
        <label>
         •
        </label>
        <p id="para2237">
         take care of minor health problems as they occur.
        </p>
       </list-item>
      </list>
     </p>
     <sec id="cesec532">
      <title>
       Traveling with Medications
      </title>
      <p id="para2238">
       When medications are necessary for travel, it is important to remember the following:
       <list id="celist435" list-type="simple">
        <list-item id="celistitem1590">
         <label>
          •
         </label>
         <p id="para2239">
          <bold>
           Original containers:
          </bold>
          All medications should be carried in their original containers with clear labels, so the contents are easily identified. Although many travelers like placing medications into small containers or packing them in the daily-dose containers, officials at ports of entry may require proper identification of medications.
         </p>
        </list-item>
        <list-item id="celistitem1591">
         <label>
          •
         </label>
         <p id="para2240">
          <bold>
           Prescriptions:
          </bold>
          Travelers should carry copies of all prescriptions, including their generic names.
         </p>
        </list-item>
        <list-item id="celistitem1592">
         <label>
          •
         </label>
         <p id="para2241">
          <bold>
           Physician notes:
          </bold>
          For controlled substances and injectable medications, travelers are advised to carry a note from the prescribing physician on letterhead stationery.
         </p>
        </list-item>
        <list-item id="celistitem1593">
         <label>
          •
         </label>
         <p id="para2242">
          <bold>
           Restricted medications:
          </bold>
          Travelers should be aware that certain medications are not permitted in certain countries. If there is a question about these restrictions, particularly with controlled substances, travelers are recommended to contact the embassy or consulate of the destination country.
         </p>
        </list-item>
        <list-item id="celistitem1594">
         <label>
          •
         </label>
         <p id="para2243">
          <bold>
           Availability:
          </bold>
          A travel health kit is useful only when it is available. It should be carried with the traveler at all times (e.g., in a carry-on bag). Due to airline security rules, sharp objects and some liquids and gels must remain in checked luggage.
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <sec id="cesec533">
      <title>
       Pre-Existing Medical Condition Supplies
      </title>
      <p id="para2244">
       Travelers with pre-existing medical conditions are advised to carry enough medication for the duration of their trip and an extra supply, in case the trip is extended for any reason. If additional supplies or medications are needed for the management of exacerbations of existing medical conditions, these should be carried as well. The health-care provider managing a traveler's pre-existing medical conditions should be consulted for the best plan of action (see the section Traveling with Chronic Medical Illnesses in Chapter 8).
      </p>
      <p id="para2245">
       Persons with pre-existing conditions, such as diabetes or allergies to envenomations or medications, should consider wearing an alert bracelet and making sure this information is on a card in their wallet and with their other travel documents.
      </p>
     </sec>
     <sec id="cesec534">
      <title>
       General Travel Health Kit Supplies
      </title>
      <p id="para2246">
       A variety of health kits is available commercially and may even be purchased over the Internet (see below); however, similar kits can be assembled at home, often at lower cost. The specific contents of the health kit are based on destination, duration of travel, type of travel, and the traveler's pre-existing medical conditions.
      </p>
      <p id="para2247">
       Although this is not a comprehensive list, basic items that should be considered are listed below. See Chapters 7 and 8 for additional suggestions that may be useful in planning the contents of a kit for travelers with specific needs.
      </p>
      <sec id="cesec535">
       <title>
        Medications
       </title>
       <p id="para2248">
        <list id="celist436" list-type="simple">
         <list-item id="celistitem1595">
          <label>
           •
          </label>
          <p id="para2249">
           Destination-related, if applicable:
           <list id="celist437" list-type="simple">
            <list-item id="celistitem1596">
             <label>
              ○
             </label>
             <p id="para2250">
              Antimalarial medications
             </p>
            </list-item>
            <list-item id="celistitem1597">
             <label>
              ○
             </label>
             <p id="para2251">
              Medication to prevent or treat high-altitude illness
             </p>
            </list-item>
           </list>
          </p>
         </list-item>
         <list-item id="celistitem1598">
          <label>
           •
          </label>
          <p id="para2252">
           Pain or fever (one or more of the following, or an alternative):
           <list id="celist438" list-type="simple">
            <list-item id="celistitem1599">
             <label>
              ○
             </label>
             <p id="para2253">
              Acetaminophen
             </p>
            </list-item>
            <list-item id="celistitem1600">
             <label>
              ○
             </label>
             <p id="para2254">
              Aspirin
             </p>
            </list-item>
            <list-item id="celistitem1601">
             <label>
              ○
             </label>
             <p id="para2255">
              Ibuprofen
             </p>
            </list-item>
           </list>
          </p>
         </list-item>
         <list-item id="celistitem1602">
          <label>
           •
          </label>
          <p id="para2256">
           Stomach upset or diarrhea:
           <list id="celist439" list-type="simple">
            <list-item id="celistitem1603">
             <label>
              ○
             </label>
             <p id="para2257">
              Over-the-counter antidiarrheal medication (such as loperamide or bismuth subsalicylate)
             </p>
            </list-item>
            <list-item id="celistitem1604">
             <label>
              ○
             </label>
             <p id="para2258">
              Antibiotic for self-treatment of moderate to severe diarrhea
             </p>
            </list-item>
            <list-item id="celistitem1605">
             <label>
              ○
             </label>
             <p id="para2259">
              Oral rehydration solution packets
             </p>
            </list-item>
            <list-item id="celistitem1606">
             <label>
              ○
             </label>
             <p id="para2260">
              Mild laxative
             </p>
            </list-item>
            <list-item id="celistitem1607">
             <label>
              ○
             </label>
             <p id="para2261">
              Antacid
             </p>
            </list-item>
           </list>
          </p>
         </list-item>
         <list-item id="celistitem1608">
          <label>
           •
          </label>
          <p id="para2262">
           Items to treat throat and respiratory symptoms:
           <list id="celist440" list-type="simple">
            <list-item id="celistitem1609">
             <label>
              ○
             </label>
             <p id="para2263">
              Antihistamine
             </p>
            </list-item>
            <list-item id="celistitem1610">
             <label>
              ○
             </label>
             <p id="para2264">
              Decongestant, alone or in combination with antihistamine
             </p>
            </list-item>
            <list-item id="celistitem1611">
             <label>
              ○
             </label>
             <p id="para2265">
              Cough suppressant/expectorant
             </p>
            </list-item>
            <list-item id="celistitem1612">
             <label>
              ○
             </label>
             <p id="para2266">
              Throat lozenges
             </p>
            </list-item>
           </list>
          </p>
         </list-item>
         <list-item id="celistitem1613">
          <label>
           •
          </label>
          <p id="para2267">
           Anti-motion sickness medication.
          </p>
         </list-item>
         <list-item id="celistitem1614">
          <label>
           •
          </label>
          <p id="para2268">
           Epinephrine auto-injector (such as an EpiPen), especially if history of severe allergic reaction. Smaller-dose packages are available for children.
          </p>
         </list-item>
         <list-item id="celistitem1615">
          <label>
           •
          </label>
          <p id="para2269">
           Any medications, prescription or over the counter, taken on a regular basis at home.
          </p>
         </list-item>
        </list>
       </p>
      </sec>
      <sec id="cesec536">
       <title>
        Basic First Aid
       </title>
       <p id="para2270">
        <list id="celist441" list-type="simple">
         <list-item id="celistitem1616">
          <label>
           •
          </label>
          <p id="para2271">
           Disposable gloves (at least two pairs)
          </p>
         </list-item>
         <list-item id="celistitem1617">
          <label>
           •
          </label>
          <p id="para2272">
           Adhesive bandages, multiple sizes
          </p>
         </list-item>
         <list-item id="celistitem1618">
          <label>
           •
          </label>
          <p id="para2273">
           Gauze
          </p>
         </list-item>
         <list-item id="celistitem1619">
          <label>
           •
          </label>
          <p id="para2274">
           Adhesive tape
          </p>
         </list-item>
         <list-item id="celistitem1620">
          <label>
           •
          </label>
          <p id="para2275">
           Elastic bandage wrap for sprains and strains
          </p>
         </list-item>
         <list-item id="celistitem1621">
          <label>
           •
          </label>
          <p id="para2276">
           Antiseptic
          </p>
         </list-item>
         <list-item id="celistitem1622">
          <label>
           •
          </label>
          <p id="para2277">
           Cotton swabs
          </p>
         </list-item>
         <list-item id="celistitem1623">
          <label>
           •
          </label>
          <p id="para2278">
           Tweezers
           <xref ref-type="fn" rid="fn3">
            *
           </xref>
          </p>
         </list-item>
         <list-item id="celistitem1624">
          <label>
           •
          </label>
          <p id="para2279">
           Scissors
           <xref ref-type="fn" rid="fn3">
            *
           </xref>
          </p>
         </list-item>
         <list-item id="celistitem1625">
          <label>
           •
          </label>
          <p id="para2280">
           Antifungal and antibacterial ointments or creams
          </p>
         </list-item>
         <list-item id="celistitem1626">
          <label>
           •
          </label>
          <p id="para2281">
           1% hydrocortisone cream
          </p>
         </list-item>
         <list-item id="celistitem1627">
          <label>
           •
          </label>
          <p id="para2282">
           Anti-itch gel or cream for insect bites and stings
          </p>
         </list-item>
         <list-item id="celistitem1628">
          <label>
           •
          </label>
          <p id="para2283">
           Aloe gel for sunburns
          </p>
         </list-item>
         <list-item id="celistitem1629">
          <label>
           •
          </label>
          <p id="para2284">
           Moleskin or molefoam for blisters
          </p>
         </list-item>
         <list-item id="celistitem1630">
          <label>
           •
          </label>
          <p id="para2285">
           Digital thermometer
          </p>
         </list-item>
         <list-item id="celistitem1631">
          <label>
           •
          </label>
          <p id="para2286">
           Saline eye drops
          </p>
         </list-item>
         <list-item id="celistitem1632">
          <label>
           •
          </label>
          <p id="para2287">
           First-aid quick reference card
          </p>
         </list-item>
        </list>
       </p>
      </sec>
      <sec id="cesec537">
       <title>
        Other Important Items
       </title>
       <p id="para2288">
        <list id="celist442" list-type="simple">
         <list-item id="celistitem1633">
          <label>
           •
          </label>
          <p id="para2289">
           Insect repellent
          </p>
         </list-item>
         <list-item id="celistitem1634">
          <label>
           •
          </label>
          <p id="para2290">
           Sunscreen (SPF 15 or greater)
          </p>
         </list-item>
         <list-item id="celistitem1635">
          <label>
           •
          </label>
          <p id="para2291">
           Antibacterial hand wipes or an alcohol-based hand sanitizer containing at least 60% alcohol
          </p>
         </list-item>
         <list-item id="celistitem1636">
          <label>
           •
          </label>
          <p id="para2292">
           Useful items in certain circumstances:
           <list id="celist443" list-type="simple">
            <list-item id="celistitem1637">
             <label>
              ○
             </label>
             <p id="para2293">
              Extra pair of contacts or prescription glasses, or both, for people who wear corrective lenses
             </p>
            </list-item>
            <list-item id="celistitem1638">
             <label>
              ○
             </label>
             <p id="para2294">
              Mild sedative (such as zolpidem), other sleep aid, or anti-anxiety medication
             </p>
            </list-item>
            <list-item id="celistitem1639">
             <label>
              ○
             </label>
             <p id="para2295">
              Latex condoms
             </p>
            </list-item>
            <list-item id="celistitem1640">
             <label>
              ○
             </label>
             <p id="para2296">
              Water purification tablets
             </p>
            </list-item>
            <list-item id="celistitem1641">
             <label>
              ○
             </label>
             <p id="para2297">
              Commercial suture/syringe kits to be used by a local health-care provider. (These items will also require a letter from the prescribing physician on letterhead stationery.)
             </p>
            </list-item>
           </list>
          </p>
         </list-item>
        </list>
       </p>
      </sec>
      <sec id="cesec538">
       <title>
        Contact Card
       </title>
       <p id="para2298">
        It is also important for travelers to locate and record important contact information, in case it is needed during their trip. Often this information is needed quickly; having a contact card with the following items will help save time in these urgent situations.
       </p>
       <p id="para2299">
        Items to include on a contact card should be the address and phone numbers of the following:
        <list id="celist444" list-type="simple">
         <list-item id="celistitem1642">
          <label>
           •
          </label>
          <p id="para2300">
           Family member or close contact still in the United States
          </p>
         </list-item>
         <list-item id="celistitem1643">
          <label>
           •
          </label>
          <p id="para2301">
           Health-care provider at home
          </p>
         </list-item>
         <list-item id="celistitem1644">
          <label>
           •
          </label>
          <p id="para2302">
           Area hospitals or clinics
          </p>
         </list-item>
         <list-item id="celistitem1645">
          <label>
           •
          </label>
          <p id="para2303">
           U.S. Embassy or Consulate in the destination country or countries
          </p>
         </list-item>
        </list>
       </p>
       <p id="para2304">
        See the next section in this chapter,
        <xref ref-type="sec" rid="subchapter44">
         Obtaining Health Care Abroad for the Ill Traveler
        </xref>
        , for information about how to locate local health care and embassy/consulate contacts.
       </p>
      </sec>
     </sec>
     <sec id="cesec539">
      <title>
       Commercial Medical Kits
      </title>
      <p id="para2305">
       Commercial medical kits are available for a wide range of circumstances, from basic first aid to advanced emergency life support. Many pharmacy, grocery, retail, and outdoor sporting goods stores sell their own basic first-aid kits. Travelers who choose to purchase a health kit rather than assemble their own should be certain to review the contents of the kit carefully to ensure that it has everything needed; additional items may be necessary.
      </p>
      <p id="para2306">
       For more adventurous travelers, a number of companies produce advanced medical kits and will even customize kits based on specific travel needs.
      </p>
      <p id="para2307">
       In addition, specialty kits are available for managing diabetes, dealing with dental emergencies, and handling aquatic environments.
      </p>
      <p id="para2308">
       Below is a list of websites supplying a wide range of medical kits. There are many suppliers, and this list is not meant to be all-inclusive.
       <list id="celist445" list-type="simple">
        <list-item id="celistitem1646">
         <label>
          •
         </label>
         <p id="para2309">
          American Red Cross:
          <ext-link ext-link-type="uri" id="interref126" xlink:href="http://www.redcrossstore.org">
           www.redcrossstore.org
          </ext-link>
         </p>
        </list-item>
        <list-item id="celistitem1647">
         <label>
          •
         </label>
         <p id="para2310">
          Adventure Medical Kits:
          <ext-link ext-link-type="uri" id="interref127" xlink:href="http://www.adventuremedicalkits.com">
           www.adventuremedicalkits.com
          </ext-link>
         </p>
        </list-item>
        <list-item id="celistitem1648">
         <label>
          •
         </label>
         <p id="para2311">
          Chinook Medical Gear:
          <ext-link ext-link-type="uri" id="interref128" xlink:href="http://www.chinookmed.com">
           www.chinookmed.com
          </ext-link>
         </p>
        </list-item>
        <list-item id="celistitem1649">
         <label>
          •
         </label>
         <p id="para2312">
          Travel Medicine, Inc.:
          <ext-link ext-link-type="uri" id="interref129" xlink:href="http://www.travmed.com">
           www.travmed.com
          </ext-link>
         </p>
        </list-item>
        <list-item id="celistitem1650">
         <label>
          •
         </label>
         <p id="para2313">
          Wilderness Medicine Outfitters:
          <ext-link ext-link-type="uri" id="interref130" xlink:href="http://www.wildernessmedicine.com">
           www.wildernessmedicine.com
          </ext-link>
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <ref-list id="cebib43">
      <title>
       References
      </title>
      <ref id="bib418">
       <label>
        1
       </label>
       <element-citation id="sbref363" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Weiss
          </surname>
          <given-names>
           EA
          </given-names>
         </name>
         <name>
          <surname>
           Franco-Paredes
          </surname>
          <given-names>
           C
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         Travel health and medical kits
        </chapter-title>
        <person-group person-group-type="editor">
         <name>
          <surname>
           Keystone
          </surname>
          <given-names>
           JS
          </given-names>
         </name>
         <name>
          <surname>
           Kozarsky
          </surname>
          <given-names>
           PE
          </given-names>
         </name>
         <name>
          <surname>
           Freedman
          </surname>
          <given-names>
           DO
          </given-names>
         </name>
         <name>
          <surname>
           Nothdurft
          </surname>
          <given-names>
           HD
          </given-names>
         </name>
         <name>
          <surname>
           Connor
          </surname>
          <given-names>
           BA
          </given-names>
         </name>
        </person-group>
        <source>
         Travel medicine
        </source>
        <edition>
         2nd ed.
        </edition>
        <year>
         2008
        </year>
        <publisher-name>
         Mosby
        </publisher-name>
        <publisher-loc>
         Philadelphia
        </publisher-loc>
        <fpage>
         69
        </fpage>
        <lpage>
         74
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib419">
       <label>
        2
       </label>
       <element-citation id="sbref364" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Reynolds
          </surname>
          <given-names>
           SA
          </given-names>
         </name>
         <name>
          <surname>
           Levy
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Walker
          </surname>
          <given-names>
           ES
          </given-names>
         </name>
        </person-group>
        <article-title>
         Hand sanitizer alert
        </article-title>
        <source>
         Emerg Infect Dis
        </source>
        <volume>
         12
        </volume>
        <issue>
         3
        </issue>
        <year>
         2006
        </year>
        <fpage>
         527
        </fpage>
        <lpage>
         529
        </lpage>
        <pub-id pub-id-type="pmid">
         16710985
        </pub-id>
       </element-citation>
      </ref>
     </ref-list>
    </sec>
    <sec id="subchapter44">
     <sec-meta>
      <contrib-group>
       <contrib contrib-type="author" id="au77">
        <name>
         <surname>
          Sommers
         </surname>
         <given-names>
          Theresa
         </given-names>
        </name>
       </contrib>
       <contrib contrib-type="author" id="au78">
        <name>
         <surname>
          Brunette
         </surname>
         <given-names>
          Gary W.
         </given-names>
        </name>
       </contrib>
      </contrib-group>
     </sec-meta>
     <title>
      OBTAINING HEALTH CARE ABROAD FOR THE ILL TRAVELER
     </title>
     <p id="para2314">
      An important aspect of preparing for a trip abroad is to consider the possibility of becoming sick or injured during travel. The following resources and information will be useful to travelers, should they require medical assistance abroad.
     </p>
     <sec id="cesec540">
      <title>
       Traveling While Ill
      </title>
      <p id="para2315">
       Health-care providers should advise their patients about the possible need to avoid traveling if they become ill during their trip. Those with certain health conditions may need to postpone their travel arrangements, including air and public ground transportation. In general, travelers who are ill with a communicable disease that is spread easily to other people should discuss the need for rescheduling travel with their provider.
      </p>
      <p id="para2316">
       Travelers should be aware that some airlines check for visibly sick passengers in the waiting area and during boarding. If a waiting passenger looks visibly ill, the airline may prohibit that person from getting on the airplane.
      </p>
     </sec>
     <sec id="cesec541">
      <title>
       Locating a Health-Care Provider
      </title>
      <p id="para2317">
       Several resources are available to American citizens who require medical attention during their travels. The following resources can assist travelers in finding adequate care:
       <list id="celist446" list-type="simple">
        <list-item id="celistitem1651">
         <label>
          •
         </label>
         <p id="para2318">
          The U.S. Department of State:
          <list id="celist447" list-type="simple">
           <list-item id="celistitem1652">
            <label>
             ○
            </label>
            <p id="para2319">
             A U.S. consular officer can assist in locating appropriate medical services, as well as in notifying friends, family, or employer of an emergency.
            </p>
           </list-item>
           <list-item id="celistitem1653">
            <label>
             ○
            </label>
            <p id="para2320">
             For more information, see
             <ext-link ext-link-type="uri" id="interref131" xlink:href="http://travel.state.gov/travel/tips/brochures/brochures_1215.html">
              http://travel.state.gov/travel/tips/brochures/brochures_1215.html
             </ext-link>
             .
            </p>
           </list-item>
          </list>
         </p>
        </list-item>
        <list-item id="celistitem1654">
         <label>
          •
         </label>
         <p id="para2321">
          The International Society of Travel Medicine (ISTM):
          <list id="celist448" list-type="simple">
           <list-item id="celistitem1655">
            <label>
             ○
            </label>
            <p id="para2322">
             ISTM maintains a directory of health-care professionals with expertise in travel medicine in almost 50 countries worldwide.
            </p>
           </list-item>
           <list-item id="celistitem1656">
            <label>
             ○
            </label>
            <p id="para2323">
             To access the directory, see
             <ext-link ext-link-type="uri" id="interref132" xlink:href="http://www.istm.org">
              www.istm.org
             </ext-link>
             .
            </p>
           </list-item>
          </list>
         </p>
        </list-item>
        <list-item id="celistitem1657">
         <label>
          •
         </label>
         <p id="para2324">
          The American Society of Tropical Medicine and Hygiene (ASTMH):
          <list id="celist449" list-type="simple">
           <list-item id="celistitem1658">
            <label>
             ○
            </label>
            <p id="para2325">
             ASTMH maintains a worldwide directory of providers specializing in tropical medicine, medical parasitology, and travelers' health.
            </p>
           </list-item>
           <list-item id="celistitem1659">
            <label>
             ○
            </label>
            <p id="para2326">
             To access the directory, see
             <ext-link ext-link-type="uri" id="interref133" xlink:href="http://www.astmh.org">
              www.astmh.org
             </ext-link>
             .
            </p>
           </list-item>
          </list>
         </p>
        </list-item>
        <list-item id="celistitem1660">
         <label>
          •
         </label>
         <p id="para2327">
          International Association for Medical Assistance to Travelers (IAMAT):
          <list id="celist450" list-type="simple">
           <list-item id="celistitem1661">
            <label>
             ○
            </label>
            <p id="para2328">
             IAMAT maintains an international network of physicians, hospitals, and clinics who have agreed to treat IAMAT members in need of medical care while abroad.
            </p>
           </list-item>
           <list-item id="celistitem1662">
            <label>
             ○
            </label>
            <p id="para2329">
             Membership is free, although a donation to support IAMAT efforts is suggested. Members receive a directory of participating physicians and medical centers and have access to a variety of travel-related informational brochures.
            </p>
           </list-item>
           <list-item id="celistitem1663">
            <label>
             ○
            </label>
            <p id="para2330">
             For more information, see
             <ext-link ext-link-type="uri" id="interref134" xlink:href="http://www.iamat.org">
              www.iamat.org
             </ext-link>
             .
            </p>
           </list-item>
          </list>
         </p>
        </list-item>
        <list-item id="celistitem1664">
         <label>
          •
         </label>
         <p id="para2331">
          Travel Health Online:
          <list id="celist451" list-type="simple">
           <list-item id="celistitem1665">
            <label>
             ○
            </label>
            <p id="para2332">
             This resource maintains a list of travel medicine providers worldwide. Information is obtained from a variety of sources, so the quality of services and the expertise of the providers cannot be guaranteed.
            </p>
           </list-item>
           <list-item id="celistitem1666">
            <label>
             ○
            </label>
            <p id="para2333">
             For more information, see
             <ext-link ext-link-type="uri" id="interref135" xlink:href="https://www.tripprep.com">
              https://www.tripprep.com
             </ext-link>
             .
            </p>
           </list-item>
          </list>
         </p>
        </list-item>
       </list>
      </p>
      <p id="para2334">
       Travelers may also get information about local health care from embassies and consulates of other countries, hotel doctors, credit card companies, and multinational corporations, which may offer health-care services for their employees. In addition, travelers who obtain evacuation insurance before travel will have access to a 24-hour hotline for help in any medical emergency.
      </p>
     </sec>
     <sec id="cesec542">
      <title>
       Accreditation of International Health-Care Facilities
      </title>
      <p id="para2335">
       The quality of health care from foreign medical centers can be variable, particularly in developing countries. To ensure a higher quality of care abroad, Joint Commission International attempts to continuously improve the safety and quality of care in the international community through the provision of education and consultation services and international accreditation.
      </p>
      <p id="para2336">
       A list of accredited international health-care facilities is available at the Joint Commission International website (
       <ext-link ext-link-type="uri" id="interref136" xlink:href="http://www.jointcommissioninternational.org">
        www.jointcommissioninternational.org
       </ext-link>
       ).
      </p>
     </sec>
     <sec id="cesec543">
      <title>
       Drugs/Pharmaceuticals Abroad
      </title>
      <p id="para2337">
       The quality of drugs and medical products abroad cannot be guaranteed, as they may not meet U.S. standards or could be counterfeit (see
       <xref ref-type="sec" rid="subchapter40">
        Perspectives: Counterfeit Drugs
       </xref>
       earlier in this chapter). Travelers are advised to—
       <list id="celist452" list-type="simple">
        <list-item id="celistitem1667">
         <label>
          •
         </label>
         <p id="para2338">
          Bring with them all the drugs and medicines that they think they will need, including pain relievers, antidiarrheal medication, and, if applicable, antimalarials.
         </p>
        </list-item>
        <list-item id="celistitem1668">
         <label>
          •
         </label>
         <p id="para2339">
          Exercise caution when buying medications (especially those that do not require a prescription). In many developing countries, virtually any drug can be purchased without prescription.
         </p>
        </list-item>
        <list-item id="celistitem1669">
         <label>
          •
         </label>
         <p id="para2340">
          Travelers who may require an injection(s) abroad should bring their own injection supplies (see the
          <xref ref-type="sec" rid="subchapter43">
           Travel Health Kits
          </xref>
          section earlier in this chapter).
         </p>
        </list-item>
        <list-item id="celistitem1670">
         <label>
          •
         </label>
         <p id="para2341">
          Travelers who do not have their own injection supplies yet require an injection should ask if the equipment is disposable and insist that a new needle and syringe be used.
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <sec id="cesec544">
      <title>
       Emergency Care Abroad
      </title>
      <p id="para2342">
       The quality and availability of proper emergency medical care abroad may be variable and, in situations requiring a blood transfusion, the safety of blood products often cannot be guaranteed.
       <list id="celist453" list-type="simple">
        <list-item id="celistitem1671">
         <label>
          •
         </label>
         <p id="para2343">
          Not all countries have accurate, reliable, and systematic screening of blood donations for infectious agents, which increases the risk of transfusion-related transmission of disease.
         </p>
        </list-item>
        <list-item id="celistitem1672">
         <label>
          •
         </label>
         <p id="para2344">
          The 2001–2002 WHO Global Database on Blood Safety report supports this view:
          <list id="celist454" list-type="simple">
           <list-item id="celistitem1673">
            <label>
             ○
            </label>
            <p id="para2345">
             40 countries reported they did not test all donated blood for HIV, hepatitis B and C viruses, and syphilis.
            </p>
           </list-item>
           <list-item id="celistitem1674">
            <label>
             ○
            </label>
            <p id="para2346">
             39 countries reported that, due to unavailable testing supplies, blood was released for clinical use without testing for transfusion-transmissible infections.
            </p>
           </list-item>
          </list>
         </p>
        </list-item>
        <list-item id="celistitem1675">
         <label>
          •
         </label>
         <p id="para2347">
          Due to this increased risk, travelers in developing countries should only receive a blood transfusion in life-and-death situations for which there may be no other options.
         </p>
        </list-item>
        <list-item id="celistitem1676">
         <label>
          •
         </label>
         <p id="para2348">
          When a situation requires blood transfusion, travelers should make every effort to ensure that the blood has been screened for transmissible diseases, including HIV.
         </p>
        </list-item>
        <list-item id="celistitem1677">
         <label>
          •
         </label>
         <p id="para2349">
          All travelers should consider being immunized against hepatitis B virus before their trip, especially—
          <list id="celist455" list-type="simple">
           <list-item id="celistitem1678">
            <label>
             ○
            </label>
            <p id="para2350">
             Those who travel frequently to developing countries
            </p>
           </list-item>
           <list-item id="celistitem1679">
            <label>
             ○
            </label>
            <p id="para2351">
             Travelers whose itinerary indicate spending a prolonged period of time in developing countries
            </p>
           </list-item>
           <list-item id="celistitem1680">
            <label>
             ○
            </label>
            <p id="para2352">
             Travelers whose activities put them at higher risk for serious injury (e.g., adventure travel).
            </p>
           </list-item>
          </list>
         </p>
        </list-item>
        <list-item id="celistitem1681">
         <label>
          •
         </label>
         <p id="para2353">
          There are no medical indications for travelers to take blood with them from their home countries.
         </p>
        </list-item>
        <list-item id="celistitem1682">
         <label>
          •
         </label>
         <p id="para2354">
          The limited storage period of blood and the need for special equipment negate the feasibility of independent blood banking for individual travelers or small groups. The international shipment of blood for transfusion is practical only when handled by agreement between two responsible organizations, such as national blood transfusion services. This mechanism is not useful for the emergency needs of individual travelers and should not be attempted by private travelers or organizations not operating recognized blood programs.
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <ref-list id="cebib44">
      <title>
       References
      </title>
      <ref id="bib420">
       <label>
        1
       </label>
       <mixed-citation id="ceotherref56" publication-type="other">
        World Health Organization. Global database on blood safety report 2001–2002. Available from:
        <ext-link ext-link-type="uri" id="interref137" xlink:href="http://www.who.int/bloodsafety/GDBS_Report_2001-2002.pdf">
         http://www.who.int/bloodsafety/GDBS_Report_2001–2002.pdf
        </ext-link>
        . Geneva: World Health Organization [cited 2008 Jun 30].
       </mixed-citation>
      </ref>
      <ref id="bib421">
       <label>
        2
       </label>
       <element-citation id="sbref365" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kolars
          </surname>
          <given-names>
           JC
          </given-names>
         </name>
        </person-group>
        <article-title>
         Rules of the road: a consumer's guide for travelers seeking health care in foreign lands
        </article-title>
        <source>
         J Travel Med
        </source>
        <volume>
         9
        </volume>
        <issue>
         4
        </issue>
        <year>
         2002
        </year>
        <fpage>
         198
        </fpage>
        <lpage>
         201
        </lpage>
        <pub-id pub-id-type="pmid">
         12962614
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib422">
       <label>
        3
       </label>
       <mixed-citation id="ceotherref57" publication-type="other">
        Joint Commission International. c2002–08 [cited 2008 Jun 30]. Available from:
        <ext-link ext-link-type="uri" id="interref138" xlink:href="http://www.jointcommissioninternational.org">
         http://www.jointcommissioninternational.org
        </ext-link>
        .
       </mixed-citation>
      </ref>
     </ref-list>
    </sec>
    <sec id="subchapter45">
     <sec-meta>
      <contrib-group>
       <contrib contrib-type="author" id="au79">
        <name>
         <surname>
          Sommers
         </surname>
         <given-names>
          Theresa
         </given-names>
        </name>
       </contrib>
       <contrib contrib-type="author" id="au80">
        <name>
         <surname>
          Brunette
         </surname>
         <given-names>
          Gary W.
         </given-names>
        </name>
       </contrib>
      </contrib-group>
     </sec-meta>
     <title>
      TRAVEL INSURANCE AND EVACUATION INSURANCE
     </title>
     <p id="para2355">
      It is important for travelers to consider the financial consequences of a severe illness or injury abroad. A growing number of people do not have health insurance at home. Those who do need to check their policies to determine if their care abroad will be covered and what limitations may apply. Those who have adequate health insurance may not be covered for medical evacuation from a resource-poor area to a hospital where definitive care can be obtained. Even if they have a policy that would reimburse evacuation costs, the health insurance company may not have the resources to help organize the evacuation. Evacuation-only policies are available to fill this gap. Evacuation by air ambulance can cost $50,000 to $100,000 and must be paid in advance by those who do not have insurance.
     </p>
     <sec id="cesec545">
      <title>
       Paying for Health Services Abroad
      </title>
      <p id="para2356">
       Travelers who receive medical care in other countries will usually be required to pay in cash or with a credit card at the point of service, even if they have insurance coverage abroad. This could result in a large out-of-pocket expenditure of perhaps thousands of dollars for medical care.
       <list id="celist456" list-type="simple">
        <list-item id="celistitem1683">
         <label>
          •
         </label>
         <p id="para2357">
          Travelers with health insurance coverage should be sure to obtain copies of all bills and receipts from overseas medical care.
         </p>
        </list-item>
        <list-item id="celistitem1684">
         <label>
          •
         </label>
         <p id="para2358">
          The U.S. consular office can assist travelers who are U.S. citizens with transferring funds from the United States.
         </p>
        </list-item>
        <list-item id="celistitem1685">
         <label>
          •
         </label>
         <p id="para2359">
          In extreme circumstances, the U.S. consular office may be able to approve small government loans until private funds are available.
         </p>
        </list-item>
        <list-item id="celistitem1686">
         <label>
          •
         </label>
         <p id="para2360">
          Medical evacuation insurance may only cover the cost to the nearest destination where definitive care can be obtained. Some policies will cover eventual repatriation to one's home country. The traveler should be sure to understand what coverage is purchased.
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <sec id="cesec546">
      <title>
       Health Insurance Abroad
      </title>
      <p id="para2361">
       <list id="celist457" list-type="simple">
        <list-item id="celistitem1687">
         <label>
          •
         </label>
         <p id="para2362">
          Some health insurance carriers in the United States may provide coverage for emergencies that occur while traveling.
         </p>
        </list-item>
        <list-item id="celistitem1688">
         <label>
          •
         </label>
         <p id="para2363">
          The first step for travelers is to examine their present coverage and planned itinerary. Determine exactly which medical services will be covered abroad and what supplemental insurance you will need. Things to look for include—
          <list id="celist458" list-type="simple">
           <list-item id="celistitem1689">
            <label>
             ○
            </label>
            <p id="para2364">
             Exclusions for treatment of exacerbations of pre-existing medical conditions
            </p>
           </list-item>
           <list-item id="celistitem1690">
            <label>
             ○
            </label>
            <p id="para2365">
             The company's policy for “out-of-network” services
            </p>
           </list-item>
           <list-item id="celistitem1691">
            <label>
             ○
            </label>
            <p id="para2366">
             Coverage for complications of pregnancy
            </p>
           </list-item>
           <list-item id="celistitem1692">
            <label>
             ○
            </label>
            <p id="para2367">
             Exclusions for high-risk activities such as skydiving, scuba diving, and mountain climbing
            </p>
           </list-item>
           <list-item id="celistitem1693">
            <label>
             ○
            </label>
            <p id="para2368">
             Exclusions regarding psychiatric emergencies or injuries related to terrorist attacks or acts of war
            </p>
           </list-item>
           <list-item id="celistitem1694">
            <label>
             ○
            </label>
            <p id="para2369">
             Whether pre-authorization is needed for treatment, hospital admission, or other services
            </p>
           </list-item>
           <list-item id="celistitem1695">
            <label>
             ○
            </label>
            <p id="para2370">
             Whether a second opinion is required before obtaining emergency treatment
            </p>
           </list-item>
          </list>
         </p>
        </list-item>
        <list-item id="celistitem1696">
         <label>
          •
         </label>
         <p id="para2371">
          Medicare and Medicaid will not cover services outside the United States, except in very limited circumstances.
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <sec id="cesec547">
      <title>
       Travel Health and Medical Evacuation Insurance
      </title>
      <p id="para2372">
       Travelers need to evaluate their existing health insurance policies to see whether they already have adequate coverage. Short-term supplemental policies that cover health-care costs on a trip can be purchased. Evacuation coverage can be sold separately or in conjunction with overseas health insurance. Evacuation companies often have better resources and experience in some parts of the world than others. Travelers may want to check with them about their resources in a given area before making a purchase. In general, travelers should purchase a policy that provides the following:
       <list id="celist459" list-type="simple">
        <list-item id="celistitem1697">
         <label>
          •
         </label>
         <p id="para2373">
          Arrangements with hospitals to guarantee payments directly. Travelers may want to check on this possibility for the planned itinerary.
         </p>
        </list-item>
        <list-item id="celistitem1698">
         <label>
          •
         </label>
         <p id="para2374">
          Assistance via a 24-hour physician-backed support center. This is critical if the traveler is going to pay for evacuation insurance.
         </p>
        </list-item>
        <list-item id="celistitem1699">
         <label>
          •
         </label>
         <p id="para2375">
          Emergency medical transport, including repatriation. Medical evacuation can be costly, ranging from a few thousand dollars to over $100,000.
         </p>
        </list-item>
       </list>
      </p>
      <p id="para2376">
       While travel health and medical evacuation insurance is a consideration for all travelers, it is particularly important for travelers who—
       <list id="celist460" list-type="simple">
        <list-item id="celistitem1700">
         <label>
          •
         </label>
         <p id="para2377">
          Will be outside the United States for an extended period of time.
         </p>
        </list-item>
        <list-item id="celistitem1701">
         <label>
          •
         </label>
         <p id="para2378">
          Have underlying illnesses. These travelers should make certain that complications of the underlying condition will be covered by the chosen policy.
         </p>
        </list-item>
        <list-item id="celistitem1702">
         <label>
          •
         </label>
         <p id="para2379">
          Participate in activities involving greater risk for injury.
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <sec id="cesec548">
      <title>
       Finding a Travel Health and Medical Evacuation Insurance Provider
      </title>
      <p id="para2380">
       The following list, while not all-inclusive, gives a sample of resources for travelers seeking to purchase travel health and medical evacuation insurance:
       <list id="celist461" list-type="simple">
        <list-item id="celistitem1703">
         <label>
          •
         </label>
         <p id="para2381">
          U.S. Department of State (
          <ext-link ext-link-type="uri" id="interref139" xlink:href="http://www.travel.state.gov">
           www.travel.state.gov
          </ext-link>
          )
         </p>
        </list-item>
        <list-item id="celistitem1704">
         <label>
          •
         </label>
         <p id="para2382">
          International SOS (
          <ext-link ext-link-type="uri" id="interref140" xlink:href="http://www.internationalsos.com">
           www.internationalsos.com
          </ext-link>
          )
         </p>
        </list-item>
        <list-item id="celistitem1705">
         <label>
          •
         </label>
         <p id="para2383">
          MEDEX (
          <ext-link ext-link-type="uri" id="interref141" xlink:href="http://www.medexassist.com">
           www.medexassist.com
          </ext-link>
          )
         </p>
        </list-item>
        <list-item id="celistitem1706">
         <label>
          •
         </label>
         <p id="para2384">
          International Association for Medical Assistance to Travelers (
          <ext-link ext-link-type="uri" id="interref142" xlink:href="http://www.iamat.org">
           www.iamat.org
          </ext-link>
          )
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <sec id="cesec549">
      <title>
       Special Considerations for Travelers with Underlying Medical Conditions
      </title>
      <p id="para2385">
       Travelers with underlying medical conditions may want to take extra precautions in preparing for travel.
       <list id="celist462" list-type="simple">
        <list-item id="celistitem1707">
         <label>
          •
         </label>
         <p id="para2386">
          Travelers should choose a medical assistance company that allows customers to store their medical history before departure, so it can be accessed from anywhere in the world, if needed.
         </p>
        </list-item>
        <list-item id="celistitem1708">
         <label>
          •
         </label>
         <p id="para2387">
          Travelers should carry a letter from their physician listing underlying medical conditions and all current medications (including their generic names).
         </p>
        </list-item>
        <list-item id="celistitem1709">
         <label>
          •
         </label>
         <p id="para2388">
          If possible, travelers may want to carry with them the name of their medical condition and medications written in the local language(s) of the areas they plan to visit.
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <sec id="cesec550">
      <title>
       Special Considerations for Medicare/Medicaid Beneficiaries
      </title>
      <p id="para2389">
       <list id="celist463" list-type="simple">
        <list-item id="celistitem1710">
         <label>
          •
         </label>
         <p id="para2390">
          The Social Security Medicare program does not provide coverage for medical costs outside the United States, except under very limited circumstances.
         </p>
        </list-item>
        <list-item id="celistitem1711">
         <label>
          •
         </label>
         <p id="para2391">
          Medicare beneficiaries can purchase supplemental travel health insurance to cover medical expenses outside of the United States.
         </p>
        </list-item>
        <list-item id="celistitem1712">
         <label>
          •
         </label>
         <p id="para2392">
          Some Medigap plans available to people enrolled in the original Medicare plan provide limited coverage for emergency care abroad.
         </p>
        </list-item>
        <list-item id="celistitem1713">
         <label>
          •
         </label>
         <p id="para2393">
          As with all travelers, Medicare beneficiaries should examine their present coverage carefully to know exactly what will be covered abroad and supplement with additional travel health insurance as appropriate.
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <ref-list id="cebib45">
      <title>
       References
      </title>
      <ref id="bib423">
       <label>
        1
       </label>
       <mixed-citation id="ceotherref58" publication-type="other">
        U.S. Department of State. Medical information for Americans abroad. [cited 2008 Jun 30] Available from:
        <ext-link ext-link-type="uri" id="interref143" xlink:href="http://travel.state.gov/travel/tips/brochures/brochures_1215.html">
         http://travel.state.gov/travel/tips/brochures/brochures_1215.html
        </ext-link>
        .
       </mixed-citation>
      </ref>
      <ref id="bib424">
       <label>
        2
       </label>
       <mixed-citation id="ceotherref59" publication-type="other">
        Centers for Medicare and Medicaid Services. Medicare coverage outside the United States. [cited 2008 Jun 30] Available from:
        <ext-link ext-link-type="uri" id="interref144" xlink:href="http://www.medicare.gov/Publications/Pubs/pdf/11037.pdf">
         http://www.medicare.gov/Publications/Pubs/pdf/11037.pdf
        </ext-link>
        .
       </mixed-citation>
      </ref>
     </ref-list>
    </sec>
    <sec id="subchapter46">
     <sec-meta>
      <contrib-group>
       <contrib contrib-type="author" id="au81">
        <name>
         <surname>
          Balaban
         </surname>
         <given-names>
          Victor
         </given-names>
        </name>
       </contrib>
      </contrib-group>
     </sec-meta>
     <title>
      MENTAL HEALTH AND TRAVEL
     </title>
     <sec id="cesec551">
      <title>
       Description
      </title>
      <p id="para2394">
       Travel is undertaken for a number of reasons, such as adventure, pleasure, business, or personal growth. While most travelers complete their journeys with a manageable amount of stress, foreign travel can produce a wide range of psychiatric, behavioral, and neurologic issues in travelers. Any journey can produce challenges, but longer journeys to more remote and strange environments can increase the psychological stresses for travelers.
      </p>
     </sec>
     <sec id="cesec552">
      <title>
       Risk Factors
      </title>
      <p id="para2395">
       Risk factors that have been identified for developing psychiatric and neurologic problems during and after travel include—
       <list id="celist464" list-type="simple">
        <list-item id="celistitem1714">
         <label>
          •
         </label>
         <p id="para2396">
          Pre-existing psychiatric issues: Stress can trigger or exacerbate psychiatric reactions in travelers with pre-existing psychiatric or behavioral conditions.
         </p>
        </list-item>
        <list-item id="celistitem1715">
         <label>
          •
         </label>
         <p id="para2397">
          Side effects of mefloquine or other drugs:
          <list id="celist465" list-type="simple">
           <list-item id="celistitem1716">
            <label>
             ○
            </label>
            <p id="para2398">
             People with underlying psychiatric disorders should not receive the antimalarial medication mefloquine. The neuropsychiatric side effects associated with mefloquine may become pronounced in these patients.
            </p>
           </list-item>
           <list-item id="celistitem1717">
            <label>
             ○
            </label>
            <p id="para2399">
             The neuropsychiatric side effects associated with mefloquine may also be compounded when administered concurrently with the antiretroviral medication efavirenz, which also carries the risk of neurologic toxicity.
            </p>
           </list-item>
           <list-item id="celistitem1718">
            <label>
             ○
            </label>
            <p id="para2400">
             Elderly travelers and travelers with memory or cognitive deficits may be more prone to develop delirium in flight, particularly when combined with dehydration, alcohol, or the use of sleep aids such as zolpidem.
            </p>
           </list-item>
           <list-item id="celistitem1719">
            <label>
             ○
            </label>
            <p id="para2401">
             The use of recreational drugs has also been found to be a trigger for psychiatric symptoms in travelers.
            </p>
           </list-item>
          </list>
         </p>
        </list-item>
        <list-item id="celistitem1720">
         <label>
          •
         </label>
         <p id="para2402">
          Stressful events during travel, such as loneliness, a feeling of loss of control, financial difficulties, or a traumatic event such as a serious illness or viewing disturbing sights, can have behavioral and psychosocial consequences for travelers.
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <sec id="cesec553">
      <title>
       Occurrence and Risk for Travelers
      </title>
      <p id="para2403">
       Data are limited on the prevalence of travel-related psychiatric and neurologic disorders:
       <list id="celist466" list-type="simple">
        <list-item id="celistitem1721">
         <label>
          •
         </label>
         <p id="para2404">
          A study of Israeli long-term travelers to Southeast Asia found that 11.3% reported psychiatric or neurologic symptoms during travel. The most common symptoms were sleep disturbances, fatigue, and dizziness. The majority of symptoms were short-lived and transient, but 2.5% of travelers reported severe psychiatric or neurologic symptoms, and 1.2% had symptoms lasting more than 2 months.
         </p>
        </list-item>
        <list-item id="celistitem1722">
         <label>
          •
         </label>
         <p id="para2405">
          A study of urgent repatriation of British diplomats found that 41% of evacuations for nonphysical causes were due to depression.
         </p>
        </list-item>
        <list-item id="celistitem1723">
         <label>
          •
         </label>
         <p id="para2406">
          Adventure travelers in extreme settings, such as polar expeditions, have been found to undergo psychiatric changes, including disturbed sleep, impaired cognitive ability, negative affect, and interpersonal tension and conflict; approximately 5% have been found to meet the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) or the International Classification of Diseases (ICD) criteria for psychiatric disorders (including substance-related and sleep disorders).
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <sec id="cesec554">
      <title>
       Pre-Travel Mental Health Evaluation
      </title>
      <p id="para2407">
       Pre-travel screening should assess risk factors that might indicate a need for a traveler to be referred to a mental health professional for evaluation, especially prior to travel that is likely to be stressful. Factors that should be assessed include—
       <list id="celist467" list-type="simple">
        <list-item id="celistitem1724">
         <label>
          •
         </label>
         <p id="para2408">
          pre-existing psychiatric diagnoses, such as depression or anxiety disorders
         </p>
        </list-item>
        <list-item id="celistitem1725">
         <label>
          •
         </label>
         <p id="para2409">
          history of psychosis in the traveler or a close family member
         </p>
        </list-item>
        <list-item id="celistitem1726">
         <label>
          •
         </label>
         <p id="para2410">
          history of suicide attempts
         </p>
        </list-item>
        <list-item id="celistitem1727">
         <label>
          •
         </label>
         <p id="para2411">
          evidence of depressed mood at assessment
         </p>
        </list-item>
        <list-item id="celistitem1728">
         <label>
          •
         </label>
         <p id="para2412">
          exposure to prior traumas (e.g., disasters, severe injury, abuse, assault, etc.), particularly prior to travel that could involve re-exposure to traumatic events or situations
         </p>
        </list-item>
        <list-item id="celistitem1729">
         <label>
          •
         </label>
         <p id="para2413">
          recent major life stressors or emotional strain
         </p>
        </list-item>
        <list-item id="celistitem1730">
         <label>
          •
         </label>
         <p id="para2414">
          use of medications that may have psychiatric or neurologic side effects
         </p>
        </list-item>
        <list-item id="celistitem1731">
         <label>
          •
         </label>
         <p id="para2415">
          pre-travel anxieties and phobias that are severe enough to interfere with a patients' ability to function or to prepare for and enjoy their travel.
         </p>
        </list-item>
       </list>
      </p>
      <p id="para2416">
       Long-term travelers, aid workers, military personnel and other travelers likely to be exposed to stressful situations should be advised that the stresses and challenges they may face, particularly if combined with long hours of work, lack of sleep, or fatigue, can contribute to stress and anxiety. Long-term travelers should be encouraged to—
       <list id="celist468" list-type="simple">
        <list-item id="celistitem1732">
         <label>
          •
         </label>
         <p id="para2417">
          learn how to recognize signs of stress, exhaustion, depression, and anxiety in themselves;
         </p>
        </list-item>
        <list-item id="celistitem1733">
         <label>
          •
         </label>
         <p id="para2418">
          take care of themselves physically by eating and exercising regularly; and
         </p>
        </list-item>
        <list-item id="celistitem1734">
         <label>
          •
         </label>
         <p id="para2419">
          use their full allotment of time off or annual leave, particularly if they recognize signs of stress or exhaustion in themselves.
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <sec id="cesec555">
      <title>
       During Travel
      </title>
      <p id="para2420">
       Severe mental illness occurring abroad can be extremely stressful for travelers, their families, and those who try to care for them. Acute psychosis leading to disruptive behavior can land a traveler in jail in a developing country. Inpatient psychiatric facilities may be either nonexistent or completely inadequate for a foreigner. It can be very difficult to repatriate a psychotic person until the symptoms have been brought under control with medication. Someone will most often have to accompany the person home. Many evacuation insurance plans specifically exclude psychiatric illness from their coverage.
      </p>
     </sec>
     <sec id="cesec556">
      <title>
       Post-Travel Mental Health Evaluation
      </title>
      <p id="para2421">
       Returning travelers may have experienced physical illnesses, personal difficulties, or traumas that could result in psychiatric reactions. Travel-related injuries and diseases that affect quality of life can also have profound and long-term psychiatric impacts. Even in the absence of trauma, some returning long-term travelers report experiencing “reverse culture shock” after their return, characterized by feelings of disorientation, unfamiliarity, and loss of confidence. Approximately 36% of aid workers report depression shortly after returning home, and as many as 60% of returned aid workers have reported feeling predominantly negative emotions on returning home, even though many reported that their time overseas was positive and fulfilling.
      </p>
      <p id="para2422">
       Post-travel evaluations should assess—
       <list id="celist469" list-type="simple">
        <list-item id="celistitem1735">
         <label>
          •
         </label>
         <p id="para2423">
          Behavioral and psychiatric symptoms, including:
          <list id="celist470" list-type="simple">
           <list-item id="celistitem1736">
            <label>
             ○
            </label>
            <p id="para2424">
             Experiences during or soon after travel, which have been painful, hard to reconcile or which still cause distress, anxiety, or avoidance.
            </p>
           </list-item>
           <list-item id="celistitem1737">
            <label>
             ○
            </label>
            <p id="para2425">
             Persistent sleep disturbance or unusual fatigue.
            </p>
           </list-item>
           <list-item id="celistitem1738">
            <label>
             ○
            </label>
            <p id="para2426">
             Excessive use of alcohol or drugs.
            </p>
           </list-item>
           <list-item id="celistitem1739">
            <label>
             ○
            </label>
            <p id="para2427">
             Behavioral or interpersonal difficulties in home, school, work, in friendships or relationships.
            </p>
           </list-item>
          </list>
         </p>
        </list-item>
        <list-item id="celistitem1740">
         <label>
          •
         </label>
         <p id="para2428">
          Somatic symptoms that can also be indications of distress, including:
          <list id="celist471" list-type="simple">
           <list-item id="celistitem1741">
            <label>
             ○
            </label>
            <p id="para2429">
             Unexplained somatic symptoms, such as headaches, backaches, or abdominal pain; and somatic disorders such as fibromyalgia, chronic fatigue syndrome, temporomandibular disorder, and irritable bowel syndrome.
            </p>
           </list-item>
           <list-item id="celistitem1742">
            <label>
             ○
            </label>
            <p id="para2430">
             Rashes, itching, and skin diseases, such as psoriasis, atopic dermatitis, and urticaria, which can be exacerbated by stress.
            </p>
           </list-item>
          </list>
         </p>
        </list-item>
       </list>
      </p>
      <p id="para2431">
       Clinicians should be aware that some travelers may be reluctant to acknowledge psychiatric symptoms or distress. For example, many cultures have stigmas associated with experiencing or disclosing behaviors associated with mental illness, as well as different culturally appropriate ways of expressing grief, pain, and loss. In addition, some travelers may fear being penalized or stigmatized at work if they have psychiatric diagnoses noted on their medical records.
      </p>
      <p id="para2432">
       Regardless of the type or duration of travel, and whether or not travelers appear to meet criteria for a psychiatric diagnosis, returned travelers who are having difficulties functioning or who appear to be unduly depressed or distressed should be encouraged to seek appropriate treatment or counseling.
      </p>
     </sec>
     <ref-list id="cebib46">
      <title>
       References
      </title>
      <ref id="bib425">
       <label>
        1
       </label>
       <element-citation id="sbref366" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lankester
          </surname>
          <given-names>
           T
          </given-names>
         </name>
        </person-group>
        <article-title>
         Health care of the long-term traveler
        </article-title>
        <source>
         Travel Med Infect Dis
        </source>
        <volume>
         3
        </volume>
        <issue>
         3
        </issue>
        <year>
         2005
        </year>
        <fpage>
         143
        </fpage>
        <lpage>
         155
        </lpage>
        <pub-id pub-id-type="pmid">
         17292032
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib426">
       <label>
        2
       </label>
       <element-citation id="sbref367" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Beny
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Paz
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Potasman
          </surname>
          <given-names>
           I
          </given-names>
         </name>
        </person-group>
        <article-title>
         Psychiatric problems in returning travelers: features and associations
        </article-title>
        <source>
         J Travel Med
        </source>
        <volume>
         8
        </volume>
        <issue>
         5
        </issue>
        <year>
         2001
        </year>
        <fpage>
         243
        </fpage>
        <lpage>
         246
        </lpage>
        <pub-id pub-id-type="pmid">
         11703906
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib427">
       <label>
        3
       </label>
       <element-citation id="sbref368" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bhadelia
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Klotman
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Caplivski
          </surname>
          <given-names>
           D
          </given-names>
         </name>
        </person-group>
        <article-title>
         The HIV-positive traveler
        </article-title>
        <source>
         Am J Med
        </source>
        <volume>
         120
        </volume>
        <issue>
         7
        </issue>
        <year>
         2007
        </year>
        <fpage>
         574
        </fpage>
        <lpage>
         580
        </lpage>
        <pub-id pub-id-type="pmid">
         17602926
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib428">
       <label>
        4
       </label>
       <element-citation id="sbref369" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Reed
          </surname>
          <given-names>
           CM
          </given-names>
         </name>
        </person-group>
        <article-title>
         Travel recommendations for older adults
        </article-title>
        <source>
         Clin Geriatr Med
        </source>
        <volume>
         23
        </volume>
        <issue>
         3
        </issue>
        <year>
         2007
        </year>
        <fpage>
         687
        </fpage>
        <lpage>
         713
        </lpage>
        <comment>
         ix
        </comment>
        <pub-id pub-id-type="pmid">
         17631241
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib429">
       <label>
        5
       </label>
       <element-citation id="sbref370" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Potasman
          </surname>
          <given-names>
           I
          </given-names>
         </name>
         <name>
          <surname>
           Beny
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Seligmann
          </surname>
          <given-names>
           H
          </given-names>
         </name>
        </person-group>
        <article-title>
         Neuropsychiatric problems in 2,500 long-term young travelers to the tropics
        </article-title>
        <source>
         J Travel Med
        </source>
        <volume>
         7
        </volume>
        <issue>
         1
        </issue>
        <year>
         2000
        </year>
        <fpage>
         5
        </fpage>
        <lpage>
         9
        </lpage>
        <pub-id pub-id-type="pmid">
         10689231
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib430">
       <label>
        6
       </label>
       <element-citation id="sbref371" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Patel
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Easmon
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Dow
          </surname>
          <given-names>
           C
          </given-names>
         </name>
        </person-group>
        <article-title>
         Medical repatriation of British diplomats resident overseas
        </article-title>
        <source>
         J Travel Med
        </source>
        <volume>
         7
        </volume>
        <issue>
         2
        </issue>
        <year>
         2000
        </year>
        <fpage>
         64
        </fpage>
        <lpage>
         69
        </lpage>
        <pub-id pub-id-type="pmid">
         10759571
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib431">
       <label>
        7
       </label>
       <element-citation id="sbref372" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Palinkas
          </surname>
          <given-names>
           LA
          </given-names>
         </name>
         <name>
          <surname>
           Suedfeld
          </surname>
          <given-names>
           P
          </given-names>
         </name>
        </person-group>
        <article-title>
         Psychological effects of polar expeditions
        </article-title>
        <source>
         Lancet
        </source>
        <volume>
         371
        </volume>
        <issue>
         9607
        </issue>
        <year>
         2008
        </year>
        <fpage>
         153
        </fpage>
        <lpage>
         163
        </lpage>
        <pub-id pub-id-type="pmid">
         17655924
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib432">
       <label>
        8
       </label>
       <element-citation id="sbref373" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Espino
          </surname>
          <given-names>
           CM
          </given-names>
         </name>
         <name>
          <surname>
           Sundstrom
          </surname>
          <given-names>
           SM
          </given-names>
         </name>
         <name>
          <surname>
           Frick
          </surname>
          <given-names>
           HL
          </given-names>
         </name>
        </person-group>
        <article-title>
         International business travel: impact on families and travellers
        </article-title>
        <source>
         Occup Environ Med
        </source>
        <volume>
         59
        </volume>
        <issue>
         5
        </issue>
        <year>
         2002
        </year>
        <fpage>
         309
        </fpage>
        <lpage>
         322
        </lpage>
        <pub-id pub-id-type="pmid">
         11983846
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib433">
       <label>
        9
       </label>
       <element-citation id="sbref374" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bor
          </surname>
          <given-names>
           R
          </given-names>
         </name>
        </person-group>
        <article-title>
         Psychological factors in airline passenger and crew behaviour: a clinical overview
        </article-title>
        <source>
         Travel Med Infect Dis
        </source>
        <volume>
         5
        </volume>
        <issue>
         4
        </issue>
        <year>
         2007
        </year>
        <fpage>
         207
        </fpage>
        <lpage>
         216
        </lpage>
        <pub-id pub-id-type="pmid">
         17574141
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib434">
       <label>
        10
       </label>
       <element-citation id="sbref375" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Balaban
          </surname>
          <given-names>
           V
          </given-names>
         </name>
        </person-group>
        <article-title>
         Psychological assessment of children in disasters and emergencies: a review
        </article-title>
        <source>
         Disasters
        </source>
        <volume>
         30
        </volume>
        <issue>
         2
        </issue>
        <year>
         2006
        </year>
        <fpage>
         178
        </fpage>
        <lpage>
         198
        </lpage>
        <pub-id pub-id-type="pmid">
         16689917
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib435">
       <label>
        11
       </label>
       <element-citation id="sbref376" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hochedez
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Vinsentini
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Ansart
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        <article-title>
         Changes in the pattern of health disorders diagnosed among two cohorts of French travelers to Nepal, 17 years apart
        </article-title>
        <source>
         J Travel Med
        </source>
        <volume>
         11
        </volume>
        <issue>
         6
        </issue>
        <year>
         2004
        </year>
        <fpage>
         341
        </fpage>
        <lpage>
         346
        </lpage>
        <pub-id pub-id-type="pmid">
         15569569
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib436">
       <label>
        12
       </label>
       <element-citation id="sbref377" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rolfe
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Tang
          </surname>
          <given-names>
           CM
          </given-names>
         </name>
         <name>
          <surname>
           Sabally
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        <article-title>
         Psychosis and cannabis abuse in The Gambia. A case-control study
        </article-title>
        <source>
         Br J Psychiatry
        </source>
        <volume>
         163
        </volume>
        <year>
         1993
        </year>
        <fpage>
         798
        </fpage>
        <lpage>
         801
        </lpage>
        <pub-id pub-id-type="pmid">
         8306122
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib437">
       <label>
        13
       </label>
       <element-citation id="sbref378" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Crofford
          </surname>
          <given-names>
           LJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         Violence, stress, and somatic syndromes
        </article-title>
        <source>
         Trauma Violence Abuse
        </source>
        <volume>
         8
        </volume>
        <issue>
         3
        </issue>
        <year>
         2007
        </year>
        <fpage>
         299
        </fpage>
        <lpage>
         313
        </lpage>
        <pub-id pub-id-type="pmid">
         17596347
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib438">
       <label>
        14
       </label>
       <element-citation id="sbref379" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Urpe
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Buggiani
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Lotti
          </surname>
          <given-names>
           T
          </given-names>
         </name>
        </person-group>
        <article-title>
         Stress and psychoneuroimmunologic factors in dermatology
        </article-title>
        <source>
         Dermatol Clin
        </source>
        <volume>
         23
        </volume>
        <issue>
         4
        </issue>
        <year>
         2005
        </year>
        <fpage>
         609
        </fpage>
        <lpage>
         617
        </lpage>
        <pub-id pub-id-type="pmid">
         16112436
        </pub-id>
       </element-citation>
      </ref>
     </ref-list>
    </sec>
    <back>
     <fn-group>
      <fn id="fn1">
       <label>
        1
       </label>
       <p id="cenotep1">
        Estimates of prevalence of antibody to hepatitis A virus (anti-HAV), a marker of previous HAV infection, are based on limited data and might not reflect current prevalence. In addition, anti-HAV prevalence might vary within countries by subpopulation and locality. As used on this map, the terms “high,” “medium,” and “low” endemicity reflect available evidence of how widespread HAV infection is within each country, rather than precise quantitative assessments.
       </p>
      </fn>
     </fn-group>
     <fn-group>
      <fn id="fn4">
       <label>
        1
       </label>
       <p id="cenotep87">
        Measles vaccine alone is recommended for infants vaccinated before 12 months of age if it is available, otherwise MMR should be administered. Infants vaccinated before 12 months of age must be revaccinated on or after the first birthday with two doses of measles-containing vaccine separated by at least 28 days. MMRV is not licensed for children &lt;12 months of age.
       </p>
      </fn>
      <fn id="fn5">
       <label>
        2
       </label>
       <p id="cenotep88">
        MMRV vaccine is licensed for children 12 months to 12 years of age and may be used in place of MMR vaccine if vaccination for measles, mumps, rubella and varicella are needed.
       </p>
      </fn>
      <fn id="fn2">
       <label>
        *
       </label>
       <p id="cenotep85">
        <bold>
         <italic>
          Note:
         </italic>
        </bold>
        This recommendation refers to EPA-registered repellent products containing the active ingredient oil of lemon eucalyptus (or PMD). “Pure” oil of lemon eucalyptus (e.g., essential oil) is not the same product and has not received similar, validated testing for safety and efficacy, is not registered with EPA as an insect repellent, and is not covered by this recommendation.
       </p>
      </fn>
      <fn id="fn3">
       <label>
        *
       </label>
       <p id="cenotep86">
        <bold>
         <italic>
          Note:
         </italic>
        </bold>
        Pack these items in checked baggage, since they may be considered sharp objects and confiscated by airport or airline security if packed in carry-on bags.
       </p>
      </fn>
     </fn-group>
    </back>
   </article>
  </pmc-articleset>
 </body>
</html>